<SEC-DOCUMENT>0001213900-14-006670.txt : 20140916
<SEC-HEADER>0001213900-14-006670.hdr.sgml : 20140916
<ACCEPTANCE-DATETIME>20140916084232
ACCESSION NUMBER:		0001213900-14-006670
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		10
FILED AS OF DATE:		20140916
DATE AS OF CHANGE:		20140916

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RELMADA THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001553643
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				455401931
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-197109
		FILM NUMBER:		141104524

	BUSINESS ADDRESS:	
		STREET 1:		546 FIFTH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036
		BUSINESS PHONE:		212-702-7163

	MAIL ADDRESS:	
		STREET 1:		546 FIFTH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CAMP NINE, INC.
		DATE OF NAME CHANGE:	20120706
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>fs12014a1_relmada.htm
<DESCRIPTION>REGISTRATION STATEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>



<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"><B> As filed with the Securities and
Exchange Commission on September 15, 2014 </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"><B> Registration No. 333-197109 </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B> FORM S-1/A </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B> (Amendment No. 1) </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>REGISTRATION
STATEMENT UNDER THE</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B> RELMADA
THERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B> (FORMERLY
KNOWN AS CAMP NINE, INC.) </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;(Exact name
of registrant as specified in its charter)</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="width: 34%; border-bottom: Black 1.5pt solid; font: 10pt/normal Times New Roman, Times, Serif; text-align: center"><B>Nevada</B></TD>
    <TD STYLE="width: 1%; font: 10pt/normal Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1.5pt solid; font: 10pt/normal Times New Roman, Times, Serif; text-align: center"><B>3949</B></TD>
    <TD STYLE="width: 1%; font: 10pt/normal Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1.5pt solid; font: 10pt/normal Times New Roman, Times, Serif; text-align: center"><B>45-184881</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(State or other jurisdiction</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">of incorporation or organization)</P></TD>
    <TD STYLE="font: 10pt/normal Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(Primary Standard</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Industrial Classification Code Number)</P></TD>
    <TD STYLE="font: 10pt/normal Times New Roman, Times, Serif">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">(I.R.S. Employer</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">Identification Number)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>546 Fifth Avenue, 14th Floor New York,
NY 10036</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(212) 702-7163</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(Address, including zip code, and telephone
number,</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">including area code, of registrant&rsquo;s
principal executive offices)</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B> Relmada
Therapeutics, Inc. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Attention: Chief Financial Officer</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>546 Fifth Avenue, 14<FONT STYLE="font-size: 10pt">th</FONT>
Floor</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>New York, NY 10036</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>(212) 702-7163</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;(Name, address,
including zip code, and telephone number,</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">including area code, of agent for service)</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Copies to:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 35%"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Thomas Slusarczyk, Esq.</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Hiscock &amp; Barclay LLP</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>One Park Place</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>300 South State Street</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Syracuse, New York 13202</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Tel No.: (315) 235-2299</B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Fax No.: (315) 624-7359</B></P></TD></TR></TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Approximate date of commencement of proposed sale to the
public:</B> As soon as practicable after this Registration Statement becomes effective.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">If any of the securities being registered on this Form are
to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box:<FONT STYLE="font-family: Wingdings">&nbsp;&nbsp;x</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">If this Form is filed to register additional securities for
an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.<FONT STYLE="font-family: Wingdings">&nbsp;&nbsp;o</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">If this Form is a post-effective amendment filed pursuant
to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the
earlier effective registration statement for the same offering.<FONT STYLE="font-family: Wingdings">&nbsp;&nbsp;o</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">If this Form is a post-effective amendment filed pursuant
to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the
earlier effective registration statement for the same offering.<FONT STYLE="font-family: Wingdings">&nbsp;&nbsp;o</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &ldquo;large
accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b2 of the Exchange
Act.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%; line-height: normal">Large accelerated filer</TD>
    <TD STYLE="width: 25%; line-height: normal"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="width: 25%; line-height: normal">Accelerated filer</TD>
    <TD STYLE="width: 25%; line-height: normal"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">Non-accelerated filer</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="line-height: normal">Smaller reporting company</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Wingdings">x</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">(Do not check if a smaller reporting company)</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 7.7pt 0 9.9pt; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0; line-height: normal; text-indent: 0"><B> Title of Each Class Of Securities to be Registered </B></TD>
    <TD STYLE="padding: 0; line-height: normal; text-indent: 0"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding: 0; text-indent: 0"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Amount to be </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Registered </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> (1) </B></P></TD>
    <TD STYLE="padding: 0; line-height: normal; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; line-height: normal; text-indent: 0"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding: 0; text-indent: 0"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Proposed Maximum Offering
        Price per share </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> (2) </B></P></TD>
    <TD STYLE="padding: 0; line-height: normal; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; line-height: normal; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; line-height: normal; text-indent: 0"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding: 0; line-height: normal; text-align: center; text-indent: 0"><B> Proposed Maximum Aggregate
    Offering Price </B></TD>
    <TD STYLE="padding: 0; line-height: normal; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; line-height: normal; text-indent: 0"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding: 0; text-indent: 0"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Amount of </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Registration Fee </B></P></TD>
    <TD STYLE="padding: 0; line-height: normal; text-indent: 0"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 41%; line-height: normal; padding: 0; text-indent: 0"> Common stock, $0.001 par value per share </TD>
    <TD STYLE="width: 1%; line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="width: 4%; line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="width: 8%; line-height: normal; text-align: right; padding: 0; text-indent: 0"> 15,453,421 </TD>
    <TD STYLE="width: 1%; line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="width: 4%; line-height: normal; padding: 0; text-indent: 0"> $ </TD>
    <TD STYLE="width: 7%; line-height: normal; text-align: right; padding: 0; text-indent: 0"> 0.80 </TD>
    <TD STYLE="width: 1%; line-height: normal; text-align: right; padding: 0; text-indent: 0"> (2 </TD>
    <TD STYLE="width: 1%; line-height: normal; padding: 0; text-indent: 0"> ) </TD>
    <TD STYLE="width: 1%; line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="width: 4%; line-height: normal; padding: 0; text-indent: 0"> $ </TD>
    <TD STYLE="width: 10%; line-height: normal; text-align: right; padding: 0; text-indent: 0"> 12,362,737.80 </TD>
    <TD STYLE="width: 1%; line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="width: 5%; line-height: normal; padding: 0; text-indent: 0"> $ </TD>
    <TD STYLE="width: 8%; line-height: normal; text-align: right; padding: 0; text-indent: 0"> 1,592.32 </TD>
    <TD STYLE="width: 1%; line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> Common stock, $0.001 par value per share </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> 17,163,799 </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> $ </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> 1.50 </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> (2 </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> ) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> $ </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> 25,745,698.50 </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> $ </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> 3,316.04 </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: normal; padding: 0 0 0 10; text-indent: -10"> Common stock, $0.001 par value per share, issuable upon exercise of the Series A Preferred
    and Notes Warrants </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> 2,762,504 </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> $ </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> 0.80 </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> (3 </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> ) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> $ </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> 1,768,003 </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> $ </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> 227.72 </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: normal; padding: 0 0 0 10; text-indent: -10"> Common stock, $0.001 par value per share, issuable upon exercise of the Series A Warrants </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> 17,163,799 </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> $ </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> 1.50 </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> (3 </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> ) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> $ </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> 25,745,698.50 </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> $ </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> 3,316.04 </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: normal; padding: 0 0 0 10; text-indent: -10"> Common stock, $0.001 par value per share, issuable upon exercise of the Series B Warrants </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; border-bottom: Black 1.5pt solid; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; border-bottom: Black 1.5pt solid; padding: 0; text-indent: 0"> 8,581,899 </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> $ </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> 2.25 </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> (3 </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> ) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> $ </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> 19,309,272.75 </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; border-bottom: Black 1.5pt solid; padding: 0; text-indent: 0"> $ </TD>
    <TD STYLE="line-height: normal; text-align: right; border-bottom: Black 1.5pt solid; padding: 0; text-indent: 0"> 2,487.03 </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><B> Total </B></TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; border-bottom: Black 4pt double; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; border-bottom: Black 4pt double; padding: 0; text-indent: 0"> 61,125,422 </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="line-height: normal; border-bottom: Black 4pt double; padding: 0; text-indent: 0"> $ </TD>
    <TD STYLE="line-height: normal; text-align: right; border-bottom: Black 4pt double; padding: 0; text-indent: 0"> 10,939.13 </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: normal">&nbsp;</TD>
    <TD STYLE="width: 4%; line-height: normal; text-align: justify">(1)</TD>
    <TD STYLE="width: 93%">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">This registration statement includes an indeterminate number
        of additional shares of common stock issuable for no additional consideration pursuant to any stock dividend, stock split, recapitalization
        or other similar transaction effected without the receipt of consideration, which results in an increase in the number of outstanding
        shares of our common stock. In the event of a stock split, stock dividend or similar transaction involving our common stock, in
        order to prevent dilution, the number of shares registered shall be automatically increased to cover the additional shares in accordance
        with Rule 416(a) under the Securities Act of 1933, as amended.</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal; text-align: justify">(2)</TD>
    <TD>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Calculated based upon the sales price of the common stock
        held by the selling stockholders named in this Registration Statement.</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal; text-align: justify">(3)</TD>
    <TD STYLE="line-height: normal">Calculated based upon the exercise price of the warrants held by the selling stockholders named in this Registration Statement.</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"> * Previously
paid. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>The registrant hereby amends this registration statement
on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which
specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities
Act of 1933, as amended, or until the registration statement shall become effective on such date as the commission, acting pursuant
to said Section 8(a), may determine.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Red"><B>The information in this prospectus
is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities
and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer
to buy these securities in any state where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 34%; line-height: normal; text-align: center"><B>PRELIMINARY PROSPECTUS</B></TD>
    <TD STYLE="vertical-align: bottom; width: 33%; line-height: normal; text-align: center"><B>SUBJECT TO COMPLETION</B></TD>
    <TD STYLE="vertical-align: top; width: 33%; line-height: normal; text-align: center"><B> DATED&nbsp;SEPTEMBER 12, 2014 </B></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> 61,125,422 Shares of Common Stock </B></P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> RELMADA THERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> This
                                         prospectus covers the sale by the selling stockholders of up to (i) 32,617,220 shares
                                         of common stock, par value $0.001 per share, held by the selling stockholders, (ii) 2,762,504
                                         shares of our common stock issuable upon exercise of Series A Preferred and Notes Warrants
                                         held by the selling stockholders named in this prospectus at an exercise price of $0.80
                                         per share; (iii) 17,163,799 shares of our common stock issuable upon exercise of Series
                                         A Warrants held by the selling stockholders named in this prospectus at an exercise price
                                         of $1.50 per share; and (iv) 8,581,899 shares of our common stock issuable upon exercise
                                         of Series B Warrants held by the selling stockholders named in this prospectus at an
                                         exercise price of $2.25 per share. The shares being sold by the selling stockholders
                                         were issued to them in private placement transactions which were exempt from the registration
                                         and prospectus delivery requirements of the Securities Act of 1933, as amended (the &ldquo;Securities
                                         Act&rdquo;). Our common stock and warrants are more fully described in &ldquo;Description
                                         of Securities.&rdquo; </P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We are not selling any common stock under this prospectus
and will not receive any of the proceeds from the sale of shares by the selling stockholders. These shares will be offered for
sale by the selling shareholders in accordance with the &ldquo;Plan of Distribution.&rdquo; We will not receive any proceeds from
sales of shares of our common stock or warrants by the selling stockholders. However, to the extent the warrants are exercised
for cash, if at all, we will receive the exercise price of the warrants. We will pay the expenses incurred in connection with the
offering described in this prospectus, with the exception of brokerage expenses, fees, discounts and commissions, which will be
paid by selling stockholders.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Our common stock is presently traded on the OTCQB under
the symbol RLMD. However, there is no active market for our Common Stock and trading has been extremely limited.&nbsp;&nbsp;On
September 8, 2014 the closing price of our common stock was $2.55, as reported on www.otcbb.com. The prices at which the selling
stockholders may sell the shares of common stock that are part of this offering may be market prices prevailing at the time of
sale, at negotiated prices, at fixed prices, or at varying prices determined at the time of sale. See &ldquo;Plan of Distribution.&rdquo;
</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> An investment in our common stock may be considered
speculative and involves a high degree of risk, including the risk of a substantial loss of your investment. See &ldquo;Risk Factors&rdquo;
beginning on page&nbsp;4 to read about the risks you should consider before buying shares of our common stock. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left"><B>Neither the Securities and Exchange Commission nor any
state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete.
Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">The date of this prospectus is
__________, 2014</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="toc"></A><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; width: 92%; line-height: normal"><FONT STYLE="color: Black"><A HREF="#a_001">PROSPECTUS SUMMARY</A></FONT><A HREF="#a_001"></A></TD>
    <TD STYLE="vertical-align: bottom; width: 8%; line-height: normal; text-align: right"><FONT STYLE="color: Black">1</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; line-height: normal"><FONT STYLE="color: Black"><A HREF="#a_002">RISK FACTORS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: normal; text-align: right"><FONT STYLE="color: Black">4</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; line-height: normal"><FONT STYLE="color: Black"><A HREF="#a_003">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: normal; text-align: right"><FONT STYLE="color: Black">24</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; line-height: normal"><FONT STYLE="color: Black"><A HREF="#a_004">DIVIDEND POLICY</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: normal; text-align: right"><FONT STYLE="color: Black">24</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; line-height: normal"><FONT STYLE="color: Black"><A HREF="#a_005">USE OF PROCEEDS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: normal; text-align: right"><FONT STYLE="color: Black">24</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; line-height: normal"><FONT STYLE="color: Black"><A HREF="#a_006">DILUTION</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: normal; text-align: right"><FONT STYLE="color: Black">25</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; line-height: normal"><FONT STYLE="color: Black"><A HREF="#a_007">PENNY STOCK CONSIDERATIONS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: normal; text-align: right"><FONT STYLE="color: Black">25</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; line-height: normal"><FONT STYLE="color: Black"><A HREF="#a_008">SELLING STOCKHOLDERS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: normal; text-align: right"><FONT STYLE="color: Black">25</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; line-height: normal"><FONT STYLE="color: Black"><A HREF="#a_009">DESCRIPTION OF BUSINESS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: normal; text-align: right"><FONT STYLE="color: Black">53</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; line-height: normal"><FONT STYLE="color: Black"><A HREF="#a_010">MARKET PRICE OF AND
    DIVIDENDS ON OUR COMMON STOCK AND RELATED STOCKHOLDER MATTERS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: normal; text-align: right"><FONT STYLE="color: Black">59</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; line-height: normal"><FONT STYLE="color: Black"><A HREF="#a_011">MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: normal; text-align: right">61</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; line-height: normal"><FONT STYLE="color: Black"><A HREF="#a_012">CHANGES IN REGISTRANT&rsquo;S CERTIFYING ACCOUNTANT</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: normal; text-align: right"><FONT STYLE="color: Black">68</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; line-height: normal"><FONT STYLE="color: Black"><A HREF="#a_013">DIRECTORS AND EXECUTIVE OFFICERS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: normal; text-align: right"><FONT STYLE="color: Black">69</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; line-height: normal"><FONT STYLE="color: Black"><A HREF="#a_014">EXECUTIVE COMPENSATION</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: normal; text-align: right"><FONT STYLE="color: Black">72</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; line-height: normal"><FONT STYLE="color: Black"><A HREF="#a_015">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: normal; text-align: right"><FONT STYLE="color: Black">76</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; line-height: normal"><FONT STYLE="color: Black"><A HREF="#a_016">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: normal; text-align: right"><FONT STYLE="color: Black">78</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; line-height: normal"><FONT STYLE="color: Black"><A HREF="#a_017">DESCRIPTION OF SECURITIES</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: normal; text-align: right"><FONT STYLE="color: Black">79</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; line-height: normal"><FONT STYLE="color: Black"><A HREF="#a_019">PLAN OF DISTRIBUTION</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: normal; text-align: right"><FONT STYLE="color: Black">83</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; line-height: normal"><FONT STYLE="color: Black">SHARES ELIGIBLE FOR FUTURE SALE</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: normal; text-align: right"><FONT STYLE="color: Black"></FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; line-height: normal"><FONT STYLE="color: Black"><A HREF="#a_020">LEGAL MATTERS</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: normal; text-align: right"><FONT STYLE="color: Black">84</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; line-height: normal"><A HREF="#a_021">EXPERTS</A></TD>
    <TD STYLE="vertical-align: bottom; line-height: normal; text-align: right">84</TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; line-height: normal"><A HREF="#a_022">WHERE YOU CAN FIND MORE INFORMATION</A></TD>
    <TD STYLE="vertical-align: bottom; line-height: normal; text-align: right">84</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: normal">DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION OF&nbsp;SECURITIES
    ACT LIABILITIES</TD>
    <TD STYLE="vertical-align: bottom; line-height: normal">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: normal"><A HREF="#index">INDEX TO FINANCIAL STATEMENTS</A></TD>
    <TD STYLE="vertical-align: bottom; line-height: normal; text-align: right">F-1</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Please read this prospectus carefully. It describes our
business, our financial condition and results of operations. We have prepared this prospectus so that you will have the information
necessary to make an informed investment decision.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">You should rely only on information contained in this prospectus.
We have not authorized any other person to provide you with different information. This prospectus is not an offer to sell, nor
is it seeking an offer to buy, these securities in any state where the offer or sale is not permitted. The information in this
prospectus is complete and accurate as of the date on the front cover, but the information may have changed since that date.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<DIV STYLE="width: 100%">

<DIV STYLE="padding: 12pt 5; border: Black 1.5pt solid; width: 100%">

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_001"></A>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I> This summary highlights selected information
contained elsewhere in this prospectus. This summary does not contain all the information that you should consider before investing
in the common stock. You should carefully read the entire prospectus, including &ldquo;Risk Factors,&rdquo; &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and the financial statements, before making an
investment decision. Our actual results may differ significantly from the results discussed in these forward-looking statements
as a result of certain factors, including those described in &ldquo;Risk Factors&rdquo; and &ldquo;Cautionary Note Regarding Forward-Looking
Statements.&rdquo; All references to &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; and the &ldquo;Company&rdquo; mean
Relmada Therapeutics, Inc. and its subsidiary Relmada Therapeutics, Inc.(Delaware) </I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Business Overview</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> We are a clinical stage, biopharmaceutical
company focused on drugs to treat pain.&nbsp;&nbsp;In 2013, the US market for prescription pain drugs was approximately $13B,
according to IMS Health.&nbsp;&nbsp;We are concentrating our effort and resources on novel formulations and/or modes of delivery
for off-patent drugs, new indications for drugs approved for other therapeutic uses and the development of new molecular entities.&nbsp;&nbsp;We
may in-license late-stage or approved drugs to accelerate the pathway to become a fully integrated pain specialty biopharmaceutical
company with commercial capability and to reach profitability sooner. To in-license a product means that we would acquire the
rights to develop and market a product from another pharmaceutical company in exchange for upfront payments, milestone payments
and royalty payments, as applicable. We believe in-licensing will accelerate our pathway to become a fully integrated pain specialty
biopharmaceutical company with commercial capability and to reach profitability sooner because we would be able to justify the
build up a sales and marketing force sooner if we had rights to additional products in addition to our own products. We currently
do not have in-licensing arrangements. We believe our highly experienced drug development leadership provides us with a significant
competitive advantage in designing highly efficient clinical programs to deliver valuable products in areas of high unmet medical
need. In this regard, our experienced management team coordinates the manufacturing process, designs and implements the clinical
trials, and interacts with the FDA for product approval. We have not generated revenues and do not anticipate generating revenues
for the foreseeable future. We have net losses of approximately $21.3 million for the six months ended June 30, 2014. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> We intend
to realize our business objectives by implementing two core strategies: a) develop improved versions of proven drug candidates
for treating pain conditions where they can fill an unmet need; and b) develop d-methadone as an innovative NMDA antagonist platform
to&nbsp;&nbsp;treat&nbsp;&nbsp;neuropathic pain or other potential conditions.&nbsp;&nbsp;d-Methadone works as an antagonist of
the N-methyl-D-aspartate (NMDA) receptor. NMDA receptors are present in many parts of the central nervous system and play important
roles in neuronal plasticity and other functions that are important for cognitive functions such as learning and memory. They
also contribute to the maladaptive plasticity which results in neuropathic pain. Based on these premises, d-methadone is potentially
a platform that could be developed and could show benefits in several different indications. A core part of our strategy of developing
repurposed drugs for unmet needs allows us to accelerate development at a lower cost.&nbsp;&nbsp;Product development plans for
several of our lead products such as levorphanol and buprenorphine require the completion of a relatively small Phase I program
before entering Phase III pivotal clinical trials using a 505(b)(2) FDA registration strategy, subject to FDA approval.&nbsp;&nbsp;Our
two tiered approach is expected to reduce overall clinical development risks and potentially deliver valuable products in areas
of high unmet medical needs.&nbsp;&nbsp;Our lead development projects are briefly described below. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 3.3pt 3.3pt 7.7pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; line-height: normal"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="width: 94%"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left"><B> LevoCap ER </B>
        (&ldquo;Levorphanol ER&rdquo; or &ldquo;Levorphanol&rdquo; and similar terms)<B>&nbsp;</B>is a proprietary once-a-day
        extended release (ER) dosage form of the potent opioid levorphanol in a tamper resistant drug delivery system.&nbsp;&nbsp;Unlike
        other opioids, LevoCap ER modulates pain through<I> both</I> opioid pathways acting at mu, delta and kappa opioid receptors,
        and monoaminergic (noradrenergic and serotonergic) pathways thereby providing pain relief through multiple mechanisms
        in one capsule.&nbsp;&nbsp;Thus, LevoCap ER combines the pain relieving mechanisms of OxyContin&reg; (U.S. 2013 sales,
        $2.5B according to IMS Health) and Cymbalta&reg; (global 2013 sales, $5.1B, according to Eli Lilly 2013 annual report).&nbsp;&nbsp;Importantly,
        levorphanol has also been shown to partially reverse analgesic tolerance to morphine and may therefore benefit patients
        who are tolerant to the analgesic effects of their current opioid (Moulin, D.E., Ling, G.S. and Pasternak, G.W., Unidirectional
        analgesic cross-tolerance between morphine and levorphanol in the rat, Pain, 33 (1988) 233-9). &nbsp;LevoCap ER is anticipated
        to compete in the opioid market, which according to IMS Health had $8.3B in U.S. sales in 2013. </P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> We completed GMP manufacturing for the Phase I study
        of LevoCap ER and the batches have successfully passed the 12 month stability milestone. In July 2013, we completed a 30
        patient Phase I pharmacokinetic study. We are now preparing  for a Phase III development program and we are planning to
        submit a request to the FDA to discuss the final pathway to the NDA for this product. In preparation of the Phase III we have
        initiated the transfer of the formulation technology to a US manufacturer and we are planning to generate GMP batches for the
        Phase III that will be performed in the United States.&nbsp; </P></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; line-height: normal"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="width: 94%"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> d-Methadone </B> is the d-optical isomer
        of racemic methadone and an antagonist at the NMDA receptor. NMDA antagonists have been shown to provide relief to patients
        with neuropathic pain and to reduce analgesic tolerance to opioids.&nbsp;&nbsp;Our open-label Phase I/IIa study at the
        Memorial Sloan Kettering Cancer Center showed that d-methadone was safe and well tolerated with 75% of the patients completing
        the study finding d-methadone to be moderately or very effective. d-Methadone will compete in the approximately $2.4B
        neuropathic pain market (Datamonitor, 2010), which is expected to grow to $9.7B by 2018 according to a 2011 report by
        Decision Resources.&nbsp;&nbsp;Management expects D-Methadone to leverage the established analgesic efficacy and use of
        methadone but without its safety hazard. We note that the FDA has not concluded that d-methadone is safe. </P>
                           <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
                           <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> We have successfully manufactured
                           GMP d-methadone as an active pharmaceutical ingredient (API). In September 2014, we filed a Clinical
                           Trial Application (CTA) with Health Canada to conduct two pharmacokinetic studies with d-methadone.
                           The application is under review. The two studies are designed to assess the safety, tolerability and
                           pharmacokinetics of d-methadone in healthy subjects. The first study, if approved by Health Canada,
                           will investigate the safety and tolerability of single escalating oral doses of d-methadone and determine
                           the maximum tolerated dose for single drug administration. In the second study, if approved by Health
                           Canada, healthy subjects will receive daily multiple escalating oral doses of d-methadone for the assessment
                           of safety and tolerability. The safety and pharmacokinetic data from these studies will inform the
                           design of a subsequent Phase II proof of concept study in neuropathic pain. </P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> </P></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"></P>

</DIV>

</DIV>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 12pt 5; border: Black 1.5pt solid; width: 100%">

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; line-height: normal"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="width: 94%"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> BuTab ER </B> (&ldquo;Buprenorphine
        ER&rdquo; or &ldquo;Buprenorphine&rdquo; and similar terms) is a proprietary extended release (ER) oral dosage form of
        the DEA Schedule III (C-III) opioid, buprenorphine.&nbsp;&nbsp;There are no orally absorbed dosage forms of Buprenophine
        and we believe historically both patients and doctors prefer oral dosing versus sublingual or patch products.&nbsp;&nbsp;The
        Drug Enforcement Agency (&ldquo;DEA&rdquo;) classifies controlled substances from Schedule I (C-I) to C-V, where C-I opioids
        have no current medical use and the potential for abuse is greatest for C-II and lowest for C-V.&nbsp;&nbsp;BuTab ER is
        being developed for chronic pain and opioid maintenance therapy.&nbsp;&nbsp;Unlike C-II opioids, BuTab ER carries reduced
        risk of physical dependence, euphoria, and certain opioid side effects, while benefitting from the convenience of telephone
        prescribing and refills.&nbsp;&nbsp;BuTab ER will compete in the opioid pain market and the sublingual buprenorphine (Suboxone&reg;/Subutex&reg;)
        opioid dependence market, which according to Wolters Kluwer, had approximate U.S. 2013 sales of $1.4B. </P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> We have completed a preclinical program to better
        define the pharmacokinetic profile of BuTab ER and to assess the time course of systemic absorption of buprenorphine using
        several different oral extended release formulations of buprenorphine in dogs, compared to an intravenous administration.
        Based on the results of this work, we expect to generate GMP batches, file an IND with the FDA in the second half of this
        year and subsequently start a Phase I pilot study in healthy volunteers. </P></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="width: 94%">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>MepiGel</B> (&ldquo;Mepivacaine gel&rdquo; or &ldquo;Mepivacaine&rdquo;
        and similar terms) is a proprietary topical non-greasy gel dosage form of the local anesthetic mepivacaine for the treatment of
        postherpetic neuralgia and painful HIV-associated neuropathy.&nbsp;&nbsp;We have received two 7-year FDA Orphan Drug market exclusivities
        for mepivacaine, one for &ldquo;the treatment of painful HIV-associated neuropathy&rdquo; and the other for &ldquo;the management
        of postherpetic neuralgia&rdquo;.&nbsp;&nbsp;Lidoderm&reg; patch, the only approved topical local anesthetic suffers from poor
        patch adhesion, has shown to have inefficient skin absorption and low efficacy, deficiencies which MepiGel can exploit.&nbsp;&nbsp;MepiGel
        will be used alone or in combination with oral therapies for neuropathic pain such as Lyrica&reg; and Cymbalta&reg;.&nbsp;&nbsp;Management
        anticipates that it will compete with Lidoderm&reg; patch which had 2012 sales of $948M in the U.S. according to Endo Pharmaceuticals
        2012 annual report.</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> We have completed an animal study in rabbits
        to assess the time course of systemic absorption of mepivacaine from several different semi-solid topical gel formulations
        as compared to intravenous mepivacaine. The goal was to assess the absolute bioavailability of the different gels and
        finalize the optimal formulation to move into clinical development. We have identified one that performed at optimal level
        that may be selected to continue to development in humans. We are planning to generate GMP batches required for the Phase
        I portion of the development, file an IND with the FDA and start the Phase I trial with timing based on resources allocation. </P></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"> &nbsp;&nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> We believe that the market for chronic pain will continue
to be large in size for the foreseeable future and that it will represent a sizable revenue opportunity for Relmada. When closer
to the potential FDA approval of our first products, we will work on a marketing strategy appropriate for our resources. To be
competitive with our peers that have larger infrastructures, we will consider strategic agreements with larger companies to co-market
and co-promote some of our drugs in selected markets, both geographically based and focused on defined customer segments. Having
repurposed existing drugs in our portfolio could reduce the resistance of doctors to prescribe our products as they are already
familiar with many of the drug characteristics, only focusing on the potential advantages versus the existing parent drug. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> In addition to our priority drug development
projects, we have an early stage pipeline of product candidates which are briefly described in the business section of this
document. As of now none of our drugs have been approved for sale in the United States or elsewhere. We have no commercial
products nor do we have a sales or marketing infrastructure. In order to market and sell our products we must conduct
clinical trials on patients and obtain regulatory approvals from appropriate regulatory agencies, like the FDA in the United
States, and similar organizations elsewhere in the world. Research and development expense for six months ended June 30, 2014
was approximately $840,000. Research and development expense for the year ended December 31, 2013 and 2012 was approximately
$5,248,700 and $667,500, respectively.&nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 3.3pt"> On May 20, 2014, Relmada Therapeutics, Inc. (&ldquo;Relmada&rdquo;) completed a share exchange with Camp Nine, whereby Camp Nine acquired 94.9% of the issued and outstanding
capital stock of Relmada from the Relmada Stockholders in exchange for the issuance of 28,291,073, shares of Common Stock to the
Relmada Stockholders, which represented 80.9% of our issued and outstanding common stock after the consummation of the Share Exchange.&nbsp;&nbsp;Relmada&rsquo;s
outstanding options and warrants were also exchanged for options and warrants to purchase shares of Common Stock of Camp Nine
at a ratio of 10 to 1. Prior to the Share Exchange, Camp Nine had $2 million in cash, and no other assets or liabilities. As a
result of the Share Exchange, the  Relmada Stockholders became the principal stockholders of Camp Nine. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"> The Share Exchange was accounted
for as a reverse merger rather than a business combination, wherein Relmada is considered the acquirer for accounting and
financial reporting purposes. The statement of operations reflects the activities of Relmada from the commencement of its
operations on May 24, 2004.&nbsp;&nbsp;&nbsp;Unless the context suggests otherwise, when we refer in this prospectus  to
business and financial information for periods prior to the consummation of the Share Exchange, we are referring to the
business and financial information of Relmada. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"> As a result of the
Share Exchange, <FONT STYLE="font-size: 10pt">Relmada the former private company became a subsidiary of Camp Nine and Camp
Nine became the holding company.&nbsp;&nbsp;Effective August 6, 2014, the Financial
Industry Regulatory Authority (FINRA) approved the Company's application for a name change from Camp Nine, Inc. to
Relmada Therapeutics, Inc. and assigned a new trading symbol, RLMD.</FONT> </FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="color: Black"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-size: 10pt; color: Black"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 3.3pt"> Our principal executive offices are located at
546 Fifth Avenue,&nbsp;14th Floor, New York, NY 10036 and our telephone number is (212) 702-7163. Our website address is<I> www.relmada.com</I>.
The information contained therein or connected thereto shall not be deemed to be incorporated into this prospectus or the registration
statement of which it forms a part. The information on our website is not part of this prospectus.&nbsp; &nbsp;</P>

</DIV>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 3.3pt"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding: 12pt 5; border: Black 1.5pt solid; width: 100%">

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 3.3pt">&nbsp;&nbsp;<B>THE OFFERING</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 28%; line-height: normal"><B>Common stock offered by selling stockholders</B></TD>
    <TD STYLE="width: 1%; line-height: normal">&nbsp;</TD>
    <TD STYLE="width: 71%; line-height: normal"><P STYLE="margin: 0"> 32,617,220 shares of our common stock including: up to
                                         (i) 2,762,504 shares of our common stock issuable upon exercise of Series A Preferred
                                         and Notes Warrants held by the selling stockholders named in this prospectus at an exercise
                                         price of $0.80 per share;; (ii) 17,163,799 shares of our common stock issuable upon exercise
                                         of Series A Warrants held by the selling stockholders named in this prospectus at an
                                         exercise price of $1.50 per share; and (iii) 8,581,899 shares of our common stock issuable
                                         upon exercise of Series B Warrants held by the selling stockholders named in this prospectus
                                         at an exercise price of $2.25 per share. </P>


</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"><B>Common stock outstanding before the offering</B></TD>
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">40,294,226 shares of common stock (1)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"><B>Common stock outstanding after the offering</B></TD>
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><P STYLE="margin: 0"> 68,802,428 shares of common stock (2) </P>


</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"><B>Use of proceeds</B></TD>
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">We will not receive any proceeds from the sale of the common stock by the selling stockholders. However, we may receive up to approximately $47,291,672 million in the aggregate upon the exercise of warrants listed in this prospectus if the holders exercise them for cash. The registration of common stock pursuant to this prospectus does not necessarily mean that any of those shares will ultimately be offered or sold by the selling stockholders. We intend to use the proceeds, if any, received from any cash exercise of the warrants for working capital and general corporate purposes.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"><B>Trading Symbol</B></TD>
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"> RLMD </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"><B>Risk Factors</B></TD>
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">The common stock offered hereby involves a high degree of risk and should not be purchased by investors who cannot afford the loss of their entire investment. See &ldquo;Risk Factors&rdquo;.</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; line-height: normal"> &nbsp; </TD>
    <TD STYLE="width: 4%; line-height: normal"> (1) </TD>
    <TD STYLE="width: 92%; line-height: normal"> Based upon the total number of issued and outstanding shares as
    of&nbsp;September 8,     2014. </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; line-height: normal"> &nbsp; </TD>
    <TD STYLE="width: 4%; line-height: normal"> (2) </TD>
    <TD STYLE="width: 92%; line-height: normal"><P STYLE="margin: 0"> Based upon the total number of issued and outstanding
                                         shares as of&nbsp;September 8, 2014, and including (i) 2,762,504 shares of our common
                                         stock issuable upon exercise of Series A Preferred and Notes Warrants held by the selling
                                         stockholders named in this prospectus at an exercise price of $0.80 per share; ( (ii)
                                         17,163,799 shares of our common stock issuable upon exercise of Series A Warrants held
                                         by the selling stockholders named in this prospectus at an exercise price of $1.50 per
                                         share; and (iii) 8,581,899 shares of our common stock issuable upon exercise of Series
                                         B Warrants held by the selling stockholders named in this prospectus at an exercise price
                                         of $2.25 per share. </P>


</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_002"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I>An investment in our common stock involves a high degree
of risk. You should carefully consider the risks described below, together with all of the other information included in this Registration
Statement, before making an investment decision. If any of the following risks actually occurs, our business, financial condition
or results of operations could suffer. In that case, the trading price of our shares of common stock could decline and you may
lose all or part of your investment. See &ldquo;Cautionary Note Regarding Forward Looking Statements&rdquo; above for a discussion
of forward-looking statements and the significance of such statements in the context of this Registration Statement.</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Risk Related to Our Business </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Our product candidates are in early stages of clinical
testing.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our product candidates are still in the early stages of clinical
testing.&nbsp;&nbsp;None has gone beyond the Phase I/Phase IIa stage and FDA approval requires that a drug candidate complete a
Phase III study program, to test the safety and efficacy of the drug candidate on a large sample of patients.&nbsp;&nbsp;The timeline
between a Phase I study and a Phase III study and subsequent filing of a New Drug Application can be several years. We will need
to commit substantial time and additional resources to conducting further nonclinical studies and clinical trials before we can
submit an NDA with respect to any of these product candidates. We cannot predict with any certainty if or when we might submit
an NDA for regulatory approval of any of our product candidates.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We have generated no revenue from commercial sales
to date and our future profitability is uncertain.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We have a limited operating history and our business is subject
to all of the risks inherent in the establishment of a new business enterprise. Our likelihood of success must be considered in
light of the problems, expenses, difficulties, complications and delays frequently encountered in connection with this. Since we
began our business, we have focused on research, development and clinical trials of product candidates, and have incurred significant
losses since inception and generated no product revenues. If we continue to incur operating losses and fail to become a profitable
company, we may be unable to continue our operations. We expect to continue to operate at a net loss for at least the next several
years as we continue our research and development efforts, continue to conduct clinical trials and develop manufacturing, sales,
marketing and distribution capabilities. There can be no assurance that the products under development by us will be approved for
sales in the US or elsewhere. Furthermore, there can be no assurance that if such products are approved they will be successfully
commercialized, and the extent of our future losses and the timing of our profitability are highly uncertain.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>International commercialization of our product candidates
faces significant obstacles.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We may plan to commercialize some of our products internationally
through collaborative relationships with foreign partners. We have limited foreign regulatory, clinical and commercial resources.
Future partners are critical to our international success. We may not be able to enter into collaboration agreements with appropriate
partners for important foreign markets on acceptable terms, or at all. Future collaborations with foreign partners may not be effective
or profitable for us. We will need to obtain approvals from the appropriate regulatory, pricing and reimbursement authorities to
market any of our proposed products internationally, and we may be unable to obtain foreign regulatory approvals. Pursuing foreign
regulatory approvals will be time-consuming and expensive. The regulations can vary among countries and foreign regulatory authorities
may require different or additional clinical trials than we conducted to obtain FDA approval for our product candidates. In addition,
adverse clinical trial results, such as death or injury due to side effects, could jeopardize not only regulatory approval, but
if approval is granted, may also lead to marketing restrictions. Our product candidates may also face foreign regulatory requirements
applicable to controlled substances.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We need to raise additional capital to operate our
business</I></B><I>.</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> We are a company focused on product development and have
not generated any product revenues to date. Until, and if, we receive approval from the FDA and other regulatory authorities for
our product candidates, we cannot sell our drugs and will not have product revenues.&nbsp;&nbsp;Therefore, for the foreseeable
future, we will have to fund all of our operations and capital expenditures from the net proceeds of the Offering and future offerings
and grants.&nbsp;&nbsp;We expect that the net proceeds from the recent offering of approximately $22,229,300 and $2,000,000 from
principal shareholders of Camp Nine, Inc. will be sufficient to meet our working capital needs at least until the fourth calendar
quarter of 2015. &nbsp; Our actual capital requirements will depend on many factors. If we experience unanticipated cash requirements,
we may need to seek additional sources of financing, which may not be available on favorable terms, if at all. If we do not succeed
in raising additional funds on acceptable terms, we may be unable to complete planned nonclinical studies and clinical trials
or obtain approval of our product candidates from the FDA and other regulatory authorities. In addition, we could be forced to
discontinue product development, reduce or forego sales and marketing efforts and attractive business opportunities, or discontinue
operations. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We have a history of losses and we may never achieve
or sustain profitability.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> We have incurred substantial losses since our
inception, and we may not achieve profitability for the foreseeable future, if at all. We incurred a net loss of
approximately $55,318,600 since inception through June 30, 2014, which includes non-cash expenses of approximately
$41,868,700. The Company has cash and cash equivalents of approximately $25,564,400 at June 30, 2014. Even if we succeed in
developing and commercializing one or more of our product candidates, we expect to incur substantial net losses and negative
cash flows for the foreseeable future due in part to increasing research and development expenses, including clinical trials,
and increasing expenses from leasing additional facilities and hiring additional personnel. As a result, we will need to
generate significant revenues in order to achieve and maintain profitability. We may not be able to generate these revenues
or achieve profitability in the future. Even if we do achieve profitability, we may not be able to sustain or increase
profitability. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We have a limited operating history upon which to base
an investment decision.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our limited operating history may limit your ability to evaluate
our prospects due to our limited historical financial data and our unproven potential to generate profits.&nbsp;&nbsp;You should
evaluate the likelihood of financial and operational success in light of the risks, uncertainties, expenses and difficulties associated
with an early-stage business, many of which may be beyond our control, including:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: normal">&nbsp;</TD>
    <TD STYLE="width: 4%; line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="width: 93%; line-height: normal">our potential inability to continue to undertake nonclinical studies, pharmaceutical development and clinical trials,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal">our potential inability to obtain regulatory approvals, and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="line-height: normal"> our potential inability to manufacture, sell and market our products. </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our operations have been limited to organizing and staffing,
on a limited basis, our company, acquiring, developing and securing our proprietary technology and undertaking nonclinical studies
and early stage clinical trials of our principal product candidates.&nbsp;&nbsp;These operations provide a limited basis for you
to assess our ability to commercialize our product candidates and the advisability of investing in our common stock.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>If we fail to obtain the capital necessary to fund
our operations, we will be unable to continue or complete our product development and you will likely lose your entire investment.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The net proceeds from the latest Offerings will not
be sufficient to capitalize the development and commercialization of LevoCap ER and we will need to continue to seek capital
from time to time to continue the development beyond the initial Phase I and II clinical trials and to acquire and develop
other product candidates. Our first product is not expected to be commercialized until at least 2018 and the revenues it will
generate may not be sufficient to fund our ongoing operations. The Company believes that with current cash on hand it will be
able to fund the Company&rsquo;s operations until the fourth calendar quarter of 2015. Accordingly, we believe that we will
need to raise substantial additional capital to fund our continuing operations and the development and commercialization of
our product candidates in or before the second half of 2015. Our business or operations may change in a manner that would
consume available funds more rapidly than anticipated and substantial additional funding may be required to maintain
operations, fund expansion, develop new or enhanced products, acquire complementary products, business or technologies or
otherwise respond to competitive pressures and opportunities, such as a change in the regulatory environment or a change in
preferred pain treatment modalities. In addition, we may need to accelerate the growth of our sales capabilities and
distribution beyond what is currently envisioned and this would require additional capital. However, we may not be able to
secure funding when we need it or on favorable terms. If we cannot raise adequate funds to satisfy our capital requirements,
we will have to delay, scale-back or eliminate our research and development activities, clinical studies or
future operations. We may also be required to obtain funds through arrangements with collaborators, which arrangements may
require us to relinquish rights to certain technologies or products that we otherwise would not consider relinquishing,
including rights to future product candidates or certain major geographic markets. We may further have to license our
technology to others. This could result in sharing revenues which we might otherwise retain for ourselves. Any of these
actions may harm our business, financial condition and results of operations. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The amount of capital we may need depends on many factors,
including the progress, timing and scope of our product development programs; the progress, timing and scope of our nonclinical
studies and clinical trials; the time and cost necessary to obtain regulatory approvals; the time and cost necessary to further
develop manufacturing processes and arrange for contract manufacturing; our ability to enter into and maintain collaborative, licensing
and other commercial relationships; and our partners&rsquo; commitment of time and resource to the development and commercialization
of our products.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We have limited access to the capital markets and even
if we can raise additional funding, we may be required to do so on terms that are dilutive to you.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> We have limited access to the capital markets to raise
capital. The capital markets have been unpredictable in the recent past for other pain companies and unprofitable companies such
as ours. In addition, it is generally difficult for companies to raise capital under current market conditions. The amount of
capital that a company such as ours is able to raise often depends on variables that are beyond our control. As a result, we may
not be able to secure financing on terms attractive to us, or at all. If we are able to consummate a financing arrangement, the
amount raised may not be sufficient to meet our future needs. If adequate funds are not available on acceptable terms, or at all,
our business, results of operations, financial condition and our continued viability will be materially adversely affected. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Risks Related to Clinical and Regulatory Matters</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>If we or our potential collaborators fail to obtain
the necessary regulatory approvals, or if such approvals are limited, we and our potential collaborators will not be allowed to
commercialize our drug candidates, and we will not generate product revenues.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Satisfaction of all regulatory requirements for commercialization

of a drug candidate typically takes many years, is dependent upon the type, complexity and novelty of the drug candidate, and requires
the expenditure of substantial resources for research and development.&nbsp;&nbsp;Our research and clinical approaches may not
lead to drugs that the FDA considers safe for humans and effective for indicated uses we are studying. The FDA may require additional
studies, in which case we or our collaborators would have to expend additional time and resources and would likely delay the date
of potentially receiving regulatory approval. The approval process may also be delayed by changes in government regulation, future
legislation or administrative action or changes in FDA policy that occur prior to or during our regulatory review. Delays in obtaining
regulatory approvals would:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: normal">&nbsp;</TD>
    <TD STYLE="width: 4%; line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="width: 93%; line-height: normal">delay commercialization of, and product revenues from, our drug candidates; and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal">diminish the competitive advantages that we may have otherwise enjoyed, which would have an adverse effect on our operating results and financial condition.</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Even if we or our collaborators comply with all FDA regulatory
requirements, our drug candidates may never obtain regulatory approval.&nbsp;&nbsp;If we or our collaborators fail to obtain regulatory
approval for any of our drug candidates we will have fewer commercial products, if any, and corresponding lower product revenues,
if any. Even if our drug candidates receive regulatory approval, such approval may involve limitations on the indications and conditions
of use or marketing claims for our products. Further, later discovery of previously unknown problems or adverse events could result
in additional regulatory restrictions, including withdrawal of products.&nbsp;&nbsp;The FDA may also require us or our collaborators
to commit to perform lengthy Phase IV post-approval clinical efficacy or safety studies. Our expending additional resources on
such trials would have an adverse effect on our operating results and financial condition.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">In jurisdictions outside the United States, we or our collaborators
must receive marketing authorizations from the appropriate regulatory authorities before commercializing our drugs. Regulatory
approval processes outside the United States generally include all of the aforementioned requirements and risks associated with
FDA approval.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>If we or our collaborators are unable to design, conduct
and complete clinical trials successfully, our drug candidates will not be able to receive regulatory approval.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">In order to obtain FDA approval for any of our drug candidates,
we or our collaborators must submit to the FDA an NDA that demonstrates with substantive evidence that the drug candidate is both
safe and effective in humans for its intended use.&nbsp;&nbsp;This demonstration requires significant research and animal tests,
which are referred to as preclinical studies, as well as human tests, which are referred to as clinical trials.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Results from Phase I clinical programs may not support moving
a drug candidate to Phase II or Phase III clinical trials. Phase III clinical trials may not demonstrate the safety or efficacy
of our drug candidates.&nbsp;&nbsp;Success in preclinical studies and early clinical trials does not ensure that later clinical
trials will be successful.&nbsp;&nbsp;Results of later clinical trials may not replicate the results of prior clinical trials and
preclinical studies.&nbsp;&nbsp;Even if the results of Phase III clinical trials are positive, we or our collaborators may have
to commit substantial time and additional resources to conducting further preclinical studies and clinical trials before obtaining
FDA approval for any of our drug candidates.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Clinical trials are very expensive and difficult to design
and implement, in part because they are subject to rigorous requirements.&nbsp;&nbsp;The clinical trial process also consumes a
significant amount of time. Furthermore, if participating patients in clinical trials suffer drug-related adverse reactions during
the course of such clinical trials, or if we, our collaborators or the FDA believe that participating patients are being exposed
to unacceptable health risks, such clinical trials will have to be suspended or terminated. Failure can occur at any stage of the
clinical trials, and we or our collaborators could encounter problems that cause abandonment or repetition of clinical trials.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our clinical trials and our future clinical trials for other
drug candidates for treatment of pain measure clinical symptoms, such as pain and physical dependence that are not biologically
measurable. The success in clinical trials and our other drug candidates designed to reduce risks of unintended use depends on
reaching statistically significant changes in patients&rsquo; symptoms based on clinician-rated scales. Due in part to a lack of
consensus on standardized processes for assessing clinical outcomes, these scores may or may not be reliable, useful or acceptable
to regulatory agencies.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We have no history of developing drug candidates. We do not
know whether any of our planned clinical trials will result in marketable drugs.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">In addition, completion of clinical trials can be delayed
by numerous factors, including:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: normal">&nbsp;</TD>
    <TD STYLE="width: 4%; line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="width: 93%; line-height: normal">delays in identifying and agreeing on acceptable terms with prospective clinical trial sites;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal">slower than expected rates of patient recruitment and enrollment;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="line-height: normal"> unanticipated patient dropout rates; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="line-height: normal"> increases in time required to complete monitoring of patients during or after participation
    in a clinical trial; and </TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="line-height: normal"> unexpected need for additional patient-related data. </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Any of these delays could significantly impact the timing,
approval and commercialization of our drug candidates and could significantly increase our overall costs of drug development.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Even if clinical trials are completed as planned, their results
may not support expectations or intended marketing claims.&nbsp;&nbsp;The clinical trials process may fail to demonstrate that
our drug candidates are safe and effective for indicated uses.&nbsp;&nbsp;Such failure would cause us to abandon a drug candidate
and could delay development of other drug candidates.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>With respect to the Phase III clinical trial, these
discussions are not binding obligations on the part of regulatory authorities.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Regulatory authorities may revise previous guidance or decide
to ignore previous guidance at any time during the course of our clinical activities or after the completion of our clinical trials.
Even with successful clinical safety and efficacy data, including such data from a clinical trial conducted pursuant to an SPA,
we or our collaborators may be required to conduct additional, expensive clinical trials to obtain regulatory approval.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Developments by competitors may establish standards
of care that affect our ability to conduct our clinical trials as planned.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Changes in standards related to clinical trial design could
affect our ability to design and conduct clinical trials as planned. For example, regulatory authorities may not allow us to compare
our drug candidates to placebo in a particular clinical indication where approved products are available. In that case, both the
cost and the amount of time required to conduct a clinical trial could increase.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>The DEA limits the availability of the active ingredients
in certain of our current drug candidates and, as a result, quotas for these ingredients may not be sufficient to complete clinical
trials, or to meet commercial demand or may result in clinical delays.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The U.S. Drug Enforcement Administration, or DEA, regulates
chemical compounds as Schedule I, II, III, IV or V substances, with Schedule I substances considered to present the highest risk
of substance abuse and Schedule V substances the lowest risk.&nbsp;&nbsp;Certain active ingredients in our current drug candidates,
such as oxycodone, are listed by the DEA as Schedule II under the Controlled Substances Act of 1970. Consequently, their manufacture,
research, shipment, storage, sale and use are subject to a high degree of oversight and regulation. For example, all Schedule II
drug prescriptions must be signed by a physician, physically presented to a pharmacist and may not be refilled without a new prescription.&nbsp;&nbsp;Furthermore,
the amount of Schedule II substances that can be obtained for clinical trials and commercial distribution is limited by the DEA
and quotas for these substances may not be sufficient to complete clinical trials or meet commercial demand.&nbsp;&nbsp;There is
a risk that DEA regulations may interfere with the supply of the drugs used in clinical trials for our product candidates, and,
in the future, the ability to produce and distribute our products in the volume needed to meet commercial demand.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Conducting clinical trials of our drug candidates or
commercial sales of a drug candidate may expose us to expensive product liability claims and we may not be able to maintain product
liability insurance on reasonable terms or at all.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The risk of product liability is inherent in the testing
of pharmaceutical products. If we cannot successfully defend ourselves against product liability claims, we may incur substantial
liabilities or be required to limit or terminate testing of one or more of our drug candidates.&nbsp;&nbsp;Our inability to obtain
sufficient product liability insurance at an acceptable cost to protect against product liability claims could prevent or inhibit
the commercialization of our drug candidates. We currently carry clinical trial insurance but do not carry product liability insurance.&nbsp;&nbsp;If
we successfully commercialize one or more of our drug candidates, we may face product liability claims, regardless of FDA approval
for commercial manufacturing and sale. We may not be able to obtain such insurance at a reasonable cost, if at all.&nbsp;&nbsp;Even
if our agreements with any current or future corporate collaborators entitle us to indemnification against product liability losses,
such indemnification may not be available or adequate should any claim arise.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>If our drug candidates receive regulatory approval,
we and our collaborators will also be subject to ongoing FDA obligations and continued regulatory review, such as continued safety
reporting requirements, and we and our collaborators may also be subject to additional FDA post-marketing obligations or new regulations,
all of which may result in significant expense and limit our and our collaborators&rsquo; ability to commercialize our drugs.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Any regulatory approvals that our drug candidates receive
may also be subject to limitations on the indicated uses for which the drug may be marketed or contain requirements for y costly
post-marketing follow-up studies. In addition, if the FDA approves any of our drug candidates, the labeling, packaging, adverse
event reporting, storage, advertising, promotion and record keeping for the drug will be subject to extensive regulatory requirements.
The subsequent discovery of previously unknown problems with the drug, including but not limited to adverse events of unanticipated
severity or frequency, or the discovery that adverse events previously observed in preclinical research or clinical trials that
were believed to be minor actually constitute much more serious problems, may result in restrictions on the marketing of the drug,
and could include withdrawal of the drug from the market.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The FDA&rsquo;s policies may change and additional government
regulations may be enacted that could prevent or delay regulatory approval of our drug candidates. For example, on July&nbsp;9,
2012, the FDA approved a risk management program, known as a Risk Evaluation and Mitigation Strategy, or REMS, for extended-release
and long-acting opioid analgesics, or ER/LA opioid analgesics.&nbsp;&nbsp;This REMS will require companies affected by the REMS
to make available training for health care professionals who prescribe ER/LA opioid analgesics on proper prescribing practices
and also to distribute educational materials to prescribers and patients on the safe use of ER/LA opioid analgesics.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We cannot predict the likelihood, nature or extent of adverse
government regulation that may arise from future legislation or administrative action, either in the United States or abroad.&nbsp;&nbsp;If
we are not able to maintain regulatory compliance, we may be subject to fines, suspension or withdrawal of regulatory approvals,
product recalls, seizure of products, operating restrictions and criminal prosecution.&nbsp;&nbsp;Any of these events could prevent
us from marketing our drugs and our business could suffer drug candidates and we will not become competitive with our drug candidates
being developed.&nbsp;&nbsp;If time and resources devoted are limited or there is a failure to fund the continued development other
opioid drug candidates or there is otherwise a failure to perform as we expect, we may not achieve clinical and regulatory milestones
and regulatory submissions and related product introductions may be delayed or prevented, and revenues that we would receive from
these activities will be less than expected.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We may depend on independent investigators and collaborators,
such as universities and medical institutions, to conduct our clinical trials under agreements with us. These investigators and
collaborators are not our employees and we cannot control the amount or timing of resources that they devote to our programs. They
may not assign as great a priority to our programs or pursue them as diligently as we would if we were undertaking such activities
ourselves. If these investigators or collaborators fail to devote sufficient time and resources to our drug development programs,
or if their performance is substandard, the approval of our regulatory submissions and our introductions of new drugs will be delayed
or prevented.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our potential collaborators may also have relationships with
other commercial entities, some of which may compete with us. If outside collaborators assist our competitors to our detriment,
the approval of our regulatory submissions will be delayed and the sales from our products, if any are commercialized, will be
less than expected.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We may not succeed at in-licensing drug candidates
or technologies to expand our product pipeline.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We may not successfully in-license drug candidates or technologies
to expand our product pipeline. The number of such candidates and technologies is limited. Competition among large pharmaceutical
companies and biopharmaceutical companies for promising drug candidates and technologies is intense because such companies generally
desire to expand their product pipelines through in-licensing.&nbsp;&nbsp;If we fail to carry out such in-licensing and expand
our product pipeline, our potential future revenues may suffer.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>If we fail to obtain or maintain necessary U.S. Food
and Drug Administration clearances for our pain therapy products, or if such clearances are delayed, we will be unable to commercially
distribute and market our products.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our products are subject to rigorous regulation by the FDA
and numerous other federal, state and foreign governmental authorities.&nbsp;&nbsp;The process of seeking regulatory clearance
or approval to market a pain therapy product, in particular a controlled substance is expensive and time consuming and, notwithstanding
the effort and expense incurred, clearance or approval is never guaranteed. If we are not successful in obtaining timely clearance
or approval of our products from the FDA, we may never be able to generate significant revenue and may be forced to cease operations.&nbsp;&nbsp;In
particular, the FDA permits commercial distribution of a new pain therapy product only after the product has received approval
of a New Drug Application (&ldquo;NDA&rdquo;) filed with the FDA pursuant to<B> &nbsp;</B> 21 C.F.R. &sect; 314, seeking permission
to market the product in interstate commerce in the United States. The NDA process is costly, lengthy and uncertain.&nbsp;&nbsp;Any
NDA application filed by the Company will have to be supported by extensive data, including, but not limited to, technical, nonclinical,
clinical trial, manufacturing and labeling data, to demonstrate to the FDA&rsquo;s satisfaction the safety and efficacy of the
product for its intended use.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Obtaining clearances or approvals from the FDA and from the
regulatory agencies in other countries could result in unexpected and significant costs for us and consume management&rsquo;s time
and other resources. The FDA and other agencies could ask us to supplement our submissions, collect non-clinical data, conduct
additional clinical trials or engage in other time-consuming actions, or they could simply deny our applications. In addition,
even if we obtain an NDA approval or pre-market approvals in other countries, the approval could be revoked or other restrictions
imposed if post-market data demonstrates safety issues or lack of effectiveness. We cannot predict with certainty how, or when,
the FDA will act. If we are unable to obtain the necessary regulatory approvals, our financial condition and cash flow may be adversely
affected, and our ability to grow domestically and internationally may be limited.&nbsp;&nbsp;Additionally, even if cleared or
approved, the Company&rsquo;s products may not be approved for the specific indications that are most necessary or desirable for
successful commercialization or profitability.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Our clinical trials may fail to demonstrate adequately
the safety and efficacy of our product candidates, which could prevent or delay regulatory approval and commercialization.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Before obtaining regulatory approvals for the commercial
sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive nonclinical testing and clinical
trials that the product is both safe and effective for use in each target indication.&nbsp;&nbsp;Clinical trial results from the
study of chronic pain (e.g., osteoarthritis and chronic low back pain) and neuropathic pain (e.g., painful diabetic neuropathy,
postherpetic neuralgia and painful HIV-associated neuropathy) are inherently difficult to predict.&nbsp;&nbsp;The primary measure
of pain is subjective and can be influenced by factors outside of our control, and can vary widely from day to day for a particular
patient, and from patient to patient and site to site within a clinical study. The results we have obtained in completed animal
studies or we have observed in published clinical trials conducted by third parties of other dosage forms of the same drug (e.g.,
sublingual, immediate release oral, parenteral) may not be predictive of results from our future clinical trials. Additionally,
we may suffer significant setbacks in advanced clinical trials, even after promising results in earlier studies.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We cannot predict whether regulatory agencies will
determine that the data from our clinical trials support marketing approval.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The FDA&rsquo;s and other regulatory agencies&rsquo; decision
to approve our analgesic product candidates will depend on our ability to demonstrate with substantial clinical evidence through
well-controlled clinical trials, that the product candidates are effective, as measured statistically by comparing the overall
improvement in pain in actively-treated patients against improvement in pain in the control group (usually a placebo control).&nbsp;&nbsp;However,
there is a possibility that our data may fail to show a statistically significant difference from the placebo-control or the active
control. Alternatively, there is a possibility that our data may be statistically significant, but that the actual clinical benefit
of the product candidates may not be considered to be clinically significant, clinically relevant or clinically meaningful.&nbsp;&nbsp;Consequently,
we believe that the FDA may consider additional data, such as a &ldquo;responder&rdquo; analysis, secondary efficacy endpoints
and even safety when evaluating whether our product can be approved. We believe that the FDA views &ldquo;responders&rdquo; as
patients who experience at least a 30% reduction in overall pain.&nbsp;&nbsp;We cannot predict whether the regulatory agencies
will find that our clinical trial results provide compelling &ldquo;responder&rdquo; or other secondary endpoint data.&nbsp;&nbsp;Even
if we believe that the data from our trials will support marketing approval in the United States or in Europe, we cannot predict
whether the agencies will agree with our analysis and approve our applications.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We may need to focus our future efforts in new therapeutic
areas where we have little or no experience.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Although our primary strategic interest is in the area of
pain management, a number of our products have potential efficacy in other therapeutic areas such as addition. If our drug development
efforts in pain management fail, or if the competitive landscape or investment climate for analgesic dug development is less attractive,
we may need to change the company&rsquo;s strategic focus to include development of our product candidates or of newly acquired
product candidates for therapeutic areas other than pain.&nbsp;&nbsp;We have very limited drug development experience in other
therapeutic areas and we may be unsuccessful in making this change from a pain management company to a company with a focus in
areas other than pain or a company with a focus in multiple therapeutic areas including pain.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Our product candidates contain controlled substances,
the supply of which may be limited by U.S. government policy and the use of which may generate public controversy.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The active ingredients in our current product candidates,
including levorphanol, buprenorphine and d-methadone are listed by the DEA, as &ldquo;Controlled Substances&rdquo; or schedule
substances, under the Controlled Substances Act of 1970. The DEA regulates chemical compounds as Schedule I, II, III, IV or V
substances, with Schedule I substances considered to present the highest risk of substance abuse and Schedule V substances the
lowest risk.&nbsp;&nbsp;These product candidates are subject to DEA regulations relating to manufacturing, storage, distribution
and physician prescription procedures.&nbsp;&nbsp;For example, all regular Schedule II drug prescriptions must be signed by a
physician and may not be refilled. </P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Some of our drug products (e.g., buprenorphine, REL-1041)
have a less restrictive controlled substance schedule (i.e., within the Schedule III to V range) than Schedule II drugs. According
to the DEA, Schedule V drugs have lower abuse potential than Schedule II, III and IV drugs, Schedule IV drugs have lower abuse
potential than Schedule II and III drugs and Schedule III drugs have lower abuse potential than Schedule II.&nbsp;&nbsp;However,
despite the foregoing reduced risk of abuse from Schedule III, IV and V drugs, when compared to Schedule II drugs, there is no
assurance that such reduced risk can be demonstrated in well controlled non-clinical and/or clinical studies in models of physical
dependence, psychic dependence, addiction or precipitated withdrawal, or in studies of addiction or abuse liability in opioid addicts,
opioid ex-addicts or recreational drug users.&nbsp;&nbsp;In the event that a reduced risk of abuse from Schedule III, IV and V
drugs, when compared to Schedule II drugs is demonstrated in well controlled non-clinical and/or clinical studies, there is no
assurance that the FDA will agree to incorporation of such favorable language in the products prescribing information.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our LevoCap ER is a Schedule II drug in an abuse resistant,
abuse deterrent or tamper resistant dosage form. Although the dosage form is referred to as abuse resistant, abuse deterrent or
tamper resistant, a determined or persistent abuser can defeat, wholly or partially, the tamper resistance within the dosage form.
In addition, opioid addicts and recreational opioid users can over time find new methods to defeat the tamper resistance mechanism
within the dosage form.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Although our LevoCap ER is a tamper resistant dosage form,
we may elect to not seek specific language in the prescribing information to describe this feature in order to reduce the amount
of data required for our NDA, the time required to file the NDA and/or the probability of a protracted review process. The absence
of such language in the prescribing information may reduce the commercial value of the product.&nbsp;&nbsp;Even if we do seek specific
language in the prescribing information to describe the tamper resistance feature, there is no assurance that FDA will agree to
any such language.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Products containing controlled substances may generate public
controversy. Opponents of these products may seek restrictions on marketing and withdrawal of any regulatory approvals.&nbsp;&nbsp;In
addition, these opponents may seek to generate negative publicity in an effort to persuade the medical community to reject these
products.&nbsp;&nbsp;Political pressures and adverse publicity could lead to delays in, and increased expenses for, and limit or
restrict the introduction and marketing of our product candidates.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Failure to comply with the Drug Enforcement Administration
regulations, or the cost of compliance with these regulations, may adversely affect our business.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> A number of our products are opioids and subject to extensive
regulation by the DEA, due to their status as controlled substances or scheduled drugs. Although d-methadone is substantially
devoid of opioid activity, the DEA may elect to designate it as a controlled substance falling under a Schedule, up to the Schedule
II [C-II]. Any level of DEA scheduling for d-methadone, particularly Schedule II, III or IV, would substantially reduce commercial
interest in d-methadone. Additionally, d-methadone is produced by separation from racemic methadone, a scheduled drug subject
to extensive regulation by the DEA. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The manufacture, shipment, storage, sale and use of controlled
substances are subject to a high degree of regulation, including security, record-keeping and reporting obligations enforced by
the DEA.&nbsp;&nbsp;For example, all Schedule II drug prescriptions must be signed by a physician, physically presented to a pharmacist
and may not be refilled.&nbsp;&nbsp;This high degree of regulation can result in significant costs in order to comply with the
required regulations, which may have an adverse effect on the development and commercialization of our product candidates.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The DEA limits the availability and production of all scheduled
substances, including our product candidates, through a quota system.&nbsp;&nbsp;The DEA requires substantial evidence and documentation
of expected legitimate medical and scientific needs before assigning quotas to manufacturers.&nbsp;&nbsp;In future years, we may
need greater amounts of controlled substances to sustain our Phase III development program, and we will need significantly greater
amounts to implement our commercialization plans if the FDA approves our proposed formulations.&nbsp;&nbsp;Any delay or refusal
by the DEA in establishing the procurement quota or a reduction in our quota for scheduled controlled substances or a failure to
increase it over time as we anticipate could delay or stop the clinical development or commercial sale of some of our products
or product candidates. This could have a material adverse effect on our business, results of operations, financial condition and
prospects.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Some of our products for clinical trials are manufactured
outside the United States including Schedule II controlled substances.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Drug Enforcement Administration regulations require Scheduled
II controlled substances to be manufactured in the United States if the products are to be marketed in the United States. There
is no guarantee that we will secure a commercial supply agreement with a manufacturer based in the United States.&nbsp;&nbsp;Switching
or adding commercial manufacturing capability can involve substantial cost and require extensive management time and focus, as
well as additional regulatory filings. In addition, there is a natural transition period when a new manufacturing facility commences
work. As a result, delays may occur, which can materially impact our ability to meet our desired commercial timelines, thereby
increasing our costs and reducing our ability to generate revenue.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The facilities of any of our future manufacturers of controlled
substances must be approved by the FDA after we submit our NDA and before approval. We are dependent on the continued adherence
of third party manufacturers to GMP manufacturing and acceptable changes to their process. If our manufacturers cannot successfully
produce material that conforms to our specifications and the FDA's strict regulatory requirements, they will not be able to secure
FDA approval for their manufacturing facilities.&nbsp;&nbsp;If the FDA does not approve these facilities for the commercial manufacture,
we will need to find alternative suppliers, which would result in significant delays in obtaining FDA approvals. These challenges
may have a material adverse impact on our business, results of operations, financial condition and prospects.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left"> We manufacture some products outside
the United States for development and to conduct human clinical studies either in the US or outside the US. These products are
for development purposes only, and not for commercial manufacturing. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>If the supplier of active pharmaceutical ingredient
(API) or pharmaceutical excipient fails to provide us sufficient quantities, we may not be able to obtain an alternative supply
on a timely or acceptable basis.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"> We currently
rely on a single source for our supply of levorphanol. There are presently no alternative sources of pharmaceutical grade levorphanol.
We may also not be able to find alternative suppliers in a timely manner that would provide levorphanol at acceptable quantities
and prices. Any interruption in the supply of levorphanol would disrupt our ability to manufacture LevoCap ER and could have a
material adverse effect on our business. Currently this single source supplies the API for research and development purposes only.
There is no material agreement for commercial supply at this time. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left">Our pharmaceutical excipients and
other API&rsquo;s are multisource, although not all sources have an active Drug Master File (DMF) with the FDA. (A DMF is a submission
to the FDA used to provide confidential detailed information about facilities, processes, or articles used in the manufacturing,
processing, packaging, and storing of drugs to support a drug development and approval). In addition, some of the countries for
our multisource APIs are not the same as our drug manufacturing locations. Thus, any disruption in supply from our preferred vendor
could result in significant delays with our pharmaceutical development, clinical trials, NDA filing, NDA approval or commercial
sale of the finished product due to contract delays, the need to manufacture a new batch of API, out of specification API, the
need for import and export permits, and the failure of the newly sourced API to perform to the standards of the previously sourced
API.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Our pain product candidates are
in the early stages of development and we have not demonstrated that any of our products can actually treat pain.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Adverse or inconclusive results from pre-clinical testing
or clinical trials of product candidates may substantially delay, or halt entirely, any further development of one or more of our
products. The projected timetables for continued development of the technologies and related product candidates by us may otherwise
be subject to delay or suspension.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Modifications to our products may require new NDA approvals.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Once a particular company product receives FDA approval
or clearance, expanded uses or uses in new indications of our products may require additional human clinical trials and new regulatory
approvals or clearances, including additional IND and NDA submissions and premarket approvals before we can begin clinical development,
and/or prior to marketing and sales.&nbsp;&nbsp;If the FDA requires new clearances or approvals for a particular use or indication,
we may be required to conduct additional clinical studies, which would require additional expenditures and harm our operating
results.&nbsp;&nbsp;If the products are already being used for these new indications, we may also be subject to significant enforcement
actions. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Conducting clinical trials and obtaining clearances and approvals
can be a time consuming process, and delays in obtaining required future clearances or approvals could adversely affect our ability
to introduce new or enhanced products in a timely manner, which in turn would harm our future growth.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>There is no guarantee that the FDA will grant NDA approval
of our future products and failure to obtain necessary clearances or approvals for our future products would adversely affect our
ability to grow our business.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We are currently preparing to conduct several Phase I/II
clinical trials for our drug candidates and in the future expect to submit NDAs to the FDA for approval of these products. We are
in the early stages of evaluating other drug candidates in the field of pain therapy.&nbsp;&nbsp;These products would also require
FDA approval of an NDA. The FDA may not approve or clear these products for the indications that are necessary or desirable for
successful commercialization. Indeed, the FDA may refuse our requests for NDA market approval of new products, new intended uses
or indications to existing or future products. Failure to receive approval for our new products would have an adverse effect on
our ability to expand our business.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We have no manufacturing capabilities and depend on
other parties for our manufacturing operations. If these manufacturers fail to meet our requirements and strict regulatory requirements,
our product development and commercialization efforts may be materially harmed.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We currently depend on contract manufacturers. We plan to
enter into long term commercial supply agreements for our product candidates. If any manufacturer is unable to produce required
quantities on a timely basis or at all, our operations would be delayed and our business harmed. Our reliance on contract manufacturers
exposes us to additional risks, including:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: normal">&nbsp;</TD>
    <TD STYLE="width: 4%; line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="width: 93%; line-height: normal">failure of our future manufacturers to comply with strictly-enforced regulatory requirements;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal">failure to manufacture to our specifications, or to deliver sufficient quantities in a timely manner;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="line-height: normal"> the possibility that we may terminate a contract manufacturer and need to engage a replacement; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="line-height: normal"> the possibility that our future manufacturers may not be able to manufacture our product
    candidates and products without infringing the intellectual property rights of others; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="line-height: normal"> the possibility that our future manufacturers may not have adequate intellectual property
    rights to provide for exclusivity and prevent competition; and </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="line-height: normal"> insufficiency of intellectual property rights to any improvements in the manufacturing
    processes or new manufacturing processes for our products. </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Any of these factors could result in significant delay or
suspension of our clinical trials, regulatory submissions, receipt of required approvals or commercialization of our products and
harm our business.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Delays in the commencement or completion of pharmaceutical
development, manufacturing or clinical efficacy and safety testing could result in increased costs to us and delay our ability
to generate revenues.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We do not know whether our pharmaceutical development, manufacturing
or clinical efficacy and safety testing will begin on time or be completed on schedule, if at all.&nbsp;&nbsp;For example, we may
encounter delays during the manufacture of pilot scale batches including delays with our contract development or manufacturing
organization, sourcing satisfactory quantities of active pharmaceutical ingredient, narcotic import and export permits, sourcing
of excipients, contract disputes with our third party vendors and manufacturers, or failure of the product to meet specification.
Similar delays may occur a during our GMP manufacture of the product.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The commencement and completion of clinical trials can be
disrupted for a variety of reasons, including difficulties in:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: normal">&nbsp;</TD>
    <TD STYLE="width: 4%; line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="width: 93%; line-height: normal">recruiting and enrolling patients to participate in a clinical trial;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal">obtaining regulatory approval to commence a clinical trial;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="line-height: normal"> reaching agreement on acceptable terms with prospective clinical research organizations
    and trial sites; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="line-height: normal"> manufacturing sufficient quantities of a product candidate; </TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal">investigator fraud, including data fabrication by clinical trial personnel;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal">diversion of controlled substances by clinical trial personnel; and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="line-height: normal"> obtaining institutional review board approval to conduct a clinical trial at a prospective
    site. </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">A clinical trial may also be suspended or terminated by us,
the FDA or other regulatory authorities due to a number of factors, including:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: normal">&nbsp;</TD>
    <TD STYLE="width: 4%; line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="width: 93%; line-height: normal">failure to conduct the clinical trial in accordance with regulatory requirements or in accordance with our clinical protocols;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal">inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="line-height: normal"> unforeseen safety issues; or </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="line-height: normal"> inadequate patient enrollment or lack of adequate funding to continue the clinical trial. </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">In addition, changes in regulatory requirements and guidance
may occur and we may need to amend clinical trial protocols to reflect these changes, which could impact the cost, timing or successful
completion of a clinical trial.&nbsp;&nbsp;If we experience delays in the commencement or completion of our clinical trials, the
commercial prospects for our product candidates will be harmed, and our ability to generate product revenues will be delayed.&nbsp;&nbsp;Many
of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also lead to the denial
of regulatory approval of a product candidate.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I> We intend to rely on third parties to conduct our
clinical trials.&nbsp;&nbsp;If these third parties do not perform as contractually required or otherwise expected, we may not
be able to obtain regulatory approval for our product candidates. </I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> At this time we do not have any ongoing trials. However,
we do not currently intend to conduct clinical trials on our own, and instead will rely on third parties, such as contract research
organizations, medical institutions, clinical investigators and contract laboratories, to assist us with our clinical trials.&nbsp;&nbsp;We
are also required to comply with regulations and standards, commonly referred to as good clinical practices, for conducting, recording
and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the trial
participants are adequately protected. If these third parties do not successfully carry out their duties to us or regulatory obligations
or meet expected deadlines, if the third parties need to be replaced, or if the quality or accuracy of the data they obtain is
compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our nonclinical
development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain
regulatory approval for our product candidates. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Clinical trials necessary to support NDA approval of
our future products will be time consuming and expensive. Delays or failures in our clinical trials will prevent us from commercializing
our products and will adversely affect our business, operating results and prospects and could cause us to cease operations.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Initiating and completing clinical trials necessary to support
NDA approval of a new formulation of an existing product or a new product, will be time consuming and expensive and the outcome
uncertain.&nbsp;&nbsp;Moreover, the results of early clinical trials are not necessarily predictive of future results, and any
product we advance into clinical trials may not have favorable results in later clinical trials.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Some of the trials we undertake are not designed to support
final NDA approval of the product and additional trials will have to be conducted in the future before we file an NDA. In addition,
there can be no assurance that the data generated during the trials will meet our chosen safety and effectiveness endpoints or
otherwise produce results that will eventually support the filing or approval of an NDA.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Conducting successful clinical studies may require
the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Patient enrollment in clinical trials and completion of patient
participation and follow-up depends on many factors, including the size of the patient population; the nature of the trial protocol;
the attractiveness of, or the discomforts and risks associated with, the treatments received by enrolled subjects; the availability
of appropriate clinical trial investigators; support staff; and proximity of patients to clinical sites and ability to comply with
the eligibility and exclusion criteria for participation in the clinical trial and patient compliance. For example, patients may
be discouraged from enrolling in our clinical trials if the trial protocol requires them to undergo extensive post-treatment procedures
or follow-up to assess the safety and effectiveness of our products or if they determine that the treatments received under the
trial protocols are not attractive or involve unacceptable risks or discomforts. Patients may also not participate in our clinical
trials if they choose to participate in contemporaneous clinical trials of competitive products.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Development of sufficient and appropriate clinical
protocols to demonstrate safety and efficacy are required and we may not adequately develop such protocols to support clearance
and approval.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The FDA may require us to submit data on a greater number
of patients than we originally anticipated and/or for a longer follow-up period or change the data collection requirements or data
analysis applicable to our clinical trials. They may also require additional data on certain categories of patients, should it
emerge during the conduct of our clinical trials that certain categories of patients are likely to be affected in different and/or
additional manner than most of the patients. In addition to FDA requirements, our clinical trial requires the approval of the institutional
review board, or IRB, at each site selected for participation in our clinical trial.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Additional delays to the completion of clinical studies
may result from modifications being made to the protocol during the clinical trial, if such modifications are warranted and/or
required by the occurrences in the given trial</I></B><I> .</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Each of such modifications has to be submitted to the FDA.
This could result in the delay or halt of a clinical trial while the modification is evaluated. In addition, depending on the magnitude
and nature of the changes made, FDA could take the position that the data generated by the clinical trial cannot be pooled because
the same protocol was not used throughout the trial. This might require the enrollment of additional subjects, which could result
in the extension of the clinical trial and the FDA delaying clearance or approval of a product.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>There can be no assurance that the data generated using
modified protocols will be acceptable to FDA.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">There can be no assurance that the data generated using modified
protocols will be acceptable to FDA or that if future modifications during the trial are necessary, any such modifications will
be acceptable to FDA. If FDA believes that its prior approval is required for a particular modification, it can delay or halt a
clinical trial while it evaluates additional information regarding the change.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Serious injury or death resulting from a failure of one of
our drug candidates during current or future clinical trials could also result in the FDA delaying our clinical trials or denying
or delaying clearance or approval of a product.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Even though an adverse event may not be the result of the
failure of our drug candidate, FDA or an IRB could delay or halt a clinical trial for an indefinite period of time while an adverse
event is reviewed, and likely would do so in the event of multiple such events.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Any delay or termination of our current or future clinical
trials as a result of the risks summarized above, including delays in obtaining or maintaining required approvals from IRBs, delays
in patient enrollment, the failure of patients to continue to participate in a clinical trial, and delays or termination of clinical
trials as a result of protocol modifications or adverse events during the trials, may cause an increase in costs and delays in
the filing of any product submissions with the FDA, delay the approval and commercialization of our products or result in the failure
of the clinical trial, which could adversely affect our business, operating results and prospects.&nbsp;&nbsp;Lengthy delays in
the completion of clinical trials of our products would adversely affect our business and prospects and could cause us to cease
operations.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> On November 29, 2006 the FDA imposed a bold warning on
the label of racemic methadone, a parent compound to our d-methadone related to cardiac death. Although the decision was based
on case reports and not on a controlled clinical trial, as part of the development of d-methadone we will likely have to conduct
a specific study to evaluate the effects of d-methadone on QTc interval prolongation. QT interval is a measure of the time between
the start of the Q wave and the end of the T wave in the heart&rsquo;s electrical cycle.&nbsp;&nbsp;Drugs that prolong the corrected
QT interval (QTc) interval are associated with an increased risk of serious disturbances in heart rhythm, leading to sudden death.
QT interval studies can be extremely costly and there is no assurance that we will have funds to undertake such a study.&nbsp;&nbsp;In
addition, even if we do a QT interval prolongation study in accordance with regulatory guidelines, there is no assurance that
the results of the study will demonstrate an absence of QT interval prolongation with d-methadone. An adverse safety outcome from
such study could result in a similar bolded warning on the label of d-methadone or in a decision not to approve d-methadone, either
one of which could have serious consequences for our continued operation. </P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>If the third parties on which we rely to conduct our
clinical trials and to assist us with pre-clinical development do not perform as contractually required or expected, we may not
be able to obtain regulatory approval for or commercialize our products.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We do not have the ability to independently conduct all the
pre-clinical and clinical trials for our products and we must rely on third parties, such as contract research organizations, medical
institutions, clinical investigators and contract laboratories to conduct such trials.&nbsp;&nbsp;If these third parties do not
successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if these third parties need
to be replaced, or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical
protocols or regulatory requirements or for other reasons, our pre-clinical development activities or clinical trials may be extended,
delayed, suspended or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, our
products on a timely basis, if at all, and our business, operating results and prospects may be adversely affected. Furthermore,
our third-party clinical trial investigators may be delayed in conducting our clinical trials for reasons outside of their control.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>The future results of our current or future clinical
trials may not support our product candidate claims or may result in the discovery of unexpected adverse side effects.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Even if our clinical trials are completed as planned, we
cannot be certain that their results will support our drug candidate claims or that the FDA or foreign authorities will agree with
our conclusions regarding them. Success in pre-clinical studies and early clinical trials does not ensure that later clinical trials
will be successful, and we cannot be sure that the later trials will replicate the results of prior trials and pre-clinical studies.
The clinical trial process may fail to demonstrate that our drug candidates are safe and effective for the proposed indicated uses.
If FDA concludes that the clinical trials for any of our products for which we might seek clearance, have failed to demonstrate
safety and effectiveness, we would not receive FDA clearance to market that product in the United States for the indications sought.
In addition, such an outcome could cause us to abandon the product candidate and might delay development of others. Any delay or
termination of our clinical trials will delay the filing of any product submissions with the FDA and, ultimately, our ability to
commercialize our product candidates and generate revenues. It is also possible that patients enrolled in clinical trials will
experience adverse side effects that are not currently part of the product candidate&rsquo;s profile. In addition, our clinical
trials performed until now involve a relatively small patient population. Because of the small sample size, their results may not
be indicative of future results.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Future products may never achieve market acceptance.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Future products that we may develop may never gain market
acceptance among physicians, patients and the medical community.&nbsp;&nbsp;The degree of market acceptance of any of our products
will depend on a number of factors, including the actual and perceived effectiveness and reliability of our products; the results
of any long&minus;term clinical trials relating to use of our products; the availability, relative cost and perceived advantages
and disadvantages of alternative technologies; the degree to which treatments using our products are approved for reimbursement
by public and private insurers; the strength of our marketing and distribution infrastructure; and the level of education and awareness
among physicians and hospitals concerning our products. Failure of any of our products to significantly penetrate current or new
markets would negatively impact our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>To be commercially successful, physicians must be persuaded
that using our products for treatment of pain are effective alternatives to existing therapies and treatments.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We believe that pain doctors and other physicians will not
widely adopt our products unless they determine, based on experience, clinical data, and published peer reviewed journal articles,
that the use of our products provides an effective alternative to other means of treating pain.&nbsp;&nbsp;Patient studies or clinical
experience may indicate that treatment with our products does not provide patients with sufficient benefits in pain intensity and/or
quality of life. We believe that recommendations and support for the use of our products from influential physicians will be essential
for widespread market acceptance. Our products are still in the development stage and it is premature to attempt to gain support
from physicians at this time. We can provide no assurance that such support will ever be obtained. If our products do not receive
such support from these physicians and from long-term data, physicians may not use or continue to use, and hospitals may not purchase
or continue to purchase, our products.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Even if our products are approved by regulatory authorities,
if we or our suppliers fail to comply with ongoing FDA regulation or if we experience unanticipated problems with our products,
these products could be subject to restrictions or withdrawal from the market.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Any product for which we obtain clearance or approval, and
the manufacturing processes, reporting requirements, post-approval clinical data and promotional activities for such product, will
be subject to continued regulatory review, oversight and periodic inspections by the FDA.&nbsp;&nbsp;In particular, we and our
suppliers are required to comply with FDA&rsquo;s Quality System Regulations, or QSR, and International Standards Organization,
or ISO, regulations for the manufacture of our products and other regulations which cover the methods and documentation of the
design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of any product for which we
obtain clearance or approval. Regulatory bodies, such as the FDA, enforce these regulations through periodic inspections.&nbsp;&nbsp;The
failure by us or one of our suppliers to comply with applicable statutes and regulations administered by the FDA and other regulatory
bodies, or the failure to timely and adequately respond to any adverse inspectional observations or product safety issues could
result in, among other things, enforcement actions by the FDA.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">If any of these actions were to occur it would harm our reputation
and cause our product sales and profitability to suffer and may prevent us from generating revenue. Furthermore, our key component
suppliers may not currently be or may not continue to be in compliance with all applicable regulatory requirements which could
result in our failure to produce our products on a timely basis and in the required quantities, if at all.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Even if regulatory clearance or approval of a product is
granted, such clearance or approval may be subject to limitations on the intended uses for which the product may be marketed and
reduce the potential to successfully commercialize the product and generate revenue from the product. If the FDA determines that
the product promotional materials, labeling, training or other marketing or educational activities constitute promotion of an unapproved
use, it could request that we or our commercialization partners cease or modify our training or promotional materials or subject
us to regulatory enforcement actions. It is also possible that other federal, state or foreign enforcement authorities might take
action if they consider such training or other promotional materials to constitute promotion of an unapproved use, which could
result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">In addition, we may be required to conduct costly post-market
testing and surveillance to monitor the safety or effectiveness of our products, and we must comply with adverse event and phamacovigilence
reporting requirements, including the reporting of adverse events which occur in connection with, and whether or not directly related
to, our products. Later discovery of previously unknown problems with our products, including unanticipated adverse events or adverse
events of unanticipated severity or frequency, manufacturing problems, or failure to comply with regulatory requirements, may result
in changes to labeling, restrictions on such products or manufacturing processes, withdrawal of the products from the market, voluntary
or mandatory recalls, a requirement to recall, replace or refund the cost of any product we manufacture or distribute, fines, suspension
of regulatory approvals, product seizures, injunctions or the imposition of civil or criminal penalties which would adversely affect
our business, operating results and prospects.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Some of our other product candidates will require Risk
Evaluation and Mitigation Strategies (REMS).</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The FDA Amendments Act of 2007 implemented safety-related
changes to product labeling and requires the adoption of REMS. Some of our product candidates, the controlled substance-based and
maybe others, will require REMS. The REMS may include requirements for special labeling or medication guides for patients, special
communication plans to health care professionals and restrictions on distribution and use. We cannot predict the specific REMS
to be required as part of the FDA's approval of any of our products.&nbsp;&nbsp;Depending on the extent of the REMS requirements,
our costs to commercialize our products may increase significantly. Furthermore, controlled substances risks that are not adequately
addressed through proposed REMS for our product candidates may also prevent or delay their approval for commercialization.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Our revenue stream will depend upon third party reimbursement.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The commercial success of our products in both domestic and
international markets will be substantially dependent on whether third-party coverage and reimbursement is available for patients
that use our products. However, the availability of insurance coverage and reimbursement for newly approved drugs to treat pain
is uncertain, and therefore, third-party coverage may be particularly difficult to obtain even if our products are approved by
the FDA as safe and efficacious. Many patients using existing approved therapies are generally reimbursed all or part of the product
cost by Medicare or other third-party payors. Medicare, Medicaid, health maintenance organizations and other third-party payors
are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new drugs,
and, as a result, they may not cover or provide adequate payment for these products. Submission of applications for reimbursement
approval generally does not occur prior to the filing of an NDA for that product and may not be granted for as long as many months
after NDA approval. In order to obtain reimbursement arrangements for these products, we or our commercialization partners may
have to agree to a net sales price lower than the net sales price we might charge in other sales channels.&nbsp;&nbsp;The continuing
efforts of government and third-party payors to contain or reduce the costs of healthcare may limit our revenue. Initial dependence
on the commercial success of our products may make our revenues particularly susceptible to any cost containment or reduction efforts.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We are dependent on third parties for manufacturing
and marketing of our proposed proprietary products. If we are not able to secure favorable arrangements with such third parties,
our business and financial condition could be harmed.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We are not planning to manufacture any of our proposed proprietary
products for commercial sale nor do we have the resources necessary to do so.&nbsp;&nbsp;In addition, we currently do not have
the capability to market our drug products ourselves. We intend to contract with specialized manufacturing companies to manufacture
our proposed proprietary products and partner with larger pharmaceutical companies for commercialization of our products, retaining
the marketing and promotion rights for specialty medical areas. In connection with our efforts to commercialize our proposed proprietary
products, we will seek to secure favorable arrangements with third parties to distribute, promote, market and sell our proposed
proprietary products. If we are not able to secure favorable commercial terms or arrangements with third parties for distribution,
marketing, promotion and sales of our proposed proprietary products, we may have to retain promotional and marketing rights and
seek to develop the commercial resources necessary to promote or co-promote or co-market certain or all of our proprietary drug
candidates to the appropriate channels of distribution in order to reach the specific medical market that we are targeting. We
may not be able to enter into any partnering arrangements on this or any other basis. If we are not able to secure favorable partnering
arrangements, or are unable to develop the appropriate resources necessary for the commercialization of our proposed proprietary
products, our business and financial condition could be harmed. In addition, we will have to hire additional employees or consultants,
since our current employees have limited experience in these areas. Sufficient employees with relevant skills may not be available
to us. Any increase in the number of our employees would increase our expense level, and could have an adverse effect on our financial
position.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">In addition, we, or our potential commercial partners, may
not successfully introduce our proposed proprietary products or our proposed proprietary products may not achieve acceptance by
patients, health care providers and insurance companies. Further, it is possible that we may not be able to secure arrangements
to manufacture, market, distribute, promote and sell our proposed proprietary products on favorable commercial terms that would
permit us to make a profit. To the extent that corporate partners conduct clinical trials, we may not be able to control the design
and conduct of these clinical trials.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We must enter into an agreement with, and depend upon,
one or more partners to assist us in commercializing our product candidates.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Because of our limited financial and other resources, we
must actively seek and enter into a collaboration with one or more partners to assist us in our product launch, if marketing approval
is granted. Any collaboration agreement we enter into may contain unfavorable terms, for example, with respect to product candidates
covered, control over decisions and responsibilities, termination rights, payment, and other significant terms. Our ability to
receive any significant revenue from our product candidates covered by the collaboration agreement will be dependent on the efforts
of our collaboration partner and may result in lower levels of income to us than if we marketed our product candidates entirely
on our own. The collaboration partner may not fulfill its obligations or commercialize our product candidates as quickly as we
would like. We could also become involved in disputes with our partner, which could lead to delays in or termination of our commercialization
programs and time-consuming and expensive litigation or arbitration. If a collaboration partner terminates or breaches its agreement
with us, or otherwise fails to complete its obligations in a timely manner, the chances of successfully developing or commercializing
our product candidates would be materially and adversely affected.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Additionally, depending upon the collaboration partner that
we choose, other companies that might otherwise be interested in developing products with us could be less inclined to do so because
of our relationship with the collaboration partner. If our ability to work with present or future strategic partners or collaborators
is adversely affected as a result of our collaboration agreement, our business prospects may be limited and our financial condition
may be adversely affected.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We may have conflicts with our partners that could
delay or prevent the development or commercialization of our product candidates.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We may have conflicts with our partners, such as conflicts
concerning the interpretation of nonclinical or clinical data, the achievement of milestones, the interpretation of contractual
obligations, payments for services, development obligations or the ownership of intellectual property developed during our collaboration.&nbsp;&nbsp;If
any conflicts arise with any of our partners, such partner may act in a manner that is adverse to our best interests.&nbsp;&nbsp;Any
such disagreement could result in one or more of the following, each of which could delay or prevent the development or commercialization
of our product candidates, and in turn prevent us from generating revenues: unwillingness on the part of a partner to pay us milestone
payments or royalties we believe are due to us under a collaboration; uncertainty regarding ownership of intellectual property
rights arising from our collaborative activities, which could prevent us from entering into additional collaborations; unwillingness
by the partner to cooperate in the development or manufacture of the product, including providing us with product data or materials;
unwillingness on the part of a partner to keep us informed regarding the progress of its development and commercialization activities
or to permit public disclosure of the results of those activities; initiating of litigation or alternative dispute resolution options
by either party to resolve the dispute; or attempts by either party to terminate the agreement.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We have no experience selling, marketing or distributing
products and no internal capability to do so.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We currently have no sales, marketing or distribution capabilities.
In order to commercialize our products, if any are approved, we intend to develop internal sales, marketing and distribution capabilities
to target particular markets for our products, as well as make arrangements with third parties to perform these services for us
with respect to other markets for our products. We may not be able to establish these capabilities internally or hire marketing
and sales personnel with appropriate expertise to market and sell our products, if approved.&nbsp;&nbsp;In addition, even if we
are able to identify one or more acceptable collaborators to perform these services for us, we may not be able to enter into any
collaborative arrangements on favorable terms, or at all. If we enter into any collaborative arrangements for the marketing or
sale of our products, our product revenues are likely to be lower than if we marketed and sold our products ourselves.&nbsp;&nbsp;In
addition, any revenues we receive would depend upon the efforts of our collaborators, which may not be adequate due to lack of
attention or resource commitments, management turnover, change of strategic focus, business combinations, and their inability to
comply with regulatory requirements or other factors outside of our control. Depending upon the terms of our collaboration, the
remedies we have against an under-performing collaborator may be limited. If we were to terminate a relationship, it may be difficult
or impossible to find a replacement collaborator on acceptable terms, if at all.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Upon commercialization of our products, we may be dependent
on third parties to market, distribute and sell our products.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our ability to receive revenues may be dependent upon the
sales and marketing efforts of any future co-marketing partners and third-party distributors.&nbsp;&nbsp;At this time, we have
not entered into an agreement with any commercialization partner and only plan to do so after the successful completion of Phase
II clinical trials and prior to commercialization. If we fail to reach an agreement with any commercialization partner or upon
reaching such an agreement that partner fails to sell a large volume of our products, it may have a negative impact on our business,
financial condition and results of operations.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Our products will face significant competition in the
markets for such products, and if they are unable to compete successfully, our business will suffer.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our products candidates face, and will continue to face,
intense competition from large pharmaceutical companies, specialty pharmaceutical and biotechnology companies as well as academic
and research institutions.&nbsp;&nbsp;We compete in an industry that is characterized by: (i) rapid technological change, (ii)
evolving industry standards, (iii) emerging competition and (iv) new product introductions.&nbsp;&nbsp;Our competitors have existing
products and technologies that will compete with our products and technologies and may develop and commercialize additional products
and technologies that will compete with our products and technologies.&nbsp;&nbsp;Because several competing companies and institutions
have greater financial resources than us, they may be able to: (i) provide broader services and product lines, (ii) make greater
investments in research and development, (R&amp;D<B>)</B> , and (iii) carry on larger R&amp;D initiatives.&nbsp;&nbsp;Our competitors
also have greater development capabilities than we do and have substantially greater experience in undertaking nonclinical and
clinical testing of products, obtaining regulatory approvals, and manufacturing and marketing pharmaceutical products.&nbsp;&nbsp;They
also have greater name recognition and better access to customers than us.&nbsp;&nbsp;Our chief competitors include companies
such as Purdue Pharma, Pfizer, Eli Lilly, Endo, Astra Zeneca, among others.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We are faced with intense competition and rapid technological
change, which may make it more difficult for us to achieve significant market penetration. If we cannot compete successfully for
market share against other drug companies, we may not achieve sufficient product revenues and our business will suffer.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The market for our product candidates is characterized by
intense competition and rapid technological advances. If our product candidates receive FDA approval, they will compete with a
number of existing and future drugs and therapies developed, manufactured and marketed by others. If our competitors&rsquo; existing
products or new products are more effective than or considered superior to our future products, the commercial opportunity for
our product candidates will be reduced or eliminated. Existing or future competing products may provide greater therapeutic convenience
or clinical or other benefits for a specific indication than our products, or may offer comparable performance at a lower cost.
We face competition from fully integrated pharmaceutical companies and smaller companies that are collaborating with larger pharmaceutical
companies, academic institutions, government agencies and other public and private research organizations. If we are successful
in penetrating the market for pain treatment with our product candidates, other companies may be attracted to the market.&nbsp;&nbsp;Many
of our competitors have analgesics already approved or in development. In addition, many of these competitors, either alone or
together with their collaborative partners, are larger than we are and have substantially greater financial, technical, research,
marketing, sales, distribution and other resources than we do. Our competitors may develop or market products that are more effective
or commercially attractive than any that we are developing or marketing. Our competitors may obtain regulatory approvals, and introduce
and commercialize products before we do. These developments could have a significant negative effect on our financial condition.&nbsp;&nbsp;Even
if we are able to compete successfully, we may not be able to do so in a profitable manner.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Adverse events involving our products may lead the
FDA to delay or deny clearance for our products or result in product recalls that could harm our reputation, business and financial
results.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Once a product receives FDA clearance or approval, the agency
has the authority to require the recall of commercialized products in the event of adverse side effects, material deficiencies
or defects in design or manufacture. The authority to require a recall must be based on an FDA finding that there is a reasonable
probability that the device would cause serious injury or death. Manufacturers may, under their own initiative, recall a product
if any material deficiency in a product is found. A government-mandated or voluntary recall by us or one of our distributors could
occur as a result of adverse side effects, impurities or other product contamination, manufacturing errors, design or labeling
defects or other deficiencies and issues. Recalls of any of our products would divert managerial and financial resources and have
an adverse effect on our financial condition and results of operations. The FDA requires that certain classifications of recalls
be reported to FDA within 10 working days after the recall is initiated. Companies are required to maintain certain records of
recalls, even if they are not reportable to the FDA. We may initiate voluntary recalls involving our products in the future that
we determine do not require notification of the FDA. If the FDA disagrees with our determinations, they could require us to report
those actions as recalls.&nbsp;&nbsp;A future recall announcement could harm our reputation with customers and negatively affect
our sales. In addition, the FDA could take enforcement action for failing to report the recalls when they were conducted.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We may be exposed to liability claims associated with
the use of hazardous materials and chemicals.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our research and development activities involve the controlled
use of hazardous materials and chemicals. Although we believe that our safety procedures for using, storing, handling and disposing
of these materials comply with federal, state and local laws and regulations, we cannot completely eliminate the risk of accidental
injury or contamination from these materials. In the event of such an accident, we could be held liable for any resulting damages
and any liability could materially adversely affect our business, financial condition and results of operations. In addition, the
federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of hazardous or radioactive
materials and waste products may require us to incur substantial compliance costs that could materially adversely affect our business
and financial condition.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We may incur substantial liabilities and may be required
to limit commercialization of our products in response to product liability lawsuits.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The testing and marketing of medical products entail an inherent
risk of product liability. We may be held liable if serious adverse reactions from the use of our product candidates occur. If
we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to
limit commercialization of our product candidates. Our inability to obtain sufficient product liability insurance at an acceptable
cost to protect against potential product liability claims could prevent or inhibit the commercialization of pharmaceutical products
we develop, alone or with corporate collaborators. We currently do not carry product liability insurance. We, or any corporate
collaborators, may not be able to obtain insurance at a reasonable cost, if at all. Even if our agreements with any future corporate
collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate if any claim
arises.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Our business depends upon securing and protecting critical
intellectual property.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our commercial success will depend in part on our obtaining
and maintaining patent, trade secret, copyright and trademark protection of our technologies in the United States and other jurisdictions
as well as successfully enforcing this intellectual property and defending this intellectual property against third-party challenges.
We will only be able to protect our technologies from unauthorized use by third parties to the extent that valid and enforceable
intellectual property protection, such as patents or trade secrets, cover them. In particular, we place considerable emphasis on
obtaining patent and trade secret protection for significant new technologies, products and processes.&nbsp;&nbsp;Furthermore,
the degree of future protection of our proprietary rights is uncertain because legal means afford only limited protection and may
not adequately protect our rights or permit us to gain or keep our competitive advantage.&nbsp;&nbsp;Moreover, the degree of future
protection of our proprietary rights is uncertain for products that are currently in the early stages of development because we
cannot predict which of these products will ultimately reach the commercial market or whether the commercial versions of these
products will incorporate proprietary technologies.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Our patent position is highly uncertain and involves
complex legal and factual questions.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Accordingly, we cannot predict the breadth of claims that
may be allowed or enforced in our patents or in third-party patents. For example, we or our licensors might not have been the first
to make the inventions covered by each of our pending patent applications and issued patents; we or our licensors might not have
been the first to file patent applications for these inventions; others may independently develop similar or alternative technologies
or duplicate any of our technologies; it is possible that none of our pending patent applications or the pending patent applications
of our licensors will result in issued patents; our issued patents and issued patents of our licensors may not provide a basis
for commercially viable technologies, or may not provide us with any competitive advantages, or may be challenged and invalidated
by third parties; and, we may not develop additional proprietary technologies that are patentable.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">As a result, our owned and licensed patents may not be valid
and we may not be able to obtain and enforce patents and to maintain trade secret protection for the full commercial extent of
our technology. The extent to which we are unable to do so could materially harm our business.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We or our licensors have applied for and will continue to
apply for patents for certain products. Such applications may not result in the issuance of any patents, and any patents now held
or that may be issued may not provide us with adequate protection from competition. Furthermore, it is possible that patents issued
or licensed to us may be challenged successfully. In that event, if we have a preferred competitive position because of such patents,
any preferred position held by us would be lost. If we are unable to secure or to continue to maintain a preferred position, we
could become subject to competition from the sale of generic products. Failure to receive, inability to protect, or expiration
of our patents would adversely affect our business and operations.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Patents issued or licensed to us may be infringed by the
products or processes of others. The cost of enforcing our patent rights against infringers, if such enforcement is required, could
be significant, and the Company does not currently have the financial resources to fund such litigation. Further, such litigation
can go on for years and the time demands could interfere with our normal operations.&nbsp;&nbsp;There has been substantial litigation
and other proceedings regarding patent and other intellectual property rights in the pharmaceutical industry. We may become a party
to patent litigation and other proceedings. The cost to us of any patent litigation, even if resolved in our favor, could be substantial.
Some of our competitors may be able to sustain the costs of such litigation more effectively than we can because of their substantially
greater financial resources. Litigation may also absorb significant management time.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Unpatented trade secrets, improvements, confidential know-how
and continuing technological innovation are important to our scientific and commercial success. Although we attempt to and will
continue to attempt to protect our proprietary information through reliance on trade secret laws and the use of confidentiality
agreements with our corporate partners, collaborators, employees and consultants and other appropriate means, these measures may
not effectively prevent disclosure of our proprietary information, and, in any event, others may develop independently, or obtain
access to, the same or similar information.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Certain of our patent rights are licensed to us by third
parties. If we fail to comply with the terms of these license agreements, our rights to those patents may be terminated, and we
will be unable to conduct our business.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> The following is a summary of our
patents and patent applications: </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><U> Levorphanol </U> : These
patent applications cover the Levorphanol product. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%; padding: 0; text-indent: 0"></TD><TD STYLE="width: 4%; padding: 0; text-indent: 0"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD><TD STYLE="text-align: left; padding: 0; text-indent: 0; width: 93%"> Patent
                                         application 12/223.327 filed 1/29/07, Abuse Resistant and Extended Release Formulations
                                         and Method of Use Thereof. Cover US. Owned by Relmada. Currently pending. </TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0"></TD><TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD><TD STYLE="text-align: left; padding: 0; text-indent: 0"> Patent
                                         application 12/597,702 filed 4/28/08, Multimodal Abuse Resistant and Extended Release
                                         Opioid Formulations. Cover US. Owned by Relmada. Currently pending. </TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0"></TD><TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD><TD STYLE="text-align: left; padding: 0; text-indent: 0"> Patent
                                         application 13/320,989 filed 2/26/10, Extended Release Oral Pharmaceutical Compositions
                                         of 3-Hydroxy-N-Methylmorphinan and Method of Use. Cover US and EU. Owned by Relmada.
                                         Currently pending. </TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left"><U> d-Methadone </U> : The patent
is licensed from Cornell University and if terminated, may result in the loss of patent protection. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%; padding: 0; text-indent: 0"></TD><TD STYLE="width: 4%; padding: 0; text-indent: 0"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD><TD STYLE="text-align: left; padding: 0; text-indent: 0; width: 93%"> Patent
                                         No. 6,008,258 filed 1/21/98, d-Methadone, a Nonopioid Analgesic, Cover US, Patent granted,
                                         estimated expiry date 1/20/18. </TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><U> Buprenorphine </U> : This
patent application covers the buprenorphine product. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%; padding: 0; text-indent: 0"></TD><TD STYLE="width: 4%; padding: 0; text-indent: 0"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD><TD STYLE="text-align: left; padding: 0; text-indent: 0; width: 93%"> Patent
                                         application 12/989,209 filed 3/9/09, Oral Pharmaceutical Compositions of Buprenorphine
                                         and Method of Use. Cover US and EU. Owned by Relmada. Currently pending. </TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><U> Mepivacaine </U> : This
patent application covers the Mepivacaine product. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%; padding: 0; text-indent: 0"></TD><TD STYLE="width: 4%; padding: 0; text-indent: 0"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD><TD STYLE="text-align: left; padding: 0; text-indent: 0; width: 93%"> Patent
                                         application PCT/US2011/032,381 filed 4/13/11, Dermal Pharmaceutical Composition of 1-Methyl-2,6-Pipecoloxylidide
                                         and Method of Use. Cover US, EU, Canada, China, India, Japan, and South Korea. Owned
                                         by Relmada. Currently pending. </TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>If we are found to be infringing
on patents or trade secrets owned by others, we may be forced to cease or alter our product development efforts, obtain a license
to continue the development or sale of our products, and/or pay damages.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our manufacturing processes and potential products may violate
proprietary rights of patents that have been or may be granted to competitors, universities or others, or the trade secrets of
those persons and entities. As the pharmaceutical industry expands and more patents are issued, the risk increases that our processes
and potential products may give rise to claims that they infringe the patents or trade secrets of others. These other persons could
bring legal actions against us claiming damages and seeking to enjoin clinical testing, manufacturing and marketing of the affected
product or process. If any of these actions are successful, in addition to any potential liability for damages, we could be required
to obtain a license in order to continue to conduct clinical tests, manufacture or market the affected product or use the affected
process. Required licenses may not be available on acceptable terms, if at all, and the results of litigation are uncertain.&nbsp;&nbsp;If
we become involved in litigation or other proceedings, it could consume a substantial portion of our financial resources and the
efforts of our personnel.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Our ability to protect and enforce our patents does
not guaranty that we will secure the right to commercialize our patents.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">A patent is a limited monopoly right conferred upon an inventor,
and his successors in title, in return for the making and disclosing of a new and non-obvious invention.&nbsp;&nbsp;This monopoly
is of limited duration but, while in force, allows the patent holder to prevent others from making and/or using his invention.
While a patent gives the holder this right to exclude others, it is not a license to commercialize the invention, where other
permissions may be required for permissible commercialization to occur. For example, a drug cannot be marketed without the appropriate
authorization from the FDA, regardless of the existence of a patent covering the product. Further, the invention, even if patented
itself, cannot be commercialized if it infringes the valid patent rights of another party.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We rely on confidentiality agreements to protect our
trade secrets. If these agreements are breached by our employees or other parties, our trade secrets may become known to our competitors.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We rely on trade secrets that we seek to protect through
confidentiality agreements with our employees and other parties.&nbsp;&nbsp;If these agreements are breached, our competitors may
obtain and use our trade secrets to gain a competitive advantage over us. We may not have any remedies against our competitors
and any remedies that may be available to us may not be adequate to protect our business or compensate us for the damaging disclosure.
In addition, we may have to expend resources to protect our interests from possible infringement by others.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">If we are unable to obtain the statutory patent extension
related to the review time in the United States, we may need to rely on the 3-year Hatch-Waxman Act marketing exclusivity, the
six month pediatric exclusivity, any approved 7- year Orphan Drug exclusivities, potential future formulation patents and up to
ten years of data exclusivity in Europe.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We may not be able to obtain or maintain orphan drug
exclusivity for our products.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The FDA Office of Orphan Products (OOPD) has granted orphan
drug designation for mepivacaine to which we have secured rights.&nbsp;&nbsp;The orphan designations cover postherpetic neuralgia
and painful HIV neuropathy. If a product that has orphan drug designation subsequently receives FDA approval for the indication
for which it has such designation, the product is entitled to orphan exclusivity, i.e., for seven years, the FDA may not approve
any other applications to market the same drug for the same indication, except in very limited circumstances.&nbsp;&nbsp;We may
be unable to obtain orphan drug designations for any additional mepivacaine product candidates or orphan exclusivity for any of
our product candidates, or our potential competitors may obtain orphan drug exclusivity for mepivacaine-based products competitive
with our product candidates before we do, in which case we may be excluded from that market for the exclusivity period.&nbsp;&nbsp;Even
if we obtain orphan drug exclusivity for any of our product candidates, we may not be able to maintain it if a competitive product
is shown to be clinically superior to our product.&nbsp;&nbsp;Although obtaining FDA approval to market a product with orphan exclusivity
can be advantageous, there can be no assurance that it would provide us with a significant commercial advantage.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We may not be able to obtain Hatch-Waxman Act marketing
exclusivity or equivalent regulatory data exclusivity protection in other jurisdictions for our products.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We intend to rely, in part, on Hatch-Waxman exclusivity for
the commercialization of our products in the United States.&nbsp;&nbsp;The Hatch-Waxman Act provides marketing exclusivity to the
first applicant to gain approval of an NDA under specific provisions of the Food, Drug and Cosmetic Act for a product using an
active ingredient that the FDA has not previously approved (five years) or for a new dosage form, route or indication (three years).
This market exclusivity will not prevent the FDA from approving a competitor&rsquo;s NDA if the competitor&rsquo;s NDA is based
on studies it has performed and not on our studies.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">There can be no assurance that European authorities will
grant data exclusivity for our products, because it does not contain a new active molecule.&nbsp;&nbsp;Even if European data exclusivity
is granted for our products, that may not protect us from direct competition.&nbsp;&nbsp;Given the well-established use of our
product candidates as pain relievers, a competitor with a generic version of our products may be able to obtain approval of their
product during our product&rsquo;s period of data exclusivity, by submitting a marketing authorization application (MAA) with a
less than full package of nonclinical and clinical data.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We may undertake international operations, which will
subject us to risks inherent with operations outside of the United States.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Although we do not have any foreign operations at this time,
we intend to seek to obtain market clearances in foreign markets that we deem to generate significant opportunities. However, even
with the cooperating of a commercialization partner, conducting drug development in foreign countries involves inherent risks,
including, but not limited to: difficulties in staffing, funding and managing foreign operations; unexpected changes in regulatory
requirements; export restrictions; tariffs and other trade barriers; difficulties in protecting, acquiring, enforcing and litigating
intellectual property rights; fluctuations in currency exchange rates; and potentially adverse tax consequences.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">If we were to experience any of the difficulties listed above,
or any other difficulties, any international development activities and our overall financial condition may suffer and cause us
to reduce or discontinue our international development and registration efforts.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We may not be successful in hiring and retaining key
employees.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our future operations and successes depend in large part
upon the continued service of key members of our senior management team whom we are highly dependent upon to manage our business,
specifically Dr. Traversa, our CEO and our President and CSO Dr. Eliseo Salinas.&nbsp;&nbsp;If either of them terminates his employment
with us, such a departure would have a material adverse effect on our business.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our future success also depends on our ability to identify,
attract, hire or engage, retain and motivate other well-qualified managerial, technical, clinical and regulatory personnel. We
will need to hire additional qualified personnel with expertise in nonclinical pharmacology and toxicology, pharmaceutical development,
clinical research, regulatory affairs, manufacturing, sales and marketing.&nbsp;&nbsp;We compete for qualified individuals with
numerous biopharmaceutical companies, universities and other research institutions.&nbsp;&nbsp;Competition for such individuals,
particularly in the United States, is intense, and we may not be able to hire sufficient personnel to support our efforts. There
can be no assurance that these professionals will be available in the market, or that we will be able to retain existing professionals
or to meet or to continue to meet their compensation requirements. Furthermore, the cost base in relation to such compensation,
which may include equity compensation, may increase significantly, which could have a material adverse effect on us.&nbsp;&nbsp;Failure
to establish and maintain an effective management team and work force could adversely affect our ability to operate, grow and manage
our business.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Our employees may engage in misconduct or other improper
activities, including noncompliance with regulatory standards and requirements.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">We are exposed to the risk of employee
fraud or other misconduct. Misconduct by employees could include intentional failures to:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: normal">&nbsp;</TD>
    <TD STYLE="width: 4%; line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="width: 93%; line-height: normal">comply with FDA regulations or similar regulations of comparable foreign regulatory authorities; provide accurate information to the FDA or comparable foreign regulatory authorities;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal">comply with manufacturing standards we have established;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; width: 3%"> &nbsp; </TD>
    <TD STYLE="line-height: normal; width: 4%"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="line-height: normal; width: 93%"> comply with federal and state healthcare fraud and abuse laws and regulations and similar
    laws and regulations established and enforced by comparable foreign regulatory authorities; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="line-height: normal"> report financial information or data accurately; or </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="line-height: normal"> disclose unauthorized activities to us. </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left">In particular, sales, marketing and
business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks,
self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting,
marketing and promotion, sales commission, customer incentive programs and other business arrangements.&nbsp;&nbsp;Employee misconduct
could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory
sanctions and serious harm to our reputation. We have adopted a Code of Ethics, but it is not always possible to identify and deter
employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown
or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a
failure to be in compliance with such laws or regulations.&nbsp;&nbsp;If any such actions are instituted against us, and we are
not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and
results of operations, including the imposition of significant fines or other sanctions.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Our relationships with customers and payors will be
subject to applicable anti-kickback, fraud and abuse, transparency, and other healthcare laws and regulations, which could expose
us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens, and diminished profits
and future earnings.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Healthcare providers, physicians and payors play a primary
role in the recommendation and prescription of any product candidates for which we may obtain marketing approval. Our arrangements
with payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may
constrain the business or financial arrangements and relationships through which we market, sell and distribute any product candidates
for which we may obtain marketing approval. Restrictions under applicable federal, state and foreign healthcare laws and regulations
may affect our ability to operate, including:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: normal">&nbsp;</TD>
    <TD STYLE="width: 4%; line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="width: 93%; line-height: normal">the federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal">the federal False Claims Act, which imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="line-height: normal"> state and foreign anti-kickback and false claims laws, which may apply to sales or marketing
    arrangements and claims involving healthcare items or services reimbursed by non-governmental payors, including private insurers; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="line-height: normal"> the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which
    imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements
    relating to healthcare matters; </TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 and its implementing regulations, which also imposes obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal">laws which require pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restricting payments that may be made to healthcare providers; and</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal">federal laws requiring drug manufacturers to report information related to payments and other transfers of value made to physicians and other healthcare providers, as well as ownership or investment interests held by physicians and their immediate family members, including under the federal Open Payments program, as well as other state and foreign laws regulating marketing activities.</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Managing our growth as we expand operations may strain
our resources.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We expect to need to grow rapidly in order to support additional,
larger, and potentially international, pivotal clinical trials of our drug candidates, which will place a significant strain on
our financial, managerial and operational resources.&nbsp;&nbsp;In order to achieve and manage growth effectively, we must continue
to improve and expand our operational and financial management capabilities.&nbsp;&nbsp;Moreover, we will need to increase staffing
and to train, motivate and manage our employees.&nbsp;&nbsp;All of these activities will increase our expenses and may require
us to raise additional capital sooner than expected.&nbsp;&nbsp;Failure to manage growth effectively could harm our business, financial
condition or results of operations.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We may not successfully manage our growth.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our success will depend upon the expansion of our operations
and the effective management of our growth. We expect to experience significant growth in the scope of our operations and the number
of our employees. If we grow significantly, such growth will place a significant strain on our management and on our administrative,
operational and financial resources. To manage this growth, we must expand our facilities, augment our operational, financial and
management systems, internal controls and infrastructure and hire and train additional qualified personnel. Our future success
is heavily dependent upon growth and acceptance of our future products. If we are unable to scale our business appropriately or
otherwise adapt to anticipated growth and new product introduction, our business and financial condition will be harmed.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We may expand our business through the acquisition
of rights to new drug candidates that could disrupt our business, harm our financial condition and may also dilute current stockholders&rsquo;
ownership interests in our company.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our business strategy includes expanding our products and
capabilities, and we may seek acquisitions of drug candidates or technologies to do so.&nbsp;&nbsp;Acquisitions involve numerous
risks, including substantial cash expenditures; potentially dilutive issuance of equity securities; incurrence of debt and contingent
liabilities, some of which may be difficult or impossible to identify at the time of acquisition; difficulties in assimilating
the acquired technologies or the operations of the acquired companies; diverting our management&rsquo;s attention away from other
business concerns; risks of entering markets in which we have limited or no direct experience; and the potential loss of our key
employees or key employees of the acquired companies.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We cannot assure you that any acquisition will result in
short-term or long-term benefits to us. We may incorrectly judge the value or worth of an acquired product, company or business.
In addition, our future success would depend in part on our ability to manage the rapid growth associated with some of these acquisitions.
We cannot assure you that we will be able to make the combination of our business with that of acquired products, businesses or
companies work or be successful. Furthermore, the development or expansion of our business or any acquired products, business or
companies may require a substantial capital investment by us. We may not have these necessary funds or they might not be available
to us on acceptable terms or at all. We may also seek to raise funds by selling shares of our preferred or common stock, which
could dilute each current stockholder&rsquo;s ownership interest in the Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>We are unable to develop our own sales, marketing and
distribution capabilities, or if we are not successful in contracting with third parties for these services on favorable terms,
or at all, our product revenues could be disappointing</I></B><I> .</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We currently have no sales, marketing or distribution capabilities.
In order to commercialize our products, if any are approved by the FDA, we will either have to develop such capabilities internally
or collaborate with third parties who can perform these services for us.&nbsp;&nbsp;If we decide to commercialize any of our drugs
ourselves, we may not be able to hire the necessary experienced personnel and build sales, marketing and distribution operations
which are capable of successfully launching new drugs and generating sufficient product revenues. In addition, establishing such
operations will take time and involve significant expense.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">If we decide to enter into new co-promotion or other licensing
arrangements with third parties, we may be unable to locate acceptable collaborators because the number of potential collaborators
is limited and because of competition from others for similar alliances with potential collaborators.&nbsp;&nbsp;Even if we are
able to identify one or more acceptable new collaborators, we may not be able to enter into any collaborative arrangements on favorable
terms, or at all.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">In addition, any revenues we receive would depend upon our
collaborators&rsquo; efforts which may not be adequate due to lack of attention or resource commitments, management turnover, change
of strategic focus, business combinations or other factors outside of our control.&nbsp;&nbsp;Depending upon the terms of our collaboration,
the remedies we have against an under-performing collaborator may be limited. If we were to terminate the relationship, it may
be difficult or impossible to find a replacement collaborator on acceptable terms, or at all.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>If we cannot compete successfully for market share
against other drug companies, we may not achieve sufficient product revenues and our business will suffer.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The market for our drug candidates is characterized by intense
competition and rapid technological advances. If our drug candidates receive FDA approval, they will compete with a number of existing
and future drugs and therapies developed, manufactured and marketed by others. Existing or future competing products may provide
greater therapeutic convenience or clinical or other benefits for a specific indication than our products, or may offer comparable
performance at a lower cost.&nbsp;&nbsp;If our products are unable to capture and maintain market share, we may not achieve sufficient
product revenues and our business will suffer.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We and our collaborators will compete for market share against
fully integrated pharmaceutical companies or other companies that are collaborating with larger pharmaceutical companies, academic
institutions, government agencies and other public and private research organizations.&nbsp;&nbsp;Many of these competitors have
drugs already approved or drug candidates in development that will or may compete against our approved drug candidates.&nbsp;&nbsp;In
addition, many of these competitors, either alone or together with their collaborative partners, operate larger research and development
programs and have substantially greater financial resources than we do, as well as significantly greater experience in:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: normal">&nbsp;</TD>
    <TD STYLE="width: 4%; line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="width: 93%; line-height: normal">developing drugs;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal">conducting preclinical testing and human clinical trials;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="line-height: normal"> obtaining FDA and other regulatory approvals of drugs; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="line-height: normal"> formulating and manufacturing drugs; and </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="line-height: normal"> launching, marketing, distributing and selling drugs. </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Government agencies, professional and medical societies,
and other groups may establish usage guidelines that apply to our</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Law enforcement concerns over diversion of opioids and social
issues around abuse of opioids may make the regulatory approval process and commercialization of our drug candidates very difficult.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Media stories regarding the diversion of opioids and other
controlled substances are commonplace.&nbsp;&nbsp;Law enforcement agencies or regulatory agencies may apply policies that seek
to limit the availability of opioids.&nbsp;&nbsp;Such efforts may adversely affect the regulatory approval and commercialization
of our drug candidates.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Developments by competitors may render our products
or technologies obsolete or non-competitive.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Alternative technologies and products are being developed
to improve or replace the use of opioids for pain management, several of which are in clinical trials or are awaiting approval
from the FDA. In addition, the active ingredients in nearly all opioid drugs are available in generic form. Drug companies that
sell generic opioid drugs represent substantial competition. Many of these organizations competing with us have substantially greater
capital resources, larger research and development staffs and facilities, greater experience in drug development and in obtaining
regulatory approvals and greater manufacturing and marketing capabilities than we do. Our competitors may market less expensive
or more effective drugs that would compete with our drug candidates or reach market with competing drugs before we are able to
reach market with our drug candidates. These organizations also compete with us to attract qualified personnel and partners for
acquisitions, joint ventures or other collaborations.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Business interruptions could limit our ability to operate
our business.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left">Our operations as well as those of our
collaborators on which we depend are vulnerable to damage or interruption from computer viruses, human error, natural disasters,
electrical and telecommunication failures, international acts of terror and similar events. We have not established a formal disaster
recovery plan and our back-up operations and our business interruption insurance may not be adequate to compensate us for losses
we may suffer. A significant business interruption could result in losses or damages incurred by us and require us to cease or
curtail our operations.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Unfavorable media coverage of
opioid pharmaceuticals could negatively affect our business.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left">Opioid drug abuse receives a high degree
of media coverage. Unfavorable publicity regarding, for example, the use or misuse of oxycodone or other opioid drugs, the limitations
of abuse-resistant formulations, public&nbsp;&nbsp;inquiries and investigations into prescription drug abuse, litigation or regulatory
activity, or the independent actions regarding the sales, marketing, distribution or storage of our drug products, could adversely
affect our reputation.&nbsp;&nbsp;Such negative publicity could have an adverse effect on the potential size of the market for
our drug candidates and decrease revenues and royalties, which would adversely affect our business and financial results.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Risks Related to Ownership of Our
Common Stock</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>There is a limited market for
our common stock which may make it more difficult to dispose of your stock.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left"> Our common stock is currently quoted
on the OTCQB under the symbol &ldquo;RLMD&rdquo;. There is a limited trading market for our common stock. Accordingly, there can
be no assurance as to the liquidity of any markets that may develop for our common stock, the ability of holders of our common
stock to sell shares of our common stock, or the prices at which holders may be able to sell their common stock. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>A sale of a substantial number
of shares of our common stock may cause the price of the common stock to decline.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left">If our stockholders sell substantial
amounts of our common stock in the public market, the market price of our common stock could fall.&nbsp;&nbsp;&nbsp;&nbsp;These
sales also may make it more difficult for us to sell equity or equity-related securities in the future at a time and price that
we deem reasonable or appropriate.&nbsp;&nbsp;&nbsp;&nbsp;Stockholders who have been issued shares in the Reverse Merger will be
able to sell their shares pursuant to Rule 144 under the Securities Act of 1933, beginning one year after the stockholders acquired
their shares, subject to limitations imposed by the lock-up agreements.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We are subject to the reporting
requirements of federal securities laws, which can be expensive and may divert resources from other projects, thus impairing our
ability grow.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left">We are a public reporting company and,
accordingly, subject to the information and reporting requirements of the Exchange Act and other federal securities laws, including
compliance with the Sarbanes-Oxley Act of 2002 (the &ldquo;Sarbanes-Oxley Act&rdquo;).&nbsp;&nbsp;The costs of preparing and filing
annual and quarterly reports, proxy statements and other information with the SEC and furnishing audited reports to stockholders
would cause our expenses to be higher than they would be if we remained privately held and did not consummate the Reverse Merger.
In addition, we will incur substantial expenses in connection with the preparation of the registration statement and related documents
required under the terms of the Offering.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">It may be time consuming, difficult and costly for us to
develop and implement the internal controls and reporting procedures required by the Sarbanes-Oxley Act. We may need to hire additional
financial reporting, internal controls and other finance personnel in order to develop and implement appropriate internal controls
and reporting procedures. If we are unable to comply with the internal controls requirements of the Sarbanes-Oxley Act, then we
may not be able to obtain the independent accountant certifications required by such act, which may preclude us from keeping our
filings with the SEC current.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>If we fail to establish and maintain an effective system
of internal control, we may not be able to report our financial results accurately or to prevent fraud. Any inability to report
and file our financial results accurately and timely could harm our reputation and adversely impact the trading price of our Common
Stock.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Effective internal control is necessary for us to provide
reliable financial reports and prevent fraud. If we cannot provide reliable financial reports or prevent fraud, we may not be able
to manage our business as effectively as we would if an effective control environment existed, and our business and reputation
with investors may be harmed. As a result, our small size and any current internal control deficiencies may adversely affect our
financial condition, results of operation and access to capital. We have not performed an in-depth analysis to determine if historical
un-discovered failures of internal controls exist, and may in the future discover areas of our internal control that need improvement.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Public company compliance may make it more difficult
to attract and retain officers and directors.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The Sarbanes-Oxley Act and new rules subsequently implemented
by the SEC have required changes in corporate governance practices of public companies. As a public company, we expect these new
rules and regulations to increase our compliance costs in 2012 and beyond and to make certain activities more time consuming and
costly. As a public company, we also expect that these new rules and regulations may make it more difficult and expensive for us
to obtain director and officer liability insurance in the future and we may be required to accept reduced policy limits and coverage
or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract
and retain qualified persons to serve on our board of directors or as executive officers.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Our stock price may be volatile.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left">The market price of our Common Stock is likely to be highly
volatile and could fluctuate widely in price in response to various factors, many of which are beyond our control, including the
following:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: normal">&nbsp;</TD>
    <TD STYLE="width: 4%; line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="width: 93%; line-height: normal">changes in our industry;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal">competitive pricing pressures;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal">our ability to obtain working capital financing;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal">additions or departures of key personnel;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal">limited &ldquo;public float&rdquo; in the hands of a small number of persons whose sales or lack of sales could result in positive or negative pricing pressure on the market price for our Common Stock;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal">sales of our Common Stock;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal">our ability to execute our business plan;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal">operating results that fall below expectations;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal">loss of any strategic relationship;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal">regulatory developments;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal">economic and other external factors;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal">period-to-period fluctuations in our financial results; and</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal">inability to develop or acquire new or needed technology or products.</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">In addition, the securities markets have from time to time
experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies.
These market fluctuations may also materially and adversely affect the market price of our Common Stock.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Our Common Stock may be deemed a &ldquo;penny stock,&rdquo;
which would make it more difficult for our investors to sell their shares.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Our Common Stock may be subject to the &ldquo;penny stock&rdquo;
rules adopted under Section 15(g) of the Exchange Act.&nbsp;&nbsp;The penny stock rules generally apply to companies whose common
stock is not listed on The Nasdaq Stock Market or other national securities exchange and trades at less than $5.00 per share,
other than companies that have had average revenue of at least $6,000,000 for the last three years or that have tangible net worth
of at least $5,000,000 ($2,000,000 if the company has been operating for three or more years).&nbsp;&nbsp;These rules require,
among other things, that brokers who trade penny stock to persons other than &ldquo;established customers&rdquo; complete certain
documentation, make suitability inquiries of investors and provide investors with certain information concerning trading in the
security, including a risk disclosure document and quote information under certain circumstances. Many brokers have decided not
to trade penny stocks because of the requirements of the penny stock rules and, as a result, the number of broker-dealers willing
to act as market makers in such securities is limited. If we remain subject to the penny stock rules for any significant period,
it could have an adverse effect on the market, if any, for our securities. If our securities are subject to the penny stock rules,
investors will find it more difficult to dispose of our securities. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>There is a limited market for our common stock which
may make it more difficult to dispose of your stock.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Our common stock is currently quoted on the OTCQB under
the symbol &ldquo;RLMD.&rdquo;&nbsp;&nbsp;There is a limited trading market for our common stock. Accordingly, there can be no
assurance as to the liquidity of any markets that may develop for our common stock, the ability of holders of our common stock
to sell shares of our common stock, or the prices at which holders may be able to sell their common stock. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>You may have difficulty trading and obtaining quotations
for our Common Stock.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our securities are be actively traded, and the bid and asked
prices for our Common Stock on the Over-the-Counter Bulletin Board may fluctuate widely. As a result, investors may find it difficult
to dispose of, or to obtain accurate quotations of the price of, our securities.&nbsp;&nbsp;This severely limits the liquidity
of the Common Stock, and would likely reduce the market price of our Common Stock and hamper our ability to raise additional capital.&nbsp;&nbsp;There
is no active market for any of our securities including the securities in this Offering, and no market is expected to develop in
the foreseeable future for any of such securities. Further, there can be no assurance that we will ever consummate a public offering
of any of our securities. Accordingly, investors must therefore bear the economic risk of an investment in the Securities thereof,
for an indefinite period of time. Even if an active market develops for the common stock, Rule 144 promulgated under the Securities
Act (&quot;Rule 144&quot;), which provides for an exemption from the registration requirements under the Securities Act under certain
conditions, requires, among other conditions, a one-year holding period prior to the resale (in limited amounts) of securities
acquired in a non-public offering without having to satisfy the registration requirements under the Securities Act. There can be
no assurance that we will fulfill any reporting requirements in the future under the Securities Exchange Act of 1934, as amended,
or disseminate to the public any current financial or other information concerning the Company, as is required by Rule 144 as part
of the conditions of its availability. Our securities have not been registered under the Securities Act.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_003"></A>CAUTIONARY NOTE&nbsp;REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">This prospectus contains forward looking statements that
involve risks and uncertainties, principally in the sections entitled &ldquo;Description of Business,&rdquo; &ldquo;Risk Factors,&rdquo;
and &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations.&rdquo; All statements other
than statements of historical fact contained in this prospectus, including statements regarding future events, our future financial
performance, business strategy and plans and objectives of management for future operations, are forward-looking statements. We
have attempted to identify forward-looking statements by terminology including &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo;
&ldquo;can,&rdquo; &ldquo;continue,&rdquo; &ldquo;could,&rdquo; &ldquo;estimates,&rdquo; &ldquo;expects,&rdquo; &ldquo;intends,&rdquo;
&ldquo;may,&rdquo; &ldquo;plans,&rdquo; &ldquo;potential,&rdquo; &ldquo;predicts,&rdquo; &ldquo;should,&rdquo; or &ldquo;will&rdquo;
or the negative of these terms or other comparable terminology. Although we do not make forward looking statements unless we believe
we have a reasonable basis for doing so, we cannot guarantee their accuracy. These statements are only predictions and involve
known and unknown risks, uncertainties and other factors, including the risks outlined under &ldquo;Risk Factors&rdquo; or elsewhere
in this prospectus, which may cause our or our industry&rsquo;s actual results, levels of activity, performance or achievements
expressed or implied by these forward-looking statements. Moreover, we operate in a very competitive and rapidly changing environment.
New risks emerge from time to time and it is not possible for us to predict all risk factors, nor can we address the impact of
all factors on our business or the extent to which any factor, or combination of factors, may cause our actual results to differ
materially from those contained in any forward-looking statements. All forward-looking statements included in this document are
based on information available to us on the date hereof, and we assumes no obligation to update any such forward-looking statements.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">You should not place undue reliance on any forward-looking
statement, each of which applies only as of the date of this prospectus. Before you invest in our securities, you should be aware
that the occurrence of the events described in the section entitled &ldquo;Risk Factors&rdquo; and elsewhere in this prospectus
could negatively affect our business, operating results, financial condition and stock price. Except as required by law, we undertake
no obligation to update or revise publicly any of the forward-looking statements after the date of this prospectus to conform our
statements to actual results or changed expectations.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_004"></A><B>DIVIDEND POLICY</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We plan to retain any earnings for the foreseeable future
for our operations. We have never paid any dividends on our common stock and do not anticipate paying any cash dividends in the
foreseeable future. Any future determination to pay cash dividends will be at the discretion of our Board of Directors and will
depend on our financial condition, operating results, capital requirements and such other factors as our Board of Directors deems
relevant. In addition, our credit facility restricts our ability to pay dividends.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_005"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> We will not receive any proceeds from the sale of the
common stock by the selling stockholders. However, we may receive up to approximately $46.8 million in the aggregate upon the
exercise of the warrants if the holders exercise them for cash. However, as these warrants also include a cashless exercise feature
there can be no assurance that we will receive any capital from the exercise of such warrants. The registration of common stock
pursuant to this prospectus does not necessarily mean that any of those shares will ultimately be offered or sold by the selling
stockholders. We intend to use the proceeds received from any cash exercise of the warrants for working capital and general corporate
purposes. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_006"></A><B>DILUTION</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> We are not selling any of the shares of our common stock
in this offering. All of the shares sold in this offering will be held by the selling stockholders at the time of the sale, so
that no dilution will result from the sale of the shares. Assuming the 100% exercise of our Series A Warrants (which expire on
October 10, 2014), if all of the remaining warrants contained in this registration statement are exercised we will have an additional
11,344,403 shares of common stock issued and outstanding. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_007"></A>PENNY STOCK CONSIDERATIONS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our common stock will be a penny stock, therefore, trading
in our securities is subject to penny stock considerations. Broker-dealer practices in connection with transactions in &ldquo;penny
stocks&rdquo; are regulated by certain penny stock rules adopted by the SEC.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Penny stocks generally are equity securities with a price
of less than $5.00 (other than securities registered on certain national securities exchanges or quoted on the NASDAQ system).
Penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver
a standardized risk disclosure document that provides information about penny stocks and the risks in the penny stock market. The
broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the
broker-dealer and its salesperson in the transaction, and monthly account statements showing the market value of each penny stock
held in the customer&rsquo;s account. The broker-dealer must also make a special written determination that the penny stock is
a suitable investment for the purchaser and receive the purchaser&rsquo;s written agreement to the transaction. These requirements
may have the effect of reducing the level of trading activity, if any, in the secondary market for a security that becomes subject
to the penny stock rules. The additional burdens imposed upon broker-dealers by such requirements may discourage broker-dealers
from effecting transactions in our securities, which could severely limit their market price and liquidity of our securities. These
requirements may restrict the ability of broker-dealers to sell our common stock and may affect your ability to resell our common
stock.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_008"></A><B>SELLING STOCKHOLDERS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The common shares being offered for resale by the selling
stockholders consist of 32,617,220 shares of our common stock that are issued and outstanding, including up to (i) 2,762,5045
shares of our common stock issuable upon exercise of Series A Preferred and Notes Warrants held by the selling stockholders named
in this prospectus at an exercise price of $0.80 per share; (ii) 17,163,799 shares of our common stock issuable upon exercise
of Series A Warrants held by the selling stockholders named in this prospectus at an exercise price of $1.50 per share; and (iii)
8,581,899 shares of our common stock issuable upon exercise of Series B Warrants held by the selling stockholders named in this
prospectus at an exercise price of $2.25 per share. </P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The following table sets forth certain information regarding
the selling stockholders and the shares offered by them in this prospectus. Each selling stockholder&rsquo;s percentage of ownership
is based upon 43,631,535 shares of common stock outstanding as of September 12, 2014 and all securities which the person has the
right to acquire within 60 days through the exercise of any option or warrant or through the conversion of a convertible security. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; line-height: normal; text-align: center; padding-left: 0; text-indent: 0"><FONT STYLE="color: black"><B> Investor
    Name </B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; line-height: normal"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; line-height: normal; text-align: center"><FONT STYLE="color: black"><B> Shares
    Beneficially Owned prior to Offering </B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; line-height: normal"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; line-height: normal"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; line-height: normal; text-align: center"><FONT STYLE="color: black"><B> Percentage
    (%) Beneficially Owned prior to Offering </B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; line-height: normal"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; line-height: normal"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Shares to </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Offer (1) </B></P></TD>
    <TD STYLE="padding-bottom: 1.5pt; line-height: normal"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; line-height: normal"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Shares Beneficially Owned </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> after </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Offering </B></P></TD>
    <TD STYLE="padding-bottom: 1.5pt; line-height: normal"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; line-height: normal"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Percentage Beneficially
        Owned </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> After </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Offering </B></P></TD>
    <TD STYLE="padding-bottom: 1.5pt; line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 38%; line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> AAJK Investments LLC </FONT></TD>
    <TD STYLE="width: 1%; line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: normal"> &nbsp; </TD>
    <TD STYLE="width: 9%; line-height: normal; text-align: right"><FONT STYLE="color: black"> 41,667 </FONT></TD>
    <TD STYLE="width: 1%; line-height: normal"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: normal"> &nbsp; </TD>
    <TD STYLE="width: 9%; line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="width: 1%; line-height: normal"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: normal"> &nbsp; </TD>
    <TD STYLE="width: 9%; line-height: normal; text-align: right"><FONT STYLE="color: black"> 41,667 </FONT></TD>
    <TD STYLE="width: 3%; line-height: normal"><FONT STYLE="color: black"> (1) </FONT></TD>
    <TD STYLE="width: 1%; line-height: normal"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: normal"> &nbsp; </TD>
    <TD STYLE="width: 9%; line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="width: 1%; line-height: normal"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: normal"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: normal"> &nbsp; </TD>
    <TD STYLE="width: 9%; line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="width: 1%; line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Aaron Lehmann </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 30,000 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 30,000 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (2) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Abel Armando Casillas Malo </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 50,000 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 50,000 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (3) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Abelia Investment Limited </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 333,333 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 333,333 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (4) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Adam Baker </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 166,667 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 166,667 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (5) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Adam Biedrzycki </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 333,333 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 333,333 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (6) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Alan Greenhalgh &amp; Angela Greenhalgh JTWROS </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 2,499,930 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 4 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> % </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 2,499,930 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (7) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Alan H Boyd </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 83,333 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 83,333 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (8) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Alan J Reid &amp; Susan Reid JTWROS </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 166,667 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 166,667 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (9) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Albert H Konetzni Jr &amp; Shirly A Konetzni JT TEN </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 41,667 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 41,667 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (10) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Alberto Sadde Leonella Olivieri De Sadde JTWROS </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 37,734 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 37,734 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (11) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Alejandro David Gonzalez </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 41,667 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 41,667 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (12) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Alfredo F Ramirez-Macdonald </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 41,667 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 41,667 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (13) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> AMN 01012011APS </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 41,667 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 41,667 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (14) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Ana Irina Arango Martinez &amp; Witold Ruchala JTWS </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 41,667 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 41,667 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (15) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Anand Palanisamy </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 16,667 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 16,667 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (16) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Anders P Lindholm </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 83,333 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 83,333 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (17) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Andre Luiz J Franco </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 33,333 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 33,333 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (18) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Andreas Krawinkel </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 15,625 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 15,625 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (19) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Andreas Wawrla </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 1,666,665 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 3.8 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 1,666,665 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (20) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Andrew Bellamy </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 62,344 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 62,344 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (21) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Andrew Chandler </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 83,333 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 83,333 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (22) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Andrew Green </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 41,667 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 41,667 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (23) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Andrew Greg Withers </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 41,667 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 41,667 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (24) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Andrew M Klein </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 66,667 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 66,667 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (25) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Andrew P Ferrett </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 41,667 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 41,667 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (26) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Angelo De Rosa </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 96,667 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 96,667 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (27) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Angus M Mccoss </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 19,167 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 19,167 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (28) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Anthony M Gatti </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 83,333 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 83,333 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (29) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Anthony Mongelli </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 58,333 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 58,333 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (30) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Anthony N Parisi III </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 83,333 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 83,333 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (31) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Armando Mediola Carvajal </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 23,438 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 23,438 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (32) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Art Sadin </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 416,665 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 416,665 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (33) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Arthur E Pereless </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 33,333 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 33,333 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (34) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Arthur Smolensky </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 16,667 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 16,667 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (35) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> ATA Investments LLC </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 41,647 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 41,647 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (36) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Azmy M Awad </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 156,602 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 156,602 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (37) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> B Adrian Kesala &amp; Larissa Kesala JTWROS </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 41,667 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 41,667 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (38) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Balsam Capital Management </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 30,000 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 30,000 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (39) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Barry G Pallay </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 83,333 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 83,333 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (40) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Barry R Shaw </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 33,300 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 33,300 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (41) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Belleron Finance Limited </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 166,667 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 166,667 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (42) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Ben Franklin Technology Partners of Southeastern Pennsylvania </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 1,070,469 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 2.5 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 1,070,469 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (43) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Benjamin Hasty </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 130,048 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 130,048 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (44) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Benoit Dumont </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 28,125 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 28,125 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (45) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Bernard Slede &amp; Lisa Slede JTWROS </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 33,333 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 33,333 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (46) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Bernard V P Schyns &amp; Marian Schyns JTWROS </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 41,667 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 41,667 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (47) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Bernard V P Schyns Marian Schyns JTWROS </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 97,564 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 97,564 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (48) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Bernd Albrecht </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 83,333 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 83,333 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (49) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Billy Harris </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 39,063 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 39,063 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (50) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Billy W Harris </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 58,333 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 58,333 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (51) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Bioadvance </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 1,850,089 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 1.1 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> 1,850,089 </TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (52) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> BL Realty LLC </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 122,396 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 122,396 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (53) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Blowers Farms LLC </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 16,667 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 16,667 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (54) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Bohdan Chaban </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 322,917 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 322,917 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (55) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Boombeam Incorporated </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 156,250 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 156,250 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (56) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Brad Larson </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 20,000 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 20,000 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (57) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> &nbsp; -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: normal; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="color: black"> Bradley V Button </FONT></TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 23,438 </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> * </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> 23,438 </FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black"> (58) </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"><FONT STYLE="color: black"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; padding-left: 10pt; text-align: center; line-height: 115%; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Investor
    Name </B></FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Shares
    Beneficially Owned prior to Offering </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Percentage
    (%) Beneficially Owned prior to Offering </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Shares to </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Offer (1) </B></P></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Shares Beneficially Owned </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> after Offering </B></P></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Percentage Beneficially
        Owned </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> After Offering </B></P></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 38%; padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Brian
    E Jones &amp; Peggy A Jones JTWROS </FONT></TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="width: 3%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (59) </FONT></TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Brian
    Haughan </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (60) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Brian
    V Skillern </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (61) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Bruce
    E Frost </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (62) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Bruce
    G Krueger </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (63) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Bruce
    Levy </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (64) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Bruce
    Tewes </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,917 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,917 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (65) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Bruno
    J Casatelli </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 1,002,500 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 2.3 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 1,002,500 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (66) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Bryan
    J Hanks &amp; Michelle B Hanks JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 205,730 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 205,730 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (67) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Burton
    Mark Paull </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 213,002 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 213,002 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (68) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Calvin
    B Jr Klotz </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (69) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Carlos
    E Lion </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 80,730 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 80,730 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (70) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Carlos
    Espinal </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (71) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Carlos
    Estrada </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (72) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Carmel
    Resources LLC </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (73) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Carroll
    Michael B Carroll &amp; Sheila J </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (74) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Carsten
    Greiwe </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (75) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Cary
    V Sorensen </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (76) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Cesar
    Fernandez Cardenas </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 15,625 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 15,625 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (77) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Charles
    J Magolske </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (78) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Charles
    L. Weidner TTEE &amp; Alice N. Barrett Weidner TTEE FBO The Weidner Family Revocable Trust Dtd 8/13/07 </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (79) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Charles
    Morse </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (80) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Charles
    W Ganse </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 80,730 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 80,730 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (81) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Charles
    W Sandmann </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (82) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Chip
    Del Coro </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (83) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Chris
    Nigel Ffinch </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 46,875 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 46,875 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (84) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Christoph
    Lintermanns &amp; Ulrike Verschuer Lintermanns JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (85) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Christopher
    G Davison </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 250,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 250,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (86) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Christopher
    J Clemmow </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (87) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Christopher
    J L Cheadle </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 25,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 25,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (88) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Christopher
    J Mehos </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (89) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Claus
    Erik Madsen </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (90) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Conor
    Gilligan </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 32,500 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 32,500 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (91) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Constantino
    Parente </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,666 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,666 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (92 </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Cormac
    Maguire </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 17,500 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 17,500 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (93) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Craig
    William Bannister </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (94) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Daniel
    E Corallo </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (95) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Daniel
    Jacques Hernandez Zuili </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 62,500 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 62,500 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (96) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Daniel
    M Wallach &amp; Joyce Wallach JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (97) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Daniel
    Mccarthy </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (98) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Daniel
    P Wikel </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (99) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Daniel
    S Faulkner </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 17,188 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 17,188 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (100) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Danny
    Sergeant </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 17,188 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 17,188 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (101) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Darashaw
    Motashaw </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 333,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 1 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> % </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 333,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (102) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> David
    A Kuhar </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (103) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> David
    A Scott </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (104) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> David
    Estuardo Trujillo </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (105) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> David
    F Garr </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,334 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,334 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (106) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> David
    J Bommarito Trust Dtd 5-10-96 David J Bommarito TTEE </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (107) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> David
    L Hawkins </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 20,833 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 20,833 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (108) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> David
    Longley </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 58,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 58,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (109) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> David
    M Laurenson </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (110) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> David
    Norwood &amp; Yuyun Li JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (111) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> David
    P Mcquarrie </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (112) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>

    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> David
    Perlmutter &amp; Haya Perlmutter JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (113) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> David
    S Burr &amp; Cheri Ackert-Burr Burr JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (114) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> David
    Scott </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (115) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> David
    W Frost </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 358,192 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 1 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> % </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 358,192 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (116) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> David
    W Macurdy </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (117) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> De
    Pooter Be Heer </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 64,323 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 64,323 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (118) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Dean
    Beaver </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 266,666 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 266,666 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (119) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"> </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; padding-left: 10pt; text-align: center; line-height: 115%; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Investor
    Name </B></FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Shares
    Beneficially Owned prior to Offering </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Percentage
    (%) Beneficially Owned prior to Offering </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Shares to </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Offer (1) </B></P></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Shares Beneficially Owned </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> after Offering </B></P></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Percentage Beneficially
        Owned </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> After Offering </B></P></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Deborah
    L Katz </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (120) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Dennis
    Winson </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (121) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Desmond
    Murphy </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (122) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Dhiman
    Parikh </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (123) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Dianne
    M Scheck </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (124) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 38%; padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Diatou
    Diop &amp; Steven De Decker </FONT></TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="width: 3%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (125) </FONT></TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>

    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Diatou
    Diop &amp; Steven De Decker JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (126) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Dirk
    S Cox </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (127) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Donald
    E Womeldorph Jr </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 25,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 25,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (128) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Donald
    G Pence </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (129) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Donald
    K Coffey </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (130) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Donald
    P Sesterhenn </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (131) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Douglas
    A Alcott </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (132) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Douglas
    Arantes </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (133) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Douglas
    Davies </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (134) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Douglas
    E Eckert </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 80,730 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 80,730 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (135) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Douglas
    E Jasek </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 296,024 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 296,024 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (136) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Douglas
    J Amos &amp; Carol A Amos JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (137) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Douglas
    R Holroyd &amp; Jill K Holroyd JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (138) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Douglas
    W Tiffan </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (139) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Dr.
    Calvin Simmons </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (140) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Dr.
    Glen Mccracken </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 25,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 25,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (141) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Dr.
    Gurpreet S Ahluwalia </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (142) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Dr.
    Jan-Hendrik Spilgies </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 12,813 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 12,813 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (143) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Dr.
    Jeffrey Miller </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (144) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Dr.
    John E Bishop </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (145) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Dr.
    Larry Vaught </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 125,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 125,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (146) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Dr.
    Mariusz J Klin </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (147) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Dr.
    Richard Matter &amp; Anita Matter JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 131,280 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 131,280 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (148) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Intentionally
    omitted</FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="text-align: right; line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Duerr
    Capital LLC </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (150) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Eamon
    P Judge </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 20,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 20,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (151) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Earl
    R Richardson </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (152) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Ecovest
    Limited </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (153) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Eduardo
    Guemez Sarre </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (154) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Eduardo
    Raul Azcarraga Perez &amp; Luiz Emilio Azcarraga Perez JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (155) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Edward
    C Moore </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (156) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Edward
    John Mazur </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (157) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Eliana
    Cardenas &amp; Roberto Mendez JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 56,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 56,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (158) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Elie
    Ghazal </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (159) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Emily
    Coakley &amp; James Hicks JTIC </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (160) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Enguerrand
    De Ponteves </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 67,996 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 67,996 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (161) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Eric
    Knudstrup </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (162) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Eric
    Stuerken </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (163) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Eugene
    E Eubank </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 100,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 100,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (164) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> F
    Martin Anson &amp; Jacqueline O Anson JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (165) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Fernando
    Malvido Olascoaga </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 153,125 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 153,125 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (166) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Fintran
    Ltd </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 25,083 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 25,083 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (167) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Fiona
    Mcphee &amp; Andrew Charles Good JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 66,666 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 66,666 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (168) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Foster
    Jordan &amp; Camela Jordan JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 125,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 125,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (169) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Fourfathom
    Capital LLC </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (170) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Franco
    Castro-Marin </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (171) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Frank
    Farello </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (172) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Frans
    Zoetmulder </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 77,605 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 77,605 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (173) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Frans
    Zonneveld </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (174) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Garfield
    W Hardeman Tod </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 23,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 23,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (175) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Gary
    J Mabie </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (176) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Gary
    J Mabie &amp; Janelle L Mabie JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (177) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Geoff
    W Haggart </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (178) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> George
    A Meyers </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 20,833 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 20,833 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (179) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> George
    Diamantopoulos </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 80,730 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 80,730 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (180) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> George
    Elefther &amp; Karin Alexa Elefther JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (181) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp;&nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; padding-left: 10pt; text-align: center; line-height: 115%; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Investor
    Name </B></FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Shares
    Beneficially Owned prior to Offering </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Percentage
    (%) Beneficially Owned prior to Offering </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Shares to </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Offer (1) </B></P></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Shares Beneficially Owned </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> after Offering </B></P></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Percentage Beneficially
        Owned </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> After Offering </B></P></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 38%; padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> George
    M Zelinski </FONT></TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 164,063 </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 164,063 </FONT></TD>
    <TD STYLE="width: 3%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (182) </FONT></TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Georges
    Zanellato </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 75,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 75,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (183) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Gerard
    A Gabriel </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,026 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,026 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (184) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Gerard
    De Jonge </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (185) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Gerardo
    C Villarreal-Rodriguez </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (186) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Gideon
    Kaplan Ilana Kaplan JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (187) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Gonzalo
    A Salgueiro </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (188) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Graeme
    Farr </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 46,875 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 46,875 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (189) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Graham
    John Nicholson </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (190) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Graham
    M Bones </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (191) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Grant
    L Hanby </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (192) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Grant
    O'Connor </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 58,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 58,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (193) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Gregory
    Alexander </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 97,564 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 97,564 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (194) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> GSI
    Global Shipping Inc </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 333,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 1 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> % </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 333,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (195) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Guillermo
    Alejandro Browne &amp; Paula Fernandez Browne JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (196) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Gustavo
    Dos Reis Vasques </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (197) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Gustavo
    Guzman-Barron Escobedo </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (198) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Harry
    A Theochari </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (199) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Helen
    Cail </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (200) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Helmut
    Koehler </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 183,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 183,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (201) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Henri
    Derwael </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (202) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Hernan
    Zaballa </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 65,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 65,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (203) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Hernando
    Holguin </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (204) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Hochman
    Family LLP </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 76,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 76,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (205) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Horacio
    Fajer Cardona </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (206) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Horacio
    Sbrolla </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (207) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Howard
    Wool </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (208) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Huai-Hung
    Kao </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 19,400 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 19,400 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (209) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Ian
    An Wight </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (210) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Ian
    H Murray </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 361,980 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 1 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> % </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 361,980 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (211) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Immotrend
    Inc </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (212) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -9pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Inmobiliaria
    E Inversiones Jorge Arturo Troncoso Ruiz Eirl </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (213) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Island
    Capital Nominees Ltd </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 96,719 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 96,719 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (214) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> J
    Brian Boulter </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (215) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> James
    Johnson </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 111,458 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 111,458 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (216) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> James
    Kinnell </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (217) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> James
    L Payne </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 93,750 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 93,750 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (218) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> James
    Messina &amp; Margaret M Messina JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 15,625 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 15,625 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (219) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> James
    R Bement &amp; Sheryl Bement JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (220) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> James
    R Deaver </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (221) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> James
    Regan &amp; Maureen Regan JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 58,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 58,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (222) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> James
    V Cunningham </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (223) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> James
    W Anthony </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (224) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> James
    W Anthony &amp; Delsia Anthony JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (225) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Jan
    Rehnman </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (226) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Javier
    Escajadillo </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 216,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 216,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (227) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Jay
    Robert Johnson &amp; Lori Johnson JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (228) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Jean-Marc
    Simandoux </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 186,980 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 186,980 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (229) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Jeff
    C Kleinschmidt </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 381,419 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 381,419 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (230) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Jeff
    L Stevens </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 164,063 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 164,063 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (231) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Jeffery
    C Boggs </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 62,500 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 62,500 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (232) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Jeffery
    W Maier </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (233) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Jeffrey
    G Hipp </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (234) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Jeremy
    Evan Creson </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (235) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Jim
    Regan </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (236) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Jimmy
    R Hasley </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 333,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 333,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (237) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Joaquin
    Noriega &amp; Patricia C P De Noriega JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 23,438 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 23,438 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (238) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Joel
    Pruzansky </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (239) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Johan
    Peter Thomas Hinderoth </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (240) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> John
    Avon </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 20,833 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 20,833 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (241) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> John
    Evans </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (242) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> John
    Flahavan </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 66,583 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 66,583 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (243) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> John
    J Breig </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (244) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> John
    Lloyd </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 8,438 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 8,438 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (245) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> John
    Malfer &amp; Toni Malfer JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (246) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> John
    R B Gould </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (247) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> John
    R Harrison &amp; Linda L Harrison JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 183,855 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 183,855 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (248) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"> &nbsp; </P>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Investor
    Name </B></FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Shares
    Beneficially Owned prior to Offering </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Percentage
    (%) Beneficially Owned prior to Offering </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Shares to </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Offer (1) </B></P></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Shares Beneficially Owned </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> after Offering </B></P></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Percentage Beneficially
        Owned </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> After Offering </B></P></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Jon H Lytle &amp; Carrie M Lytle JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 416,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 416,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (249) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Jonas E Neihardt </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 84,063 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 84,063 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (250) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Jonathan Smith </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (251) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 38%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Jonathan Steinhouse </FONT></TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 116,667 </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 116,667 </FONT></TD>
    <TD STYLE="width: 3%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (252) </FONT></TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Jorge Enrique Borbolla </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 93,750 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 93,750 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (253) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Jorge Horacio Boldrini &amp; Paula
    X Ferradas Abalo Boldrini JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (254) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Jorge Marchena &amp; Margaret Marchena
    JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (255) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Jorge Troncoso </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (256) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Jose Da Silva &amp; Angel Da Silva
    JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (257) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Jose E Abascal </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 7,813 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 7,813 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (258) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Jose S Maiz </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 202,917 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 202,917 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (259) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Josef Keltjens &amp; Beverly Warner
    Keltjens JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (260) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Joseph A D'Elia </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 250,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 250,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (261) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Joseph Blum </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (262) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Joseph Charap </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 40,625 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 40,625 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (263) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Joseph J Ebens </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 65,105 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 65,105 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (264) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Joseph T Oppito </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (265) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Juan Antonio Winter Razmilic </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 73,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 73,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (266) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Juan Manuel Farias </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 46,875 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 46,875 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (267) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Julian Archer &amp; Ingrid E Archer
    Ven Den Berg JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 8,125 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 8,125 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (268) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Julian Bavin </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (269) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Julian P Kemble </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (270) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Julius E Talton </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 375,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 375,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (271) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Kelly Anne Paiva Alves &amp; Jaime
    E Vazquez JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (272) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Ken R Klimitchek </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 128,125 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 128,125 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (273) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Kenneth G Williamson </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 161,458 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 161,458 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (274) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Kenneth Jr Havens </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (275) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Kenneth N Larsen Trust U/A/D 9/25/2009
    Kenneth N Larsen Trustee </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 197,917 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 197,917 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (276) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Kenneth P Black </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (277) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Kermit E Reynolds Jr Family LLC </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (278) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Kevin A Rahrig </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (279) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Kevin J Poor </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 312,500 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 312,500 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (280) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Kevin Kapales </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (281) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Kevin Lynch </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 55,886 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 55,886 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (282) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Kevin O Lacour </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (283) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Kevin P Mccarthy </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (284) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Kevin Paige </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (285) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Kevin T Mcdonough </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 58,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 58,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (286) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> KMR Agency Inc </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (287) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Kristine Peters </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (288) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> L Dean Fox </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 164,063 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 164,063 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (289) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Lance Ziaks &amp; Janet Ziaks JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 26,563 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 26,563 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (290) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Larry G Majerus </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (291) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Larry W Schwartz </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 244,792 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 244,792 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (292) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Lawrence B Martel </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (293) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Lawrence Solomon Revocable Living
    Trust Lawrence Solomon TTEE </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (294) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Lee E Cleveland </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (295) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Lee Westwood </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (296) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Leonard J Pruzansky </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (297) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Linda A Casatelli </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (298) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Logan L Hurst </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 117,188 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 117,188 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (299) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Lorenzo Barrera </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (300) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Luc Verhoeven </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (301) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Luis Rafael Nunes </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (302) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Maarten Haast </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 6,250 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 6,250 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (303) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Magoba C V </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 666,665 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 1.5 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> % </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 666,665 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (304) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Mairi Pantechi &amp; Ioannis Romanos
    JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (305) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Malcolm C.S Leslie &amp; Hilary Jane
    Leslie JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 312,500 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 312,500 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (306) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Malcolm C.S. Leslie &amp; Hilary Jane
    Leslie JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 666,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 1.5 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> % </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 666,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (307) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Malcolm Hay </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 122,396 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 122,396 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (308) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Manu Prasad Parikh </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 125,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 125,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (309) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Marc Gilligan </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,283 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,283 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (310) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Marc J Boreham </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 121,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 121,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (311) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Investor
    Name </B></FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Shares
    Beneficially Owned prior to Offering </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Percentage
    (%) Beneficially Owned prior to Offering </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Shares to </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Offer (1) </B></P></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Shares Beneficially Owned </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> after Offering </B></P></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Percentage Beneficially
        Owned </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> After Offering </B></P></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 38%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Maree Casatelli </FONT></TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 66,667 </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 66,667 </FONT></TD>
    <TD STYLE="width: 3%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (312) </FONT></TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Maria De Lourdes Domenc Ii &amp; Jose
    Maiz Garcia JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 54,688 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 54,688 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (313) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Mario Rodriguez </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 24,480 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 24,480 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (314) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Mark A Bradley </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (315) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Mark A Maki &amp; Sara L Maki JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 125,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 125,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (316) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Mark A Suwyn </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 333,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 333,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (317) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Mark C Jasek </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (318) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Mark G Boulanger </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (319) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Mark J Aurig &amp; Toni H Aurig JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 25,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 25,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (320) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Mark J Campbell </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (321) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Mark J Jackson </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (322) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Mark S Heymann </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (323) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Mark Tonkin </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 15,625 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 15,625 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (324) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Matthew Luongo </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (325) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Matthew Reid </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (326) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Matthew W Dahan </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (327) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Matura
    Family Trust Ua 05-26-1998 Gary D Matura TTEE </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (328) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Maurice Schwartz &amp; Sons Partnership </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (329) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Menghui Cao </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (330) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Mercedes Del Carmen Orozoco De Ortega
    &amp; Francisco Ortega Gonzalez JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 125,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 125,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (331) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Mercedes Sepulveda </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 125,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 125,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (332) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Michael B Carroll &amp; Sheila J Carroll
    JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 312,500 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 312,500 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (333) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Michael Bundschuh </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (334) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Michael C Bellard </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (335) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 9pt; text-indent: -9pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Michael
    Chester &amp; Mary-Ann Stadtler Chester JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (336) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Michael D Watson </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (337) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Michael E Whitley </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (338) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Michael Engdall &amp; Susan Engdall
    JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 145,833 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 145,833 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (339) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Michael H Pentecost </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (340) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 13.5pt; text-indent: -13.5pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Michael
    J Angergame &amp; Sandra Angerame JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (341) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Michael J Campbell Jeanette Campbell
    JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (342) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Michael J Mathieu </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 258,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 258,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (343) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Michael Jason Maggard </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 161,458 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 161,458 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (344) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Michael K Barber &amp; Julia K Barber
    JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 96,875 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 96,875 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (345) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Michael Karsonovich </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (346) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Michael L Turner </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (347) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Miguel Angel Penaloza Bretel </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (348) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Mr Gerard Leroy &amp; Mrs Dominique
    Leroy JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (349) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Mukthar Abdul </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (350) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Muneswa Sreenivasan </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (351) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Nabil M Yazgi </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (352) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Nabil
    Yazgi Md Pa Cash Balance Plan &amp; Trust 12-28-2008 Nabil Yazgi TTEE </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 75,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 75,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (353) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Naresh Guntupalli </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (354) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Nico Van Spijker </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 11,250 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 11,250 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (355) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Nicolas A Riggio </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (356) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Octect Investment Ltd </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (357) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Oliver Schulte </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 161,458 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 161,458 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (358) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Olivier Demesy </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (359) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Oscar Storen </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (360) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Pan Feng </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 250,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 250,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (361) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Paresh Karandikar &amp; Lorna Karandikar </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (362) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Parthipan Krishnasamy </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 25,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 25,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (363) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Pascal M Lipsky </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (364) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Patrick J Wagner &amp; Janie L Wagner
    JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (365) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Patrick Larose </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (366) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Patrick Pettersson </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 22,188 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 22,188 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (367) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Patrick S Thomas </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 125,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 125,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (368) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Paul A Wildberger </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 239,583 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 239,583 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (369) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Investor
    Name </B></FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Shares
    Beneficially Owned prior to Offering </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Percentage
    (%) Beneficially Owned prior to Offering </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Shares to </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Offer (1) </B></P></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Shares Beneficially Owned </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> after Offering </B></P></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Percentage Beneficially
        Owned </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> After Offering </B></P></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 38%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Paul Clayton </FONT></TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="width: 3%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (370) </FONT></TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Paul D R Searle </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (371) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Paula Vera Ocampo &amp; Jose Ignacio
    Feretti JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (372) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Paulina Veytia &amp; Nicholas Osorio
    JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (373) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Pedro B Torres </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 58,855 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 58,855 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (374) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Per Arvid Schoyen </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (375) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Perry Family Trust William Franklin
    Perry TTEE </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (376) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Peter F Zichelle </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (377) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Peter H Colettis </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 80,730 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 80,730 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (378) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Peter J Zaborowski </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (379) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Peter Thomson </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (380) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Philip Davie </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 90,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 90,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (381) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Philip Ireland </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (382) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Philip Stephenson </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (383) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Philippe Chauffard </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 250,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 250,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (384) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Pieter M Duplessis </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,051 </FONT></TD>
    <TD> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,051 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (385) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Principle Financial Holdings LLC </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (386) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Proctor Investments Ltd </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (387) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> R Scott Mccay &amp; Rebecca E Mccay
    JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (388) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Rafael Penunuri </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 149,802 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 149,802 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (389) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Raja Appachi </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 91,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 91,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (390) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Rajinder Kaur &amp; Lester Alvis JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 500,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 1.1 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 500,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (391) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Ram V Seetharam &amp; Rani J Seetharam
    JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (392) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Randal E Margo </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (393) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Randal J Dirlam </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (394) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Randall L Payne &amp; Kathy S Payne
    JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 51,232 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 51,232 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (395) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Randy E Johnson &amp; Cheryl A Johnson
    JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (396) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Ravi Mullapudi &amp; Padmaja Mullapudi
    JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (397) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Reed Family Trust Dtd 06/24/1999 Clayton
    A Reed &amp; Stephanie S Reed TTEEs </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (398) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Rene St Pierre &amp; Cindi St Pierre
    JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (399) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Revocable
    Living Trust FBO Daniel Carr Daniel Carr Trustee </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 66,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 66,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (400) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Ricardo Noriega Erosa </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 23,438 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 23,438 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (401) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Richard Brosch </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (402) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Richard Burgess </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 121,771 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 121,771 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (403) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Richard D Pence </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (404) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Richard E Brooks </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (405) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Richard L Bowen </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (406) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Richard Levine </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 312,500 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 312,500 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (407) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Richard Lock </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 66,355 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 66,355 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (408) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Richard Tyler &amp; Jane Tyler JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (409) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Rippee Mineral Management LLC </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 34,375 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 34,375 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (410) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Robert Barr </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 31,083 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 31,083 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (411) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Robert Bruce Waters </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (412) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Robert Chilton </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (413) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Robert D Priday </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 361,795 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 361,795 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (414) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Robert D Selinger </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (415) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Robert Dunn &amp; Judy Dunn JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (416) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Robert Ian Chaplin </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (417) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Robert J Laubenthal </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 57,292 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 57,292 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (418) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Robert John Kline-Schoder Rev Living
    Trust Dtd 1-27-95 </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (419) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Robert
    M Jennings Jr Trust U/W Robert M Jennings Jr Daniel Carr Trustee FBO Eve Jennings W/ Residual To Children </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (420) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Robert M Jennings Jr Trust Uad 8/4/2006
    Daniel Carr Trustee </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (421) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Robert N Preite </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (422) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Robert R Hair </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 66,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 66,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (423) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Robert Zens </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 58,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 58,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (424) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Roberto Lupi </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (425) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Roberto Mendez Eliana Cardenas Mendez
    JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 23,438 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 23,438 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (426) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Robinhood II Lp </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 468,750 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 1.1 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 468,750 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (427) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Roger P Bakale </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (428) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Rohn M Householder </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (429) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Ron D Craig </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 234,375 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 234,375 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (430) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Ronald A Soicher </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (431) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Ronald Grimaldi </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (432) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; padding-left: 10pt; text-align: center; line-height: 115%; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Investor
    Name </B></FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Shares
    Beneficially Owned prior to Offering </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Percentage
    (%) Beneficially Owned prior to Offering </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Shares to </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Offer (1) </B></P></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Shares Beneficially Owned </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> after Offering </B></P></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Percentage Beneficially
        Owned </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> After Offering </B></P></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 38%; padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Ronald
    J Woodward </FONT></TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 55,000 </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 55,000 </FONT></TD>
    <TD STYLE="width: 3%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (433) </FONT></TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Ross
    Rodgers </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (434) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Rowen
    Grierson </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (435) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Rs
    Draughting &amp; Engineering Services Ltd </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (436) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Russel
    T Davies </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (437) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> S
    Alexei Gitter </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (438) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sal
    Dimeglio &amp; Kathleen Dimeglio JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 26,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 26,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (439) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Samuel
    A Medici &amp; Anita L Medici JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (440) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Samuel
    Gorman </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 203,125 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 203,125 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (441) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sandeep
    M Shishodia </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (442) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sandra
    F Tomlinson </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 37,500 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 37,500 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (443) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sankar
    K Aiyar </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 25,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 25,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (444) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Santi
    A Greco &amp; Nancy A Greco JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (445) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Santo
    Chiarelli </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 26,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 26,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (446) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Scott
    L Byer </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (447) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Seamus
    Dunne </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 31,250 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 31,250 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (448) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sean
    A Tyndale-Biscoe </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (449) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sean
    W Meitner </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (450) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sharon
    Mckenna Smith </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 25,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 25,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (451) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Simon
    C Guscott </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 210,397 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 210,397 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (452) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Srinivas
    Dodda </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (453) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Stacy
    Porter </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (454) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Standard
    Sand &amp; Silica Co Inc </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 20,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 20,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (455) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Stanley
    Mansfield </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (456) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Stassi
    Anastassov </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (457) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Stefaan
    Verhelst &amp; Katharine DeMeestere JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (458) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Stephen
    E Gately </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (459) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Stephen
    H Christiansen </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,594 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,594 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (460) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Stephen
    H Cook </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (461) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Stephen
    Hart </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 25,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 25,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (462) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Stephen
    Herrmann </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 500,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 1.1 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 500,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (463) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Stephen
    J Farley </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (464) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Stephen
    L Gill </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 20,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 20,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (465) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Stephen
    M Kane </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (466) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Stephen
    Park &amp; Tracy Park JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 48,782 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 48,782 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (467) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F Algis J Rajeckas IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (468) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F Art Sadin IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (469) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F Brian Mark Miller Roth IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (470) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F Charles L Weidner Roth IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (471) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F David Gelchie Sep IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (472) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F David W Frost IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 250,521 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 250,521 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (473) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F Dean Beaver R/O IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 425,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 1.0 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 425,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (474) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F Dr Gary W Chmielewski IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 58,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 58,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (475) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F Edwin A Schermerhorn Roth IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 58,726 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 58,726 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (476) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F Garner Mcnett IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (477) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F Graham C Short IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 236,980 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 236,980 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (478) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F H Louis Salomonsky Roth IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (479) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F John H Welsh Roth IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 64,583 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 64,583 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (480) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F John J Mccullough R/O IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (481) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F John L Sommer IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (482) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F John R Evans IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (483) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F Jonathan Steinhouse R/O IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (484) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F Joseph Acquavella R/O IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 125,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 125,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (485) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F Joshua J Gooden IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 108,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 108,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (486) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F Mercedes Sepulveda Roth IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 121,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 121,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (487) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"> </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Investor
    Name </B></FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Shares
    Beneficially Owned prior to Offering </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Percentage
    (%) Beneficially Owned prior to Offering </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Shares to </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Offer (1) </B></P></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Shares Beneficially Owned </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> after Offering </B></P></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Percentage Beneficially
        Owned </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> After Offering </B></P></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F Pat Schneider IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (488) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F Randy Payne IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 85,938 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 85,938 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (489) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F Randy Poston Sep IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (490) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F Richard W Rupnik IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 25,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 25,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (491) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F Robert L Wallerius R/O IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (492) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F Scott W Osborne R/O IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 58,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 58,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (493) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F Thomas Turley Sep IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (494) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F Vincent Petrucci IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (495) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F Walter J Lachewitz Jr IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 136,458 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 136,458 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (496) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F Willard L Simons IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (497) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sterne
    Agee &amp; Leach Inc C/F William Bellinger IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 100,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 100,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (498) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sternee
    Agee &amp; Leach Inc C/F Christina G Einstein IRA </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (499) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 38%; padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Steve
    Lisi </FONT></TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="width: 3%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (500) </FONT></TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Steve
    Octaviano </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (501) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Steve
    Pesner </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (502) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Steven
    A Hobbs </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (503) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Steven
    D Sehnert </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (504) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Steven
    J Henry </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (505) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Steven
    K Nelson </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 156,250 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (506) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Steven
    Kaye </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (507) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Steven
    Shaw </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (508) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Stuart
    R Oliver </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 239,583 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 239,583 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (509) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Suleiman
    Al Hedaithy </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 125,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 125,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (510) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Sylvain
    Pavlowski </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (511) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Taylor
    Cardall </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 25,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 25,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (512) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Theodore
    K Krampf </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (513) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Thierry
    De Beyssac &amp; Florence De Beyssac JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (514) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Thomas
    A Mckenna </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (515) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Thomas
    C Pugh </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 21,875 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 21,875 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (516) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Thomas
    E Vandenberg </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (517) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Thomas
    G Hoffman </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 244,792 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 244,792 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (518) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Tim
    Engels </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (519) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Tim
    Wells </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (520) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Timothy
    A Kippenhan </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (521) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Timothy
    Charles Davis </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (522) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Timothy
    J Kane &amp; Annette K Kane JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 100,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 100,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (523) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Timothy
    P Johnston </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (524) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Timothy
    Williams </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (525) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Todd
    Johnson &amp; Luann Johnson Jt Ten </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 93,750 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 93,750 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (526) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Todd
    Mcgregor </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (527) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Tom
    Ayala </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 43,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 43,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (528) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Tommy
    W Filler </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (529) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Town
    Yield Development Ltd </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (530) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> TQ
    Electronics </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 7,656 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 7,656 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (531) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Trond
    Christensen </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 40,833 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 40,833 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (532) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Trust
    Of Teena Lerner U/A/D 3/31/04 </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (533) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Uday
    Dandamudi </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 51,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 51,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (534) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Ulises
    Vazquez </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 48,782 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 48,782 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (535) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Vincent
    Litrico </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (536) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> VOFPretium
    Plus </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 15,625 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 15,625 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (537) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Wade
    Welborn &amp; Adriana Welborn JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (538) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Waleed
    Suhail Al-Nasrawi </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (539) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Walter
    W Gloyer </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 66,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 66,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (540) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Warren
    S Thune </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,125 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (541) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Wayne
    Young </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 20,833 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 20,833 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (542) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Willem
    Hendrickx </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (543) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> William
    &amp; Sally S Atkins Living Trust August 1998 William &amp; Sally Atkins TTEEs </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 53,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 53,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (544) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> William
    A Valka &amp; Barbara B Valka JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (545) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> William
    A Valka Barbara B Valka JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 97,876 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 97,876 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (546) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> William
    Allan Lucier TOD </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 125,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 125,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (547) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> William
    Bishop </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 283,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 283,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (548) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> William
    Bradley Jr </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (5749) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> William
    G Hicks </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 39,063 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (550) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> William
    J Klaus </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>

    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (551) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> William
    L Lane &amp; Leann Lane JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 122,396 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 122,396 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (552) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> William
    Ryan Wallace </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 33,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (553) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> William
    S Lehmann </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (554) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> William
    Wade Brawley </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (555) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Wilson
    Family Second Restated Trust Dtd Nov 9 2010 As Amended Patricia White Wilson TTEE </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (556) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Wolfgang
    Graaff &amp; Brigditte Graaff JTWROS </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 50,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (557) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Wonpung
    Mulsan Co., Ltd. </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 1,875,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 4.3 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 1,875,000 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (558) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> WTPC
    LLC </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,333 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (559) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Yasoda
    Krishna Prasad Dhulipalla </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (560) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Yogesh
    Desai </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 166,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (561) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Zover
    B V </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> * </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,667 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (562) </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Total </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 61,125,422 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 61,125,422 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"> </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; line-height: normal; text-align: left; padding: 0"> (1) </TD>
    <TD STYLE="width: 95%; line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 16,667 shares of common stock and (ii)
    16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares of common
    stock issuable upon the exercise of the Series B warrants. Alok K. Agraw&nbsp;may be deemed to be the beneficial owner of
    the shares of our common stock held by&nbsp;AAJK Investments LLC (AAJK Investments LLC). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="color: black">(2)</FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 12,000 shares of common stock and (ii) 12,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 6,000 shares of common stock issuable upon the exercise of the Series B warrants (Aaron Lehmann).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0">(3)</TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 20,000 shares of common stock and (ii) 20,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 10,000 shares of common stock issuable upon the exercise of the Series B warrants (Abel Armando Casillas Malo).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0"> (4) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 133,333 shares of common stock and (ii) 133,333
    shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 66,667 shares of common stock
    issuable upon the exercise of the Series B warrants. Peter Mellamara may be deemed to be the beneficial owner of the shares
    of our common stock held by&nbsp;Abelia Investment Limited (Abelia Investment Limited). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="color: black">(5)</FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 66,667 shares of common stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares of common stock issuable upon the exercise of the Series B warrants (Adam Baker).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="color: black">(6)</FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 133,333 shares of common stock and (ii) 133,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 66,667 shares of common stock issuable upon the exercise of the Series B warrants (Adam Biedrzycki).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (7) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 999,972 shares of common
    stock and (ii) 999,972 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 499,986
    shares of common stock issuable upon the exercise of the Series B warrants (Alan Greenhalgh &amp; Angela Greenhalgh JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="color: black">(8)</FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 33,333 shares of common stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares of common stock issuable upon the exercise of the Series B warrants (Alan H Boyd).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0">(9)</TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 66,667 shares of common stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares of common stock issuable upon the exercise of the Series B warrants (Alan J Reid &amp; Susan Reid JTWROS).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0">(10)</TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 16,667 shares of common stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares of common stock issuable upon the exercise of the Series B warrants (Albert H Konetzni Jr &amp; Shirly A Konetzni JT TEN).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0">(11)</TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 30,188 shares of common stock and (ii) 7,547 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (Alberto Sadde Leonella Olivieri De Sadde JTWROS).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0">(12)</TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 16,667 shares of common stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares of common stock issuable upon the exercise of the Series B warrants (Alejandro David Gonzalez).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0">(13)</TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 16,667 shares of common stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares of common stock issuable upon the exercise of the Series B warrants (Alfredo F Ramirez-Macdonald).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0">(14)</TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 16,667 shares of common stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares of common stock issuable upon the exercise of the Series B warrants. Allan Monk Nielsen may be deemed to be the beneficial owner of the shares of our common stock held by&nbsp;AMN 01012011APS (AMN 01012011APS).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0">(15)</TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 16,667 shares of common stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares of common stock issuable upon the exercise of the Series B warrants. (Ana Irina Arango Martinez &amp; Witold Ruchala JTWS).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0"> (16) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 6,667 shares of common
    stock and (ii) 6,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 3,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Anand Palanisamy). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0"> (17) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Anders P Lindholm). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0"> (18) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 13,333 shares of common
    stock and (ii) 13,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 6,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Andre Luiz J Franco). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0"> (19) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 12,500 shares of common
    stock and (ii) 3,125 shares of common stock issuable upon the exercise of the Series A warrants (Andreas Krawinkel). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0"> (20) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 666,666 shares of common
    stock and (ii) 666,666 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 333,333
    shares of common stock issuable upon the exercise of the Series B warrants (Andreas Wawrla). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0"> (21) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 49,875 shares of common
    stock and (ii) 12,469 shares of common stock issuable upon the exercise of the Series A warrants (Andrew Bellamy). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0"> (22) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Andrew Chandler). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0"> (23) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Andrew Green). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0"> (24) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Andrew Greg Withers). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0"> (25) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 26,667 shares of common
    stock and (ii) 26,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 13,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Andrew M Klein). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0"> (26) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Andrew P Ferrett). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0"> (27) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 38,667 shares of common
    stock and (ii) 38,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 19,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Angelo De Rosa). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0"> (28) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 7,667 shares of common
    stock and (ii) 7,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 3,833 shares
    of common stock issuable upon the exercise of the Series B warrants (Angus M Mccoss). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0"> (29) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Anthony M Gatti). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0"> (30) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 23,333 shares of common
    stock and (ii) 23,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 11,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Anthony Mongelli). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0"> (31) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Anthony N Parisi III). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0"> (32) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 18,750 shares of common
    stock and (ii) 4,688 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (Armando
    Mediola Carvajal). </FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0; width: 5%"> (33) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0; width: 95%"><FONT STYLE="color: black"> Includes (i) 166,666
    shares of common stock (ii) 166,666 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 83,333
    shares of common stock issuable upon the exercise of the Series B warrants&nbsp;&nbsp;(Art Sadin). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0"> (34) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 13,333 shares of common
    stock and (ii) 13,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 6,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Arthur E Pereless). </FONT></TD></TR>
</TABLE>
<P STYLE="margin: 0"> &nbsp; </P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0; width: 5%"> (35) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0; width: 95%"><FONT STYLE="color: black"> Includes (i) 6,667 shares
    of common stock and (ii) 6,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii)
    3,333 shares of common stock issuable upon the exercise of the Series B warrants (Arthur Smolensky). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left; padding: 0; text-indent: 0"> (36) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 16,659 shares of common
    stock and (ii) 16,659 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,329 shares
    of common stock issuable upon the exercise of the Series B warrants.&nbsp; Alok K. Agrawal may be deemed to be the beneficial
    owner of the shares of our common stock held by&nbsp;this&nbsp;selling&nbsp;stockholder&nbsp;(ATA Investments LLC). </FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: normal; text-indent: 0"> (37) </TD>
    <TD STYLE="padding: 0; line-height: normal; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 126,602 shares of common
    stock and (ii) 30,000 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Azmy
    M Awad). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (38) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (B Adrian Kesala &amp; Larissa Kesala JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (39) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 12,000 shares of common
    stock and (ii) 12,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 6,000 shares
    of common stock issuable upon the exercise of the Series B warrants. Arnold Balsam may be deemed to be the beneficial owner
    of the shares of our common stock held by&nbsp;this selling stockholde (Balsam Capital Management). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (40) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Barry G Pallay). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (41) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 13,320 shares of common
    stock and (ii) 13,320 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 6,660 shares
    of common stock issuable upon the exercise of the Series B warrants (Barry R Shaw). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (42) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants. Dan Williams may be deemed to be the beneficial owner
    of the shares of our common stock held by&nbsp;this selling stockholder&nbsp;(Belleron Finance Limited). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (43) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 1,070,469 shares of
    common stock. Terrence H. Hicks may be deemed to be the beneficial owner of the shares of our common stock held by&nbsp;this
    selling stockholder (Ben Franklin Technology Partners of Southeastern Pennsylvania). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (44) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 84,696 shares of common
    stock (ii) 14,063 shares of common stock issuable upon the exercise of the Series A Preferred Stock and Notes warrants (iii)
    20,000 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 10,000 shares of common stock issuable
    upon the exercise of the Series B warrants&nbsp;&nbsp;(Benjamin Hasty). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (45) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 22,500 shares of common
    stock and (ii) 5,625 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Benoit
    Dumont). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (46) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 13,333 shares of common
    stock and (ii) 13,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 6,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Bernard Slede &amp; Lisa Slede JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (47) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Bernard V P Schyns &amp; Marian Schyns JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (48) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 78,814 shares of common
    stock and (ii) 18,750 shares of common stock issuable upon the exercise of the Series A Preferred&nbsp;&nbsp;and Note warrants
    (Bernard V P Schyns Marian Schyns JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (49) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Bernd Albrecht). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (50) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 31,250 shares of common
    stock and (ii)&nbsp;&nbsp;7,813 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants
    (Billy Harris). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (51) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 23,333 shares of common
    stock and (ii) 23,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 11,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Billy W Harris). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (52) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 1,550,089 shares of
    common stock and (ii) 200,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii)
    100,000 shares of common stock issuable upon the exercise of the Series B warrants. Barbara Schilberg may be deemed to be
    the beneficial owner of the shares of our common stock held by&nbsp;this selling stockholder&nbsp;(Bioadvance). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (53) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 64,583 shares of common
    stock (ii) 7,813 shares of common stock issuable upon the exercise of the Series A Preferred Stock and Notes warrants (iii)
    33,333 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 16,667 shares of common stock issuable
    upon the exercise of the Series B warrants. James W. Lees and James D. Baker may be deemed to be the beneficial owners of
    the shares of our common stock held by&nbsp;this selling stockholder&nbsp;(BL Realty LLC). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (54) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 6,667 shares of common
    stock and (ii) 6,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 3,333 shares
    of common stock issuable upon the exercise of the Series B warrants. Daniel Blowers may be deemed to be the beneficial owner
    of the shares of our common stock held by&nbsp;this selling stockholder&nbsp;(Blowers Farms LLC). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (55) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 191,667 shares of common
    stock (ii) 31,250 shares of common stock issuable upon the exercise of the Series A Preferred Stock and Notes warrants (iii)
    66,667 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 33,333 shares of common stock issuable
    upon the exercise of the Series B warrants&nbsp;&nbsp;(Bohdan Chaban). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (56) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 125,000 shares of common
    stock and (ii) 31,250 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants.&nbsp;Jung
    Ah Hong&nbsp;may be deemed to be the beneficial owner of the shares of our common stock held by&nbsp;this selling stockholder&nbsp;(Boombeam
    Incorporated). </FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (57) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 8,000 shares of common
    stock and (ii) 8,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 4,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Brad Larson). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (58) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 18,750 shares of common
    stock and (ii) 4,688 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (Bradley
    V Button). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (59) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 125,000 shares of common
    stock and (ii) 31,250 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Brian
    E &amp; Peggy A Jones). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (60) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 125,000 shares of common
    stock and (ii) 31,250 shares of common stock issuable upon the exercise of the Series A warrants (Brian Haughan). </FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (61) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 31,250 shares of common
    stock and (ii) 7,813 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Brian
    V Skillern). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (62) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 6,667 shares of common
    stock and (ii) 6,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 3,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Bruce E Frost). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (63) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Bruce G Krueger). </FONT></TD></TR>
</TABLE>
<P STYLE="margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (64) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Bruce Levy). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (65) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 16,767 shares of common
    stock and (ii) 16,767 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,383 shares
    of common stock issuable upon the exercise of the Series B warrants (Bruce Tewes). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (66) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 526,000 shares of common
    stock (ii) 62,500 shares of common stock issuable upon the exercise of the Series A Preferred Stock and Notes warrants (iii)
    276,000 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 138,000 shares of common stock
    issuable upon the exercise of the Series B warrants&nbsp;&nbsp;(Bruno J Casatelli). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (67) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 97,917 shares of common
    stock (ii) 7,813 shares of common stock issuable upon the exercise of the Series A Preferred Stock and Notes warrants (iii)
    66,667 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 33,333 shares of common stock issuable
    upon the exercise of the Series B warrants&nbsp;&nbsp;(Bryan J Hanks &amp; Michelle B Hanks JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (68) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 120,814 shares of common
    stock (ii) 17,188 shares of common stock issuable upon the exercise of the Series A Preferred Stock and Notes warrants (iii)
    50,000 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 25,000 shares of common stock issuable
    upon the exercise of the Series B warrants&nbsp;&nbsp;(Burton Mark Paull). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (69) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Calvin B Jr Klotz). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (70) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 47,917 shares of common
    stock (ii) 7,813 shares of common stock issuable upon the exercise of the Series A Preferred Stock and Notes warrants (iii)
    16,667 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 8,333 shares of common stock issuable
    upon the exercise of the Series B warrants&nbsp;&nbsp;(Carlos E Lion). </FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; line-height: normal; padding: 0; text-indent: 0"> (71) </TD>
    <TD STYLE="width: 95%; line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 16,667
    shares of common stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii)
    8,333 shares of common stock issuable upon the exercise of the Series B warrants (Carlos Espinal). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (72) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Carlos Estrada). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (73) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 62,500 shares of common
    stock and (ii) 15,625 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants. Anthony
    Gatt&nbsp;may be deemed to be the beneficial owner of the shares of our common stock held by&nbsp;this selling stockholder&nbsp;(Carmel
    Resources LLC). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (74) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Carroll Michael B Carroll &amp; Sheila J). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (75) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Carsten Greiwe). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (76) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Cary V Sorensen). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (77) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 12,500 shares of common
    stock and (ii) 3,125 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (Cesar
    Fernandez Cardenas). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (78) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Charles J Magolske). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (79) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Charles L. Weidner TTEE &amp; Alice N. Barrett Weidner
    TTEE FBO The Weidner Family Revocable Trust Dtd 8/13/07). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (80) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Charles Morse). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (81) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 47,917 shares of common
    stock (ii) 7,813 shares of common stock issuable upon the exercise of the Series A Preferred Stock and Notes warrants (iii)
    16,667 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 8,333 shares of common stock issuable
    upon the exercise of the Series B warrants&nbsp;&nbsp;(Charles W Ganse). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (82) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Charles W Sandmann). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (83) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Chip Del Coro). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (84) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 37,500 shares of common
    stock and (ii) 9,375 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Chris
    Nigel Ffinch). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (85) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 31,250 shares of common
    stock and (ii) 7,813 shares of common stock issuable upon the exercise of the Series A Preferred &amp; Notes warrants (Christopher
    &amp; Urlike Verschuer Lintermans, JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (86) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 100,000 shares of common
    stock and (ii) 100,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 50,000
    shares of common stock issuable upon the exercise of the Series B warrants (Christopher G Davison). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (87) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Christopher J Clemmow). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (88) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 10,000 shares of common
    stock and (ii) 10,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 5,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Christopher J L Cheadle). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (89) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 62,500 shares of common
    stock and (ii) 15,625 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Christopher
    J Methos). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (90) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Claus Erik Madsen). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (91) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 13,000 shares of common
    stock and (ii) 13,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 6,500 shares
    of common stock issuable upon the exercise of the Series B warrants (Conor Gilligan). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (92) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 66,666 shares of common
    stock and (ii) 66,666 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,334 shares
    of common stock issuable upon the exercise of the Series B warrants (Constantino Parente). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (93) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 7,000 shares of common
    stock and (ii) 7,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 3,500 shares
    of common stock issuable upon the exercise of the Series B warrants (Cormac Maguire). </FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0; width: 5%"> (94) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0; width: 95%"><FONT STYLE="color: black"> Includes (i) 62,500
    shares of common stock and (ii) 15,625shares of common stock issuable upon the exercise of the Series A Preferred and Notes
    warrants (Craig William Bannister). </FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"> &nbsp; </P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (95) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Daniel E Corallo). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (96) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 50,000 shares of common
    stock and (ii) 12,500 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Daniel
    Jazques Hernandez Zuli). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (97) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Daniel M Wallach &amp; Joyce Wallach JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (98) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Daniel Mccarthy). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (99) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Daniel P Wikel). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (100) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 13,750 shares of common
    stock and (ii) 3,438 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (Daniel
    S Faulkner). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (101) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 13,750 shares of common
    stock and (ii) 3,438 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (Danny
    Sergeant). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (102) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 133,333 shares of common
    stock and (ii) 133,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 66,667
    shares of common stock issuable upon the exercise of the Series B warrants (Darashaw Motashaw). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (103) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (David A Kuhar). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (104) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (David A Scott). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (105) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 20,000 shares of common
    stock and (ii) 20,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 10,000 shares
    of common stock issuable upon the exercise of the Series B warrants (David Estuardo Trujillo). </FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; line-height: normal; padding: 0; text-indent: 0"> (106) </TD>
    <TD STYLE="width: 95%; line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 33,334
    shares of common stock and (ii) 33,334 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii)
    16,666 shares of common stock issuable upon the exercise of the Series B warrants (David F Garr). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"> (107) </TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (David J Bommarito Trust Dtd 5-10-96 David J Bommarito
    TTEE). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (108) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 8,333 shares of common
    stock and (ii) 8,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 4,167 shares
    of common stock issuable upon the exercise of the Series B warrants (David L Hawkins). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (109) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 23,333 shares of common
    stock and (ii) 23,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 11,667 shares
    of common stock issuable upon the exercise of the Series B warrants (David Longley). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (110) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (David M Laurenson). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (111) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 13,333 shares of common
    stock and (ii) 13,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 6,667 shares
    of common stock issuable upon the exercise of the Series B warrants (David Norwood &amp; Yuyun Li JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (112) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 125,000 shares of common
    stock and (ii) 31,250shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (David
    P McQuarrie). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (113) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 125,000 shares of common
    stock and (ii) 31,250shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (David
    Perlmutter &amp; Haya Perlmutter JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (114) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 13,333 shares of common
    stock and (ii) 13,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 6,667 shares
    of common stock issuable upon the exercise of the Series B warrants (David S Burr &amp; Cheri Ackert-Burr Burr JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (115) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 20,000 shares of common
    stock and (ii) 20,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 10,000 shares
    of common stock issuable upon the exercise of the Series B warrants (David Scott). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (116) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 201,629 shares of common
    stock (ii) 26,563 shares of common stock issuable upon the exercise of the Series A Preferred Stock and Notes warrants (iii)
    86,666 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 43,334 shares of common stock issuable
    upon the exercise of the Series B warrants&nbsp;&nbsp;(David W Frost). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (117) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 31,250 shares of common
    stock and (ii) 7,813 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (David
    W Macurdy). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (118) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 34,792 shares of common
    stock (ii) 4,531 shares of common stock issuable upon the exercise of the Series A Preferred Stock and Notes warrants (iii)
    16,667 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 8,333 shares of common stock issuable
    upon the exercise of the Series B warrants&nbsp;&nbsp;(De Pooter Be Heer). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (119) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 106,666 shares of common
    stock and (ii) 106,666 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 53,334
    shares of common stock issuable upon the exercise of the Series B warrants (Dean Beaver). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (120) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 31,250 shares of common
    stock and (ii) 7,813shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Deborah
    L Katz). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (121) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Dennis Winson). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (122) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Desmond Murphy). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (123) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 6,667 shares of common
    stock and (ii) 6,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 3,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Dhiman Parikh). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (124) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 62,500 shares of common
    stock and (ii) 15,625 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Diance
    Scheck). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (125) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Diatou Diop &amp; Steven De Decker). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (126) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 62,500 shares of common
    stock and (ii) 15,625 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Diatou
    Diop &amp; Steven De Decker JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (127) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 31,250 shares of common
    stock and (ii) 7,813 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Dirk
    S Cox). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (128) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 10,000 shares of common
    stock and (ii) 10,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 5,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Donald E Womeldorph Jr). </FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0; width: 5%"><FONT STYLE="color: black">(129)</FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0; width: 95%"><FONT STYLE="color: black">Includes (i) 16,667 shares of common stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares of common stock issuable upon the exercise of the Series B warrants (Donald G Pence).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (130) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 31,250 shares of common
    stock (ii) 7,813 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Donald K
    Coffey). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">(131)</FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 16,667 shares of common stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares of common stock issuable upon the exercise of the Series B warrants (Donald P Sesterhenn).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">(132)</FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 31,250 shares of common stock (ii) 7,813 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Douglas A Alcott).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">(133)</FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 33,333 shares of common stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares of common stock issuable upon the exercise of the Series B warrants (Douglas Arantes).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">(134)</FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 66,667 shares of common stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares of common stock issuable upon the exercise of the Series B warrants (Douglas Davies).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">(135)</FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 47,917 shares of common stock (ii) 7,813 shares of common stock issuable upon the exercise of the Series A Preferred Stock and Notes warrants (iii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 8,333 shares of common stock issuable upon the exercise of the Series B warrants&nbsp;&nbsp;(Douglas E Eckert).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (136) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 171,024 shares of common
    stock (ii) 25,000 shares of common stock issuable upon the exercise of the Series A Preferred Stock and Notes warrants (iii)
    66,667 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 33,333 shares of common stock issuable
    upon the exercise of the Series B warrants&nbsp;&nbsp;(Douglas E Jasek). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">(137)</FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 62,500 shares of common stock and&nbsp;&nbsp;(ii) 15,625 hares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Douglas J Amos &amp; Carol A Amos JTWROS).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">(138)</FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 16,667 shares of common stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares of common stock issuable upon the exercise of the Series B warrants (Douglas R Holroyd &amp; Jill K Holroyd JTWROS).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">(139)</FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 31,250 shares of common stock and (ii) 7,813 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Douglas W Tiffan).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">(140)</FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 33,333 shares of common stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares of common stock issuable upon the exercise of the Series B warrants (Dr Calvin Simmons).</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: normal; text-indent: 0"><FONT STYLE="color: black"> (141) </FONT></TD>
    <TD STYLE="padding: 0; line-height: normal; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 10,000 shares of common stock and (ii)
    10,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 5,000 shares of common
    stock issuable upon the exercise of the Series B warrants (Dr . Glen Mccracken). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (142) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 33,333 shares of common stock and (ii) 33,333 shares
    of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares of common stock issuable
    upon the exercise of the Series B warrants (Dr. Gurpreet S Ahluwalia). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">(143)</FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 10,250 shares of common stock and (ii) 2,563 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (Dr. Jan-Hendrik Spilgies).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">(144)</FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 62,500 shares of common stock and (ii) 15,625 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Dr. Jeffrey Miller).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (145) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Dr. John E Bishop). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (146) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 50,000 shares of common
    stock and (ii) 50,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 25,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Dr. Larry Vaught). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (147) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 6,667 shares of common
    stock and (ii) 6,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 3,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Dr. Mariusz J Klin). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (148) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 106,592 shares of common
    stock and (ii) 24,688 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (Dr Richard
    Matter &amp; Anita Matter JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0">(149)</TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0">Intentionally omitted</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">(150)</FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 66,667 shares of common stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares of common stock issuable upon the exercise of the Series B warrants. Peter Duerr may be deemed to be the beneficial owner of the shares of our common stock held by&nbsp;this&nbsp;selling&nbsp;stockholder&nbsp;(Duerr Capital LLC).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">(151)</FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 8,000 shares of common stock and (ii) 8,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 4,000 shares of common stock issuable upon the exercise of the Series B warrants (Eamon P Judge).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">(152)</FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 33,333 shares of common stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares of common stock issuable upon the exercise of the Series B warrants (Earl R Richardson).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">(153)</FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 22,667 shares of common stock (ii) 3,000 shares of common stock issuable upon the exercise of the Series A Preferred Stock and Notes warrants (iii) 10,667 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 5,333 shares of common stock issuable upon the exercise of the Series B warrants&nbsp;(Ecovest Limited).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">(154)</FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 66,667 shares of common stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares of common stock issuable upon the exercise of the Series B warrants (Eduardo Guemez Sarre).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (155) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Eduardo Raul Azcarraga Perez &amp; Luiz Emilio Azcarraga
    Perez JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">(156)</FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 66,667 shares of common stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares of common stock issuable upon the exercise of the Series B warrants (Edward C Moore).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">(157)</FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 66,667 shares of common stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares of common stock issuable upon the exercise of the Series B warrants (Edward John Mazur).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">(158)</FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 22,667 shares of common stock and (ii) 22,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 11,333 shares of common stock issuable upon the exercise of the Series B warrants (Eliana Cardenas &amp; Roberto Mendez JTWROS).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">(159)</FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 6,667 shares of common stock and (ii) 6,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 3,333 shares of common stock issuable upon the exercise of the Series B warrants (Elie Ghazal).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">(160)</FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black">Includes (i) 6,667 shares of common stock and (ii) 6,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 3,333 shares of common stock issuable upon the exercise of the Series B warrants (Emily Coakley &amp; James Hicks JTIC).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> (161) </FONT></TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="color: black"> Includes (i) 31,730 shares of common
    stock (ii) 2,266 shares of common stock issuable upon the exercise of the Series A Preferred Stock and Notes warrants (iii)
    22,667 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 11,333 shares of common stock issuable
    upon the exercise of the Series B warrants&nbsp;&nbsp;(Enguerrand De Ponteves). </FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (162) </FONT></TD>
    <TD STYLE="width: 95%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 31,250 shares
    of common stock and (ii) 7,813 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants
    (Eric Knudstrup). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (163) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 13,333 shares of common
    stock and (ii) 13,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;(iii) 6,667 shares of
    common stock issuable upon the exercise of the Series B warrants (Eric Stuerken). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (164) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 40,000 shares of common
    stock and (ii) 40,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;(iii) 20,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Eugene E Eubank). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (165) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (F Martin Anson &amp; Jacqueline O Anson JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (166) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 102,500 shares of common
    stock (ii) 20,625 shares of common stock issuable upon the exercise of the Series A Preferred Stock and Notes warrants (iii)
    20,000 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 10,000 shares of common stock issuable
    upon the exercise of the Series B warrants&nbsp;&nbsp;(Fernando Malvido Olascoaga). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (167) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 10,033 shares of common
    stock and (ii) 10,033 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 5,017 shares
    of common stock issuable upon the exercise of the Series B warrants.&nbsp;Robert Nelson&nbsp;may be deemed to be the beneficial
    owner of the shares of our common stock held by&nbsp;this&nbsp;selling&nbsp;stockholder&nbsp;(Fintran Ltd). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (168) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 26,667 shares of common
    stock and (ii) 26,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 13,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Fiona Mcphee &amp; Andrew Charles Good JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (169) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 50,000 shares of common
    stock and (ii) 50,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 25,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Foster Jordan &amp; Camela Jordan JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (170) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants. Brian M. Miller may be deemed to be the beneficial owner
    of the shares of our common stock held by&nbsp;this selling stockholder&nbsp;(Fourfathom Capital LLC). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (171) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 6,667 shares of common
    stock and (ii) 6,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 3,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Franco Castro-Marin). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (172) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Frank Farello). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (173) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 55,417 shares of common
    stock (ii) 12,188 shares of common stock issuable upon the exercise of the Series A Preferred Stock and Notes warrants (iii)
    6,667 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 3,333 shares of common stock issuable
    upon the exercise of the Series B warrants&nbsp;&nbsp;(Frans Zoetmulder). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (174) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Frans Zonneveld). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (175) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 9,333 shares of common
    stock and (ii) 9,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 4,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Garfield W Hardeman TOD). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (176) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Gary J and Janelle L. Mabie JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (177) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 62,500 shares of common
    stock and (ii) 15,625 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Gary
    J Mabie &amp; Janelle L Mabie JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (178) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Geoff W Haggart). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (179) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 8,333 shares of common
    stock and (ii) 8,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 4,167 shares
    of common stock issuable upon the exercise of the Series B warrants (George A Meyers). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (180) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 47,917 shares of common
    stock (ii) 7,813 shares of common stock issuable upon the exercise of the Series A Preferred Stock and Notes warrants (iii)
    16,667 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 8,333 shares of common stock issuable
    upon the exercise of the Series B warrants&nbsp;&nbsp;(George Diamantopoulos). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (181) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (George Elefther &amp; Karin Alexa Elefther JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (182) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 81,250 shares of common
    stock (ii) 7,813 shares of common stock issuable upon the exercise of the Series A Preferred Stock and Notes warrants (iii)
    50,000 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 25,000 shares of common stock issuable
    upon the exercise of the Series B warrants&nbsp;&nbsp;(George M Zelinski). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (183) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 30,000 shares of common
    stock and (ii) 30,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 15,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Georges Zanellato). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (184) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 31,526 shares of common
    stock and (ii) 7,500 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (Gerard
    A Gabriel). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (185) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 13,333 shares of common
    stock and (ii) 13,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 6,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Gerard De Jonge). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (186) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Gerardo C Villarreal-Rodriguez). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (187) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Gideon Kaplan Ilana Kaplan JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (188) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 13,333 shares of common
    stock and (ii) 13,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 6,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Gonzalo A Salgueiro). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (189) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 37,500 shares of common
    stock and (ii) 9,375shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Graeme
    Farr). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (190) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Graham John Nicholson). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (191) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 31,250 shares of common
    stock and (ii) 7,813shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Grahman
    M Bones). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (192) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Grant L Hanby). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (193) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 23,333 shares of common
    stock and (ii) 23,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 11,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Grant O'Connor). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (194) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 78,814 shares of common
    stock and (ii) 18,750 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Gregory
    Alexander). </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"> &nbsp; &nbsp;</P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (195) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 133,333 shares of common
    stock and (ii) 133,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 66,667
    shares of common stock issuable upon the exercise of the Series B warrants. T.P.J. Fredrichs may be deemed to be the beneficial
    owner of the shares of our common stock held by&nbsp;this selling stockholder&nbsp;(GSI Global Shipping Inc). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (196) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 62,500 shares of common
    stock and (ii) 15,625 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Guillermo
    Alejandro Browne &amp; Paula Fernandez Browne JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (197) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 13,333 shares of common
    stock and (ii) 13,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 6,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Gustavo Dos Reis Vasques). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (198) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 6,667 shares of common
    stock and (ii) 6,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 3,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Gustavo Guzman-Barron Escobedo). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (199) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Harry A Theochari). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (200) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Helen Cail). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (201) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 73,333 shares of common
    stock and (ii) 73,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 36,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Helmut Koehler). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (202) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Henri Derwael). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (203) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 26,000 shares of common
    stock and (ii) 26,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 13,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Hernan Zaballa). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (204) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Hernando Holguin). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (205) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 30,667 shares of common
    stock and (ii) 30,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 15,333 shares
    of common stock issuable upon the exercise of the Series B warrants. Lawrence D. Hochman may be deemed to be the beneficial
    owner of the shares of our common stock held by&nbsp;this selling stockholder (Hochman Family LLP). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (206) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 6,667 shares of common
    stock and (ii) 6,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 3,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Horacio Fajer Cardona). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (207) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Horacio Sbrolla). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (208) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Howard Wool). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (209) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 19,400 shares of common
    stock (Huai-Hung Kao). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (210) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Ian An Wight). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (211) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 222,917 shares of common
    stock (ii) 39,063 shares of common stock issuable upon the exercise of the Series A Preferred Stock and Notes warrants (iii)
    66,667 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 33,333 shares of common stock issuable
    upon the exercise of the Series B warrants&nbsp;&nbsp;(Ian H Murray). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (212) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 125,000 shares of common
    stock and (ii) 31,250 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants.&nbsp;
    Stephen Herrman may be deemed to be the beneficial owner of the shares of our common stock held by&nbsp;this selling stockholder&nbsp;(Immotrend,
    Inc.). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (213) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 125,000 shares of common
    stock and (ii) 31,250 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (Inmobiliaria
    E Inversones Jorger Arturo Troncoso Ruiz Eirl). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (214) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 77,375 shares of common
    stock and (ii) 19,344 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants.&nbsp;
    David Sykes may be deemed to be the beneficial owner of the shares of our common stock held by&nbsp;this selling stockholder&nbsp;(Island
    Capital Nominees Ltd). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (215) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (J Brian Boulter). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (216) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 75,833 shares of common
    stock (ii) 15,625 shares of common stock issuable upon the exercise of the Series A Preferred Stock and Notes warrants (iii)
    13,333 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 6,667 shares of common stock issuable
    upon the exercise of the Series B warrants&nbsp;&nbsp;(James Johnson). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (217) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (James Kinnell). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (218) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 75,000 shares of common
    stock and (ii) 18,750 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (James
    L Payne). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (219) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 12,500 shares of common
    stock and (ii) 3,125 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (James
    &amp; Margaret M Messina, JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (220) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (James R Bement &amp; Sheryl Bement JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (221) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (James R Deaver). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (222) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 23,333 shares of common
    stock and (ii) 23,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 11,667 shares
    of common stock issuable upon the exercise of the Series B warrants (James Regan &amp; Maureen Regan JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (223) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (James V Cunningham). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (224) </FONT></TD>
    <TD STYLE="width: 95%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares
    of common stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii)
    16,667 shares of common stock issuable upon the exercise of the Series B warrants (James W Anthony). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (225) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (James W Anthony &amp; Delsia Anthony JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (226) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 31,250 shares of common
    stock and (ii)&nbsp;7,813 shares of common stock issuable upon the exercise of the Series A warrants (Jan Rehnman). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (227) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 86,667 shares of common
    stock and (ii) 86,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 43,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Javier Escajadillo). </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"> &nbsp; </P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (228) </FONT></TD>
    <TD STYLE="width: 95%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 13,333 shares
    of common stock and (ii) 13,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii)
    6,667 shares of common stock issuable upon the exercise of the Series B warrants (Jay Robert Johnson &amp; Lori Johnson JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (229) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 132,917 shares of common
    stock (ii) 29,063 shares of common stock issuable upon the exercise of the Series A Preferred Stock and Notes warrants (iii)
    16,667 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 8,333 shares of common stock issuable
    upon the exercise of the Series B warrants&nbsp;&nbsp;(Jean-Marc Simandoux). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (230) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 239,231 shares of common
    stock (ii) 42,188 shares of common stock issuable upon the exercise of the Series A Preferred Stock and Notes warrants (iii)
    66,667 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 33,333 shares of common stock issuable
    upon the exercise of the Series B warrants&nbsp;&nbsp;(Jeff C Kleinschmidt). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (231) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 81,250 shares of common
    stock (ii) 7,813 shares of common stock issuable upon the exercise of the Series A Preferred Stock and Notes warrants (iii)
    50,000 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 25,000 shares of common stock issuable
    upon the exercise of the Series B warrants&nbsp;&nbsp;(Jeff L Stevens). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (232) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 50,000 shares of common
    stock and (ii) 12,500 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Jeffrey
    C Boggs). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (233) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Jeffery W Maier). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (234) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 20,000 shares of common
    stock and (ii) 20,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 10,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Jeffrey G Hipp). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (235) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Jeremy Evan Creson). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (236) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 62,500 shares of common
    stock and (ii) 15,625 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Jim
    Regan). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (237) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 133,333 shares of common
    stock and (ii) 133,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 66,667
    shares of common stock issuable upon the exercise of the Series B warrants (Jimmy R Hasley). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (238) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 18,750 shares of common
    stock and (ii) 4,688 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (Joaquin
    Noriega &amp; Patricia CP DE Noriega, JTWROS) </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (239) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Joel Pruzansky). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (240) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Johan Peter Thomas Hinderoth). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (241) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 8,333 shares of common
    stock and (ii) 8,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 4,167 shares
    of common stock issuable upon the exercise of the Series B warrants (John Avon). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (242) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (John Evans). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (243) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 26,633 shares of common
    stock and (ii) 26,633 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 13,317 shares
    of common stock issuable upon the exercise of the Series B warrants (John Flahavan). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (244) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 31,250 shares of common
    stock and (ii) 7,813 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (John
    J Breig). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (245) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 6,750 shares of common
    stock and (ii) 1,688 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (John Lloyd). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (246) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (John Malfer &amp; Toni Malfer JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (247) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (John R B Gould). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (248) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 80,417 shares of common
    stock (ii) 3,438 shares of common stock issuable upon the exercise of the Series A Preferred Stock and Notes warrants (iii)
    66,667 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 33,333 shares of common stock issuable
    upon the exercise of the Series B warrants&nbsp;&nbsp;(John R Harrison &amp; Linda L Harrison JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (249) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 166,667 shares of common
    stock and (ii) 166,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 83,333
    shares of common stock issuable upon the exercise of the Series B warrants (Jon H Lytle &amp; Carrie M Lytle JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (250) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 49,250 shares of common
    stock (ii) 7,813 shares of common stock issuable upon the exercise of the Series A Preferred Stock and Notes warrants (iii)
    18,000 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 9,000 shares of common stock issuable
    upon the exercise of the Series B warrants&nbsp;&nbsp;(Jonas E Neihardt). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (251) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Jonathan Smith). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (252) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 46,667 shares of common
    stock and (ii) 46,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 23,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Jonathan Steinhouse). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (253) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 53,000 shares of common
    stock (ii) 7,750 shares of common stock issuable upon the exercise of the Series A Preferred Stock and Notes warrants (iii)
    22,000 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 11,000 shares of common stock issuable
    upon the exercise of the Series B warrants&nbsp;&nbsp;(Jorge Enrique Borbolla). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (254) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 62,500 shares of common
    stock and (ii) 15,625 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Jorge
    Horacio Boldrini &amp; Paula X Ferradas Abalo Boldrini JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (255) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 20,000 shares of common
    stock and (ii) 20,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 10,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Jorge Marchena &amp; Margaret Marchena JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (256) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 13,333 shares of common
    stock and (ii) 13,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 6,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Jorge Troncoso). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (257) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Jose Da Silva &amp; Angel Da Silva JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (258) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 6,250 shares of common
    stock and (ii) 1,5,63 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (Jose
    E Abascal). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (259) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 95,667 shares of common
    stock (ii) 7,250 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrant (iii) 66,667
    shares of common stock issuable upon the exercise of the Series A warrants and (iv) 33,333 shares of common stock issuable
    upon the exercise of the Series B warrants (Jose S Maiz). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (260) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 20,000 shares of common
    stock and (ii) 20,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 10,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Josef Keltjens &amp; Beverly Warner Keltjens JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (261) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 100,000 shares of common
    stock and (ii) 100,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 50,000
    shares of common stock issuable upon the exercise of the Series B warrants (Joseph A D'Elia). </FONT></TD></TR>
</TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"> &nbsp; </P>

<P STYLE="margin-top: 0; margin-bottom: 0"> </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (262) </FONT></TD>
    <TD STYLE="width: 95%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares
    of common stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii)
    8,333 shares of common stock issuable upon the exercise of the Series B warrants (Joseph Blum). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (263) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 22,500 shares of common
    stock (ii) 3,125 shares of common stock issuable upon the exercise of the Series A Preferred Stock and Notes warrants (iii)
    10,000 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 5,000 shares of common stock issuable
    upon the exercise of the Series B warrants&nbsp;&nbsp;(Joseph Charap). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (264) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 35,417 shares of common
    stock (ii) 4,688 shares of common stock issuable upon the exercise of the Series A Preferred Stock and Notes warrants (iii)
    16,667 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 8,333 shares of common stock issuable
    upon the exercise of the Series B warrants&nbsp;&nbsp;(Joseph J Ebens). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (265) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 20,000 shares of common
    stock and (ii) 20,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 10,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Joseph T Oppito). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (266) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 29,333 shares of common
    stock and (ii) 29,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 14,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Juan Antonio Winter Razmilic). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (267) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 37,500 shares of common
    stock and (ii) 9,375 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (Juan Manual
    Farias). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (268) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 6,500 shares of common
    stock and (ii) 1,625 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Julian
    &amp; Ingride E Archer Ven Den Berg, JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (269) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Julian Bavin). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (270) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Julian P Kemble). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (271) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 150,000 shares of common
    stock and (ii) 150,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 75,000
    shares of common stock issuable upon the exercise of the Series B warrants (Julius E Talton). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (272) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Kelly Anne Paiva Alves &amp; Jaime E Vazquez JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (273) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 82,500 shares of common
    stock&nbsp;&nbsp;(ii) 15,625 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants
    (iii) 20,000 shares of common stock issuable upon the exercise of the Series A warrants and (iv) 10,000 shares of common stock
    issuable upon the exercise of the Series B warrants (Ken R Klimitchek). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (274) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 95,833 shares of common
    stock (ii) 15,625 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (iii) 33,333
    shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iv) 16,667 shares of common stock issuable
    upon the exercise of the Series B warrants (Kenneth G Williamson). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (275) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 125,000 shares of common
    stock and (ii) 31,250 shares of common stock issuable upon the exercise of the Series A warrants (Kenneth Jr. Havens). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (276) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 141,667 shares of common
    stock (ii) 31,250 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (iii) 16,667
    shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iv) 8,333 shares of common stock issuable
    upon the exercise of the Series B warrants (Kenneth N Larsen Trust U/A/D 9/25/2009 Kenneth N Larsen Trustee). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (277) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Kenneth P Black). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (278) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants.&nbsp;&nbsp;Kermit E. Reynolds, Jr. may be deemed to be
    the beneficial owner of the shares of our common stock held by&nbsp;this selling stockholder&nbsp; (Kermit E Reynolds Jr Family
    LLC). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (279) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Kevin A Rahrig). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (280) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 250,000 shares of common
    stock and (ii) 62,500 shares of common stock issuable upon the exercise of the Series A warrants (Kevin J Poor). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (281) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Kevin Kapales). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (282) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 28,042 shares of common
    stock (ii) 2,844 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (iii) 16,667
    shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iv) 8,333 shares of common stock issuable
    upon the exercise of the Series B warrants (Kevin Lynch). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (283) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Kevin O Lacour). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (284) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Kevin P Mccarthy). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (285) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Kevin Paige). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (286) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 23,333 shares of common
    stock and (ii) 23,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 11,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Kevin T Mcdonough). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (287) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants.&nbsp; _____may be deemed to be the beneficial owner of
    the shares of our common stock held by&nbsp;this selling stockholder&nbsp;(KMR Agency Inc). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (288) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 62,500 shares of common
    stock and (ii) 15,625 shares of common stock issuable upon the exercise of the Series A warrants (Kristine Peters). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (289) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 81,250 shares of common
    stock (ii) 7,813 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (iii) 50,000
    shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iv) 25,000 shares of common stock issuable
    upon the exercise of the Series B warrants (L Dean Fox). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (290) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 21,250 shares of common
    stock and (ii) 5,313 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Lance
    Ziaks &amp; Janet Ziaks JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (291) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Larry G Majerus). </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (292) </FONT></TD>
    <TD STYLE="width: 95%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 129,167 shares
    of common stock (ii) 15,625 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants
    (iii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iv) 33,333 shares of common
    stock issuable upon the exercise of the Series B warrants (Larry W Schwartz). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (293) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 125,000 shares of common
    stock and (ii) 31,250 shares of common stock issuable upon the exercise of the Series A warrants (Lawrence B Martel). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (294) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Lawrence Solomon Revocable Living Trust Lawrence Solomon
    TTEE). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (295) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Lee E Cleveland). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (296) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Lee Westwood). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (297) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Leonard J Pruzansky). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (3298) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 6,667 shares of common
    stock and (ii) 6,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 3,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Linda A Casatelli). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (299) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 93,750 shares of common
    stock and (ii) 23,488 shares of common stock issuable upon the exercise of the Series A warrants (Logan Hurst). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (300) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 125,000 shares of common
    stock and (ii) 31,250 shares of common stock issuable upon the exercise of the Series A warrants (Lorenzo Barrera). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (301) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 6,667 shares of common
    stock and (ii) 6,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 3,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Luc Verhoeven). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (302) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 6,667 shares of common
    stock and (ii) 6,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 3,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Luis Rafael Nunes). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (303) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 5,000 shares of common
    stock and (ii) 1,250 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Maarten
    Haast). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (304) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 266,666 shares of common
    stock and (ii) 266,666 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 133,333
    shares of common stock issuable upon the exercise of the Series B warrants.&nbsp; Stiching Magdoak may be deemed to be the
    beneficial owner of the shares of our common stock held by&nbsp;this selling stockholder&nbsp;(Magoba C V). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (305) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Mairi Pantechi &amp; Ioannis Romanos JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (306) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 250,000 shares of common
    stock and (ii) 62,500 shares of common stock issuable upon the exercise of the Series A warrants (Malcolm C.S Leslie &amp;
    Hilary Jane Leslie JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (307) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 266,666 shares of common
    stock and (ii) 266,666 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 133,333
    shares of common stock issuable upon the exercise of the Series B warrants (Malcolm C.S. Leslie &amp; Hilary Jane Leslie JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (308) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 64,583 shares of common
    stock (ii) 7,813 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (iii) 33,333
    shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iv) 16,667 shares of common stock issuable
    upon the exercise of the Series B warrants (Malcolm Hay). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (309) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 50,000 shares of common
    stock and (ii) 50,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 25,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Manu Prasad Parikh). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (310) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,313 shares of common
    stock and (ii) 33,313 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,657 shares
    of common stock issuable upon the exercise of the Series B warrants (Marc Gilligan). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (311) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 48,667 shares of common
    stock and (ii) 48,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 24,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Marc J Boreham). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (312) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 26,667 shares of common
    stock and (ii) 26,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 13,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Maree Casatelli). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (313) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 43,750 shares of common
    stock and (ii) 10,938 shares of common stock issuable upon the exercise of the Series A warrants (Maria De Lourdes Domenc
    Garcia&nbsp;&nbsp;II &amp; Jose Maiz Garcia, JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (314) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 12,917 shares of common
    stock (ii) 1,563 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (iii) 6,667
    shares of common stock issuable upon the exercise of the Series A warrants&nbsp;(iv) 3,333 shares of common stock issuable
    upon the exercise of the Series B warrants (Mario Rodriguez). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (315) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 20,000 shares of common
    stock and (ii) 20,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 10,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Mark A Bradley). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (316) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 50,000 shares of common
    stock and (ii) 50,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 25,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Mark A Maki &amp; Sara L Maki JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (317) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 133,333 shares of common
    stock and (ii) 133,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 66,667
    shares of common stock issuable upon the exercise of the Series B warrants (Mark A Suwyn). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (318) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Mark C Jasek). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (319) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 31,250 shares of common
    stock and (ii) 7,813 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Mark
    G Boulanger). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (320) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 10,000 shares of common
    stock and (ii) 10,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 5,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Mark J Aurig &amp; Toni H Aurig JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (321) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Mark J Campbell). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (322) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 31,250 shares of common
    stock and (ii) 7,813 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (Mark J
    Jackson). </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (323 </FONT></TD>
    <TD STYLE="width: 95%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares
    of common stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii)
    8,333 shares of common stock issuable upon the exercise of the Series B warrants (Mark S Heymann). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (324) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 12,500 shares of common
    stock and (ii) 3,125 shares of common stock issuable upon the exercise of the Series A warrants (Mark Tonkin). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (325) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 6,667 shares of common
    stock and (ii) 6,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 3,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Matthew Luongo). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (326) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Matthew Reid). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (327) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Matthew W Dahan). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (328) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Matura Family Trust Ua 05-26-1998 Gary D Matura TTEE). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (329) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 13,333 shares of common
    stock and (ii) 13,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 6,667 shares
    of common stock issuable upon the exercise of the Series B warrants. James and Jon Schwartz may be deemed to be the beneficial
    owners of the shares of our common stock held by&nbsp;this selling stockholder&nbsp;(Maurice Schwartz &amp; Sons Partnership). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (330) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Menghui Cao). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (331) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 50,000 shares of common
    stock and (ii) 50,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 25,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Mercedes Del Carmen Orozoco De Ortega &amp; Francisco
    Ortega Gonzalez JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (332) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 50,000 shares of common
    stock and (ii) 50,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 25,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Mercedes Sepulveda). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (333) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 250,000 shares of common
    stock and (ii) 62,500 shares of common stock issuable upon the exercise of the Series A warrants (Michael &amp; Sheila Carroll
    JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (334) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 6,667 shares of common
    stock and (ii) 6,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 3,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Michael Bundschuh). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (335) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Michael C Bellard). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (336) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Michael Chester &amp; Mary-Ann Stadtler Chester JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (337 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Michael D Watson). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (338) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 13,333 shares of common
    stock and (ii) 13,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 6,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Michael E Whitley). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (339) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 83,333 shares of common
    stock (ii) 12,500 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (iii) 33,333
    shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iv) 16,667 shares of common stock issuable
    upon the exercise of the Series B warrants (Michael Engdall &amp; Susan Engdall JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (340) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 13,333 shares of common
    stock and (ii) 13,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 6,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Michael H Pentecost). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (341) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 31,250 shares of common
    stock and (ii) 7,813 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (Michael
    J Angergame &amp; Sandra Angerame JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (342) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Michael J Campbell Jeanette Campbell JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (343) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 103,333 shares of common
    stock and (ii) 103,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 51,667
    shares of common stock issuable upon the exercise of the Series B warrants (Michael J Mathieu). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (344) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 95,833 shares of common
    stock (ii) 15,625 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (iii) 33,333
    shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iv) 16,667 shares of common stock issuable
    upon the exercise of the Series B warrants (Michael Jason Maggard). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (345) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 57,500 shares of common
    stock (ii) 9,375 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (iii) 20,000
    shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iv) 10,000 shares of common stock issuable
    upon the exercise of the Series B warrants (Michael K Barber &amp; Julia K Barber JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (346) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Michael Karsonovich). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (347) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 20,000 shares of common
    stock and (ii) 20,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 10,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Michael L Turner). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (348) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Miguel Angel Penaloza Bretel). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (349) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Mr Gerard Leroy &amp; Mrs Dominique Leroy JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (350) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 13,333 shares of common
    stock and (ii) 13,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 6,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Mukthar Abdul). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (351) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Muneswa Sreenivasan). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (352) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 125,000 shares of common
    stock and (ii) 31,250 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (Nabil
    M Yazgi). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (353) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 30,000 shares of common
    stock and (ii) 30,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 15,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Nabil Yazgi Md Pa Cash Balance Plan &amp; Trust 12-28-2008
    Nabil Yazgi TTEE). </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (354) </FONT></TD>
    <TD STYLE="width: 95%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 6,667 shares
    of common stock and (ii) 6,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii)
    3,333 shares of common stock issuable upon the exercise of the Series B warrants (Naresh Guntupalli). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (355) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 9,000 shares of common
    stock and (ii)&nbsp;&nbsp;2,250 shares of common stock issuable upon the exercise of the Series A warrants (Nico Van Spikler). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (356) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 6,667 shares of common
    stock and (ii) 6,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 3,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Nicolas A Riggio). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (357) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants. Anthony R. White may be deemed to be the beneficial owner
    of the shares of our common stock held by&nbsp;this selling stockholder&nbsp;(Octect Investment Ltd). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (358) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 95,833 shares of common
    stock (ii) 15,625 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (iii) 33,333
    shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iv) 16,667 shares of common stock issuable
    upon the exercise of the Series B warrants (Oliver Schulte). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (359) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 31,250 shares of common
    stock and (ii)7,813 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (Oliver
    Demesy). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (360) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Oscar Storen). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (361) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 100,000 shares of common
    stock and (ii) 100,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 50,000
    shares of common stock issuable upon the exercise of the Series B warrants (Pan Feng). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (362) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 125,000 shares of common
    stock and (ii) 31,250 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (Paresh
    Karandikar &amp; Lorna Karandikar). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (363) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 10,000 shares of common
    stock and (ii) 10,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 5,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Parthipan Krishnasamy). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (364) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Pascal M Lipsky). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (365) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Patrick J Wagner &amp; Janie L Wagner JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (366) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Patrick Larose). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (367) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i)&nbsp;&nbsp;17,750 shares
    of common stock and (ii) 4,438 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants
    (Patrick Petterson). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (368) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 50,000 shares of common
    stock and (ii) 50,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 25,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Patrick S Thomas). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (369) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 158,833 shares of common
    stock (ii) 31,250 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (iii) 33,333
    shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iv) 16,667 shares of common stock issuable
    upon the exercise of the Series B warrants (Paul A Wildberger). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (370) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Paul Clayton). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (371) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Paul D R Searle). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (372) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 31,250 shares of common
    stock and (ii) 7,813 shares of common stock issuable upon the exercise of the Series A&nbsp;&nbsp;Preferred and Note warrants
    (Paula Vera Ocampo &amp; Jose Ignacio Feretti JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (373) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Paulina Veytia &amp; Nicholas Osorio JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (374) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 30,417 shares of common
    stock (ii) 3,438 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (iii) 16,667
    shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iv) 8,333 shares of common stock issuable
    upon the exercise of the Series B warrants (Pedro B Torres). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (375) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 125,000 shares of common
    stock and (ii) 31,250 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (Per Arvid
    Schoyen). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (376) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 20,000 shares of common
    stock and (ii) 20,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 10,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Perry Family Trust William Franklin Perry TTEE). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (377) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Peter F Zichelle). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (378) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 47,917 shares of common
    stock (ii) 7,813 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (iii) 16,667
    shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iv) 8,333 shares of common stock issuable
    upon the exercise of the Series B warrants (Peter H Colettis). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (379) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Peter J and Tiffany B. Zaborowski JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (380) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 31,250 shares of common
    stock and (ii) 7,813 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (Peter
    Thomson). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (381) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 36,000 shares of common
    stock and (ii) 36,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 18,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Philip Davie). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (382) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Philip Ireland). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (383) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Philip Stephenson). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (384) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 100,000 shares of common
    stock and (ii) 100,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 50,000
    shares of common stock issuable upon the exercise of the Series B warrants (Philippe Chauffard). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (385) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 63,051 shares of common
    stock and (ii) 15,000 shares of common stock issuable upon the exercise of the Series A Preferred&nbsp;&nbsp;and Note warrants
    (Pieter M Duplessis). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (386) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants.&nbsp;Chad Elms be deemed to be the beneficial owner of
    the shares of our common stock held by&nbsp;this selling stockholder (Principle Financial Holdings LLC). </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"> </P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (387) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants. Julian Proctor may be deemed to be the beneficial owner
    of the shares of our common stock held by&nbsp;this selling stockholder&nbsp;(Proctor Investments Ltd). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (388) </FONT></TD>
    <TD STYLE="width: 95%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 13,333 shares
    of common stock and (ii) 13,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii)
    6,667 shares of common stock issuable upon the exercise of the Series B warrants (R Scott Mccay &amp; Rebecca E Mccay JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (389) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 88,364 shares of common
    stock (ii) 13,438 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (iii) 32,000
    shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iv) 16,000 shares of common stock issuable
    upon the exercise of the Series B warrants (Rafael Penunuri). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (390) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 36,667 shares of common
    stock and (ii) 36,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 18,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Raja Appachi). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (391) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 200,000 shares of common
    stock and (ii) 200,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 100,000
    shares of common stock issuable upon the exercise of the Series B warrants (Rajinder Kaur &amp; Lester Alvis JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (392) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Ram V Seetharam &amp; Rani J Seetharam JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (393) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 125,000 shares of common
    stock and (ii) 31,250 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (Randal
    E Margo). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (394) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Randal J Dirlam). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (395) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 41,857 shares of common
    stock and (ii) 9,375 shares of common stock issuable upon the exercise of the Series A&nbsp;&nbsp;Preferred and Note warrants
    (Randall L Payne &amp; Kathy S Payne JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (396) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Randy E and Cherly A Johnson JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (397) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Ravi Mullapudi &amp; Padmaja Mullapudi JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (398) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 20,000 shares of common
    stock and (ii) 20,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 10,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Reed Family Trust Dtd 06/24/1999 Clayton A Reed &amp;
    Stephanie S Reed TTEEs). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (399) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Rene St Pierre &amp; Cindi St Pierre JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (400) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 26,667 shares of common
    stock and (ii) 26,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 13,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Revocable Living Trust FBO Daniel Carr Daniel Carr Trustee). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (401) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 18,750 shares of common
    stock and (ii) 4,688 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (Richardo
    Noriega Erosa). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (402) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Richard Brosch). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (403) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 58,083 shares of common
    stock&nbsp;&nbsp;(ii) 4,688 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants
    (iii) 39,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;and (iv) 19,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Richard Burgess). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (404) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Richard D Pence). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (405) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Richard E Brooks). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (406) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 62,500 shares of common
    stock and&nbsp;&nbsp;(ii) 15,625 shares of common stock issuable upon the exercise of the Series Preferred and Notes A warrants
    (Richard L Bowen). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (407) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 250,000 shares of common
    stock and (ii) 62,500 shares of common stock issuable upon the exercise of the Series A warrants (Richard Levine). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (408) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 43,417 shares of common
    stock&nbsp;&nbsp;(ii) 8,438 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants
    (iii) 9,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;and (iv) 4,833 shares of
    common stock issuable upon the exercise of the Series B warrants (Richard Lock). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (409) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Richard Tyler &amp; Jane Tyler JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (410) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 27,500 shares of common
    stock and (ii) 6,875 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants.&nbsp;&nbsp;David
    S. Rippee be deemed to be the beneficial owner of the shares of our common stock held by&nbsp;this selling stockholder&nbsp;
    (Rippee Mineral Management LLC). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (411) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 12,433 shares of common
    stock and (ii) 12,433 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 6,217 shares
    of common stock issuable upon the exercise of the Series B warrants (Robert Barr). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (412) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 6,667 shares of common
    stock and (ii) 6,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 3,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Robert Bruce Waters). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (413) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 13,333 shares of common
    stock and (ii) 13,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 6,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Robert Chilton). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (414) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 224,295 shares of common
    stock&nbsp;&nbsp;(ii) 37,500 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants
    (iii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;and (iv) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Robert D Priday). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (415) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Robert D Selinger). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (416) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 62,500 shares of common
    stock and&nbsp;&nbsp;(ii) 15,625 shares of common stock issuable upon the exercise of the Series Preferred and Notes A warrants
    (Robert Dunn &amp; Judy Dunn JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (417) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 6,667 shares of common
    stock and (ii) 6,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 3,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Robert Ian Chaplin). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (418) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 29,167 shares of common
    stock&nbsp;&nbsp;(ii) 3,125 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants
    (iii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;and (iv) 8,333 shares of
    common stock issuable upon the exercise of the Series B warrants (Robert J Laubenthal). </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (419) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Robert John Kline-Schoder Rev Living Trust Dtd 1-27-95). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (420) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Robert M Jennings Jr Trust U/W Robert M Jennings Jr Daniel
    Carr Trustee FBO Eve Jennings W/ Residual To Children). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (421) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Robert M Jennings Jr Trust Uad 8/4/2006 Daniel Carr Trustee). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (422) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Robert N Preite). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (423) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 26,667 shares of common
    stock and (ii) 26,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 13,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Robert R Hair). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (424) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 23,333 shares of common
    stock and (ii) 23,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 11,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Robert Zens). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (425) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 20,000 shares of common
    stock and (ii) 20,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 10,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Roberto Lupi). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (426) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 18,750 shares of common
    stock and (ii) 4,688 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (Roberto
    Mendez Eliana Cardenas Mendez JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (427) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 375,000 shares of common
    stock and (ii) 93,750 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants.&nbsp;
    Nancy T. Cheng may be deemed to be the beneficial owner of the shares of our common stock held by&nbsp;this selling stockholder&nbsp;(Robinhood
    II LP). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (428) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Roger P Bakale). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (429) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Rohn M Householder). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (430) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 187,500 shares of common
    stock and (ii) 46,875 shares of common stock issuable upon the exercise of the Series A Preferred Stock warrants (Ron D Craig). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (431) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Ronald A Soicher). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (432) </FONT></TD>
    <TD STYLE="width: 95%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares
    of common stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii)
    8,333 shares of common stock issuable upon the exercise of the Series B warrants (Ronald Grimaldi). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (433) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 22,000 shares of common
    stock and (ii) 22,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 11,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Ronald J Woodward). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (434) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 6,667 shares of common
    stock and (ii) 6,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 3,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Ross Rodgers). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (435) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Rowen Grierson). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (436) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants.&nbsp;&nbsp;Ross Sutherland be deemed to be the beneficial
    owner of the shares of our common stock held by&nbsp;this selling stockholder&nbsp; (Rs Draughting &amp; Engineering Services
    Ltd). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (437) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Russel T Davies). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (438) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 13,333 shares of common
    stock and (ii) 13,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 6,667 shares
    of common stock issuable upon the exercise of the Series B warrants (S Alexei Gitter). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (439) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 10,667 shares of common
    stock and (ii) 10,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 5,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Sal Dimeglio &amp; Kathleen Dimeglio JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (440) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Samuel A Medici &amp; Anita L Medici JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (441) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 162,500 shares of common
    stock and (ii) 40,625 shares of common stock issuable upon the exercise of the Series A Preferred Stock warrants (Samuel Gorman). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (442) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Sandeep M Shishodia). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (443) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 15,000 shares of common
    stock and (ii) 15,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 7,500 shares
    of common stock issuable upon the exercise of the Series B warrants (Balsam Capital Management). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (444) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 10,000 shares of common
    stock and (ii) 10,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 5,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Sankar K Aiyar). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (445) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Santi A Greco &amp; Nancy A Greco JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (446) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 10,667 shares of common
    stock and (ii) 10,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 5,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Santo Chiarelli). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (447) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 31,250 shares of common
    stock and (ii) 7,813 shares of common stock issuable upon the exercise of the Series A&nbsp;&nbsp;Preferred and Note warrants
    (Scott Byer). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (448) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 25,000 shares of common
    stock and (ii) 6,250 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (Seamus
    Dunne). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (449) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Sean A Tyndale-Biscoe). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (450) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 13,333 shares of common
    stock and (ii) 13,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 6,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Sean W Meitner). </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"> &nbsp; &nbsp;</P>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (451) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 10,000 shares of common
    stock and (ii) 10,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 5,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Sharon Mckenna Smith). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (452) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 135,397 shares of common
    stock&nbsp;&nbsp;(ii) 25,000 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants
    (iii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;and (iv) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Simon C Guscott). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (453) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 6,667 shares of common
    stock and (ii) 6,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 3,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Srinivas Dodda). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (454) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 6,667 shares of common
    stock and (ii) 6,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 3,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Stacy Porter). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (455) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 8,000 shares of common
    stock and (ii) 8,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 4,000 shares
    of common stock issuable upon the exercise of the Series B warrants.&nbsp;&nbsp;Lemui Baylis Canes, III may be deemed to be
    the beneficial owner of the shares of our common stock held by&nbsp;this selling stockholder&nbsp; (Standard Sand &amp; Silica
    Co Inc). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (456) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Stanley Mansfield). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (457) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Stassi Anastassov). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (458) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Stefaan Verhelst &amp; Katharine DeMeestere JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (459) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Stephen E Gately). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (460) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 26,875 shares of common
    stock and (ii) 6,719 shares of common stock issuable upon the exercise of the Series A&nbsp;&nbsp;Preferred and Note warrants
    (Stephen H Christian). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (461) </FONT></TD>
    <TD STYLE="width: 95%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares
    of common stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii)
    8,333 shares of common stock issuable upon the exercise of the Series B warrants (Stephen H Cook). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (462) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 10,000 shares of common
    stock and (ii) 10,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 5,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Stephen Hart). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (463) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 200,000 shares of common
    stock and (ii) 200,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 100,000
    shares of common stock issuable upon the exercise of the Series B warrants (Stephen Herrmann). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (464) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Stephen J Farley). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (465) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 8,000 shares of common
    stock and (ii) 8,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 4,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Stephen L Gill). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (466) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 20,000 shares of common
    stock and (ii) 20,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 10,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Stephen M Kane). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (467) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 39,407 shares of common
    stock and (ii) 9,375 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (Stephen
    &amp; Tracy Park JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (468) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Sterne Agee &amp; Leach Inc C/F Algis J Rajeckas IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (469) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Sterne Agee &amp; Leach Inc C/F Art Sadin IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (470) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Sterne Agee &amp; Leach Inc C/F Brian Mark Miller Roth
    IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (471) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 62,500 shares of common
    stock and (ii) 15,625 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Sterne
    Agee &amp; Leach Inc C/F Charles L Weidner Roth IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (472) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Sterne Agee &amp; Leach Inc C/F David Gelchie Sep IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (473) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 147,083 shares of common
    stock&nbsp;&nbsp;(ii) 23,438 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants
    (iii) 53,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;and (iv) 26,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Sterne Agee &amp; Leach Inc C/F David W Frost IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (474) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 170,000 shares of common
    stock and (ii) 170,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 85,000
    shares of common stock issuable upon the exercise of the Series B warrants (Sterne Agee &amp; Leach Inc C/F Dean Beaver R/O
    IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (475) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 23,333 shares of common
    stock and (ii) 23,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 11,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Sterne Agee &amp; Leach Inc C/F Dr Gary W Chmielewski
    IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (476) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 47,476 shares of common
    stock and (ii) 11,250 shares of common stock issuable upon the exercise of the Series A warrants (Sterne Agee &amp; Leach
    Inc C/F Edwin A Schermerhorn Roth IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (477) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Sterne Agee &amp; Leach Inc C/F Garner Mcnett IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (478) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 122,917 shares of common
    stock&nbsp;&nbsp;(ii) 14,063 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants
    (iii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;and (iv) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Sterne Agee &amp; Leach Inc C/F Graham C Short IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (479) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Sterne Agee &amp; Leach Inc C/F H Louis Salomonsky Roth
    IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (480) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 38,333 shares of common
    stock&nbsp;&nbsp;(ii) 6,250 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants
    (iii) 13,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;and (iv) 6,667 shares of
    common stock issuable upon the exercise of the Series B warrants (Sterne Agee &amp; Leach Inc C/F John H Welsh Roth IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (481) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Sterne Agee &amp; Leach Inc C/F John J Mccullough R/O
    IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (482) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 125,000 shares of common
    stock and (ii) 31,250 shares of common stock issuable upon the exercise of the Series A warrants (Sterne Agee &amp; Leach
    Inc C/F John L Sommer IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (483) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 6,667 shares of common
    stock and (ii) 6,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 3,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Sterne Agee &amp; Leach Inc C/F John R Evans IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (484) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Sterne Agee &amp; Leach Inc C/F Jonathan Steinhouse R/O
    IRA). </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="margin-top: 0; margin-bottom: 0"> &nbsp; </P>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (485) </FONT></TD>
    <TD STYLE="width: 95%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 50,000 shares
    of common stock and (ii) 50,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii)
    25,000 shares of common stock issuable upon the exercise of the Series B warrants (Sterne Agee &amp; Leach Inc C/F Joseph
    Acquavella R/O IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (486) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 43,333 shares of common
    stock and (ii) 43,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 21,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Sterne Agee &amp; Leach Inc C/F Joshua J Gooden IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (487) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 48,667 shares of common
    stock and (ii) 48,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 24,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Sterne Agee &amp; Leach Inc C/F Mercedes Sepulveda Roth
    IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (488) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Sterne Agee &amp; Leach Inc C/F Pat Schneider IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (489) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 68,750 shares of common
    stock and (ii) 17,188 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (Sterne
    Agee &amp; Leach Inc C/F Randy Payne IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (490) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 13,333 shares of common
    stock and (ii) 13,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 6,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Sterne Agee &amp; Leach Inc C/F Randy Poston Sep IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (491) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 10,000 shares of common
    stock and (ii) 10,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 5,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Sterne Agee &amp; Leach Inc C/F Richard W Rupnik IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (492) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Sterne Agee &amp; Leach Inc C/F Robert L Wallerius R/O
    IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (493) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 23,333 shares of common
    stock and (ii) 23,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 11,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Sterne Agee &amp; Leach Inc C/F Scott W Osborne R/O IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (494) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 125,000 shares of common
    stock and (ii) 31,250 shares of common stock issuable upon the exercise of the Series A warrants (Sterne Agee &amp; Leach
    Inc C/F Thomas Turley Sep IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (495) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Sterne Agee &amp; Leach Inc C/F Vincent Petrucci IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (496) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 85,833 shares of common
    stock&nbsp;&nbsp;(ii) 15,625 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants
    (iii) 23,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;and (iv) 11,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Sterne Agee &amp; Leach Inc C/F Walter J Lachewitz Jr
    IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (497) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Sterne Agee &amp; Leach Inc C/F Willard L Simons IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (498) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 40,000 shares of common
    stock and (ii) 40,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 20,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Sterne Agee &amp; Leach Inc C/F William Bellinger IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (499) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 125,000 shares of common
    stock and (ii) 31,250 shares of common stock issuable upon the exercise of the Series A warrants (Sternee Agee &amp; Leach
    Inc C/F Christina G Einstein IRA). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (500) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 62,500 shares of common
    stock and (ii) 15,625 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Steve
    Lisi). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (501) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Steve Octaviano). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (502) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 6,667 shares of common
    stock and (ii) 6,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 3,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Steve Pesner). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (503) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Steven A Hobbs). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (504) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 6,667 shares of common
    stock and (ii) 6,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 3,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Steven D Sehnert). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (505) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Steven J Henry). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (506) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 125,000 shares of common
    stock and (ii) 31,250 shares of common stock issuable upon the exercise of the Series A warrants (Steven K Nelson). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (507) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 13,333 shares of common
    stock and (ii) 13,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 6,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Steven Kaye). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (508) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 6,667 shares of common
    stock and (ii) 6,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 3,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Steven Shaw). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (509) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 158,833 shares of common
    stock&nbsp;&nbsp;(ii) 31,250 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants
    (iii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;and (iv) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Stuart R Oliver). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (510) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 50,000 shares of common
    stock and (ii) 50,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 25,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Suleiman Al Hedaithy). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (511) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Sylvain Pavlowski). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (512) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 10,000 shares of common
    stock and (ii) 10,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 5,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Taylor Cardall). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (513) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Theodore K Krampf). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (514) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Thierry De Beyssac &amp; Florence De Beyssac JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (515) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Thomas A Mckenna). </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"> &nbsp; &nbsp;</P>
<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (516) </FONT></TD>
    <TD STYLE="width: 95%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 17,500 shares
    of common stock and (ii) 4,375 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants
    (Thomas C Pugh). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (517) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 62,500 shares of common
    stock and (ii) 15,625 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Thomas
    E Vandenberg). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (518) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 129,167 shares of common
    stock&nbsp;&nbsp;(ii) 15,625 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants
    (iii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;and (iv) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Thomas G Hoffman). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (519) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 13,333 shares of common
    stock and (ii) 13,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 6,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Tim Engels). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (520) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Tim Wells). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (521) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Timothy A Kippenhan). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (522) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Timothy Charles Davis). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (523) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 40,000 shares of common
    stock and (ii) 40,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 20,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Timothy J Kane &amp; Annette K Kane JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (524) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Timothy P Johnston). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (525) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Timothy Williams). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (526) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 75,000 shares of common
    stock and (ii) 18,750 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (Todd
    &amp; Luann Johnson, JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (527) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 13,333 shares of common
    stock and (ii) 13,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 6,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Todd Mcgregor). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (528) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 17,333 shares of common
    stock and (ii) 17,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Tom Ayala). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (529) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Tommy W Filler). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (530) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants.&nbsp; David Dawes may be deemed to be the beneficial
    owner of the shares of our common stock held by&nbsp;this selling stockholder&nbsp;(Town Yield Development Ltd). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (531) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 6,125 shares of common
    stock and (ii) 1,531 shares of common stock issuable upon the exercise of the Series A warrants.&nbsp; Raimo Makela may be
    deemed to be the beneficial owner of the shares of our common stock held by&nbsp;this selling stockholder&nbsp;(TQ Electronics). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (532) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,333 shares of common
    stock and (ii) 16,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,167 shares
    of common stock issuable upon the exercise of the Series B warrants (Sandra F Tomlinson). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (533) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 62,500 shares of common
    stock and (ii) 15,625 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Trust
    Of Teena Lerner U/A/D 3/31/04). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (534) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 20,667 shares of common
    stock and (ii) 20,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 10,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Uday Dandamudi). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (535) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 39,407 shares of common
    stock and (ii) 9,375 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (Ulises
    Vazquez). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (536) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Vincent Litrico). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (537) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 12,500 shares of common
    stock and (ii) 3,125 shares of common stock issuable upon the exercise of the Series A warrants.&nbsp; Philip DeBie may be
    deemed to be the beneficial owner of the shares of our common stock held by&nbsp;this selling stockholder&nbsp;(VOF Petium
    Plus). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (538) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (Wade Welborn &amp; Adriana Welborn JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (539) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Waleed Suhail Al-Nasrawi). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (540) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 26,667 shares of common
    stock and (ii) 26,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 13,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Walter W Gloyer). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (541) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 62,500 shares of common
    stock and (ii) 15,625 shares of common stock issuable upon the exercise of the Series A Preferred and Notes warrants (Warren
    S Thune). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (542) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 8,333 shares of common
    stock and (ii) 8,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 4,167 shares
    of common stock issuable upon the exercise of the Series B warrants (Wayne Young). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (543) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Willem Hendrickx). </FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"> </P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (544) </FONT></TD>
    <TD STYLE="width: 95%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 21,333 shares
    of common stock and (ii) 21,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii)
    10,667 shares of common stock issuable upon the exercise of the Series B warrants (William &amp; Sally S Atkins Living Trust
    August 1998 William &amp; Sally Atkins TTEEs). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (545) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (William A Valka &amp; Barbara B Valka JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (546) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 79,126 shares of common
    stock and (ii) 18,750 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants (William
    A Valka Barbara B Valka JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (547) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 50,000 shares of common
    stock and (ii) 50,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 25,000 shares
    of common stock issuable upon the exercise of the Series B warrants. &nbsp;(William Allan Lucier TOD). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (548) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 113,333 shares of common
    stock and (ii) 113,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 56,667
    shares of common stock issuable upon the exercise of the Series B warrants (William Bishop). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (549) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 13,333 shares of common
    stock and (ii) 13,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 6,667 shares
    of common stock issuable upon the exercise of the Series B warrants (William Bradley Jr). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (550) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 31,250 shares of common
    stock and (ii) 7,813 shares of common stock issuable upon the exercise of the Series A Preferrred and Note warrants (William
    G Hicks). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (551) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (William J Klaus). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (552) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 64,583 shares of common
    stock&nbsp;&nbsp;(ii) 7,813 shares of common stock issuable upon the exercise of the Series A Preferred and Note warrants
    (iii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;and (iv) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants (William L Lane &amp; Leann Lane JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (553) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 13,333 shares of common
    stock and (ii) 13,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 6,667 shares
    of common stock issuable upon the exercise of the Series B warrants (William Ryan Wallace). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (554) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (William S Lehmann). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (555) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 16,667 shares of common
    stock and (ii) 16,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 8,333 shares
    of common stock issuable upon the exercise of the Series B warrants (William Wade Brawley). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (556) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Wilson Family Second Restated Trust Dtd Nov 9 2010 As
    Amended Patricia White Wilson TTEE). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (557) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 20,000 shares of common
    stock and (ii) 20,000 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 10,000 shares
    of common stock issuable upon the exercise of the Series B warrants (Wolfgang Graaff &amp; Brigditte Graaff JTWROS). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (558) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 1,875,000 shares of common
    stock.&nbsp; Doosik Yi may be deemed to be the beneficial owner of the shares of our common stock held by&nbsp;this selling
    stockholder&nbsp;(Wonpung Mulsan Co., Ltd.). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (559) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 33,333 shares of common
    stock and (ii) 33,333 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 16,667 shares
    of common stock issuable upon the exercise of the Series B warrants.&nbsp; Walter W. Gloyer may be deemed to be the beneficial
    owner of the shares of our common stock held by&nbsp;this selling stockholder&nbsp;(WTPC LLC). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (560) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 6,667 shares of common
    stock and (ii) 6,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 3,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Yasoda Krishna Prasad Dhulipalla). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (561) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 66,667 shares of common
    stock and (ii) 66,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 33,333 shares
    of common stock issuable upon the exercise of the Series B warrants (Yogesh Desai). </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (562) </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Includes (i) 6,667 shares of common
    stock and (ii) 6,667 shares of common stock issuable upon the exercise of the Series A warrants&nbsp;&nbsp;(iii) 3,333 shares
    of common stock issuable upon the exercise of the Series B warrants.&nbsp; Frans Zoetmulder may be deemed to be the beneficial
    owner of the shares of our common stock held by&nbsp;this selling stockholder&nbsp;(Zover B V). </FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">* Indicated less than 1%.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 7.7pt 0 19.8pt">Except as disclosed in the table above, to
our knowledge, none of the selling stockholders or beneficial owners:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; line-height: normal; text-align: center"><FONT STYLE="color: black">&#9679;</FONT></TD>
    <TD STYLE="width: 94%; line-height: normal"><FONT STYLE="color: black">has had a material relationship with us other than as a stockholder at any time within the past three years;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: center"><FONT STYLE="color: black">&#9679;</FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black">has ever been one of our officers or directors or an officer or director of our affiliates; or</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: center"><FONT STYLE="color: black">&#9679;</FONT></TD>
    <TD STYLE="line-height: normal"><FONT STYLE="color: black">are broker-dealers or affiliated with broker-dealers.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">With respect to those selling stockholders noted above who
are or were affiliated with registered broker-dealers, each has represented to us that the shares being registered for resale
were purchased in the ordinary course of business and, at the time of purchase, such selling stockholder had no agreements or
understandings, directly or indirectly, with any person to distribute the shares.&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_009"></A>DESCRIPTION OF BUSINESS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Company Overview</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> We are a clinical stage biopharmaceutical company
focused on drugs to treat pain.&nbsp;&nbsp;In 2013, the US market for prescription pain drugs was approximately $13B, according
to IMS Health.&nbsp;&nbsp;We are concentrating our effort and resources on novel formulations and/or modes of delivery for off-patent
drugs, new indications for drugs approved for other therapeutic uses and the development of new molecular entities.&nbsp;&nbsp;We
may in-license late-stage or approved drugs to accelerate the pathway to become a fully integrated pain specialty biopharmaceutical
company with commercial capability and to reach profitability sooner. To in-license a product means that we would acquire the
rights to develop and market a product from another pharmaceutical company in exchange for upfront payments, milestone payments
and royalty payments, as applicable. We believe in-licensing will accelerate our pathway to become a fully integrated pain specialty
biopharmaceutical company with commercial capability and to reach profitability sooner because we would be able to justify the
build up a sales and marketing force sooner if we had rights to additional products in addition to our own products. We currently
do not have any in-licensing arrangements. We believe our highly experienced drug development leadership provides us with a significant
competitive advantage in designing highly efficient clinical programs to deliver valuable products in areas of high unmet medical
need. In this regard, our experienced management team coordinates the manufacturing process, designs and implements the clinical
trials, and interacts with the FDA for product approval. We intend to hire third parties to manufacture our products and conduct
clinical trials, </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> We intend to realize our business objectives by implementing
two core strategies: a) develop improved versions of proven drug candidates for treating pain conditions where they can fill an
unmet need; and b) develop d-methadone as an innovative NMDA antagonist platform to&nbsp;&nbsp;treat&nbsp;&nbsp;neuropathic pain
or other potential conditions.&nbsp;&nbsp;d-Methadone works as an antagonist of the N-methyl-D-aspartate (NMDA) receptor. NMDA
receptors are present in many parts of the central nervous system and play important roles in neuronal plasticity and other functions
that are important for cognitive functions such as learning and memory. They also contribute to the maladaptive plasticity which
results in neuropathic pain. Based on these premises, d-methadone is potentially a platform that could be developed and could
show benefits in several different indications. A core part of our strategy of developing repurposed drugs for unmet needs allows
us to accelerate development at a lower cost.&nbsp;&nbsp;Product development plans for several of our lead products such as levorphanol
and buprenorphine require the completion of a relatively small Phase I program before entering Phase III pivotal clinical trials
using a 505(b)(2) FDA registration strategy, subject to FDA approval.&nbsp;&nbsp;Our two tiered approach is expected to reduce
overall clinical development risks and potentially deliver valuable products in areas of high unmet medical needs.&nbsp;&nbsp;Our
lead development projects are briefly described below. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; font: 10pt/normal Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="width: 94%; font: 10pt/normal Times New Roman, Times, Serif; text-align: left"><B> LevoCap ER </B> (&ldquo;Levorphanol
    ER&rdquo; or &ldquo;Levorphanol&rdquo; and similar terms)<B>&nbsp;</B>is a proprietary once-a-day extended release (ER) dosage
    form of the potent opioid levorphanol in a tamper resistant drug delivery system.&nbsp;&nbsp;Unlike other opioids, LevoCap
    ER modulates pain through<I>&nbsp;&nbsp;both</I>&nbsp;&nbsp;opioid pathways acting at mu, delta and kappa opioid receptors,
    and monoaminergic (noradrenergic and serotonergic) pathways thereby providing pain relief through multiple mechanisms in one
    capsule.&nbsp;&nbsp;Thus, LevoCap ER combines the pain relieving mechanisms of OxyContin&reg; (U.S. 2013 sales, $2.5B according
    to IMS Health) and Cymbalta&reg; (global 2013 sales, $5.1B, according to Eli Lilly 2013 annual report).&nbsp;&nbsp;Importantly,
    levorphanol has also been shown to partially reverse analgesic tolerance to morphine and may therefore benefit patients who
    are tolerant to the analgesic effects of their current opioid (Moulin, D.E., Ling, G.S. and Pasternak, G.W., Unidirectional
    analgesic cross-tolerance between morphine and levorphanol in the rat, Pain, 33 (1988) 233-9).&nbsp;&nbsp;LevoCap ER is anticipated
    to compete in the opioid market, which according to IMS Health had $8.3B in U.S. sales in 2013. </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; font: 10pt/normal Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="width: 94%; font: 10pt/normal Times New Roman, Times, Serif; text-align: left"><B> d-Methadone </B> is
    the d-optical isomer of racemic methadone and an antagonist at the N-methyl-D-aspartate (NMDA) receptor. NMDA antagonists
    have been shown to provide relief to patients with neuropathic pain and to reduce analgesic tolerance to opioids.&nbsp;&nbsp;Our
    open-label Phase I/IIa study at the Memorial Sloan Kettering Cancer Center showed that d-methadone was safe and well tolerated
    with 75% of the patients completing the study finding d-methadone to be moderately or very effective. d-Methadone will compete
    in the approximately $2.4B neuropathic pain market (Datamonitor, 2010), which is expected to grow to $9.7B by 2018 according
    to a 2011 report by Decision Resources.&nbsp;&nbsp;Management expects d-Methadone to leverage the established analgesic efficacy
    and use of methadone but without its safety hazard. </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; font: 10pt/normal Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="width: 94%; font: 10pt/normal Times New Roman, Times, Serif"><B> BuTab ER </B> (&ldquo;Buprenorphine ER&rdquo;
    or &ldquo;Buprenorphine&rdquo; and similar terms) is a proprietary extended release (ER) oral dosage form of the DEA Schedule
    III (C-III) opioid, buprenorphine.&nbsp;&nbsp;There are no orally absorbed dosage forms of Buprenophine and we believe historically
    both patients and doctors prefer oral dosing versus sublingual or patch products.&nbsp;&nbsp;The Drug Enforcement Agency (&ldquo;DEA&rdquo;)
    classifies controlled substances from Schedule I (C-I) to C-V, where C-I opioids have no current medical use and the potential
    for abuse is greatest for C-II and lowest for C-V.&nbsp;&nbsp;BuTab ER is being developed for chronic pain and opioid maintenance
    therapy.&nbsp;&nbsp;Unlike C-II opioids, BuTab ER carries reduced risk of physical dependence, euphoria, and certain opioid
    side effects, while benefitting from the convenience of telephone prescribing and refills.&nbsp;&nbsp;BuTab ER will compete
    in the opioid pain market and the sublingual buprenorphine (Suboxone&reg;/Subutex&reg;) opioid dependence market, which according
    to Wolters Kluwer, had approximate U.S. 2013 sales of $1.4B. </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; font: 10pt/normal Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="width: 94%; font: 10pt/normal Times New Roman, Times, Serif"><B>MepiGel</B> (&ldquo;Mepivacaine gel&rdquo; or &ldquo;Mepivacaine&rdquo; and similar terms) is a proprietary topical non-greasy gel dosage form of the local anesthetic mepivacaine for the treatment of postherpetic neuralgia and painful HIV-associated neuropathy.&nbsp;&nbsp;We have received two 7-year FDA Orphan Drug market exclusivities for mepivacaine, one for &ldquo;the treatment of painful HIV-associated neuropathy&rdquo; and the other for &ldquo;the management of postherpetic neuralgia&rdquo;.&nbsp;&nbsp;Lidoderm&reg; patch, the only approved topical local anesthetic suffers from poor patch adhesion, has shown to have inefficient skin absorption and low efficacy, deficiencies which MepiGel can exploit.&nbsp;&nbsp;MepiGel will be used alone or in combination with oral therapies for neuropathic pain such as Lyrica&reg; and Cymbalta&reg;.&nbsp;&nbsp;Management anticipates that it will compete with Lidoderm&reg; patch which had 2012 sales of $948M in the U.S. according to Endo Pharmaceuticals 2012 annual report.</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> In addition to our priority drug development projects,
we have an early stage pipeline of product candidates which are briefly described in the business section of this document. As
of now none of our drugs have been approved for sale in the United States or elsewhere. We have no commercial products nor do
we have a sales or marketing infrastructure. In order to market and sell our products we must conduct clinical trials on patients
and obtain regulatory approvals from appropriate regulatory agencies, like the FDA in the United States, and similar organizations
elsewhere in the world. Research and development expense for six months ended June 30, 2014 was approximately $784,700. Research
and development expense for the years ended December 31, 2013 and 2012 was approximately $5,248,700 and $667,500, respectively.&nbsp; </P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> </P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> </P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> Below is a summary of the development
status for our products: </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD><TD STYLE="text-align: left; width: 93%"> LevoCap
                                         ER: We completed GMP manufacturing for the Phase I study of LevoCap ER and the batches
                                         have successfully passed the 12 month stability milestone. In July 2013 we completed
                                         a 30 patient Phase I pharmacokinetic study. We are now preparing for a Phase III development
                                         program and we are planning to submit a request to the FDA to discuss the final pathway
                                         to the NDA for this product. In preparation of the Phase III we have initiated the transfer
                                         of the formulation technology to a US manufacturer and we are planning to generate GMP
                                         batches for the Phase III that will be performed in the United States. We rely on a single
                                         source of API for levorphanol for the development of the product. Currently this single
                                         source supplies the API for research and development purposes only. </TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD><TD STYLE="text-align: left; width: 93%"><P STYLE="margin: 0"> d-Methadone:
                                                                                                                                                     We
                                                                                                                                                     have
                                                                                                                                                     successfully
                                                                                                                                                     manufactured
                                                                                                                                                     GMP
                                                                                                                                                     d-methadone
                                                                                                                                                     as
                                                                                                                                                     an
                                                                                                                                                     active
                                                                                                                                                     pharmaceutical
                                                                                                                                                     ingredient
                                                                                                                                                     (API).
                                                                                                                                                     In
                                                                                                                                                     September,
                                                                                                                                                     2014,
                                                                                                                                                     we
                                                                                                                                                     filed
                                                                                                                                                     a
                                                                                                                                                     Clinical
                                                                                                                                                     Trial
                                                                                                                                                     Application
                                                                                                                                                     (CTA)
                                                                                                                                                     with
                                                                                                                                                     Health
                                                                                                                                                     Canada
                                                                                                                                                     to
                                                                                                                                                     conduct
                                                                                                                                                     two
                                                                                                                                                     pharmacokinetic
                                                                                                                                                     studies
                                                                                                                                                     with
                                                                                                                                                     d-methadone.
                                                                                                                                                     The
                                                                                                                                                     application
                                                                                                                                                     is
                                                                                                                                                     under
                                                                                                                                                     review.
                                                                                                                                                     The
                                                                                                                                                     two
                                                                                                                                                     studies
                                                                                                                                                     are
                                                                                                                                                     designed
                                                                                                                                                     to
                                                                                                                                                     assess
                                                                                                                                                     the
                                                                                                                                                     safety,
                                                                                                                                                     tolerability
                                                                                                                                                     and
                                                                                                                                                     pharmacokinetics
                                                                                                                                                     of
                                                                                                                                                     d-methadone
                                                                                                                                                     in
                                                                                                                                                     healthy
                                                                                                                                                     subjects.
                                                                                                                                                     The
                                                                                                                                                     first
                                                                                                                                                     study,
                                                                                                                                                     if
                                                                                                                                                     approved
                                                                                                                                                     by
                                                                                                                                                     Health
                                                                                                                                                     Canada,
                                                                                                                                                     will
                                                                                                                                                     investigate
                                                                                                                                                     the
                                                                                                                                                     safety
                                                                                                                                                     and
                                                                                                                                                     tolerability
                                                                                                                                                     of
                                                                                                                                                     single
                                                                                                                                                     escalating
                                                                                                                                                     oral
                                                                                                                                                     doses
                                                                                                                                                     of
                                                                                                                                                     d-methadone
                                                                                                                                                     and
                                                                                                                                                     determine
                                                                                                                                                     the
                                                                                                                                                     maximum
                                                                                                                                                     tolerated
                                                                                                                                                     dose
                                                                                                                                                     for
                                                                                                                                                     single
                                                                                                                                                     drug
                                                                                                                                                     administration.
                                                                                                                                                     In
                                                                                                                                                     the
                                                                                                                                                     second
                                                                                                                                                     study,
                                                                                                                                                     if
                                                                                                                                                     approved
                                                                                                                                                     by
                                                                                                                                                     Health
                                                                                                                                                     Canada,
                                                                                                                                                     healthy
                                                                                                                                                     subjects
                                                                                                                                                     will
                                                                                                                                                     receive
                                                                                                                                                     daily
                                                                                                                                                     multiple
                                                                                                                                                     escalating
                                                                                                                                                     oral
                                                                                                                                                     doses
                                                                                                                                                     of
                                                                                                                                                     d-methadone
                                                                                                                                                     for
                                                                                                                                                     the
                                                                                                                                                     assessment
                                                                                                                                                     of
                                                                                                                                                     safety
                                                                                                                                                     and
                                                                                                                                                     tolerability.
                                                                                                                                                     The
                                                                                                                                                     safety
                                                                                                                                                     and
                                                                                                                                                     pharmacokinetic
                                                                                                                                                     data
                                                                                                                                                     from
                                                                                                                                                     these
                                                                                                                                                     studies
                                                                                                                                                     will
                                                                                                                                                     inform
                                                                                                                                                     the
                                                                                                                                                     design
                                                                                                                                                     of
                                                                                                                                                     a
                                                                                                                                                     subsequent
                                                                                                                                                     Phase
                                                                                                                                                     II
                                                                                                                                                     proof
                                                                                                                                                     of
                                                                                                                                                     concept
                                                                                                                                                     study
                                                                                                                                                     in
                                                                                                                                                     neuropathic
                                                                                                                                                     pain. </P>


</TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD><TD STYLE="text-align: left; width: 93%"> BuTab
                                         ER: We have completed a preclinical program to better define the pharmacokinetic profile
                                         of BuTab ER and to assess the time course of systemic absorption of buprenorphine using
                                         several different oral extended release formulations of buprenorphine in dogs, compared
                                         to an intravenous administration. Based on the results of this work, we expect to generate
                                         GMP batches, file an IND with the FDA in the second half of this year and subsequently
                                         start a Phase I pilot study in healthy volunteers. </TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD><TD STYLE="text-align: left; width: 93%"> MepiGel:
                                         We have completed an animal study in rabbits to assess the time course of systemic absorption
                                         of mepivacaine from several different semi-solid topical gel formulations as compared
                                         to intravenous mepivacaine. The goal was to assess the absolute bioavailability of the
                                         different gels and finalize the optimal formulation to move into clinical development.
                                         We have identified one that performed at optimal level that may be selected to continue
                                         to development in humans. We are planning to generate GMP batches required for the Phase
                                         I portion of the development, file an IND with the FDA and start the Phase I trial with
                                         timing based on resources allocation. </TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> &nbsp; </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Properties </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp;&nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> We do not own any property. We are on a month to month
leases for our office space at 546 Fifth Avenue, 14th Floor, New York, NY, 10036. This lease is $15,300 per month. We also lease
an office at Village Square Professional Building Two, 686 DeKalb Pike, Suite 202, Blue Bell, PA 19422 for approximately $3,100
expiring July 2017.&nbsp;&nbsp;We entered into a sublease agreement in June 2013 for twenty eight months whereby a tenant will
be reimbursing us $2,350 for rent per month. </P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Our Corporate History and Background</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Camp Nine, Inc. was formed as a Nevada corporation on
May 31, 2012. Upon completing the share exchange in May 2014 with Relmada Therapeutics, Inc., a Delaware corporation (&ldquo;Relmada&rdquo;),
we became a holding company and Relmada became our wholly-owned subsidiary. We are a clinical stage, biopharmaceutical company
focused on developing novel versions of proven drug products that potentially address areas of high unmet medical need in the
treatment of pain.&nbsp;In May 2014, the stockholders of Relmada exchanged 10 shares of Relmada common stock for 1 share of Camp
Nine, Inc. common stock in connection with the Share Exchange. &nbsp;On July 8, 2014, the Company changed its name from Camp Nine,
Inc., to Relmada Therapeutics, Inc. This became effective in accordance with the Certificate of Amendment to Articles of Incorporation
filed with the State of Nevada.&nbsp; On August 5, 2014, FINRA approved our name change and new ticker symbol to RLMD, which became
effective on August 6, 2014. During the six months ended June 30, 2014, the Company changed its year end to June 30. </P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Acquisition of Relmada</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> On the May 20, 2014, Relmada completed a Share
Exchange with Camp Nine, whereby we acquired 94.9% of the issued and outstanding capital stock of Relmada from the Relmada
Stockholders in exchange for the issuance of 28,291,073, shares of Camp Nine, Inc. Common Stock to the Relmada Stockholders,
which represented 80.9% of our issued and outstanding common stock after the consummation of the Share
Exchange.&nbsp;&nbsp;Relmada&rsquo;s outstanding options and warrants were also exchanged for options and warrants to
purchase shares of Common Stock of Camp Nine at a ratio of 10 to 1. Prior to the Share Exchange, Camp Nine had $2 million in
cash, and no other assets or liabilities. As a result of the Share Exchange, the Relmada Stockholders became the principal
stockholders of Camp Nine. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The Share Exchange was accounted for as a &ldquo;reverse
merger&quot; rather than a business combination, wherein Relmada is considered the acquirer for accounting and financial reporting
purposes. The statement of operations reflects the activities of Relmada from the commencement of its operations on May 24, 2004.&nbsp;&nbsp;&nbsp;Unless
the context suggests otherwise, when we refer in this Report to business and financial information for periods prior to the consummation
of the Share Exchange, we are referring to the business and financial information of Relmada.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Effective at the Closing of the Share Exchange, Elliot Maza
has resigned from his officer positions as the sole member of the Board of Directors of the Company. Also effective on the closing
of the Share Exchange, Sergio Traversa, Shreeram Agharkar, Nabil M. Yazgi and Sandesh Seth were appointed to our Board of Directors.
In addition, our Board of Directors appointed Sergio Traversa to serve as our Chief Executive Officer, Eliseo Salinas to serve
as our President and Chief Medical Officer, and Douglas Beck, CPA to serve as our Chief Financial Officer, effective immediately
upon the closing of the Share Exchange.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> As a result of the Share Exchange, Relmada became a subsidiary
of Camp Nine and Camp Nine assumed the business and operations of Relmada. Effective August 6, 2014, the Financial Industry Regulatory
Authority (FINRA) approved the Company's application for a name change from Camp Nine, Inc. to Relmada Therapeutics, Inc. and
assigned a new trading symbol, RLMD.<FONT STYLE="color: #666666"> </FONT>&nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> &nbsp; </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Corporate History of Relmada</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Relmada is a development stage company
and commenced its operations&nbsp;in May 24, 2004. The Company was incorporated as a Delaware Limited Liability Company (LLC) under
the name TheraQuest Biosciences, LLC.&nbsp;&nbsp;&nbsp;The Company converted from LLC to a C Corporation in February 2007 and the
Company changed its name to Relmada Therapeutics, Inc. in November 2011.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Summary of Scientific and Business Achievements</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Relmada&rsquo;s corporate and drug development achievements
during and after the closing of its $8 million Series A Preferred Stock on September 30, 2013 are summarized as follows:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; font: 10pt/normal Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="width: 94%; font: 10pt/normal Times New Roman, Times, Serif">In February 2014, Relmada appointed Dr. Eliseo Salinas, MD, MSC as President and Chief Scientific Officer.&nbsp;&nbsp;Dr. Salinas was previously EVP, Specialty Pharma, Global R&amp;D and Chief Scientific Officer at Shire Pharmaceuticals, EVP - Head of R&amp;D and Chief Medical Officer at Elan Pharmaceuticals, and was Head of Worldwide CNS at Wyeth. Dr. Salinas has been the driving force behind the development of several highly successful drugs including Effexor XR, Adderall XR;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; font: 10pt/normal Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="width: 94%; font: 10pt/normal Times New Roman, Times, Serif"> In December 2013, we completed the acquisition
    of Medeor, Inc., from whom we had licensed D-methadone; </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; font: 10pt/normal Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="width: 94%; font: 10pt/normal Times New Roman, Times, Serif">In December 2013, Relmada appointed Doug Beck, CPA as Chief Financial Officer.&nbsp;&nbsp;Mr. Beck has been the CFO of several public companies including Lev Pharmaceuticals, Inc., which was acquired by ViroPharma, Incorporated for $618 million in 2008;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; font: 10pt/normal Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="width: 94%; font: 10pt/normal Times New Roman, Times, Serif">During 2013, we completed good manufacturing practices, or GMP manufacturing for LevoCap ER additional strengths, and also completed a 30 patient pharmacokinetic study for LevoCap ER and announced a positive outcome;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; font: 10pt/normal Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="width: 94%; font: 10pt/normal Times New Roman, Times, Serif"> In 2013, we successfully manufactured GMP d-methadone
    active pharmaceutical ingredients, or API; </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; font: 10pt/normal Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="width: 94%; font: 10pt/normal Times New Roman, Times, Serif">In 2013, we completed a successful preclinical study with MepiGel that resulted in the selection of the optimal formulation;</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp; &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; font: 10pt/normal Times New Roman, Times, Serif"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="width: 94%; font: 10pt/normal Times New Roman, Times, Serif"> In 2013, we completed a successful preclinical
    study with BuTab ER that resulted in achieving proof of concept for gastrointestinal bioavailability of buprenorphine in an
    animal model. </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Business Strategy</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Our strategy is to leverage its considerable industry
experience, analgesic therapy knowledge and development expertise to identify, develop and commercialize product candidates with
strong market potential that can fulfill unmet medical needs in the treatment of pain. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left"> We plan to further develop our new
and proprietary drug products to provide improved efficacy, safety and patient convenience primarily using the 505(b)(2) development
pathway and develop new indications where use exclusivity is available under the Hatch-Waxman Act, orphan drug regulations and
through the generation of IP (Intellectual Property).&nbsp;&nbsp;We will also pursue the development of d-methadone via the traditional
NDA route.&nbsp;&nbsp;As the drug d-Methadone is not been an already approved product by the FDA, the regulatory pathway to approval
will be the more traditional NDA development, which will consist of conducting a full clinical development program. We will continue
to prioritize our product development activities after taking into account the resources we have available, market dynamics and
potential for value addition.&nbsp;&nbsp;We will continue to outsource development of our products, while retaining scientific,
operational and financial oversight and control. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> We intend to seek and execute licensing and/or co-development
agreements with companies capable of supporting the final stage development of the Company&rsquo;s products and their subsequent
commercialization in the U.S. and international markets.&nbsp;&nbsp;We are planning to develop our own internal sales and marketing
capabilities to commercialize some or all of our products to selected specialty medical segments in the U.S. while out-licensing
sales and marketing for the international market. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> We may in-license late-stage or approved drugs to accelerate
the pathway to become a fully integrated pain specialty biopharmaceutical company with commercial capability and to reach profitability
sooner. Alternatively, we might consider a trade sale of our products or the entire company if we deem that it is in the best
interests of our stockholders. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Market Opportunity</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left">Analgesics continue to be among the most widely prescribed
medications and there is little to suggest that their preeminence will change in the near future, given the prominent role of pain
in many diseases.&nbsp;&nbsp;Survey data indicate substantial patient dissatisfaction with current pain management modalities.&nbsp;&nbsp;According
to the Chronic Pain in America Study published in 1999 by AAPM, APS, and Jansen and the Voice of Chronic Pain Survey by the American
Pain Foundation in May 2006; only 55% of patients with chronic pain feel their pain is &ldquo;under control&rdquo; and only 23%
believe their pain medications are &ldquo;very effective.&rdquo;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">According to IMS Health, the U.S. opioid market was worth
approximately $8.3B in 2013, with ER (Extended Release) opioids accounting for approximately $4.8B in sales.&nbsp;&nbsp;Significant
market value has been maintained in the presence of low-cost high-volume generics over the last two decades through the introduction
of new products that were approved via the 505(b)(2) FDA approval route.&nbsp;&nbsp;These products are branded and differentiated
formulations such as fixed dose combinations, extended-release products, transdermal patches, etc. and thus provide both market
exclusivity and the possibility of a high price point.&nbsp;&nbsp;Per Decision Resources, the cost of therapy for branded ER opioids
is approximately $11.00 per day versus generics which cost $3.00 per day.&nbsp;&nbsp;Our ER opioids LevoCap ER and BuTab ER are
pharmacologically differentiated from commercially available immediate release (IR) and ER opioids, including OxyContin&reg;, Embeda&reg;,
Opana&reg; ER, Duragesic&reg;, Avinza&reg;, Kadian&reg;, Remoxy&reg; &amp; Exalgo&reg;.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Many patients with neuropathic pain have suboptimal relief
with monotherapy and treatment is frequently multimodal, involving use of two or more drugs from different pharmacologic classes.&nbsp;&nbsp;Our
topical local anaesthetic mepivacaine and oral d-methadone are anticipated to be used for the treatment of painful peripheral
neuropathies.&nbsp;&nbsp;According to Decision Resources, the market for neuropathic pain drugs is expected to grow to $9.7B by
2018 in the U.S. According to GlobalData, the U.S. neuropathic pain market consists of approximately 4.7M patients and is expected
to grow to more than 6.1M patients in 2018.&nbsp;&nbsp;d-Methadone is anticipated to compete with the current available therapies
for neuropathic pain, including Cymbalta&reg; which had $5.1B in worldwide 2013 sales, according to Eli Lilly 2013 annual report
Lyrica&reg; which had $4.6B in worldwide 2013 sales, according to Pfizer 2013 annual report and Lidoderm&reg; which had $948M
in U.S. 2012 sales, according to Endo Pharmaceuticals 2012 annual report. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> Our orphan designated topical MepiGel
is anticipated to compete with topical Lidoderm&reg; patch with $948M in U.S. 2012 sales (according to Endo Pharmaceuticals 2012
annual report) and may also be used in combination with oral therapies for neuropathic pain. MepiGel is developed for the relief
of pain associated with post-herpetic neuralgia which is the same indication as that of the topical Lidoderm patch. Hence, we
believe that MepiGel is anticipated to compete with Lidoderm&reg;. Lidoderm&reg; patch is the only topical local anaesthetic approved
for the treatment of neuropathic pain. Lidoderm&reg; provides only modest pain relief in patients with postherpetic neuralgia.&nbsp;&nbsp;According
to the March 2010 issue of UK National Institute of Health and Clinical Excellence (NICE) clinical guideline on neuropathic pain,
there is a &ldquo;lack of evidence for the efficacy of topical lidocaine for treating neuropathic pain&rdquo; and topical lidocaine
should be considered as &ldquo;third line&rdquo; treatment for neuropathic pain. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"><B>Product Development</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> We believe that we have executed our lower clinical risk
strategy by developing a portfolio of improved versions of proven drug candidates for treating unmet medical need in various types
of pain conditions.&nbsp;&nbsp;Relmada has successfully completed a 15-subject, 5-way crossover bioavailability study of its abuse
resistant once-a-day dosage forms of the multimodal strong opioid analgesic, LevoCap ER under a U.S. FDA IND (Investigational
New Drug) application.&nbsp;&nbsp;LevoCap IND was filed with the FDA on September 30, 2008 by Relmada. Currently this IND is open.
The study evaluated 4 promising GMP formulations of LevoCap ER against immediate release (IR) levorphanol.&nbsp;&nbsp;The results
of the study show that all 4 LevoCap ER dosage forms provide robust extended release characteristics suitable for once-a-day dosing.
The company has recently completed a 30-subject Phase I pharmacokinetic study for LevoCap. The results showed good bioavailability
for the ER formulations with dose proportionality and a profile that is suitable for a once a day administration.&nbsp;&nbsp;No
serious events or unexpected side effects were experienced during the study.&nbsp;&nbsp;Following the manufacturing technology
transfer of LevoCap ER from the UK to the United States, we may be in a position to proceed directly into a Phase III development
program using the 505(b)(2) pathway, subject to FDA approval.&nbsp;&nbsp;We anticipate filing IND&rsquo;s for topical MepiGel
and oral BuTab ER in 2014.&nbsp;&nbsp;Similarly to LevoCap, after a small Phase I/II program we may be in a position to proceed
directly into Phase III development using the 505(b)(2) pathway, subject to FDA approval.&nbsp;&nbsp;We plan to conduct a Phase
IIb study in neuropathic pain for d-methadone. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Operations</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Our operations are primarily devoted to development of
its lead product candidates LevoCap ER, d-methadone, BuTab ER and MepiGel.&nbsp;&nbsp;We will prioritize the order of development
after taking into consideration the resources available to us, development hurdles, competitive conditions and other factors that
could have bearing on the commercial viability of our programs. Currently, key ongoing activities for LevoCap ER include the preparation
of the material required for an &ldquo;end of Phase II&rdquo; meeting and the preliminary work for the manufacturing technology
transfer from the UK to the U.S. The Company is also devoting time to the preparation of the U.S. IND for topical MepiGel and
BuTab ER and the selection of a GMP manufacturer for both products.&nbsp;&nbsp;Concurrently with these activities we are preparing
to open the U.S. IND for d-methadone and requesting a meeting with FDA to discuss the Phase II development program. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Intellectual Property Portfolio and Market Exclusivity</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We have secured Orphan Drug Designation from the FDA for
MepiGel for &ldquo;the treatment of painful HIV-associated neuropathy&rdquo; and for &ldquo;the management of postherpetic neuralgia&rdquo;
which would, upon NDA approval, carry 7-year FDA Orphan Drug marketing exclusivity.&nbsp;&nbsp;In the European Union, some of our
products may be eligible up to 10 years of market exclusivity which includes 8 years data exclusivity and 2 years market exclusivity.&nbsp;&nbsp;In
addition to any granted patents, our products will be eligible for market exclusivity to run concurrently with the term of the
patent for 3.5 years in the U.S. (Hatch Waxman plus pediatric exclusivity) and up to 10 years of in the E.U.&nbsp;&nbsp;Management
believes Relmada&rsquo;s technology and products are protected by an extensive intellectual property estate of several patents
or patent applications.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> The following is a summary of our
patents and patent applications: </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><U> Levorphanol </U> : These
patent applications cover the Levorphanol product. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD><TD STYLE="text-align: left; width: 93%"> Patent
                                         application 12/223.327 filed 1/29/07, Abuse Resistant and Extended Release Formulations
                                         and Method of Use Thereof. Cover US. Owned by Relmada. Currently pending. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD><TD STYLE="text-align: left; width: 93%"> Patent
                                         application 12/597,702 filed 4/28/08, Multimodal Abuse Resistant and Extended Release
                                         Opioid Formulations. Cover US. Owned by Relmada. Currently pending. </TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD><TD STYLE="text-align: left; width: 93%"> Patent
                                         application 13/320,989 filed 2/26/10, Extended Release Oral Pharmaceutical Compositions
                                         of 3-Hydroxy-N-Methylmorphinan and Method of Use. Cover US and EU. Owned by Relmada.
                                         Currently pending. </TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><U> D-Methadone </U> : The patent
is licensed from Cornell University. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD><TD STYLE="text-align: left; width: 93%"> Patent
                                         No. 6,008,258 filed 1/21/98, d-Methadone, a Nonopioid Analgesic, Cover US, Patent granted,
                                         estimated expiry date 1/20/18. </TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left"><U> Buprenorphine </U> : This patent
application covers the buprenorphine product. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD><TD STYLE="text-align: left; width: 93%"> Patent
                                         application 12/989,209 filed 3/9/09, Oral Pharmaceutical Compositions of Buprenorphine
                                         and Method of Use. Cover US and EU. Owned by Relmada. Currently pending. </TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><U> Mepivacaine </U> : This
patent application covers the Mepivacaine product. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD><TD STYLE="text-align: left; width: 93%"> Patent
                                         application PCT/US2011/032,381 filed 4/13/11, Dermal Pharmaceutical Composition of 1-Methyl-2,6-Pipecoloxylidide
                                         and Method of Use. Cover US, EU, Canada, China, India, Japan, and South Korea. Owned
                                         by Relmada. Currently pending. </TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Key Strengths</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We believe that the key elements for our market success include:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: normal">&nbsp;</TD>
    <TD STYLE="width: 4%; line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="width: 93%; line-height: normal"><B>A multiple product portfolio with a balanced risk reward profile:</B> We have four products at various stages of development, and each has its own development risk profile and indication.&nbsp;&nbsp;Accordingly, management believes that we are well positioned to become a competitive player in a large unsatisfied market.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD>
    <TD STYLE="line-height: normal"><B> Products are differentiated and address significant unmet needs: </B> All four
    lead development programs are well differentiated value added pain drugs that address significant unmet medical needs.&nbsp;&nbsp;Pain
    management remains a critical area of unmet medical need.&nbsp;&nbsp;Increasingly, patients, advocacy groups, pain related
    professional organizations and the media are highlighting the limitations of pain management and are demanding changes in
    the medical system.&nbsp;&nbsp;Neuropathic pain in particular is a large and unsatisfied segment where d-methadone could play
    an important role.&nbsp;&nbsp;In addition, the abuse potential of leading pain medications such as the OxyContin franchise,
    Vicodin, etc has been reported extensively.&nbsp;&nbsp; Our LevoCap ER dosage form cannot be easily manipulated for intravenous,
    intranasal or inhalational use, and for oral ingestion to provide high peak concentrations to opioid addicts and recreational
    drug users. </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal"><B>Scientific support of leading experts:</B> Our scientific advisory board includes clinicians and scientists&nbsp;&nbsp;who are affiliated with a number of highly regarded medical institutions.&nbsp;&nbsp;The board consists of individuals who have served as executives of leading national and international societies in pain, rheumatology and the FDA.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal"><B>Efficient development strategy:</B> The 505(b) (2) pathway lowers the risk of drug development.&nbsp;&nbsp;Our strategy of combining proven drug candidates with novel delivery methods and pharmaceutical compositions reduces clinical development time and costs and lowers regulatory risks, while delivering valuable products in areas of high unmet need to the market place.&nbsp;&nbsp;Abuse resistant and once a day formulations improve the commercial potential of opioids, addressing the risk of opioid abuse and opioid diversion by making the dosage form tamper resistant, thereby frustrating attempts at physical manipulation of the dosage.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal"><B>Substantial IP portfolio and market protection:</B> We have secured an intellectual property portfolio comprised of several patents and patent applications.&nbsp;&nbsp;In addition, some of our drugs have also been designated as Orphan Drugs by the FDA, thereby providing seven years of market exclusivity at launch.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="line-height: normal"><B>Experienced management:</B> We combine business expertise with what we believe is an internationally recognized research team.&nbsp;&nbsp;We believe our highly experienced drug development leadership provides us with a significant competitive advantage in designing highly efficient clinical programs with predictable regulatory outcomes.</TD></TR></TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Competition Overview</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The pain market has peculiar characteristics with regards
to competition. While there are several products in development both in the narcotic and neuropathic pain space, the market history
has shown that a new entry in the therapeutic area does not significantly cannibalize existing products, but instead expands the
market. The reasons behind this behavior can be found in the &ldquo;opioid rotation&rdquo; phenomena. As there is considerable
variability in the efficacy and side effect response of patients to opioid analgesics, many patients rotate from one opioid to
another, offering growth opportunity to new entries. The limited availability of sustained release formulations is also a contributor
to the additive role of new product entries. In the case of the neuropathic pain indication, it is mostly the limited efficacy
of the existing therapies that creates a strong demand for new entries, a model also validated by the considerable off-label use
of opioids, tricyclic antidepressant and NSAIDS in neuropathic pain.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Because of the large opportunity, the current competitive
landscape includes a significant number of pharmaceutical companies such as Pfizer, Johnson &amp; Johnson, Eli Lilly, Endo Pharmaceutical
Holding, Purdue Pharma, Actavis, Mallinckrodt and Teva Pharmaceutical.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">In addition to the marketed drugs, we expect competition
from product candidates that are or will be in development by the companies mentioned above and others.&nbsp;&nbsp;We are aware
that several companies not mentioned before are working on new delivery forms of pain products and abuse deterrent formulations,
including Acura Pharmaceutical, Altea Therapeutics, Arcion Therapeutics, Biodelivery Science, Collegium Pharmaceutical, Egalet
A/S, Elite Pharmaceutical, Inspirion Delivery Technologies, Intellipharmaceutics International, Orexo AB, QRx Pharma, and Zogenix.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Government Regulation</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Governmental authorities in the United States and other
countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, promotion, advertising,
distribution and marketing of active pharmaceutical ingredients, excipients, controlled substances and finished pharmaceutical
products such as those being developed by Relmada. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">In the United States, the FDA regulates such products under
the Federal Food, Drug and Cosmetic Act (FDCA), as amended and regulations pursuant to the FDCA.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The U.S. Drug Enforcement Agency (DEA), a division of the
Department of Justice, administers the federal Controlled Substances Act (&ldquo;CSA&rdquo;) of 1970, as amended.&nbsp;&nbsp;The
CSA imposes various registration, record-keeping and reporting requirements, procurement and manufacturing quotas, import and export
controls, labeling and packaging requirements, security controls, and a restriction on prescription refills on certain pharmaceutical
products.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">To meet its responsibilities, the DEA conducts periodic inspections
of registered establishments that handle controlled substances.&nbsp;&nbsp;Failure of companies to maintain compliance, particularly
as manifested in loss or diversion, can result in regulatory action including civil and criminal penalties, refusal to renew necessary
registrations, or initiating proceedings to revoke those registrations.&nbsp;&nbsp;If a manufacturer or distributor has its registration
revoked, it can no longer lawfully possess or distribute controlled substances meaning effectively that the operations of such
an organization must cease with respect to controlled substances.&nbsp;&nbsp;In certain circumstances, violations also can lead
to criminal proceedings.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Most states impose similar controls over controlled substances
under state law as regulated by the Board of Pharmacy or other state regulatory authorities.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The U.S. Federal Trade Commission (FTC) and the Office of
the Inspector General of the U.S. Department of Health and Human Services (HHS) also regulate certain pharmaceutical marketing
practices. Thus, reimbursement practices of the HHS covering medicine and medical services are important to the success of our
products.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We are also subject to numerous federal, state and local
laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control,
and disposal of hazardous or potentially hazardous substances.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left">Failure to comply with applicable FDA, DEA, FTC, HHS and
other federal and state regulations and requirements, both before and after drug approval may subject us to administrative and
judicial sanctions, such as a delay in approving or refusal by the FDA to approve pending applications, warning letters, product
recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines and/or criminal prosecution.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left"> Relmada believes that a two tiered
approach can reduce overall clinical development risks. Our approach consists of: (1) developing improved versions of proven drug
candidates and filings under 505(b)(2) which may require an abbreviated clinical development program; and (2) developing a drug
in treating conditions that have not been approved by the FDA, and filings under the traditional NDA which would require a full
clinical development program. In general, drugs for the 505(b)(2) filing possess less risks as compared to drugs filed under the
traditional NDA route. As with all drugs filed with the FDA, there is no guarantee of approval. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: left; text-indent: -0.25in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left"> Relmada has obtained the right to
two orphan drug designations for MepiGel from Cinergen, LLC. for the management of postherpetic neuralgia and the treatment of
painful HIV-associated neuropathy. With an approval from the FDA, 7-year market exclusivities for these two indications are possible. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> Please see &ldquo;Company Overview&rdquo;
above for a status of our drug development. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>U.S. Food and Drug Administration Regulation</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Our research, development and clinical programs, as well
as our manufacturing and marketing operations, are subject to extensive regulation in the United States and other countries. Most
notably, all of our products sold in the United States are subject to the FDCA as implemented and enforced by the FDA. Certain
of our product candidates in the United States require FDA pre-marketing approval of an NDA pursuant to 21 C.F.R. &sect; 314.
Foreign countries may require similar or more onerous approvals to manufacture or market these products.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Failure by us or by our
suppliers to comply with applicable regulatory requirements can result in enforcement action by the FDA, the DEA or other regulatory
authorities, which may result in sanctions including, but not limited to: untitled letters, warning letters, fines, injunctions,
consent decrees and civil penalties; customer notifications or repair, replacement, refunds, recall, detention or seizure of our
products; operating restrictions or partial suspension or total shutdown of production; refusing or delaying our requests for
NDA premarket approval of new products or modified products; withdrawing NDA approvals that have already been granted; refusal
to grant export approval for our products; or criminal prosecution.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Legal Proceedings</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>The Pennsylvania Litigation:&nbsp;&nbsp;</B>Relmada has
sued its former President and Chief Scientific Officer, Najib Babul, in the United States District Court for the Eastern District
of Pennsylvania.&nbsp;&nbsp;Mr. Babul resigned from his executive positions in September 2012 and was later removed from Relmada&rsquo;s
board of directors.&nbsp;&nbsp;The Complaint alleges that, during the course of an audit, Relmada discovered approximately $1.5
million in questionable expenses incurred by Mr. Babul during his management of the company from 2004 until his resignation in
2012 (the &ldquo;Questionable Expenses&rdquo;). Outside the lawsuit, Relmada has also cancelled warrants to purchase 6,682,125
shares (or 668,212 shares post Share Exchange) of common stock (the &ldquo;Cancelled Warrants&rdquo;) on the ground, among others,
that Babul could not and did not satisfy the conditions for holding or exercising the warrants after his voluntary resignation
from the Company.&nbsp;&nbsp;The Company also has not exchanged Mr. Babul&rsquo;s equity in Relmada for Company common stock pursuant
to the Share Exchange that closed on May 20, 2014.&nbsp;&nbsp;Mr. Babul has answered the complaint, denying any liability, and
has filed a counterclaim seeking specific performance and reinstatement of the Warrants, as well as compensatory damages and other
relief.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>The Delaware Litigation:&nbsp;&nbsp;</B>After the Pennsylvania
Litigation was brought against him, Mr. Babul brought an action in the Court of Chancery Delaware (the state in which Relmada is
incorporated), demanding that Relmada advance his litigation expenses in the Delaware and Pennsylvania Litigation pursuant to,
among other things, a Delaware Statute that requires a corporation to advance the reasonable litigation expenses of a former officer
or director who is a party to litigation by reason of that relationship, and the Court ordered Relmada to advance such expenses.&nbsp;&nbsp;Depending
upon the outcome of that litigation, Relmada may or may not be entitled to be reimbursed for the advanced expenses, but there can
be no assurance that, even if Relmada prevails, Mr. Babul will be able to repay Relmada.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Other Potential Litigation:&nbsp;&nbsp;</B>In addition
to the aforementioned disputes, Relmada has been informed that Mr. Babul is contemplating making additional claims in the Pennsylvania
litigation or elsewhere, as is Relmada.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Management believes that Relmada has good grounds for its
claims against Mr. Babul and for its defenses against Mr. Babul&rsquo;s claims, but the outcome of any litigation is impossible
to predict with certainty.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Employees</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> As of September 3, 2014, we have&nbsp;7 full-time employees
and no part-time employees.&nbsp;&nbsp;None of these employees are covered by a collective bargaining agreement, and we believe
our relationship with our employees is good.&nbsp;&nbsp;We also engage consultants on an as-needed basis to supplement existing
staff. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Available Information</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Reports we file with the SEC pursuant to the Exchange Act
of 1934, as amended (the &ldquo;Exchange Act&rdquo;), including annual and quarterly reports, and other reports we file, can be
inspected and copied at the public reference facilities maintained by the SEC at 100 F Street.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_010"></A><B>MARKET PRICE OF AND DIVIDENDS ON OUR
COMMON STOCK AND RELATED STOCKHOLDER MATTERS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Market Information</B> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Our common stock is listed on OTCQB, under the symbol
&ldquo;RLMD&rdquo;. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left"> The following table shows, for the
for the fiscal period June 30, 2014 and 2013 indicated, the high and low bid prices per share of our common stock as reported
by the OTCQB quotation service. These bid prices represent prices quoted by broker-dealers on the OTCQB quotation service. The
quotations reflect inter-dealer prices, without retail mark-up, mark-down or commissions, and may not represent actual transactions. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> For the Six Months
    Ended June 30, 2014 </FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> High </FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Low </FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Three months ended March 31, 2014 </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Three months ended June 30, 2014 </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 3.00 </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 0.01 </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: underline; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> For
    the Year Ended December 31, 2013 </FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> High </B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Low </B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Three months ended March 31, 2013 </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Three months ended June 30, 2013 </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Three Months ended September 30, 2013 </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Three Months ended December 31,2013 </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-decoration: underline; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> For
    the Year Ended December 31, 2012 </FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> High </B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Low </B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Three months ended March 31, 2012 </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Three months ended June 30, 2012 </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Three Months ended September 30, 2012 </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Three Months ended December 31,2012 </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"> - &nbsp;Did not trade </P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Lack of a Public Market for Common Stock </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Prior to our share exchange there was no public market
for our common stock. We completed a share exchange on May 20, 2014 as described in the business section of this 10-K. In addition,
on August 5, 2014, FIRNA approved our symbol change from CMPE to RLMD. This became effective on August 6, 2014. There is no assurance
that our shares will continue to be traded on the bulletin board, or if traded, that a public market will materialize. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The Securities Exchange Commission has adopted rules
that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities
with a price of less than $5.00, other than securities registered on certain national securities exchanges or quoted on the NASDAQ
system, provided that current price and volume information with respect to transactions in such securities is provided by the
exchange or system. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock, to deliver a standardized
risk disclosure document prepared by the Commission, that: (a) contains a description of the nature and level of risk in the market
for penny stocks in both public offerings and secondary trading;(b) contains a description of the broker's or dealer's duties
to the customer and of the rights and remedies available to the customer with respect to a violation to such duties or other requirements
of Securities' laws; (c) contains a brief, clear, narrative description of a dealer market, including bid and ask prices for penny
stocks and the significance of the spread between the bid and ask price;(d) contains a toll-free telephone number for inquiries
on disciplinary actions;(e) defines significant terms in the disclosure document or in the conduct of trading in penny stocks;
and;(f) contains such other information and is in such form, including language, type, size and format, as the Commission shall
require by rule or regulation. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The broker-dealer also must provide, prior to effecting
any transaction in a penny stock, the customer with; (a) bid and offer quotations for the penny stock;(b) the compensation of
the broker-dealer and its salesperson in the transaction;(c) the number of shares to which such bid and ask prices apply, or other
comparable information relating to the depth and liquidity of the market for such stock; and (d) a monthly account statements
showing the market value of each penny stock held in the customer's account. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> In addition, the penny stock rules require that prior
to a transaction in a penny stock not otherwise exempt from those rules; the broker-dealer must make a special written determination
that the penny stock is a suitable investment for the purchaser and receive the purchaser's written acknowledgment of the receipt
of a risk disclosure statement, a written agreement to transactions involving penny stocks, and a signed and dated copy of a written
suitability statement. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> These disclosure requirements may have the effect of
reducing the trading activity in the secondary market for our stock if it becomes subject to these penny stock rules. Therefore,
because our common stock is subject to the penny stock rules, stockholders may have difficulty selling those securities. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp;&nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Holders </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> As of August 25, 2014, 40,301,717 shares of Common Stock
were issued and outstanding, which were held by&nbsp;638 holders of record. There are 3,337,309 shares of Class A Convertible
Preferred Stock outstanding held by 10 holders. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> Of the 40,301,717 shares of Common Stock issued and outstanding,
39,964,417 of such shares are restricted shares under the Securities Act. None of these restricted shares are eligible for resale
absent registration or an exemption from registration under the Securities Act. As of the date hereof, the exemption from registration
provided by Rule 144 under the Securities Act is not available for these shares pursuant to Rule 144(i). &nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Registration Rights</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> In connection with Relmada&rsquo;s May 2014 private placement
offering that closed on May 15, 2014, we are obligated to file within 45 days of the final closing of the offering a registration
statement registering for resale all shares of common stock of Relmada issued as part of the units and all common shares of Relmada
issuable upon exercise of the Series A and Series B Warrants issued in the offering.&nbsp;&nbsp;Also, in connection with Camp
Nine&rsquo;s May 2014 private placement offering that closed on June 10, 2014, we were obligated to file within 45 days of the
final closing of the offering a registration statement registering for resale all shares of common stock of Camp Nine issued as
part of the units and all common shares of Camp Nine issuable upon exercise of the Series A and Series B Warrants issued in the
offering.&nbsp;&nbsp;We are also obligated to include in the registration statement (i) Relmada&rsquo;s Series A Preferred Stock
that converted into Common Stock at the Share Exchange, (ii)&nbsp;&nbsp;Relmada Notes that converted into Common Stock at the
Share Exchange, (iii)&nbsp;&nbsp;underlying Common Stock included with the Series A Preferred Warrants and Notes Warrants; (iv) underlying common stock in connection with warrants issued to the placement agent in the Relmada&rsquo;s Series A Preferred
financing and (v) Notes financing. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Dividends</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We have never declared or paid a cash dividend. Any future
decisions regarding dividends are made by our Board of Directors. We currently intend to retain and use any future earnings for
the development and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. Our Board
of Directors has complete discretion on whether to pay dividends. Even if our Board of Directors decides to pay dividends, the
form, frequency and amount will depend upon our future operations and earnings, capital requirements and surplus, general financial
condition, contractual restrictions and other factors that the Board of Directors may deem relevant.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Securities Authorized for Issuance Under Equity Compensation
Plans</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Relmada has a 2014 Equity incentive Plan in which its
directors, officers, employees and consultants shall be eligible to participate. As of June 30, 2014, the Company has 4,693,693
awards available to be issued.&nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_011"></A>MANAGEMENT&rsquo;S DISCUSSION&nbsp;AND
ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 7.7pt 0 9.9pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I> The information and financial data discussed below
is derived from the consolidated financial statements of Relmada for the six months ended June 30, 2014 and for the years ended
December 31, 2013 and 2012. The consolidated financial statements of Relmada were prepared and presented in accordance with generally
accepted accounting principles in the United States.&nbsp;&nbsp;The information and financial data discussed below is only a summary
and should be read in conjunction with the historical financial statements and related notes of Relmada contained elsewhere in
this Report.&nbsp;&nbsp;The consolidated financial statements contained elsewhere in this Report fully represent Relmada&rsquo;s
financial condition and operations; however, they are not indicative of the Company&rsquo;s future performance.&nbsp;&nbsp;See
&ldquo;Cautionary Note Regarding Forward Looking Statements&rdquo; above for a discussion of forward-looking statements and the
significance of such statements in the context of this Report. </I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> This discussion contains forward-looking statements reflecting
our current expectations that involve risks and uncertainties.&nbsp;&nbsp;Actual results may differ materially from those discussed
in these forward-looking statements due to a number of factors, including those set forth in the section entitled &ldquo;<B> Risk
Factors</B> &rdquo; and elsewhere herein. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Relmada Therapeutics, Inc. (the &ldquo;Company&rdquo;)
is a clinical stage, biopharmaceutical company focused on developing novel versions of proven drug products that potentially address
areas of high unmet medical need in the treatment of pain.&nbsp;&nbsp;We have a diversified portfolio of four lead products at
different stages of development and an early stage pipeline of an additional three products.&nbsp;&nbsp;We have not earned revenues
from its products since inception. &nbsp;Our product development efforts are guided by what we believe is the internationally
recognized scientific expertise of its research team with inputs from a world-class scientific advisory board.&nbsp;&nbsp;Our
approach is expected to reduce overall clinical development risks and potentially deliver valuable products in areas of high unmet
medical needs. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> We were incorporated in the State of Nevada on May 31,
2012. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> On May 20, 2014, we completed a share exchange with Relmada
Therapeutics, Inc. (&ldquo;Relmada&rdquo; or &ldquo;RTI&rdquo;, our wholly-owned subsidiary), pursuant to which we acquired 94.6%
of the issued and outstanding equity securities of Relmada in exchange for the issuance of 28,291,073 shares of common stock.
This represented 80.9% of our issued and outstanding common stock after the consummation of the share exchange (the &ldquo;Share
Exchange&rdquo;). Relmada&rsquo;s outstanding options and warrants were exchanged for options and warrants to purchase shares
of common stock of Relmada. Prior to the Share Exchange, Camp Nine had no assets or liabilities. Pursuant to the Share Exchange
Agreement, the principal shareholders of Relmada invested $2,000,000 and we issued 3,337,310 shares of common stock and 3,337,309
shares of Class A convertible preferred stock. The Company increased its authorized shares of common stock to 500,000,000 and
preferred stock to 200,000,000. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The Share Exchange was accounted for as a reverse merger
rather than a business combination, wherein RTI is considered the acquirer for accounting and financial reporting purposes. Accordingly,
the statement of operations reflects the activities of RTI from the date of inception, May 24, 2004. As a result of the Share
Exchange, the Company became the holding company and RTI became the subsidiary. The operating entity is that of RTI. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Camp Nine amended it articles of incorporation to change
its name to Relmada Therapeutics, Inc. on July 8, 2014. On August 5, 2014, FINRA approved our name change and new ticker symbol,
RLMD, which became effective on August 6, 2014.&nbsp; </P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The information and financial data discussed below is
only a summary and should be read in conjunction with the historical financial statements and related notes of Relmada Therapeutics,
Inc. contained elsewhere in this&nbsp;document. Relmada&rsquo;s current consolidated financial position and consolidated results
of operations are not necessarily indicative of the Company&rsquo;s future performance. See &ldquo;Cautionary Note Regarding Forward
Looking Statements&rdquo; above for a discussion of forward-looking statements and the significance of such statements in the
context of this document. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> We are developing drugs for treatment of pain. We have
product candidates with indications for the treatment of moderate to severe chronic pain, cancer-associated chronic pain and neuropathic
pain. One of our drug candidates also has commercial potential for opioid maintenance therapy. As of now none of our drugs have
been approved for sale in the United States or elsewhere. We have no commercial products nor do we have a sales or marketing infrastructure.
In order to market and sell our products we must conduct clinical trials on patients and obtain regulatory approvals from appropriate
regulatory agencies like the FDA in the United States and similar organizations elsewhere in the world. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> We have a diversified portfolio of four products at different
stage of development for the treatment of pain. LevoCap ER, our most advanced product is a proprietary once-a-day extended release
(ER) dosage form of the potent opioid levorphanol in an abuse resistant drug delivery system. d-Methadone is the d optical isomer
of racemic methadone and an antagonist at the N-methyl-D-aspartate (NMDA) receptor. NMDA antagonists have been shown to provide
analgesia in patients with neuropathic pain. NMDA antagonists have also been shown to reduce tolerance or hyperalgesia to opioid
analgesics. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> MepiGel is a proprietary topical non-greasy gel dosage
form of the local anesthetic mepivacaine for the treatment of postherpetic neuralgia and painful HIV-associated neuropathy. We
have received two FDA Orphan Drug Designations which provide for 7 years market exclusivity upon marketing, one each for &ldquo;the
treatment of painful HIV-associated neuropathy&rdquo; and for &ldquo;the management of postherpetic neuralgia&rdquo;. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> BuTab ER is a proprietary extended release (ER) oral
dosage form of the Schedule III (C-III) opioid, buprenorphine. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Below is a summary of our product development: </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: normal"> &nbsp; </TD>
    <TD STYLE="width: 4%; line-height: normal"> &#9679; </TD>
    <TD STYLE="width: 93%; line-height: normal; text-align: left"> LevoCap ER: We completed GMP manufacturing for the Phase
    I study of LevoCap ER and the batches have successfully passed the 12 month stability milestone. In July 2013 we completed
    a 30 patient Phase I pharmacokinetic study. We are now preparing the Phase III development program and we are planning to
    submit a request to the FDA to discuss the final pathway to the NDA for this product. In preparation of the Phase III we have
    initiated the transfer of the formulation technology to a US manufacturer and planning to generate GMP batches for the Phase
    III that will be performed in the United States. </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: left"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: left"> &#9679; </TD>
    <TD STYLE="line-height: normal; text-align: left"> d-Methadone: We have successfully manufactured GMP d-Methadone API.
    We are preparing and planning to file a new corporate IND for d-Methadone in 2014 to perform a Phase I dose ranging pharmacokinetic
    study and confer with the FDA on the next step of the development plan for a Phase II study in neuropathic pain. </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: left"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: left"> &#9679; </TD>
    <TD STYLE="line-height: normal; text-align: left"> BuTab ER: We have completed a preclinical program to better define
    the pharmacokinetic profile of BuTab ER and to assess the time course of systemic absorption of buprenorphine using several
    different oral extended release formulations of buprenorphine in dogs, compared to an intravenous administration. Based on
    the results of this work, we expect to generate GMP batches, file an IND with the FDA in the second half of this year and
    subsequently start a Phase I pilot study in healthy volunteers. </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: left"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; text-align: left"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: left"> &#9679; </TD>
    <TD STYLE="line-height: normal; text-align: left"> MepiGel: We have completed an animal study in rabbits to assess the
    time course of systemic absorption of mepivacaine from several different semi-solid topical gel formulations as compared to
    intravenous mepivacaine. The goal was to assess the absolute bioavailability of the different gels and finalize the optimal
    formulation to move into clinical development. We have identified one that performed at optimal level that may be selected
    to continue to development in humans. We are planning to generate GMP batches required for the Phase I portion of the development,
    file an IND with the FDA and start the Phase I trial with timing based on resources allocation. </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> In April 2012, the Company entered into a license
agreement with Medeor Inc. (&ldquo;Medeor&rdquo;) and issued 17,890 shares of stock for the license agreement. The Chief
Executive Officer was a shareholder of Medeor. At December 31, 2013, the Company issued 2,500,000 shares of common stock in
exchange for all the outstanding stock of Medeor whose only asset was a research and development project. The transaction was
valued at its fair value of $3,750,000 and was expensed to research and development expense. The fair value of the shares was
determined via a third party valuation.&nbsp;&nbsp;&nbsp;In connection with the Company&rsquo;s merger of Medeor, the Company
assumed the obligation to pay a third party for a license agreement. The licensee will earn royalties and a milestone payment
as defined in the license agreement. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><U> Results of Operations </U></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Six Months Ended June 30, 2014 </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Research and Development Expense </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Research and development expense for the six months ended
June 30, 2014 was approximately $840,000. This balance primarily comsists of expenses related to the advancement of a clinical
development program, salaries and stock-based compensation expense of $115,500. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> General and Administrative Expense </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B> &nbsp; </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"> General and administrative expense
for the six months ended June 30, 2014 was approximately $12,106,900. This balance primarily is comprised of stock-based compensation
expense of approximately $10,203,700, professional fees of approximately $964,000, salaries of approximately $366,700, insurance
expense of approximately $146,800, consulting and financial advisory fees of approximately $138,200, rent expense of approximately
$67,800 and other general expenses of approximately $219,700. The Company is involved in litigation with its founder, see Item
3 Legal Proceeding, the Company will incur expenditures in the future related to this matter which is not known at this time.
A Delaware Statute requires a corporation to advance reasonable litigation expenses of a former officer or director who is a party
to litigation, and the Court ordered Relmada to advance such expenses. Depending upon the outcome of this litigation, Relmada
may or may not be entitled to be reimbursed for the advanced payments made for the founder&rsquo;s legal expenses. There can be
no assurance that, even if Relmada prevails, Mr. Babul will be able to repay Relmada. </P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Other Income (Expense) </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Change in Fair Value of Derivative Liabilities </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The change in the fair value of derivative liabilities
for the six months ended June 30, 2014 was a non-cash loss of approximately $7,955,000. The change in the fair value of the derivative
liabilities during the six months ended June 30, 2014 was principally due to the Share Exchange, an increase in the number of
warrants, and the change in the common stock price. The fair value of the common stock was determined by a third party valuation
firm. The Black-Scholes option pricing method was used at June 30, 2014. The calculation of the fair value of the derivative liabilities
is affected by factors which are subject to significant fluctuations and are not directly under the Company&rsquo;s control. Therefore,
the resulting effect upon our net income or loss is subject to significant fluctuations and will continue to be subject to significant
fluctuations until the derivative is reduced to zero by having all the Series A warrant holders and Series B warrant holders either
exercise their warrants or the warrants expire. The accounting guidance applicable to these warrants requires the Company (assuming
all other inputs to the pricing model remain constant) to record a non-cash loss when the Company&rsquo;s stock price is rising
and to record non-cash gain when the Company&rsquo;s stock price is decreasing. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><B> Interest
Expense </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Interest expense for the six months ended June 30, 2014
was approximately $435,600 which consisted of approximately $186,000 resulting from a beneficial conversion feature that existed
with the September 2013 notes payable at the issuance date. The value that was recorded was based upon the difference between
the effective conversion price of $0.60 per share and the fair value of the common stock as of the commitment date of $0.80 per
share. There was no beneficial conversion feature on the December 2013 notes payable at the date of issuance. The Company recorded
for the six months ended June 30, 2014, approximately $219,800 for the remaining unamortized amount of the debt discount and debt
issuance costs resulting from the subordinated notes sold with warrants. There was also approximately $27,600 of interest expense
associated with subordinated notes for the six months ended June 30, 2014. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Income Taxes </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The Company did not provide for income taxes for the
six months June 30, 2014 since there was a loss. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Loss per Common Share </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Based upon the above, the Company recorded a net loss
of approximately $21,336,000, or $1.73 per common share, during the six months ended June 30, 2014, based on the factors described
above. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> For the Years Ended December 31, 2013 versus December
31, 2012 </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Research and Development Expense </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Research and development expense for the year ended December
31, 2013 was approximately $5,248,700 compared to $667,500 for the year ended December 31, 2012, a difference of $4,581,200. The
primary increase of $4,581,200 is a non-cash expense related to the merger with Medeor which occurred on December 31, 2013. In
April 2012, the Company entered into a license agreement with Medeor and issued 17,089 shares of stock for the license agreement.
The Chief Executive Officer was a shareholder of Medeor. At December 31, 2013, the Company issued 2,500,000 shares of common stock
in exchange for all the outstanding stock of Medeor whose only asset was a research and development project. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> In addition, other increases primarily relate to the
development program that the Company initiated during 2013. The Company completed GMP manufacturing for LevoCap ER additional
strengths. A 30 patient pharmacokinetic study for LevoCap ER was completed and the Company successfully manufactured GMP d-methadone
API. In addition, the Company completed a successful pre-clinical study for MepiGel and a successful pre-clinical study was completed
for BuTab ER. Consulting fees were paid to Malvern Consulting Group Inc. for d-methadone product development and to Scilucent,
Inc. for levorphanol product development. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> General and Administrative Expense </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> General and administrative expense for the year ended
December 31, 2013 was approximately $1,525,300 compared to $2,489,200 for the year ended December 31, 2012, a difference of $963,900.
The difference is related to the 1,725,000 shares of Series A Preferred Stock that the Company issued to Wonpung during 2012 that
generated approximately $1,000,000 of stock-based compensation, while there was no such issuance to Wonpung in 2013. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> &nbsp; </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Other Income (Expense) </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The&nbsp;change in the fair value of derivative liabilities
is a non-cash expense. For the year ended December 31, 2013, this&nbsp;resulted in non-cash loss of approximately $12,877,700
as compared to non-cash loss of $3,688,400 for the comparable period in 2012. This resulted in an increase in non-cash loss of
approximately $9,189,300 for the year ended December 31, 2013 as compared to the comparable period in 2012. These liabilities
resulted from the anti-dilution features that were contained in the Series A Preferred Stock unit offerings and also the note
offerings.&nbsp;&nbsp;The derivative liabilities were for the Series A Preferred Stock and the warrants. The anti-dilution feature
for the Series A Preferred Stock will be eliminated upon the conversion into common stock when a public transaction occurs. The
calculations of the derivative liabilities are affected by factors which are subject to significant fluctuations and are not under
the Company&rsquo;s control. Therefore, the resulting effect upon our net income or loss is subject to significant fluctuations
and will continue to be subject to significant fluctuations until the derivatives are reduced to zero when the Series A Preferred
Stock is converted to common stock (due to a public offering). The accounting guidance applicable to these warrants requires the
Company (assuming all other inputs to the pricing model remain constant) to record a non-cash loss when the Company&rsquo;s stock
price is rising and to record non-cash gain when the Company&rsquo;s stock price is decreasing. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Interest Expense </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Interest expense for the year ended December 31, 2013
consisted of our subordinated 8% promissory notes (&ldquo;Notes&rdquo;) and related debt discount. Costs associated with the issuance
of the Notes, the fair market value of the warrants that were included in the Units to the Notes and the discount the debt holders
paid that was less than the principal amount of the Notes are considered debt discount.&nbsp;&nbsp;Debt discount is being expensed
to interest and amortized on a straight-line basis. Interest expense for the year ended December 31, 2012 primarily consisted
of&nbsp;interest expense on&nbsp;debts that were exchanged for Series A Preferred Stock by Ben Franklin and BioAdvance in April
2012. Interest expense for the year ended December 31, 2013 was approximately $220,300 compared to $27,700 for the year ended
December 31, 2012, a difference of $192,600 from the comparable period in 2012 due to the Company having additional debt outstanding
in 2013 compared to 2012. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The Company determined a beneficial conversion feature
existed on the September 2013 notes payable at the issuance date of approximately $186,800 which represented the difference between
the effective conversion price of $0.60 per share and the fair value of the common stock as of the commitment date of $0.80 per
share. The beneficial conversion feature will be recorded as interest expense in the event these notes are converted to common
stock in connection with a public offering. There was no beneficial conversion feature on the December 2013 notes payable at the
date of issuance. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Income Taxes </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The Company did not provide for income taxes for the
year-end December 31, 2013 and 2012 since there was a loss. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Loss per Share </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The losses for the years ended December 31, 2013 and
2012 were approximately $19,872,000 and $6,860,000 or $8.18 per share and $3.17 per share, respectively, based on the factors
described above. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Liquidity </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B> &nbsp; </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> To date, we have financed our operations primarily through
issuance of units of common stock including warrants that occurred on May 12, 2014, May 15, 2014 and June 10, 2014 and we received
net proceeds of approximately $22,229,300. In connection with the Share Exchange, the principal shareholders of Camp Nine, Inc.
invested $2,000,000 for common stock and Class A preferred stock. In addition, we received net proceeds of approximately $6,714,000
from the sale of units of Series A preferred stock including warrants that closed from December 2012 to September 2013. The Series
A stockholders converted their shares to common stock upon the share exchange in May 2014. &nbsp;For the years ended December
31, 2013 and 2012, we received net proceeds of $501,600 and $154,900, respectively, from the issuance of units of subordinated
8% promissory notes including warrants, net of deferred financing fees. Both promissory notes, effective interest rate was 36.9%.
The note holders converted their debt and accrued interest of approximately $960,900 to common stock upon the Share Exchange in
May 2014. During 2007, the Company received a licensing fee of $1,500,000 and proceeds from the sale of common stock of $1,500,000.
During 2004 and 2005, the Company received proceeds from two note holders aggregating $975,000. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Since our inception, we have not generated any product
revenue and do not anticipate generating any revenues for the foreseeable future.&nbsp;&nbsp;We have incurred losses since inception
to June 30, 2014 of approximately $55,318,600 and generated negative cash flows from operations since inception. The non-cash
items since inception through June 30, 2014 were approximately $41,868,700. We expect to incur increasing expenses over the next
several years developing our products. The Company has litigation against its founders, See Item 3, Legal Proceedings and will
incur expenses in the future. The amount of such expenses is not known at this time. A Delaware Statute that requires a corporation
to advance the reasonable litigation expenses of a former officer or director who is a party to litigation by reason of that relationship,
and the Court ordered Relmada to advance such expenses. Depending upon the outcome of that litigation, Relmada may or may not
be entitled to be reimbursed for the advanced expenses, but there can be no assurance that, even if Relmada prevails, Mr. Babul
will be able to repay Relmada. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> We will need to raise additional funds in order to continue
our clinical trials. Insufficient funds may cause us to delay, reduce the scope of or eliminate one or more of our development
programs. We anticipated that our cash and cash equivalent on hand at June 30 2014 will fund future operations until the fourth
quarter of 2015. Our future capital needs and the adequacy of our available funds will depend on many factors, including the cost
of clinical studies and other actions needed to obtain regulatory approval of our products in development. We do not currently
contemplate any acquisitions. If additional funds are required, we may raise such funds from time to time through public or private
sales of equity or debt securities or from bank or other loans or through strategic research and development, or licensing.&nbsp;&nbsp;Financing
may not be available on acceptable terms, or at all, and our failure to raise capital when needed could materially adversely impact
our growth plans and our financial condition or results of operations. Additional equity financing, if available, may be dilutive
to our shareholders. We will need substantial additional financing to fund our operations and to commercially develop our product
candidates. These factors raise substantial doubt about our ability to continue as a going concern.&nbsp;&nbsp;The financial statements
do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and
classification of liabilities that might result from the outcome of this uncertainty. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B> &nbsp; </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Effects of Inflation </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Our assets are primarily monetary, consisting of cash
and cash equivalents and short-term investments. Because of their liquidity, these assets are not directly affected by inflation.
Because we intend to retain and continue to use our equipment, we believe that the incremental inflation related to replacement
costs of such items will not materially affect our operations. However, the rate of inflation affects our expenses, such as those
for employee compensation and contract services, which could increase our level of expenses and the rate at which we use our resources. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Contractual Obligations </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B> &nbsp; </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> The following tables sets forth
our contractual obligations for the next five year and thereafter: </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding: 0; text-indent: 0"> &nbsp; </TD><TD STYLE="font-weight: bold; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding: 0; text-indent: 0"> Total </TD><TD STYLE="font-weight: bold; padding: 0; text-indent: 0"> &nbsp; </TD><TD STYLE="font-weight: bold; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding: 0; text-indent: 0"> Less
    than &nbsp;1&nbsp;year </TD><TD STYLE="font-weight: bold; padding: 0; text-indent: 0"> &nbsp; </TD><TD STYLE="font-weight: bold; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding: 0; text-indent: 0"> 1
    - 2 years </TD><TD STYLE="font-weight: bold; padding: 0; text-indent: 0"> &nbsp; </TD><TD STYLE="font-weight: bold; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding: 0; text-indent: 0"> 3
    - 5 years </TD><TD STYLE="font-weight: bold; padding: 0; text-indent: 0"> &nbsp; </TD><TD STYLE="font-weight: bold; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding: 0; text-indent: 0"> More
    than 5&nbsp;years </TD><TD STYLE="font-weight: bold; padding: 0; text-indent: 0"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left; padding: 0; text-indent: 0"> Office lease </TD><TD STYLE="width: 1%; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left; padding: 0; text-indent: 0"> $ </TD><TD STYLE="width: 9%; text-align: right; padding: 0; text-indent: 0"> 123,800 </TD><TD STYLE="width: 1%; text-align: left; padding: 0; text-indent: 0"> &nbsp; </TD><TD STYLE="width: 1%; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left; padding: 0; text-indent: 0"> $ </TD><TD STYLE="width: 9%; text-align: right; padding: 0; text-indent: 0"> 37,300 </TD><TD STYLE="width: 1%; text-align: left; padding: 0; text-indent: 0"> &nbsp; </TD><TD STYLE="width: 1%; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left; padding: 0; text-indent: 0"> $ </TD><TD STYLE="width: 9%; text-align: right; padding: 0; text-indent: 0"> 76,800 </TD><TD STYLE="width: 1%; text-align: left; padding: 0; text-indent: 0"> &nbsp; </TD><TD STYLE="width: 1%; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left; padding: 0; text-indent: 0"> $ </TD><TD STYLE="width: 9%; text-align: right; padding: 0; text-indent: 0"> 9,700 </TD><TD STYLE="width: 1%; text-align: left; padding: 0; text-indent: 0"> &nbsp; </TD><TD STYLE="width: 1%; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left; padding: 0; text-indent: 0"> $ </TD><TD STYLE="width: 9%; text-align: right; padding: 0; text-indent: 0"> - </TD><TD STYLE="width: 1%; text-align: left; padding: 0; text-indent: 0"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding: 0 0 1.5pt; text-indent: 0"> Note payable </TD><TD STYLE="padding: 0 0 1.5pt; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="text-align: left; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"> &nbsp; </TD><TD STYLE="text-align: right; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"> 58,537 </TD><TD STYLE="text-align: left; padding: 0 0 1.5pt; text-indent: 0"> &nbsp; </TD><TD STYLE="padding: 0 0 1.5pt; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="text-align: left; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"> &nbsp; </TD><TD STYLE="text-align: right; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"> 58,537 </TD><TD STYLE="text-align: left; padding: 0 0 1.5pt; text-indent: 0"> &nbsp; </TD><TD STYLE="padding: 0 0 1.5pt; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="text-align: left; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"> &nbsp; </TD><TD STYLE="text-align: right; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"> - </TD><TD STYLE="text-align: left; padding: 0 0 1.5pt; text-indent: 0"> &nbsp; </TD><TD STYLE="padding: 0 0 1.5pt; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="text-align: left; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"> &nbsp; </TD><TD STYLE="text-align: right; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"> - </TD><TD STYLE="text-align: left; padding: 0 0 1.5pt; text-indent: 0"> &nbsp; </TD><TD STYLE="padding: 0 0 1.5pt; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="text-align: left; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"> &nbsp; </TD><TD STYLE="text-align: right; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"> - </TD><TD STYLE="text-align: left; padding: 0 0 1.5pt; text-indent: 0"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding: 0 0 4pt; text-indent: 0"> Total obligations </TD><TD STYLE="padding: 0 0 4pt; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="text-align: left; padding-top: 0; padding-right: 0; border-bottom: Black 4pt double; padding-left: 0; text-indent: 0"> $ </TD><TD STYLE="text-align: right; padding-top: 0; padding-right: 0; border-bottom: Black 4pt double; padding-left: 0; text-indent: 0"> 182,337 </TD><TD STYLE="text-align: left; padding: 0 0 4pt; text-indent: 0"> &nbsp; </TD><TD STYLE="padding: 0 0 4pt; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="text-align: left; padding-top: 0; padding-right: 0; border-bottom: Black 4pt double; padding-left: 0; text-indent: 0"> $ </TD><TD STYLE="text-align: right; padding-top: 0; padding-right: 0; border-bottom: Black 4pt double; padding-left: 0; text-indent: 0"> 95,837 </TD><TD STYLE="text-align: left; padding: 0 0 4pt; text-indent: 0"> &nbsp; </TD><TD STYLE="padding: 0 0 4pt; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="text-align: left; padding-top: 0; padding-right: 0; border-bottom: Black 4pt double; padding-left: 0; text-indent: 0"> $ </TD><TD STYLE="text-align: right; padding-top: 0; padding-right: 0; border-bottom: Black 4pt double; padding-left: 0; text-indent: 0"> 76,800 </TD><TD STYLE="text-align: left; padding: 0 0 4pt; text-indent: 0"> &nbsp; </TD><TD STYLE="padding: 0 0 4pt; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="text-align: left; padding-top: 0; padding-right: 0; border-bottom: Black 4pt double; padding-left: 0; text-indent: 0"> $ </TD><TD STYLE="text-align: right; padding-top: 0; padding-right: 0; border-bottom: Black 4pt double; padding-left: 0; text-indent: 0"> 9,700 </TD><TD STYLE="text-align: left; padding: 0 0 4pt; text-indent: 0"> &nbsp; </TD><TD STYLE="padding: 0 0 4pt; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="text-align: left; padding-top: 0; padding-right: 0; border-bottom: Black 4pt double; padding-left: 0; text-indent: 0"> $ </TD><TD STYLE="text-align: right; padding-top: 0; padding-right: 0; border-bottom: Black 4pt double; padding-left: 0; text-indent: 0"> - </TD><TD STYLE="text-align: left; padding: 0 0 4pt; text-indent: 0"> &nbsp; </TD></TR>
</TABLE>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"> The following
tables sets forth selected cash flow information for the periods indicated below: </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> For the Six Months Ended
    <BR>June 30, </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> For the Years Ended <BR>December
    31, </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2014 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2013 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2012 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left"> Cash used in operating activities </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> (2,164,254 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> (2,237,529 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> (1,583,975 </TD><TD STYLE="width: 1%; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Cash used in investing activities </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (3,673 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> (8,871 </TD><TD STYLE="text-align: left"> ) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> -&nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Cash provided by financing activities </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 24,209,828 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 3,996,028 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 3,334,928 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Net increase in cash and cash equivalents </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 22,041,901 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1,749,628 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1,750,953 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> For the six months ended months ended June 30, 2014,
cash used in operating activities was approximately $2,164,000 primarily due to the loss for the six months ended June 30, 2014,
of approximately $21,336,000, offset by non-cash expenses including stock based compensation expenses, the change in the fair
value of derivative liabilities, beneficial conversion feature, amortization of debt discount and deferred financing cost and
depreciation of approximately $18,691,700 and increases from net amounts from prepaid expenses and other assets, accounts payable
and accrued expenses of approximately $480,000. For the six months ended June 30, 2013, cash provided by financing activities
was approximately $24,209,800 resulting from the net proceeds from the May and June 2014 private placements of common stock and
Series A and B warrants of approximately $22,229,300 and from investment from the principal shareholders of Camp Nine, Inc. of
$2,000,000 offset by principal payments of notes payable of approximately $19,500. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Net cash used in operating activities was approximately
$2,237,500 for the year ended December 31, 2013 compared to approximately $1,584,000 used in operations for the same period in
2012. The net loss for the year ended December 31, 2013 was approximately $19,872,000 as compared to approximately $6,860,000
for the year ending December 31, 2012. The net loss increased by $13,012,000 for the year ended December 31, 2013 as compared
to the same comparable prior year period. Non-cash expenses for the years ended December 31, 2013 and December 31, 2012 primarily
consisted of the change in the fair value of derivative liabilities, stock-based compensation, common stock issued for services,
amortization of deferred financing costs and debt discounts. These non-cash expenses for the years ending December 31, 2013 and
2012 were approximately $17,215,500 and $5,056,500, respectively. For the years ended December 31, 2013 and 2012, the increase
for the non-cash changes was due to the fair value of derivative liabilities of approximately $12,877,700 and $3,688,400 and stock-based
compensation of approximately $3,767,000 and $1,330,800, respectively. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Net cash provided by financing activities was approximately
$3,996,000 for the year ended December 31, 2013 compared to $3,334,900 for the same period in 2012.&nbsp;&nbsp;For the years ended
December 31, 2013 and 2012, we received net proceeds of approximately $3,494,400 and $3,220,000, respectively, net of offering
costs for the issuance of units from the sales of Series A Preferred Stock including warrants.&nbsp;&nbsp;For the years ended
December 31, 2013 and 2012, we received net proceeds of $501,600 and $154,900, respectively, from the issuance of units of subordinated
8% promissory notes including warrants, net of deferred financing fees. Up until May 20, 2014, the date of the share exchange,
the Company was in default of the September 2013 notes with the principal amount due of $216,000 and approximately $33,300 of
accrued interest. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Off-Balance Sheet Arrangements </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> We do not have any off-balance sheet
arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial
condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material
to investors. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Seasonality </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> We do not have a seasonal business cycle. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Critical Accounting Policies and Use of Estimates </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amounts of revenues and expenses for the reporting period.&nbsp;&nbsp;Actual results
could differ from those estimates. The significant estimates are valuation and recovery of intangible assets, stock-based compensation
expense, valuation of derivative financial liability and income taxes and valuation of income taxes. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Research and Development </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Research and development costs primarily consist of salaries
and benefits, research contracts for the advancement of product development, stock-based compensation, and consultants. The Company
expenses all research and development costs in the periods in which they are incurred. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Stock-Based Compensation </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The Company measures the cost of employee services received
in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the
period during which an employee is required to provide service in exchange for the award - the requisite service period. The grant-date
fair value of employee share options is estimated using the Black-Scholes option pricing model adjusted for the unique characteristics
of those instruments. Compensation expense for options and warrants granted to non-employees is determined by the fair value of
the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured. Compensation
expense for options granted to non-employees is measured each period as the underlying options or warrants vest. The expense is
subsequently adjusted to fair value at the end of each reporting period until such options and warrants vest, and the fair value
of such instruments, as adjusted, is expensed over the related vesting period. Adjustments to fair value at each reporting date
may result in income or expense, depending upon the estimate of fair value and the amount of expense recorded prior to the adjustment.
The Company reviews its agreements and the future performance obligation with respect to the unvested options or warrants for
its vendors or consultants. When appropriate, the Company will expense the unvested options or warrants at the time when management
deems the service obligation for future services has ceased. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Income Taxes </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The Company accounts for income taxes using the asset
and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences attributable
to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases.
Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which
those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change
in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are recognized when
it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than not that
all or a portion of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future
deductibility is uncertain. As of June 30, 2014 and December 31, 2013, the Company had recognized a valuation allowance to the
full extent of our net deferred tax assets since the likelihood of realization of the benefit does not meet the more likely than
not threshold. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Derivatives </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> All derivatives are recorded at fair value and recorded
on the balance sheet. Fair values for securities traded in the open market and derivatives are based on quoted market prices.
Where market prices are not readily available, fair values are determined using market based pricing models incorporating readily
observable market data and requiring judgment and estimates. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Fair Value of Financial Instruments </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Fair value is defined as the price that would be received
to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. A fair value hierarchy
has been established for valuation inputs that gives the highest priority to quoted prices in active markets for identical assets
or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows: </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: normal"> &nbsp; </TD>
    <TD STYLE="width: 4%; line-height: normal"> &#9679; </TD>
    <TD STYLE="width: 93%; line-height: normal"> Level 1 Inputs &ndash; Unadjusted quoted prices in active markets for identical
    assets or liabilities that the reporting entity has the ability to access at the measurement date. </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &#9679; </TD>
    <TD STYLE="line-height: normal"> Level 2 Inputs &ndash; Inputs other than quoted prices included in Level 1 that are observable
    for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities
    in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other
    than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds,
    credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means. </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &#9679; </TD>
    <TD STYLE="line-height: normal"> Level 3 Inputs &ndash; Unobservable inputs for determining the fair values of assets or
    liabilities that reflect an entity's own assumptions about the assumptions that market participants would use in pricing the
    assets or liabilities. </TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0"> &nbsp; </P>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Opportunities, Challenges and Risks </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The market for drugs for pain treatment is large and
in need of new solutions. Where successful, pain products can generate hundreds of millions of dollars in annual sales. A number
of large pharmaceutical and biotechnology companies regularly acquire products in development, with preference given to products
in Phase II or later clinical trials. These deals are typically structured to include an upfront payment that ranges from several
million dollars to tens of millions of dollars or more, and additional milestone payments tied to development, regulatory and
sales milestones. Our goal is to develop products up to the point where our resources are sufficient to sustain the costs, and
subsequently partner them with larger companies to share further development expenses and leverage their sales and marketing infrastructure.
We plan to retain the marketing or co-marketing rights for selected specialty medical areas in the U.S. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> We believe our future success will be heavily dependent
upon our ability to successfully conduct clinical trials and nonclinical development of our drug candidates. This will in turn
depend on our ability to hire competent employees, continue our close collaboration with our suppliers and our Scientific Advisory
Board. It is possible that despite our best efforts our clinical trials results may not meet regulatory requirements for approval.
If our efforts are successful, we will be able to partner our development stage products on commercially favorable terms only
if they enjoy appropriate market exclusivity. For that reason we intend to continue our efforts to maintain existing and generate
new intellectual property.&nbsp;&nbsp;Intellectual property is a key factor in the success of our business. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> To achieve the goals discussed above
we intend to continue to invest in research and development at likely increasing rates thus incurring further losses until one
or more of our products is/are sufficiently developed to partner them to large pharmaceutical and biotechnology companies. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B> &nbsp; </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Off-Balance Sheet Arrangements </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"><B> &nbsp; </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> We do not have any off-balance sheet arrangements that
have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues
or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><I></I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_012"></A><B>CHANGES IN REGISTRANT&rsquo;S CERTIFYING
ACCOUNTANT</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dismissal
of Independent Accountant Previously Engaged as Principal Accountant.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 20, 2014, the Company dismissed
MaloneBailey, LLP (&ldquo;Malone Bailey&rdquo;), as the independent registered public accounting firm of the Company.&nbsp; The
dismissal was approved by the Board of Directors.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The reports of Malone Bailey on the financial statements
of the Company for the fiscal years ended August 31, 2013 and 2012 and for the period from May 23, 2011 to August 31, 2013 did
not contain any adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or
accounting principles except an explanatory paragraph as to an uncertainty with respect to the Company&rsquo;s ability to continue
as a going concern.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">During the fiscal years ended August 31, 2013 and 2012 and
for the period from May 23, 2011 from to August 31, 2013, and through the date of this report, there were no (1) disagreements
with Malone Bailey on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure,
which disagreements if not resolved to the satisfaction of Malone Bailey, would have caused them to make reference thereto in their
reports on the financial statements for such years; or (2) &ldquo;reportable events&rdquo; as defined in Item 304(a)(1)(v) of Regulation
S-K.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The Company has requested that Malone Bailey furnish it with
a letter addressed to the SEC stating whether or not it agrees with the above statements and, if not, stating the respects in which
it does not agree.&nbsp;&nbsp;A copy of such letter, dated May 20, 2014, indicating that it is in agreement with such disclosures
is filed as Exhibit 16.1 to our Form 8-K filed on May 27, 2014.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Engagement
of New Independent Accountant as Principal Accountant.</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">On May 20, 2014, the Board of Directors approved the appointment
of GBH CPAs, PC (&ldquo;GBH&rdquo;) as the independent registered public accounting firm of the Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">During the Company&rsquo;s two most recent fiscal years and
the subsequent interim periods preceding GBH&rsquo;s engagement, neither the Company nor anyone on behalf of the Company consulted
with GBH&nbsp;&nbsp;regarding the application of accounting principles to any specific completed or contemplated transaction, or
the type of audit opinion that might be rendered on the Company&rsquo;s financial statements, and&nbsp;&nbsp;GBH did not provide
any written or oral advice that was an important factor considered by the Company in reaching a decision as to any accounting,
auditing or financial reporting issue or any matter that was the subject of a &ldquo;disagreement&rdquo; or a &ldquo;reportable
event,&rdquo; as such terms are defined in Item 304(a)(1) of Regulation S-K.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_013"></A><B>DIRECTORS AND EXECUTIVE OFFICERS</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The following sets forth information about our directors
and executive officers as of June 26, 2014:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">N ame </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Age </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"> Position </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 33%; text-align: left"> Sergio Traversa, PharmD, MBA </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: center"> &nbsp; </TD><TD STYLE="width: 31%; text-align: center"> 54 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 32%; text-align: left"> Chief Executive Officer and Director </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Eliseo O. Salinas MD, MSc </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: center"> 58 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> President and Chief Scientific Officer </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Douglas Beck, CPA </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: center"> 53 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Chief Financial Officer </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Sandesh Seth, MS, MBA </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: center"> 50 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> Lead Director </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Shreeram Agharkar, Ph.D. </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: center"> 67 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> Director </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Nabil Yazgi, MD </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: center"> 60 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD> Director </TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Sergio Traversa, PharmD, MBA </B> has been
our Chief Executive Officer and director since April 2012. Previously, from January 2010 to April 2012 he was the CEO of
Medeor Inc., a spinoff pharmaceutical company from Cornell University. From January 2008 to January 2010 Dr. Traversa was a
partner at Ardana Capital. Dr. Traversa has over twenty-five years of experience in the healthcare sector in the United
States and Europe, ranging from management positions in the pharmaceutical industry to investing and strategic advisory
roles. He has held financial analyst, portfolio management and strategic advisory positions at large U.S. investment firms
specializing in healthcare, including Mehta and Isaly and Mehta Partners, ING Barings, Merlin BioMed and Rx Capital. Dr.
Traversa was a founding partner of Ardana Capital, a pharmaceutical and biotechnology investment advisory firm. In Europe, he
held the position of Area Manager for Southern Europe of Therakos Inc., a cancer and immunology division of Johnson &amp;
Johnson. Prior to Therakos, Dr. Traversa was at Eli Lilly, where he served as Marketing Manager of the Hospital Business
Unit. He was also a member of the CNS (Central Nervous System) team at Eli Lilly, where he participated in the launch of
Prozac and the early development of Zyprexa and Cymbalta. Dr. Traversa started his career as a sales representative at
Farmitalia Carlo Erba, the largest pharmaceutical company in Italy, now part of Pfizer. Dr. Traversa is also a board member
of Actinium Pharmaceuticals, Inc. and previously served as interim CEO and CFO of Actinium. Dr. Traversa holds a Laurea
degree in Pharmacy from the University of Turin (Italy) and an MBA in Finance and International Business from the New York
University Leonard Stern School of Business. As Chief Executive Officer of the Company, Dr. Traversa is the most senior
executive of the Company and as such provides our Board of Directors with the greatest insight into the
Company&rsquo;s business and the challenges and material risks it faces. Dr. Traversa has more than 28 years of healthcare
industry experience and is especially qualified to understand the risks and leadership challenges facing a growing
pharmaceutical company from a senior management and financial expertise perspective led us to conclude that Dr. Traversa
should serve as Chief Executive Officer and Director of the Company. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Eliseo O. Salinas MD, MSc </B> joined Relmada
in February 2014 as President and Chief Scientific Officer. Dr. Salinas has more than 20 years of experience developing therapeutic
products for CNS disorders in many key jurisdictions worldwide, including the United States, Canada, the European Union, and Japan.
Under Dr. Salinas&rsquo; leadership, 15 programs obtained regulatory approval in the United States and other major international
markets. Prior to joining us, from October 2012 to February 2014, Dr. Salinas was Executive Vice President and Head of Research
and Development at StemCells, Inc. Before joining StemCells, from June 2010 to March 2012, Dr. Salinas was Executive Vice President,
Head of&nbsp;&nbsp;Development and Chief Medical Officer of Elan Pharmaceuticals; From June 2009 to June 2010, Dr. Salinas was
Senior Vice President&nbsp;&nbsp;- Head of&nbsp;&nbsp;Research and Development and Chief Medical Officer of Adolor Corporation.
Dr. Salinas earned his medical degree from the University of Buenos Aires, Argentina, performed a residency in psychiatry in Paris
at the Clinique des Maladies Mentales et de l'Enc&eacute;phale, and obtained a master's degree in pharmacology from the Universit&eacute;
Pierre et Marie Curie, Acad&eacute;mie de Paris, France. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Douglas Beck, CPA</B> is our Chief Financial Officer since
December 2013. Mr. Beck brings extensive previous experience in corporate management as chief financial officer of public companies,
including two biopharmaceutical companies.&nbsp;&nbsp;From May 2011 to February 2013 Mr. Beck served as CFO at iBio Inc. (NYSE
AMEX:IBIO).&nbsp;&nbsp;Previously, in 2005 he was appointed CFO of Lev Pharmaceuticals, Inc. also a publicly traded company where
he headed financial planning, financial reporting and accounting. At Lev, he was part of the executive team and was instrumental
in the successful sale of the company to ViroPharma Incorporated for $618 million in cash and stock.&nbsp;&nbsp;He was employed
at various times as an independent consultant.&nbsp;&nbsp;Mr. Beck serves on the SEC Practice Committee and the Chief Financial
Officers Committee for the New York State Society of CPAs. Mr. Beck holds a B.S. from the Fairleigh Dickinson University.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Board of Directors</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Sandesh Seth, MS, MBA, </B> has been our Lead
Director since October 2012 and serves as our Lead Director.&nbsp;&nbsp;Mr. Seth is the Head of Healthcare Investment Banking
at Laidlaw &amp; Company (UK) Ltd.&nbsp;&nbsp;He is also Executive Chairman and Chairman of the Board of Actinium Pharmaceuticals,
Inc., a NYSE Market company.&nbsp;&nbsp;He has over 20 years of experience which includes prior investment banking at Cowen &amp;
Co., equity research at Bear Stearns and Commonwealth Associates and in the pharmaceutical industry at Pfizer, Warner-Lambert,
and SmithKline Beecham in strategic planning, business development and R&amp;D project management respectively. Mr. Seth&rsquo;s
financial services experience includes 100+ completed transactions in which $5B+ in capital was raised. Transactions included
venture investments, private placements, IPOs, FOs, PIPEs, and Convertible and High-Yield Debt. Mr. Seth was also involved with
various strategic initiatives such as mergers and acquisitions, leveraged and management buy-outs, and licensing and joint ventures,
including the $100B merger of Pfizer and Warner-Lambert and the $20B merger of Pharmacia &amp; Upjohn with Monsanto.&nbsp;&nbsp;Mr.
Seth has an MBA in Finance from New York University; an M.S. in the Pharmaceutical Sciences from the University of Oklahoma Health
Center and a B.Sc. in Chemistry from Bombay University.&nbsp;&nbsp;He has published several scientific articles and was awarded
the University Regents Award for Research Excellence at the University of Oklahoma.&nbsp;&nbsp;Mr. Seth was designated as Regulatory
Affairs Certified (R.A.C.) by the Regulatory Affairs Professionals Society which signifies proficiency with United States FDA
regulations.&nbsp;&nbsp;He also holds the following Securities Industry Licenses: Series 7, 79 and 63.&nbsp;That Mr. Seth has
served in various business executive-level positions over the course of his career, has significant investment banking experience,
has developed significant management and leadership skills and is well accustomed to interfacing with investors, analysts, auditors,
C-level executives, and outside advisors, led us to conclude that Mr. Seth should serve as a director. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Shreeram N. Agharkar, PhD,</B> has been our director since
February 2014 and is the former Vice President, Deputy Head, Global Chemistry, Manufacturing &amp; Control (GCMC) and Scientific
Affairs at Sanofi, where he represented Global CMC development on several corporate R&amp;D committees, provided CMC related scientific
and strategic advice to R&amp;D teams, reviewed and approved for Global registration scientific content of all CMC dossiers, co-chaired
alliance partnership projects and Chaired GCMC portfolio reviews. He joined Sanofi from Aventis as a result of their merger. At
Aventis he served as Vice President and Head of Global Pharmaceutical Development. Prior to this, he served as Executive Director
of Pharmaceutics R&amp;D for Bristol-Myers Squibb Company. Earlier in his career, Dr. Agharkar served as the Senior Section Leader
of Sterile Products Formulation R&amp;D for Schering-Plough and as a Research Pharmacist for Parenteral Products Formulation R&amp;D
at Abbott Labs. Dr. Agharkar has 40 years of experience in the pharmaceutical industry and has served in various key positions
building extensive experience in all aspects of biopharmaceutical product development, R&amp;D, CMC functions, and management functions.
Under his leadership and direction, over 30 pharmaceutical products were developed and approved.&nbsp;&nbsp;He is a former member
of the American Association of Pharmaceutical Scientists the Parenteral Drug Association the Drug Information Association of and
the PhRMA's Pharmaceutical Development Committee. Dr. Agharkar has a B.S., Tech. Pharm./Chem. from Bombay University, India, a
M.S., in Pharmaceutics from Columbia University in New York and a PhD. in Pharmaceutics from the University of Kansas. That Dr.
Agharkar brings over 40 years of pharmaceutical experience to our Board, having served in various pharmaceutical executive-level
positions over the course of his career, and that Dr. Agharkar has developed significant management and leadership skills relating
to the pharmaceutical industry led us to conclude that Dr. Agharkar should serve as a director.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Nabil M. Yazgi, MD</B> has been our director since February
2014.&nbsp;&nbsp;Dr. Yazgi received his Medical Degree from University of Damascus, Syria in 1985.&nbsp;&nbsp;He moved to the United
States and completed a Medical Residency Program at Atlantic City Medical Center from 1981 through 1984.&nbsp;&nbsp;He completed
EEG and EMG Competence Studies.&nbsp;&nbsp;He then completed a Neurology Residency at the Medical College of Virginia from 1985
through 1987 earning status of Chief Resident.&nbsp;&nbsp;His studies included two months of Neuroradiology (CAT, Myelogram and
Angiography Training). Dr. Yazgi earned his Board Certification in Neurology and Psychiatry in December 1991.&nbsp;&nbsp;His professional
memberships include American Academy of Neurology and the Neurological Association of New Jersey.&nbsp;&nbsp;Dr. Yazgi has practiced
General Neurology in Wayne, New Jersey for 25 years.&nbsp;&nbsp;He is associated with St. Joseph Medical Center, Wayne NJ.&nbsp;&nbsp;Dr.
Yazgi practices Pain Management performing Epidural Injections and Trigger Point Injections.&nbsp;&nbsp;That Dr. Yazgi brings over
25 years of clinical experience in pain treatment to our Board, is well accustomed to interfacing with patients, and physicians
led us to conclude that Dr. Yazgi should serve as a director.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Corporate Governance</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The business and affairs of the Company are managed under
the direction of the Board of Directors (the &ldquo;Board&rdquo;), which following the closing of the Share Exchange is Sergio
Traversa, MBA, Shreeram N. Agharkar, PhD, Sandesh Seth, MS, MBA, Nabil M. Yazgi, MD.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Term of Office</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Directors are appointed until removed from office in accordance
with our bylaws. Our officers are appointed by our Board and hold office until removed by our Board.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">All officers and directors listed above will remain in office
until their successors have been duly elected and qualified.&nbsp;&nbsp;Our bylaws provide that officers are appointed by our Board
and each executive officer serves at the discretion of our Board.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B><I>Director Independence</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We use the definition of &ldquo;independence&rdquo; of
the NYSE MKT to make this determination. We are not listed on the NYSE MKT, so although we use its definition of
&ldquo;independence&rdquo;, its &ldquo;independence&rdquo; rules are inapplicable to us. NYSE MKT corporate governance rule
Sec. 803(A)(2) provides that an &ldquo;independent director&rdquo; means a person other than an executive officer or employee
of the company. No director qualifies as independent unless the issuer's board of directors affirmatively determines that the
director does not have a relationship that would interfere with the exercise of independent judgment in carrying out
the responsibilities of a director. The following is a non-exclusive list of persons who shall not be considered independent
under NYSE MKT rules:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: normal">&nbsp;</TD>
    <TD STYLE="width: 4%; line-height: normal"><FONT STYLE="font-family: Symbol">&#183; &nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 93%; line-height: normal">a director who is, or during the past three years was, employed by the company, other than prior employment as an interim executive officer (provided the interim employment did not last longer than one year);</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: normal">&nbsp;</TD>
    <TD STYLE="width: 4%; line-height: normal"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD>
    <TD STYLE="width: 93%">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">a director who accepted or has an immediate family member
        who accepted any compensation from the company in excess of $120,000 during any period of twelve consecutive months within the
        three years preceding the determination of independence, other than the following:</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">(i)&nbsp;&nbsp; compensation for board or board committee
        service,</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">(ii)&nbsp; compensation paid to an immediate family member
        who is an employee (other than an executive officer) of the company,</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">(iii) compensation received for former service as an interim
        executive officer (provided the interim employment did not last longer than one year) (See Commentary .08), or</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">(iv) benefits under a tax-qualified retirement plan, or non-discretionary
        compensation;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: normal; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 4%; line-height: normal; padding: 0; text-indent: 0"><FONT STYLE="font-family: Symbol">&#183; &nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 93%; line-height: normal; padding: 0; text-indent: 0">a director who is an immediate family member of an individual who is, or at any time during the past three years was, employed by the company as an executive officer;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: normal; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: normal; text-indent: 0"><FONT STYLE="font-family: Symbol">&#183; &nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; line-height: normal; text-indent: 0">a director who is, or has an immediate family member who is, a partner in, or a controlling shareholder or an executive officer of, any organization to which the company made, or from which the company received, payments (other than those arising solely from investments in the company's securities or payments under non-discretionary charitable contribution matching programs) that exceed 5% of the organization's gross revenues for that year, or $200,000, whichever is more, in any of the most recent three fiscal years;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: normal; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: normal; text-indent: 0"><FONT STYLE="font-family: Symbol">&#183; &nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; line-height: normal; text-indent: 0">a director who is, or has an immediate family member who is, employed as an executive officer of another entity where at any time during the most recent three fiscal years any of the issuer's executive officers serve on the compensation committee of such other entity; or</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="line-height: normal; padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: normal; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; line-height: normal; text-indent: 0"><FONT STYLE="font-family: Symbol">&#183; &nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; line-height: normal; text-indent: 0">a director who is, or has an immediate family member who is, a current partner of the company's outside auditor, or was a partner or employee of the company's outside auditor who worked on the company's audit at any time during any of the past three years.</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0">Our Common Stock is not currently quoted or listed on any
national exchange or interdealer quotation system with a requirement that a majority of our board of directors be independent and,
therefore, the Company is not subject to any director independence requirements. Under the above-mentioned NYSE MKT director independence
rules Shreeram N. Agharkar and Nabil M. Yazgi are independent directors of the Company.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Committees of the Board of Directors</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">We currently have no committees of the board.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Family Relationships</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">There are no family relationships among any of our officers
or directors.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Involvement in Certain Legal Proceedings</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> None of our current directors or executive officers has,
during the past ten years: </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: normal">&nbsp;</TD>
    <TD STYLE="width: 4%; line-height: normal">&#9679;</TD>
    <TD STYLE="width: 93%">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">been convicted in a criminal proceeding or been subject to
        a pending criminal proceeding (excluding traffic violations and other minor offenses);</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&#9679;</TD>
    <TD>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">had any bankruptcy petition filed by or against the business
        or property of the person, or of any partnership, corporation or business association of which he was a general partner or executive
        officer, either at the time of the bankruptcy filing or within two years prior to that time;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&#9679;</TD>
    <TD>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">been subject to any order, judgment, or decree, not subsequently
        reversed, suspended or vacated, of any court of competent jurisdiction or federal or state authority, permanently or temporarily
        enjoining, barring, suspending or otherwise limiting, his involvement in any type of business, securities, futures, commodities,
        investment, banking, savings and loan, or insurance activities, or to be associated with persons engaged in any such activity;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&#9679;</TD>
    <TD>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">been found by a court of competent jurisdiction in a civil
        action or by the SEC or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities
        law, and the judgment has not been reversed, suspended, or vacated;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&#9679;</TD>
    <TD>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">been the subject of, or a party to, any federal or state
        judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated (not including
        any settlement of a civil proceeding among private litigants), relating to an alleged violation of any federal or state securities
        or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies including, but
        not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or
        permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting mail or wire fraud or fraud
        in connection with any business entity; or</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&#9679;</TD>
    <TD STYLE="line-height: normal">been the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.</TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Except as set forth in our discussion below in &ldquo;Certain
Relationships and Related Transactions,&rdquo; none of our directors or executive officers has been involved in any transactions
with us or any of our directors, executive officers, affiliates or associates which are required to be disclosed pursuant to the
rules and regulations of the SEC.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Code of Ethics</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The Company has adopted a code of ethics, a copy of which
is attached as Exhibit 14.1 to our Form 8-K filed on May 27, 2014.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Whistle Blowing Policy</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> We have adopted a Company Whistle Blowing Policy, for
which a copy will be provided to any person requesting same without charge.&nbsp;&nbsp;To request a copy of our Whistle Blowing
Policy please make written request to our CFO, at Relmada Therapeutics, Inc. 546 Fifth Avenue, 14<FONT STYLE="font-size: 10pt"><SUP>
th</SUP></FONT> Floor, New York, NY 10036. We believe our Whistle Blowing Policy is reasonably designed to provide an environment
where our employees and consultants may raise concerns about any and all dishonest, fraudulent or unacceptable behavior, which,
if disclosed, could reasonably be expected to raise concerns regarding the integrity, ethics or bona fides of the Company. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_014"></A>EXECUTIVE COMPENSATION</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Summary Compensation Table</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> &nbsp; </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The following table provides information regarding the
compensation earned during the years ended December 31, 2013 and 2012, for our Executive officers: </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; line-height: normal"><B> Name/Position </B></TD>
    <TD STYLE="padding-bottom: 1.5pt; line-height: normal"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; line-height: normal; text-align: center"><B> Year </B></TD>
    <TD STYLE="padding-bottom: 1.5pt; line-height: normal"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; line-height: normal; text-align: right"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; line-height: normal; text-align: center"><B> Salary </B></TD>
    <TD STYLE="padding-bottom: 1.5pt; line-height: normal"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; line-height: normal; text-align: right"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; line-height: normal; text-align: center"><B> Bonus </B></TD>
    <TD STYLE="padding-bottom: 1.5pt; line-height: normal"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; line-height: normal; text-align: right"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Option </B></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Awards (4) </B></P></TD>
    <TD STYLE="padding-bottom: 1.5pt; line-height: normal"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 1.5pt; line-height: normal; text-align: right"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; line-height: normal; text-align: center"><B> Total </B></TD>
    <TD STYLE="padding-bottom: 1.5pt; line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: bottom; width: 38%"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Sergio Traversa, </P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> CEO and Director </P></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; line-height: normal"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; width: 2%; line-height: normal"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; width: 8%"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"> 2013 </P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"> 2012 </P></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; line-height: normal"> (1) </TD>
    <TD STYLE="vertical-align: top; width: 1%; line-height: normal"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; width: 2%; line-height: normal"> $ </TD>
    <TD STYLE="vertical-align: bottom; width: 8%"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"> 222,503 </P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"> 134,750 </P></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; line-height: normal"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; width: 1%; line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; width: 2%; line-height: normal"> $ </TD>
    <TD STYLE="vertical-align: bottom; width: 8%"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"> 75,000 </P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"> 0 </P></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; line-height: normal"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; width: 1%; line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; width: 3%; line-height: normal"> $ </TD>
    <TD STYLE="vertical-align: bottom; width: 8%"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"> 359,051 </P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"> 103,692 </P></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; line-height: normal"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; width: 1%; line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; width: 2%; line-height: normal"> $ </TD>
    <TD STYLE="vertical-align: bottom; width: 8%"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"> 656,554 </P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: right"> 238,442 </P></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Douglas Beck, CPA </P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Chief Financial Officer </P></TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> 2013 </TD>
    <TD STYLE="line-height: normal"> (2) </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> $ </TD>
    <TD STYLE="line-height: normal; text-align: right"> 16,667 </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> $ </TD>
    <TD STYLE="line-height: normal; text-align: right"> 0 </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> $ </TD>
    <TD STYLE="line-height: normal; text-align: right"> 181,391 </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD>
    <TD STYLE="line-height: normal; text-align: right"> &nbsp; </TD>
    <TD STYLE="line-height: normal"> $ </TD>
    <TD STYLE="line-height: normal; text-align: right"> 198,058 </TD>
    <TD STYLE="line-height: normal"> &nbsp; </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp;&nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The following table provides information regarding the
compensation earned for the six months ended June 30, 2014, for our Executive officers: </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"> Name/Position </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Salary </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Bonus </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Option <BR>Awards (4) </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Total </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: justify"> Sergio Traversa, <BR>CEO and Director </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 132,501 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 50,000 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> -&nbsp; </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 182,051 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Eliseo Salinas, MD, MSc, <BR>President and Chief Scientific Officer (3) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 167,468 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 50,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 937,631 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1,155,109 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Douglas Beck, CPA <BR>Chief Financial Officer </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 100,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 40,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> -&nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 140,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> </P>

<P STYLE="margin-top: 0; margin-bottom: 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; line-height: normal"> (2) </TD>
    <TD STYLE="width: 94%; line-height: normal"> Hired as CFO on December 2, 2013.&nbsp;&nbsp;Does not include $16,667 that
    was paid as a consultant in November 2013. In May 2014, Mr. Beck was awarded a total bonus of $40,000 for obtaining certain
    milestones pursuant to his offer letter with the Company. </TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: normal"> (3) </TD>
    <TD STYLE="width: 97%; line-height: normal"> Hired as President and Chief Scientific Officer on February 24, 2014. Mr. Salinas
    was awarded a $50,000 bonus for obtaining certain milestones pursuant to his offer letter with the company. </TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: normal"> (4) </TD>
    <TD STYLE="width: 97%; line-height: normal"> This column shows the grant date fair value of awards computed in accordance
    with stock-based compensation accounting rules Accounting Standards Codification Topic 718. </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> &nbsp; </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Employment Agreements </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><U> Compensatory Plan with Sergio Traversa (Principal
Executive Officer) </U></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Effective April 15, 2013, the Company and Sergio Traversa
entered into an agreement (the &ldquo;Employment Agreement&rdquo;), to employ Mr. Traversa (&ldquo;Employee&rdquo;) as the Company&rsquo;s
Chief Executive Officer. The term of the agreement is two years. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;<U> Salary </U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD><TD STYLE="width: 93%"> The initial
                                         base annual salary is $225,000. Increases in the base salary shall be reviewed annually
                                         by the Board during the term and any such increases will be at the Board's or its designee's
                                         sole discretion and will otherwise be consistent with the Company's annual policies and
                                         budget for payroll increases.&nbsp; </TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;<U> Bonus </U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD><TD STYLE="text-align: left; width: 93%"> Upon
                                         the Company's receipt of aggregate proceeds in the amount of at least $5,000,000 pursuant
                                         to a private offering of its securities, whether they be equity, debt or a combination
                                         thereof, (the &quot;Private Offering&quot;), Employee shall receive an incentive cash
                                         bonus of $50,000 <U>(&quot;Initial Bonus&quot;).</U> If anytime after the Initial Bonus
                                         is paid, the Company receives additional proceeds in the aggregate amount of $2,000,000
                                         pursuant to the Private Offering, Employee shall receive an incentive cash bonus of $25,000
                                         (the <U>&quot;Additional Bonus&quot;).</U> Thereafter, Employee shall be eligible to
                                         receive an incentive cash bonus <U>(&quot;Bonus&quot;)</U> up to the amount, based upon
                                         the criteria, and payable at such times, as may be determined by the Board in its sole
                                         and absolute discretion, which shall be binding and final, and shall be paid in a one-time
                                         lump sum payment (less payroll taxes). </TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD><TD STYLE="width: 93%"> Upon the Company's
                                         completion of an initial public offering of its common stock or other event resulting
                                         in the Company's common stock becoming publicly traded, including the successful registration
                                         of the Company's common stock for resale under the Securities Act of 1933, as amended,
                                         Employee shall receive an incentive cash bonus of $50,000 <U>(&quot;Going Public Bonus&quot;).
                                         </U>Within three months of the Company's common stock becoming publicly traded, the Company
                                         will review Employee's compensation package, and if required, adjust Employees compensation
                                         package to within the twenty-fifth to seventy-fifth percentile of compensation packages
                                         of other peer group chief executive officer agreements of comparable public companies
                                         in its related industry. </TD></TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;<U> Benefits </U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD><TD STYLE="width: 93%"> In addition
                                         to the salary and cash bonus referred to above, Employee shall be entitled during the
                                         Term to participate in such employee benefits plans or programs of the Company, and shall
                                         be entitled to such other fringe benefits, as are from time to time adopted by the Board
                                         and made available by the Company generally to employees of Employee's position, tenure,
                                         salary, age, health and other qualifications. Without limiting the generality of the
                                         foregoing, Employee shall be eligible for such awards, if any, under the Company's employee
                                         benefits plans or programs as shall be granted to Employee in the sole discretion of
                                         the Board or its designee. Employee acknowledges and agrees that the Company does not
                                         guarantee the adoption or continuance of any particular employee benefits plan or program
                                         or other fringe benefits during the term, and participation by Employee in any such plan
                                         or program shall be subject to the rules and regulations applicable thereto. </TD></TR></TABLE>



<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;&nbsp;<U> Share Issuance. </U> </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD><TD STYLE="text-align: left; width: 93%"> Employee
                                         shall receive a total of 153,102 shares (the <U>&quot;Traversa Common Stock&quot;)
                                         </U>of the Company's common stock, par value $0.01 per share (the <U>&quot;Common Stock&quot;),
                                         </U>pursuant to the following conditions and vesting schedule: </TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Courier New, Courier, Monospace"> o </FONT></TD><TD STYLE="text-align: left"> 68,356
                                         shares (post share exchange) of Common Stock upon the satisfaction of the Financing Condition.
                                         For Financing Condition is intended the first Series A closing of a minimum of $3,000,000
                                         that effectively happened on July 10, 2012; </TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Courier New, Courier, Monospace"> o </FONT></TD><TD STYLE="text-align: left"> 56,394
                                         shares (post share exchange) of Common Stock twelve (12) months after the satisfaction
                                         of the Financing Condition (so long as Employee on such date remains employed by the
                                         Company, other than on account of a termination of employment by the Company without
                                         Cause); </TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Courier New, Courier, Monospace"> o </FONT></TD><TD STYLE="text-align: left"> 29,052
                                         shares (post share exchange) of Common Stock eighteen (18) months after the satisfaction
                                         of the Financing Condition (so long as Employee on such date remains employed by the
                                         Company, other than on account of a termination of employment by the Company without
                                         cause </TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;<U> Options </U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD><TD STYLE="text-align: left; width: 93%"> Immediately
                                         after the commencement date, Employee shall receive stock options (the &quot;Options&quot;)
                                         from the Company's Employee Stock Option Plan, if any, to bring Employee's total equity
                                         ownership in the Company equal to five percent (5%) of the fully diluted capitalization
                                         of the Company as of July 10, 2012, which is the date the Financing Condition was met.
                                         In addition, immediately upon the final close of the later of the bridge financing contemplated
                                         by the Company and (ii) additional offerings up to a maximum of $8,000,000 in total (each
                                         an &quot;Additional&nbsp;&nbsp;Financing&quot; and collectively, the &quot;Additional
                                         Financings&quot;), Employee is entitled to receive Options from the Company's Employee
                                         Stock Option Plan, if any, to again bring Employee's total equity ownership in the Company
                                         equal to five percent (5%) of the Fully Diluted Capitalization, as hereinafter defined,
                                         of the Company. For purposes of calculating Employee's ownership of five percent (5%)
                                         of the Fully Diluted Capitalization of the Company, Employee shall be deemed to own 100%
                                         of the Traversa Common Stock, even though such shares may not have vested pursuant to
                                         the terms of the agreement. For the avoidance of doubt, following satisfaction of each
                                         of the Financing Condition and the final closing of Additional Financings, if any, Employee's
                                         total equity ownership in the Company shall be equal to five percent (5%) of the then
                                         Fully Diluted Capitalization of the Company. <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0">&nbsp;</P>
                                                                                         <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 0"> The Options shall have a term of four (4) years
and the exercise price of the Options shall be equal to $0.08 ($0.80 post share exchange). The Options are subject to the following
vesting schedule: Twenty-five percent of the Options shall vest on the grant date and the remaining seventy-five percent (3/4)
to vest in equal quarterly increments over a four (4) year period. </P></TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"><U> Compensatory Plan with Eliseo
Salinas (President and chief Scientific Officer) </U></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Effective January 31, 2014, the Company and Eliseo Salinas
entered into an agreement (the &ldquo;Employment Agreement&rdquo;), to employ Mr. Salinas (&ldquo;Employee&rdquo;) as the Company&rsquo;s
President and Chief Scientific Officer. The initial term of employment shall be a period of one (1) year from the Start Date (the
&quot;Initial Term&quot;), provided that employee&rsquo;s employment with the Company will be on an &quot;at will&quot; basis,
meaning that either employee or the Company may terminate your employment at any time for any reason or no reason, upon written
notification to the other party, without further obligation or liability, except that upon termination of employee&rsquo;s employment
by employee for Termination for Good Reason (as defined in the Employment Agreement), or by the Company, including change of control
during the Initial Term, other than for cause, employee will be entitled to severance equal to 12 months base salary and health
benefits. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;<U> Salary </U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD><TD STYLE="width: 93%"> employee will
                                         be paid an annual base salary of four hundred thousand and seventy-five thousand dollars
                                         ($475,000). Upon the one year anniversary of Employee&#8217;s Start Date, the Board will
                                         review your base salary with the help of an independent compensation consultant to adjust
                                         upward, if appropriate, employee&#8217;s base salary to be competitively aligned to a
                                         range between the 25<FONT STYLE="font-size: 10pt">th</FONT> (twenty-fifth) and 75<FONT STYLE="font-size: 10pt">th
                                         </FONT>(seventy-fifth) percentile of the relevant market data of President and Chief
                                         Medical Officer (&quot;CMO&quot;) positions of similarly situated publicly traded Biotechnology/Specialty
                                         Pharmaceutical companies; the Board shall review the amount of Employee&#8217;s base
                                         salary and performance bonus, and shall determine the appropriate upward adjustments
                                         to each component of Employee&#8217;s compensation within 60 days of the start of each
                                         calendar year. </TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;<U> Bonus </U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD><TD STYLE="width: 93%"> Employee shall
                                         be entitled to participate in an executive bonus program, which shall be established
                                         by the Board pursuant to which the Board shall award bonuses to Employee, based upon
                                         the achievement of written individual and corporate objectives such as the Board shall
                                         determine. Upon the attainment of such performance objectives, in addition to Employee&#8217;s
                                         base salary, Employee shall be entitled to a cash bonus in an amount to be determined
                                         by the Board with a target of fifty percent (50%) of employee&#8217;s base salary. As
                                         part of Employee&#8217;s annual target bonus for 2014, $50,000 (fifty thousand) will
                                         be paid at the end of the first quarter in which the Company's stock becomes publicly
                                         traded and the Company has raised a minimum of $10 million (ten million) in financing
                                         as part of the going public process. Within sixty (60) days after the Start Date, the
                                         Board shall establish written individual and corporate performance objectives for 2014
                                         and the amount of the performance pro-rata bonus payable upon the attainment of each
                                         objective. At least thirty (30) days before each subsequent calendar year, the Board
                                         shall establish written individual and corporate performance objectives for such calendar
                                         year and the amount of the performance bonus payable upon the attainment of such objectives.
                                         Within sixty (60) days after the end of each calendar year, the Board shall determine
                                         the amount of any performance bonus payable under the Employment Agreement. In addition,
                                         Employee will be eligible for, a special, one-time, sign-on bonus of $50,000 (fifty thousand)
                                         within 7 (seven) days after the Start Date, however, if the Employee leaves without Good
                                         Reason (as defined in the Employment Agreement) or is terminated for cause within twelve
                                         months of the Start Date, the Employee shall be required to pay back the full amount
                                         of the sign-on bonus to the Company within 7 (seven) days of leaving or termination. </TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;<U> Options </U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD><TD STYLE="text-align: left; width: 92%"> The
                                         Board has agreed to grant to Employee an option to purchase common shares of the Company
                                         (the &quot;Initial Grant&quot;) under the Company's current Stock Option Plan. The Initial
                                         Grant will consist of an option grant to purchase up to 1,003,774 (post share exchange)
                                         common shares (the &quot;Options&quot;) of the Company representing three percent (3.0%)
                                         of the fully-diluted common shares of the Company as of the date of the Employment Letter.
                                         The stock options of the Initial Grant will have an exercise price equal to $1.50 per
                                         share of the Company's common stock which is<FONT STYLE="font-size: 10pt">: </FONT>equal
                                         to fair market value of the Company as determined by the Board of Directors on the date
                                         of the grant. The stock options of the Initial Grant shall have a term of 10 years starting
                                         at the signing of this Employment Letter (the &quot;Grant Date&#8221;). The stock options
                                         of the Initial Grant shall begin to vest on the Grant Date based on the following vesting
                                         schedule: Twenty-five percent (25%) of the stock options of the Initial Grant shall vest
                                         on the first anniversary of the Grant Date and the remaining seventy-five percent (75%)
                                         shall vest in equal quarterly increments of 6.25% of the initial Option Grant over the
                                         following three (3) year period. </TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><U> Compensatory Plan with Douglas Beck (Principal Financial
and Accounting Officer) </U></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Effective November 25, 2013, the Company and Douglas
Beck entered into an agreement (the &ldquo;Employment Agreement&rdquo;), to employ Mr. Beck (&ldquo;Employee&rdquo;) as the Company&rsquo;s
Chief Financial Officer. The initial term of the employment shall be a period of one (1) years from the Start Date (the &quot;Initial
Term&quot;), provided that Employees&rsquo; employment with the Company will be on an &quot;at will&quot; basis, meaning that
either Employee or the Company may terminate Employee&rsquo;s employment at any time for any reason or no reason, upon written
notification to the other party, without further obligation or liability, except that upon termination of Employee&rsquo;s employment
by the Company, including change of control during the Initial Term, other than for cause, Employee will be entitled to severance
equal to 6 months base salary and health benefits. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;<U> Salary </U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 3%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD><TD STYLE="text-align: left; width: 93%"> Employee
                                         will be paid an annual base salary of two hundred thousand dollars ($200,000), which
                                         will be paid in accordance with the Company's regular payroll practices. Upon the one
                                         year anniversary of the start date, the Board will review Employee&#8217;s base salary
                                         with the help of an independent compensation consultant to adjust Employee&#8217;s base
                                         salary is to be competitively aligned to a range between the 25<FONT STYLE="font-size: 10pt">th
                                         </FONT>(twenty-fifth) and 75<FONT STYLE="font-size: 10pt">th</FONT> (seventy-fifth) percentile
                                         of the relevant market data of CFO positions of similarly situated publicly traded Biotech
                                         companies; the Board shall review the amount of Employee&#8217;s base salary and performance
                                         bonus, and shall determine the appropriate adjustments to each component of your compensation
                                         within 60 days of the start of each calendar year. </TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;<U> Bonus </U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD><TD STYLE="text-align: left; width: 92%"> Employee
                                         shall be entitled to participate in an executive bonus program, which shall be established
                                         by the Board pursuant to which the Board shall award bonuses to employee, based upon
                                         the achievement of written individual and corporate objectives such as the Board shall
                                         determine. Upon the attainment of such performance objectives, in addition to your base
                                         salary, Employee shall be entitled to a cash bonus in an amount to be determined by the
                                         Board with a target of thirty-five percent (35%) of Employee&#8217;s base salary. In
                                         addition, Employee will be eligible for a special bonus of $30,000 at the end of the
                                         first quarter in which the Company's stock becomes publicly traded and the Company has
                                         raised a minimum of $10 million in financing as part of the going public process. Employee
                                         is also eligible to receive a $20,000 bonus if, in Employee&#8217;s position as CFO,
                                         Employee completes the Company's 2013 financial audit by February 28, 2014; such bonus
                                         shall be reduced to $10,000 if such audit is complete by March 15, 2014. </TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;<U> Options </U></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4%"></TD><TD STYLE="width: 4%"><FONT STYLE="font-family: Symbol"> &#183; </FONT></TD><TD STYLE="text-align: left; width: 92%"> The
                                         Board has agreed to grant to employee an option to purchase common shares of the Company
                                         (the &quot;Initial Grant&quot;) under the Company's current Stock Option Plan. The Initial
                                         Grant will consist of an option grant to purchase up to 334,1,98 (post share exchange)
                                         common shares (the &quot;Options&quot;) of the Company representing one percent (1.0%)
                                         of the fully-diluted common shares of the Company as of the date of the Employment Letter.
                                         The stock options of the Initial Grant will have an exercise price equal to $0.80 cents
                                         per share of the Company's common stock which is equal to fair market value of the Company
                                         as of the most recently concluded private financing and is as determined by the Board
                                         of Directors on the date of the grant. The stock options of the Initial Grant shall have
                                         a term of 10 years starting at the signing of this Employment Letter (the &quot;Grant
                                         Date&quot;). The stock options of the Initial Grant shall begin to vest on the Grant
                                         Date based on the following vesting schedule: Twenty-five percent (25%) of the stock
                                         options of the Initial Grant shall vest on the first anniversary of the Grant Date and
                                         the remaining seventy-five percent (75%) shall vest in equal quarterly increments of
                                         6.25% of the initial Option Grant over the following three (3) year period. </TD></TR></TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Director Compensation</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Historically non-management directors of Relmada did
not receive any cash compensation. Commencing March 2014, non-management Directors of Relmada began to receive a quarterly
cash retainer of $7,500 per calendar quarter for their service on the Board of Directors. They also received an initial
option grant to purchase 48,662 shares of common stock at an exercise price of $1.50 per share, the vesting schedule is according
to the Company&rsquo;s Option Plan. They also receive reimbursement for out-of-pocket expenses. Camp Nine will continue Relmada&rsquo;s
director compensation package. </P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The following table sets forth the compensation of our
directors for the six month ended June 30, 2014: </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Name </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Fees&nbsp;Earned<BR>
or
    Paid in Cash </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Stock&nbsp;Awards </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Option<BR>Awards
    (1) </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> All Other Compensation </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Total </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-align: left"> Shreeram Agharkar, Ph.D.&nbsp;(2) </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 12,100 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> -&nbsp; </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 45,405 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> -&nbsp; </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 57,405 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Sandesh Seth, MS, MBA </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 10,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> -&nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 45,405 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> -&nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 55,405 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Nabil M. Yazgi, MD </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 10,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> -&nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 45,405 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> -&nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 55,405 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B> &nbsp; </B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; line-height: normal"> (1) </TD>
    <TD STYLE="width: 94%; line-height: normal"> This column shows the grant date fair value of awards computed in accordance
    with stock-based compensation accounting rules Accounting Standards Codification Topic 718. </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; line-height: normal"> (2) </TD>
    <TD STYLE="width: 94%; line-height: normal"> Includes $2,100 of consulting fees and $10,000 of director fees. </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Scientific Advisory Board</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Scientific Advisory Board Members may receive cash compensation
for their services rendered on the Scientific Advisory Board at the rate of $2,500 per day or $1,500 per half day of service pursuant
to consulting agreements with us. We have also reserved 12,000 options to be issued for shares of common stock to the Scientific
Board of Advisors who may be entitled to such shares pursuant to the consulting agreements. We have not issued any options to
members of the Scientific Advisory Board. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">The following distinguished individuals serve on our Scientific
Advisory Board.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Troels Jensen, MD</B> is Past-President of the International
Association for the Study of Pain, and Professor of Experimental and Clinical Pain Research, Aarhus University, Denmark.&nbsp;&nbsp;Dr.
Jensen received his MD from the University of Aarhus, completed his residency in Neurology, Neurosurgery, and Neurophysiology at
University Hospitals in Aarhus and Copenhagen and his postgraduate clinical fellowship at the H&ocirc;pital de la Salp&ecirc;tri&egrave;re
in Paris.&nbsp;&nbsp;He has authored more than 300 scientific papers in peer-reviewed journals on neurophysiology, neuropharmacology
and mechanisms and treatment of neuropathic and muscle pain.&nbsp;&nbsp;Dr. Jensen is editor of several books on pain and he has
served as Section Editor for the journal PAIN.&nbsp;&nbsp;He serves on the editorial board and reviewer for several international
journals.&nbsp;&nbsp;Dr. Jensen leads the Danish Pain Research Center at Aarhus University, Denmark.&nbsp;&nbsp;He is a former
President of the Scandinavian Association for the Study of Pain.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Nathaniel Katz, MD, MS</B> is President and CEO of Analgesic
Solutions, an organization that guides pharmaceutical companies on the efficient development and commercialization of better treatments
for pain.&nbsp;&nbsp;Dr. Katz served as Chair of the Advisory Committee, Anesthesia, Critical Care, and Addiction Products Division,
at the FDA.&nbsp;&nbsp;He received his medical degree from the Medical College of Pennsylvania and his M.S.&nbsp;&nbsp;in Biostatistics
at Columbia University.&nbsp;&nbsp;After his neurology residency at Tufts-New England Medical Center he entered a Pain Management
fellowship in the Department of Anesthesia at Brigham &amp; Women&rsquo;s Hospital and then served as a Staff Neurologist in the
Pain Management Center of Brigham &amp; Women&rsquo;s Hospital, Harvard Medical School.&nbsp;&nbsp;Subsequently, he founded the
Pain &amp; Symptom Management Program at Dana Farber Cancer Institute, and the Pain Trials Center unit at Brigham &amp; Women&rsquo;s
Hospital, Harvard Medical School.&nbsp;&nbsp;Dr. Katz&rsquo;s interests include clinical research methods, analgesic clinical trials,
neuropathic pain, cancer pain and opioid therapy for chronic pain.&nbsp;&nbsp;He is an internationally recognized expert in pain
management and analgesic clinical trials, and he has conducted and published numerous clinical investigations of treatments for
pain, with a particular focus on opioids and risk management.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Arthur G. Lipman, PharmD</B>, is a Professor of Pharmacotherapy,
College of Pharmacy and Director of Clinical Pharmacology at the Pain Management Center, University of Utah Hospitals and Clinics.&nbsp;&nbsp;Before
moving to Utah, Dr. Lipman was Drug Information Director at the Yale-New Haven Medical Center and he held concurrent faculty appointments
at the Yale University School of Medicine, Yale University Graduate School of Nursing and University of Connecticut School of Pharmacy.&nbsp;&nbsp;He
served on both the Acute and Cancer Pain Management Guideline Panels of the U.S. Department of Health and Human Services, co-chaired
the Arthritis Pain Management Clinical Guidelines Panel of the American Pain Society, and is a member of the International Association
for the Study of Pain Acute Pain Taskforce.&nbsp;&nbsp;Dr. Lipman has published over 300 articles, chapters and reviews, and is
editor of the Journal of Pain and Palliative Care Pharmacotherapy.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Cynthia McCormick, MD</B>, is President of McCormick Consultation
LLC and the former Director of the FDA&rsquo;s Division of Anesthetic, Critical Care and Addiction Drug Products (since renamed
the Division of Analgesics, Anti-inflammatory and Rheumatology Products).&nbsp;&nbsp;As Head of this Division, Dr. McCormick was
responsible for providing scientific and regulatory oversight for a large number of investigational and marketed analgesic products,
including opioids and drugs for the treatment of neuropathic pain.&nbsp;&nbsp;She received her medical degree from the Medical
College of Pennsylvania, and then undertook a Residency and Fellowship in Pediatric Neurology at the University of Michigan and
a Residency in Neurology at the University of Pennsylvania.&nbsp;&nbsp;Dr. McCormick has worked at the U.S. Department of Health
and Human Services, including the FDA and NIH for over 15 years.&nbsp;&nbsp;After serving as Director of the FDA&rsquo;s Division
of Anesthetic, Critical Care and Addiction Drug Products for five years, she served as Deputy Director, Division of Extramural
Research, National Institute of Neurological Disorders and Stroke at the NIH.&nbsp;&nbsp;Dr. McCormick has extensive experience
in regulatory and clinical aspects of analgesic drug development and consults to a number of pharmaceutical companies.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Richard Payne, MD</B>, is Professor of Medicine, Duke
University and Director of the Duke Institute on Care at the End of Life.&nbsp;&nbsp;Dr. Payne is an internationally known expert
in the areas of pain relief, care for those near death, oncology, and neurology.&nbsp;&nbsp;Prior to his appointment at Duke, he
was Professor of Neurology and Pharmacology at Cornell University Medical College and Chief, Pain &amp; Palliative Care Service
at Memorial Sloan-Kettering Cancer Center. Dr. Payne has held various academic appointments, including Chief of Neurology at the
Cincinnati VA Medical Center, and Vice-Chairman, Department of Neurology at the University of Cincinnati Medical School and Chief
of the Pain and Symptom Management Section and Professor of Neurology at the University of Texas, MD Anderson Cancer Center. Dr.
Payne has served on the Editorial Board of numerous journals including Pain, American Pain Society Journal, Journal of Pain and
Symptom Management, Pain Forum and Journal of Pain.&nbsp;&nbsp;He has published over 200 scientific communications, including abstracts,
manuscripts, book chapters and books.&nbsp;&nbsp;Dr. Payne is a former President of the American Pain Society.&nbsp;&nbsp;He is
a fellow of the American Academy of Hospice and Palliative Medicine, The American Academy of Neurology, and the American Academy
of Pain Medicine.&nbsp;&nbsp;Dr. Payne has received a Distinguished Service Award from the American Pain Society; the Humanitarian
Award from the Urban Resources Institute; and the Janssen Excellence in Pain Award.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Frank Porreca, PhD</B>, is Professor of Pharmacology and
Anesthesiology, College of Medicine at the University of Arizona and an internationally recognized pharmacologist.&nbsp;&nbsp;He
is an Executive Editor-in-Chief of Life Sciences and the Pharmacology Section Editor of the journal PAIN.&nbsp;&nbsp;Dr. Porreca
has received numerous awards and recognition for his research, including Distinguished Professor, Mayo Clinic, Founder&rsquo;s
Day Speaker, University of Arizona, F.W. Kerr Award, American Pain Society, 9th Covino Lecturer, Harvard University, Sterling Professor
Pharmacology, Albany Medical School and the NIH MERIT Award.&nbsp;&nbsp;He is inducted as a Research Fellow by the American Academy
for the Advancement of Sciences.&nbsp;&nbsp;Dr. Porreca has published over 250 manuscripts, 28 book chapters and hundreds of scientific
abstracts.&nbsp;&nbsp;Dr. Porreca is a sought after speaker at both national and international basic and clinical research meetings.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Raymond Sinatra, MD, PhD</B>, is Professor of Anesthesiology
at Yale University Medical School.&nbsp;&nbsp;Dr. Sinatra received his MD and PhD in neuroscience at SUNY Downstate School of
Medicine.&nbsp;&nbsp;He completed his residency in Anesthesiology and Fellowship in Pain Management at Brigham &amp; Women's Hospital,
Harvard Medical School.&nbsp;&nbsp;Dr. Sinatra is Senior Editor of two textbooks on pain, Acute Pain: Mechanisms and Management
and Acute Pain Management.&nbsp;&nbsp;He has authored over 200 scientific papers, review articles, abstracts and textbook chapters
on pain management and obstetrical anesthesiology.&nbsp;&nbsp;Dr. Sinatra serves as a reviewer for several journals and he has
been a principal investigator for dozens of clinical trials evaluating novel analgesics and analgesic delivery systems.&nbsp;&nbsp;He
is a frequent presenter at national and international meetings on pain management.&nbsp;</P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Arthur Weaver, MD</B>, is Clinical Professor of Medicine
(Emeritus), Division of Rheumatology at the University of Nebraska Medical Center in Omaha, Nebraska.&nbsp;&nbsp;Board-certified
in internal medicine and rheumatology, Dr. Weaver has been an active Fellow of the American College of Rheumatology (ACR) for many
years, serving on the Board of Directors and as President of the ACR. Dr. Weaver received his medical degree from Northwestern
University and completed his residency and fellowship in internal medicine and rheumatology at the Mayo Clinic.&nbsp;&nbsp;He has
served as a principal investigator in over 115 clinical trials, published over 150 manuscripts and abstracts in rheumatology and
made over 1500 scientific presentations in the field of clinical rheumatology.&nbsp;&nbsp;Dr. Weaver is a recipient of numerous
awards, including the Arthritis Foundation Founders Award, the Mayo Clinic Philip Hench award for excellence in rheumatology and
the American College of Rheumatology Pauldine Phelps Award.&nbsp;&nbsp;Dr. Weaver is a sought after speaker at both national and
international meetings.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_015"></A><B>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
OWNERS AND MANAGEMENT</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The following table shows the pro forma beneficial ownership
of our common stock as of August 25, 2014.&nbsp;&nbsp;The table shows the common stock holdings of (i) each person known to us
to be the beneficial owner of at least five percent (5%) of our common stock; (ii) each director; (iii) each executive officer;
and (iv) all directors and executive officers as a group. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Beneficial ownership is determined in accordance with
the rules of the SEC, and generally includes voting power and/or investment power with respect to the securities held.&nbsp;&nbsp;Shares
of common stock subject to options and warrants currently exercisable or exercisable within 60 days as August 25, 2014, are deemed
outstanding and beneficially owned by the person holding such options or warrants for purposes of computing the number of shares
and percentage beneficially owned by such person, but are not deemed outstanding for purposes of computing the percentage beneficially
owned by any other person.&nbsp;&nbsp;Except as indicated in the footnotes to this table, the persons or entities named have sole
voting and investment power with respect to all shares of our common stock shown as beneficially owned by them. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The percentages in the table below are based on 43,638,926&nbsp;outstanding
shares of common stock and Class A Convertible Preferred stock. Unless otherwise indicated, the principal mailing address of each
of the persons below is c/o Relmada Therapeutics, Inc., 546 Fifth Avenue, 14<FONT STYLE="font-size: 10pt"><SUP> th</SUP></FONT>
Floor, New York, NY 10036.&nbsp;&nbsp;The Company&rsquo;s executive office is located at 546 Fifth Avenue, 14th floor, New York,
NY 10036. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp;&nbsp; </P><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> 5
                                         % Stockholders </B></P></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Number of Common Shares
    Beneficially Owned </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> Percentage Ownership </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Southern Biotech, Inc. (1) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left"> 555 South Federal Highway #450 <BR>&nbsp;Boca Raton, FL 33432 </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 4,320,254 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 9.9 </TD><TD STYLE="width: 1%; text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Alan &amp; Angela Greenhalgh, JTWROS <BR>&nbsp;CL4 CMR Wigan Lane, Ballamodha <BR>&nbsp;Ballasalla,
    Isle of Man. 1m9 3EP <BR>&nbsp;United Kingdom </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,499,933 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 5.7 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Sergio Traversa, PharmD, MBA </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Director and Chief Executive Officer (2) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,212,700 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2.7 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Eliseo&nbsp;&nbsp;Salinas, MD, MSc </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> President and Chief Scientific Officer (3) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> NA </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> NA </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Douglas Beck, CPA, </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Chief Financial Officer (4) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> NA </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> NA </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Shreeram Agharkar, Ph.D.&nbsp;&nbsp;(5) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Director </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> NA </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> NA </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Sandesh Seth, MS, MBA&nbsp;&nbsp;(6) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Lead Director </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> NA </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> NA </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Nabil M. Yazgi, MD (7) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Director </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 231,250 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0.5 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> All Directors and Executive Officers </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,443,950 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 3.3 </TD><TD STYLE="text-align: left"> % </TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal"> (1) </TD>
    <TD STYLE="line-height: normal"> Includes 1,865,333 Class A Convertible Preferred shares that are convertible to common
    stock within sixty days. Barry Hoenig maybe deemed the beneficial owner of these shares. </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: normal">&nbsp;</TD>
    <TD STYLE="line-height: normal">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: normal"> (2) </TD>
    <TD STYLE="width: 97%; line-height: normal"> Excludes unvested options of 628,720 that have an exercise price of $0.80 per
    share. The original options vest 25% at the date of grant and the remaining 75% of the options shall vest in equal quarterly
    increments over the next four (4) years.&nbsp;&nbsp;As of August 25, 2014, 714,992 options were vested that have an exercise
    price of $0.80 per share.&nbsp;&nbsp;Includes 343,906 common shares that were received from the Medeor transactions.&nbsp;&nbsp;Includes
    153,802 common shares that were granted pursuant to his employment contract. </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: normal"> (3) </TD>
    <TD STYLE="width: 97%; line-height: normal"> Excludes options to purchase 1,003,774 shares of common stock at an exercise
    price of $1.50 per share. 25% of the options shall vest upon the optionee's first anniversary of employment with the Company.
    The remaining 75% of the options shall thereafter vest each quarter over the next three years. </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp;&nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: normal"> (4) </TD>
    <TD STYLE="width: 97%; line-height: normal"> Excludes options to purchase 334,199 shares of common stock at an exercise
    price of $0.80 per share. 25% of the options shall vest upon the optionee's first anniversary of employment with the Company.
    The remaining 75% of the options shall thereafter vest each quarter over the next three years. </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: normal"> (5) </TD>
    <TD STYLE="width: 97%; line-height: normal"> Excludes options to purchase 48,662 shares of common stock at an exercise price
    of $1.50 per share. The vesting schedule is according to the Company ESOP wherein 25% of the options shall vest upon the first
    anniversary of the grant date. The remaining 75% of the options shall thereafter vest each quarter over the next three years. </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: normal"> (6) </TD>
    <TD STYLE="width: 97%; line-height: normal"> Excludes options to purchase 48,662 shares of common stock at an exercise price
    of $1.50 per share.&nbsp;&nbsp;The vesting schedule is according to the Company ESOP wherein 25% of the options shall vest
    upon the first anniversary of the grant date.&nbsp;&nbsp;The remaining 75% of the options shall thereafter vest each quarter
    over the next three years. Also excludes warrants held by (i) the Placement Agent or its affiliates in connection with the
    following offering consummated by Relmada: an offering that closed on September 30, 2013 (the &ldquo;2012 Offering&rdquo;),
    May 15, 2014 (the &ldquo;Going Public Offering&rdquo;) and the notes financing and (ii) by designees of the Advisory Firm.&nbsp;&nbsp;Mr.
    Seth is affiliated with the Placement Agent and the Advisory Firm and it is expected that he and/or his affiliates will be
    deemed the beneficial owner of a proportion of the warrants due to each respective entity. </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: normal"> (7) </TD>
    <TD STYLE="width: 97%; line-height: normal"> Excludes options to purchase 48,662 shares of common stock at an exercise price
    of $1.50 per share. The vesting schedule is according to the Company ESOP wherein 25% of the options shall vest upon the first
    anniversary of the grant date. The remaining 75% of the options shall thereafter vest each quarter over the next three years.
    Includes 125,000 Series A preferred shares that were purchased in the Series A offering and were converted to common stock.
    In addition, includes warrants to purchase 31,250 shares of common stock at an exercise price of $0.80 per share. Includes
    30,000 common shares that were purchased in the May 2014 offering of common stock. In addition, includes Series A warrants
    and Series B warrants to purchase 30,000 and 15,000 shares of common stock at an exercise price of $1.50 and $2.25, respectively
    per share. </TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> The following has been excluded
from above: </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The Company&rsquo;s 2014 Option Plan. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> We have reserved 12,000 options to be issued for shares
of common stock, to the Scientific Board of Advisors who may be entitled to such shares pursuant to consulting agreements with
the Company. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Equity Compensation Plan Information </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The Company has established the 2012 Stock Option Plan
(the&nbsp;&ldquo;Plan&rdquo;), which allows for the granting of common stock awards, stock appreciation rights, and incentive
and nonqualified stock options to purchase shares of the Company&rsquo;s common stock to designated employees, nonemployee directors,
and consultants and advisors. The Plan allowed for 2,409,436 options to be granted in July 2012. On March 10, 2014, the Board
of Directors increased the shares under the Plan to 4,000,000.&nbsp; The shareholders approved to increase the shares available
under the plan to 8,058,844. At June 30, 2014, no stock appreciation rights have been issued. Stock options are exercisable generally
for a period of 10&nbsp;years from the date of grant and generally vest over four years. As of June 30, 2014, 4,693,673 shares
were available for future grants under the Plan. </P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Outstanding Equity Awards at Fiscal Year-End Table </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> OUTSTANDING EQUITY AWARDS AT JUNE
30, 2014 </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The following table sets forth all unexercised options
and unvested restricted stock that have been awarded to our named executives by the Company and were outstanding as of June 30,
2014. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="14" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8pt"> Option
    Awards </FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="18" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8pt"> Stock
    Awards </FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8pt"> Name (a) </FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8pt"> Number
    of <BR>Securities <BR>Underlying <BR>Unexercised <BR>Options <BR>(#) <BR>(Exercisable) (b) </FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8pt"> Number
    of <BR>Securities <BR>Underlying <BR>Unexercised <BR>Options <BR>(#) <BR>(Unexercisable) (c) </FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B> Equity </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B> Incentive </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B> Plan </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B> Awards: </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B> Number
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              of </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B> Securities </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B> Underlying </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B> Unexercised </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B> Unearned </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B> Options </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B> (#) </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B> (d) </B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B> Option </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B> Exercise </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B> Price </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B> ($) </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B> (e) </B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8pt"> Option
    <BR>Expiration <BR>Date <BR>(f) </FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B> Number&nbsp;of </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B> Shares
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              or </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B> Units
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     of </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B> Stock&nbsp;That </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B> Have
                                                                                                                                                                                                                                                             Not </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B> Vested </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B> (#) </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-size: 8pt"><B> (g) </B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8pt"> Market
    <BR>Value of <BR>Shares <BR>or Units <BR>of Stock <BR>That <BR>Have&nbsp;Not <BR>Vested() <BR>($) <BR>(h) </FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8pt"> Equity
    <BR>Incentive <BR>Plan <BR>Awards: <BR>Number <BR>of <BR>Unearned <BR>Shares, <BR>Units or <BR>Other <BR>Rights <BR>That <BR>Have
    Not <BR>Vested <BR>(#) <BR>(i) </FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 8pt"> Equity
    <BR>Incentive <BR>Plan <BR>Awards: <BR>Market&nbsp;or <BR>Payout <BR>Value of <BR>Unearned <BR>Shares, <BR>Units or <BR>Other
    <BR>Rights <BR>That <BR>Have Not <BR>Vested <BR>($) <BR>(j) </FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; width: 1%"><FONT STYLE="font-size: 8pt"> Sergio Traversa </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt"> 391,946 </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt"> 286,016 </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt"> -&nbsp;&nbsp; </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt"> 0.80 </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt"> 07 </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt"> /11/2022 </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt"> -&nbsp;&nbsp; </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt"> -&nbsp;&nbsp; </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt"> -&nbsp;&nbsp; </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="width: 8%; text-align: right"><FONT STYLE="font-size: 8pt"> -&nbsp;&nbsp; </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> Sergio Traversa </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> 260,059 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> 405,691 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> -&nbsp;&nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> 0.80 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> 09 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> /30/2023 </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> -&nbsp;&nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> -&nbsp;&nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> -&nbsp;&nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> -&nbsp;&nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> Douglas Beck, CPA </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> -&nbsp;&nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> 334,199 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> -&nbsp;&nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> 0.80 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> 12 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> /02/2023 </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> -&nbsp;&nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> -&nbsp;&nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> -&nbsp;&nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> -&nbsp;&nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> Eliseo Salinas </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> -&nbsp;&nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> 1,003,774 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> -&nbsp;&nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> 1.50 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> 02 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> /24/2024 </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> -&nbsp;&nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> -&nbsp;&nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> -&nbsp;&nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt"> -&nbsp;&nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt"> &nbsp; </FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp;&nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> &nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_016"></A>CERTAIN RELATIONSHIPS&nbsp;AND RELATED
TRANSACTIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Acquisition of Medeor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"> On October 24, 2013, Relmada entered into
an engagement agreement which was amended December 19, 2013 with its Placement Agent, of which Mr. Seth, a director of the Company,
is Head of Healthcare Investment Banking, to advise on the merger of Medeor Inc. (&ldquo;Medeor&rdquo;) In consideration for its
services, the Placement Agent was eligible to receive (a) a cash success fee equal to 200,000 less $50,000 for Fairness Opinion,
and (b) a $50,000 activation fee The Placement Agent or its designees also received five-year warrants to purchase 2,000,000 shares
of Relmada common stock.&nbsp;&nbsp;As a result of the Share Exchange, these warrants were exchanged for a five-year warrant to
purchase 200,000 shares of the Company&rsquo;s common stock at a price of $1.10 per share.&nbsp;&nbsp;In April 2012, Relmada entered
into a license agreement with Medeor and issued 17,890 shares of stock for the license agreement.&nbsp;&nbsp;On December 31, 2013,
Relmada entered into a Merger Agreement with Medeor.&nbsp;&nbsp;This transaction occurred by the exchange of Medeor&rsquo;s shares,
for Relmada&rsquo;s common stock.&nbsp;&nbsp;Following the transaction, the corporate existence of Medeor ceased and Relmada continued
as the surviving corporation under Delaware law (the &quot;Merger&quot;).&nbsp;&nbsp;In connection with the Merger, each share
of common stock of Medeor was converted into the right to receive a pro rata share of Relmada&rsquo;s common stock based upon
an exchange ratio. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left"> As a result of this transaction,
Medeor stockholders, which included Dr. Sergio Traversa, CEO of Relmada, Cornell University, and several other persons, obtained
equity ownership in the Company.&nbsp;&nbsp;As of December 31, 2013, Relmada issued 25,000,000 (or 2,500,000 after the closing
of the&nbsp;Share Exchange)&nbsp;shares of common stock in exchange for all the outstanding stock of Medeor whose only asset was
a research and development project.&nbsp;&nbsp;As a result of the transactions from Medeor, our CEO received 343,906 shares of
common stock of Relmada. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Placement Agent</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left"> On December 6, 2011, Relmada entered
into an engagement agreement with the Placement Agent for its series A preferred stock and notes offering (collectively the &quot;Financings&quot;),&nbsp;&nbsp;of
which Mr. Seth, a director of the Company is Head of Healthcare Investment Banking.&nbsp;&nbsp;The agreement was amended April
12, 2012 and February 25, 2013.&nbsp;&nbsp;Pursuant to the agreement, the Placement Agent was engaged on an exclusive basis for
the Financings and as a financial advisor for assisting Relmada with the restructuring of its capitalization and negotiating the
conversion of its outstanding debt obligations to enable a successful financing (the &quot;Notes Conversion&quot;).&nbsp; In consideration
for its services, the Placement Agent received (a) an activation fee of $25,000&nbsp;&nbsp;and a re-activation fee of $15,000,
(b) a cash fee equal to 7% of the Notes Conversion and 10% of the gross proceeds raised in the Financings, and (c) non-accountable
expense reimbursement equal to 2% of the gross proceeds raised.&nbsp;&nbsp;&nbsp;In connection with the series A preferred stock
private placement, the Placement Agent or its designees also received five-year warrants to purchase 12,500,000 shares of Relmada
common stock at a price of $0.08 per share.&nbsp;&nbsp;As a result of the Share Exchange, these warrants were exchanged for a
five-year warrant to purchase 1,250,000 shares of the Company&rsquo;s common stock at a price of $0.80 per share.&nbsp;&nbsp;In
connection with the notes offering private placement, the Placement Agent or its designees also received five-year warrants to
purchase 1,406,250 shares of Relmada common stock at a price of $0.08 per share.&nbsp;&nbsp;As a result of the Share Exchange,
these warrants were exchanged for a five-year warrant to purchase 140,625 shares of the Company&rsquo;s common stock at a price
of $0.80 per share. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left"> On February 18, 2014, Relmada entered
into an engagement agreement with the Placement Agent for the Relmada&rsquo;s May 2014 Offering, of which Mr. Seth, a director
of the Company is Head of Healthcare Investment Banking.&nbsp;&nbsp;We agreed to pay Placement Agent a cash commission in the
amount of ten percent (10%) of the gross proceeds of the Offering received from investors at a Closing as well as a non-accountable
expense reimbursement equal to two percent (2%) of the gross proceeds of the Offering received from investors at a Closing.&nbsp;&nbsp;The
Placement Agent or its designees also received five-year warrants to purchase 25,085,183 shares of Relmada common stock at a price
of $0.15 per share.&nbsp;&nbsp;As a result of the Share Exchange, these warrants were exchanged for a five-year warrant to purchase
2,508,518 shares of the Company&rsquo;s common stock at a price of $1.50 per share. The Placement Agent shall also be entitled
to the compensation set forth above as well for any cash exercise of Warrants within six (6) months of the final closing of the
Offering as well as a five percent (5%) solicitation fee for any Warrants exercised as a result of any redemption of any Warrants.&nbsp;&nbsp;If
the Company elects to call the warrants, the Placement Agent shall receive a warrant solicitation fee equal to 5% of the funds
solicited by the Placement Agent upon exercise of the warrants. </P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">On May 19, 2014, Camp Nine entered into an
engagement agreement with the Placement Agent for Camp Nine&rsquo;s May 2014 Offering, of which Mr. Seth, a director of the Company
is Head of Healthcare Investment Banking.&nbsp;&nbsp;We agreed to pay Placement Agent a cash commission in the amount of ten percent
(10%) of the gross proceeds of the Offering received from investors at a Closing as well as a non-accountable expense reimbursement
equal to two percent (2%) of the gross proceeds of the Offering received from investors at a Closing.&nbsp;&nbsp;The Placement
Agent or its designees also received five-year warrants to purchase 1,782,431 shares of Camp Nine common stock at a price of $1.50
per share.&nbsp;&nbsp;The Placement Agent shall also be entitled to the compensation set forth above as well for any cash exercise
of Warrants within six (6) months of the final closing of the Offering as well as a five percent (5%) solicitation fee for any
Warrants exercised as a result of any redemption of any Warrants.&nbsp;&nbsp;If the Company elects to call the warrants, the Placement
Agent shall receive a warrant solicitation fee equal to 5% of the funds solicited by the Placement Agent upon exercise of the
warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Advisory Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left"> On October 17, 2012 the Company entered into an advisory
agreement with Jamess Capital Group, LLC (formerly known as Amerasia Capital Group, LLC), a consulting firm affiliated with Mr.
Seth, a Director of the Company (&ldquo;Advisory Firm&rdquo;) to provide non-investment banking services related to: a) recruiting
key level personnel of the Company and negotiating their contracts; b) advising Relmada on prioritizing its product development
programs per strategic objectives and assisting with qualifying and retaining key consultants to assist with product development
activities for its key pipeline drugs levorphanol and d-methadone and if required other products as well; c) assessing the state
of Relmada&rsquo;s financial records per US GAAP requirements, and; d) assisting with the selection and oversight of appropriate
financial, accounting and auditing professionals to prepare the financial records and reporting of the Company to public company
standards; and advising Relmada on the structure and composition of its Board of Directors in order to qualify for a public listing
and assisting with the recruiting and contract negotiations for at least two Board Members. The Advisory Firm is due a monthly
fee of $12,500 and the agreement is terminable by either party with three months written notice and is to be issued fully vested
warrants to purchase common stock equal to 12% of the fully diluted shares of the Company as of the Closing Date of the Share
Exchange exercisable at an exercise price of $0.001 per share.&nbsp;&nbsp;The Advisory Firm is also eligible to be reimbursed
upon the submission of proper documentation for ordinary and necessary out-of-pocket expenses not to exceed $5,000 per month.
Jamess Capital Group, LLC has not requested to be reimbursed for any expenses. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Employment and Non-Competition Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">Our executive officers have signed employment
agreement or offer letters with the Company, pursuant to which they agree to be employed by the Company initially for one or two
years which may be extended and should they be terminated undertake not to compete with the Company with respect to any drug that
is under development by, or commercialized by, the Company, for a period of three years following the termination of their employment.&nbsp;&nbsp;They
also agree that all inventions made by them in connection with the performance of their services become the immediate property
of Camp Nine.&nbsp;&nbsp;The agreements provide that the executive officers will hold proprietary information in the strictest
confidence and not use the confidential information for any purpose not expressly authorized by us.&nbsp;&nbsp;In addition, they
will be eligible to receive stock options under the Company&rsquo;s stock option plan, when, as and to the extent determined by
the Board of Directors.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_017"></A><B>DESCRIPTION OF&nbsp;SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I> The following summary of our capital stock is subject in
all respects to our Articles of Incorporation and our Bylaws. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> The total authorized shares of capital stock currently consists
of 700,000,000 shares, consisting of 500,000,000 shares of Common Stock, par value $0.001 per share, and 200,000,000 shares of
Preferred Stock, par value $0.001 per share, 3,500,000 of which shall be designated Class A Convertible Preferred Stock. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> As of June 24, 2014, there were 40,317,717 shares of common
and outstanding. Each share of our Common Stock entitles the holder to receive notice of and to attend all meetings of our stockholders
with the entitlement to one vote.&nbsp;&nbsp;Holders of Common Stock are entitled, subject to the rights, privileges, restrictions
and conditions attaching to any other class of shares ranking in priority to the Common Stock, to receive any dividend declared
by the board of directors.&nbsp;&nbsp;If we are voluntarily or involuntarily liquidated, dissolved or wound-up, the holders of
Common Stock will be entitled to receive, after distribution in full of the preferential amounts, if any, all of the remaining
assets available for distribution ratably in proportion to the number of shares of Common Stock held by them. Holders of Common
Stock have no redemption or conversion rights.&nbsp;&nbsp;The rights, preferences and privileges of holders of shares of Common
Stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of Preferred Stock that
we may designate and issue in the future. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> As of September 2, 2014, there were 3,337,309 shares of Class
A Convertible Preferred Stock issued and outstanding. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The rights and preferences of the Company&rsquo;s Class A Convertible
Preferred Stock include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Liquidation Preference</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In the event of any dissolution, liquidation or winding up of the
Company, whether voluntary or involuntary, the Holders of Class A Convertible Preferred Stock shall be entitled to participate
in any distribution out of the assets of the Company on an equal basis per share with the holders of the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Dividends</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Class A Convertible Preferred Stock shall, with respect to dividend
rights, be entitled to two times the amount of any dividend granted by the Board of Directors of the Corporation to the holders
of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Conversion</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Optional Conversion</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Subject to the following sentence, each share of Class A Convertible
Preferred Stock shall be convertible at the option of the holder thereof and without the payment of additional consideration by
the holder thereof, at any time, into shares of Common Stock at a conversion rate of one (1) share of Common Stock for every one
(1) share of Class A Convertible Preferred Stock, Notwithstanding the foregoing sentence, a Holder of Class A Convertible Preferred
Stock shall not have the ability to convert Class A Convertible Preferred Stock to Common Stock if such conversion would cause
the Holder or any &ldquo;group&rdquo; (within the meaning of Section 13(d) of the U.S. Securities Exchange Act of 1934 (the &ldquo;Act&rdquo;))
of which such holder is or deemed to be a part, to &ldquo;beneficially own&rdquo; (within the meaning of Rule 13d-3 under the Act)
more than 9.9% of the number of shares of Common Stock of the Corporation listed as outstanding by the Corporation in the most
recent public filing made by the Corporation with the SEC prior to the Corporation receiving the Conversion Demand (as hereinafter
defined).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Automatic Conversion</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Subject to the limitation on conversion provided above, on the first
day of each month until there are no shares of Class A Convertible Stock outstanding, each share of Class A Convertible Preferred
Stock shall convert without the payment of additional consideration by the Holder thereof into shares of Common Stock on the Automatic
Conversion Date at a conversion rate of one (1) share of Common Stock (the &ldquo;Conversion Rate &rdquo;) for every one (1) share
of Class A Convertible Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Voting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The holders of Class A Convertible Preferred Stock shall have no
right to vote on any matter submitted to a vote of the holders of our common stock, including the election of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><A NAME="a_018"></A>DESCRIPTION OF WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Series A Preferred Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> In connection with Relmada&rsquo;s sale of Series A preferred
stock and 8% senior subordinated unsecured convertible notes in 2012 and 2013, Relmada sold to the purchasers 25,000,000 warrants
to purchase Common Stock at an exercise price of $0.08 per share. Upon the closing of the Share Exchange, after taking into account
the exchange ratio, we issued 2,500,000 warrants and these warrants now have an exercise price of $0.80 per share, and the warrants
contain substantially identical terms of the Series A Warrants issued by Relmada (the <B>&ldquo;Series A Preferred Warrants&rdquo;</B>). </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Series A Preferred Warrants have a seven year term from their
issuance dates, which occurred between July 10, 2012 and September 26, 2013. The exercise price of the Series A Preferred Warrants
is subject to adjustment upon certain events.&nbsp;&nbsp;If the Company at any time while the Series A Warrants remain outstanding
and unexpired shall declare a dividend or make a distribution on the outstanding Common Stock payable in shares of its capital
stock, or split, subdivide or combine the Common Stock into a different number of securities of the same class, the exercise price
for the Series A Warrants shall be proportionately decreased in the case of a dividend, split or subdivision or proportionately
increased in the case of a combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Notes Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> In connection with Relmada's 2013 notes financing, Relmada
sold to the purchasers 2,812,500 warrants to purchase Common Stock at an exercise price of $0.08 per share.&nbsp;&nbsp;Upon the
closing of the Share Exchange, after taking into account the exchange ratio, we issued&nbsp;281,250 warrants and these warrants
now have an exercise price of $0.80 per share, and the warrants contain substantially identical terms of the Series A Warrants
issued by Relmada (the<B> &quot;Note Warrants&quot;</B>). The Note Warrants have a seven year term from their issuance dates and
have substantially the same terms as the Series A Preferred Warrants (as described above). </P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Advisory Firm Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> In connection with the agreement with the Advisory Firm,
Relmada agreed to issue to the Advisory Firm warrants (&quot;Advisory Firm Warrants&quot;) to purchase 12% of the fully diluted
shares of Relmada. Upon the closing of the Share Exchange, these warrants were exchanged for Advisory Firm Warrants issued by
the Company. The Advisory Firm Warrants are exercisable at $0.001 per share, and provide for cashless exercise, and expire seven
years after the date of issuance. Shares purchased by exercise of the Advisory Firm Warrants have unlimited piggyback registration
rights should the Company have a public offering registered with the SEC, and are subject to lock-ups, if any, required by SEC
regulations or other applicable law, or by investors. </P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Series A Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> In connection with Relmada's sale of units on
May 12, 2014 and May 15, 2014, Relmada sold to the purchasers 100,340,733 &lrm;Series A warrants to purchase Common Stock at
an exercise price of $0.15 per share (the&nbsp;&nbsp;&quot;Series A Warrants&quot;). The Series A Warrants have a 120 day
term from their issuance date (October 10, 2014). There is no cashless exercise provision. Upon the closing of the share exchange,
taking into account an exchange ratio of 10 to 1, the new exercise price of the warrants is $1.50 per share and there are
10,034,073 Series A Warrants issued. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In connection with Camp Nine's sale of units on June 10, 2014, Camp
Nine sold to the purchasers 7,129,725 &lrm;Series A warrants to purchase Common Stock at an exercise price of $1.50 per share.&nbsp;&nbsp;The
Series A Warrants have a 120 day term from their issuance date. There is no cashless exercise provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> For so long as there are any Series A Warrants outstanding,
if and whenever at any time and from time to time after the warrant issue date, as applicable, the Company shall issue any shares
of Common Stock or Common Stock equivalents for no consideration or a consideration per share less than the exercise price, then,
forthwith upon such issue or sale, the Series A Warrants shall be subject to a proportional adjustment determined by multiplying
such warrant exercise price by the following fraction: </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font: 10pt/115% Calibri, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> N(0)
    + N(1) </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt/115% Calibri, Helvetica, Sans-Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> N(0)
    + N(2) </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.55in"> Where: </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.55in"> N(0) = the number of shares of Common
Stock outstanding (calculated on a fully diluted basis) immediately prior to the issuance of such additional shares of Common
Stock or Common Stock equivalents; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.55in"> N(1) = the number of shares of Common
Stock which the aggregate consideration, if any (including the aggregate net consideration per share with respect to the issuance
of Common Stock equivalents), received or receivable by the Company for the total number of such additional shares of Common Stock
so issued or deemed to be issued would purchase at the Series A Warrant exercise price, as applicable, in effect immediately prior
to such issuance; and </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.55in"> N(2) = the number of such additional
shares of Common Stock so issued or deemed to be issued. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Series B Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> In connection with Relmada&rsquo;s sale of units on May
12, 2014 and May 15, 2014, Relmada sold to the purchasers &lrm;an aggregate of 50,170,366 Series B warrants to purchase common
stock at an exercise price of $0.225 per share (the&nbsp;&quot;Series B Warrants&quot;).&nbsp;The Series B Warrants have a 5 year
term from their issuance date. There is a cashless exercise provision. Upon the closing of the Reverse Merger, taking into account
the exchange ratio, the new exercise price of the warrants is $2.25 per share and there are 5,017,036 warrants issued We may call
this warrant for redemption upon written notice to all purchasers at any time the closing price of the Common Stock exceeds $3.75
for 20 consecutive trading days, as reported by Bloomberg, provided at such time there is an effective registration statement
covering the resale of the shares. In the 60 business days following the date the redemption notice is deemed given investors
may choose to exercise this Warrant or a portion of the Warrant by paying the then applicable Exercise Price. Any Shares not exercised
on the last day of the exercise period will be redeemed by the Company at $0.001 per share. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In connection with Camp Nine's sale of units on June 10, 2014, Camp
Nine sold to the purchasers &lrm;an aggregate of 3,564,852 Series B warrants to purchase common stock at an exercise price of $2.25
per share.&nbsp;&nbsp;The Series B Warrants have a 5 year term from their issuance date. There is a cashless exercise provision.
We may call this warrant for redemption upon written notice to all purchasers at any time the closing price of the Common Stock
exceeds $3.75 for 20 consecutive trading days, as reported by Bloomberg, provided at such time there is an effective registration
statement covering the resale of the shares. In the 60 business days following the date the redemption notice is deemed given investors
may choose to exercise this Warrant or a portion of the Warrant by paying the then applicable Exercise Price. Any Shares not exercised
on the last day of the exercise period will be redeemed by the Company at $0.001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The Series B Warrants have substantially the same proportional
adjustment provisions as the Series A Warrants described above. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Placement Agent Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left"> In connection with Relmada's sale
of Series A Preferred Stock and 8% senior subordinated unsecured convertible notes in 2012 and 2013, Relmada issued to the Placement
Agent warrants to purchase 12,500,000 shares of Common Stock at an exercise price of $0.08 per share.&nbsp;&nbsp;Upon the closing
of the Share Exchange, after taking into account the exchange ratio, these warrants now have an exercise price of $0.80 per share
and there are 1,250,000 warrants issued.These warrants include a cashless exercise provision and have substantially the same terms
as the Series A Preferred Warrants. In connection with the 2013 notes financing, the Placement Agent or
its designees also received five-year warrants to purchase 1,406,250 shares of Relmada common stock at a price of $0.08 per share.&nbsp;&nbsp;As
a result of the Share Exchange, these warrants were exchanged for a five-year warrant to purchase 140,625 shares of the Company&rsquo;s
common stock at a price of $0.80 per share. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> In connection with Relmada's merger with Medeor in December
2013, Relmada issued to the Placement Agent 2,000,000 warrants exercisable for shares of Common Stock at an exercise price of
$0.11 per share. Upon the closing of the Reverse Merger, after taking into account the exchange ratio, these warrants now have
an exercise price of $1.10 per share and there are 200,000 warrants issued. In connection with Relmada's May 12, 2014 and May
15, 2014 offering, Relmada also issued to the Placement Agent warrants to purchase 25,085,183 shares of Common Stock at an exercise
price of $0.15 per share. Upon the closing of the Share Exchange, after taking into account the exchange ratio, these warrants
now have an exercise price of $1.50 per share and there are 2,508,518 warrants issued. These warrants include a cashless exercise
provision and have substantially the same terms as the Series A Warrants that are described above. In connection with Camp Nine&rsquo;s
May 2014 offering, Camp Nine issued to the Placement Agent warrants to purchase 1,782,431 shares of Common Stock at an exercise
price of $1.50 per share. The Placement Agent warrants issued in 2014 have substantially the same proportional adjustment provisions
as the Series A Warrants described above. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Anti-takeover Effects of Our Articles of Incorporation and By-laws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Our Articles of Incorporation and Bylaws contain certain provisions
that may have anti-takeover effects, making it more difficult for or preventing a third party from acquiring control of our Company
or changing our Board of Directors and management. According to our Bylaws and Articles of Incorporation, neither the holders of
our common stock nor the holders of our preferred stock have cumulative voting rights in the election of our directors. The combination
of the present ownership by a few stockholders of a significant portion of our issued and outstanding common stock and lack of
cumulative voting makes it more difficult for other stockholders to replace our Board of Directors or for a third party to obtain
control of our Company by replacing our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Anti-takeover Effects of Nevada Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Business Combinations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The &ldquo;business combination&rdquo; provisions of Sections 78.411
to 78.444, inclusive, of the Nevada Revised Statutes, or NRS, generally prohibit a Nevada corporation with at least 200 stockholders
of record, a &ldquo;resident domestic corporation,&rdquo; from engaging in various &ldquo;combination&rdquo; transactions with
any &ldquo;interested stockholder&rdquo; unless certain conditions are met or the corporation has elected in its articles of incorporation
to not be subject to these provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">A &ldquo;combination&rdquo; is generally defined to include (a)
a merger or consolidation of the resident domestic corporation or any subsidiary of the resident domestic corporation with the
interested stockholder or affiliate or associate of the interested stockholder; (b) any sale, lease, exchange, mortgage, pledge,
transfer, or other disposition, in one transaction or a series of transactions, by the resident domestic corporation or any subsidiary
of the resident domestic corporation to or with the interested stockholder or affiliate or associate of the interested stockholder
having: (i) an aggregate market value equal to 5% or more of the aggregate market value of the assets of the resident domestic
corporation, (ii) an aggregate market value equal to 5% or more of the aggregate market value of all outstanding shares of the
resident domestic corporation, or (iii) 10% or more of the earning power or net income of the resident domestic corporation; (c)
the issuance or transfer in one transaction or series of transactions of shares of the resident domestic corporation or any subsidiary
of the resident domestic corporation having an aggregate market value equal to 5% or more of the resident domestic corporation
to the interested stockholder or affiliate or associate of the interested stockholder; and (d) certain other transactions with
an interested stockholder or affiliate or associate of the interested stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">An &ldquo;interested stockholder&rdquo; is generally defined as
a person who, together with affiliates and associates, owns (or within three years, did own) 10% or more of a corporation&rsquo;s
voting stock. An &ldquo;affiliate&rdquo; of the interested stockholder is any person that directly or indirectly through one or
more intermediaries is controlled by or is under common control with the interested stockholder. An &ldquo;associate&rdquo; of
an interested stockholder is any (a) corporation or organization of which the interested stockholder is an officer or partner or
is directly or indirectly the beneficial owner of 10% or more of any class of voting shares of such corporation or organization;
(b) trust or other estate in which the interested stockholder has a substantial beneficial interest or as to which the interested
stockholder serves as trustee or in a similar fiduciary capacity; or (c) relative or spouse of the interested stockholder, or any
relative of the spouse of the interested stockholder, who has the same home as the interested stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">If applicable, the prohibition is for a period of two years after
the date of the transaction in which the person became an interested stockholder, unless such transaction is approved by the board
of directors prior to the date the interested stockholder obtained such status; or the combination is approved by the board of
directors and thereafter is approved at a meeting of the stockholders by the affirmative vote of stockholders representing at least
60% of the outstanding voting power held by disinterested stockholders; and extends beyond the expiration of the two-year period,
unless (a) the combination was approved by the board of directors prior to the person becoming an interested stockholder; (b) the
transaction by which the person first became an interested stockholder was approved by the board of directors before the person
became an interested stockholder; (c) the transaction is approved by the affirmative vote of a majority of the voting power held
by disinterested stockholders at a meeting called for that purpose no earlier than two years after the date the person first became
an interested stockholder; or (d) if the consideration to be paid to all stockholders other than the interested stockholder is,
generally, at least equal to the highest of: (i) the highest price per share paid by the interested stockholder within the three
years immediately preceding the date of the announcement of the combination or in the transaction in which it became an interested
stockholder, whichever is higher, plus compounded interest and less dividends paid, (ii) the market value per share of common shares
on the date of announcement of the combination and the date the interested stockholder acquired the shares, whichever is higher,
plus compounded interest and less dividends paid, or (iii) for holders of preferred stock, the highest liquidation value of the
preferred stock, plus accrued dividends, if not included in the liquidation value. With respect to (i) and (ii) above, the interest
is compounded at the rate for one-year United States Treasury obligations from time to time in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Applicability of the Nevada business combination law would discourage
parties interested in taking control of our company if they cannot obtain the approval of our board of directors. These provisions
could prohibit or delay a merger or other takeover or change in control attempt and, accordingly, may discourage attempts to acquire
our company even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above the
prevailing market price. The Company has elected to not be governed by the Nevada business combination provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>Control Share Acquisitions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The &ldquo;control share&rdquo; provisions of Sections 78.378 to
78.3793, inclusive, of the NRS, apply to &ldquo;issuing corporations,&rdquo; which are Nevada corporations with at least 200 stockholders
of record, including at least 100 stockholders of record who are Nevada residents, and which conduct business directly or indirectly
in Nevada, unless the corporation has elected to not be subject to these provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The control share statute prohibits an acquirer of shares of an
issuing corporation, under certain circumstances, from voting its shares of a corporation&rsquo;s stock after crossing certain
ownership threshold percentages, unless the acquirer obtains approval of the target corporation&rsquo;s disinterested stockholders.
The statute specifies three thresholds: (a) one-fifth or more but less than one-third, (b) one-third but less than a majority,
and (c) a majority or more, of the outstanding voting power. Generally, once a person acquires shares in excess of any of the thresholds,
those shares and any additional shares acquired within 90 days thereof become &ldquo;control shares&rdquo; and such control shares
are deprived of the right to vote until disinterested stockholders restore the right. These provisions also provide that if control
shares are accorded full voting rights and the acquiring person has acquired a majority or more of all voting power, all other
stockholders who do not vote in favor of authorizing voting rights to the control shares are entitled to demand payment for the
fair value of their shares in accordance with statutory procedures established for dissenters&rsquo; rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">A corporation may elect to not be governed by, or &ldquo;opt out&rdquo;
of, the control share provisions by making an election in its articles of incorporation or bylaws, provided that the opt-out election
must be in place on the 10th day following the date an acquiring person has acquired a controlling interest, that is, crossing
any of the three thresholds described above. We have opted out of the control share statutes, and, provided the &ldquo;opt out&rdquo;
election remains in place, we will not be subject to the control share statutes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The effect of the Nevada control share statute is that the acquiring
person, and those acting in association with the acquiring person, will obtain only such voting rights in the control shares as
are conferred by a resolution of the stockholders at an annual or special meeting. The Nevada control share law, if applicable,
could have the effect of discouraging takeovers of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> Our common stock is quoted on the OTCQB under the symbol &ldquo;RLMD. &rdquo;
&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Transfer Agent</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The transfer agent and registrar for our common
stock and preferred stock is Empire Stock Transfer Inc. The transfer agent&rsquo;s address 1859 Whitney Mesa Dr., Henderson, NV
89014, and its telephone number is (702) 818-5898.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_019"></A><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The common shares being offered for resale by the selling
stockholders consist of 61,125,422 shares. We will pay any fees and expenses incurred by us incident to the registration of the
securities. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Each selling stockholder of the securities and any of their pledgees,
assignees and successors-in-interest may, from time to time, sell any or all of their securities covered hereby on the OTCBB or
any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales
may be at fixed or negotiated prices. A selling stockholder may use any one or more of the following methods when selling securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 4%">&#9679;</TD>
    <TD STYLE="width: 92%">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD>block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD>purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</TD></TR>
<TR STYLE="vertical-align: top">

    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD>an exchange distribution in accordance with the rules of the applicable exchange;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD>privately negotiated transactions;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD>settlement of short sales entered into after the effective date of the registration statement of which this prospectus is a part;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD>in transactions through broker-dealers that agree with the selling stockholders to sell a specified number of such securities at a stipulated price per security;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD>through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD>a combination of any such methods of sale; or</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&#9679;</TD>
    <TD>any other method permitted pursuant to applicable law.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The selling stockholders may also sell securities under Rule 144
under the Securities Act, if available, rather than under this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Broker-dealers engaged by the selling stockholders may arrange for
other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the selling stockholders
(or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but,
except as set forth in a supplement to this prospectus, in the case of an agency transaction not in excess of a customary brokerage
commission in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or markdown in compliance with
FINRA IM-2440.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In connection with the sale of the securities or interests therein,
the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in
turn engage in short sales of the securities in the course of hedging the positions they assume. The selling stockholders may also
sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers
that in turn may sell these securities. The selling stockholders may also enter into option or other transactions with broker-dealers
or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or
other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution
may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The selling stockholders and any broker-dealers or agents that are
involved in selling the securities may be deemed to be &ldquo;underwriters&rdquo; within the meaning of the Securities Act in connection
with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities
purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each selling stockholder
has informed us that it does not have any written or oral agreement or understanding, directly or indirectly, with any person to
distribute the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The resale securities will be sold only through registered or licensed
brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered
hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the
registration or qualification requirement is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 49.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Under applicable rules and regulations under the Securities Exchange
Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), any person engaged in the distribution of the resale securities may not
simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined
in Regulation M, prior to the commencement of the distribution. In addition, the selling stockholders will be subject to applicable
provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of
purchases and sales of securities of the common stock by the selling stockholders or any other person. We will make copies of this
prospectus available to the selling stockholders and have informed them of the need to deliver a copy of this prospectus to each
purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_020"></A><B>LEGAL MATTERS</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The validity of the shares of common stock offered by this prospectus
and certain other legal matters as to Delaware law will be passed upon for us by Hiscock &amp; Barclay, LLP, Syracuse, New York.
&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_021"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> Relmada&rsquo;s Therapeutics,
Inc&rsquo;s&nbsp;&nbsp;audited financial statements as of June 30, 2014 and December 31, 2013, for the six months ended June
30, 2014 and for the years ended December 31, 2013 and 2012 appearing in this prospectus and registration statement have been
audited by GBH CPAs, PC, an independent registered public accounting firm, as set forth in their report thereon appearing
elsewhere herein and in the registration statement, and are included in reliance upon such report given on the authority of
such firm as experts in accounting and auditing. &nbsp;We have also relied on the valuation reports of Vantage Point
Advisors, Inc. dated September 4, 2014, February 25, 2014, February 28, 2014 and April 17, 2014. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_022"></A><B>WHERE YOU&nbsp;CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We filed with the SEC a registration statement under the Securities
Act for the common stock in this offering. This prospectus does not contain all of the information in the registration statement
and the exhibits and schedule that were filed with the registration statement. For further information with respect to us and our
common stock, we refer you to the registration statement and the exhibits that were filed with the registration statement. Statements
contained in this prospectus about the contents of any contract or any other document that is filed as an exhibit to the registration
statement are not necessarily complete, and we refer you to the full text of the contract or other document filed as an exhibit
to the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We file annual, quarterly, and current reports and other
information with the SEC. Our filings with the SEC are available to the public on the SEC&rsquo;s website at www.sec.gov.
Those filings are also available to the public on our corporate website at www.relmada.com. The information we file
with the SEC or contained on, or linked to through, our corporate website or any other website that we may maintain is not
part of this prospectus or the registration statement of which this prospectus is a part. You may also read and copy, at the
SEC&rsquo;s prescribed rates, any document we file with the SEC, including the registration statement (and its exhibits) of
which this prospectus is a part, at the SEC&rsquo;s Public Reference Room located at 100 F Street, N.E., Washington, D.C.
20549. You can call the SEC at 1-800-SEC-0330 to obtain information on the operation of the Public Reference Room.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><B> RELMADA
THERAPEUTICS, INC. </B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> (formerly Camp Nine, Inc.) </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><B> &nbsp; </B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><B> Audited
Financial Statements </B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><B> &nbsp; </B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> As
of June 30, 2014 and December 31, 2013, </FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> for
the six months ended June 30, 2014 and for the years ended December 31, 2013 and 2012 </FONT></P>




<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal"></P>

<!-- Field: Page; Sequence: 89; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"> <A
NAME="index"></A><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><B>RELMADA
THERAPEUTICS, INC.</B></FONT> </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><B> (formerly
Camp Nine, Inc.) </B></FONT> <BR>
<FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><B>INDEX TO FINANCIAL
STATEMENTS</B></FONT> </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt/normal Times New Roman, Times, Serif; border-collapse: collapse; letter-spacing: normal; word-spacing: normal">
<TR STYLE="vertical-align: top; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; padding-bottom: 1.5pt; width: 90%; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; font: 10pt/normal Times New Roman, Times, Serif; padding-left: 0; text-align: center; width: 10%; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> Page </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: right; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><A

       HREF="#report"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">Report
    of Independent Registered Public Accounting Firm</FONT></A></TD>
    <TD STYLE="padding: 0; font: 10pt/normal Times New Roman, Times, Serif; text-align: center; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> F-3 </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt/normal Times New Roman, Times, Serif; text-align: center; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><A

       HREF="#a_024">Consolidated<FONT STYLE="font: 10pt/115% Calibri, Helvetica, Sans-Serif"> </FONT><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">Balance
    Sheets as of June 30, 2014 and December 31, 2013</FONT></A></TD>
    <TD STYLE="padding: 0; font: 10pt/normal Times New Roman, Times, Serif; text-align: center; letter-spacing: normal; word-spacing: normal"> F-<FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">4</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt/normal Times New Roman, Times, Serif; text-align: center; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><A

       HREF="#a_025">Consolidated<FONT STYLE="font: 10pt/115% Calibri, Helvetica, Sans-Serif"> </FONT><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">Statements
    of Operations for the Six Months Ended June 30, 2014 and for the Years Ended December 31, 2013 and 2012</FONT></A></TD>
    <TD STYLE="padding: 0; font: 10pt/normal Times New Roman, Times, Serif; text-align: center; letter-spacing: normal; word-spacing: normal"> F-<FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">5</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; text-align: right; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><A

       HREF="#a_026">Consolidated<FONT STYLE="font: 10pt/115% Calibri, Helvetica, Sans-Serif"> </FONT><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">Statement
    of Stockholders&rsquo; Deficit for the Period from December 31, 2011 to June 30, 2014</FONT></A></TD>
    <TD STYLE="padding: 0; font: 10pt/normal Times New Roman, Times, Serif; text-align: center; letter-spacing: normal; word-spacing: normal"> F-<FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">6
    - F-7</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">&nbsp;</TD>
    <TD STYLE="padding: 0; font: 10pt/normal Times New Roman, Times, Serif; text-align: center; letter-spacing: normal; word-spacing: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><A

       HREF="#a_027">Consolidated<FONT STYLE="font: 10pt/115% Calibri, Helvetica, Sans-Serif"> </FONT><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">Statements
    of Cash Flows for the Six Months Ended June 30, 2014 and for the Years Ended December 31, 2013 and 2012</FONT></A></TD>
    <TD STYLE="padding: 0; font: 10pt/normal Times New Roman, Times, Serif; text-align: center; letter-spacing: normal; word-spacing: normal"> F-<FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">8
    - F-9</FONT> </TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; font: 10pt/normal Times New Roman, Times, Serif; text-align: center; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><A

       HREF="#a_028"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">Notes
    to Consolidated Financial Statements</FONT></A></TD>
    <TD STYLE="padding: 0; font: 10pt/normal Times New Roman, Times, Serif; text-align: center; letter-spacing: normal; word-spacing: normal"> F-<FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">10
    - F-26</FONT> </TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal"></P>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><A NAME="report"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Report
of Independent Registered Public Accounting Firm </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; padding: 0"></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> The
Board of Directors and Stockholders </FONT> <BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif">Relmada Therapeutics, Inc.</FONT> </P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> New
York, NY </FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; padding: 0"></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"> We have audited the accompanying consolidated balance
sheets of Relmada Therapeutics, Inc. (&ldquo;Company&rdquo;)<B> </B>(formerly Camp Nine, Inc.)<B> </B>as of June 30, 2014 and
December 31, 2013 and the related consolidated statements of operations, stockholders&rsquo; deficit and cash flows for six months
ended June 30, 2014 and for the periods from December 31, 2011 to June 30, 2014. These financial statements are the responsibility
of the Company&rsquo;s management. Our responsibility is to express an opinion on these financial statements based on our audits. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> We
conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are
free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management,
as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for
our opinion. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; padding: 0"> In our opinion, the financial statements referred
to above present fairly, in all material respects, the financial position of Relmada Therapeutics, Inc. as of June 30, 2014 and
December 31, 2013 and results of its operations and its cash flows for the six months ended June 30, 2014 and for the periods
from December 31, 2011 to June 30, 2014 in conformity with accounting principles generally accepted in the United States of America. </P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> GBH
CPAs, PC </FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> www.gbhcpas.com </FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Houston,
Texas </FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0; padding: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> September
3, 2014 </FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">&nbsp;</FONT></P>




<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"></P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Relmada
Ther<FONT STYLE="letter-spacing: normal; word-spacing: normal; line-height: normal">apeutics, Inc.</FONT> </B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> (formerly Camp Nine, Inc.) </B> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"> <A
NAME="a_024"></A><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><B>Consolidated
Balance Sheets</B></FONT> </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><B> &nbsp; </B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> As
    of &nbsp; </B></FONT> <BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>June&nbsp;30,</B></FONT><BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2014</B></FONT> </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="3" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> As
    of December&nbsp;31, </B></FONT> <BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2013</B></FONT> </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Assets </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="3" STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="3" STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Current assets: </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="3" STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="3" STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; padding-left: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Cash
    and cash equivalents </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 25,564,351 </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 3,522,450 </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Prepaid expenses </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 178,158 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 10,325 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Deferred financing
    costs, net of accumulated amortization of $0 and $69,546, respectively </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,724 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Total current assets </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 25,742,509 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 3,611,499 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Fixed assets, net of accumulated depreciation
    of $2,230 and $373, respectively </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 9,841 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 8,498 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Other assets </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 12,100 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 12,100 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Total assets </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 25,764,450 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 3,632,097 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Liabilities
    and Stockholders&rsquo; Deficit </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Current liabilities: </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Accounts payable </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 746,098 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 180,319 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Accrued expenses </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 382,023 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 438,658 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Note payable </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 58,357 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Derivative liabilities </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 25,586,933 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 20,103,425 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Subordinated
    promissory notes payable, net of debt discount of $0 and $141,049, respectively </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 758,951 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Total current liabilities </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 26,773,411 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 21,481,353 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Long-term liability &ndash; accrued
    expense </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 100,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 100,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Total liabilities </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 26,873,411 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 21,581,353 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Commitments and contingencies </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Stockholders&rsquo; deficit: </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Preferred
    stock, $0.001 par value, 200,000,000 shares authorized, liquidation </FONT> <BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif">value of $0.80 per share:</FONT> </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 30pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Series
    A preferred stock, 0 and 255,000,000 shares authorized (private company), </FONT> <BR> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">0
    and 13,604,128 shares issued and outstanding, respectively</FONT> </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 13,604 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0; text-indent: 0; line-height: 115%"><P STYLE="padding-left: 30pt; text-indent: -10pt; line-height: 115%"> Class
                                                                   A convertible preferred stock, 3,500,000 shares authorized,<BR>
                                                                   3,337,309 and 0 shares issued and outstanding, respectively </P>


</TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 3,337 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> - </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Common
    stock, $0.001 par value, 500,000,000 shares authorized, </FONT> <BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif">40,294,217 and 4,958,778 shares issued and outstanding, respectively</FONT> </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 40,294 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 4,959 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Additional
    paid-in capital </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><P STYLE="margin: 0"> 54,166,055 </P>


</TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 16,014,840 </FONT></TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Accumulated deficit </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (55,318,647 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (33,982,659 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> ) </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Total stockholders&rsquo; deficit </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (1,108,961 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (17,949,256 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> ) </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Total liabilities and stockholders&rsquo;
    deficit </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 25,764,450 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 3,632,097 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal"></P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> The
accompanying notes are an integral part of these consolidated financial statements. </FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">&nbsp;</FONT></P>




<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"></P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><B> Relmada
Therapeutics, Inc. </B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"><B> (formerly
Camp Nine, Inc.) </B></P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"> <A
NAME="a_025"></A><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><B>Consolidated
Statements of Operations</B></FONT> </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; padding-bottom: 1.5pt"> For
    the Six Months Ended <BR> June 30, </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> For
    the Year Ended <BR> December 31, </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2014 </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2013 </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"> 2012 </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; font-weight: bold"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> Revenue </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> Operating expenses: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"> Research and development </TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0"> (839,959 </P>


</TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"> (5,248,669 </TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"> (667,474 </TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> &nbsp;&nbsp;&nbsp;&nbsp;General
    and administrative </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0"> (12,106,859 </P>


</TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> (1,525,257 </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> (2,489,235 </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> Total operating expenses </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0"> (12,946,818 </P>


</TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> (6,773,926 </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> (3,156,709 </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> Loss from operations </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0"> (12,946,818 </P>


</TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> (6,773,926 </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> (3,156,709 </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> Other (expenses) income: </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"> Loss on change in fair value
    of derivative liabilities </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"> (7,954,970 </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"> (12,877,675 </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"> (3,688,353 </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"> Interest income </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"> 1,411 </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"> 12,753 </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> &nbsp;&nbsp;&nbsp;&nbsp;Interest
    expense </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> (435,611 </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> (220,307 </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> (27,721 </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> Total other (expenses)
    income </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> (8,389,170 </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> (13,097,982 </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> (3,703,321 </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"> Net loss </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"> (21,335,988 </TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"> (19,871,908 </TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"> (6,860,030 </TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"> Net loss per common share
    - basic and diluted </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"> (1.73 </TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"> (8.18 </TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"> (3.17 </TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding: 0; text-indent: 0"> Weighted average number
    of common shares outstanding - basic and diluted </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"> 12,332,331 </TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"> 2,429,267 </TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"> 2,166,498 </TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
</TABLE>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> The
accompanying notes are an integral part of these consolidated financial statements. </FONT></P>




<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"></P>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Relmada Therapeutics, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B> (formerly Camp Nine, Inc.) </B> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <A NAME="a_026"></A><B>Consolidated Statement
of Stockholders' Deficit</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B> For the Period From December 31, 2011
to June 30, 2014 </B></P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 5pt; text-indent: -5pt"> &nbsp; </TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> Series
    A Preferred Stock </B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> Class
    A Preferred Stock </B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> Common
    Stock </B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> Additional
    Paid-in </B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"> Accumulated </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 5pt; text-indent: -5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> Shares </B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> Par&nbsp;Value </B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> Shares </B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> Par&nbsp;Value </B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> Shares </B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> Par&nbsp;Value </B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> Capital </B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> Deficit </B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> &nbsp; </B></FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"><B> Total </B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 5pt; text-indent: -5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5pt; text-indent: -5pt; width: 10%"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> Balance
    &ndash; December 31, 2011 </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 1,519,759 </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 1,520 </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 4,409,230 </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> (7,250,721 </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> ) </FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="width: 7%; text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> (2,839,971 </FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> ) </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5pt; text-indent: -5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5pt; text-indent: -5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> Issuance
    of common stock and warrants to a related party </FONT> <BR><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">for
    liabilities</FONT> </TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 255,750 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 256 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 869,019 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 869,275 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5pt; text-indent: -5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> Forgiveness
    of liabilities by founder </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 353,246 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 353,246 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5pt; text-indent: -5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> Issuance
    of Series A preferred stock for conversion of </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">loans and accrued interest</FONT> </TD>
    <TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">1,879,128</FONT> </TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">1,879</FONT> </TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">-</FONT> </TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">-</FONT> </TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">-</FONT> </TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">-</FONT> </TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">1,539,301</FONT> </TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">-</FONT> </TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
    <TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">1,541,180</FONT> </TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT> <BR>
    <FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT> </TD>
</TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5pt; text-indent: -5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> Issuance
    of common stock for cashless exercise of warrants </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 541,430 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 541 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> (541 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> ) </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5pt; text-indent: -5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> Issuance
    of common stock to acquire license at fair value </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 17,089 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 17 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 5,110 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 5,127 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5pt; text-indent: -5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> Issuance
    of Series A preferred stock to Wonpung for services </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 1,725,000 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 1,725 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 1,004,349 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 1,006,074 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5pt; text-indent: -5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> Issuance
    of common stock for fair value of services </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 68,356 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 68 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 20,439 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 20,507 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5pt; text-indent: -5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> Stock-based
    compensation </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 37,335 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 37,335 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5pt; text-indent: -5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> Issuance
    of Series A preferred stock and warrants for cash, net of offering costs </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 4,899,375 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 4,900 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 2,151,038 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 2,155,938 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5pt; text-indent: -5pt; padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> Net
    loss </FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> (6,860,030 </FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> ) </FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> (6,860,030 </FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> ) </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 5pt; text-indent: -5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> Balance -
    December 31, 2012 </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 8,503,503 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 8,504 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 2,402,384 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 2,402 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 10,388,526 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> (14,110,751 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> ) </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> (3,711,319 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> ) </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5pt; text-indent: -5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5pt; text-indent: -5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> Issuance
    of Series A preferred stock and warrants for cash net of offering costs. </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 5,100,625 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 5,100 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 1,479,610 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 1,484,710 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5pt; text-indent: -5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> Issuance
    of common stock to acquire Medeor, Inc. at fair value </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 2,500,000 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 2,500 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 3,747,500 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 3,750,000 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5pt; text-indent: -5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> Issuance
    of common stock for fair value of services </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 56,394 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 57 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 16,861 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 16,918 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5pt; text-indent: -5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> Stock-based
    compensation expense </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 382,343 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 382,343 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5pt; text-indent: -5pt; padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> Net
    loss </FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> (19,871,908 </FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> ) </FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> (19,871,908 </FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> ) </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 5pt; text-indent: -5pt"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> Balance -
    December 31, 2013 </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 13,604,128 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 13,604 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 4,958,778 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 4,959 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> 16,014,840 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> (33,982,659 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> ) </FONT></TD><TD><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> (17,949,256 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> ) </FONT></TD></TR>
</TABLE>




<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal"></P>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"><B> Relmada
Therapeutics, Inc. </B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> (formerly Camp Nine, Inc.) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"><B> Consolidated
Statement of Stockholders' Deficit </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"><B> For
the Period From December 31, 2011 to June 30, 2014 </B></FONT></P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 5pt; text-indent: -5pt; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Series
    A Preferred Stock </B></FONT></TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Class
    A Preferred Stock </B></FONT></TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Common
    Stock </B></FONT></TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Additional
    Paid-in </B></FONT></TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Accumulated </B></FONT></TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 5pt; text-align: center; line-height: 115%; text-indent: -5pt"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Shares </B></FONT></TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Par&nbsp;Value </B></FONT></TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Shares </B></FONT></TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Par&nbsp;Value </B></FONT></TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Shares </B></FONT></TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Par&nbsp;Value </B></FONT></TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Capital </B></FONT></TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Deficit </B></FONT></TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Total </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 10%; padding-left: 5pt; text-indent: -5pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Issuance
    of common stock, Series A warrants and Series B warrants for cash, net of offering cost </FONT> s </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 7%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 7%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 7%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 7%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 7%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 17,163,799 </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="width: 7%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 17,164 </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="width: 7%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 22,212,157 </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 7%; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 7%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 22,229,321 </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5pt; text-indent: -5pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Issuance
    of common stock for services </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 29,052 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 29 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 8,685 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 8,714 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 5pt; text-indent: -5pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Stock-based
    compensation expense </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><P STYLE="margin: 0"> 10,319,137 </P>


</TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><P STYLE="margin: 0"> 10,319,137 </P>


</TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5pt; text-indent: -5pt; line-height: 115%"> Fair value of warrant derivative liabilities issued
    in units offering </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><P STYLE="margin: 0"> (4,333,163 </P>


</TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><P STYLE="margin: 0"> (4,333,163 </P>


</TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> ) </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 5pt; text-indent: -5pt; line-height: 115%"><P STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"> Reclassification
                                                                        of derivative liabilities to APIC upon Share Exchange </P>


</TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 6,804,625 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 6,804,625 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5pt; text-indent: -5pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Conversion
    of Series A preferred stock, notes payable and accrued interest to common stock </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (13,604,128 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (13,604 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 14,805,278 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 14,805 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 959,721 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 960,922 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 5pt; text-indent: -5pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Issuance
    of common stock and Class A preferred stock in connection with share exchange </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 3,337,309 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 3,337 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 3,337,310 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 3,337 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 1,993,326 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 2,000,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5pt; text-indent: -5pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Beneficial
    conversion feature </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 186,727 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>

    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 186,727 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-left: 5pt; text-indent: -5pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Net
    loss </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (21,335,988 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (21,335,988 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> ) </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 5pt; text-indent: -5pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Balance
    &ndash; June 30, 2014 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 3,337,309 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 3,337 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 40,294,217 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 40,294 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 115%"> 54,166,055 </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (55,318,647 </FONT></TD>
    <TD STYLE="line-height: 115%; text-align: left; vertical-align: bottom; padding-bottom: 5px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (1,108,961 </FONT></TD>
    <TD STYLE="line-height: 115%; text-align: left; vertical-align: bottom; padding-bottom: 5px"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> )&nbsp; </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> </FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif"> &nbsp; </FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: normal 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> The
accompanying notes are an integral part of these consolidated financial statements </FONT> . </P>




<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 29.7pt; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: normal 8pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 29.7pt; letter-spacing: normal; word-spacing: normal"></P>

<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 29.7pt; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: normal 8pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 29.7pt; letter-spacing: normal; word-spacing: normal"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"><B> Relmada
Therapeutics, Inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B> (formerly Camp Nine, Inc.) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> <A NAME="a_027"></A><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"><B>Consolidated
Statements of Cash Flows</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> &nbsp;For
    the Six Months Ended </B></FONT></TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> For
    the Year Ended </B></FONT></TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> June&nbsp;30, </B></FONT></TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> December
    31, </B></FONT></TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> 2014 </B></FONT></TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> 2013 </B></FONT></TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> 2012 </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Cash flows from operating activities </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; padding-left: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Net
    loss </B></FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><P STYLE="margin: 0"> (21,335,988 </P>


</TD>
    <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (19,871,908 </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (6,860,030 </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> ) </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Adjustments to
    reconcile net loss to net cash&nbsp;used in operating activities: </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Depreciation expense </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 2,330 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 373 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Common stock issued
    for services </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 8,714 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 3,766,918 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 1,330,849 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Stock-based compensation </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><P STYLE="margin: 0"> 10,319,137 </P>


</TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 382,343 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 37,335 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Amortization of
    debt discount </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 327,776 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 118,639 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> - </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Amortization of
    deferred financing costs </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 78,724 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 69,546 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> - </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; line-height: 115%"> Loss on c<FONT STYLE="font: 10pt Times New Roman, Times, Serif">hange
    in fair value of derivative liabilities</FONT> </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><P STYLE="margin: 0"> 7,954,970 </P>


</TD>
    <TD> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 12,877,675 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 3,688,353 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Changes in operating
    assets and liabilities: </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 30pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Prepaid expenses
    and other assets </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (89,983 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 160,283 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (182,708 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> ) </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 30pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Accounts payable </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 565,779 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (57,102 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 32,299 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 30pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Accrued expenses </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 4,287 </FONT></TD>
    <TD STYLE="line-height: 115%"></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 315,704 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 369,927 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Net cash used in operating activities </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (2,164,254 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (2,237,529 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (1,583,975 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> ) </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Cash flows from investing activities </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Purchase of fixed
    assets </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (3,673 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (8,871 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Net cash used in investing activities </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (3,673 </FONT></TD>
    <TD STYLE="line-height: 115%"> ) </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (8,871 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Cash flows from financing activities </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Proceeds from
    sale of Series A preferred stock and warrants </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 3,494,428 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 3,220,018 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Proceeds from
    sale of common stock and warrants </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 22,229,321 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Proceeds from
    sales of common and Class A Series A preferred stock, pursuant to Share Exchange </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 2,000,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Payment of notes
    payable </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (19,493 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> ) </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (39,990 </FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> )&nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 30pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Proceeds
    from subordinated promissory notes payable, net of financing costs </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 501,600 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 154,900 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Net cash provided by financing
    activities </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 24,209,828 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 3,996,028 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 3,334,928 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Net increase in cash </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 22,041,901 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 1,749,628 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 1,750,953 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Cash at beginning of the period </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 3,522,450 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 1,772,822 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 21,869 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Cash at end of the period </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> $ </B></FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> 25,564,351 </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> $ </B></FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> 3,522,450 </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="border-bottom: black 4.5pt double; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> $ </B></FONT></TD>
    <TD STYLE="border-bottom: black 4.5pt double; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> 1,772,822 </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: normal 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> The
accompanying notes are an integral part of these consolidated financial statements </FONT> <FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">.</FONT> </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal"></P>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; letter-spacing: normal; word-spacing: normal">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> Relmada
Therapeutics, Inc. </B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> (formerly Camp Nine, Inc.) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Consolidated Statements of Cash Flows </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B> &nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> For
    the Six Months Ended June&nbsp;30,&nbsp;&nbsp; </B></FONT></TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> For
    the Year Ended </B></FONT> <BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>December 31,</B></FONT> </TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> 2014 </B></FONT></TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> 2013 </B></FONT></TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: center; line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B> 2012 </B></FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Supplemental disclosure of cash flow
    information: </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Cash paid during
    the period for: </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Income taxes </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 64%; padding-left: 20pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Interest </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 1,103 </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="width: 9%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Non-cash investing and financing transactions: </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-indent: -10pt; line-height: 115%"> Conversion<FONT STYLE="font: 10pt Times New Roman, Times, Serif">
    of Series A Preferred Stock and Subordinated Notes to common stock</FONT> </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 900,000 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-indent: -10pt; line-height: 115%"> Conversion of accrued interest to common stock </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 60,922 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Note
    payable issued in connection with director and officer insurance policy </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 77,850 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-indent: -10pt; line-height: 115%"> Fair value of derivative reclassified to additional
    paid-in-capital in connection with Share Exchange </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> 6,804,625 </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><P STYLE="padding-left: 0; text-indent: -10pt; line-height: 115%; margin-left: 14"> Fair
                                                                          value of warrant derivatives issued with units offering </P>


</TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"> 4,333,163 </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-indent: -10pt; line-height: 115%"> Beneficial conversion feature </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> $ </TD>
    <TD STYLE="text-align: right; line-height: 115%"> 186,727 </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> - </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"> - </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Fair
    value of derivatives issued in connection with issuance of preferred stock </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 1,761,063 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 984,465 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Fair
    value of derivative warrants issued to lenders in </FONT> <BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif">connection with issuance of subordinated promissory notes</FONT> </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 83,363 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 26,325 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Fair
    value of warrants issued in connection with deferred </FONT> <BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif">financing costs</FONT> </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 41,681 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 13,089 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Fair
    value of derivative warrants issued for offering costs in </FONT> <BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif">connection with the issuance of Series A preferred stock</FONT> </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 248,655 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 79,615 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Fair
    value of derivative issued to Wonpung for services </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 299,141 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Exchange
    of loans and accrued interest for common stock </FONT> <BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif">from founder</FONT> </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 1,222,321 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Exchange
    of subordinated notes and accrued interest for </FONT> <BR>
    <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Series A preferred stock</FONT> </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 1,541,180 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> Cashless
    exercise of warrants for common stock </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> - </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 54,143 </FONT></TD>
    <TD STYLE="line-height: 115%"> &nbsp; </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> The
accompanying notes are an integral part of these consolidated financial statements. </FONT></P>




<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal">&nbsp;</P>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal">&nbsp;<FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">&nbsp;</FONT></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B> Relmada Therapeutics, Inc. </B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><B> (formerly Camp Nine, Inc.) </B></P>



<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"> <A NAME="a_028"></A><B>Notes to Consolidated Financial Statements</B> </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> &nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> NOTE 1 &ndash; BUSINESS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Relmada Therapeutics, Inc., formerly Camp Nine, Inc.
(the &ldquo;Company&rdquo;), was formed as a Nevada corporation on May 31, 2012 and began as a manufacturer and retailer
of surfboards and related accessories. The Company is a clinical stage biopharmaceutical company focused on drugs to treat pain.
The Company has a portfolio of four products at different stages of development and an early stage pipeline of an additional three
products. The Company&rsquo;s&rsquo;s approach is expected to reduce overall clinical development risks and potentially deliver
valuable products in areas of high unmet medical needs. The Company&rsquo;s office is located in New York City. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> On May 20, 2014, Relmada Therapeutics, Inc. (&ldquo;Relmada&rdquo;)
completed a Share Exchange with the Company, whereby the Company acquired 94.6% of the issued and outstanding capital stock of
Relmada from the stockholders in exchange (&ldquo;Share Exchange&rdquo;) for the issuance of 28,291,073 shares of common stock
to the Company&rsquo;s stockholders, which represented 80.9% of Relmada&rsquo;s issued and outstanding common stock after the
consummation of the Share Exchange. In addition, the outstanding options and warrants were exchanged for options and warrants
to purchase shares of common stock of the Company at a ratio of 10 to 1. Prior to the Share Exchange, the Company had no other
assets or liabilities. The principal shareholders of the Company contributed $2 million for 3,337,310 shares of the Company&rsquo;s
common stock and 3,337,309 shares of Class A convertible preferred shares. </P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> As a result of the Share Exchange, the stockholders of
the Relmada became the principal stockholders of Relmada. In addition, i<FONT STYLE="background-color: white">n connection with
the Share Exchange, the Company changed its name to Relmada Therapeutics, Inc. and increased its authorized common stock to 500,000,000
shares and its authorized preferred stock to 200,000,000 shares.</FONT> </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The Share Exchange was accounted for as a reverse merger
rather than a business combination, wherein Relmada is considered the acquirer for accounting and financial reporting purposes.
The statement of operations reflects the activities of Relmada from the date of its inception, May 24, 2004. As a result of the
Share Exchange, the Company became the holding company and Relmada became the subsidiary. The operating entity is that of Relmada. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> In addition to the normal risks associated with a new business
venture, there can be no assurance that the Company&rsquo;s research and development will be successfully completed or that any
product will be approved or commercially viable. The Company is subject to risks common to companies in the biotechnology industry
including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new
technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with Food and Drug
Administration (&ldquo;FDA&rdquo;) and other governmental regulations and approval requirements. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> NOTE 2 &ndash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white"><B> Principles of Consolidation </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white"> &nbsp; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white"> The consolidated financial
statements include the Company&rsquo;s accounts and those of the Company&rsquo;s wholly owned subsidiaries. All significant intercompany
accounts and transactions have been eliminated in consolidation. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> &nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> Use of Estimates </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> The preparation of financial statements in conformity with accounting
principles generally accepted in the United States (&ldquo;U.S. GAAP&rdquo;) requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ
from those estimates. The significant estimates are the valuation of derivative liabilities, stock-based compensation expenses
and income taxes and its associated valuation allowance. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> Cash and Cash Equivalents </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> The Company considers cash deposits and all highly liquid investments
with a maturity of three months or less when purchased to be cash equivalents. The Company's cash deposits are held at two high-credit-quality
financial institutions. The Company's cash deposits at these institutions exceed federally insured limits. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> &nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> Patents </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> Costs related to filing and pursuing patent applications are
recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Relmada Therapeutics, Inc. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> (formerly Camp Nine, Inc.) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Notes to Consolidated Financial Statements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B> &nbsp; </B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> NOTE 2 &ndash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> &nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> Fixed Assets </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> Fixed assets are stated at cost less accumulated depreciation.
Fixed assets are comprised of computers and software. Depreciation is calculated using the straight-line method over the estimated
useful life of the related assets, which is three years. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> Derivatives </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> All derivatives are recorded at fair value on the balance sheet.
The Company has determined fair values using market based pricing models incorporating readily observable market data and requiring
judgment and estimates. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> Fair Value of Financial Instruments </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> The Company&rsquo;s financial instruments primarily include
cash, derivative liabilities, accounts payable and subordinated promissory notes. Due to the short-term nature of cash, derivative
liability, accounts payable and promissory notes the carrying amounts of these assets and liabilities approximate their fair value.
Derivatives are recorded at fair value at each period end. Fair value is defined as the price that would be received to sell an
asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date.
The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies
in measuring fair value: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> Level 1 - Quoted prices in active markets for identical assets
or liabilities. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> Level 2 - Valuations for assets and liabilities that can be
obtained from readily available pricing sources via independent providers for market transactions involving similar assets or
liabilities. The Company's principal markets for these securities are the secondary institutional markets, and valuations are
based on observable market data in those markets. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> Level 3 - Valuations for assets and liabilities that are derived
from other valuation methodologies, including option pricing models, discounted cash flow models and similar techniques, and are
not based on market exchange or dealer- or broker-traded transactions. Level 3 valuations incorporate certain assumptions and
projections in determining the fair value assigned to such assets or liabilities. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> Fair Value on a Recurring Basis </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> As required by Accounting Standard Codification (&ldquo;ASC&rdquo;)
Topic No. 820 &ndash; 10 <I>Fair Value Measurement</I>, financial assets and liabilities are classified based on the lowest level
of input that is significant to the fair value measurement. The Company&rsquo;s assessment of the significance of a particular
input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities
and their placement within the fair value hierarchy levels. The estimated fair value of the derivative instruments which include
Series A preferred stock with down-round protection provisions and warrants with down-round protection provisions was calculated
with the assistance of a third party valuation firm, see Note 4. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> The following table sets forth, by level
within the fair value hierarchy, the Company&rsquo;s financial liabilities that were accounted for at fair value on a recurring
basis as of June 30, 2014: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center"> Quoted Prices </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center"> In Active </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center"> Significant </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center"> Total </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center"> Markets for </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center"> Other </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center"> Significant </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center"> Carrying </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center"> Identical </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center"> Observable </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center"> Unobservable </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center"> Value as of </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center"> Assets </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center"> Inputs </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center"> Inputs </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center"> June 30, </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"> Description </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> (Level
    1) </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> (Level
    2) </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> (Level
    3) </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> 2014 </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"> Derivative liabilities
    &ndash; warrant instruments </TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left; border-bottom: Black 4pt double"> $ </TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right; border-bottom: Black 4pt double"> - </TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"> &nbsp; </TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left; border-bottom: Black 4pt double"> $ </TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right; border-bottom: Black 4pt double"> - </TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"> &nbsp; </TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left; border-bottom: Black 4pt double"> $ </TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right; border-bottom: Black 4pt double"> 25,586,933 </TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"> &nbsp; </TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left; border-bottom: Black 4pt double"> $ </TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right; border-bottom: Black 4pt double"> 25,586,933 </TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"> &nbsp; </TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Relmada Therapeutics, Inc. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> (formerly Camp Nine, Inc.) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Notes to Consolidated Financial Statements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> &nbsp;&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> The following table sets forth, by level
within the fair value hierarchy, the Company&rsquo;s financial liabilities that were accounted for at fair value on a recurring
basis as of December 31, 2013: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> Quoted Prices </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> In Active </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> Significant </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> Total </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> Markets for </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> Other </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> Significant </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> Carrying </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> Identical </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> Observable </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> Unobservable </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> Value as of </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> Assets </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> Inputs </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> Inputs </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> December 31, </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid"> Description </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> (Level 1) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> (Level 2) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> (Level 3) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> 2013 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left"> Derivative liabilities &ndash; warrant instruments </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 4,089,284 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 4,089,284 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> Derivative liabilities &ndash; Series A preferred stock </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 16,014,141 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 16,014,141 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt"> Total derivative liabilities </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> - </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> - </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 20,103,425 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 20,103,425 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> The following table sets forth a reconciliation
of changes in the fair value of financial liabilities classified as level 3 in the fair value hierarchy: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B> &nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="10" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> Significant
    Unobservable Inputs (Level 3) </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center"> Six Month <BR> Ended<BR> June 30, </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center"> Year <BR> Ended <BR> December 31, </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"><P STYLE="font-family: Times New Roman, Times, Serif; text-align: center"> Year<BR>
                    Ended<BR>
                    December 31, </P>


</TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> 2014 </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> 2013 </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> 2012 </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-family: Times New Roman, Times, Serif; text-align: left"> Beginning balance </TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"> (20,103,425 </TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"> (5,090,988 </TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> Change in fair value of derivative liabilities
    included in net loss for the six months ended June 30, 2014 and for the years ended&nbsp; December 31, 2013 and 2012, respectively </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0"> (7,954,970 </P>


</TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"> (12,877,675 </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"> (3,688,353 </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> Additions &ndash; warrant instruments </TD><TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (4,333,163 </FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> ) </FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> (37 </FONT> <FONT STYLE="font-size: 10pt">3,699</FONT> </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"> (119,029 </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> Transfer of warrant instruments to additional
    paid in capital </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"> 6,804,625 </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> Additions &ndash; conversion
    feature of Series A preferred stock </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> (1,761,063 </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> (1,283,606 </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"> Ending balance </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"> (25,586,933 </TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"> (20,103,425 </TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"> (5,090,988 </TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> Income Taxes </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> The Company accounts for income taxes using the asset and liability
method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences
between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets
and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary
differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in the tax
rate is recognized in income or expense in the period that the change is effective. Tax benefits are recognized when it is probable
that the deduction will be sustained. A valuation allowance is established when it is more likely than not that all or a portion
of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future deductibility is
uncertain. At June 30, 2014 and December 31, 2013, the Company had recognized a valuation allowance to the full extent of the
Company&rsquo;s net deferred tax assets since the likelihood of realization of the benefit does not meet the more likely than
not threshold. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> &nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> The Company files a U.S. Federal income tax return and various
state returns. Uncertain tax positions taken on our tax returns will be accounted for as liabilities for unrecognized tax benefits.
The Company will recognize interest and penalties, if any, related to unrecognized tax benefits in general and administrative
expenses in the statements of operations. There were no liabilities recorded for uncertain tax positions at June 30, 2014 and
December 31, 2013. The open tax years, subject to potential examination by the applicable taxing authority, for the Company were
from 2010 through 2014. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Relmada Therapeutics, Inc. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> (formerly Camp Nine, Inc.) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Notes to Consolidated Financial Statements </B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> &nbsp; </B> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> Research and Development </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> Research and development costs primarily consist of research
contracts for the advancement of product development, stock-based compensation, and consultants. The Company expenses all research
and development costs in the period incurred. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> Stock-Based Compensation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> The Company measures the cost of employee services received
in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the
period during which an employee is required to provide service in exchange for the award - the requisite service period. The grant-date
fair value of employee share options is estimated using the Black-Scholes option pricing model adjusted for the unique characteristics
of those instruments. Compensation expense for options and warrants granted to non-employees is determined by the fair value of
the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured, and is recognized
over the service period. The expense is subsequently adjusted to fair value at the end of each reporting period until such options
and warrants vest, and the fair value of such instruments, as adjusted, is expensed over the related vesting period. Adjustments
to fair value at each reporting date may result in income or expense, depending upon the estimate of fair value and the amount
of expense recorded prior to the adjustment. The Company reviews its agreements and the future performance obligation with respect
to the unvested options or warrants for its vendors or consultants. When appropriate, the Company will expense the unvested options
or warrants at the time when management deems the service obligation for future services has ceased. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> Net Loss per Common Share </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> Basic net loss per common share attributable to common stockholders
is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding
for the period, without consideration for common stock equivalents. Diluted net loss per common share attributable to common stockholders
is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents
outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of Class
A convertible preferred stock, Series A Preferred Stock, warrants for the purchase of common stock and options. For all periods
presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&rsquo;s
net loss position. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> Potentially dilutive securities are not included in the calculation
of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common
stock equivalent shares): </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> Six Month <BR>
    Ended <BR>June 30, <BR>
    2014 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"> Year </P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"> Ended
                                                                                <BR>December 31, <BR>
                                                                                2013 </P></TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> Year<BR>
    Ended <BR>December 31,<BR>
    2012 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; padding-left: 0pt"> Class A convertible preferred stock </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 3,337,309 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt"> Series A preferred stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 136,041,275 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 8,503,503 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0pt"> Common stock warrants </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 43,144,557 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 89,265,160 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4,.865,235 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"> Common stock options </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 3,365,171 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 18,654,097 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 677,962 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 5.4pt"> Total </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 49,847,037 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 243,960,532 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 14,046,700 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> &nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B> Recent Accounting Pronouncements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> In June 2014, the FASB issued ASU 2014-10, &ldquo;Development
Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest
Entities Guidance in Topic 810, Consolidation&rdquo;. The guidance eliminates the definition of a development stage entity thereby
removing the incremental financial reporting requirements from U.S. GAAP for development stage entities, primarily presentation
of inception to date financial information. The provisions of the amendments are effective for annual reporting periods beginning
after December 15, 2014, and the interim periods therein. However, early adoption is permitted. Accordingly, the Company has adopted
this standard during the six months ending June 30, 2014. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"> The Company does not expect the adoption of
any other recent accounting pronouncements to have a material impact on its financial statements. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B> Subsequent Events </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"> The Company&rsquo;s management reviewed all
material events through the date the financial statements were issued for subsequent event disclosure consideration. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> NOTE 3 &ndash; NOTES PAYABLE </B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Subordinated 8% promissory notes payable
consisted of the following at June 30, 2014 and December 31, 2013: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"> June 30,<BR>
    2014 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: center"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> December 31, <BR>
    2013 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt"> Subordinated 8% promissory notes due
    December 2013 </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 216,000 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"> Subordinated 8% promissory
    notes due September 2014 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 684,000 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0pt"> Total notes payable </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 900,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt"> Less: debt discount </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (141,049 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 4pt; padding-left: 0pt"> Total notes payable, less debt discount </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> - </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 758,951 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Relmada Therapeutics, Inc. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> (formerly Camp Nine, Inc.) </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Notes to Consolidated Financial
Statements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> December 2012 Subordinated Promissory Notes Payable </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> In December 2012, the Company issued $216,000 of subordinated
8% promissory notes payable for cash proceeds of $180,000 which were due on December 6, 2013. In addition, the note holders received
seven-year warrants to purchase 67,500 shares of common stock with an exercise price of $0.80 per share. The Company recorded
the fair value of the warrants as a debt discount on the notes payable which resulted in a debt discount of $26,325. The difference
between the face value and the cash proceeds of $36,000 was also treated as debt discount and was amortized to interest expense
over the one year maturity of the notes. The Company also paid debt issuance costs of $25,100 to the placement agent that were
recorded as deferred financing costs and amortized over the one year maturity of the notes. The effective interest rate was 36.9%.
The Company also issued 33,750 warrants to purchase common stock at $0.80 per share to the placement agent which the Company recorded
as a discount on the notes at the fair value of $13,089. All of the debt discount of $62,325 and deferred financing costs of $38,189
were fully amortized and recorded as interest expense during 2013 for these notes. These notes and accrued interest of approximately
$960,900 were converted to 1,201,153 common stock upon the Share Exchange on May 20, 2014. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The notes and accrued interest were automatically converted
into common stock at $0.80 per share upon the Share Exchange on May 20, 2014. The warrants contained an anti-dilution provision
if the Company raises equity in the future at a price lower than $0.80 per share, the warrants to purchase common stock and the
notes payable conversion price will be adjusted for the anti-dilutive effects of such future issuance. As a result, the warrants
issued with the debt are accounted for as derivative liabilities and recorded at fair value at each period end. The anti-dilution
feature was eliminated upon the Share Exchange. The Company recorded the fair market value of the derivative financial instrument
at the date of the Share Exchange on May 20, 2014. </P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> September 2013 Subordinated Promissory Notes Payable </B></P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> In September 2013, the Company issued $684,000 of subordinated
8% promissory notes payable for cash proceeds of $570,000 which are due in September 2014. In addition, the note holders received
seven-year warrants to purchase 213,750 shares of common stock with an exercise price of $0.80 per share. The Company recorded
the fair value of the warrants as a debt discount on the notes payable which resulted in a debt discount of $83,363. The difference
between the face value and the cash proceeds of $114,000 was also treated as debt discount and is amortized to interest expense
over the one year maturity of the notes. The Company also paid debt issuance costs of $68,400 to the placement agent that were
recorded as deferred financing costs and are amortized over its one year maturity of the notes. The effective interest rate was
36.9%. The Company also issued 106,875 warrants to purchase common stock at $0.80 per share to the placement agent which the Company
recorded as a discount on the notes at the fair value of $41,681. The Company has amortized debt discount for deferred financing
costs of $219,773 and $31,357 to interest expense for these notes during the six months ended June 30, 2014 and for the year ended
December 31, 2013, respectively. </P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The Company determined that there was a beneficial conversion
feature on the September 2013 notes payable at the issuance date of approximately $186,800 which represented the difference between
the effective conversion price of $0.60 per share and the fair value of the common stock as of the commitment date of $0.80 per
share. The beneficial conversion feature was recorded as interest expense upon the Share Exchange. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The notes and accrued interest of approximately $960,900
were automatically converted into 1,201,153 shares of common stock at $0.80 per share upon the Share Exchange on May 20, 2014.
The warrants contained an anti-dilution feature if the Company raises equity in the future at a price lower than $0.80 per share,
the warrants to purchase common stock and the notes payable conversion price will be adjusted for the anti-dilutive effects of
such future issuance. As a result, the warrants issued with the debt are accounted for as derivative liabilities and recorded
at fair value at balance sheet date. The anti-dilution feature was terminated upon the Share Exchange. The Company recorded the
fair market value of the derivative financial instrument at the date of the Share Exchange on May 20, 2014. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white"> In May 6, 2014,
the Company entered into a finance agreement for $77,850 for its director and officer liability insurance policy. The Company
paid its initial down payment of approximately $6,800 and has eleven monthly installments of approximately $6,60. The interest
rate is 3.436% per annum. At June 30, 2014, the Company owed $58,357 in co </FONT> nnection with this note payable. </P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Relmada Therapeutics, Inc. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> (formerly Camp Nine, Inc.) </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Notes to Consolidated Financial
Statements </B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> &nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> NOTE 4 &ndash; DERIVATIVE LIABILITIES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> &nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"> ASC Topic No. 815 &ndash; <I>Derivatives and
Hedging</I> provides guidance on determining what types of instruments or embedded features in an instrument issued by a reporting
entity can be considered indexed to its own stock for the purpose of evaluating the first criteria of the scope exception in the
pronouncement on accounting for derivatives. These requirements can affect the accounting for warrants and convertible preferred
instruments issued by the Company. As the conversion features within the Series A preferred stock, and certain detachable warrants
issued in connection with the subordinated promissory notes payable and equity offerings in 2012 and 2013, do not have fixed settlement
provisions because their conversion and exercise prices may be lowered if the Company issues securities at lower prices in the
future, the Company concluded that the instruments are not indexed to the Company&rsquo;s stock and are to be treated as derivative
liabilities. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"> The Company obtained valuations prepared by
Vantage Point Advisors, Inc. for purposes of determining the fair value of the derivatives and stock compensation expense. In
determining the fair value of the derivatives, the Company used the Monte Carlo Simulations using Geometric Brownian method for
the initial valuation and then the Black-Scholes option pricing model was used for the valuation at June 30, 2014. </P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"> The
following is a summary of the assumptions used in the valuation model as of the initial valuations of the derivative warrant instruments
issued during the six months ended June 30, 2014: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> Initial </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> At </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> valuation </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> June 30 </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> 2014 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> 2014 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; text-align: left"> Common stock issuable upon exercise of warrants &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 11%; text-align: right"> 30,036,648 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 11%; text-align: right"> 30,036,648 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Market value of common stock on measurement date (1) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.17 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 2.00 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Exercise price </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 1.50
                                       and 2.25 </FONT></TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 1.50
                                       and 2.25 </FONT></TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Risk free interest rate (2) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1.7 </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1.6 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Expected life in years </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp;0.3
                                            and 5 </FONT></TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 0.3
                                            and 4.9 </FONT></TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Expected volatility (3) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp;71
                                            and 73 </FONT></TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp;&nbsp;71
                                            and 73&nbsp; </FONT></TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Expected dividend yields (4) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> None </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> None </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 5.4pt; padding-left: 0pt"> (1) </TD>
    <TD STYLE="width: 96%; padding-right: 5.4pt; padding-left: 0pt"> The market value is the calculated fair value of the common
    stock pursuant to the valuation technique as described above. </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"> (2) </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"> The risk-free interest rate was determined by management using the
    1<FONT STYLE="font: 10pt Times New Roman, Times, Serif"> and 5 - year Treasury Bill as of the measurement date.</FONT> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"> (3) </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"> The historical trading volatility was determined by calculating the
    volatility of the Company&rsquo;s peer group. </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Relmada Therapeutics, Inc. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> (formerly Camp Nine, Inc.) </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Notes to Consolidated Financial
Statements </B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> The following is a summary of the assumptions used in the valuation
model as of the initial valuations of the derivative warrant instruments and convertible Series A preferred stock issued during
the years ended December 31, 2013 and December 31, 2012, respectively, and as of December 31, 2013, and December 31, 2012, respectively: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp;&nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> Initial </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> Initial </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> At </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> At </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> valuations </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> valuations </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> December&nbsp;31, </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> December&nbsp;31, </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> 2013 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> 2012 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> 2013 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> 2012 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left"> Common stock issuable upon exercise of warrants </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 22,333,593 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 19,385,157 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 41,718,750 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 19,385,157 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -5.5pt; padding-left: 5.5pt"> Common stock issuable upon conversion of Series
    A preferred stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 51,006,250 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 85,035,025 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 136,041,275 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 85,035,025 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -5.5pt; padding-left: 5.5pt"> Market value of common stock on measurement date
    (1) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.30 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.50 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> Exercise price </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Risk free interest rate (2) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0.19 </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0.20 </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0.38 </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0.19 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Expected life in years </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1.4 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1.6 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2.0 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1.4 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Expected volatility (3) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 68 </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 72 </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 68 </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 73 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Expected dividend yields (4) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> None </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> None </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> None </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> None </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> &nbsp; </B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; padding-right: 5.4pt; padding-left: 0pt"> (1) </TD>
    <TD STYLE="width: 96%; padding-right: 5.4pt; padding-left: 5.4pt"> The market value is the calculated fair value of the
    common stock pursuant to the valuation technique as described above. </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"> (2) </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"> The risk-free interest rate was determined by management using the
    1, 2 or 3 - year Treasury Bill as of the measurement date. </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 0pt"> (3) </TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"> The historical trading volatility was determined by calculating the
    volatility of the Company&rsquo;s peer group. </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Change in fair value of derivative liabilities
during the six months ended June 30, 2014 was as follows:&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>


<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: normal; font-style: normal; text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> Balance
    at December&nbsp;31, </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: normal; font-style: normal; text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> Initial
    valuation of derivative </FONT> <BR>
    <FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">liabilities upon</FONT> <BR>
    <FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">issuance of new warrants during </FONT> <BR>
    <FONT STYLE="font: normal 10pt Times New Roman, Times, Serif">the</FONT> </TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: normal; font-style: normal; text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> Increase
    (decrease) in fair value of derivative </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: normal; font-style: normal; text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> Fair
    value of </FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"> derivatives<FONT STYLE="font-weight: normal; font-style: normal; font-variant: normal">
    </FONT></FONT> <BR><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> upon reclass to additional paid-in</FONT> </TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: normal; font-style: normal; text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> Balance
    at </FONT> <BR><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> June 30,</FONT> </TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: center; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: normal; font-style: normal; text-align: center; border-bottom: Black 1.5pt solid; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> 2013 </FONT></TD><TD STYLE="padding: 0; font-weight: normal; font-style: normal; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: normal; font-style: normal; text-align: center; border-bottom: Black 1.5pt solid; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> period </FONT></TD><TD STYLE="padding: 0; font-weight: normal; font-style: normal; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: normal; font-style: normal; text-align: center; border-bottom: Black 1.5pt solid; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> liabilities </FONT></TD><TD STYLE="padding: 0; font-weight: normal; font-style: normal; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: normal; font-style: normal; text-align: center; border-bottom: Black 1.5pt solid; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> capital </FONT></TD><TD STYLE="padding: 0; font-weight: normal; font-style: normal; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: normal; font-style: normal; text-align: center; border-bottom: Black 1.5pt solid; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> 2014 </FONT></TD><TD STYLE="padding: 0; font-weight: normal; font-style: normal; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; font-style: normal; padding: 0 0 0 10; text-indent: -10"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> Convertible
    preferred derivative liability issued in&nbsp;connection with Series A preferred stock offering </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> 11,762,115 </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> (7,214,804 </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> )&nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> (4,547,311 </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> )&nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> $ </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; font-weight: normal; font-style: normal; text-align: left; text-indent: -10; padding: 0 0 0 10"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> Convertible
    preferred derivative liability issued to Wonpung for services </FONT></TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="width: 9%; font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> 2,030,589 </FONT></TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="width: 9%; font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> -&nbsp; </FONT></TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="width: 9%; font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> (1,370,262 </FONT></TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> ) </FONT></TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="width: 9%; font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> (660,327 </FONT></TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> ) </FONT></TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="width: 9%; font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; text-indent: -10; padding: 0 0 0 10"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> Convertible
    preferred derivative liability issued to lenders in connection with exchange of debt for Series A preferred stock </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> 2,219,854 </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> (1,262,858 </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> ) </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> (956,996 </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> ) </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; text-indent: -10; padding: 0 0 0 10"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> Warrants
    issued in connection with Series A preferred stock offering </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> 2,424,167 </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> (1,945,669 </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> ) </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> (478,498 </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> ) </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; text-indent: -10; padding: 0 0 0 10"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> Warrants
    issued as offering costs to placement agent </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> 1,217,083 </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> (1,109,421 </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> ) </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> (107,662 </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> ) </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; text-indent: -10; padding: 0 0 0 10"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> Warrants
    issued to lenders in connection with subordinated promissory notes offering </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> 313,258 </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> (259,427 </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> ) </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> (53,831 </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> ) </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; text-indent: -10; padding: 0 0 0 10"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> Warrants
    issued to placement agent in connection with subordinated promissory notes offering </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> 136,359 </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> (136,359 </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> ) </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; text-indent: -10; padding: 0 0 0 10"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> Series
    A warrants issued in May and June 2014 offering </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> 842,370 </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> 9,198,452 </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> 10,040,822 </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; text-indent: -10; padding: 0 0 0 10"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> Series
    B warrants issued in connection with May and June 2014 offering </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> 2,494,655 </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> 7,400,275 </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> 9,894,930 </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; text-indent: -10; padding: 0 0 0 10"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> Placement
    Agent warrants issued in connection with May and June 2014 offering </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0; font-weight: normal; font-style: normal; text-align: right; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="padding: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0; font-weight: normal; font-style: normal; text-align: right; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> 996,138 </FONT></TD><TD STYLE="padding: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0; font-weight: normal; font-style: normal; text-align: right; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> 4,655,043 </FONT></TD><TD STYLE="padding: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0; font-weight: normal; font-style: normal; text-align: right; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> - </FONT></TD><TD STYLE="padding: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; padding: 0; font-weight: normal; font-style: normal; text-align: right; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> 5,651,181 </FONT></TD><TD STYLE="padding: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> Total </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="border-bottom: Black 4pt double; padding: 0; font-weight: normal; font-style: normal; text-align: right; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> 20,103,425 </FONT></TD><TD STYLE="padding: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="border-bottom: Black 4pt double; padding: 0; font-weight: normal; font-style: normal; text-align: right; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> 4,333,163 </FONT></TD><TD STYLE="padding: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="border-bottom: Black 4pt double; padding: 0; font-weight: normal; font-style: normal; text-align: right; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> 7,954,970 </FONT></TD><TD STYLE="padding: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="border-bottom: Black 4pt double; padding: 0; font-weight: normal; font-style: normal; text-align: right; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> (6,804,625 </FONT></TD><TD STYLE="padding: 0 0 4px; font-weight: normal; font-style: normal; text-align: left; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> ) </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding: 0; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; padding: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> $ </FONT></TD><TD STYLE="border-bottom: Black 4pt double; padding: 0; font-weight: normal; font-style: normal; text-align: right; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> 25,586,933 </FONT></TD><TD STYLE="padding: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></TD></TR>
</TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Relmada Therapeutics, Inc. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> (formerly Camp Nine, Inc.) </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Notes to Consolidated Financial
Statements </B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> Change in fair value of derivative liability
during the year ended December 31, 2013 was as follows: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> Initial valuation </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> of derivative </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> liabilities upon </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"></TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> Balance at </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> issuance of new derivatives </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> Increase in fair value of </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> Balance at </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> December 31, </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> during </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> derivative </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> December 31, </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> 2012 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> the period </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> liabilities </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> 2013 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 52%; text-align: left; text-indent: -9.05pt; padding-left: 9.05pt"> Convertible preferred derivative liability
    issued in connection with Series A preferred stock offering </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 2,492,166 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 1,647,910 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 7,622,039 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 11,762,115 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt"> Convertible preferred derivative liability issued
    to Wonpung for services </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 880,214 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,150,375 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,030,589 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt"> Convertible preferred derivative liability issued
    to lenders in connection with exchange of debt for Series A preferred stock </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 958,861 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,260,993 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,219,854 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt"> Warrants issued in connection with Series A preferred
    stock offering </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 475,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 113,153 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,836,014 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,424,167 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9.05pt"> Warrants issued as offering costs to placement agent </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 242,500 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 248,655 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 725,928 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,217,083 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt"> Warrants issued to lenders in connection with
    subordinated promissory notes offering </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 29,158 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 83,363 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 200,737 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 313,258 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -9.05pt; padding-left: 9.05pt"> Warrants issued to placement
    agent in connection with subordinated promissory notes offering </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 13,089 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 41,681 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 81,589 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 136,359 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt"> Total </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 5,090,988 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 2,134,762 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 12,877,675 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 20,103,425 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.2in; text-indent: -0.2in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.2in; text-indent: -0.2in"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.2in; text-indent: -0.2in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"> Change in fair value of derivative
liability during the year ended December 31, 2012 was as follows: </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> Initial valuation </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> of derivative </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> liabilities upon </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> Balance at </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> liabilities upon issuance of new <BR>derivatives </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> Increase&nbsp;in fair value of </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> Balance at </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> December 31, </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> during </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> derivative </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> December 31, </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: normal; font-style: normal; text-align: center; border-bottom: Black 1.5pt solid"> 2011 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; font-style: normal"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: normal; font-style: normal; text-align: center; border-bottom: Black 1.5pt solid"> the
    period </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; font-style: normal"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: normal; font-style: normal; text-align: center; border-bottom: Black 1.5pt solid"> liabilities </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; font-style: normal"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: normal; font-style: normal; text-align: center; border-bottom: Black 1.5pt solid"> 2012 </TD><TD STYLE="padding-bottom: 1.5pt; font-weight: normal; font-style: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; font-weight: normal; font-style: normal; text-align: left; text-indent: -9.05pt; padding-left: 9.05pt"> Convertible
    preferred derivative liability issued in connection with Series A preferred stock offering </TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left"> $ </TD><TD STYLE="width: 9%; font-weight: normal; font-style: normal; text-align: right"> - </TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left"> $ </TD><TD STYLE="width: 9%; font-weight: normal; font-style: normal; text-align: right"> 872,688 </TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left"> $ </TD><TD STYLE="width: 9%; font-weight: normal; font-style: normal; text-align: right"> 1,619,478 </TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left"> $ </TD><TD STYLE="width: 9%; font-weight: normal; font-style: normal; text-align: right"> 2,492,166 </TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; text-indent: -9.05pt; padding-left: 9.05pt"> Convertible
    preferred derivative liability issued to Wonpung for services </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right"> 299,141 </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right"> 581,073 </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right"> 880,214 </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; text-indent: -9.05pt; padding-left: 9.05pt"> Convertible
    preferred derivative liability issued to lenders in connection with exchange of debt for Series A preferred stock </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right"> - </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right"> 958,861 </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right"> 958,861 </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; text-indent: -9.05pt; padding-left: 9.05pt"> Warrants
    issued in connection with Series A preferred stock offering </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right"> - </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right"> 111,777 </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right"> 363,223 </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right"> 475,000 </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; text-indent: -9.05pt; padding-left: 9.05pt"> Warrants
    issued as offering costs to placement agent </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right"> 79,615 </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right"> 162,885 </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right"> 242,500 </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; text-indent: -9.05pt; padding-left: 9.05pt"> Warrants
    issued to lenders in connection with subordinated promissory notes offering </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right"> - </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right"> 26,325 </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right"> 2,833 </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right"> 29,158 </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt; text-indent: -9.05pt; padding-left: 9.05pt"> Warrants
    issued to placement agent in connection with subordinated promissory notes offering </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 13,089 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> - </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 13,089 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> - </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 1,402,635 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 3,688,353 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 5,090,988 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B> Relmada
Therapeutics, Inc. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> (formerly Camp Nine, Inc.) </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Notes to Consolidated Financial
Statements </B></P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><B> NOTE 5 &ndash; STOCKHOLDERS&rsquo;
EQUITY </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><B> Class A Convertible Preferred Stock (&ldquo;Class
A Stock&rdquo;) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0"> On May 20, 2014, Relmada Therapeutics, Inc. (&ldquo;Relmada&rdquo;)
completed a Share Exchange with the Company, whereby the Company acquired 94.6% of the issued and outstanding capital stock of
Relmada from the stockholders in exchange (&ldquo;Share Exchange&rdquo;) for the issuance of 28,291,073 shares of common stock
to the Company&rsquo;s stockholders, which represented 80.9% of Relmada&rsquo;s issued and outstanding common stock after the
consummation of the Share Exchange. In addition, the outstanding options and warrants were exchanged for options and warrants
to purchase shares of common stock of the Company at a ratio of 10 to 1. Prior to the Share Exchange, the Company had no other
assets or liabilities. The principal shareholders of the Company contributed $2 million for 3,337,310 shares of the Company&rsquo;s
common stock and 3,337,309 shares of Class A preferred convertible shares. </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> The Class A Stock shall has dividend rights to two times the
amount of any dividend granted by the Board of Directors of the Company to the holders of common stock. In the event of any dissolution,
liquidation or winding up of the Company, whether voluntary or involuntary, the holders of Class A Stock shall be entitled to
participate in any distribution out of the assets of the Corporation on an equal basis per share with the holders of the Company&rsquo;s
common stock. The holders of Class A Stock shall have no right to vote on any matter submitted to a vote of the holders of the
Company&rsquo;s common stock, including the election of directors. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> The Class A Stock is automatically converted on a monthly basis
into common stock on a one for one basis by action of the Corporation, in the event the total of all shares of common stock and
Class A Stock held by the shareholder do not exceed 9.9% of the issued and outstanding shares of common stock of the company.
In no event, can Class A Stock be converted into common stock of the Corporation if such conversion would cause the holder to
own, beneficially or otherwise, more than 9.9% of the Company&rsquo;s stock. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> Series A Preferred Stock </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Each share of Series A preferred stock automatically
converted into common stock on a one for one basis upon the Share Exchange. There were 1,360,413 shares that were converted to
common stock. In addition, the conversion price was subject to adjustment upon a future down round if any future stock offerings
are issued below $0.80 per share. This anti-dilution feature for the Series A preferred stock and for the warrants, made these
instruments a derivative liability. The anti-dilution feature was terminated upon the Share Exchange. The dividend rate was seven
percent (7%) per annum on the amount paid for each Unit of the Series A preferred stock on an &ldquo;as declared&rdquo; basis.
The Board of Directors has not declared any dividends on these shares. Each Series A preferred share had a liquidation value equal
to the subscription price of each Series A preferred share plus any accrued and unpaid dividends. The liquidation preference of
the Series A preferred stock at December 31, 2013 was approximately $10,883,300. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> In April 2012, the Company exchanged an aggregate of 1,879,128
shares of Series A preferred stock to convert the outstanding notes from the years 2004 and 2005 totaling $975,000 from lenders
and accrued interest of approximately $566,180. In addition, the Company provided the lenders with 619,377 warrants to purchase
common stock at $0.80 per share, and also allowed the lenders to exercise the warrants on a cashless basis for 541,430 shares
of common stock. During 2012, the lenders exercised the warrants on a cashless basis resulting in the issuance of 541,430 shares
of common stock. The Company determined that the fair value of the debt and accrued interest was more reliably determined than
the fair value of the Series A preferred stock and warrants provided to the lenders and, accordingly, recorded no gain or loss
on the exchange. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> In April 2012, the Company issued 1,725,000 Series A
preferred stock to Wonpung in exchange for services. The Company recorded compensation expense of approximately $1,305,200 based
on the fair value of the Series A preferred stock at the issuance date, and recorded as additional paid-in capital for approximately
$1,006,100 and a derivative liability for approximately $299,100. The Company recorded the fair value of the shares issued as
stock-based compensation expense of $1,305,200, which was recorded as equity for approximately $1,006,100 and derivative liability
for approximately $299,100. The fair value of the shares was determined via a third party valuation, see Note 4. In addition,
because the shares contained certain anti-dilution protection, the conversion feature of the preferred stock was accounted for
as a derivative liability. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Relmada Therapeutics, Inc. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> (formerly Camp Nine, Inc.) </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Notes to Consolidated Financial
Statements </B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> During 2012, in a series of closings, the Company issued
investors 4,899,375 shares of Series A preferred stock and 1,224,844 warrants to purchase shares of common stock with an exercise
price of $0.80 per share for gross proceeds of approximately $3,919,500 ($3,220,018 net of offering costs). In addition, the Company
issued the placement agent 612,422 warrants to purchase common stock with an exercise price of $0.80 per share. Both the warrants
and the Series A preferred stock contain anti-dilution features deemed to be derivatives. The anti-dilution provision was eliminated
upon the Share Exchange. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> The table below reflects the gross proceeds received in connection
with the 2012 offerings allocated to components of stockholders&rsquo; equity and to derivative liabilities based upon fair value: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left; padding-left: 0pt"> Par value of Series A preferred stock issued </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 4,898 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0pt"> Additional paid-in-capital </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 2,151,040 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0pt"> Derivative warrant liabilities </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 111,777 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt"> Derivative preferred stock conversion feature </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 872,688 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0pt; padding-bottom: 1.5pt"> Derivative&nbsp;&nbsp;Warrants issued to placement
    agent as offering costs </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid"> &nbsp; </TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid"> 79,615 </TD><TD STYLE="text-align: left; padding-bottom: 1.5pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt"> Net proceeds </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 3,220,018 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"> Offering costs paid in cash </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 699,482 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; padding-left: 0pt"> Gross proceeds </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 3,919,500 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> During 2013, in a series of closings, the Company issued
investors 5,100,625 shares of Series A preferred stock and 1,275,156 warrants to purchase shares of common stock for proceeds
of approximately $4,080,500 ($3,494,428 net of offering costs). The Company also issued the investors 1,275,156 warrants to purchase
common stock with an exercise price of $0.80 per share. In addition, the Company issued the placement agent 637,578 warrants to
purchase common stock with an exercise price of $0.80 per share. Both the warrants and the Series A preferred stock contain an
anti-dilution features deemed to be derivatives, see Note 4. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The table below reflects the gross proceeds received
in connection with the 2013 offerings allocated to components of stockholders&rsquo; equity and to derivative liabilities based
upon fair value: </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left; padding-left: 0pt"> Par value of Series A preferred stock issued </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"><P STYLE="margin: 0"> 5,100 </P>


</TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0pt"> Additional paid-in-capital </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"><P STYLE="margin: 0"> 1,479,610 </P>


</TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0pt"> Derivative warrant liabilities </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 113,153 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt"> Derivative preferred stock conversion feature </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,647,910 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0pt; padding-bottom: 1.5pt"> Derivative Warrants issued to placement agent as
    offering costs </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid"> &nbsp; </TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid"> 248,655 </TD><TD STYLE="text-align: left; padding-bottom: 1.5pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt"> Net proceeds </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 3,494,428 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"> Offering costs paid in cash </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 586,072 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; padding-left: 0pt"> Gross proceeds </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 4,080,500 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> Common Stock </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U> Common stock issued in connection with settlement agreements </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> In April 2012, the Company issued 255,750 shares of common
stock and warrants to purchase 868,213 shares of common stock with an exercise price of $0.80 per share that expire in April 2019
to exchange the outstanding liabilities owed to the founder of approximately $869,300. In addition, the founder forgave excess
liabilities of approximately $353,246 and the Company recorded this as a contribution of additional paid-in-capital. On January
29, 2014, the Company cancelled the aforementioned warrants to the founder for failure to perform his fiduciary duties to the
Company, see Note 8. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I> &nbsp; </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U> Common stock issued for services </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> During 2012, an executive was granted 153,802 shares of common
stock. The grant date fair value of the common stock was $0.30 per share (based on a third party valuation), or approximately
$46,100 in total. The vesting schedule provided that approximately 68,350 shares vested on July 10, 2012, 56,390 shares vested
on July 10, 2013 and 29,052 shares vested on January 10, 2014. As a result, the Company recorded stock-based compensation expense
of approximately $8,700, $16,900 and $20,500 for the six months ended June 30, 2014 and for the years ended December 31, 2013
and 2012, respectively, in connection with this agreement.&nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B> Relmada Therapeutics,
Inc. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> (formerly Camp Nine, Inc.) </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Notes to Consolidated Financial
Statements </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"> &nbsp; </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U> Common stock issued for cash </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> On May 12, May 15 and June 10, 2014, the Company completed
on a private placement for the sale of units for gross proceeds of $25,745,699. The units consist of 17,163,799 shares of the
Company&rsquo;s common stock, Series A warrants to purchase 17,163,799 shares of common stock at an exercise price of $1.50 per
share and Series B warrants to purchase 8,581,894 shares of common stock, at a exercise price of $2.25 per share. The Series A
Warrants are exercisable immediately through October 10, 2014 and the Series B Warrants are exercisable immediately up to a period
of five years from the date of issuance. The Company may call the Series B warrant for redemption upon written notice to all investors
of the May and June 2014 units &nbsp;(&ldquo;investors&rdquo;) at any time if the closing price of the common stock exceeds $3.75
per share for twenty (20) consecutive trading days provided that there an effective registration statement.&nbsp;In sixty days
(60) business days following the date the redemption notice &ldquo;Exercise Period&rdquo; that is sent to the investors, each
may choose to exercise their Series B warrant or a portion of their Series B warrant, by paying the exercise price of $2.25 per
share. <FONT STYLE="color: #1F497D">&nbsp;</FONT>Any warrants not exercised on the last day of the Exercise Period, will be redeemed
by the Company at $0.001 per share.&nbsp; <FONT STYLE="color: #1F497D">T</FONT>he Placement Agent shall receive a warrant solicitation
fee equal to five (5) % of the aggregate exercise price paid by the Series B holders upon such exercise, following a call for
redemption by the Company. &nbsp;The Company shall direct the Series B holder to make such solicitation fee payment directly to
the Placement Agent and the Series B warrant holder shall comply with such direction. <FONT STYLE="background-color: white">The
Company issued warrants to purchase 4,290,950 shares of common stock at $1.50 to its Placement Agent (&ldquo;Agent Warrants&rdquo;).
The Agent Warrants are immediately exercisable and expire five years from the date of issuance. The Company paid approximately
$3,516,000 including expenses to the Placement Agent and the net proceeds were approximately $22,229,300. </FONT>All the warrants
in this transaction have an anti-dilution provision and shall terminate upon an up-listing of the Company to a national securities
exchange such as NYSE or NASDAQ. <FONT STYLE="background-color: white">A registration rights agreement was entered into in connection
with the private placement that required the Company to file a registration statement for the resale of shares of common stock
and common stock issuable upon the exercise of the Series A and Series B warrants. The Company was required to use commercially
reasonable efforts to have the registration statement declared effective within 45 days from the filing date. If the SEC reviews
the registration statement, the Company has 180 days to have the registration statement declared effective. If the registration
statement is not filed on time or declared effective within the pre-requisite time frame, the penalty is one percent (1%) up to
the purchase price with a maximum penalty of six percent (6%).</FONT> </P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white"> &nbsp; </FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> The table below reflects the gross proceeds received in connection
with the May and June 2014 offerings allocated to components of stockholders&rsquo; equity and to derivative liabilities based
upon fair value: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; font-family: Times New Roman, Times, Serif"> Par value of common stock issued </TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"> 17,164 </TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif"> Additional paid-in-capital </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"> 17,878,994 </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> Derivative warrant liabilities </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"> 3,337,025 </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> Derivative warrants issued
    to placement agent as offering costs </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1.5pt solid"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1.5pt solid"> 996,138 </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> Net proceeds </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"> 22,222,321 </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> Offering costs paid in cash </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1.5pt solid"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1.5pt solid"> 3,516,378 </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"> Gross proceeds </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"> 25,745,699 </TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U> Common stock issued in connection with exercise of warrants </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> In April 2012, two lenders exercised their 618,766 warrants
on a cashless basis and received 541,293 shares of common stock of the Company. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U> Common stock issued for acquisition of Medeor </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> In April 2012, the Company issued 17,089 shares of common
stock to Medeor Inc. (&ldquo;Medeor&rdquo;) in connection with the acquisition of a license agreement. Management determined the
fair value of the common stock to be $0.30 per share based on a third party valuation, and recorded stock-based compensation expense
to research and development of approximately $5,100. At December 31, 2013, the Company issued 25,000,000 shares of common stock
in exchange for all the outstanding stock of Medeor whose only asset was a pending research and development project. The transaction
was valued at its fair value of $3,750,000 and was expensed to research and development expense. The fair value of the shares
was determined via a third party valuation. </P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> &nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> Options and warrants </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> The Company has established the 2012 Stock Option Plan (the
&ldquo;Plan&rdquo;), which allows for the granting of common stock awards, stock appreciation rights, and incentive and nonqualified
stock options to purchase shares of the Company&rsquo;s common stock to designated employees, nonemployee directors, and consultants
and advisors. The Plan allowed for 2,409,436 options to be granted in July 2012. On March 10, 2014, the Board of Directors increased
the shares under the Plan to 4,000,000. The shareholders approved to increase the shares available under the plan to 8,058,844.
At June 30, 2014, no stock appreciation rights have been issued. Stock options are exercisable generally for a period of 10 years
from the date of grant and generally vest over four years. As of June 30, 2014, 4,693,673 shares were available for future grants
under the Plan. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> The Company utilizes the Black-Scholes option pricing model
to estimate the fair value of stock options and warrants. The current price of common stock was determined from a third party
valuation, see Note 4. The risk-free interest rate assumptions were based upon the observed interest rates appropriate for the
expected term of the equity instruments. The expected dividend yield was assumed to be zero as the Company has not paid any dividends
since its inception and does not anticipate paying dividends in the foreseeable future. The expected volatility was based upon
its peer group. The Company routinely reviews its calculation of volatility changes in future volatility, the Company&rsquo;s
life cycle, its peer group, and other factors. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> The Company uses the simplified method for share-based compensation
to estimate the expected term for employee option awards for share-based compensation in its option-pricing model. The Company
uses the contractual term for non-employee options to estimate the expected term, for share-based compensation in its option-pricing
model. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B> Relmada Therapeutics,
Inc. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> (formerly Camp Nine, Inc.) </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Notes to Consolidated Financial
Statements </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Stock-based compensation &ndash; options </B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"> The
Company granted an officer options to purchase 677,962 and 665,750 shares of its common stock in July 2012 and September 2013,
respectively. Each of the options granted have a ten-year term and at an $0.80 exercise price. 25% of each of the options vest
immediately and the remaining 75% of the options vest in equal quarterly increments over a four-year period. The fair value of
the options as of the grant dates was $103,700 and $359,100, respectively. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> During November 2013, the Company granted a consultant
options to purchase 187,500 shares of common stock. The options have a 10 year term and an $0.80 exercise price. 25% of the options
vest on the one year anniversary of the grant date and the remaining options vest in equal quarterly increments over the following
3 years. The fair value of the options on the grant date was $114,800. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> During December 2013 and January 2014, the Company granted an
officer options to purchase 334,199 and 1,003,774 shares of common stock, respectively. The options have a 10 year term and an
exercise price of $0.80 and $1.50 per share, respectively. 25% of the options vest on the one anniversary of the grant date and
the remaining options vest quarterly over the following 3 years. The fair value of the options on the grant date during December
2013 and January 2014 was $181,400 and $937,600, respectively. </P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> During February 2014, the Company granted to three of
its board of directors, an aggregate of options to purchase 145,986 shares of common stock, respectively. Each option has a 10
year term and an exercise price of $1.50 per share, respectively. 25% of the options vest on the one year anniversary of the grant
date and the remaining options vest quarterly over the following 3 years. The fair value of the options on the grant date was
approximately $136,200. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> During May 2014, the Company granted to its various employees,
options to purchase 350,000 shares of common stock, respectively. Each option has a 10 year term and an exercise price of $1.50
per share, respectively. 25% of the options vest on the one year anniversary of the grant date and the remaining options vest
quarterly over the following 3 years. The fair value of the options on the grant date was $250,200. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> In May 2014, the Board of Directors granted options to
three officers options based upon a percentage of the fully diluted shares that exist after the exercise or forfeiture of the
Series A warrants in October 2014. The Company will record stock-based compensation expense at fair value when the options are
issued. The option price has been established at fair market value. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> A summary of the changes in options outstanding during the six
months ended June 30, 2014 and years ended December 31, 2013 and 2012 is as follows: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> Number of<BR> Shares </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> Weighted<BR> Average<BR> Exercise<BR> Price<BR>
    Per Share </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> Weighted<BR> Average<BR> Remaining<BR> Contractual<BR>
    Term (Years) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> Aggregate<BR> Intrinsic<BR> Value </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Outstanding at December 31, 2011 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 52%; text-indent: -8.65pt; padding-left: 17.3pt"> Granted </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 677,962 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 0.80 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> - </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Outstanding and expected to vest at December 31, 2012 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 677,962 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 9.5 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -8.65pt; padding-left: 17.3pt"> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,187,449 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> - </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Outstanding and expected to vest at December 31, 2013 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1,865,411 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.80 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 8.8 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1,305,000 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp;&nbsp;&nbsp;Granted </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 1,499,760 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 1.50 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 9.7 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 3,000,000 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt"> Outstanding and expected to vest at June 30, 2014 <BR> </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 3,365,171 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 1.11 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 8.9 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 5,238,000 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt"> Options exercisable at June 30, 2014 </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 652,005 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 0.80 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 9.0 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 782,400 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Relmada Therapeutics, Inc. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> (formerly Camp Nine, Inc.) </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Notes to Consolidated Financial
Statements </B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> For the six months ended June 30, 2014 and for years ending
December 31, 2013 and 2012, the Company recorded approximately $115,500, $4,800 and $0, respectively, of stock-based compensation
expense to research and development expense. For the six months ended and for years ending December 31, 2013 and 2012, the Company
recorded approximately $77,700, $129,600 and $35,100, respectively, of stock based compensation expense to general and administrative
expense. At June 30, 2014, and December 31, 2013 and 2012, the Company has unrecognized stock based compensation expense of approximately
$1,760,900, $589,500 and $0 related to stock options, respectively. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> The weighted average fair value of options granted during the
six months ended June 30, 2014 and for the years ended December 31, 2013 and 2012 was approximately $0.72, $0.58 per share and
$0.15 per share respectively, on the date of grant using the Black-Scholes option pricing model with the following assumptions: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; padding-bottom: 1.5pt"> Six Month<BR>
    Ended&nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> For the Years Ended<BR>
    December 31, </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> June 30, 2014 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> 2013 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> 2012 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%"> Current price of common stock </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 2.00 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 0.80 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 0.30 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Risk free interest rate </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1.5% to 1.6 </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 1.4 </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0.6 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Dividend yield </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> Volatility </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp;76% to 77 </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 73% to 80 </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 82 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Expected term (in years) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 6.25 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 5.75 to 10 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 5.75 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp;&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> Stock-based compensation &ndash; warrants </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> In connection with the Series A preferred stock offerings, during
2013 and 2012, the Company issued the investors 1,275,156 and 1,224,845 warrants, respectively, to purchase common stock of the
Company, exercisable at $0.80 per share. During 2013 and 2012, the Company also issued the Placement Agent 637,578 and 612,422
warrants, respectively to purchase common stock exercisable at $0.80 per share. The warrants have a seven-year term. These warrants
contain anti-dilution features with down-round protection, thus the Company accounts for these warrants as derivative liabilities. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> &nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> In connection with the debt offerings in
2013 and 2012, the Company issued debt holders 213,750 and 67,500 warrants, respectively, to purchase common stock of the Company,
exercisable at $0.80 per share. During 2013 and 2012, the Company also issued the placement agent 106,875 and 33,750 warrants,
respectively to purchase common stock exercisable at $0.80 per share. The warrants have a seven-year term. These warrants contain
anti-dilution features with down-round protection, thus the Company accounts for these warrants as derivative liabilities. The
anti-dilution feature was been eliminated upon the Share Exchange. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> During 2012, warrant holders exercised 619,377 warrants to purchase
common stock in a cashless exercise which resulted in the issuance of 541,430 shares of common stock. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> During 2012, the Company issued its founder 868,213 warrants
to purchase common stock in connection with a transaction that exchanged debt for stock. These warrants were cancelled by the
Company in January 2014, see Note 8. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> In 2013, the Company purchased Medeor Inc. and in connection
with the purchase the Company issued the Placement Agent 200,000 warrants to purchase common stock of the Company. The warrants
have a seven-year term and were fully vested upon issuance and have an exercise price of $1.10 per share. The Company recorded
stock-based compensation of $237,400 in connection with the issuance of these warrants. </P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> In conjunction with a strategic advisor agreement, during
2013 and 2012, the Company issued warrants to purchase shares of common stock, at an exercise
price of $0.001 per share that expires in seven years. The warrants have performance based requirements for vesting and will become
fully vested upon completion of a public transaction. The Company has not recorded any stock based compensation expense prior
to the Share Exchange since the performance requirements were not met. During the six months ended June 30, 2014, the performance
achievement was met. The Company recorded the fair value of stock based compensation expense of approximately $10,119,000 based
upon the Black-Scholes option pricing model for the 8,655,783 vested options. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> During the six months ended June 30, 2014 and for the
years ended December 31, 2013 and 2012, the Company issued to consultants 12,500, 21,500 and 40,000 warrants, respectively, to
purchase shares of common stock of the Company. The exercise price of the warrants issued during the years ended December 31,
2013 and 2012 were all at $0.80 per share. The grant date fair value of the warrants issued for the six months ended June 30,
2014 and for the years ended December, 31, 2013 and 2012 was approximately $14,300, $10,800 and $5,600, respectively, and the
fair value was amortized over the term of the agreements. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Relmada Therapeutics, Inc. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> (formerly Camp Nine, Inc.) </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Notes to Consolidated Financial
Statements </B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> A summary of the changes in outstanding warrants during
the six months ended June 30, 2014 and for the years ended December 31, 2013 and 2012 is as follows: </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> Number of<BR> Shares </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> Weighted<BR> Average<BR> Exercise<BR> Price<BR>
    Per Share </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%"> Outstanding at December 31, 2011 </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> 6,251 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 1.00 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 5,478,360 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.50 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt"> Exercised </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> (619,377 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 0.80 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> Outstanding at December 31, 2012 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4,865,234 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> &nbsp; </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt"> Granted </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 4,061,283 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 0.54 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD> Outstanding at December 31, 2013 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 8,926,517 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 0.54 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD> Granted </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 35,086,253 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 1.58 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt"> Forfeited (1) </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> (868,213 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> ) </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 0.80 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt"> Outstanding and vested at June 30, 2014 </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 43,144,557 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 1.25 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> For the six months ended June 30, 2014 and for the years
ending December 31, 2013 and 2012, the Company recorded approximately $0, $1,800 and $2,200, respectively, of stock-based compensation
expense related to warrants to research and development expense. For the six months ended June 30, 2014 and for the years ending
December 31, 2013 and 2012, the Company recorded to general and administrative expense approximately $12,124,500, $246,100 and
$0 of stock-based compensation expense related to warrants for the six months ended June 30, 2014 and for the years ended December
31, 2013 and 2012, respectively. At June 30, 2014 and December 31, 2013 and 2012, the Company has unrecognized stock based compensation
expense of approximately $6,500, $3,600 and $3,400, respectively related to outstanding warrants. </P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"> (1) </TD>
    <TD STYLE="width: 96%; text-align: justify"><P STYLE="margin: 0"> The warrants issued to Mr. Babul were cancelled on January
                                                29, 2014, see Note 8. </P>


</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"> The weighted average fair value of warrants
granted during the six months ended June 30, 2014 and for the years ended December 31, 2013 and 2012 was $1.40, $0.80 and $0.14
per share, respectively, on the date of grant, using the Black-Scholes option pricing model using the following assumptions: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; padding-bottom: 1.5pt"><P STYLE="margin-top: 0; margin-bottom: 0"> Six Month
                                                                      <BR>
                                                                      Ended, </P>
                                                                      <P STYLE="margin-top: 0; margin-bottom: 0"> June 30, </P></TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> Year Ended December 31, </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> 2014 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> 2013 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> 2012 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%"> Current price of common stock </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 2.00 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; text-align: right"> $0.80 - $1.50 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"> $ </TD><TD STYLE="width: 9%; text-align: right"> 0.30 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Risk-free interest rate </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0.7% to 2.0 </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0.9% to 1.8 </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0.6% to .7 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Dividend yield </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 0 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"> Expected volatility </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 75% to 76 </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 73% to&nbsp;83 </TD><TD STYLE="text-align: left"> % </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 82% to 83 </TD><TD STYLE="text-align: left"> % </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> Expected term (in years) </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4 and 7 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 4-7 </TD><TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 5 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B> &nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B> NOTE 6 &ndash; RELATED PARTY TRANSACTIONS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> &nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> Placement Agent </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> On December 6, 2011, the Company entered into an engagement
agreement with its placement agent (&ldquo;Placement Agent&rdquo;) for the Series A Preferred Stock and Notes Offering (collectively
the &ldquo;Financings&rdquo;), of which Mr. Seth, a director of the Company, is also the Head of Healthcare Investment Banking.
The agreement was amended on April 12, 2012 and again on February 25, 2013. Pursuant to the agreement, the placement agent was
engaged on an exclusive basis for the Series A Preferred Stock and Notes Offering and as a financial advisor for assisting the
Company with the restructuring of its capitalization and negotiating the conversion of its outstanding debt obligations to enable
a successful financing (the &quot;Notes Conversion&quot;). In consideration for its services, the placement agent received: (a)
re-activation fee of $15,000, (b) a cash fee equal to 7% of the Notes Conversion and 10% of the gross proceeds raised in the Financings,
and (c) non-accountable expense reimbursement equal to 2% of the gross proceeds raised. The placement agent or its designees also
received warrants to purchase shares of the Company&rsquo;s common stock in an amount equal to 10% of the shares of common stock
and warrants issued or issuable as part of the units sold in the Series A Preferred Stock Offering and Notes Offerings. The agreement
also provides that: (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than
a Share Exchange in a going public transaction) with any party introduced to it by the placement agent, the placement agent would
receive a success fee equal to 8% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months
after termination of the services described above, the Company requires a financing or advisory transaction the placement agent
will have the right to act as the Company&rsquo;s financial advisor and investment banker in such financing or transaction pursuant
to a set fee schedule set forth in the February 25, 2013 engagement agreement. For a period ending one year after the expiration
of all lock-up agreements entered into in connection with the Share Exchange, any change in the size of the Company board of directors
must be approved by the placement agent. See Note 3 and 4 on the warrants issued with respect to the Series A Preferred Stock
and subordinated promissory notes. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> Due to the Share Exchange, the anti-dilution feature for the
warrants that were issued for the Series A Preferred Stock and Notes Offering were terminated, see Note 4. There were Series A
warrants, Series B warrants and Placement Agent warrants, see Note 5, common stock. These warrants contain an anti-dilution feature
and shall terminate upon an up-listing to a national stock exchange, see Note 4. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Relmada Therapeutics, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> (formerly Camp Nine, Inc.) </B> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Notes to Consolidated Financial Statements </B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> On October 24, 2013, the Company entered into an engagement
agreement which was amended December 19, 2013 with its Placement Agent to advise on the acquisition of Medeor Inc. In consideration
for its services, the Placement Agent was eligible to receive: (a) a cash success fee equal to 8% of the value of the transaction
plus a 2% non-reimbursable expense fee which was subsequently modified to a maximum of $150,000 plus, (b) $50,000 for a Fairness
Opinion fee deductible against the success fee, and (c) a $50,000 activation fee. The agreement also provides that: (i) if the
Company consummates any merger, acquisition, business combination or other transaction (other than the Share Exchange) with any
party introduced to it by the Placement Agent, the placement agent would receive a fee equal to 8% of the aggregate consideration
in such transactions, and (ii) if, within a period of 12 months after termination of the advisory services described above, the
Company requires a financing or similar advisory transaction the Placement Agent will have the right to act as the Company&rsquo;s
financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the engagement
agreement. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> On February 18, 2014 and May 19, 2014, the Company entered into
two engagement agreements with the Placement Agent for the May 2014 offering The Company agreed to pay Placement Agent: (a) a
cash commission in the amount of ten percent (10%) of the gross proceeds of the Offering received from investors at a Closing
as well as a non-accountable expense reimbursement equal to two percent; and (b) (2%) of the gross proceeds of the Offering received
from investors at a Closing and an activation fee of $25,000. The Placement Agent or its designees also received five-year warrants
to purchase 4,290,950 shares of Relmada&rsquo;s common stock at a price of $1.50 per share. The Placement Agent shall also be
entitled to the compensation set forth above as well for any cash exercise of Warrants within six (6) months of the final closing
of the Offering as well as a five percent (5%) solicitation fee for any Warrants exercised as a result of any redemption of any
Warrants. If the Company elects to call the warrants, the Placement Agent shall receive a warrant solicitation fee equal to 5%
of the funds solicited by the Placement Agent upon exercise of the warrants. The Company shall pay the Placement Agent a non-refundable
financial advisory fee to be paid monthly, at the rate of $25,000 per month for a period of six months commencing after the May
offerings. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The Placement Agent also received cash proceeds from
the Company of approximately $3,089,500, $554,700 and $470,300, for the six months ended June 30, 2014 and for the year ended
December 31, 2013 and 2012, respectively, from the equity offerings in May and June 2014 and from the Series A preferred stock
offerings. The Placement Agent received cash proceeds from the Company of $68,400 and $25,100, respectively, for the subordinated
promissory notes issued during 2013 and 2012. The Placement Agent also received a strategic advisory fee of approximately $272,000
for restructuring the Company in 2012. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> The
Placement Agent received the following warrants during the year ended December 31, 2012: </FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> Number of warrants </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> Exercise price per share </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> Expiration </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left"> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-weight: normal; font-style: normal; text-align: left"> Series A preferred offering </TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; font-weight: normal; font-style: normal; text-align: right"> 612,422 </TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left"> $ </TD><TD STYLE="width: 9%; font-weight: normal; font-style: normal; text-align: right"> 0.80 </TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; font-weight: normal; font-style: normal; text-align: center"> 2019 </TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt"> Subordinated promissory note
    offering </TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; border-bottom: Black 1.5pt solid"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; border-bottom: Black 1.5pt solid"> 33,750 </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt"> $ </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding-bottom: 1.5pt"> 0.80 </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: center; padding-bottom: 1.5pt"> 2019 </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: right; border-bottom: Black 2.5pt double"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; border-bottom: Black 2.5pt double"> 646,172 </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding-bottom: 2.5pt"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding-bottom: 2.5pt"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt"> &nbsp; </TD></TR>
</TABLE>


<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> The
Placement Agent received the following warrants during the year ended December 31, 2013: </FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> &nbsp; </FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: normal; font-style: normal; text-align: center; border-bottom: Black 1.5pt solid"> Number
    of warrants </TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: normal; font-style: normal; text-align: center; border-bottom: Black 1.5pt solid"> Exercise
    price per share </TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: normal; font-style: normal; text-align: center; border-bottom: Black 1.5pt solid"> Expiration </TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1.5pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: normal; font-style: normal; text-align: center"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: normal; font-style: normal; text-align: center"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: normal; font-style: normal; text-align: center"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-weight: normal; font-style: normal; text-align: left"> Series A preferred offering </TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; font-weight: normal; font-style: normal; text-align: right"> 637,578 </TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left"> $ </TD><TD STYLE="width: 9%; font-weight: normal; font-style: normal; text-align: right"> 0.80 </TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="width: 9%; font-weight: normal; font-style: normal; text-align: center"> 2020 </TD><TD STYLE="width: 1%; font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> Subordinated promissory note offering </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right"> 106,875 </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> $ </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right"> 0.80 </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: center"> 2020 </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1.5pt"> Acquisition of Medeor </TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; border-bottom: Black 1.5pt solid"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; border-bottom: Black 1.5pt solid"> 200,000 </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt"> $ </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding-bottom: 1.5pt"> 1.10 </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: center; padding-bottom: 1.5pt"> 2020 </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; border-bottom: Black 2.5pt double"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; border-bottom: Black 2.5pt double"> 944,453 </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; padding-bottom: 2.5pt"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: center; padding-bottom: 2.5pt"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: center"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="12" STYLE="font-weight: normal; font-style: normal"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> The
                                                                     Placement Agent received the following warrants during the
                                                                     six months ended June 30, 2014: </FONT></P></TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: center"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: normal; font-style: normal; text-align: center; border-bottom: Black 1.5pt solid"> Number
    of <BR> warrants </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: normal; font-style: normal; text-align: center; border-bottom: Black 1.5pt solid"> Exercise<BR>
    price per <BR>
    share </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-weight: normal; font-style: normal; text-align: center; border-bottom: Black 1.5pt solid"> Expiration </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: center"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"> May
    and June 2014 offering </FONT></TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt; border-bottom: Black 2pt double"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right; border-bottom: Black 2pt double"> 4,290,950 </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left"> $ </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: right"> 1.50 </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; padding-bottom: 2.5pt"> &nbsp; </TD>
    <TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt"> &nbsp; </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: center"> 2019 </TD><TD STYLE="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Relmada Therapeutics, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> (formerly Camp Nine, Inc.) </B> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Notes to Consolidated Financial Statements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"> &nbsp; </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> Advisory Firm </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> On December 6, 2011, the Company entered into an advisory
agreement with Jamess Capital Group, LLC (formerly known as Amerasia Capital Group, LLC), a consulting firm affiliated with Mr.
Seth, a Director of the Company (&ldquo;Advisory Firm&rdquo;) to provide non-investment banking related advisory services. The
Advisory Firm is due a monthly fee of $12,500 and the agreement is terminable by either party with three months written notice
and is to be issued fully vested warrants to purchase common stock equal to 12% of the fully diluted shares of the Company as
of the Share Exchange (exercisable at an exercise price of $0.001 per share), see Note 5. The Advisory Firm is also eligible to
be reimbursed upon the submission of proper documentation for ordinary and necessary out-of-pocket expenses not to exceed $5,000
per month. </P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> Acquisition of Medeor </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> &nbsp; </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> In April 2012, the Company (sublicensee) entered into a license
agreement with Medeor (licensee) and issued 17,089 shares of stock for the license agreement. The Chief Executive Officer was
a shareholder of Medeor. At December 31, 2013, the Company issued 2,500,000 shares of common stock in exchange for all the outstanding
stock of Medeor whose only asset was a research and development project. The parties also amended the license agreement on December
31, 2013. The transaction was valued at its fair value of $3,750,000 and was expensed to research and development expense. The
fair value of the shares was determined via a third party valuation. <FONT STYLE="background-color: white">The Company will make
royalty and a milestone payments as defined in the amended license agreement. The Company (A) will make royalty payments up to
2% on net sales of licensed products that are not sold by sublicensee and (B) on each and every sublicense earned royalty payment
received by licensee from its sublicensee on sales of license product by sublicensee, the higher of (i) 20% of the royalties received
by licensee; or (ii) up to 2% of net sales of sublicensee. The Company will also make milestone payments of up to $4 million and
up to $2 million, for the first commercial sale of product in the field that has a single active pharmaceutical ingredient, and
for the first commercial sale of product in the field of product that has more than one active pharmaceutical ingredient, respectively.</FONT> </P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white"> &nbsp; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> NOTE 7 &ndash; INCOME TAXES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> No provision or benefit for federal or state income taxes has
been recorded because the Company has incurred net losses for all periods presented and has provided a valuation allowance against
its deferred tax assets. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> The components of the Company&rsquo;s deferred tax assets are
as follows at: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Calibri, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> June
    30, <BR> 2014 </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-family: Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"> December
    31,<BR> 2013 </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Times New Roman, Times, Serif"> Deferred tax assets: </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD><TD> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: right"> &nbsp; </TD><TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"> Net operating
    loss </TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"> 3,556,600 </TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="width: 9%; font-family: Times New Roman, Times, Serif; text-align: right"> 2,765,600 </TD><TD STYLE="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"> Stock based compensation </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"> 4,248,700 </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"> Research and development tax
    credits </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"> 197,700 </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"> 436,300 </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt"> Accruals </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"> 22,900 </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"> 44,700 </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-left: 10pt"> Other </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"> 2,900 </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: right"> 46,000 </TD><TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"> Valuation allowance </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> (8,028,800 </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif; text-align: right"> (3,292,600 </TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif; text-align: left"> ) </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"> Total </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font-family: Times New Roman, Times, Serif; padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; font-family: Times New Roman, Times, Serif; text-align: right"> - </TD><TD STYLE="padding-bottom: 4pt; font-family: Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> The Company has maintained a full valuation allowance against
its deferred tax at June 30, 2014 and December 31, 2013. A valuation allowance is required to be recorded when it is more likely
than not that some portion or all of the net deferred tax assets will not be realized. Since the Company cannot be assured of
realizing the net deferred tax asset, a full valuation allowance has been provided. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> At June 30, 2014, the Company had federal and state net
operating loss carryforwards of approximately $8,762,000, which begin expiring in 2025. The Company also had federal research
and development tax credit carryforwards of approximately $197,700 which will begin to expire in 2025. The United States Tax Reform
Act of 1986 contains provisions that may limit the Company&rsquo;s net operating loss carryforwards available to be used in any
given year in the event of significant changes in the ownership interests of significant stockholders, as defined. The effect
of an ownership change would be the imposition of an annual limitation on the use of NOL carryforwards attributable to periods
before the change. The amount of the annual limitation depends upon the value of the Company immediately before the change, changes
to the Company&rsquo;s capital during a specified period prior to the change, and the federal published interest rate. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Relmada Therapeutics, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B> (formerly
Camp Nine, Inc.) </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Notes to Consolidated Financial Statements </B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> A reconciliation of the statutory tax rate to the effective
tax rate is as follows: </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">
<TR STYLE="vertical-align: bottom; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">
    <TD STYLE="text-align: center; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> Six
    Month Ended June&nbsp;30, </FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> Year
    Ended December, </FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">
    <TD STYLE="text-align: center; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> 2014 </FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> 2013 </FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> 2012 </FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">
    <TD STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD><TD STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD><TD STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD><TD STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD><TD STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD><TD STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD><TD STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">
    <TD STYLE="width: 64%; text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> Statutory
    federal income tax rate </FONT></TD><TD STYLE="width: 1%; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD><TD STYLE="width: 9%; text-align: right; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> 34 </FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> % </FONT></TD><TD STYLE="width: 1%; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD><TD STYLE="width: 9%; text-align: right; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> 34 </FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> % </FONT></TD><TD STYLE="width: 1%; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD><TD STYLE="width: 9%; text-align: right; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> 34 </FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">
    <TD STYLE="text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> State
    (net of federal benefit) </FONT></TD><TD STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD><TD STYLE="text-align: right; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> 6.6 </FONT></TD><TD STYLE="text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> % </FONT></TD><TD STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD><TD STYLE="text-align: right; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> 6.6 </FONT></TD><TD STYLE="text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> % </FONT></TD><TD STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD><TD STYLE="text-align: right; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> 6.6 </FONT></TD><TD STYLE="text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> % </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">
    <TD STYLE="text-indent: -8.65pt; padding-left: 8.65pt; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> Non-deductible
    expenses </FONT></TD><TD STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD><TD STYLE="text-align: right; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><P STYLE="margin: 0"> (13.1 </P>


</TD><TD STYLE="text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> )% </FONT></TD><TD STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD><TD STYLE="text-align: right; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> (29.7 </FONT></TD><TD STYLE="text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> )% </FONT></TD><TD STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD>
    <TD STYLE="text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD><TD STYLE="text-align: right; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> (18.8 </FONT></TD><TD STYLE="text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> )% </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">
    <TD STYLE="text-indent: -8.65pt; padding-left: 8.65pt; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> Other </TD><TD STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </TD>
    <TD STYLE="text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </TD><TD STYLE="text-align: right; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><P STYLE="margin: 0"> (2.3 </P>


</TD><TD STYLE="text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> )% </TD><TD STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </TD>
    <TD STYLE="text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </TD><TD STYLE="text-align: right; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> - </TD><TD STYLE="text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </TD><TD STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </TD>
    <TD STYLE="text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </TD><TD STYLE="text-align: right; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> - </TD><TD STYLE="text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> Change
    in valuation allowance </FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt/normal Times New Roman, Times, Serif; text-align: left; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt/normal Times New Roman, Times, Serif; text-align: right; letter-spacing: normal; word-spacing: normal"><P STYLE="margin: 0"> (25.2 </P>


</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> )% </FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt/normal Times New Roman, Times, Serif; text-align: left; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt/normal Times New Roman, Times, Serif; text-align: right; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> (10.9 </FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> )% </FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt/normal Times New Roman, Times, Serif; text-align: left; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt/normal Times New Roman, Times, Serif; text-align: right; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> (21.8 </FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> )% </FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal">
    <TD STYLE="text-align: left; padding-bottom: 4pt; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> Effective
    income tax rate </FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt/normal Times New Roman, Times, Serif; text-align: left; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt/normal Times New Roman, Times, Serif; text-align: right; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> 0 </FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> % </FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt/normal Times New Roman, Times, Serif; text-align: left; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt/normal Times New Roman, Times, Serif; text-align: right; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> 0 </FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> % </FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt/normal Times New Roman, Times, Serif; text-align: left; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt/normal Times New Roman, Times, Serif; text-align: right; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> 0 </FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left; font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> % </FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> &nbsp; </FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"> The
Company has no uncertain tax positions at June 30, 2014 and December 31, 2013 that would affect its effective tax rate. The Company
does not anticipate a significant change in the amount of unrecognized tax benefits over the next twelve months. Because the Company
is in a loss carryforward position, the Company is generally subject to US federal and state income tax examinations by tax authorities
for all years for which a loss carryforward is available. If and when applicable, the Company will recognize interest and penalties
as part of income tax expense. </FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; letter-spacing: normal; word-spacing: normal"><FONT STYLE="font: 10pt/normal Times New Roman, Times, Serif; letter-spacing: normal; word-spacing: normal"><B> &nbsp; </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> NOTE 8 &ndash; COMMITMENTS AND CONTINGENCIES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> License Agreements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> Wonpung </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> On August 20, 2007, the Company entered into a License
Development and Commercialization Agreement with Wonpung, a shareholder of the Company. Wonpung has exclusive territorial rights
in countries it selects in Asia to market up to two drugs the Company is currently developing and a right of first refusal (&ldquo;ROFR&rdquo;)
for up to an additional five drugs that the Company may develop in the future as defined in more detail in the license agreement. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> The Company received an upfront license fee of $1,500,000
and will earn royalties of up to 12% of net sales for up to two licensed products it is currently developing. The licensing terms
for the ROFR products are subject to future negotiations and binding arbitration. The terms of each licensing agreement will expire
on the earlier of any time from 15 years to 20 years after licensing or on the date of commercial availability of a generic product
to such licensed product in the licensed territory. The Company&rsquo;s current focus is on developing and marketing its products
in the United States and not Asia. It will be several years before the Company markets its products in Asia. </P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> Third Party Licensor </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white"> Based upon the
Medeor transaction, the Company assumed an obligation to pay a third party (A) royalty payments up to 2% on net sales of licensed
products that are not sold by sublicensee and (B) on each and every sublicense earned royalty payment received by licensee from
its sublicensee on sales of license product by sublicensee, the higher of (i) 20% of the royalties received by licensee; or (ii)
up to 2% of net sales of sublicensee. The Company will also make milestone payments of up to $4 million and up to $2 million,
for the first commercial sale of product in the field that has a single active pharmaceutical ingredient, and for the first commercial
sale of product in the field of product that has more than one active pharmaceutical ingredient, respectively, see Note 6. </FONT></P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="background-color: white"><I> &nbsp; </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> Leases </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> The Company currently leases its corporate office space for
its New York City on a month-to month basis. The Company has a non-cancelable operating lease expiring in 2017 for its Pennsylvania
office location. Future minimum lease payments are as follows: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> For the year ended June 30,: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> Year </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"> Amount </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: left"> 2015 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> $ </TD><TD STYLE="text-align: right"> 37,300 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 1%; text-align: left"> &nbsp; </TD><TD STYLE="width: 50%; text-align: left"> 2016 </TD><TD STYLE="width: 1%"> &nbsp; </TD>
    <TD STYLE="width: 1%; text-align: left"></TD><TD STYLE="width: 9%; text-align: right"> 38,000 </TD><TD STYLE="width: 1%; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: left"> 2017 </TD><TD> &nbsp; </TD>
    <TD STYLE="text-align: left"> &nbsp; </TD><TD STYLE="text-align: right"> 38,800 </TD><TD STYLE="text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> 2018 </TD><TD STYLE="padding-bottom: 1.5pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"> &nbsp; </TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"> 9,700 </TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> Total </TD><TD STYLE="padding-bottom: 4pt"> &nbsp; </TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"> $ </TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"> 127,800 </TD><TD STYLE="padding-bottom: 4pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: left"> The Company incurred rent expense of
approximately $67,800 and $64,600 for years ended December 31,&nbsp;2013 and 2012, respectively, and approximately $13,300 for
the six months ended June 30, 2014. </P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B> Relmada Therapeutics,
Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B> (formerly
Camp Nine, Inc.) </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B> Notes to Consolidated Financial Statements </B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> &nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B> Legal </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P> <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> The Pennsylvania Litigation:&nbsp;&nbsp; </B> Relmada
has sued its former President and Chief Scientific Officer, Najib Babul, in the United States District Court for the Eastern District
of Pennsylvania.&nbsp;&nbsp;Mr. Babul resigned from his executive positions in September 2012 and was later removed from Relmada&rsquo;s
board of directors.&nbsp;&nbsp;The Complaint alleges that, during the course of an audit, Relmada discovered approximately $1.5
million in questionable expenses incurred by Mr. Babul during his management of the company from 2004 until his resignation in
2012 (the &ldquo;Questionable Expenses&rdquo;). Outside the lawsuit, Relmada has also cancelled warrants to purchase 868,213 common
stock (the &ldquo;Cancelled Warrants&rdquo;) on the grounds, among others, that Babul could not and did not satisfy the conditions
for holding or exercising the warrants after his voluntary resignation from the Company.&nbsp;&nbsp;The Company also has not exchanged
Mr. Babul&rsquo;s equity in Relmada for Company common stock pursuant to the Share Exchange that closed on May 20, 2014.&nbsp;&nbsp;Mr.
Babul has answered the complaint, denying any liability, and has filed a counterclaim seeking specific performance and reinstatement
of the Warrants, as well as compensatory damages and other relief. </P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> The Delaware Litigation:&nbsp;&nbsp; </B> After
the Pennsylvania Litigation was brought against him, Mr. Babul brought an action in the Court of Chancery Delaware (the state
in which Relmada is incorporated), demanding that Relmada advance his litigation expenses in the Delaware and Pennsylvania Litigation
pursuant to, among other things, a Delaware Statute that requires a corporation to advance the reasonable litigation expenses
of a former officer or director who is a party to litigation by reason of that relationship, and the Court ordered Relmada to
advance such expenses.&nbsp;&nbsp;Depending upon the outcome of that litigation, Relmada may or may not be entitled to be reimbursed
for the advanced expenses, but there can be no assurance that, even if Relmada prevails, Mr. Babul will be able to repay Relmada. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B> Other Potential Litigation:&nbsp;&nbsp; </B> In
addition to the aforementioned disputes, Relmada has been informed that Mr. Babul is contemplating making additional claims in
the Pennsylvania litigation or elsewhere, as is Relmada. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Management believes that Relmada has meritorious claims
against Mr. Babul and for its defenses against Mr. Babul&rsquo;s claims, but the outcome of any litigation is impossible to predict
with certainty at such time. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B> NOTE 9 &ndash; SUBSEQUENT EVENTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"> On July 18, 2014, the Company entered into
an agreement with a consultant for investor communication and public relations for one year. The consultant shall receive an upfront
cash fee of $250,000 and $250,000 quarterly cash installments commencing in September 2014. In addition, the Company shall issue
250,000 shares of the Company&rsquo;s within fifteen (15) days of the agreement and the remaining 250,000 shares shall be issued
in six monthly installments commencing in September 2014. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> 61,125,422 Shares of Common Stock&nbsp; </B> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> RELMADA THERAPEUTICS, INC. </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> (FORMERLY CAMP NINE, INC.)&nbsp; </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"> &nbsp; </P>

<HR SIZE="2" NOSHADE ALIGN="LEFT" STYLE="width: 100%; color: black">

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> PROSPECTUS </B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"> &nbsp; </P>

<HR SIZE="2" NOSHADE ALIGN="LEFT" STYLE="width: 100%; color: black">

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp;&nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> YOU SHOULD RELY ONLY ON THE INFORMATION CONTAINED IN
THIS DOCUMENT OR THAT WE HAVE REFERRED YOU TO. WE HAVE NOT AUTHORIZED ANYONE TO PROVIDE YOU WITH INFORMATION THAT IS DIFFERENT.
THIS PROSPECTUS IS NOT AN OFFER TO SELL COMMON STOCK AND IS NOT SOLICITING AN OFFER TO BUY COMMON STOCK IN ANY STATE WHERE THE
OFFER OR SALE IS NOT PERMITTED. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"> Until _____________, all dealers that effect transactions
in these securities whether or not participating in this offering may be required to deliver a prospectus. This is in addition
to the dealer&rsquo;s obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments
or subscriptions. </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B> The date of this prospectus is
__________, 2014&nbsp; </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 116 -->
    <DIV STYLE="margin-top: 10; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 10pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>PART II&mdash; INFORMATION NOT REQUIRED
IN THE PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 13. Other Expenses Of Issuance And Distribution.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; text-align: left">Securities and Exchange Commission registration fee</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">11,200</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Transfer Agent Fees</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accounting fees and expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">12,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Legal fees and expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">20,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Total</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">49,200</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">All amounts are estimates other than the SEC&rsquo;s registration
fee. We are paying all expenses of the offering listed above. No portion of these expenses will be borne by the selling stockholders.
The selling stockholders, however, will pay any other expenses incurred in selling their common stock, including any brokerage
commissions or costs of sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 14. Indemnification of Directors and Officers.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We are a Nevada corporation and generally governed by the Nevada
Private Corporations Code, Title 78 of the Nevada Revised Statutes, or NRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Section 78.138 of the NRS provides that, unless the corporation&rsquo;s
Articles of Incorporation provide otherwise, a director or officer will not be individually liable unless it is proven that (i)
the director&rsquo;s or officer&rsquo;s acts or omissions constituted a breach of his or her fiduciary duties, and (ii) such breach
involved intentional misconduct, fraud, or a knowing violation of the law. Our Articles of Incorporation provide that no director
or officer shall be personally liable to the corporation or any of its stockholders for damages for any breach of fiduciary duty
as a director or officer except for liability of a director or officer for (i) acts or omissions involving intentional misconduct,
fraud, or a knowing violation of law or (ii) payment of dividends in violation of Section 78-300 of the NRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Section 78.7502 of the NRS permits a company to indemnify its directors
and officers against expenses, judgments, fines, and amounts paid in settlement actually and reasonably incurred in connection
with a threatened, pending, or completed action, suit, or proceeding, if the officer or director (i) is not liable pursuant to
NRS 78.138, or (ii) acted in good faith and in a manner the officer or director reasonably believed to be in or not opposed to
the best interests of the corporation and, if a criminal action or proceeding, had no reasonable cause to believe the conduct of
the officer or director was unlawful. Section 78.7502 of the NRS also precludes indemnification by the corporation if the officer
or director has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals, to be liable to the corporation
or for amounts paid in settlement to the corporation, unless and only to the extent that the court determines that in view of all
the circumstances, the person is fairly and reasonably entitled to indemnity for such expenses and requires a corporation to indemnify
its officers and directors if they have been successful on the merits or otherwise in defense of any claim, issue, or matter resulting
from their service as a director or officer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Section 78.751 of the NRS permits a Nevada company to indemnify
its officers and directors against expenses incurred by them in defending a civil or criminal action, suit, or proceeding as they
are incurred and in advance of final disposition thereof, upon determination by the stockholders, the disinterested board members,
or by independent legal counsel. Section 78.751 of NRS requires a corporation to advance expenses as incurred upon receipt of an
undertaking by or on behalf of the officer or director to repay the amount if it is ultimately determined by a court of competent
jurisdiction that such officer or director is not entitled to be indemnified by the company if so provided in the corporations
articles of incorporation, bylaws, or other agreement. Section 78.751 of the NRS further permits the company to grant its directors
and officers additional rights of indemnification under its articles of incorporation, bylaws, or other agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Section 78.752 of the NRS provides that a Nevada company may purchase
and maintain insurance or make other financial arrangements on behalf of any person who is or was a director, officer, employee,
or agent of the company, or is or was serving at the request of the company as a director, officer, employee, or agent of another
company, partnership, joint venture, trust, or other enterprise, for any liability asserted against him and liability and expenses
incurred by him in his capacity as a director, officer, employee, or agent, or arising out of his status as such, whether or not
the company has the authority to indemnify him against such liability and expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The Bylaws implement the indemnification and insurance provisions
permitted by Chapter 78 of the NRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">At the present time, except as provided in &ldquo;Legal Proceedings&rdquo;
above, there is no pending litigation or proceeding involving a director, officer, employee, or other agent of ours in which indemnification
would be required or permitted.&nbsp;&nbsp;Except as described in &ldquo;Legal Proceedings&rdquo; above, we are not aware of any
threatened litigation or proceeding that may result in a claim for such indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 117; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 15. Recent Sales of Unregistered Securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> On May 15, 2014, Relmada completed a private placement pursuant
to which Relmada issued an aggregate of 150.5 units to investors (the &ldquo;Investors&rdquo;), pursuant to subscription agreements
and Unit Purchase Agreements for aggregate gross proceeds in the amount of $15,051,110.&nbsp;&nbsp;Each unit consisted of an aggregate
of (i) 666,666 shares of common stock of RTI (the &ldquo;Relmada Stock&rdquo;); (ii) an &ldquo;A&rdquo; warrant to purchase 666,666
shares of Relmada Stock, exercisable at a price of $0.15 per share, expiring after a period of one hundred and twenty (120) days
from the date of the final closing of the Offering; and (iii) a &ldquo;B&rdquo; warrant to purchase 333,333 shares of Relmada
Stock, exercisable at a price of $0.225 per share for a period of five (5) years from the date of the final closing (collectively,
the &ldquo;Relmada Warrants&rdquo;). The shares of Relmada Common Stock and Relmada Warrants issued in the offering were exchanged
for an aggregate of 10,034,073 shares of our Common Stock, &ldquo;A&rdquo; warrants to purchase 10,034,073 shares of our Common
Stock at an exercisable at $1.50 per share that expire after a period of one hundred and twenty (120) days from the date of the
final closing of the Offering (October 10, 2014) and &ldquo;B&rdquo; warrants to purchase 5,017,037 shares of our Common Stock,
exercisable at price of $2.25 per share and expiring after a period of five (5) years from the date of the final closing. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On May 14, 2014, Camp Nine closed a private offering of Class A
Preferred Convertible Stock sold at a price of $0.60 per share, par value $0.001. A total of 3,337,310 shares of Class A Stock
were sold to a total of 10 purchasers, resulting in total proceeds of $2,000,000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> On May 20, 2014, Relmada completed a Share Exchange with Camp
Nine, whereby Camp Nine acquired 94.9% of the issued and outstanding capital stock of Relmada from the Relmada Stockholders in
exchange for the issuance of 28,291,073, shares of Common Stock to the Relmada Shareholders, which represented 80.9% of our issued
and outstanding common stock after the consummation of the Share Exchange.&nbsp;&nbsp;Relmada&rsquo;s outstanding options and
warrants were also exchanged for options and warrants to purchase shares of Common Stock of Camp Nine at a ratio of 10 to 1. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On June 10, 2014, Camp Nine, Inc. completed a final closing of the
sale of units pursuant to a Unit Purchase Agreement, dated June 10, 2014 (the &ldquo;Purchase Agreement&rdquo;), and Subscription
Agreement, dated June 10, 2014&nbsp;&nbsp;(the &ldquo;Subscription Agreement&rdquo;), among the Company and certain accredited
investors named therein. The securities sold in the offering consisted of an aggregate of (i) 7,129,725 shares (the &ldquo;Shares&rdquo;)
of its common stock par value $0.001 per share (the &ldquo;Common Stock&rdquo;), (ii) Series A (the &ldquo;Series A Warrants&rdquo;)
warrants to purchase 7,129,725 shares of its Common Stock at an in exercise price of $1.50 per share, subject to adjustment, and
(iii) Series B (the &ldquo;Series B Warrants&rdquo;) warrants to purchase 3,564,862 shares of its Common Stock at an in exercise
price of $2.25 per share, subject to adjustment. The Series A Warrants are exercisable for a period of 120 days from the date of
issuance and the Series B Warrants are exercisable for a period of 5 years from the date of issuance.&nbsp;&nbsp;&nbsp;The Company
received an aggregate of $10,694,588 in aggregate gross proceeds from the sale of securities under the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The above securities were offered and sold in reliance upon exemptions
from registration pursuant to Section 4(2) of the Securities Act and Rule 506 of Regulation D (&ldquo;Regulation D&rdquo;) promulgated
under the Securities Act.&nbsp;&nbsp;The Company made this determination based on the representations of the investors which included,
in pertinent part, that each such investor was an &ldquo;accredited investor&rdquo; within the meaning of Rule 501 of Regulation
D (there were no non-accredited investors in any of the offerings) and upon such further representations from each investor that
(i) such investor is acquiring the securities for its own account for investment and not for the account of any other person and
not with a view to or for distribution, assignment or resale in connection with any distribution within the meaning of the Securities
Act, (ii) such investor agrees not to sell or otherwise transfer the purchased securities or shares underlying such securities
unless they are registered under the Securities Act and any applicable state securities laws, or an exemption or exemptions from
such registration are available, (iii) such investor has knowledge and experience in financial and business matters such that such
investor is capable of evaluating the merits and risks of an investment in us, (iv) such investor&nbsp;&nbsp;had access to all
of the Company&rsquo;s documents, records, and books pertaining to the investment and was provided the opportunity to ask questions
and receive answers regarding the terms and conditions of the Offering and to obtain any additional information which the Company
possessed or was able to acquire without unreasonable effort and expense, and (v) such investor has no need for the liquidity in
its investment in us and could afford the complete loss of such investment. In addition, there was no general solicitation or advertising
for securities issued in reliance upon Regulation D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 16. Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">See Exhibit Index following the signature page.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 17. Undertakings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The undersigned registrant hereby undertakes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(1) To file, during any period in which offers or sales are being
made, a post-effective amendment to this registration statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 69.3pt">i. To include any prospectus required by section
10(a)(3) of the Securities Act of 1933;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 69.3pt">ii. To reflect in the prospectus any facts
or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof)
which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement.
Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering
range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in
volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &ldquo;Calculation
of Registration Fee&rdquo; table in the effective registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 69.3pt">iii. To include any material information with
respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information
in the registration statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(2) That, for the purpose of determining any liability under the
Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(3) To remove from registration by means of a post-effective amendment
any of the securities being registered which remain unsold at the termination of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(4) Insofar as indemnification for liabilities arising under the
Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing
provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification
is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification
against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel
the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(5) Each prospectus filed pursuant to Rule 424(b) as part of a registration
statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in
reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used
after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration
statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus
that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede
or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or
made in any such document immediately prior to such date of first use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 59.4pt"> Pursuant to the requirements of the Securities
Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereonto
duly authorized, in the City of New York, State of New York, on September 15, 2014. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 59.4pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 59.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 59.4pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><B>RELMADA THERAPEUTICS, INC. </B>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 60%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 3%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 37%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0 0 1.5pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1.5pt; text-indent: 0">By:</TD>
    <TD STYLE="padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0">/s/ Sergio Traversa</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">Sergio Traversa</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><P STYLE="margin-top: 0; margin-bottom: 0">Chief Executive Officer</P>
                                                          <P STYLE="margin-top: 0; margin-bottom: 0">(Duly Authorized Officer and Principal Executive Officer)</P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 59.4pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 59.4pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 59.4pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0 0 1.5pt; text-indent: 0; width: 60%">&nbsp;</TD>
    <TD STYLE="padding: 0 0 1.5pt; text-indent: 0; width: 3%">By:</TD>
    <TD STYLE="padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0; width: 37%">/s/ Douglas Beck</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">Douglas Beck</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Chief Financial Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Duly&nbsp;Authorized Officer and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(Principal Financial and Accounting Officer)</P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 59.4pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 59.4pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 59.4pt">Pursuant to the requirements of the Securities
Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border-bottom: Black 1.5pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0"><B> Signature </B></TD>
    <TD STYLE="width: 1%; padding: 0 0 1.5pt; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="width: 32%; border-bottom: Black 1.5pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0"><B> Capacity </B></TD>
    <TD STYLE="width: 1%; padding: 0 0 1.5pt; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="width: 32%; border-bottom: Black 1.5pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0"><B> Date </B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0"> /s/
    Sergio Traversa </TD>
    <TD STYLE="vertical-align: top; padding: 0 0 1.5pt; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; padding: 0 0 1.5pt; text-indent: 0"> Chief Executive Officer and Director </TD>
    <TD STYLE="vertical-align: top; padding: 0 0 1.5pt; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; padding: 0 0 1.5pt; text-indent: 0"> September 15, 2014 </TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"> Sergio Traversa </TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"> (Principal Executive officer) </TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"> &nbsp; </TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="vertical-align: top; padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="vertical-align: bottom; padding: 0; text-indent: 0"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0"> /s/ Douglas
    Beck </TD>
    <TD STYLE="padding: 0 0 1.5pt; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0 0 1.5pt; text-indent: 0"> Chief Financial Officer </TD>
    <TD STYLE="padding: 0 0 1.5pt; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0 0 1.5pt; text-indent: 0"> September 15, 2014 </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"> Douglas Beck </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> (Principal Financial and Accounting Officer) </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0; text-indent: 0"> * </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> Director </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> September 15, 2014 </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"> Sheeram Agharkar </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0; text-indent: 0"> * </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> Director </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> September 15, 2014 </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"> Sandesh Seth </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; padding: 0; text-indent: 0"> * </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> Director </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> September 15, 2014 </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"> Nabil Yazgi </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 4%; padding: 0 0 1.5pt; text-indent: 0"> *By: </TD>
    <TD STYLE="width: 36%; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0"> /s/&nbsp;Sergio
    Traversa </TD>
    <TD STYLE="width: 60%; padding: 0 0 1.5pt; text-indent: 0"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"> Sergio
                                         Traversa </P>


</TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD>
    <TD STYLE="padding: 0; text-indent: 0"> Attorney-in-Fact </TD>
    <TD STYLE="padding: 0; text-indent: 0"> &nbsp; </TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"> &nbsp; </P>

<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 10%; border-bottom: Black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Exhibit</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Number</B></P></TD>
    <TD STYLE="vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 88%; border-bottom: Black 1.5pt solid"><B>Description</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>2.1</TD>
    <TD>&nbsp;</TD>
    <TD>Share Exchange Agreement, dated May 20, 2014, by and among Camp Nine, Inc., Relmada Therapeutics, Inc., and the stockholders of Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>3.1</TD>
    <TD>&nbsp;</TD>
    <TD>(i) Articles of Incorporation of Camp Nine, Inc. (incorporated by reference to Exhibit 3.1 of Camp Nine, Inc.&rsquo;s Registration Statement on Form S-1 filed with the SEC on November 13, 2012).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(ii) Certificate of Designation dated May 13, 2014 (incorporated by reference to Exhibit 4.1 to Camp Nine, Inc.&rsquo;s Report on Form 8-K filed with the SEC on May 19, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(iii) Nevada Certificate of Amendment to Articles of Incorporation of Camp Nine, Inc., effective May 30, 2014 (incorporated by reference to Exhibit 3.1 of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>3.2</TD>
    <TD>&nbsp;</TD>
    <TD>(i) Amended and Restated Certificate of Incorporation of Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 3.2(i) of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>(ii) Amendment effective April 19, 2013 to Certificate of Incorporation of Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 3.2(ii) of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>3.3</TD>
    <TD>&nbsp;</TD>
    <TD>By-laws of Camp Nine, Inc. (incorporated by reference to Exhibit 3.3 of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>3.4</TD>
    <TD>&nbsp;</TD>
    <TD>By-laws of Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 3.4 of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>4.1</TD>
    <TD>&nbsp;</TD>
    <TD>Form of Warrants to Purchase Common Stock issued in 2012 and 2013 in connection with Relmada Therapeutics, Inc. Series A Preferred Stock (incorporated by reference to Exhibit 4.1 of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>4.2</TD>
    <TD>&nbsp;</TD>
    <TD>Form of Warrants to Purchase Common Stock issued in 2012 and 2013 in connection with Relmada Therapeutics, Inc. 8% Senior Subordinated Promissory Notes (incorporated by reference to Exhibit 4.2 of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>4.3</TD>
    <TD>&nbsp;</TD>
    <TD>Form of A Warrant dated May __, 2014 issued to investors by Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 4.3 of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>4.4</TD>
    <TD>&nbsp;</TD>
    <TD>Form of B Warrant dated May __, 2014 issued to investors by Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 4.4 of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>4.5</TD>
    <TD>&nbsp;</TD>
    <TD>(i) Option dated July 10, 2012 to Sergio Traversa to purchase common stock of Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 4.5(i) of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>

    <TD>(ii) Option dated September 30, 2013 to Sergio Traversa to purchase common stock of Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 4.5(ii) of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>4.6</TD>
    <TD>&nbsp;</TD>
    <TD>Option dated December 2, 2013 to Douglas J. Beck to purchase common stock of Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 4.6 of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>4.7</TD>
    <TD>&nbsp;</TD>
    <TD>Option dated February 24, 2014 to Dr. Eliseo O. Salinas to purchase common stock of Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 4.7 of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>4.8</TD>
    <TD>&nbsp;</TD>
    <TD>Option dated November 25, 2013 to Dr. H. Danny Kao to purchase common stock of Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 4.8 of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>4.9</TD>
    <TD>&nbsp;</TD>
    <TD>Form of D&amp;O Lock Up Letter Agreement (May 2014 financing) (incorporated by reference to Exhibit 4.9 of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>4.10</TD>
    <TD>&nbsp;</TD>
    <TD>Form of CEO Lock Up Letter Agreement (May 2014 financing) (incorporated by reference to Exhibit 4.10 of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="width: 10%">4.11</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 88%">Form of Lock Up Letter Agreement (Class A Preferred Convertible Stock) (incorporated by reference to Exhibit 4.11 of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>4.12</TD>
    <TD>&nbsp;</TD>
    <TD>Form of A Warrant dated June 10, 2014 issued to investors by Camp Nine, Inc. (incorporated by reference to Exhibit 4.1 of Camp Nine&rsquo;s Form 8-K filed with the SEC on June 16, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>4.13</TD>
    <TD>&nbsp;</TD>
    <TD>Form of B Warrant dated June 10, 2014 issued to investors by Camp Nine, Inc. (incorporated by reference to Exhibit 4.2 of Camp Nine&rsquo;s Form 8-K filed with the SEC on June 16, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>5.1</TD>
    <TD>&nbsp;</TD>
    <TD>Opinion of Hiscock &amp; Barclay, LLP. *</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>10.1</TD>
    <TD>&nbsp;</TD>
    <TD>Agreement and Plan of Merger dated as of December 31, 2013 between Relmada Therapeutics, Inc. and Medeor, Inc. (incorporated by reference to Exhibit 10.1 of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>10.2</TD>
    <TD>&nbsp;</TD>
    <TD>Non-Disclosure, Assignment of Inventions, Non-Solicitation and Non-Compete Agreement dated as of April 18, 2012 between Sergio Traversa and Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 10.2 of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>10.3</TD>
    <TD>&nbsp;</TD>
    <TD>Employment Agreement dated April 15, 2013 between Sergio Traversa and Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 10.3 of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>10.4</TD>
    <TD>&nbsp;</TD>
    <TD>Offer letter dated November 25, 2013 between Douglas J. Beck and Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 10.4 of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>10.5</TD>
    <TD>&nbsp;</TD>
    <TD>Employment Agreement dated January 31, 2014 between Dr. Eliseo Salinas and Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 10.5 of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>10.6</TD>
    <TD>&nbsp;</TD>
    <TD>Confidential Information and Invention Assignment Agreement dated January 31, 2014 between and Dr. Eliseo Salinas and Relmada Therapeutics, Inc. (incorporated by reference to Exhibit 10.6 of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>10.7</TD>
    <TD>&nbsp;</TD>
    <TD>Form of Unit Purchase Agreement dated May _, 2014 by and among Relmada Therapeutics, Inc. and the Purchasers party thereto (incorporated by reference to Exhibit 10.7 of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>10.8</TD>
    <TD>&nbsp;</TD>
    <TD>Form of 2014 Unit Investor Rights Agreement dated __________, 2014 by and among Relmada Therapeutics, Inc. and the Investors party thereto (incorporated by reference to Exhibit 10.8 of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>10.9</TD>
    <TD>&nbsp;</TD>
    <TD>Form of Subscription Agreement dated as of May 12, 2014 and May 15, 2014 by and among Relmada Therapeutics, Inc. and the Purchasers party thereto (incorporated by reference to Exhibit 10.9 of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>10.10</TD>
    <TD>&nbsp;</TD>
    <TD>Indemnification Agreement dated July 10, 2012 between Relmada Therapeutics, Inc. and Sergio Traversa (incorporated by reference to Exhibit 10.10 of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>10.11</TD>
    <TD>&nbsp;</TD>
    <TD>2012 Relmada Therapeutics, Inc. Stock Option and Equity Incentive Plan (incorporated by reference to Exhibit 10.11 of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>10.12</TD>
    <TD>&nbsp;</TD>
    <TD>Unit Purchase Agreement, dated June 10, 2014, by and among Camp Nine, Inc. and signatories thereto (incorporated by reference to Exhibit 10.1 of Camp Nine&rsquo;s Form 8-K filed with the SEC on June 16, 2014).</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><A HREF="#toc">TABLE OF CONTENTS</A></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="width: 10%">10.13</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 88%">Subscription Agreement, dated June 10, 2014, by and among Camp Nine, Inc. and signatories thereto (incorporated by reference to Exhibit 10.2 of Camp Nine&rsquo;s Form 8-K filed with the SEC on June 16, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>10.14</TD>
    <TD>&nbsp;</TD>
    <TD>Form of Investor Rights Agreement, dated June 10, 2014, by and among Camp Nine, Inc. and signatories thereto (incorporated by reference to Exhibit 10.3 of Camp Nine&rsquo;s Form 8-K filed with the SEC on June 16, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>16.1</TD>
    <TD>&nbsp;</TD>
    <TD>Letter from MaloneBailey, LLP (incorporated by reference to Exhibit 16.1 of Camp Nine&rsquo;s Form 8-K filed with the SEC on May 27, 2014).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD> 21.1 </TD>
    <TD> &nbsp; </TD>
    <TD> List of Subsidiaries (incorporated by reference to Exhibit 21.1 of Relmada&rsquo;s Form 10-K filed with the SEC on
    September 9, 2014) </TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>23.1</TD>
    <TD>&nbsp;</TD>
    <TD>Consent of GBH CPAs, PC **</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD> 23.2 </TD>
    <TD> &nbsp; </TD>
    <TD> Consent of valuation firm** </TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD>23.2</TD>
    <TD>&nbsp;</TD>
    <TD>Consent of Hiscock &amp; Barclay, LLP (included in Exhibit 5.1).</TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD> 101 </TD>
    <TD> &nbsp; </TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> Interactive Data Files as of June 30, 2014 and December 31,
        2013, for the six months ended June 30, 2014 and for the years ended December 31, 2013 and 2012 furnished in XBRL.** </P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">* To be filed by amendment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">** Filed herewith</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;II-7&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>fs12014a1ex23i_relmada.htm
<DESCRIPTION>CONSENT LETTER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">We hereby consent to the inclusion in this Amendment No. 1 to Registration
Statement on Form S-1 of our report dated September 3, 2014 relating to the financial statements of Relmada Therapeutics, Inc.
as of June 30, 2014 and December 31, 2013, for the six months ended June 30, 2014 and for the years ended December 31, 2013 and
2012. We also consent to the reference to our firm under the heading<I> &quot;Experts&quot;</I> appearing therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">GBH CPAs, PC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">www.gbhcpas.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Houston, Texas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">September 15, 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>3
<FILENAME>fs12014a1ex23ii_relmada.htm
<DESCRIPTION>CONSENT OF VALUATION FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 10pt; text-align: right; margin-bottom: 0"><B>Exhibit 23.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0 2.05in; text-indent: 140pt; text-align: right"><B>VANTAGE
POINT ADVISORS, INC.</B><BR>
Take aim</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0 2.05in; text-indent: 140pt; text-align: right"><B>&nbsp;</B><BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.05in; text-indent: 140pt; text-align: right">12636 High Bluff
Drive, Suite 120</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.05in; text-indent: 140pt; text-align: right">San Diego,
CA 92130</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.05in; text-indent: 140pt; text-align: right">T
858.509.7545</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.05in; text-indent: 140pt; text-align: right">F
858.876.3088</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.05in; text-indent: 140pt; text-align: right">www.vpadvisors.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.05in; text-indent: 140pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.05in; text-indent: 140pt; text-align: right">SAN DIEGO<BR>

ORANGE COUNTY<BR>
 LOS ANGELES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.05in; text-indent: 140pt; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0 2.05in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;CONSENT
OF INDEPENDENT VALUATION EXPERT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.05in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.05in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The undersigned hereby consents to
the references to our firm in the form and context in which they appear in the Registration Statement on Form S-1 (File No. 333-197109),
as amended, of Relmada Therapeutics, Inc. and the related prospectus that is a part thereof. We hereby further consent to the use
in such Registration Statement and related prospectus of information contained in our reports dated May 20, 2014 and June 10, 2014
relating to the fair value of Relmada Therapeutics, Inc.&rsquo;s warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We further consent to the reference
to this firm under the heading &quot;EXPERTS&quot; in the Registration Statement and related prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;<IMG SRC="image_001.gif" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Vantage Point Advisors, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.7in 0 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 5.7in 0 0">San Diego, California September 15, 2014</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>4
<FILENAME>relm-20140630.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated using Ez-XBRL version 7.1.0.0 [09/16/2014 02:29:26 AM] -->
<!-- Based on XBRL 2.1 -->
<!--XBRL Document Modified with Ez-Editor Version 1.1.0.1 on Tuesday, September 16, 2014 02:33:15 AM -->
<xbrli:xbrl xmlns:relm="http://www.relmada.com/20140630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2012-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr">
<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="relm-20140630.xsd"/>
<!-- Context Section  -->
<xbrli:context id="Context_Custom_25_Dec_2007T00_00_00_TO_31_Dec_2007T00_00_00_IndefiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2007-12-25
</xbrli:startDate>
<xbrli:endDate>
2007-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_25_Dec_2007T00_00_00_TO_31_Dec_2007T00_00_00_IndefiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2007-12-25
</xbrli:startDate>
<xbrli:endDate>
2007-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_25_Dec_2007T00_00_00_TO_31_Dec_2007T00_00_00_IndefiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2007-12-25
</xbrli:startDate>
<xbrli:endDate>
2007-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2011T00_00_00_TO_06_Dec_2011T00_00_00_AwardTypeAxis_AdvisoryFirmMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:AdvisoryFirmMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-12-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-06
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Dec_2011T00_00_00_TO_06_Dec_2011T00_00_00_AwardTypeAxis_PlacementAgentThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:PlacementAgentThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-12-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-06
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2011T00_00_00_TO_31_Dec_2011T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2011T00_00_00_TO_31_Dec_2011T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2011T00_00_00_TO_31_Dec_2011T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2011T00_00_00_TO_31_Dec_2011T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2011T00_00_00_TO_31_Dec_2011T00_00_00_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2011T00_00_00_TO_31_Dec_2011T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2011T00_00_00_TO_31_Dec_2011T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2011T00_00_00_TO_31_Dec_2011T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember_LegalEntityAxis_MedeorIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">relm:MedeorIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-04-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-04-01
</xbrli:startDate>
<xbrli:endDate>
2012-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-04-01
</xbrli:startDate>
<xbrli:endDate>
2012-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-04-01
</xbrli:startDate>
<xbrli:endDate>
2012-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember_LegalEntityAxis_MedeorIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">relm:MedeorIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-04-01
</xbrli:startDate>
<xbrli:endDate>
2012-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-04-01
</xbrli:startDate>
<xbrli:endDate>
2012-04-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_09_Jul_2012T00_00_00_TO_10_Jul_2012T00_00_00_StatementEquityComponentsAxis_CommonStockIssuedForServicesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">relm:CommonStockIssuedForServicesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-07-09
</xbrli:startDate>
<xbrli:endDate>
2012-07-10
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jul_2012T00_00_00_TO_31_Jul_2012T00_00_00_AwardTypeAxis_OfficerOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:OfficerOptionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-07-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2012T00_00_00_TO_31_Jul_2012T00_00_00_AwardTypeAxis_OfficerOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:OfficerOptionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-07-01
</xbrli:startDate>
<xbrli:endDate>
2012-07-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_AwardTypeAxis_PlacementAgentThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:PlacementAgentThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockIssuedForServicesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">relm:CommonStockIssuedForServicesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_DebtInstrumentAxis_PromissoryNotesDueTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">relm:PromissoryNotesDueTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementClassOfStockAxis_CommonStockWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">relm:CommonStockWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementClassOfStockAxis_CommonStockOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">relm:CommonStockOptionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_IndefiniteLivedIntangibleAssetsByMajorClassAxis_LeaseAgreementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_AwardTypeAxis_FounderWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:FounderWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">relm:InitialValuationsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionAxis_SeriesAPreferredStockOfferingsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">relm:SeriesAPreferredStockOfferingsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionAxis_DebtOfferingsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">relm:DebtOfferingsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">relm:ConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementClassOfStockAxis_PreferredClassAMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_ClassOfWarrantOrRightAxis_SeriesAPreferredStockMember_AwardTypeAxis_PlacementAgentThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:PlacementAgentThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_AwardTypeAxis_PlacementAgentThreeMember_ClassOfWarrantOrRightAxis_SubordinatedPromissoryNoteOfferingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:PlacementAgentThreeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">relm:SubordinatedPromissoryNoteOfferingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_AwardTypeAxis_PlacementAgentThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:PlacementAgentThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockIssuedForServicesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">relm:CommonStockIssuedForServicesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_DebtInstrumentAxis_PromissoryNotesDueTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">relm:PromissoryNotesDueTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">relm:InitialValuationsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">relm:ConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_ClassOfWarrantOrRightAxis_SeriesAPreferredStockMember_AwardTypeAxis_PlacementAgentThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:PlacementAgentThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_AwardTypeAxis_PlacementAgentThreeMember_ClassOfWarrantOrRightAxis_SubordinatedPromissoryNoteOfferingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:PlacementAgentThreeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">relm:SubordinatedPromissoryNoteOfferingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FinancialInstrumentAxis_LongTermDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FinancialInstrumentAxis_SecuritiesPledgedAsCollateralMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SecuritiesPledgedAsCollateralMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:JuniorSubordinatedDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:JuniorSubordinatedDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_InvestorsMember_RelatedPartyTransactionAxis_SeriesAPreferredStockOfferingsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">relm:InvestorsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">relm:SeriesAPreferredStockOfferingsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionAxis_SeriesAPreferredStockOfferingsMember_RelatedPartyTransactionsByRelatedPartyAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">relm:SeriesAPreferredStockOfferingsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">relm:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionAxis_DebtOfferingsMember_RelatedPartyTransactionsByRelatedPartyAxis_DebtHoldersMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">relm:DebtOfferingsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">relm:DebtHoldersMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionAxis_DebtOfferingsMember_RelatedPartyTransactionsByRelatedPartyAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">relm:DebtOfferingsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">relm:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionAxis_StrategicAdvisorAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">relm:StrategicAdvisorAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_FinancialInstrumentAxis_LongTermDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_FinancialInstrumentAxis_SecuritiesPledgedAsCollateralMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SecuritiesPledgedAsCollateralMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:JuniorSubordinatedDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:JuniorSubordinatedDebtMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_FinancialInstrumentAxis_SecuritiesPledgedAsCollateralMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SecuritiesPledgedAsCollateralMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:JuniorSubordinatedDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:JuniorSubordinatedDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_FinancialInstrumentAxis_LongTermDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_09_Jul_2013T00_00_00_TO_10_Jul_2013T00_00_00_StatementEquityComponentsAxis_CommonStockIssuedForServicesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">relm:CommonStockIssuedForServicesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-07-09
</xbrli:startDate>
<xbrli:endDate>
2013-07-10
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_AwardTypeAxis_OfficerOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:OfficerOptionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">relm:PromissoryNotesDueOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">relm:PromissoryNotesDueThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_AwardTypeAxis_OfficerOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:OfficerOptionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-09-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">relm:PromissoryNotesDueOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-09-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">relm:PromissoryNotesDueThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-09-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2013T00_00_00_TO_24_Oct_2013T00_00_00_AwardTypeAxis_PlacementAgentThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:PlacementAgentThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-10-01
</xbrli:startDate>
<xbrli:endDate>
2013-10-24
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Nov_2013T00_00_00_TO_30_Nov_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">relm:ConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-11-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Nov_2013T00_00_00_TO_30_Nov_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">relm:ConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-11-01
</xbrli:startDate>
<xbrli:endDate>
2013-11-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_AdvisoryFirmMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:AdvisoryFirmMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_PlacementAgentThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:PlacementAgentThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockIssuedForServicesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">relm:CommonStockIssuedForServicesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_OfficerOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:OfficerOptionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">relm:PromissoryNotesDueTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementClassOfStockAxis_CommonStockWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">relm:CommonStockWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementClassOfStockAxis_CommonStockOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">relm:CommonStockOptionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_IndefiniteLivedIntangibleAssetsByMajorClassAxis_LeaseAgreementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">relm:InitialValuationsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionAxis_SeriesAPreferredStockOfferingsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">relm:SeriesAPreferredStockOfferingsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionAxis_DebtOfferingsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">relm:DebtOfferingsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">relm:ConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementClassOfStockAxis_PreferredClassAMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_ClassOfWarrantOrRightAxis_SeriesAPreferredStockMember_AwardTypeAxis_PlacementAgentThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:PlacementAgentThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_PlacementAgentThreeMember_ClassOfWarrantOrRightAxis_SubordinatedPromissoryNoteOfferingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:PlacementAgentThreeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">relm:SubordinatedPromissoryNoteOfferingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">relm:PromissoryNotesDueThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PlacementAgentMember_LegalEntityAxis_MedeorIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">relm:PlacementAgentMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">relm:MedeorIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_PlacementAgentThreeMember_ClassOfWarrantOrRightAxis_AcquisitionOfMedeorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:PlacementAgentThreeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">relm:AcquisitionOfMedeorMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_PlacementAgentThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:PlacementAgentThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_OfficerOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:OfficerOptionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">relm:PromissoryNotesDueTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">relm:InitialValuationsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">relm:ConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementClassOfStockAxis_PreferredClassAMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_ClassOfWarrantOrRightAxis_SeriesAPreferredStockMember_AwardTypeAxis_PlacementAgentThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:PlacementAgentThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_PlacementAgentThreeMember_ClassOfWarrantOrRightAxis_SubordinatedPromissoryNoteOfferingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:PlacementAgentThreeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">relm:SubordinatedPromissoryNoteOfferingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FinancialInstrumentAxis_LongTermDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FinancialInstrumentAxis_SecuritiesPledgedAsCollateralMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SecuritiesPledgedAsCollateralMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:JuniorSubordinatedDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:JuniorSubordinatedDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_InvestorsMember_RelatedPartyTransactionAxis_SeriesAPreferredStockOfferingsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">relm:InvestorsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">relm:SeriesAPreferredStockOfferingsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionAxis_SeriesAPreferredStockOfferingsMember_RelatedPartyTransactionsByRelatedPartyAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">relm:SeriesAPreferredStockOfferingsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">relm:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionAxis_DebtOfferingsMember_RelatedPartyTransactionsByRelatedPartyAxis_DebtHoldersMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">relm:DebtOfferingsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">relm:DebtHoldersMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionAxis_DebtOfferingsMember_RelatedPartyTransactionsByRelatedPartyAxis_PlacementAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">relm:DebtOfferingsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">relm:PlacementAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_FinancialInstrumentAxis_LongTermDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_FinancialInstrumentAxis_SecuritiesPledgedAsCollateralMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SecuritiesPledgedAsCollateralMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:JuniorSubordinatedDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:JuniorSubordinatedDebtMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:JuniorSubordinatedDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:JuniorSubordinatedDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">relm:PromissoryNotesDueOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">relm:PromissoryNotesDueThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PlacementAgentMember_LegalEntityAxis_MedeorIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">relm:PlacementAgentMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">relm:MedeorIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_PlacementAgentThreeMember_ClassOfWarrantOrRightAxis_AcquisitionOfMedeorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:PlacementAgentThreeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">relm:AcquisitionOfMedeorMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">relm:PromissoryNotesDueMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementBasisAxis_PortionAtFairValueFairValueDisclosureMember_FinancialInstrumentAxis_SecuritiesPledgedAsCollateralMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtFairValueFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SecuritiesPledgedAsCollateralMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">relm:IssuedInMayAndJune2014OfferingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_09_Jan_2014T00_00_00_TO_10_Jan_2014T00_00_00_StatementEquityComponentsAxis_CommonStockIssuedForServicesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">relm:CommonStockIssuedForServicesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-09
</xbrli:startDate>
<xbrli:endDate>
2014-01-10
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_AwardTypeAxis_OfficerOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:OfficerOptionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-01-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_AwardTypeAxis_OfficerOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:OfficerOptionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-01-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_28_Feb_2014T00_00_00_TO_28_Feb_2014T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-02-28
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Feb_2014T00_00_00_TO_28_Feb_2014T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-02-01
</xbrli:startDate>
<xbrli:endDate>
2014-02-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_10_Mar_2014T00_00_00_TO_10_Mar_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-03-10
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_06_May_2014T00_00_00_TO_06_May_2014T00_00_00_FinancialInstrumentAxis_FinancialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">relm:FinancialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-05-06
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_05_May_2014T00_00_00_TO_06_May_2014T00_00_00_FinancialInstrumentAxis_FinancialAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">relm:FinancialAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-05-05
</xbrli:startDate>
<xbrli:endDate>
2014-05-06
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2014T00_00_00_TO_19_May_2014T00_00_00_AwardTypeAxis_PlacementAgentThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:PlacementAgentThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-05-01
</xbrli:startDate>
<xbrli:endDate>
2014-05-19
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_20_May_2014T00_00_00_TO_20_May_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-05-20
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_20_May_2014T00_00_00_TO_20_May_2014T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">relm:PromissoryNotesDueThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-05-20
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_15_May_2014T00_00_00_TO_20_May_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-05-15
</xbrli:startDate>
<xbrli:endDate>
2014-05-20
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_May_2014T00_00_00_TO_31_May_2014T00_00_00_AwardTypeAxis_OfficerOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:OfficerOptionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-05-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2014T00_00_00_TO_31_May_2014T00_00_00_IndefiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-05-01
</xbrli:startDate>
<xbrli:endDate>
2014-05-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2014T00_00_00_TO_31_May_2014T00_00_00_AwardTypeAxis_OfficerOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:OfficerOptionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-05-01
</xbrli:startDate>
<xbrli:endDate>
2014-05-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_12_May_2014T00_00_00_TO_10_Jun_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-05-12
</xbrli:startDate>
<xbrli:endDate>
2014-06-10
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_IndefiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_PlacementAgentThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:PlacementAgentThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_CommonStockIssuedForServicesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">relm:CommonStockIssuedForServicesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_CommonStockWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">relm:CommonStockWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_CommonStockOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">relm:CommonStockOptionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_IndefiniteLivedIntangibleAssetsByMajorClassAxis_LeaseAgreementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">relm:InitialValuationsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">relm:ConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_PreferredClassAMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">relm:PromissoryNotesDueThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_InvestorsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:InvestorsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">relm:InitialValuationsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">relm:InitialValuationsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesBWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">relm:SeriesBWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_BusinessAcquisitionAxis_MedeorMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">relm:MedeorMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_TaxCreditCarryforwardAxis_ResearchMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-06-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_PlacementAgentThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:PlacementAgentThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDeficitDuringDevelopmentStageMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">relm:ConsultantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_PreferredClassAMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassAMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FinancialInstrumentAxis_LongTermDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FinancialInstrumentAxis_SecuritiesPledgedAsCollateralMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SecuritiesPledgedAsCollateralMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:JuniorSubordinatedDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:JuniorSubordinatedDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_FinancialInstrumentAxis_LongTermDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_FinancialInstrumentAxis_SecuritiesPledgedAsCollateralMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SecuritiesPledgedAsCollateralMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:JuniorSubordinatedDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:JuniorSubordinatedDebtMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_FinancialInstrumentAxis_SecuritiesPledgedAsCollateralMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SecuritiesPledgedAsCollateralMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:JuniorSubordinatedDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:JuniorSubordinatedDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_DebtInstrumentAxis_PromissoryNotesDueOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">relm:PromissoryNotesDueOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">relm:PromissoryNotesDueThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_DebtInstrumentAxis_PromissoryNotesDueMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">relm:PromissoryNotesDueMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_PortionAtFairValueFairValueDisclosureMember_FinancialInstrumentAxis_SecuritiesPledgedAsCollateralMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtFairValueFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SecuritiesPledgedAsCollateralMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">relm:IssuedInMayAndJune2014OfferingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">relm:InitialValuationsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">relm:InitialValuationsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesBWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">relm:SeriesBWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_TaxCreditCarryforwardAxis_ResearchMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_PortionAtFairValueFairValueDisclosureMember_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtFairValueFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_PortionAtFairValueFairValueDisclosureMember_FinancialInstrumentAxis_LongTermDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtFairValueFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_PortionAtFairValueFairValueDisclosureMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtFairValueFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_PortionAtFairValueFairValueDisclosureMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtFairValueFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:JuniorSubordinatedDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember_FairValueByMeasurementBasisAxis_PortionAtFairValueFairValueDisclosureMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:JuniorSubordinatedDebtMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtFairValueFairValueDisclosureMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_PortionAtFairValueFairValueDisclosureMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtFairValueFairValueDisclosureMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_PlacementAgentThreeMember_ClassOfWarrantOrRightAxis_SubordinatedPromissoryNoteOfferingOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">relm:PlacementAgentThreeMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">relm:SubordinatedPromissoryNoteOfferingOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesAWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">relm:SeriesAWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_AgentWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">relm:AgentWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_PortionAtFairValueFairValueDisclosureMember_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtFairValueFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">relm:IssuedInMayAndJune2014OfferingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">relm:IssuedInMayAndJune2014OfferingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_IndefiniteLivedIntangibleAssetsByMajorClassAxis_LegalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">relm:LegalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_PortionAtFairValueFairValueDisclosureMember_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtFairValueFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">relm:IssuedInMayAndJune2014OfferingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_PortionAtFairValueFairValueDisclosureMember_StatementClassOfStockAxis_SeriesBPreferredStockMember_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtFairValueFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">relm:IssuedInMayAndJune2014OfferingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_PortionAtFairValueFairValueDisclosureMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:PortionAtFairValueFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">relm:IssuedInMayAndJune2014OfferingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">relm:IssuedInMayAndJune2014OfferingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_StatementClassOfStockAxis_SeriesBPreferredStockMember_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">relm:IssuedInMayAndJune2014OfferingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">relm:IssuedInMayAndJune2014OfferingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">relm:IssuedInMayAndJune2014OfferingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">relm:IssuedInMayAndJune2014OfferingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">relm:IssuedInMayAndJune2014OfferingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">relm:IssuedInMayAndJune2014OfferingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_StatementClassOfStockAxis_SeriesBPreferredStockMember_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">relm:IssuedInMayAndJune2014OfferingMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_15_Jul_2014T00_00_00_TO_18_Jul_2014T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001553643</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-15
</xbrli:startDate>
<xbrli:endDate>
2014-07-18
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<!-- Unit Section  -->
<!--
I~1\FVPHexeD5678YReqi>IhkevEkirxw76c444c555cT{h>EEF9IG;7165GH18G6:1F7JI1IF4E675=G9JJ -->
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id="Drugs"><xbrli:measure>relm:Drugs</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Warrant"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>relm:Warrant</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">RELMADA THERAPEUTICS, INC.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">0001553643</dei:EntityCentralIndexKey>
<dei:AmendmentFlag contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">false</dei:AmendmentFlag>
<dei:DocumentType contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">S-1</dei:DocumentType>
<dei:DocumentPeriodEndDate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">2014-06-30</dei:DocumentPeriodEndDate>
<dei:EntityFilerCategory contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">Smaller Reporting Company</dei:EntityFilerCategory>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2011T00_00_00_TO_31_Dec_2011T00_00_00" unitRef="USD" decimals="0">21869</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">1772822</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">3522450</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">25564351</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">10325</us-gaap:PrepaidExpenseCurrent>
<us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">178158</us-gaap:PrepaidExpenseCurrent>
<us-gaap:DeferredFinanceCostsCurrentNet contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">78724</us-gaap:DeferredFinanceCostsCurrentNet>
<us-gaap:DeferredFinanceCostsCurrentNet contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">3611499</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">25742509</us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">8498</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">9841</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:OtherAssets contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">12100</us-gaap:OtherAssets>
<us-gaap:OtherAssets contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">12100</us-gaap:OtherAssets>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">3632097</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">25764450</us-gaap:Assets>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">180319</us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">746098</us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">438658</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">382023</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:ConvertibleNotesPayableCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">58357</us-gaap:ConvertibleNotesPayableCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2011T00_00_00_TO_31_Dec_2011T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">5090988</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember" unitRef="USD" decimals="0">3688353</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember" unitRef="USD" decimals="0">1402635</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">20103425</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">20103425</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">4089284</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember" unitRef="USD" decimals="0">12877675</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember" unitRef="USD" decimals="0">2134762</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_StatementEquityComponentsAxis_WarrantMember" unitRef="USD" decimals="0">4089284</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">16014141</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementBasisAxis_PortionAtFairValueFairValueDisclosureMember_FinancialInstrumentAxis_SecuritiesPledgedAsCollateralMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">25586933</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">25586933</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember" unitRef="USD" decimals="0">7954970</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember" unitRef="USD" decimals="0">4333163</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:DerivativeLiabilitiesCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_PortionAtFairValueFairValueDisclosureMember" unitRef="USD" decimals="0">-6804625</us-gaap:DerivativeLiabilitiesCurrent>
<us-gaap:NotesPayableCurrent contextRef="Context_As_Of_30_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember" unitRef="USD" decimals="0">186800</us-gaap:NotesPayableCurrent>
<us-gaap:NotesPayableCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">758951</us-gaap:NotesPayableCurrent>
<us-gaap:NotesPayableCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">21481353</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">26773411</us-gaap:LiabilitiesCurrent>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">100000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">100000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
<us-gaap:Liabilities contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">21581353</us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">26873411</us-gaap:Liabilities>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">13604</us-gaap:PreferredStockValue>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementClassOfStockAxis_PreferredClassAMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_PreferredClassAMember" unitRef="USD" decimals="0">3337</us-gaap:PreferredStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">4959</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">40294</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">16014840</us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">54166055</us-gaap:AdditionalPaidInCapital>
<us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">33982659</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
<us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">55318647</us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2011T00_00_00_TO_31_Dec_2011T00_00_00" unitRef="USD" decimals="0">-2839971</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2011T00_00_00_TO_31_Dec_2011T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">1520</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2011T00_00_00_TO_31_Dec_2011T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2011T00_00_00_TO_31_Dec_2011T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4409230</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2011T00_00_00_TO_31_Dec_2011T00_00_00_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-7250721</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2011T00_00_00_TO_31_Dec_2011T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">-3711319</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">2402</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">8504</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">10388526</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-14110751</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-17949256</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">4959</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">13604</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">16014840</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-33982659</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-1108961</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">40294</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">54166055</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-55318647</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember" unitRef="USD" decimals="0">3337</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">3632097</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">25764450</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:AccumulatedAmortizationDeferredFinanceCosts contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">69546</us-gaap:AccumulatedAmortizationDeferredFinanceCosts>
<us-gaap:AccumulatedAmortizationDeferredFinanceCosts contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">0</us-gaap:AccumulatedAmortizationDeferredFinanceCosts>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">373</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">2230</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">141049</us-gaap:DebtInstrumentUnamortizedDiscount>
<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">0</us-gaap:DebtInstrumentUnamortizedDiscount>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="0">200000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="0">255000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementClassOfStockAxis_PreferredClassAMember" unitRef="shares" decimals="0">3500000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="0">200000000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_PreferredClassAMember" unitRef="shares" decimals="0">3500000</us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="0">13604128</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementClassOfStockAxis_PreferredClassAMember" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_PreferredClassAMember" unitRef="shares" decimals="0">3337309</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="0">13604128</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementClassOfStockAxis_PreferredClassAMember" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_PreferredClassAMember" unitRef="shares" decimals="0">3337309</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockLiquidationPreference contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:PreferredStockLiquidationPreference>
<us-gaap:PreferredStockLiquidationPreference contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:PreferredStockLiquidationPreference>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="0">500000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="0">500000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="0">4958778</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="0">40294217</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_30_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember_LegalEntityAxis_MedeorIncMember" unitRef="shares" decimals="0">25000000</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="0">4958778</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="0">40294217</us-gaap:CommonStockSharesOutstanding>
<us-gaap:LicenseAndServicesRevenue contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:LicenseAndServicesRevenue contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:LicenseAndServicesRevenue contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_Custom_01_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember_LegalEntityAxis_MedeorIncMember" unitRef="USD" decimals="0">3750000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">-667474</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-5248669</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-839959</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">-2489235</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-1525257</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-12106859</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:OperatingExpenses contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">-3156709</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-6773926</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-12946818</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">-3156709</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-6773926</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-12946818</us-gaap:OperatingIncomeLoss>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">-3688353</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-12877675</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-7954970</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:InvestmentIncomeInterest contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">12753</us-gaap:InvestmentIncomeInterest>
<us-gaap:InvestmentIncomeInterest contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:InvestmentIncomeInterest contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">1411</us-gaap:InvestmentIncomeInterest>
<us-gaap:InterestExpense contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">27721</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">220307</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">435611</us-gaap:InterestExpense>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">-3703321</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-13097982</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:OtherNonoperatingIncomeExpense contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-8389170</us-gaap:OtherNonoperatingIncomeExpense>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">-6860030</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-6860030</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-19871908</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-19871908</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-21335988</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" decimals="0">-21335988</us-gaap:NetIncomeLoss>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD_per_Share" decimals="2">-3.17</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD_per_Share" decimals="2">-8.18</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2">-1.73</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="shares" decimals="0">2166498</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="0">2429267</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="0">12332331</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Dec_2011T00_00_00_TO_31_Dec_2011T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">1519759</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Dec_2011T00_00_00_TO_31_Dec_2011T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Dec_2011T00_00_00_TO_31_Dec_2011T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">2402384</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">8503503</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">4958778</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="0">13604128</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">40294217</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember" unitRef="shares" decimals="0">3337309</us-gaap:SharesOutstanding>
<relm:IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesValue contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">869275</relm:IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesValue>
<relm:IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesValue contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">256</relm:IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesValue>
<relm:IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesValue contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true"/>
<relm:IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesValue contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">869019</relm:IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesValue>
<relm:IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesValue contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember" unitRef="USD" xsi:nil="true"/>
<relm:IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesShares contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">255750</relm:IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesShares>
<relm:IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesShares contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="shares" xsi:nil="true"/>
<relm:IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesShares contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:DebtInstrumentDecreaseForgiveness contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">353246</us-gaap:DebtInstrumentDecreaseForgiveness>
<us-gaap:DebtInstrumentDecreaseForgiveness contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:DebtInstrumentDecreaseForgiveness contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:DebtInstrumentDecreaseForgiveness contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">353246</us-gaap:DebtInstrumentDecreaseForgiveness>
<us-gaap:DebtInstrumentDecreaseForgiveness contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:DebtInstrumentDecreaseForgiveness contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember" unitRef="USD" xsi:nil="true"/>
<relm:StockIssuedDuringPeriodValueIssuedForConversionOfLoansAndAccruedInterest contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">1541180</relm:StockIssuedDuringPeriodValueIssuedForConversionOfLoansAndAccruedInterest>
<relm:StockIssuedDuringPeriodValueIssuedForConversionOfLoansAndAccruedInterest contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<relm:StockIssuedDuringPeriodValueIssuedForConversionOfLoansAndAccruedInterest contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">1879</relm:StockIssuedDuringPeriodValueIssuedForConversionOfLoansAndAccruedInterest>
<relm:StockIssuedDuringPeriodValueIssuedForConversionOfLoansAndAccruedInterest contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1539301</relm:StockIssuedDuringPeriodValueIssuedForConversionOfLoansAndAccruedInterest>
<relm:StockIssuedDuringPeriodValueIssuedForConversionOfLoansAndAccruedInterest contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<relm:StockIssuedDuringPeriodValueIssuedForConversionOfLoansAndAccruedInterest contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember" unitRef="USD" xsi:nil="true"/>
<relm:StockIssuedDuringPeriodSharesIssuedForConversionOfLoansAndAccruedInterest contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" xsi:nil="true"/>
<relm:StockIssuedDuringPeriodSharesIssuedForConversionOfLoansAndAccruedInterest contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">1879128</relm:StockIssuedDuringPeriodSharesIssuedForConversionOfLoansAndAccruedInterest>
<relm:StockIssuedDuringPeriodSharesIssuedForConversionOfLoansAndAccruedInterest contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember" unitRef="shares" xsi:nil="true"/>
<relm:StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" xsi:nil="true"/>
<relm:StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">541</relm:StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants>
<relm:StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true"/>
<relm:StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-541</relm:StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants>
<relm:StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<relm:StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember" unitRef="USD" xsi:nil="true"/>
<relm:StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants contextRef="Context_Custom_01_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00" unitRef="shares" decimals="INF">618766</relm:StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants>
<relm:StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants contextRef="Context_Custom_01_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="shares" decimals="INF">541293</relm:StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants>
<relm:StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">541430</relm:StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants>
<relm:StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="shares" xsi:nil="true"/>
<relm:StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">5127</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
<us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">17</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
<us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">5110</us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets>
<us-gaap:StockIssuedDuringPeriodValuePurchaseOfAssets contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">17089</us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets>
<us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="shares" xsi:nil="true"/>
<relm:IssuanceOfSeriesAPreferredStockToWonpungForServicesValue contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">1006074</relm:IssuanceOfSeriesAPreferredStockToWonpungForServicesValue>
<relm:IssuanceOfSeriesAPreferredStockToWonpungForServicesValue contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<relm:IssuanceOfSeriesAPreferredStockToWonpungForServicesValue contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">1725</relm:IssuanceOfSeriesAPreferredStockToWonpungForServicesValue>
<relm:IssuanceOfSeriesAPreferredStockToWonpungForServicesValue contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1004349</relm:IssuanceOfSeriesAPreferredStockToWonpungForServicesValue>
<relm:IssuanceOfSeriesAPreferredStockToWonpungForServicesValue contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<relm:IssuanceOfSeriesAPreferredStockToWonpungForServicesShares contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" xsi:nil="true"/>
<relm:IssuanceOfSeriesAPreferredStockToWonpungForServicesShares contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">1725000</relm:IssuanceOfSeriesAPreferredStockToWonpungForServicesShares>
<relm:IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">2155938</relm:IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue>
<relm:IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<relm:IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">4900</relm:IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue>
<relm:IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">2151038</relm:IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue>
<relm:IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<relm:IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember" unitRef="USD" xsi:nil="true"/>
<relm:IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">1484710</relm:IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue>
<relm:IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<relm:IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">5100</relm:IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue>
<relm:IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1479610</relm:IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue>
<relm:IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<relm:IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember" unitRef="USD" xsi:nil="true"/>
<relm:IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsShares contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" xsi:nil="true"/>
<relm:IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsShares contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">4899375</relm:IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsShares>
<relm:IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsShares contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember" unitRef="shares" xsi:nil="true"/>
<relm:IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsShares contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" xsi:nil="true"/>
<relm:IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsShares contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="0">5100625</relm:IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsShares>
<relm:IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsShares contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">3750000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">2500</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3747500</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="Context_Custom_01_May_2014T00_00_00_TO_31_May_2014T00_00_00_IndefiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_IndefiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="Context_Custom_01_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00" unitRef="shares" decimals="0">17089</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
<us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">2500000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
<us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember" unitRef="shares" xsi:nil="true"/>
<relm:IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsValue contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">22229321</relm:IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsValue>
<relm:IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsValue contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">17164</relm:IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsValue>
<relm:IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsValue contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">22212157</relm:IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsValue>
<relm:IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsShares contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">17163799</relm:IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsShares>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">20507</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">68</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">20439</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_AccumulatedDeficitDuringDevelopmentStageMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">16918</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">57</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">16861</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">8714</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">29</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">8685</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_Custom_01_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="0">1725000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">68356</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">56394</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="0">1275156</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">29052</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Context_Custom_15_Jul_2014T00_00_00_TO_18_Jul_2014T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="shares" decimals="INF">250000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_Custom_15_May_2014T00_00_00_TO_20_May_2014T00_00_00" unitRef="USD" decimals="0">2000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">37335</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">37335</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">382343</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">382343</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">10319137</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">10319137</us-gaap:ShareBasedCompensation>
<relm:IssuanceOfFairValueOfWarrantDerivativeLiabilitiesIssuedInUnitsOfferingDuringPeriodValue. contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-4333163</relm:IssuanceOfFairValueOfWarrantDerivativeLiabilitiesIssuedInUnitsOfferingDuringPeriodValue.>
<relm:IssuanceOfFairValueOfWarrantDerivativeLiabilitiesIssuedInUnitsOfferingDuringPeriodValue. contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-4333163</relm:IssuanceOfFairValueOfWarrantDerivativeLiabilitiesIssuedInUnitsOfferingDuringPeriodValue.>
<relm:IssuanceOfEliminatingDerivativeLiabilitiesUponShareExchangeDuringPeriodValue contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">6804625</relm:IssuanceOfEliminatingDerivativeLiabilitiesUponShareExchangeDuringPeriodValue>
<relm:IssuanceOfEliminatingDerivativeLiabilitiesUponShareExchangeDuringPeriodValue contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">6804625</relm:IssuanceOfEliminatingDerivativeLiabilitiesUponShareExchangeDuringPeriodValue>
<relm:SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureValue contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">960922</relm:SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureValue>
<relm:SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureValue contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">14805</relm:SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureValue>
<relm:SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureValue contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">-13604</relm:SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureValue>
<relm:SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureValue contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">959721</relm:SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureValue>
<relm:SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureShares contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">14805278</relm:SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureShares>
<relm:SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureShares contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="0">-13604128</relm:SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureShares>
<relm:IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">2000000</relm:IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange>
<relm:IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">3337</relm:IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange>
<relm:IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1993326</relm:IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange>
<relm:IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember" unitRef="USD" decimals="0">3337</relm:IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange>
<relm:IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">3337310</relm:IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares>
<relm:IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_PreferredClassAMember" unitRef="shares" decimals="0">3337309</relm:IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares>
<us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-186727</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
<us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-186727</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
<us-gaap:Depreciation contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:Depreciation contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">373</us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">2330</us-gaap:Depreciation>
<relm:CommonStockIssuedForServices contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">-1330849</relm:CommonStockIssuedForServices>
<relm:CommonStockIssuedForServices contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-3766918</relm:CommonStockIssuedForServices>
<relm:CommonStockIssuedForServices contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-8714</relm:CommonStockIssuedForServices>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">118639</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfDebtDiscountPremium contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">327776</us-gaap:AmortizationOfDebtDiscountPremium>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">69546</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:AmortizationOfFinancingCosts contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">78724</us-gaap:AmortizationOfFinancingCosts>
<us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">3688353</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
<us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">12877675</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
<us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">7954970</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
<us-gaap:IncreaseDecreaseInPrepaidExpensesOther contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">182708</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
<us-gaap:IncreaseDecreaseInPrepaidExpensesOther contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-160283</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
<us-gaap:IncreaseDecreaseInPrepaidExpensesOther contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">89983</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">32299</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-57102</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">565779</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">369927</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">315704</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">4287</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">-1583975</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-2237529</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-2164254</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:PaymentsToAcquireProductiveAssets contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:PaymentsToAcquireProductiveAssets contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">8871</us-gaap:PaymentsToAcquireProductiveAssets>
<us-gaap:PaymentsToAcquireProductiveAssets contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">3673</us-gaap:PaymentsToAcquireProductiveAssets>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-8871</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">-3673</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">3220018</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
<us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">3494428</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
<us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">22229321</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">2000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
<us-gaap:RepaymentsOfNotesPayable contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">39990</us-gaap:RepaymentsOfNotesPayable>
<us-gaap:RepaymentsOfNotesPayable contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:RepaymentsOfNotesPayable contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">19493</us-gaap:RepaymentsOfNotesPayable>
<relm:ProceedsFromSubordinatedPromissoryNotesNetOfDeferredFinancingCosts contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">154900</relm:ProceedsFromSubordinatedPromissoryNotesNetOfDeferredFinancingCosts>
<relm:ProceedsFromSubordinatedPromissoryNotesNetOfDeferredFinancingCosts contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">501600</relm:ProceedsFromSubordinatedPromissoryNotesNetOfDeferredFinancingCosts>
<relm:ProceedsFromSubordinatedPromissoryNotesNetOfDeferredFinancingCosts contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">3334928</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">3996028</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">24209828</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashPeriodIncreaseDecrease contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">1750953</us-gaap:CashPeriodIncreaseDecrease>
<us-gaap:CashPeriodIncreaseDecrease contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">1749628</us-gaap:CashPeriodIncreaseDecrease>
<us-gaap:CashPeriodIncreaseDecrease contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">22041901</us-gaap:CashPeriodIncreaseDecrease>
<us-gaap:IncomeTaxesPaid contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxesPaid contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxesPaid contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:InterestPaid contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:InterestPaid contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:InterestPaid contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">1103</us-gaap:InterestPaid>
<relm:ShareExchangeOfSubordinatedDebt contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" xsi:nil="true"/>
<relm:ShareExchangeOfSubordinatedDebt contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<relm:ShareExchangeOfSubordinatedDebt contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">900000</relm:ShareExchangeOfSubordinatedDebt>
<relm:ShareExchangeOfAccruedInterest contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" xsi:nil="true"/>
<relm:ShareExchangeOfAccruedInterest contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<relm:ShareExchangeOfAccruedInterest contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">60922</relm:ShareExchangeOfAccruedInterest>
<relm:IssuanceOfDebtInConnectionWithCompensationPolicy contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<relm:IssuanceOfDebtInConnectionWithCompensationPolicy contextRef="Context_Custom_05_May_2014T00_00_00_TO_06_May_2014T00_00_00_FinancialInstrumentAxis_FinancialAgreementMember" unitRef="USD" decimals="0">77850</relm:IssuanceOfDebtInConnectionWithCompensationPolicy>
<relm:IssuanceOfDebtInConnectionWithCompensationPolicy contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">77850</relm:IssuanceOfDebtInConnectionWithCompensationPolicy>
<relm:FairValueOfDerivativesTerminatedInConnectionWithShareExchange contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" xsi:nil="true"/>
<relm:FairValueOfDerivativesTerminatedInConnectionWithShareExchange contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<relm:FairValueOfDerivativesTerminatedInConnectionWithShareExchange contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">6804625</relm:FairValueOfDerivativesTerminatedInConnectionWithShareExchange>
<relm:FairValueOfDerivativesIssuedInConnectionWithIssuanceOfCommonStock contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" xsi:nil="true"/>
<relm:FairValueOfDerivativesIssuedInConnectionWithIssuanceOfCommonStock contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<relm:FairValueOfDerivativesIssuedInConnectionWithIssuanceOfCommonStock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">4333163</relm:FairValueOfDerivativesIssuedInConnectionWithIssuanceOfCommonStock>
<relm:BeneficialConversionFeature contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" xsi:nil="true"/>
<relm:BeneficialConversionFeature contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<relm:BeneficialConversionFeature contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">186727</relm:BeneficialConversionFeature>
<relm:FairValueOfDerivativesIssuedInConnectionWithIssuanceOfPreferredStock contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">984465</relm:FairValueOfDerivativesIssuedInConnectionWithIssuanceOfPreferredStock>
<relm:FairValueOfDerivativesIssuedInConnectionWithIssuanceOfPreferredStock contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">1761063</relm:FairValueOfDerivativesIssuedInConnectionWithIssuanceOfPreferredStock>
<relm:FairValueOfDerivativesIssuedInConnectionWithIssuanceOfPreferredStock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<relm:FairValueOfDerivativeWarrantsIssuedToLendersInConnectionWithIssuanceOfSubordinatedPromissoryNotes contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">26325</relm:FairValueOfDerivativeWarrantsIssuedToLendersInConnectionWithIssuanceOfSubordinatedPromissoryNotes>
<relm:FairValueOfDerivativeWarrantsIssuedToLendersInConnectionWithIssuanceOfSubordinatedPromissoryNotes contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">83363</relm:FairValueOfDerivativeWarrantsIssuedToLendersInConnectionWithIssuanceOfSubordinatedPromissoryNotes>
<relm:FairValueOfDerivativeWarrantsIssuedToLendersInConnectionWithIssuanceOfSubordinatedPromissoryNotes contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">13089</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">41681</us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<relm:FairValueOfDerivativeWarrantsIssuedForOfferingCostsInConnectionWithTheIssuanceOfSeriesAPreferredStock contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">79615</relm:FairValueOfDerivativeWarrantsIssuedForOfferingCostsInConnectionWithTheIssuanceOfSeriesAPreferredStock>
<relm:FairValueOfDerivativeWarrantsIssuedForOfferingCostsInConnectionWithTheIssuanceOfSeriesAPreferredStock contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">248655</relm:FairValueOfDerivativeWarrantsIssuedForOfferingCostsInConnectionWithTheIssuanceOfSeriesAPreferredStock>
<relm:FairValueOfDerivativeWarrantsIssuedForOfferingCostsInConnectionWithTheIssuanceOfSeriesAPreferredStock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<relm:FairValueOfDerivativeIssuedToWonpungForServices contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">299141</relm:FairValueOfDerivativeIssuedToWonpungForServices>
<relm:FairValueOfDerivativeIssuedToWonpungForServices contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<relm:FairValueOfDerivativeIssuedToWonpungForServices contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<relm:ExchangeOfLoansAndAccruedInterestForCommonStockFromFounder contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">1222321</relm:ExchangeOfLoansAndAccruedInterestForCommonStockFromFounder>
<relm:ExchangeOfLoansAndAccruedInterestForCommonStockFromFounder contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<relm:ExchangeOfLoansAndAccruedInterestForCommonStockFromFounder contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<relm:ExchangeOfSubordinatedNotesAndAccruedInterestForSeriesAPreferredStock contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">1541180</relm:ExchangeOfSubordinatedNotesAndAccruedInterestForSeriesAPreferredStock>
<relm:ExchangeOfSubordinatedNotesAndAccruedInterestForSeriesAPreferredStock contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<relm:ExchangeOfSubordinatedNotesAndAccruedInterestForSeriesAPreferredStock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<relm:CashlessExerciseOfWarrantsForCommonStock contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">54143</relm:CashlessExerciseOfWarrantsForCommonStock>
<relm:CashlessExerciseOfWarrantsForCommonStock contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<relm:CashlessExerciseOfWarrantsForCommonStock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;NOTE 1 &amp;#8211; BUSINESS&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Relmada Therapeutics, Inc., formerly Camp Nine, Inc. (the &amp;#8220;Company&amp;#8221;), was formed as a Nevada corporation on May 31, 2012 and began as a manufacturer and retailer of surfboards and related accessories. The Company is a clinical stage biopharmaceutical company focused on drugs to treat pain. The Company has a portfolio of four products at different stages of development and an early stage pipeline of an additional three products. The Company&amp;#8217;s&amp;#8217;s approach is expected to reduce overall clinical development risks and potentially deliver valuable products in areas of high unmet medical needs. The Company&amp;#8217;s office is located in New York City.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;On May 20, 2014, Relmada Therapeutics, Inc. (&amp;#8220;Relmada&amp;#8221;) completed a Share Exchange with the Company, whereby the Company acquired 94.6% of the issued and outstanding capital stock of Relmada from the stockholders in exchange (&amp;#8220;Share Exchange&amp;#8221;) for the issuance of 28,291,073 shares of common stock to the Company&amp;#8217;s stockholders, which represented 80.9% of Relmada&amp;#8217;s issued and outstanding common stock after the consummation of the Share Exchange. In addition, the outstanding options and warrants were exchanged for options and warrants to purchase shares of common stock of the Company at a ratio of 10 to 1. Prior to the Share Exchange, the Company had no other assets or liabilities. The principal shareholders of the Company contributed $2 million for 3,337,310 shares of the Company&amp;#8217;s common stock and 3,337,309 shares of Class A convertible preferred shares.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;As a result of the Share Exchange, the stockholders of the Relmada became the principal stockholders of Relmada. In addition, i&lt;font style="background-color: white;"&gt;n connection with the Share Exchange, the Company changed its name to Relmada Therapeutics, Inc. and increased its authorized common stock to 500,000,000 shares and its authorized preferred stock to 200,000,000 shares.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Share Exchange was accounted for as a reverse merger rather than a business combination, wherein Relmada is considered the acquirer for accounting and financial reporting purposes. The statement of operations reflects the activities of Relmada from the date of its inception, May 24, 2004. As a result of the Share Exchange, the Company became the holding company and Relmada became the subsidiary. The operating entity is that of Relmada.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;In addition to the normal risks associated with a new business venture, there can be no assurance that the Company&amp;#8217;s research and development will be successfully completed or that any product will be approved or commercially viable. The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with Food and Drug Administration (&amp;#8220;FDA&amp;#8221;) and other governmental regulations and approval requirements.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;NOTE 2 &amp;#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="background-color: white;"&gt;&lt;b&gt;Principles of Consolidation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="background-color: white;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="background-color: white;"&gt;The consolidated financial statements include the Company&amp;#8217;s accounts and those of the Company&amp;#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States (&amp;#8220;U.S. GAAP&amp;#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. The significant estimates are the valuation of derivative liabilities, stock-based compensation expenses and income taxes and its associated valuation allowance.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company considers cash deposits and all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company's cash deposits are held at two high-credit-quality financial institutions. The Company's cash deposits at these institutions exceed federally insured limits.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Patents&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Fixed Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Fixed assets are stated at cost less accumulated depreciation. Fixed assets are comprised of computers and software. Depreciation is calculated using the straight-line method over the estimated useful life of the related assets, which is three years.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none;
 text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Derivatives&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;All derivatives are recorded at fair value on the balance sheet. The Company has determined fair values using market based pricing models incorporating readily observable market data and requiring judgment and estimates.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Fair Value of Financial Instruments&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company&amp;#8217;s financial instruments primarily include cash, derivative liabilities, accounts payable and subordinated promissory notes. Due to the short-term nature of cash, derivative liability, accounts payable and promissory notes the carrying amounts of these assets and liabilities approximate their fair value. Derivatives are recorded at fair value at each period end. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Level 1 - Quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Level 2 - Valuations for assets and liabilities that can be obtained from readily available pricing sources via independent providers for market transactions involving similar assets or liabilities. The Company's principal markets for these securities are the secondary institutional markets, and valuations are based on observable market data in those markets.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Level 3 - Valuations for assets and liabilities that are derived from other valuation methodologies, including option pricing models, discounted cash flow models and similar techniques, and are not based on market exchange or dealer- or broker-traded transactions. Level 3 valuations incorporate certain assumptions and projections in determining the fair value assigned to such assets or liabilities.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Fair Value on a Recurring Basis&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;As required by Accounting Standard Codification (&amp;#8220;ASC&amp;#8221;) Topic No. 820 &amp;#8211; 10&amp;#160;&lt;i&gt;Fair Value Measurement&lt;/i&gt;, financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&amp;#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels. The estimated fair value of the derivative instruments which include Series A preferred stock with down-round protection provisions and warrants with down-round protection provisions was calculated with the assistance of a third party valuation firm, see Note
 4.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The following table sets forth, by level within the fair value hierarchy, the Company&amp;#8217;s financial liabilities that were accounted for at fair value on a recurring basis as of June 30, 2014:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Quoted Prices&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;In Active&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Significant&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Markets for&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Other&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Significant&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Carrying&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Identical&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Observable&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Unobservable&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Value as of&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Assets&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Inputs&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Inputs&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;June 30,&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;(Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;(Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times,
 serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;(Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;Derivative liabilities &amp;#8211; warrant instruments&lt;/td&gt;&lt;td style="width: 16px; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;-&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;-&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;25,586,933&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;25,586,933&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The following table sets forth, by level within the fair value hierarchy, the Company&amp;#8217;s financial liabilities that were accounted for at fair value on a recurring basis as of December 31, 2013:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Quoted Prices&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;In Active&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Significant&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Total&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Markets for&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Other&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Significant&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Carrying&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Identical&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Observable&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Unobservable&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Value as of&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Assets&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Inputs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Inputs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;December 31,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;(Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;(Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;(Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left;"&gt;Derivative liabilities &amp;#8211; warrant instruments&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;4,089,284&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;4,089,284&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Derivative liabilities &amp;#8211; Series A preferred stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;16,014,141&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;16,014,141&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Total derivative liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;20,103,425&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;20,103,425&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as level 3 in the fair value hierarchy:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0"
 cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="10"&gt;Significant Unobservable Inputs (Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Six Month&amp;#160;&lt;br /&gt;Ended&lt;br /&gt;June 30,&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Year&amp;#160;&lt;br /&gt;Ended&amp;#160;&lt;br /&gt;December 31,&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="text-align: center; font-family: 'times new roman', times, serif;"&gt;Year&lt;br /&gt;Ended&lt;br /&gt;December 31,&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; text-align: left; font-family: 'times new roman', times, serif;"&gt;Beginning balance&lt;/td&gt;&lt;td style="width: 16px; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; font-family: 'times new roman', times, serif;"&gt;(20,103,425&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;td style="width: 16px; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif;"&gt;(5,090,988&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;td style="width: 15px; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif;"&gt;-&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;Change in fair value of derivative liabilities included in net loss for the six months ended June 30, 2014 and for the years ended&amp;#160; December 31, 2013 and 2012, respectively&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;&lt;p style="margin: 0px;"&gt;(7,954,970&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;(12,877,675&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;(3,688,353&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;Additions &amp;#8211; warrant instruments&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(4,333,163&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(37&lt;/font&gt;&lt;font style="font-size: 10pt;"&gt;3,699&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;(119,029&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;Transfer of warrant instruments to additional paid in capital&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new
 roman', times, serif;"&gt;6,804,625&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;Additions &amp;#8211; conversion feature of Series A preferred stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(1,761,063&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(1,283,606&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(25,586,933&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(20,103,425&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(5,090,988&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future deductibility is uncertain. At June 30, 2014 and December 31, 2013, the Company had recognized a valuation allowance to the full extent of the Company&amp;#8217;s net deferred tax assets since the likelihood of realization of the benefit does not meet the more likely than not threshold.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company files a U.S. Federal income tax return and various state returns. Uncertain tax positions taken on our tax returns will be accounted for as liabilities for unrecognized tax benefits. The Company will recognize interest and penalties, if any, related to unrecognized tax benefits in general and administrative expenses in the statements of operations. There were no liabilities recorded for uncertain tax positions at June 30, 2014 and December 31,
 2013. The open tax years, subject to potential examination by the applicable taxing authority, for the Company were from 2010 through 2014.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Research and Development&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Research and development costs primarily consist of research contracts for the advancement of product development, stock-based compensation, and consultants. The Company expenses all research and development costs in the period incurred.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which an employee is required to provide service in exchange for the award - the requisite service period. The grant-date fair value of employee share options is estimated using the Black-Scholes option pricing model adjusted for the unique characteristics of those instruments. Compensation expense for options and warrants granted to non-employees is determined by the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured, and is recognized over the service period. The expense is subsequently adjusted to fair value at the end of each reporting period until such options and warrants vest, and the fair value of such instruments, as adjusted, is expensed over the related vesting period. Adjustments to fair value at each reporting date may result in income or expense, depending upon the estimate of fair value and the amount of expense recorded prior to the adjustment. The Company reviews its agreements and the future performance obligation with respect to the unvested options or warrants for its vendors or consultants. When appropriate, the Company will expense the unvested options or warrants at the time when management deems the service obligation for future services has ceased.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Net Loss per Common Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Basic net loss per common share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per common share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of Class A convertible preferred stock, Series A Preferred Stock, warrants for the purchase of common stock and options. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&amp;#8217;s net loss position.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Potentially dilutive securities are not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares):&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:
 center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Six Month&amp;#160;&lt;br /&gt;Ended&amp;#160;&lt;br /&gt;June 30,&amp;#160;&lt;br /&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;Year&lt;/p&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;Ended&amp;#160;&lt;br /&gt;December 31,&amp;#160;&lt;br /&gt;2013&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Year&lt;br /&gt;Ended&amp;#160;&lt;br /&gt;December 31,&lt;br /&gt;2012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; text-align: left; padding-left: 0pt;"&gt;Class A convertible preferred stock&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;3,337,309&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;Series A preferred stock&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;136,041,275&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;8,503,503&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;Common stock warrants&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;43,144,557&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;89,265,160&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;4,.865,235&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Common stock options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;3,365,171&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;18,654,097&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;677,962&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 5.4pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;49,847,037&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;243,960,532&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;14,046,700&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;In June 2014, the FASB issued ASU 2014-10, &amp;#8220;Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation&amp;#8221;. The guidance eliminates the definition of a development stage entity thereby removing the incremental financial reporting requirements from U.S. GAAP for development stage entities, primarily presentation of inception to date
 financial information. The provisions of the amendments are effective for annual reporting periods beginning after December 15, 2014, and the interim periods therein. However, early adoption is permitted. Accordingly, the Company has adopted this standard during the six months ending June 30, 2014.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company does not expect the adoption of any other recent accounting pronouncements to have a material impact on its financial statements.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Subsequent Events&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company&amp;#8217;s management reviewed all material events through the date the financial statements were issued for subsequent event disclosure consideration.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
<us-gaap:DebtDisclosureTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"&gt;&lt;b&gt;NOTE 3 &amp;#8211; NOTES PAYABLE&lt;/b&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: left;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"&gt;Subordinated 8% promissory notes payable consisted of the following at June 30, 2014 and December 31, 2013:&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center;" colspan="2"&gt;June 30,&lt;br /&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;December 31,&amp;#160;&lt;br /&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1179px; text-align: justify; text-indent: -9pt; padding-left: 9pt;"&gt;Subordinated 8% promissory notes due December 2013&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;216,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt;"&gt;Subordinated 8% promissory notes due September 2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;684,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: justify; padding-left: 0pt;"&gt;Total notes payable&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;900,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Less: debt discount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;(141,049&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: justify; padding-bottom: 4pt; padding-left: 0pt;"&gt;Total notes payable, less debt discount&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;758,951&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px;
 -webkit-text-stroke-width: 0px; margin: 0px;"&gt;&lt;b&gt;December 2012 Subordinated Promissory Notes Payable&lt;/b&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"&gt;In December 2012, the Company issued $216,000 of subordinated 8% promissory notes payable for cash proceeds of $180,000 which were due on December 6, 2013. In addition, the note holders received seven-year warrants to purchase 67,500 shares of common stock with an exercise price of $0.80 per share. The Company recorded the fair value of the warrants as a debt discount on the notes payable which resulted in a debt discount of $26,325. The difference between the face value and the cash proceeds of $36,000 was also treated as debt discount and was amortized to interest expense over the one year maturity of the notes. The Company also paid debt issuance costs of $25,100 to the placement agent that were recorded as deferred financing costs and amortized over the one year maturity of the notes. The effective interest rate was 36.9%. The Company also issued 33,750 warrants to purchase common stock at $0.80 per share to the placement agent which the Company recorded as a discount on the notes at the fair value of $13,089. All of the debt discount of $62,325 and deferred financing costs of $38,189 were fully amortized and recorded as interest expense during 2013 for these notes. These notes and accrued interest of approximately $960,900 were converted to 1,201,153 common stock upon the Share Exchange on May 20, 2014.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"&gt;The notes and accrued interest were automatically converted into common stock at $0.80 per share upon the Share Exchange on May 20, 2014. The warrants contained an anti-dilution provision if the Company raises equity in the future at a price lower than $0.80 per share, the warrants to purchase common stock and the notes payable conversion price will be adjusted for the anti-dilutive effects of such future issuance. As a result, the warrants issued with the debt are accounted for as derivative liabilities and recorded at fair value at each period end. The anti-dilution feature was eliminated upon the Share Exchange. The Company recorded the fair market value of the derivative financial instrument at the date of the Share Exchange on May 20, 2014.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"&gt;&lt;b&gt;September 2013 Subordinated Promissory Notes Payable&lt;/b&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"&gt;In September 2013, the Company issued $684,000 of subordinated 8% promissory notes payable for cash proceeds of $570,000 which are due in September 2014. In addition, the note holders received seven-year warrants to purchase 213,750 shares of common stock with an exercise price of $0.80 per share. The Company recorded the fair value of the warrants as a debt discount on the notes payable which resulted in a debt discount of $83,363. The difference between the face value and the cash proceeds of $114,000 was also treated as debt discount and is amortized to interest expense over the one year maturity of the notes. The Company also paid debt issuance costs of $68,400 to the placement agent that were recorded as deferred financing costs and are amortized over its one year maturity of the notes. The effective interest rate was 36.9%. The Company also issued 106,875 warrants to purchase common stock at $0.80 per share to the placement agent which the Company recorded as a discount on the notes at the fair value of $41,681. The Company has amortized debt discount for deferred financing costs of $219,773 and $31,357 to interest expense for these notes during the six months ended June 30, 2014 and for the year ended December 31, 2013, respectively.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size:
 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"&gt;The Company determined that there was a beneficial conversion feature on the September 2013 notes payable at the issuance date of approximately $186,800 which represented the difference between the effective conversion price of $0.60 per share and the fair value of the common stock as of the commitment date of $0.80 per share. The beneficial conversion feature was recorded as interest expense upon the Share Exchange.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"&gt;The notes and accrued interest of approximately $960,900 were automatically converted into 1,201,153 shares of common stock at $0.80 per share upon the Share Exchange on May 20, 2014. The warrants contained an anti-dilution feature if the Company raises equity in the future at a price lower than $0.80 per share, the warrants to purchase common stock and the notes payable conversion price will be adjusted for the anti-dilutive effects of such future issuance. As a result, the warrants issued with the debt are accounted for as derivative liabilities and recorded at fair value at balance sheet date. The anti-dilution feature was terminated upon the Share Exchange. The Company recorded the fair market value of the derivative financial instrument at the date of the Share Exchange on May 20, 2014.&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"&gt;&lt;font style="background-color: white;"&gt;In May 6, 2014, the Company entered into a finance agreement for $77,850 for its director and officer liability insurance policy. The Company paid its initial down payment of approximately $6,800 and has eleven monthly installments of approximately $6,60. The interest rate is 3.436% per annum. At June 30, 2014, the Company owed $58,357 in co&lt;/font&gt;nnection with this note payable.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
<us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;NOTE 4 &amp;#8211; DERIVATIVE LIABILITIES&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;ASC Topic No. 815 &amp;#8211;&amp;#160;&lt;i&gt;Derivatives and Hedging&lt;/i&gt;&amp;#160;provides guidance on determining what types of instruments or embedded features in an instrument issued by a reporting entity can be considered indexed to its own stock for the purpose of evaluating the first criteria of the scope exception in the pronouncement on accounting for derivatives. These requirements can affect the accounting for warrants and convertible preferred instruments issued by the Company. As the conversion features within the Series A preferred stock, and certain detachable warrants issued in connection with the subordinated promissory notes payable and equity offerings in 2012 and 2013, do not have fixed settlement provisions because their conversion and exercise prices may be lowered if the Company issues securities at lower prices in the future, the Company concluded that the instruments are not indexed to the Company&amp;#8217;s stock and are to be treated as derivative liabilities.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company obtained valuations prepared by Vantage Point Advisors, Inc. for purposes of determining the fair value of the derivatives and stock compensation expense. In determining the fair value of the derivatives, the Company used the Monte Carlo Simulations using Geometric Brownian method for the initial valuation and then the Black-Scholes option pricing model was used for the valuation at June 30, 2014.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The following is a summary of the assumptions used in the valuation model as of the initial valuations of the derivative warrant instruments issued during the six months ended June 30, 2014:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Initial&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;At&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;valuation&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;June 30&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1129px; text-align: left;"&gt;Common stock issuable upon exercise of warrants &amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 173px; text-align: right;"&gt;30,036,648&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 172px; text-align: right;"&gt;30,036,648&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Market value of common stock on measurement date (1)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.17&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;1.50 and 2.25&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;1.50 and 2.25&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Risk free interest rate (2)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.7&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.6&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Expected life in years&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;0.3 and 5&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;0.3 and 4.9&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Expected volatility (3)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;71 and 73&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&amp;#160;71 and 73&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Expected dividend yields (4)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;None&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;None&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 55.81px; padding-right: 5.4pt; padding-left: 0pt;"&gt;(1)&lt;/td&gt;&lt;td style="width: 1496.81px; padding-right: 5.4pt; padding-left: 0pt;"&gt;The market value is the calculated fair value of the common stock pursuant to the valuation technique as described above.&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding-right: 5.4pt; padding-left: 0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding-right: 5.4pt; padding-left: 0pt;"&gt;The risk-free interest rate was determined by management using the 1&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;and 5 - year Treasury Bill as of the measurement date.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding-right: 5.4pt; padding-left: 0pt;"&gt;(3)&lt;/td&gt;&lt;td style="padding-right: 5.4pt; padding-left: 0pt;"&gt;The historical trading volatility was determined by calculating the volatility of the Company&amp;#8217;s peer group.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The following is a summary of the assumptions used in the valuation model as of the initial valuations of the derivative warrant instruments and convertible Series A preferred stock issued during the years ended December 31, 2013 and December 31, 2012, respectively, and as of December 31, 2013, and December 31, 2012, respectively:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Initial&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Initial&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;At&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;At&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;valuations&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;valuations&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left;"&gt;Common stock issuable upon exercise of warrants&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;22,333,593&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;19,385,157&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align:
 right;"&gt;41,718,750&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;19,385,157&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -5.5pt; padding-left: 5.5pt;"&gt;Common stock issuable upon conversion of Series A preferred stock&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;51,006,250&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;85,035,025&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;136,041,275&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;85,035,025&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -5.5pt; padding-left: 5.5pt;"&gt;Market value of common stock on measurement date (1)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.80&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.30&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.80&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.80&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.80&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.80&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.80&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Risk free interest rate (2)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.19&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.20&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.38&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.19&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Expected life in years&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.4&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.6&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2.0&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.4&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Expected volatility (3)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;68&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;72&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;68&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;73&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Expected dividend yields (4)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;None&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;None&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;None&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;None&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 55.81px; padding-right: 5.4pt; padding-left: 0pt;"&gt;(1)&lt;/td&gt;&lt;td style="width: 1489.62px; padding-right: 5.4pt; padding-left: 5.4pt;"&gt;The market value is the calculated fair value of the common stock pursuant to the valuation technique as described above.&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding-right: 5.4pt; padding-left: 0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding-right: 5.4pt; padding-left: 5.4pt;"&gt;The risk-free interest rate was determined by management using the 1, 2 or 3 - year Treasury Bill as of the measurement date.&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding-right: 5.4pt; padding-left: 0pt;"&gt;(3)&lt;/td&gt;&lt;td style="padding-right: 5.4pt; padding-left: 5.4pt;"&gt;The historical trading volatility was determined by calculating the volatility of the Company&amp;#8217;s peer group.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width:
 0px;"&gt;Change in fair value of derivative liabilities during the six months ended June 30, 2014 was as follows:&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 13px/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table style="font: 8pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Balance at December&amp;#160;31,&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Initial valuation of derivative&lt;/font&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&lt;br /&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal;"&gt;liabilities upon&lt;/font&gt;&lt;/font&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&lt;br /&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal;"&gt;issuance of new warrants during&amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&lt;br /&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal;"&gt;the&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Increase (decrease) in fair value of derivative&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Fair value of&lt;/font&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;derivatives&lt;font style="font-style: normal; font-variant: normal; font-weight: normal;"&gt;&amp;#160;&lt;br /&gt;upon reclass to additional paid-in&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Balance at&amp;#160;&lt;/font&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&lt;br /&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal;"&gt;June 30,&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;2013&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;period&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times,
 serif;"&gt;liabilities&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;capital&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px 0px 0px 10px; text-indent: -10px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Convertible preferred derivative liability issued in&amp;#160;connection with Series A preferred stock offering&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;11,762,115&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(7,214,804&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(4,547,311&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding: 0px 0px 0px 10px; width: 617px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Convertible preferred derivative liability issued to Wonpung for services&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 16px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 16px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 142px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;2,030,589&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 16px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 16px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 16px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 142px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new
 roman', times, serif;"&gt;-&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 16px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 16px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 16px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 141px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(1,370,262&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 15px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 15px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 15px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 141px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(660,327&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 15px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 15px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 15px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 141px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 15px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Convertible preferred derivative liability issued to lenders in connection with exchange of debt for Series A preferred stock&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;2,219,854&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(1,262,858&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(956,996&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Warrants issued in connection with Series A preferred stock offering&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight:
 normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;2,424,167&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(1,945,669&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(478,498&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Warrants issued as offering costs to placement agent&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;1,217,083&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(1,109,421&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(107,662&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px;
 font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Warrants issued to lenders in connection with subordinated promissory notes offering&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;313,258&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(259,427&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(53,831&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Warrants issued to placement agent in connection with subordinated promissory notes offering&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;136,359&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(136,359&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td
 style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Series A warrants issued in May and June 2014 offering&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;842,370&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;9,198,452&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;10,040,822&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Series B warrants issued in connection with May and June 2014 offering&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;2,494,655&lt;/font&gt;&lt;/td&gt;&lt;td
 style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;7,400,275&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;9,894,930&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Placement Agent warrants issued in connection with May and June 2014 offering&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;996,138&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;4,655,043&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;5,651,181&lt;/font&gt;&lt;/td&gt;&lt;td
 style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;20,103,425&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;4,333,163&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;7,954,970&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(6,804,625&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px 0px 4px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;25,586,933&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 13px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 13px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Change in fair value of derivative liability during the year ended December 31, 2013 was as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Initial valuation&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;of
 derivative&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;liabilities upon&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Balance at&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;issuance of new derivatives&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Increase in fair value of&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Balance at&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;December 31,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;during&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;derivative&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;December 31,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;the period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 802.93px; text-align: left; text-indent: -9.05pt; padding-left: 9.05pt;"&gt;Convertible preferred derivative liability issued in connection with Series A preferred stock offering&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;2,492,166&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;1,647,910&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;7,622,039&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;11,762,115&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt;"&gt;Convertible preferred derivative liability issued to Wonpung for services&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;880,214&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,150,375&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,030,589&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt;"&gt;Convertible preferred derivative liability issued to lenders in connection with exchange of debt for Series A preferred stock&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;958,861&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,260,993&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,219,854&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt;"&gt;Warrants issued in connection with Series A preferred stock offering&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;475,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;113,153&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,836,014&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,424,167&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -9pt; padding-left: 9.05pt;"&gt;Warrants issued as offering costs to placement agent&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;242,500&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;248,655&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;725,928&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,217,083&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt;"&gt;Warrants issued to lenders in connection with subordinated promissory notes offering&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;29,158&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;83,363&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;200,737&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;313,258&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -9.05pt; padding-bottom: 1.5pt; padding-left: 9.05pt;"&gt;Warrants issued to placement agent in connection with subordinated promissory notes offering&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;13,089&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;41,681&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;81,589&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;136,359&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;5,090,988&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,134,762&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;12,877,675&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;20,103,425&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.2in; color: #000000; text-transform: none; text-indent: -0.2in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.2in; color: #000000; text-transform: none; text-indent: -0.2in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.2in; color: #000000; text-transform: none; text-indent: -0.2in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Change in fair value of derivative liability during the year ended December 31, 2012 was as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Initial valuation&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;of derivative&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:
 bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;liabilities upon&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Balance at&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;liabilities upon issuance of new&amp;#160;&lt;br /&gt;derivatives&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Increase&amp;#160;in fair value of&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Balance at&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;December 31,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;during&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;derivative&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;December 31,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2011&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;the period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 802.93px; text-align: left; text-indent: -9.05pt; padding-left: 9.05pt; font-style: normal; font-weight: normal;"&gt;Convertible preferred derivative liability issued in connection with Series A preferred stock offering&lt;/td&gt;&lt;td style="width: 16px; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-style: normal; font-weight: normal;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; font-style: normal; font-weight: normal;"&gt;-&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-style: normal; font-weight: normal;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; font-style: normal; font-weight: normal;"&gt;872,688&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-style: normal; font-weight: normal;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-style: normal; font-weight: normal;"&gt;1,619,478&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-style: normal; font-weight: normal;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-style: normal; font-weight: normal;"&gt;2,492,166&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt; font-style: normal; font-weight: normal;"&gt;Convertible preferred derivative liability issued to Wonpung for services&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;299,141&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;581,073&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;880,214&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt; font-style: normal; font-weight: normal;"&gt;Convertible preferred derivative liability issued to lenders in connection with exchange of debt for Series A preferred stock&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;958,861&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;958,861&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt; font-style: normal; font-weight: normal;"&gt;Warrants issued in connection with Series A preferred stock offering&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;111,777&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;363,223&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;475,000&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt; font-style: normal; font-weight: normal;"&gt;Warrants issued as offering costs to placement agent&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;79,615&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;162,885&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;242,500&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt; font-style: normal; font-weight: normal;"&gt;Warrants issued to lenders in connection with subordinated promissory notes offering&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;26,325&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;2,833&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;29,158&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -9.05pt; padding-bottom: 1.5pt; padding-left: 9.05pt; font-style: normal; font-weight: normal;"&gt;Warrants issued to placement agent in connection with subordinated promissory notes offering&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;13,089&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;13,089&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black;
 border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,402,635&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;3,688,353&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;5,090,988&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;NOTE 5 &amp;#8211; STOCKHOLDERS&amp;#8217; EQUITY&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Class A Convertible Preferred Stock (&amp;#8220;Class A Stock&amp;#8221;)&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;On May 20, 2014, Relmada Therapeutics, Inc. (&amp;#8220;Relmada&amp;#8221;) completed a Share Exchange with the Company, whereby the Company acquired 94.6% of the issued and outstanding capital stock of Relmada from the stockholders in exchange (&amp;#8220;Share Exchange&amp;#8221;) for the issuance of 28,291,073 shares of common stock to the Company&amp;#8217;s stockholders, which represented 80.9% of Relmada&amp;#8217;s issued and outstanding common stock after the consummation of the Share Exchange. In addition, the outstanding options and warrants were exchanged for options and warrants to purchase shares of common stock of the Company at a ratio of 10 to 1. Prior to the Share Exchange, the Company had no other assets or liabilities. The principal shareholders of the Company contributed $2 million for 3,337,310 shares of the Company&amp;#8217;s common stock and 3,337,309 shares of Class A preferred convertible shares.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Class A Stock shall has dividend rights to two times the amount of any dividend granted by the Board of Directors of the Company to the holders of common stock. In the event of any dissolution, liquidation or winding up of the Company, whether voluntary or involuntary, the holders of Class A Stock shall be entitled to participate in any distribution out of the assets of the Corporation on an equal basis per share with the holders of the Company&amp;#8217;s common stock. The holders of Class A Stock shall have no right to vote on any matter submitted to a vote of the holders of the Company&amp;#8217;s common stock, including the election of directors.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Class A Stock is automatically converted on a monthly basis into common stock on a one for one basis by action of the Corporation, in the event the total of all shares of common stock and Class A Stock held by the shareholder do not exceed 9.9% of the issued and outstanding shares of common stock of the company. In no event, can Class A Stock be converted into common stock of the Corporation if such conversion would cause the holder to own, beneficially or otherwise, more than 9.9% of the Company&amp;#8217;s stock.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Series A Preferred Stock&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Each share of Series A preferred stock automatically converted into common stock on a one for one basis upon the Share Exchange. There were 1,360,413 shares that were converted to common stock. In addition, the conversion price was subject to adjustment upon a future down round if any future stock offerings are issued below $0.80 per share. This anti-dilution feature for the Series A preferred stock and for the warrants, made these instruments a derivative liability. The anti-dilution feature was terminated upon the Share Exchange. The dividend rate was seven percent (7%) per annum on the amount paid for each Unit of the Series A preferred stock on an &amp;#8220;as declared&amp;#8221; basis. The Board of Directors has not declared any dividends on these shares. Each Series A preferred share had a liquidation value equal to the subscription price of each Series A preferred share plus any accrued and unpaid dividends. The liquidation preference of the Series A preferred stock at December 31, 2013 was approximately $10,883,300.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal;
 -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;In April 2012, the Company exchanged an aggregate of 1,879,128 shares of Series A preferred stock to convert the outstanding notes from the years 2004 and 2005 totaling $975,000 from lenders and accrued interest of approximately $566,180. In addition, the Company provided the lenders with 619,377 warrants to purchase common stock at $0.80 per share, and also allowed the lenders to exercise the warrants on a cashless basis for 541,430 shares of common stock. During 2012, the lenders exercised the warrants on a cashless basis resulting in the issuance of 541,430 shares of common stock. The Company determined that the fair value of the debt and accrued interest was more reliably determined than the fair value of the Series A preferred stock and warrants provided to the lenders and, accordingly, recorded no gain or loss on the exchange.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;In April 2012, the Company issued 1,725,000 Series A preferred stock to Wonpung in exchange for services. The Company recorded compensation expense of approximately $1,305,200 based on the fair value of the Series A preferred stock at the issuance date, and recorded as additional paid-in capital for approximately $1,006,100 and a derivative liability for approximately $299,100. The Company recorded the fair value of the shares issued as stock-based compensation expense of $1,305,200, which was recorded as equity for approximately $1,006,100 and derivative liability for approximately $299,100. The fair value of the shares was determined via a third party valuation, see Note 4. In addition, because the shares contained certain anti-dilution protection, the conversion feature of the preferred stock was accounted for as a derivative liability.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;During 2012, in a series of closings, the Company issued investors 4,899,375 shares of Series A preferred stock and 1,224,844 warrants to purchase shares of common stock with an exercise price of $0.80 per share for gross proceeds of approximately $3,919,500 ($3,220,018 net of offering costs). In addition, the Company issued the placement agent 612,422 warrants to purchase common stock with an exercise price of $0.80 per share. Both the warrants and the Series A preferred stock contain anti-dilution features deemed to be derivatives. The anti-dilution provision was eliminated upon the Share Exchange.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The table below reflects the gross proceeds received in connection with the 2012 offerings allocated to components of stockholders&amp;#8217; equity and to derivative liabilities based upon fair value:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 1379px; text-align: left; padding-left: 0pt;"&gt;Par value of Series A preferred stock issued&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 141px; text-align: right;"&gt;4,898&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-left: 0pt;"&gt;Additional paid-in-capital&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;2,151,040&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-left: 0pt;"&gt;Derivative warrant liabilities&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;111,777&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-left: 0pt;"&gt;Derivative preferred stock conversion feature&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;872,688&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Derivative&amp;#160;&amp;#160;Warrants issued to placement agent as offering costs&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;79,615&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-left: 0pt;"&gt;Net proceeds&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align:
 left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;3,220,018&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Offering costs paid in cash&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;699,482&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 4pt; padding-left: 0pt;"&gt;Gross proceeds&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;3,919,500&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;During 2013, in a series of closings, the Company issued investors 5,100,625 shares of Series A preferred stock and 1,275,156 warrants to purchase shares of common stock for proceeds of approximately $4,080,500 ($3,494,428 net of offering costs). The Company also issued the investors 1,275,156 warrants to purchase common stock with an exercise price of $0.80 per share. In addition, the Company issued the placement agent 637,578 warrants to purchase common stock with an exercise price of $0.80 per share. Both the warrants and the Series A preferred stock contain an anti-dilution features deemed to be derivatives, see Note 4.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The table below reflects the gross proceeds received in connection with the 2013 offerings allocated to components of stockholders&amp;#8217; equity and to derivative liabilities based upon fair value:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 1379px; text-align: left; padding-left: 0pt;"&gt;Par value of Series A preferred stock issued&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 141px; text-align: right;"&gt;
&lt;p style="margin: 0px;"&gt;5,100&lt;/p&gt;
&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-left: 0pt;"&gt;Additional paid-in-capital&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;
&lt;p style="margin: 0px;"&gt;1,479,610&lt;/p&gt;
&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-left: 0pt;"&gt;Derivative warrant liabilities&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;113,153&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-left: 0pt;"&gt;Derivative preferred stock conversion feature&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,647,910&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Derivative Warrants issued to placement agent as offering costs&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;248,655&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-left: 0pt;"&gt;Net proceeds&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;3,494,428&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Offering costs paid in cash&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;586,072&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 4pt; padding-left: 0pt;"&gt;Gross proceeds&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;4,080,500&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times,
 serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Common Stock&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Common stock issued in connection with settlement agreements&lt;/u&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;In April 2012, the Company issued 255,750 shares of common stock and warrants to purchase 868,213 shares of common stock with an exercise price of $0.80 per share that expire in April 2019 to exchange the outstanding liabilities owed to the founder of approximately $869,300. In addition, the founder forgave excess liabilities of approximately $353,246 and the Company recorded this as a contribution of additional paid-in-capital. On January 29, 2014, the Company cancelled the aforementioned warrants to the founder for failure to perform his fiduciary duties to the Company, see Note 8.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Common stock issued for services&lt;/u&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;During 2012, an executive was granted 153,802 shares of common stock. The grant date fair value of the common stock was $0.30 per share (based on a third party valuation), or approximately $46,100 in total. The vesting schedule provided that approximately 68,350 shares vested on July 10, 2012, 56,390 shares vested on July 10, 2013 and 29,052 shares vested on January 10, 2014. As a result, the Company recorded stock-based compensation expense of approximately $8,700, $16,900 and $20,500 for the six months ended June 30, 2014 and for the years ended December 31, 2013 and 2012, respectively, in connection with this agreement.&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Common stock issued for cash&lt;/u&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;On May 12, May 15 and June 10, 2014, the Company completed on a private placement for the sale of units for gross proceeds of $25,745,699. The units consist of 17,163,799 shares of the Company&amp;#8217;s common stock, Series A warrants to purchase 17,163,799 shares of common stock at an exercise price of $1.50 per share and Series B warrants to purchase 8,581,894 shares of common stock, at a exercise price of $2.25 per share. The Series A Warrants are exercisable immediately through October 10, 2014 and the Series B Warrants are exercisable immediately up to a period of five years from the date of issuance. The Company may call the Series B warrant for redemption upon written notice to all investors of the May and June 2014 units &amp;#160;(&amp;#8220;investors&amp;#8221;) at any time if the closing price of the common stock exceeds $3.75 per share for twenty (20) consecutive trading days provided that there an effective registration statement.&amp;#160;In sixty days (60) business days following the date the redemption notice &amp;#8220;Exercise Period&amp;#8221; that is sent to the investors, each may choose to exercise their Series B warrant or a portion of their Series B warrant, by paying the exercise price of $2.25 per share.&amp;#160;&lt;font style="color: #1f497d;"&gt;&amp;#160;&lt;/font&gt;Any warrants not exercised on the last day of the Exercise Period, will be redeemed by the Company at $0.001 per share.&amp;#160;&amp;#160;&lt;font style="color:
 #1f497d;"&gt;T&lt;/font&gt;he Placement Agent shall receive a warrant solicitation fee equal to five (5) % of the aggregate exercise price paid by the Series B holders upon such exercise, following a call for redemption by the Company. &amp;#160;The Company shall direct the Series B holder to make such solicitation fee payment directly to the Placement Agent and the Series B warrant holder shall comply with such direction.&amp;#160;&lt;font style="background-color: white;"&gt;The Company issued warrants to purchase 4,290,950 shares of common stock at $1.50 to its Placement Agent (&amp;#8220;Agent Warrants&amp;#8221;). The Agent Warrants are immediately exercisable and expire five years from the date of issuance. The Company paid approximately $3,516,000 including expenses to the Placement Agent and the net proceeds were approximately $22,229,300.&amp;#160;&lt;/font&gt;All the warrants in this transaction have an anti-dilution provision and shall terminate upon an up-listing of the Company to a national securities exchange such as NYSE or NASDAQ.&amp;#160;&lt;font style="background-color: white;"&gt;A registration rights agreement was entered into in connection with the private placement that required the Company to file a registration statement for the resale of shares of common stock and common stock issuable upon the exercise of the Series A and Series B warrants. The Company was required to use commercially reasonable efforts to have the registration statement declared effective within 45 days from the filing date. If the SEC reviews the registration statement, the Company has 180 days to have the registration statement declared effective. If the registration statement is not filed on time or declared effective within the pre-requisite time frame, the penalty is one percent (1%) up to the purchase price with a maximum penalty of six percent (6%).&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="background-color: white;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The table below reflects the gross proceeds received in connection with the May and June 2014 offerings allocated to components of stockholders&amp;#8217; equity and to derivative liabilities based upon fair value:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 1379px; font-family: 'times new roman', times, serif;"&gt;Par value of common stock issued&lt;/td&gt;
&lt;td style="width: 16px; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;"&gt;$&lt;/td&gt;
&lt;td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif;"&gt;17,164&lt;/td&gt;
&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="font-family: 'times new roman', times, serif;"&gt;Additional paid-in-capital&lt;/td&gt;
&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;17,878,994&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;Derivative warrant liabilities&lt;/td&gt;
&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;3,337,025&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;Derivative warrants issued to placement agent as offering costs&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;996,138&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;Net proceeds&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;22,222,321&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;Offering costs paid in cash&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; font-family:
 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;3,516,378&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;Gross proceeds&lt;/td&gt;
&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;25,745,699&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Common stock issued in connection with exercise of warrants&lt;/u&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;In April 2012, two lenders exercised their 618,766 warrants on a cashless basis and received 541,293 shares of common stock of the Company.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;u&gt;Common stock issued for acquisition of Medeor&lt;/u&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;In April 2012, the Company issued 17,089 shares of common stock to Medeor Inc. (&amp;#8220;Medeor&amp;#8221;) in connection with the acquisition of a license agreement. Management determined the fair value of the common stock to be $0.30 per share based on a third party valuation, and recorded stock-based compensation expense to research and development of approximately $5,100. At December 31, 2013, the Company issued 25,000,000 shares of common stock in exchange for all the outstanding stock of Medeor whose only asset was a pending research and development project. The transaction was valued at its fair value of $3,750,000 and was expensed to research and development expense. The fair value of the shares was determined via a third party valuation.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Options and warrants&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company has established the 2012 Stock Option Plan (the &amp;#8220;Plan&amp;#8221;), which allows for the granting of common stock awards, stock appreciation rights, and incentive and nonqualified stock options to purchase shares of the Company&amp;#8217;s common stock to designated employees, nonemployee directors, and consultants and advisors. The Plan allowed for 2,409,436 options to be granted in July 2012. On March 10, 2014, the Board of Directors increased the shares under the Plan to 4,000,000. The shareholders approved to increase the shares available under the plan to 8,058,844. At June 30, 2014, no stock appreciation rights have been issued. Stock options are exercisable generally for a period of 10 years from the date of grant and generally vest over four years. As of June 30, 2014, 4,693,673 shares were available for future grants under the Plan.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px;
 letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company utilizes the Black-Scholes option pricing model to estimate the fair value of stock options and warrants. The current price of common stock was determined from a third party valuation, see Note 4. The risk-free interest rate assumptions were based upon the observed interest rates appropriate for the expected term of the equity instruments. The expected dividend yield was assumed to be zero as the Company has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future. The expected volatility was based upon its peer group. The Company routinely reviews its calculation of volatility changes in future volatility, the Company&amp;#8217;s life cycle, its peer group, and other factors.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company uses the simplified method for share-based compensation to estimate the expected term for employee option awards for share-based compensation in its option-pricing model. The Company uses the contractual term for non-employee options to estimate the expected term, for share-based compensation in its option-pricing model.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Stock-based compensation &amp;#8211; options&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company granted an officer options to purchase 677,962 and 665,750 shares of its common stock in July 2012 and September 2013, respectively. Each of the options granted have a ten-year term and at an $0.80 exercise price. 25% of each of the options vest immediately and the remaining 75% of the options vest in equal quarterly increments over a four-year period. The fair value of the options as of the grant dates was $103,700 and $359,100, respectively.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;During November 2013, the Company granted a consultant options to purchase 187,500 shares of common stock. The options have a 10 year term and an $0.80 exercise price. 25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal quarterly increments over the following 3 years. The fair value of the options on the grant date was $114,800.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;During December 2013 and January 2014, the Company granted an officer options to purchase 334,199 and 1,003,774 shares of common stock, respectively. The options have a 10 year term and an exercise price of $0.80 and $1.50 per share, respectively. 25% of the options vest on the one anniversary of the grant date and the remaining options vest quarterly over the following 3 years. The fair value of the options on the grant date during December 2013 and January 2014 was $181,400 and $937,600, respectively.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;During February 2014, the Company granted to three of its board of directors, an aggregate of options to purchase 145,986 shares of common stock, respectively. Each option has a 10 year term and an exercise price of $1.50 per share, respectively. 25% of the options vest on the one year anniversary of the grant date and the remaining options vest quarterly over the following 3 years. The fair value of the options on the grant date was approximately $136,200.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent:
 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;During May 2014, the Company granted to its various employees, options to purchase 350,000 shares of common stock, respectively. Each option has a 10 year term and an exercise price of $1.50 per share, respectively. 25% of the options vest on the one year anniversary of the grant date and the remaining options vest quarterly over the following 3 years. The fair value of the options on the grant date was $250,200.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;In May 2014, the Board of Directors granted options to three officers options based upon a percentage of the fully diluted shares that exist after the exercise or forfeiture of the Series A warrants in October 2014. The Company will record stock-based compensation expense at fair value when the options are issued. The option price has been established at fair market value.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;A summary of the changes in options outstanding during the six months ended June 30, 2014 and years ended December 31, 2013 and 2012 is as follows:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Number of&lt;br /&gt;Shares&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Exercise&lt;br /&gt;Price&lt;br /&gt;Per Share&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Remaining&lt;br /&gt;Contractual&lt;br /&gt;Term (Years)&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Aggregate&lt;br /&gt;Intrinsic&lt;br /&gt;Value&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td&gt;Outstanding at December 31, 2011&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="width: 791.93px; text-indent: -8.65pt; padding-left: 17.3pt;"&gt;Granted&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 142px; text-align: right;"&gt;677,962&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 142px; text-align: right;"&gt;0.80&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 141px; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 141px; text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left;"&gt;Outstanding and expected to vest at December 31, 2012&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;677,962&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.80&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;9.5&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-indent: -8.65pt; padding-left: 17.3pt;"&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,187,449&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.80&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;-&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color:
 #cceeff;"&gt;
&lt;td style="text-align: left;"&gt;Outstanding and expected to vest at December 31, 2013&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,865,411&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.80&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;8.8&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1,305,000&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Granted&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;1,499,760&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;1.50&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;9.7&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;3,000,000&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Outstanding and expected to vest at June 30, 2014&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;3,365,171&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1.11&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;8.9&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;5,238,000&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 4pt;"&gt;Options exercisable at June 30, 2014&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;652,005&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;0.80&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;9.0&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;782,400&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;For the six months ended June 30, 2014 and for years ending December 31, 2013 and 2012, the Company recorded approximately $115,500, $4,800 and $0, respectively, of stock-based compensation expense to research and development expense. For the six months ended and for years ending December 31, 2013 and 2012, the Company recorded approximately $77,700, $129,600 and $35,100, respectively, of stock based compensation expense to general and administrative expense. At June 30, 2014, and December 31, 2013 and 2012, the Company has unrecognized stock based compensation expense of approximately $1,760,900, $589,500 and $0 related to stock options, respectively.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space:
 normal; -webkit-text-stroke-width: 0px;"&gt;The weighted average fair value of options granted during the six months ended June 30, 2014 and for the years ended December 31, 2013 and 2012 was approximately $0.72, $0.58 per share and $0.15 per share respectively, on the date of grant using the Black-Scholes option pricing model with the following assumptions:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1.5pt;" colspan="2"&gt;Six Month&lt;br /&gt;Ended&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;For the Years Ended&lt;br /&gt;December 31,&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;June 30, 2014&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2013&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 1003px;"&gt;Current price of common stock&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 142px; text-align: right;"&gt;2.00&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 141px; text-align: right;"&gt;0.80&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 141px; text-align: right;"&gt;0.30&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Risk free interest rate&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.5% to 1.6&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.4&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.6&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left;"&gt;Dividend yield&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;Volatility&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;76% to 77&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;73% to 80&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;82&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left;"&gt;Expected term (in years)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;6.25&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;5.75 to 10&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;5.75&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Stock-based compensation &amp;#8211; warrants&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;In connection with the Series A preferred stock offerings, during 2013 and 2012, the Company issued the investors
 1,275,156 and 1,224,845 warrants, respectively, to purchase common stock of the Company, exercisable at $0.80 per share. During 2013 and 2012, the Company also issued the Placement Agent 637,578 and 612,422 warrants, respectively to purchase common stock exercisable at $0.80 per share. The warrants have a seven-year term. These warrants contain anti-dilution features with down-round protection, thus the Company accounts for these warrants as derivative liabilities.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;In connection with the debt offerings in 2013 and 2012, the Company issued debt holders 213,750 and 67,500 warrants, respectively, to purchase common stock of the Company, exercisable at $0.80 per share. During 2013 and 2012, the Company also issued the placement agent 106,875 and 33,750 warrants, respectively to purchase common stock exercisable at $0.80 per share. The warrants have a seven-year term. These warrants contain anti-dilution features with down-round protection, thus the Company accounts for these warrants as derivative liabilities. The anti-dilution feature was been eliminated upon the Share Exchange.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;During 2012, warrant holders exercised 619,377 warrants to purchase common stock in a cashless exercise which resulted in the issuance of 541,430 shares of common stock.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;During 2012, the Company issued its founder 868,213 warrants to purchase common stock in connection with a transaction that exchanged debt for stock. These warrants were cancelled by the Company in January 2014, see Note 8.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;In 2013, the Company purchased Medeor Inc. and in connection with the purchase the Company issued the Placement Agent 200,000 warrants to purchase common stock of the Company. The warrants have a seven-year term and were fully vested upon issuance and have an exercise price of $1.10 per share. The Company recorded stock-based compensation of $237,400 in connection with the issuance of these warrants.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;In conjunction with a strategic advisor agreement, during 2013 and 2012, the Company issued warrants to purchase shares of common stock, at an exercise price of $0.001 per share that expires in seven years. The warrants have performance based requirements for vesting and will become fully vested upon completion of a public transaction. The Company has not recorded any stock based compensation expense prior to the Share Exchange since the performance requirements were not met. During the six months ended June 30, 2014, the performance achievement was met. The Company recorded the fair value of stock based compensation expense of approximately $10,119,000 based upon the Black-Scholes option pricing model for the 8,655,783 vested options.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;During the six months ended June 30, 2014 and for the years ended December 31, 2013 and 2012, the Company issued to consultants 12,500, 21,500 and 40,000 warrants, respectively, to purchase shares of common stock of the Company. The exercise price of the warrants issued during the years ended December 31, 2013 and 2012 were all at $0.80 per share. The grant date fair value of the warrants issued for the six months ended June 30, 2014 and for the years ended December, 31, 2013 and 2012 was approximately $14,300, $10,800 and $5,600, respectively, and the fair value was amortized over the term of the agreements.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal;
 -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;A summary of the changes in outstanding warrants during the six months ended June 30, 2014 and for the years ended December 31, 2013 and 2012 is as follows:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Number of&lt;br /&gt;Shares&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Exercise&lt;br /&gt;Price&lt;br /&gt;Per Share&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 1191px;"&gt;Outstanding at December 31, 2011&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 142px; text-align: right;"&gt;6,251&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 141px; text-align: right;"&gt;1.00&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;5,478,360&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.50&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;Exercised&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(619,377&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;0.80&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;Outstanding at December 31, 2012&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;4,865,234&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;Granted&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;4,061,283&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;0.54&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td&gt;Outstanding at December 31, 2013&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;8,926,517&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.54&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td&gt;Granted&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;35,086,253&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right;"&gt;1.58&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="padding-bottom: 4pt;"&gt;Forfeited (1)&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(868,213&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;)&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;0.80&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Outstanding and vested at June 30, 2014&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;
 border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;43,144,557&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;
&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1.25&lt;/td&gt;
&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;For the six months ended June 30, 2014 and for the years ending December 31, 2013 and 2012, the Company recorded approximately $0, $1,800 and $2,200, respectively, of stock-based compensation expense related to warrants to research and development expense. For the six months ended June 30, 2014 and for the years ending December 31, 2013 and 2012, the Company recorded to general and administrative expense approximately $12,124,500, $246,100 and $0 of stock-based compensation expense related to warrants for the six months ended June 30, 2014 and for the years ended December 31, 2013 and 2012, respectively. At June 30, 2014 and December 31, 2013 and 2012, the Company has unrecognized stock based compensation expense of approximately $6,500, $3,600 and $3,400, respectively related to outstanding warrants.&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 63px;"&gt;(1)&lt;/td&gt;
&lt;td style="width: 1504px; text-align: justify;"&gt;
&lt;p style="margin: 0px;"&gt;The warrants issued to Mr. Babul were cancelled on January 29, 2014, see Note 8.&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The weighted average fair value of warrants granted during the six months ended June 30, 2014 and for the years ended December 31, 2013 and 2012 was $1.40, $0.80 and $0.14 per share, respectively, on the date of grant, using the Black-Scholes option pricing model using the following assumptions:&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; padding-bottom: 1.5pt;" colspan="2"&gt;
&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;Six Month&amp;#160;&lt;br /&gt;Ended,&lt;/p&gt;
&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;June 30,&lt;/p&gt;
&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;Year Ended December 31,&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2013&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2012&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="width: 1003px;"&gt;Current price of common stock&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 142px; text-align: right;"&gt;2.00&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 141px; text-align: right;"&gt;$0.80 - $1.50&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;
&lt;td style="width: 141px; text-align: right;"&gt;0.30&lt;/td&gt;
&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Risk-free interest rate&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.7% to 2.0&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.9% to 1.8&lt;/td&gt;
&lt;td style="text-align:
 left;"&gt;%&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0.6% to .7&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left;"&gt;Dividend yield&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;0&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left;"&gt;Expected volatility&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;75% to 76&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;73% to&amp;#160;83&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;82% to 83&lt;/td&gt;
&lt;td style="text-align: left;"&gt;%&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left;"&gt;Expected term (in years)&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;4 and 7&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;4-7&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: right;"&gt;5&lt;/td&gt;
&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;NOTE 6 &amp;#8211; RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Placement Agent&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;On December 6, 2011, the Company entered into an engagement agreement with its placement agent (&amp;#8220;Placement Agent&amp;#8221;) for the Series A Preferred Stock and Notes Offering (collectively the &amp;#8220;Financings&amp;#8221;), of which Mr. Seth, a director of the Company, is also the Head of Healthcare Investment Banking. The agreement was amended on April 12, 2012 and again on February 25, 2013. Pursuant to the agreement, the placement agent was engaged on an exclusive basis for the Series A Preferred Stock and Notes Offering and as a financial advisor for assisting the Company with the restructuring of its capitalization and negotiating the conversion of its outstanding debt obligations to enable a successful financing (the "Notes Conversion"). In consideration for its services, the placement agent received: (a) re-activation fee of $15,000, (b) a cash fee equal to 7% of the Notes Conversion and 10% of the gross proceeds raised in the Financings, and (c) non-accountable expense reimbursement equal to 2% of the gross proceeds raised. The placement agent or its designees also received warrants to purchase shares of the Company&amp;#8217;s common stock in an amount equal to 10% of the shares of common stock and warrants issued or issuable as part of the units sold in the Series A Preferred Stock Offering and Notes Offerings. The agreement also provides that: (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than a Share Exchange in a going public transaction) with any party introduced to it by the placement agent, the placement agent would receive a success fee equal to 8% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the services described above, the Company requires a financing or advisory transaction the placement agent will have the right to act as the Company&amp;#8217;s financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the February 25, 2013 engagement agreement. For a period ending one year after the expiration of all lock-up agreements entered into in connection with the Share Exchange, any change in the size of the Company board of directors must be approved by the placement agent. See Note 3 and 4 on the warrants issued with respect to the Series A Preferred Stock and subordinated promissory notes.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Due to the Share Exchange, the anti-dilution feature for the warrants that were issued for the Series A Preferred Stock and Notes Offering were terminated, see Note 4. There were Series A warrants, Series B warrants and Placement Agent warrants, see Note 5, common stock. These warrants contain an anti-dilution feature and shall terminate upon an up-listing to a national stock exchange, see Note 4.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;On October 24, 2013, the Company entered into an engagement agreement which was amended December 19, 2013 with its Placement Agent to advise on the acquisition of Medeor Inc. In consideration for its services, the Placement Agent was eligible to receive: (a) a cash success fee equal to 8% of the value of the transaction plus a 2% non-reimbursable expense fee which was subsequently modified to a maximum of $150,000 plus, (b) $50,000 for a Fairness Opinion fee deductible against the success fee, and (c) a $50,000 activation fee. The agreement also provides that: (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than the Share Exchange) with any party introduced to it by the Placement Agent, the placement agent would receive a fee equal to 8% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the advisory services described above, the Company requires a financing or similar advisory transaction the Placement Agent will have the right to act as the Company&amp;#8217;s financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the engagement agreement.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;On February 18, 2014 and May 19, 2014, the Company entered into two engagement agreements with the Placement Agent for the May 2014 offering The Company agreed to pay Placement Agent: (a) a cash commission in the amount of ten percent (10%) of the gross proceeds of the
 Offering received from investors at a Closing as well as a non-accountable expense reimbursement equal to two percent; and (b) (2%) of the gross proceeds of the Offering received from investors at a Closing and an activation fee of $25,000. The Placement Agent or its designees also received five-year warrants to purchase 4,290,950 shares of Relmada&amp;#8217;s common stock at a price of $1.50 per share. The Placement Agent shall also be entitled to the compensation set forth above as well for any cash exercise of Warrants within six (6) months of the final closing of the Offering as well as a five percent (5%) solicitation fee for any Warrants exercised as a result of any redemption of any Warrants. If the Company elects to call the warrants, the Placement Agent shall receive a warrant solicitation fee equal to 5% of the funds solicited by the Placement Agent upon exercise of the warrants. The Company shall pay the Placement Agent a non-refundable financial advisory fee to be paid monthly, at the rate of $25,000 per month for a period of six months commencing after the May offerings.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Placement Agent also received cash proceeds from the Company of approximately $3,089,500, $554,700 and $470,300, for the six months ended June 30, 2014 and for the year ended December 31, 2013 and 2012, respectively, from the equity offerings in May and June 2014 and from the Series A preferred stock offerings. The Placement Agent received cash proceeds from the Company of $68,400 and $25,100, respectively, for the subordinated promissory notes issued during 2013 and 2012. The Placement Agent also received a strategic advisory fee of approximately $272,000 for restructuring the Company in 2012.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal calibri, helvetica, sans-serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;The Placement Agent received the following warrants during the year ended December 31, 2012:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal calibri, helvetica, sans-serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Number of warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Exercise price per share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Expiration&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 665.33px; text-align: left; font-style: normal; font-weight: normal;"&gt;Series A preferred offering&lt;/td&gt;&lt;td style="width: 10.66px; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10.66px; text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 94px; text-align: right; font-style: normal; font-weight: normal;"&gt;612,422&lt;/td&gt;&lt;td style="width: 10.66px; text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10.66px; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10.66px; text-align: left; font-style: normal; font-weight: normal;"&gt;$&lt;/td&gt;&lt;td style="width: 93.33px; text-align: right; font-style: normal; font-weight: normal;"&gt;0.80&lt;/td&gt;&lt;td style="width: 10px; text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10px; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10px; text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 93.33px; text-align: center; font-style: normal; font-weight: normal;"&gt;2019&lt;/td&gt;&lt;td style="width: 10px; text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;Subordinated promissory note offering&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;33,750&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-weight:
 normal;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;0.80&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;2019&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;646,172&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal calibri, helvetica, sans-serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal calibri, helvetica, sans-serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;The Placement Agent received the following warrants during the year ended December 31, 2013:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal calibri, helvetica, sans-serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Number of warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Exercise price per share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Expiration&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-style: normal; font-weight: normal;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-style: normal; font-weight: normal;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-style: normal; font-weight: normal;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 665.33px; text-align: left; font-style: normal; font-weight: normal;"&gt;Series A preferred offering&lt;/td&gt;&lt;td style="width: 10.66px; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10.66px; text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 94px; text-align: right; font-style: normal; font-weight: normal;"&gt;637,578&lt;/td&gt;&lt;td style="width: 10.66px; text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10.66px; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10.66px; text-align: left; font-style: normal; font-weight: normal;"&gt;$&lt;/td&gt;&lt;td style="width: 93.33px; text-align: right; font-style: normal; font-weight: normal;"&gt;0.80&lt;/td&gt;&lt;td style="width: 10px; text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10px; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10px; text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 93.33px; text-align: center; font-style: normal; font-weight: normal;"&gt;2020&lt;/td&gt;&lt;td style="width: 10px; text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align:
 bottom; background-color: white;"&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;Subordinated promissory note offering&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;106,875&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;0.80&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-style: normal; font-weight: normal;"&gt;2020&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;Acquisition of Medeor&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;200,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;1.10&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;2020&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;944,453&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-style: normal; font-weight: normal;" colspan="12"&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;The Placement Agent received the following warrants during the six months ended June 30, 2014:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt;
 border-bottom-style: solid;" colspan="2"&gt;Number of&amp;#160;&lt;br /&gt;warrants&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Exercise&lt;br /&gt;price per&amp;#160;&lt;br /&gt;share&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Expiration&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;May and June 2014 offering&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 2pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 2pt; border-bottom-style: double;"&gt;4,290,950&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-style: normal; font-weight: normal;"&gt;2019&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal calibri, helvetica, sans-serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Advisory Firm&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;On December 6, 2011, the Company entered into an advisory agreement with Jamess Capital Group, LLC (formerly known as Amerasia Capital Group, LLC), a consulting firm affiliated with Mr. Seth, a Director of the Company (&amp;#8220;Advisory Firm&amp;#8221;) to provide non-investment banking related advisory services. The Advisory Firm is due a monthly fee of $12,500 and the agreement is terminable by either party with three months written notice and is to be issued fully vested warrants to purchase common stock equal to 12% of the fully diluted shares of the Company as of the Share Exchange (exercisable at an exercise price of $0.001 per share), see Note 5. The Advisory Firm is also eligible to be reimbursed upon the submission of proper documentation for ordinary and necessary out-of-pocket expenses not to exceed $5,000 per month.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p
 style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Acquisition of Medeor&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;In April 2012, the Company (sublicensee) entered into a license agreement with Medeor (licensee) and issued 17,089 shares of stock for the license agreement. The Chief Executive Officer was a shareholder of Medeor. At December 31, 2013, the Company issued 2,500,000 shares of common stock in exchange for all the outstanding stock of Medeor whose only asset was a research and development project. The parties also amended the license agreement on December 31, 2013. The transaction was valued at its fair value of $3,750,000 and was expensed to research and development expense. The fair value of the shares was determined via a third party valuation.&amp;#160;&lt;font style="background-color: white;"&gt;The Company will make royalty and a milestone payments as defined in the amended license agreement. The Company (A) will make royalty payments up to 2% on net sales of licensed products that are not sold by sublicensee and (B) on each and every sublicense earned royalty payment received by licensee from its sublicensee on sales of license product by sublicensee, the higher of (i) 20% of the royalties received by licensee; or (ii) up to 2% of net sales of sublicensee. The Company will also make milestone payments of up to $4 million and up to $2 million, for the first commercial sale of product in the field that has a single active pharmaceutical ingredient, and for the first commercial sale of product in the field of product that has more than one active pharmaceutical ingredient, respectively.&lt;/font&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
<us-gaap:IncomeTaxDisclosureTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;NOTE 7 &amp;#8211; INCOME TAXES&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;No provision or benefit for federal or state income taxes has been recorded because the Company has incurred net losses for all periods presented and has provided a valuation allowance against its deferred tax assets.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The components of the Company&amp;#8217;s deferred tax assets are as follows at:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;June 30,&amp;#160;&lt;br /&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;December 31,&lt;br /&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1177.67px; text-align: left; padding-left: 10pt; font-family: 'times new roman', times, serif;"&gt;Net operating loss&lt;/td&gt;&lt;td style="width: 16px; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; font-family: 'times new roman', times, serif;"&gt;3,556,600&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif;"&gt;2,765,600&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-left: 10pt; font-family: 'times new roman', times, serif;"&gt;Stock based compensation&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;4,248,700&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-left: 10pt; font-family: 'times new roman', times, serif;"&gt;Research and development tax credits&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;197,700&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;436,300&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-left: 10pt; font-family: 'times new roman', times, serif;"&gt;Accruals&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;22,900&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;44,700&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td
 style="padding-left: 10pt; font-family: 'times new roman', times, serif;"&gt;Other&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;2,900&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;46,000&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(8,028,800&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(3,292,600&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company has maintained a full valuation allowance against its deferred tax at June 30, 2014 and December 31, 2013. A valuation allowance is required to be recorded when it is more likely than not that some portion or all of the net deferred tax assets will not be realized. Since the Company cannot be assured of realizing the net deferred tax asset, a full valuation allowance has been provided.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;At June 30, 2014, the Company had federal and state net operating loss carryforwards of approximately $8,762,000, which begin expiring in 2025. The Company also had federal research and development tax credit carryforwards of approximately $197,700 which will begin to expire in 2025. The United States Tax Reform Act of 1986 contains provisions that may limit the Company&amp;#8217;s net operating loss carryforwards available to be used in any given year in the event of significant changes in the ownership interests of significant stockholders, as defined. The effect of an ownership change would be the imposition of an annual limitation on the use of NOL carryforwards attributable to periods before the change. The amount of the annual limitation depends upon the value of the Company immediately before the change, changes to the Company&amp;#8217;s capital during a specified period prior to the change, and the federal published interest rate.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;A reconciliation of the statutory tax rate to the effective tax rate is as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: normal; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform:
 none; text-indent: 0px; letter-spacing: normal; word-spacing: normal; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; vertical-align: bottom;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; letter-spacing: normal; word-spacing: normal;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;Six Month Ended June&amp;#160;30,&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;Year Ended December,&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; vertical-align: bottom;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;2013&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;2012&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; vertical-align: bottom;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal;
 word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 1003px; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;Statutory federal income tax rate&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 142px; text-align: right; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;34&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;34&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;34&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;State (net of federal benefit)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;6.6&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;6.6&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif;
 letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;6.6&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -8.65pt; letter-spacing: normal; padding-left: 8.65pt; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;Non-deductible expenses&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;"&gt;&lt;p style="margin: 0px;"&gt;(13.1&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;(29.7&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;(18.8&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -8.65pt; letter-spacing: normal; padding-left: 8.65pt; word-spacing: normal;"&gt;Other&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;"&gt;&lt;p style="margin: 0px;"&gt;(2.3&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;)%&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;"&gt;-&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;"&gt;-&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td
 style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;p style="margin: 0px;"&gt;(25.2&lt;/p&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;(10.9&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;(21.8&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; padding-bottom: 4pt; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;Effective income tax rate&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 4pt; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; padding-bottom: 4pt; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 4pt; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; padding-bottom: 4pt; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 4pt; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font:
 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; padding-bottom: 4pt; word-spacing: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: normal; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: normal; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;The Company has no uncertain tax positions at June 30, 2014 and December 31, 2013 that would affect its effective tax rate. The Company does not anticipate a significant change in the amount of unrecognized tax benefits over the next twelve months. Because the Company is in a loss carryforward position, the Company is generally subject to US federal and state income tax examinations by tax authorities for all years for which a loss carryforward is available. If and when applicable, the Company will recognize interest and penalties as part of income tax expense.&lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;NOTE 8 &amp;#8211; COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;License Agreements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;Wonpung&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;On August 20, 2007, the Company entered into a License Development and Commercialization Agreement with Wonpung, a shareholder of the Company. Wonpung has exclusive territorial rights in countries it selects in Asia to market up to two drugs the Company is currently developing and a right of first refusal (&amp;#8220;ROFR&amp;#8221;) for up to an additional five drugs that the Company may develop in the future as defined in more detail in the license agreement.&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; text-indent: 0.5in; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;The Company received an upfront license fee of $1,500,000 and will earn royalties of up to 12% of net sales for up to two licensed products it is currently developing. The licensing terms for the ROFR products are subject to future negotiations and binding arbitration. The terms of each licensing agreement will expire on the earlier of any time from 15 years to 20 years after licensing or on the date of commercial availability of a generic product to such licensed product in the licensed territory. The Company&amp;#8217;s current focus is on developing and marketing its products in the United States and not Asia. It will be several years before the Company markets its products in Asia.&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;Third Party Licensor&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="background-color: white;"&gt;Based upon the Medeor transaction, the Company assumed an obligation to pay a third party (A) royalty payments up to 2% on net sales of licensed products that are not sold by sublicensee and (B) on each and every sublicense earned royalty payment received by licensee from its sublicensee on sales of license product by sublicensee, the higher of (i) 20% of the royalties received by licensee; or (ii) up to 2% of net sales of sublicensee. The Company will also make milestone payments of up to $4 million and up to $2 million, for the first commercial sale of product in the field that has a single active pharmaceutical ingredient, and for the first commercial sale of product in the field of product that has more than one active pharmaceutical ingredient, respectively, see Note 6.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="background-color: white;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;The Company currently leases its corporate office space for its New York City on a month-to month basis. The Company has a non-cancelable operating lease expiring in 2017 for its Pennsylvania office location. Future minimum lease payments are as follows:&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;For the year ended June 30,:&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;table align="center" style="font: 10pt/normal times new roman, times, serif; width: 80%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;2015&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;37,300&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 50%; text-align: left;"&gt;2016&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align:
 right;"&gt;38,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;2017&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;38,800&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;9,700&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;127,800&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;The Company incurred rent expense of approximately $67,800 and $64,600 for years ended December 31,&amp;#160;2013 and 2012, respectively, and approximately $13,300 for the six months ended June 30, 2014.&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;Legal&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;&lt;/b&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;The Pennsylvania Litigation:&amp;#160;&amp;#160;&lt;/b&gt;Relmada has sued its former President and Chief Scientific Officer, Najib Babul, in the United States District Court for the Eastern District of Pennsylvania.&amp;#160;&amp;#160;Mr. Babul resigned from his executive positions in September 2012 and was later removed from Relmada&amp;#8217;s board of directors.&amp;#160;&amp;#160;The Complaint alleges that, during the course of an audit, Relmada discovered approximately $1.5 million in questionable expenses incurred by Mr. Babul during his management of the company from 2004 until his resignation in 2012 (the &amp;#8220;Questionable Expenses&amp;#8221;). Outside the lawsuit, Relmada has also cancelled warrants to purchase 868,213 common stock (the &amp;#8220;Cancelled Warrants&amp;#8221;) on the grounds, among others, that Babul could not and did not satisfy the conditions for holding or exercising the warrants after his voluntary resignation from the Company.&amp;#160;&amp;#160;The Company also has not exchanged Mr. Babul&amp;#8217;s equity in Relmada for Company common stock pursuant to the Share Exchange that closed on May 20, 2014.&amp;#160;&amp;#160;Mr. Babul has answered the complaint, denying any liability, and has filed a counterclaim seeking specific performance and reinstatement of the Warrants, as well as compensatory damages and other relief.&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; text-indent: 0.5in; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;The Delaware Litigation:&amp;#160;&amp;#160;&lt;/b&gt;After the Pennsylvania Litigation was brought against him, Mr. Babul brought an action in the Court of Chancery Delaware (the state in which Relmada is incorporated), demanding that Relmada advance his litigation expenses in the Delaware and Pennsylvania Litigation pursuant to, among other things, a Delaware Statute that requires a corporation to advance the reasonable litigation expenses of a former officer or director who is a party to litigation by reason of that relationship, and the Court ordered Relmada to advance such expenses.&amp;#160;&amp;#160;Depending upon the outcome of that litigation, Relmada may or may not be entitled to be reimbursed for the advanced expenses, but there can be no assurance that, even if Relmada prevails, Mr. Babul will be able to repay Relmada.&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; text-indent: 0.5in; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;Other Potential Litigation:&amp;#160;&amp;#160;&lt;/b&gt;In addition to the aforementioned disputes, Relmada has been informed that Mr. Babul is contemplating making additional claims in the Pennsylvania litigation or elsewhere, as is Relmada.&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; text-indent: 0.5in; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;Management believes that Relmada has meritorious claims against Mr. Babul and for its defenses against Mr. Babul&amp;#8217;s claims, but the outcome of any litigation is impossible to predict with certainty at such time.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify;"&gt;&lt;b&gt;NOTE 9 &amp;#8211; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left;"&gt;On July 18, 2014, the Company entered into an agreement with a consultant for investor communication and public relations for one year. The consultant shall receive an upfront cash fee of $250,000 and $250,000 quarterly cash installments commencing in September 2014. In addition, the Company shall issue 250,000 shares of the Company&amp;#8217;s within fifteen (15) days of the agreement and the remaining 250,000 shares shall be issued in six monthly installments commencing in September 2014.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:ConsolidationPolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="background-color: white;"&gt;&lt;b&gt;Principles of Consolidation&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="background-color: white;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="background-color: white;"&gt;The consolidated financial statements include the Company&amp;#8217;s accounts and those of the Company&amp;#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/font&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
<us-gaap:UseOfEstimates contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt times new roman, times, serif; margin: 0;"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt times new roman, times, serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt times new roman, times, serif; margin: 0;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States (&amp;#8220;U.S. GAAP&amp;#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. The significant estimates are the valuation of derivative liabilities, stock-based compensation expenses and income taxes and its associated valuation allowance.&lt;/p&gt;</us-gaap:UseOfEstimates>
<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt times new roman, times, serif; margin: 0;"&gt;&lt;b&gt;Cash and Cash Equivalents &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt times new roman, times, serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt times new roman, times, serif; margin: 0;"&gt;The Company considers cash deposits and all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company's cash deposits are held at two high-credit-quality financial institutions. The Company's cash deposits at these institutions exceed federally insured limits.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
<relm:PatentsPolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt times new roman, times, serif; margin: 0;"&gt;&lt;b&gt;Patents&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt times new roman, times, serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt times new roman, times, serif; margin: 0;"&gt;Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.&lt;/p&gt;</relm:PatentsPolicyTextBlock>
<relm:FixedAssetsPolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt times new roman, times, serif; margin: 0;"&gt;&lt;b&gt;Fixed Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt times new roman, times, serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt times new roman, times, serif; margin: 0;"&gt;Fixed assets are stated at cost less accumulated depreciation. Fixed assets are comprised of computers and software. Depreciation is calculated using the straight-line method over the estimated useful life of the related assets, which is three years.&lt;/p&gt;</relm:FixedAssetsPolicyTextBlock>
<us-gaap:DerivativesPolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt times new roman, times, serif; margin: 0;"&gt;&lt;b&gt;Derivatives&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt times new roman, times, serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt times new roman, times, serif; margin: 0;"&gt;All derivatives are recorded at fair value on the balance sheet. The Company has determined fair values using market based pricing models incorporating readily observable market data and requiring judgment and estimates.&lt;/p&gt;&lt;p style="font: 10pt times new roman, times, serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Fair Value on a Recurring Basis&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;As required by Accounting Standard Codification (&amp;#8220;ASC&amp;#8221;) Topic No. 820 &amp;#8211; 10&amp;#160;&lt;i&gt;Fair Value Measurement&lt;/i&gt;, financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&amp;#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels. The estimated fair value of the derivative instruments which include Series A preferred stock with down-round protection provisions and warrants with down-round protection provisions was calculated with the assistance of a third party valuation firm, see Note 4.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The following table sets forth, by level within the fair value hierarchy, the Company&amp;#8217;s financial liabilities that were accounted for at fair value on a recurring basis as of June 30, 2014:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Quoted Prices&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;In Active&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Significant&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Markets for&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Other&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Significant&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Carrying&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Identical&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Observable&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Unobservable&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Value as of&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Assets&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Inputs&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Inputs&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;June 30,&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;(Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;(Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;(Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;Derivative liabilities &amp;#8211; warrant instruments&lt;/td&gt;&lt;td style="width: 16px; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;-&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;-&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;25,586,933&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;25,586,933&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The following table sets forth, by level within the fair value hierarchy, the Company&amp;#8217;s financial liabilities that were accounted for at fair value on a recurring basis as of December 31, 2013:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Quoted Prices&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;In Active&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Significant&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="text-align: center;" colspan="2"&gt;Total&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Markets for&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Other&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Significant&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Carrying&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Identical&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Observable&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Unobservable&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Value as of&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Assets&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Inputs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Inputs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;December 31,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;(Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;(Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;(Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left;"&gt;Derivative liabilities &amp;#8211; warrant instruments&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;4,089,284&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;4,089,284&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Derivative liabilities &amp;#8211; Series A preferred stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;16,014,141&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;16,014,141&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Total derivative liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;20,103,425&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;20,103,425&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width:
 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as level 3 in the fair value hierarchy:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="10"&gt;Significant Unobservable Inputs (Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Six Month&amp;#160;&lt;br /&gt;Ended&lt;br /&gt;June 30,&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Year&amp;#160;&lt;br /&gt;Ended&amp;#160;&lt;br /&gt;December 31,&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="text-align: center; font-family: 'times new roman', times, serif;"&gt;Year&lt;br /&gt;Ended&lt;br /&gt;December 31,&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; text-align: left; font-family: 'times new roman', times, serif;"&gt;Beginning balance&lt;/td&gt;&lt;td style="width: 16px; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; font-family: 'times new roman', times, serif;"&gt;(20,103,425&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;td style="width: 16px; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif;"&gt;(5,090,988&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;td style="width: 15px; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif;"&gt;-&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;Change in fair value of derivative liabilities included in net loss for the six months ended June 30, 2014 and for the years ended&amp;#160; December 31, 2013 and 2012, respectively&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;&lt;p style="margin: 0px;"&gt;(7,954,970&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;(12,877,675&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;(3,688,353&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;Additions &amp;#8211; warrant instruments&lt;/td&gt;&lt;td&gt;&lt;font style="font:
 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(4,333,163&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(37&lt;/font&gt;&lt;font style="font-size: 10pt;"&gt;3,699&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;(119,029&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;Transfer of warrant instruments to additional paid in capital&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;6,804,625&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;Additions &amp;#8211; conversion feature of Series A preferred stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(1,761,063&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(1,283,606&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(25,586,933&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(20,103,425&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(5,090,988&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
<us-gaap:IncomeTaxPolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt times new roman, times, serif; margin: 0;"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt times new roman, times, serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt times new roman, times, serif; margin: 0;"&gt;The Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future deductibility is uncertain. At June 30, 2014 and December 31, 2013 the Company had recognized a valuation allowance to the full extent of the Company&amp;#8217;s net deferred tax assets since the likelihood of realization of the benefit does not meet the more likely than not threshold.&lt;/p&gt;&lt;p style="font: 10pt times new roman, times, serif; margin: 0;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt times new roman, times, serif; margin: 0;"&gt;The Company files a U.S. Federal income tax return and various state returns. Uncertain tax positions taken on our tax returns will be accounted for as liabilities for unrecognized tax benefits. The Company will recognize interest and penalties, if any, related to unrecognized tax benefits in general and administrative expenses in the statements of operations. There were no liabilities recorded for uncertain tax positions at June 30, 2014 and December 31, 2013. The open tax years, subject to potential examination by the applicable taxing authority, for the Company were from 2010 through 2014&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt times new roman, times, serif; margin: 0;"&gt;&lt;b&gt;Research and Development&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt times new roman, times, serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt times new roman, times, serif; margin: 0;"&gt;Research and development costs primarily consist of research contracts for the advancement of product development, stock-based compensation, and consultants. The Company expenses all research and development costs in the period incurred.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt times new roman, times, serif; margin: 0;"&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt times new roman, times, serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt times new roman, times, serif; margin: 0;"&gt;The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which an employee is required to provide service in exchange for the award - the requisite service period. The grant-date fair value of employee share options is estimated using the Black-Scholes option pricing model adjusted for the unique characteristics of those instruments. Compensation expense for options and warrants granted to non-employees is determined by the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured, and is recognized over the service period. The expense is subsequently adjusted to fair value at the end of each reporting period until such options and warrants vest, and the fair value of such instruments, as adjusted, is expensed over the related vesting period. Adjustments to fair value at each reporting date may result in income or expense, depending upon the estimate of fair value and the amount of expense recorded prior to the adjustment. The Company reviews its agreements and the future performance obligation with respect to the unvested options or warrants for its vendors or consultants. When appropriate, the Company will expense the unvested options or warrants at the time when management deems the service obligation for future services has ceased.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Net Loss per Common Share&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Basic net loss per common share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per common share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of Class A convertible preferred stock, Series A Preferred Stock, warrants for the purchase of common stock and options. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&amp;#8217;s net loss position.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;Potentially dilutive securities are not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares):&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Six Month&amp;#160;&lt;br /&gt;Ended&amp;#160;&lt;br /&gt;June 30,&amp;#160;&lt;br /&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;Year&lt;/p&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;Ended&amp;#160;&lt;br /&gt;December 31,&amp;#160;&lt;br /&gt;2013&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Year&lt;br /&gt;Ended&amp;#160;&lt;br /&gt;December 31,&lt;br /&gt;2012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; text-align: left; padding-left: 0pt;"&gt;Class A convertible preferred stock&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;3,337,309&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;Series A preferred stock&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;136,041,275&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;8,503,503&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;Common stock warrants&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;43,144,557&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;89,265,160&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;4,.865,235&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Common stock options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;3,365,171&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;18,654,097&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;677,962&lt;/td&gt;&lt;td style="text-align: left; padding-bottom:
 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 5.4pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;49,847,037&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;243,960,532&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;14,046,700&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;In June 2014, the FASB issued ASU 2014-10, &amp;#8220;Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation&amp;#8221;. The guidance eliminates the definition of a development stage entity thereby removing the incremental financial reporting requirements from U.S. GAAP for development stage entities, primarily presentation of inception to date financial information. The provisions of the amendments are effective for annual reporting periods beginning after December 15, 2014, and the interim periods therein. However, early adoption is permitted. Accordingly, the Company has adopted this standard during the six months ending June 30, 2014.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The Company does not expect the adoption of any other recent accounting pronouncements to have a material impact on its financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: left;"&gt;&lt;b&gt;Subsequent Events&lt;/b&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: left;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: left;"&gt;The Company&amp;#8217;s management reviewed all material events through the date the financial statements were issued for subsequent event disclosure consideration.&lt;/p&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Quoted Prices&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;In Active&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Significant&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Markets for&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Other&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Significant&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Carrying&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Identical&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Observable&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Unobservable&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Value as of&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Assets&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Inputs&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Inputs&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;June 30,&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;(Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;(Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;(Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left; font-family: 'times new roman', times, serif;"&gt;Derivative liabilities &amp;#8211; warrant instruments&lt;/td&gt;&lt;td style="width: 16px; font-family: 'times new roman', times,
 serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; font-family: 'times new roman', times, serif;"&gt;-&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; font-family: 'times new roman', times, serif;"&gt;-&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif;"&gt;25,586,933&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif;"&gt;25,586,933&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Quoted Prices&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;In Active&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Significant&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Total&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Markets for&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Other&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Significant&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Carrying&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Identical&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Observable&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Unobservable&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Value as of&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Assets&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Inputs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Inputs&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;December 31,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Description&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;(Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;(Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;(Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left;"&gt;Derivative liabilities &amp;#8211; warrant instruments&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;4,089,284&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;4,089,284&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Derivative liabilities &amp;#8211; Series A preferred stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;16,014,141&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;16,014,141&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Total derivative liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;20,103,425&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;20,103,425&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1568px; height: 213px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="10"&gt;Significant Unobservable Inputs (Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Six Month&amp;#160;&lt;br /&gt;Ended&lt;br /&gt;June 30,&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2"&gt;Year&amp;#160;&lt;br /&gt;Ended&amp;#160;&lt;br /&gt;December 31,&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="text-align: center; font-family: 'times new roman', times, serif;"&gt;Year&lt;br /&gt;Ended&lt;br /&gt;December 31,&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; text-align: left; font-family: 'times new roman', times, serif;"&gt;Beginning balance&lt;/td&gt;&lt;td style="width: 16px; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; font-family: 'times new roman', times, serif;"&gt;(20,103,425&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;td style="width: 16px; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif;"&gt;(5,090,988&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;td style="width: 15px; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif;"&gt;-&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;Change in fair value of derivative liabilities included in net loss for the six months ended June 30, 2014 and for the years ended&amp;#160; December 31, 2013 and 2012, respectively&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;&lt;p style="margin: 0px;"&gt;(7,954,970&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;(12,877,675&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;(3,688,353&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;Additions&amp;#8211; warrant instruments&lt;/td&gt;&lt;td&gt;&lt;font&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(4,333,163&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(37&lt;/font&gt;&lt;font style="font-size: 10pt;"&gt;3,699&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;(119,029&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;Transfer of warrant instruments to
 additional paid in capital&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;6,804,625&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;Additions &amp;#8211; conversion feature of Series A preferred stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(1,761,063&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(1,283,606&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;Ending balance&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(25,586,933&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(20,103,425&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(5,090,988&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Six Month &lt;br /&gt; Ended &lt;br /&gt;June 30, &lt;br /&gt; 2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;Year&lt;/p&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;Ended &lt;br /&gt;December 31, &lt;br /&gt; 2013&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Year&lt;br /&gt; Ended &lt;br /&gt;December 31,&lt;br /&gt; 2012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 64%; text-align: left; padding-left: 0pt;"&gt;Class A convertible preferred stock&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;3,337,309&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;Series A preferred stock&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;136,041,275&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;8,503,503&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;Common stock warrants&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;43,144,557&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;89,265,160&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;4,.865,235&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Common stock options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;3,365,171&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;18,654,097&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;677,962&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 5.4pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;49,847,037&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;243,960,532&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;14,046,700&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
<relm:ScheduleOfPromissoryNotesDueLoanTableTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center;" colspan="2"&gt;June 30,&lt;br /&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;December 31,&amp;#160;&lt;br /&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1179px; text-align: justify; text-indent: -9pt; padding-left: 9pt;"&gt;Subordinated 8% promissory notes due December 2013&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;216,000&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt;"&gt;Subordinated 8% promissory notes due September 2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;684,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: justify; padding-left: 0pt;"&gt;Total notes payable&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;900,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Less: debt discount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;(141,049&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: justify; padding-bottom: 4pt; padding-left: 0pt;"&gt;Total notes payable, less debt discount&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;758,951&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;</relm:ScheduleOfPromissoryNotesDueLoanTableTextBlock>
<relm:ScheduleOfDerivativeLiabilitiesValuationsModelsTableTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Initial&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;At&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;valuation&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;June 30&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1129px; text-align: left;"&gt;Common stock issuable upon exercise of warrants &amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 173px; text-align: right;"&gt;30,036,648&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 172px; text-align: right;"&gt;30,036,648&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Market value of common stock on measurement date (1)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.17&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;1.50 and 2.25&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;1.50 and 2.25&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Risk free interest rate (2)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.7&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.6&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Expected life in years&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;0.3 and 5&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;0.3 and 4.9&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Expected volatility (3)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;71 and 73&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&amp;#160;71 and 73&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Expected dividend yields (4)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;None&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;None&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 55.81px; padding-right: 5.4pt; padding-left: 0pt;"&gt;(1)&lt;/td&gt;&lt;td style="width: 1496.81px; padding-right: 5.4pt; padding-left: 0pt;"&gt;The market value is the calculated fair value of the common stock pursuant to the valuation technique as described above.&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding-right: 5.4pt; padding-left: 0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding-right: 5.4pt; padding-left: 0pt;"&gt;The risk-free interest rate was determined by management using the 1&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;and 5 - year Treasury Bill as of the measurement date.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding-right: 5.4pt; padding-left: 0pt;"&gt;(3)&lt;/td&gt;&lt;td style="padding-right: 5.4pt; padding-left: 0pt;"&gt;The historical trading volatility was determined by calculating the volatility of the Company&amp;#8217;s peer group.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal;
 -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Initial&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Initial&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;At&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;At&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;valuations&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;valuations&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;December&amp;#160;31,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left;"&gt;Common stock issuable upon exercise of warrants&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;22,333,593&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;19,385,157&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;41,718,750&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;19,385,157&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -5.5pt; padding-left: 5.5pt;"&gt;Common stock issuable upon conversion of Series A preferred stock&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;51,006,250&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;85,035,025&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;136,041,275&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;85,035,025&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -5.5pt; padding-left: 5.5pt;"&gt;Market value of common stock on measurement date (1)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.80&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.30&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.80&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.80&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.80&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.80&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.80&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Risk free interest rate (2)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.19&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.20&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.38&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.19&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Expected life in years&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.4&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.6&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2.0&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.4&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Expected volatility (3)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="text-align: right;"&gt;68&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;72&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;68&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;73&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Expected dividend yields (4)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;None&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;None&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;None&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;None&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 55.81px; padding-right: 5.4pt; padding-left: 0pt;"&gt;(1)&lt;/td&gt;&lt;td style="width: 1489.62px; padding-right: 5.4pt; padding-left: 5.4pt;"&gt;The market value is the calculated fair value of the common stock pursuant to the valuation technique as described above.&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding-right: 5.4pt; padding-left: 0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding-right: 5.4pt; padding-left: 5.4pt;"&gt;The risk-free interest rate was determined by management using the 1, 2 or 3 - year Treasury Bill as of the measurement date.&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding-right: 5.4pt; padding-left: 0pt;"&gt;(3)&lt;/td&gt;&lt;td style="padding-right: 5.4pt; padding-left: 5.4pt;"&gt;The historical trading volatility was determined by calculating the volatility of the Company&amp;#8217;s peer group.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</relm:ScheduleOfDerivativeLiabilitiesValuationsModelsTableTextBlock>
<us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 8pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Balance at December&amp;#160;31,&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Initial valuation of derivative&lt;/font&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&lt;br /&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal;"&gt;liabilities upon&lt;/font&gt;&lt;/font&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&lt;br /&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal;"&gt;issuance of new warrants during&amp;#160;&lt;/font&gt;&lt;/font&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&lt;br /&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal;"&gt;the&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Increase (decrease) in fair value of derivative&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Fair value of&lt;/font&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;derivatives&lt;font style="font-style: normal; font-variant: normal; font-weight: normal;"&gt;&amp;#160;&lt;br /&gt;upon reclass to additional paid-in&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Balance at&amp;#160;&lt;/font&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&lt;br /&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal;"&gt;June 30,&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;2013&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;period&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;liabilities&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times
 new roman', times, serif;"&gt;capital&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px 0px 0px 10px; text-indent: -10px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Convertible preferred derivative liability issued in&amp;#160;connection with Series A preferred stock offering&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;11,762,115&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(7,214,804&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(4,547,311&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding: 0px 0px 0px 10px; width: 617px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Convertible preferred derivative liability issued to Wonpung for services&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 16px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 16px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 142px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;2,030,589&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 16px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 16px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 16px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 142px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 16px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 16px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 16px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times,
 serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 141px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(1,370,262&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 15px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 15px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 15px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 141px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(660,327&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 15px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 15px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 15px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 141px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; width: 15px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Convertible preferred derivative liability issued to lenders in connection with exchange of debt for Series A preferred stock&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;2,219,854&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(1,262,858&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(956,996&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Warrants issued in connection with Series A preferred stock offering&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;2,424,167&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal
 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(1,945,669&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(478,498&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Warrants issued as offering costs to placement agent&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;1,217,083&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(1,109,421&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(107,662&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding: 0px 0px 0px 10px;
 text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Warrants issued to lenders in connection with subordinated promissory notes offering&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;313,258&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(259,427&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(53,831&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Warrants issued to placement agent in connection with subordinated promissory notes offering&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;136,359&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(136,359&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style:
 normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Series A warrants issued in May and June 2014 offering&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;842,370&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;9,198,452&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;10,040,822&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Series B warrants issued in connection with May and June 2014 offering&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;2,494,655&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style:
 normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;7,400,275&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;9,894,930&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Placement Agent warrants issued in connection with May and June 2014 offering&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;996,138&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;4,655,043&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;5,651,181&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;Total&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px;
 text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;20,103,425&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;4,333,163&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;7,954,970&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;(6,804,625&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px 0px 4px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;25,586,933&lt;/font&gt;&lt;/td&gt;&lt;td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 13px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 13px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Initial valuation&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;of derivative&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;liabilities upon&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Balance at&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;issuance of new derivatives&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Increase in fair value of&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Balance at&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;December
 31,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;during&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;derivative&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;December 31,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;the period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 802.93px; text-align: left; text-indent: -9.05pt; padding-left: 9.05pt;"&gt;Convertible preferred derivative liability issued in connection with Series A preferred stock offering&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;2,492,166&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;1,647,910&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;7,622,039&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;11,762,115&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt;"&gt;Convertible preferred derivative liability issued to Wonpung for services&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;880,214&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,150,375&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,030,589&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt;"&gt;Convertible preferred derivative liability issued to lenders in connection with exchange of debt for Series A preferred stock&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;958,861&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,260,993&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,219,854&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt;"&gt;Warrants issued in connection with Series A preferred stock offering&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;475,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;113,153&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,836,014&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,424,167&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -9pt; padding-left: 9.05pt;"&gt;Warrants issued as offering costs to placement agent&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;242,500&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;248,655&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;725,928&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,217,083&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt;"&gt;Warrants issued to lenders in connection with subordinated promissory notes offering&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;29,158&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;83,363&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;200,737&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;313,258&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td
 style="text-align: left; text-indent: -9.05pt; padding-bottom: 1.5pt; padding-left: 9.05pt;"&gt;Warrants issued to placement agent in connection with subordinated promissory notes offering&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;13,089&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;41,681&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;81,589&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;136,359&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;5,090,988&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,134,762&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;12,877,675&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;20,103,425&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.2in; color: #000000; text-transform: none; text-indent: -0.2in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Initial valuation&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;of derivative&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;liabilities upon&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Balance at&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;liabilities upon issuance of new&amp;#160;&lt;br /&gt;derivatives&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Increase&amp;#160;in fair value of&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;Balance at&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;December 31,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;during&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;derivative&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;December 31,&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2011&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;the period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight:
 normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 802.93px; text-align: left; text-indent: -9.05pt; padding-left: 9.05pt; font-style: normal; font-weight: normal;"&gt;Convertible preferred derivative liability issued in connection with Series A preferred stock offering&lt;/td&gt;&lt;td style="width: 16px; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-style: normal; font-weight: normal;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; font-style: normal; font-weight: normal;"&gt;-&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-style: normal; font-weight: normal;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; font-style: normal; font-weight: normal;"&gt;872,688&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-style: normal; font-weight: normal;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-style: normal; font-weight: normal;"&gt;1,619,478&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-style: normal; font-weight: normal;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-style: normal; font-weight: normal;"&gt;2,492,166&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt; font-style: normal; font-weight: normal;"&gt;Convertible preferred derivative liability issued to Wonpung for services&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;299,141&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;581,073&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;880,214&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt; font-style: normal; font-weight: normal;"&gt;Convertible preferred derivative liability issued to lenders in connection with exchange of debt for Series A preferred stock&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;958,861&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;958,861&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt; font-style: normal; font-weight: normal;"&gt;Warrants issued in connection with Series A preferred stock offering&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;111,777&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;363,223&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;475,000&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt; font-style: normal; font-weight: normal;"&gt;Warrants issued as offering costs to placement agent&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;79,615&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;162,885&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;242,500&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt; font-style: normal; font-weight: normal;"&gt;Warrants issued to lenders in connection with subordinated promissory notes offering&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;26,325&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;2,833&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-weight: normal;"&gt;29,158&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-weight: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: -9.05pt; padding-bottom: 1.5pt; padding-left: 9.05pt; font-style: normal; font-weight: normal;"&gt;Warrants issued to placement agent in connection with subordinated promissory notes offering&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;13,089&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;13,089&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,402,635&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;3,688,353&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;5,090,988&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
<relm:ScheduleOfCashProceedsReceivedFromOfferingsTableTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The table below reflects the gross proceeds received in connection with the 2012 offerings allocated to components of stockholders&amp;#8217; equity and to derivative liabilities based upon fair value:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px; text-align: left; padding-left: 0pt;"&gt;Par value of Series A preferred stock issued&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;4,898&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-left: 0pt;"&gt;Additional paid-in-capital&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;2,151,040&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;Derivative warrant liabilities&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;111,777&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;Derivative preferred stock conversion feature&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;872,688&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Derivative&amp;#160;&amp;#160;Warrants issued to placement agent as offering costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;79,615&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;Net proceeds&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;3,220,018&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Offering costs paid in cash&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;699,482&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 0pt;"&gt;Gross proceeds&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;3,919,500&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The table below reflects the gross proceeds received in connection with the 2013 offerings allocated to components of stockholders&amp;#8217; equity and to derivative liabilities based upon fair value:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px; text-align: left; padding-left: 0pt;"&gt;Par value of Series A preferred stock issued&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;&lt;p style="margin: 0px;"&gt;5,100&lt;/p&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-left: 0pt;"&gt;Additional paid-in-capital&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;p style="margin: 0px;"&gt;1,479,610&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;Derivative warrant liabilities&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;113,153&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;Derivative preferred stock conversion feature&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,647,910&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Derivative Warrants issued to placement agent as offering costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align:
 right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;248,655&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;Net proceeds&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;3,494,428&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Offering costs paid in cash&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;586,072&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 0pt;"&gt;Gross proceeds&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;4,080,500&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;The table below reflects the gross proceeds received in connection with the May and June 2014 offerings allocated to components of stockholders&amp;#8217; equity and to derivative liabilities based upon fair value:&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1379px; font-family: 'times new roman', times, serif;"&gt;Par value of common stock issued&lt;/td&gt;&lt;td style="width: 16px; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif;"&gt;17,164&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;Additional paid-in-capital&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;17,878,994&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;Derivative warrant liabilities&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;3,337,025&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;Derivative warrants issued to placement agent as offering costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;996,138&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;Net proceeds&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif;"&gt;22,222,321&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;Offering costs paid in cash&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;3,516,378&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;Gross proceeds&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: 'times
 new;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;25,745,699&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</relm:ScheduleOfCashProceedsReceivedFromOfferingsTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Number of&lt;br /&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Exercise&lt;br /&gt;Price&lt;br /&gt;Per Share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Remaining&lt;br /&gt;Contractual&lt;br /&gt;Term (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Aggregate&lt;br /&gt;Intrinsic&lt;br /&gt;Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Outstanding at December 31, 2011&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 791.93px; text-indent: -8.65pt; padding-left: 17.3pt;"&gt;Granted&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;677,962&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;0.80&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Outstanding and expected to vest at December 31, 2012&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;677,962&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.80&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;9.5&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;-&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: -8.65pt; padding-left: 17.3pt;"&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,187,449&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.80&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Outstanding and expected to vest at December 31, 2013&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,865,411&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.80&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;8.8&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;1,305,000&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;1,499,760&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;9.7&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;3,000,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Outstanding and expected to vest at June 30, 2014&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width:
 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;3,365,171&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1.11&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;8.9&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;5,238,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;Options exercisable at June 30, 2014&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;652,005&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;0.80&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;9.0&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;782,400&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;" colspan="2"&gt;Six Month&lt;br /&gt;Ended&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;For the Years Ended&lt;br /&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;June 30, 2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px;"&gt;Current price of common stock&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;2.00&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;0.80&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;0.30&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Risk free interest rate&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.5% to 1.6&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.4&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.6&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;76% to 77&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;73% to 80&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;82&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;6.25&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.75 to 10&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5.75&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
<relm:ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Number of&lt;br /&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Weighted&lt;br /&gt;Average&lt;br /&gt;Exercise&lt;br /&gt;Price&lt;br /&gt;Per Share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px;"&gt;Outstanding at December 31, 2011&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;6,251&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;1.00&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5,478,360&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.50&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;(619,377&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;0.80&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Outstanding at December 31, 2012&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;4,865,234&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;4,061,283&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;0.54&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td&gt;Outstanding at December 31, 2013&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;8,926,517&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.54&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;35,086,253&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;1.58&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-bottom: 4pt;"&gt;Forfeited (1)&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;(868,213&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;0.80&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Outstanding and vested at June 30, 2014&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;43,144,557&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;1.25&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;</relm:ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 625px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;" colspan="2"&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;Six Month&amp;#160;&lt;br /&gt;Ended,&lt;/p&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;June 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 388px;"&gt;Current price of common stock&lt;/td&gt;&lt;td style="width: 6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 6px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 56px; text-align: right;"&gt;2.00&lt;/td&gt;&lt;td style="width: 11px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 6px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 56px; text-align: right;"&gt;$0.80 - $1.50&lt;/td&gt;&lt;td style="width: 11px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 6px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 6px; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 56px; text-align: right;"&gt;0.30&lt;/td&gt;&lt;td style="width: 11px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.7% to 2.0&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.9% to 1.8&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0.6% to .7&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;0&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left;"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;75% to 76&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;73% to&amp;#160;83&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;82% to 83&lt;/td&gt;&lt;td style="text-align: left;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;4 and 7&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;4-7&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;5&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
<us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-family: calibri, helvetica, sans-serif; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;The Placement Agent received the following warrants during the year ended December 31, 2012:&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-family: calibri, helvetica, sans-serif; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Number of warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Exercise price per share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Expiration&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; font-weight: normal; font-style: normal; text-align: left;"&gt;Series A preferred offering&lt;/td&gt;&lt;td style="width: 16px; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; font-weight: normal; font-style: normal; text-align: right;"&gt;612,422&lt;/td&gt;&lt;td style="width: 16px; font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; font-weight: normal; font-style: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; font-weight: normal; font-style: normal; text-align: right;"&gt;0.80&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; font-weight: normal; font-style: normal; text-align: center;"&gt;2019&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt;"&gt;Subordinated promissory note offering&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;33,750&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: right; padding-bottom: 1.5pt;"&gt;0.80&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: center; padding-bottom: 1.5pt;"&gt;2019&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-weight: normal; font-style: normal; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;646,172&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: right; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: right; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-size: 10pt; font-style:
 normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-family: calibri, helvetica, sans-serif; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-family: calibri, helvetica, sans-serif; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;The Placement Agent received the following warrants during the year ended December 31, 2013:&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-family: calibri, helvetica, sans-serif; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Number of warrants&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Exercise price per share&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Expiration&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: center;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; font-weight: normal; font-style: normal; text-align: left;"&gt;Series A preferred offering&lt;/td&gt;&lt;td style="width: 16px; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; font-weight: normal; font-style: normal; text-align: right;"&gt;637,578&lt;/td&gt;&lt;td style="width: 16px; font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; font-weight: normal; font-style: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; font-weight: normal; font-style: normal; text-align: right;"&gt;0.80&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; font-weight: normal; font-style: normal; text-align: center;"&gt;2020&lt;/td&gt;&lt;td style="width: 15px; font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;Subordinated promissory note offering&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: right;"&gt;106,875&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: right;"&gt;0.80&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: center;"&gt;2020&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;"&gt;Acquisition of Medeor&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;200,000&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal;
 text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: right; padding-bottom: 1.5pt;"&gt;1.10&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: center; padding-bottom: 1.5pt;"&gt;2020&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; font-style: normal; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;"&gt;944,453&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: right; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: center; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; font-style: normal;" colspan="12"&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;The Placement Agent received the following warrants during the six months ended June 30, 2014:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Number of&amp;#160;&lt;br /&gt;warrants&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Exercise&lt;br /&gt;price per&amp;#160;&lt;br /&gt;share&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Expiration&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align:
 right;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-weight: normal; font-style: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;May and June 2014 offering&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: right;"&gt;4,290,950&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: right;"&gt;1.50&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: center;"&gt;2024&lt;/td&gt;&lt;td style="font-weight: normal; font-style: normal; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-family: calibri, helvetica, sans-serif; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;June 30,&amp;#160;&lt;br /&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;December 31,&lt;br /&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;" colspan="2"&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1177.671875px; font-family: 'times new roman', times, serif; text-align: left; padding-left: 10pt;"&gt;Net operating loss&lt;/td&gt;&lt;td style="width: 16px; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; font-family: 'times new roman', times, serif; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; font-family: 'times new roman', times, serif; text-align: right;"&gt;3,556,600&lt;/td&gt;&lt;td style="width: 16px; font-family: 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; font-family: 'times new roman', times, serif; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; font-family: 'times new roman', times, serif; text-align: right;"&gt;2,765,600&lt;/td&gt;&lt;td style="width: 15px; font-family: 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-family: 'times new roman', times, serif; text-align: left; padding-left: 10pt;"&gt;Stock based compensation&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; text-align: right;"&gt;4,248,700&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-family: 'times new roman', times, serif; text-align: left; padding-left: 10pt;"&gt;Research and development tax credits&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; text-align: right;"&gt;197,700&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; text-align: right;"&gt;436,300&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-family: 'times new roman', times, serif; padding-left: 10pt;"&gt;Accruals&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; text-align: right;"&gt;22,900&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; text-align: right;"&gt;44,700&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-family: 'times new roman', times, serif; padding-left: 10pt;"&gt;Other&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; text-align: right;"&gt;2,900&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; text-align: right;"&gt;46,000&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt;"&gt;Valuation allowance&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-family: 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-family: 'times new roman', times, serif; text-align: right;"&gt;(8,028,800&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif; text-align: left;"&gt;)&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-family: 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-family: 'times new roman', times, serif; text-align: right;"&gt;(3,292,600&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif; text-align: left;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-family: 'times new roman', times, serif; padding-bottom: 4pt;"&gt;Total&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-family: 'times new roman', times, serif; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-family: 'times new roman', times, serif; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-family: 'times new roman', times, serif; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-family: 'times new roman', times, serif; text-align: left;"&gt;$&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-family: 'times new roman', times, serif; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: normal; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;td style="text-align: center; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;" colspan="2"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;Six Month Ended June&amp;#160;30,&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;" colspan="6"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;Year Ended December,&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;td style="text-align: center; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;" colspan="2"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;" colspan="2"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;2013&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom:
 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;" colspan="2"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;2012&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;" colspan="2"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;" colspan="2"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;" colspan="2"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant:
 normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;Statutory federal income tax rate&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 142px; text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;34&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;34&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;34&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; background-color: white;"&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;State (net of federal benefit)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;
 letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;6.6&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;6.6&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;6.6&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; background-color: #cceeff;"&gt;&lt;td style="text-indent: -8.65pt; padding-left: 8.65pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;Non-deductible expenses&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;p style="margin: 0px;"&gt;(13.1&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal;
 word-spacing: normal;"&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;(29.7&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;(18.8&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; background-color: white;"&gt;&lt;td style="text-indent: -8.65pt; padding-left: 8.65pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;Other&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;p style="margin: 0px;"&gt;(2.3&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;)%&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;-&lt;/td&gt;&lt;td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height:
 normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;"&gt;&lt;p style="margin: 0px;"&gt;(25.2&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;(10.9&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;(21.8&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;)%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height:
 normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;Effective income tax rate&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;/p&gt;&lt;table align="center" style="font: 10pt/normal times new roman, times, serif; width: 80%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;2015&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;$&lt;/td&gt;&lt;td style="text-align: right;"&gt;37,300&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 50%; text-align: left;"&gt;2016&lt;/td&gt;&lt;td style="width: 1%;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right;"&gt;38,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;2017&lt;/td&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right;"&gt;38,800&lt;/td&gt;&lt;td style="text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;2018&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;9,700&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;127,800&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="Context_As_Of_20_May_2014T00_00_00_TO_20_May_2014T00_00_00" unitRef="pure" decimals="3">0.946</us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="Context_Custom_15_May_2014T00_00_00_TO_20_May_2014T00_00_00" unitRef="shares" decimals="0">28291073</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
<us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage contextRef="Context_As_Of_20_May_2014T00_00_00_TO_20_May_2014T00_00_00" unitRef="pure" decimals="3">0.809</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
<us-gaap:StockholdersEquityNoteStockSplit contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">The outstanding options and warrants were exchanged for options and warrants to purchase shares of common stock of the Company at a ratio of 10 to 1.</us-gaap:StockholdersEquityNoteStockSplit>
<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="Context_As_Of_31_Dec_2011T00_00_00_TO_31_Dec_2011T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">-5090988</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">-20103425</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">-25586933</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
<us-gaap:IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">-3688353</us-gaap:IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption>
<us-gaap:IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">-12877675</us-gaap:IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption>
<us-gaap:IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">-7954970</us-gaap:IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption>
<relm:FairValueOfWarrantsInstruments contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">-119029</relm:FairValueOfWarrantsInstruments>
<relm:FairValueOfWarrantsInstruments contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">-373699</relm:FairValueOfWarrantsInstruments>
<relm:FairValueOfWarrantsInstruments contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">-4333163</relm:FairValueOfWarrantsInstruments>
<relm:TransferOfFairValueWarrantInstrumentsAdditionalPaidInCapital contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" xsi:nil="true"/>
<relm:TransferOfFairValueWarrantInstrumentsAdditionalPaidInCapital contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" xsi:nil="true"/>
<relm:TransferOfFairValueWarrantInstrumentsAdditionalPaidInCapital contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">6804625</relm:TransferOfFairValueWarrantInstrumentsAdditionalPaidInCapital>
<relm:ConversionOfSeriesAPreferredStock contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">-1283606</relm:ConversionOfSeriesAPreferredStock>
<relm:ConversionOfSeriesAPreferredStock contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="0">-1761063</relm:ConversionOfSeriesAPreferredStock>
<relm:ConversionOfSeriesAPreferredStock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" xsi:nil="true"/>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="shares" decimals="INF">14046700</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">8503503</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementClassOfStockAxis_CommonStockWarrantsMember" unitRef="shares" decimals="INF">4865235</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementClassOfStockAxis_CommonStockOptionsMember" unitRef="shares" decimals="INF">677962</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementClassOfStockAxis_PreferredClassAMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="INF">243960532</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">136041275</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementClassOfStockAxis_CommonStockWarrantsMember" unitRef="shares" decimals="INF">89265160</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementClassOfStockAxis_CommonStockOptionsMember" unitRef="shares" decimals="INF">18654097</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementClassOfStockAxis_PreferredClassAMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="INF">49847037</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" xsi:nil="true"/>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_CommonStockWarrantsMember" unitRef="shares" decimals="INF">43144557</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_CommonStockOptionsMember" unitRef="shares" decimals="INF">3365171</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_PreferredClassAMember" unitRef="shares" decimals="INF">3337309</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:LoansPayableCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">900000</us-gaap:LoansPayableCurrent>
<us-gaap:LoansPayableCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueOneMember" unitRef="USD" decimals="0">684000</us-gaap:LoansPayableCurrent>
<us-gaap:LoansPayableCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueMember" unitRef="USD" decimals="0">216000</us-gaap:LoansPayableCurrent>
<us-gaap:LoansPayableCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:LoansPayableCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_DebtInstrumentAxis_PromissoryNotesDueOneMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:LoansPayableCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_DebtInstrumentAxis_PromissoryNotesDueMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_DebtInstrumentAxis_PromissoryNotesDueTwoMember" unitRef="pure" decimals="3">0.369</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
<us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="Context_As_Of_30_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember" unitRef="pure" decimals="3">0.369</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
<us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="Context_As_Of_06_May_2014T00_00_00_TO_06_May_2014T00_00_00_FinancialInstrumentAxis_FinancialAgreementMember" unitRef="pure" decimals="5">0.03436</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
<us-gaap:NotesPayable contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_DebtInstrumentAxis_PromissoryNotesDueTwoMember" unitRef="USD" decimals="0">216000</us-gaap:NotesPayable>
<us-gaap:NotesPayable contextRef="Context_As_Of_30_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember" unitRef="USD" decimals="0">684000</us-gaap:NotesPayable>
<us-gaap:DebtInstrumentMaturityDate contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_DebtInstrumentAxis_PromissoryNotesDueTwoMember">2013-12-06</us-gaap:DebtInstrumentMaturityDate>
<us-gaap:DebtInstrumentMaturityDate contextRef="Context_Custom_01_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember">2014-09-30</us-gaap:DebtInstrumentMaturityDate>
<relm:DebtDiscountAmortizationPeriod contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_DebtInstrumentAxis_PromissoryNotesDueTwoMember">P7Y</relm:DebtDiscountAmortizationPeriod>
<relm:DebtDiscountAmortizationPeriod contextRef="Context_Custom_01_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember">P7Y</relm:DebtDiscountAmortizationPeriod>
<us-gaap:ProceedsFromNotesPayable contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_DebtInstrumentAxis_PromissoryNotesDueTwoMember" unitRef="USD" decimals="0">180000</us-gaap:ProceedsFromNotesPayable>
<us-gaap:ProceedsFromNotesPayable contextRef="Context_Custom_01_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember" unitRef="USD" decimals="0">570000</us-gaap:ProceedsFromNotesPayable>
<us-gaap:SharePrice contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_DebtInstrumentAxis_PromissoryNotesDueTwoMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_30_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueOneMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_30_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_20_May_2014T00_00_00_TO_20_May_2014T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember" unitRef="USD_per_Share" decimals="1">0.8</us-gaap:SharePrice>
<us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_DebtInstrumentAxis_PromissoryNotesDueTwoMember" unitRef="USD" decimals="0">26325</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
<us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet contextRef="Context_As_Of_30_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember" unitRef="USD" decimals="0">83363</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
<relm:CashProceedForDebtDiscountInterestRate contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_DebtInstrumentAxis_PromissoryNotesDueTwoMember" unitRef="USD" decimals="0">36000</relm:CashProceedForDebtDiscountInterestRate>
<relm:CashProceedForDebtDiscountInterestRate contextRef="Context_Custom_01_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember" unitRef="USD" decimals="0">114000</relm:CashProceedForDebtDiscountInterestRate>
<relm:DebtDiscountInterestRateOfMaturity contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_DebtInstrumentAxis_PromissoryNotesDueTwoMember">P1Y</relm:DebtDiscountInterestRateOfMaturity>
<relm:DebtDiscountInterestRateOfMaturity contextRef="Context_Custom_01_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember">P1Y</relm:DebtDiscountInterestRateOfMaturity>
<relm:PurchaseOfWarrantShares contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_DebtInstrumentAxis_PromissoryNotesDueTwoMember" unitRef="shares" decimals="INF">67500</relm:PurchaseOfWarrantShares>
<relm:PurchaseOfWarrantShares contextRef="Context_Custom_01_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember" unitRef="shares" decimals="0">213750</relm:PurchaseOfWarrantShares>
<us-gaap:PaymentsOfDebtIssuanceCosts contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_DebtInstrumentAxis_PromissoryNotesDueTwoMember" unitRef="USD" decimals="0">25100</us-gaap:PaymentsOfDebtIssuanceCosts>
<us-gaap:PaymentsOfDebtIssuanceCosts contextRef="Context_Custom_01_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember" unitRef="USD" decimals="0">68400</us-gaap:PaymentsOfDebtIssuanceCosts>
<relm:AmortizedDeferredFinancingCostsMaturityDate contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_DebtInstrumentAxis_PromissoryNotesDueTwoMember">P1Y</relm:AmortizedDeferredFinancingCostsMaturityDate>
<relm:AmortizedDeferredFinancingCostsMaturityDate contextRef="Context_Custom_01_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember">P1Y</relm:AmortizedDeferredFinancingCostsMaturityDate>
<us-gaap:DebtInstrumentInterestRateStatedPercentageRateRangeMinimum contextRef="Context_Custom_01_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueOneMember" unitRef="pure" decimals="2">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentageRateRangeMinimum>
<relm:AmortizationOfDebtIssuanceCosts1 contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueTwoMember" unitRef="USD" decimals="0">62325</relm:AmortizationOfDebtIssuanceCosts1>
<relm:AmortizationOfDebtIssuanceCosts1 contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember" unitRef="USD" decimals="0">219773</relm:AmortizationOfDebtIssuanceCosts1>
<relm:AmortizationOfDebtIssuanceCosts1 contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember" unitRef="USD" decimals="0">219773</relm:AmortizationOfDebtIssuanceCosts1>
<relm:WarrantsValueForPlacementAgent contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_DebtInstrumentAxis_PromissoryNotesDueTwoMember" unitRef="shares" decimals="INF">33750</relm:WarrantsValueForPlacementAgent>
<relm:WarrantsValueForPlacementAgent contextRef="Context_Custom_01_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember" unitRef="shares" decimals="INF">106875</relm:WarrantsValueForPlacementAgent>
<relm:WarrantsValueForPlacementAgentPerShare contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_DebtInstrumentAxis_PromissoryNotesDueTwoMember" unitRef="USD_per_Share" decimals="2">0.80</relm:WarrantsValueForPlacementAgentPerShare>
<relm:WarrantsValueForPlacementAgentPerShare contextRef="Context_Custom_01_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember" unitRef="USD_per_Share" decimals="2">0.80</relm:WarrantsValueForPlacementAgentPerShare>
<relm:FairValueOfDebtDisoumt contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_DebtInstrumentAxis_PromissoryNotesDueTwoMember" unitRef="USD" decimals="0">13089</relm:FairValueOfDebtDisoumt>
<relm:FairValueOfDebtDisoumt contextRef="Context_As_Of_30_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember" unitRef="USD" decimals="0">41681</relm:FairValueOfDebtDisoumt>
<us-gaap:DeferredFinanceCostsNet contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueTwoMember" unitRef="USD" decimals="0">38189</us-gaap:DeferredFinanceCostsNet>
<us-gaap:DeferredFinanceCostsNet contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember" unitRef="USD" decimals="0">31357</us-gaap:DeferredFinanceCostsNet>
<us-gaap:DeferredFinanceCostsNet contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember" unitRef="USD" decimals="0">31357</us-gaap:DeferredFinanceCostsNet>
<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="Context_As_Of_30_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember" unitRef="USD_per_Share" decimals="2">0.60</us-gaap:DebtInstrumentConvertibleConversionPrice1>
<us-gaap:InducedConversionOfConvertibleDebtExpense contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_DebtInstrumentAxis_PromissoryNotesDueTwoMember" unitRef="USD" decimals="0">960900</us-gaap:InducedConversionOfConvertibleDebtExpense>
<us-gaap:InducedConversionOfConvertibleDebtExpense contextRef="Context_Custom_01_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember" unitRef="USD" decimals="0">960900</us-gaap:InducedConversionOfConvertibleDebtExpense>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_DebtInstrumentAxis_PromissoryNotesDueTwoMember" unitRef="shares" decimals="0">1201153</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="Context_Custom_01_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_DebtInstrumentAxis_PromissoryNotesDueThreeMember" unitRef="shares" decimals="0">1201153</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<relm:DebtInConnectionWithDownPaymentOfInsurancePolicy contextRef="Context_As_Of_06_May_2014T00_00_00_TO_06_May_2014T00_00_00_FinancialInstrumentAxis_FinancialAgreementMember" unitRef="USD" decimals="0">6800</relm:DebtInConnectionWithDownPaymentOfInsurancePolicy>
<relm:DebtInConnectionWithPaymentOfMonthlyInstallemt contextRef="Context_Custom_05_May_2014T00_00_00_TO_06_May_2014T00_00_00_FinancialInstrumentAxis_FinancialAgreementMember" unitRef="USD" decimals="0">660</relm:DebtInConnectionWithPaymentOfMonthlyInstallemt>
<relm:NumberOfInstallments contextRef="Context_Custom_05_May_2014T00_00_00_TO_06_May_2014T00_00_00_FinancialInstrumentAxis_FinancialAgreementMember" unitRef="Drugs" decimals="INF">11</relm:NumberOfInstallments>
<relm:CommonStockIssuableUponExerciseOfWarrants contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="shares" decimals="0">19385157</relm:CommonStockIssuableUponExerciseOfWarrants>
<relm:CommonStockIssuableUponExerciseOfWarrants contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember" unitRef="shares" decimals="0">19385157</relm:CommonStockIssuableUponExerciseOfWarrants>
<relm:CommonStockIssuableUponExerciseOfWarrants contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="0">41718750</relm:CommonStockIssuableUponExerciseOfWarrants>
<relm:CommonStockIssuableUponExerciseOfWarrants contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember" unitRef="shares" decimals="0">22333593</relm:CommonStockIssuableUponExerciseOfWarrants>
<relm:CommonStockIssuableUponExerciseOfWarrants contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="0">30036648</relm:CommonStockIssuableUponExerciseOfWarrants>
<relm:CommonStockIssuableUponExerciseOfWarrants contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember" unitRef="shares" decimals="0">30036648</relm:CommonStockIssuableUponExerciseOfWarrants>
<relm:IssuanceOfSeriesAPreferredStockAndWarrantsShares contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="shares" decimals="0">85035025</relm:IssuanceOfSeriesAPreferredStockAndWarrantsShares>
<relm:IssuanceOfSeriesAPreferredStockAndWarrantsShares contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember" unitRef="shares" decimals="0">85035025</relm:IssuanceOfSeriesAPreferredStockAndWarrantsShares>
<relm:IssuanceOfSeriesAPreferredStockAndWarrantsShares contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="0">136041275</relm:IssuanceOfSeriesAPreferredStockAndWarrantsShares>
<relm:IssuanceOfSeriesAPreferredStockAndWarrantsShares contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember" unitRef="shares" decimals="0">51006250</relm:IssuanceOfSeriesAPreferredStockAndWarrantsShares>
<relm:MarketValueOfCommonStockOnMeasurementPerStock contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD_per_Share" decimals="2" id="Footnote-1_1">0.80</relm:MarketValueOfCommonStockOnMeasurementPerStock>
<relm:MarketValueOfCommonStockOnMeasurementPerStock contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember" unitRef="USD_per_Share" decimals="2" id="Footnote-1_2">0.30</relm:MarketValueOfCommonStockOnMeasurementPerStock>
<relm:MarketValueOfCommonStockOnMeasurementPerStock contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD_per_Share" decimals="2" id="Footnote-1_3">1.50</relm:MarketValueOfCommonStockOnMeasurementPerStock>
<relm:MarketValueOfCommonStockOnMeasurementPerStock contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember" unitRef="USD_per_Share" decimals="2" id="Footnote-1_4">0.80</relm:MarketValueOfCommonStockOnMeasurementPerStock>
<relm:MarketValueOfCommonStockOnMeasurementPerStock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2" id="Footnote-1_5">2.00</relm:MarketValueOfCommonStockOnMeasurementPerStock>
<relm:MarketValueOfCommonStockOnMeasurementPerStock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember" unitRef="USD_per_Share" decimals="2" id="Footnote-1_6">1.17</relm:MarketValueOfCommonStockOnMeasurementPerStock>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">1.50</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">2.25</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">1.50</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsExercisePrice contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">2.25</us-gaap:FairValueAssumptionsExercisePrice>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="pure" decimals="4" id="Footnote-2_1">0.0019</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember" unitRef="pure" decimals="4" id="Footnote-2_2">0.0020</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="pure" decimals="4" id="Footnote-2_3">0.0038</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember" unitRef="pure" decimals="4" id="Footnote-2_4">0.0019</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="pure" decimals="3" id="Footnote-2_5">0.016</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember" unitRef="pure" decimals="3" id="Footnote-2_6">0.017</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00">P1Y4M24D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember">P1Y7M6D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00">P2Y</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember">P1Y4M24D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember_RangeAxis_MinimumMember">P3M18D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember_RangeAxis_MaximumMember">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RangeAxis_MinimumMember">P3M18D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedTerm contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RangeAxis_MaximumMember">P4Y10M24D</us-gaap:FairValueAssumptionsExpectedTerm>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="pure" decimals="2" id="Footnote-3_1">0.73</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember" unitRef="pure" decimals="2" id="Footnote-3_2">0.72</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="pure" decimals="2" id="Footnote-3_3">0.68</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember" unitRef="pure" decimals="2" id="Footnote-3_4">0.68</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember_RangeAxis_MinimumMember" unitRef="pure" decimals="2">0.71</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember_RangeAxis_MaximumMember" unitRef="pure" decimals="2">0.73</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RangeAxis_MinimumMember" unitRef="pure" decimals="2">0.71</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RangeAxis_MaximumMember" unitRef="pure" decimals="2">0.73</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="pure" xsi:nil="true"/>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember" unitRef="pure" xsi:nil="true"/>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="pure" xsi:nil="true"/>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember" unitRef="pure" xsi:nil="true"/>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="pure" xsi:nil="true"/>
<us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByFairValueHierarchyLevelAxis_InitialValuationsMember" unitRef="pure" xsi:nil="true"/>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_31_Dec_2011T00_00_00_TO_31_Dec_2011T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">958861</us-gaap:ConvertibleDebtFairValueDisclosures>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">2492166</us-gaap:ConvertibleDebtFairValueDisclosures>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FinancialInstrumentAxis_LongTermDebtMember" unitRef="USD" decimals="0">880214</us-gaap:ConvertibleDebtFairValueDisclosures>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FinancialInstrumentAxis_SecuritiesPledgedAsCollateralMember" unitRef="USD" decimals="0">958861</us-gaap:ConvertibleDebtFairValueDisclosures>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">1619478</us-gaap:ConvertibleDebtFairValueDisclosures>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_FinancialInstrumentAxis_LongTermDebtMember" unitRef="USD" decimals="0">581073</us-gaap:ConvertibleDebtFairValueDisclosures>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_FinancialInstrumentAxis_SecuritiesPledgedAsCollateralMember" unitRef="USD" decimals="0">958861</us-gaap:ConvertibleDebtFairValueDisclosures>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_FinancialInstrumentAxis_SecuritiesPledgedAsCollateralMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">872688</us-gaap:ConvertibleDebtFairValueDisclosures>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_FinancialInstrumentAxis_LongTermDebtMember" unitRef="USD" decimals="0">299141</us-gaap:ConvertibleDebtFairValueDisclosures>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">11762115</us-gaap:ConvertibleDebtFairValueDisclosures>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FinancialInstrumentAxis_LongTermDebtMember" unitRef="USD" decimals="0">2030589</us-gaap:ConvertibleDebtFairValueDisclosures>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FinancialInstrumentAxis_SecuritiesPledgedAsCollateralMember" unitRef="USD" decimals="0">2219854</us-gaap:ConvertibleDebtFairValueDisclosures>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">7622039</us-gaap:ConvertibleDebtFairValueDisclosures>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_FinancialInstrumentAxis_LongTermDebtMember" unitRef="USD" decimals="0">1150375</us-gaap:ConvertibleDebtFairValueDisclosures>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_FinancialInstrumentAxis_SecuritiesPledgedAsCollateralMember" unitRef="USD" decimals="0">1260993</us-gaap:ConvertibleDebtFairValueDisclosures>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">1647910</us-gaap:ConvertibleDebtFairValueDisclosures>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementBasisAxis_PortionAtFairValueFairValueDisclosureMember_FinancialInstrumentAxis_SecuritiesPledgedAsCollateralMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FinancialInstrumentAxis_LongTermDebtMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FinancialInstrumentAxis_SecuritiesPledgedAsCollateralMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">-7214804</us-gaap:ConvertibleDebtFairValueDisclosures>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_FinancialInstrumentAxis_LongTermDebtMember" unitRef="USD" decimals="0">-1370262</us-gaap:ConvertibleDebtFairValueDisclosures>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_FinancialInstrumentAxis_SecuritiesPledgedAsCollateralMember" unitRef="USD" decimals="0">-1262858</us-gaap:ConvertibleDebtFairValueDisclosures>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_FinancialInstrumentAxis_SecuritiesPledgedAsCollateralMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_PortionAtFairValueFairValueDisclosureMember_FinancialInstrumentAxis_SecuritiesPledgedAsCollateralMember" unitRef="USD" decimals="0">-956996</us-gaap:ConvertibleDebtFairValueDisclosures>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_PortionAtFairValueFairValueDisclosureMember_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">-4547311</us-gaap:ConvertibleDebtFairValueDisclosures>
<us-gaap:ConvertibleDebtFairValueDisclosures contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_PortionAtFairValueFairValueDisclosureMember_FinancialInstrumentAxis_LongTermDebtMember" unitRef="USD" decimals="0">-660327</us-gaap:ConvertibleDebtFairValueDisclosures>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2011T00_00_00_TO_31_Dec_2011T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">475000</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">242500</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember" unitRef="USD" decimals="0">29158</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember" unitRef="USD" decimals="0">13089</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">363223</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">162885</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember" unitRef="USD" decimals="0">2833</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">111777</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">79615</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember" unitRef="USD" decimals="0">26325</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember" unitRef="USD" decimals="0">13089</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">2424167</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">1217083</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember" unitRef="USD" decimals="0">313258</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember" unitRef="USD" decimals="0">136359</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">1836014</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">725928</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember" unitRef="USD" decimals="0">200737</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember" unitRef="USD" decimals="0">81589</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">113153</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">248655</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember" unitRef="USD" decimals="0">83363</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember" unitRef="USD" decimals="0">41681</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">-1945669</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">-1109421</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember" unitRef="USD" decimals="0">-259427</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember" unitRef="USD" decimals="0">-136359</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_PortionAtFairValueFairValueDisclosureMember_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">-478498</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_PortionAtFairValueFairValueDisclosureMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">-107662</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_PortionAtFairValueFairValueDisclosureMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember" unitRef="USD" decimals="0">-53831</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember_LongtermDebtTypeAxis_JuniorSubordinatedDebtMember_FairValueByMeasurementBasisAxis_PortionAtFairValueFairValueDisclosureMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_PortionAtFairValueFairValueDisclosureMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_PortionAtFairValueFairValueDisclosureMember_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_PortionAtFairValueFairValueDisclosureMember_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_PortionAtFairValueFairValueDisclosureMember_StatementClassOfStockAxis_SeriesBPreferredStockMember_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_PortionAtFairValueFairValueDisclosureMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember" unitRef="USD" decimals="0">996138</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember" unitRef="USD" decimals="0">9198452</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_StatementClassOfStockAxis_SeriesBPreferredStockMember_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember" unitRef="USD" decimals="0">7400275</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_ChangeDuringPeriodFairValueDisclosureMember_SubsidiarySaleOfStockAxis_PrivatePlacementMember_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember" unitRef="USD" decimals="0">4655043</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember" unitRef="USD" decimals="0">10040822</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesBPreferredStockMember_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember" unitRef="USD" decimals="0">9894030</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember" unitRef="USD" decimals="0">5651181</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_StatementClassOfStockAxis_SeriesAPreferredStockMember_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember" unitRef="USD" decimals="0">842370</us-gaap:OtherLiabilitiesFairValueDisclosure>
<us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_FairValueByMeasurementBasisAxis_CarryingReportedAmountFairValueDisclosureMember_StatementClassOfStockAxis_SeriesBPreferredStockMember_StatementScenarioAxis_IssuedInMayAndJune2014OfferingMember" unitRef="USD" decimals="0">2494655</us-gaap:OtherLiabilitiesFairValueDisclosure>
<relm:AllocationOfCashToPreferredStockIssuance contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">4898</relm:AllocationOfCashToPreferredStockIssuance>
<relm:AllocationOfCashToPreferredStockIssuance contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">5100</relm:AllocationOfCashToPreferredStockIssuance>
<relm:AllocationOfCashToCommonStockIssuance contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">17164</relm:AllocationOfCashToCommonStockIssuance>
<relm:AllocationOfCashToAdditionalPaidInCapital contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">2151040</relm:AllocationOfCashToAdditionalPaidInCapital>
<relm:AllocationOfCashToAdditionalPaidInCapital contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">17878994</relm:AllocationOfCashToAdditionalPaidInCapital>
<relm:AllocationOfCashToAdditionalPaidInCapital contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">1479610</relm:AllocationOfCashToAdditionalPaidInCapital>
<relm:AllocationOfCashToDerivativeLiability contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">111777</relm:AllocationOfCashToDerivativeLiability>
<relm:AllocationOfCashToDerivativeLiability contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">3337025</relm:AllocationOfCashToDerivativeLiability>
<relm:AllocationOfCashToDerivativeLiability contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">113153</relm:AllocationOfCashToDerivativeLiability>
<relm:AllocationOfCashToDerivativePreferredStockConversion contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">872688</relm:AllocationOfCashToDerivativePreferredStockConversion>
<relm:AllocationOfCashToDerivativePreferredStockConversion contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">1647910</relm:AllocationOfCashToDerivativePreferredStockConversion>
<relm:AllocationOfCashToDerivativeWarrantsIssuance contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">79615</relm:AllocationOfCashToDerivativeWarrantsIssuance>
<relm:AllocationOfCashToDerivativeWarrantsIssuance contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">996138</relm:AllocationOfCashToDerivativeWarrantsIssuance>
<relm:AllocationOfCashToDerivativeWarrantsIssuance contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">248655</relm:AllocationOfCashToDerivativeWarrantsIssuance>
<relm:ProceedsFromIssuanceOfOfferingsNet contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">3220018</relm:ProceedsFromIssuanceOfOfferingsNet>
<relm:ProceedsFromIssuanceOfOfferingsNet contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">22222319</relm:ProceedsFromIssuanceOfOfferingsNet>
<relm:ProceedsFromIssuanceOfOfferingsNet contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">3494425</relm:ProceedsFromIssuanceOfOfferingsNet>
<relm:OfferingCosts contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">699482</relm:OfferingCosts>
<relm:OfferingCosts contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">3516378</relm:OfferingCosts>
<relm:OfferingCosts contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">586072</relm:OfferingCosts>
<relm:ProceedsFromIssuanceOfOfferingsGross contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">3919500</relm:ProceedsFromIssuanceOfOfferingsGross>
<relm:ProceedsFromIssuanceOfOfferingsGross contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">25745699</relm:ProceedsFromIssuanceOfOfferingsGross>
<relm:ProceedsFromIssuanceOfOfferingsGross contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">4080500</relm:ProceedsFromIssuanceOfOfferingsGross>
<relm:ProceedsFromIssuanceOfOfferingsGross contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">22229300</relm:ProceedsFromIssuanceOfOfferingsGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="Context_As_Of_31_Dec_2011T00_00_00_TO_31_Dec_2011T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="shares" decimals="0">677962</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="0">1865411</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="0">3365171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="shares" decimals="0">677962</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">1538010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockIssuedForServicesMember" unitRef="shares" decimals="0">153802</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="0">1187449</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="0">1499760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="0">652005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD_per_Share" decimals="2">0.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD_per_Share" decimals="2">0.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2">1.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD_per_Share" decimals="2">0.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD_per_Share" decimals="2">0.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2">1.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00">P9Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00">P8Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">P8Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
<relm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1 contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">P9Y8M12D</relm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">1305000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">5238000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
<relm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">3000000</relm:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">782400</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<relm:CurrentPriceOfCommonStock contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">0.30</relm:CurrentPriceOfCommonStock>
<relm:CurrentPriceOfCommonStock contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.03</relm:CurrentPriceOfCommonStock>
<relm:CurrentPriceOfCommonStock contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.80</relm:CurrentPriceOfCommonStock>
<relm:CurrentPriceOfCommonStock contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MaximumMember" unitRef="USD_per_Share" decimals="2">1.50</relm:CurrentPriceOfCommonStock>
<relm:CurrentPriceOfCommonStock contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MinimumMember" unitRef="USD_per_Share" decimals="2">0.80</relm:CurrentPriceOfCommonStock>
<relm:CurrentPriceOfCommonStock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">2.00</relm:CurrentPriceOfCommonStock>
<relm:CurrentPriceOfCommonStock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">2.00</relm:CurrentPriceOfCommonStock>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="3">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="3">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" unitRef="pure" decimals="3">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" unitRef="pure" decimals="3">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">0.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="2">0.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="2">0.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">0.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="2">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="2">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="2">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="2">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">0.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_WarrantMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P5Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember">P5Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MaximumMember">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MinimumMember">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MaximumMember">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember_RangeAxis_MinimumMember">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="Context_As_Of_31_Dec_2011T00_00_00_TO_31_Dec_2011T00_00_00" unitRef="shares" decimals="0">6251</us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="shares" decimals="0">4865234</us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_AwardTypeAxis_PlacementAgentThreeMember" unitRef="shares" decimals="0">646172</us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_ClassOfWarrantOrRightAxis_SeriesAPreferredStockMember_AwardTypeAxis_PlacementAgentThreeMember" unitRef="shares" decimals="0">612422</us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_AwardTypeAxis_PlacementAgentThreeMember_ClassOfWarrantOrRightAxis_SubordinatedPromissoryNoteOfferingMember" unitRef="shares" decimals="0">33750</us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="0">8926517</us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_PlacementAgentThreeMember" unitRef="shares" decimals="0">944453</us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_ClassOfWarrantOrRightAxis_SeriesAPreferredStockMember_AwardTypeAxis_PlacementAgentThreeMember" unitRef="shares" decimals="0">637578</us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_PlacementAgentThreeMember_ClassOfWarrantOrRightAxis_SubordinatedPromissoryNoteOfferingMember" unitRef="shares" decimals="0">106875</us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_PlacementAgentThreeMember_ClassOfWarrantOrRightAxis_AcquisitionOfMedeorMember" unitRef="shares" decimals="0">200000</us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="0">5881575</us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_PlacementAgentThreeMember" unitRef="shares" decimals="0">4290950</us-gaap:ClassOfWarrantOrRightOutstanding>
<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_PlacementAgentThreeMember_ClassOfWarrantOrRightAxis_SubordinatedPromissoryNoteOfferingOneMember" unitRef="shares" decimals="0">106875</us-gaap:ClassOfWarrantOrRightOutstanding>
<relm:ClassOfWarrantOrRightGranted contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="shares" decimals="0">5478360</relm:ClassOfWarrantOrRightGranted>
<relm:ClassOfWarrantOrRightGranted contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="0">4061283</relm:ClassOfWarrantOrRightGranted>
<relm:ClassOfWarrantOrRightGranted contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="0">35086253</relm:ClassOfWarrantOrRightGranted>
<relm:ClassOfWarrantOrRightExercised contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="shares" decimals="0">-619377</relm:ClassOfWarrantOrRightExercised>
<relm:ClassOfWarrantOrRightForfeited contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="0">-868213</relm:ClassOfWarrantOrRightForfeited>
<relm:ClassOfWarrantOrRightVestedOutstanding contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="0">43144557</relm:ClassOfWarrantOrRightVestedOutstanding>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2011T00_00_00_TO_31_Dec_2011T00_00_00" unitRef="USD_per_Share" decimals="2">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember_LegalEntityAxis_MedeorIncMember" unitRef="USD_per_Share" decimals="2">0.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Jul_2012T00_00_00_TO_31_Jul_2012T00_00_00_AwardTypeAxis_OfficerOptionsMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.08</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD_per_Share" decimals="2">0.08</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantsMember" unitRef="USD_per_Share" decimals="2">0.08</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_ClassOfWarrantOrRightAxis_SeriesAPreferredStockMember_AwardTypeAxis_PlacementAgentThreeMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_AwardTypeAxis_PlacementAgentThreeMember_ClassOfWarrantOrRightAxis_SubordinatedPromissoryNoteOfferingMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_InvestorsMember_RelatedPartyTransactionAxis_SeriesAPreferredStockOfferingsMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionAxis_SeriesAPreferredStockOfferingsMember_RelatedPartyTransactionsByRelatedPartyAxis_PlacementAgentMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionAxis_DebtOfferingsMember_RelatedPartyTransactionsByRelatedPartyAxis_DebtHoldersMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionAxis_DebtOfferingsMember_RelatedPartyTransactionsByRelatedPartyAxis_PlacementAgentMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionAxis_StrategicAdvisorAgreementMember" unitRef="USD_per_Share" decimals="2">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_AwardTypeAxis_OfficerOptionsMember" unitRef="USD_per_Share" decimals="2">0.08</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Nov_2013T00_00_00_TO_30_Nov_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantsMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD_per_Share" decimals="2">0.54</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_OfficerOptionsMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantsMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_ClassOfWarrantOrRightAxis_SeriesAPreferredStockMember_AwardTypeAxis_PlacementAgentThreeMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_PlacementAgentThreeMember_ClassOfWarrantOrRightAxis_SubordinatedPromissoryNoteOfferingMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_InvestorsMember_RelatedPartyTransactionAxis_SeriesAPreferredStockOfferingsMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionAxis_SeriesAPreferredStockOfferingsMember_RelatedPartyTransactionsByRelatedPartyAxis_PlacementAgentMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionAxis_DebtOfferingsMember_RelatedPartyTransactionsByRelatedPartyAxis_DebtHoldersMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionAxis_DebtOfferingsMember_RelatedPartyTransactionsByRelatedPartyAxis_PlacementAgentMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PlacementAgentMember_LegalEntityAxis_MedeorIncMember" unitRef="USD_per_Share" decimals="2">0.11</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_PlacementAgentThreeMember_ClassOfWarrantOrRightAxis_AcquisitionOfMedeorMember" unitRef="USD_per_Share" decimals="2">1.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_AwardTypeAxis_OfficerOptionsMember" unitRef="USD_per_Share" decimals="2">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_28_Feb_2014T00_00_00_TO_28_Feb_2014T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember" unitRef="USD_per_Share" decimals="2">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_May_2014T00_00_00_TO_31_May_2014T00_00_00_AwardTypeAxis_OfficerOptionsMember" unitRef="USD_per_Share" decimals="2">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_PlacementAgentThreeMember" unitRef="USD_per_Share" decimals="2">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantsMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesBWarrantsMember" unitRef="USD_per_Share" decimals="2">2.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_PlacementAgentThreeMember_ClassOfWarrantOrRightAxis_SubordinatedPromissoryNoteOfferingOneMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesAWarrantsMember" unitRef="USD_per_Share" decimals="2">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_AgentWarrantsMember" unitRef="USD_per_Share" decimals="2">1.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<relm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD_per_Warrant" decimals="2">0.05</relm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted>
<relm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD_per_Warrant" decimals="2">0.54</relm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted>
<relm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Warrant" decimals="2">1.58</relm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted>
<relm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD_per_Warrant" decimals="2">0.08</relm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised>
<relm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeited contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Warrant" decimals="2">0.80</relm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeited>
<relm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedOutstanding contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD_per_Warrant" decimals="2">1.25</relm:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedOutstanding>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="3">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="3">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="3">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="3">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="3">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_WarrantMember" unitRef="pure" decimals="3">0.020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
<us-gaap:CommonStockConversionBasis contextRef="Context_Custom_15_May_2014T00_00_00_TO_20_May_2014T00_00_00">One for one</us-gaap:CommonStockConversionBasis>
<us-gaap:CommonStockConversionFeatures contextRef="Context_Custom_15_May_2014T00_00_00_TO_20_May_2014T00_00_00">More than 9.9</us-gaap:CommonStockConversionFeatures>
<us-gaap:ConversionOfStockSharesIssued1 contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">1360413</us-gaap:ConversionOfStockSharesIssued1>
<us-gaap:PreferredStockLiquidationPreferenceValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">10883300</us-gaap:PreferredStockLiquidationPreferenceValue>
<us-gaap:ConversionOfStockSharesConverted1 contextRef="Context_Custom_01_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="0">1879128</us-gaap:ConversionOfStockSharesConverted1>
<us-gaap:LineOfCredit contextRef="Context_As_Of_30_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00" unitRef="USD" decimals="0">975000</us-gaap:LineOfCredit>
<us-gaap:InterestReceivable contextRef="Context_As_Of_30_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00" unitRef="USD" decimals="0">566180</us-gaap:InterestReceivable>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_30_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00" unitRef="shares" decimals="0">541430</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="shares" decimals="INF">541430</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_InvestorsMember_RelatedPartyTransactionAxis_SeriesAPreferredStockOfferingsMember" unitRef="shares" decimals="0">1224845</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionAxis_SeriesAPreferredStockOfferingsMember_RelatedPartyTransactionsByRelatedPartyAxis_PlacementAgentMember" unitRef="shares" decimals="0">612422</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionAxis_DebtOfferingsMember_RelatedPartyTransactionsByRelatedPartyAxis_DebtHoldersMember" unitRef="shares" decimals="0">67500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionAxis_DebtOfferingsMember_RelatedPartyTransactionsByRelatedPartyAxis_PlacementAgentMember" unitRef="shares" decimals="0">33750</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_InvestorsMember_RelatedPartyTransactionAxis_SeriesAPreferredStockOfferingsMember" unitRef="shares" decimals="0">1275156</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionAxis_SeriesAPreferredStockOfferingsMember_RelatedPartyTransactionsByRelatedPartyAxis_PlacementAgentMember" unitRef="shares" decimals="0">637578</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionAxis_DebtOfferingsMember_RelatedPartyTransactionsByRelatedPartyAxis_DebtHoldersMember" unitRef="shares" decimals="0">213750</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionAxis_DebtOfferingsMember_RelatedPartyTransactionsByRelatedPartyAxis_PlacementAgentMember" unitRef="shares" decimals="0">106875</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesBWarrantsMember" unitRef="shares" decimals="0">8581894</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesAWarrantsMember" unitRef="shares" decimals="0">17163799</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_AgentWarrantsMember" unitRef="shares" decimals="0">4290950</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
<relm:WarrantToPurchaseOfCommonStock contextRef="Context_Custom_01_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00" unitRef="shares" decimals="0">619377</relm:WarrantToPurchaseOfCommonStock>
<relm:WarrantToPurchaseOfCommonStock contextRef="Context_Custom_01_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">868213</relm:WarrantToPurchaseOfCommonStock>
<relm:WarrantToPurchaseOfCommonStock contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="shares" decimals="0">619377</relm:WarrantToPurchaseOfCommonStock>
<relm:WarrantToPurchaseOfCommonStock contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">1224844</relm:WarrantToPurchaseOfCommonStock>
<relm:WarrantToPurchaseOfCommonStock contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="shares" decimals="INF">612422</relm:WarrantToPurchaseOfCommonStock>
<relm:WarrantToPurchaseOfCommonStock contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_AwardTypeAxis_FounderWarrantsMember" unitRef="shares" decimals="0">868213</relm:WarrantToPurchaseOfCommonStock>
<relm:WarrantToPurchaseOfCommonStock contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantsMember" unitRef="shares" decimals="0">40000</relm:WarrantToPurchaseOfCommonStock>
<relm:WarrantToPurchaseOfCommonStock contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="0">1275156</relm:WarrantToPurchaseOfCommonStock>
<relm:WarrantToPurchaseOfCommonStock contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantsMember" unitRef="shares" decimals="0">21500</relm:WarrantToPurchaseOfCommonStock>
<relm:WarrantToPurchaseOfCommonStock contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PlacementAgentMember_LegalEntityAxis_MedeorIncMember" unitRef="shares" decimals="0">200000</relm:WarrantToPurchaseOfCommonStock>
<relm:WarrantToPurchaseOfCommonStock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantsMember" unitRef="shares" decimals="0">12500</relm:WarrantToPurchaseOfCommonStock>
<us-gaap:DividendsShareBasedCompensation contextRef="Context_Custom_01_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00" unitRef="USD" decimals="0">1305200</us-gaap:DividendsShareBasedCompensation>
<us-gaap:DividendsShareBasedCompensation contextRef="Context_Custom_01_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">1305200</us-gaap:DividendsShareBasedCompensation>
<us-gaap:DividendsShareBasedCompensation contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">637578</us-gaap:DividendsShareBasedCompensation>
<us-gaap:CommonStocksIncludingAdditionalPaidInCapital contextRef="Context_As_Of_30_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00" unitRef="USD" decimals="0">1006100</us-gaap:CommonStocksIncludingAdditionalPaidInCapital>
<us-gaap:CommonStocksIncludingAdditionalPaidInCapital contextRef="Context_As_Of_30_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">1006100</us-gaap:CommonStocksIncludingAdditionalPaidInCapital>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of_30_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00" unitRef="USD" decimals="0">299100</us-gaap:DerivativeLiabilities>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of_30_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">299100</us-gaap:DerivativeLiabilities>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">3220018</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_AwardTypeAxis_PlacementAgentThreeMember" unitRef="USD" decimals="0">470300</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">3494428</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_PlacementAgentThreeMember" unitRef="USD" decimals="0">554700</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_PlacementAgentThreeMember" unitRef="USD" decimals="0">3089500</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_InvestorsMember" unitRef="USD" decimals="0">25745700</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
<relm:IssuanceOfSeriesAPreferredStockSharesToPurchaseCommonStock contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="0">4899375</relm:IssuanceOfSeriesAPreferredStockSharesToPurchaseCommonStock>
<relm:IssuanceOfSeriesAPreferredStockSharesToPurchaseCommonStock contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="0">5100625</relm:IssuanceOfSeriesAPreferredStockSharesToPurchaseCommonStock>
<relm:PlacementAgentExpenses contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">3516000</relm:PlacementAgentExpenses>
<relm:ClassOfWarrantOrRightsRedemptionTerms contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesBWarrantsMember">&lt;div&gt;The Company may call the Series B warrant for redemption upon written notice to all investors of the May and June 2014 units &amp;#160;(&amp;#8220;investors&amp;#8221;) at any time if the closing price of the common stock exceeds $3.75 per share for twenty (20) consecutive trading days provided that there an effective registration statement.&amp;#160;In sixty days (60) business days following the date the redemption notice &amp;#8220;Exercise Period&amp;#8221; that is sent to the investors, each may choose to exercise their Series B warrant or a portion of their Series B warrant, by paying the exercise price of $2.25 per share. &lt;font style="color: #1f497d;"&gt;&amp;#160;&lt;/font&gt;Any warrants not exercised on the last day of the Exercise Period, will be redeemed by the Company at $0.001 per share.&lt;/div&gt;</relm:ClassOfWarrantOrRightsRedemptionTerms>
<relm:PercentageOfSolicitationFeeOnWarrantsExercised contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementClassOfStockAxis_SeriesBWarrantsMember" unitRef="pure" decimals="2">0.05</relm:PercentageOfSolicitationFeeOnWarrantsExercised>
<us-gaap:InterestExpenseRelatedParty contextRef="Context_Custom_01_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">353246</us-gaap:InterestExpenseRelatedParty>
<us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="Context_Custom_12_May_2014T00_00_00_TO_10_Jun_2014T00_00_00" unitRef="USD" decimals="0">25745699</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
<us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">22229300</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
<relm:IssuanceOfCommonStockToPurchaseCommonStock contextRef="Context_Custom_01_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">255750</relm:IssuanceOfCommonStockToPurchaseCommonStock>
<us-gaap:OtherAccruedLiabilitiesNoncurrent contextRef="Context_As_Of_30_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">869300</us-gaap:OtherAccruedLiabilitiesNoncurrent>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_Custom_01_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember_LegalEntityAxis_MedeorIncMember" unitRef="USD" decimals="0">5100</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">20500</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockIssuedForServicesMember" unitRef="USD" decimals="0">20500</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockIssuedForServicesMember" unitRef="USD" decimals="0">16900</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_StatementEquityComponentsAxis_CommonStockIssuedForServicesMember" unitRef="USD" decimals="0">8700</us-gaap:AllocatedShareBasedCompensationExpense>
<relm:IssuanceOfCommonStockInConnectionWithAcquistionOfLicienseAgreement contextRef="Context_Custom_01_Apr_2012T00_00_00_TO_30_Apr_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember_LegalEntityAxis_MedeorIncMember" unitRef="shares" decimals="0">17089</relm:IssuanceOfCommonStockInConnectionWithAcquistionOfLicienseAgreement>
<us-gaap:SaleOfStockPricePerShare contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockIssuedForServicesMember" unitRef="USD_per_Share" decimals="2">0.30</us-gaap:SaleOfStockPricePerShare>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">46100</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
<us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockIssuedForServicesMember" unitRef="USD" decimals="0">46100</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensationGross>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD_per_Share" decimals="2">0.03</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="Context_Custom_09_Jul_2012T00_00_00_TO_10_Jul_2012T00_00_00_StatementEquityComponentsAxis_CommonStockIssuedForServicesMember" unitRef="shares" decimals="0">68350</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="Context_Custom_09_Jul_2013T00_00_00_TO_10_Jul_2013T00_00_00_StatementEquityComponentsAxis_CommonStockIssuedForServicesMember" unitRef="shares" decimals="0">56390</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="Context_Custom_09_Jan_2014T00_00_00_TO_10_Jan_2014T00_00_00_StatementEquityComponentsAxis_CommonStockIssuedForServicesMember" unitRef="shares" decimals="0">29052</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="INF">8655783</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="0">2409436</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<relm:NumberOfSharesAvailableForFutureGrantsUnderStockOptionPlan contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="shares" decimals="0">4693673</relm:NumberOfSharesAvailableForFutureGrantsUnderStockOptionPlan>
<relm:StockOptionsPlanStockOptionsExercisablePeriod contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">P10Y</relm:StockOptionsPlanStockOptionsExercisablePeriod>
<relm:StockOptionsExercisablePeriodDescription contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">&lt;div&gt;Vest over four years&lt;/div&gt;</relm:StockOptionsExercisablePeriodDescription>
<relm:OptionsToPurchaseOfcommonStock contextRef="Context_Custom_01_Jul_2012T00_00_00_TO_31_Jul_2012T00_00_00_AwardTypeAxis_OfficerOptionsMember" unitRef="shares" decimals="0">677962</relm:OptionsToPurchaseOfcommonStock>
<relm:OptionsToPurchaseOfcommonStock contextRef="Context_Custom_01_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_AwardTypeAxis_OfficerOptionsMember" unitRef="shares" decimals="0">665750</relm:OptionsToPurchaseOfcommonStock>
<relm:OptionsToPurchaseOfcommonStock contextRef="Context_Custom_01_Nov_2013T00_00_00_TO_30_Nov_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantsMember" unitRef="shares" decimals="0">187500</relm:OptionsToPurchaseOfcommonStock>
<relm:OptionsToPurchaseOfcommonStock contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_OfficerOptionsMember" unitRef="shares" decimals="0">334199</relm:OptionsToPurchaseOfcommonStock>
<relm:OptionsToPurchaseOfcommonStock contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_AwardTypeAxis_OfficerOptionsMember" unitRef="shares" decimals="0">1003774</relm:OptionsToPurchaseOfcommonStock>
<relm:OptionsToPurchaseOfcommonStock contextRef="Context_Custom_01_Feb_2014T00_00_00_TO_28_Feb_2014T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember" unitRef="shares" decimals="0">145986</relm:OptionsToPurchaseOfcommonStock>
<relm:OptionsToPurchaseOfcommonStock contextRef="Context_Custom_01_May_2014T00_00_00_TO_31_May_2014T00_00_00_AwardTypeAxis_OfficerOptionsMember" unitRef="shares" decimals="0">350000</relm:OptionsToPurchaseOfcommonStock>
<relm:StockOptionsContractualTerm contextRef="Context_Custom_01_Jul_2012T00_00_00_TO_31_Jul_2012T00_00_00_AwardTypeAxis_OfficerOptionsMember">P10Y</relm:StockOptionsContractualTerm>
<relm:StockOptionsContractualTerm contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionAxis_SeriesAPreferredStockOfferingsMember">P7Y</relm:StockOptionsContractualTerm>
<relm:StockOptionsContractualTerm contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionAxis_DebtOfferingsMember">P7Y</relm:StockOptionsContractualTerm>
<relm:StockOptionsContractualTerm contextRef="Context_Custom_01_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_AwardTypeAxis_OfficerOptionsMember">P10Y</relm:StockOptionsContractualTerm>
<relm:StockOptionsContractualTerm contextRef="Context_Custom_01_Nov_2013T00_00_00_TO_30_Nov_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantsMember">P10Y</relm:StockOptionsContractualTerm>
<relm:StockOptionsContractualTerm contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_OfficerOptionsMember">P10Y</relm:StockOptionsContractualTerm>
<relm:StockOptionsContractualTerm contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionAxis_SeriesAPreferredStockOfferingsMember">P7Y</relm:StockOptionsContractualTerm>
<relm:StockOptionsContractualTerm contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionAxis_DebtOfferingsMember">P7Y</relm:StockOptionsContractualTerm>
<relm:StockOptionsContractualTerm contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_AwardTypeAxis_OfficerOptionsMember">P10Y</relm:StockOptionsContractualTerm>
<relm:StockOptionsContractualTerm contextRef="Context_Custom_01_Feb_2014T00_00_00_TO_28_Feb_2014T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember">P10Y</relm:StockOptionsContractualTerm>
<relm:StockOptionsContractualTerm contextRef="Context_Custom_01_May_2014T00_00_00_TO_31_May_2014T00_00_00_AwardTypeAxis_OfficerOptionsMember">P10Y</relm:StockOptionsContractualTerm>
<relm:OptionsVestPercentage contextRef="Context_Custom_01_Jul_2012T00_00_00_TO_31_Jul_2012T00_00_00_AwardTypeAxis_OfficerOptionsMember" unitRef="pure" decimals="2">0.25</relm:OptionsVestPercentage>
<relm:OptionsVestPercentage contextRef="Context_Custom_01_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_AwardTypeAxis_OfficerOptionsMember" unitRef="pure" decimals="2">0.25</relm:OptionsVestPercentage>
<relm:OptionsVestPercentage contextRef="Context_Custom_01_Nov_2013T00_00_00_TO_30_Nov_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantsMember" unitRef="pure" decimals="2">0.25</relm:OptionsVestPercentage>
<relm:OptionsVestPercentage contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_OfficerOptionsMember" unitRef="pure" decimals="2">0.25</relm:OptionsVestPercentage>
<relm:OptionsVestPercentage contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_AwardTypeAxis_OfficerOptionsMember" unitRef="pure" decimals="2">0.25</relm:OptionsVestPercentage>
<relm:OptionsVestPercentage contextRef="Context_Custom_01_Feb_2014T00_00_00_TO_28_Feb_2014T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember" unitRef="pure" decimals="2">0.25</relm:OptionsVestPercentage>
<relm:OptionsVestPercentage contextRef="Context_Custom_01_May_2014T00_00_00_TO_31_May_2014T00_00_00_AwardTypeAxis_OfficerOptionsMember" unitRef="pure" decimals="2">0.25</relm:OptionsVestPercentage>
<relm:RemainingOptionsVestPercentage contextRef="Context_Custom_01_Jul_2012T00_00_00_TO_31_Jul_2012T00_00_00_AwardTypeAxis_OfficerOptionsMember" unitRef="pure" decimals="2">0.75</relm:RemainingOptionsVestPercentage>
<relm:RemainingOptionsVestPercentage contextRef="Context_Custom_01_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_AwardTypeAxis_OfficerOptionsMember" unitRef="pure" decimals="2">0.75</relm:RemainingOptionsVestPercentage>
<relm:RemainingOptionsVestPeriodDescription contextRef="Context_Custom_01_Jul_2012T00_00_00_TO_31_Jul_2012T00_00_00_AwardTypeAxis_OfficerOptionsMember">&lt;div&gt;Options vest in equal quarterly increments over a four-year period&lt;/div&gt;</relm:RemainingOptionsVestPeriodDescription>
<relm:RemainingOptionsVestPeriodDescription contextRef="Context_Custom_01_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_AwardTypeAxis_OfficerOptionsMember">Options vest in equal quarterly increments over a four-year period.</relm:RemainingOptionsVestPeriodDescription>
<relm:RemainingOptionsVestPeriodDescription contextRef="Context_Custom_01_Nov_2013T00_00_00_TO_30_Nov_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantsMember">&lt;div&gt;Options vest on the one year anniversary of the grant date and the remaining options vest in equal quarterly increment over the following 3 years&lt;/div&gt;</relm:RemainingOptionsVestPeriodDescription>
<relm:RemainingOptionsVestPeriodDescription contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_OfficerOptionsMember">&lt;div&gt;Options vest on the one anniversary of the grant date and the remaining options vest quarterly over the following 3 years&lt;/div&gt;</relm:RemainingOptionsVestPeriodDescription>
<relm:RemainingOptionsVestPeriodDescription contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_AwardTypeAxis_OfficerOptionsMember">&lt;div&gt;Options vest on the one anniversary of the grant date and the remaining options vest quarterly over the following 3 years&lt;/div&gt;</relm:RemainingOptionsVestPeriodDescription>
<relm:RemainingOptionsVestPeriodDescription contextRef="Context_Custom_01_Feb_2014T00_00_00_TO_28_Feb_2014T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember">Options vest on the one year anniversary of the grant date and the remaining options vest quarterly over the following 3 years.</relm:RemainingOptionsVestPeriodDescription>
<relm:RemainingOptionsVestPeriodDescription contextRef="Context_Custom_01_May_2014T00_00_00_TO_31_May_2014T00_00_00_AwardTypeAxis_OfficerOptionsMember">Options vest on the one year anniversary of the grant date and the remaining options vest quarterly over the following 3 years.</relm:RemainingOptionsVestPeriodDescription>
<relm:FairValueOfOptionsOnGrantDate contextRef="Context_Custom_01_Jul_2012T00_00_00_TO_31_Jul_2012T00_00_00_AwardTypeAxis_OfficerOptionsMember" unitRef="USD" decimals="0">103700</relm:FairValueOfOptionsOnGrantDate>
<relm:FairValueOfOptionsOnGrantDate contextRef="Context_Custom_01_Sep_2013T00_00_00_TO_30_Sep_2013T00_00_00_AwardTypeAxis_OfficerOptionsMember" unitRef="USD" decimals="0">359100</relm:FairValueOfOptionsOnGrantDate>
<relm:FairValueOfOptionsOnGrantDate contextRef="Context_Custom_01_Nov_2013T00_00_00_TO_30_Nov_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantsMember" unitRef="USD" decimals="0">114800</relm:FairValueOfOptionsOnGrantDate>
<relm:FairValueOfOptionsOnGrantDate contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_OfficerOptionsMember" unitRef="USD" decimals="0">181400</relm:FairValueOfOptionsOnGrantDate>
<relm:FairValueOfOptionsOnGrantDate contextRef="Context_Custom_01_Jan_2014T00_00_00_TO_31_Jan_2014T00_00_00_AwardTypeAxis_OfficerOptionsMember" unitRef="USD" decimals="0">937600</relm:FairValueOfOptionsOnGrantDate>
<relm:FairValueOfOptionsOnGrantDate contextRef="Context_Custom_01_Feb_2014T00_00_00_TO_28_Feb_2014T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember" unitRef="USD" decimals="0">136200</relm:FairValueOfOptionsOnGrantDate>
<relm:FairValueOfOptionsOnGrantDate contextRef="Context_Custom_01_May_2014T00_00_00_TO_31_May_2014T00_00_00_AwardTypeAxis_OfficerOptionsMember" unitRef="USD" decimals="0">250200</relm:FairValueOfOptionsOnGrantDate>
<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">0</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" decimals="0">35100</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember_AwardTypeAxis_WarrantMember" unitRef="USD" decimals="0">0</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember_AwardTypeAxis_WarrantMember" unitRef="USD" decimals="0">2200</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">4800</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" decimals="0">129600</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember_AwardTypeAxis_WarrantMember" unitRef="USD" decimals="0">246100</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember_AwardTypeAxis_WarrantMember" unitRef="USD" decimals="0">1800</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PlacementAgentMember_LegalEntityAxis_MedeorIncMember" unitRef="USD" decimals="0">237400</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">10119000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">115500</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" decimals="0">77700</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember_AwardTypeAxis_WarrantMember" unitRef="USD" decimals="0">12124500</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember_AwardTypeAxis_WarrantMember" unitRef="USD" decimals="0">0</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_AwardTypeAxis_WarrantMember" unitRef="USD" decimals="0">3400</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">589500</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_WarrantMember" unitRef="USD" decimals="0">3600</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">1760900</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_WarrantMember" unitRef="USD" decimals="0">6500</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">0.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_WarrantMember" unitRef="USD_per_Share" decimals="2">1.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<relm:WarrantsContractualTerm contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionAxis_SeriesAPreferredStockOfferingsMember">P7Y</relm:WarrantsContractualTerm>
<relm:WarrantsContractualTerm contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionAxis_DebtOfferingsMember">P7Y</relm:WarrantsContractualTerm>
<relm:FairValueOfWarrantsIssued contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">5600</relm:FairValueOfWarrantsIssued>
<relm:FairValueOfWarrantsIssued contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">10800</relm:FairValueOfWarrantsIssued>
<relm:FairValueOfWarrantsIssued contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">14300</relm:FairValueOfWarrantsIssued>
<relm:FairValueOfWarrantsIssued contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_ConsultantsMember" unitRef="USD" decimals="0">0</relm:FairValueOfWarrantsIssued>
<us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased contextRef="Context_As_Of_10_Mar_2014T00_00_00_TO_10_Mar_2014T00_00_00" unitRef="shares" decimals="0">4000000</us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased>
<relm:NumberOfSharesIncreasedByShareholders contextRef="Context_As_Of_10_Mar_2014T00_00_00_TO_10_Mar_2014T00_00_00" unitRef="shares" decimals="0">8058844</relm:NumberOfSharesIncreasedByShareholders>
<relm:ClassOfWarrantOrRightsExpiration contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_ClassOfWarrantOrRightAxis_SeriesAPreferredStockMember_AwardTypeAxis_PlacementAgentThreeMember">2019</relm:ClassOfWarrantOrRightsExpiration>
<relm:ClassOfWarrantOrRightsExpiration contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_AwardTypeAxis_PlacementAgentThreeMember_ClassOfWarrantOrRightAxis_SubordinatedPromissoryNoteOfferingMember">2019</relm:ClassOfWarrantOrRightsExpiration>
<relm:ClassOfWarrantOrRightsExpiration contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_ClassOfWarrantOrRightAxis_SeriesAPreferredStockMember_AwardTypeAxis_PlacementAgentThreeMember">2020</relm:ClassOfWarrantOrRightsExpiration>
<relm:ClassOfWarrantOrRightsExpiration contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_PlacementAgentThreeMember_ClassOfWarrantOrRightAxis_SubordinatedPromissoryNoteOfferingMember">2020</relm:ClassOfWarrantOrRightsExpiration>
<relm:ClassOfWarrantOrRightsExpiration contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_PlacementAgentThreeMember_ClassOfWarrantOrRightAxis_AcquisitionOfMedeorMember">2020</relm:ClassOfWarrantOrRightsExpiration>
<relm:ClassOfWarrantOrRightsExpiration contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_PlacementAgentThreeMember">2019</relm:ClassOfWarrantOrRightsExpiration>
<us-gaap:ProfessionalFees contextRef="Context_Custom_01_Dec_2011T00_00_00_TO_06_Dec_2011T00_00_00_AwardTypeAxis_AdvisoryFirmMember" unitRef="USD" decimals="0">12500</us-gaap:ProfessionalFees>
<us-gaap:ProfessionalFees contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_AwardTypeAxis_PlacementAgentThreeMember" unitRef="USD" decimals="0">272000</us-gaap:ProfessionalFees>
<us-gaap:ProfessionalFees contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">12500</us-gaap:ProfessionalFees>
<us-gaap:ProfessionalFees contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_PlacementAgentThreeMember" unitRef="USD" decimals="0">25000</us-gaap:ProfessionalFees>
<relm:PercentageOfVestedWarrantsToPurchaseCommonStock contextRef="Context_Custom_01_Dec_2011T00_00_00_TO_06_Dec_2011T00_00_00_AwardTypeAxis_AdvisoryFirmMember" unitRef="pure" decimals="2">0.12</relm:PercentageOfVestedWarrantsToPurchaseCommonStock>
<relm:PercentageOfVestedWarrantsToPurchaseCommonStock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_PlacementAgentThreeMember" unitRef="pure" decimals="2">0.05</relm:PercentageOfVestedWarrantsToPurchaseCommonStock>
<invest:InvestmentWarrantsExercisePrice contextRef="Context_Custom_01_Dec_2011T00_00_00_TO_06_Dec_2011T00_00_00_AwardTypeAxis_AdvisoryFirmMember" unitRef="USD_per_Share" decimals="2">0.01</invest:InvestmentWarrantsExercisePrice>
<invest:InvestmentWarrantsExercisePrice contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_PlacementAgentThreeMember" unitRef="USD_per_Share" decimals="2">1.50</invest:InvestmentWarrantsExercisePrice>
<relm:IssuanceOfWarrantsToPurchaseCommonStock contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_PlacementAgentThreeMember" unitRef="shares" decimals="0">4290950</relm:IssuanceOfWarrantsToPurchaseCommonStock>
<relm:IssuanceOfWarrantsToPurchaseCommonStockDescription contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_PlacementAgentThreeMember">The Placement Agent shall also be entitled to the compensation set forth above as well for any cash exercise of Warrants within six (6) months of the final closing of the Offering as well as a five percent (5%) solicitation fee for any Warrants exercised as a result of any redemption of any Warrants. If the Company elects to call the warrants, the Placement Agent shall receive a warrant solicitation fee equal to 5% of the funds solicited by the Placement Agent upon exercise of the warrants.</relm:IssuanceOfWarrantsToPurchaseCommonStockDescription>
<relm:TermOfWarrants contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_AwardTypeAxis_PlacementAgentThreeMember">P5Y</relm:TermOfWarrants>
<relm:ReimbursementExpenses contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_AdvisoryFirmMember" unitRef="USD" decimals="0">5000</relm:ReimbursementExpenses>
<us-gaap:OtherResearchAndDevelopmentExpense contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">3750000</us-gaap:OtherResearchAndDevelopmentExpense>
<us-gaap:ProceedsFromIssuanceOfSubordinatedLongTermDebt contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_AwardTypeAxis_PlacementAgentThreeMember" unitRef="USD" decimals="0">25100</us-gaap:ProceedsFromIssuanceOfSubordinatedLongTermDebt>
<us-gaap:ProceedsFromIssuanceOfSubordinatedLongTermDebt contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_AwardTypeAxis_PlacementAgentThreeMember" unitRef="USD" decimals="0">68400</us-gaap:ProceedsFromIssuanceOfSubordinatedLongTermDebt>
<us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="Context_Custom_01_Dec_2011T00_00_00_TO_06_Dec_2011T00_00_00_AwardTypeAxis_PlacementAgentThreeMember">In consideration for its services, the placement agent received: (a re-activation fee of $15,000, (b) a cash fee equal to 7% of the Notes Conversion and 10% of the gross proceeds raised in the Financings, and (c) non-accountable expense reimbursement equal to 2% of the gross proceeds raised. The placement agent or its designees also received warrants to purchase shares of the Company's common stock in an amount equal to 10% of the shares of common stock and warrants issued or issuable as part of the units sold in the Series A Preferred Stock Offering and Notes Offerings.</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
<us-gaap:RelatedPartyTransactionDescriptionOfTransaction contextRef="Context_Custom_01_Oct_2013T00_00_00_TO_24_Oct_2013T00_00_00_AwardTypeAxis_PlacementAgentThreeMember">In consideration for its services, the Placement Agent was eligible to receive: (a) a cash success fee equal to 8% of the value of the transaction plus a 2% non-reimbursable expense fee which was subsequently modified to a maximum of $150,000 plus, (b) $50,000 for a Fairness Opinion fee deductible against the success fee, and (c) a $50,000 activation fee.</us-gaap:RelatedPartyTransactionDescriptionOfTransaction>
<relm:InvestorOfferingPriceDescription contextRef="Context_Custom_01_May_2014T00_00_00_TO_19_May_2014T00_00_00_AwardTypeAxis_PlacementAgentThreeMember">(a) a cash commission in the amount of ten percent (10%) of the gross proceeds of the Offering received from investors at a Closing as well as a non-accountable expense reimbursement equal to two percent (b) (2%) of the gross proceeds of the Offering received from investors at a Closing and an activation fee of $25,000.</relm:InvestorOfferingPriceDescription>
<relm:NumberOfEngagementAgreement contextRef="Context_Custom_01_May_2014T00_00_00_TO_19_May_2014T00_00_00_AwardTypeAxis_PlacementAgentThreeMember" unitRef="Drugs" decimals="INF">2</relm:NumberOfEngagementAgreement>
<relm:ActivationFees contextRef="Context_Custom_01_May_2014T00_00_00_TO_19_May_2014T00_00_00_AwardTypeAxis_PlacementAgentThreeMember" unitRef="USD" decimals="0">25000</relm:ActivationFees>
<us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableDescription contextRef="Context_Custom_01_Dec_2011T00_00_00_TO_06_Dec_2011T00_00_00_AwardTypeAxis_PlacementAgentThreeMember">8% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the services.</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableDescription>
<us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableDescription contextRef="Context_Custom_01_Oct_2013T00_00_00_TO_24_Oct_2013T00_00_00_AwardTypeAxis_PlacementAgentThreeMember">8% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the services.</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableDescription>
<relm:RoyaltyPaymentsDescription contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_BusinessAcquisitionAxis_MedeorMember">&lt;div&gt;(A) royalty payments up to 2% on net sales of licensed products that are not sold by sublicensee and (B) on each and every sublicense earned royalty payment received by licensee from its sublicensee on sales of license product.&lt;/div&gt;</relm:RoyaltyPaymentsDescription>
<relm:RoyaltyReceivedByLicenseeDescription contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_BusinessAcquisitionAxis_MedeorMember">&lt;div&gt;&amp;#160;(i) 20% of the royalties received by licensee; or (ii) up to 2% of net sales of sublicensee. The Company will also make milestone payments of up to $4 million and up to $2 million, for the first commercial sale of product in the field that has a single active pharmaceutical ingredient, and for the first commercial sale of product in the field of product that has more than one active pharmaceutical ingredient, respectively.&lt;/div&gt;</relm:RoyaltyReceivedByLicenseeDescription>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">2765600</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">3556600</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">4248700</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">436300</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">197700</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">44700</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">22900</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
<us-gaap:DeferredTaxAssetsOther contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">46000</us-gaap:DeferredTaxAssetsOther>
<us-gaap:DeferredTaxAssetsOther contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">2900</us-gaap:DeferredTaxAssetsOther>
<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">3292600</us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">8028800</us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:DeferredTaxAssetsNet contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:DeferredTaxAssetsNet contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="pure" decimals="2">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="pure" decimals="2">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="pure" decimals="2">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="pure" decimals="3">0.066</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="pure" decimals="3">0.066</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="pure" decimals="3">0.066</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="pure" decimals="3">-0.188</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="pure" decimals="3">-0.297</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="pure" decimals="3">-0.131</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="pure" xsi:nil="true"/>
<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="pure" xsi:nil="true"/>
<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="pure" decimals="3">-0.023</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="pure" decimals="3">-0.218</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="pure" decimals="3">-0.109</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="pure" decimals="3">-0.252</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="pure" decimals="2">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="pure" decimals="2">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="pure" decimals="2">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
<us-gaap:TaxCreditCarryforwardAmount contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_TaxCreditCarryforwardAxis_ResearchMember" unitRef="USD" decimals="0">197700</us-gaap:TaxCreditCarryforwardAmount>
<us-gaap:OperatingLossCarryforwards contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">8762000</us-gaap:OperatingLossCarryforwards>
<us-gaap:TaxCreditCarryforwardExpirationDate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">2025-12-31</us-gaap:TaxCreditCarryforwardExpirationDate>
<us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_TaxCreditCarryforwardAxis_ResearchMember">2025-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
<us-gaap:OperatingLossCarryforwardsLimitationsOnUse contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">The United States Tax Reform Act of 1986 contains provisions that may limit the Company's net operating loss carryforwards available to be used in any given year in the event of significant changes in the ownership interests of significant stockholders, as defined. The effect of an ownership change would be the imposition of an annual limitation on the use of NOL carryforwards attributable to periods before the change. The amount of the annual limitation depends upon the value of the Company immediately before the change, changes to the Company's capital during a specified period prior to the change, and the federal published interest rate.</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">37300</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">38000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">38800</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">9700</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">127800</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
<us-gaap:ProceedsFromLicenseFeesReceived contextRef="Context_Custom_25_Dec_2007T00_00_00_TO_31_Dec_2007T00_00_00_IndefiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember" unitRef="USD" decimals="0">1500000</us-gaap:ProceedsFromLicenseFeesReceived>
<relm:NumberOfLicensedProducts contextRef="Context_Custom_25_Dec_2007T00_00_00_TO_31_Dec_2007T00_00_00_IndefiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember" unitRef="Drugs" decimals="INF">2</relm:NumberOfLicensedProducts>
<relm:LicenseExpiryTerm contextRef="Context_Custom_25_Dec_2007T00_00_00_TO_31_Dec_2007T00_00_00_IndefiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember_RangeAxis_MinimumMember">P15Y</relm:LicenseExpiryTerm>
<relm:LicenseExpiryTerm contextRef="Context_Custom_25_Dec_2007T00_00_00_TO_31_Dec_2007T00_00_00_IndefiniteLivedIntangibleAssetsByMajorClassAxis_LicensingAgreementsMember_RangeAxis_MaximumMember">P20Y</relm:LicenseExpiryTerm>
<us-gaap:LeaseAndRentalExpense contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_IndefiniteLivedIntangibleAssetsByMajorClassAxis_LeaseAgreementsMember" unitRef="USD" decimals="0">13300</us-gaap:LeaseAndRentalExpense>
<us-gaap:LeaseAndRentalExpense contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_IndefiniteLivedIntangibleAssetsByMajorClassAxis_LeaseAgreementsMember" unitRef="USD" decimals="0">64600</us-gaap:LeaseAndRentalExpense>
<us-gaap:LeaseAndRentalExpense contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00_IndefiniteLivedIntangibleAssetsByMajorClassAxis_LeaseAgreementsMember" unitRef="USD" decimals="0">67800</us-gaap:LeaseAndRentalExpense>
<relm:DoubtfulExpense contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_IndefiniteLivedIntangibleAssetsByMajorClassAxis_LegalMember" unitRef="USD" decimals="-5">1500000</relm:DoubtfulExpense>
<relm:CommonStockSharesExchange contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00_IndefiniteLivedIntangibleAssetsByMajorClassAxis_LegalMember" unitRef="shares" decimals="INF">868213</relm:CommonStockSharesExchange>
<relm:RoyaltiesDescription contextRef="Context_6ME_01_Jan_2014T00_00_00_TO_30_Jun_2014T00_00_00">License fee of $1,500,000 and will earn royalties of up to 12% of net sales for up to two licensed products it is currently developing.</relm:RoyaltiesDescription>
<relm:UpfrontCashFee contextRef="Context_Custom_15_Jul_2014T00_00_00_TO_18_Jul_2014T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD" decimals="0">250000</relm:UpfrontCashFee>
<us-gaap:SubsequentEventDescription contextRef="Context_Custom_15_Jul_2014T00_00_00_TO_18_Jul_2014T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">The consultant shall receive an upfront cash fee of $250,000 and $250,000 quarterly cash installments commencing in September 2014. In addition, the Company shall issue 250,000 shares of the Company's within fifteen (15) days of the agreement and the remaining 250,000 shares shall be issued in six monthly installments commencing in September 2014.</us-gaap:SubsequentEventDescription>

<!-- Footnote Section -->
<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<link:loc xlink:type="locator" xlink:href="#Footnote-1_1" xlink:label="lab_Footnote-1_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-1_2" xlink:label="lab_Footnote-1_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-1_3" xlink:label="lab_Footnote-1_3"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_3"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-1_4" xlink:label="lab_Footnote-1_4"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_4"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-1_5" xlink:label="lab_Footnote-1_5"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_5"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-1_6" xlink:label="lab_Footnote-1_6"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-1" xlink:from="lab_Footnote-1_6"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-2_1" xlink:label="lab_Footnote-2_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-2" xlink:from="lab_Footnote-2_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-2_2" xlink:label="lab_Footnote-2_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-2" xlink:from="lab_Footnote-2_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-2_3" xlink:label="lab_Footnote-2_3"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-2" xlink:from="lab_Footnote-2_3"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-2_4" xlink:label="lab_Footnote-2_4"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-2" xlink:from="lab_Footnote-2_4"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-2_5" xlink:label="lab_Footnote-2_5"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-2" xlink:from="lab_Footnote-2_5"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-2_6" xlink:label="lab_Footnote-2_6"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-2" xlink:from="lab_Footnote-2_6"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-3_1" xlink:label="lab_Footnote-3_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-3" xlink:from="lab_Footnote-3_1"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-3_2" xlink:label="lab_Footnote-3_2"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-3" xlink:from="lab_Footnote-3_2"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-3_3" xlink:label="lab_Footnote-3_3"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-3" xlink:from="lab_Footnote-3_3"/>
<link:loc xlink:type="locator" xlink:href="#Footnote-3_4" xlink:label="lab_Footnote-3_4"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1.0" xlink:to="Footnote-3" xlink:from="lab_Footnote-3_4"/>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-1">The market value is the calculated fair value of the common stock pursuant to the valuation technique as described above.</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-2">The risk-free interest rate was determined by management using the 1 and 5 - year Treasury Bill as of measurement date.</link:footnote>
<link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" xlink:label="Footnote-3">The historical trading volatility was determined by calculating the volatility of the Company's peer group.</link:footnote>
</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>relm-20140630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.1.0.1 on Tuesday, September 16, 2014 02:33:15 AM -->
<schema targetNamespace="http://www.relmada.com/20140630" elementFormDefault="qualified" xmlns:relm="http://www.relmada.com/20140630" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
<annotation><appinfo>
<link:roleType roleURI="http://www.relmada.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
<link:definition>001 - Document - Document and Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>002 - Statement - Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
<link:definition>003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
<link:definition>004 - Statement - Consolidated Statements of Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/ConsolidatedStatementOfStockholdersDeficit" id="ConsolidatedStatementOfStockholdersDeficit">
<link:definition>005 - Statement - Consolidated Statement of Stockholders' Deficit</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
<link:definition>006 - Statement - Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/Business" id="Business">
<link:definition>007 - Disclosure - Business</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/NotesPayable" id="NotesPayable">
<link:definition>009 - Disclosure - Notes Payable</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/DerivativeLiabilities" id="DerivativeLiabilities">
<link:definition>010 - Disclosure - Derivative Liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/StockholdersEquity" id="StockholdersEquity">
<link:definition>011 - Disclosure - Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>012 - Disclosure - Related Party Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>013 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>014 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>015 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/SummaryofSignificantAccountingPoliciesPolicies" id="SummaryofSignificantAccountingPoliciesPolicies">
<link:definition>016 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/SummaryofSignificantAccountingPoliciesTables" id="SummaryofSignificantAccountingPoliciesTables">
<link:definition>017 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/NotePayableTables" id="NotePayableTables">
<link:definition>018 - Disclosure - Notes Payable (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/DerivativeLiabilitiesTables" id="DerivativeLiabilitiesTables">
<link:definition>019 - Disclosure - Derivative Liabilities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
<link:definition>020 - Disclosure - Stockholders' Equity (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/RelatedPartyTransactionsTables" id="RelatedPartyTransactionsTables">
<link:definition>021 - Disclosure - Related Party Transactions (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>022 - Disclosure - Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/CommitmentsandContingenciesTables" id="CommitmentsandContingenciesTables">
<link:definition>023 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/BusinessDetails" id="BusinessDetails">
<link:definition>024 - Disclosure - Business (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/SummaryofSignificantAccountingPoliciesDetails" id="SummaryofSignificantAccountingPoliciesDetails">
<link:definition>025 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/SummaryOfSignificantAccountingPoliciesDetails1" id="SummaryOfSignificantAccountingPoliciesDetails1">
<link:definition>026 - Disclosure - Summary of Significant Accounting Policies (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/SummaryOfSignificantAccountingPoliciesDetails2" id="SummaryOfSignificantAccountingPoliciesDetails2">
<link:definition>027 - Disclosure - Summary of Significant Accounting Policies (Details 2)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" id="SummaryOfSignificantAccountingPoliciesDetailsTextual">
<link:definition>028 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/NotePayableDetails" id="NotePayableDetails">
<link:definition>029 - Disclosure - Notes Payable (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/NotePayableDetailsTextual" id="NotePayableDetailsTextual">
<link:definition>030 - Disclosure - Notes Payable (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/DerivativeLiabilitiesDetails" id="DerivativeLiabilitiesDetails">
<link:definition>031 - Disclosure - Derivative Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/DerivativeLiabilitiesDetails1" id="DerivativeLiabilitiesDetails1">
<link:definition>032 - Disclosure - Derivative Liabilities (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/DerivativeLiabilitiesDetailsTextual" id="DerivativeLiabilitiesDetailsTextual">
<link:definition>033 - Disclosure - Derivative Liabilities (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
<link:definition>034 - Disclosure - Stockholders' Equity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/StockholdersEquityDetails1" id="StockholdersEquityDetails1">
<link:definition>035 - Disclosure - Stockholders' Equity (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/StockholdersEquityDetails2" id="StockholdersEquityDetails2">
<link:definition>036 - Disclosure - Stockholders' Equity (Details 2)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/StockholdersEquityDetails3" id="StockholdersEquityDetails3">
<link:definition>037 - Disclosure - Stockholders' Equity (Details 3)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/StockholdersEquityDetails4" id="StockholdersEquityDetails4">
<link:definition>038 - Disclosure - Stockholders' Equity (Details 4)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/StockholdersEquityDetailsTextual" id="StockholdersEquityDetailsTextual">
<link:definition>039 - Disclosure - Stockholders' Equity (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/StockholdersEquityDetailsTextual1" id="StockholdersEquityDetailsTextual1">
<link:definition>040 - Disclosure - Stockholders' Equity (Details Textual 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/StockholdersEquityDetailsTextual2" id="StockholdersEquityDetailsTextual2">
<link:definition>041 - Disclosure - Stockholders' Equity (Details Textual 2)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
<link:definition>042 - Disclosure - Related Party Transactions (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/RelatedPartyTransactionsDetailsTextual" id="RelatedPartyTransactionsDetailsTextual">
<link:definition>043 - Disclosure - Related Party Transactions (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
<link:definition>044 - Disclosure - Income Taxes (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
<link:definition>045 - Disclosure - Income Taxes (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/IncomeTaxesDetailsTextual" id="IncomeTaxesDetailsTextual">
<link:definition>046 - Disclosure - Income Taxes (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/CommitmentsandContingenciesDetails" id="CommitmentsandContingenciesDetails">
<link:definition>047 - Disclosure - Commitments and Contingencies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/CommitmentsAndContingenciesDetailsTextual" id="CommitmentsAndContingenciesDetailsTextual">
<link:definition>048 - Disclosure - Commitments and Contingencies (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.relmada.com/role/SubsequentEventsDetails" id="SubsequentEventsDetails">
<link:definition>049 - Disclosure - Subsequent Events (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="relm-20140630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="relm-20140630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="relm-20140630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="relm-20140630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
</appinfo></annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<import namespace="http://fasb.org/us-gaap/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/exch/2014-01-31" schemaLocation="http://xbrl.sec.gov/exch/2014/exch-2014-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
<import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<import namespace="http://fasb.org/us-types/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-types-2014-01-31.xsd"/>
<element name="DocumentAndEntityInformationAbstract" id="relm_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesValue" id="relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesShares" id="relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodValueIssuedForConversionOfLoansAndAccruedInterest" id="relm_StockIssuedDuringPeriodValueIssuedForConversionOfLoansAndAccruedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodSharesIssuedForConversionOfLoansAndAccruedInterest" id="relm_StockIssuedDuringPeriodSharesIssuedForConversionOfLoansAndAccruedInterest" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants" id="relm_StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants" id="relm_StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceOfSeriesAPreferredStockToWonpungForServicesValue" id="relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceOfSeriesAPreferredStockToWonpungForServicesShares" id="relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue" id="relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsShares" id="relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsValue" id="relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsShares" id="relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpense" id="relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpenseShares" id="relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpenseShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceOfFairValueOfWarrantDerivativeLiabilitiesIssuedInUnitsOfferingDuringPeriodValue." id="relm_IssuanceOfFairValueOfWarrantDerivativeLiabilitiesIssuedInUnitsOfferingDuringPeriodValue." type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceOfEliminatingDerivativeLiabilitiesUponShareExchangeDuringPeriodValue" id="relm_IssuanceOfEliminatingDerivativeLiabilitiesUponShareExchangeDuringPeriodValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureValue" id="relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureShares" id="relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange" id="relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares" id="relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockIssuedForServices" id="relm_CommonStockIssuedForServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProceedsFromSubordinatedPromissoryNotesNetOfDeferredFinancingCosts" id="relm_ProceedsFromSubordinatedPromissoryNotesNetOfDeferredFinancingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CashPaidDuringPeriodAbstract" id="relm_CashPaidDuringPeriodAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareExchangeOfSubordinatedDebt" id="relm_ShareExchangeOfSubordinatedDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareExchangeOfAccruedInterest" id="relm_ShareExchangeOfAccruedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceOfDebtInConnectionWithCompensationPolicy" id="relm_IssuanceOfDebtInConnectionWithCompensationPolicy" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfDerivativesTerminatedInConnectionWithShareExchange" id="relm_FairValueOfDerivativesTerminatedInConnectionWithShareExchange" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfDerivativesIssuedInConnectionWithIssuanceOfCommonStock" id="relm_FairValueOfDerivativesIssuedInConnectionWithIssuanceOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="BeneficialConversionFeature" id="relm_BeneficialConversionFeature" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfDerivativesIssuedInConnectionWithIssuanceOfPreferredStock" id="relm_FairValueOfDerivativesIssuedInConnectionWithIssuanceOfPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfDerivativeWarrantsIssuedToLendersInConnectionWithIssuanceOfSubordinatedPromissoryNotes" id="relm_FairValueOfDerivativeWarrantsIssuedToLendersInConnectionWithIssuanceOfSubordinatedPromissoryNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfDerivativeWarrantsIssuedForOfferingCostsInConnectionWithTheIssuanceOfSeriesAPreferredStock" id="relm_FairValueOfDerivativeWarrantsIssuedForOfferingCostsInConnectionWithTheIssuanceOfSeriesAPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfDerivativeIssuedToWonpungForServices" id="relm_FairValueOfDerivativeIssuedToWonpungForServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ExchangeOfLoansAndAccruedInterestForCommonStockFromFounder" id="relm_ExchangeOfLoansAndAccruedInterestForCommonStockFromFounder" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ExchangeOfSubordinatedNotesAndAccruedInterestForSeriesAPreferredStock" id="relm_ExchangeOfSubordinatedNotesAndAccruedInterestForSeriesAPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CashlessExerciseOfWarrantsForCommonStock" id="relm_CashlessExerciseOfWarrantsForCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PatentsPolicyTextBlock" id="relm_PatentsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FixedAssetsPolicyTextBlock" id="relm_FixedAssetsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="GoingConcernPolicyTextBlock" id="relm_GoingConcernPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DevelopmentStageCompanyPolicyTextBlock" id="relm_DevelopmentStageCompanyPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DecemberSubordinatedPromissoryNotesPayablePolicyTextBlock" id="relm_DecemberSubordinatedPromissoryNotesPayablePolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeptemberSubordinatedPromissoryNotesPayablePolicyTextBlock" id="relm_SeptemberSubordinatedPromissoryNotesPayablePolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ScheduleOfPromissoryNotesDueLoanTableTextBlock" id="relm_ScheduleOfPromissoryNotesDueLoanTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ScheduleOfDerivativeLiabilitiesValuationsModelsTableTextBlock" id="relm_ScheduleOfDerivativeLiabilitiesValuationsModelsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ScheduleOfCashProceedsReceivedFromOfferingsTableTextBlock" id="relm_ScheduleOfCashProceedsReceivedFromOfferingsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock" id="relm_ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ScheduleOfOutstandingWarrantsByCategoryTableTextBlock" id="relm_ScheduleOfOutstandingWarrantsByCategoryTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OrganizationConsolidationAndPresentationOfFinancialStatementsTable" id="relm_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
<element name="OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" id="relm_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="BusinessTextualsAbstract" id="relm_BusinessTextualsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfWarrantsInstruments" id="relm_FairValueOfWarrantsInstruments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TransferOfFairValueWarrantInstrumentsAdditionalPaidInCapital" id="relm_TransferOfFairValueWarrantInstrumentsAdditionalPaidInCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConversionOfSeriesAPreferredStock" id="relm_ConversionOfSeriesAPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockWarrantsMember" id="relm_CommonStockWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockOptionsMember" id="relm_CommonStockOptionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SignificantAccountingPoliciesTextualsAbstract" id="relm_SignificantAccountingPoliciesTextualsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NotesPayableTable" id="relm_NotesPayableTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
<element name="PromissoryNotesDueMember" id="relm_PromissoryNotesDueMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PromissoryNotesDueOneMember" id="relm_PromissoryNotesDueOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NotesPayableLineItems" id="relm_NotesPayableLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PromissoryNotesDueTwoMember" id="relm_PromissoryNotesDueTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PromissoryNotesDueThreeMember" id="relm_PromissoryNotesDueThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FinancialAgreementMember" id="relm_FinancialAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NotesPayableDetailsTextualAbstract" id="relm_NotesPayableDetailsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DebtDiscountAmortizationPeriod" id="relm_DebtDiscountAmortizationPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CashProceedForDebtDiscountInterestRate" id="relm_CashProceedForDebtDiscountInterestRate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DebtDiscountInterestRateOfMaturity" id="relm_DebtDiscountInterestRateOfMaturity" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PurchaseOfWarrantShares" id="relm_PurchaseOfWarrantShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmortizedDeferredFinancingCostsMaturityDate" id="relm_AmortizedDeferredFinancingCostsMaturityDate" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AmortizationOfDebtIssuanceCosts1" id="relm_AmortizationOfDebtIssuanceCosts1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantsValueForPlacementAgent" id="relm_WarrantsValueForPlacementAgent" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantsValueForPlacementAgentPerShare" id="relm_WarrantsValueForPlacementAgentPerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfDebtDisoumt" id="relm_FairValueOfDebtDisoumt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TotalDebtIssuanceCostsIncurredIn2012" id="relm_TotalDebtIssuanceCostsIncurredIn2012" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FinanceAgreementPaymentDescription" id="relm_FinanceAgreementPaymentDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DebtInConnectionWithDownPaymentOfInsurancePolicy" id="relm_DebtInConnectionWithDownPaymentOfInsurancePolicy" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DebtInConnectionWithPaymentOfMonthlyInstallemt" id="relm_DebtInConnectionWithPaymentOfMonthlyInstallemt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfInstallments" id="relm_NumberOfInstallments" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="InitialValuationsMember" id="relm_InitialValuationsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockIssuableUponExerciseOfWarrants" id="relm_CommonStockIssuableUponExerciseOfWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceOfSeriesAPreferredStockAndWarrantsShares" id="relm_IssuanceOfSeriesAPreferredStockAndWarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MarketValueOfCommonStockOnMeasurementPerStock" id="relm_MarketValueOfCommonStockOnMeasurementPerStock" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuedInMayAndJune2014OfferingMember" id="relm_IssuedInMayAndJune2014OfferingMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AllocationOfCashToPreferredStockIssuance" id="relm_AllocationOfCashToPreferredStockIssuance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AllocationOfCashToCommonStockIssuance" id="relm_AllocationOfCashToCommonStockIssuance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AllocationOfCashToAdditionalPaidInCapital" id="relm_AllocationOfCashToAdditionalPaidInCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AllocationOfCashToDerivativeLiability" id="relm_AllocationOfCashToDerivativeLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AllocationOfCashToDerivativeSeriesAWarrantLiabilities" id="relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AllocationOfCashToDerivativeSeriesAWarrantLiabilitiesOne" id="relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilitiesOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AllocationOfCashToDerivativePreferredStockConversion" id="relm_AllocationOfCashToDerivativePreferredStockConversion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AllocationOfCashToDerivativeWarrantsIssuance" id="relm_AllocationOfCashToDerivativeWarrantsIssuance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProceedsFromIssuanceOfOfferingsNet" id="relm_ProceedsFromIssuanceOfOfferingsNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OfferingCosts" id="relm_OfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ProceedsFromIssuanceOfOfferingsGross" id="relm_ProceedsFromIssuanceOfOfferingsGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" id="relm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" id="relm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CurrentPriceOfCommonStock" id="relm_CurrentPriceOfCommonStock" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ClassOfWarrantOrRightGranted" id="relm_ClassOfWarrantOrRightGranted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ClassOfWarrantOrRightExercised" id="relm_ClassOfWarrantOrRightExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ClassOfWarrantOrRightForfeited" id="relm_ClassOfWarrantOrRightForfeited" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ClassOfWarrantOrRightVestedOutstanding" id="relm_ClassOfWarrantOrRightVestedOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted" id="relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted" type="us-types:perUnitItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" id="relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" type="us-types:perUnitItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeited" id="relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeited" type="us-types:perUnitItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedOutstanding" id="relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedOutstanding" type="us-types:perUnitItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeriesAWarrantsMember" id="relm_SeriesAWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeriesBWarrantsMember" id="relm_SeriesBWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AgentWarrantsMember" id="relm_AgentWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="InvestorsMember" id="relm_InvestorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantToPurchaseOfCommonStock" id="relm_WarrantToPurchaseOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceOfSeriesAPreferredStockSharesToPurchaseCommonStock" id="relm_IssuanceOfSeriesAPreferredStockSharesToPurchaseCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommissionsAndNonAccountableExpenses" id="relm_CommissionsAndNonAccountableExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PlacementAgentExpenses" id="relm_PlacementAgentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ClassOfWarrantOrRightsRedemptionTerms" id="relm_ClassOfWarrantOrRightsRedemptionTerms" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfSolicitationFeeOnWarrantsExercised" id="relm_PercentageOfSolicitationFeeOnWarrantsExercised" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockIssuedForServicesMember" id="relm_CommonStockIssuedForServicesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RelatedPartyMember" id="relm_RelatedPartyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConsultantsMember" id="relm_ConsultantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FounderWarrantsMember" id="relm_FounderWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MedeorIncMember" id="relm_MedeorIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WonpungMember" id="relm_WonpungMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceOfSharesOfCommonStockToSettleLoanFromTheFounder" id="relm_IssuanceOfSharesOfCommonStockToSettleLoanFromTheFounder" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ForgivenessOfInterestExpenseOnLoan" id="relm_ForgivenessOfInterestExpenseOnLoan" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ObligationDueToRelatedParty" id="relm_ObligationDueToRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceOfCommonStockToPurchaseCommonStock" id="relm_IssuanceOfCommonStockToPurchaseCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceOfCommonStockInConnectionWithAcquistionOfLicienseAgreement" id="relm_IssuanceOfCommonStockInConnectionWithAcquistionOfLicienseAgreement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OfficerOptionsMember" id="relm_OfficerOptionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConsultantOptionsMember" id="relm_ConsultantOptionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeriesAPreferredStockOfferingsMember" id="relm_SeriesAPreferredStockOfferingsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DebtOfferingsMember" id="relm_DebtOfferingsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StrategicAdvisorAgreementMember" id="relm_StrategicAdvisorAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DebtHoldersMember" id="relm_DebtHoldersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PlacementAgentMember" id="relm_PlacementAgentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfSharesAvailableForFutureGrantsUnderStockOptionPlan" id="relm_NumberOfSharesAvailableForFutureGrantsUnderStockOptionPlan" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockOptionsPlanStockOptionsExercisablePeriod" id="relm_StockOptionsPlanStockOptionsExercisablePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockOptionsExercisablePeriodDescription" id="relm_StockOptionsExercisablePeriodDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OptionsToPurchaseOfcommonStock" id="relm_OptionsToPurchaseOfcommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockOptionsContractualTerm" id="relm_StockOptionsContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OptionsVestPercentage" id="relm_OptionsVestPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RemainingOptionsVestPercentage" id="relm_RemainingOptionsVestPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RemainingOptionsVestPeriodDescription" id="relm_RemainingOptionsVestPeriodDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfOptionsOnGrantDate" id="relm_FairValueOfOptionsOnGrantDate" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WarrantsContractualTerm" id="relm_WarrantsContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UnvestedWarrantsToPurchaseCommonStock" id="relm_UnvestedWarrantsToPurchaseCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FairValueOfWarrantsIssued" id="relm_FairValueOfWarrantsIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfSharesIncreasedByShareholders" id="relm_NumberOfSharesIncreasedByShareholders" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PlacementAgentThreeMember" id="relm_PlacementAgentThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SeriesAPreferredStockOneMember" id="relm_SeriesAPreferredStockOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SubordinatedPromissoryNoteOfferingMember" id="relm_SubordinatedPromissoryNoteOfferingMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SubordinatedPromissoryNoteOfferingOneMember" id="relm_SubordinatedPromissoryNoteOfferingOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AcquisitionOfMedeorMember" id="relm_AcquisitionOfMedeorMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MayAndJune2014OfferingMember" id="relm_MayAndJune2014OfferingMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ClassOfWarrantOrRightsExpiration" id="relm_ClassOfWarrantOrRightsExpiration" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AdvisoryFirmMember" id="relm_AdvisoryFirmMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SingleActivePharmaceuticalIngredientMember" id="relm_SingleActivePharmaceuticalIngredientMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ActivePharmaceuticalIngredientsMember" id="relm_ActivePharmaceuticalIngredientsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MedeorMember" id="relm_MedeorMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfVestedWarrantsToPurchaseCommonStock" id="relm_PercentageOfVestedWarrantsToPurchaseCommonStock" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceOfWarrantsToPurchaseCommonStock" id="relm_IssuanceOfWarrantsToPurchaseCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssuanceOfWarrantsToPurchaseCommonStockDescription" id="relm_IssuanceOfWarrantsToPurchaseCommonStockDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="TermOfWarrants" id="relm_TermOfWarrants" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ReimbursementExpenses" id="relm_ReimbursementExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="InvestorOfferingPriceDescription" id="relm_InvestorOfferingPriceDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfEngagementAgreement" id="relm_NumberOfEngagementAgreement" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ActivationFees" id="relm_ActivationFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RoyaltyPaymentsDescription" id="relm_RoyaltyPaymentsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RoyaltyReceivedByLicenseeDescription" id="relm_RoyaltyReceivedByLicenseeDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LegalMember" id="relm_LegalMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfLicensedProducts" id="relm_NumberOfLicensedProducts" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LicenseExpiryTerm" id="relm_LicenseExpiryTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DoubtfulExpense" id="relm_DoubtfulExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CancellationOfWarrantsToPurchaseCommonStock" id="relm_CancellationOfWarrantsToPurchaseCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockSharesExchange" id="relm_CommonStockSharesExchange" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RoyaltiesDescription" id="relm_RoyaltiesDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="UpfrontCashFee" id="relm_UpfrontCashFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>relm-20140630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.1.0.1 on Tuesday, September 16, 2014 02:33:15 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#ConsolidatedBalanceSheets" roleURI="http://www.relmada.com/role/ConsolidatedBalanceSheets"/>
<calculationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssets" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_NotesPayableCurrent" order="50" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" order="40" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" order="20" use="optional" weight="1"/></calculationLink>





<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.relmada.com/role/ConsolidatedStatementsOfOperations"/>
<calculationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="loc_us-gaap_InvestmentIncomeInterest" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestExpense" order="30" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet" order="20" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_InvestmentIncomeInterest" order="30" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_InterestExpense" order="40" use="optional" weight="-1"/></calculationLink>


<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.relmada.com/role/ConsolidatedStatementsOfCashFlows"/>
<calculationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_Depreciation" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CommonStockIssuedForServices" xlink:label="loc_relm_CommonStockIssuedForServices"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_relm_CommonStockIssuedForServices" order="30" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts" order="60" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" order="70" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="80" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" order="90" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" order="100" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets" order="10" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable" order="40" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ProceedsFromSubordinatedPromissoryNotesNetOfDeferredFinancingCosts" xlink:label="loc_relm_ProceedsFromSubordinatedPromissoryNotesNetOfDeferredFinancingCosts"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_relm_ProceedsFromSubordinatedPromissoryNotesNetOfDeferredFinancingCosts" order="50" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" order="20" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" order="30" use="optional" weight="1"/></calculationLink>



<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#NotePayableDetails" roleURI="http://www.relmada.com/role/NotePayableDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/NotePayableDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaap_LoansPayableCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="loc_us-gaap_LoansPayableCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount" order="20" use="optional" weight="-1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#StockholdersEquityDetails" roleURI="http://www.relmada.com/role/StockholdersEquityDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/StockholdersEquityDetails">
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ProceedsFromIssuanceOfOfferingsNet" xlink:label="loc_relm_ProceedsFromIssuanceOfOfferingsNet"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToPreferredStockIssuance" xlink:label="loc_relm_AllocationOfCashToPreferredStockIssuance"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_relm_ProceedsFromIssuanceOfOfferingsNet" xlink:to="loc_relm_AllocationOfCashToPreferredStockIssuance" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToCommonStockIssuance" xlink:label="loc_relm_AllocationOfCashToCommonStockIssuance"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_relm_ProceedsFromIssuanceOfOfferingsNet" xlink:to="loc_relm_AllocationOfCashToCommonStockIssuance" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToAdditionalPaidInCapital" xlink:label="loc_relm_AllocationOfCashToAdditionalPaidInCapital"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_relm_ProceedsFromIssuanceOfOfferingsNet" xlink:to="loc_relm_AllocationOfCashToAdditionalPaidInCapital" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToDerivativeLiability" xlink:label="loc_relm_AllocationOfCashToDerivativeLiability"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_relm_ProceedsFromIssuanceOfOfferingsNet" xlink:to="loc_relm_AllocationOfCashToDerivativeLiability" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToDerivativePreferredStockConversion" xlink:label="loc_relm_AllocationOfCashToDerivativePreferredStockConversion"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_relm_ProceedsFromIssuanceOfOfferingsNet" xlink:to="loc_relm_AllocationOfCashToDerivativePreferredStockConversion" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToDerivativeWarrantsIssuance" xlink:label="loc_relm_AllocationOfCashToDerivativeWarrantsIssuance"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_relm_ProceedsFromIssuanceOfOfferingsNet" xlink:to="loc_relm_AllocationOfCashToDerivativeWarrantsIssuance" order="60" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ProceedsFromIssuanceOfOfferingsGross" xlink:label="loc_relm_ProceedsFromIssuanceOfOfferingsGross"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_relm_ProceedsFromIssuanceOfOfferingsGross" xlink:to="loc_relm_AllocationOfCashToPreferredStockIssuance" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_relm_ProceedsFromIssuanceOfOfferingsGross" xlink:to="loc_relm_AllocationOfCashToCommonStockIssuance" order="20" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_relm_ProceedsFromIssuanceOfOfferingsGross" xlink:to="loc_relm_AllocationOfCashToAdditionalPaidInCapital" order="30" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_relm_ProceedsFromIssuanceOfOfferingsGross" xlink:to="loc_relm_AllocationOfCashToDerivativeLiability" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilities" xlink:label="loc_relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilities"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_relm_ProceedsFromIssuanceOfOfferingsGross" xlink:to="loc_relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilities" order="50" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilitiesOne" xlink:label="loc_relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilitiesOne"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_relm_ProceedsFromIssuanceOfOfferingsGross" xlink:to="loc_relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilitiesOne" order="60" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_relm_ProceedsFromIssuanceOfOfferingsGross" xlink:to="loc_relm_AllocationOfCashToDerivativePreferredStockConversion" order="70" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_relm_ProceedsFromIssuanceOfOfferingsGross" xlink:to="loc_relm_AllocationOfCashToDerivativeWarrantsIssuance" order="80" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_OfferingCosts" xlink:label="loc_relm_OfferingCosts"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_relm_ProceedsFromIssuanceOfOfferingsGross" xlink:to="loc_relm_OfferingCosts" order="90" use="optional" weight="1"/></calculationLink>

<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#IncomeTaxesDetails" roleURI="http://www.relmada.com/role/IncomeTaxesDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/IncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsOther" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" order="60" use="optional" weight="-1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#CommitmentsandContingenciesDetails" roleURI="http://www.relmada.com/role/CommitmentsandContingenciesDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/CommitmentsandContingenciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="40" use="optional" weight="1"/>
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>relm-20140630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.1.0.1 on Tuesday, September 16, 2014 02:33:15 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#ConsolidatedBalanceSheets" roleURI="http://www.relmada.com/role/ConsolidatedBalanceSheets"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.relmada.com/role/ConsolidatedBalanceSheetsParenthetical"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#ConsolidatedStatementOfStockholdersDeficit" roleURI="http://www.relmada.com/role/ConsolidatedStatementOfStockholdersDeficit"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#BusinessDetails" roleURI="http://www.relmada.com/role/BusinessDetails"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.relmada.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#SummaryOfSignificantAccountingPoliciesDetails1" roleURI="http://www.relmada.com/role/SummaryOfSignificantAccountingPoliciesDetails1"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#SummaryOfSignificantAccountingPoliciesDetails2" roleURI="http://www.relmada.com/role/SummaryOfSignificantAccountingPoliciesDetails2"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#NotePayableDetails" roleURI="http://www.relmada.com/role/NotePayableDetails"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#NotePayableDetailsTextual" roleURI="http://www.relmada.com/role/NotePayableDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#DerivativeLiabilitiesDetails" roleURI="http://www.relmada.com/role/DerivativeLiabilitiesDetails"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#DerivativeLiabilitiesDetails1" roleURI="http://www.relmada.com/role/DerivativeLiabilitiesDetails1"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#StockholdersEquityDetails" roleURI="http://www.relmada.com/role/StockholdersEquityDetails"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#StockholdersEquityDetails2" roleURI="http://www.relmada.com/role/StockholdersEquityDetails2"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#StockholdersEquityDetails4" roleURI="http://www.relmada.com/role/StockholdersEquityDetails4"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#StockholdersEquityDetailsTextual" roleURI="http://www.relmada.com/role/StockholdersEquityDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#StockholdersEquityDetailsTextual1" roleURI="http://www.relmada.com/role/StockholdersEquityDetailsTextual1"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#StockholdersEquityDetailsTextual2" roleURI="http://www.relmada.com/role/StockholdersEquityDetailsTextual2"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#RelatedPartyTransactionsDetails" roleURI="http://www.relmada.com/role/RelatedPartyTransactionsDetails"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#RelatedPartyTransactionsDetailsTextual" roleURI="http://www.relmada.com/role/RelatedPartyTransactionsDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#IncomeTaxesDetailsTextual" roleURI="http://www.relmada.com/role/IncomeTaxesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#CommitmentsAndContingenciesDetailsTextual" roleURI="http://www.relmada.com/role/CommitmentsAndContingenciesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#SubsequentEventsDetails" roleURI="http://www.relmada.com/role/SubsequentEventsDetails"/>
<definitionLink xlink:type="extended" xlink:role="http://www.relmada.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaap_PreferredClassAMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_PreferredClassAMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AssetsAbstract_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6" xlink:to="loc_us-gaap_AssetsCurrentAbstract_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7" xlink:to="loc_us-gaap_AssetsCurrent_11" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6" xlink:to="loc_us-gaap_OtherAssets_13" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6" xlink:to="loc_us-gaap_Assets_14" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_16" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16" xlink:to="loc_us-gaap_AccountsPayableCurrent_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_18" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_19" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_20" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16" xlink:to="loc_us-gaap_NotesPayableCurrent_21" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16" xlink:to="loc_us-gaap_LiabilitiesCurrent_22" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_23" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_Liabilities_24" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_CommitmentsAndContingencies_25" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_StockholdersEquityAbstract_26" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_26" xlink:to="loc_us-gaap_PreferredStockValue_27" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_26" xlink:to="loc_us-gaap_CommonStockValue_28" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_26" xlink:to="loc_us-gaap_AdditionalPaidInCapital_29" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_26" xlink:to="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_30" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_26" xlink:to="loc_us-gaap_StockholdersEquity_31" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_32" order="50" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.relmada.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaap_PreferredClassAMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_PreferredClassAMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:label="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_8" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_9" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_10" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_11" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_12" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaap_PreferredStockLiquidationPreference_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockLiquidationPreference_13" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_14" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_15" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_16" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_17" order="120" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.relmada.com/role/ConsolidatedStatementOfStockholdersDeficit">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaap_PreferredClassAMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_PreferredClassAMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_RetainedEarningsMember_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" xlink:label="loc_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember_9" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquity_10" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharesOutstanding_11" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesValue" xlink:label="loc_relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesValue_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesValue_12" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesShares" xlink:label="loc_relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesShares_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesValue_12" xlink:to="loc_relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesShares_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaap_DebtInstrumentDecreaseForgiveness_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentDecreaseForgiveness_14" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_StockIssuedDuringPeriodValueIssuedForConversionOfLoansAndAccruedInterest" xlink:label="loc_relm_StockIssuedDuringPeriodValueIssuedForConversionOfLoansAndAccruedInterest_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_relm_StockIssuedDuringPeriodValueIssuedForConversionOfLoansAndAccruedInterest_15" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_StockIssuedDuringPeriodSharesIssuedForConversionOfLoansAndAccruedInterest" xlink:label="loc_relm_StockIssuedDuringPeriodSharesIssuedForConversionOfLoansAndAccruedInterest_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_StockIssuedDuringPeriodValueIssuedForConversionOfLoansAndAccruedInterest_15" xlink:to="loc_relm_StockIssuedDuringPeriodSharesIssuedForConversionOfLoansAndAccruedInterest_16" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants" xlink:label="loc_relm_StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_relm_StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants_17" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants" xlink:label="loc_relm_StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants_17" xlink:to="loc_relm_StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants_18" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_19" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_20" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesValue" xlink:label="loc_relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesValue_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesValue_21" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesShares" xlink:label="loc_relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesShares_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesValue_21" xlink:to="loc_relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesShares_22" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue" xlink:label="loc_relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue_23" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsShares" xlink:label="loc_relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsShares_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue_23" xlink:to="loc_relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsShares_24" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_25" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_25" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_26" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsValue" xlink:label="loc_relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsValue_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsValue_27" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsShares" xlink:label="loc_relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsShares_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsValue_27" xlink:to="loc_relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsShares_28" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_29" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_29" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_30" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_31" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther_31" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_32" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_33" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_33" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_34" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpense" xlink:label="loc_relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpense_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpense_35" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpenseShares" xlink:label="loc_relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpenseShares_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpense_35" xlink:to="loc_relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpenseShares_36" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_37"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensation_37" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForCash" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForCash_38"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForCash_38" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForCash" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForCash_39"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForCash_38" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForCash_39" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfFairValueOfWarrantDerivativeLiabilitiesIssuedInUnitsOfferingDuringPeriodValue." xlink:label="loc_relm_IssuanceOfFairValueOfWarrantDerivativeLiabilitiesIssuedInUnitsOfferingDuringPeriodValue._40"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_relm_IssuanceOfFairValueOfWarrantDerivativeLiabilitiesIssuedInUnitsOfferingDuringPeriodValue._40" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfEliminatingDerivativeLiabilitiesUponShareExchangeDuringPeriodValue" xlink:label="loc_relm_IssuanceOfEliminatingDerivativeLiabilitiesUponShareExchangeDuringPeriodValue_41"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_relm_IssuanceOfEliminatingDerivativeLiabilitiesUponShareExchangeDuringPeriodValue_41" order="190" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureValue" xlink:label="loc_relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureValue_42"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureValue_42" order="200" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureShares" xlink:label="loc_relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureShares_43"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureValue_42" xlink:to="loc_relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureShares_43" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange" xlink:label="loc_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange_44"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange_44" order="210" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares" xlink:label="loc_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares_45"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange_44" xlink:to="loc_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares_45" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_46"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_46" order="220" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_47"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_47" order="230" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.relmada.com/role/BusinessDetails">
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="loc_relm_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_0"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="loc_relm_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_relm_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_0" xlink:to="loc_relm_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_relm_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaap_PreferredClassAMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_PreferredClassAMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_BusinessTextualsAbstract" xlink:label="loc_relm_BusinessTextualsAbstract_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_0" xlink:to="loc_relm_BusinessTextualsAbstract_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_BusinessTextualsAbstract_6" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_BusinessTextualsAbstract_6" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_BusinessTextualsAbstract_6" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplit_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_BusinessTextualsAbstract_6" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplit_10" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange" xlink:label="loc_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_BusinessTextualsAbstract_6" xlink:to="loc_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange_11" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares" xlink:label="loc_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_BusinessTextualsAbstract_6" xlink:to="loc_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares_12" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_BusinessTextualsAbstract_6" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_13" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_BusinessTextualsAbstract_6" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_14" order="70" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.relmada.com/role/SummaryofSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7" xlink:to="loc_us-gaap_EquityComponentDomain_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7" xlink:to="loc_us-gaap_EquityComponentDomain_8_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8" xlink:to="loc_us-gaap_WarrantMember_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_10" xlink:to="loc_us-gaap_ClassOfStockDomain_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_11_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_10" xlink:to="loc_us-gaap_ClassOfStockDomain_11_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_11" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="loc_us-gaap_FairValueNetAssetLiabilityAbstract_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueNetAssetLiabilityAbstract_13" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetAssetLiabilityAbstract_13" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_14" order="0" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.relmada.com/role/SummaryOfSignificantAccountingPoliciesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems" xlink:label="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable" xlink:label="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems_0" xlink:to="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems_0" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" xlink:label="loc_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems_0" xlink:to="loc_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FairValueOfWarrantsInstruments" xlink:label="loc_relm_FairValueOfWarrantsInstruments_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems_0" xlink:to="loc_relm_FairValueOfWarrantsInstruments_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_TransferOfFairValueWarrantInstrumentsAdditionalPaidInCapital" xlink:label="loc_relm_TransferOfFairValueWarrantInstrumentsAdditionalPaidInCapital_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems_0" xlink:to="loc_relm_TransferOfFairValueWarrantInstrumentsAdditionalPaidInCapital_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ConversionOfSeriesAPreferredStock" xlink:label="loc_relm_ConversionOfSeriesAPreferredStock_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems_0" xlink:to="loc_relm_ConversionOfSeriesAPreferredStock_9" order="50" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.relmada.com/role/SummaryOfSignificantAccountingPoliciesDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaap_PreferredClassAMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_PreferredClassAMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CommonStockWarrantsMember" xlink:label="loc_relm_CommonStockWarrantsMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_relm_CommonStockWarrantsMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CommonStockOptionsMember" xlink:label="loc_relm_CommonStockOptionsMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_relm_CommonStockOptionsMember_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8" order="10" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.relmada.com/role/NotePayableDetails">
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_NotesPayableLineItems" xlink:label="loc_relm_NotesPayableLineItems_0"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_NotesPayableTable" xlink:label="loc_relm_NotesPayableTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_relm_NotesPayableLineItems_0" xlink:to="loc_relm_NotesPayableTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_relm_NotesPayableTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PromissoryNotesDueMember" xlink:label="loc_relm_PromissoryNotesDueMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3" xlink:to="loc_relm_PromissoryNotesDueMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PromissoryNotesDueOneMember" xlink:label="loc_relm_PromissoryNotesDueOneMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3" xlink:to="loc_relm_PromissoryNotesDueOneMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaap_LoansPayableCurrent_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableLineItems_0" xlink:to="loc_us-gaap_LoansPayableCurrent_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_7" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableLineItems_0" xlink:to="loc_us-gaap_NotesPayableCurrent_8" order="30" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.relmada.com/role/NotePayableDetailsTextual">
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_NotesPayableLineItems" xlink:label="loc_relm_NotesPayableLineItems_0"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_NotesPayableTable" xlink:label="loc_relm_NotesPayableTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_relm_NotesPayableLineItems_0" xlink:to="loc_relm_NotesPayableTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_relm_NotesPayableTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CommonStockOptionsMember" xlink:label="loc_relm_CommonStockOptionsMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_relm_CommonStockOptionsMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CommonStockWarrantsMember" xlink:label="loc_relm_CommonStockWarrantsMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_relm_CommonStockWarrantsMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_relm_NotesPayableTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PromissoryNotesDueMember" xlink:label="loc_relm_PromissoryNotesDueMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8" xlink:to="loc_relm_PromissoryNotesDueMember_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PromissoryNotesDueOneMember" xlink:label="loc_relm_PromissoryNotesDueOneMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8" xlink:to="loc_relm_PromissoryNotesDueOneMember_10" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PromissoryNotesDueTwoMember" xlink:label="loc_relm_PromissoryNotesDueTwoMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8" xlink:to="loc_relm_PromissoryNotesDueTwoMember_11" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PromissoryNotesDueThreeMember" xlink:label="loc_relm_PromissoryNotesDueThreeMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8" xlink:to="loc_relm_PromissoryNotesDueThreeMember_12" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_relm_NotesPayableTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_13" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_13" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_14_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_13" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_14_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FinancialAgreementMember" xlink:label="loc_relm_FinancialAgreementMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_14" xlink:to="loc_relm_FinancialAgreementMember_15" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_NotesPayableDetailsTextualAbstract" xlink:label="loc_relm_NotesPayableDetailsTextualAbstract_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableLineItems_0" xlink:to="loc_relm_NotesPayableDetailsTextualAbstract_16" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_us-gaap_NotesPayable_18" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_19" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_DebtDiscountAmortizationPeriod" xlink:label="loc_relm_DebtDiscountAmortizationPeriod_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_relm_DebtDiscountAmortizationPeriod_20" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_21" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_us-gaap_SharePrice_22" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_23" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CashProceedForDebtDiscountInterestRate" xlink:label="loc_relm_CashProceedForDebtDiscountInterestRate_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_relm_CashProceedForDebtDiscountInterestRate_24" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_DebtDiscountInterestRateOfMaturity" xlink:label="loc_relm_DebtDiscountInterestRateOfMaturity_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_relm_DebtDiscountInterestRateOfMaturity_25" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PurchaseOfWarrantShares" xlink:label="loc_relm_PurchaseOfWarrantShares_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_relm_PurchaseOfWarrantShares_26" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_27" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AmortizedDeferredFinancingCostsMaturityDate" xlink:label="loc_relm_AmortizedDeferredFinancingCostsMaturityDate_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_relm_AmortizedDeferredFinancingCostsMaturityDate_28" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum_29" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AmortizationOfDebtIssuanceCosts1" xlink:label="loc_relm_AmortizationOfDebtIssuanceCosts1_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_relm_AmortizationOfDebtIssuanceCosts1_30" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_WarrantsValueForPlacementAgent" xlink:label="loc_relm_WarrantsValueForPlacementAgent_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_relm_WarrantsValueForPlacementAgent_31" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_WarrantsValueForPlacementAgentPerShare" xlink:label="loc_relm_WarrantsValueForPlacementAgentPerShare_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_relm_WarrantsValueForPlacementAgentPerShare_32" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FairValueOfDebtDisoumt" xlink:label="loc_relm_FairValueOfDebtDisoumt_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_relm_FairValueOfDebtDisoumt_33" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_34" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtPercentageBearingFixedInterestAmount" xlink:label="loc_us-gaap_LongtermDebtPercentageBearingFixedInterestAmount_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_us-gaap_LongtermDebtPercentageBearingFixedInterestAmount_35" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_TotalDebtIssuanceCostsIncurredIn2012" xlink:label="loc_relm_TotalDebtIssuanceCostsIncurredIn2012_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_relm_TotalDebtIssuanceCostsIncurredIn2012_36" order="190" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_37"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_us-gaap_NotesPayableCurrent_37" order="200" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_38"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_38" order="210" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_39"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_39" order="220" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FinanceAgreementPaymentDescription" xlink:label="loc_relm_FinanceAgreementPaymentDescription_40"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_relm_FinanceAgreementPaymentDescription_40" order="230" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_41"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_41" order="240" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_42"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_42" order="250" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfDebtInConnectionWithCompensationPolicy" xlink:label="loc_relm_IssuanceOfDebtInConnectionWithCompensationPolicy_43"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_relm_IssuanceOfDebtInConnectionWithCompensationPolicy_43" order="260" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_DebtInConnectionWithDownPaymentOfInsurancePolicy" xlink:label="loc_relm_DebtInConnectionWithDownPaymentOfInsurancePolicy_44"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_relm_DebtInConnectionWithDownPaymentOfInsurancePolicy_44" order="270" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_DebtInConnectionWithPaymentOfMonthlyInstallemt" xlink:label="loc_relm_DebtInConnectionWithPaymentOfMonthlyInstallemt_45"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_relm_DebtInConnectionWithPaymentOfMonthlyInstallemt_45" order="280" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_NumberOfInstallments" xlink:label="loc_relm_NumberOfInstallments_46"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_relm_NumberOfInstallments_46" order="290" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_47"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_16" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_47" order="300" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.relmada.com/role/DerivativeLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_InitialValuationsMember" xlink:label="loc_relm_InitialValuationsMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_relm_InitialValuationsMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CommonStockIssuableUponExerciseOfWarrants" xlink:label="loc_relm_CommonStockIssuableUponExerciseOfWarrants_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_relm_CommonStockIssuableUponExerciseOfWarrants_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfSeriesAPreferredStockAndWarrantsShares" xlink:label="loc_relm_IssuanceOfSeriesAPreferredStockAndWarrantsShares_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_relm_IssuanceOfSeriesAPreferredStockAndWarrantsShares_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_MarketValueOfCommonStockOnMeasurementPerStock" xlink:label="loc_relm_MarketValueOfCommonStockOnMeasurementPerStock_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_relm_MarketValueOfCommonStockOnMeasurementPerStock_11" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_FairValueAssumptionsExercisePrice_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueAssumptionsExercisePrice_12" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_13" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_14" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_15" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_16" order="80" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.relmada.com/role/DerivativeLiabilitiesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_2" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_2" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ChangeDuringPeriodFairValueDisclosureMember" xlink:label="loc_us-gaap_ChangeDuringPeriodFairValueDisclosureMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3" xlink:to="loc_us-gaap_ChangeDuringPeriodFairValueDisclosureMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7" xlink:to="loc_us-gaap_ClassOfStockDomain_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_8_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7" xlink:to="loc_us-gaap_ClassOfStockDomain_8_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_10" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_11" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_11" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_12_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_11" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_12_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMember" xlink:label="loc_us-gaap_LongTermDebtMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_12" xlink:to="loc_us-gaap_LongTermDebtMember_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecuritiesPledgedAsCollateralMember" xlink:label="loc_us-gaap_SecuritiesPledgedAsCollateralMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_12" xlink:to="loc_us-gaap_SecuritiesPledgedAsCollateralMember_14" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_15" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_15" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_15" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16" xlink:to="loc_us-gaap_PrivatePlacementMember_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_18" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_18" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_19" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_19_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_18" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_19_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_JuniorSubordinatedDebtMember" xlink:label="loc_us-gaap_JuniorSubordinatedDebtMember_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_19" xlink:to="loc_us-gaap_JuniorSubordinatedDebtMember_20" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1" xlink:to="loc_us-gaap_StatementScenarioAxis_21" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_21" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_22" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_22_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_21" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_22_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuedInMayAndJune2014OfferingMember" xlink:label="loc_relm_IssuedInMayAndJune2014OfferingMember_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_22" xlink:to="loc_relm_IssuedInMayAndJune2014OfferingMember_23" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_24" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_25" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_26" order="30" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.relmada.com/role/StockholdersEquityDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_us-gaap_CommonStockMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToPreferredStockIssuance" xlink:label="loc_relm_AllocationOfCashToPreferredStockIssuance_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_relm_AllocationOfCashToPreferredStockIssuance_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToCommonStockIssuance" xlink:label="loc_relm_AllocationOfCashToCommonStockIssuance_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_relm_AllocationOfCashToCommonStockIssuance_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToAdditionalPaidInCapital" xlink:label="loc_relm_AllocationOfCashToAdditionalPaidInCapital_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_relm_AllocationOfCashToAdditionalPaidInCapital_10" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToDerivativeLiability" xlink:label="loc_relm_AllocationOfCashToDerivativeLiability_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_relm_AllocationOfCashToDerivativeLiability_11" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilities" xlink:label="loc_relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilities_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilities_12" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilitiesOne" xlink:label="loc_relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilitiesOne_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilitiesOne_13" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToDerivativePreferredStockConversion" xlink:label="loc_relm_AllocationOfCashToDerivativePreferredStockConversion_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_relm_AllocationOfCashToDerivativePreferredStockConversion_14" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToDerivativeWarrantsIssuance" xlink:label="loc_relm_AllocationOfCashToDerivativeWarrantsIssuance_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_relm_AllocationOfCashToDerivativeWarrantsIssuance_15" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ProceedsFromIssuanceOfOfferingsNet" xlink:label="loc_relm_ProceedsFromIssuanceOfOfferingsNet_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_relm_ProceedsFromIssuanceOfOfferingsNet_16" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_OfferingCosts" xlink:label="loc_relm_OfferingCosts_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_relm_OfferingCosts_17" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ProceedsFromIssuanceOfOfferingsGross" xlink:label="loc_relm_ProceedsFromIssuanceOfOfferingsGross_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_relm_ProceedsFromIssuanceOfOfferingsGross_18" order="110" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.relmada.com/role/StockholdersEquityDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CurrentPriceOfCommonStock" xlink:label="loc_relm_CurrentPriceOfCommonStock_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_relm_CurrentPriceOfCommonStock_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_11" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_12" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_13" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_14" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_15" order="70" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.relmada.com/role/StockholdersEquityDetails4">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CurrentPriceOfCommonStock" xlink:label="loc_relm_CurrentPriceOfCommonStock_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_relm_CurrentPriceOfCommonStock_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_11" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_12" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_13" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_14" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_15" order="70" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.relmada.com/role/StockholdersEquityDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SeriesAWarrantsMember" xlink:label="loc_relm_SeriesAWarrantsMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_relm_SeriesAWarrantsMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SeriesBWarrantsMember" xlink:label="loc_relm_SeriesBWarrantsMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_relm_SeriesBWarrantsMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AgentWarrantsMember" xlink:label="loc_relm_AgentWarrantsMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_relm_AgentWarrantsMember_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_InvestorsMember" xlink:label="loc_relm_InvestorsMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:to="loc_relm_InvestorsMember_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_12" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_12" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_12" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13" xlink:to="loc_us-gaap_PrivatePlacementMember_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_15" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_15" xlink:to="loc_us-gaap_EquityComponentDomain_16" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_16_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_15" xlink:to="loc_us-gaap_EquityComponentDomain_16_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaap_PreferredClassAMember_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_16" xlink:to="loc_us-gaap_PreferredClassAMember_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_16" xlink:to="loc_us-gaap_CommonStockMember_18" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockConversionBasis" xlink:label="loc_us-gaap_CommonStockConversionBasis_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockConversionBasis_19" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockConversionFeatures" xlink:label="loc_us-gaap_CommonStockConversionFeatures_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockConversionFeatures_20" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_21" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_22" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_23" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_24" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LineOfCredit_25" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaap_InterestReceivable_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_InterestReceivable_26" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_27" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_28" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_WarrantToPurchaseOfCommonStock" xlink:label="loc_relm_WarrantToPurchaseOfCommonStock_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_relm_WarrantToPurchaseOfCommonStock_29" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_30" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DividendsShareBasedCompensation" xlink:label="loc_us-gaap_DividendsShareBasedCompensation_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DividendsShareBasedCompensation_31" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:label="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_32" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DerivativeLiabilities_33" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ProceedsFromIssuanceOfOfferingsGross" xlink:label="loc_relm_ProceedsFromIssuanceOfOfferingsGross_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_relm_ProceedsFromIssuanceOfOfferingsGross_34" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_35" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfSeriesAPreferredStockSharesToPurchaseCommonStock" xlink:label="loc_relm_IssuanceOfSeriesAPreferredStockSharesToPurchaseCommonStock_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_relm_IssuanceOfSeriesAPreferredStockSharesToPurchaseCommonStock_36" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CommissionsAndNonAccountableExpenses" xlink:label="loc_relm_CommissionsAndNonAccountableExpenses_37"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_relm_CommissionsAndNonAccountableExpenses_37" order="190" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PlacementAgentExpenses" xlink:label="loc_relm_PlacementAgentExpenses_38"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_relm_PlacementAgentExpenses_38" order="200" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockTermsOfConversion_39"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ConvertiblePreferredStockTermsOfConversion_39" order="210" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ClassOfWarrantOrRightsRedemptionTerms" xlink:label="loc_relm_ClassOfWarrantOrRightsRedemptionTerms_40"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_relm_ClassOfWarrantOrRightsRedemptionTerms_40" order="220" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PercentageOfSolicitationFeeOnWarrantsExercised" xlink:label="loc_relm_PercentageOfSolicitationFeeOnWarrantsExercised_41"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_relm_PercentageOfSolicitationFeeOnWarrantsExercised_41" order="230" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_42"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_42" order="240" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_43"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_43" order="250" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_44"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_44" order="260" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplit_45"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplit_45" order="270" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange" xlink:label="loc_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange_46"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange_46" order="280" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares" xlink:label="loc_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares_47"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares_47" order="290" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.relmada.com/role/StockholdersEquityDetailsTextual1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CommonStockIssuedForServicesMember" xlink:label="loc_relm_CommonStockIssuedForServicesMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_relm_CommonStockIssuedForServicesMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7" xlink:to="loc_us-gaap_RelatedPartyDomain_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_8_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7" xlink:to="loc_us-gaap_RelatedPartyDomain_8_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_RelatedPartyMember" xlink:label="loc_relm_RelatedPartyMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8" xlink:to="loc_relm_RelatedPartyMember_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ConsultantsMember" xlink:label="loc_relm_ConsultantsMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8" xlink:to="loc_relm_ConsultantsMember_10" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FounderWarrantsMember" xlink:label="loc_relm_FounderWarrantsMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8" xlink:to="loc_relm_FounderWarrantsMember_11" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_12" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_12" xlink:to="loc_dei_EntityDomain_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_13_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_12" xlink:to="loc_dei_EntityDomain_13_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_MedeorIncMember" xlink:label="loc_relm_MedeorIncMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_13" xlink:to="loc_relm_MedeorIncMember_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_WonpungMember" xlink:label="loc_relm_WonpungMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_13" xlink:to="loc_relm_WonpungMember_15" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfSharesOfCommonStockToSettleLoanFromTheFounder" xlink:label="loc_relm_IssuanceOfSharesOfCommonStockToSettleLoanFromTheFounder_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_relm_IssuanceOfSharesOfCommonStockToSettleLoanFromTheFounder_16" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromLoanOriginations1" xlink:label="loc_us-gaap_ProceedsFromLoanOriginations1_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProceedsFromLoanOriginations1_17" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ForgivenessOfInterestExpenseOnLoan" xlink:label="loc_relm_ForgivenessOfInterestExpenseOnLoan_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_relm_ForgivenessOfInterestExpenseOnLoan_18" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ObligationDueToRelatedParty" xlink:label="loc_relm_ObligationDueToRelatedParty_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_relm_ObligationDueToRelatedParty_19" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="loc_us-gaap_InterestExpenseRelatedParty_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_InterestExpenseRelatedParty_20" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_21" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockToPurchaseCommonStock" xlink:label="loc_relm_IssuanceOfCommonStockToPurchaseCommonStock_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_relm_IssuanceOfCommonStockToPurchaseCommonStock_22" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_WarrantToPurchaseOfCommonStock" xlink:label="loc_relm_WarrantToPurchaseOfCommonStock_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_relm_WarrantToPurchaseOfCommonStock_23" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_24" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_25" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_26" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DividendsShareBasedCompensation" xlink:label="loc_us-gaap_DividendsShareBasedCompensation_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_DividendsShareBasedCompensation_27" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_28" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockInConnectionWithAcquistionOfLicienseAgreement" xlink:label="loc_relm_IssuanceOfCommonStockInConnectionWithAcquistionOfLicienseAgreement_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_relm_IssuanceOfCommonStockInConnectionWithAcquistionOfLicienseAgreement_29" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_30" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_31" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_32" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_33" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_34" order="190" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_35" order="200" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_36" order="210" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants" xlink:label="loc_relm_StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants_37"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_relm_StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants_37" order="220" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants" xlink:label="loc_relm_StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants_38"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_relm_StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants_38" order="230" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_39"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_39" order="240" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_40"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_40" order="250" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_41"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_41" order="260" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.relmada.com/role/StockholdersEquityDetailsTextual2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_us-gaap_WarrantMember_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FounderWarrantsMember" xlink:label="loc_relm_FounderWarrantsMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_relm_FounderWarrantsMember_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_OfficerOptionsMember" xlink:label="loc_relm_OfficerOptionsMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_relm_OfficerOptionsMember_11" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ConsultantOptionsMember" xlink:label="loc_relm_ConsultantOptionsMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_relm_ConsultantOptionsMember_12" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_13" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_13" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_14_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_13" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_14_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SeriesAPreferredStockOfferingsMember" xlink:label="loc_relm_SeriesAPreferredStockOfferingsMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_14" xlink:to="loc_relm_SeriesAPreferredStockOfferingsMember_15" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_DebtOfferingsMember" xlink:label="loc_relm_DebtOfferingsMember_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_14" xlink:to="loc_relm_DebtOfferingsMember_16" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_StrategicAdvisorAgreementMember" xlink:label="loc_relm_StrategicAdvisorAgreementMember_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_14" xlink:to="loc_relm_StrategicAdvisorAgreementMember_17" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_18" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_18" xlink:to="loc_us-gaap_RelatedPartyDomain_19" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_19_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_18" xlink:to="loc_us-gaap_RelatedPartyDomain_19_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_DebtHoldersMember" xlink:label="loc_relm_DebtHoldersMember_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_19" xlink:to="loc_relm_DebtHoldersMember_20" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_InvestorsMember" xlink:label="loc_relm_InvestorsMember_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_19" xlink:to="loc_relm_InvestorsMember_21" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PlacementAgentMember" xlink:label="loc_relm_PlacementAgentMember_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_19" xlink:to="loc_relm_PlacementAgentMember_22" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ConsultantsMember" xlink:label="loc_relm_ConsultantsMember_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_19" xlink:to="loc_relm_ConsultantsMember_23" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_24" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_24" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_25" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_25_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_24" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_25_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="loc_us-gaap_BoardOfDirectorsChairmanMember_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_25" xlink:to="loc_us-gaap_BoardOfDirectorsChairmanMember_26" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_25" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_27" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_dei_LegalEntityAxis_28" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_28" xlink:to="loc_dei_EntityDomain_29" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_29_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_28" xlink:to="loc_dei_EntityDomain_29_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_MedeorIncMember" xlink:label="loc_relm_MedeorIncMember_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_29" xlink:to="loc_relm_MedeorIncMember_30" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_31" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_NumberOfSharesAvailableForFutureGrantsUnderStockOptionPlan" xlink:label="loc_relm_NumberOfSharesAvailableForFutureGrantsUnderStockOptionPlan_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_relm_NumberOfSharesAvailableForFutureGrantsUnderStockOptionPlan_32" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_StockOptionsPlanStockOptionsExercisablePeriod" xlink:label="loc_relm_StockOptionsPlanStockOptionsExercisablePeriod_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_relm_StockOptionsPlanStockOptionsExercisablePeriod_33" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_StockOptionsExercisablePeriodDescription" xlink:label="loc_relm_StockOptionsExercisablePeriodDescription_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_relm_StockOptionsExercisablePeriodDescription_34" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_OptionsToPurchaseOfcommonStock" xlink:label="loc_relm_OptionsToPurchaseOfcommonStock_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_relm_OptionsToPurchaseOfcommonStock_35" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_StockOptionsContractualTerm" xlink:label="loc_relm_StockOptionsContractualTerm_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_relm_StockOptionsContractualTerm_36" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_OptionsVestPercentage" xlink:label="loc_relm_OptionsVestPercentage_37"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_relm_OptionsVestPercentage_37" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_RemainingOptionsVestPercentage" xlink:label="loc_relm_RemainingOptionsVestPercentage_38"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_relm_RemainingOptionsVestPercentage_38" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_RemainingOptionsVestPeriodDescription" xlink:label="loc_relm_RemainingOptionsVestPeriodDescription_39"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_relm_RemainingOptionsVestPeriodDescription_39" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FairValueOfOptionsOnGrantDate" xlink:label="loc_relm_FairValueOfOptionsOnGrantDate_40"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_relm_FairValueOfOptionsOnGrantDate_40" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_41"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_41" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_42"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_42" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_43"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_43" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_44"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_44" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_45"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_45" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_46"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_46" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_WarrantsContractualTerm" xlink:label="loc_relm_WarrantsContractualTerm_47"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_relm_WarrantsContractualTerm_47" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_WarrantToPurchaseOfCommonStock" xlink:label="loc_relm_WarrantToPurchaseOfCommonStock_48"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_relm_WarrantToPurchaseOfCommonStock_48" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_UnvestedWarrantsToPurchaseCommonStock" xlink:label="loc_relm_UnvestedWarrantsToPurchaseCommonStock_49"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_relm_UnvestedWarrantsToPurchaseCommonStock_49" order="190" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FairValueOfWarrantsIssued" xlink:label="loc_relm_FairValueOfWarrantsIssued_50"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_relm_FairValueOfWarrantsIssued_50" order="200" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_51"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_51" order="210" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_52"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_52" order="220" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_53"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_53" order="230" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_NumberOfSharesIncreasedByShareholders" xlink:label="loc_relm_NumberOfSharesIncreasedByShareholders_54"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_relm_NumberOfSharesIncreasedByShareholders_54" order="240" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.relmada.com/role/RelatedPartyTransactionsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PlacementAgentThreeMember" xlink:label="loc_relm_PlacementAgentThreeMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_relm_PlacementAgentThreeMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_6" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SeriesAPreferredStockOneMember" xlink:label="loc_relm_SeriesAPreferredStockOneMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_6" xlink:to="loc_relm_SeriesAPreferredStockOneMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SubordinatedPromissoryNoteOfferingMember" xlink:label="loc_relm_SubordinatedPromissoryNoteOfferingMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_6" xlink:to="loc_relm_SubordinatedPromissoryNoteOfferingMember_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SubordinatedPromissoryNoteOfferingOneMember" xlink:label="loc_relm_SubordinatedPromissoryNoteOfferingOneMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_6" xlink:to="loc_relm_SubordinatedPromissoryNoteOfferingOneMember_10" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AcquisitionOfMedeorMember" xlink:label="loc_relm_AcquisitionOfMedeorMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_6" xlink:to="loc_relm_AcquisitionOfMedeorMember_11" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_MayAndJune2014OfferingMember" xlink:label="loc_relm_MayAndJune2014OfferingMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_6" xlink:to="loc_relm_MayAndJune2014OfferingMember_12" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_13" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_14" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ClassOfWarrantOrRightsExpiration" xlink:label="loc_relm_ClassOfWarrantOrRightsExpiration_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_relm_ClassOfWarrantOrRightsExpiration_15" order="30" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.relmada.com/role/RelatedPartyTransactionsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PlacementAgentThreeMember" xlink:label="loc_relm_PlacementAgentThreeMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_relm_PlacementAgentThreeMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AdvisoryFirmMember" xlink:label="loc_relm_AdvisoryFirmMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_relm_AdvisoryFirmMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SingleActivePharmaceuticalIngredientMember" xlink:label="loc_relm_SingleActivePharmaceuticalIngredientMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7" xlink:to="loc_relm_SingleActivePharmaceuticalIngredientMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ActivePharmaceuticalIngredientsMember" xlink:label="loc_relm_ActivePharmaceuticalIngredientsMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7" xlink:to="loc_relm_ActivePharmaceuticalIngredientsMember_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_MedeorMember" xlink:label="loc_relm_MedeorMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7" xlink:to="loc_relm_MedeorMember_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_11" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_11" xlink:to="loc_us-gaap_EquityComponentDomain_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_12_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_11" xlink:to="loc_us-gaap_EquityComponentDomain_12_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_12" xlink:to="loc_us-gaap_CommonStockMember_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_14" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_14" xlink:to="loc_us-gaap_ClassOfStockDomain_15" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_15_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_14" xlink:to="loc_us-gaap_ClassOfStockDomain_15_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_15" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_16" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_dei_LegalEntityAxis_17" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_17" xlink:to="loc_dei_EntityDomain_18" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_18_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_17" xlink:to="loc_dei_EntityDomain_18_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_WonpungMember" xlink:label="loc_relm_WonpungMember_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_18" xlink:to="loc_relm_WonpungMember_19" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_20" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_20" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_21" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_21_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_20" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_21_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_21" xlink:to="loc_us-gaap_SubsequentEventMember_22" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ProfessionalFees_23" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PercentageOfVestedWarrantsToPurchaseCommonStock" xlink:label="loc_relm_PercentageOfVestedWarrantsToPurchaseCommonStock_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_relm_PercentageOfVestedWarrantsToPurchaseCommonStock_24" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExercisePrice" xlink:label="loc_invest_InvestmentWarrantsExercisePrice_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_invest_InvestmentWarrantsExercisePrice_25" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfWarrantsToPurchaseCommonStock" xlink:label="loc_relm_IssuanceOfWarrantsToPurchaseCommonStock_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_relm_IssuanceOfWarrantsToPurchaseCommonStock_26" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfWarrantsToPurchaseCommonStockDescription" xlink:label="loc_relm_IssuanceOfWarrantsToPurchaseCommonStockDescription_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_relm_IssuanceOfWarrantsToPurchaseCommonStockDescription_27" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_TermOfWarrants" xlink:label="loc_relm_TermOfWarrants_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_relm_TermOfWarrants_28" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ReimbursementExpenses" xlink:label="loc_relm_ReimbursementExpenses_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_relm_ReimbursementExpenses_29" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_30" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_31" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_32" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_33" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_34"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_34" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_35"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_35" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSubordinatedLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSubordinatedLongTermDebt_36"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSubordinatedLongTermDebt_36" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_37"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_RestructuringCharges_37" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction_38"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction_38" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_39"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_39" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_InvestorOfferingPriceDescription" xlink:label="loc_relm_InvestorOfferingPriceDescription_40"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_relm_InvestorOfferingPriceDescription_40" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_NumberOfEngagementAgreement" xlink:label="loc_relm_NumberOfEngagementAgreement_41"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_relm_NumberOfEngagementAgreement_41" order="190" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ActivationFees" xlink:label="loc_relm_ActivationFees_42"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_relm_ActivationFees_42" order="200" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription_43"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription_43" order="210" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_RoyaltyPaymentsDescription" xlink:label="loc_relm_RoyaltyPaymentsDescription_44"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_relm_RoyaltyPaymentsDescription_44" order="220" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_RoyaltyReceivedByLicenseeDescription" xlink:label="loc_relm_RoyaltyReceivedByLicenseeDescription_45"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_relm_RoyaltyReceivedByLicenseeDescription_45" order="230" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.relmada.com/role/IncomeTaxesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_3" xlink:to="loc_us-gaap_ResearchMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0" xlink:to="loc_us-gaap_OperatingLossCarryforwards_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="loc_us-gaap_TaxCreditCarryforwardExpirationDate_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0" xlink:to="loc_us-gaap_TaxCreditCarryforwardExpirationDate_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_8" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_9" order="50" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.relmada.com/role/CommitmentsAndContingenciesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3" xlink:to="loc_us-gaap_LicensingAgreementsMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaap_LeaseAgreementsMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3" xlink:to="loc_us-gaap_LeaseAgreementsMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_LegalMember" xlink:label="loc_relm_LegalMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3" xlink:to="loc_relm_LegalMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_us-gaap_RangeAxis_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_7" xlink:to="loc_us-gaap_RangeMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_7" xlink:to="loc_us-gaap_RangeMember_8_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_8" xlink:to="loc_us-gaap_MinimumMember_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_8" xlink:to="loc_us-gaap_MaximumMember_10" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_11" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_11" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_12_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_11" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_12_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_MedeorMember" xlink:label="loc_relm_MedeorMember_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_12" xlink:to="loc_relm_MedeorMember_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_14" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_NumberOfLicensedProducts" xlink:label="loc_relm_NumberOfLicensedProducts_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_relm_NumberOfLicensedProducts_15" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_LicenseExpiryTerm" xlink:label="loc_relm_LicenseExpiryTerm_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_relm_LicenseExpiryTerm_16" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_us-gaap_LeaseAndRentalExpense_17" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_DoubtfulExpense" xlink:label="loc_relm_DoubtfulExpense_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_relm_DoubtfulExpense_18" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CancellationOfWarrantsToPurchaseCommonStock" xlink:label="loc_relm_CancellationOfWarrantsToPurchaseCommonStock_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_relm_CancellationOfWarrantsToPurchaseCommonStock_19" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CommonStockSharesExchange" xlink:label="loc_relm_CommonStockSharesExchange_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_relm_CommonStockSharesExchange_20" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_RoyaltiesDescription" xlink:label="loc_relm_RoyaltiesDescription_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_relm_RoyaltiesDescription_21" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_22" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_RoyaltyPaymentsDescription" xlink:label="loc_relm_RoyaltyPaymentsDescription_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_relm_RoyaltyPaymentsDescription_23" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_RoyaltyReceivedByLicenseeDescription" xlink:label="loc_relm_RoyaltyReceivedByLicenseeDescription_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_relm_RoyaltyReceivedByLicenseeDescription_24" order="110" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.relmada.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_UpfrontCashFee" xlink:label="loc_relm_UpfrontCashFee_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_relm_UpfrontCashFee_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_us-gaap_SubsequentEventDescription_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventDescription_7" order="30" use="optional"/>
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>relm-20140630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.1.0.1 on Tuesday, September 16, 2014 02:33:16 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_DocumentAndEntityInformationAbstract" xlink:label="loc_JG5F7864H0KK_relm_DocumentAndEntityInformationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document And Entity Information [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_DocumentAndEntityInformationAbstract" xlink:to="lab_LI7H9086J2MM_relm_DocumentAndEntityInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_FFG0JH2876HI9H71G8KJ_dei_EntityRegistrantName"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_dei_EntityRegistrantName" xlink:to="lab_HHI2LJ4098JK1J93I0ML_dei_EntityRegistrantName"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_JG5F7864H0KK_dei_EntityCentralIndexKey"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_dei_EntityCentralIndexKey" xlink:to="lab_LI7H9086J2MM_dei_EntityCentralIndexKey"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_FFG0JH2876HI9H71G8KJ_dei_AmendmentFlag"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_dei_AmendmentFlag" xlink:to="lab_HHI2LJ4098JK1J93I0ML_dei_AmendmentFlag"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_JG5F7864H0KK_dei_DocumentType"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_dei_DocumentType" xlink:to="lab_LI7H9086J2MM_dei_DocumentType"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_FFG0JH2876HI9H71G8KJ_dei_DocumentPeriodEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_dei_DocumentPeriodEndDate" xlink:to="lab_HHI2LJ4098JK1J93I0ML_dei_DocumentPeriodEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_JG5F7864H0KK_dei_EntityFilerCategory"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_dei_EntityFilerCategory" xlink:to="lab_LI7H9086J2MM_dei_EntityFilerCategory"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StatementOfFinancialPositionAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StatementOfFinancialPositionAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_JG5F7864H0KK_us-gaap_StatementTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_StatementTable" xlink:to="lab_LI7H9086J2MM_us-gaap_StatementTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StatementClassOfStockAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StatementClassOfStockAxis" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StatementClassOfStockAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_JG5F7864H0KK_us-gaap_ClassOfStockDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ClassOfStockDomain" xlink:to="lab_LI7H9086J2MM_us-gaap_ClassOfStockDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_SeriesAPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Derivative liabilities Series A preferred stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Perferred stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SeriesAPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_JG5F7864H0KK_us-gaap_PreferredClassAMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_PreferredClassAMember" xml:lang="en-US">Preferred Class A [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_PreferredClassAMember" xml:lang="en-US">Class A Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_PreferredClassAMember" xml:lang="en-US">Class A convertible preferred stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_PreferredClassAMember" xlink:to="lab_LI7H9086J2MM_us-gaap_PreferredClassAMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StatementLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StatementLineItems" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StatementLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_JG5F7864H0KK_us-gaap_AssetsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_AssetsAbstract" xlink:to="lab_LI7H9086J2MM_us-gaap_AssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_AssetsCurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_AssetsCurrentAbstract" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_AssetsCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_JG5F7864H0KK_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash at beginning of the period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash at end of the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_LI7H9086J2MM_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_PrepaidExpenseCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_PrepaidExpenseCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_JG5F7864H0KK_us-gaap_DeferredFinanceCostsCurrentNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_DeferredFinanceCostsCurrentNet" xml:lang="en-US">Deferred Finance Costs, Current, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_DeferredFinanceCostsCurrentNet" xml:lang="en-US">Deferred financing costs, net of accumulated amortization of $0 and $69,546 respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="lab_LI7H9086J2MM_us-gaap_DeferredFinanceCostsCurrentNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_AssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_AssetsCurrent" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_JG5F7864H0KK_us-gaap_PropertyPlantAndEquipmentNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Fixed assets, net of accumulated depreciation of $2,230 and $373, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_LI7H9086J2MM_us-gaap_PropertyPlantAndEquipmentNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_OtherAssets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OtherAssets" xml:lang="en-US">Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OtherAssets" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_OtherAssets" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OtherAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_JG5F7864H0KK_us-gaap_Assets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_Assets" xlink:to="lab_LI7H9086J2MM_us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders' Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_JG5F7864H0KK_us-gaap_LiabilitiesCurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_LI7H9086J2MM_us-gaap_LiabilitiesCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_AccountsPayableCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_AccountsPayableCurrent" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_AccountsPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_JG5F7864H0KK_us-gaap_AccruedLiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_LI7H9086J2MM_us-gaap_AccruedLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ConvertibleNotesPayableCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ConvertibleNotesPayableCurrent" xml:lang="en-US">Convertible Notes Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ConvertibleNotesPayableCurrent" xml:lang="en-US">Note payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ConvertibleNotesPayableCurrent" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ConvertibleNotesPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_JG5F7864H0KK_us-gaap_DerivativeLiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_DerivativeLiabilitiesCurrent" xml:lang="en-US">Derivative Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_DerivativeLiabilitiesCurrent" xml:lang="en-US">Derivative liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_LI7H9086J2MM_us-gaap_DerivativeLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_NotesPayableCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_NotesPayableCurrent" xml:lang="en-US">Notes Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_NotesPayableCurrent" xml:lang="en-US">Total notes payable, less debt discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_NotesPayableCurrent" xml:lang="en-US">Subordinated promissory notes payable, net of debt discount of $0 and $141,049, respectively</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_NotesPayableCurrent" xml:lang="en-US">Issuance date if notes payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_NotesPayableCurrent" xml:lang="en-US">Total notes payable, less debt discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_NotesPayableCurrent" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_NotesPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_JG5F7864H0KK_us-gaap_LiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_LiabilitiesCurrent" xlink:to="lab_LI7H9086J2MM_us-gaap_LiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Long-term liability - accrued expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_JG5F7864H0KK_us-gaap_Liabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_Liabilities" xlink:to="lab_LI7H9086J2MM_us-gaap_Liabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_CommitmentsAndContingencies"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_CommitmentsAndContingencies" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_CommitmentsAndContingencies"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_JG5F7864H0KK_us-gaap_StockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' deficit:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_StockholdersEquityAbstract" xlink:to="lab_LI7H9086J2MM_us-gaap_StockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_PreferredStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock,Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_PreferredStockValue" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_PreferredStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_JG5F7864H0KK_us-gaap_CommonStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.001 par value, 500,000,000 shares authorized, 40,294,217 and 4,958,778 shares issued and outstanding, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_CommonStockValue" xlink:to="lab_LI7H9086J2MM_us-gaap_CommonStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_AdditionalPaidInCapital"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_AdditionalPaidInCapital" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_AdditionalPaidInCapital"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="loc_JG5F7864H0KK_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xml:lang="en-US">Development Stage Enterprise, Deficit Accumulated During Development Stage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xml:lang="en-US">Deficit accumulated during the development stage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:to="lab_LI7H9086J2MM_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockholdersEquity" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockholdersEquity" xml:lang="en-US">Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StockholdersEquity" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_JG5F7864H0KK_us-gaap_LiabilitiesAndStockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders' deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_LI7H9086J2MM_us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_AccumulatedAmortizationDeferredFinanceCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xml:lang="en-US">Accumulated Amortization, Deferred Finance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xml:lang="en-US">Amortization of deferred financing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_AccumulatedAmortizationDeferredFinanceCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_JG5F7864H0KK_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_LI7H9086J2MM_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_DebtInstrumentUnamortizedDiscount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Debt Instrument, Unamortized Discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Less: debt discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Debt discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US">Less: debt discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DebtInstrumentUnamortizedDiscount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_JG5F7864H0KK_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_LI7H9086J2MM_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_PreferredStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_PreferredStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_JG5F7864H0KK_us-gaap_PreferredStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_PreferredStockSharesIssued" xlink:to="lab_LI7H9086J2MM_us-gaap_PreferredStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_PreferredStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_PreferredStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_JG5F7864H0KK_us-gaap_PreferredStockLiquidationPreference"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_PreferredStockLiquidationPreference" xml:lang="en-US">Preferred Stock, Liquidation Preference Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_PreferredStockLiquidationPreference" xml:lang="en-US">Liquidation Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_PreferredStockLiquidationPreference" xlink:to="lab_LI7H9086J2MM_us-gaap_PreferredStockLiquidationPreference"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_CommonStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_CommonStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_JG5F7864H0KK_us-gaap_CommonStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_LI7H9086J2MM_us-gaap_CommonStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_CommonStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_CommonStockSharesIssued" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_CommonStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_JG5F7864H0KK_us-gaap_CommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_LI7H9086J2MM_us-gaap_CommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_IncomeStatementAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_IncomeStatementAbstract" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_IncomeStatementAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_JG5F7864H0KK_us-gaap_LicenseAndServicesRevenue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_LicenseAndServicesRevenue" xml:lang="en-US">License and Services Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_LicenseAndServicesRevenue" xml:lang="en-US">Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_LicenseAndServicesRevenue" xlink:to="lab_LI7H9086J2MM_us-gaap_LicenseAndServicesRevenue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_OperatingExpensesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_OperatingExpensesAbstract" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OperatingExpensesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_JG5F7864H0KK_us-gaap_ResearchAndDevelopmentExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_LI7H9086J2MM_us-gaap_ResearchAndDevelopmentExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_GeneralAndAdministrativeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_GeneralAndAdministrativeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_JG5F7864H0KK_us-gaap_OperatingExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_OperatingExpenses" xlink:to="lab_LI7H9086J2MM_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_OperatingIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_OperatingIncomeLoss" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OperatingIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingGainsLossesAbstract" xlink:label="loc_JG5F7864H0KK_us-gaap_NonoperatingGainsLossesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_NonoperatingGainsLossesAbstract" xml:lang="en-US">Nonoperating Gains (Losses) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_NonoperatingGainsLossesAbstract" xml:lang="en-US">Other (expenses) income:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_NonoperatingGainsLossesAbstract" xlink:to="lab_LI7H9086J2MM_us-gaap_NonoperatingGainsLossesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_DerivativeGainLossOnDerivativeNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Loss on change in fair value of derivative liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DerivativeGainLossOnDerivativeNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_JG5F7864H0KK_us-gaap_InvestmentIncomeInterest"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Investment Income, Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_InvestmentIncomeInterest" xlink:to="lab_LI7H9086J2MM_us-gaap_InvestmentIncomeInterest"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_InterestExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_InterestExpense" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_InterestExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_JG5F7864H0KK_us-gaap_OtherNonoperatingIncomeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Total other expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Total other (expenses) income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_LI7H9086J2MM_us-gaap_OtherNonoperatingIncomeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_NetIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_NetIncomeLoss" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_JG5F7864H0KK_us-gaap_EarningsPerShareBasicAndDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net loss per common share - basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_LI7H9086J2MM_us-gaap_EarningsPerShareBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average number of common shares outstanding - basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_JG5F7864H0KK_us-gaap_StatementOfStockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_LI7H9086J2MM_us-gaap_StatementOfStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StatementEquityComponentsAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StatementEquityComponentsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_JG5F7864H0KK_us-gaap_EquityComponentDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_EquityComponentDomain" xlink:to="lab_LI7H9086J2MM_us-gaap_EquityComponentDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_CommonStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_CommonStockMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_CommonStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_JG5F7864H0KK_us-gaap_AdditionalPaidInCapitalMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_LI7H9086J2MM_us-gaap_AdditionalPaidInCapitalMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_RetainedEarningsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_RetainedEarningsMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_RetainedEarningsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" xlink:label="loc_JG5F7864H0KK_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" xml:lang="en-US">Accumulated Deficit during Development Stage [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" xml:lang="en-US">Accumulated Deficit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" xlink:to="lab_LI7H9086J2MM_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_SharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SharesOutstanding" xml:lang="en-US">Beginning Balance, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SharesOutstanding" xml:lang="en-US">Ending Balance, Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_SharesOutstanding" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SharesOutstanding"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesValue" xlink:label="loc_JG5F7864H0KK_relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesValue" xml:lang="en-US">Issuance Of Stock And Warrants To A Related Party For Liabilities, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesValue" xml:lang="en-US">Issuance of common stock and warrants to a related party for liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesValue" xml:lang="en-US">Issuance of common stock and warrants to a related party for liabilities.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesValue" xlink:to="lab_LI7H9086J2MM_relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesValue"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesShares" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesShares" xml:lang="en-US">Issuance Of Stock And Warrants To A Related Party For Liabilities, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesShares" xml:lang="en-US">Issuance of common stock and warrants to a related party for liabilities, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesShares" xml:lang="en-US">Number of common stock and warrants to a related party for liabilities.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesShares" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_JG5F7864H0KK_us-gaap_DebtInstrumentDecreaseForgiveness"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_DebtInstrumentDecreaseForgiveness" xml:lang="en-US">Debt Instrument, Decrease, Forgiveness</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_DebtInstrumentDecreaseForgiveness" xml:lang="en-US">Forgiveness of liabilities by founder</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_DebtInstrumentDecreaseForgiveness" xlink:to="lab_LI7H9086J2MM_us-gaap_DebtInstrumentDecreaseForgiveness"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_StockIssuedDuringPeriodValueIssuedForConversionOfLoansAndAccruedInterest" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_StockIssuedDuringPeriodValueIssuedForConversionOfLoansAndAccruedInterest"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_StockIssuedDuringPeriodValueIssuedForConversionOfLoansAndAccruedInterest" xml:lang="en-US">Stock Issued During Period Value Issued For Conversion Of Loans And Accrued Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_StockIssuedDuringPeriodValueIssuedForConversionOfLoansAndAccruedInterest" xml:lang="en-US">Issuance of Series A preferred stock for conversion of loans and accrued interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_StockIssuedDuringPeriodValueIssuedForConversionOfLoansAndAccruedInterest" xml:lang="en-US">Value of shares issued for conversion of loans and accrued interest.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_StockIssuedDuringPeriodValueIssuedForConversionOfLoansAndAccruedInterest" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_StockIssuedDuringPeriodValueIssuedForConversionOfLoansAndAccruedInterest"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_StockIssuedDuringPeriodSharesIssuedForConversionOfLoansAndAccruedInterest" xlink:label="loc_JG5F7864H0KK_relm_StockIssuedDuringPeriodSharesIssuedForConversionOfLoansAndAccruedInterest"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_StockIssuedDuringPeriodSharesIssuedForConversionOfLoansAndAccruedInterest" xml:lang="en-US">Stock Issued During Period Shares Issued For Conversion Of Loans And Accrued Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_StockIssuedDuringPeriodSharesIssuedForConversionOfLoansAndAccruedInterest" xml:lang="en-US">Issuance of Series A preferred stock for conversion of loans and accrued interest, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_StockIssuedDuringPeriodSharesIssuedForConversionOfLoansAndAccruedInterest" xml:lang="en-US">Number of shares issued for conversion of loans and accrued interest.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_StockIssuedDuringPeriodSharesIssuedForConversionOfLoansAndAccruedInterest" xlink:to="lab_LI7H9086J2MM_relm_StockIssuedDuringPeriodSharesIssuedForConversionOfLoansAndAccruedInterest"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants" xml:lang="en-US">Stock Issued During Period Value Issued For Cashless Exercise Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants" xml:lang="en-US">Issuance of common stock for cashless exercise of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants" xml:lang="en-US">Value of shares issued for cashless exercise of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants" xlink:label="loc_JG5F7864H0KK_relm_StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants" xml:lang="en-US">Stock Issued During Period Shares Issued For Cashless Exercise Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants" xml:lang="en-US">Issuance of common stock for cashless exercise of warrants, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants" xml:lang="en-US">Number of shares issued for cashless exercise of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants" xlink:to="lab_LI7H9086J2MM_relm_StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xml:lang="en-US">Stock Issued During Period, Value, Purchase of Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xml:lang="en-US">Issuance of common stock to acquire license at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_JG5F7864H0KK_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xml:lang="en-US">Stock Issued During Period, Shares, Purchase of Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xml:lang="en-US">Issuance of common stock to acquire license at fair value, Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:to="lab_LI7H9086J2MM_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesValue" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesValue" xml:lang="en-US">Issuance Of Series A Preferred Stock To Wonpung For Services, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesValue" xml:lang="en-US">Issuance of Series A preferred stock to Wonpung for services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesValue" xml:lang="en-US">Value of shares issued for Wonpung for services.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesValue" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesValue"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesShares" xlink:label="loc_JG5F7864H0KK_relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesShares" xml:lang="en-US">Issuance Of Series A Preferred Stock To Wonpung For Services, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesShares" xml:lang="en-US">Issuance of Series A preferred stock to Wonpung for services, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesShares" xml:lang="en-US">Number of shares issued for Wonpung for services.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesShares" xlink:to="lab_LI7H9086J2MM_relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesShares"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue" xml:lang="en-US">Issuance Of Series A Preferred Stock And Warrants For Cash, Net Of Offering Costs, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue" xml:lang="en-US">Issuance of Series A preferred stock and warrants for cash, net of offering costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue" xml:lang="en-US">Value of Series A preferred stock and warrants for cash, net of offering costs.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsShares" xlink:label="loc_JG5F7864H0KK_relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsShares" xml:lang="en-US">Issuance Of Series A Preferred Stock And Warrants For Cash, Net Of Offering Costs, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsShares" xml:lang="en-US">Common stock issuable upon conversion of Series A preferred stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsShares" xml:lang="en-US">Issuance of Series A preferred stock and warrants for cash, net of offering costs, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsShares" xml:lang="en-US">Number of Series A preferred stock and warrants for cash, net of offering costs.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsShares" xlink:to="lab_LI7H9086J2MM_relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Issuance of common stock to acquire Medeor, License agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xml:lang="en-US">Issuance of common stock to acquire Medeor, Inc. at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_JG5F7864H0KK_us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xml:lang="en-US">Issuance of common stock to acquire Medeor, Inc. at fair value, Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_LI7H9086J2MM_us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsValue" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsValue" xml:lang="en-US">Issuance Of Common Stock For Series A Warrants And Series B Warrants Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsValue" xml:lang="en-US">Issuance of common stock, Series A warrants and Series B warrants for cash, net of offering cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsValue" xml:lang="en-US">Value of common stock issued for series A warrants and series B warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsValue" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsValue"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsShares" xlink:label="loc_JG5F7864H0KK_relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsShares" xml:lang="en-US">Issuance Of Common Stock For Series A Warrants And Series B Warrants Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsShares" xml:lang="en-US">Issuance of common stock, Series A warrants and Series B for cash, net of offering cost, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsShares" xml:lang="en-US">Number shares of common stock issued for series A and series B warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsShares" xlink:to="lab_LI7H9086J2MM_relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Issuance of common stock for services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_JG5F7864H0KK_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Issuance of common stock for services, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Issuance of common stock for services, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_LI7H9086J2MM_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Shares issued to the consultant for investor communication and public relations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_LI7H9086J2MM_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StockIssuedDuringPeriodValueOther"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockIssuedDuringPeriodValueOther" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockIssuedDuringPeriodValueOther" xml:lang="en-US">Issuance of common stock to pay off founder loans and forgiveness of interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockIssuedDuringPeriodValueOther"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_JG5F7864H0KK_us-gaap_StockIssuedDuringPeriodSharesOther"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_StockIssuedDuringPeriodSharesOther" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_StockIssuedDuringPeriodSharesOther" xml:lang="en-US">Issuance of common stock to pay off founder loans and forgiveness of interest expense, Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_LI7H9086J2MM_us-gaap_StockIssuedDuringPeriodSharesOther"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of stock to shareholders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of common stock to founder for cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_JG5F7864H0KK_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Warrants to purchase shares of common stock issued, but not vested</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of common stock to founder for cash, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Number of common stock issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_LI7H9086J2MM_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of stock to shareholders, Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_LI7H9086J2MM_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpense" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpense" xml:lang="en-US">Issuance Of Common Stock For Exchange Of Related Party Loan And Accrued Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpense" xml:lang="en-US">Issuance of common stock for exchange of related party loan and accrued interest expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpense" xml:lang="en-US">Issuance of common stock for exchange of related party loan and accrued interest expense.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpense" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpense"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpenseShares" xlink:label="loc_JG5F7864H0KK_relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpenseShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpenseShares" xml:lang="en-US">Issuance Of Common Stock For Exchange Of Related Party Loan And Accrued Interest Expense, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpenseShares" xml:lang="en-US">Issuance of common stock for exchange of related party loan and accrued interest expense, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpenseShares" xml:lang="en-US">Number of common stock for exchange of related party loan and accrued interest expense.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpenseShares" xlink:to="lab_LI7H9086J2MM_relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpenseShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ShareBasedCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensation" xml:lang="en-US">Interest expense converted to common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ShareBasedCompensation" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForCash" xlink:label="loc_JG5F7864H0KK_us-gaap_StockIssuedDuringPeriodValueIssuedForCash"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_StockIssuedDuringPeriodValueIssuedForCash" xml:lang="en-US">Development Stage Entities, Stock Issued, Value, Issued for Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_StockIssuedDuringPeriodValueIssuedForCash" xml:lang="en-US">Issuance of common stock for cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_StockIssuedDuringPeriodValueIssuedForCash" xlink:to="lab_LI7H9086J2MM_us-gaap_StockIssuedDuringPeriodValueIssuedForCash"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForCash" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StockIssuedDuringPeriodSharesIssuedForCash"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockIssuedDuringPeriodSharesIssuedForCash" xml:lang="en-US">Development Stage Entities, Stock Issued, Shares, Issued for Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockIssuedDuringPeriodSharesIssuedForCash" xml:lang="en-US">Issuance of common stock for cash, Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StockIssuedDuringPeriodSharesIssuedForCash" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockIssuedDuringPeriodSharesIssuedForCash"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfFairValueOfWarrantDerivativeLiabilitiesIssuedInUnitsOfferingDuringPeriodValue." xlink:label="loc_JG5F7864H0KK_relm_IssuanceOfFairValueOfWarrantDerivativeLiabilitiesIssuedInUnitsOfferingDuringPeriodValue."/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfFairValueOfWarrantDerivativeLiabilitiesIssuedInUnitsOfferingDuringPeriodValue." xml:lang="en-US">Issuance Of Fair Value Of Warrant Derivative Liabilities Issued In Units Offering During Period Value.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfFairValueOfWarrantDerivativeLiabilitiesIssuedInUnitsOfferingDuringPeriodValue." xml:lang="en-US">Establishing warrant derivative liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfFairValueOfWarrantDerivativeLiabilitiesIssuedInUnitsOfferingDuringPeriodValue." xml:lang="en-US">Issuance of fair value of warrant derivative liabilities issued in units offering during period value.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_IssuanceOfFairValueOfWarrantDerivativeLiabilitiesIssuedInUnitsOfferingDuringPeriodValue." xlink:to="lab_LI7H9086J2MM_relm_IssuanceOfFairValueOfWarrantDerivativeLiabilitiesIssuedInUnitsOfferingDuringPeriodValue."/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfEliminatingDerivativeLiabilitiesUponShareExchangeDuringPeriodValue" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_IssuanceOfEliminatingDerivativeLiabilitiesUponShareExchangeDuringPeriodValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfEliminatingDerivativeLiabilitiesUponShareExchangeDuringPeriodValue" xml:lang="en-US">Issuance Of Eliminating Derivative Liabilities Upon Share Exchange During Period Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfEliminatingDerivativeLiabilitiesUponShareExchangeDuringPeriodValue" xml:lang="en-US">Reclassification of derivative liabilities to APIC upon Share Exchange</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfEliminatingDerivativeLiabilitiesUponShareExchangeDuringPeriodValue" xml:lang="en-US">Issuance of eliminating derivative liabilities upon Share exchange during period value.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_IssuanceOfEliminatingDerivativeLiabilitiesUponShareExchangeDuringPeriodValue" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfEliminatingDerivativeLiabilitiesUponShareExchangeDuringPeriodValue"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureValue" xlink:label="loc_JG5F7864H0KK_relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureValue" xml:lang="en-US">Series A Preferred Stock Notes And Accrued Interest For Common Stock Automatic Conversion Feature Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureValue" xml:lang="en-US">Conversion of Series A preferred stock, notes payable and accrued interest to common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureValue" xml:lang="en-US">Series A Preferred Stock Notes And Accrued Interest For Common Stock Automatic Conversion Feature Value.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureValue" xlink:to="lab_LI7H9086J2MM_relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureValue"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureShares" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureShares" xml:lang="en-US">Series A Preferred Stock Notes And Accrued Interest For Common Stock Automatic Conversion Feature Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureShares" xml:lang="en-US">Conversion of Series A preferred stock, notes payable and accrued interest to common stock, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureShares" xml:lang="en-US">Series A Preferred Stock Notes And Accrued Interest For Common Stock Automatic Conversion Feature Shares.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureShares" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureShares"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange" xlink:label="loc_JG5F7864H0KK_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange" xml:lang="en-US">Issuance Of Common Stock And Preferred Stock In Connection With Share Exchange</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange" xml:lang="en-US">Issuance of common stock and Class A preferred stock in connection with share exchange</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange" xml:lang="en-US">Issuance Of Common Stock And Preferred Stock In Connection With Share Exchange.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange" xlink:to="lab_LI7H9086J2MM_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares" xml:lang="en-US">Issuance Of Common Stock And Preferred Stock In Connection With Share Exchange Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares" xml:lang="en-US">Issuance of common stock and Class A preferred stock in connection with share exchange, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares" xml:lang="en-US">Issuance Of Common Stock And Preferred Stock In Connection With Share Exchange Shares.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_JG5F7864H0KK_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xml:lang="en-US">Debt Instrument, Convertible, Beneficial Conversion Feature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xml:lang="en-US">Beneficial conversion feature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xml:lang="en-US">Amortization of beneficial conversion feature</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="lab_LI7H9086J2MM_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StatementOfCashFlowsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StatementOfCashFlowsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_JG5F7864H0KK_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_LI7H9086J2MM_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_JG5F7864H0KK_us-gaap_Depreciation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_Depreciation" xml:lang="en-US">Depreciation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_Depreciation" xlink:to="lab_LI7H9086J2MM_us-gaap_Depreciation"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CommonStockIssuedForServices" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_CommonStockIssuedForServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_CommonStockIssuedForServices" xml:lang="en-US">Common Stock Issued For Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_CommonStockIssuedForServices" xml:lang="en-US">Common stock issued for services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_CommonStockIssuedForServices" xml:lang="en-US">Value of stock issued for services.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_CommonStockIssuedForServices" xml:lang="en-US">Common stock issued for services</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_CommonStockIssuedForServices" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_CommonStockIssuedForServices"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_JG5F7864H0KK_us-gaap_AmortizationOfDebtDiscountPremium"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US">Amortization of debt discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_LI7H9086J2MM_us-gaap_AmortizationOfDebtDiscountPremium"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_AmortizationOfFinancingCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of Financing Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of deferred financing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_AmortizationOfFinancingCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_JG5F7864H0KK_us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xml:lang="en-US">Increase (Decrease) in Derivative Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xml:lang="en-US">Loss on change in fair value of derivative liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="lab_LI7H9086J2MM_us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_JG5F7864H0KK_us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xml:lang="en-US">Prepaid expenses and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="lab_LI7H9086J2MM_us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_JG5F7864H0KK_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_LI7H9086J2MM_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_JG5F7864H0KK_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows from investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_LI7H9086J2MM_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_PaymentsToAcquireProductiveAssets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_PaymentsToAcquireProductiveAssets" xml:lang="en-US">Payments to Acquire Productive Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_PaymentsToAcquireProductiveAssets" xml:lang="en-US">Purchase of fixed assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_PaymentsToAcquireProductiveAssets" xml:lang="en-US">Purchase of fixed assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_PaymentsToAcquireProductiveAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_JG5F7864H0KK_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_LI7H9086J2MM_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows from financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_JG5F7864H0KK_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xml:lang="en-US">Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xml:lang="en-US">Proceeds from sale of Series A preferred stock and warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:to="lab_LI7H9086J2MM_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xml:lang="en-US">Proceeds from sale of common stock and warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_JG5F7864H0KK_us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Proceeds from sales of common and Class A Series A preferred stock, pursuant to Share Exchange</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_LI7H9086J2MM_us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_RepaymentsOfNotesPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Repayments of Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Payment of notes payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US">Payment of notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_RepaymentsOfNotesPayable"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ProceedsFromSubordinatedPromissoryNotesNetOfDeferredFinancingCosts" xlink:label="loc_JG5F7864H0KK_relm_ProceedsFromSubordinatedPromissoryNotesNetOfDeferredFinancingCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_ProceedsFromSubordinatedPromissoryNotesNetOfDeferredFinancingCosts" xml:lang="en-US">Proceeds From Subordinated Promissory Notes, Net Of Deferred Financing Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_ProceedsFromSubordinatedPromissoryNotesNetOfDeferredFinancingCosts" xml:lang="en-US">Proceeds from subordinated promissory notes payable, net of financing costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_ProceedsFromSubordinatedPromissoryNotesNetOfDeferredFinancingCosts" xml:lang="en-US">Proceeds from subordinated promissory notes, net of deferred financing costs.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_ProceedsFromSubordinatedPromissoryNotesNetOfDeferredFinancingCosts" xlink:to="lab_LI7H9086J2MM_relm_ProceedsFromSubordinatedPromissoryNotesNetOfDeferredFinancingCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_JG5F7864H0KK_us-gaap_CashPeriodIncreaseDecrease"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_CashPeriodIncreaseDecrease" xml:lang="en-US">Cash, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_CashPeriodIncreaseDecrease" xml:lang="en-US">Net increase in cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_CashPeriodIncreaseDecrease" xlink:to="lab_LI7H9086J2MM_us-gaap_CashPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_SupplementalCashFlowInformationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SupplementalCashFlowInformationAbstract"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CashPaidDuringPeriodAbstract" xlink:label="loc_JG5F7864H0KK_relm_CashPaidDuringPeriodAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_CashPaidDuringPeriodAbstract" xml:lang="en-US">Cash Paid During Period [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_CashPaidDuringPeriodAbstract" xml:lang="en-US">Cash paid during the period for:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_CashPaidDuringPeriodAbstract" xml:lang="en-US">Cash paid during period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_CashPaidDuringPeriodAbstract" xlink:to="lab_LI7H9086J2MM_relm_CashPaidDuringPeriodAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_IncomeTaxesPaid"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income Taxes Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_IncomeTaxesPaid" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_IncomeTaxesPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_JG5F7864H0KK_us-gaap_InterestPaid"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_InterestPaid" xml:lang="en-US">Interest Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_InterestPaid" xml:lang="en-US">Interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_InterestPaid" xlink:to="lab_LI7H9086J2MM_us-gaap_InterestPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Non-cash investing and financing transactions:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ShareExchangeOfSubordinatedDebt" xlink:label="loc_JG5F7864H0KK_relm_ShareExchangeOfSubordinatedDebt"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_ShareExchangeOfSubordinatedDebt" xml:lang="en-US">Share Exchange Of Subordinated Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_ShareExchangeOfSubordinatedDebt" xml:lang="en-US">Conversion of Series A Preferred Stock and Subordinated Notes to common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_ShareExchangeOfSubordinatedDebt" xml:lang="en-US">Share exchange of subordinated notes to common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_ShareExchangeOfSubordinatedDebt" xlink:to="lab_LI7H9086J2MM_relm_ShareExchangeOfSubordinatedDebt"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ShareExchangeOfAccruedInterest" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_ShareExchangeOfAccruedInterest"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ShareExchangeOfAccruedInterest" xml:lang="en-US">Share Exchange Of Accrued Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ShareExchangeOfAccruedInterest" xml:lang="en-US">Conversion of accrued interest to common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ShareExchangeOfAccruedInterest" xml:lang="en-US">Share exchange of accrued interest to common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_ShareExchangeOfAccruedInterest" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_ShareExchangeOfAccruedInterest"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfDebtInConnectionWithCompensationPolicy" xlink:label="loc_JG5F7864H0KK_relm_IssuanceOfDebtInConnectionWithCompensationPolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfDebtInConnectionWithCompensationPolicy" xml:lang="en-US">Note payable issued in connection with director and officer insurance policy</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfDebtInConnectionWithCompensationPolicy" xml:lang="en-US">Note payable issued in connection with director and officer insurance policy</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfDebtInConnectionWithCompensationPolicy" xml:lang="en-US">Note payable issued in connection with director and officer insurance policy</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfDebtInConnectionWithCompensationPolicy" xml:lang="en-US">Note payable issued in connection with director and officer policy.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_IssuanceOfDebtInConnectionWithCompensationPolicy" xlink:to="lab_LI7H9086J2MM_relm_IssuanceOfDebtInConnectionWithCompensationPolicy"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FairValueOfDerivativesTerminatedInConnectionWithShareExchange" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_FairValueOfDerivativesTerminatedInConnectionWithShareExchange"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_FairValueOfDerivativesTerminatedInConnectionWithShareExchange" xml:lang="en-US">Fair Value Of Derivatives Terminated In Connection With Share Exchange</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_FairValueOfDerivativesTerminatedInConnectionWithShareExchange" xml:lang="en-US">Fair value of derivative reclassified to additional paid-in-capital in connection with Share Exchange</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_FairValueOfDerivativesTerminatedInConnectionWithShareExchange" xml:lang="en-US">Fair value of derivative terminated in connection with share exchange and transferred to additional paid-in-capital.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_FairValueOfDerivativesTerminatedInConnectionWithShareExchange" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_FairValueOfDerivativesTerminatedInConnectionWithShareExchange"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FairValueOfDerivativesIssuedInConnectionWithIssuanceOfCommonStock" xlink:label="loc_JG5F7864H0KK_relm_FairValueOfDerivativesIssuedInConnectionWithIssuanceOfCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_FairValueOfDerivativesIssuedInConnectionWithIssuanceOfCommonStock" xml:lang="en-US">Fair Value Of Derivatives Issued In Connection With Issuance Of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_FairValueOfDerivativesIssuedInConnectionWithIssuanceOfCommonStock" xml:lang="en-US">Fair value of warrant derivatives issued with units offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_FairValueOfDerivativesIssuedInConnectionWithIssuanceOfCommonStock" xml:lang="en-US">Fair value of derivatives issued in connection with issuance of common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_FairValueOfDerivativesIssuedInConnectionWithIssuanceOfCommonStock" xlink:to="lab_LI7H9086J2MM_relm_FairValueOfDerivativesIssuedInConnectionWithIssuanceOfCommonStock"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_BeneficialConversionFeature" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_BeneficialConversionFeature"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_BeneficialConversionFeature" xml:lang="en-US">Beneficial Conversion Feature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_BeneficialConversionFeature" xml:lang="en-US">Beneficial conversion feature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_BeneficialConversionFeature" xml:lang="en-US">Beneficial conversion feature.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_BeneficialConversionFeature" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_BeneficialConversionFeature"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FairValueOfDerivativesIssuedInConnectionWithIssuanceOfPreferredStock" xlink:label="loc_JG5F7864H0KK_relm_FairValueOfDerivativesIssuedInConnectionWithIssuanceOfPreferredStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_FairValueOfDerivativesIssuedInConnectionWithIssuanceOfPreferredStock" xml:lang="en-US">Fair Value Of Derivatives Issued In Connection With Issuance Of Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_FairValueOfDerivativesIssuedInConnectionWithIssuanceOfPreferredStock" xml:lang="en-US">Fair value of derivatives issued in connection with issuance of preferred stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_FairValueOfDerivativesIssuedInConnectionWithIssuanceOfPreferredStock" xml:lang="en-US">Fair value of derivatives issued in connection with issuance of preferred stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_FairValueOfDerivativesIssuedInConnectionWithIssuanceOfPreferredStock" xlink:to="lab_LI7H9086J2MM_relm_FairValueOfDerivativesIssuedInConnectionWithIssuanceOfPreferredStock"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FairValueOfDerivativeWarrantsIssuedToLendersInConnectionWithIssuanceOfSubordinatedPromissoryNotes" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_FairValueOfDerivativeWarrantsIssuedToLendersInConnectionWithIssuanceOfSubordinatedPromissoryNotes"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_FairValueOfDerivativeWarrantsIssuedToLendersInConnectionWithIssuanceOfSubordinatedPromissoryNotes" xml:lang="en-US">Fair Value Of Derivative Warrants Issued To Lenders In Connection With Issuance Of Subordinated Promissory Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_FairValueOfDerivativeWarrantsIssuedToLendersInConnectionWithIssuanceOfSubordinatedPromissoryNotes" xml:lang="en-US">Fair value of derivative warrants issued to lenders in connection with issuance of subordinated promissory notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_FairValueOfDerivativeWarrantsIssuedToLendersInConnectionWithIssuanceOfSubordinatedPromissoryNotes" xml:lang="en-US">Fair value of derivative warrants issued to lenders in connection with issuance of subordinated promissory notes.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_FairValueOfDerivativeWarrantsIssuedToLendersInConnectionWithIssuanceOfSubordinatedPromissoryNotes" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_FairValueOfDerivativeWarrantsIssuedToLendersInConnectionWithIssuanceOfSubordinatedPromissoryNotes"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_JG5F7864H0KK_us-gaap_FairValueAdjustmentOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US">Fair value of warrants issued in connection with deferred financing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_LI7H9086J2MM_us-gaap_FairValueAdjustmentOfWarrants"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FairValueOfDerivativeWarrantsIssuedForOfferingCostsInConnectionWithTheIssuanceOfSeriesAPreferredStock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_FairValueOfDerivativeWarrantsIssuedForOfferingCostsInConnectionWithTheIssuanceOfSeriesAPreferredStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_FairValueOfDerivativeWarrantsIssuedForOfferingCostsInConnectionWithTheIssuanceOfSeriesAPreferredStock" xml:lang="en-US">Fair Value Of Derivative Warrants Issued For Offering Costs In Connection With The Issuance Of Series A Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_FairValueOfDerivativeWarrantsIssuedForOfferingCostsInConnectionWithTheIssuanceOfSeriesAPreferredStock" xml:lang="en-US">Fair value of derivative warrants issued for offering costs in connection with the issuance of Series A preferred stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_FairValueOfDerivativeWarrantsIssuedForOfferingCostsInConnectionWithTheIssuanceOfSeriesAPreferredStock" xml:lang="en-US">Fair value of derivative warrants issued for offering costs in connection with the issuance of Series A preferred stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_FairValueOfDerivativeWarrantsIssuedForOfferingCostsInConnectionWithTheIssuanceOfSeriesAPreferredStock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_FairValueOfDerivativeWarrantsIssuedForOfferingCostsInConnectionWithTheIssuanceOfSeriesAPreferredStock"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FairValueOfDerivativeIssuedToWonpungForServices" xlink:label="loc_JG5F7864H0KK_relm_FairValueOfDerivativeIssuedToWonpungForServices"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_FairValueOfDerivativeIssuedToWonpungForServices" xml:lang="en-US">Fair Value Of Derivative Issued To Wonpung For Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_FairValueOfDerivativeIssuedToWonpungForServices" xml:lang="en-US">Fair value of derivative issued to Wonpung for services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_FairValueOfDerivativeIssuedToWonpungForServices" xml:lang="en-US">Fair value of derivative issued to Wonpung for services.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_FairValueOfDerivativeIssuedToWonpungForServices" xlink:to="lab_LI7H9086J2MM_relm_FairValueOfDerivativeIssuedToWonpungForServices"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ExchangeOfLoansAndAccruedInterestForCommonStockFromFounder" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_ExchangeOfLoansAndAccruedInterestForCommonStockFromFounder"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ExchangeOfLoansAndAccruedInterestForCommonStockFromFounder" xml:lang="en-US">Exchange Of Loans And Accrued Interest For Common Stock From Founder</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ExchangeOfLoansAndAccruedInterestForCommonStockFromFounder" xml:lang="en-US">Exchange of loans and accrued interest for common stock from founder</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ExchangeOfLoansAndAccruedInterestForCommonStockFromFounder" xml:lang="en-US">Exchange of loans and accrued interest for common stock from founder.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_ExchangeOfLoansAndAccruedInterestForCommonStockFromFounder" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_ExchangeOfLoansAndAccruedInterestForCommonStockFromFounder"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ExchangeOfSubordinatedNotesAndAccruedInterestForSeriesAPreferredStock" xlink:label="loc_JG5F7864H0KK_relm_ExchangeOfSubordinatedNotesAndAccruedInterestForSeriesAPreferredStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_ExchangeOfSubordinatedNotesAndAccruedInterestForSeriesAPreferredStock" xml:lang="en-US">Exchange Of Subordinated Notes And Accrued Interest For Series A Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_ExchangeOfSubordinatedNotesAndAccruedInterestForSeriesAPreferredStock" xml:lang="en-US">Exchange of subordinated notes and accrued interest for Series A preferred stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_ExchangeOfSubordinatedNotesAndAccruedInterestForSeriesAPreferredStock" xml:lang="en-US">Exchange of subordinated notes and accrued interest for Series A preferred stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_ExchangeOfSubordinatedNotesAndAccruedInterestForSeriesAPreferredStock" xlink:to="lab_LI7H9086J2MM_relm_ExchangeOfSubordinatedNotesAndAccruedInterestForSeriesAPreferredStock"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CashlessExerciseOfWarrantsForCommonStock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_CashlessExerciseOfWarrantsForCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_CashlessExerciseOfWarrantsForCommonStock" xml:lang="en-US">Cashless Exercise Of Warrants For Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_CashlessExerciseOfWarrantsForCommonStock" xml:lang="en-US">Cashless exercise of warrants for common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_CashlessExerciseOfWarrantsForCommonStock" xml:lang="en-US">Cashless exercise of warrants for common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_CashlessExerciseOfWarrantsForCommonStock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_CashlessExerciseOfWarrantsForCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_JG5F7864H0KK_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Business [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_LI7H9086J2MM_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">BUSINESS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_JG5F7864H0KK_us-gaap_AccountingPoliciesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_LI7H9086J2MM_us-gaap_AccountingPoliciesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_SignificantAccountingPoliciesTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SignificantAccountingPoliciesTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="loc_JG5F7864H0KK_us-gaap_NotesPayableAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_NotesPayableAbstract" xml:lang="en-US">Notes Payable [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_NotesPayableAbstract" xlink:to="lab_LI7H9086J2MM_us-gaap_NotesPayableAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_DebtDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">NOTES PAYABLE</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DebtDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_JG5F7864H0KK_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xml:lang="en-US">Derivative Laibilities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_LI7H9086J2MM_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xml:lang="en-US">DERIVATIVE LIABILITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_JG5F7864H0KK_us-gaap_StockholdersEquityNoteAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Deficit [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_LI7H9086J2MM_us-gaap_StockholdersEquityNoteAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">STOCKHOLDERS' DEFICIT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_JG5F7864H0KK_us-gaap_RelatedPartyTransactionsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_LI7H9086J2MM_us-gaap_RelatedPartyTransactionsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_JG5F7864H0KK_us-gaap_IncomeTaxDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Taxes [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Taxes [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_LI7H9086J2MM_us-gaap_IncomeTaxDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_IncomeTaxDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">INCOME TAXES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_IncomeTaxDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_JG5F7864H0KK_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitment and Contingencies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_LI7H9086J2MM_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_JG5F7864H0KK_us-gaap_SubsequentEventsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_SubsequentEventsAbstract" xlink:to="lab_LI7H9086J2MM_us-gaap_SubsequentEventsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_SubsequentEventsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">SUBSEQUENT EVENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SubsequentEventsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_JG5F7864H0KK_us-gaap_ConsolidationPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ConsolidationPolicyTextBlock" xml:lang="en-US">Principles of Consolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_LI7H9086J2MM_us-gaap_ConsolidationPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_UseOfEstimates"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_UseOfEstimates" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_UseOfEstimates"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_JG5F7864H0KK_us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_LI7H9086J2MM_us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PatentsPolicyTextBlock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_PatentsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_PatentsPolicyTextBlock" xml:lang="en-US">Patents [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_PatentsPolicyTextBlock" xml:lang="en-US">Patents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_PatentsPolicyTextBlock" xml:lang="en-US">Patents.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_PatentsPolicyTextBlock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_PatentsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FixedAssetsPolicyTextBlock" xlink:label="loc_JG5F7864H0KK_relm_FixedAssetsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_FixedAssetsPolicyTextBlock" xml:lang="en-US">Fixed Assets [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_FixedAssetsPolicyTextBlock" xml:lang="en-US">Fixed Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_FixedAssetsPolicyTextBlock" xml:lang="en-US">Fixed assets.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_FixedAssetsPolicyTextBlock" xlink:to="lab_LI7H9086J2MM_relm_FixedAssetsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_DerivativesPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DerivativesPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_JG5F7864H0KK_us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value on a Recurring Basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_LI7H9086J2MM_us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_IncomeTaxPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_IncomeTaxPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_JG5F7864H0KK_us-gaap_ResearchAndDevelopmentExpensePolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_LI7H9086J2MM_us-gaap_ResearchAndDevelopmentExpensePolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Stock-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_JG5F7864H0KK_us-gaap_EarningsPerSharePolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Net Loss per Common Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_LI7H9086J2MM_us-gaap_EarningsPerSharePolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_JG5F7864H0KK_us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="lab_LI7H9086J2MM_us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_GoingConcernPolicyTextBlock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_GoingConcernPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_GoingConcernPolicyTextBlock" xml:lang="en-US">Going Concern [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_GoingConcernPolicyTextBlock" xml:lang="en-US">Going Concern</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_GoingConcernPolicyTextBlock" xml:lang="en-US">Going concern.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_GoingConcernPolicyTextBlock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_GoingConcernPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_DevelopmentStageCompanyPolicyTextBlock" xlink:label="loc_JG5F7864H0KK_relm_DevelopmentStageCompanyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_DevelopmentStageCompanyPolicyTextBlock" xml:lang="en-US">Development Stage Company [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_DevelopmentStageCompanyPolicyTextBlock" xml:lang="en-US">Development Stage Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_DevelopmentStageCompanyPolicyTextBlock" xml:lang="en-US">Development stage comnpany.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_DevelopmentStageCompanyPolicyTextBlock" xlink:to="lab_LI7H9086J2MM_relm_DevelopmentStageCompanyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US">Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_JG5F7864H0KK_us-gaap_RevenueRecognitionPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_LI7H9086J2MM_us-gaap_RevenueRecognitionPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_DecemberSubordinatedPromissoryNotesPayablePolicyTextBlock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_DecemberSubordinatedPromissoryNotesPayablePolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_DecemberSubordinatedPromissoryNotesPayablePolicyTextBlock" xml:lang="en-US">December Subordinated Promissory Notes Payable [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_DecemberSubordinatedPromissoryNotesPayablePolicyTextBlock" xml:lang="en-US">December 2012 Subordinated Promissory Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_DecemberSubordinatedPromissoryNotesPayablePolicyTextBlock" xml:lang="en-US">December subordinated promissory notes payable.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_DecemberSubordinatedPromissoryNotesPayablePolicyTextBlock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_DecemberSubordinatedPromissoryNotesPayablePolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SeptemberSubordinatedPromissoryNotesPayablePolicyTextBlock" xlink:label="loc_JG5F7864H0KK_relm_SeptemberSubordinatedPromissoryNotesPayablePolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_SeptemberSubordinatedPromissoryNotesPayablePolicyTextBlock" xml:lang="en-US">September Subordinated Promissory Notes Payable [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_SeptemberSubordinatedPromissoryNotesPayablePolicyTextBlock" xml:lang="en-US">September 2013 Subordinated Promissory Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_SeptemberSubordinatedPromissoryNotesPayablePolicyTextBlock" xml:lang="en-US">September subordinated promissory notes payable.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_SeptemberSubordinatedPromissoryNotesPayablePolicyTextBlock" xlink:to="lab_LI7H9086J2MM_relm_SeptemberSubordinatedPromissoryNotesPayablePolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Fair value, financial liabilities measured on recurring basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_JG5F7864H0KK_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Fair value of the Company Level Three financial liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_LI7H9086J2MM_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Summary of anti-dilutive securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ScheduleOfPromissoryNotesDueLoanTableTextBlock" xlink:label="loc_JG5F7864H0KK_relm_ScheduleOfPromissoryNotesDueLoanTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_ScheduleOfPromissoryNotesDueLoanTableTextBlock" xml:lang="en-US">Schedule Of Promissory Notes Due Loan [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_ScheduleOfPromissoryNotesDueLoanTableTextBlock" xml:lang="en-US">Schedule of promissory notes due loan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_ScheduleOfPromissoryNotesDueLoanTableTextBlock" xml:lang="en-US">Schedule of promissory notes due loan.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_ScheduleOfPromissoryNotesDueLoanTableTextBlock" xlink:to="lab_LI7H9086J2MM_relm_ScheduleOfPromissoryNotesDueLoanTableTextBlock"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ScheduleOfDerivativeLiabilitiesValuationsModelsTableTextBlock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_ScheduleOfDerivativeLiabilitiesValuationsModelsTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ScheduleOfDerivativeLiabilitiesValuationsModelsTableTextBlock" xml:lang="en-US">Schedule Of Derivative Liabilities Valuations Models [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ScheduleOfDerivativeLiabilitiesValuationsModelsTableTextBlock" xml:lang="en-US">Schedule of Derivative Liabilities Valuations Models</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ScheduleOfDerivativeLiabilitiesValuationsModelsTableTextBlock" xml:lang="en-US">Schedule Of Derivative Liabilities Valuations Models.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_ScheduleOfDerivativeLiabilitiesValuationsModelsTableTextBlock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_ScheduleOfDerivativeLiabilitiesValuationsModelsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_JG5F7864H0KK_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="lab_LI7H9086J2MM_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ScheduleOfCashProceedsReceivedFromOfferingsTableTextBlock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_ScheduleOfCashProceedsReceivedFromOfferingsTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ScheduleOfCashProceedsReceivedFromOfferingsTableTextBlock" xml:lang="en-US">Schedule Of Cash Proceeds Received From Offerings [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ScheduleOfCashProceedsReceivedFromOfferingsTableTextBlock" xml:lang="en-US">Gross proceeds received in connection with offerings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ScheduleOfCashProceedsReceivedFromOfferingsTableTextBlock" xml:lang="en-US">Tabular disclosure of cash proceeds from offerings of tha reporting entity.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_ScheduleOfCashProceedsReceivedFromOfferingsTableTextBlock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_ScheduleOfCashProceedsReceivedFromOfferingsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_JG5F7864H0KK_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Summary of changes in options outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_LI7H9086J2MM_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Weighted average fair value of options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock" xlink:label="loc_JG5F7864H0KK_relm_ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock" xml:lang="en-US">Schedule Of Share Based Compensation Warrants Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock" xml:lang="en-US">Summary of changes in warrants outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock" xml:lang="en-US">Schedule Of Share Based Compensation Warrants Activity.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock" xlink:to="lab_LI7H9086J2MM_relm_ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ScheduleOfOutstandingWarrantsByCategoryTableTextBlock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_ScheduleOfOutstandingWarrantsByCategoryTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ScheduleOfOutstandingWarrantsByCategoryTableTextBlock" xml:lang="en-US">Schedule Of Outstanding Warrants By Category [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ScheduleOfOutstandingWarrantsByCategoryTableTextBlock" xml:lang="en-US">Summary of outstanding warrants by category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ScheduleOfOutstandingWarrantsByCategoryTableTextBlock" xml:lang="en-US">Schedule Of Outstanding Warrants By Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_ScheduleOfOutstandingWarrantsByCategoryTableTextBlock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_ScheduleOfOutstandingWarrantsByCategoryTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="loc_JG5F7864H0KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xml:lang="en-US">Weighted average fair value of warrants granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:to="lab_LI7H9086J2MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Schedule of received warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US">Schedule of received warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_JG5F7864H0KK_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_LI7H9086J2MM_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Reconciliation of the statutory tax rate to the effective tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_JG5F7864H0KK_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xml:lang="en-US">Schedule of future minimum lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="lab_LI7H9086J2MM_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="loc_JG5F7864H0KK_relm_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xml:lang="en-US">Organization Consolidation And Presentation Of Financial Statements [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="lab_LI7H9086J2MM_relm_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_BusinessTextualsAbstract" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_BusinessTextualsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_BusinessTextualsAbstract" xml:lang="en-US">Business Textuals [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_BusinessTextualsAbstract" xml:lang="en-US">Business (Textuals)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_BusinessTextualsAbstract" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_BusinessTextualsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_JG5F7864H0KK_us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Ownership percentage of Relmada</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_LI7H9086J2MM_us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Issuance of shares in exchange for ownership interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="loc_JG5F7864H0KK_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xml:lang="en-US">Percentage of acquired shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:to="lab_LI7H9086J2MM_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StockholdersEquityNoteStockSplit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockholdersEquityNoteStockSplit" xml:lang="en-US">Stockholders' Equity Note, Stock Split</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockholdersEquityNoteStockSplit" xml:lang="en-US">Stock split ratio description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StockholdersEquityNoteStockSplit" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockholdersEquityNoteStockSplit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_JG5F7864H0KK_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_LI7H9086J2MM_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_JG5F7864H0KK_us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_LI7H9086J2MM_us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_FairValueInputsLevel1Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Quoted Prices In Active Markets for Identical Assets (Level 1) [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_FairValueInputsLevel1Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_JG5F7864H0KK_us-gaap_FairValueInputsLevel2Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Significant Other Observable Inputs (Level 2) [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_LI7H9086J2MM_us-gaap_FairValueInputsLevel2Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_FairValueInputsLevel3Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Significant Unobservable Inputs (Level 3) [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_FairValueInputsLevel3Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_JG5F7864H0KK_us-gaap_WarrantMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_WarrantMember" xml:lang="en-US">Derivative liabilities warrant instruments [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_WarrantMember" xml:lang="en-US">Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_WarrantMember" xlink:to="lab_LI7H9086J2MM_us-gaap_WarrantMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="loc_JG5F7864H0KK_us-gaap_FairValueNetAssetLiabilityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_FairValueNetAssetLiabilityAbstract" xml:lang="en-US">Fair value hierarchy, the Company's financial liabilities that were accounted for at fair value on a recurring basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_FairValueNetAssetLiabilityAbstract" xlink:to="lab_LI7H9086J2MM_us-gaap_FairValueNetAssetLiabilityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable" xml:lang="en-US">Fair Value Inputs, Liabilities, Quantitative Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems" xlink:label="loc_JG5F7864H0KK_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems" xml:lang="en-US">Fair Value Inputs, Liabilities, Quantitative Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems" xlink:to="lab_LI7H9086J2MM_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" xlink:label="loc_JG5F7864H0KK_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" xml:lang="en-US">Increase (Decrease) in Fair Value Adjustments on Other Assets (Liabilities) Carried at Fair Value under Fair Value Option</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" xml:lang="en-US">Change in fair value of derivative liabilities included in net loss for the six months ended June 30, 2014 and for the years ended December 31, 2013 and 2012, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" xlink:to="lab_LI7H9086J2MM_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FairValueOfWarrantsInstruments" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_FairValueOfWarrantsInstruments"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_FairValueOfWarrantsInstruments" xml:lang="en-US">Fair Value Of Warrants Instruments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_FairValueOfWarrantsInstruments" xml:lang="en-US">Additions - warrant instruments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_FairValueOfWarrantsInstruments" xml:lang="en-US">Fair Value Of Warrants Instruments.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_FairValueOfWarrantsInstruments" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_FairValueOfWarrantsInstruments"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_TransferOfFairValueWarrantInstrumentsAdditionalPaidInCapital" xlink:label="loc_JG5F7864H0KK_relm_TransferOfFairValueWarrantInstrumentsAdditionalPaidInCapital"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_TransferOfFairValueWarrantInstrumentsAdditionalPaidInCapital" xml:lang="en-US">Transfer Of Fair Value Warrant Instruments Additional Paid In Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_TransferOfFairValueWarrantInstrumentsAdditionalPaidInCapital" xml:lang="en-US">Transfer of - warrant instruments to additional paid in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_TransferOfFairValueWarrantInstrumentsAdditionalPaidInCapital" xml:lang="en-US">Transfer of fair value warrant instruments additional paid in capital.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_TransferOfFairValueWarrantInstrumentsAdditionalPaidInCapital" xlink:to="lab_LI7H9086J2MM_relm_TransferOfFairValueWarrantInstrumentsAdditionalPaidInCapital"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ConversionOfSeriesAPreferredStock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_ConversionOfSeriesAPreferredStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ConversionOfSeriesAPreferredStock" xml:lang="en-US">Conversion Of Series A Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ConversionOfSeriesAPreferredStock" xml:lang="en-US">Additions - conversion feature of Series A preferred stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ConversionOfSeriesAPreferredStock" xml:lang="en-US">Conversion Of Series A Preferred Stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_ConversionOfSeriesAPreferredStock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_ConversionOfSeriesAPreferredStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_JG5F7864H0KK_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="lab_LI7H9086J2MM_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CommonStockWarrantsMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_CommonStockWarrantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_CommonStockWarrantsMember" xml:lang="en-US">Common Stock Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_CommonStockWarrantsMember" xml:lang="en-US">Common stock warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_CommonStockWarrantsMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_CommonStockWarrantsMember"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CommonStockOptionsMember" xlink:label="loc_JG5F7864H0KK_relm_CommonStockOptionsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_CommonStockOptionsMember" xml:lang="en-US">Common Stock Options [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_CommonStockOptionsMember" xml:lang="en-US">Common Stock Options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_CommonStockOptionsMember" xlink:to="lab_LI7H9086J2MM_relm_CommonStockOptionsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_EarningsPerShareBasicLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_EarningsPerShareBasicLineItems" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_EarningsPerShareBasicLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_JG5F7864H0KK_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Anti-dilutive securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_LI7H9086J2MM_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SignificantAccountingPoliciesTextualsAbstract" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_SignificantAccountingPoliciesTextualsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_SignificantAccountingPoliciesTextualsAbstract" xml:lang="en-US">Significant Accounting Policies Textuals [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_SignificantAccountingPoliciesTextualsAbstract" xml:lang="en-US">Significant Accounting Policies (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_SignificantAccountingPoliciesTextualsAbstract" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_SignificantAccountingPoliciesTextualsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_JG5F7864H0KK_us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Useful life, assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Useful life, assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_LI7H9086J2MM_us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_NotesPayableTable" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_NotesPayableTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_NotesPayableTable" xml:lang="en-US">Notes Payable [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_NotesPayableTable" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_NotesPayableTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_JG5F7864H0KK_us-gaap_DebtInstrumentAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_DebtInstrumentAxis" xlink:to="lab_LI7H9086J2MM_us-gaap_DebtInstrumentAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_DebtInstrumentNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DebtInstrumentNameDomain"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PromissoryNotesDueMember" xlink:label="loc_JG5F7864H0KK_relm_PromissoryNotesDueMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_PromissoryNotesDueMember" xml:lang="en-US">Promissory Notes Due [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_PromissoryNotesDueMember" xml:lang="en-US">Subordinated 8% promissory notes due December 2013</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_PromissoryNotesDueMember" xml:lang="en-US">promissory notes due.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_PromissoryNotesDueMember" xlink:to="lab_LI7H9086J2MM_relm_PromissoryNotesDueMember"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PromissoryNotesDueOneMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_PromissoryNotesDueOneMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_PromissoryNotesDueOneMember" xml:lang="en-US">Promissory Notes Due One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_PromissoryNotesDueOneMember" xml:lang="en-US">Subordinated 8% promissory notes due September 2014</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_PromissoryNotesDueOneMember" xml:lang="en-US">promissory notes due one.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_PromissoryNotesDueOneMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_PromissoryNotesDueOneMember"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_NotesPayableLineItems" xlink:label="loc_JG5F7864H0KK_relm_NotesPayableLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_NotesPayableLineItems" xml:lang="en-US">Subordinated Promissory Notes Payable [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_NotesPayableLineItems" xlink:to="lab_LI7H9086J2MM_relm_NotesPayableLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_LoansPayableCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_LoansPayableCurrent" xml:lang="en-US">Loans Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_LoansPayableCurrent" xml:lang="en-US">Total notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_LoansPayableCurrent" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_LoansPayableCurrent"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PromissoryNotesDueTwoMember" xlink:label="loc_JG5F7864H0KK_relm_PromissoryNotesDueTwoMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_PromissoryNotesDueTwoMember" xml:lang="en-US">Promissory Notes Due Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_PromissoryNotesDueTwoMember" xml:lang="en-US">December 2012 Subordinated Promissory Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_PromissoryNotesDueTwoMember" xml:lang="en-US">Promissory notes due two.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_PromissoryNotesDueTwoMember" xlink:to="lab_LI7H9086J2MM_relm_PromissoryNotesDueTwoMember"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PromissoryNotesDueThreeMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_PromissoryNotesDueThreeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_PromissoryNotesDueThreeMember" xml:lang="en-US">Promissory Notes Due Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_PromissoryNotesDueThreeMember" xml:lang="en-US">September 2013 Subordinated Promissory Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_PromissoryNotesDueThreeMember" xml:lang="en-US">Promissory notes due three.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_PromissoryNotesDueThreeMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_PromissoryNotesDueThreeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_JG5F7864H0KK_us-gaap_FinancialInstrumentAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_FinancialInstrumentAxis" xlink:to="lab_LI7H9086J2MM_us-gaap_FinancialInstrumentAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FinancialAgreementMember" xlink:label="loc_JG5F7864H0KK_relm_FinancialAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_FinancialAgreementMember" xml:lang="en-US">Financial Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_FinancialAgreementMember" xml:lang="en-US">Financial Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_FinancialAgreementMember" xml:lang="en-US">Financial agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_FinancialAgreementMember" xlink:to="lab_LI7H9086J2MM_relm_FinancialAgreementMember"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_NotesPayableDetailsTextualAbstract" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_NotesPayableDetailsTextualAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_NotesPayableDetailsTextualAbstract" xml:lang="en-US">Notes Payable Details Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_NotesPayableDetailsTextualAbstract" xml:lang="en-US">Subordinated Promissory Notes Payable (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_NotesPayableDetailsTextualAbstract" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_NotesPayableDetailsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_JG5F7864H0KK_us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US">Effective interest rates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_LI7H9086J2MM_us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_NotesPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_NotesPayable" xml:lang="en-US">Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_NotesPayable" xml:lang="en-US">8% Promissory notes payable issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_NotesPayable" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_NotesPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_JG5F7864H0KK_us-gaap_DebtInstrumentMaturityDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt Instrument, Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Notes payable due date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_LI7H9086J2MM_us-gaap_DebtInstrumentMaturityDate"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_DebtDiscountAmortizationPeriod" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_DebtDiscountAmortizationPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_DebtDiscountAmortizationPeriod" xml:lang="en-US">Debt Discount Amortization Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_DebtDiscountAmortizationPeriod" xml:lang="en-US">Debt discount amortization period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_DebtDiscountAmortizationPeriod" xml:lang="en-US">Fair Value Of Warrant Price Per Share.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_DebtDiscountAmortizationPeriod" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_DebtDiscountAmortizationPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_JG5F7864H0KK_us-gaap_ProceedsFromNotesPayable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Proceeds from Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Proceeds from Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Proceeds from Notes Payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_LI7H9086J2MM_us-gaap_ProceedsFromNotesPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_SharePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SharePrice" xml:lang="en-US">Common stock exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_SharePrice" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SharePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="loc_JG5F7864H0KK_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium), Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xml:lang="en-US">Fair value of warrants debt discount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="lab_LI7H9086J2MM_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CashProceedForDebtDiscountInterestRate" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_CashProceedForDebtDiscountInterestRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_CashProceedForDebtDiscountInterestRate" xml:lang="en-US">Cash Proceed For Debt Discount Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_CashProceedForDebtDiscountInterestRate" xml:lang="en-US">Cash proceed for debt discount interest rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_CashProceedForDebtDiscountInterestRate" xml:lang="en-US">Cash proceed for debt discount interest rate.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_CashProceedForDebtDiscountInterestRate" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_CashProceedForDebtDiscountInterestRate"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_DebtDiscountInterestRateOfMaturity" xlink:label="loc_JG5F7864H0KK_relm_DebtDiscountInterestRateOfMaturity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_DebtDiscountInterestRateOfMaturity" xml:lang="en-US">Debt Discount Interest Rate Of Maturity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_DebtDiscountInterestRateOfMaturity" xml:lang="en-US">Debt discount interest rate of maturity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_DebtDiscountInterestRateOfMaturity" xml:lang="en-US">Debt discount interest rate of maturity.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_DebtDiscountInterestRateOfMaturity" xlink:to="lab_LI7H9086J2MM_relm_DebtDiscountInterestRateOfMaturity"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PurchaseOfWarrantShares" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_PurchaseOfWarrantShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_PurchaseOfWarrantShares" xml:lang="en-US">Purchase Of Warrant Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_PurchaseOfWarrantShares" xml:lang="en-US">Purchase of warrant shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_PurchaseOfWarrantShares" xml:lang="en-US">Purchase of warrant shares.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_PurchaseOfWarrantShares" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_PurchaseOfWarrantShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_JG5F7864H0KK_us-gaap_PaymentsOfDebtIssuanceCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_PaymentsOfDebtIssuanceCosts" xml:lang="en-US">Payments of Debt Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_PaymentsOfDebtIssuanceCosts" xml:lang="en-US">Cash paid for debt issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_LI7H9086J2MM_us-gaap_PaymentsOfDebtIssuanceCosts"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AmortizedDeferredFinancingCostsMaturityDate" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_AmortizedDeferredFinancingCostsMaturityDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_AmortizedDeferredFinancingCostsMaturityDate" xml:lang="en-US">Amortized Deferred Financing Costs Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_AmortizedDeferredFinancingCostsMaturityDate" xml:lang="en-US">Amortized deferred financing costs maturity date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_AmortizedDeferredFinancingCostsMaturityDate" xml:lang="en-US">Amortized deferred financing costs maturity date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_AmortizedDeferredFinancingCostsMaturityDate" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_AmortizedDeferredFinancingCostsMaturityDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum" xlink:label="loc_JG5F7864H0KK_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum" xml:lang="en-US">Notes payable interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum" xlink:to="lab_LI7H9086J2MM_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AmortizationOfDebtIssuanceCosts1" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_AmortizationOfDebtIssuanceCosts1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_AmortizationOfDebtIssuanceCosts1" xml:lang="en-US">Amortization Of Debt Issuance Costs1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_AmortizationOfDebtIssuanceCosts1" xml:lang="en-US">Amortization of debt issuance costs1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_AmortizationOfDebtIssuanceCosts1" xml:lang="en-US">Amortization of debt issuance costs1.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_AmortizationOfDebtIssuanceCosts1" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_AmortizationOfDebtIssuanceCosts1"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_WarrantsValueForPlacementAgent" xlink:label="loc_JG5F7864H0KK_relm_WarrantsValueForPlacementAgent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_WarrantsValueForPlacementAgent" xml:lang="en-US">Warrants Value For Placement Agent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_WarrantsValueForPlacementAgent" xml:lang="en-US">Warrants Value for placement agent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_WarrantsValueForPlacementAgent" xml:lang="en-US">Warrants Value for placement agent .</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_WarrantsValueForPlacementAgent" xlink:to="lab_LI7H9086J2MM_relm_WarrantsValueForPlacementAgent"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_WarrantsValueForPlacementAgentPerShare" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_WarrantsValueForPlacementAgentPerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_WarrantsValueForPlacementAgentPerShare" xml:lang="en-US">Warrants Value For Placement Agent,Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_WarrantsValueForPlacementAgentPerShare" xml:lang="en-US">Warrants value for placement agent, Per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_WarrantsValueForPlacementAgentPerShare" xml:lang="en-US">Warrants Value for placement agent,per share.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_WarrantsValueForPlacementAgentPerShare" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_WarrantsValueForPlacementAgentPerShare"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FairValueOfDebtDisoumt" xlink:label="loc_JG5F7864H0KK_relm_FairValueOfDebtDisoumt"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_FairValueOfDebtDisoumt" xml:lang="en-US">Fair Value Of Debt Disoumt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_FairValueOfDebtDisoumt" xml:lang="en-US">Fair value of debt disount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_FairValueOfDebtDisoumt" xml:lang="en-US">Fair value of debt disount.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_FairValueOfDebtDisoumt" xlink:to="lab_LI7H9086J2MM_relm_FairValueOfDebtDisoumt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_DeferredFinanceCostsNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DeferredFinanceCostsNet" xml:lang="en-US">Deferred financing costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DeferredFinanceCostsNet" xml:lang="en-US">Deferred financing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DeferredFinanceCostsNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtPercentageBearingFixedInterestAmount" xlink:label="loc_JG5F7864H0KK_us-gaap_LongtermDebtPercentageBearingFixedInterestAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_LongtermDebtPercentageBearingFixedInterestAmount" xml:lang="en-US">Long-term Debt, Percentage Bearing Fixed Interest, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_LongtermDebtPercentageBearingFixedInterestAmount" xml:lang="en-US">Notes payable loan amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_LongtermDebtPercentageBearingFixedInterestAmount" xlink:to="lab_LI7H9086J2MM_us-gaap_LongtermDebtPercentageBearingFixedInterestAmount"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_TotalDebtIssuanceCostsIncurredIn2012" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_TotalDebtIssuanceCostsIncurredIn2012"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_TotalDebtIssuanceCostsIncurredIn2012" xml:lang="en-US">Total Debt Issuance Costs Incurred In 2012</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_TotalDebtIssuanceCostsIncurredIn2012" xml:lang="en-US">Total debt issuance costs incurred in 2013</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_TotalDebtIssuanceCostsIncurredIn2012" xml:lang="en-US">Total debt issuance costs incurred in 2012.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_TotalDebtIssuanceCostsIncurredIn2012" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_TotalDebtIssuanceCostsIncurredIn2012"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_JG5F7864H0KK_us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Note payable, conversion price per share (in Dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_LI7H9086J2MM_us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DebtInstrumentInterestRateDuringPeriod" xml:lang="en-US">Debt Instrument, Interest Rate During Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DebtInstrumentInterestRateDuringPeriod" xml:lang="en-US">Promissory notes payable, Interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FinanceAgreementPaymentDescription" xlink:label="loc_JG5F7864H0KK_relm_FinanceAgreementPaymentDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_FinanceAgreementPaymentDescription" xml:lang="en-US">Finance Agreement Payment Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_FinanceAgreementPaymentDescription" xml:lang="en-US">Finance agreement payment description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_FinanceAgreementPaymentDescription" xml:lang="en-US">Finance Agreement Payment Description.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_FinanceAgreementPaymentDescription" xlink:to="lab_LI7H9086J2MM_relm_FinanceAgreementPaymentDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_InducedConversionOfConvertibleDebtExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_InducedConversionOfConvertibleDebtExpense" xml:lang="en-US">Induced Conversion of Convertible Debt Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_InducedConversionOfConvertibleDebtExpense" xml:lang="en-US">Accrued interest converted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_InducedConversionOfConvertibleDebtExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_JG5F7864H0KK_us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Conversion into common stock share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_LI7H9086J2MM_us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_DebtInConnectionWithDownPaymentOfInsurancePolicy" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_DebtInConnectionWithDownPaymentOfInsurancePolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_DebtInConnectionWithDownPaymentOfInsurancePolicy" xml:lang="en-US">Debt In Connection With Down Payment Of Insurance Policy</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_DebtInConnectionWithDownPaymentOfInsurancePolicy" xml:lang="en-US">Debt in connection with down payment of insurance policy</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_DebtInConnectionWithDownPaymentOfInsurancePolicy" xml:lang="en-US">Debt in connection with down payment of insurance policy.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_DebtInConnectionWithDownPaymentOfInsurancePolicy" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_DebtInConnectionWithDownPaymentOfInsurancePolicy"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_DebtInConnectionWithPaymentOfMonthlyInstallemt" xlink:label="loc_JG5F7864H0KK_relm_DebtInConnectionWithPaymentOfMonthlyInstallemt"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_DebtInConnectionWithPaymentOfMonthlyInstallemt" xml:lang="en-US">Relm_Debt In Connection With Payment Of Monthly Installemt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_DebtInConnectionWithPaymentOfMonthlyInstallemt" xml:lang="en-US">Debt in connection with payment of monthly installment, Insurance policy</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_DebtInConnectionWithPaymentOfMonthlyInstallemt" xml:lang="en-US">Debt in connection with payment of monthly installemt.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_DebtInConnectionWithPaymentOfMonthlyInstallemt" xlink:to="lab_LI7H9086J2MM_relm_DebtInConnectionWithPaymentOfMonthlyInstallemt"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_NumberOfInstallments" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_NumberOfInstallments"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_NumberOfInstallments" xml:lang="en-US">Number Of Installments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_NumberOfInstallments" xml:lang="en-US">Number of installments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_NumberOfInstallments" xml:lang="en-US">Number of monthly installments.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_NumberOfInstallments" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_NumberOfInstallments"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_InitialValuationsMember" xlink:label="loc_JG5F7864H0KK_relm_InitialValuationsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_InitialValuationsMember" xml:lang="en-US">Initial Valuation [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_InitialValuationsMember" xlink:to="lab_LI7H9086J2MM_relm_InitialValuationsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_RangeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_RangeAxis" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_RangeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_JG5F7864H0KK_us-gaap_RangeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_RangeMember" xlink:to="lab_LI7H9086J2MM_us-gaap_RangeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_MaximumMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_MaximumMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_MaximumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_JG5F7864H0KK_us-gaap_MinimumMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_MinimumMember" xlink:to="lab_LI7H9086J2MM_us-gaap_MinimumMember"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CommonStockIssuableUponExerciseOfWarrants" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_CommonStockIssuableUponExerciseOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_CommonStockIssuableUponExerciseOfWarrants" xml:lang="en-US">Common Stock Issuable Upon Exercise Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_CommonStockIssuableUponExerciseOfWarrants" xml:lang="en-US">Common stock issuable upon exercise of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_CommonStockIssuableUponExerciseOfWarrants" xml:lang="en-US">Common stock issuable upon exercise of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_CommonStockIssuableUponExerciseOfWarrants" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_CommonStockIssuableUponExerciseOfWarrants"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfSeriesAPreferredStockAndWarrantsShares" xlink:label="loc_JG5F7864H0KK_relm_IssuanceOfSeriesAPreferredStockAndWarrantsShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfSeriesAPreferredStockAndWarrantsShares" xml:lang="en-US">Issuance Of Series A Preferred Stock And Warrants Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfSeriesAPreferredStockAndWarrantsShares" xml:lang="en-US">Common stock issuable upon conversion of Series A preferred stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfSeriesAPreferredStockAndWarrantsShares" xml:lang="en-US">Issuance of series A preferred stock and warrants shares.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_IssuanceOfSeriesAPreferredStockAndWarrantsShares" xlink:to="lab_LI7H9086J2MM_relm_IssuanceOfSeriesAPreferredStockAndWarrantsShares"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_MarketValueOfCommonStockOnMeasurementPerStock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_MarketValueOfCommonStockOnMeasurementPerStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_MarketValueOfCommonStockOnMeasurementPerStock" xml:lang="en-US">Market Value Of Common Stock On Measurement Per Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_MarketValueOfCommonStockOnMeasurementPerStock" xml:lang="en-US">Market value of common stock on measurement date (1)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_MarketValueOfCommonStockOnMeasurementPerStock" xml:lang="en-US">Market Value Of Common Stock On Measurement Per Stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_MarketValueOfCommonStockOnMeasurementPerStock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_MarketValueOfCommonStockOnMeasurementPerStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_JG5F7864H0KK_us-gaap_FairValueAssumptionsExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_FairValueAssumptionsExercisePrice" xml:lang="en-US">Fair Value Assumptions, Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_FairValueAssumptionsExercisePrice" xml:lang="en-US">Exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_FairValueAssumptionsExercisePrice" xlink:to="lab_LI7H9086J2MM_us-gaap_FairValueAssumptionsExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free interest rate (2)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_JG5F7864H0KK_us-gaap_FairValueAssumptionsExpectedTerm"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_FairValueAssumptionsExpectedTerm" xml:lang="en-US">Expected life in years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="lab_LI7H9086J2MM_us-gaap_FairValueAssumptionsExpectedTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility (3)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_JG5F7864H0KK_us-gaap_FairValueAssumptionsExpectedDividendRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_FairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yields (4)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="lab_LI7H9086J2MM_us-gaap_FairValueAssumptionsExpectedDividendRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_FairValueByBalanceSheetGroupingTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_FairValueByBalanceSheetGroupingTable" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_FairValueByBalanceSheetGroupingTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_JG5F7864H0KK_us-gaap_FairValueByMeasurementBasisAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_FairValueByMeasurementBasisAxis" xml:lang="en-US">Measurement Basis [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_LI7H9086J2MM_us-gaap_FairValueByMeasurementBasisAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_FairValueDisclosureItemAmountsDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_FairValueDisclosureItemAmountsDomain" xml:lang="en-US">Fair Value Measurement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_FairValueDisclosureItemAmountsDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_JG5F7864H0KK_us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_PortionAtFairValueFairValueDisclosureMember" xml:lang="en-US">Portion at Fair Value Measurement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_PortionAtFairValueFairValueDisclosureMember" xml:lang="en-US">Fair value of derivatives upon reclass to paid-in capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_LI7H9086J2MM_us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ChangeDuringPeriodFairValueDisclosureMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ChangeDuringPeriodFairValueDisclosureMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ChangeDuringPeriodFairValueDisclosureMember" xml:lang="en-US">Changes Measurement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ChangeDuringPeriodFairValueDisclosureMember" xml:lang="en-US">Increase (decrease) in fair value of derivative liabilities [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ChangeDuringPeriodFairValueDisclosureMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ChangeDuringPeriodFairValueDisclosureMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_JG5F7864H0KK_us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xml:lang="en-US">Reported Value Measurement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xml:lang="en-US">Initial valuation of derivative liabilities upon issuance of new warrants period [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_LI7H9086J2MM_us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_SeriesBPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SeriesBPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMember" xlink:label="loc_JG5F7864H0KK_us-gaap_LongTermDebtMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_LongTermDebtMember" xml:lang="en-US">Long-term Debt [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_LongTermDebtMember" xml:lang="en-US">Wonpung services [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_LongTermDebtMember" xlink:to="lab_LI7H9086J2MM_us-gaap_LongTermDebtMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecuritiesPledgedAsCollateralMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_SecuritiesPledgedAsCollateralMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SecuritiesPledgedAsCollateralMember" xml:lang="en-US">Securities Pledged as Collateral [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SecuritiesPledgedAsCollateralMember" xml:lang="en-US">Exchange of debt for Series A preferred stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_SecuritiesPledgedAsCollateralMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SecuritiesPledgedAsCollateralMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_JG5F7864H0KK_us-gaap_SubsidiarySaleOfStockAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Subsidiary, Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_LI7H9086J2MM_us-gaap_SubsidiarySaleOfStockAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_SaleOfStockNameOfTransactionDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock, Name of Transaction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SaleOfStockNameOfTransactionDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_JG5F7864H0KK_us-gaap_PrivatePlacementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_PrivatePlacementMember" xml:lang="en-US">Placement Agent [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_PrivatePlacementMember" xlink:to="lab_LI7H9086J2MM_us-gaap_PrivatePlacementMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_LongtermDebtTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_LongtermDebtTypeAxis" xml:lang="en-US">Long-term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_LongtermDebtTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_JG5F7864H0KK_us-gaap_LongtermDebtTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_LongtermDebtTypeDomain" xml:lang="en-US">Long-term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_LI7H9086J2MM_us-gaap_LongtermDebtTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_JuniorSubordinatedDebtMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_JuniorSubordinatedDebtMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_JuniorSubordinatedDebtMember" xml:lang="en-US">Junior Subordinated Debt [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_JuniorSubordinatedDebtMember" xml:lang="en-US">Subordinated promissory notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_JuniorSubordinatedDebtMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_JuniorSubordinatedDebtMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_JG5F7864H0KK_us-gaap_StatementScenarioAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_StatementScenarioAxis" xlink:to="lab_LI7H9086J2MM_us-gaap_StatementScenarioAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ScenarioUnspecifiedDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ScenarioUnspecifiedDomain" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ScenarioUnspecifiedDomain"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuedInMayAndJune2014OfferingMember" xlink:label="loc_JG5F7864H0KK_relm_IssuedInMayAndJune2014OfferingMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_IssuedInMayAndJune2014OfferingMember" xml:lang="en-US">Issued In May And June 2014 Offering [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_IssuedInMayAndJune2014OfferingMember" xlink:to="lab_LI7H9086J2MM_relm_IssuedInMayAndJune2014OfferingMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_JG5F7864H0KK_us-gaap_ConvertibleDebtFairValueDisclosures"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ConvertibleDebtFairValueDisclosures" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ConvertibleDebtFairValueDisclosures" xml:lang="en-US">Convertible preferred derivative liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_LI7H9086J2MM_us-gaap_ConvertibleDebtFairValueDisclosures"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_OtherLiabilitiesFairValueDisclosure"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OtherLiabilitiesFairValueDisclosure" xml:lang="en-US">Other Liabilities, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OtherLiabilitiesFairValueDisclosure" xml:lang="en-US">Warrants issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OtherLiabilitiesFairValueDisclosure"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_JG5F7864H0KK_us-gaap_ScheduleOfStockByClassTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_LI7H9086J2MM_us-gaap_ScheduleOfStockByClassTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ClassOfStockLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ClassOfStockLineItems" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ClassOfStockLineItems"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToPreferredStockIssuance" xlink:label="loc_JG5F7864H0KK_relm_AllocationOfCashToPreferredStockIssuance"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_AllocationOfCashToPreferredStockIssuance" xml:lang="en-US">Allocation Of Cash To Preferred Stock Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_AllocationOfCashToPreferredStockIssuance" xml:lang="en-US">Par value of Series A preferred stock issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_AllocationOfCashToPreferredStockIssuance" xml:lang="en-US">Allocation Of Cash to Preferred Stock Issuance.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_AllocationOfCashToPreferredStockIssuance" xlink:to="lab_LI7H9086J2MM_relm_AllocationOfCashToPreferredStockIssuance"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToCommonStockIssuance" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_AllocationOfCashToCommonStockIssuance"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_AllocationOfCashToCommonStockIssuance" xml:lang="en-US">Allocation Of Cash To Common Stock Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_AllocationOfCashToCommonStockIssuance" xml:lang="en-US">Par value of common stock issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_AllocationOfCashToCommonStockIssuance" xml:lang="en-US">Allocation of cash to common stock issuance.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_AllocationOfCashToCommonStockIssuance" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_AllocationOfCashToCommonStockIssuance"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToAdditionalPaidInCapital" xlink:label="loc_JG5F7864H0KK_relm_AllocationOfCashToAdditionalPaidInCapital"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_AllocationOfCashToAdditionalPaidInCapital" xml:lang="en-US">Allocation Of Cash To Additional Paid In Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_AllocationOfCashToAdditionalPaidInCapital" xml:lang="en-US">Additional paid-in-capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_AllocationOfCashToAdditionalPaidInCapital" xml:lang="en-US">Allocation Of Cash to Additional Paid In Capital.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_AllocationOfCashToAdditionalPaidInCapital" xlink:to="lab_LI7H9086J2MM_relm_AllocationOfCashToAdditionalPaidInCapital"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToDerivativeLiability" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_AllocationOfCashToDerivativeLiability"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_AllocationOfCashToDerivativeLiability" xml:lang="en-US">Allocation Of Cash To Derivative Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_AllocationOfCashToDerivativeLiability" xml:lang="en-US">Derivative warrant liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_AllocationOfCashToDerivativeLiability" xml:lang="en-US">Allocation Of Cash to Derivative Liability.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_AllocationOfCashToDerivativeLiability" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_AllocationOfCashToDerivativeLiability"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilities" xlink:label="loc_JG5F7864H0KK_relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilities" xml:lang="en-US">Allocation Of Cash To Derivative Series A Warrant Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilities" xml:lang="en-US">Derivative Series A warrant liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilities" xml:lang="en-US">Allocation of cash to derivative series A warrant liabilities.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilities" xlink:to="lab_LI7H9086J2MM_relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilities"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilitiesOne" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilitiesOne"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilitiesOne" xml:lang="en-US">Allocation Of Cash To Derivative Series A Warrant Liabilities One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilitiesOne" xml:lang="en-US">Derivative Series A warrant liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilitiesOne" xml:lang="en-US">Allocation of cash to derivative series A warrant liabilities one.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilitiesOne" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilitiesOne"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToDerivativePreferredStockConversion" xlink:label="loc_JG5F7864H0KK_relm_AllocationOfCashToDerivativePreferredStockConversion"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_AllocationOfCashToDerivativePreferredStockConversion" xml:lang="en-US">Allocation Of Cash To Derivative Preferred Stock Conversion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_AllocationOfCashToDerivativePreferredStockConversion" xml:lang="en-US">Derivative preferred stock conversion feature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_AllocationOfCashToDerivativePreferredStockConversion" xml:lang="en-US">Allocation Of Cash to Derivative Preferred Stock Conversion.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_AllocationOfCashToDerivativePreferredStockConversion" xlink:to="lab_LI7H9086J2MM_relm_AllocationOfCashToDerivativePreferredStockConversion"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToDerivativeWarrantsIssuance" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_AllocationOfCashToDerivativeWarrantsIssuance"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_AllocationOfCashToDerivativeWarrantsIssuance" xml:lang="en-US">Allocation Of Cash To Derivative Warrants Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_AllocationOfCashToDerivativeWarrantsIssuance" xml:lang="en-US">Derivative Warrants issued to placement agent as offering costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_AllocationOfCashToDerivativeWarrantsIssuance" xml:lang="en-US">Allocation Of Cash to Derivative Warrants Issuance.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_AllocationOfCashToDerivativeWarrantsIssuance" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_AllocationOfCashToDerivativeWarrantsIssuance"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ProceedsFromIssuanceOfOfferingsNet" xlink:label="loc_JG5F7864H0KK_relm_ProceedsFromIssuanceOfOfferingsNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_ProceedsFromIssuanceOfOfferingsNet" xml:lang="en-US">Proceeds From Issuance Of Offerings Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_LI7H9086J2MM_relm_ProceedsFromIssuanceOfOfferingsNet" xml:lang="en-US">Net proceeds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_ProceedsFromIssuanceOfOfferingsNet" xml:lang="en-US">Proceeds from issuance of offerings net.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_ProceedsFromIssuanceOfOfferingsNet" xlink:to="lab_LI7H9086J2MM_relm_ProceedsFromIssuanceOfOfferingsNet"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_OfferingCosts" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_OfferingCosts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_OfferingCosts" xml:lang="en-US">Offering Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_OfferingCosts" xml:lang="en-US">Offering costs paid in cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_OfferingCosts" xml:lang="en-US">Offering Costs.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_OfferingCosts" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_OfferingCosts"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ProceedsFromIssuanceOfOfferingsGross" xlink:label="loc_JG5F7864H0KK_relm_ProceedsFromIssuanceOfOfferingsGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_ProceedsFromIssuanceOfOfferingsGross" xml:lang="en-US">Proceeds From Issuance Of Offerings Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_ProceedsFromIssuanceOfOfferingsGross" xml:lang="en-US">Gross proceeds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_LI7H9086J2MM_relm_ProceedsFromIssuanceOfOfferingsGross" xml:lang="en-US">Gross proceeds</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_ProceedsFromIssuanceOfOfferingsGross" xml:lang="en-US">Proceeds From Issuance Of Offerings Gross.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_ProceedsFromIssuanceOfOfferingsGross" xlink:to="lab_LI7H9086J2MM_relm_ProceedsFromIssuanceOfOfferingsGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Number of Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Number of Shares, Outstanding and expected to vest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_JG5F7864H0KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of Shares, Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Awarded stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_LI7H9086J2MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Number of Shares, exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_JG5F7864H0KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price Per Share, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price Per Share, Outstanding and expected to vest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_LI7H9086J2MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price Per Share, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_JG5F7864H0KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price Per Share, exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_LI7H9086J2MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted Average Remaining Contractual Term, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:label="loc_JG5F7864H0KK_relm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term 1</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted Average Remaining Contractual Term, Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:to="lab_LI7H9086J2MM_relm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted Average Remaining Contractual Term, exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_JG5F7864H0KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_LI7H9086J2MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Granted Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" xml:lang="en-US">Share Based compensation arrangement by share based payment award options granted intrinsic value.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_JG5F7864H0KK_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Aggregate Intrinsic Value, exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_LI7H9086J2MM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_JG5F7864H0KK_us-gaap_AwardTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_AwardTypeAxis" xlink:to="lab_LI7H9086J2MM_us-gaap_AwardTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Equity Award [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_JG5F7864H0KK_us-gaap_EmployeeStockOptionMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Option [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_EmployeeStockOptionMember" xlink:to="lab_LI7H9086J2MM_us-gaap_EmployeeStockOptionMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CurrentPriceOfCommonStock" xlink:label="loc_JG5F7864H0KK_relm_CurrentPriceOfCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_CurrentPriceOfCommonStock" xml:lang="en-US">Current Price Of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_CurrentPriceOfCommonStock" xml:lang="en-US">Current price of common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_CurrentPriceOfCommonStock" xml:lang="en-US">Current Price of Common Stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_CurrentPriceOfCommonStock" xlink:to="lab_LI7H9086J2MM_relm_CurrentPriceOfCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_JG5F7864H0KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_LI7H9086J2MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_JG5F7864H0KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xml:lang="en-US">Volatility, minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_LI7H9086J2MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xml:lang="en-US">Volatility, maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_JG5F7864H0KK_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_LI7H9086J2MM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ClassOfWarrantOrRightOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Number of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Number of Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Number of Shares, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ClassOfWarrantOrRightOutstanding"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ClassOfWarrantOrRightGranted" xlink:label="loc_JG5F7864H0KK_relm_ClassOfWarrantOrRightGranted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_ClassOfWarrantOrRightGranted" xml:lang="en-US">Class Of Warrant Or Right Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_ClassOfWarrantOrRightGranted" xml:lang="en-US">Number of Shares, Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_ClassOfWarrantOrRightGranted" xml:lang="en-US">Class Of Warrant Or Right Granted.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_ClassOfWarrantOrRightGranted" xlink:to="lab_LI7H9086J2MM_relm_ClassOfWarrantOrRightGranted"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ClassOfWarrantOrRightExercised" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_ClassOfWarrantOrRightExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ClassOfWarrantOrRightExercised" xml:lang="en-US">Class Of Warrant Or Right Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ClassOfWarrantOrRightExercised" xml:lang="en-US">Number of Shares, Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ClassOfWarrantOrRightExercised" xml:lang="en-US">Class Of Warrant Or Right Exercised.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_ClassOfWarrantOrRightExercised" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_ClassOfWarrantOrRightExercised"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ClassOfWarrantOrRightForfeited" xlink:label="loc_JG5F7864H0KK_relm_ClassOfWarrantOrRightForfeited"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_ClassOfWarrantOrRightForfeited" xml:lang="en-US">Class Of Warrant Or Right Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_ClassOfWarrantOrRightForfeited" xml:lang="en-US">Number of Shares, Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_ClassOfWarrantOrRightForfeited" xml:lang="en-US">Class of warrant or right forfeited.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_ClassOfWarrantOrRightForfeited" xlink:to="lab_LI7H9086J2MM_relm_ClassOfWarrantOrRightForfeited"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ClassOfWarrantOrRightVestedOutstanding" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_ClassOfWarrantOrRightVestedOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ClassOfWarrantOrRightVestedOutstanding" xml:lang="en-US">Class Of Warrant Or Right Vested Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ClassOfWarrantOrRightVestedOutstanding" xml:lang="en-US">Number of Shares, Outstanding and vested</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ClassOfWarrantOrRightVestedOutstanding" xml:lang="en-US">Class Of Warrant Or Right Vested Outstanding.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_ClassOfWarrantOrRightVestedOutstanding" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_ClassOfWarrantOrRightVestedOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_JG5F7864H0KK_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Exercise price per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Exercise price per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Weighted Average Exercise Price Per Share, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Weighted Average Exercise Price Per Share, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Weighted Average Exercise Price Per Share, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_LI7H9086J2MM_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted" xml:lang="en-US">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted" xml:lang="en-US">Weighted Average Exercise Price Per Share, Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted" xml:lang="en-US">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Granted.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xlink:label="loc_JG5F7864H0KK_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xml:lang="en-US">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xml:lang="en-US">Weighted Average Exercise Price Per Share, Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xml:lang="en-US">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xlink:to="lab_LI7H9086J2MM_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeited" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeited"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeited" xml:lang="en-US">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeited" xml:lang="en-US">Weighted Average Exercise Price Per Share, Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeited" xml:lang="en-US">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Forfeited.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeited" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeited"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedOutstanding" xlink:label="loc_JG5F7864H0KK_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedOutstanding" xml:lang="en-US">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Vested Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedOutstanding" xml:lang="en-US">Weighted Average Exercise Price Per Share, Outstanding and vested</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedOutstanding" xml:lang="en-US">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Vested Outstanding.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedOutstanding" xlink:to="lab_LI7H9086J2MM_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xml:lang="en-US">Risk-free interest rate, minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_JG5F7864H0KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xml:lang="en-US">Risk-free interest rate, maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_LI7H9086J2MM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SeriesAWarrantsMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_SeriesAWarrantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_SeriesAWarrantsMember" xml:lang="en-US">Series A Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_SeriesAWarrantsMember" xml:lang="en-US">Series A warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_SeriesAWarrantsMember" xml:lang="en-US">Series A warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_SeriesAWarrantsMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_SeriesAWarrantsMember"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SeriesBWarrantsMember" xlink:label="loc_JG5F7864H0KK_relm_SeriesBWarrantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_SeriesBWarrantsMember" xml:lang="en-US">Series B Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_SeriesBWarrantsMember" xml:lang="en-US">Series B warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_SeriesBWarrantsMember" xml:lang="en-US">Series B Warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_SeriesBWarrantsMember" xlink:to="lab_LI7H9086J2MM_relm_SeriesBWarrantsMember"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AgentWarrantsMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_AgentWarrantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_AgentWarrantsMember" xml:lang="en-US">Agent Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_AgentWarrantsMember" xml:lang="en-US">Agent warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_AgentWarrantsMember" xml:lang="en-US">Agent warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_AgentWarrantsMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_AgentWarrantsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_JG5F7864H0KK_us-gaap_ConvertiblePreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Series A convertible preferred stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_LI7H9086J2MM_us-gaap_ConvertiblePreferredStockMember"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_InvestorsMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_InvestorsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_InvestorsMember" xml:lang="en-US">Investors [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_InvestorsMember" xml:lang="en-US">Investors in connection with Series A preferred offering [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_InvestorsMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_InvestorsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockConversionBasis" xlink:label="loc_JG5F7864H0KK_us-gaap_CommonStockConversionBasis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_CommonStockConversionBasis" xml:lang="en-US">Common Stock, Conversion Basis</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_CommonStockConversionBasis" xml:lang="en-US">Common stock conversion basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_CommonStockConversionBasis" xlink:to="lab_LI7H9086J2MM_us-gaap_CommonStockConversionBasis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockConversionFeatures" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_CommonStockConversionFeatures"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_CommonStockConversionFeatures" xml:lang="en-US">Common Stock, Conversion Features</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_CommonStockConversionFeatures" xml:lang="en-US">Common stock conversion beneficially, Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_CommonStockConversionFeatures" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_CommonStockConversionFeatures"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_JG5F7864H0KK_us-gaap_ConversionOfStockSharesIssued1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ConversionOfStockSharesIssued1" xml:lang="en-US">Conversion of Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ConversionOfStockSharesIssued1" xml:lang="en-US">Number of shares converted to common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ConversionOfStockSharesIssued1" xlink:to="lab_LI7H9086J2MM_us-gaap_ConversionOfStockSharesIssued1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_PreferredStockDividendRatePercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_PreferredStockDividendRatePercentage" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_PreferredStockDividendRatePercentage" xml:lang="en-US">Divident rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_PreferredStockDividendRatePercentage" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_PreferredStockDividendRatePercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_JG5F7864H0KK_us-gaap_PreferredStockLiquidationPreferenceValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_PreferredStockLiquidationPreferenceValue" xml:lang="en-US">Preferred Stock, Liquidation Preference, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_PreferredStockLiquidationPreferenceValue" xml:lang="en-US">Preferred stock, liquidation preference, Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="lab_LI7H9086J2MM_us-gaap_PreferredStockLiquidationPreferenceValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ConversionOfStockSharesConverted1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ConversionOfStockSharesConverted1" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ConversionOfStockSharesConverted1" xml:lang="en-US">Series A preferred stock oustanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ConversionOfStockSharesConverted1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_JG5F7864H0KK_us-gaap_LineOfCredit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_LineOfCredit" xml:lang="en-US">Long-term Line of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_LineOfCredit" xml:lang="en-US">Lenders amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_LineOfCredit" xlink:to="lab_LI7H9086J2MM_us-gaap_LineOfCredit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestReceivable" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_InterestReceivable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_InterestReceivable" xml:lang="en-US">Interest Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_InterestReceivable" xml:lang="en-US">Accured interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_InterestReceivable" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_InterestReceivable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_JG5F7864H0KK_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US">Warrants issued, number of shares of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_LI7H9086J2MM_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_WarrantToPurchaseOfCommonStock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_WarrantToPurchaseOfCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_WarrantToPurchaseOfCommonStock" xml:lang="en-US">Warrant to purchase of common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_WarrantToPurchaseOfCommonStock" xml:lang="en-US">Warrant to purchase of common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_WarrantToPurchaseOfCommonStock" xml:lang="en-US">Warrant to purchase of common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_WarrantToPurchaseOfCommonStock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_WarrantToPurchaseOfCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DividendsShareBasedCompensation" xlink:label="loc_JG5F7864H0KK_us-gaap_DividendsShareBasedCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_DividendsShareBasedCompensation" xml:lang="en-US">Dividends, Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_DividendsShareBasedCompensation" xml:lang="en-US">Fair value of common stock for the services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_DividendsShareBasedCompensation" xml:lang="en-US">Share based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_DividendsShareBasedCompensation" xlink:to="lab_LI7H9086J2MM_us-gaap_DividendsShareBasedCompensation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xml:lang="en-US">Common Stocks, Including Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xml:lang="en-US">Additional paid -in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_CommonStocksIncludingAdditionalPaidInCapital"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_JG5F7864H0KK_us-gaap_DerivativeLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_DerivativeLiabilities" xlink:to="lab_LI7H9086J2MM_us-gaap_DerivativeLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xml:lang="en-US">Proceeds from sale of Series A preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfSeriesAPreferredStockSharesToPurchaseCommonStock" xlink:label="loc_JG5F7864H0KK_relm_IssuanceOfSeriesAPreferredStockSharesToPurchaseCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfSeriesAPreferredStockSharesToPurchaseCommonStock" xml:lang="en-US">Issuance Of Series A Preferred Stock Shares To Purchase Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfSeriesAPreferredStockSharesToPurchaseCommonStock" xml:lang="en-US">Issuance of Series A preferred stock shares to purchase common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfSeriesAPreferredStockSharesToPurchaseCommonStock" xml:lang="en-US">Issuance of Series A preferred stock shares to purchase common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_IssuanceOfSeriesAPreferredStockSharesToPurchaseCommonStock" xlink:to="lab_LI7H9086J2MM_relm_IssuanceOfSeriesAPreferredStockSharesToPurchaseCommonStock"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CommissionsAndNonAccountableExpenses" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_CommissionsAndNonAccountableExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_CommissionsAndNonAccountableExpenses" xml:lang="en-US">Commissions And Non Accountable Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_CommissionsAndNonAccountableExpenses" xml:lang="en-US">Commissions and non accountable expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_CommissionsAndNonAccountableExpenses" xml:lang="en-US">Commissions and non accountable expenses.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_CommissionsAndNonAccountableExpenses" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_CommissionsAndNonAccountableExpenses"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PlacementAgentExpenses" xlink:label="loc_JG5F7864H0KK_relm_PlacementAgentExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_PlacementAgentExpenses" xml:lang="en-US">Placement Agent Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_PlacementAgentExpenses" xml:lang="en-US">Placement agent expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_PlacementAgentExpenses" xml:lang="en-US">Placement agent expenses.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_PlacementAgentExpenses" xlink:to="lab_LI7H9086J2MM_relm_PlacementAgentExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ConvertiblePreferredStockTermsOfConversion" xml:lang="en-US">Convertible Preferred Stock, Terms of Conversion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ConvertiblePreferredStockTermsOfConversion" xml:lang="en-US">Converitble series A preferred stock term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ClassOfWarrantOrRightsRedemptionTerms" xlink:label="loc_JG5F7864H0KK_relm_ClassOfWarrantOrRightsRedemptionTerms"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_ClassOfWarrantOrRightsRedemptionTerms" xml:lang="en-US">Class Of Warrant Or Rights Redemption Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_ClassOfWarrantOrRightsRedemptionTerms" xml:lang="en-US">Warrants redemption terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_ClassOfWarrantOrRightsRedemptionTerms" xml:lang="en-US">Class of warrant or rights redemption terms.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_ClassOfWarrantOrRightsRedemptionTerms" xlink:to="lab_LI7H9086J2MM_relm_ClassOfWarrantOrRightsRedemptionTerms"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PercentageOfSolicitationFeeOnWarrantsExercised" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_PercentageOfSolicitationFeeOnWarrantsExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_PercentageOfSolicitationFeeOnWarrantsExercised" xml:lang="en-US">Percentage Of Solicitation Fee On Warrants Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_PercentageOfSolicitationFeeOnWarrantsExercised" xml:lang="en-US">Percentage of solicitation fee on warrants exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_PercentageOfSolicitationFeeOnWarrantsExercised" xml:lang="en-US">Percentage of solicitation fee on warrants exercised.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_PercentageOfSolicitationFeeOnWarrantsExercised" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_PercentageOfSolicitationFeeOnWarrantsExercised"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CommonStockIssuedForServicesMember" xlink:label="loc_JG5F7864H0KK_relm_CommonStockIssuedForServicesMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_CommonStockIssuedForServicesMember" xml:lang="en-US">Common Stock Issued For Services [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_CommonStockIssuedForServicesMember" xml:lang="en-US">Common stock issued for services [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_CommonStockIssuedForServicesMember" xml:lang="en-US">Common stock issued for services.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_CommonStockIssuedForServicesMember" xlink:to="lab_LI7H9086J2MM_relm_CommonStockIssuedForServicesMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_JG5F7864H0KK_us-gaap_RelatedPartyDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_RelatedPartyDomain" xlink:to="lab_LI7H9086J2MM_us-gaap_RelatedPartyDomain"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_RelatedPartyMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_RelatedPartyMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_RelatedPartyMember" xml:lang="en-US">Related Party [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_RelatedPartyMember" xml:lang="en-US">Related Party.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_RelatedPartyMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_RelatedPartyMember"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ConsultantsMember" xlink:label="loc_JG5F7864H0KK_relm_ConsultantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_ConsultantsMember" xml:lang="en-US">Consultants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_ConsultantsMember" xml:lang="en-US">Consultants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_ConsultantsMember" xlink:to="lab_LI7H9086J2MM_relm_ConsultantsMember"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FounderWarrantsMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_FounderWarrantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_FounderWarrantsMember" xml:lang="en-US">Founder Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_FounderWarrantsMember" xml:lang="en-US">Founder Warrants [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_FounderWarrantsMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_FounderWarrantsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_JG5F7864H0KK_dei_LegalEntityAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_dei_LegalEntityAxis" xlink:to="lab_LI7H9086J2MM_dei_LegalEntityAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_FFG0JH2876HI9H71G8KJ_dei_EntityDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_dei_EntityDomain" xlink:to="lab_HHI2LJ4098JK1J93I0ML_dei_EntityDomain"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_MedeorIncMember" xlink:label="loc_JG5F7864H0KK_relm_MedeorIncMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_MedeorIncMember" xml:lang="en-US">Medeor Inc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_MedeorIncMember" xlink:to="lab_LI7H9086J2MM_relm_MedeorIncMember"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_WonpungMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_WonpungMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_WonpungMember" xml:lang="en-US">Wonpung [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_WonpungMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_WonpungMember"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfSharesOfCommonStockToSettleLoanFromTheFounder" xlink:label="loc_JG5F7864H0KK_relm_IssuanceOfSharesOfCommonStockToSettleLoanFromTheFounder"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfSharesOfCommonStockToSettleLoanFromTheFounder" xml:lang="en-US">Issuance Of Shares Of Common Stock To Settle Loan From The Founder</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfSharesOfCommonStockToSettleLoanFromTheFounder" xml:lang="en-US">Issuance of shares of common stock to settle loan from the founder/related party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfSharesOfCommonStockToSettleLoanFromTheFounder" xml:lang="en-US">Issuance of shares of common stock to settle loan from the founder.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_IssuanceOfSharesOfCommonStockToSettleLoanFromTheFounder" xlink:to="lab_LI7H9086J2MM_relm_IssuanceOfSharesOfCommonStockToSettleLoanFromTheFounder"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromLoanOriginations1" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ProceedsFromLoanOriginations1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ProceedsFromLoanOriginations1" xml:lang="en-US">Proceeds from Loan Originations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ProceedsFromLoanOriginations1" xml:lang="en-US">Loan from the founder/related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ProceedsFromLoanOriginations1" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ProceedsFromLoanOriginations1"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ForgivenessOfInterestExpenseOnLoan" xlink:label="loc_JG5F7864H0KK_relm_ForgivenessOfInterestExpenseOnLoan"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_ForgivenessOfInterestExpenseOnLoan" xml:lang="en-US">Forgiveness Of Interest Expense On Loan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_ForgivenessOfInterestExpenseOnLoan" xml:lang="en-US">Forgiveness of interest expense on loan by the founder</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_ForgivenessOfInterestExpenseOnLoan" xml:lang="en-US">Forgiveness of interest expense on loan by the founder.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_ForgivenessOfInterestExpenseOnLoan" xlink:to="lab_LI7H9086J2MM_relm_ForgivenessOfInterestExpenseOnLoan"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ObligationDueToRelatedParty" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_ObligationDueToRelatedParty"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ObligationDueToRelatedParty" xml:lang="en-US">Obligation Due To Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ObligationDueToRelatedParty" xml:lang="en-US">Obligation due to related party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ObligationDueToRelatedParty" xml:lang="en-US">Obligation due to related party.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_ObligationDueToRelatedParty" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_ObligationDueToRelatedParty"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="loc_JG5F7864H0KK_us-gaap_InterestExpenseRelatedParty"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_InterestExpenseRelatedParty" xml:lang="en-US">Interest Expense, Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_InterestExpenseRelatedParty" xml:lang="en-US">Interest expense due from related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_InterestExpenseRelatedParty" xlink:to="lab_LI7H9086J2MM_us-gaap_InterestExpenseRelatedParty"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Aggregate proceeds from private placement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockToPurchaseCommonStock" xlink:label="loc_JG5F7864H0KK_relm_IssuanceOfCommonStockToPurchaseCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfCommonStockToPurchaseCommonStock" xml:lang="en-US">Issuance Of Common Stock To Purchase Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfCommonStockToPurchaseCommonStock" xml:lang="en-US">Issuance of common stock and warrants to purchase common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfCommonStockToPurchaseCommonStock" xml:lang="en-US">Issuance of common stock to purchase common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_IssuanceOfCommonStockToPurchaseCommonStock" xlink:to="lab_LI7H9086J2MM_relm_IssuanceOfCommonStockToPurchaseCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OtherAccruedLiabilitiesNoncurrent" xml:lang="en-US">Other Accrued Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OtherAccruedLiabilitiesNoncurrent" xml:lang="en-US">Outstanding liabilities owed to the founder</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_JG5F7864H0KK_us-gaap_AllocatedShareBasedCompensationExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_LI7H9086J2MM_us-gaap_AllocatedShareBasedCompensationExpense"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockInConnectionWithAcquistionOfLicienseAgreement" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_IssuanceOfCommonStockInConnectionWithAcquistionOfLicienseAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfCommonStockInConnectionWithAcquistionOfLicienseAgreement" xml:lang="en-US">Issuance Of Common Stock In Connection With Acquistion Of Liciense Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfCommonStockInConnectionWithAcquistionOfLicienseAgreement" xml:lang="en-US">Issuance of common stock in connection with acquistion of liciense agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfCommonStockInConnectionWithAcquistionOfLicienseAgreement" xml:lang="en-US">Issuance of common stock in connection with acquistion of liciense agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_IssuanceOfCommonStockInConnectionWithAcquistionOfLicienseAgreement" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfCommonStockInConnectionWithAcquistionOfLicienseAgreement"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_JG5F7864H0KK_us-gaap_SaleOfStockPricePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Common stock per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_LI7H9086J2MM_us-gaap_SaleOfStockPricePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xml:lang="en-US">Stock Granted, Value, Share-based Compensation, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xml:lang="en-US">Fair value of the common granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_JG5F7864H0KK_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xml:lang="en-US">Grant date fair value of the common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="lab_LI7H9086J2MM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US">Share based compensation shares vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_JG5F7864H0KK_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_LI7H9086J2MM_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_IncomeStatementLocationAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_IncomeStatementLocationAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_JG5F7864H0KK_us-gaap_IncomeStatementLocationDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_LI7H9086J2MM_us-gaap_IncomeStatementLocationDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ResearchAndDevelopmentExpenseMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ResearchAndDevelopmentExpenseMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_JG5F7864H0KK_us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_LI7H9086J2MM_us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_OfficerOptionsMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_OfficerOptionsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_OfficerOptionsMember" xml:lang="en-US">Officer Options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_OfficerOptionsMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_OfficerOptionsMember"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ConsultantOptionsMember" xlink:label="loc_JG5F7864H0KK_relm_ConsultantOptionsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_ConsultantOptionsMember" xml:lang="en-US">Consultant Options [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_ConsultantOptionsMember" xml:lang="en-US">Chief Scientific Officer and President [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_ConsultantOptionsMember" xlink:to="lab_LI7H9086J2MM_relm_ConsultantOptionsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_RelatedPartyTransactionAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_RelatedPartyTransactionAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_JG5F7864H0KK_us-gaap_RelatedPartyTransactionDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_LI7H9086J2MM_us-gaap_RelatedPartyTransactionDomain"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SeriesAPreferredStockOfferingsMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_SeriesAPreferredStockOfferingsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_SeriesAPreferredStockOfferingsMember" xml:lang="en-US">Series A Preferred Stock Offerings [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_SeriesAPreferredStockOfferingsMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_SeriesAPreferredStockOfferingsMember"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_DebtOfferingsMember" xlink:label="loc_JG5F7864H0KK_relm_DebtOfferingsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_DebtOfferingsMember" xml:lang="en-US">Debt Offerings [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_DebtOfferingsMember" xlink:to="lab_LI7H9086J2MM_relm_DebtOfferingsMember"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_StrategicAdvisorAgreementMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_StrategicAdvisorAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_StrategicAdvisorAgreementMember" xml:lang="en-US">Strategic Advisor Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_StrategicAdvisorAgreementMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_StrategicAdvisorAgreementMember"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_DebtHoldersMember" xlink:label="loc_JG5F7864H0KK_relm_DebtHoldersMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_DebtHoldersMember" xml:lang="en-US">Debt Holders [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_DebtHoldersMember" xlink:to="lab_LI7H9086J2MM_relm_DebtHoldersMember"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PlacementAgentMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_PlacementAgentMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_PlacementAgentMember" xml:lang="en-US">Placement Agent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_PlacementAgentMember" xml:lang="en-US">Placement agent in connection with Series A preferred offering [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_PlacementAgentMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_PlacementAgentMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_JG5F7864H0KK_us-gaap_TitleOfIndividualAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_TitleOfIndividualAxis" xlink:to="lab_LI7H9086J2MM_us-gaap_TitleOfIndividualAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="loc_JG5F7864H0KK_us-gaap_BoardOfDirectorsChairmanMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_BoardOfDirectorsChairmanMember" xml:lang="en-US">Board of Directors Chairman [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_BoardOfDirectorsChairmanMember" xml:lang="en-US">Board of Directors [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_BoardOfDirectorsChairmanMember" xlink:to="lab_LI7H9086J2MM_us-gaap_BoardOfDirectorsChairmanMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ChiefExecutiveOfficerMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ChiefExecutiveOfficerMember" xml:lang="en-US">Chief Executive Officer [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ChiefExecutiveOfficerMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ChiefExecutiveOfficerMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_JG5F7864H0KK_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_LI7H9086J2MM_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Number of shares available for grant authorized under 2012 Stock Option Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_NumberOfSharesAvailableForFutureGrantsUnderStockOptionPlan" xlink:label="loc_JG5F7864H0KK_relm_NumberOfSharesAvailableForFutureGrantsUnderStockOptionPlan"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_NumberOfSharesAvailableForFutureGrantsUnderStockOptionPlan" xml:lang="en-US">Number Of Shares Available For Future Grants Under Stock Option Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_NumberOfSharesAvailableForFutureGrantsUnderStockOptionPlan" xml:lang="en-US">Number of shares available for future grants under stock option plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_NumberOfSharesAvailableForFutureGrantsUnderStockOptionPlan" xml:lang="en-US">Number of shares available for future grants under stock option plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_NumberOfSharesAvailableForFutureGrantsUnderStockOptionPlan" xlink:to="lab_LI7H9086J2MM_relm_NumberOfSharesAvailableForFutureGrantsUnderStockOptionPlan"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_StockOptionsPlanStockOptionsExercisablePeriod" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_StockOptionsPlanStockOptionsExercisablePeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_StockOptionsPlanStockOptionsExercisablePeriod" xml:lang="en-US">Stock Options Plan Stock Options Exercisable Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_StockOptionsPlanStockOptionsExercisablePeriod" xml:lang="en-US">Stock options plan stock options exercisable period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_StockOptionsPlanStockOptionsExercisablePeriod" xml:lang="en-US">Stock options plan stock options exercisable period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_StockOptionsPlanStockOptionsExercisablePeriod" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_StockOptionsPlanStockOptionsExercisablePeriod"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_StockOptionsExercisablePeriodDescription" xlink:label="loc_JG5F7864H0KK_relm_StockOptionsExercisablePeriodDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_StockOptionsExercisablePeriodDescription" xml:lang="en-US">Stock Options Exercisable Period Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_StockOptionsExercisablePeriodDescription" xml:lang="en-US">Stock options exercisable period description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_StockOptionsExercisablePeriodDescription" xml:lang="en-US">Stock options exercisable period description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_StockOptionsExercisablePeriodDescription" xlink:to="lab_LI7H9086J2MM_relm_StockOptionsExercisablePeriodDescription"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_OptionsToPurchaseOfcommonStock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_OptionsToPurchaseOfcommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_OptionsToPurchaseOfcommonStock" xml:lang="en-US">Options To Purchase Of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_OptionsToPurchaseOfcommonStock" xml:lang="en-US">Options to purchase of common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_OptionsToPurchaseOfcommonStock" xml:lang="en-US">Options to purchase of common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_OptionsToPurchaseOfcommonStock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_OptionsToPurchaseOfcommonStock"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_StockOptionsContractualTerm" xlink:label="loc_JG5F7864H0KK_relm_StockOptionsContractualTerm"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_StockOptionsContractualTerm" xml:lang="en-US">Stock Options Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_StockOptionsContractualTerm" xml:lang="en-US">Stock options term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_StockOptionsContractualTerm" xml:lang="en-US">Stock Options Contractual Term.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_StockOptionsContractualTerm" xlink:to="lab_LI7H9086J2MM_relm_StockOptionsContractualTerm"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_OptionsVestPercentage" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_OptionsVestPercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_OptionsVestPercentage" xml:lang="en-US">Options Vest Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_OptionsVestPercentage" xml:lang="en-US">Options vest percentgae</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_OptionsVestPercentage" xml:lang="en-US">Options vest percentgae.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_OptionsVestPercentage" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_OptionsVestPercentage"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_RemainingOptionsVestPercentage" xlink:label="loc_JG5F7864H0KK_relm_RemainingOptionsVestPercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_RemainingOptionsVestPercentage" xml:lang="en-US">Remaining Options Vest Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_RemainingOptionsVestPercentage" xml:lang="en-US">Remaining options vest percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_RemainingOptionsVestPercentage" xml:lang="en-US">Remaining options vest percentgae.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_RemainingOptionsVestPercentage" xlink:to="lab_LI7H9086J2MM_relm_RemainingOptionsVestPercentage"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_RemainingOptionsVestPeriodDescription" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_RemainingOptionsVestPeriodDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_RemainingOptionsVestPeriodDescription" xml:lang="en-US">Remaining Options Vest Period Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_RemainingOptionsVestPeriodDescription" xml:lang="en-US">Remaining options vest period description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_RemainingOptionsVestPeriodDescription" xml:lang="en-US">Remaining options vest period description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_RemainingOptionsVestPeriodDescription" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_RemainingOptionsVestPeriodDescription"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FairValueOfOptionsOnGrantDate" xlink:label="loc_JG5F7864H0KK_relm_FairValueOfOptionsOnGrantDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_FairValueOfOptionsOnGrantDate" xml:lang="en-US">Fair Value Of Options On Grant Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_FairValueOfOptionsOnGrantDate" xml:lang="en-US">Fair value of options on grant date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_FairValueOfOptionsOnGrantDate" xml:lang="en-US">Fair value of options on grant date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_FairValueOfOptionsOnGrantDate" xlink:to="lab_LI7H9086J2MM_relm_FairValueOfOptionsOnGrantDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xml:lang="en-US">Allocated Share-based Compensation Expense, Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_JG5F7864H0KK_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Unrecognized stock based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_LI7H9086J2MM_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted average fair value of options and warrants granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_WarrantsContractualTerm" xlink:label="loc_JG5F7864H0KK_relm_WarrantsContractualTerm"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_WarrantsContractualTerm" xml:lang="en-US">Warrants Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_WarrantsContractualTerm" xml:lang="en-US">Warrants contractual term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_WarrantsContractualTerm" xml:lang="en-US">Warrants contractual term.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_WarrantsContractualTerm" xlink:to="lab_LI7H9086J2MM_relm_WarrantsContractualTerm"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_UnvestedWarrantsToPurchaseCommonStock" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_UnvestedWarrantsToPurchaseCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_UnvestedWarrantsToPurchaseCommonStock" xml:lang="en-US">Unvested Warrants To Purchase Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_UnvestedWarrantsToPurchaseCommonStock" xml:lang="en-US">Unvested warrants to purchase common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_UnvestedWarrantsToPurchaseCommonStock" xml:lang="en-US">Unvested warrants to purchase common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_UnvestedWarrantsToPurchaseCommonStock" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_UnvestedWarrantsToPurchaseCommonStock"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FairValueOfWarrantsIssued" xlink:label="loc_JG5F7864H0KK_relm_FairValueOfWarrantsIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_FairValueOfWarrantsIssued" xml:lang="en-US">Fair Value Of Warrants Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_FairValueOfWarrantsIssued" xml:lang="en-US">Fair value of warrants issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_FairValueOfWarrantsIssued" xml:lang="en-US">Fair value of warrants issued.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_FairValueOfWarrantsIssued" xlink:to="lab_LI7H9086J2MM_relm_FairValueOfWarrantsIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xml:lang="en-US">Issuance of remaining common stock, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_JG5F7864H0KK_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xml:lang="en-US">Issuance of remaining common stock, Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="lab_LI7H9086J2MM_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xml:lang="en-US">Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xml:lang="en-US">Number of shares increased by the Board of Directors</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_NumberOfSharesIncreasedByShareholders" xlink:label="loc_JG5F7864H0KK_relm_NumberOfSharesIncreasedByShareholders"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_NumberOfSharesIncreasedByShareholders" xml:lang="en-US">Number Of Shares Increased By Shareholders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_NumberOfSharesIncreasedByShareholders" xml:lang="en-US">Number of shares increased by shareholders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_NumberOfSharesIncreasedByShareholders" xml:lang="en-US">Number of shares increased by shareholders.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_NumberOfSharesIncreasedByShareholders" xlink:to="lab_LI7H9086J2MM_relm_NumberOfSharesIncreasedByShareholders"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ClassOfWarrantOrRightTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ClassOfWarrantOrRightTable" xml:lang="en-US">Class of Warrant or Right [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ClassOfWarrantOrRightTable"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PlacementAgentThreeMember" xlink:label="loc_JG5F7864H0KK_relm_PlacementAgentThreeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_PlacementAgentThreeMember" xml:lang="en-US">Placement Agent Three [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_PlacementAgentThreeMember" xml:lang="en-US">May and June 2014 offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_PlacementAgentThreeMember" xml:lang="en-US">Placement Agent [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_PlacementAgentThreeMember" xlink:to="lab_LI7H9086J2MM_relm_PlacementAgentThreeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ClassOfWarrantOrRightAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ClassOfWarrantOrRightAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_JG5F7864H0KK_us-gaap_ClassOfWarrantOrRightDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_LI7H9086J2MM_us-gaap_ClassOfWarrantOrRightDomain"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SeriesAPreferredStockOneMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_SeriesAPreferredStockOneMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_SeriesAPreferredStockOneMember" xml:lang="en-US">Series A Preferred Stock One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_SeriesAPreferredStockOneMember" xml:lang="en-US">Series A Preferred stock One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_SeriesAPreferredStockOneMember" xml:lang="en-US">Series A Preferred Stock One.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_SeriesAPreferredStockOneMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_SeriesAPreferredStockOneMember"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SubordinatedPromissoryNoteOfferingMember" xlink:label="loc_JG5F7864H0KK_relm_SubordinatedPromissoryNoteOfferingMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_SubordinatedPromissoryNoteOfferingMember" xml:lang="en-US">Subordinated Promissory Note Offering [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_SubordinatedPromissoryNoteOfferingMember" xml:lang="en-US">Subordinated promissory note offering [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_SubordinatedPromissoryNoteOfferingMember" xml:lang="en-US">Subordinated promissory note offering.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_SubordinatedPromissoryNoteOfferingMember" xlink:to="lab_LI7H9086J2MM_relm_SubordinatedPromissoryNoteOfferingMember"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SubordinatedPromissoryNoteOfferingOneMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_SubordinatedPromissoryNoteOfferingOneMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_SubordinatedPromissoryNoteOfferingOneMember" xml:lang="en-US">Subordinated Promissory Note Offering One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_SubordinatedPromissoryNoteOfferingOneMember" xml:lang="en-US">Subordinated promissory note offering One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_SubordinatedPromissoryNoteOfferingOneMember" xml:lang="en-US">Subordinated Promissory Note Offering One.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_SubordinatedPromissoryNoteOfferingOneMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_SubordinatedPromissoryNoteOfferingOneMember"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AcquisitionOfMedeorMember" xlink:label="loc_JG5F7864H0KK_relm_AcquisitionOfMedeorMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_AcquisitionOfMedeorMember" xml:lang="en-US">Acquisition Of Medeor [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_AcquisitionOfMedeorMember" xml:lang="en-US">Acquisition of Medeor [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_AcquisitionOfMedeorMember" xml:lang="en-US">Acquisition of medeor.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_AcquisitionOfMedeorMember" xlink:to="lab_LI7H9086J2MM_relm_AcquisitionOfMedeorMember"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_MayAndJune2014OfferingMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_MayAndJune2014OfferingMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_MayAndJune2014OfferingMember" xml:lang="en-US">May And June 2014 Offering [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_MayAndJune2014OfferingMember" xml:lang="en-US">May and June 2014 offering [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_MayAndJune2014OfferingMember" xml:lang="en-US">May and June 2014 offering.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_MayAndJune2014OfferingMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_MayAndJune2014OfferingMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_JG5F7864H0KK_us-gaap_ClassOfWarrantOrRightLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ClassOfWarrantOrRightLineItems" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_LI7H9086J2MM_us-gaap_ClassOfWarrantOrRightLineItems"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ClassOfWarrantOrRightsExpiration" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_ClassOfWarrantOrRightsExpiration"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ClassOfWarrantOrRightsExpiration" xml:lang="en-US">Class Of Warrant Or Rights Expiration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ClassOfWarrantOrRightsExpiration" xml:lang="en-US">Expiration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ClassOfWarrantOrRightsExpiration" xml:lang="en-US">Class of warrant or rights expiration.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_ClassOfWarrantOrRightsExpiration" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_ClassOfWarrantOrRightsExpiration"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AdvisoryFirmMember" xlink:label="loc_JG5F7864H0KK_relm_AdvisoryFirmMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_AdvisoryFirmMember" xml:lang="en-US">Advisory Firm [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_AdvisoryFirmMember" xml:lang="en-US">Advisory Firm [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_AdvisoryFirmMember" xlink:to="lab_LI7H9086J2MM_relm_AdvisoryFirmMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_BusinessAcquisitionAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_BusinessAcquisitionAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_JG5F7864H0KK_us-gaap_BusinessAcquisitionAcquireeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_LI7H9086J2MM_us-gaap_BusinessAcquisitionAcquireeDomain"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SingleActivePharmaceuticalIngredientMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_SingleActivePharmaceuticalIngredientMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_SingleActivePharmaceuticalIngredientMember" xml:lang="en-US">Single Active Pharmaceutical Ingredient [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_SingleActivePharmaceuticalIngredientMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_SingleActivePharmaceuticalIngredientMember"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ActivePharmaceuticalIngredientsMember" xlink:label="loc_JG5F7864H0KK_relm_ActivePharmaceuticalIngredientsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_ActivePharmaceuticalIngredientsMember" xml:lang="en-US">Active Pharmaceutical Ingredients [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_ActivePharmaceuticalIngredientsMember" xlink:to="lab_LI7H9086J2MM_relm_ActivePharmaceuticalIngredientsMember"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_MedeorMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_MedeorMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_MedeorMember" xml:lang="en-US">Medeor [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_MedeorMember" xml:lang="en-US">Medeor [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_MedeorMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_MedeorMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_JG5F7864H0KK_us-gaap_SubsequentEventTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_LI7H9086J2MM_us-gaap_SubsequentEventTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_SubsequentEventTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SubsequentEventTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_JG5F7864H0KK_us-gaap_SubsequentEventMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_SubsequentEventMember" xlink:to="lab_LI7H9086J2MM_us-gaap_SubsequentEventMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ProfessionalFees"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ProfessionalFees" xml:lang="en-US">Professional Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ProfessionalFees" xml:lang="en-US">Advisory services fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ProfessionalFees" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ProfessionalFees"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PercentageOfVestedWarrantsToPurchaseCommonStock" xlink:label="loc_JG5F7864H0KK_relm_PercentageOfVestedWarrantsToPurchaseCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_PercentageOfVestedWarrantsToPurchaseCommonStock" xml:lang="en-US">Percentage Of Vested Warrants To Purchase Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_PercentageOfVestedWarrantsToPurchaseCommonStock" xml:lang="en-US">Percent of fully vested warrants to purchase common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_PercentageOfVestedWarrantsToPurchaseCommonStock" xml:lang="en-US">Percentage of vested warrants to purchase common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_PercentageOfVestedWarrantsToPurchaseCommonStock" xlink:to="lab_LI7H9086J2MM_relm_PercentageOfVestedWarrantsToPurchaseCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExercisePrice" xlink:label="loc_FFG0JH2876HI9H71G8KJ_invest_InvestmentWarrantsExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_invest_InvestmentWarrantsExercisePrice" xml:lang="en-US">Investment Warrants, Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_invest_InvestmentWarrantsExercisePrice" xml:lang="en-US">Exercise price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_invest_InvestmentWarrantsExercisePrice" xlink:to="lab_HHI2LJ4098JK1J93I0ML_invest_InvestmentWarrantsExercisePrice"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfWarrantsToPurchaseCommonStock" xlink:label="loc_JG5F7864H0KK_relm_IssuanceOfWarrantsToPurchaseCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfWarrantsToPurchaseCommonStock" xml:lang="en-US">Issuance Of Warrants To Purchase Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfWarrantsToPurchaseCommonStock" xml:lang="en-US">Issuance of warrants to purchase common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_IssuanceOfWarrantsToPurchaseCommonStock" xml:lang="en-US">Issuance of Warrants to Purchase Common Stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_IssuanceOfWarrantsToPurchaseCommonStock" xlink:to="lab_LI7H9086J2MM_relm_IssuanceOfWarrantsToPurchaseCommonStock"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfWarrantsToPurchaseCommonStockDescription" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_IssuanceOfWarrantsToPurchaseCommonStockDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfWarrantsToPurchaseCommonStockDescription" xml:lang="en-US">Issuance Of Warrants To Purchase Common Stock Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfWarrantsToPurchaseCommonStockDescription" xml:lang="en-US">Issuance of warrants to purchase common stock description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfWarrantsToPurchaseCommonStockDescription" xml:lang="en-US">Issuance of Warrants to Purchase Common Stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_IssuanceOfWarrantsToPurchaseCommonStockDescription" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_IssuanceOfWarrantsToPurchaseCommonStockDescription"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_TermOfWarrants" xlink:label="loc_JG5F7864H0KK_relm_TermOfWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_TermOfWarrants" xml:lang="en-US">Term Of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_TermOfWarrants" xml:lang="en-US">Term of warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_TermOfWarrants" xml:lang="en-US">Term of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_TermOfWarrants" xlink:to="lab_LI7H9086J2MM_relm_TermOfWarrants"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ReimbursementExpenses" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_ReimbursementExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ReimbursementExpenses" xml:lang="en-US">Reimbursement Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ReimbursementExpenses" xml:lang="en-US">Maximum reimbursement expenses, monthly</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ReimbursementExpenses" xml:lang="en-US">Reimbursement expenses.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_ReimbursementExpenses" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_ReimbursementExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_JG5F7864H0KK_us-gaap_OtherResearchAndDevelopmentExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_OtherResearchAndDevelopmentExpense" xml:lang="en-US">Other Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_OtherResearchAndDevelopmentExpense" xml:lang="en-US">Research and development expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="lab_LI7H9086J2MM_us-gaap_OtherResearchAndDevelopmentExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSubordinatedLongTermDebt" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ProceedsFromIssuanceOfSubordinatedLongTermDebt"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ProceedsFromIssuanceOfSubordinatedLongTermDebt" xml:lang="en-US">Proceeds from Issuance of Subordinated Long-term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ProceedsFromIssuanceOfSubordinatedLongTermDebt" xml:lang="en-US">Proceeds from issuance of subordinated promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ProceedsFromIssuanceOfSubordinatedLongTermDebt" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ProceedsFromIssuanceOfSubordinatedLongTermDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_JG5F7864H0KK_us-gaap_RestructuringCharges"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_RestructuringCharges" xml:lang="en-US">Restructuring Charges</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_RestructuringCharges" xml:lang="en-US">Restructuring charges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_RestructuringCharges" xlink:to="lab_LI7H9086J2MM_us-gaap_RestructuringCharges"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xml:lang="en-US">Related Party Transaction, Description of Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xml:lang="en-US">Related party transaction, Description of Transaction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_RelatedPartyTransactionDescriptionOfTransaction"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_JG5F7864H0KK_us-gaap_BusinessCombinationConsiderationTransferred1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_BusinessCombinationConsiderationTransferred1" xml:lang="en-US">Business Combination, Consideration Transferred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_BusinessCombinationConsiderationTransferred1" xml:lang="en-US">Business combination commercial sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_LI7H9086J2MM_us-gaap_BusinessCombinationConsiderationTransferred1"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_InvestorOfferingPriceDescription" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_InvestorOfferingPriceDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_InvestorOfferingPriceDescription" xml:lang="en-US">Investor Offering Price Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_InvestorOfferingPriceDescription" xml:lang="en-US">Offering price description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_InvestorOfferingPriceDescription" xml:lang="en-US">Offering price.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_InvestorOfferingPriceDescription" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_InvestorOfferingPriceDescription"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_NumberOfEngagementAgreement" xlink:label="loc_JG5F7864H0KK_relm_NumberOfEngagementAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_NumberOfEngagementAgreement" xml:lang="en-US">Number Of Engagement Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_NumberOfEngagementAgreement" xml:lang="en-US">Number of agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_NumberOfEngagementAgreement" xml:lang="en-US">Number of agreements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_NumberOfEngagementAgreement" xlink:to="lab_LI7H9086J2MM_relm_NumberOfEngagementAgreement"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ActivationFees" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_ActivationFees"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ActivationFees" xml:lang="en-US">Activation Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ActivationFees" xml:lang="en-US">Activation fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_ActivationFees" xml:lang="en-US">Activation fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_ActivationFees" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_ActivationFees"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription" xlink:label="loc_JG5F7864H0KK_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription" xml:lang="en-US">Business acquisition, Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription" xlink:to="lab_LI7H9086J2MM_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_RoyaltyPaymentsDescription" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_RoyaltyPaymentsDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_RoyaltyPaymentsDescription" xml:lang="en-US">Royalty Payments Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_RoyaltyPaymentsDescription" xml:lang="en-US">Royalty payments description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_RoyaltyPaymentsDescription" xml:lang="en-US">Description of Royalty Payments.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_RoyaltyPaymentsDescription" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_RoyaltyPaymentsDescription"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_RoyaltyReceivedByLicenseeDescription" xlink:label="loc_JG5F7864H0KK_relm_RoyaltyReceivedByLicenseeDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_RoyaltyReceivedByLicenseeDescription" xml:lang="en-US">Royalty Received By Licensee Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_relm_RoyaltyReceivedByLicenseeDescription" xml:lang="en-US">Royalty received by licensee description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_RoyaltyReceivedByLicenseeDescription" xml:lang="en-US">Royalty Received by Licensee Description.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_RoyaltyReceivedByLicenseeDescription" xlink:to="lab_LI7H9086J2MM_relm_RoyaltyReceivedByLicenseeDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xml:lang="en-US">Deferred tax assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_JG5F7864H0KK_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_LI7H9086J2MM_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xml:lang="en-US">Stock based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_JG5F7864H0KK_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Research and development tax credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_LI7H9086J2MM_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xml:lang="en-US">Accruals</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_JG5F7864H0KK_us-gaap_DeferredTaxAssetsOther"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Deferred Tax Assets, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_LI7H9086J2MM_us-gaap_DeferredTaxAssetsOther"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_DeferredTaxAssetsValuationAllowance"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_DeferredTaxAssetsValuationAllowance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_JG5F7864H0KK_us-gaap_DeferredTaxAssetsNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_LI7H9086J2MM_us-gaap_DeferredTaxAssetsNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xml:lang="en-US">Reconciliation of the statutory tax rate to the effective tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_JG5F7864H0KK_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Statutory federal income tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_LI7H9086J2MM_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">State (net of federal benefit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_JG5F7864H0KK_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xml:lang="en-US">Non-deductible expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_LI7H9086J2MM_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_JG5F7864H0KK_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_LI7H9086J2MM_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective income tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_JG5F7864H0KK_us-gaap_TaxCreditCarryforwardTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_TaxCreditCarryforwardTable" xml:lang="en-US">Tax Credit Carryforward [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_LI7H9086J2MM_us-gaap_TaxCreditCarryforwardTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_TaxCreditCarryforwardAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_TaxCreditCarryforwardAxis" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_TaxCreditCarryforwardAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_JG5F7864H0KK_us-gaap_TaxCreditCarryforwardNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_TaxCreditCarryforwardNameDomain" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_LI7H9086J2MM_us-gaap_TaxCreditCarryforwardNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ResearchMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ResearchMember" xml:lang="en-US">Research Tax Credit Carryforward [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ResearchMember" xml:lang="en-US">Federal research and development tax credit carryforwards [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ResearchMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ResearchMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_JG5F7864H0KK_us-gaap_TaxCreditCarryforwardLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_TaxCreditCarryforwardLineItems" xml:lang="en-US">Tax Credit Carryforward [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_LI7H9086J2MM_us-gaap_TaxCreditCarryforwardLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_TaxCreditCarryforwardAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax credit carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_TaxCreditCarryforwardAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_JG5F7864H0KK_us-gaap_OperatingLossCarryforwards"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Federal and state net operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_OperatingLossCarryforwards" xlink:to="lab_LI7H9086J2MM_us-gaap_OperatingLossCarryforwards"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_TaxCreditCarryforwardExpirationDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_TaxCreditCarryforwardExpirationDate" xml:lang="en-US">Tax Credit Carryforward, Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_TaxCreditCarryforwardExpirationDate" xml:lang="en-US">Tax credit carryforwards, expiring date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_TaxCreditCarryforwardExpirationDate" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_TaxCreditCarryforwardExpirationDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_JG5F7864H0KK_us-gaap_OperatingLossCarryforwardsExpirationDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_OperatingLossCarryforwardsExpirationDate" xml:lang="en-US">Operating Loss Carryforwards, Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_OperatingLossCarryforwardsExpirationDate" xml:lang="en-US">Federal and state net operating loss carryforwards, expiring date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:to="lab_LI7H9086J2MM_us-gaap_OperatingLossCarryforwardsExpirationDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xml:lang="en-US">Operating Loss Carryforwards, Limitations on Use</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xml:lang="en-US">Net operating loss carryforwards, limit description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_JG5F7864H0KK_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xml:lang="en-US">Schedule of future minimum lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="lab_LI7H9086J2MM_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US">2015</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_JG5F7864H0KK_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xml:lang="en-US">2016</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_LI7H9086J2MM_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xml:lang="en-US">2017</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_JG5F7864H0KK_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xml:lang="en-US">2018</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="lab_LI7H9086J2MM_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_JG5F7864H0KK_us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_LI7H9086J2MM_us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_JG5F7864H0KK_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_LI7H9086J2MM_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_LicensingAgreementsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_LicensingAgreementsMember" xml:lang="en-US">Licensing Agreements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_LicensingAgreementsMember" xml:lang="en-US">License fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_LicensingAgreementsMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_LicensingAgreementsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_JG5F7864H0KK_us-gaap_LeaseAgreementsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_LeaseAgreementsMember" xml:lang="en-US">Lease Agreements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_LeaseAgreementsMember" xml:lang="en-US">Number of licensed products</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_LeaseAgreementsMember" xlink:to="lab_LI7H9086J2MM_us-gaap_LeaseAgreementsMember"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_LegalMember" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_LegalMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_LegalMember" xml:lang="en-US">Legal [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_LegalMember" xml:lang="en-US">License expiry term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_LegalMember" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_LegalMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_JG5F7864H0KK_us-gaap_OperatingLeasedAssetsLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_OperatingLeasedAssetsLineItems" xml:lang="en-US">Operating Leased Assets [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_OperatingLeasedAssetsLineItems" xml:lang="en-US">Rent expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_LI7H9086J2MM_us-gaap_OperatingLeasedAssetsLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ProceedsFromLicenseFeesReceived"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ProceedsFromLicenseFeesReceived" xml:lang="en-US">Proceeds from License Fees Received</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ProceedsFromLicenseFeesReceived" xml:lang="en-US">Questionable expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_ProceedsFromLicenseFeesReceived"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_NumberOfLicensedProducts" xlink:label="loc_JG5F7864H0KK_relm_NumberOfLicensedProducts"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_NumberOfLicensedProducts" xml:lang="en-US">Number Of Licensed Products</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_NumberOfLicensedProducts" xml:lang="en-US">Number of licensed products</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_NumberOfLicensedProducts" xml:lang="en-US">Number of licensed products.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_NumberOfLicensedProducts" xlink:to="lab_LI7H9086J2MM_relm_NumberOfLicensedProducts"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_LicenseExpiryTerm" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_LicenseExpiryTerm"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_LicenseExpiryTerm" xml:lang="en-US">License Expiry Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_LicenseExpiryTerm" xml:lang="en-US">Common stock shares exchange</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_LicenseExpiryTerm" xml:lang="en-US">License expiry term.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_LicenseExpiryTerm" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_LicenseExpiryTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_JG5F7864H0KK_us-gaap_LeaseAndRentalExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_LeaseAndRentalExpense" xml:lang="en-US">Operating Leases, Rent Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_LeaseAndRentalExpense" xml:lang="en-US">Royalties description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_LeaseAndRentalExpense" xlink:to="lab_LI7H9086J2MM_us-gaap_LeaseAndRentalExpense"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_DoubtfulExpense" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_DoubtfulExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_DoubtfulExpense" xml:lang="en-US">Doubtful Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_DoubtfulExpense" xml:lang="en-US">Questionable expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_DoubtfulExpense" xml:lang="en-US">Doubtful expense.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_DoubtfulExpense" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_DoubtfulExpense"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CancellationOfWarrantsToPurchaseCommonStock" xlink:label="loc_JG5F7864H0KK_relm_CancellationOfWarrantsToPurchaseCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_CancellationOfWarrantsToPurchaseCommonStock" xml:lang="en-US">Cancellation Of Warrants To Purchase Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_CancellationOfWarrantsToPurchaseCommonStock" xml:lang="en-US">Cancellation of warrants to purchase common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_CancellationOfWarrantsToPurchaseCommonStock" xml:lang="en-US">Cancellation of warrants to purchase common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_CancellationOfWarrantsToPurchaseCommonStock" xlink:to="lab_LI7H9086J2MM_relm_CancellationOfWarrantsToPurchaseCommonStock"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CommonStockSharesExchange" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_CommonStockSharesExchange"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_CommonStockSharesExchange" xml:lang="en-US">Common Stock Shares Exchange</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_CommonStockSharesExchange" xml:lang="en-US">Common stock shares exchange</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_CommonStockSharesExchange" xml:lang="en-US">Common stock shares exchange.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_CommonStockSharesExchange" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_CommonStockSharesExchange"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_RoyaltiesDescription" xlink:label="loc_JG5F7864H0KK_relm_RoyaltiesDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_relm_RoyaltiesDescription" xml:lang="en-US">Royalties Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_relm_RoyaltiesDescription" xml:lang="en-US">Royalties description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_LI7H9086J2MM_relm_RoyaltiesDescription" xml:lang="en-US">Royalties description.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_relm_RoyaltiesDescription" xlink:to="lab_LI7H9086J2MM_relm_RoyaltiesDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_FFG0JH2876HI9H71G8KJ_us-gaap_SubsequentEventTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_us-gaap_SubsequentEventTable" xlink:to="lab_HHI2LJ4098JK1J93I0ML_us-gaap_SubsequentEventTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_JG5F7864H0KK_us-gaap_SubsequentEventLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_SubsequentEventLineItems" xlink:to="lab_LI7H9086J2MM_us-gaap_SubsequentEventLineItems"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_UpfrontCashFee" xlink:label="loc_FFG0JH2876HI9H71G8KJ_relm_UpfrontCashFee"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_UpfrontCashFee" xml:lang="en-US">Upfront Cash Fee Received By The Consultant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_UpfrontCashFee" xml:lang="en-US">Upfront cash fee received by the consultant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_HHI2LJ4098JK1J93I0ML_relm_UpfrontCashFee" xml:lang="en-US">Upfront cash fee.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_FFG0JH2876HI9H71G8KJ_relm_UpfrontCashFee" xlink:to="lab_HHI2LJ4098JK1J93I0ML_relm_UpfrontCashFee"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_JG5F7864H0KK_us-gaap_SubsequentEventDescription"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LI7H9086J2MM_us-gaap_SubsequentEventDescription" xml:lang="en-US">Subsequent Event, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LI7H9086J2MM_us-gaap_SubsequentEventDescription" xml:lang="en-US">Description of the company's agreement with a consultant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_JG5F7864H0KK_us-gaap_SubsequentEventDescription" xlink:to="lab_LI7H9086J2MM_us-gaap_SubsequentEventDescription"/>
</labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>relm-20140630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.1.0.1 on Tuesday, September 16, 2014 02:33:16 AM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#DocumentAndEntityInformation" roleURI="http://www.relmada.com/role/DocumentAndEntityInformation"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#ConsolidatedBalanceSheets" roleURI="http://www.relmada.com/role/ConsolidatedBalanceSheets"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.relmada.com/role/ConsolidatedBalanceSheetsParenthetical"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#ConsolidatedStatementsOfOperations" roleURI="http://www.relmada.com/role/ConsolidatedStatementsOfOperations"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#ConsolidatedStatementOfStockholdersDeficit" roleURI="http://www.relmada.com/role/ConsolidatedStatementOfStockholdersDeficit"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://www.relmada.com/role/ConsolidatedStatementsOfCashFlows"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#Business" roleURI="http://www.relmada.com/role/Business"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.relmada.com/role/SummaryOfSignificantAccountingPolicies"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#NotesPayable" roleURI="http://www.relmada.com/role/NotesPayable"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#DerivativeLiabilities" roleURI="http://www.relmada.com/role/DerivativeLiabilities"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#StockholdersEquity" roleURI="http://www.relmada.com/role/StockholdersEquity"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#RelatedPartyTransactions" roleURI="http://www.relmada.com/role/RelatedPartyTransactions"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#IncomeTaxes" roleURI="http://www.relmada.com/role/IncomeTaxes"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#CommitmentsAndContingencies" roleURI="http://www.relmada.com/role/CommitmentsAndContingencies"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#SubsequentEvents" roleURI="http://www.relmada.com/role/SubsequentEvents"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.relmada.com/role/SummaryofSignificantAccountingPoliciesPolicies"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.relmada.com/role/SummaryofSignificantAccountingPoliciesTables"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#NotePayableTables" roleURI="http://www.relmada.com/role/NotePayableTables"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#DerivativeLiabilitiesTables" roleURI="http://www.relmada.com/role/DerivativeLiabilitiesTables"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#StockholdersEquityTables" roleURI="http://www.relmada.com/role/StockholdersEquityTables"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#RelatedPartyTransactionsTables" roleURI="http://www.relmada.com/role/RelatedPartyTransactionsTables"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#IncomeTaxesTables" roleURI="http://www.relmada.com/role/IncomeTaxesTables"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#CommitmentsandContingenciesTables" roleURI="http://www.relmada.com/role/CommitmentsandContingenciesTables"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#BusinessDetails" roleURI="http://www.relmada.com/role/BusinessDetails"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.relmada.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#SummaryOfSignificantAccountingPoliciesDetails1" roleURI="http://www.relmada.com/role/SummaryOfSignificantAccountingPoliciesDetails1"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#SummaryOfSignificantAccountingPoliciesDetails2" roleURI="http://www.relmada.com/role/SummaryOfSignificantAccountingPoliciesDetails2"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#SummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://www.relmada.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#NotePayableDetails" roleURI="http://www.relmada.com/role/NotePayableDetails"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#NotePayableDetailsTextual" roleURI="http://www.relmada.com/role/NotePayableDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#DerivativeLiabilitiesDetails" roleURI="http://www.relmada.com/role/DerivativeLiabilitiesDetails"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#DerivativeLiabilitiesDetails1" roleURI="http://www.relmada.com/role/DerivativeLiabilitiesDetails1"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#DerivativeLiabilitiesDetailsTextual" roleURI="http://www.relmada.com/role/DerivativeLiabilitiesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#StockholdersEquityDetails" roleURI="http://www.relmada.com/role/StockholdersEquityDetails"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#StockholdersEquityDetails1" roleURI="http://www.relmada.com/role/StockholdersEquityDetails1"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#StockholdersEquityDetails2" roleURI="http://www.relmada.com/role/StockholdersEquityDetails2"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#StockholdersEquityDetails3" roleURI="http://www.relmada.com/role/StockholdersEquityDetails3"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#StockholdersEquityDetails4" roleURI="http://www.relmada.com/role/StockholdersEquityDetails4"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#StockholdersEquityDetailsTextual" roleURI="http://www.relmada.com/role/StockholdersEquityDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#StockholdersEquityDetailsTextual1" roleURI="http://www.relmada.com/role/StockholdersEquityDetailsTextual1"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#StockholdersEquityDetailsTextual2" roleURI="http://www.relmada.com/role/StockholdersEquityDetailsTextual2"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#RelatedPartyTransactionsDetails" roleURI="http://www.relmada.com/role/RelatedPartyTransactionsDetails"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#RelatedPartyTransactionsDetailsTextual" roleURI="http://www.relmada.com/role/RelatedPartyTransactionsDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#IncomeTaxesDetails" roleURI="http://www.relmada.com/role/IncomeTaxesDetails"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#IncomeTaxesDetails1" roleURI="http://www.relmada.com/role/IncomeTaxesDetails1"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#IncomeTaxesDetailsTextual" roleURI="http://www.relmada.com/role/IncomeTaxesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#CommitmentsandContingenciesDetails" roleURI="http://www.relmada.com/role/CommitmentsandContingenciesDetails"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#CommitmentsAndContingenciesDetailsTextual" roleURI="http://www.relmada.com/role/CommitmentsAndContingenciesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="relm-20140630.xsd#SubsequentEventsDetails" roleURI="http://www.relmada.com/role/SubsequentEventsDetails"/>
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_DocumentAndEntityInformationAbstract" xlink:label="loc_relm_DocumentAndEntityInformationAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityRegistrantName_1" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_AmendmentFlag_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentType_4" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_5" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityFilerCategory_6" order="50" use="optional"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaap_PreferredClassAMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_PreferredClassAMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_AssetsAbstract_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7" xlink:to="loc_us-gaap_AssetsCurrentAbstract_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8" xlink:to="loc_us-gaap_AssetsCurrent_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7" xlink:to="loc_us-gaap_OtherAssets_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7" xlink:to="loc_us-gaap_Assets_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_AccountsPayableCurrent_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_NotesPayableCurrent_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_17" xlink:to="loc_us-gaap_LiabilitiesCurrent_23" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16" xlink:to="loc_us-gaap_Liabilities_25" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16" xlink:to="loc_us-gaap_CommitmentsAndContingencies_26" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16" xlink:to="loc_us-gaap_StockholdersEquityAbstract_27" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_27" xlink:to="loc_us-gaap_PreferredStockValue_28" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_27" xlink:to="loc_us-gaap_CommonStockValue_29" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_27" xlink:to="loc_us-gaap_AdditionalPaidInCapital_30" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_27" xlink:to="loc_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage_31" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_27" xlink:to="loc_us-gaap_StockholdersEquity_32" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_16" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_33" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaap_PreferredClassAMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_PreferredClassAMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:label="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_PreferredStockSharesIssued_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaap_PreferredStockLiquidationPreference_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_PreferredStockLiquidationPreference_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_15" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_16" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_CommonStockSharesIssued_17" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_18" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/ConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_us-gaap_LicenseAndServicesRevenue_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_LicenseAndServicesRevenue_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2" xlink:to="loc_us-gaap_OperatingExpenses_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingGainsLossesAbstract" xlink:label="loc_us-gaap_NonoperatingGainsLossesAbstract_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NonoperatingGainsLossesAbstract_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingGainsLossesAbstract_7" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingGainsLossesAbstract_7" xlink:to="loc_us-gaap_InvestmentIncomeInterest_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingGainsLossesAbstract_7" xlink:to="loc_us-gaap_InterestExpense_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingGainsLossesAbstract_7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/ConsolidatedStatementOfStockholdersDeficit">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaap_PreferredClassAMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_PreferredClassAMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_RetainedEarningsMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDeficitDuringDevelopmentStageMember" xlink:label="loc_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_AccumulatedDeficitDuringDevelopmentStageMember_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockholdersEquity_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_SharesOutstanding_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesValue" xlink:label="loc_relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesValue_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesValue_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesShares" xlink:label="loc_relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesShares_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesValue_13" xlink:to="loc_relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesShares_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentDecreaseForgiveness" xlink:label="loc_us-gaap_DebtInstrumentDecreaseForgiveness_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_DebtInstrumentDecreaseForgiveness_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_StockIssuedDuringPeriodValueIssuedForConversionOfLoansAndAccruedInterest" xlink:label="loc_relm_StockIssuedDuringPeriodValueIssuedForConversionOfLoansAndAccruedInterest_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_relm_StockIssuedDuringPeriodValueIssuedForConversionOfLoansAndAccruedInterest_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_StockIssuedDuringPeriodSharesIssuedForConversionOfLoansAndAccruedInterest" xlink:label="loc_relm_StockIssuedDuringPeriodSharesIssuedForConversionOfLoansAndAccruedInterest_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_StockIssuedDuringPeriodValueIssuedForConversionOfLoansAndAccruedInterest_16" xlink:to="loc_relm_StockIssuedDuringPeriodSharesIssuedForConversionOfLoansAndAccruedInterest_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants" xlink:label="loc_relm_StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_relm_StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants" xlink:label="loc_relm_StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants_18" xlink:to="loc_relm_StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_20" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets_20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesValue" xlink:label="loc_relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesValue_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesValue_22" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesShares" xlink:label="loc_relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesShares_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesValue_22" xlink:to="loc_relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesShares_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue" xlink:label="loc_relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue_24" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsShares" xlink:label="loc_relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsShares_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue_24" xlink:to="loc_relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsShares_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_26" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_26" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_27" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsValue" xlink:label="loc_relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsValue_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsValue_28" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsShares" xlink:label="loc_relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsShares_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsValue_28" xlink:to="loc_relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsShares_29" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_30" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_30" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_31" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_32" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther_32" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_33" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_34" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_34" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_35" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpense" xlink:label="loc_relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpense_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpense_36" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpenseShares" xlink:label="loc_relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpenseShares_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpense_36" xlink:to="loc_relm_IssuanceOfCommonStockForExchangeOfRelatedPartyLoanAndAccruedInterestExpenseShares_37" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_ShareBasedCompensation_38" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForCash" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForCash_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForCash_39" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForCash" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForCash_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForCash_39" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForCash_40" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfFairValueOfWarrantDerivativeLiabilitiesIssuedInUnitsOfferingDuringPeriodValue." xlink:label="loc_relm_IssuanceOfFairValueOfWarrantDerivativeLiabilitiesIssuedInUnitsOfferingDuringPeriodValue._41"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_relm_IssuanceOfFairValueOfWarrantDerivativeLiabilitiesIssuedInUnitsOfferingDuringPeriodValue._41" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfEliminatingDerivativeLiabilitiesUponShareExchangeDuringPeriodValue" xlink:label="loc_relm_IssuanceOfEliminatingDerivativeLiabilitiesUponShareExchangeDuringPeriodValue_42"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_relm_IssuanceOfEliminatingDerivativeLiabilitiesUponShareExchangeDuringPeriodValue_42" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureValue" xlink:label="loc_relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureValue_43"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureValue_43" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureShares" xlink:label="loc_relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureShares_44"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureValue_43" xlink:to="loc_relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureShares_44" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange" xlink:label="loc_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange_45"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange_45" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares" xlink:label="loc_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares_46"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange_45" xlink:to="loc_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares_46" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_47"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_47" order="210" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_48"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_NetIncomeLoss_48" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_49"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_StockholdersEquity_49" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_50"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_10" xlink:to="loc_us-gaap_SharesOutstanding_50" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_Depreciation_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CommonStockIssuedForServices" xlink:label="loc_relm_CommonStockIssuedForServices_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_relm_CommonStockIssuedForServices_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_ShareBasedCompensation_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_10" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_10" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpensesOther_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_10" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_10" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_15" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_15" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_22" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ProceedsFromSubordinatedPromissoryNotesNetOfDeferredFinancingCosts" xlink:label="loc_relm_ProceedsFromSubordinatedPromissoryNotesNetOfDeferredFinancingCosts_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_relm_ProceedsFromSubordinatedPromissoryNotesNetOfDeferredFinancingCosts_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_18" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_24" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashPeriodIncreaseDecrease_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_26" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_27" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_28" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CashPaidDuringPeriodAbstract" xlink:label="loc_relm_CashPaidDuringPeriodAbstract_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_28" xlink:to="loc_relm_CashPaidDuringPeriodAbstract_29" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_CashPaidDuringPeriodAbstract_29" xlink:to="loc_us-gaap_IncomeTaxesPaid_30" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_CashPaidDuringPeriodAbstract_29" xlink:to="loc_us-gaap_InterestPaid_31" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_32" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ShareExchangeOfSubordinatedDebt" xlink:label="loc_relm_ShareExchangeOfSubordinatedDebt_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_32" xlink:to="loc_relm_ShareExchangeOfSubordinatedDebt_33" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ShareExchangeOfAccruedInterest" xlink:label="loc_relm_ShareExchangeOfAccruedInterest_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_32" xlink:to="loc_relm_ShareExchangeOfAccruedInterest_34" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfDebtInConnectionWithCompensationPolicy" xlink:label="loc_relm_IssuanceOfDebtInConnectionWithCompensationPolicy_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_32" xlink:to="loc_relm_IssuanceOfDebtInConnectionWithCompensationPolicy_35" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FairValueOfDerivativesTerminatedInConnectionWithShareExchange" xlink:label="loc_relm_FairValueOfDerivativesTerminatedInConnectionWithShareExchange_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_32" xlink:to="loc_relm_FairValueOfDerivativesTerminatedInConnectionWithShareExchange_36" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FairValueOfDerivativesIssuedInConnectionWithIssuanceOfCommonStock" xlink:label="loc_relm_FairValueOfDerivativesIssuedInConnectionWithIssuanceOfCommonStock_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_32" xlink:to="loc_relm_FairValueOfDerivativesIssuedInConnectionWithIssuanceOfCommonStock_37" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_BeneficialConversionFeature" xlink:label="loc_relm_BeneficialConversionFeature_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_32" xlink:to="loc_relm_BeneficialConversionFeature_38" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FairValueOfDerivativesIssuedInConnectionWithIssuanceOfPreferredStock" xlink:label="loc_relm_FairValueOfDerivativesIssuedInConnectionWithIssuanceOfPreferredStock_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_32" xlink:to="loc_relm_FairValueOfDerivativesIssuedInConnectionWithIssuanceOfPreferredStock_39" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FairValueOfDerivativeWarrantsIssuedToLendersInConnectionWithIssuanceOfSubordinatedPromissoryNotes" xlink:label="loc_relm_FairValueOfDerivativeWarrantsIssuedToLendersInConnectionWithIssuanceOfSubordinatedPromissoryNotes_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_32" xlink:to="loc_relm_FairValueOfDerivativeWarrantsIssuedToLendersInConnectionWithIssuanceOfSubordinatedPromissoryNotes_40" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_41"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_32" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_41" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FairValueOfDerivativeWarrantsIssuedForOfferingCostsInConnectionWithTheIssuanceOfSeriesAPreferredStock" xlink:label="loc_relm_FairValueOfDerivativeWarrantsIssuedForOfferingCostsInConnectionWithTheIssuanceOfSeriesAPreferredStock_42"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_32" xlink:to="loc_relm_FairValueOfDerivativeWarrantsIssuedForOfferingCostsInConnectionWithTheIssuanceOfSeriesAPreferredStock_42" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FairValueOfDerivativeIssuedToWonpungForServices" xlink:label="loc_relm_FairValueOfDerivativeIssuedToWonpungForServices_43"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_32" xlink:to="loc_relm_FairValueOfDerivativeIssuedToWonpungForServices_43" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ExchangeOfLoansAndAccruedInterestForCommonStockFromFounder" xlink:label="loc_relm_ExchangeOfLoansAndAccruedInterestForCommonStockFromFounder_44"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_32" xlink:to="loc_relm_ExchangeOfLoansAndAccruedInterestForCommonStockFromFounder_44" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ExchangeOfSubordinatedNotesAndAccruedInterestForSeriesAPreferredStock" xlink:label="loc_relm_ExchangeOfSubordinatedNotesAndAccruedInterestForSeriesAPreferredStock_45"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_32" xlink:to="loc_relm_ExchangeOfSubordinatedNotesAndAccruedInterestForSeriesAPreferredStock_45" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CashlessExerciseOfWarrantsForCommonStock" xlink:label="loc_relm_CashlessExerciseOfWarrantsForCommonStock_46"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_32" xlink:to="loc_relm_CashlessExerciseOfWarrantsForCommonStock_46" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/Business">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/NotesPayable">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="loc_us-gaap_NotesPayableAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NotesPayableAbstract_0" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/DerivativeLiabilities">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/StockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/SummaryofSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PatentsPolicyTextBlock" xlink:label="loc_relm_PatentsPolicyTextBlock_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_relm_PatentsPolicyTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FixedAssetsPolicyTextBlock" xlink:label="loc_relm_FixedAssetsPolicyTextBlock_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_relm_FixedAssetsPolicyTextBlock_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_GoingConcernPolicyTextBlock" xlink:label="loc_relm_GoingConcernPolicyTextBlock_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_relm_GoingConcernPolicyTextBlock_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_DevelopmentStageCompanyPolicyTextBlock" xlink:label="loc_relm_DevelopmentStageCompanyPolicyTextBlock_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_relm_DevelopmentStageCompanyPolicyTextBlock_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_16" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_17" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_DecemberSubordinatedPromissoryNotesPayablePolicyTextBlock" xlink:label="loc_relm_DecemberSubordinatedPromissoryNotesPayablePolicyTextBlock_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_relm_DecemberSubordinatedPromissoryNotesPayablePolicyTextBlock_18" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SeptemberSubordinatedPromissoryNotesPayablePolicyTextBlock" xlink:label="loc_relm_SeptemberSubordinatedPromissoryNotesPayablePolicyTextBlock_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_relm_SeptemberSubordinatedPromissoryNotesPayablePolicyTextBlock_19" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/SummaryofSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/NotePayableTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="loc_us-gaap_NotesPayableAbstract_0"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ScheduleOfPromissoryNotesDueLoanTableTextBlock" xlink:label="loc_relm_ScheduleOfPromissoryNotesDueLoanTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NotesPayableAbstract_0" xlink:to="loc_relm_ScheduleOfPromissoryNotesDueLoanTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/DerivativeLiabilitiesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ScheduleOfDerivativeLiabilitiesValuationsModelsTableTextBlock" xlink:label="loc_relm_ScheduleOfDerivativeLiabilitiesValuationsModelsTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_relm_ScheduleOfDerivativeLiabilitiesValuationsModelsTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/StockholdersEquityTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ScheduleOfCashProceedsReceivedFromOfferingsTableTextBlock" xlink:label="loc_relm_ScheduleOfCashProceedsReceivedFromOfferingsTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_relm_ScheduleOfCashProceedsReceivedFromOfferingsTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock" xlink:label="loc_relm_ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_relm_ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ScheduleOfOutstandingWarrantsByCategoryTableTextBlock" xlink:label="loc_relm_ScheduleOfOutstandingWarrantsByCategoryTableTextBlock_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_relm_ScheduleOfOutstandingWarrantsByCategoryTableTextBlock_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/RelatedPartyTransactionsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/CommitmentsandContingenciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/BusinessDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="loc_relm_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_relm_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaap_PreferredClassAMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_PreferredClassAMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="loc_relm_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_1" xlink:to="loc_relm_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_BusinessTextualsAbstract" xlink:label="loc_relm_BusinessTextualsAbstract_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_6" xlink:to="loc_relm_BusinessTextualsAbstract_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_BusinessTextualsAbstract_7" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_BusinessTextualsAbstract_7" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_BusinessTextualsAbstract_7" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplit_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_BusinessTextualsAbstract_7" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplit_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange" xlink:label="loc_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_BusinessTextualsAbstract_7" xlink:to="loc_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares" xlink:label="loc_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_BusinessTextualsAbstract_7" xlink:to="loc_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_BusinessTextualsAbstract_7" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_BusinessTextualsAbstract_7" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_15" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/SummaryofSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7" xlink:to="loc_us-gaap_EquityComponentDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8" xlink:to="loc_us-gaap_WarrantMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_10" xlink:to="loc_us-gaap_ClassOfStockDomain_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_11" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="loc_us-gaap_FairValueNetAssetLiabilityAbstract_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13" xlink:to="loc_us-gaap_FairValueNetAssetLiabilityAbstract_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetAssetLiabilityAbstract_14" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/SummaryOfSignificantAccountingPoliciesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable" xlink:label="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems" xlink:label="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTable_1" xlink:to="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems_5" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption" xlink:label="loc_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems_5" xlink:to="loc_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FairValueOfWarrantsInstruments" xlink:label="loc_relm_FairValueOfWarrantsInstruments_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems_5" xlink:to="loc_relm_FairValueOfWarrantsInstruments_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_TransferOfFairValueWarrantInstrumentsAdditionalPaidInCapital" xlink:label="loc_relm_TransferOfFairValueWarrantInstrumentsAdditionalPaidInCapital_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems_5" xlink:to="loc_relm_TransferOfFairValueWarrantInstrumentsAdditionalPaidInCapital_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ConversionOfSeriesAPreferredStock" xlink:label="loc_relm_ConversionOfSeriesAPreferredStock_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems_5" xlink:to="loc_relm_ConversionOfSeriesAPreferredStock_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems_5" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/SummaryOfSignificantAccountingPoliciesDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaap_PreferredClassAMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_PreferredClassAMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CommonStockWarrantsMember" xlink:label="loc_relm_CommonStockWarrantsMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_relm_CommonStockWarrantsMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CommonStockOptionsMember" xlink:label="loc_relm_CommonStockOptionsMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_relm_CommonStockOptionsMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SignificantAccountingPoliciesTextualsAbstract" xlink:label="loc_relm_SignificantAccountingPoliciesTextualsAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_relm_SignificantAccountingPoliciesTextualsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_SignificantAccountingPoliciesTextualsAbstract_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/NotePayableDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="loc_us-gaap_NotesPayableAbstract_0"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_NotesPayableTable" xlink:label="loc_relm_NotesPayableTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NotesPayableAbstract_0" xlink:to="loc_relm_NotesPayableTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PromissoryNotesDueMember" xlink:label="loc_relm_PromissoryNotesDueMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3" xlink:to="loc_relm_PromissoryNotesDueMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PromissoryNotesDueOneMember" xlink:label="loc_relm_PromissoryNotesDueOneMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3" xlink:to="loc_relm_PromissoryNotesDueOneMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_NotesPayableLineItems" xlink:label="loc_relm_NotesPayableLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableTable_1" xlink:to="loc_relm_NotesPayableLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaap_LoansPayableCurrent_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableLineItems_6" xlink:to="loc_us-gaap_LoansPayableCurrent_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableLineItems_6" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableLineItems_6" xlink:to="loc_us-gaap_NotesPayableCurrent_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/NotePayableDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="loc_us-gaap_NotesPayableAbstract_0"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_NotesPayableTable" xlink:label="loc_relm_NotesPayableTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NotesPayableAbstract_0" xlink:to="loc_relm_NotesPayableTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CommonStockOptionsMember" xlink:label="loc_relm_CommonStockOptionsMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_relm_CommonStockOptionsMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CommonStockWarrantsMember" xlink:label="loc_relm_CommonStockWarrantsMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_relm_CommonStockWarrantsMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PromissoryNotesDueMember" xlink:label="loc_relm_PromissoryNotesDueMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8" xlink:to="loc_relm_PromissoryNotesDueMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PromissoryNotesDueOneMember" xlink:label="loc_relm_PromissoryNotesDueOneMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8" xlink:to="loc_relm_PromissoryNotesDueOneMember_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PromissoryNotesDueTwoMember" xlink:label="loc_relm_PromissoryNotesDueTwoMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8" xlink:to="loc_relm_PromissoryNotesDueTwoMember_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PromissoryNotesDueThreeMember" xlink:label="loc_relm_PromissoryNotesDueThreeMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8" xlink:to="loc_relm_PromissoryNotesDueThreeMember_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_13" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FinancialAgreementMember" xlink:label="loc_relm_FinancialAgreementMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_14" xlink:to="loc_relm_FinancialAgreementMember_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_NotesPayableLineItems" xlink:label="loc_relm_NotesPayableLineItems_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableTable_1" xlink:to="loc_relm_NotesPayableLineItems_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_NotesPayableDetailsTextualAbstract" xlink:label="loc_relm_NotesPayableDetailsTextualAbstract_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableLineItems_16" xlink:to="loc_relm_NotesPayableDetailsTextualAbstract_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_us-gaap_NotesPayable_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_DebtDiscountAmortizationPeriod" xlink:label="loc_relm_DebtDiscountAmortizationPeriod_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_relm_DebtDiscountAmortizationPeriod_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_us-gaap_SharePrice_23" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_24" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CashProceedForDebtDiscountInterestRate" xlink:label="loc_relm_CashProceedForDebtDiscountInterestRate_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_relm_CashProceedForDebtDiscountInterestRate_25" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_DebtDiscountInterestRateOfMaturity" xlink:label="loc_relm_DebtDiscountInterestRateOfMaturity_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_relm_DebtDiscountInterestRateOfMaturity_26" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PurchaseOfWarrantShares" xlink:label="loc_relm_PurchaseOfWarrantShares_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_relm_PurchaseOfWarrantShares_27" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_28" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AmortizedDeferredFinancingCostsMaturityDate" xlink:label="loc_relm_AmortizedDeferredFinancingCostsMaturityDate_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_relm_AmortizedDeferredFinancingCostsMaturityDate_29" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum_30" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AmortizationOfDebtIssuanceCosts1" xlink:label="loc_relm_AmortizationOfDebtIssuanceCosts1_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_relm_AmortizationOfDebtIssuanceCosts1_31" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_WarrantsValueForPlacementAgent" xlink:label="loc_relm_WarrantsValueForPlacementAgent_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_relm_WarrantsValueForPlacementAgent_32" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_WarrantsValueForPlacementAgentPerShare" xlink:label="loc_relm_WarrantsValueForPlacementAgentPerShare_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_relm_WarrantsValueForPlacementAgentPerShare_33" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FairValueOfDebtDisoumt" xlink:label="loc_relm_FairValueOfDebtDisoumt_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_relm_FairValueOfDebtDisoumt_34" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_35" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtPercentageBearingFixedInterestAmount" xlink:label="loc_us-gaap_LongtermDebtPercentageBearingFixedInterestAmount_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_us-gaap_LongtermDebtPercentageBearingFixedInterestAmount_36" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_TotalDebtIssuanceCostsIncurredIn2012" xlink:label="loc_relm_TotalDebtIssuanceCostsIncurredIn2012_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_relm_TotalDebtIssuanceCostsIncurredIn2012_37" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_us-gaap_NotesPayableCurrent_38" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_39" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_40" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FinanceAgreementPaymentDescription" xlink:label="loc_relm_FinanceAgreementPaymentDescription_41"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_relm_FinanceAgreementPaymentDescription_41" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_42"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_us-gaap_InducedConversionOfConvertibleDebtExpense_42" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_43"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_43" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfDebtInConnectionWithCompensationPolicy" xlink:label="loc_relm_IssuanceOfDebtInConnectionWithCompensationPolicy_44"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_relm_IssuanceOfDebtInConnectionWithCompensationPolicy_44" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_DebtInConnectionWithDownPaymentOfInsurancePolicy" xlink:label="loc_relm_DebtInConnectionWithDownPaymentOfInsurancePolicy_45"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_relm_DebtInConnectionWithDownPaymentOfInsurancePolicy_45" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_DebtInConnectionWithPaymentOfMonthlyInstallemt" xlink:label="loc_relm_DebtInConnectionWithPaymentOfMonthlyInstallemt_46"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_relm_DebtInConnectionWithPaymentOfMonthlyInstallemt_46" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_NumberOfInstallments" xlink:label="loc_relm_NumberOfInstallments_47"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_relm_NumberOfInstallments_47" order="290" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaap_ConvertibleNotesPayableCurrent_48"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_relm_NotesPayableDetailsTextualAbstract_17" xlink:to="loc_us-gaap_ConvertibleNotesPayableCurrent_48" order="300" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/DerivativeLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_InitialValuationsMember" xlink:label="loc_relm_InitialValuationsMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3" xlink:to="loc_relm_InitialValuationsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CommonStockIssuableUponExerciseOfWarrants" xlink:label="loc_relm_CommonStockIssuableUponExerciseOfWarrants_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9" xlink:to="loc_relm_CommonStockIssuableUponExerciseOfWarrants_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfSeriesAPreferredStockAndWarrantsShares" xlink:label="loc_relm_IssuanceOfSeriesAPreferredStockAndWarrantsShares_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9" xlink:to="loc_relm_IssuanceOfSeriesAPreferredStockAndWarrantsShares_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_MarketValueOfCommonStockOnMeasurementPerStock" xlink:label="loc_relm_MarketValueOfCommonStockOnMeasurementPerStock_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9" xlink:to="loc_relm_MarketValueOfCommonStockOnMeasurementPerStock_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaap_FairValueAssumptionsExercisePrice_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9" xlink:to="loc_us-gaap_FairValueAssumptionsExercisePrice_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9" xlink:to="loc_us-gaap_FairValueAssumptionsRiskFreeInterestRate_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedVolatilityRate_16" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_17" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/DerivativeLiabilitiesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_2" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ChangeDuringPeriodFairValueDisclosureMember" xlink:label="loc_us-gaap_ChangeDuringPeriodFairValueDisclosureMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3" xlink:to="loc_us-gaap_ChangeDuringPeriodFairValueDisclosureMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_3" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7" xlink:to="loc_us-gaap_ClassOfStockDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_11" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMember" xlink:label="loc_us-gaap_LongTermDebtMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_12" xlink:to="loc_us-gaap_LongTermDebtMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SecuritiesPledgedAsCollateralMember" xlink:label="loc_us-gaap_SecuritiesPledgedAsCollateralMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_12" xlink:to="loc_us-gaap_SecuritiesPledgedAsCollateralMember_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_15" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_16" xlink:to="loc_us-gaap_PrivatePlacementMember_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_18" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_JuniorSubordinatedDebtMember" xlink:label="loc_us-gaap_JuniorSubordinatedDebtMember_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_19" xlink:to="loc_us-gaap_JuniorSubordinatedDebtMember_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1" xlink:to="loc_us-gaap_StatementScenarioAxis_21" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_21" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuedInMayAndJune2014OfferingMember" xlink:label="loc_relm_IssuedInMayAndJune2014OfferingMember_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_22" xlink:to="loc_relm_IssuedInMayAndJune2014OfferingMember_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_1" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_24" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_24" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_24" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_26" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_24" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_27" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/DerivativeLiabilitiesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedDividendRate_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/StockholdersEquityDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5" xlink:to="loc_us-gaap_EquityComponentDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6" xlink:to="loc_us-gaap_CommonStockMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_ClassOfStockLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToPreferredStockIssuance" xlink:label="loc_relm_AllocationOfCashToPreferredStockIssuance_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8" xlink:to="loc_relm_AllocationOfCashToPreferredStockIssuance_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToCommonStockIssuance" xlink:label="loc_relm_AllocationOfCashToCommonStockIssuance_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8" xlink:to="loc_relm_AllocationOfCashToCommonStockIssuance_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToAdditionalPaidInCapital" xlink:label="loc_relm_AllocationOfCashToAdditionalPaidInCapital_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8" xlink:to="loc_relm_AllocationOfCashToAdditionalPaidInCapital_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToDerivativeLiability" xlink:label="loc_relm_AllocationOfCashToDerivativeLiability_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8" xlink:to="loc_relm_AllocationOfCashToDerivativeLiability_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilities" xlink:label="loc_relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilities_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8" xlink:to="loc_relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilities_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilitiesOne" xlink:label="loc_relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilitiesOne_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8" xlink:to="loc_relm_AllocationOfCashToDerivativeSeriesAWarrantLiabilitiesOne_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToDerivativePreferredStockConversion" xlink:label="loc_relm_AllocationOfCashToDerivativePreferredStockConversion_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8" xlink:to="loc_relm_AllocationOfCashToDerivativePreferredStockConversion_15" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AllocationOfCashToDerivativeWarrantsIssuance" xlink:label="loc_relm_AllocationOfCashToDerivativeWarrantsIssuance_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8" xlink:to="loc_relm_AllocationOfCashToDerivativeWarrantsIssuance_16" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ProceedsFromIssuanceOfOfferingsNet" xlink:label="loc_relm_ProceedsFromIssuanceOfOfferingsNet_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8" xlink:to="loc_relm_ProceedsFromIssuanceOfOfferingsNet_17" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_OfferingCosts" xlink:label="loc_relm_OfferingCosts_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8" xlink:to="loc_relm_OfferingCosts_18" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ProceedsFromIssuanceOfOfferingsGross" xlink:label="loc_relm_ProceedsFromIssuanceOfOfferingsGross_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8" xlink:to="loc_relm_ProceedsFromIssuanceOfOfferingsGross_19" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/StockholdersEquityDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:label="loc_relm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_relm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue" xlink:label="loc_relm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_relm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/StockholdersEquityDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CurrentPriceOfCommonStock" xlink:label="loc_relm_CurrentPriceOfCommonStock_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_relm_CurrentPriceOfCommonStock_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_16" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/StockholdersEquityDetails3">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ClassOfWarrantOrRightGranted" xlink:label="loc_relm_ClassOfWarrantOrRightGranted_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_relm_ClassOfWarrantOrRightGranted_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ClassOfWarrantOrRightExercised" xlink:label="loc_relm_ClassOfWarrantOrRightExercised_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_relm_ClassOfWarrantOrRightExercised_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ClassOfWarrantOrRightForfeited" xlink:label="loc_relm_ClassOfWarrantOrRightForfeited_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_relm_ClassOfWarrantOrRightForfeited_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ClassOfWarrantOrRightVestedOutstanding" xlink:label="loc_relm_ClassOfWarrantOrRightVestedOutstanding_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_relm_ClassOfWarrantOrRightVestedOutstanding_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted" xlink:label="loc_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised" xlink:label="loc_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeited" xlink:label="loc_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeited_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeited_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedOutstanding" xlink:label="loc_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedOutstanding_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedOutstanding_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/StockholdersEquityDetails4">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CurrentPriceOfCommonStock" xlink:label="loc_relm_CurrentPriceOfCommonStock_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_relm_CurrentPriceOfCommonStock_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_16" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/StockholdersEquityDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SeriesAWarrantsMember" xlink:label="loc_relm_SeriesAWarrantsMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_relm_SeriesAWarrantsMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SeriesBWarrantsMember" xlink:label="loc_relm_SeriesBWarrantsMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_relm_SeriesBWarrantsMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AgentWarrantsMember" xlink:label="loc_relm_AgentWarrantsMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_relm_AgentWarrantsMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_InvestorsMember" xlink:label="loc_relm_InvestorsMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:to="loc_relm_InvestorsMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_12" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_13" xlink:to="loc_us-gaap_PrivatePlacementMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_15" xlink:to="loc_us-gaap_EquityComponentDomain_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredClassAMember" xlink:label="loc_us-gaap_PreferredClassAMember_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_16" xlink:to="loc_us-gaap_PreferredClassAMember_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_16" xlink:to="loc_us-gaap_CommonStockMember_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockConversionBasis" xlink:label="loc_us-gaap_CommonStockConversionBasis_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19" xlink:to="loc_us-gaap_CommonStockConversionBasis_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockConversionFeatures" xlink:label="loc_us-gaap_CommonStockConversionFeatures_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19" xlink:to="loc_us-gaap_CommonStockConversionFeatures_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_22" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_23" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_24" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_25" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaap_LineOfCredit_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19" xlink:to="loc_us-gaap_LineOfCredit_26" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaap_InterestReceivable_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19" xlink:to="loc_us-gaap_InterestReceivable_27" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_28" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_29" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_WarrantToPurchaseOfCommonStock" xlink:label="loc_relm_WarrantToPurchaseOfCommonStock_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19" xlink:to="loc_relm_WarrantToPurchaseOfCommonStock_30" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_31" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DividendsShareBasedCompensation" xlink:label="loc_us-gaap_DividendsShareBasedCompensation_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19" xlink:to="loc_us-gaap_DividendsShareBasedCompensation_32" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStocksIncludingAdditionalPaidInCapital" xlink:label="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19" xlink:to="loc_us-gaap_CommonStocksIncludingAdditionalPaidInCapital_33" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19" xlink:to="loc_us-gaap_DerivativeLiabilities_34" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ProceedsFromIssuanceOfOfferingsGross" xlink:label="loc_relm_ProceedsFromIssuanceOfOfferingsGross_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19" xlink:to="loc_relm_ProceedsFromIssuanceOfOfferingsGross_35" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_36" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfSeriesAPreferredStockSharesToPurchaseCommonStock" xlink:label="loc_relm_IssuanceOfSeriesAPreferredStockSharesToPurchaseCommonStock_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19" xlink:to="loc_relm_IssuanceOfSeriesAPreferredStockSharesToPurchaseCommonStock_37" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CommissionsAndNonAccountableExpenses" xlink:label="loc_relm_CommissionsAndNonAccountableExpenses_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19" xlink:to="loc_relm_CommissionsAndNonAccountableExpenses_38" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PlacementAgentExpenses" xlink:label="loc_relm_PlacementAgentExpenses_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19" xlink:to="loc_relm_PlacementAgentExpenses_39" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockTermsOfConversion_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19" xlink:to="loc_us-gaap_ConvertiblePreferredStockTermsOfConversion_40" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ClassOfWarrantOrRightsRedemptionTerms" xlink:label="loc_relm_ClassOfWarrantOrRightsRedemptionTerms_41"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19" xlink:to="loc_relm_ClassOfWarrantOrRightsRedemptionTerms_41" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PercentageOfSolicitationFeeOnWarrantsExercised" xlink:label="loc_relm_PercentageOfSolicitationFeeOnWarrantsExercised_42"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19" xlink:to="loc_relm_PercentageOfSolicitationFeeOnWarrantsExercised_42" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_43"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_43" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_44"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_44" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_45"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_45" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplit_46"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplit_46" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange" xlink:label="loc_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange_47"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19" xlink:to="loc_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange_47" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares" xlink:label="loc_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares_48"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_19" xlink:to="loc_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares_48" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/StockholdersEquityDetailsTextual1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_WarrantMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CommonStockIssuedForServicesMember" xlink:label="loc_relm_CommonStockIssuedForServicesMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_relm_CommonStockIssuedForServicesMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7" xlink:to="loc_us-gaap_RelatedPartyDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_RelatedPartyMember" xlink:label="loc_relm_RelatedPartyMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_8" xlink:to="loc_relm_RelatedPartyMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ConsultantsMember" xlink:label="loc_relm_ConsultantsMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_8" xlink:to="loc_relm_ConsultantsMember_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FounderWarrantsMember" xlink:label="loc_relm_FounderWarrantsMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_8" xlink:to="loc_relm_FounderWarrantsMember_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_12" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_12" xlink:to="loc_dei_EntityDomain_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_MedeorIncMember" xlink:label="loc_relm_MedeorIncMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_13" xlink:to="loc_relm_MedeorIncMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_WonpungMember" xlink:label="loc_relm_WonpungMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_13" xlink:to="loc_relm_WonpungMember_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfSharesOfCommonStockToSettleLoanFromTheFounder" xlink:label="loc_relm_IssuanceOfSharesOfCommonStockToSettleLoanFromTheFounder_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_relm_IssuanceOfSharesOfCommonStockToSettleLoanFromTheFounder_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromLoanOriginations1" xlink:label="loc_us-gaap_ProceedsFromLoanOriginations1_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_ProceedsFromLoanOriginations1_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ForgivenessOfInterestExpenseOnLoan" xlink:label="loc_relm_ForgivenessOfInterestExpenseOnLoan_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_relm_ForgivenessOfInterestExpenseOnLoan_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ObligationDueToRelatedParty" xlink:label="loc_relm_ObligationDueToRelatedParty_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_relm_ObligationDueToRelatedParty_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="loc_us-gaap_InterestExpenseRelatedParty_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_InterestExpenseRelatedParty_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_22" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockToPurchaseCommonStock" xlink:label="loc_relm_IssuanceOfCommonStockToPurchaseCommonStock_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_relm_IssuanceOfCommonStockToPurchaseCommonStock_23" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_WarrantToPurchaseOfCommonStock" xlink:label="loc_relm_WarrantToPurchaseOfCommonStock_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_relm_WarrantToPurchaseOfCommonStock_24" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_25" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesNoncurrent_26" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_27" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DividendsShareBasedCompensation" xlink:label="loc_us-gaap_DividendsShareBasedCompensation_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_DividendsShareBasedCompensation_28" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_29" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfCommonStockInConnectionWithAcquistionOfLicienseAgreement" xlink:label="loc_relm_IssuanceOfCommonStockInConnectionWithAcquistionOfLicienseAgreement_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_relm_IssuanceOfCommonStockInConnectionWithAcquistionOfLicienseAgreement_30" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_31" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_32" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross_33" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_34" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_35" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_36" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_37" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants" xlink:label="loc_relm_StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_relm_StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants_38" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants" xlink:label="loc_relm_StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_relm_StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants_39" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_40" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_41"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_41" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_42"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_42" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/StockholdersEquityDetailsTextual2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_us-gaap_WarrantMember_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FounderWarrantsMember" xlink:label="loc_relm_FounderWarrantsMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_relm_FounderWarrantsMember_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_OfficerOptionsMember" xlink:label="loc_relm_OfficerOptionsMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_relm_OfficerOptionsMember_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ConsultantOptionsMember" xlink:label="loc_relm_ConsultantOptionsMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7" xlink:to="loc_relm_ConsultantOptionsMember_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_13" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SeriesAPreferredStockOfferingsMember" xlink:label="loc_relm_SeriesAPreferredStockOfferingsMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_14" xlink:to="loc_relm_SeriesAPreferredStockOfferingsMember_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_DebtOfferingsMember" xlink:label="loc_relm_DebtOfferingsMember_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_14" xlink:to="loc_relm_DebtOfferingsMember_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_StrategicAdvisorAgreementMember" xlink:label="loc_relm_StrategicAdvisorAgreementMember_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_14" xlink:to="loc_relm_StrategicAdvisorAgreementMember_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_18" xlink:to="loc_us-gaap_RelatedPartyDomain_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_DebtHoldersMember" xlink:label="loc_relm_DebtHoldersMember_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_19" xlink:to="loc_relm_DebtHoldersMember_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_InvestorsMember" xlink:label="loc_relm_InvestorsMember_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_19" xlink:to="loc_relm_InvestorsMember_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PlacementAgentMember" xlink:label="loc_relm_PlacementAgentMember_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_19" xlink:to="loc_relm_PlacementAgentMember_22" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ConsultantsMember" xlink:label="loc_relm_ConsultantsMember_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_19" xlink:to="loc_relm_ConsultantsMember_23" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_24" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_24" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="loc_us-gaap_BoardOfDirectorsChairmanMember_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_25" xlink:to="loc_us-gaap_BoardOfDirectorsChairmanMember_26" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ChiefExecutiveOfficerMember" xlink:label="loc_us-gaap_ChiefExecutiveOfficerMember_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_25" xlink:to="loc_us-gaap_ChiefExecutiveOfficerMember_27" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_dei_LegalEntityAxis_28" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_28" xlink:to="loc_dei_EntityDomain_29" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_MedeorIncMember" xlink:label="loc_relm_MedeorIncMember_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_29" xlink:to="loc_relm_MedeorIncMember_30" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_32" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_NumberOfSharesAvailableForFutureGrantsUnderStockOptionPlan" xlink:label="loc_relm_NumberOfSharesAvailableForFutureGrantsUnderStockOptionPlan_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31" xlink:to="loc_relm_NumberOfSharesAvailableForFutureGrantsUnderStockOptionPlan_33" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_StockOptionsPlanStockOptionsExercisablePeriod" xlink:label="loc_relm_StockOptionsPlanStockOptionsExercisablePeriod_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31" xlink:to="loc_relm_StockOptionsPlanStockOptionsExercisablePeriod_34" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_StockOptionsExercisablePeriodDescription" xlink:label="loc_relm_StockOptionsExercisablePeriodDescription_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31" xlink:to="loc_relm_StockOptionsExercisablePeriodDescription_35" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_OptionsToPurchaseOfcommonStock" xlink:label="loc_relm_OptionsToPurchaseOfcommonStock_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31" xlink:to="loc_relm_OptionsToPurchaseOfcommonStock_36" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_StockOptionsContractualTerm" xlink:label="loc_relm_StockOptionsContractualTerm_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31" xlink:to="loc_relm_StockOptionsContractualTerm_37" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_OptionsVestPercentage" xlink:label="loc_relm_OptionsVestPercentage_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31" xlink:to="loc_relm_OptionsVestPercentage_38" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_RemainingOptionsVestPercentage" xlink:label="loc_relm_RemainingOptionsVestPercentage_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31" xlink:to="loc_relm_RemainingOptionsVestPercentage_39" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_RemainingOptionsVestPeriodDescription" xlink:label="loc_relm_RemainingOptionsVestPeriodDescription_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31" xlink:to="loc_relm_RemainingOptionsVestPeriodDescription_40" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FairValueOfOptionsOnGrantDate" xlink:label="loc_relm_FairValueOfOptionsOnGrantDate_41"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31" xlink:to="loc_relm_FairValueOfOptionsOnGrantDate_41" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_42"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_42" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_43"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_43" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_44"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_44" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_45"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_45" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_46"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_46" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_47"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_47" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_WarrantsContractualTerm" xlink:label="loc_relm_WarrantsContractualTerm_48"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31" xlink:to="loc_relm_WarrantsContractualTerm_48" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_WarrantToPurchaseOfCommonStock" xlink:label="loc_relm_WarrantToPurchaseOfCommonStock_49"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31" xlink:to="loc_relm_WarrantToPurchaseOfCommonStock_49" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_UnvestedWarrantsToPurchaseCommonStock" xlink:label="loc_relm_UnvestedWarrantsToPurchaseCommonStock_50"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31" xlink:to="loc_relm_UnvestedWarrantsToPurchaseCommonStock_50" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_FairValueOfWarrantsIssued" xlink:label="loc_relm_FairValueOfWarrantsIssued_51"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31" xlink:to="loc_relm_FairValueOfWarrantsIssued_51" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_52"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_52" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_53"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_53" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_54"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_54" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_NumberOfSharesIncreasedByShareholders" xlink:label="loc_relm_NumberOfSharesIncreasedByShareholders_55"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31" xlink:to="loc_relm_NumberOfSharesIncreasedByShareholders_55" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/RelatedPartyTransactionsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PlacementAgentThreeMember" xlink:label="loc_relm_PlacementAgentThreeMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_relm_PlacementAgentThreeMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_6" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SeriesAPreferredStockOneMember" xlink:label="loc_relm_SeriesAPreferredStockOneMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_6" xlink:to="loc_relm_SeriesAPreferredStockOneMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SubordinatedPromissoryNoteOfferingMember" xlink:label="loc_relm_SubordinatedPromissoryNoteOfferingMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_6" xlink:to="loc_relm_SubordinatedPromissoryNoteOfferingMember_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SubordinatedPromissoryNoteOfferingOneMember" xlink:label="loc_relm_SubordinatedPromissoryNoteOfferingOneMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_6" xlink:to="loc_relm_SubordinatedPromissoryNoteOfferingOneMember_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AcquisitionOfMedeorMember" xlink:label="loc_relm_AcquisitionOfMedeorMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_6" xlink:to="loc_relm_AcquisitionOfMedeorMember_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_MayAndJune2014OfferingMember" xlink:label="loc_relm_MayAndJune2014OfferingMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_6" xlink:to="loc_relm_MayAndJune2014OfferingMember_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_13" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_13" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ClassOfWarrantOrRightsExpiration" xlink:label="loc_relm_ClassOfWarrantOrRightsExpiration_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_13" xlink:to="loc_relm_ClassOfWarrantOrRightsExpiration_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/RelatedPartyTransactionsDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PlacementAgentThreeMember" xlink:label="loc_relm_PlacementAgentThreeMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_relm_PlacementAgentThreeMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_AdvisoryFirmMember" xlink:label="loc_relm_AdvisoryFirmMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_relm_AdvisoryFirmMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_SingleActivePharmaceuticalIngredientMember" xlink:label="loc_relm_SingleActivePharmaceuticalIngredientMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7" xlink:to="loc_relm_SingleActivePharmaceuticalIngredientMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ActivePharmaceuticalIngredientsMember" xlink:label="loc_relm_ActivePharmaceuticalIngredientsMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7" xlink:to="loc_relm_ActivePharmaceuticalIngredientsMember_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_MedeorMember" xlink:label="loc_relm_MedeorMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7" xlink:to="loc_relm_MedeorMember_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_11" xlink:to="loc_us-gaap_EquityComponentDomain_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_12" xlink:to="loc_us-gaap_CommonStockMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_14" xlink:to="loc_us-gaap_ClassOfStockDomain_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_15" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_dei_LegalEntityAxis_17" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_17" xlink:to="loc_dei_EntityDomain_18" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_WonpungMember" xlink:label="loc_relm_WonpungMember_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_18" xlink:to="loc_relm_WonpungMember_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_20" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_20" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_21" xlink:to="loc_us-gaap_SubsequentEventMember_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_23" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProfessionalFees" xlink:label="loc_us-gaap_ProfessionalFees_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23" xlink:to="loc_us-gaap_ProfessionalFees_24" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_PercentageOfVestedWarrantsToPurchaseCommonStock" xlink:label="loc_relm_PercentageOfVestedWarrantsToPurchaseCommonStock_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23" xlink:to="loc_relm_PercentageOfVestedWarrantsToPurchaseCommonStock_25" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentWarrantsExercisePrice" xlink:label="loc_invest_InvestmentWarrantsExercisePrice_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23" xlink:to="loc_invest_InvestmentWarrantsExercisePrice_26" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfWarrantsToPurchaseCommonStock" xlink:label="loc_relm_IssuanceOfWarrantsToPurchaseCommonStock_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23" xlink:to="loc_relm_IssuanceOfWarrantsToPurchaseCommonStock_27" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_IssuanceOfWarrantsToPurchaseCommonStockDescription" xlink:label="loc_relm_IssuanceOfWarrantsToPurchaseCommonStockDescription_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23" xlink:to="loc_relm_IssuanceOfWarrantsToPurchaseCommonStockDescription_28" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_TermOfWarrants" xlink:label="loc_relm_TermOfWarrants_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23" xlink:to="loc_relm_TermOfWarrants_29" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ReimbursementExpenses" xlink:label="loc_relm_ReimbursementExpenses_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23" xlink:to="loc_relm_ReimbursementExpenses_30" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_31" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_32" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_33" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_34" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_35"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_35" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_36"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_36" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSubordinatedLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSubordinatedLongTermDebt_37"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSubordinatedLongTermDebt_37" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_38"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23" xlink:to="loc_us-gaap_RestructuringCharges_38" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDescriptionOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction_39"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23" xlink:to="loc_us-gaap_RelatedPartyTransactionDescriptionOfTransaction_39" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_40"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_40" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_InvestorOfferingPriceDescription" xlink:label="loc_relm_InvestorOfferingPriceDescription_41"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23" xlink:to="loc_relm_InvestorOfferingPriceDescription_41" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_NumberOfEngagementAgreement" xlink:label="loc_relm_NumberOfEngagementAgreement_42"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23" xlink:to="loc_relm_NumberOfEngagementAgreement_42" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_ActivationFees" xlink:label="loc_relm_ActivationFees_43"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23" xlink:to="loc_relm_ActivationFees_43" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription_44"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription_44" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_RoyaltyPaymentsDescription" xlink:label="loc_relm_RoyaltyPaymentsDescription_45"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23" xlink:to="loc_relm_RoyaltyPaymentsDescription_45" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_RoyaltyReceivedByLicenseeDescription" xlink:label="loc_relm_RoyaltyReceivedByLicenseeDescription_46"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_23" xlink:to="loc_relm_RoyaltyReceivedByLicenseeDescription_46" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/IncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/IncomeTaxesDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_1" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/IncomeTaxesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_3" xlink:to="loc_us-gaap_ResearchMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5" xlink:to="loc_us-gaap_OperatingLossCarryforwards_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="loc_us-gaap_TaxCreditCarryforwardExpirationDate_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5" xlink:to="loc_us-gaap_TaxCreditCarryforwardExpirationDate_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5" xlink:to="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_5" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/CommitmentsandContingenciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/CommitmentsAndContingenciesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3" xlink:to="loc_us-gaap_LicensingAgreementsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="loc_us-gaap_LeaseAgreementsMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3" xlink:to="loc_us-gaap_LeaseAgreementsMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_LegalMember" xlink:label="loc_relm_LegalMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_3" xlink:to="loc_relm_LegalMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_us-gaap_RangeAxis_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_7" xlink:to="loc_us-gaap_RangeMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_8" xlink:to="loc_us-gaap_MinimumMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_8" xlink:to="loc_us-gaap_MaximumMember_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_11" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_MedeorMember" xlink:label="loc_relm_MedeorMember_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_12" xlink:to="loc_relm_MedeorMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_14" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_NumberOfLicensedProducts" xlink:label="loc_relm_NumberOfLicensedProducts_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_14" xlink:to="loc_relm_NumberOfLicensedProducts_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_LicenseExpiryTerm" xlink:label="loc_relm_LicenseExpiryTerm_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_14" xlink:to="loc_relm_LicenseExpiryTerm_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_14" xlink:to="loc_us-gaap_LeaseAndRentalExpense_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_DoubtfulExpense" xlink:label="loc_relm_DoubtfulExpense_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_14" xlink:to="loc_relm_DoubtfulExpense_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CancellationOfWarrantsToPurchaseCommonStock" xlink:label="loc_relm_CancellationOfWarrantsToPurchaseCommonStock_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_14" xlink:to="loc_relm_CancellationOfWarrantsToPurchaseCommonStock_20" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_CommonStockSharesExchange" xlink:label="loc_relm_CommonStockSharesExchange_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_14" xlink:to="loc_relm_CommonStockSharesExchange_21" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_RoyaltiesDescription" xlink:label="loc_relm_RoyaltiesDescription_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_14" xlink:to="loc_relm_RoyaltiesDescription_22" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_14" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_23" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_RoyaltyPaymentsDescription" xlink:label="loc_relm_RoyaltyPaymentsDescription_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_14" xlink:to="loc_relm_RoyaltyPaymentsDescription_24" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_RoyaltyReceivedByLicenseeDescription" xlink:label="loc_relm_RoyaltyReceivedByLicenseeDescription_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_14" xlink:to="loc_relm_RoyaltyReceivedByLicenseeDescription_25" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.relmada.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="relm-20140630.xsd#relm_UpfrontCashFee" xlink:label="loc_relm_UpfrontCashFee_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5" xlink:to="loc_relm_UpfrontCashFee_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_us-gaap_SubsequentEventDescription_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5" xlink:to="loc_us-gaap_SubsequentEventDescription_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.gif
M1TE&.#EAW@`R`/<``/______S/__F?__9O__,___`/_,___,S/_,F?_,9O_,
M,__,`/^9__^9S/^9F?^99O^9,_^9`/]F__]FS/]FF?]F9O]F,_]F`/\S__\S
MS/\SF?\S9O\S,_\S`/\`__\`S/\`F?\`9O\`,_\``,S__\S_S,S_F<S_9LS_
M,\S_`,S,_\S,S,S,F<S,9LS,,\S,`,R9_\R9S,R9F<R99LR9,\R9`,QF_\QF
MS,QFF<QF9LQF,\QF`,PS_\PSS,PSF<PS9LPS,\PS`,P`_\P`S,P`F<P`9LP`
M,\P``)G__YG_S)G_F9G_9IG_,YG_`)G,_YG,S)G,F9G,9IG,,YG,`)F9_YF9
MS)F9F9F99IF9,YF9`)EF_YEFS)EFF9EF9IEF,YEF`)DS_YDSS)DSF9DS9IDS
M,YDS`)D`_YD`S)D`F9D`9ID`,YD``&;__V;_S&;_F6;_9F;_,V;_`&;,_V;,
MS&;,F6;,9F;,,V;,`&:9_V:9S&:9F6:99F:9,V:9`&9F_V9FS&9FF69F9F9F
M,V9F`&8S_V8SS&8SF68S9F8S,V8S`&8`_V8`S&8`F68`9F8`,V8``#/__S/_
MS#/_F3/_9C/_,S/_`#/,_S/,S#/,F3/,9C/,,S/,`#.9_S.9S#.9F3.99C.9
M,S.9`#-F_S-FS#-FF3-F9C-F,S-F`#,S_S,SS#,SF3,S9C,S,S,S`#,`_S,`
MS#,`F3,`9C,`,S,```#__P#_S`#_F0#_9@#_,P#_``#,_P#,S`#,F0#,9@#,
M,P#,``"9_P"9S`"9F0"99@"9,P"9``!F_P!FS`!FF0!F9@!F,P!F```S_P`S
MS``SF0`S9@`S,P`S````_P``S```F0``9@``,P``````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````"P`````W@`R```(_P`!"!Q(L*#!@P@3*ES(L*'#
MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ;-
MFSASZMS)LZ=/BRM6X%P1R(K'%5:26A'ZDV>@:X%LKF!%-1!3C%:H:KW&BJO5
MID2-T@P4B%54FEG%,CS+<&K1JP"0EF7+TRQ<F$177%,;TPK=A4\=$E5(E!5?
MG&1K#K9R;2RKAT_O7LSZV&76Q@>[VDP*P.S,LI(1,CZ<<2IFED4K%WQ*&F94
MQJ%7>A:\-R39V"(')UY=N^97JC+]0C0\DC7*HG&OW=6+NR5GYC%W.YP]4J_J
MD9P[_P70&^U9T*ZW*_^$;5*O^(Z#!2I??7VF:N(OP0N&7WX]1.D-OP+`#X"\
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MM>]`01'H$)5QW8RP<O`QEBNJ$U$G7UH"A^;TTT+3;)56<Z;<%=3NLK@SRU19
MZF542/D%55&7(=RB?U1)9E;9-PM\<\*TP<7HI^O-_R6SBO9U';=`8?X(,*!?
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@R\5PR4N?G"J"O0SF30P(2F$:\R6U.J8RE\E,608$`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EBOBK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>May 20, 2014</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockConversionBasis', window );">Common stock conversion basis</a></td>
        <td class="text">One for one<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockConversionFeatures', window );">Common stock conversion beneficially, Description</a></td>
        <td class="text">More than 9.9<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Lenders amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 975,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Accured interest</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">566,180<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued, number of shares of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">541,430<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">541,430<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.54<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 1.00<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_WarrantToPurchaseOfCommonStock', window );">Warrant to purchase of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">619,377<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">619,377<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsShareBasedCompensation', window );">Share based compensation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,305,200<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStocksIncludingAdditionalPaidInCapital', window );">Additional paid -in capital</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,006,100<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">299,100<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ProceedsFromIssuanceOfOfferingsGross', window );">Gross proceeds</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,919,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from sale of Series A preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">3,494,428<span></span></td>
        <td class="nump">3,220,018<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_PlacementAgentExpenses', window );">Placement agent expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,516,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage of Relmada</a></td>
        <td class="nump">94.60%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Issuance of shares in exchange for ownership interest</a></td>
        <td class="nump">28,291,073<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Percentage of acquired shares</a></td>
        <td class="nump">80.90%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplit', window );">Stock split ratio description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The outstanding options and warrants were exchanged for options and warrants to purchase shares of common stock of the Company at a ratio of 10 to 1.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange', window );">Issuance of common stock and Class A preferred stock in connection with share exchange</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Preferred Class A [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange', window );">Issuance of common stock and Class A preferred stock in connection with share exchange</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,337<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares', window );">Issuance of common stock and Class A preferred stock in connection with share exchange, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,337,309<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Common Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_WarrantToPurchaseOfCommonStock', window );">Warrant to purchase of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">868,213<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">29,052<span></span></td>
        <td class="nump">56,394<span></span></td>
        <td class="nump">68,356<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ProceedsFromIssuanceOfOfferingsGross', window );">Gross proceeds</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,745,699<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange', window );">Issuance of common stock and Class A preferred stock in connection with share exchange</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,337<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares', window );">Issuance of common stock and Class A preferred stock in connection with share exchange, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,337,310<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Placement Agent [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.08<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_WarrantToPurchaseOfCommonStock', window );">Warrant to purchase of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">612,422<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsShareBasedCompensation', window );">Share based compensation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">637,578<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ProceedsFromIssuanceOfOfferingsGross', window );">Gross proceeds</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">22,229,300<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Investors [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from sale of Series A preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,745,700<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series A Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Number of shares converted to common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,360,413<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Preferred stock, liquidation preference, Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,883,300<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Series A preferred stock oustanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,879,128<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 0.08<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_WarrantToPurchaseOfCommonStock', window );">Warrant to purchase of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,275,156<span></span></td>
        <td class="nump">1,224,844<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,725,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,275,156<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsShareBasedCompensation', window );">Share based compensation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,305,200<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStocksIncludingAdditionalPaidInCapital', window );">Additional paid -in capital</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,006,100<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">299,100<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ProceedsFromIssuanceOfOfferingsGross', window );">Gross proceeds</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 4,080,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfSeriesAPreferredStockSharesToPurchaseCommonStock', window );">Issuance of Series A preferred stock shares to purchase common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,100,625<span></span></td>
        <td class="nump">4,899,375<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series A warrants [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued, number of shares of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">17,163,799<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.50<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series B warrants [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued, number of shares of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,581,894<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2.25<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ClassOfWarrantOrRightsRedemptionTerms', window );">Warrants redemption terms</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text"><div>The Company may call the Series B warrant for redemption upon written notice to all investors of the May and June 2014 units &#160;(&#8220;investors&#8221;) at any time if the closing price of the common stock exceeds $3.75 per share for twenty (20) consecutive trading days provided that there an effective registration statement.&#160;In sixty days (60) business days following the date the redemption notice &#8220;Exercise Period&#8221; that is sent to the investors, each may choose to exercise their Series B warrant or a portion of their Series B warrant, by paying the exercise price of $2.25 per share. <font style="color: #1f497d;">&#160;</font>Any warrants not exercised on the last day of the Exercise Period, will be redeemed by the Company at $0.001 per share.</div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_PercentageOfSolicitationFeeOnWarrantsExercised', window );">Percentage of solicitation fee on warrants exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Agent warrants [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued, number of shares of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,290,950<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.50<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_ClassOfWarrantOrRightsRedemptionTerms">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Class of warrant or rights redemption terms.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_ClassOfWarrantOrRightsRedemptionTerms</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance Of Common Stock And Preferred Stock In Connection With Share Exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance Of Common Stock And Preferred Stock In Connection With Share Exchange Shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_IssuanceOfSeriesAPreferredStockSharesToPurchaseCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of Series A preferred stock shares to purchase common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_IssuanceOfSeriesAPreferredStockSharesToPurchaseCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_PercentageOfSolicitationFeeOnWarrantsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of solicitation fee on warrants exercised.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_PercentageOfSolicitationFeeOnWarrantsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_PlacementAgentExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Placement agent expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_PlacementAgentExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_ProceedsFromIssuanceOfOfferingsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds From Issuance Of Offerings Gross.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_ProceedsFromIssuanceOfOfferingsGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_WarrantToPurchaseOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrant to purchase of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_WarrantToPurchaseOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of equity interests issued or issuable to acquire entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConversionBasis">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Describe the conversion features of common stock if such stock is convertible. That is, shares of common stock into which another convertible security was converted, or shares of common stock into which another class of common stock was converted.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockConversionBasis</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConversionFeatures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Basis of conversion of convertible common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -Subparagraph (a),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockConversionFeatures</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStocksIncludingAdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of par value plus amounts in excess of par value or issuance value for common stock issued.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29,30(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStocksIncludingAdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConversionOfStockSharesConverted1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConversionOfStockSharesIssued1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13495-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34720828&amp;loc=SL20225862-175312<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36459792&amp;loc=SL20226008-175313<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared and applicable to holders of share-based compensation, for example, but not limited to, non-vested shares, stock options, or restricted stock units.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DividendsShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityMethodInvestmentOwnershipPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LineOfCredit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockLiquidationPreferenceValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Stock Split<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteStockSplit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E3PBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">0 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Medeor [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2007

</div>
          <div>Licensing Agreements [Member]

</div>
          <div>Drugs</div>
        </th>
        <th class="th">
          <div>May 31, 2014

</div>
          <div>Licensing Agreements [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Licensing Agreements [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2007

</div>
          <div>Licensing Agreements [Member]

</div>
          <div>Minimum [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2007

</div>
          <div>Licensing Agreements [Member]

</div>
          <div>Maximum [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Lease Agreements [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Lease Agreements [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Lease Agreements [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Legal [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Questionable expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_NumberOfLicensedProducts', window );">Number of licensed products</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_LicenseExpiryTerm', window );">Common stock shares exchange</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">15 years<span></span></td>
        <td class="text">20 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Royalties description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">67,800<span></span></td>
        <td class="nump">64,600<span></span></td>
        <td class="nump">13,300<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_DoubtfulExpense', window );">Questionable expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,500,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_CommonStockSharesExchange', window );">Common stock shares exchange</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">868,213<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_RoyaltiesDescription', window );">Royalties description</a></td>
        <td class="text">License fee of $1,500,000 and will earn royalties of up to 12% of net sales for up to two licensed products it is currently developing.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock to acquire Medeor, License agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 3,750,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_RoyaltyPaymentsDescription', window );">Royalty payments description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text"><div>(A) royalty payments up to 2% on net sales of licensed products that are not sold by sublicensee and (B) on each and every sublicense earned royalty payment received by licensee from its sublicensee on sales of license product.</div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_RoyaltyReceivedByLicenseeDescription', window );">Royalty received by licensee description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text"><div>&#160;(i) 20% of the royalties received by licensee; or (ii) up to 2% of net sales of sublicensee. The Company will also make milestone payments of up to $4 million and up to $2 million, for the first commercial sale of product in the field that has a single active pharmaceutical ingredient, and for the first commercial sale of product in the field of product that has more than one active pharmaceutical ingredient, respectively.</div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_CommonStockSharesExchange">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock shares exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_CommonStockSharesExchange</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_DoubtfulExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Doubtful expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_DoubtfulExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_LicenseExpiryTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>License expiry term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_LicenseExpiryTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_NumberOfLicensedProducts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of licensed products.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_NumberOfLicensedProducts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_RoyaltiesDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Royalties description.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_RoyaltiesDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_RoyaltyPaymentsDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of Royalty Payments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_RoyaltyPaymentsDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_RoyaltyReceivedByLicenseeDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Royalty Received by Licensee Description.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_RoyaltyReceivedByLicenseeDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LeaseAndRentalExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasedAssetsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash received from licensees for license fees during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromLicenseFeesReceived</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued pursuant to acquisitions during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueAcquisitions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0!NR'4D#`(``#@>```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F4MNVS`41><%N@>!T\*B
M^6F:%I8SZ&?8!FBZ`$9ZM@1+)$$RJ;W[4G(2%('KP(B!WHD%2^2[1QR<@>[B
M:COTQ3V%V#E;,5'.64&V=DUGUQ7[=?-M=LF*F(QM3.\L56Q'D5TMW[Y9W.P\
MQ2+OMK%B;4K^$^>Q;FDPL72>;'ZR<F$P*?\-:^Y-O3%KXG(^O^"ULXELFJ5Q
M!ELNOM#*W/6I^+K-M_<D@?K(BL_[A6-6Q8SW?5>;E$GYO6V>I<P>$LJ\<UH3
MV\['=QF#\8,)XY-_!SSL^Y&/)G0-%=<FI.]FR!A\V_/?+FQNG=N4QX<<H'2K
M55=3X^J[(9]`&7T@T\26*`U].5W+P73VD?M(_K0X\NDBS@PROM\T^$0."<*A
M0#@T",=[$(X+$(X/(!R7(!P?03C$'`4$Q:@"1:D"Q:D"1:H"Q:H"1:L"Q:L"
M1:P"Q:P2Q:P2Q:P2Q:P2Q:P2Q:P2Q:P2Q:P2Q:P2Q:P2Q:P*Q:P*Q:P*Q:P*
MQ:P*Q:P*Q:P*Q:P*Q:P*Q:P*Q:P:Q:P:Q:P:Q:P:Q:P:Q:P:Q:P:Q:P:Q:P:
MQ:SZ?YDUY5Z.^/3[>I5-8UXHAF+:]13/_#%W/_2EY-8$:GZFD!O,LP/\/?L8
M1^[WKH/S,3>=@4X_A<<J<]P]\WD0A=314YEYJ!1\2LPMZ>F!SUI)&GO8AIH#
MV7SJ?9=_````__\#`%!+`P04``8`"````"$`M54P(_4```!,`@``"P`(`E]R
M96QS+RYR96QS(*($`BB@``(`````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````````(R2ST[#,`S&[TB\
M0^3[ZFY("*&ENTQ(NR%4'L`D[A^UC:,D0/?VA`."2F/;T?;GSS];WN[F:50?
M'&(O3L.Z*$&Q,V)[UVIXK9]6#Z!B(F=I%,<:CAQA5]W>;%]XI)2;8M?[J+*+
MBQJZE/PC8C0=3Q0+\>QRI9$P4<IA:-&3&:AEW)3E/8:_'E`M/-7!:@@'>P>J
M/OH\^;*W-$UO>"_F?6*73HQ`GA,[RW;E0V8+J<_;J)I"RTF#%?.<TQ')^R)C
M`YXFVEQ/]/^V.'$B2XG02.#S/-^*<T#KZX$NGVBI^+W./.*GA.%-9/AAP<4/
M5%\```#__P,`4$L#!!0`!@`(````(0!+1T5B-P(``'T=```:``@!>&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;',@H@0!**```0``````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````"\F4]KVT`4Q.^%?@>Q]WB][ZV<I$3.)11R;=,/(*RU
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ME`B'30-A')O&01QA5W6!55W855U@55=V8BE,+,].+(\3B^TZ#KJ.8T_'P>DH
M.\\5YKEGY[F'>5[.FN>QK<?0?$UC?@427V/BXC1*"/IL$`Q;QE#%CCT:!V4C
ML\KF'<U"8`T4=@T46`.5;<@*#5G954=AU?'LJN-AU?'LJN-AU6'30)ARUNR,
MZ73(K\"G-SE_CI$%LY4"A>+8GN>@YSFVYSGH><(V&8$FHW3I0.TH>ULKW->>
M_3SEX?.4L/-28%[Z65WO'>7&PR<&-@V$80MGTHV]^&BZ_@T``/__`P!02P,$
M%``&``@````A`%\AUX?B`P``]@X```\```!X;"]W;W)K8F]O:RYX;6R4EUUO
MFTH0AN\KG?^`N#^U^;#=1'&JYJ-JI*HG.G;;R]4&UO$JL.NR2VS_^PY8QB\L
M0?&5O<"^S+SSS`!7GW=YYKV*PDBMYG[P<>Q[0B4ZE>IY[O]<?OWWD^\9RU7*
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M7EEI]^Q!'=R7FDI8N?Y`F06^5UQ*^E,\I$$5.*K<DHDZDRDGB]@-S[A*!%M4
M6PU(A"`1GB'!'CFH1*!2>_UF(`M+\53E-DROV'\;`2HQJ,2#L30JE<C"Z@14
MR/?&E,G[5.I8;CGZ,@65F@G,Z*8T4@F#UT\(B.:VL^YM%V6>\V)?1RN?E23N
MN;+L2Y+H4ED,'DOZJ2OS0UMAR/D]?\K0N`E6\:*[ZTX4\I6:ZE6P[Y(_R4Q:
M28U_PF@20>S!N+N_\O=EK;.4VI#=_RD)1]R,50L<"O^O^ID`?.0%4;PLN#(\
MJ1L<-;!F@8/A`\VP7+`EW[7#QAH%/=CEN;0'U*I&HGZP-`AI(':RGV'V#G>+
M\LF(/R41R^Y?*VXQ;IJG3=$#![;AJE.E:Z:J1IY<H)##V[`0%;\1FB*&@<-A
M"R`RE##"?*9(7^#@UP]2CPSB&#@\]O#4HX%,TK3M#+>WL:JDT!#$,W3P1+1Z
M@D`N0X?+6SU`&,,@D-30(?4X3MB=L%QF6)&P%7X/G$-SA2QLP`A;J9R)*@5Q
M$FKE<B:J%,1)"/LN=%`=9IZ".`EA%X8.M6WF>RS&W@L=6GNWLZ78V9+3:T@3
MQ133B1Q@W^@=-YP(>Y`6'?"'=7"F1-B%M#A+"&=*A*U(BXY07SN[:4VQ2)$+
MLON,.78#:R6%&--KU_MC8:V4$.+(A7@@&FRJJ%5S%^$!&6RIJ.6-`_"`P<0A
M(H@D1P[)PSKH\@R?(K'#\K`0^CQ#F&,'YH$I3@1!9C-D.798'M9I988LQP[+
MK<>!"W&,TY@6'?KZ=K?HC9%>6KQGOSMI8H27%AV5X:<2FA$COK0X2ZA5YI8O
M+L#=5ZAC:T.%8V27%A3+J)ZM]&V4\"RAC[;JIWI9JGD<'3]9K_\"``#__P,`
M4$L#!!0`!@`(````(0"OM&;<HP0``.`0```8````>&PO=V]R:W-H965T<R]S
M:&5E=#0N>&ULE)A=;ZLX$(;O5]K_@+@O8!MLB)(<%5!WC[1'6JWVXYH2)T$%
M'`%MVG^_8TP`.Z<)5:4F@8?A?6?&3)SUM_>JM-YXTQ:BWMC(\6R+U[G8%?5A
M8__S]]-#:%MME]6[K!0UW]@?O+6_;7_]97T6S4M[Y+RS($+=;NQCUYU6KMOF
M1UYEK2-.O(8S>]%460<?FX/;GAJ>[?J+JM+%GD?=*BMJ6T58-4MBB/V^R'DJ
M\M>*UYT*TO`RZT!_>RQ.[25:E2\)5V7-R^OI(1?5"4(\%V71??1!;:O*5]\/
MM6BRYQ)\OR,_RR^Q^P]7X:LB;T0K]IT#X5PE]-ISY$8N1-JN=P4XD&FW&K[?
MV(]HE2)FN]MUGZ!_"WYN9^^M]BC.OS7%[H^BYI!MJ).LP+,0+Q+]OI.'X&+W
MZNJGO@)_-M:.[[/7LOM+G'_GQ>'80;D#<"2-K78?*6]SR"B$<7`@(^6B!`'P
MWZH*V1J0D>R]?ST7N^ZXL0EU`N81!+CUS-ONJ9`A;2M_;3M1_:<@-(120?`0
M!%Z'("AP?!RP\"M1R!`%7B]1\)>E^$,0>)V"X#!``;UOR%7)Z7.=9EVV73?B
M;$$#@_WVE,GE@%80^9)DE9(Q[9]E'=(M@SS**!N;VA8DM(56>=L&T=I]@^KF
M`Q(K!/Z/"-*)Y#H(]70DO2"R;\#`Z`+*,W?Q\Q:YB)6P%"M;1JJ/U8&Y-*S?
M-[DF$-.1]!JADT%-+'3!<K$2ALZ=I8T:XF*%0/'&S/JZMN0ND=XB-/%PF^7B
M);RQ(3.C,DIT:;%"YN*QX2^YCZ0W$4T_+/WE^B5L)-](;:R0N7Z#2.X2Z2U"
M$P\+;+EX"1O)#XSD*R3L%^Q#2*+(7+6)1@38#RDU%G:J(90RGTT9T-2SKZB7
ML*&>&NH5,JA'&'DTO-*O,P&&/W/A:@@XC#"9\J09D-\L9L_*VT\9"1L&C#O'
M"AD-1#X-4:B;3#2&,D8B;.0AU1`"XX!Y4XTT`]%7#$C8,&"(BQ5RVX#&_-R`
MAMPT@.!;Q/(2]+2Q?J?,J&?_P-Q:P/>1]":BE0#)$39K(CEP";BZW4S]57HQ
MF#$;XX$9JL&BP(],)M$9A$/&*)NZO4])JD.$AB$)IL>V[D9.O9F;.R[4C)S/
M`S;-R*$>BE$ND(^,\PE2Y^?U,@=&.C!##,P^52^GWG+U:D9JZHU1%2/%##7P
M24"O#6@(QA[QC.="JD?!C.$I"WKZY=Q;;D#21A--=1W2KYC!0$C""%TWD<8@
MXD4L"HU,I$B#"'SM)I^ZD/-ON0LU+;4R3`-G<*$8I@8;1H0$46@\O!*YEX!T
M#!"*0H8BSX!2':(A]:!>XR-:+X8<A#,;"U>V&I^:'6-!QD@QD;*#'&94+=&!
MT#&G2*H#Q)E]>]4]R&'X=0]JA&H>C"$5PTY19ONR)J$;")FZNB];HC'8QS#J
MKI;&/`Q&E/K15#)E16THU2:GXLV!)[PL6RL7KW*SB"&)X]%Q(_N(Y6[`.)[(
M#:X\[HXG8']YR@[\1]8<BKJU2KZ'D)[#H)4:M4-5'SIQZK=6SZ*#G67_]@B_
M)'#8;7@.P'LANLL'>8/QMXGM_P```/__`P!02P,$%``&``@````A`#T!M=-G
M!```@1$``!D```!X;"]W;W)K<VAE971S+W-H965T,S@N>&ULE%A=CZI($'W?
M9/\#X7V`5KXTZLUHW]F]R=UDL]F/9\16R0!M:&:<^?=;1?/5C2+C`PI]^G!.
M51=%N_KVD:7&.RM$PO.U22S'-%@>\T.2G];F/W^_/(6F(<HH/T0IS]G:_&3"
M_+;Y]9?5E1>OXLQ8:0!#+M;FN2PO2]L6\9EED;#XA>4P<N1%%I5P6IQL<2E8
M=*@F9:D]<QS?SJ(D-R7#LIC"P8_')&:4QV\9RTM)4K`T*D&_."<7T;!E\12Z
M+"I>WRY/,<\N0+%/TJ3\K$A-(XN7/TXY+Z)]"KX_B!O%#7=U,J#/DKC@@A]+
M"^AL*73H>6$O;&#:K`X).,"P&P4[KLUGLJ0D-.W-J@K0OPF[BMYO0YSY];<B
M.?Q,<@;1ACQA!O:<OR+TQP$OP61[,/NERL"?A7%@Q^@M+?_BU]]9<CJ7D&X/
M'*&QY>&3,A%#1('&FGG(%/,4!,#1R!)<&A"1Z*/ZOB:'\KPVY[[E!<Z<`-S8
M,U&^)$AI&O&;*'GVGP21FDJ2S&H2^*Y)B&>Y,R\(O\(RKUG<CF5FS4*/>/YC
M+;;T586)1F6T617\:L#:`^7B$N%*)DM@;N(CW;01NQ<PB!22/"/+VO1-`V(A
M(,OOFR!P5O8[9":N,5N)@6.+(2IB-V3Q-1+:0##GX*"U`:'MV[B=WD8M@E$M
MIAOE;^6%OK29)FV((($*H4.(WQE4Q$(F^V(QYN[=-=F(QDFP^GKA"SQ?E;"5
M&$AC&V)71>P>(N@80G$!M^F[&`\Y@M<FA*A3YFK:MA(35,M'C[\<@V,W7W5&
M)6)1S7:L>3NJ:(8H3]>,8%5S$'09E2M'8L)0KGG+43_D^U,GI)JP4R:$UD+]
MS`<3J#+!'[V#8A6*<;I5!.M6M11L)::VZEB.-KY3QHD5J,X6WY^T"529$$QW
M%GS%&8)59ZZK5>Y68AIG[<J1"1L;I'<&E43@JT3O"3M>)PA6Y0:>+E=B&KE6
MX&F*]7%M"5)M/.SRHNA>?$4W@G7=H:IK*S&=;NWIM=/&0UWW_7%%-X&7A.D!
MK]"J<M?3J[P&C3Q^=H\A]`;$#[N'H&H"&]WD54-D6^P_7OU`7S8U:-2$Y!F!
MT%$6U0(VQ)Z%:6V.R#8ZWN=JT(C.W6,('86H5K`I]JR,US"1+;2?#7?0[&K0
MJ(6F%>/[%+&T,J>C#*I\N,L7Y"/Z845(4%^^[^H%32:`Z`W0O9K`5C@]"[)Q
M]K/@!POMD81;`?#:M]'=7#[_'T/H*$3-!/:\GH6)-2$[Y8.:D*!1*P\AE(Q!
M5"O8^WI6'M2$[)3];-RH"0D:M=!`L"8<2VLQE#3#M]X35?G8!:?+ESU3D3_L
M$A+4EQ\$6A/;P6977W$#$.Z(=5"W+*4-N>.56[F,%2>V8VDJC)B_X6YV!N^C
M[=5VI_T\PRV/=GV'.W"\;K<#L`&^1"?V1U2<DEP8*3L"I0,O&J91R"VT/"GY
MI=I`[GD)6]_JYQG^ZF"PI7(L`!\Y+YL3O$'[Y\GF?P```/__`P!02P,$%``&
M``@````A`!UP[_>A"P``)$T``!D```!X;"]W;W)K<VAE971S+W-H965T,SDN
M>&ULG)Q9;^,Z$H7?!YC_8/C]VMH7(\E%2USF`C/`8##+L]M1$J-C*[#=R_WW
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M[,]T\;W;8&%KP[MJXQ94Y6!)%I=E[>]'ZP"S\:LI99'ZC`B9Q"=D2,3(-14B
M!;)-3R!1?MV2YXKI#O-=L?#]TJA_M+'\T!WL;QQC^L>(P<41,JC$!$M(EE`L
MH2G"<\DT9^R2[5NI&0;I&K(K8;?0P6P<X[M578_4X&@;,M@MEI`LH5A"4X3G
MEAG?QF[1+ED8NX3Z5N,8L_UK32$'6D>XWEF7>12A84*P$I(E%$MHBO`L,D/:
M?(LLC"RJ4/L:QU`6.:(:!K"\*&(L(5@)R1**)31%>!:9.6QLT;P^9U?"5J'1
ML7$,994CP*HLSE+DMF`E)$LH;B.:DO"<LCEY-//3_<W"OD,9GKP;QU`..:(>
MBBE:H1%+L.M+?_T<=6?E?XSDM?O4=?:/@^M94M]BB85]2\H*3<R-8RA+'.&*
MIHCKM$1CO6`E)$LH;B.:DO`<BLW\-;]J!AI[A.)-`Q!E$B#.I3B-<G,JYD]W
M@E>1/*)X1).([Y7-E+-[6.P2J!>3*E3A#4"D5TX'O#*GK''HE4,(%<EO2/&(
M)A'?*QL^YWOEHJKO%8Z4L8.(5K:`.*^2NIZPBA61_'84CV@2\:VR^7.^52ZM
MCJU*ZX_ASZ7OF(JT+D[RB.`1R2,*$'=,S*[6)I;Y?5V3*KY7YNB/O9H7!V*[
M%AZVT-E(`Q!97DZ'0,2$2H(F$0D,.)+569:@N4WY2&*&QQ@A>F)+'Z.+;YK-
MH_,+S*77<8&5%9K$&GO=QCA*.-'RB``$C,CC(@CLDE=1/*))Q/?*!M/Y7KD8
M._8JK]&!:F('5:Z9T:K.\GK\@\:Y%GC"6\$CDD<4CV@2\8VS.75DW,R>Z=*M
M;R`^[XO'&3FI$C.LERATM,"0IE%)>A@4):^B>$23B&^:S;`CT^C,'KO$.S;+
M]!A_+&T`NE9;%=6F5WW\!-7F1$GC6$3"5@D5Q2.:1'SC;,`=&6>KK31C$F.@
MB\6^@<'<265GF#M91,0A4D3!1!!"'T/XL"DUH8,032*>:PD*^]:UC'5M6,N?
M/>,8];\&(*(`6AX1@+B1TDQZ]L>O;\FK*![1).)[=E/H3\+07T2!5VQ<;T&'
ML%/PB.01Q2.:1'RO3,_"O9*_0)K8M?SZJO$4``SA1\LC@D?D!(+SFYI@<)\D
M$=\SE/YG]LGP+&"B3_)G`0F+"$`@I*7XZQO)2R@>T23B&V:*`!?9C$',KN47
M61RCH]8D#B*KC$4$J'P8ED:HG"6_(<4CFD1\SVQ<'TV7]#1IOWU$7N&KQ`TP
MI%5.AD`$KR)Y1/&()A'?JIM.`)+P!""\C@H0840+R,^NI/(*DD<4CV@2\7U"
M>9\IJ3#GAQ=7$S:@MX"XOE4558*#B.!%)(\H'M$DXEN%4OZ\4Z,D3/OAM,@F
M\Q9DB.(3@$#JJLW56)RYW&8<D!=IC09.Y2D459JCBRN:W`O?+)N)YP]5+D&/
M$WUX-2QA8W;+(P(0<"DOL[S`QT/R,HI'-(EX9MEP-39K7G@8UL)S(0ZI`!%U
MT_*(`,29EH;A@9=0/*))Q#<,I?F9AH6I/@P/*9_J>40`\F%8&N,S(%Y%\8@F
M$=\SE.KID3X-TWR!QXL&(+*XG`Z!"%Y%\HCB$4TBOE<HS3->A2D^3`\I&]%;
M'A$\(GE$`?(>4R)TJ5.3$KY1YL".1R[&*$O[(U88'U('$173\HC@$<DC"A#7
MC8LXR?!)I"9%?*MN"N]I&-[+*AC<V6C>@@[AIN`1"0CXD);F/DL_6RA>1).(
M;]5-X3T-PWL8'@`B?&AY1`#B?$C,3YT&5[9X&<4CFD1\LVY*\.E4@D<'LP&(
M-(L-^8)7D3RB>$23B._5+T7X-(SP986B<0,0Z1D;\P6H0('9=%J&!<;**'YG
M-(GXIMT4Y=,PRF?!N,4G>9`A[!0\(GE$\8@F$<^J;"+(VU1+3XO#6GA:1->:
M&H`(0UH>$8"X^HK3(LKPF;?D512/:!+Q/9O(\C,\"[-\6:.(W61\EN<1P2,2
M$+`UJJHTF!<4+Z-)Q#?MIC"?A6&^#&XV`8@L,*<#S:R,!K[C0?`JDD<4CV@2
M\;VZ*<QG<\(\0*17;-X7H/(>P]$L+.F/%?HX"/'D/OH&F7;,#_&9I?%HA2XU
M-0"1!CD=`A&\B@0$2C(I[6,W*)HB),FJ#%WXTN2&?*]0BI]W$=!^L8$\PQ>=
M&F`(/UI`H+%E,G%G/*\B?95IR]@3"TUNR+?LIC2?A6D^//$!B/3*Z8!7D_>F
M\BJ21Q2/:!+QO;HIS&=381[5=@,0Z973`:\F[TWE522/*![1).)[A<(\$[*F
M0CRZBZ;)V&C=`N*\FKPWE1>1/*)X1).(;]5-$3X+(WQX0@T0659LS!>@`@_B
M1544W%4J^0TI'M$DXGF5_U*&']9"LV*-9T6`*,]X1/"(!,05:6YNGS:/HJ)9
MT4.RJC:/."!$DQOR/4,9GNZ*^51VQ^>(`)%>L?%>\"J21Q2/:!+QO4+1?5Z"
MR"<B?(7O>0.(],SI$(@`%9@-RM@\ZHO#BN2WI'A$DXAOVDT9/I^3X0$BG&AY
M1`#B,GR\0EU(\@J*1S2)^#Z9YLR/\KFE\:"%\P-`I$].AT`$KR)Y1/&()A'?
MJU^*\GD8Y<U+!_S!M0&(,*3E$0&(ZXA57L45_@9.\BJ*1S2)^)[=E.7S,,N'
M7XP!1'KE=`A$@(KKA^;]"T%'9"44OR.:1'RC;@KRN0O@]F&CZT/198W:T`!E
MOQJX4JBWMC,8`0QAIYPAHV8PFF9\QU"<=_,B>_$T=Y'=6'=]NP,L,CZ]+VK#
M10(6C5TH\;.S,EQ/A8NTM\AO%`K>,R?[,("7-7YV)V?3=<LC`I#K<P:C-TNX
M9REX#<4CFD0\QPH4O^DH.=!X!D,7TAJ`QD<:=QL>$3PB>43QB"81WRL4N^=5
M5S$1OX,9#"#2,SY^@XJ;P;*DCLQ3@_Y4*?D-*1[1).)[AN(W4U]A[`YG,/.V
M)1NC2*]81(#*SY(DOQ'%(_;%4#_?5>>3>_&3>QG1H3L]=VWW^GI>[/JO]J5.
M]E!>E[H73IE!?F.'0#/8HD_,JZ@^#>,R6B[CC1K>YX26?S)*GR:5S-RW:28_
M,3/>Q@[OX=;-)+:Q`WCXB9FZ-G8<-Y^LK[M@WE'UMGWN_K$]/>^/Y\5K]V2:
M&ZWLXT@G]Y8K]\>E?QM>S_2YOYBW4PV_OIBWD77F;471RL!/?7]Y_\-NX/I^
MLX?_`P``__\#`%!+`P04``8`"````"$`&N_GV"D,```,6P``&0```'AL+W=O
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M_;?47ZZJV*<_:N&WF]5^=]@]'^]8N`[?T?IG'G?&'1;I\?YIPSY!4>VM_?KY
MH?V'-,GE0;OS>'^JH'2S_GVX^'_K\+K[;>PW3\[F?<UJFQVGX@C\W.W^+*CU
M5!2QE3NUM?73$?#WK:?U\_+7VS'<_3;7FY?7(SO<`_:)B@\V>?I'71]6K$99
MF#N^&ZO=&]L!]K.UW11-@]7(\N_3[]^;I^/K0[NGW`V&W9[$>.OG^G#4-T7(
M=FOUZW#<;3..I&*GSD'D,@C[70:1!G=]>3`<?25*KXS"?E=16,`;=Z%?KLQ^
MGU>^D_I=Y0L?@WW@4UVPWU6,;WP,I8S",JR*(M_)HX$T^,J^C,LHTF>=RM+7
MZU2J*E4:GG='[G^U8B3V67@KN?A0HR]'J3Z3_'F0;F]L'=YP3WF@+H_+Q_O]
M[G>+G5Q8TSQ\+(M3E30I(E<9P-OK.2?^+258,RZB_%&$>6BS@\=:^X'E\5^/
MP_'XOO,7R[U5::;<L)]G,Q@KHIG5XRB]H6C4RA0Y5&Q<JP>6Q%7T:I7/32M=
MD1@5J:*:5=2JP*H*/H.0S=A5C$]!-S.O2!75J:)6!6Y5<!&$5L&B;LBN>-5V
M+J*03^Q7I-IR4!5<K$.W'%:F6BFJ"CY7JAW5N#+52@DM2'D!^WEN&^0#9=4J
MGX+6;5X1MID.:][G-LY.`D(;OWYVKYIRH8NF7.WLE!>,NZ=FW9>&0]*P9]4:
MG[LVZI+*5NMFJ/3$)JC5C2P*O2XDDAU&G2BD*LTKI#L0MV1Q<WE`R+[8=4'W
M95XG=%^<.AEUR9;<NJG5W:)N2!2O+NC^^G5"]S>HD]J^A#>8J&Y&]!C$UPPY
MW,DU,Q*/95HWI&ZRNJ!UD]?)1=T(Z<8NFD*Z%9>4'NN:-:==L9:0=KR`I5V5
MB#-*5%J@T0*=%ABTP*0%%B^X;/FC+LD@^P8SO\$X-QCWFA$/\`(3#Q,?DP"3
M\!KIB_L;73.D)Q#?8)(;3'J#R6XP>;,1$H!UHX0$:&[XA18:/B^X;/B4J+1`
MHP4Z+3!H@4D++%[`[TV*?I5-"^:TP*$%+BU8T`*/%OBT(*@*+B^GY%(95J8Z
M-T2T(*8%"2U(:4%&"_*+`N$`LUL<X0#?=H8KUGIHL_/HN8\SZI*NQ)0;MMVS
M(;DS@T*%0H-"A\*`PH3"@L*&8@Z%`X7+Q?#4P>L->G*?G(P6,(0'A0]%`$4(
M101%#$4"10I%!D7>)(1L8W>5W\BV8BV2;1+IE$^Y:<HV+D:GEL&>R/0'"KVM
M56$030@BR_*X1V\/=!C$@,*$PH+"AF(.A0.%"\4""@\*'XH`BA"*"(H8B@2*
M%(H,BKQ)"`G''G9](^&*M6C"D7[SE)NFA(-"A4*#0H?"@,*$PH+"AF(.A0.%
MRT5U$AL,!^0\N(`A/"A\*`(H0B@B*&(H$BA2*#(H\B8A9%LQEG3Y!+;Y;J'0
M8I8-1^1N?LI-4Y9!H7+!VXPBC7M#\N!!@R%T*`RT$1.&L"Y#L.$2>F&U+Y?+
M4FWY_')YO\O^B;>J#MP#]S+"2!G)$KE76<`0'A0^%`$4(101%#$4"10I%!D4
M>9,0LHN-FGPANPHM9E>?#E%,N6G*+BA4+L:G;F7WCCROT^#ZNKC^@-PC&N)B
M$M[D2_G=#KE`6XUKVHU+Y^+2+MFL(RXF2]W&I0N^M*'./2A\*`)Q'T@:AW#]
M"(H8B@2*%(H,BKQ)".DCL>>V0O[<]JCCM)J82&PP6SRU3DO4<%1GF*B8:)CH
MF!B8F)A8F-B8S#%Q,'%+PB_R(Z5^6[K`03Q,?$P"3$),(DQB3!),4DPR3/)&
M(J9A,;1YV4F\,0WYB.CE(T?Z^&(J<=.8A9"H.(J&B8Z)@8F)B86)C<D<$P<3
M%Y-%2<H[N'%W0$ZEG@`&2F],>@2^`)11;T"><`9X+T),(DQB3!),4DPR3/)&
M(B9@,?SYC03DHZ:7"3BB]P?3XB4EUNMLS$!(U#(*;R-2C[41>B^CX0WIF!B8
MF)A8F-B8S#%Q,'$Q66#B8>)C$F`28A)A$F.28))BDF&2-Q(Q#XMAV,L\;'Y:
M4KS`1V[H))H6TQ(UYA^/TT!4'$7#1,?$P,3$Q,+$QF2.B8.)B\D"$P\3OR3E
M=;1;>QH4"&!0:RHAWD:$28Q)@DE:DK+W/J3-.A.62\J8@EP`LE`;8LZQ9B_D
M7-'Y[+/A.Y![Q6KT'I#T2Z821PV)-<-$Q43#1,?$P,3$Q,+$QF2.B8.)B\D"
M$P\3'Y.@)&479M@=D;<C0APCPB3&),$DQ23#)&\D8A86X^5?N/+QX76QYTE>
M\IP67W5`/4](5!Q%PT3'Q,#$Q,3"Q,9DCHF#B8O)`A,/$Q^3`),0DPB3&),$
MDQ23#).\)-63^,]GOF+N%4/G7\@]/M)^F7M#^B+]5&H:CC]]KV&&B8J)5I+R
MK-H?CX?TQ7E=)-)HV.^34Z\A$(6]`Z^09Q`FWA4+$QN3.28.)BXF"TP\3/R2
ME/4_Z+&WB<D@8X"CA)A$F,28))BDF&28Y"6YJ)?/%B5F7S&4_H7LXR/OE]DW
MDLCCKFGQA2YTY8-$Q5$T3'1,#$Q,3"Q,;$SFF#B8N)@L,/$P\4O"FUE?J=W3
M!3A&B$F$28Q)@DF*289)7I)KM2+F7C'0?IE[-PX\\/%Y,0?)&R33XGN1*`<A
M47$4#1,=$P,3$Q,+$QN3.28.)BXF"TP\3/R25+VL[F<WZ]31"7"($),(DQB3
M!),4DPR3O)&(25@,UW\C"?DHOYB$Y+V+J=3T*D#9#85$Q5&TDO`SSD@9L*^W
MDV:@XR@&)B8F%B8V)G-,'$Q<3!:8>)CXF`28A)A$)>%'6JZ/5L8"*$8K27\X
M$4`Q6DE`BO<BPR1O)$(&RM][#>:T&GT$2NZLIB4JJZMX!9$^J9V5I.$IJ8J)
MAHF.B8&)B8F%B8W)'!,'$Q>3!28>)CXF`28A)A$F,28))BDF&29Y(Q'S\'OO
MP<A7WH,AIY1I:1IR;(:)BHF&B8Z)<87(G_?/IPNW><60\1<+$QN3.28.)BXF
M"TP\3/PS*>8I&?3).[#!>?&_?@DSQ"3"),8DP23%),,D;R1B#K(.Y3=ZHW*Q
MFG@M').:GY:F,0=YF`:BEE'X!55A3S,5\O1'P]O1,3$P,3&Q,+$QF6/B8.)B
MLL#$P\0O"3]$+`/[/7(Z#G"0D`9AWZL4WS".<)`8DP23%),,D[R1B#GXM==@
MY/IK,`-25]/2-"36#!,5$ZTD_&&`I/T@.Z*#Y0;>A(F)A8F-R1P3!Q,7DP4F
M'B8^)@$F(281)C$F"28I)ADF>2,1$X_EAW#Q:WX'IIA1C5ST%#H(7YK&Q.-A
M&HB*HV@EX5_\^3'JC<<#<B^JBV0@]T>*0HPA&D49]H>D5VGBG;$PL3&98^)@
MXF*RP,3#Q,<D*$DY%P7[JF[M:4"(HT28Q)@DF*289)CDC43,OZ^]!5-,7TGR
MC[[Y/BU-0W+-,%$QT4K".SW]KCSNRW26+5TTX\%H."1/;`V\)1,3"Q,;DSDF
M#B8N)@M,/$Q\3(*2E$_C3NE''\>%.$R$28Q)@DF*289),<?NOP_%\03D<^CR
MN4.WZ_W+>K9^>SNT5KM?Q?RX[#V:Q_MS,9^\-Y(F;*)'-D,3*<_8I+[7RJ?R
M9-J_XF?R9':M7)4G;"*L>GQ-GK#YL.KENCQATV+5RPUYPF;'JI>;\H1-DE4O
M9Y,2_W&M?"9-V-RD=:]+$S:[:+W<EB9L.M!ZN2=-V-R<]?)`FH2G\LZY0ME<
MQ!_+E[6[W+]LW@^MM_4S.Q;=NR$[G'L^FS'_X[C[.$WU^G-W9+,0G_[[RF:=
M7K-9OKIW##_O=L?J#[;ASGD>Z\?_`P``__\#`%!+`P04``8`"````"$`8L/J
MNGX:``"*SP``&0```'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6RDG4ESW,B2
MA.]C-O^!QOLC"=3*,DG/HO9]WV]LJB316F3)2':K^]^/9P$H`IDI>%#3AY84
M^<&QA6<@L61]^.\_C]\O_CX\OSP<GSY>!E<WEQ>'I_OCYX>GKQ\O5\OV?ZJ7
M%R^O=T^?[[X?GPX?+_\]O%S^]]/__L^'G\?G/U^^'0ZO%U!X>OEX^>WU]4?M
M^OKE_MOA\>[EZOCC\(26+\?GQ[M7_//YZ_7+C^?#W>?30H_?K\.;F_+UX]W#
MTV6D4'O6:!R_?'FX/S2/]W\]'IY>(Y'GP_>[5VS_R[>''R^)VN.]1N[Q[OG/
MOW[\Y_[X^`,2?SQ\?WC]]R1Z>?%X7^M]?3H^W_WQ'?O]3U"\NT^T3_]PY!\?
M[I^/+\<OKU>0NXXVU-WGV^O;:RA]^O#Y`7M@#OO%\^'+QTL):K(-JY?7GSZ<
MCM#ZX?#S)?7WBY=OQY^=YX?/PX>G`PXW3I0Y!7\<CW\:M/?9A+#PM;-T^W0*
MIL\7GP]?[O[Z_CH__NP>'KY^>\7Y+F&7S)[5/O_;/+S<XY!"YBHL&:7[XW=L
M`/Y_\?A@<@.'Y.Z?TY\_'SZ_?OMX62A?E2HWA0#XQ1^'E]?V@Y&\O+C_Z^7U
M^+B)H""6BD3"6`1_QB)!Z:H8EBK5]Z@48A7\F:C<JC>A&"^,/Y.%R^_?!.SR
MZ6C@ST0E?/?1*,<BE;1(6"T%I?([CBD<>MH4_!EORF^<&!R_DPC^C$7"\M6[
M-R5`5D9)8M+SM[,D..?:VQD.@_>?I"`YU\';;OW&L0F3O0I3FP-I;<XG6V'.
MZ?_CX(9)NIB__/[!#9%MIW,4OAV4,'S_N2XD1Z60,C,DE4>E<#9QZJ!6KH+B
MS7MROY`<V]+O)-QUU,6=>LSFW>O=IP_/QY\7J$/(OY<?=Z:J!36CG/254<]V
M[CU_U7FBUS0J8F0^7N)LH5]\09?_]Z=J>//A^F_TTO<Q4X\8_/_,E`N5+--P
MF2!+-%VB;*VHE2"F9S=;U[8#'3O030(YV];S,-::^Q[$WL6!RUB[.(R(],&T
M=W&4(,DNCNW`Q`Y,HT!4I,Q1F=F!N1U8V(%E%,C;LE6")%NVMD4V=F!K!W:V
MQMX.2)QP;WLCY_1*5BSG9#I'SLESCCBY(DZRR#E;4LEAG7B)$RAS9.PS+W$&
ME4_7"2?;Q`F3BL3ID8K$Z8!#\.8;>_5Q/J09*ZGDG"$Y,D[2R#EKWI:RA>,\
MRNRZO7UQ:J7VZIQ;OQ969)LXZ2;G?/NU<)R!N5L<)^5IBZ_15YX[3)2`3(?I
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MBV:I3%FT`PT[T+0#+3O0M@,=.]"-`FG?5$,K3WLN4[XM9@M>WV6J-U9M'2B8
MH8(9*9BQAPFM;9XHF*F"F2F8N8)9*)BEC[$N/E8*9JU@-@IFJV!V"F;O8ZP+
M+Q$?5,TFHM0U4.RE;-K;2K&_LM"MM;K8<_E0[,-\*/9F!BK8=<7GUX+E,_$8
MMNI`/L<ZD,^R#N3SK`/Y3%NP#"D^USJ0S[8.Y/.M`_F,ZT`^YSJ0S[H%RY;B
M\ZX#^<SK0#[W.I#/O@[D\V\*RM0UW&W+U+7\>F;H3#VS`PT[T+0#+3O0M@,=
M.]"-`F\W07I)X&UT6;VQ"EP_89(AZ<`.#.W`R`Z,[<#$#DR3P-N65*I6GS-3
M,'.7<<KQ0L$L$R;9ZY4=6">!MRVNAN5L![A1,%N7<;9XIV#V"9-LL8@3J3N1
M.,_>4D+B1$M%XDQ+1>)42T7B7$M%G&23<[:=M]#)+7&22YSL$B>]Q,DO<1),
M/!E6#>V"Y4DQ%_+DF`N=D^R\LTY*B9-3XDTJ>R.]665#GK1*;V2F[\+#ETS?
M9:[)BPCF]V%F*5R[IVXS5@M6_M<C!EEWOA5I5;4&)9J4:%&B38D.);J4Z%&B
M3XD!)8:4&%%B3(D))::4F%%B3HD%)9:46%%B38D-);:4V%%B3PD1CG#7";>=
M<-\)-YYPYPFWGG#O"3>?</<)MY]P_PDWH'`'"K>@<`\*-Z%P%PJWH7`?"C>B
M<"<*MZ+D>C%3^O!,YS=*GUGJXR7N%9_+6M5^>%>/F+S21XDF)5J4:$=$]71;
M-RS>W!;M(MVA&EU*]"C1I\2`$D-*C"@QIL2$$E-*S"@QI\2"$DM*K"BQIL2&
M$EM*["BQIX0(1[CKI,%5N.^$&T]BY^7T`,*M)]Q[PLTGW'W"[2?<?\(-*-R!
MPBTHW(/"32C<A<)M*-R'PHTHW(G"K2BY7LR4/KSLYI0^_B3&+&67/NL^33UB
M<A*_$1%142J6;POEBG77J4DU6I1H4Z)#B2XE>I3H4V)`B2$E1I084V)"B2DE
M9I284V)!B24E5I184V)#B2TE=I384T*$(]QU$MLNQYC"?2?<>,*=)]QZPKTG
MW'S"W2?<?L+])]R`PATHW(+"/2C<A,)=*-R&PGTHW(C"G2C<BI+KQ4SI,U_N
MV"\Q\])GEK)+GW7;M1XQ.0YKN$0E]:[$Z?WCILM8MTU;E&A3HD.)+B5ZE.A3
M8D")(25&E!A38D*)*25FE)A38D&))256E%A38D.)+25VE-A30H0CW'?B,9YE
M*N&^$VX\X<X3;CWAWA-N/N'N$VX_X?X3;D#A#A1N0>$>%&Y"X2X4;D/A/A1N
M1.%.%&Y%R?5BIOCA0R2G^)FO'=_Y!8^1P4=`F9N@]IN>]0@JX);+^4ZI9;I&
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MC0]/W5B2`FG.<\;%<\KQ`:JKYSGI^.34Y3RG73SG73PG7CQG7CRG'A^2NNOU
MG'Q\.NIRGM,OGO,OG@003P;@\T]W'9X<$$\22#8+LKT"WDM_3Z]@<.M.4M'Z
M[J8>1%"Z4[`OG3G2Y$B+(VV.=#C2C9'HJ4]0+-U6K=<%>URDGQ6I5DHWUE<`
M`RXRY,B((V..3#@RY<B,(W..+#BRY,B*(VN.;#BRY<B.(WN.H(^F3D.?S9F&
M@E'X$7T\7Y?"D9B&@.MD/5F`F6P[81*"2":V[<U-H5*Q.B*4C#13+I=@R^R;
M\*@@&:12N2U;/1X*2AHI%(K!K75['?4E0G)Z1=0;SBB,B7K$=1361+WB.@IS
MHIYQ'84],>$!UU$8%/4P3R=;'\UGU>D'+N2J.?H*.WMKR7I!H&[N/*&(YF1"
M@R--CK0XTN9(AR-=#^(\&NIY(,N-?0_BZ`P\D*4SY,B((V,/4BY:A7^B@:8>
MR-KD&4?F'%EP9.E!G+U:::"U![+V:L.1+4=V'-ES!-62^@[5DC,*<XK"G:B6
M?%T*?Z):<AV50U$P727'?RB9&LIG4U?+YU274I@5M=/=*BL;Q6=6FU%X511F
M1>WDVZ.P*VHGU_'9U=XOA5LQ=N3KRO=KMG::3[;?43NC+[RQ"><G+M6BM1OU
M(()R:R=%FEREQ9$V1SH<Z<9(-;I*-?-T9J\_>URCSS0&7&/(D1%'QAR9<&3*
MD1E'YAQ9<&3)D15'UAS9<&3+D1U']AQ!K:0F0JWD3$/!*-R(6LG7I?`C:B77
MH8Y$G8Q4?NE9U$A&));\M4;BR%\3"D.B+O(]5E@28TJNHS`EZB+74=@2=9'K
M*(R),27745@38\H\G6Q=1/5Z3UTTN'W/U2H2=3,K+AM34J3)55H<:7.DPY$N
M1WH<Z7-DP)$A1T8<&7-DPI$I1V8<F7-DP9$E1U8<67-DPY$M1W8<V7,$M9$:
M";61,PT%HW`D:B-?E\*3J(U<1^%*5$>ND_CR7-LJ5H>&NZZ1RJ\)A2MQUY5O
MB\*7&#ER'84S,7+D.@IOXJDAUU&X$T\5N8["GQ@Y<IU\AV8KI)DJX!TCQVAF
M`3-Z30T=K3MU=?.F($IDWOM!#0735#`M!=-6,!T%T_4QU:(UR5K/1UF#ZW[,
MX%2>#Z.%#!0R0P4S4C!C!3-1,%,%,U,P<P6S4#!+!;-2,&L%LU$P6P6S4S![
M!8/BR5V(ZJF`-%[%?5B%DL:M>%=%H:3Q*]YF\2@YAD49C;`<-V*8Z9/R/,'D
M4HEK\U:G<2T&G)YMLKH1U%,%I#$N*JI"26-=U%2%DL:\J*H*)8U]45<52L3`
MV<IJYA!(5U8S8U8%*_G'^XM!R>3N033U`"IL\NI?/0ZEWOMJN*&F&VJYH;8;
MZKBAKAOJN:%^'$KG<;5H?><]<)<;NJ&1&QJ[H8D;FKJAF1N:NZ&%&UJZH94;
M6KNAC1O:NJ&=&]J[(73;40*DSC9Z:3?F20'TP2[G20+TL"[G20/TGRZ7)$+V
MK-OO8"2YD=Z+)!4R2Y:L5UCQ@D>TS@Q5M/4]"8/NT-U:3\K@_IK+>9(&]\]<
MSI,VN#_F<I[$P?TOE_.D#NYOI;ELGV(^\4[W*:0OB;X(SURLEZPW:NH!_6R\
MP9$F1UH<:7.DPY%NC$2SU`>%,GXJSW[00_>YGQ4)BE5;9,"W9,B1$4?&')EP
M9,J1&4?F'%EP9,F1%4?6'-EP9,N1'4?V'$'/3K,./3UG%'9$)>`Z"D.B4G`=
MA25122*=R)-AZ<;Q)*["T\AMH5*V'8>+\#12*-T&#I*X,C8_7D1TD,25,5+%
M;Z99_0-N9O'=5M@2%]]<1V%,7'IS'84U<>'-=13FQ&4WUU'8$Q?=7"??H-GR
M:#X"?T=YC+X93Y=')Z'J`?VPO!$CR<NO07#KO"';Y#(MCK0YTN%(ER.]&(EV
M*2Q4'(OTN<B`(T..C#@RYLB$(U..S#@RY\B"(TN.K#BRYLB&(UN.[#BRYP@*
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MV7,$Q3`R9([74`PYDQ@R3T?A2!1#OBZ%)U$,N8["E2B&7$?A2Q1#KJ-P)HHA
MUU%X$P61ZRC<B2$CUU'X$T-&KJ-P*(:,7$?A40P9N4Z^2S/5TOPX_6]4R]-B
MUIN"):O.U6,HQWF-&(FO+G#+`T/'[+W*YEDE6_-/DP"VSHV_?(^@G5E%J7KK
M7'ETN$B7(SV.]#DRX,B0(R..C#DRX<B4(S..S#FRX,B2(RN.K#FRX<B6(SN.
M[#F"'^.-)FO(,1E^C9<SB1/S=!(K1FXM.T:2Q(X14'"'"EDS%IR[*J+PHBC,
M*`HWBL*.HO`C?H27'UZ%(T5A2?P*+U^7PI2B<*4H;"D*7XK"F/@=7KY?"FN*
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MH;9QG<15.:<.M2W22<:DEKDP]LMOM]UE&P"#OK3`S965NRAF^>V)P_)V0N$R
M#/:B]>3I)#[+8Q*SY3&)X_*8Q'9YC,)[*&1\OQ+WY:TKL6`>D_C0SV0+&9CW
M%#*#9P=YU9*5B_4P@OQK/]FTP9$F1UH<:7.DPY$N1WH<Z7-DP)$A1T8<&7-D
MXD&<&2"G'LBZ73;CR)PC"XXL.;+R(,X^K3V0M4\;CFPYLN/(GB,HB]1O*(N<
M49@299'K*&R)LLAU%,9$6>0Z"FMBR,=U%.9$E>0Z"GMBR,=U?`:U\A1#/JZC
M,*@H'(K;HGQ="H^B4G(=A4=Q6Y3KY+LT6RG-)];O&/)%7V2GAWR5JG5SJAY&
M4/Q,/L!W0]9\'(V8P)Z\C1RSPZXF%6EQD39'.ASI<J07(]$NXZ5F_)?=GSX7
M&61$`GR196D,,T`8.,`H`YR>SV2W8LRW8L*1*4=F')ES9,&1)4=6'%ES9,.1
M+4=V'-ES!,4QLEB.@5`<.:,P(HHCUU%X$<61ZR1NC'Q4+5=Q4SJ;P:B-7":Q
M8][A41@2HT>^KL24>>M*?)G'**R)423?'H4Y\<B0ZRCLB=K(=10&16WD.@J+
MHC9RG7R39FNC^>C_';4QFB,@71NK]O.A>AA!.9G0B)'X;B2>)5IEH)D!2LXK
M;2V^CG9&(KAQOM/I<(TN1WH<Z7-D$"/1`;$.QI`O/^+(F",3CDPY,N/(G",+
MCBPYLN+(FB,;CFPYLN/(GB.HB]1>J(N<23R88U/41:ZCL"+J(M=1V!&%D>LH
M#(E!(]=)+)EW?!3.Q+LT?%T*;Z(P<AV%.U$8N8["GRB,7$?A4!1&KJ/P*`HC
MU\EW:;8PFBD"TH51]SUC&,TLD"V0UM"P'D,YF=7@2),CK1B)+C7C=]FRUYIM
MKM+A2)<C/8[T.3+@R)`C(XZ,.3+AR)0C,X[,.;+@R)(C*XZL.;+AR)8C.X[L
M.8)JR:?Z4/@1KYYR'84C\08JUU%X$E]L<!V%*_'TD>LH?(EA)-=1.!/5DNLH
MO(EJR744[D2UY#H*?Z):<AV%0U$MN8["HZB67"??I=EJ:68:^(UJ&4U0D*V6
MUO/K>AA!N=62(DVNTHJ1^,;,3:GJ_#I1FZMT.-+E2(\C?8X,.#+DR(@C8XY,
M.#+ER(PC<XXL.++DR(HC:XYL.++ER(XC>XZ@6E(C86S)F8:"43@2U9*O2^%)
M5$NNHW`EJB774?@2U9+K*)R):LEU%-Y$M>0Z"G>B6G(=A3]1+;F.PJ&HEEQ'
MX5%42ZZ3[]*H6EZ_?#L<7IMWKW>?/CP>GK\>&H?OWU\N[H]_/>$A88!?@$_%
M+YX/7SY>8E[64NTT.2LF9CXO$[=AVNN:F`EC/6V8[;J&:12\;9CDNG::0-:S
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M&6H2U$P`[2YCTM.?G28YS630[C*RO356O_$U82'_B3#GP<S4[<J9;/8GL\EE
M,VNWNXS)9'\BFSPV,WB[RY@L]B>QR6$SF[>[#'[\H&;F]'9;9(Z#,/<?A`6:
M%OZF)9J6_J85FE;^IC6:UOZF#9HV_J8AFH;^IA&:1OZF,9K&_J8)FB;^IBF:
MIOZF&9IF_J8VFMK^I@Z:.OZF+IJZ_J8>FGK^ICZ:^OZF`9H&WJ;]+?H<;Z(+
MEA%_4QU-=7]3`TT-?U,334U_4PM-+6\3TLF?34@F?RXAE?R9A$3RYQ'<[C?[
M[A9=M>_@((7\&80$\N</TL>?/4@>?^[`?G[WP7Q^[R%M_%F#I/'G#%+&GS%(
M&'^^P')^Q\%PO_`;SJWW("*+_$F$1/'G"=+$GR6PF=]E,-DO/#8+3._FZ_>6
M:%EY6S9HV?I:ZF&M7O1H-<):PQ=OAK6F+]X*:RU?O!W6VKYX)ZQU?''!AOKB
MPP#IZ=E.[+)WCW<!>@</C][)="B^EC%:HG5<GZ^27SY]^''W]3"Z>_[Z\/1R
M\?WP!5?9F(<`;U`\/WPU#W2B?[P>?^#J^_+BC^/KZ_'Q]-=OA[O/AV<#`/YR
M/+XF_T#!NOYY?/[S="7_Z?\$````__\#`%!+`P04``8`"````"$`H]-I"G\$
M```[$0``&0```'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6R<6-N.HT80?8^4
M?T"\#]#<;=E>#9=)5DJD*-I-GC%NVVB`MH`9S_Q]JBG#T&T;<%YL0YT^U*E+
MT^75MX\B5]YI56>L7*M$,U2%EBG;9>5AK?[\\?+DJTK=).4NR5E)U^HGK=5O
MFU]_69U9]5H?*6T48"CKM7ILFM-2U^OT2(NDUMB)EF#9LZI(&KBL#GI]JFBR
M:Q<5N6X:AJL725:JR+"LYG"P_3Y+:<32MX*6#9)4-$\:\+\^9J>Z8RO2.71%
M4KV^G9Y25IR`8IOE6?/9DJI*D2Z_'TI6)=L<='\0.TD[[O;BBK[(THK5;-]H
M0*>CH]>:%_I"!Z;-:I>!`AYVI:+[M?I,EC%Q5'VS:@/T3T;/]>"W4A_9^;<J
MV_V1E12B#7GB&=@R]LJAWW?\%BS6KU:_M!GXJU)V=)^\Y<W?[/P[S0['!M+M
M@"(N;+G[C&B=0D2!1C-;-U*6@P/PJ109+PV(2/+1?I^S77-<JY:K.9YA$8`K
M6UHW+QFG5)7TK6Y8\2^""'>J)S$O)/!](2&.9IN.YS_"8EU8["\64S-]ASCN
M`[Z`UZT@^.Y\,35B&S,X=(Q-&^HH:9+-JF)G!>H7U->GA'<#60)O%V.,2!_U
M>T&'0'&29\ZR5EU5@7C64"GO&\\U5_H[9#>]8`+$P&>/(2(BO&9Q#1$2=1">
M(O[DN&/EA022>EV0KZ&NVS73N<_!W/V.-<`;0U\E->$U@GB2K]<05U(<7T,\
MU^II!$%00O,%<3"4^R#6EB<].T`,5&2?#[M_<AO;<!(132+B,82@#QR9KX^#
MURI$K_?=LUS1^P`Q?EN-_L)T'3E!X1!A^ZYC6E($HB$"NDP*88QF^.S=^"(0
MQ$%GS1?'P;(XJ;8"Q*`XRS%\<.ZK;C![0PCL$<3T)40T1#BVYUMRN\6(F"$0
M6G^^0`Z6!+I?@6N]#Q!S^\FH;Q(1(0*#].22A>5)88S'.(0$>H_HXV!9GR-5
M)V(NOOFN;Q(I.R$B1B(032+B,82@CY^9!J^!\>V2@R5]5]V'&-3G^#YQ/"D"
MX1!QLS^C(>)F?\:(N!TC0=]"U,=?<Q8<2,9U\D623E?>91"#.FV+V+;C2$46
M(N2VDVTI1Y.(>`PA""6@:IC)>4K;59)46WKW!A?0HMU1#<V16C:4[+Y8\='%
M[+7+Y9WT[EI1''_;#\ITIC@\(PAO"UMR("`(LM$[S9&\#P7[M?A(LAM2M<>]
M??)=0?BAX'&1>)001+I2)08M]5H=*<5P&A+U$'[.,S1#"E7<VZ>E\M/!XU+Q
M3"%*E9P(2'?P0"<E<]B;;_F(33D-B4<A8N5"S/^'4KYJLBT1-)I4A-SKW(B(
M=BE8\5VS*)$?%AY/)AXQQ&0NQ*TCX%,?Q*%K3E-JKK"WCV2SH[@+X;,L/N46
M!*7BK(H#5$&K`PUIGM=*RM[X'&K"YM'?[6?D9Y//%=+]D"QAEN%#2V^`T?64
M'.B?277(REK)Z1XH#<T#KRH<?O&B8:=V;-NR!H;6]N<1_J2@,`W!OJ0J>\::
M[H(_H/_;8_,?````__\#`%!+`P04``8`"````"$`%`HT$U0$```4$0``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6R46%V/HDH0?=_D_@?"^P#M"*A1
M-R/LW+O);K*YN1_/B*V2`=K0.,[\^ZVB$.C&0<8'1ZA#]3GUT47/\NM;EAJO
MO)")R%<FLQS3X'DL=DE^6)G__O/\,#,-64;Y+DI%SE?F.Y?FU_4?7Y874;S(
M(^>E`1YRN3*/97E:V+:,CSR+I"5./`?+7A195,)E<;#EJ>#1KGHH2^V)XWAV
M%B6Y21X6Q1@?8K]/8AZ*^)SQO"0G!4^C$OC+8W*25V]9/,9=%A4OY]-#++(3
MN-@F:5*^5TY-(XL7WP^Y**)M"KK?V#2*K[ZKBY[[+(D+(<6^M,"=343[FN?V
MW`9/Z^4N`048=J/@^Y7YQ!8AFYGV>ED%Z+^$7V3GMR&/XO)GD>Q^)#F':$.>
M,`-;(5X0^GV'M^!AN_?T<Y6!7X6QX_OHG)9_B\M?/#D<2TBW"XI0V&+W'G(9
M0T3!C35QT5,L4B``WT:68&E`1**WZN\EV97'E?GH6:[O/#*`&ULNR^<$79I&
M?):ER/XG$*M=D9-)[60*[&N[9TUF+G.]^UYL8E0)#*,R6B\+<3&@:F!->8JP
M!MD"/%^5$8]&ZT=202,Z>4(O*],S#5`A(3^O:]]UE_8KQ#2N,1O"P'>#82HB
MZ'OQ'!427B&8+5#0R(#@=&7<3LR5+8*1+28*Z6_H1I?:1%TWZ".8KT+"/L1K
M!2ID'U6R&//IA]5T)8T/0=UTPN>[GDIA0QA(8Q/BJ8H([B+"(82B`I89'W($
MKTP(4<MLJG';$,:ORD>//]GFE<VQ9JJJ4+4ZCXU9(0PA'D\8P3IAO:()`XNW
MHIJ5J\(*"#&;5;R9-?WVH`D+%81G.>J'?7OX0`STVG@Q"-;%:.6[(4Q-56N[
M8,@8?F!48N]_ABZ"=;I:RC>$&8K]741(B*MD:];F1N&.4[RS10[O+0A6N?NN
M'FK"-.OZ6AL'NKTM@:JJ0K+?UJXPGW^&.8)UYGK4"=,RUY0%FEU[/"3S".(,
M1O3XF%=HE?K4;?=>VN-K4'=QWYUK_7H#I.U2X0V(WQE32OP9CJO1I5.A51F>
MKT5X4X.Z,C2&P7U(.`A1)>!8ZT@8-ZP8#</A:56#!J60GP%(..A%E8*CK2-E
MN)$9#4)U9.D3H`;5#<$LK[?!!S5D4,+HF<O`S2<D(%HMJ!M]0:`!?D&U*KRC
M=`:=WWFWH4WI!J@M3#4/.//&YX$F9#</GJ_U[09?QD%IEV&[.(WB^Y!P$*)*
MP)G7D3"R*VA2WND*`@U*N0L)V1!$E8)3L"/E3E?0S.QF8SKM=84R6.&U9ZY^
M;C0)/3$@.F1#$%41SL?QBFB:*HKZPV-HY-;UU8=TYT+=)'U06Z<D@@ZA=$;+
M>''@`4]3:<3BC`?,";Q)-G>;P^_3!,\RVOT`#\5XWVX,<"8]10?^,RH.22Z-
ME._!I6/YT#T%G6KIHA2GZF2X%26<1JN?1_CO`X>SDF,!>"]$>;W`!?`T71TM
MU[\!``#__P,`4$L#!!0`!@`(````(0!S.<\UDP0``,(1```9````>&PO=V]R
M:W-H965T<R]S:&5E=#,U+GAM;)Q876^C1A1]K]3_@'A?8/BV97L50&E7ZDI5
MU>X^8SRV48"Q`,?)O^\=+L8S`R'VYL$8.!S.N1]S/5E]?2L+[9763<ZJM4X,
M2]=HE;%=7AW6^G__/G\)=:UITVJ7%JRB:_V=-OK7S>^_K2ZL?FF.E+8:,%3-
M6C^V[6EIFDUVI&7:&.Q$*[BS9W69MG!:'\SF5--TUSU4%J9M6;Y9IGFE(\.R
MOH>#[?=Y1A.6G4M:M4A2TR)M07]SS$_-E:W,[J$KT_KE?/J2L?($%-N\R-OW
MCE37RFSY[5"Q.MT6X/N-N&EVY>Y.1O1EGM6L8?O6`#H3A8X]+\R%"4R;U2X'
M!SSL6DWW:_V)+!,2ZN9FU07H1TXOC?!=:X[L\D>=[_[**PK1ACSQ#&P9>^'0
M;SM^"1XV1T\_=QGXN]9V=)^>B_8?=OF3YH=C"^GVP!$WMMR])[3)(*)`8]@>
M9\I8`0+@4RMS7AH0D?2M.U[R77M<ZXYO>('E$(!K6]JTSSFGU+7LW+2L_(D@
MTE,AB=V3P+$GL5W#M;T@?(3%Z5G@>&5Q'F=Q>Q8X]BS$-^S0(Y[_N2,3H],%
M.TG;=+.JV46#"@;_S2GE_4"6P'R-,L9DB/M'88=X<Y(GSK+6?5V#B#90*Z^;
MP/%6YBOD-^LQ$6+@<\`0&1&/67Q+AB17"*\<<##8@`2)-J:+Y*J6@[E:7C1<
M?H071&FV_-YXC""!#$G&$/]F4!(+=7"_6`Z&VA7"Y@0W7M2/&$C?$%I7%A=_
MBDCF$))Z>,W]ZCEXK4-H!F6!X\O:(L2$7=F0T/=<HOB+180?!`M?24^"`/@<
M7F/?())ZZ/W[U7.PJEY)>X287KV[6`1JS<82@H2!ZR[D""0B0O$GB8<&$\7S
M9G5@89VO=OZ0:B*4!42(01..XWM$+;%81$PF*1$1<R8"V<2\>`Y6Q2O1BQ"#
MXGT/QK2R\L0($*M#:8]D#B%E@/^Z4);+SS/`'U),N,K"%B%FT36!95A*@N+Y
MVPG>GG8HZ5_\BG[^D*I?:=$(,:B?&&H&Q+MC=\F'MR7M!$I=#;X+K3-?0=U3
MJOK;XH`+:`^ZRB?$$O\4K[&$GK#S\7W9#Q]F#Q<3P1$H+:FNH_1S#[J6DUI-
M_>WI>NDBDLQ"9!M\\#UN`\>E;$-IRX@@2-09N&IM38*4&9-,@FY+N6R(C\+'
M#>$`E0TI@8_(>,H&ZC2()T!*8))9B&P&@O<+9OA32M-XZI)%$"1EQQOURA@T
M,C,'D<WP02EDYI/.Q[$J9<0;=3Z"`OSUX5@>-+[<3#'?=4`P1)_"KXN^7<:8
MFTW9`Y^3]WO`J2I[&'6[.'H=7+E4#P@1/=ST]1;F(+(%/B[OMX##5;8P2@."
M<(A[MA-.I$&$D*E,)00AHDLA4[('/C+O]X`#5O:@!#""W3"O$RRE(+3=<27-
MS>D^"W,0=(!;9MS%E;0^T)@61:-E[,RWPS94\G!UV*H_V7RWHUR/^1:>7S>'
M&["#/J4'^CVM#WG5:`7=`Z5E!%#>->[!\:1EIV[ON&4M[)V[KT?X7PF%W91E
M`'C/6'L]X2\8_ONR^1\``/__`P!02P,$%``&``@````A`&_MK!,Y"@``8C(`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,S$N>&ULK%M=;^,Z#GU?8/]#D/=)
M8CMQDJ+MQ?A#V@O<!1:+_7C.I&X;3!(7<3J=^?=+62(M49'M+NX\-%/Z'%J'
MI"1:<>]_^WDZ3GY4E^90GQ^FT6PQG53G??UT.+\\3/_]+_%E,YTTU]WY:7>L
MS]7#]%?53'][_.M?[C_JR_?FM:JN$_!P;AZFK]?KV]U\WNQ?J].NF=5OU1FN
M/->7T^X*OUY>YLW;I=H]M:33<1XO%NG\M#N<I]K#W66,C_KY^;"OBGK_?JK.
M5^WD4AUW5QA_\WIX:]#;:3_&W6EW^?[^]F5?G][`Q;?#\7#]U3J=3D[[N]]?
MSO5E]^T(NG]&R]T>?;>_>.Y/A_VE;NKGZPS<S?5`?<W;^78.GA[OGPZ@0(5]
M<JF>'Z9?HSNY7$WGC_=M@/YSJ#X:Z_^3YK7^D)?#TQ^'<P71ACRI#'RKZ^\*
M^ON3,@%Y[K%%FX%_7"9/U?/N_7C]9_WQM^KP\GJ%=*]`D1)V]_2KJ)H]1!3<
MS.)V&/OZ"`.`GY/3094&1&3WL_W\.#Q=7Q^F23I;K1=)!/#)MZJYBH-R.9WL
MWYMK??JO!D5J4.0D-D[@$YVL9O%F%:U2Y:6'F1@F?")SMHX6VV3=SUL:'GPB
M+^Z&W7-#<-OJA4\DCKIA:GCPB;QQ-UP;(GPBL>^&<YV?-MW%[KI[O+_4'Q.8
M0Y"!YFVG9F1T![XPSUHJ93Z4>$B6<O)5>7F8@@C(:0/5^N,Q72_NYS^@PO8&
MD_F8R$7DB%`UH-P6:+#<,J\E0I`CN$%:ACF()N5057^"<N5%*<?[9VCHQAPS
MF8A`2H&&CA*M74Z)$.0(-'2<E(53(@0XCG"8%%PX+"6!J8T95B28Q$Z&V0TS
MC8&Y0U6P=&7DB$`9!1J"E!(12!%H"%(D(KAP&!D7GL#*>'M-0^&*]#"%6)*H
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MHASC1CANHMG6<R,'W#AQ@R';<>LO$`7FP=JZ*C.-Z2L01%"!H*%;;M(UFY8E
M8I`DT&"36+%*Q`#)$1W!#F&K;CND,=72$MT()`M6#)D!]86`("BG,!939(M9
MRF9]B0#01*MRND[=Z`M$Z5I=S-:LQ"0"0F[<.*D^RYI5_=41Z:[,V587+"69
M`=G!B5D`<\)TT=&N^UBEQQ)DZ2+&[R4)X]6(:K7&:]>-F:T]7?-U)-(@6P4K
M\YP@G?1!4NF1!%DZY>Q.DB"><-5J6<+5Y!CN)2/=H,%/JSIY,VE`O0&P&CWS
MP("6SC/34I)?C)H@2Y`D">(%`,9G!V"@ZA7:71+BK5?U&J3WP!BV)7?:YI&^
M;K629`D**`G2J48W09*T2>Y<5YV6E?8!U;HOL^L]WO*M0!TN0&A@4%9-L'4M
M)Q"J*,C2T;R$HV<DB6&2)(B7<-51C9>N^R];^HT]P#1IH74XCS3`SCA:>F0C
MI).-EB!)VG=R,ZYZJ?&R=>=ERT[77L:Q/0L.)X\0@AH*L@1))4&0),@2)$F"
M>/E6#9(E?.0*I]NJ@15.@^R29[6;1PA!+059@EI*@B!)D"5(D@3Q`J`:(RL`
M`W-=MU%VYF^L<!H4>.S)(WW9+G>T!,=?>B1!EB!)$H2+CEG3UR^Z1?-EG9>[
M`=G93C?LB3\G$*:N($M014D0)`FR!$F2()[T3_5Q\:T^CO5HF0%1O[IF>WUN
M`%;&R1)44!*DD^UW?FQ"29OD+'`QE.SX,F_1;L;3#5.5&9"=<3:<G""HH2!+
MCW`U5+55(DD,DR1!O'RKELF:W^,6N%@W6OT+G`'U!D#[Z;04PZ22(%T`T$TP
M:M(FN9F'\?$`#!\+QHKE5H!_+FA`>F,/'`P:C!T![5JSXCA)DM66/9J5'DLX
M]PH<#MHL-P:LH5-%,"(&?F.71*Q=S=2Q"FOLO%F`$,QG84@Z!*L(OON+O=-1
M<HPLX;`"9X0VRPV!ZH[8/!@1`MU3N?L=TY?%&H3['3_<S\WU@;-"QXM_-C;*
MB6!.6%G)(2=NQ#[5$\9^3^AW!@;4NV)X/:$AA0X-R6=7)]I%@"!M@BOX1B\8
MC3D*BG4;YU8)?^(W(#HZ7"^<?Y%_DH@,Z(ZLAR:6TP)1>C+=.@0L$=+K2"#*
M+$S^62("0F[<8*J>SIIO`RV60KO+K?\,&6M0;_4@!(NAN$%*O6\C"(0T018K
M]!O6^$@"`<T1KQ866[Q:;T=54DMTX^`_4!I07QP(@H(*8Z$FS3M41`!$T*HV
M?JB(*%TD<*C(8X*`D!LW3I]J1I-;S2C?CPS(#@X_Z,L)TT7';RTYJ_18@BQ=
MQ#A+$L:K$=:1CMN3$]T<VDM-NF%+0F9`=@S8GI43I`N!]MQ#*CV2($L7`78G
M21`O`*JILU:(<9UIHEM!^&E5*6_-#:A'2TZ0+@"#36;ID019NN%X`4"_7@!@
M?'8`^I?(1*'=I<'?8`U(;WTW#A?-=:L;)4M00$D0#)4@2Y`D">*I9KWH@&J_
M!_4WA@0;S&XXZ8:E(2<0JBC(TM$8J20(D@19@B1)$$\ZZT$'I/N]YXV]0(-H
M6>=?\N2)!M@91TM00>F1!%F")$D03S9K)$>N='Y#F6Z\U1Z[Q>"P\@0AF,*"
M+$%221`D";($29(@7@!N-);#7Z,DNJL<6.DTJ'>E0PAJ*8SG'E))$"0)LO0$
MP+J3N\^KMLQ:Z@<*7S=Q]AYW8Z73('SH8H61)_JR7?9H"8Z_]$B"+$&2)`C/
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M[@A$K5N_":]?C3Y5EY<JKX['9K*OW]5;[O`FS.,]F<TK^,L8WL&/U>1D5Z""
MX4IR\\H2KK1+D,=9X1O][`J\ZO_UYEVBN[Q]7Y[A"_C3@%OV++[+;_DIXCMX
MO=A7(4!>:Y_3#>`-_[?=2_7WW>7E<&XFQ^H98@//^!#.B_X;`?W+M7Z#F,%[
M_O45WNUO__L*?\M1P3O=BQF`G^OZBK^H#-!?ASS^#P``__\#`%!+`P04``8`
M"````"$`:\#(#T82```\@```&0```'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6R<G5UOW+@5AN\+]#\8OM]8U+>")$4E<ML"+5`4_;B>V)/$6-MC>&8WN_^^
MASJ4A^>0>PX]-]G-[B-*CWA(O9)F.!_^].OCP]4O^Y?C_>'IX[5Y5UU?[9]N
M#W?W3U\_7O_GWS_^,%Y?'4^[I[O=P^%I__'ZM_WQ^D^?_OB'#]\/+S\=O^WW
MIRMHX>GX\?K;Z?3\_N;F>/MM_[@[OCL\[Y_@_WPYO#SN3O#7EZ\WQ^>7_>YN
MW>CQX::NJO[F<7?_=(TMO'\I:>/PY<O][=X>;G]^W#^=L)&7_</N!,=__';_
M?-Q:>[PM:>YQ]_+3S\\_W!X>GZ&)S_</]Z??UD:OKQYOW__MZ]/A9??Y`;Q_
M->WN=FM[_4O2_./][<OA>/AR>@?-W>"!IL[3S70#+7WZ<'</!OZT7[WLOWR\
M_K-Y[TS37=]\^K">H?_>[[\?HW^_.GX[?/_+R_W=W^^?]G"ZH:-\%WP^''[R
MZ-_N_'^"C6^2K7]<N^"?+U=W^R^[GQ]._SI\_^O^_NNW$_1W!TK>[/W=;W9_
MO(53"LV\J]?#N#T\P`'`GU>/][XVX)3L?EW_^?W^[O3MXW73O^N&JC&`7WW>
M'T\_WOLFKZ]N?SZ>#H__0\CX@WIMI`Z-P#]#(P;^M7#C)FP,NWO=^%T]=J;K
M]4.X09WU[-C=:??IP\OA^Q74'!SP\7GG*]B\_]W3`0J>_;.'UTW`]`B=^,NG
M?AP_W/P"Y_TV,'/*U)184L(,%+$ITAN*N`Q2=:_,#>B].L(YCAU]U[>JJ]\(
M.OGZ*G*=7MM?S\>,3!LQ+246E;`JX22">,+!<L\&!DJ^Q+<^]1M]O(9]G#VG
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M6Z&P8T>&+#IB=<2)"+7T^2&R+*Q;3!WPYSG^C#SF&2F:K"=DT1&K(W`'))Q6
M:@NG/K:50Y#Q-)^'DKI%*.[3M&Z1P;HUM1FJD4UG-NPKA`U($15+DRX0\8[.
MQ4,M?:!@?:K'!'];E]BR,#,'*'\0H4_3.',^3HQ$>BM.1*BM3Q7,5@\+!K.(
M4L%28`FV*F+#KH1SYD2$VOIL$=DJ%8Q)A,Y*204CA*77]9TQ(T,6(R6:T*<J
MXL16J*7/%Y%EX:R$J83:]C2QST:*+J%/5<3JK3@1H;8^9;S=%K.)4L%2@`FV
M*F*-BC@1(;8U2TIR!:^T-@<'*!YAR1P<F#`'-WW3L>N5943%+V@NLYOSS$8=
MWY2/ZEP^8L]VY@#%CN>=8T_JB-41)R+4TL>9-]=MC2%(KML`B;;8CH!8O14G
M(M36IPQFJU]5:[\5KU]V:9\#%*ND]8L-A8!0-57'Z].&9A`9QZHVK$)<9D=G
MA-K"P5Q@Z[?BMBRCSS5"L>WY($(EJXC56W$B0FTSB4G/$/[Y,=@JE:S&H26T
M(YP0JR-.1*AM)C$55#(F'7IU32HYC4-I)2,3*KDVT]BQ_K=UC&0?>P8B?\ZH
MK0\FT;A5KC<88XAEG<S%:M99:A6Q.N)$A%I>E)AJ3#I*!:MQ:`GMY'MC'=)6
M1YR(4%L?2*(^+7NL5&.,(7V;/+0/4*R25C`V%+*$&?K:&':G9$,[H<K;J38]
MBZ).WA41]L,S%I:+>*7Y-,PR_1P@430PFT3=FIZ-!4N0=H#[5C8G.'E'5)/E
MIK+<W^3R$TMW<X!B73;K+#IB=<2)"+7U"895L7[5:?Q6VE4G0*(MMB,@5F_%
MB0BU]0$FLE5*&.,.':M)"2,4QF%5M=68C-4&&5%319S8"M6$/<6:A27LMZ(C
M=N`#:6X0$E06';$ZXD2$VEX4G.`3"P4EK`>GT(YP0JR..!&AMCZ6E)<PAABE
MA$G2&:<6DCU]8K$TB(B6*N+$5J@E"TQE%]<F#4Y#E0Q8-14MH1W15FW%B:U0
MVXN"4U,2G`(DJ"PZ8G7$B0BU9<%)F81S@2GI4X1BRW023AEV\;6-BC@1(9KM
MF^+22M/)-_DL0&#P4O-#/U8M?'R(#=3`Q&>"6^J($Q%J>5%::M.T-%3\\P`!
M$E06';$ZXD2$VOJ\$DV^91?6%E,.7.&%-U4!$FVQ'0&Q>BM.1*BMSR21K3Q0
M6TPP\J4F0+%",E`S3%+">EH26Z&:<#2QIN_4'@:OHNNWH@,6/E)(1^/<(A3K
M,I5%1ZR..!&AMA>E)7]+H`;^`(FV:J"R>BM.1*BM#R7E)8P11BEAA,(LW#4C
MGZ>75DU"5D><B%#)3%CRIT@IX%Q88M4YMVK,673$ZH@3$6I[45AJ2\)2@,0"
MQG8$Q.JM.!&AMCZ2E!<P!ABE@!$*!6RJH>_9I7=IU2!D=<2)"+'L6%8JFX+7
MK?@4S`+1'""APQ8=L3KB1(3:7I29.LQ,<HH(D&B+[0B(U5MQ(D)M?6HIKN#.
MT[1/^XG'_0!A!4]3;QKV?F<)A"B)>Q(0)[9")5E4\@4\J%-PET:FH6)/:.<`
M"<>YZ(C5$2<BU!8.)N[2LAC<^:VTAX8!$FVQ'0&Q>BM.1*BMSRSE!8P)1YZ"
M.X1BA20&9QAV=;8ZXD2$:K*H5-BI:60:*O9\?N[40+3HB-41)R+4]J+,U&$<
M4N9@/3.%=N+^3_I6;<6)K5#;3&;RKT3DA-AAUJ&ES)X,S@':'DKT5<-?52X!
M$6W56.7$5J@MRTR%:2+-3O`9279#UZG!:-$1JR-.1(BMOU6-IZ>R<;MNI4W&
M`1(Z;M$1JR-.1*AM)COIE=QCYI$K.4"ADJ>NAV1!NW\)2'Q"^+QM,PP;VTY$
MJ*X/*<77GM[3-#SQF],Y,+$".[PE@Z26N"NA&9=IYKPG:IE)3_H-;)]+3_R5
M:X"$XUQTQ.J($Q%J"P<3]VGA@/5;J0,6(=%616RO(DY$J"U+3]ZV8,#F4A2_
M]/0(A0';=NW0&':KL`1&."-61YR(4%V6HN0K;)^FI_1N)T";YC"V$[LL+0$1
M+=4,YL16J&4F/?DY7+'%2!//PH-).E7-/4NO(E9'G(A0VTQZ*IB>,-+(6;%7
M<\^B(U9'G(A06Y:>E#Y-4U.F@M/4Q"\H2Y\RYZL%?GQ+1YR($,TA$YOT$EZW
MHE?8@<\Y<X"$T;CHB-41)R+4-A.;]!(>,#;))1P@T1;;$1"KM^)$A-J^*34-
M:6I*2SA`L4)2PAF&E["..!&AFIG8I%]:ATQL,NP!\!R@6)>I+#IB=<2)"+6%
M@WE[;!K\5EIL"I!HB^T(B-5;<2)";5ELDF=A_ZB1!?],"2,4*Z0EG#*LWVW8
M5]P,0YR(4,TWQ:4AC4O)_4U@,"T-4]=.`XL8"T%,/0Y#/[#7!I8P#:R5TG3L
MY:X+2/Y$4,N+XM*0BTOL(.8`Y0\"O\B@(U9'G(A0VXOBTE`2EP(DVJJ)RNJM
M.!&AMF^*2T-)7`I0;)D.5#TN99I)!JK4"M$<+XI+ZU8\+K&#F`,4ZS)DT1&K
M(TY$J.U%<6DLB4L!$FWUN*2WXD2$VKXI+HTE<2E`X9ZU[J8V>2I,$%A3;6C8
M:P-+B9$O?./"_\^?2FJ824IZ_!US28E=*.8`Y0\")V`=L3KB1(3:PL&\/2F-
M?BLM*05(M,5V!,3JK3@1H;9O2DIC25(*4*A>8RHH7_Y@B3`#5'C-'LI80IB^
M'D=6.RX0^5-%)5E.*GNE,:9Y:3#LF?8<H/Q!A`+&=@3$ZJTX$:&VF;Q4,%PQ
M+\&@%3YF.2(DJ"PZ8G7$B0BU97E)COHCYAN8A,^6R0<D`H0%W/9=5[4L."X!
M$4Z$U1$G(M22Y21?P?HG),8T+PU\R<$Y0(+*HB-61YR($-LI$Y?T"EZWTJ;@
M`$FV.F)UQ(D(M65Q2:[@">.-7,$!VJ;@S%H)"T%&6&:)O?NQ`8C/%,_1+L.<
MPR>59"FI[+7-E*:EP;`KQ1R@^$#/!X%3L(Y8'7$B0FTO2DP3)B9Y"@Z0:(OM
M"(C56W$B0FUA3SPQZ4_2)K\5O;OID^_R!NBUD.%[#LG'+0D#7^.MFN1Y!$&Z
M$3ZUR29T%XC\.:.V+#&5A8DI34Z#84-N#E#^($(E8SL"8O56G(A0VTQT*IB*
M,?(HE:SFHF52$:LC3D2H;28Z%50RIB(Z);/'9O.$T%;)4,8C7]IN(8RI^VJ:
M6)U:@F3750A$OD*H+8M.A7-R&J&&.K%%*'\0H9)5Q$XJXD2$VF8B5$$E8X12
M*ADAT59%[*0B3D2(K:DR&4HO9=Q,FY4W*A3S`,O4P-?IV*=]*`0K+-15PR8\
M6-+2'^7':VS(]&9J!W9YAS4MD<F?72;]IBAEJI(LM5';R)W:KN^9R$(A,S9]
MQ9?N`5G<'38$F:RNV>@&5T2*7#.)2G\%:ZI,I.*WY_-&Y8\#QV\!`\JX-Z$=
M<)88UK\^V40?Z"J;L6!1Y[7*Y$&\4<*Q0C=C2P(#SBH#SA+#G&%GL;-\>V`J
MC_,!S!Z_0/\BA:4XP0(^;<=>8H(K,O#GZ[TR&^/@JC+@*C',]:)L9:I,N.+W
M*N"L1B=P5AEP5AEPEACF?%'",E5)Q-HHH0_!60]9!0PX2^TP9Y:SM)K.!:RT
MIN.$-;155?/[`'!%1C@?T+\J`ZX2PUQ]B+E@SL+L`W/CZ^@;^/4":EI-2."L
M,N"L,N`L,<S91YD+G#$!:?.TFI/`667`667`66*H\[KV=N2LU'18JCONW^1M
M/#P[7R=SG*;;IFE,SR+#0IG:-"U$+1K%8$WMN!W3PDUTPY^F;TQ^:#!5%K/*
M;H%-6+D[5AYJ=DF9-RI_'"%ZB&N`KPPX2U%J96`I<8EASCZE1-U;&#W".MY*
M28NK?6_._@#$I<?!667`66*8LT\ID;-6TAAJH/W7*2O]'(W)K/7-K]50U-@4
M%CZ\N^1E#ZHQ`?7,U_(`423RA<1$`8I%2PO:;T:S%KS+HH,/"AJI_'%LG:LR
M8*PRX"PQS-E'E*AS2PL:DPV<VW,G\V?'X"SEG\U99<!99<!98I@SRUI:06.B
MT0HZS3V9@D8("[IN1WBK1.L$7&-D@._E,@),TSV=IT]FZ@,*ZUW]A9$)"WS'
MQD/-WWENE%S14D):*P",50:<)88Y^X#"G/4G/+!8^CJ*M8J6TL]6T2H#SBH#
MSA+#G'U`B9RUBL8\$_=O;HI.4T^FHA$*V<3T?,EY4(T)TZ3+<6]$OI"HZ+IT
M=R1:.$6'%;]CX8%_F&8VXKK@H7-U!G[70WI4M;8#/^PA,<PYD[,*"CJL_ZT4
MM+A*^.8LY:.5`6>5`6>)8<[057%!^WXN>&X95@&/^SE]FV3$M<(W9W\`2LX*
M[839?)I,R^Y&05EJABG[H')!:?O->/I@3T^AM)'*#[%-666@FU4&G"6&.?N@
MPIQ+2MMOIKWC-^*RX9LSMB2<%W!6&7"6&.;L@PIS+BEMS#=:::<I*)VSQ17&
MM_&L-P36*?1[261=YYM9%SRG#LN#Q]9#S1Z[0W5+B6CK:96!GE89<)88UM.9
M]%52W9AU8!1)V5I<4GQSEE+3UM$J`\X2PYQ]:&']7%+=F'7B?LY-W%(BVIR1
MP4G9].TP\:]'0C_'S`C1-ODIQPW)3PQ,V0><2%D)7]G5R]F%`TJZ)'R1M<GA
M3M?P[U>`*DE?D*,']@EAZ-UT5[\WBGU/QJK^LEQP/[%NQJY1?'G<&:(A-"Y>
M<N%WQE0&?FA,9>"7QB2&=N^Z#GC4O85WR&'Y<&44BXN,AXK6&7"6HM7:#CA+
M#'/VL25R5DHZ+!Y.1V]2TH'"D3FV=9-\J0A^"5`K`5!5&5"5&*;JTTJD6EK2
M&')B9?CF/+V9AY)&*C^+;-VK,N"L,N`L,<S9IQ7F7'!A"LN)PWZD"Y.XZ/CF
M+,6EE0%GE0%GB6'./JM$SEI)8[2)^S=SBQR6',>?=:[;R7],F-8`3%E22-I<
M509<)09=\>??\0?.GW=?]__8O7R]?SI>/>R_0(]5[_Q4_8(__HY_.1V>UQ\T
M_WPXP8^VK__Z;;^[V\.OG5?O`/YR.)RVO_B?E_<_.K_^B/JG_PL```#__P,`
M4$L#!!0`!@`(````(0#/L3F/F0(``*P&```9````>&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;(Q5VX[;(!!]K]1_0+ROL9TXR49Q5KEHVY6Z4E7U\DPPME&,
ML8!LDK_O8!)O+MTF+[:!P^',F6$\>=K)"KUQ;82J4QP%(4:\9BH3=9'B7S^?
M'T88&4OKC%:JYBG><X.?II\_3;9*KTW)N47`4)L4E]8V8T(,*[FD)E`-KV$E
M5UI2"T-=$--H3K-VDZQ('(8#(JFHL6<8ZWLX5)X+QI>*;22OK2?1O*(6])M2
M-.;()MD]=)+J]:9Y8$HV0+$2E;#[EA0CR<8O1:TT7540]R[J4W;D;@=7]%(P
MK8S*;0!TQ`N]COF1/!)@FDXR`1$XVY'F>8IGT7C9QV0Z:?WY+?C6G'PC4ZKM
M%RVR;Z+F8#:DR25@I=3:05\R-P6;R=7NYS8!WS7*>$XWE?VAME^Y*$H+V4X@
M(!?7.-LON6%@*-`$<>*8F*I``#R1%*XRP!"Z:]];D=DRQ3W8O>+&/@M'A1';
M&*OD'[\8'2C\YOBP&=Z'S5$2].-D.(K@L'M9>@>6_CM+',2C)$H&MUF(CZ>U
M9TDMG4ZTVB(H.5!N&NH*.!H#\]$7'TWGU$=&@4..9.984CS`"+PPD-RWZ;`7
M3\@;9(0=,'./@6>'B<X1BVN607@.61XA+M<001<&6'L:QK_3>E3KP$ZM2[.3
M/_<3I](NQ"^N$='P0MHU9/`>X)E8R.3]8AT8JNW$MGC4/S]Z[C&0OL[:"\3B
M)F+Y/\29>CCF?O4.G&*PIE/6"Y,+]1YSJCZ^M/\V!)J'.^D#%A^`[PZ^_"77
M!5_PJC*(J8V[^3'4;3?;-:59[,KD8GX!S:J]XJ1;@&;1T(*_4EV(VJ"*YT`9
M!D.XW]JW&S^PJFDOW4I9:!?M9PE_!0YE&`8`SI6RQX$K\NX_,_T+``#__P,`
M4$L#!!0`!@`(````(0"G$&7.)`0``+8-```9````>&PO=V]R:W-H965T<R]S
M:&5E=#,T+GAM;)17T8ZC-A1]K]1_0+PO8`P8HB2K`33M2EVIJMKM,P$G00,8
M83*9^?M>8T*PLT.9/$!PC@_GW'MMWVR_OM65\4H[7K)F9R++,0W:Y*PHF]/.
M_.?OYR^A:?`^:XJL8@W=F>^4FU_WO_ZRO;+NA9\I[0U@:/C.//=]N[%MGI]I
MG7&+M;2!7XZLJ[,>'KN3S=N.9L4PJ:YLUW$"N\[*QI0,FVX-!SL>RYRF++_4
MM.DE24>KK`?]_%RV_,96YVOHZJQ[N;1?<E:W0'$HJ[)_'TA-H\XWWTX-Z[)#
M!;[?D)?E-^[AX8&^+O..<7;L+:"SI=!'SY$=V<"TWQ8E.!!A-SIZW)E/:),B
M;-K[[1"@'R6]\MEW@Y_9];>N+/XH&PK1ACR)#!P8>Q'0;X48@LGVP^SG(0-_
M=D9!C]FEZO]BU]]I>3KWD&X?'`ECF^(]I3R'B`*-Y?J"*6<5"("K49>B-"`B
MV=MPOY9%?]Z9.+!\XF`$<.-`>?]<"DK3R"^\9_6_$H1&*DGBCB1P'TE08'FN
M3\+/L."1!>XCB^M9R'."3RCQ1@ZXW^RX:^W8,C1#I-.LS_;;CET-*%\PS]M,
M+`:T`>);B&5`IJ!_%',(MB!Y$BP[,S`-"">'0GG=$XRW]BLD-Q\QL<3`=<($
MC@I)'FF0BDAO"%$VX&"R`=F9V_AYA=S4"K!0*RI&R(]O`S-IVHL3"9FK=S5I
M2PA%*]3`>JT"K&C5!Q(Y,%<6:G%-'R'>/3N*-BB!]=H$&-;4+*,$>VI48HF!
MZY1U#9'\+R)=0BCJ857/U8MBQK#K+%>#F+0S(7N30AQJ&F.)(4-E>V$4JB83
M^?."R71.X"/GGB!%/RR@N?YEW0*LZO8<K29CB5D0EDA$.#A#!`6:\W2)0=%.
M/J-=@%7M./35H,82(Y6Y"(+FW:,V+-MDCD`D)&$4Z?(5B$>B`-U)%/FB9YCM
M@\NA%V!=?J#)EY@QL`@10E1`,@=@C(GC:A%(YPB$,/(_6+21JGU=V8M)N@=-
M8BPQTD-(W"#4"U\"%NHKG5-`=9'HHP0@6*CS#*QS,<S2;.A%$(\@Z4/4@!;H
M1`%$`,":T51!N%X8^'<.I8Z0.*%6%]*`UN2'D5HH\0B2\K$+32C2Y"4*Q!4?
MC#2:5,%@+_*@B9G>I'H01]EZ#_+@4S;0Z+[*Y`F+)$AZ"&"=AMI6E2@([*,`
M$\UEJD#\,'#(G40U(`Z\]0;D\:@:T,[_&/I<L5[D$8`C%/FS35QN1PH$&D3/
M!Z-3A`>,:)?O-)X3.G,:Z4&VP[))JVEWH@FM*F[D["):70P[]30ZM>%/0Q>N
MC2>B/1=-CC8>NYMXP-O3#]`UM]F)?L^Z4]EPHZ)'>)5C$3BV.MEWRX>>M4/+
M>&`]],O#US/\/Z+01#D6@(^,];<'T:)-_[CV_P$``/__`P!02P,$%``&``@`
M```A`(L+7AW3!```0A0``!D```!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL
MG)C;<JI(%(;OIVK>@>)^`XV`:*F[XOGLU-0<K@FV2D5H"TA,WGZOI@W":@=P
M<J%Q]<?/ZEY_'Z#W\S,\*Q\T3@(6]56B&:I"(Y_M@^C85__^:_K#594D]:*]
M=V81[:M?-%%_#G[_K7=E\5MRHC150"%*^NHI32]=74_\$PV]1&,7&D'+@<6A
ME\+/^*@GEYAZ^^RB\*R;AN'HH1=$JE#HQDTTV.$0^'3,_/>01JD0B>G92R'_
MY!1<DF^UT&\B%WKQV_OEA\_""TB\!N<@_<I$527TNXMCQ&+O]0S]_B26YW]K
M9S\D^3#P8Y:P0ZJ!G"X2E?O<T3LZ*`UZ^P!ZP(==B>FAK[Z0[JZMZH->-C[_
M!/2:%/Y7DA.[SN)@OPXB"H,-9>(%>&7LC:.+/0_!Q;IT]30KP!^QLJ<'[_V<
M_LFN<QH<3RE4VX8.\7YU]U]CFO@PH""CF397\MD9$H!/)0RX,V!`O,_L^QKL
MTU-?;3F:W39:!'#EE2;I-."2JN*_)RD+_Q40N4D)$?,F`M\W$0+_-KRX=;O8
M*ERLF:Y-;.>)%"#9K!_PG:>@$<MX1L.Y:<#W7>/I3-HWE4ZN8CK/]X>`$T1A
M8.AOV;1,S3+MMOM,:7@AA,Y]?/]'A;FEA,Q]@%NDX0#KPG.9A<=>Z@UZ,;LJ
ML"Q`UY*+QQ<9TOUOTX);.?S"Z;X*Q0$_)C#1/@:NW>GI'S`[_!LSE!FS3(QD
M@K3+R%A&'%)&)C+2=EIE9BHSCF&7F9E@X#/O$\IW+A,XWX6,X'R7,H)55C*"
M5=8R@E4V,H)5MC*"^KR3B<)]=#!/[B!P]Q,.XC1W$%\&N:6&.##"@3$.3'!@
MB@,S$8`^Y#5U.E:Y[O,&S*(!LVS`K!HPZP;,I@&S;<#LJIE2>6%O*)67[VXM
M6!D?[V[?"P6_JE1F'!CAP!@')C@PQ8&9"(B-D)MIC@,+'%A^!PK.,-'BLVK`
MK&7&=8RRPS8-F.TC!JUTNT?,?;Z6J@4[3*E:U57B-%2S,$U<O(0.!0.?^51"
M$VE42XQKB4DM,:TE9K7$O)98U!++6F)52ZQKB4TML:TE=E5$R31PGGC"-)SN
MJ[""W`W107OJ4#!N=D*P79?8;42,BH3;,1V[L+UD&\.X2%BN8YLM9+R)(*";
M]TS*,W!:U(!C*)I8LV*S97:,CHVF\+Q(="S+LM$)8U$$',LA[?O$S+JQ+`&M
M-IP=RSFN2@`Q+1,IK(L`,1P7C^6F"+3@%J@3VV+[(X%=$8!G1_C+<RP9!0Y^
M3QB%T]@H3BXL=G_!5)1P)(A.9B5#LY$'QN5F-+:3RM:I:&UGTM@:Q2N)AMP[
M%ZT5:2]JB67Q#H:&,E]5MJXK6S>5K=O*UEVQ%1XN,C/D'_=!*MD"'K>>L`6G
ML2W0#CP43,7XCFJ)<2TQJ26FM<1,)EP'>70N,XA8U!)+F8`EL3R95H\8=*?U
M(P;I;!XQ2&<K,XB`-RZ\SL4:%C,6!A+O5,0#:4CC(QW1\SE1?/;.WY<X,#/S
M:/XJYZ7%'QY0?$BZPT?Q$>G"25/FQZ0+!TXY/B%=.'?*\2GIPO$3XGI^8WB%
M<_&.=./%QR!*E#,]0,J&UH;%-!8O@<2/E%VRQ^Q7EL++F^S?$[RKHW!>A?5,
M50Z,I=\_^`WRMW^#7P```/__`P!02P,$%``&``@````A`.K,\4>7#```'ED`
M`!D```!X;"]W;W)K<VAE971S+W-H965T-#,N>&ULG-Q;DZ+($@?P]Q-QOH/A
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M$AMF/_WM;(YKVJ/4S9W9%SVM]V^T`O1G:[<5J4%[9/77^>\?VZ?3ZT.[.[CK
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MXEV(*$NQ!;[>J[9V@6ZTM0LK#/OLJ4[8!D12U&U`?"&7#4A@KS-=:*L_UXVV
M&U+=:/TL=,.V,9.B;AOS"[EL8Z'WJJW=4C<W!_^>TOZ:^W1R4'*_^L1]27&A
M18I?5F8L`Z/..=U[QG`X4G-L<EGB9\(/!UW5.+HQ5>'JPF`5X>EDP/:V+PGM
MFVOQ60/63:`;;7U#W?"UF>J$;5*D"]Y)K!.^28E.V.?,I+"&UR-DJ?MVKG=A
M#5FUIE6&[=V%;MBJ9+K@FYSKA&]RH1-M?9>ZN?DD)?_I^O:)_!=:R7\9H/R_
M5,2$$X<'7![P>,"7`351V6$+=--C=15B,M6)Q8Y]A$F,25)!!NQ<,=/-8-1C
MV=K`I`W,HH')&IB\@2ET8PU9;2SKC9*R-,S]1,H*K:2L#-RF+"<.#[@\X/&`
M+P-R7"[&$@$/A#PPY8&(!V(>2'A@=@G\/*4/NBRMYA=S*=&4!Q8\D/%`S@,%
M#RQO`LK1HMN*3QPMH>D>2+E$L;(>2T.?=[V,L2*90.%`X4+A0>%#$4`10C&%
M(H(BAB*!8@;%'(H4B@44&10Y%`44RSJA%`"-;C]1`$(_M.GZ?4UN:\@+0)JZ
M`H#"D4*.BN@I08==]5S8@P>%#T4`10C%%(H(BAB*!(H9%',H4B@64LCC)@X;
M.VX9["%7>AC2\T+617$+*E)C6?<12N;3(Q,E\\5SA2X]P:B_QQ)+\0I@)_BQ
M-'45`(4#A0N%!X4/10!%",44B@B*&(H$BAD4<RA2*!926-;YEJYSU^FK8^0,
M]I!#4;#/,/AXM:X'I0C$D_[;AVOUR2^TFOP]_GQL+$U=\D/A0.%"X4'A0Q%`
M$4(QA2*"(H8B@6(&Q1R*%(J%%*-S[AMW//7A\CD4Q>TG4'6QYQS+N@Z4S*='
MW4KF-SO]BZ74"K"&;"O'TM15`!0.%"X4'A0^%`$4(113*"(H8B@2*&90S*%(
MH5A((<_^/7/4&?79"":#?>10%%`LZX12"&(J2JL$8T1W$/47@_-RO!;8;,FX
M1'7%@(F#B8N)AXF/28!)B,D4DPB3&),$DQDF<TQ23!85Q!JR1_Q9!6+CZQR3
M`I-E+5$K1$S8-!\E&7)^1[U+9@^(QR6J+0S93PUQ<"\N)AXF/B8!)B$F4TPB
M3&),$DQFF,PQ23%95)"!Q;(^JT",Y)@4F"QKB5H88B;GMC":#:(,.0&D%@A[
M+CPN44WV3S!Q,'$Q\3#Q,0DP"3&98A)A$F.28#+#9(Y)BLD"DPR3'),"DV5)
MY`A/><:EUH:8,_J%VI!33;>U,;2T495$M;4!B2.^/40W,[>]F.Q!@EL:N;'=
MWJC7,]F5S%.)28_L#$;\BD]BIZX`DQ"3*281)C$F"28S3.:8I)@L2E(>HXY%
M=QS\ED,A_7YOR$6N"&KO<E'@-5G6$K4Z*.M^I3K$8NR>P]"N'!+)_2&>(&L/
MD2>&)/3G=2*#):2#B8N)AXF/28!)B,D4DPB3&),$DQDF<TQ23!:89)CDF!28
M+&N)6AYB_NX7+AYRVN_VXC'2JJ-N:O#\1<.)^(HPNS!HU0&)BWOQ,/%+4A:S
MN-RR<UN@"&-8,>T4JL0<BF\-JT_EIPJAQS9]=B6,%-"G[S&P71(K8&!U^4<D
M):@YZ<PPF6.28K+`),,DQZ3`9%E+U+(0DWN_4!9R3O"V+(P..WQCHV[BL*P+
M260N&D.ZTJI)Y.`^7$P\3'Q,`DQ"3*:81"6YK5!6HC'N)<%DALD<DQ23!289
M)CDF!2;+6J(6AYCTNRT.\/A6SA'>%H7%OUTX-NHF$LNB@,3!O;@ED4G4'5:<
MYSW<BX])@$F(R123"),8DP23&29S3%),%IADF.28%)@L:XE:%F)&\+8L&CZC
MDA.):GFPR<:Q^.%,_4!I@HF#B8N)AXF/28!)B,D4DPB3&),$DQDF<TQ23!:8
M9"619SEZPLO'LKD"S+[!08$_9%E+U-(0<X2\-,P>_`Z4^)D8OPNWV'AY7**:
MT>X$$P<3%Q,/$Q^3`),0DRDF$28Q)@DF,TSF%<2RV%<^TTK$!MB+"L1(ADF.
M28')LI8H-2)^TZC5B-&EV]_ZX=5Y.?:DRN+?%"E178U@XF#B8N)AXF,28!)B
M,L4DPB3&),%D5D$L_D!^7H%8;J>8+##),,DQ*3!9UA*U0CXW.RY^PJM=/-B7
M`,8EJBT,/#N.>W$Q\3#Q,0DP"3&98A)A$F.28#*[$O%;:G;UGU\;__4!>XK)
M`I,,DQR3`I-E+5$+@FX:E$L&N%((SJ\4;`9M;$I46Q"0.+@7%Q,/$Q^3`),0
MDRDF$28Q)@DFLY+\ZZ\?YKB/%),%)ADF.28%)LM:HA:%F&SF]QH#>*MARCEJ
M2NWK1)W%'[N.2U1;'/I<-[M`.[@7%Q,/$Q^3`),0DRDF$28Q)@DF,TSF%<0:
ML4?):1.TJ$#L:&>8Y)@4F"QKB5HBE,!*B8#KAN#T4A2E-D;\$94I59>F+JX5
MQ/;%I(%Q&ABW@?$:&+^!"1J8L(&9-C!1`Q,W,$EI:LY3LP;=S!N8M(%9-#!9
M`Y,W,$4#LZPW:JF(Z6=^-3$Z^*Y<3EM3S5Q^;CX6;X^B,J("N80F>LC10ZX>
M\O20KX<"/13JH:D>BO10K(>2,G2;9=:(C<]G^G)S/93JH84>RO10KH<*/;14
M0NKQ%3.MM\<7G`KEQ"P[%;*G5&-3JOI3(39.@W[<!L9K8/P&)FA@P@9FVL!$
M#4S<P"2EN4U2=E6:->AFWL"D#<RB@<D:F+R!*1J89;U12X5/^XKY+</"(VLY
M;ZN<"F5(.15J(8=>6,A.F*X>\O20KX<"/13JH:D>BO10K(>2,G2;91;_WLY,
M7VZNAU(]M-!#F1[*]5"AA\1;('_N5'E\Y5L=Y:OP=IO#RV:R>7L[MM;[[^*-
MC3WQ&\MK6+Y.DE+=%BM*%S+60@ENB_756RBM;;':>@LELRW67F^A%+;%1N@M
ME+B7-UJR-:`SD"V.K;X,G7=L<8CU%CK;V.)(ZRUTCK'%`==;Z+1ABT.JM]#)
MPA9'5F^AT0EMS_D%F&RM:4Q"VU/5\DB]/5;V1M<9>US9,J&6264+75-L45CZ
MNM&5Q!;UI;?0]<,69::WT%7#%M6FM]"UPA9%I[?0R)/V6]66TGB3]EM5"XTR
M*=^J6FAL2?E6U4(C2LJWJA8:1U*^5;70#0%M3U4+W0;0]E2UT."?\JVJA8;\
ME&]5+330IWRK:J'A/>5;5<LCM3Q6MHRI18PN]7U--UR4!U4M=)M%>5#50C=7
ME`=5+71+17E0U4*OEWWL57R^:]CT=DE]O2+#II<VZO',L.E%AWI\;-KCJOXG
MICVIBCNF32^OTOMQ39O>8:7'/=.F5UE1_/Y:EO1VVH_5RR99'5ZV[\?6V^:9
MSH6=NR$-X@_R_;;R/Z?]Q_G-H=_V)WHO[?F?K_0>X@V]^ZIS1_AYOS]=_B,^
MX/IFXZ__````__\#`%!+`P04``8`"````"$`KFU`KNP"``#;"```&0```'AL
M+W=O<FMS:&5E=',O<VAE970T-"YX;6R4EEMOFS`8AN\G[3\@WY>#PS$*J9I4
MW29MTC3M<.V`"58!(]MIVG^_SSBE'-:.W@0(CU^>[[,Y;*X?Z\IZH$(RWJ3(
MLUUDT2;C.6N.*?KU\^XJ1I94I,E)Q1N:HB<JT?7VXX?-F8M[65*J+$AH9(I*
MI=JUX\BLI#61-F]I`V<*+FJBX%`<'=D*2O)N4%TYV'5#IR:L029A+99D\*)@
M&;WEV:FFC3(A@E9$@;\L62N?T^IL25Q-Q/VIO<IXW4+$@55,/76AR*JS]9=C
MPP4Y5%#WH^>3[#F[.YC%URP37/)"V1#G&-%YS8F3.)"TW>0,*M!MMP0M4G3C
MK?<)<K:;KC^_&3W+P;XE2W[^)%C^E344F@W3I"?@P/F]1K_D^B\8[,Q&WW43
M\%U8.2W(J5(_^/DS9<=2P6P'4)"N:YT_W5*904,AQL:!3LIX!0+P:]5,KPQH
M"'GLMF>6JS)%J\`.(G?E`6X=J%1W3$<B*SM)Q>L_!O(N428$7T)@>PGQ8'?A
MX-5E,&S[P3:.`R\(_Z_@F'*Z[MP21;8;P<\6K#@0EBW1Z]=;0_*_VP%]T.R-
MAKLA4*F$*7S8QDFP<1Z@[]F%V<T9/";V<\*+>L0!KUX.FK-<3L,P*\CJY0(O
M['.[`G:&\0>,/R;V;Q$C-[C0<C<-IPBR!VXO-1LWPT1=6U=!$(:N.W$;$C@*
M@R$Q<H,"E[MI>.H6CZ^\,TS<N?G8CZ.9FR'@MZ\0O\S[2`YNE^5R&I[*)1,Y
MPQ@Y+XGF;D/`7X6K@?S(+'R/F88G9G@R83O#&#.,D\%UNRG?#\_[_E!\Y!6]
MQTO#8R\OF=X&AKEXS;6&IWU89"]EC;3TFW'QHT/#8ZT`>Y.)-(S1NHI=',>#
M2YN.C9`53O"K]T#R'CL-C^VBZ2U@D%<6N)%[$S&M,^\G\P1NR9%^(^+(&FE5
MM(`;Q[4C6*O"O)W,@>)M]\0]<`5OE6ZWA(\("H]CUP:XX%P]'^CW7_]9LOT+
M``#__P,`4$L#!!0`!@`(````(0"'OXC^$@T``)E^```-````>&PO<W1Y;&5S
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M#&N5RF8?"N(]9Q4&NV`3O05QO6"S<59V$>6L-^N!I*M+?^^97K335L'>C^;Z
M,-NDQ=^\7\_U<UV+35X&:P#QIU_W0?3='^(_;_[\YDW_/]]^]Z^?[/6_?_ZF
M^-W/W^J]5`V1"3ZHEOFV7RD6OHXE]Q(+KBXW@4\,F0%-R-;%HQ]\\4W\#H(!
MS,.?75WN?M,^6RYL&2"\5>`&H1:!E\$^ML6W/#O^Q=)RG;O0P9]M+,]QG^/-
M0]S``B/YG>>`FW!C+]9P6CUWB":U:8HP.)M&N(7:Y(%)%FZLMLGZY8!-G*YQ
MO:XV_'&ZF!75=DG358R+`H=M=&6^(GK"^[NY;II00P;]/M)*'=:1LMFR#_I.
MINQ\?#++1N;(G$BUC(O%HM]0X<B4266-0O/=Y/ID=,I75F9=4H9/E0&8<')9
M="!U*_)[8N+K%'%RX@&M&X\QJ5S19ZDGJS9R4=BQ+BXP.M:UIT'8L:XLV(F>
M9#`;F,9L<BTSV"N482++3>5#R@YGU:WCV3OMH_U%^RGP+!\MIE,K%K/<S+!9
MX#46WRS6&HN']57TSG7N_7@VO-MO8<&U"IUMA)9GM)%1\C!M\F?7'00>\]L.
M'.JX;K94&HUQ,0%;KBYAU1;9H6_"!RUY?_N\A:6$#PM,Y*,7_Z[FU_>A]3P8
ML@FUV`Z[P'76B.)^R18PB>G+\QMS></T$F2B*$J$FN9RTH'0F\5L*1_I<C:3
M+71HPDNRT'=C?$D6:L)_2VF<)EEKR`*9R=,B!QL._;>3V6PV'9Q/I].9,1H8
M!B/Y+HEHQU_;3S;V(*315$0P!@2ST71V/@0@?6/*5)T4P0@`3,;CZ7@P&QKP
M/RN;W2.0S>E85^U5@D"15PD"15YE:]Z>A,J?9`JT_Q3G*D&@R*L$@2*O3B17
MX(ERKQ($BKQ*$"CR*NO42LQ5:*LKSE6"0)%7"0)%7I4V^4PJ,!S+4.Q5@D"1
M5PF"4WLU758M;VY,UK<KSLRDS8\373B);ZZ+K1IAG7H7A&M8CJ<']08&K!'C
M;5>7KKV)8$4:.O</^#<*MO#O71!%<+3PZG+M6/>!;[GPMI?ND?ZMV!..I\*A
MT[D>/3BK1U#&M>MB;F(576G(\L/`U80Q,?H38SP\CQ=LDE1[]MK9>T7K,MT'
MXQ)H1&[K#2<<^IF2)!SREG$/O9"X3W`/YFKF:<$=(";2D!#<0X:-^>$341O)
M'F(VDAT$;21[B-H(J7,HN5(FU\$>#N6_=+!I3OO]N$<HJJ=:(`%^(&(.@R#[
M%/FLW>4`H[7[-+45ZDLA-Q9#?+'9\0%+:_8HVEFSPP$K:_80M9&/F]2[G/"L
M=8'E^0"2%WQS/S\.!BB*=R1X2(5/RE/>=Q>N=KRU!34O+)&E1]2*`]R"(SHP
M_`A`P-6A43H9KF'T7]FN^PG'XW]NLBD`=-6N+I\VY`0<."L*SU#!\WOP+;2N
MD[?Q<!]_`%UE.PU+=]*L[=9]_KCW[NS09*=*,15L*[;(\T\+-D_)/[,#"I[-
M^H)Z+.;',(CL5<1.Y6)'E\KPC$KP#!)!(GC:Z#=*]`-/PGRTT0]]IX-.!%Z4
MZH?@$M8O,Q[PI+4DJ,$%-*BK\,A$`-V%%`$X004"/,DNX0#"4P4"6+6E""!`
M<P0`IR(JVN3!@%0SB(%<)>CO2B74F-1*3F6'5I:57]!?8:7)E=]6-)-Z"X&>
MTPP?*@"T4EE68E65&.)VR+2<`OA008$)HZZ<(6]05O.5$4**+F#(&8$R4,6(
MO*@D-1=TY@"J&5E(G(>0H,!2I!H"P%$"@3ABH&C\'5`,BD9@&@V*AF`*@1N#
M3Y@3U!/<"*D(`^!1DA7Y/&'`C1@GI(%`4%4A230,595(BD%5C<Q=,515(@D$
M5162>D)5B:085-5(X@I5)9)``$:45$CJ"54EDF)052-S5XQ4E4@"056%))X8
M=5PB>[1M&C=12?]TAE<.EK4>P4'I\O^EKYXVM8W40=FB"62EN\>KIWCE"+Y@
M:RFRE$9P%IZ,C;U3[2$(G=]@D8F7-ZY@@QWJ>#ELY*SHEB^AM;VUGV`I&A]V
M>MJT,K`&4ZX?6NNZUD2Y='Y:8!'P=`T1M9:S17UM8_Y%9/#-[=H(J06!=B88
MI-,O*3PQ:U33A#TPU1A@D%2.@88+#)AUQ;!1-6L4JTA&TO`&3-P$YJA2VD1Y
M^]K0HC#A<E*JY8>RM`D;%-#HY=*BRA<F:P:V+V$D-QM@.5Q(34AR'">3P)6$
MD&:-;/<=ZRHI62,S=CA`V%"MBIU%TL=-/54Z13J6GBXBF;*%)[`TG!V1R.D:
M'3M91@">\M2CE(J"+LG&T<N61%7\"=8N"J^EQSM`=W1N<%CJ4I6G2CAQNZ+N
M!'!%`[$L>VKH;3YR'46ZJ!5EZ<1-!>#F.Y7U7'V0G!JN*+UE05*#]^L(DF[&
M?%HZTK9(;:TKXYE+QL*LI#G-\F<JU0B/FM%2!D4#5:P.%!BLPG=4W6HYSO)Y
MU3U<47J5QV?+F,#P$%JPRTF0U]*<Z'JF_LM^%SF;9X&Y>EE^=EP^6@,$W'=L
MM9><M5PU+2^-'1J\QR&2W;NO'9!8.S9MS9*U7S4?(@.2$$O"`V=)7%7#Y*M^
M*2!)?;*ND[`XY&AX.XNXE01GUO>J#KEP/:N.DU$:4"G>I4G9=ABL&;9%TD+"
M&D34BI*<X5L0KW_-Q$7K">"*TBLT5RKB_1J#!"*I:D#D8[JTSM),K*@1\;5W
MA6)&#V32:L85B6+?183NHU8`4H<N/*>UBN%7@!#"_74CK`E2H;#,9FU-YP1E
M\ZB:28%(=!Z17:(EC(P00^B=B2V=!&=5M5-/JAS?"ZW;.E!>6DQD!%2QSC6:
MJ7$3CAH\1\1)VQK&3R5>'SY`E*_J!EU4L",RC<9;%P0V2;RNL=`A7VZP%4=Z
MOC3PV:!D_.S"N930YK5EB'-6575V"!/Y5Z&\9DRNBB.A2<01?B'4=(&NMB1@
M7"1=(.JF&BRO:/9"">06C/('I9;N[0#=T>ZMQO(UN/<$PX"@O\M2B..X"+<Y
MR4>-94?,4\H+0;&I454SC\+;DG1P!IGX%4X+^#I(YV>O-87L*):/F9+!#<5?
MQS#.T5/#3NFX75LZ07`V,I[\Z`Q5#G5$ZNRIY4R2P*F9)535AE*_4'1M:Q=7
M@6L"A5\VG`(>`,I+50TZ(3S"2<UU5(5C6Z1V-L*9M]K$D9/$P+="2YK#P$NA
M-JH,Y,(R*?ZL5?Y5^8Y="P=7OY%[B?%W$LNNE=/P,3SPV,#^'[4S[=T*`R(;
MO`=X[>3><>'6M7B0'J]C7,%Y"8&WB#<F5YY5R<JZ[+@0IK*@1#25!1+B?O@0
MG$]EP5'TIK)`?2QK!-8267";M<:R8'A.9.&5QSE?!F1X4URP2R*+YWXLR+UQ
MR(_L&OT<%YHL@HO*ROV(M9W(`I.;RLK]"(ZCLL#DIK)R/P)"(LL`)4UEY7X$
M+U!9$&Y-965^-+`ZY7R-!;D_/^A'/E;Q@EH17%16[D<^5D>"L4IEY7[D8Q5-
M;HHK]R-()7P9\$536;D?^3IA"-8):F/N1Y[[L2#W+RLJ'_%#P8B/I>2^@W>$
M(YP-BG`42\F]QD?Y2##*8RFYO_CX-@3C.Y:2>PKD$8L,^$+<HLQ'(YY=0Y#=
MA;5.JRX?,#C.B,"`1V"M]BX\^#?`QP:S"\9QP4X,PMN#"$EZL%>/VA+N_YD)
MXO,!AU$103=/6]?RK2@(GS6\2#P3QSM]+"CN+T&0<<1+&,)'$4`_P$.6X?G-
M&O`2,\3',![-;2(FRP6>'KQC5!,QL'>,AH\_/$C31`SL'8OABRK.GT3$O/>W
M^\Q#?"W%H5M$Q`?'?[37?.3P#&-S24321WL?A586?WQ*#06)^8AWC<UD\"4B
M?L1@>HO;9/[Y$6X2FY*(,VV2.]C!$P'^MWU$:,2]B!`\V"XBY-:)X-[>:1)S
M(A"6D(@`;MR0B7A1401E_,,*?<P6+G5?Q&B)1?EM,&#VOW[*[R#,>(_P,>3L
MWL+9>@"(6ML;:^]&M]F7<SU__U=VUWP(IN17/SJ?@XB)F.OY^P_X.`+(8CC8
M#N7FPPYN<0]_M7WHS/7_WBPFL^L;<W@V[2^F9\;('I_-QHOKL[&Q7%Q?F[/^
ML+_\'U"&SVR_@(=^MW@F.GMV.]P(8V!<[%QX<GJ8&)N`_Y1OF^OD0PR?W8,<
M8,.IG:D1O5WV3/FK_P,``/__`P!02P,$%``&``@````A`&!Q!6/*>```LK0!
M`!0```!X;"]S:&%R9613=')I;F=S+GAM;.R=VVX<R9GG[Q?8=T@(,IH"BFR2
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MB]MR/"^`HS@9SX?S3\7IV$T`W-]\/?_VFZ_UJGM]K_A^,I[?S'AU4`[RI_]K
M,=XHNIN=8GMS:R=_&&<Z6CI3\6]'E[/YM->?_^_\RZ_R'SR<;\OKH3X!^M>]
MVS)_ZZNW)Z^^/WIQ5%S\_N3MT=G)NXO3X_-.<?KZ>"-_U0]X#"*FO1$(&)0?
MBW\M/^7O?;6YN;FUN]O=V^GFCX[`XL`P^7+4N\Z??G75&\T:$$:47'RZ:SS\
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MSLOA1Z!S:%@*U*!$O/O#"JCMSG;7`];=[W96@O5F?@-UW>CYS`ZZY<\">4;#
MWN5P-)P/RR:-COJF7V;%7>]3[W+4X$">3Q>LK8TTKR?SLNW;%S#W>Y;\OBP2
M$/(5G"\N)U.4J1'O;CJY'<YF<'DQ9N0(5D3JH+R<%X/AS*!.R;NUL]79W#E<
MC<DZ+5<`]6HROEZ?E]/;"/FG8EULEB(C7XD;?<6HB.7M<"[E,G-R@0Z&F;$F
MD"8?[7P^Z?]T,QD-L#Q?%8/R:M@?SILRQI#P^4PO=^#U#10;])@6B-JB[!2[
MFYL=E)W^6\QN>G!_T5O,;R;3X5_*0:?8V>QL'^YTMK?V#:"=SN'N06=__R"\
M"RU$?1F5R6)N5@Z`5R/Y:#"`UR9CI$92O3X<%_W>W1`IRI<(<T6Q]0O,7W$X
MM>7EN%C^:H)^`_M!GY[#J6#FJ$`3>55CZ"_^[?OR]K*<-DQ9]9[#_!^%[1R@
MXQ%RR:#]R1CW83Y$O`K4@)_`/FR=8*6J/H..6.]R/NSW1L_:5/=1I@C!\%(M
MFH-=IPH`>[V5O_<B%<7\88Z@BB?O?;/!IOD7K_"!9,2DX)<COB8441KR<22.
ME>S<.^W2UYV`/&CD1(#R]QO8\L`L'[WM[143U-CI?(ZN=5H(^_CFKIP:+EM]
M@*WME=[BB\1%V,Y7=HJG?(N3$:9<X1Z^+=^7XZ84>?BP^<$&-93@VW)6]J9]
MYVP,&&8TN=/Z<F"^*\>L=61ZH3>X'8[-[92!RM]T:@<W7:A)IL[?>S5!PJ\P
M6H5_%P\K?\>9[[4`_;-B:#AIK,+&@A_[-SUL`F\55[VA5^2R=!B"!YC3TS%F
MJR3R<+/DP,3''IS\N5^X>1P-D/.77^-]C<!`V^\%^$/[.2F3\<&&7O9FP[Y1
M8#`<+7!$\X]_*(?7-W)0>RC-'H@8+Z2"A8%TJ%EJD!XR[G(1T+"FZJ-UP=F4
MI6W3JH:@'.:@Z2O)7&T^O"I9_5)B1\^\'3UV=K35:J2J.ZRCS80])^H:C\7<
M(1+HS8M4EAM12^.+#L&#<RGN^?(4-\*"C82(\EB,#S[TIHK]9L5\4O2*:>G<
M>+0V(2P!;/3`EOA(O]:X82$Y75\2F:,=QB52#NBI;W$IX!8$F-/\HQ2HZ%C<
M979?"W-^@=(*-OBD-W9N87`SAUZ4_^X3M"T_74F0/2.;04]0-Q)BRH_EM#^<
ME5I$H.4JD!\WTJ-A$Q?U<1#0-J-A7_%D`6-7JO3!H-TWT$,@:Z4_@_\P&=\M
M$#\A<U9.WP-L0Y.F%'CL6+\(/GG\@9@&H6+X&(5-KG`EI3HL#%^%T5:@'S/!
M0U;2X*J'H+3UH[8936.O8\.P3WRL=(7S0UO,*8F=%1JVX2W57P]`B']3Q=SX
M+.62VI(2%OZ^')23*6FS,0F=7RP0[:,%H'.FJ"\M7U)W]>MAT'L_:\,$`X00
M+W*U.-#_^ORAO)Z#^;/G"QITN4B%]>;3G1"!7XZ&LQLQE5_(`_W"MV5?X>@0
MY\9Q+-IZN4<I.WQT=GI<+.ZP3&;ABY./SBO-`<*IPDL+)BSB.+-V+#)-YCC_
MV^=2@I'3K"GO_N-F:D-V&VT-_.#Q92N5UXY9'RO#"/(^#.<W+I6"E5R.P;_/
M+&UKRG,"E_@V<G>5X:Q(>57VYHMI(RAJBO#*0D']]0"11'CE9[!4E:2.<:/Y
M7Y90?CF:?&@-5>V-*WLCC<J0%@H2P_>6`\TYZVCPI\7,9^5@0O(=$Q)RY&J4
M7%9X(];4ORV-O9#JA\I5;%B-W`CI7J1IWQ83<9QD(8JAR[>M<@G:3%!C68WT
M3Y(YS5\^MIASEBW,TOK&[HGGVUCD69:]MP\F*W+6"AOOQ64#0OR/(J'L$,4S
ML]B\PG_^S=F"I`"V6I[I59*BS]]K`/20P7-6JVH3*P":3OIE.?`I@QG5$('6
MIC8-D<%<Y3"?+1TJU:"/_-PDS'\OTQ@T7!MTG>)N,558-Y=\G%MXWV8FSGJ?
MK*3&8L>I);AG48^J#%3X7^J41AI38G@_I.A9*(*+]:1VFNE#<BE49V$DRV7/
M;G*XC1=0;)<QIF:E2(`2(-3WVEXOE5:_]T4KC0T6YF]78\HI;X@BSIVR;?/>
MQR6A1$LT^7HR7C=I3)@>N"K4J#([$WY0S(T9T=;+'`!T`A&"2G8NQV&^5DK.
MU\8&C[+Y>5A\G\>@*4)I*BC6)>9Y0*38GQ.#"48"&\*P*72>+5AVGP$HF/8;
ME<*7;9DYQO)N%FMG>;U&,01D6S'$>"ES%59+47W2ION'^G;FP]P.6@7(J81(
M+6?!YX\Q_/6)*Z\Q3K@$K0(EI'PR)RF'I6WXX.'&:<`G]6/F-T.%F:[Y6>F,
MLY37\J+BZOF#P@W(7+*VAU92'KPPV?M`*1PQ2MO+N$/"GRZR33.O7E]%OK!"
MT/J07$10[E)9H]9DE4L6I#Z-.6(MN;)TS!K-QJ8?))(-L1>R'KIT*>;6)%4#
MU!QQSQ>SH7)_;;^O*&8\?W=^^OKD_#S_]/6;BY-BJ_C;7_]/T?;*VW)TVQOT
MB@NJ_KV[<D&5;^;B]HX@OBVGHT\T@]S>%:^!SD?T:V*.O_WU/_`F[^C\^-M?
M_^^S#O*#IZ$OU)M`;O5U^5X#]R=3&D5\%#@NON]]"AT>VZ8$L6*]L?OBMC=>
M7*'[B0:<@IR6\YYUH\`$J,BKRTEOBC\C0H7,+00#9U28R]F&%A&Z46`W8.B/
M*+M0ME3+%,G]R^'D#M?AMM>WA5H<8BL`\+[YVH11@^GBVKSP.59XKJHR_4GI
MR#AY#*WNERO4]40<"L--J;9.!HL^TL17@Z&25E2%W,SF[B2U(EL"RZ:0!'H=
M<'?#NQ)PS4D31BI=/K^9EBKFNN%KP/SMK_\^TW^+WAW/>U2E6+=\_[Z*&L@:
M5G&!89E@-^G;J1"2`C,=SGYB!+!ZAR#0)<";GXC71V2C74E(S1H1`&D+$O%@
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M^(P'HTG\`$TBFO`19;:6O<>:"0[Z%GO-7(DH1XLGGJ>W!)3:C\`5J;8VA;:M
M#?HQAD*Z0V$=?@=R^/ZF-R"T*-*PL^#+)&YU['^'&]T?WDG_""Y?]0NL%$8#
M>_/I\%+ER>+I=G$['*%5J,<R8K?3[>YWND!8+2RG;XW^XDO_T>9A\E&(KY@+
MF6YTAQC6&N)W)#T'GRQ&UO?6I*K#2LI@86V!_2_+/DV61N\$&:DH0`#_<L8C
MR$CN=+5!$#%IB044"TIX;/-.PN!+#)QQ6PBVW$=5MU)#K);U-H%L395\A5BA
M]Q6*&%;$3'379DU1#41?-.3%K"FV3;VW#"9>,*LSI=]@2FB(7;Y&^.!A=>O-
M63>DNO0>A&"_5(\;;.1U&\@,)$$!2UZ)2@6F4.HK6%,WC9M4.5\QDX_,8&%T
MAF_X1-KN)G1..B;'>KD&#]&^:DS@_:L19@A3:E.$A)C>"J!$Y4A_C=D]81.*
ME";F'7,6MG?4#KJYLU$\D!T#,R2L)\%S!21G[;6P`$/R&CXA:!GVII_<RJJL
MFXPB!6)0!ZI-&`+/YBY7HN:")AFK\1K\.2N+LZ(6)U!O@5./9-^'BG*4?^7^
MF&"A_?K0]9+<(*$=$8Z+$0T"X=0OU)2\M/FRIA0FP>HSQ&QACM+50J8=_O"V
M4?I.*\*+"_8]?F(NQ7L`Y26^@.64NN7S][1XCLJ:A1=J0-^?(+B6[=:JCU!D
M_*T)>V-UO<&(@AU/;%[V;\:3T>0:O(X')$6G^D=_M!"I.J!DKO0-2I4N1C'J
MI(-+0@UL0`<CS"+M,!KU:.>$SVGZM+K^M>LTTINQ+T>IEP1=6HW83"#1TT8L
M;GZ,J!`A,C>&?H6)&DJ1E7SFGTJPA1PJ)AR1FIIJ,7I3S,U?J#H\5]831_S4
M,6G2I%@)+<"H_W)"/[:X\05.9W&4=`DQECR:ER^.S!O0.\[<7,N5P]\:JU%X
M6EZK$5DPVC".9/;`BM+6=]50-^>RU4`'L.?#Z[%5:?!4CRK)/U,>8DD+Q,._
M7!&MG+_[_ONCMS\6;UX6YZ??O3Y]>7I\]/JB.#H^?O/N]<7IZ^^*LS>O3H]/
M3Y;',]L6S_S\0<Z<4290$P*.09WK4@>)N3!?P*G2E>X%F+#2AE'KF<*":9V1
M.S9&)R+"A_+JVU&&+EC4-A,FK&AO?4`Y(5.3#V/&CQK(PIDC1'>6$,BJ5TZ4
M/F6C)UFSXH9>)D2^Q,>4\+A>9V=-JZ4VF.*=`X^BWQ!'KIG1$RZP;G3*&+]I
M*2W8$,HP6(CM)Z_C*L9",N01"?ET(EM,8DM!X[-\KQS>D4SBKW,9%HHOB,&[
MC?.-XKNCHS,3AJFZ^]%X!0$C89TE>U$RM[V?\!<#_$X>T)JWWF=T>HZP3"J*
MQ3A[QCST\&-EC1M<:[M]FCAS]K?:P*G/H)RU=):H<@!2*,VL+0V2T-HW;I9@
MV33C4GSINS9P9.UI4G2#^XJ.!=G)%[)K+O&+A21V-N&7RR85MQ@-?"CJ^@8=
M%T8<>0.>L%A\I`C/9E%K=Z1XDLY)UMIQSLZ*3@6W`D@?$\:&+W.>*H-83869
MF7R0FFRPJ4M^@S/[QPF,P%>0H9$V$;]Z:309EK\#2DC1R(Q,9C8WXS"5!;'(
MX,A:?>%"%7M,=7K^A;6PRN)G$V!%XQ@V[6C"F%C&AP!R'*,0&2O97)LLV8E2
MLYA?-8`!X3<E!,,<SS],#*AU*@'TMZ__&;)J^HJ#R!ECO$C7H)[N&=<8$>E.
M/U%<19A>7-&HH<2`3*]X6SR,X,X:>#]#%I=@^=C2AU/?1L>RK]C[X5U'J]@8
M>]JW2E%@58*U8K6DK]F,(0F,VL#8HMXM:^D,:ZR"6EX([!/82?MDT)K\RXV&
M:72[3XQ2^#SL!-(V'W#(XA36DJL@Y4Y::=Q8HMM7<V3BG%N"=,^-B8;I?Z.5
M,JB."5#XR0X#E*7O9=\H&I]+B^,D`;PID]L[HC_84\I@-KF:$P/C7]4*NH!.
M(JOO]QW)T[\V^=1>-O6PKEONB#S,#2Z%?`1[&N1Y4)#>POF#O%?1#`6R.0T6
M<@-,Y!).G_`HFXSP@B*3VV?3$#G9*]@I/#8\532>)VUQ<M^D]"[]MC#;B5AC
M8ZS8C,'`"A8,-%W%&@@DM,7CPOQ$ULFU1X',OC!R.R%M928YI!WY47L=A[*Q
MES,ZWRR7Y3]&._<,Z<ZD:(0_+0;79E%$BX"^)AHLVV[[`43!EZZTA^X]12ZG
MMCFR@9Y$(YGEKPNS_P@;B_V="ERXVOP*J1%YH`&QT#!NL<*M=,8U;EYR/+2J
M(@%C+=#M+LTQ8W?.W&T^PE$(UJUM1KFQR^;#YZWOI!)Q^[CDGX32Q,#R.YJH
MS63>,<Y'<S_$';2C5U27-`0$("<U[5'C++1GJ3RHLXD%LH_X1>:1!J"@8BP%
M@PE,L8Y,'1]^,(.)YH9K2X(*4^2S$K8F#C.@I?"M1"KTR>FZ0M!ZD2*?BC7>
M+#_2T6W#/H.(^E9J3IG>I+J)@9A_D)/F6?&.%F1X^,Z:DV4"`*T*N>5&./GP
M^!=>K[4Q1:H/-G6=6G(5^!(#M<X&/.G&&_Y/@2&4<ZD_X");SIY%WM4<0_I"
M\150#]'_JNRP4R<*TGSL=DO:=X$/1R-IQ&FC3/M*P1=UA_7B#PLB(]+*0K'%
M?E;YQGJ:[#I7!L.,+Z4DO6<+V=2*PQMJVHV^S>@2/V].7()DJ2-FE/6!].12
MFA^(+/,0]$+O/54&G^)V:F1&/E\0$^F"H!!VBJA6SD=3:T)/N82H6N/[R>B]
M$#3#D([8&[=\56E%`5<`#/E,88H:Z(.TS$KLG#43&=^+:/PT80NX1<S1#P"#
M_F.D%.45R>CDQ2E*Q:C+U:`YWPI2_"`MB.\^#O&25%-=`>DNBHVPD<F2Q?(L
MU@%_/@/@<[W&.T*GT^SH0;\=D_',OU*73E#[9CX]VBWTUO[UF<.&`%$^(:+!
M4R_FX2'HH,27G*Y+R"^GDY_X)[25@Y*2>*-P'-A-$0S8WN"@]YQ_(<+'X$.0
MP3S*CUBP#K*#<=/B1--*H/0E/KGFG2AQPU8C%V/<(QFFYB04EA[I%6_%.":L
MS]D'D]FCJ3;RDU+SP91UJ!Q5@1K!EQ@,/YNS!V(;IV*QH_-CB\(N)G?LK7D]
MV2@.MC<M)M_:#!N:&5S_.>-_AE]S#,!?A"N.,]A\PE_D;5@(2[[E_((M_3)]
MB3?M7CG&T;V<#O7K50\!(MND+[?U@QUH4+H?\`HF4_WXM<TR_S99_/>FI"PN
M='Y<`LX_`A0JI]$?\)03_1.E9H*<]&Y$IA0CP-`H=%Q*:5&<"]/0X`NC@/5*
M$P+>AB><X_2S+;WF3KF$!%PTFYES8W$,>B2&?E@1?J.L:68(+U-M*5B&X"<L
MGR-PSRRZ34[8;JGR]JI0NY)V/V\RFF9MB:#!&?C`#;@;4;$UN)4U\UF"9(QH
MY!S2?$`4G+?4>=0BA>/$FU)8%)PO9R*#X]56]W=1X8"4S?I4NW(DV2$!:!9"
M+<K.F:^*66K.O?<3U=`3+]]RA`)7"@$;+UMO5`()B*9H9?+A`_2KX?266)SH
M]#7P%#M>@\/]R6$<%U(UI)PF'TSQF-DSNXE%F^-GDBUUG'</JFL5L<R?33G=
M.5;X(L%SE"%`_N'FA(*8)96:@KY"'F!UD,%JZ=\MX_D@#5_#>QAGYF'D4=OI
M6"D1'+G\P7GD^\:VS>\KUR3_Z@VD:&S`.O9>;O[R:7!K\@=OHOG-G[P;5Z8Y
M?^;4NF$D?W2T-&(]-;\N?S<@,__]13GK3X>6*<L?K3ESM]4XK<,_V&Y[T&T\
MJ%SXFC)4?XH7%)1.E,8<D*?Y#^OY#SI1(YB@ZOB9_W8<_X+HPW:AAJ-0&ER?
MOI$C8062VQ1:/H3;EYOHR$2@&^^NU"=.JJW%O3J/I%_U?TNYI6H@32HGD]*W
M(A5X-41Y(`-.075A%E/FR0#1$C10EHA\D0H:$;L%0)Z;FTQ[/OSH=J0W.>N$
MT*#1;_LC:9.65YL_Z^4<H]7.5Y\>R5]8HR%F:[/;V=G>S1\U1&YMM[-YN-DY
M/#C(7STV*@B'"?[0M\O)SGN6C;`@<4S>Q?8J2)&+A#-PY#.B!-P0*>@9.]3)
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M*><1,DV423G#QCP7TUD+RY7I0[`\(\FOJC2OSUTKC[E5D"[T`>I92/A4P8$E
MD<VO798K(XU$;`\Z;4%+0(O^,:EM?\R4NO$MQ,4'9D^^:T6Y9WD^9E"*6+.5
M8Y(T+%5?4>L#\+2?4$E\\EADOWH?;9&>"%X5.^GF#^=)NWH3[2%WE.G)5J3H
M$&;3D2]C"I_)H2Y.Z7Q4DKT3_4L73.`F/H1H<#F]GU&_B6!A-0JAE)/V]`12
MOP!F],4%J41]XC.(YL#J[S`@"#%H\"L!3OBV]G;5`%E2,K@5A4@%,B5AP:7C
M"85Q&@W]M[!D`-$$"496/UO`#\I.P:8*<KU7'VMA&J?*]-$_HIJ3&Y[=5]J`
M_A/'C#$X"<<QF0X#7.4MEN;Z50E+7/S01**#HB1*(:$)(K2C_;)$REP5,,B?
MO'+U@L(`9,]&R(0MQF.@HZELVBLG'WZ1=B`8">VT^E(<V=:\RK4WB6W8@UJ8
M05%`G;^1>KVE:!)S@F"UNK`2E:VT:/WD5V'1BFQ8$PV*KQ5EZ6W#Y_!&+1I\
M[Y8;*Z%ZP:^:L`XA$<9O.=S./FVA!W*J5J1&9NVB@DT%-.F1PDK>+UUY+O"H
M,7&)YE%260D^<KD+0%:A'`#U`+E_QP*LPF5,;Z5.BT?GU,>A/_]90"5)M_LB
M,J!7KE[-R<^JTK"F^1;C!/D:(7!^+=?@QHMO`OR<\(^,AB7!4"\C'0Y'J@\I
M':.&0QD*NK5.()GT#0,VS/(2H:6819FH6"V"K)K2#$Y8VEI+Z:I*%RB`K1HI
MTQ*KA!D.$=ZF:]-@6H<.ID61@"53B@3F57]4[+.&0<ERN5:]T*CDZZ0F9KV/
M9@#<(6ISD!7<J""0MA++9N,TT<AZ0T:"CFR=I=E@L[=DDV.3V(NJ0RJWXK7W
MTDXJMUF$7#6Y4Z7F9/JP44X\_-C\1K94?7\!U-[@O3(7(>^$*I3F0_ABBU9[
M`X%+)VD>.AI4&JESFM?8R`NR#H]5RTM&!\P9X-2U.E)NQ>,&DL[5G+I.PA0Q
M$)+#H0LYDE*9]1;4%52L'HS"P.B-)I](QLS\<1L`Z*M*@!+3SL(2"KN'[V=Z
M1OT"9'62.+A*68NUK_$7Y^O65E+WV_701A&*X%.#`Y4;!9'A0UG8F[:!*^4X
M6PT0$63[S)IL\`-HKW9EC[`2H;(&?YR:VH#^;3EE.BSBVF.'RL6J%<3I9^I'
MCLW>`%.E\JK"]W.2@C^MG_?1J"A,UQD.I$D=&,=9FZV]/A-@[D1;67*Q*`5%
M'*R^Z0CGJ218WZA1G_6*$Y0Z:^E"-[HP%>@:L\DQK`6^J]6Q2:\)D";I3):(
MO9R%B:QB!G79^TOXQ#7M^T(?TH6'3(^43#@J5CV;\H-5O]-AC%+&1N9H32-W
M>(:M$2VLGT_4I&8.[YP!(XI9=[(H[^00YDDY6$&V*F9Z[EM0]ANY^L;2OGYU
MX3@XFQBSJDA"+=Y#"7AR8UJ<TPK!$J8/=B9LY79@X&S5M^375Y&!;G*G[#;*
M1FWQ2$+#?U1@`;-8)&2G6@C\P,%"1SJ#\^%]B=QPY1DMFB-86DS@G!JW1*G2
MNB*D4VQ8?H#9Y(5>4__5*_S3#^_=,58,_](UISPR1WM<.V:S-#,+4@P1)EI8
M$Y30Y]OG@,&'I[YLR_!TIPVL?]:.EZI4]`_R3*T7%>#Q3>I.G/F[@9^<5(HD
M+7-Y3J(K$;.M<9.FOP'K=$HWL&RR*DFJ7W?4P&HJZ2,"^-BY/M?.ZU<Z?P$D
M2?35N7PN/92_J%I:OSJN0:_W_;884UMY"!@>IIL>X,\DS8].&'!<A#&,\!'3
M*P\9RBN4#_X@N_7''&0G%&E")PDH#MQ_MN4XNQYUD=Y*%Y$>KDR4Z0[6JX#^
MV0C!V-H>F'\@.M*EU([XJV,&@<98N$:DR@!I?R#*]-.ZV^KA"MD>(>I(;\.9
MA8D\1#9,/]&$K.SFZK-;.=$$<X6A:QP;"]G"F781ZK`="F53@T+ZP`LT73'0
M57Z3H[YB5!PH;3<)NP_@4GSD*F:7MC/^C&<DFJ'VS2-HJ,C3<EGJ!R_&O4C)
MIKE!U89T##IL)^F_,R>2:-G%$+HT9/6,\A;&`^`E.1SL*'1G;1)CXC%4LSJH
M,'0.\`"?CX/M4YY6$R++SO=XD.2QMVF!2\#"!]3I)U7[$![:<#T")E\&O>.*
M;O0S`TR-*++DA/NLR"/I62-Y'6*.9@(YC3V:3Q_`6+EZBVP&._C\D?%W_AX4
MDXITO!\X,']II[-QL+?+Z>.-7&SM<\^2^==O\9=!2M*5<#:=C*FXNF`B:VB8
M?WLZ=L&9@A]G<EX>G3_'&;!CI8_.WUE8M+[%=E+Z&)(`2*WF;`\^@6P*38LU
MU]MPN+7[[+?%B6^B]TQS[&/KE['$_S9NC'HK4DZ=[;6MTFXSB_S[ZJ1_V.6/
MA$^61CD-H7&<^KO0TP67."@.!.\Q$5#<ID#[A;/^50-8:/1WUI"\!ON>PX:4
M7AIJ*31FJ>!540;2;/M>@9G&)M^(@M2X-=!05.4J*_?-=XPX#\-"S]B>;^YQ
M&GHELUG,C\[SL:/7-C&APJQNVY?)DQ(:U=S#ZFX)MW`+2%R5'14GG<1N/W>3
M`DX/\A8S=`91;SQV??&D(2VC&E1>=82*V\P:I6EKU]U'4?F?EL48WD9M::C3
MUO#?TZZ!K]WQF[E[`\?-\D&9AF9J-&J6>!;`7N-9GZM]@R*BK&_9'-=YXZ,S
MO5ROKXA002,LC_0OD@EB=DHNEQP\82L`"?:T]<LU92GH0-Y\&DBS@.=$WD09
MVUS2PPE3]`2##-';#(HFD.M9D:S*P#2T]WF,'XH3[7=KR'$"O:7J$H_/^;F@
M2H8K`@'^Y>V&Y(=6:(ZZ_K$,))?_\7I!1K,*:0H;"ZL2=WO4`K/&8EYCBF8%
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M,Z?5PE-EISYJ!RH.%T9$`:QN6]DXV)26=9_F(;'/YYH6B-W*@>F#RV*)@SH1
MP^Z$&B_YBI:+^Y$=[+,,:\)*!M'V7J>[O>L@23SG4/MSL`"]ZCOH81^?-ZG0
M=>140QB7`*G9O#3!YN_ZI!K"WG(G\`$9F(TI]Q!FQ]P.ET99/EK*D^P?/H!7
M`K;8.@9M8G<@F-8I5K/4@<NG"O_;NS0BV/$)6EC5IH>+@2&Q2I`Q4$QF&/C>
MK?2:&3/C!M1*V"J`A5:E]5$05^8^KERE2T-,=X_S+98LS$L.5?S]W<WE?%ES
MT]&-&;\)T\O6'6J?E9%/UP_7Q!ME?#QEXN\3'4ERR*2QV]D\.,1_P-YY2M7I
MKY?VML5TQDVQI)5C5^]U#SI;!X?.^KF=X!6^A?T4S(C(P$+>'9'V-J>*E2.+
M%=N$/PP,?`B[O":.PO26$'+;.XC;GA[NT98"\QB#8)/PH62YP"GM!9M;G:W=
M;CU.BKDT2\O$4V(EK3I5*)P2TS#1%UXON718`S*;GR,<)DB$MB$`6P4-\-=/
MBE7?8LX&#P7,*ME1[S")WXR@]'\5,;(<]/'[H?5M4",3AP5GD:U>M/!:UL)J
M!/;0)[D`C"JOJ49U$%LA=IS#ZHQ'A('%125<9W:OF.HJT.'%`',3A=)UR+P&
MQDC70VCNQ-/R[):X]1`'A0)W0QNX3QG$#$(OI68#A`EC?HNH7:\Z'",S9GHE
M[`^JE?7J?%UK.@5CC:U"8I8Z,4+KC)1LLJ&ZA>AU11,%2J";9/M=!T[]1X&.
MD%?>:I7<%LO9TJ71_">/%(&:Y]3]V7Y(?9CECLC>P<ZOY(CL[J>.B&@N/P2[
M6P-CYU?S0K:WG"GP22TP71.)_U9N".U9W;WN+W=#MLBDZ#:OA_DA1*^504&W
M1.T?;,BCC'I0>O>[(7L'G9U?UPU1RJ[NBBB\?8CS]`M<D:W-/5H7=__+^B)<
M>K=WP#E9TI&!.'887L14W3618E[ICVS3$KF_WS6/X2G-SMW=_:7>JP9"`T8/
MHS4S@C6H)49L9/^U<WO)$O%2C&1"AW6]VW2I"Q%6G-0"S,$%,+C%!,3WP[2<
M<!["BIKZZCH/BKT<ED$(NCZ81I?':#I/6[11'D@N&\>YF:7PIP\29Z2!1\6:
M#4/.#'@U>TDP9:C38'6'5+_4U")6T=LD_>PN'(Q09YZ28QW7--2&)"$RFDW^
MW=`A;8;WF^S6V0L@=>Z+!1:/=$A7.H25@]IB*_X13F+P2_[I(KK\_M_+1:R=
M46"<[=BXW4MTM4(+U]N8M:9#([M'<?O/\1+)-"F0<MD=7T$)6H]X'C6GM`=V
MO>>SJAC)T&M@7OA3^NX/"*:E<64OEYYV'7KNK,=I03<36LJ=>UVW+*[5G5&L
ME$&J6;OGI"=5>)#.R>))IQ`EZ[))I?:(T"Q`D'5#1"=OFM#.U2R6?;NWZ6:/
MZL;R!S@TW8V=[A[95`(JE1%N"5:R'L"Z'TSHQ3&.7&PJ8X:SBJJM'1QM.7[I
MI:#R&\;F!9EU?Y/M*\I$_C+=7+VE;_6&X:T52>87)V]/_WAT<?K'D^+5Z='S
MTU>G%VU';.U8MODA'["WD%W$Y\>^5F6[@;=V]7DH1B9[;_]16X$KU+B0__?E
M@-OG_/7:"3S_B+W`7SY;,#\@:H_5.B+\X$2HR/+!6L*YS-LL:17W\2>MV.2[
M!W)9O+J7.,"(QM!NUVJH;](VH1@ZE+@0$F7W_,$'<&$X\5'G&>@":?GG\FD1
M*E?$#7Z2/]Y1(L81SM:&#I2FFX;3&=TAI`U5_`EV?]:GTU4-@;Y^!X!ZF757
MM2/Y/DE=25,-(IO/3/3P[FJ514&>["'.OHXI#`F\<V?R4TU33/HT@F^6\4K-
M\@X"-7&'(IIE3OQ*VDKBKCC8]P5A2,JY(U;6C<#Y:9>J`:IZ::(>=(5R@/-:
MHD?(`GVS7SBUW9B`'-FV.6G*R-%SIK[#N:O/N>M'W`8*TY8QH:1=*+YKP796
M)RL7(NLI=AVP]HD/;$>Z*?]Z-LI61\$R.9]"G1O*/5EZR,`TOK'=`'4]R<R^
M.2-XT0E/([?XU%I/PJT:R5/.RH*.:\VYXV78&4AK:?*H1H/)H03MM6US3W0P
M=/&($,_Z"`ZKT;EWR`S\\T?LOBKH9Q-,!;V#).IH@?,'HXNOO?B8,*=B;HAH
ME"$2*3!BND7UD\;CT'IJ>8Y'#5A'.*TJ"#TX_!Z;""8Y>IR;5(9VD[WM#W"=
M3=^5[*EB$U._>#Y%-W!8I=\\%7-[P1Y'!!G@C.SD_@%]N?+Q#9R@<I*A,N/:
ML(X7K*`J6"KC@!S%\RRU/GJI%N'0/YO%BW$UB9TEHIRACUP:*XI/*O*$J+S&
MI5Z^'QR/-BJGIVK36')7>6-;>@0^]P/@VZH/1_"8!C*_,THSRXPJ*=CE:G_T
M]^X@+<U@^468KQH1O9V<*>$"N[7F7O"36FTNAW%K`Z=0@KJ]T=RR^I9S<3F/
MIU1J#[M")ZAM.RO6FAO+?Y,/?&(M#?"U'6L&G6VK1?[6E\^;&R[)T&A#"@]V
M-AH;,^/8[R<C*@-V_MY:<WOPE\_[6[:V_491^PN;T>/#)M[C!-;\26*B^#3D
M_#_:CW8:VWBY-Z?172!)J`4*"(/X/W2Y@99[8G=45;Q325]&)G,'U^KT')=9
MU^$`^"'L_2*#MU0DZ67\:7T)%27J06DQ``HTZ>:H>BFWOGP6?^RR@<#*Q!>^
MM[)XKLUQE:3FO+@4%KIH.-;7CI32^3WRL1(:-B$*"-.+AH:*X%Y!>.-@9N>N
MQ+Y=L\WFKC&Y")XSGZCT7T9?"<>IL]3FV02?,E%L)EGTC2U-GYD`Y$FU;`NW
M\Y8<*?-7\5\$6OYS-D)#>T9^;;00A9&^?";#EY/DD2KS$9\G[A2<TX;=?$"Q
MR"^5'SHR%"[H=*Y?)D#'<=ML77DDEC!QIRC)V`%3$IMZDQK"7D_%2N[XCY.%
MV6^;DO+<'P9)\FPE^;S-3+05N*[`R[&;0BNSF#\WFVD[(K@OCE/`HZ5T2VO"
MR5KS,4[#E6UK@])=WO8,:Y:IWW807Z9NX9?/U8NSYNQFV<D86<NX<C'5/3'*
MF*P/&PNL\-H<S35"YLM)4)8_:CEXX'CIO1+50F))EE2,2]<-QU\^(RZUW$B;
MP."GT3,20_C*=5EOKHB3(;8I6AUL-AK$GBUY>:>SNZ,+-AK7SS]^0=#B(1=;
M<:Q"E\+F]E[C8N6U/3HBNMO[.<I_%B@KKBZ+6_=,;&CLD1?>AOH<&,`'=+)\
MC?-$U@YW.=KAL'$FQ`]A=T(DO$S0+Z,[4!SN[';V]AI>V]K./L7`PP9T.11F
MAQQ3`8[VAT*_K(%IR=JW-@\Y=J7!+6M;FYPXTB1I/BMSK"#,ZGQ`FPRL;>\*
MI@;;K.UV.P?=!JA+0,J6+<V54^AG@K9%&UMWMT&DR&P?FKRA#+1\`3,>I#9V
M6H7?CY)<I]W.80\?]2R>-7=D36Q+0,R1\_#!UY2DWNGL-:.@1YA=]KQ41M>,
M?9M7EIG<G)\;AC1_8:5=K<Q*_EEN42LST/#3HN',K64^IEMRX]>80\R?R"%9
M;MP>KTZ7R$/D8%)#OIW196[:I/3O0-]M5W2N7*H<!XD9=]>K9X1IVL,'4.K+
MY_M(=9[L=/RJ.+'][#EH]7=>V+7@\Q7%B_.+-\?_^OLWKZA)G']5O#CASI#3
MBWQ0M<<30NHXN?1]HK;BY`_O3B]^S#\(VZ-2ECB+!#48[?J)\)[]HL-/\X'>
MU%L0_WE1W3\OJJLNY8D61!Y&V)DYTUYA2S/6TVWU##NA$#4=[9%2JO+_IXOJ
M*KV*M55K\%#GH3BL-?(N"J!K,JH7R1O9'0+:6:WDVE2W))B;I]LUM)_<I<OH
M\UKX@C([H6(N+ISGX$M&SW7UJ(CPPM_@'%/$/C<D_U%&)VQ^X-64LI:]UW.W
MOXBGVG=%)SC;^NP6#W:3V/4C?D,<.R4H?2@CM;C3M/K4SZ0#'C@TFRP462U`
MMZN<=!I:_-,E_A-(EB&':HG5"#ECRWS?</X\M0$TO(?.G69F6Q_9%^[A\.>1
M1:AJ%[Q2+Z!:1;G>G>$:-V?8YO(<0\FJ++=6Q]A%'9W+%F';T=BD;,35,MZK
MLJYB(]BEH7L.EO!=W2X\/>?(*'O#831!T2I0TF/)]1[-!>[H+E`0>AQ"9:D*
M3@5^'695*UH:S05R[%9PJ+-6BQ0CMB[^1PE%3B'A_]V+L"A[\/S^5+>.2!*!
M;EAW?*>G\XFN#@-TB4B+'I('7H?=KJ;QPF`?.=R%NJ/*OS#2H;]+5/-X;UQ#
MI7=]MLSHN8GUWD$[$Q?H:E!WK(I=!P?N]8J!69=@*DA,1(2.F[+F<_>9-;&[
M^QYB/=3+KMB$RA='(<=KR^D@$<99U?0#'?@==ZH*A<MQ;<5>0*OJ9$-31;\Q
M<S-RA^)$5U@8ID2H^%6E%6=RLEJY:0E"Q%]-UK%LDHAU;F=7G'SL6_K/"O(4
M56UO!`D+$A,[;/OPI*OV]50D`&<IJRYIRD[P;M5A\UZ1S7!G8'6TB7-6:3*R
MLK'K^W$';;LCP\(#AX/@<2-;0.R9[K*D#IUO?M"J)(*UO1:AC2Z4(MMQ#1^'
MEX))AQ%Z`R3*>E/3?@-M#6N4G_VUDLOG5ZR&MK+#P&#I582IC%3<Y&0[[!3P
MV`[>M?W?/*LZEJ0V1&)OZ*RO2@NQO0^Z:RWH]=:EFS[%K_X/8"3!R>'PY0`W
MV*D?XY5BB7V4]1U3P@]?>)OBS#'FTZ"BZ\-QU49A/+\,!F--'?VGBU8()]C;
M*V7G"I;.V,!^6B+L%,^Q=CT(6ILMM'7@N]%"/"$=ZO8L26$MQF[?FW<>9FZ1
MZ>Q.%$N?.#81@N+X%$=J%ZC%A$E".]Q]WG6QVQV-&=6.*#;Z'ZAQ?W.SH3=.
MQ\414C/2=F^J(IK.*QLUWIC,@AYD_)J&/([UL4+N%MWDAYVM[8,@N*M4B0FP
M>5HV>JJQ(2+KBI>UNDJ0[F1E1FJZFYN[SJ;(6WEZN,^)PW0FV^LAV:7W`GIC
ME1=HLA:^W;T]-JC1B<=R0UZ[OEAK9%$)2A@(HUOGYQZ]Y-W]_2I]SX*BMYVJ
MIB4[N'QI2OLLL8G6P9>.STBQE*[?@_2+A3EGE,N2;".P,\:2K%TZY7>Z;1M:
M.2+&Y6\J6H:5A&G<^E;.XW9+">7>P*?!_7T`7"3\DU1G8R=.O?2C-;M]5\O(
M*,7%!H#DD+'ZB$[Y-$=<)I#.J#%+7'I%<"?A`5-P%%1+3_.-7;2X#=><HRJ+
M;<?(.$43Y>0QLN6M"2<AL]-57-T*-#P2LO],'632#,;,G__G=$@0VP@NO,EI
M83.GT^)&F89L8(4W.4D%&.`S!,"OZC%XG9O41#[1$0F.\R,LD#+('2ZBKR?!
MX7=#N8QB[4QB.1^:32O:`VPBOM3J+?MN^Q#%A)Z[IP\Z]J2(!;WWX6D"J&;_
M5]PZ*=W_-.+-GXMGBC==L.^MNW=QRPSZO4MKDL>O0E*3R(DNFM+-74NN]>!P
M3'IC7BMJR?>Z75:]?`$[>%E^5VG?]R76W0WD:>Z"%Z=8$Z\L>$)@3>C.K9@@
M]DV8L)^ABQ^64KPA8C6%AWS0L^6,)7/I5E74V*RNZ#V5W5V<.F..DAX\TV5[
ME,<@G[9*HYB10A5WAQ_L[%3*)#4)U2@UX_#@77Z&`=I`.`$"G,;C$S+YZ'8.
ML4LZW&#M:1>`V-&X=6`'3@%^\%SQG"E`/5MA]CPVC"RQ/N$VV>_A#^QL*Q<\
MU<F@KHX5LDP_;VD;>'/<5J/9XJC"J'YH1;EG//1`//L*%17;:754G\RV=6E6
MHN0=J_I'IO-=@`;//6#/;1X]70"H;L33]B?%`?ACU57T&<U0!>ZJ/]B2-=3J
MDEJPC'2D%`R/?\`=IFXI4MW$5,(ZY#1UY#,*RCE[Q6*8XXBP9CP@;]$I<_/V
M*UW1:'0YX^2,J`M;2>"X)$?&4:-!8+VEB/^B`M'3/9;M`34?-WD[5Q5-I=+^
ML7JF?@B\&_B\48IU+6!IO38?4><W!D',G[WQ[0-.T,RNR6N2YY:_^EU-HO.G
ME1[K6F+E9^@Q.S%#%<!'Z#%<ZJW=O4H8'Z#'I)\#.L2<F5YB5R_'O`2]M'.X
M@PYIUTN2IV.7F'&GD00Z\7NEH5&XJP#]N;KHM"T62(#(*]A[74Z4V3]8CK&?
M"\@O4HJ/U8LUJY^SX:^LW[K_Z?HMT26_ABZ`5]7!?*YP(L>=?^9R1YZ%EJC^
M9/-$W./64(&P9EM4[D?>WMVUXV5:O`W9AFAB4ZD^8$L[YQ$D.N+G<2TVF^P#
M487N<V"9$=Q#F>(8ILC0I1%_6CEVX;"+OJYTW1TI]:9".=C#.9-#WQ#7\`T:
MZ9K#:36ICLVJ3='03]S1T]G>V;.H0L!!M3OE:*+C;MOHY)'*:"=5"D9JM7<;
MQ1M.B.QQ%N"4XV(.PPE_Z?AL.NISWZ_,.[/V@-E.<R3=Q$\II?0X69E:_48+
M<"PBNE.6N7J7I,F0L^Z'=O4)51[L/<^3^1(I/UCM-)/;(3G0=T>=RA4/]2F.
MR:&G9+N%4UR`9>^ZWOW*R1`1!4J=L1B93=OD+JK"S5H,.%LBE&=V[T=N85Q8
M",]9O<$!$H[>UDV>@P7^F;EZ+I^C6N<=?\=\&"+09=^`%YUP1+3.^"0=KT,Q
M7?Z$KK/NX3VO=8V1(/GF;L14,J!G"3\F4=:1&"L]CZ;!?P^)/>O+>7K0V=\$
MZJ><U*9SCR3[3PD(9(1EK46+>UIH]4EX]?Y^;(<>5N'O!M*51Y"CZ>0J)Q[V
M\6XTFT)8>[4?Q.LU0=%TGVPW*#*FABBE*>W_=VVEULX5$%P/]6#`NQ$'+%M.
MPXXP8O<KK!$#G;#D&8?DBFLYQ1^/6[]FOCS/="39OEH##SDTZP*4NI=9=+BI
M8FM?UW9U]@\/`VMY0?`T;A0BDZ.74PT0DXM+!V11%=+$VDO/K[.-,96DB;[>
MNT^ZVFIV@0NT2.L>[B2PIU.1SV$NJ8K\J#QMO:F$VN$F1A+1Z*J$XC^V^&EX
M2]2F(]P1N7"\YIO^?'*)$0C4-/J*>R/H#QJ.NC8K@]Y$'>Z*G2L=X^SX.B:;
M[1Q/""2^DVYV@'M247W1#E?*F+7I/96,0ZA4<!6#U0LLR/K`YE4.CU9APJY]
MMXQOXL1Z7FBV]#D^^O)95R!'G]<N0C;J@AZ=4.\/8_`Y#=2;/ZE0\*5T,BM8
M#E"VW0U2&A4+&*]_(*3D*OGMS6>25NVOM!.NPV:60>^3)1U429&A`@#&AW)B
MLG`U%>KKFGTPUCRB';[04%M!D6\L-'J&"6R<M3UFN=1.'#O,4D-7VU4$ME%`
M_TA0Z;$'*DX"IYT9&545,H#0*3I,/-B[B#$=DTMITPC'U4J4?V""R*Y,PW6_
MD8\"(9%T^$0G`^+5.0HM><WNKF77K'+B@C>.&JGP-!."H.ONV1,^O;[\W9.7
M+[=>[ASNO_BU[JM^X-PLY%>])OL()\JCU57G`I9B1IF-!=3L$"PO"AF%=4L`
M`G?I^,&2.KXK(`@E[(@+L;FY5;$U7/?`]?Y=<.T[!>\A\Z^-:E@P;R;&EP%W
M/N4$3P<&U]G>?7+LQN!7I'MC5=-TXMKNL^(W@1Y5B2^0SJL9JUAZ6D01"ATN
MIORL_R%\I;NDPC70JF(!F)1/(N5UNFX47SY?L*9`9K<6U_YB\I;-*<&^Y<HQ
MUW716&$XR,,-(//B/.,<9;*)DN8X>L"9[S]Q8*!;=2^A96]ME6Y8]`6LET+M
M_9<H`LP:#?E.9UM7I58^)Q)04]KB;#/9?"47)(=5ML%UC?_@,UHR$,YDU7]W
MO0J)<?54,:.K)?N0[?$FT;@@\SR[G5U_/#"GK/LSZ7VE*48D^5H"WG4Y0DPD
MN;,R:U[ZT^UM\MHN^/OR^<C;XHA?^?\*A#!$U+A<EY([0YRT3BU5;*&`97TU
MM2/K/#1$^):0,?^_/M*M3>AXKY\"/T*37N%N4J-6E1Q*$*-<8PP"G-<_GI^H
M.OCZZ/S%T1]@D*.ZL?2=@M$G1DQ)0Z<'X"QUHQ7-Z."6U'4U6^B/M7!\G("K
MJ_Z`>;FA-F$4X^/`>[\7G/"'UEWG2M!5^\%\)66_8Q-)D/F`,R],1^:ZY9+E
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M.W__:$IU<^J)WIEWLN%K7L4H\9'L5`_(061Q@]P3`GL?Z8',[VS\;+D4JGSR
MZ"DMB,3FF"`17S>N@[:\O8'_83L+(D">5?**.&\*B"F)9/-)KP^RS7XK[Q7L
MHS&`,Z_!T0D97!!Z4.5?89]-JQ'HY;XRM2,LA=%-7^P>*UBZA"^,._)DS6HX
M_-]FL/5P[P(R)9N130>W2X)@#8_&A%.VGCI9]%X7<(EC#8A0F4O7VC+/6I&>
ML=3IQ%>0$-U3,#FO0BVP4!3.KJ;>.J6GM1EGP+GGP%@>3(\H`K-)VDJ9E%(I
MY.2^9?>\`TTXH9_>R0J<3I`DEEANTE9N`4]_[]T/^H)21UV[RM4+"2P+EI)S
M1@,AN8KR^FI,;KGD;1NB=Q/N/G2/NS*`P*`Q^0?;2VJ/`25:+B.-@<2.ZLKL
MFY\"KFA0>3B_O/&'V56P/G=8]DSRF^-/-4Q;N/K`\JA\.2FID]&*($0[U3]T
M!V(RC!@P8P/-Z\`3YB@.NE6+,=I@45(T_/!$1V.DOUUBUY:<4E$OT9/DQM$>
MF(.I2H#SLW.`"\<>M@B>D]K=T)*`A&]<XNFOO'`Z&KJHG;]%Q6.Y-%]S59^)
M_VJR\1T>>4_"X%B#B%&TUJ[)S]`P8QA@0:&`3`K5]VYMQR%I^BC7-OK:(6]S
M/@O)%DR@=0[.C.@(\TO3D0D+6J0DA2,*^_5(BK9L</`E:[4LNG3P[+EHO]G5
M_5$KJ*VR+V<''E8[^I$`A.E@S;J7.GF>?XS;^[$R8>RNM[HR"'O]A^H:TO$8
M?YFS@#6/J27TE.[",**9JVRW7XI&\.U1N]3CV?/@A.BE>5N^>9\`08QEYF^:
M5QZV4<!/->V3K=7M1TE.N8V2T"%`0B*Y?4DSR!7"BHBO;N%A0X0C_&Z:<8Y"
MRQ^OT=@*9*=!GWJES27:5R"_Y7[@-I$8GUGR5[6N8,%83#ON"<AD827.7!OJ
M:R^2]\HRQ&7Y*-K`E%&O,Y%=RMI5RCDL"@XP!4Y9.Y%YB#\R5!<2Q6J+ED9(
M@LERXQV@]'`JN++F1\[\T:W>.ZES^?XYGF'9^1$$YF"%75*TW=C%I157P>LH
M'F1<7_]A[,:N?AJ#):OSY/Q2D`=G8?,R%]R.C;`?27=VG9QV"J"IM(+Y64LH
M'4N&-(F;K$.0(3]"30T#AJM<Z=%RT=-X7DX66LY]F]G2)Y;7;5WT`@4W/[8$
MM#%+:X%U\N'D`KNA#87S0I_Q=88-3CK=,-5KQH3P,&>Z5V#?/MW2SMHX3E?:
M94G]Z8R-($0FB4^'&6DN5H97Y4RT'7_CONZ&!)2U</-3B>C%,'6PX?KH`R=7
MJD)+G\Z',B?^-0BQ'&1ALE#7;H?@*J7V@01RUR*J5?:=56:"KFW<6A1`\'-L
M"]120O`=DG2;_KM/MKTKY#9S%S78)L@'&*<16TLKS\29W9%V9_*B)[K79[".
M\87P]0B8NW3`=ACS9&@7AT,#`VCO`QY-$F=P:Z/-AU^*35A`H%C7!$`>?-):
M^C#Q>'*[10&/_.T<&G\+'=0*$/G_F"@SX[J9P`R]?ZDEQ>Z16/&!5"ZBG)+:
M[#I?F4L>('1Q)5_$W)C5G8UU],D8SZ79A?*:"]25Y!#2R/9HIA;'F9%/IN]5
M!XX)&568SB/?>#PT.\NW%4DE'%(0Q7XU[(R6'%".")?,SB;ECI!0YX0GZ'RS
MN56B.H$T:#+*TA+-T46`KGM>>KMQ5F]%?>!0?VZI]CFD<K_P0`:(6/4=3;2@
M<W[%`,.9/"4=-)V)@9X21M)4T>J0AF_EUM:#U0VBS4*U\N4AET?]\5LD3XK7
M7_OXVC=+I.HW3I]TCS5D[JR@(,UX"7/,E6?\2<?;W,(T_.,6CO)T86W'AD\K
MW$\"YIH.8KAX0F+@]G7OY_/Q\<QSA7J/'@%"6)R`#2@7?SV.9>*I+%C"MUV6
M%:F?=Y,-M$'*PI/'VQFW/LDX=7EF5BGGRY@J=*36`'83&[Y[C7R#<MG`CX=(
MX=.O^^>A!UWMPKNAWD.4R_1==+DEL>.*-O=1GG$V.LX?&=0[7>#\1P^:?AB/
ML8"[3H\TI0&O2(GF?Y]>)V/>!(E=Y_4B]E:)9]5A8,=CRPXG7DO3EJ+ZV%+5
M+?5$_@H\>E&Z^U0\&]V-`1)TIY!#2=B)C$!NF(&?6*[LR^GL;'Q^I?R_H"6D
M`$OTW**#C&+BC,BNK;I:2-US&]T:[](5@_])*E4F]>@%$:1Q4,EDDT=K_1`!
M&/B$&Y5R&9D]CYF:_$9QP;R9;'5M=HCCMMHL9]9)1'ONY@L<6LSD&EEM[AO`
MY0?6$U./PWF,=9MCBQ@(&W#Y,:^J)/86)KFG9Z6^=6"!L_*O?Q^K(TCM[M]!
ME8$DRL>?A4R7\N^OE>-3_1$JL:^6/[R)^FOYPVYCM)0_'<J>7OD'FM:\ZCRT
M$PM^RY=>*"N6I+>3\H?OU.>Y_./^X@J"<(\KY%`>0=5%[B^J-:I1UUH&W:.Q
M`.G,(9].Q]I5'\2/662KW)`23G[]Y1/`;+F98O)*T]QC/]RVP`;,5<#F6F^5
M,#V'55SS/LCR3'="UDYY(EOI4K0-!V<BW*)2&C+1G$Q3TD]-_75MJ+!3$&ZA
MBFF(_2`:>WWR@46MC7JW*BWLUC>'V1M2:TE$0+WSW6UYJ8V@31IUL\7@M$'-
M(M)05-^RQ>"+M)6.3NG*$'+I+(%=;Q"*WBG.V_TLUSTIL>+%1.?U=F(3;]T]
MZ+ZD3K`XG?)4">G9%%7.]>%C+S0T/7>=75]@HYJ_N.5W++21DD8E,7X*C'%$
MNKXX82YN@"%R^RAT;\;I=?BZ!(FZASE^AV*WOO:(6"<&SL/'<C"[E`X$O<;P
MF>9OQ<F[G)3I+D(W\,EFT.T20-=P[UI47<\V%DSF0*WDT0&A]E>P]:K(+-X.
M8^FC9Y)ZY3GL+F8SY4^ZV`;<W!XH'^YIH5\^1NK2EXH';*Q535J?QBY9YH4M
M7_PNN3O+7VAPOVUK/JKZCS[:LA\>KY?O/&OYB5=0C(P6*M'V4)FQ`K=:8="=
M%C6N\K/HD?A2JOK.I*E=%ET[8A`?G3]0."I(']L-$5+11DIU505R*(C3G8SU
MR`\Q2SVVU[Z*\/',(,R/.RJ5NQX:(X7659$H=-S63V2?]Y?H@]=F:F9`$X+"
M[R&"VX'S78UB`9T`+RN,VV#W0[T,RD.0%5'AD2:54Z9)\3)E34LF.IP>DVL7
M_Q^WO;/*V"ZHYH3=]WY!!"FNFFIW##D=4$!C+&9/T<_\._#F4V)780Q75JM4
MZ<4]9'6JB>F)A*3]+Z<>>R<&_.(T6CL!]_%%++0/X'>E&T*,@6Z0$]!-'&$J
MJ(O)ZFVH_W\C&PL$=5*M>:G<)KLX7];^J61J3]T/)N.(D+[SE=2",%Q`!.SU
MF^/H;EEEC[6TB2ND.:.*IK,>3QFK"T498E!+6LX,`I[?RL"4Y'V)]76Q&#+2
M?S_M`%?)XPF19JFGP91WV_64.Q[:GYN*5'$;BX@V)8'M?&@AH>T;3GTZZEJ^
M%W[_V[IZ]/Z=QE28%TI6TM7IV(=P%%]HL;$!+HX[Q?Q2RQ''`6:'X,Z)]%:(
M&Q2\V0`U#+G31/8=I&$YIX+)!CMJ,_YZCS\2QV4FN`XS]IPL&3N;+HL$H.]L
MXM"5=[<'8PD0WV#&XGL8^7\O)IZD'#(HK8*&2IH3ZDHM=Z3)!KN!7I!0F8OX
M>6<Z+T:$A<S2U4L:(&*^553!B?$H)A>UO18D]B9PIDQUG2!X1OEF_`[Q<;<R
M6O/VI)CK#*4/Z]A"F0>*"/KN0HF^^0GS9Q7MA:`UKK0%64@G^5US$**PE;4S
M(6*?3E75O&Z8#%@\[%WF@E<&F#]E]"RT.PN!?KL6V<9:6S+JU%>)7B>M2&\,
M>Z3\EN;HHF3I',W$%"19)+9>)[%J]<P[!]DMW23/E&;=^NH&;6/4<"I++=#2
MUS!2HH'U>'5;Q>>/M^*Y!;NM(OP@0Y;CQ<@B+G\]^ZW-\"*K4J_(&-4D)7O3
M/1.;&U8+*]I[T.9;;=6AK?!TWZ)"979:K*^4]ISN9H`N,V>OMT?ODJE41ZYC
MI8L?\@DW-<WP;--&U_<C@H=I=.E9K*9<3GO4W*<=QC1.=<KV595,\\'H.:%\
MMHR1N6]#\&8[L/72\/<4WY/F'@\@Y<[6*2>#'N7,'YD.*#N93T1.!VZ&7<O/
M@O.WLM-7@FI5ZC<M)V;M4!UV>M;/5_[-YQYR0.!V3.-;"1K3(%!<L\#0(=O;
M]%N*2-+-N0W?I9%G0YW4&]74&1EMEYX0O)*Y2RS1%++E$[R9+;1U7\F/0@!0
M+7=`5E)CDUZ?##2RZTSSC-26[\ZZ;F.O&C6$GEMB1O5]:[/TVI=JR/PM7:G;
M`7'DDD8VN"7-L@UH3D/3#AY5"5>Q_T1LC?Q[-:/)VM'QXL*%1V-CD+62C(K4
MH63`L+#UA_VUZ?._F<.6E!,D>)Z#LKZV\:!1]-LXQ2??X9E=O9EKMO'C7L\W
M:T[7:C+@/Y3-9#^U`BXE'W4A?]]3:\H?Y8SMF(19/H87V_RCFVN5>W-=3=1A
M`1MKU1BK]35WMZY5[M;D5?VQUUFKC#F6?51Y?]U5^^LOCRLQ\WC37JE_>&`7
MM(+B38@ZT+".DK7#QO*>E_OO?W)@#,R;9R]W#I\]';W>>7/XC]'AFYV]@YW=
MPQ?[>P?E\GN:!;-MLV"N_U+A!2W7W)\T5+%M[6<VVOHM'C#:,%BR-"G+6+R3
MM[C%S&I(>I#7*,N]4?K.5#U<0&#E2I$')T_UZ^2I/D@-<_>L1_-^;'2W<D)M
MMSR?/WKG#BO^>'X^P?A#(,V]!`2A\-.[<PH8Q(T.&"F!DI<J**("%PPX<HKG
MWOM-XOV_QG3CYG7^]^+JW8E2#E[0.WI^97O]YFCR`U]QI3O;.(8358T6X^?&
M>^&:_%:FFTKM/_*^O9-1DWGUT'[>6AN]+F;5IG6#M58X(J6:.OJM$%.'\3.E
MSW/5IF!3L9F/0:L!R2ZH\#14DF`<W0):CF!0J$T6DJ+IFZ)&*!I7LP5YR9:[
M!OI$!:$7X_D_/0-<7YB,W]*=A'^'R!3&DK(K@ZVMEW+1XYYFK&_:?O,(/FZ*
M$+P<%W_ZXD3=MK#?(\BL:<5`7SC%[*:UO_`&I++,Z"L2^H9H5_K@//0P[D8V
M1KWUT/QJM')T#Q%Y7X7>\IUSS.IFP%;O$'_&GET=K1S?"QY&^RDU.H`;\ICP
M5@)FG&9C/?U>-/V9'3&1(;DD&QIWBV7EY)X*A(#H1&->+&32*#SG[X\A*[^A
M"1)87H"D\TM.UN7E#7CR"B42Q?RN1,0T*@"'D[QXC>F:D4M=^(1K"_(-W?L3
ME!E"FG7PRC1%ER*E)/N#ZB$PY9M3=3@WY!(V'3?K#6[HTY!PV<MP$IO1)]J<
M9U[>>HLT66T_N#&7%51RSGC4EL?1'0+D%UEQ":XARLO?CF><85,N2G\727FU
MJ6&?Q]Q`=S^%P1RY[VFTXM4.>,CDSRX\1T+HZ.U4UZMV6]US!BWWE+"CY/&K
MV90N;M`8A\>TA.`&+BB@^V;XA)%`!GPUW,<VZ3].!-?T]FA?0R"VY@69*YNP
MI+"_<FZX5%<6^BQH8_BM8LW5ID^4@1@];0V[/&'-T1_OM4KK\AG?;;D6G&H9
MXP-UXG?N$J5W1R/H[0H7N'%?HOF!1>EI6`]L0E184G_-7+53CZN:@#E&P!#X
MCU@)SSM,.2C<M#3?7+%%$N?@1JGYG/V!?@7OM)*`J,1.IP3W[):$:`2:**E)
MAL]2!''-!B+%QX>#B-[!/]RG:#\)K^OUE6C3KPZ>ME=6'!0AGY-!$B]RE#MU
M+O+H_8(<K&.NOLJW5-;53<O2!D++\2VCL@=112_YB<FVD&:AZR$L]K(-G>+@
M(-'*>GJZ&*=5;0I(]/XZ?7;'TZ)@3[":G]Q\P8$+QB<&(6WS-;?3Y-G2#1HS
M?"`999[+B0IDGTAKQL^G]G%92S=AHE#U$JO.5D;YR3FZL=8LA"&F&:+AG%)'
M0-S.#NF@*NP(N0=H8(N+II,*!Y>W3C&E,M9Q9^`\J,X'C3@EM9))K1!WFW-<
M3R,V)=2=B:X>)L,?+[@'SHW0I(F4:!/L8D.0OU_B3&+H1N1]`%Y8>'"I>E-^
MPG1)]"L;0<?W`CMW;<>CI<L8>VK>K0O28E$V?6:$SB$M939VC:2EIHAGN9XN
M0#3B!B4`Q!*1H0K.JZOM!&.W#U>WW(6NZ3:N=-T)2>JFJ(Z>4S=CHG3_DMRV
MH*>1AX1Z:MLT51QF(7@SH=4H54=DG/DGVLK>'T_^&T]J<8]KR_B"$IRV+TM3
M8[I`9VID?*M_U^\HVY-T_C0A3Q$HE>4#PKY`TK^*L.\RSKL87%(*:*`B7N2>
M#Y6/!.94E)"T6)XZLG1]B-I!]#6[727ZHG"*!2HPL3-4.E2,0^YB%.ZF09A&
M2A%SR11;G$D2!+FG.Q[4G&;BI3IAHB^J"((XPCH=A;HMG_#7I/<GN\:JT)N,
M-X6NF1MH`SVDV?U$+V7]+]+E9C:8\!8`^P^38C(;5S9O&4"DL.R#VECU3B?.
MRLKS66+IJ6.;5Y9&!4`:3++YNGK,X0ICC-Q1;?D9.IOXO[6>`RN>\=H-G4M[
M,[K0\SC7\ZLPX%-L$%JX3-G.C?I[=(PRF,[+!(0T3,8CQ%1#4R[_'L<T!%M#
M0;B5[7O1R`A$(FW\(DYUB?24**=%%-;=+M'?0TZW:A,8@4G?CD%<CDYTA>Y)
M2I(^(Z4X:UX8_A+?2YV[X@6R&9[F+$D-9..!.9LOS]TQV[#Y\'0-<C+1<;=&
MG"PFIXAN[_+8J-WE)RQW)FXPOANA\O..X#LTNOLZUW(AOV^X"?FNZ1*5246'
M#M0**!,JL2X*^`VNWJE%-$2G)=7G02"HH;(2$41W]HPYSI+UPQ-9+%:\AI%X
M8E9-I9086>1A=1183*T"7Y/8$H\Q.L1>.6'`*&Z[V?2]`1@QH8.6.9/ZAM/?
MA]90(9SS\.&#ICK[P:-UCW9''IN![HKG<$"/^X2*U#B!JP*E,K"1@(4FSO$E
M)#2(%0LO,@3LFTFPI%>2(7&9W+V>2I(6Z>8`-\#;'5JLI])8SKFJ7/<6""*'
M0;LMU)MUYDEW`VD,*D&*;8Y.?)6G63E]UF>[2>Z_R%$GV/:G"LI($V!73N5*
MG'<16X)""S3!HWCMXJ;TJZ+:/32P667_IVJT9-G]YY^NOO[//S4U1#&I("3Y
M)\Y>/Q?]".4O'302J:-Z='$\G>&ID/'*!Z?2"::S#TK*TCUW%:-\Z?/A:ZO"
MUT[CZ1/?<;OME@$:ON\52.D(Z_JO2!XE@"ZM.<KZ%5CVK"J\JYE`WUGL1&?;
M\_/9^_*S&.+)9KY6:"H9!\D5Y1KI7XG0X&#=#2/_&(>TN%P=O7RY.UKARN&5
MQ>K\84*&O<3O#O\FEH+*5SU.AS$L8\_RDC@X`VAD@EIY&@6:^IO'G9Z&N>HZ
M>]VU>)6MIVZ^=8N)2:7"@T6@PC3+PC>H#\;ZI[31:`4Y0VIA4[&M4UQ-S01N
M"4<`N>.Y:<:F!52#+-X(+A4;,_9A1/WO.T2D^XR#<J_&`"8ST83;?>?-H6G:
M!_(W>J7R),M(7RWE4>(5-=[%0%(S-IJ`16?Y<H%0SBW\Y:!E%(]6@N;AP0$T
M^<Z4W2()E7-.CK"'/:@U9L\8M^1`8<_1TP$S2EUJD3'14@%"SE<<\71ZLI#3
M-T238/O.QF!=0B+U/-"K-1Y97-V?GMV_Q,6*HS?$>#SI%&K!G:7YY'<*9::2
M$+B(6ATU<TH$OM`2<GQ/JG46ZZU[1?IU"MZGE>8]/_GY`F`VRAZ6?K!1.>EH
M/RE^O$LJZAEIL'$JP'YH"&3^,S<-0FMLD.C?M_2:Q!^BUM+VU`4B]%Q,25AC
M5T8K+;)#M$;7H&N"<BX"5AZ2C'I*^#S>J\X6C\AO!"KQ9^'DE/S:B^FE^?<Y
M^J:UHVZ4)N<8%<&=3`73%RO\R`-8[=)I,G>Y"5'_$OTA?_W%SMNKOMRM8@W5
M9],/UA%8:(-ET6P8A*LU\-$'H0]4J7H)E1\:X[B$JXBW"F>.GL1L=^0:XT1;
MWTGK>KMAL1L&:'#)U)C:*"0L:XJ%7(B*Z<AXG8D]\YR"BH0:L@MD9[[R#0X'
MZ$D3(;092(!KW3S%+S@I\:V%#0=`8!YA9B-KAD^CNLDPL%AU<TVU>@FD&(M@
M+`#RV_".E@`P'6Z.8I2;ZVS5Q9&#(#KL^OA_*!IFH;@&16=M%#6[HG*X.E<C
M;D-ZQW$"@B][YX%.^T*N'*$K_)$HG_^QT=:1MOAN=6^]2[<A05N)>P]D06=.
M3L;.2@GZZ.&(3H6&+7-D=(F`>$^!%VWK,)*A):8$G9Y#8NX&CHSJ9E_+H$@?
MMOG1_(M&2M#Q\J^'B)-EMW2P<#8^'AT>_<QI?;]S+-OBY.I_EBK3B[W=_5?/
M1H<[_^-9=_;0(\L>&GPL:"&>FC'#EIYP[8@R0@UG-#:>@33^TX:O@#T#Z\K`
M2GTXH";D&31^G,WRC==13_&:2H$EZ:YLGC6;TOH*ZB`?"?5J%@R<5/T8C"ST
M%N?LTV&.C-6Y\.25Z4]>EJ-$&RA$UP5.,;8/`!F<`Z]0MY$.])><3AAV*J82
MP#2_5<<J=OV!Q6TJJ.NJ4K"?UM^NGM%@3VD"[`&U3A.]RY,\L(!57492/O>F
M3]YHY[14/04=Y3L[)R?T@+JH_JXN&@56RU=7Z+NZ2=_5]2K!;X7A=D\VE6A:
MOI,S!IVCFMV%><XD':$@WO`XB\QNHX\.$;G3N2PZ;HC\FZ/9M+9`K=9U!DKG
M$;N[%^<_>*(95W@"Q[>;/=<UO(QC>YQD`SL5,7>1C`D?+6`?HW?P/\>G1*.Y
M!#BK&I+#-SD)3ZD`7]>#A>FQRPNB$CW:_0F9);UX3+<R7I^*M^P4"&WK4._(
MBHOW7@S:+[X`:1,PX,]F'[C%:/E<7T`O/%AJU6Y^CMBG^1C?B!0O'`':'_^]
MN;X9].W(+4R&Y"#TZE<-O2^%9..)]=:(`4@?_2-83*=6Z5D;F&^9S<9I'*"O
MPZ@.N5AOQFST_6@'B<M&-]3E+,2M`YL2]PP*PWM<8BJ"=1=DSE^6(K%I@.Q.
M3;J!FO8CM_!;!(5W&1"P(@Z5F1L\:BA-"!5Z0EXV_5;U#$8N67?OSB]Y2;H^
MK?RU@_P-4W1#Q3:4E=0NE_`^B\N.%\&65O//C#PU"#K7MVBT2M`DE=-)OC.F
MDH01(</Y#$)?3[(OK;BW_[(XNZ,K'X-IYIOLXR`<CH5__XI_V8'+@D"L6G_N
M=$RD`.),UEDKA!UI+F_167V([(6`4<`1[/F!AKS'Z%Y#]:!)BP>S'7)D6%;\
MYRNYWJ&EXC6S!"[K?AX/R3S7]<65WC;%-2W_@Q0H<*AU=$47=,3%CPZMFM,[
M`-M,4DN_P.T:>58)JH/8[B-DD,NO^^LO6^O7R3*OGM$%<KCB3AO]P<`L)8?=
MN-&*W9.SA)Z@D52]-?8(QZ%UQ&A_M);+15<VMM:JWD_WOJP>VWQ2)Z2O;#RN
M\]=7-M>VRK=W4R:32&R94(7K5<53A"[7GI3+KFQVY,\_2^/QEJ#SL"%7:[%(
MFW0J@\<SR[<10<3[*KVF73[5+62A-A[T2X\?;`P[E/954UG;.NAJ6RTUO>1:
MD;$UU[K56T@0!UJ`B6%F&?%/QC_#:0G2$OUS/Q55*1UZ*'0/WV0@!LI7B^LD
M++3E(,^'\B6\A1@^,N8E,+X]2(39B,?L(,8_'\4$1=K4^94\6ER]F^(\D^D5
M]5ZO+M._/"^F"S+=U1]#3WP+_NF+IK8@:S$:Q2;;4*<F?-:/*3%].TYX(2:W
MN2&:K-D6Y#Q!3ZB2".%X,/!@E0/`+E$V!+AB9.-*IVP>MF^VGATP9#!C7KTX
M?/5L[_!@M+/W=+2[OW?X8N\OS_9V7_18-H_-LKG1>R_#+)2=."BV@O[OT\GE
M8O*VQ,`^#K7%6^4=,NN6_UM_U,:Z[!;I;[!O9:'%[SS-W$$Z.>'&;=F8*9\@
M<4];^+STN[G\FHT/+),\:Z/PF-UI_%BA(@`0(#'(#)$;IG]!\)8Q/M.AHY#,
M0\"8O^_(Y0VTH5^BF^'*6#B=+=Y*DTF23OIQZ.K/30@N+BEPVA+!:S4@E"1R
M"YHXWP)OA8VK>;/__$VJ_O`O*%6AF6UML?/X03A+_E6I4>%CD2^$!O*-BJ(?
M3'5G6`G7)#X7W"F-I[LBZ9PS(E,M\9_]H"C@@4&+BBLD%[I%8N51M!LH#5)N
MG5'C40$!OL/@R98,<Z^-KGB#WK!RYF5R"Z0+P\Y%_0VS",A_=`8B1`F[T1<"
MGT`]RKA40%6JPI!V*M#).+=,WZ/9\;G"E6@1_A6HA[79A3FRFF\VT0)C+::]
MH[P%#?1H=G'NKB:IJ&'J%RXL.I@Y?X/"-N/4#(^F-TN#E[#.*8JVOGV2+DCD
M>SZ?@)](=L<Q09O*N&41K^63EQ@MJ.!4,0Z[&!]:4LDS5>26X+S/<-!S0T#`
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M;#Q*GWP]GDSF'RY^/)H@T0F\"RAJ-`)O?[Z@5`_-F`1I#5&TG61!%GX:L`:?
MPZ+%Y;*<D9A<5%F..^]5FU:SJDR/B%Y@8[G!7!/;+QQ'VX^:/@G;C$8*F3+.
M.^OLI5]_4<J^23?ERY3I2Z:E7$)736X5"?[T"S$$:G?#"14=A//VZ**]3P9/
M7GTMTFF=Q4L4?J]G_.I7^OCZ*Q\WO_F0N>Q.7&^F-#_2_.XSS`ST,<S-/W^Q
MH3_\:?;:X`B9F$95%J(57:*$H'J.7N,!(M\`B2>T>!3V`#4>A1ZZ&84P[.IH
M[^B_SX^]N)^B61?V;5'W5+UDSS&)=IE"XM$"X?(9@[?'*$;I9XXW1XH-T6X:
M!PB<MXJ.6>!+,W:)WX=)\8UQ"@"MJ2Z;!KU"H!=<1.50O;="(%LD3T2MJX?L
M^SHI"=X+.:85A!B_!;NR;5,[+.T%U9FZ2B-0[O$"S_HJCD!+<Z7">'XB$U0B
MLR"NM8<QEB7,4>4PEY9E=SJZ*/C!F`OZV`<K7/8V"J$WC-#`(<>J:S#HT+BF
M8)O$!'F`+<_XII&>=C2ZUX%OZAJD:7E_RP%XYC,"K7::X6\T?U#VB9:_./II
M3GI?LT,Q7_/&-GT=.O,Y8F,[Z6YH3QXVCZ/Z=A6I`;^GH[^'O%NS!X+:1VGJ
M`O<<Y@YO4GT&'#/^94X&QPA'0&QO@DHE>CT]]_]6I^/YF6>-X@_C8,S[*D5;
M%I-T-?XS9(*8XLP&$_"NA@IM=!D`A\J[R!%H"!9*@F[6(AGI:L%'[6D9,8^`
M_G>Q'89IEB%9DM.()"/PHKK70E9>X:?O'K136@P=)[@MP"*(4[*56Z$TX!=?
M2=]U.3*9JX0+K9>5^(P3.70]GGQPE5;>Z:-C4ZS=%:F3]FF_RG8"(]BH7(WW
M2HI1#7ST:J)Z9TW*="`DP!"!XPY:QD,@U'C2+-XDSPL22]J6E_+TZ#W$[0:)
MU[C.R*P9GP56FX_Q39SU*4T9.,(QQO7OPE5W4D5DSLXR:"`P_#U0M,SA6'GT
M[OS]:D,8S<_P$Z+3G";TX:0F)@H"Y4?$0_>!')"P7[M*AF0][+ZB2%+0L/PW
M02,Y)8_IE-;\;N$9V<0'22"SF*FHGHEO02Q)IY#')UDSZ:,ZW+Y]9N3:NKEL
M!&+1;6Z`=P^P.`S6?5:!&V$6"M",(GA"13:)NPM2<*3)5R;-7-E1,E73\8$T
M'=EQY':;><3BV2IP6U]>J`XP(4+$/0B1^&W(CH.8MFY21&(&J!F>$7MV"Y]:
MJ$&W)=E<9!-!]B9`[%L-(`V7E9<#\/4_XG+'[7('_IGEF(F!"+J`+9],H.-3
M4;DY3[@><&NM@JO7@HIVZOHZ#9<5/Z)B/6[GD@%^.$UXN^$@T5Z-\9?96/9?
M>*/O>NX#%*H%.;@(I*.+[$Y\]5OJ/2\:UY)HRC`%RHPW<<(<)$+[<D%(KT%_
M"I:>3XRFQ#:AU`8AD!(2!@8''[78/?DMQD8;)Y;QRG2%6K>F.7$32!?S,<[;
M&2Y;6`4K]^/UZNM7C0)P+.9(8Q*'+1Z?&4<X1.3QTWB?`$;D/,T6=)=%.E(#
M%:ZV"U\]YNX0L?V&G)0/%RE8@B_;#M!;N&\>ZTFAIE.I@Y8U&F(,%`N`3"_Z
M1X&M-.F#5`8Z>J98YE"FR\&WWQP\^]NW.(A'S[Z3F[BM@5]]O:=F.4_,*;ST
MV?TP-#!6P[5](4!B]]Z]N5!5=!?[YE)*L,*MAECK&@.&P=5[.E"XZ64:2VC-
M,%-'(7$9>UZ&K(R9-4NA@KQ4_:/%\/GB6`S^2-Z'E:",\(-5CT1?I&8,14\D
MA2W^CV8BE3UK8OGBPGWV`BL4M"!!6IHT9=_9M6FCP:&QE$H&K/EG^!NJDG//
MI"`9Z81RJK-SY"1\9F7CX3WD_(?T;(-$T:,N9S-*KUC=/PP3"^F<`)U,-"R>
MZ^^M))&#9OC/019\(CU&6H^N]6NK;F*'*_&_RJCCZ.?W%U^9S?_G+Z!Y)62/
MO_AZ5V5FVIC]QS,*9;#+C*)+&`[9^6YP^H5^+DX532"&SZM'B&>`6#*3+9VT
M-G5N?3<EI42`JQSBK4J>NC)1!%%\S>(^"`B%D,.P#A&O3B(XBQ5?$S6BND(N
M0%%&XZG3)LW*?SL>$W/CH)NBK$81M,P0XY+F$W"W\L^AJY!MR'6_%FA.%>=6
M$1-&G5@X6RE1\S54"CYM>BU0]JW!]M[C+%GH.4<A(2\?Y\M;\MK(P-3J4I`1
MD431,",0%D<_F\@+AP#%"2_N<>`?KG6!=,Q!R0(<0%)C,W1P+5HK0[U"M%N(
MH)F,--4P^I6/.17R-2_?E6D\)RF^+,!T4N:#@@UGYPFD80-\,6@G4AKU2LA'
M,/&F?\<%L^@MP+%NBK!J2]GB6;84SI1CUQ`D++5:",.CS44-8DZT#/-:6^Y-
MS,(R9AF?^YXMWY^,)?;(UE#N8D*6M,$:B0Y%J&8`$<KPZ7"Z@[U&T3E2GI9M
M)F"`EGZZ'NPPW(^8:^`Q"5Y>Q&`Z>[QN_+RY_<IRRO#;G>08%!G+]B+0#4OI
M8KX*-M58B'.D=4"6VW;^;CK%AHQ)9B:2XG)ATY0J<$>DBKX?LZA>[3D.>)^,
M[4JH'_)*9'"R*J6+?[MV0,.9D$S:,#JVCW,2`<O=CU,*C8N$'[CVWT84&\TW
M+J&KHQ]@/M";1JO;=;"E5)(.C7#[`F_EGHO+H6_ES$9_ZDTM\#L:MV#KI6/B
M-DDW(!`LF#&>/*".CPQ"G,"%3=([<^G]@*[D\LZH2:-,?-7X:'`+PZ8-3@C;
M.K:@[^<;%,"6D>L[_92<#T<'GX6/P!Z,)^)8;Q(B+I/BGZ4^6.8#E-#D*>AM
MDPDA%P)D1?F3<`UJW1.(!VL=XC-K6NZL!Z48O8DH/]0EKZ?.J7N(I8RBCS=2
M+,=BDB70&1@E5J@-()#.J[A!LUB\4'%3+U'=+]#T5$?5^9ER:SO!M,!)][^C
MUPJ24=L]T^?*YS-49`UTR(:9"V2,_3K*L6>-%E\??3#VM]*#H(.3=V17D4D/
MQX#EY\666!(+11F.)B4T3S%)PL29E\'-),WC.M_H>?6[F%`U'[V:GH[K-.8<
MSIXU8.)V0EJK*E^TU.N0`'EW).4-PZ4/8(H)R1\"'5[)#5EXR(\[C>[4FLR$
M>P)DX!(I<92=F(MAN^MQ)%E6A%2^&*<]7F^H6?EV]V>37_3COYN6",UYRP__
M`V-G?HV6M)BVJ&@QLGW8]&.['OVDLXCPE'"\\.H%M)QK4F2'3"W7?//)&9GE
MBC"._G2K7KK,+T'05[IC?N7GOI&BK'+9E:>61#.G1\FW!T]'=TK+Y^MU[A_]
M%<))]J]SB**B<H-J@?V4/HPVF@VM#2Z-<L47<0`+_`>;4(8GMRPZW-V43BM&
MP5PN\KKU)>NK)>O`URL?]B*,^26.#NG7YV1#64M!FY-9/GQ7FDYV:=),0:D&
MD01=.D>871F)%[WU'(I>ZJ\2-LNV3_*@"O^6/A8%"SR-["N#DE\D+]5MN83R
M-0E9;CCM7F`VH8Q__\J&PU>U1!E[6&H=+R,5RC/68K_T*O<VDY64@6)*G;Q#
M&<BV=E?QB-B;-A?(IHV;OE.H=^CH29I+*U1/E4%YG<F)_`/AV')QVXNOORV0
MHC`KC<Z=RXU"=8`Z\[XZFE&\ZT;]"\5:K>YLQXJ21BNN#FS<^]S+COX7)G,2
MQ?D>#_@S`.\@Q")I>-"NCS!N::/]$-T$ZSEINN-YGUYRLQ]-DWE!]B:8#TC>
M[$?RQZW2OX,;X_2V`?A8%'X[F?:A;^MZZ+O>"I\)=9_Z\1NA[0;>P\`?1]SS
ME4;Q7(5+B$#I16%&P59B`JNDE7>)W.N\6W+\YIWF<XTFOCKZ&U/-Z*B%X(!9
MO;"XAWL"OG^)(D#6XOC]O!(.N\G_E#/:,^1C)X_!QK]8X"^1P)9SPI+NH[F7
MG+GXGJP0/N84F:5GEG5\U#UP=<Z/GMRR)Y7KT$[Y*?&1[*G1_2B6<_Y>/FYJ
M)R)35D_G"^8X;,(_UGA*VK^W#RF7R[^.@?`C&0X*>IZ-*8W!VN4C?;RC7.DC
MY/-HL]+!GI&V+)N$\.[,,PU6R?-AQ#I!Q`_2+93$8:J"J%6G*)OWD,1PUQ]>
MF>]Y-$0K.Y#7_=/S"RJN!ZW0M'%`"3K*L"`*T/E#X>H2,^K19\+3KM/MAU'G
M?0]_#'*#GENA..?M<M%7L86^%[^=DSRO>KDS"Q&JBKDD@KM;[H$I_[[7MNB7
MZ6=$WKP#B6LPR;9O+S-TR.TGH^TPBEOKLR$V!FV(YTGK:PHC^D[LJ>H42C00
MW$+OM!J-C:WJQVMM>B5NH7P]+[NZ<B>@113*Y^B6^KKTEA!%-P7%(UKE&WMV
M>/$9>5:4$%\^]51S/BWO#()2RA0M1<+`!<PI:NC+%^X^ZJ85H'/GA64Z^<>#
M+ZA<HG7C0D(5L02IO.6C)G:(>@$]3"W=SM,<ZO(=BY8%7XK9<ZVGX=(9GLMW
MV^AH/2H`Z,*_P/GUH7SM[H8AI?SSZP56")&F#/8>&]%A/B(534+*`-:I6J+%
MR93ZVG+I'3\IA&%R)P3K!L9J;R1@.\]]KT4=K8WV?,K%.4CH@*ZRQOX>&V*:
M;\PV1:Y#/A"Y_$IZPT];:"C>6#7I8F9L^7*;3.)YBT>63SZ-UDF!K?*YY":P
M*A(<\9,<8>73>_RH_&==1W4F3Q+9B%IA,C]W.J&0Q<H`&KFNTE\K7@]_GZD-
M4CH67Q&V6GYXM_D4#VMZ9)8OV8DJHW!I%H5?4;/!8PJWZ!7?\`)?&6G?EPI?
M5R3?MPY8B'E["'TUSC2]B"";_BSQ/[QNZBR7OU:1O^_;&W(+^6@>$?N[7GU3
M8BJS6ULNY&5"K5%\5ZG`D?0T#3%?XU6,#J/DX+D+'GTY8B@F;EP&4HA0+`;T
MX>\W*A7Y^\WJ3W<WNSEP8$(C6N&X1VWS@25+E)CX?JM:\A51%"7R]XG%NP_\
MDW((#2_^*I0$]*ZT%1?8>-P)W0O:)"C?2XPC6!`]JEC<[Z.XXO8-%\1\7+KQ
M4')6XK`?2BVZ!`=R\<VZ9Z$AXI1/A83"SPH'0'O.DK:;!(X-(\*'V!(R9A@G
M9B3X8?2-`I4L(5GE5&F744RL<N()#%(WE>JE'D94<9E6WDQ)ZP"&!T\6^-.E
MOLNWECW,)]O>MLLQ;$_9V)?5IY=<1K-PE]NNWQQ=&(,Z>*>HLC5D!*[54:/P
M'6"0>AHQ?1@]5VKH_N5<I?%CG=;6:,4-D_3JUL4D33C-%YYHO0-G:%K;4A[!
M!\!GWY5IJ=7H->V06=];KY.XW2$L?-6[>M]ST/$G03VP[L=M*-8GRR]GSM&^
MG3^+<["CKB)=(IF%S;D.FX7IA3X[\E,1%#[PC<IG@J'J5F7<UZ=^H%2*HD\E
M="Y!,)GO7C$"%,_[C;>AEU8^?<7??T]`\''T=RN;[[L5I7SYK!_[0QQ"'R9^
MW_.Y-I.YE0.Z'4YU*Z`L97>?A4*7?O4/0:J?G5/C$I4"-QZMG([]OY@"B#LW
MBS[V.L6CM"C/YS;6_%3LWQ(,'\>O;^GC?7SJ,^&[[W-_D*,8`.]W/:5K\^U;
MHHK;X=RW!,Q2+OJ9:'7I=_\@1/L;\&_W6<AUF;E)H\+=2J*U0CY9B6:Z8J),
M:.Z0'-ON<^]5P*/;X=8_Q$E][/W]3%L'HCYF4Y/S;P_#'Q)A-^""GP]CM\4:
M/Q^$2_G6;TE@2X'Y=";ZV3'Y^7P8RQR%?6%5\Z14V=?+?/V>C`!/#HZ8`5?]
MX`<&_)=->./`DD]7K5\&A9KRO99T5S_\%T(R'6&@^L%],H+"JN8JS@O4J/JM
MXF+U"B$PJY!6"5?*&-\A\X2F"YJY,3O1I%G+6\RS0#(X/F&5GFU_'!S7PL<-
MEKX)HM[028'H`-Y>?,UXW$^4TTQ^PXR.#@.HNOOXNO&7].23&!7IB;/<?1*6
MW`X/+CV>(=A[#BA]Y'&"9K,S2%.A>^AC`PB/'RPWL_.6<FO:)BDWC0Y#$U*3
M+,)$M'8`[0-O]6QXX(T!J(>9"1FG*\Z0/-\H:8=]^7W&6>ZKQ-6Z@U)DI=XV
M!"=W9K"/MQX0(;*4/T?XU")%.ZBBIX-!RN^FBO^0S$YZ-4$JQ0U+;+<>\=!B
M^<C=[4!^,1Y8/1`B;Z-(R-4#Q"(MDZ_\81B;)*#V5"+L7%(\'])\JD;*-7^,
M/*^*R=>//I^2BJ;N[R6H]:,9-1J?$J^NWZNN2P2F9L#QE^K;-UBC%_X;K'&]
MC0V?W0/.+D3:EEZ"-]T!UEZ:[7^^AX!#2+P\TN$=1'VECP9;J5&D:"!?+;.S
MLSSP[CZ9M0INT?NA!*-W(1O$<D*$7>7]3P<*45ZE'HE/ZA;B+Y4]2PX+"6,=
M23;DKY"&VN2OE,`5T=+5T63Q_IA@,9J7Y:Q8_#I/9>E90$FSJ;Z%EX=>,6:G
M,DO@XKG$%,NE8VHM8MF2<+.X6/EHIIS&4H@J,-Q.BU/O7NTR*?U%-++\0F,!
MHV41Q`WE]U4ZS(O0+*0_;[7A-`'#3ESP%B%Q"'%->'*N:3*K>#,H9B2C0!+%
MX5?SAE67I^4.^G9*C5/43\M7%':.SI'>U\,N<@(8VD1:)WE:^OSFX<EO&I],
MWY.)BB%UVC<8/J[4\+B](34;Z^[OH02,W="U0[V:2*X@#8,_EC#8)<^^8CZD
M8FXBF-#KS<1QR$QKJ;.;4I&:A`.:R9#$].LOFA^9'K<.>BK^BAV727G3ZVH1
M)W75$]G"FCFF53K'_,#YZ,[6VJ.'35*;P4PWCXG*7C?7[RGA3+7#EKX=<TVL
MEPLI#3Z1*;:1((/]B)(\&P6@9&\T-_6%=(I+A>LTR"*?@K1_/F#KK&SSE>-8
M>&A_.B/5;OJ3X-=>+)5/_Y&A<C*EDFI,@Y__$P6EK!?R7D$(+X$1<K8T0DK7
M1.\FC-'[2M/9[.!H@8#QPQ/C:`CQ*(7@U4'"K%M])KH?LZQY$NDBX&G5=`IW
M-M<V,V2OC9SFH#7]/[7LG/\S=/&T-IXGTPL^/7M[_.<OGC_?>/[@R:.GZNXY
M>XX5XL_MTJKB>'9>-@'=U!_FU&S3<@ROXY^_0.6;SO+.H$,]2+-OL]/WX]!4
M]#8^NP.AILO,*2;4TXO"FY.0W4!J,^0?J+8X8`8(A:X.(@>`LVPK'7&\DQS^
MG6*H9\AD`K_9M&(()JL[K0:U`TX"-)YDI8UYDDYZKH_G7$N[&'`_P`762.+3
MN(&Z_0$F:6@:-2!'IC\F)7FKS>AH+P8B(3/"&DD]*Q\)3+/W][\>#0*89;?*
MA\Z92?^9+TL)^NOB(FV[@CK_L=+[,1<]*S]VOE$BO:6XQZ8<UA*PW&9C!X9$
M="HWR=P2&Z6/`3FU,3NK?#$7?BTV*QZ>R..Z8B]7NJ.*HC+-Z4\N]T7M9VAP
MZ'(E(.VL@A8H0KG>C&@O7^W=@U*,BK1CJYVV7K:ZIB0:TS885IH:>Y5K<S=5
M2V2J2"-LRJ?:P`O6L(&WW?XSL^9=/K2#[MFK]LGR0WU:9=1CN\VW7@1QKN$X
MC*Y/:`!6?5%*6)]G$T^25<E3HM5G85!(G*["@W+QY^/CM1&3^3K9PS=3N08X
MI3B0NI]+!+FW4^6VQ63'_E<MK_R:C_T7K8)DA?1S2]72O,77L^-SLD?+*X",
MPXX*3TN)I\#%^K_\W"]5:E#<"R([1?^8A0_V+VA\,<PGKH[-.%CXL>)@;V@G
MEV8)Y\-CGGF?UE[0#NBQC`:R.OJ+9F1@#XD%[9S*Y^/:&*I96*,?[F?TN)Q^
M&)M.J[3-EM.)RYSL,++KT=5"ET.(C$3ZV%'.%3+$LN;,#>7O5D9.FG-DU\DN
M/SVW;6P2XQ/IU@3YB-8W@\<_'#MFUZ0\\B5KA^X8]@GU\-+"SJ2F;AG`\:LU
MG=;\`>I!>*+UCO4MEU_=JKP\-%R"U5XBJ!?9\R23ST]FYP9#^>YW:CEE(Z]@
M.K-N9YICA"ZA-["T;>AHW-45%E'YX;BHN*.8N+2GMT>5#Z/Q`<?%\A>PB,MU
M^U]`H1_"Q-T61$%_C!TUH?L)9LC,9ZF[6>2D9`:%;H7$Q"RY]EO0-CTT#=-Z
MLK%*0MUET"KGYZC:_-_5UY\/'$0PG1BYS`U<Y\H^\YH==FE[J2`L,=T'X&='
M50E(^^2&=H?6H^VIS_-B=M_*)OQ*#6/_HY8LH6SK(Y$^H+.&CLI7OE7E4.2`
MSDEJYU5T")4O)[_L$5OFHA2IA!&`EDYIH'2XFF,E'YI;"EAU7>KV'I.JZFIZ
M"6#%38T(S3E'8$*7I-8V;K:&.8B"GE2^.=02:EF,>"A-!N7H[.-K.9JWY=?M
MTVEV3O"^-0-1@\G5]W2*:$>["]7]C<U6&Y*C=Q&)3TJD\<?-:BKS-3`9==)>
MC=3MKQZE$W1[Z]@K[^;<BY<EB+#>0>O;IME6U:K[)U>HO0_LQ\H\#*KC!\J*
M&-;;A^CT5#2*:,90M\A#DY&LDQ*MYIL,6K'PSLT-N]R"2%<ME]&YP5:>Y(U>
M'A2;AUQ4E*50U^L^#"Z>:M`NYE-US&2WY^I1&]UGP)54/@Q(6BQ1<4Z7XV.8
MLPK7&+EY8<J:')&R?Y)?1TA+>G=H#*VF'RO;]V)PF2=,OE+P?Y$\E^&/T:1(
M'^%CR`+Y%X,&,EIY^.6]4>6^D;4K8-*WDP]'2ZDGE)PF@DY/9:[%\)?X'DVQ
M'3QIO7HTC$WDU)+C-QZE-Z[JQBQB0<T!^7)XN@;9)3P+/_Q2<!E.4$EQ9%HG
M:CG]`Y<M/V&>Y;C!^&Z$JA*4A^AV>B@^4!):K*Y,XP9,RXA!#$)QJE.]J&(F
M+8LE3&O,WRP_TXZQ2.#$\,$\;\Z`)Z95.E<N$WE9F/&`IV#N\S1:<3+M][#Y
MK5SD[@OS<6@"3G!8BW[D<(^,P<\693^OAH=NO.7C5Z,5D=1]?5D=+]$18HOV
MC8?JT+XZ6CF^Q^';W=!/Z;`?I</>LXIHW'E(?PL?2M!OK*??*<ILM9L\(G7'
MNNJ(4D+UI`_=X+V5DWL4OT^`R)J.F&T1G6'%P9IB"=EI8E_4DSN^Y,U?2PP$
M-&&O:'@33BIC(1$OB<9:EDB(`H6/A8M%H[><^ZF2`L/*(Y4-MC)T-*NTWFMI
M1Z[&J'FST1=)4;K](I6X50^K<,,2)I=Z08!+->(J7X_L:5Y=LNM25'F554G,
MC(>W<99"P*0(+-$/4Q1H,X=O,J<C6HT$A"K->!S_@?(7+P2FZD*LCW,6940J
M:)&&EO0.YP*$BQC$.$+O_90FY^<N$YAD%VK/^>:=C3`10.L[H=\)?S$N;.U6
MK:WD_B5>B'`W3IMIW7$`A>@XVQNC,0(A'XWB@NT+5F$]GD<(?`U8T7<S?(I^
MH`]!!M4)BD!V0BB]CI.D@?KN1<06MS'@/@&0;H`YD%/X24,PCFB?Y.$Y4&R2
MD__UF7\WN*V:SYL`@[>L;-XR;.!>%[#F:)O&T2K<-\9!<@,7,=6KKW=:JY5<
M.+4?=?<R";#328N+ER_<;8C^**6*8?%D?)P#]:$CS3V`1HVPSL^IUSI30$G3
MBC@!T"F/`T>):RDT3/`)8;*<4$^,L8>3CH*APL.;Z0<Z@7^(73G4&*#7E_/_
M_OS47O2D"X).$\;V:G9`+ZJ(?'->FXTX;.8M=RWU[UFKO]^LU>K,"2UJ^%5H
MMKS,5N]\FNAH>?N[GUN6JP40HUWT?=KZ[N(D^8"(0A$>3IZ,XPK$-BR3P1H9
M9E-9I2[9I).P6L7X]-43_VKK.=(1-))"*0-R2Y9;W,/4&OJ,TGIH$#UT;ZPU
M<7M>IX!Y,P;4]^I3:_SNR>-M!?DTIL,ZFO^(LP(^BC!$8"E9PK\CV;CKAA#Z
MFKHY#D$7!W>C=:%>8E8N@L(J.^HMUM#$O-=1Z-('TXULJ9*:04K2?)A-D@8@
MT.X(Y9@!;;P$4\8.MZRS_`WSN@47$IS>!EWY\)%#H(_S5F3W$5"-JYUX3\N?
M;,8DD&JC-M3*A)!0)%DXF<@':Z@(LL#5!?:E1_;V7[:IH)J:XQ*&V8#"OG_%
MO^S*=:9V2`FI/G=J@^5")PB!V%+UPL$`-UD1YU`32EOU(?I<V58M-M`^SM"U
MDG;^1H]'<=8C*E^0C,3!4:4Y2[WHZ[@LU;_/2"-0O,GF7,T9%Y".R.;35$PA
M7BH.L8ETY7;C5<^=Z?7F]%VR\E;%+U__.B^YIF!^J$W[,H9WO=>7>N2R1MOK
MC\H]^VQX\9D43.T/_]D\[.L]R/SCWO/8AVRX)WS3%B0,Z9VXAIR8K1&UP6`M
M]])HFD%Q@$!GT]/%2=UP3ZA%K7=/_-P;QY/Z9E>@7/;N1D_;*'RHW6$V5_64
MFC&@N-QUU.N"&)>XL['Z$(=`'-MFZ4Q<`,:*F.)HB1YGC'O3/=MPFUR,5DFH
MWDC<?Y+^7VT?EX4RW]3,#%[*_0_WB3.H[M^+S.-RDJ.)[X;>^"-WS]*CF!CP
M8()'Z?!MC1`H?TP$TUL*D>S.Z#X>J.GZMAR,EZN#QJA2@E1YX@=ADH#G)$6^
MEAXWCV8TW<P[,3S1KUS^::/-2CPX+.9%1'@F(\GL#ZP/V2T^_*]<QT1X\[.R
M5'"WAFU*,/UKS`9DTW_LR8!_FL^OOOZ_`@```/__`P!02P,$%``&``@````A
M`.S/_4G7`P``[@X``!@```!X;"]W;W)K<VAE971S+W-H965T,RYX;6R45TV/
MHS@0O8^T_P%Q;\!\)"%*,IJDMW='VI5&HYG=,P$G00T887>G^]]/F:()-H&!
M'`+$SR_/KXHJ>_/Y+<^,5UKQE!5;DUB.:=`B9DE:G+?FSQ]/#RO3X"(JDBAC
M!=V:[Y2;GW=_?-I<6?7,+Y0*`Q@*OC4O0I1KV^;QA>81MUA)"Q@YL2J/!#Q6
M9YN7%8V2>E*>V:[C+.P\2@L3&=;5%`YV.J4Q?63Q2TX+@205S2(!^ODE+?D'
M6QY/H<NCZOFE?(A97@+%,<U2\5Z3FD8>K[^>"U9%QPS6_4;\*/[@KA]Z]'D:
M5XRSD["`SD:A_36'=F@#TVZ3I+`":;M1T=/6_$+6!Q*:]FY3&_1?2J^\<V_P
M"[O^5:7)/VE!P6V(DXS`D;%G"?V:R)]@LMV;_51'X%ME)/04O63B.[O^3=/S
M14"X`UB17-@Z>7^D/`9'@<9R`\D4LPP$P+>1IS(UP)'HK;Y>TT1<MJ:WL(*E
MXQ&`&T?*Q5,J*4TC?N&"Y?\CB#142.(V)'!M2`C<3ISL-9/AVDZVW%5`@L7O
M)=BXG-J=QTA$NTW%K@:D'`CF9203F*R!6=KB@;GW;0$_Y)PO<E(]%=`<8OFZ
M\Q<;^Q7LCQO(O@]Q5<2ACR#+%F*#O%8C>#1?HYRT->'[IO%&7R]CCY!EO0"G
M_>MZ[-`=6X1!9WV*-+"L*VW<-@G6)*W4O]TC9%5+<EU/5X7#?CWL+;UVLJ+)
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M/DV+:7`CQB;58`:4(<$D95I3F+@AZG<'O_?6(@9,&LZZ,8@:VEG-@=SI#KVL
M0PQZY&%>M6G5U)0QB"IO5J,@=SI%+_,0T\CS8//CW+8:C3R$Z"F@"IO5+.!`
M\OO$Z[8"[[XPA-P7AB<6W).7T9G^&U7GM.!&1D^0)XZUA-RM\+R"#X*5]=[[
MR`2<,^K;"YPK*6S,'0O`)\;$QX,\$;4GU=TO````__\#`%!+`P04``8`"```
M`"$`;7!Y!7(%``"K%@``&````'AL+W=O<FMS:&5E=',O<VAE970R+GAM;)28
M76^K.!"&[U?:_X"X;\`VGU&2HP-5=X^T1UJM]N.:$I*@!HB`-NV_WS'C@FT2
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M6KM-EZ!_\^S:2.^-YE1=?ZOS_1]YF4&VH4Z\`L]5]<+1'WO^)[C8&EW]U%7@
MS]K89X?D]=S^55U_S_+CJ85RN[`BOK#U_N,Q:U+(*(1949='2JLS"(#?1I'S
MUH",)._=ZS7?MZ>MR;R5Z]N,`&X\9TW[E/.0II&^-FU5_(=0MZ(^"!5!X%4$
M(?!VYL5,7`RO_<4K&KC$];Z68.%RNNP\)FVRV]35U8"6`\'-)>$-3-80^78Z
M(`^<_<[A[A)8:0,U?-L1;V.]0=I3@41CA*I$/":(WR,6R.JU06[F:^,P%,4T
M!FU!'[:3'R'B2(BC$O$4H4B#^\R7QN&M";$'::%ZXP@1O\LI=5W/82Y1D5A&
MF$NIX]H]H6B#!<[7QF%5&QW"8MH0";#>?D!<+:^Q`MB,NK=UP3Z1=?$=Z-S=
M@9\MQR_2]&F)B1`!$7UZJ=YSB.`2_,"G0]V5S'FJPNG-P&%-&>L7CIE#!&]+
M7=^AKJT5/I81YA'BA`.A:/-5;?.RQR_2-`Y+1XV(H,8P<+3DQO+7@1,.I5?$
M<9></44XK(D:.@9%(2):CA);:\GX_O>*K'")+`YKLO3AADA?3\^1]V"G/)81
MYC%JAW>&&P$+FY^SCE;'&QT"8]($(V\$K=CQ)**DCBPS!ASJ\HBC0ZL(><A@
M]GS'LZ5FPMQU]]R:HNP!>.N=O<!=<T'N<*HKXH;`0APR>&L64)MJ>SGN[ODI
MSF&!)XU!-7.+O(&,S8%IW1X)!L6Y`7.URL<"N%UY51R?U;-W*N&TNB>8-B`B
MP:`XL*[`"]DH=QA',#:Q&8S"?E:J`OFHE@3.FW/\24X7JGE`)!@Y22.?$`P*
M]=T@E%Q8E;G(*LC8*_0<18(1.?)\GSE$RW6L,L0)"'.'7*L"-;^8]C(R-@JF
MS8Y(,"@01C+\]"44^U<V"XU0Q2WR"S(V##9TC]B_LB-0+[B9/86!QYB)["UR
M#C*V#J9;AV"FNP_CW&&4#-)%[M'1JGLP;89$@I%OKG5`/(FH\C3WX+O8`\G3
M74C'+L)T%Q$,=J%CTW`D4K89)W2'2:\J7&0A=&PA;`B,+2@85.8ZQ/-L5VO3
M6&&(9\,6=H9=I`I<9"-T;"-28"$0&13XX+J,!)ZCM4$L`@F(L3"@WMT<0K/(
ML_J+ZG):-1/]:3.BR(B[$V('H:</08WQ0R>D[K#=U"3><!/V=1^.W<31W83_
MRPVK0:7P;'_K65!A)A\&Z2([Z6@MDX,-B&*CY4QNYRE$3>,B,Z%H`]!M_3]D
MXVF#S*2\*425M\A.Z-A.'&V(1(*1Y8V>%02#'4"89P]!5'6:E_!9.*,'QY[B
M:-,DHF._&#1T;1!/(HI,+FG^9N[H+QQ%,'(2=7F3B"I/<Y3I60,GB:-9H]T[
M$@R>N3"FMR@_C>0Q9/E2#Z`X/&[$`[5+<LQ^)O4Q+QOCG!V@RO;*ARE1XV$C
M?FBK2W>`]ERU<$C8O3W!H7`&IVOV"N!#5;6?'_AQ9G_,O/L?``#__P,`4$L#
M!!0`!@`(````(0#[8J5ME`8``*<;```3````>&PO=&AE;64O=&AE;64Q+GAM
M;.Q93V_;-A2_#]AW('1O;2>V&P=UBMBQFZU-&\1NAQYIF9984Z)`TDE]&]KC
M@`'#NF&7`;OM,&PKT`*[=)\F6X>M`_H5]DA*LAC+2](&&];5AT0B?WS_W^,C
M=?7:@XBA0R(DY7';JUVN>HC$/A_3.&A[=X;]2QL>D@K'8\QX3-K>G$COVM;[
M[UW%FRHD$4&P/I:;N.V%2B6;E8KT81C+RSPA,<Q-N(BP@E<15,8"'P'=B%76
MJM5F)<(T]E",(R![>S*A/D%#3=+;RHCW&+S&2NH!GXF!)DV<%08[GM8T0LYE
MEPETB%G;`SYC?C0D#Y2'&)8*)MI>U?R\RM;5"MY,%S&U8FUA7=_\TG7I@O%T
MS?`4P2AG6NO76U=V<OH&P-0RKM?K=7NUG)X!8-\'3:TL19KU_D:MD]$L@.SC
M,NUNM5&MN_@"_?4EF5N=3J?12F6Q1`W(/M:7\!O59GU[S<$;D,4WEO#USG:W
MVW3P!F3QS25\_TJK67?Q!A0R&D^7T-JA_7Y*/8=,.-LMA6\`?*.:PA<HB(8\
MNC2+"8_5JEB+\'TN^@#00(85C9&:)V2"?8CB+HY&@F+-`&\27)BQ0[Y<&M*\
MD/0%353;^S#!D!$+>J^>?__J^5/TZOF3XX?/CA_^=/SHT?'#'RTM9^$NCH/B
MPI???O;GUQ^C/YY^\_+Q%^5X6<3_^L,GO_S\>3D0,F@AT8LOG_SV[,F+KS[]
M_;O')?!M@4=%^)!&1*);Y`@=\`AT,X9Q)2<C<;X5PQ!39P4.@78)Z9X*'>"M
M.69EN`YQC7=70/$H`UZ?W7=D'81BIF@)YQMAY`#W.&<=+DH-<$/S*EAX.(N#
M<N9B5L0=8'Q8QKN+8\>UO5D"53,+2L?VW9`X8NXS'"L<D)@HI.?XE)`2[>Y1
MZMAUC_J"2SY1Z!Y%'4Q+33*D(R>0%HMV:01^F9?I#*YV;+-W%W4X*]-ZAQRZ
M2$@(S$J$'Q+FF/$ZGBD<E9$<XH@5#7X3J[!,R,%<^$5<3RKP=$`81[TQD;)L
MS6T!^A:<?@-#O2IU^QZ;1RY2*#HMHWD3<UY$[O!I-\114H8=T#@L8C^04PA1
MC/:Y*H/O<3=#]#OX`<<KW7V7$L?=IQ>".S1P1%H$B)Z9B1)?7B?<B=_!G$TP
M,54&2KI3J2,:_UW99A3JMN7PKFRWO6W8Q,J29_=$L5Z%^P^6Z!T\B_<)9,7R
M%O6N0K^KT-Y;7Z%7Y?+%U^5%*88JK1L2VVN;SCM:V7A/*&,#-6?DIC2]MX0-
M:-R'0;W.'#I)?A!+0GC4F0P,'%P@L%F#!%<?414.0IQ`WU[S-)%`IJ0#B1(N
MX;QHADMI:SST_LJ>-AOZ'&(KA\1JCX_M\+H>SHX;.1DC56#.M!FC=4W@K,S6
MKZ1$0;?785;30IV96\V(9HJBPRU769O8G,O!Y+EJ,)A;$SH;!/T06+D)QW[-
M&LX[F)&QMKOU4>86XX6+=)$,\9BD/M)Z+_NH9IR4Q<J2(EH/&PSZ['B*U0K<
M6IKL&W`[BY.*[.HKV&7>>Q,O91&\\!)0.YF.+"XF)XO14=MK-=8:'O)QTO8F
M<%2&QR@!KTO=3&(6P'V3KX0-^U.3V63YPINM3#$W"6IP^V'MOJ2P4P<2(=4.
MEJ$-#3.5A@"+-2<K_UH#S'I1"I14H[-)L;X!P?"O20%V=%U+)A/BJZ*S"R/:
M=O8U+:5\IH@8A.,C-&(S<8#!_3I409\QE7#C82J"?H'K.6UM,^46YS3IBI=B
M!F?',4M"G)9;G:)9)ENX*4BY#.:M(![H5BJ[4>[\JIB4OR!5BF'\/U-%[R=P
M!;$^UA[PX7988*0SI>UQH4(.52@)J=\7T#B8V@'1`E>\,`U!!7?4YK\@A_J_
MS3E+PZ0UG"35`0V0H+`?J5`0L@]ER43?*<1JZ=YE2;*4D(FH@K@RL6*/R"%A
M0UT#FWIO]U`(H6ZJ25H&#.YD_+GO:0:-`MWD%//-J63YWFMSX)_N?&PR@U)N
M'38-36;_7,2\/5CLJG:]69[MO45%],2BS:IG60',"EM!*TW[UQ3AG%NMK5A+
M&J\U,N'`B\L:PV#>$"5PD83T']C_J/"9_>"A-]0A/X#:BN#[A28&80-1?<DV
M'D@72#LX@L;)#MI@TJ2L:=/625LMVZPON-/-^9XPMI;L+/X^I['SYLQEY^3B
M11H[M;!C:SNVTM3@V9,I"D.3["!C'&.^E!4_9O'1?7#T#GPVF#$E33#!IRJ!
MH8<>F#R`Y+<<S=*MOP```/__`P!02P,$%``&``@````A`#I/]D.:`@``E@8`
M`!D```!X;"]W;W)K<VAE971S+W-H965T-#DN>&ULE%7;CMHP$'VOU'^P_+ZY
M08`@PFHIHEVIE:JJEV?C.(E%'$>VN>S?=QP7-PO;7<I#%#MGSIPY8P^+^Y-H
MT($IS66;XSB(,&(ME05OJQS_^+ZYFV&D#6D+TLB6Y?B):7R_?/]N<91JIVO&
M#`*&5N>X-J:;AZ&F-1-$![)C+7PII1+$P%)5H>X4(T4?))HPB:))*`AOL6.8
MJULX9%ERRM:2[@5KC2-1K"$&].N:=_K,)N@M=(*HW;Z[HU)T0+'E#3=//2E&
M@LX?JU8JLFV@[E,\)O3,W2^NZ`6G2FI9F@#H0B?TNN8LS$)@6BX*#A58VY%B
M98X?XOEJBL/EHO?G)V='/7A'NI;'CXH7GWG+P&QHDVW`5LJ=A3X6=@N"PZOH
M3=^`KPH5K"3[QGR3QT^,5[6!;J=0D*UK7CRMF:9@*-`$26J9J&Q``#R1X/9D
M@"'DE.,$$O/"U#D>38)T&HUB@*,MTV;#+25&=*^-%+\<*.Y%.:Y>VIH8LEPH
M>430;D#KCMC#$\^!^*S),7B5_Q()ZBS)@V7)\00CR*_!V,,R2^)%>``WZ!_,
MRF'@Z3%I-O&8$/1X42!D*.IE@\ZY+=CFMH99,2NW,4PTFTQ?3C3ZGT06W+OO
M"YA-9I[7Y7:8\:#(L4<\*Q$@MY=HP=#M`6N6))[797:8&S+#61EFMAT?P5E^
MW60;]+SV+!E=*'"8:=_^)(W@YP'/2H=C<BE@#+&O"[!!EP+^6NLL<)C9FP*F
MUP+B]$T+;-2E@M17Z!0XS+`)67)YQMU\<)=0,%6Q#ZQI-*)R;^]^#.K]KA]+
M#TE_B?T'&`L=J=@7HBK>:M2P$D*C8`HV*C=8W,+(KK_B6VE@(/2O-<Q_!M<D
M"@!<2FG."SNZ_#_*\C<```#__P,`4$L#!!0`!@`(````(0`!T_YS(`<``)$F
M```9````>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;)R:6Y.B.A#'WT_5^0X4
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M!RG\)=WE69$=RA&$&[..RO>LC_4Q1'I[W:=P!W38E3PYK-0U,2*R4,=OK]4`
M_9,FGT7K?Z4X99].GN[#])K`:(-.5('W+/M&46]/37#Q6+K:KA3X(U?VR2'^
M.)=_9I]NDAY/)<@]ASNB-V;L?YI)L8,1A3"CZ9Q&VF5GZ`#\5BXI30T8D?C'
M2IU"P^F^/*W4F3::+R8S`KCRGA2EG=*0JK+[*,KL\B^#2!V*!9G50>!O'81H
MHY?I?+%\)LI+'07^_O^N0*>K^]$?02:C!9GHL\7P^R$@0Q6%/(9ENGC^CD@S
M,/2?9F3FH^ER3N8:/KYCIE4EO1F7\=MKGGTJ4$^@1G&+:742@X9N1&<2W=/@
M5UD`\M,H:QIFI6JJ`@(7D+K?W_3)XG7\'=)M5S,;QL#O.T-X8BL3VH1'3!D1
M@E@R,=<U/HHM,]I,Z*XC,T)++B/:-RVUY#4,+1<Z4CX:-F@N>8R3.`IA@S11
MHR8JK6]0]BXO)!TG;W<M-RI2FJK8A-TTAD=7IOQ(;F6""`-I,@1Z>-=="&+)
MA#Y9\@W9C%DNJN1Z(0M=R`Q'#B(TX\J$U(PW@/%E1F@ID`EQ5$(9T83\BF3D
MT0ZG,M3M$RI3FE-9-&Q%@\D,;0F7FLX+9,F,/A$8>P#C#&#<`8PW@/$[&"+D
M53"`"0<P41?S4)S3$Y:M)_2D-*>G:-B*!I,9V,I+9R6K,3QJ5)N)XC5,,SLX
MHL%M#*TH"R&*U\4(,X;?,$U+@6@(14/4,G!#"2OU$T-):7AL:4U5.GG47#6!
M;Q@#[=VGLQ>^$K8H8:*$A1(V2C@HX:*$AQ(^2@0H$:)$U$=P@L-R_(3@E*Z>
M6.]BZF3&R[EA3)_@*&&BA,4(MKR1^83^\/VPT1@.2K@HX:&$CQ(!2H0H$?41
MG."+IP2GM"BX4+\;QO0)CA(F2E@-01^6A3G&;GR_G&,<E'!1PD,)'R4"E`A1
M(NHC.*GI3D/[9:7_:9;2HM1SOJ8VC.F3&B5,E+!0PD8)!R5<F=")\.+C=3'B
MZBLS0H$$*!&B1-1'<*+#Z_<3HE-:%%UXE=@PID]TE#!1PD()&R4<E'!1PD,)
MGQ'+ZLU*6RS%A2?@_"^:Z`_;?C*;B?ZHKP><U'2SY`FM*UP46UR]:ZA/;1PQ
M<<3"$1M''!QQ<<3#$1]'`AP)<22J$99>XI,-+S_=Q1@^OQ.VZ0%OR:V'-W&"
MKZ%>^5F<'L3$HU@X8N.(@R,NCG@XXN-(@",ACD0UPN1?:LMIZ_F:5Y]N=[35
MIUN1&LP(_:L\W5=%9_P::DNL$^'-=-L!"0N?B2,6CM@XXN"(BR,>CO@X$N!(
MB"-1+\(G`MTI$1-AAB<"VV#AIH.I\`ZUH5O<D"WM1!`TWM8(>Q.#K7[Y3<S$
MHU@X8G<@4^%%P!G`N!V,<$\>CO@X$N!(B"-1+\(G`LC$)0(R$U`<OL=H9\!2
M?VRQL>T;PJ@9O%_>EPUAN+8#&+-F>C+)&A#&'L`X`QAW`.,-8/P!3#"`"0<P
M43_#IP+=_Q'G!#(!*Y(3;-\(<J+92]S0KS0A32`!&M-6-IFUJ2WO4A>JTY*O
MLV63(YM<V>3))E\V!;(IE$T19^+'D6ZKM,<1&3ZV"R.4E/2(S:C^DL(9DS"F
M/>9"95HUTM>4/8!Q!C#N`,8;P/@#F&``$PY@HGZ&3P6Z[=).A>JKWR6^SK+M
M&JZDF(DK*<EDPMD%<>U=ZI+`TG5V?5TKNB.;7-GDR29?-@6R*91-].#%8]9@
MX\@.4K!OTR])?DRVR?E<*+OL@QZ2F.KP/GTWLQ,<(+-!VX.)1_"`N`9M5O:`
MI,VQ#^$:F#_!4YW$$#QKN&;=&6T#GDVG9PN>;:<'BLZP.CU0:@:51^XU%)A!
M59(]4%8&%4OV0#$95#/9`R5D4.ED#ZR-T$[7&,"*".UT>6`=A':Z/+#Z03M=
M'ECS0+DN#ZQTH%R7!\[KK%\Z^NP2:+[#'A`(U&'?3(U-5YSMU(!O]N0Q64./
MUIT]VH"'KG_R-?#(`^IW>>`I!M3O\L"S"ZA?><;W!(0#0;?XF$1Q?DROA7).
M#E`+<&P&%MV<'2EB'\KL5AT^><]*.`I4_7N"HU\)?!DY&0%\R+*R^0#='=\/
MD[W]!P``__\#`%!+`P04``8`"````"$`T@VL'W<"``!F!@``&0```'AL+W=O
M<FMS:&5E=',O<VAE970T-RYX;6R45<MNVS`0O!?H/Q"\1Y3DAVS!<I#`<!N@
M!8JBCS--4181411(^O7W79*V8L=-X%PLT3L[L[-+4K/[O6S0EFLC5%O@)(HQ
MXBU3I6C7!?[]:WDWP<A8VI:T42TO\($;?#___&FV4_K9U)Q;!`RM*7!M;9<3
M8EC-)361ZG@+D4II22TL]9J83G-:^B39D#2.QT12T>+`D.M;.%15"<87BFTD
M;VT@T;RA%NHWM>C,B4VR6^@DU<^;[HXIV0'%2C3"'CPI1I+E3^M6:;IJP/<^
M&5)VXO:+*WHIF%9&538".A(*O?8\)5,"3/-9*<"!:SO2O"KP0Y(_9IC,9[X_
M?P3?F;-W9&JU^Z)%^4VT')H-8W(#6"GU[*!/I?L+DLE5]M(/X(=&):_HIK$_
MU>XK%^O:PK1'8,CYRLO#@AL&#06:*!TY)J8:*`!^D11N9T!#Z-X_=Z*T=8$'
MXVB4Q8,$X&C%C5T*1XD1VQBKY-\`2HY4@20]DL#S2)+`Z_O))!3B?2VHI?.9
M5CL$>P6D3$?=SDMR8'&&!M"6_QL")R[GP27Y5$`;&,)V/HW',[*%SK$CYO$:
MD_8(`N)]!:#Z\0I<$E2*45_!:#KL^7V5CP$S/,.\("XJ`)KS"M[W[L`%3KWK
M-$Y&KT1#.//A03:(XSY^(0E5W2[IP&>2KSL=PI,@.8G?DH0-=KND`Y])9KV+
MT-H0/DF"9A^_<#G^B*0#GTE.>LH@&<)!<IJ]I9A]1-&!G>++)LI>JP9(&&>2
M9M=.PU41CE1'U_P[U6O1&M3P"K9F'&70*ATNBK"PJO-'9Z4L''#_6L-]SN%<
MQ1&`*Z7L:>&NHOX+,?\'``#__P,`4$L#!!0`!@`(````(0"AD"G@S0(``/`'
M```9````>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;)15VVZC,!!]7VG_P?)[
MPR470A12M5MUM]*NM%KMY=DQ!JQBC&RG:?]^9W!#2=*TZ0O"<.:<,Q>&Y>6C
MJLF#,%;J)J/1**1$-%SGLBDS^N?W[<6<$NM8D[-:-R*C3\+2R]7G3\NM-O>V
M$L(18&AL1BOGVD406%X)Q>Q(MZ*!-X4VBCDXFC*PK1$L[X)4'<1A.`L4DPWU
M#`MS#H<N"LG%C>8;)1KG28RHF0/_MI*MW;$I?@Z=8N9^TUYPK5J@6,M:NJ>.
ME!+%%W=EHPU;UY#W8S1A?,?='8[HE>1&6UVX$=`%WNAQSFF0!L"T6N82,L"R
M$R.*C%Y%B^LHI,%JV17HKQ1;.[@GMM+;KT;FWV4CH-K0)^S`6NM[A-[E^`B"
M@Z/HVZX#/PW)1<$VM?NEM]^$+"L'[9Y"1IC8(G^Z$99#18%F%$^1B>L:#,"5
M*(FC`15ACQF-05CFKLKH>#::)N$X`CA9"^MN)5)2PC?6:?7/@Z+.E.?JK-TP
MQU9+H[<$^@UHVS*<GF@!Q*][`1.(O4)P1F>4@(R%`CZLYFFR#!X@:?Z,N?88
MN/:8J$<$(-HK@]KYR@A&9:P*6KGV#X8R\>LRXX_((!C*.C`_3^<]KU?VF,D`
M,^D1>PD"9)@@MGL,0_-VB3&H:W%?OGF:]OS>@<<DO@')##[CL$?L.8"Q&#IX
M6QG!^\KI@-<K>\RT4Y[,POA$S6%"AKJ8>9R\FSI&'1IXF1UOP&.&Q4_#$R:2
M8Q/OEQ^##CV,^^)Z#QXS]'!B`'!QG_UM(?B]T?.8,Y33CR@C^##GEXQ\SA[C
M1RY*DV0P&7L3!_MS+^?SAKZ+.K0P/2C[,^CT\/G%Z[>;$J847T1=6\+U!I=J
M!$/;/^T7_E7<;<?^!>S;EI7B!S.E;"RI10&AX2B!P3=^8_N#TVVW.]?:P:;M
M;BOXLPI83>$(P(76;G?`?T+_KU[]!P``__\#`%!+`P04``8`"````"$`S-T&
M!5H#``"F"@``&0```'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6R45EUOFS`4
M?9^T_X!X+Y^!0)2D:F#=*FW2-.WCV0&36`6,;*=I__VN<4)CTZ8)#WSY^'#.
MO=?XSF^?F]IZPHP3VBYLW_%L"[<%+4F[6=A_?M_?)+;%!6I+5-,6+^P7S.W;
MY>=/\SUECWR+L;"`H>4+>RM$-W-=7FQQ@[A#.]S"2$59@P0\LHW+.X91V4]J
M:C?PO-AM$&EMQ3!CEW#0JB(%SFFQ:W`K%`G#-1*@GV])QX]L37$)78/8XZZ[
M*6C3`<6:U$2\]*2VU12SATU+&5K7X/O9GZ#BR-T_C.@;4C#*:24<H'.5T+'G
MU$U=8%K.2P(.9-@MAJN%?>?/\M1VE_,^/G\)WO.3>XMOZ?XK(^5WTF((-J1)
M)F!-Z:.$/I3R%4QV1[/O^P3\9%:)*[2KQ2^Z_X;)9BL@VQ$8DKYFY4N.>0$!
M!1HGB"1306L0`&>K(;(R("#HN;_N22FV"SN,G6CJA3[`K37FXIY(2MLJ=ES0
MYI\"^0<J11(<2.!Z(/$C9Q)$T^0:EO#`,GEE"9P@B?PH_EB+JWSU8<J10,LY
MHWL+2@^4\P[)0O9GP'R,CW(S1.R]@$&D),F=9%G8L6U!+#@D^6F9I/'<?8+,
M%`?,2F'@/&!\'9&-66)/A^1'B,PY.!AL0&A/;;R=WJ-:"99J9;JE_)5Z<2HM
MT+^;C1'^5(?D8TC\:E`3"YD\%2MC'D)EGQ<M)P'N)'Q1:JA<*0RD<0CQ1!>9
M?8C(SR$T%_"94Q?GU4OPPH80#<JB(-6UK10F2?KZ\9S0U/[!>/[^N*8;UNWE
MNB78T!T:-;E2F(/NV(D][0B_W!AIRJZ=D%\Q0;,*"_)RJQ)L6GTM8+50%.9@
M]<9S_-#7S!KXS,0':9QJAUX"N8GWDV1`:,ZFUSB38-V9/_H[*<S16>"\D38%
M@2H;:C@P,IN?A6@&9']Q\M\]OWHD6#<0A<;O9Z4P1P-R.S/$92;"]XP5F)N(
MP'\G_.DUZB784#\Q"F6E,`?UQ@++S@U"\R#91S-5L%5?H#:\!K,-SG!=<ZN@
M.[GG!_"G&=X.[<A=(#<&XWT&;4J_J;O#`+0)'=K@'XAM2,NM&E=`Z3E36*Q,
M-1KJ0="NWV;75$"#T-]NH1_$L/%X#H`K2L7Q06YK0X>Y_`\``/__`P!02P,$
M%``&``@````A`"\EX5?)`@``R@<``!@```!X;"]W;W)K<VAE971S+W-H965T
M,2YX;6R4E=MNG#`0AN\K]1TLWX?3GE?+1DFCM)5:J>KQVFL,6`%,;6\V>?N.
MF5TOY%"1&\#P^_\\X_&PN7RH*W(OM)&J26D<1)2(AJM,-D5*?_V\O5A28BQK
M,E:I1J3T41AZN7W_;G-0^LZ40E@"#HU):6EMNPY#PTM1,Q.H5C3P)5>Z9A:&
MN@A-JP7+NDEU%291-`]K)AN*#FL]QD/EN>3B1O%]+1J+)EI4S,+Z32E;<W*K
M^1B[FNF[?7O!5=V"Q4Y6TCYVII34?/VY:)1FNPKB?HBGC)^\N\$S^UIRK8S*
M;0!V(2[T><RK<!6"TW:328C`I9UHD:?T*EY?KVBXW73Y^2W%P?2>B2G5X:.6
MV1?9"$@V;)-ENQ^B$MR*##:.$K<A.Z7NW-3/\"H"AND$CF'^GBA7B:.$'M-_
M/B%ONUW[IDDF<K:O['=U^"1D45H@S2`++AGK[/%&&`Z[`*P@F3E7KBJP@"NI
MI2LGR")[P-7)S)8IG<R#V2*:Q"`G.V'LK726E/"]L:K^@Z+X:(4FR=$$[@?\
MGBS'FH2XH"[6&V;9=J/5@4"A`=*TS)5MO`;CEP."2)SVRHE3.H>4I]1`5N^W
MT2:\A[SQH^(:%7#UBM@K0D!Z+K#&<YW8<5UBW4*N\44?D[R,F0PQ;M\F4#+_
M#]--`ETOB(EW1SXJICW%U"L&88)D?)A.G%*(S2=OYEV1BXH^=^X5`RY4U7BN
M$P^Y"^^*7%3TN4NO&'"A-L9SG7C(77E7Y**BSXW/%3<`+]X"=N(A.#Z7*9)1
M,B"_4F+NOS#Z!#GQ$_+3VD+)K#M>TWB9O!+PZBU8)WZ"/1<L!HR20<#GZL-4
M8ZO$]E$+78@/HJH,X6KO6E\,*_9O?2L_-EG_`;IBRPKQE>E"-H94(H>I4;"`
M"M/85W%@5=LUIYVRT`^[QQ+^F0).?Q2`.%?*G@:NB_N_\/8?````__\#`%!+
M`P04``8`"````"$`L\BZ4`,)``!L.@``&0```'AL+W=O<FMS:&5E=',O<VAE
M970S,"YX;6R<FUUSXCH2AN^W:O\#Q?T`LK$Q5))38_SMW:JM4V=WKPDX"36`
M4]B9S/S[E2S!T&U&+^Q<3()XZ+;TJB5U!SW\\6._&WROCLVV/CP.Q6@R'%2'
M=;W9'EX?A__^*_D2#`=-NSIL5KOZ4#T.?U;-\(^GO__MX;,^?FO>JJH=2`N'
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M,ZNVKV^ME-N3/5(=6VQ^1E6SEB,JS8P<3UE:USOY`/+_P7ZKIH8<D=6/[N?G
M=M.^/0Y=?^3-)JZ0^."Y:MIDJTP.!^N/IJWW_]60,*:T$<<8D3^-$>&-IHXW
M"^ZQXAHK\N?)BG^_E:FQ(G\:*\[\?BNR[WI89,>-F=O'9:S'N),L6K6KIX=C
M_3F0<2"-->\K%55B(>2+DUAZ:,_R_4X]*9NR\E69>1SZPX$4II%3[ON3[_H/
MX^]RFJP-$VI&_G]F!"66?<*?4"3J(]Z<.8K[C._.J)U$,^2!F:OTA*@9JCJ9
MW6`W[S.LDT6?X)TL3XB*,JG362PYF8E8UR/JI(FBE2:GYP]/#;\$<.BH+/N$
M8`,7:228=2)/Q<SWJ(U8`[(+9YG]*1O:I,]P/VD?\=E(9E<0[BGO,ZS/19_@
MSU)JY%>?9_-SGXD^<ID@^JA@<N7Z:==)?8KHQ!N6O"'2#62,W>#\3-ULC?N,
M,^,Z7&.8GND-3':-8<^3W\`4-S"EG2%ZR`67Z&'70=%$!]ZPY`V1;J`Z_)H;
M6H<3<PK#A#>DO"'C#3EO*'A#>=%`AD#N&F0(;IN2ZE-RZI(89M$7:D;Z/<?Y
ME,[`)20B2,202""10B*#1`Z)`A*EC2"BR6V)B&:?MXI^',HUZBR$/V6+7*@9
MFUB0B#01!-W*[XZFT_@+<Q-#(PDD4N)F,G+]8$[^T4F6W8?GT'\!B=)&$!UG
M=^FH:*ZC2WL;:L:F(R0B2,202""1:D(?$QSA3R9L[\DN`3^8]H`<^B@@4=H(
M(I5*/B_/P?:04S27BJU^H69L4D$B@D0,B002J28\<Z+S!>M)1M^?"Q;U.?10
M0**T$42H^5U"*9H+Q0XXH69L0D$B@D0,B002:9_PIRSYR6Y@\C[#)"\@4=H(
M(IB0!^`[0JO#N60L"0D-9-,,(Q%&8HPD&$D-HG=.$<BECB^&A)"UCAZ18S<%
M1DHK0F532>CM*Z*J'?0BC:4`H8&LLFD[%B3"5F*#S+LE;3)BSY%@"ZG=0F9_
M.\<."HR4OW5"A5+9Z1U"Z626'A=9SA(*#5E46&(DPDB,D00CJ4%T?#F^Z[`E
M/B-`X+H^.U?EV$F!D=**4-%4%GLIVFUYF=#)+Q'/8VM):""K>-J.!8FPE1@C
M"492@YBTXLI!D0!"7#DI8B\%1DHK0M63`T?4LY\6A<+9EN;Q=-I`%DF6&(DP
M$F,DP4AZ!?$]=C#,;H'R*Q`_C6"DM")4/)6&7X8>$$]G[33DV/(1JC]O2(6M
MXD$DPE9BC"0820VB0\Z?>?WCB'Y8LZ`*5R(T$<VQEP(CI16AJJFD^P[5=(Y.
M56/3*A2V1+XKWBTQ$F$DQDB"D=0@1A1/]%73_3&RJI2:BP8[7.#G**T(%4VE
MWY>BW;C+Z:R=BL>V]%#84GLC'D0B;"7&2(*1]`IR9;WL/W`/RJ]88A.[P$AI
M1:B(*C6_%!&LESJ3I^*Q)#44MG3?B`>1"%N)#6**EI/1I)<*0#<I=I-A),=(
M@9'2BE#95()^AVPZGZ>R]=)N6])O9(-()"`28R0QB%GLG-Z9/\4V,HSDQ(TC
MYK,9V_L+2)16-T0TY[Y:28?S@R6;X:&!;&<3C$08B3&28"0UB-;5[9\\,@*(
MB1_,V-:08R\%1DHK0E7CI9+;MCGG2LG$XYFX@:SJX9()MA)C),%(:I#?%%XR
M^]LY=E!@I+0B5#BYW-VQ1CH*9^'&O[L1&L@JF+9C02)L)<9(@I'4(#K<A#L)
MV`3,"#`5?L`2UQP[*3!26A$J&B^=V,\CSI62"?\F26@@BR)+C$08B3&2&,0L
M@('@BJ381H:1G+H1KL<V^P(!I=4)E4P.[#UQIG`>9ZRV$#H:NI3,8<S2,'HH
M9UXPYU67Z(H5=IB.,9)@),5(9A`3BH$O_T[`\C=LI,!(:46H;JH,<'F&O'%C
MT]4#<I;D%==0?9<3E$PP$F$DQDB"D10CF4%.>Q_+>7)LH<!(:46H>"K9OQ0/
MK).Z-D!%8[$0.K"`L,1(A)$8(PE&4H/HB)K[DSF/J`P2.7938*2T(E0V50.X
M0S9=,J"RL0-QZ/3K"DS9)48BC,0823"2&L0LA,Y$"(\E71E&<NRHP$AI1:AP
MJI)P*9Q:+*=RE0-QIPL0EP***=N+0T=#9B.;!;P<NS2`;3>,D)'XBA$V31*,
MI!C),))CI,!(:46H>JHHP=7#W]UU="WC4CW?9RM_:*!+<=BX+C$2&43/@?[A
M(,8F$HRD&,DPDF.DP$AI18AZ2JC_0[WN8_R@R6//0#;U,!*=D>YN!,\:X_/;
MO[[$R:9(@I$4(QE&<HP4&"FM"!6/ET_L"Z9[I6SB\Z*7@:RBX;+)V8H23;#$
M-SZ_:]$,^DBQE0PC.48*C)16A&HF5SP2<$`SA?-`8Y6&4-Y)4Y#^RJ@7]#+2
MI0$LHD88B3&28"3%2(:1'",%1M1EOM^G4EHV?5E/W_S:5\?7:EGM=LU@77^H
MBWA3^3VI<^OYDN#7J;HZQ-H3L9`7H_KMH;,(K_%+9R&O34A^?#8D[_J]KUZK
M?ZZ.K]M#,]A5+_(1)J.9/"H=]6U!_:*MW[O[:<]U*V_Y=;^^R5N=E;R*-1E)
M^*6NV],+Y>!\3_3I?P```/__`P!02P,$%``&``@````A`%NP&35@`@``6P4`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,C@N>&ULC%1=;YLP%'V?M/]@^;V8
MCX2V"%(UB[I5VJ1IVL>S8RY@%6-D.TW[[W>-$YJMW907P'!\[CGW'E/>/*F>
M/(*Q4@\53:*8$AB$KN705O3'][N+*TJLXT/->SU`19_!TIO5^W?E7IL'VP$X
M@@R#K6CGW%@P9D4'BMM(CS#@ET8;Q1TN3<OL:(#7TR;5LS2.<Z:X'&A@*,PY
M'+III("-%CL%@PLD!GKN4+_MY&B/;$J<0Z>X>=B-%T*K$2FVLI?N>2*E1(GB
MOAVTX=L>?3\E"RZ.W-/B%;V2PFBK&Q<A'0M"7WN^9M<,F59E+=&!;SLQT%3T
M-BG6"\I6Y=2?GQ+V]N29V$[O/QI9?Y8#8+-Q3'X`6ZT?//2^]J]P,WNU^VX:
MP%=#:FCXKG??]/X3R+9S..TE&O*^BOIY`U9@0Y$F2I>>2>@>!>"5*.F3@0WA
M3]-]+VO7533+H^5EG"4()UNP[DYZ2DK$SCJM?@50<J`*).F!!.\'DF09+=+E
MY=49+"PHF@QNN..KTN@]P=!@33MR'\&D0.:CLZ!C]OHOJ^C1D]QZEHKFE*`+
MB^-Y7.597+)'[*DX8-8!@]<9D\P(AFIF22CC5-+;33Y6]F!?V3?=2UF'%Z=E
MTK?+9'^6\<XS3,;_R_E-B#LQD6<O-H*"@%F<8!9O*T#(^48]N*+H;FY?GKTX
M"Y4#YK1RGF5_U0XA#QE08%KX`'UOB=`['^`$AS>_G<_6;3H=C_D#9GOD+7SA
MII6#)3TTN#6.+C',)IR.L'!ZG!*VU0Y3/3UV^!,#G%,<(;C1VAT7_OS-O\75
M;P```/__`P!02P,$%``&``@````A`(:ZFDO=30``=_<!`!D```!X;"]W;W)K
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MLT--:5[X(G?S'J%_V?8R=VY_,/^RZ87NM`=-?]YE5SH_O#F<7UQ=G_:E)ZKL
MW`YD_F7C:W7[D#EB-KY6MQ?MEMWH93O#SNU&YE_<DQ[>7%]<'"ZOKY[>`W=N
M3S+_XA[[Y-.^G8[WT\?'\?W7]S]^_^7ACU?Z4%;=Q]_?FX_XW7=F:^Z#8WJG
MYX^2/_LDT4>(V<I?S&9^>*WW0!\6C_K\^\>/^ZNS[]_^0Q]9'^R:=URS"U?<
MNA7F\\EL]AA#$D,:0Q9#'D,10QE#%4,=0Q-#&T,70Q_#$,/HP5OEF1OI,/I/
M-#*;,8W<N_O.P1+M/`KB5KB''&-(8DACR&+(8RAB*&.H8JAC:&)H8^ABZ&,8
M8A@]"(+HT^D_$<1LYH?7^F_OH(D.B7=VC7]D':)(\Y*Y$B2!I)`,DD,*2`FI
M(#6D@;20#M)#!LCH2Q!-IX7_1#2S&7U8:M?PJD7'S;MIT?ZI:O.2N1HD@:20
M#))#"D@)J2`UI(&TD`[20P;(Z$M032?"H-KZ!:T[#9G5ISCN37TWB4HXN84<
M(0DDA620'%)`2D@%J2$-I(5TD!XR0$9?@C=>^^Z&-]ZL#M_X2?:ZN/&.DWWT
MT34O<G6.D`220C)(#BD@):2"U)`&TD(Z2`\9(*,O00N]B1M:F-5ABTG\@P!R
MA"20%))!<D@!*2$5I(8TD!;207K(`!E]"=YX71!O>./-ZO"-M^)]^D".D`22
M0C)(#BD@):2"U)`&TD(Z2`\9(*,OP1NO47?#&V]6AV_\)/X>#SE"$D@*R2`Y
MI("4D`I20QI("^D@/62`C+X$;[RY9;#AG3\M#]]Z2]$G?WS1NJR:/_I)"2DE
M9:2<5)!*4D6J20VI)76DGC20QH#"/&9&].?UIZ^'S%V<Z,BPY!\:I",I(:6D
MC)23"E))JD@UJ2&UI([4DP;2&%#8PHR'&UI,TZ0F![?'OS-3A/+H4'%T2SJ2
M$E)*RD@YJ2"5I(I4DQI22^I(/6D@C0&%+<S8MZ'%-"5J>^Z-?V?N/9H6WKF:
M="0EI)24D7)202I)%:DF-:26U)%ZTD`:`PI;F&'.;V'N*>ZOS1<>[&WUE]]6
MG.;"H),E72Q[@\5%-%B8F\#F@V^I>20EI)24D7)202I)%:DF-:26U)%ZTD`:
M`PK3F7'03_?,Z66:'H,\_D!YNHE[:^ZJAT?6D9204E)&RDD%J215I)K4D%I2
M1^I)`VD,*&QAQL$-+:;I,6AA:3D(;LV7*>+C`I1P54K*2#FI()6DBE23&E)+
MZD@]:2"-`84MS(2XH<4T4`8M_!G3'A>@H_E:4'BH)*24E)%R4D$J216I)C6D
MEM21>M)`&@,*6YBAT6]A3B_G^NK7]K.+'3_]JX!Y(O7/+I?QV65>Y2X?CN9K
M9^&!E9!24D;*206I)%6DFM206E)'ZDD#:0PH+&>F3K_<,V>7:4@-CB)_;K5'
M$>BX`R6DE)21<E)!*DD5J28UI);4D7K20!H#"EJ<;YOS3\O#.=^1=W8A'4D)
M*25EI)Q4D$I21:I)#:DE=:2>-)#&@,(6VX;Z<P[UEOSAA70D):24E)%R4D$J
M216I)C6DEM21>M)`&@,*6\1#_3>?7<XY[SO2%9<WNUQ%9Y=EU7QV(26DE)21
M<E)!*DD5J28UI);4D7K20!H#"LMMNP5PSEL`EH*C"'<%CER5D%)21LI)!:DD
M5:2:U)!:4D?J20-I#"AL$=\">/I,?\XQWY%_=N%,SU4)*25EI)Q4D$I21:I)
M#:DE=:2>-)#&@,(69OQ^^567N4MC+F2]BV)+P7'!F9ZK$E)*RD@YJ2"5I(I4
MDQI22^I(/6D@C0&%+<RLO:&%'<W]%A-%7UVYCD\A\ZKE%`)*SD$I*2/EI()4
MDBI236I(+:DC]:2!-`84YC'C]X8\T[0>'"H8X&_/04=20DI)&2DG%:225)%J
M4D-J21VI)PVD,:"PA1FH-[2P\[=_J&`DOST''4D)*25EI)Q4D$I21:I)#:DE
M=:2>-)#&@,(69J#>T&*:OX/C`B/YK?D!@_!>UY&4D%)21LI)!:DD5:2:U)!:
M4D?J20-)/RSBO3E!BWT\N'_[5U=.FPI/]8YT9O`FE)OH]+*LFD\OI(24DC)2
M3BI():DBU:2&U)(Z4D\:2&-`8;IM<_Z><[XE_TJ,="0EI)24D7)202I)%:DF
M-:26U)%ZTD`:`PI;Q'/^TQ/*GL.\(V]"(1U)"2DE9:2<5)!*4D6J20VI)76D
MGC20QH#"%MLF]STG=TO!<<')G:L24DK*2#FI()6DBE23&E)+ZD@]:2"-`84M
MXLG]WSB]<*K?SR.\=WJYCGY0Z'99M9Q>Y@<Z2K@J)66DG%202E)%JDD-J25U
MI)XTD,:`PG3;!OT]!WU+P6'$09^K$E)*RD@YJ2"5I(I4DQI22^I(/6D@C0&%
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M#OR.@GMCU]&/_MXNJ^:S"RDAI:2,E),*4DFJ2#6I(;6DCM23!M(84%ANVSV`
M`^\!6`J.(MX#X*J$E)(R4DXJ2"6I(M6DAM22.E)/&DAC0&&+^![`,V<7SOD'
MC.NWI",I(:6DC)23"E))JD@UJ2&UI([4DP;2&%#88MM0?^!0;RDX+CC4<U5"
M2DD9*2<5I))4D6I20VI)':DG#:0QH+#%MJ'^P*'>47@*B7\J?EFUG$+LMI;+
MM82K4E)&RDD%J215I)K4D%I21^I)`VD,*,RS;<X_<,ZW%!PJTRJ/CER5D%)2
M1LI)!:DD5:2:U)!:4D?J20-I#"AL$<_YSYQ".,L?YEG>'02WI",I(:6DC)23
M"E))JD@UJ2&UI([4DP;2&%#88MO@?N#@;LD["&Y)1U)"2DD9*2<5I))4D6I2
M0VI)':DG#:0QH*#%Q;;!_;0\'-P=J=+R%?KK^,?KW:K#?,?RZ,A_X/DN^MI+
M8E?I&Z3-+W$[7-]$WUJ6+IO1<1F^MFV#\`4'84OF^TJ]UQ;_;.>RRGTR'!TM
MW_V36-(M>O-"SG<7N[-#]&+3X&'A:XD'R:<_ORXX+3KRW^[]=?R31&Z5W\EN
MZV9.E]A5-LINM[NZBKYI/'4;.CTJ?"GQ9'6:B?5K('41^,RKXI!U,9'Y+FRO
M4/2'N76K]O-+.#KR"TW;LH6NK\XOK[&SS4^'G2V>44ZO2B?KK[_<?_CUW8/^
M=-J_5E[?7OO#Z=[C7RXXMS@*HT5_JENWRH\V;4M?5W7[9&)7Z1QI=L"KF\M=
MM".G;CLKS>*K?O/J=A=OS.^%/+W`OS[\_F<O4%WG5SA=Y_OW8"\FB@+&W^#C
M5BTOY^C(#SAMRP;<G^N7_NZB]RH-'A;NE_'5=/P:7Q:1%]D7EH*(-]&Q?^M6
M^1&G!P81)[(1+V]N#O$-G]1M:*5B?$%Z>H7ZU;A1Q`V[+*]9+R8*/S-OXJ]Y
M+*O<_GFT9*X;YD-YY7PP;5Z?^J=?ZGFSN[DXB][*U&W\M&N$C>/+P+CQ"_=C
M7AY>3.1?DI".I(24DC)23BI():DBU:2&U)(Z4D\:2&-`82,=)QN^KG-AED>7
M)):6X?36K5KH2$I(*2DCY:2"5)(J4DUJ2"VI(_6D@30&%+2XW'9Y>%H>MK#D
M'Q>D(RDAI:2,E),*4DFJ2#6I(;6DCM23!M(84-@BOIPUGUW?]'/FE[S2=:33
MR_SAN[^)OY:PK)H_M4D)*25EI)Q4D$I21:I)#:DE=:2>-)#&@,)RVR[>+WGQ
M;BDXBJ95'AVY*B&EI(R4DPI22:I(-:DAM:2.U),&TAA0V,)<P;_\NP8NIPM^
M_XK5T7(JN24=20DI)66DG%202E)%JDD-J25UI)XTD,:`PA;QS+0R'GG3PR7G
M(TO>07!+.I(24DK*2#FI()6DBE23&E)+ZD@]:2"-`84MS.RTX;B81JW@N+`4
MGD+BKR5<SJN64P@HX:J4E)%R4D$J216I)C6DEM21>M)`&@,*\YBY;T.>:4P,
M\DP4'"J@XR4H(:6DC)23"E))JD@UJ2&UI([4DP;2&%#8(AZCG_G8XHQ\:<D_
MA8".7)604E)&RDD%J215I)K4D%I21^I)`VD,*&P1#_3/M.#@?LG!G70D):24
ME)%R4D$J216I)C6DEM21>M)`&@,*6VP;W"\YN#O2_[-,(?A:@EOEW2ESY#_P
M'%]+L*OL;6O=@(]O'"V;T<DI>&U7VP;AT_)P$+84WA>[CF[!WBZKYM.C(^]&
MIR5[HW-W,#=SX]<2/"Q\+?$@^?0Q<\5IT9'_=O-K"6Z5U\F1][4$2_/7$O:[
MB^B:(0T>%;Z4>+(ZS<0O^5K"%8<L2]&MZ/AK"6Z5=RO:D5_(3F?35WMVETK$
M0M,:/1_VMGA(.;TLG2%>?F?VBH.+HZ#:3?R5.K?*KS9MR[\/;5?9^]#GA^O+
MBVA73MV&>!_Z*K[N_[:[L*?-1`?9-")$">.O)M@'ZE!<#K+Y@8X2N\I]->%P
M<SB<QU]-<%M:26@N:OT+MO@UONBK">;K*]'-34=AQ>CHOW6K_(K3MH**$]F*
M%]>79U?1+9_4;6BEHKE4Q"O\=[Z:<#5=?/I7K9;"3TU\-6%9Y>H=+3WSU02[
MRGXUX7!V?<:O)KB-KS0VUVQX!S9_5>S*7OHM'Q_O+/D7ZZ0C*2&EI(R4DPI2
M2:I(-:DAM:2.U),&TAA0>(;8=H%XQ0M$1][%.NE(2D@I*2/EI()4DBI236I(
M+:DC]:2!-`84MM!G5G"\/'/A899'G^\3!<<%Z'@%2D@I*2/EI()4DBI236I(
M+:DC]:2!-`84M+C>=D%[6AZVL&1^MFZY6+^)K@)NEU7S1S,I(:6DC)23"E))
MJD@UJ2&UI([4DP;2&%"89]LU^C6OT2WYAPKI2$I(*2DCY:2"5)(J4DUJ2"VI
M(_6D@30&%+:(AXRG/[:N.5DX\DXAI",I(:6DC)23"E))JD@UJ2&UI([4DP;2
M&%#8(IZ,GFG!*>C:#C-^"]"1JQ)22LI(.:D@E:2*5),:4DOJ2#UI((T!A2WB
M,>Z9%M.(Y5_=7T]DOE_'.X7$WY.XK%I.(?,#'25<E9(R4DXJ2"6I(M6DAM22
M.E)/&DAC0&&>>`)])@]'S6L[,?J'"NC(50DI)66DG%202E)%JDD-J25UI)XT
MD,:`PA;QK/Q,"P["UY;\%J`C5R6DE)21<E)!*DD5J28UI);4D7K20!H#"EO$
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M!0/*[CSZ&LGMLLH=/4=20DI)&2DG%:225)%J4D-J21VI)PVD,:`PS[99_H:S
MO*7@4.$LSU4)*25EI)Q4D$I21:I)#:DE=:2>-)#&@,(6VV;Y&\[RCKP!A70D
M):24E)%R4D$J216I)C6DEM21>M)`&@,*6VP;W&\XN%L*C@L.[ER5D%)21LI)
M!:DD5:2:U)!:4D?J20-I#"AL869L_S+WFP>4&SNM>U_E=10.*-'W&-PNJY:S
MB]W6<JPE7)62,E).*D@EJ2+5I(;4DCI23QI(8T!AN6UC_@W'?$O!4<0QGZL2
M4DK*2#FI()6DBE23&E)+ZD@]:2"-`84MXC'_Z6'QAK.\H^!0B;^CZG99M1PJ
M=EO^H0)*^<",E),*4DFJ2#6I(;6DCM23!M(84)AGVRQ_PUG>4G"H<);GJH24
MDC)23BI():DBU:2&U)(Z4D\:2&-`00M]4VITQGGZ6)G6A].\LV!LV=_$WP;G
M+9L/EQ5+5BQ=L6S%\A4K5JQ<L6K%ZA5K5JQ=L6[%^A4;5FP,+2JV;>3?G7'F
M=^8?0"MV7#'EF;;G/59Y8,H#4QZ8\L"4!Z8\,.6!*0],>6#*`U,>F/+`E,>W
M*,^VNP"[,]X&F&TYB]RNF/+8QR[KE`>F/##E@2D/3'E@R@-3'ICRP)0'ICPP
MY8$I#TQY8,KC6Y1GVUV`W1EO`SCSC@#EX8V`%5,>K%,>F/+`E`>F/##E@2D/
M3'E@R@-3'ICRP)0'ICPPY?$MRA/?&#A]'[/I^>'OCU\?/N5W]S^?:/67VW@_
MO:E?=X1OYYO-OZP[Q#^6H9;VH<MAI4,-II8PM82I)4PM86H)4TN86L+4$J:6
M,+6$J25,+6%J"5-+WZ*6VVXL[,YX9\%9>*CQWL+*.N7!.N6!*0],>6#*`U,>
MF/+`E`>F/##E@2D/3'E@R@-3'M^B/&:J]^\U/'?E9^\">'<4=F?6EB-%1P],
M1P],>6#*`U,>F/+`E`>F/##E@2D/3'E@R@-3'ICRP)0'ICR^17FVW5#8G?&.
M@K/PZ.$]A95URH-UR@-3'ICRP)0'ICPPY8$I#TQY8,H#4QZ8\L"4!Z8\OD5Y
MMMUCV)WQ)L-LV@GF[Q@XG,6_N\I;YLU-N*F@8C`5@ZD83,5@*@93,9B*P50,
MIF(P%8.I&$S%8"H&4S'?HF+;;COLSGC?P5EX0/'.P\HZY<$ZY8$I#TQY8,H#
M4QZ8\L"4!Z8\,.6!*0],>6#*`U,>W\(\NXTW(D[KHQL1SOS3$>VXHR4KEJY8
MMF+YBA4K5JY8M6+UBC4KUJY8MV+]B@TK-H86Y3$3[X:KA=TT(?O?@:-?W#E=
MD@=Y8,H#4QZ8\L"4!Z8\,.6!*0],>6#*`U,>F/+`E`>F/+!AQ93'7Q?E,1/O
MECQV0O8OYM3J]`-0NJ+W3D?Q=Q_LEF7+Z6BQY:'G\?UR1;3/8'],^4H_J!S^
MU;IJ.O\AM/7H-9JQ<<MKG,9,;=']0=_M=I.%/^")'XOWEKF':J^<'^I,+V@R
M_3VKYM=#[JZNKZ[U.S+QFOQ'1J_)C$];7I,=MX+79,WOQA^/W^WF9>[/K]<$
MTVNR-D7:[_=79^?1CUDID__`Z"69D<-_2:>O8;[DA^1WNVE:"8M-%A0[G$4_
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MI`S321FFDS),)V683LJ^A7OA^<9+VM/ZZ)+6F7_-1#ON:,F*I2N6K5B^8L6*
ME2M6K5B]8LV*M2O6K5B_8L.*C:%%><SEU(:C1[\S)OX!\9VU8""D*<_T6&^=
M\L"4!Z8\,.6!*0],>6#*`U,>F/+`E`>F/##E@2D/3'E\B_*8*\$M>>R5H_\9
M;GXSB\XWP5>F#V?1!=JMOL76+5L^PVDJAG4J!E,QF(K!5`RF8C`5@ZD83,5@
M*@93,9B*P50,IF*^1<7,=>Z68M-U<7`Z,E<0*N8=*,H#TP$%4QZ8\L"4!Z8\
M,.6!*0],>6#*`U,>F/+`E`>F/##E@2F/;U$><\V^)8^]Q@\.*&O!Z0BF/##E
M@2D/3'E@R@-3'ICRP)0'ICPPY8$I#TQY8,H#4QZ8\O@6Y3%3QY8\TY02'CUV
MN@GRP)0'ICPPY8$I#TQY8,H#4QZ8\L"4!Z8\,.6!*0],>6#*`U,>WZ(\9H#:
MDL<.7,'18TW_F">_PUDT7.OS;E[FG8Y@*@93,9B*P50,IF(P%8.I&$S%8"H&
M4S&8BL%4#*9B,!7S+2IFYL,MQ:9Y,CR@["`:'%`P'5`PY8$I#TQY8,H#4QZ8
M\L"4!Z8\,.6!*0],>6#*`U,>F/+X%N4Q<^V6/'8.#@XH:T$>F/+`E`>F/##E
M@2D/3'E@R@-3'ICRP)0'ICPPY8$I#TQY8,KC6Y3'S+5;\DQS<'CT^+.QO;=P
M#E,>F/+`E`>F/##E@2D/3'E@R@-3'ICRP)0'ICPPY8$I#TQY?`OS[#?>6SBM
MC^XM6(NFH_CWH>R69<OIB):LK$M7+%NQ?,6*%2M7K%JQ>L6:%6M7K%NQ?L6&
M%1M#BXJ947?#`:6;G[C=8"V8CFC''4UY_%'[=#`J#TQY8,H#4QZ8\L"4!Z8\
M,.6!*0],>6#*`U,>F/+X%N4Q<^V6/-,<''S>[:WYIR.:\F"=\L"4!Z8\,.6!
M*0],>6#*`U,>F/+`E`>F/##E@2D/3'E\B_*8N79+GFD.#O/XL[$]'>GWTT;W
M&Y0'ICPPY8$I#TQY8,H#4QZ8\L"4!Z8\,.6!*0],>6#*`U,>WZ(\9J[U\WSS
M#R[N]G9$]J_SG.EBWQN<XM^M,C]T.?X4TY^X3]$5$Z:8,,6$*29,,6&*"5-,
MF&+"%!.FF##%A"DF3#%ABNE;%--,P7[,9[[(J=]9S3.5/TF[8PVF/##E@2D/
M3'E@R@-3'ICRP)0'ICPPY8$I#TQY8,H#4QZ8\O@6Y3$C[Y8\=D0.#JC)]-M4
MW37=[4Y7%:>/PL64!Z8\,.6!*0],>6#*`U,>F/+`E`>F/##E@2D/3'E@R@-3
M'M^B/&;DW9)G&I'#,Y4_-KNC!Z8\,.6!*0],>6#*`U,>F/+`E`>F/##E@2D/
M3'E@R@-3'ICR^!;E,2/OECQV1`Z.GLG,LWBGH^@;%'1`S<O<0:9B,!6#J1A,
MQ6`J!E,QF(K!5`RF8C`5@ZD83,5@*@93,9B*^185,U/PEF+3U!P>4/XD[0XH
MF/+`E`>F/##E@2D/3'E@R@-3'ICRP)0'ICPPY8$I#TQY8,KC6YCGL/%.Q&E]
M="?"V7+A=KNC'5<L6;%TQ;(5RU>L6+%RQ:H5JU>L6;%VQ;H5ZU=L6+$QM"B/
M&7DW'#V':40.CAYK.NFY#S+E\4?ITQ&E/##E@2D/3'E@R@-3'ICRP)0'ICPP
MY8$I#TQY8,H#4QZ8\O@6Y3$CKY_'#$[[ZS?F*U%;?^3Q8,=G_U3E3-<KWJDJ
M^B8SU?0G;U<3IIHPU82I)DPU8:H)4TV8:L)4$Z::,-6$J29,-6&J"5--WZ*:
M9D+V:SXS.1VFB3H\V/PIVYZJ[#KO`-3!AG7*`U,>F/+`E`>F/##E@2D/3'E@
MR@-3'ICRP)0'ICPPY?$MRF-FWBUY[(P<'%#^W.SRP)0'ICPPY8$I#TQY8,H#
M4QZ8\L"4!Z8\,.6!*0],>6#*`U,>WZ(\9N;=DF>:D<.CQY^;71Z8\L"4!Z8\
M,.6!*0],>6#*`U,>F/+`E`>F/##E@2D/3'E@RN-;E,?,O'Z>;[_'=YC&Y["<
MM>!,%7_3M,Y4\S)W+:*8,,6$*29,,6&*"5-,F&+"%!.FF##%A"DF3#%AB@E3
M3)AB^A;%-!.R'_.?N\/[#]]]_-?Q[O'#W6==*YR9:Y`?OS\=0W_17_JH]?%5
MNS]ENV,-ICPPY8$I#TQY8,H#4QZ8\L"4!Z8\,.6!*0],>6#*`U,>F/+X%N4Q
MX_"6/-/X'!Y0UH*K=ICRP)0'ICPPY8$I#TQY8,H#4QZ8\L"4!Z8\,.6!*0],
M>6#*XUN4QXS#6_),XW.8QQ^IW=$#4QZ8\L"4!Z8\,.6!*0],>6#*`U,>F/+`
ME`>F/##E@2D/3'E\"_/H+UC<E.>T/OIP<Z:/T&5PVD4_5W6[6Y8MIR-:LK(N
M7;%LQ?(5*U:L7+%JQ>H5:U:L7;%NQ?H5&U9L#"TJ9B;D#0?4Q311!P>4-6](
M4AY_\CX=9,<54QZL4QZ8\L"4!Z8\,.6!*0],>6#*`U,>F/+`E`>F/##E\2W*
M8T;>+7GLB.P/3A?^V&P_[VC*@W7*`U,>F/+`E`>F/##E@2D/3'E@R@-3'ICR
MP)0'ICPPY?$MRF-&WBUYIA$Y/'K\L=GE@2D/3'E@R@-3'ICRP)0'ICPPY8$I
M#TQY8,H#4QZ8\L"4!Z8\OD5YS,B[)8\=D8.C9[+P2TX[_'#^Q;S,.QW!5`RF
M8C`5@ZD83,5@*@93,9B*P50,IF(P%8.I&$S%8"KF6U3,3,%;BDU3<WA`^9.T
M.Z!@.J!@R@-3'ICRP)0'ICPPY8$I#TQY8,H#4QZ8\L"4!Z8\,.7Q+<ICYMHM
M>>P<'!Q0_FSL\L"4!Z8\,.6!*0],>6#*`U,>F/+`E`>F/##E@2D/3'E@R@-3
M'M^B/&:NW9)GFH/#H\>?C5T>F/+`E`>F/##E@2D/3'E@R@-3'ICRP)0'ICPP
MY8$I#TQY8,KC6Y3'S+5^GF^_CZ>_P0EWA9QI__`&)_S"CF69=Z;R)^Y3=,6$
M*29,,6&*"5-,F&+"%!.FF##%A"DF3#%AB@E33)AB^A;%-%.P'_.9^W@7T]0<
M'FO^).V.-9B.-9CRP)0'ICPPY8$I#TQY8,H#4QZ8\L"4!Z8\,.6!*0],>7P+
M\UQNO!-Q6A_=B7#FW\>C'7>T9,72%<M6+%^Q8L7*%:M6K%ZQ9L7:%>M6K%^Q
M8<7&T*(\9N3=</1<3B-R</18"VX[T)3''Z_MAQM->;!.>6#*`U,>F/+`E`>F
M/##E@2D/3'E@R@-3'ICR^!;E,2/OECQV1/:O\R[GL=D_'>%70"S+EM,130?4
MO#FW3L5@*@93,9B*P50,IF(P%8.I&$S%8"H&4S&8BL%4S+>HF)F"MQ2;IN;P
M@/(G:7LZNH3I@((I#TQY8,H#4QZ8\L"4!Z8\,.6!*0],>6#*`U,>F/+`E,>W
M*(\9>;?DF4;D,(^UX'0$4QZ8\L"4!Z8\,.6!*0],>6#*`U,>F/+`E`>F/##E
M@2D/3'E\B_*8D7=+GFE$#O/X8[,[>F#*`U,>F/+`E`>F/##E@2D/3'E@R@-3
M'ICRP)0'ICPPY8$ICV]1'C/R^GF^?7"ZM--S<*::)VK_3(7?#N$>NAQ_BCD_
MU)V5%!.FF##%A"DF3#%AB@E33)ABPA03II@PQ80I)DPQ88KI6Q33#,A^S&<&
MI\MIH`Z/-7_(=L<:3'E@R@-3'ICRP)0'ICPPY8$I#TQY8,H#4QZ8\L"4!Z8\
M,.7Q+<IC1MXM>>R('!Q0_MCL\L"4!Z8\,.6!*0],>6#*`U,>F/+`E`>F/##E
M@2D/3'E@R@-3'M^B/&;DW9)G&I'#H\<?FUT>F/+`E`>F/##E@2D/3'E@R@-3
M'ICRP)0'ICPPY8$I#TQY8,KC6YCG*K[M\.UGJM.FHCL2SO3IZMWBPR^.6):Y
ML])Q1TM6+%VQ;,7R%2M6K%RQ:L7J%6M6K%VQ;L7Z%1M6;`PMBFD&Y`W'VM4T
M4`?'FK7@)@5->?QA_'1,*@],>6#*`U,>F/+`E`>F/##E@2D/3'E@R@-3'ICR
MP)3'MRB/F8:WY+'3LW^FNO(G:OM12%,>K%,>F/+`E`>F/##E@2D/3'E@R@-3
M'ICRP)0'ICPPY8$ICV]1'C,-;\DS3<_AT>-/U"X/3'E@R@-3'ICRP)0'ICPP
MY8$I#TQY8,H#4QZ8\L"4!Z8\,.7Q+<ICIF$_S[]QIK*#=7!@S<.V?Z;"+XZX
MFI=Y9RJ88L(4$Z:8,,6$*29,,6&*"5-,F&+"%!.FF##%A"DF3#%]BV*:V=F/
M^<Q,=37-VN&QYL_?[EB#Z5B#*0],>6#*`U,>F/+`E`>F/##E@2D/3'E@R@-3
M'ICRP)3'MRB/F8:WY+'3<W!`^1.URP-3'ICRP)0'ICPPY8$I#TQY8,H#4QZ8
M\L"4!Z8\,.6!*0],>7R+\IAI>$N>:7H.CQY_HG9Y8,H#4QZ8\L"4!Z8\,.6!
M*0],>6#*`U,>F/+`E`>F/##E@2F/;U$>,PUOR6.GY^#HF2=J_W2$7QQQ-2_S
M3D<P%8.I&$S%8"H&4S&8BL%4#*9B,!6#J1A,Q6`J!E,QF(KY%A4S`_*68M-`
M'1Y0_I#M#BB8#BB8\L"4!Z8\,.6!*0],>6#*`U,>F/+`E`>F/##E@2D/3'E\
M"_-<QS<IGKE:.*V/[D0X6VZ&W^YHQQ5+5BQ=L6S%\A4K5JQ<L6K%ZA5K5JQ=
ML6[%^A4;5FP,+<IC1MX-1\_U-"('1X^UX+8#37G\\?ITE"D/3'E@R@-3'ICR
MP)0'ICPPY8$I#TQY8,H#4QZ8\L"4Q[<HCQEYM^2Q([)_.KJ>QV;_=(1?#K$L
M6TY'-!6;-^?6J1A,Q6`J!E,QF(K!5`RF8C`5@ZD83,5@*@93,9B*^185,U/P
MEF+3U!P>4/XD;4]'US`=4##E@2D/3'E@R@-3'ICRP)0'ICPPY8$I#TQY8,H#
M4QZ8\O@6Y3%S[98\=@X.#BA_-G9Y8,H#4QZ8\L"4!Z8\,.6!*0],>6#*`U,>
MF/+`E`>F/##E@2F/;U$>,]=NR3/-P>'1X\_&+@],>6#*`U,>F/+`E`>F/##E
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M<`C#U-5:T!6FKGBLNL+4=7ZL]X[$?T.QNL[+W#NBKMB<NL+4=7ZL_Q31;3IU
MG9>YIU!7;$Y=8>J*QRHB3!']QX81;^+[)^9+9[N+-^8K`%]_N?_PZ[L'`Z]?
MK=Q7V2^_V>>TF>BVBC._+>VXLZ:_#<2]`\F*I<[TEQ"[==F*Y<[,WR[B?=Q'
MWUA2>,O<YDIGWE-4*U8[BYXBFGD;;YE[BM:9]Q3=BO7.O'=E6+'1V;2]J*T9
M_/T#-&[[UX??_ZRM_VN;;J8;",&!ZTS7VLN;O(].>+>[99E[!]3;;NYF[JC>
MDYF_@';>W'G\BU*T"^"AV@6L+7_%M78!K%/OESR%=@$\5+L`GD*[`-:I]TN>
M0KL`'JI=`$^A76!>Y[\IN/)ZT;-J1YFWIA31CF+N-_@[RLK!'NP0]OZ$?X:^
MF<S\_H^YX&$?G2FU0TS+]#=,>CN$M65SVB$FTV^P__'[?_QX>75U<QF=K[0W
MX'':&[!][0WSNN6/=A[_4CCM(/8IST]/>?8F^JC6KC%OQ_W9M6O@^;1K8)UV
MC7GC_I\ANK32KH&':M?`4VC7F-?YF^.N\9)GU:XQ;XV[AKG7X>\:IV^MN#S]
M:MGG]I+I-DGXL6%-)R1O+\&WI]_89<LQK8^-^:'NW==>,IG^`N`G]A(\3GL)
MMJ^]9%ZW_-'6]A+[E&=_NI?,VW%_3NTE>#[M)5BGO238^,V;Z(W1_H$':?_`
MQK5_S.N>>#$ZH<S/YR^+]DKM'_/6N'^8FRW^_O'<3F%OSBS'^KO=S63/?G1,
MR\*/#FO+YK133&8_.G8:30Z'Z-2LSPX\4'L%GD![Q;S.?X>B`TV?'?8Y__RS
M8]Z.MU?@^;178)WVBGGC_I\AJJ1]`P_5OH&GT+XQK_,W%[TD[1LO>5;M&_/6
MN&^8.SW^OK'ALV.Z211^=E@+/SNBZSJ=8>RRX+-C?JA[][6;3&8_.W2OXN*P
M<L&!!VHWP1-H-YG7/?&>:C>QS_GG'Q[S=MP?5!\>>#[M)EBGW238^/6;Z[/@
M/]%$J?T%V]#^@N?2_C*O>^*U:7^Q3S]]%NLOL;O0TX>WT[2WS-OBWF)N%L5[
MRS=,(O:>T_*)H`^8R<Q?:^V==:(W1'O.O,R]^3KK6%OV)NTYUBY/IP#]#L&;
MJ\OHE>H#QBY:_AS:<_`$VG/F)UC^;&NG';MLNA[:Q6<&79S@^;3GX/FTY\S/
MYU[D_R?MW)8DMZT$^"L*O^^X6%U]F_`J0G._W_Y`ZQW+CK4]#FF\^_N;IP""
M`/*H>RCIH24E`((\"9`X+!:+D3-L_/;!U>WPS[2J9^2H+T:.^F+DM+[N.#9&
M3JU6XGE11JU&3M_GM'R->T_SR#E>;SGLFN?L26CK_:Q-'\.HLO$$-"T3&4:U
MVC9D&$:%\4NV:]091I7=GH?1Q<75)4^(CX?-,&I]K@T91NJ`8=0ZN"/4G(!J
MM9LR=!\LRW".F+IG5*E[1I6Z9U2U[M?=9%0-?=T\F*[!#"-MG&&DC3.,VL;O
M.#:&4:U6XGEYO(@3X!A/3D!]G],PBEM=\S!:KAYPRCH/G-\RBNK=LV$4%3:=
MC*;@,(I:M36BC*+">*?LRAA%A?&ZT/,2^/)XF'\+G$%4M[7M!H-(VV<0M>W?
M$6@&4:U6`ITE2NJ/4:/^&#6MO_5X&#7#QJ>P,&:T:<:,-LV8:9N^XU`8,Z5:
MC=[US?&4#)F^RVG(Q(TU#9GN[MDZ9NY;%<=VYMMGA0V/O=R*,2C$&!1B#`(Q
M!H$8@T`,XV*<&L20+(9D,22+858,LV*8%4.C&#.]9X,VILBD[6X]I?ZHI['M
M;N3CA#U)V-.$/4O8\X2]2-C+A+U*V.N$O4G8VX2]2]C[A'U(V,>$?1K9I"?N
M5/6SZCX]]<[6=GI[=#P4UL^>A*%']=`CAAXQ](BA1PP]8N@10X\8>L30(X8>
M,?2(H4<,/6+HZ=FD)^X6]7K.:=UE7"?__.]?OG[YQXO/?_OI?*LY_=2@NY%X
M/)0;3WV:UQCKO6VQ?IHNY,RUVG2;?\@40Z88,L60*89,,62*(5,,F6+(%$.F
M&#+%D"F&3#%DBB&S9Y/,N+73R[QOKM5;0<-<*VR<:V+H$4./&'K$T".&'C'T
MB*%'##UBZ!%#CQAZQ-`CAAXQ](BAIV>3GKB[LD=/N1LS3JC*MIG"[!%#CQAZ
MQ-`CAAXQ](BA1PP]8N@10X\8>L30(X8>,?2(H4<,/3V;],3MC#UZZNV/8?84
M-LX>,?2(H4<,/6+H$4./&'K$T".&'C'TB*%'##UBZ!%#CQAZQ-#3LTE/W#/8
MHZ?<8QAG3V7CY6A*E)E0K=J:RF!,#&-B&!/#F!C&Q#`FAC$QC(EA3`QC8A@3
MPY@8QL0P)H:QGDW&(CW?8ZRF\\.$*FR<4&+H$4./&'K$T".&'C'TB*%'##UB
MZ!%#CQAZQ-`CAAXQ](BAIV>3GDB%]^@IJ?,XH2H;+D=BZ!%#CQAZQ-`CAAXQ
M](BA1PP]8N@10X\8>L30(X8>,?2(H:=GDYY(>??H*2GRJ*>R08\8>L30(X8>
M,?2(H4<,/6+H$4./&'K$T".&'C'TB*%'##UBZ.G9J&?9>=OA7'^Z[;"R7H_9
MD^/*F,M=%C4]0O&TJ[9>MIXUMG7Q/&$O&AN[F#XL>-E56[MXE;#7"7N3L+<)
M>]?8>9>GH$<BV\^)<V;:W:+[I@?<>!:)S<PN*ML"];C5VQ@N:KT^4,>C7;1J
M:Z!PH2YP(8:+PH8'TH[+]/0-+EJUM0M<B.%"#!=BN!##16')`VE'3C2)B]]S
MA[UL<O92T]VEW2;'BQA>"N,W<>+6^8FO74UW&9@?K<H:,)QH4S@1PTEM&X])
M_N_WW%'QU&@UUJVC0UM"AQ@Z6MNZ]6D\(:?56+>.G'Y+TT2)+/2NB?)M][*/
M2\EFZ6GM]E%C@Y%:;V,8*8P?55G;HD`,!6J+`C$4J"US0(R@JRU!%R/H:DN8
MQ0ASWW8*<V23?9CON>&RU.QS"&=E_*L[N4^SG3'?JJW1),*5<95J38_SLW`$
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MP]Y=O>&N-<E[F]Q%AKK'7=2?%PF%C1_#GZ;9P!QLU=9CP5UEVU#`76'3')P^
MOL9A:YH?Y^I0O>*P-5WW!(=9KY?3R,%E:WI'K[A4K[AL3==><=EZC9E_,RT\
MD-G:Y-U-,B.?W2.SYK];])F(E0T3\5(WZ=9JV]1`9FNZ'B`R"ZL3,1YVU@50
MK9AXE6U;1YKJ(:UM?0O/Z7**(M+4%$/J`D.JAZ'611B*9&<\`!SUK28AD<'N
M$1+UY]E5V'`/CJMWU.L8T1<C^F+,&S'B+4:\Q8BW&,$5([AB!%>,X(H13K'W
M"?N0L(\)^S2R44]\1V:/GG/]2<_*..NV!<C%O`I\?-RJK7/C2<*>)NQ9PIXG
M[$7"7B;L5<)>)^Q-PMXF[%W"WB?L0\(^)NS3R"9CD1'OF%`\DJP)55DW>=!3
ML^_^7H,9>E0//6+H$4./&'K$T".&'C'TB*%'##UBZ!%#CQAZQ-#3LTE/Y,1[
M]-0<NK\`Q5(^SFU<^=J$.EU.>07&6K5N0HEA3`QC8A@3PY@8QL0P)H8Q,8R)
M84P,8V(8$\.8&,;$/HUL,A;I]1YC-1T?C!4V3B@QSG=BZ!%#CQAZQ-`CAAXQ
M](BA1PP]8N@10X\8>L30(X8>,?3T;-(3V?,>/37;'O14MIW;F#UBZ!%#CQAZ
MQ-`CAAXQ](BA1PP]8N@10X\8>L30(X8>,?2(H:=GDY[(D_?H*7GU<`>#A[BF
MM1QZQ-`CAAXQ](BA1PP]8N@10X\8>L30(X8>,?2(H4<,/6+H$4-/SR8]D0KW
M>G[[XW7'FE4/$ZNR?NEWNIQNWB"S5>NN5&+(%$.F&#+%D"F&3#%DBB%3#)EB
MR!1#IA@RQ9`IADPQ9/9LDAFI<"_SGKN]?$'$2[_"QBN5&'--##UBZ!%#CQAZ
MQ-`CAAXQ](BA1PP]8N@10X\8>L30(X:>GDUZ(@O>HZ=FS<.$*HREWSI3F#UB
MZ!%#CQAZQ-`CAAXQ](BA1PP]8N@10X\8>L30(X8>,?2(H:=GDY[(JO?H*5GX
M>*529HX>,?2(H4<,/6+H$4./&'K$T".&'C'TB*%'##UBZ!%#CQAZQ-#3LU%/
M?-H\Z/GM5ZKSIJ:;%"OC[-KE5-.=K,?'K=HZ_YXD[&G"GB7L><)>).QEPEXE
M['7"WB3L;<+>)>Q]PCXD[&/"/HULDAD)\HZY=E$2ZF&N539<J<S0TR?CYUO>
MZ!%#CQAZQ-`CAAXQ](BA1PP]8N@10X\8>L30(X8>,?3T;-(3&?(>/26C'O54
MUN=4\8%%W+S=&'K$T".&'C'TB*%'##UBZ!%#CQAZQ-`CAAXQ](BA1PP]8NCI
MV:0GLN$]>DKV/.KI,^KRCKOCA1AZQ-`CAAXQ](BA1PP]8N@10X\8>L30(X8>
M,?2(H4<,/6+HZ=FD)[+A/7IJ]MRO\RY:1MU?CJ9/H;D<M6K=Y4@,8V(8$\.8
M&,;$,":&,3&,B6%,#&-B&!/#F!C&Q#`FAK&>3<8B0=YCK"34XX3JD^QU0HDQ
MH<30(X8>,?2(H4<,/6+H$4./&'K$T".&'C'TB*%'##UBZ.G9I"=2WCUZ:HH\
M3*@^;5[UB*%'##UBZ!%#CQAZQ-`CAAXQ](BA1PP]8N@10X\8>L30(X:>GDUZ
M(N7=HZ>DR./LZ=/F58\8>L30(X8>,?2(H4<,/6+H$4./&'K$T".&'C'TB*%'
M##UBZ.G9I"=2WCUZ2HH\ZJF,0=!E1WKVZ*)5ZRY'8A@3PY@8QL0P)H8Q,8R)
M84P,8V(8$\.8&,;$,":&,3&,]6PR%EGP'F,E:QZ-]9GT.J'$F%!BZ!%#CQAZ
MQ-`CAAXQ](BA1PP]8N@10X\8>L30(X8>,?3T;-1SFN]$W'.;]5Q_NMVPLBT3
M>LS;0-`^94=F3Y-ZSQ+V/&$O$O8R8:\2]CIA;Q+V-F'O$O8^81\2]C%AGT8V
MZ8F\=L?L.94\>)@]E7'16T]DZ.GSY?.,>I(P]*@>>L30(X8>,?2(H4<,/6+H
M$4./&'K$T".&'C'TB*&G9Y.>R&M[/;_]/MZIILC].F]EXY5*3UINU5;!R.PS
M[K-@9(HA4PR98L@40Z88,L60*89,,62*(5,,F6+(%$.F&#)[-LF,++B7>=^I
ML&3-XUSK,^EZI3J)H4<,/6+H$4./&'K$T".&'C'TB*%'##UBZ!%#CQAZQ-`C
MAIZ>37HBY=VCIZ;(PX3JT^95CQAZQ-`CAAXQ](BA1PP]8N@10X\8>L30(X8>
M,?2(H4<,/6+HZ=FD)U+>/7I*BCS.GCYM7O6(H4<,/6+H$4./&'K$T".&'C'T
MB*%'##UBZ!%#CQAZQ-`CAIZ>37HBY>WU_(XK5<V>AXE5V7BEFA[B9]G1JG57
M*C%DBB%3#)EBR!1#IA@RQ9`IADPQ9(HA4PR98L@40Z88,GLVR8P$N9=YWY6J
M)-3C7.N3['6NB3'7Q-`CAAXQ](BA1PP]8N@10X\8>L30(X8>,?2(H4<,/6+H
MZ=FD)[+A/7IJ]CQ,J#ZC7O6(H4<,/6+H$4./&'K$T".&'C'TB*%'##UBZ!%#
MCQAZQ-`CAIZ>37HB&]ZCIV3/X^SI,^I5CQAZQ-`CAAXQ](BA1PP]8N@10X\8
M>L30(X8>,?2(H4<,/6+HZ=FHAS>*CGI^^Y7JO*GI9L7*.+MN=__FEU`_/F[5
MMBN5V=.DWK.$/4_8BX2]3-BKA+U.V)N$O4W8NX2]3]B'A'U,V*>133(C=]XQ
MU^*7#.*V47\JK&RX?V'VY&B&GCYW/\]3](BA1PP]8N@10X\8>L30(X8>,?2(
MH4<,/6+H$4-/SR8]D0WOT5.SYT%/RZBW"95\(XIW1>B&H!G&5`]C8A@3PY@8
MQL0P)H8Q,8R)84P,8V(8$\.8&,;$,-:SR5@DR'N,E81ZG%!]DETO7I=B3"@Q
M](BA1PP]8N@10X\8>L30(X8>,?2(H4<,/6+H$4./&'IZ-NF)!'F/GII0#Q.J
M)=G;A#I=Z2NYO.K#$TH,8V(8$\.8&,;$,":&,3&,B6%,#&-B&!/#F!C&Q#`F
MAK&>3<8B9]YCK.38XX3J\^YU0HDQH<30(X8>,?2(H4<,/6+H$4./&'K$T".&
M'C'TB*%'##UBZ.G9I">RX#UZ:M8\3*@^DU[UB*%'##UBZ!%#CQAZQ-`CAAXQ
M](BA1PP]8N@10X\8>L30(X:>GDUZ(@O>HZ=DS>/LZ3/I58\8>L30(X8>,?2(
MH4<,/6+H$4./&'K$T".&'C'TB*%'##UBZ.G9I">RX#UZ:M8\S)X^DU[UB*&G
M,O9F2ZS\7K"MVII884R;PY@8QM(NIO<_(+%56[M`8K^Y*4B1B^X)4LE=QS%<
M6?\9ZZ480:IL#-)T;6=8MVKK$1`D;8X@B1&DUK;W,'VAFB"U:FL7!*G?W!BD
MJSDKO^>6X[G^E,BMK`^2V9/CRK;O!3U-V+/&MNT]3]B+QL:@3U_<>]E5VR*R
M[LJYBRDBD5;M&#97)0T;ALW*MB-X?#0C(K7M$!$Q(E+9MCTB(D9$6MM^C$Q?
M$"$BK5H7D7YS4T0B;>DC$G=N=O\.V?&J9C_]26AEVX$1J#Y+.I^8"%1A?+-E
MW6.&CAB!4EL")4:@6ML^4-.CRP2J55N[?;6R\OV`*5"10-P5J&]\8>!5243&
M(549*][M-*R?%SZN3;=7[A"\VG1[5QS!*XR70,3[<*ZXF3"^#X=0JA6A;#NQ
MQH-0MGK;CAWG-Z<0RMIA>7_>U!M1;5MARU-48Y'?1_6^4U1-"H9Q5EA\1;^+
MWG2J8.BU:NOQ$;W*MLT1O<)X'/C\-J'3]<W%?*N1`*HA`50'!+#5V_8M"V#M
M<_U!S6E6$\*V'8<P%N)]"'_C#"[K^7%<5D;G6V3G7R8FLJU:%]G"^);"RHAL
M9>/FIJL<L:V;X\+6>N5;Q^,8)MSJE7"W7KNFR7AM.Q**DS<PKML^SZIIQ,;"
M^JYP?^MYH"[0MZ'WZ'A5V#B2KSR26[4UMHSDRK;-$>_"ZD@^\9N??`=A#"/1
M5D-"JPX(K>HQ[VL'6Z>,U+[>%+I8]-X5NF][.?%5;&9>IE0V#*WY8!FIK5H7
MN<+&D5H8GQ?&`#D=KI;CC<=IW=AVZB5RZH#(M0[N'I2UVNG<Y^'!_)8"0MMW
M.(4VELIWA?9;1V5=<F]&&96%3:-R.D41VU:MBVUEV^88E87547ESRZ1=I@>Y
M&95J2&S5`;%M]>Z.;>VSG5^G:4!LVX;8^RFVL<+N8WO?-:JNR+>#)H:5W3<^
M6[4NAI5MPXP8%E:O\!>7AQNN\AZ@:DD0U0-!;/7N#F+MM%[E'UQ.#S42Q+8A
M!?%ZSD5^VU7JO)EI[E<VC<_I>O'XN%7;8EL9'SRO[.E:+S[M;)>?TY5&Z+HY
M5I&M6G*56JMMU\$7K0>&W-;45ZEUYW[MAR?7[?`Z*8<[5OS]F#V'^W>]>_RZ
M)A']L%[9&*MI7!#ZVK1?N%;&ZRJZT)=Z?`G_?-J]6'A-\*4C7[>V38CG20^$
MN6Z-L^:=8:[5UA^)G5]_^6K=$&\]=)PCB5"<N_?M?^-Y][HD(\/JJ[+A,U2S
M)T<S!G%-;K;<ZUG"B)OJ$3>QEPDC+*KW.F%O$O8V8>\2]CYA'Q+V,6&?1C:>
MTJ\C(^FUW7-*/]>?3SLUJ]E"S$`70X\8>L30(X8>,?2(H4<,/6+H$4./&'K$
MT".&'C'TB*%'##T]F_1PF=RE)^K/>@H;9X\8>L30(X8>,?2(H4<,/6+H$4./
M&'K$T".&'C'TB*%'##UBZ.G9I"?2IW[VQ,7EXN9!O.9K[V]B7I=4;#SQ548F
MT4[<IRL]F+HVW28@-EO3[JHBADTQ;(IA4PR;8M@4PZ88-L6P*89-,6R*85,,
MFV+8[-ED,Q*VWN9]Y\*2X(W&"ALGFQAZQ)AL8N@10X\8>L30(X8>,?2(H4<,
M/6+H$4./&'K$T".&GIY->B+IVZ.G)HG#,JVR;:9PJ1)#CQAZQ-`CAAXQ](BA
M1PP]8N@10X\8>L30(X8>,?2(H4<,/3V;]$3>N$=/R3/'V5/8.'O$T".&'C'T
MB*%'##UBZ!%#CQAZQ-`CAAXQ](BA1PP]8N@10T_/)CV1D?9ZXE)U//]Z\WVG
MN9K+#O.H,+[P%/G)?TPWNIE3I3P>C=@N7-?;#Q2,^W8SI\3W[-&Y_K3*J6P8
M.F9/CF9/$_8L8<\3]B)A+Q/V*F&O$_8F86\3]BYA[Q/V(6$?$_9I9).>R`O[
MH7.?GIJ6]@/FIK+^Q&N&'M5#CQAZQ-`CAAXQ](BA1PP]8N@10X\8>L30(X8>
M,?2(H:=GDY[(/O?H*=GJ<.*]40;[^&B&'M5#CQAZQ-`CAAXQ](BA1PP]8N@1
M0X\8>L30(X8>,?2(H:=GDY[([O;HJ=G@,'M:AMB?3G76O6G5UC4_QL0P)H8Q
M,8R)84P,8V(8$\.8&,;$,":&,3&,B6%,#&-B&.O99"P2OCW&2H(X3J@^::S/
M'=V(H4<,/6+H$4./&'K$T".&'C'TB*%'##UBZ!%#CQAZQ-`CAIZ>37HB@]NC
MIV9\PX3JL\!5CQAZQ-`CAAXQ](BA1PP]8N@10X\8>L30(X8>,?2(H4<,/6+H
MZ=FD)S*X/7I*QC?.GCX+7/6(H4<,/6+H$4./&'K$T".&'C'TB*%'##UBZ!%#
MCQAZQ-`CAIZ>37HB@]NCIV9\P^SIL\!5CQAZ*N-?+0O@)X[&#]XQUJJMERV,
M:7,8$\-8:[MU<;J>/@!$8JNV=H%$,22*(5$,B6)(K.R\Q)V"'GG9GJ"7/&Z<
M$Y4-*V@Q@EX9>]."?KJ>'C,EZ*W:&A&"KLT1=#&"KK9$6(P(BQ%A,2(L1H3%
MB'!E682S]';_TWLW2:Z[LB'PM=[&"'QE?>"/A^GS=0+?JG6!U^8(O!B!+ZQ[
M0)#`BQ%X,0(O1N#%"+P8@2\L>QKP=L[=?__GJ^=-3NG]RK9/CQ\?5];_DG!E
M1"AN3/#CRXK_5F.+O[?T/-GZBY7Q%:JZ=9UHZI:HL6[]U=J*'\A>V>N$O5G9
MMO5ITK[M:JQ;>K>RLO7QM',;26-_VCF[V?^9['D[LY":D+).VTXSIRG:.&K5
MUCU^TAB#JC4]SI_Z/UVK\6-TYV"/5XUG:W'Y+/I\$<*9>L-99=N'Y"]7%K]S
MU_;@=#WM/.+4%''J`G&MWK8Y'1#V2K5Z0(<'T^!!9=L.P9I41H+9J[SG'LQM
M24B'*TAE\:-;W5'K\:6UVC:$458V5QZP.`<;/X7%V[&[S4U/F^"I-=VJZ>>`
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M`4YKM6V&X+0U78\3IX6-%RH_@.NFG%#5!0+5!0(+XVN2<9D]+=<7TRD<>6J&
M*6T>4ZJ'J<+J&66ZV&"H;S+IB"1VCXZ2](Y3K$^$SR.;V(L1>S%B+\;D$2/0
M8@1:C$"+$5DQ(BM&9,6(K!CA%'N?L`\)^YBP3R.;]$2ZNT=/38^'V5(8K\Q>
MASQZQ-`CAAXQ](BA1PP]8N@10X\8>L30(X8>,?2(H4<,/6+H$4-/SXJ>/_[R
MU\^?OS[Y\>N/W__I'Y]__NGSX\]___LOW_WYR[__R2KMXA!?A6K\NY\__^4_
M__"([3P\;PP+*KLY4L;G&VG9192=+TQN=XJR\PG.99=1=IEO\RK*SHFUVMU&
M&6,\VY?KV"9/]Z1ET8Y'2]*R.':>:TC+;J+L_$RT]N7F0!F?)F?M;I8H.^=[
M:G<9<>&5#EF[RS@&/C1/R^(8.$NG97$,?),Z*[L.?SRAFI:%/QX_S,I.<>SE
M>7`=P^DVRLX+1Y5=1EQXV52VS<N("V_T2<MB/WEW3%H6^UER:O5WBG:\&#=K
M=XIV/*20EH4'7@F:EH4'WD>9EH4'7F^8EH4'OBN3E5U$N_)X@H[A(MJ5LZ#+
MP@.OJ$^W&1YX/WI6=@H/O+0\+0L/O!DZ*[N(=N4.D_<EVO%K56F[\,#B,RT+
M#^5[1=YF>.`78=)VX8'OQV1EQVC'S]VF9=&.AS#3LO#`3W>F9>&A/(BO_3R&
M!WZT,&T7'GA8/RL[1-DA+UNBK-S!<'_A@653MLUC>.`[+VE9>"B)NK<9'OAZ
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M9K^RGHCUV9*OSY8ECGU)QV`L)_+5Q!*K"?[D>Q(1RU<3RR$B]BNKB5B=+?GJ
M;#G$",Q79[<TX\9V<EZ]I1&W1[,2!'!;+BLA_'GV'3<0N!F1M2'TM^EHO:$-
MSTPD;6YHPV?]60E1Y\/HI.26H//A:U9"R/ED+2LAX'QDDY1$`I^OLV*9E:^R
M;HAUOL:*)6N^8HT%:[Y>O2'6^5V06.SD:YTKXI:O=*YIDZ^K8IF:KU)CD9JO
M46.)FJ]0KXA;OKZY(F[YZN:*N.5KFROBEJ]LKHA;OJZ)96*^2HR+8GY-C"5&
MOL*(!4:^OHCE3+Z:N:1-OI:)I6&^,HP+87X=C&5%OJJ(146^IH@E1;ZBB`5%
MOIZ(Y42^FHB+7W[MBZ5$OI*(A42^CHAE1+Z*B$5$OH:()42^@CC2)K_>Q?(A
M7SW$XB%?.\32(5\YQ,(A7S?$LB%?-<1%+K_&G6]=I.?>6##DZX58+N2KA5@L
MY&N%\RV+]#RZT&9)S[T+?I:\#;'.UPA'8IVO$,XW*M)S[Y%8_\KJ`#^_LDZA
M3?EX1RL88KVDU[D%/TL:ZX58+^EU;B'6Y5FGN1^:I"UHD*ZH"7,:98*<QI@0
MIU>W\T(DN[K%8X</SP]H^2K&YR:'AWQ0DK7C,Y##PY=Y&9]G'![R`4;6[H?E
MX0_I%3.D95?2T)SQF%`)_^'$]O.51)S4DA;Q=LR'O'$E[26B\R@>7W-T^(++
M]4/^9&7QZ"J12U<G\81EE&7^XB'`*,NV&<^T/N1/5A;/MCX\/_+G_8QG7+&1
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M/X87<0PO\WUY%/OR*"]['&6/\[(G4?8T/P;*N%;EQT`9Y\'\&"CC/)@?PY,X
MAJ=U7_[8%D&_?/^G?_WXT^>W/_[\T]_^^<MW?__\%QXI.#R(5VK\_+>?XN'B
M\C]?O_R+IX7_\-U_??GZ]<L_SO_YU\\__O?GGZ,"E?_RY<O7]7^XX/WQ_[[\
M_#_GQQ:^_W\!````__\#`%!+`P04``8`"````"$`NR?:PNX2``!M<```&0``
M`'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6RLW5MSVSB6P/'WK=KOX/+[V+K[
M4DFF8O%^JZVMV=UGQU$25]M6RE)WNK_]')"`@(,_V[:RF8=QYP?PB#H$*1P*
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MT/BLOC$Y4Y=6\Q_^02^7R\7J\I7\3.50#`_[UF-R/@RI?H0FM_O;#^^>MS].
MY+27,;/[?FLN(M-K$]:-S>%)'T;KWPU6&:4FRD<3YOVI'#<9ACLYP_[XL+A<
MO#O_0\Z*.]OGAGVFNL?:]3"G@`F;Q)#&D,60QU#$4,90Q5#'T,30QM`%<"ZI
M/>17QL6OR*\)8_+K,G/CP"=\%B73]7";)#&D,60QY#$4,90Q5#'4,30QM#%T
M`:ADRIGR*Y)IPL@U5`W6I<[>C>VC1K3NLCYT.608DD(R2`XI("6D@M20!M)"
MNE!4LN5B\"N2;<+(Q44.:7!I6.E4W@R=YB]E^]#ED&U("LD@.:2`E)`*4D,:
M2`OI0E'9EA=$E>WQN8&[W)K>?5)=,FX&D0PZ64,22`K)(#FD@)20"E)#&D@+
MZ4)1"9.Q<D3"3&^=L$'F,L4(QN6%'I?K0R>7U0220C)(#BD@):2"U)`&TD*Z
M4%0.Y<D?D4/36^=PD'#001)("LD@.:2`E)`*4D,:2`OI0E$),Q59.%MZ^2PU
MO77"!I%!Y\;3&I)`4D@&R2$%I(14D!K20%I(%XI*F$RHCTB8Z:T3-D@XPB`)
M)(5DD!Q20$I(!:DA#:2%=*&HA)F*XHB,]=UURBQ%5[;+Z,KF>[FAF)!24D;*
M206I)%6DFM206E*G2*?4S,W??M9.AZF\S%A<9FXLA<.0E)!24D;*206I)%6D
MFM206E*G2.?/3,>/R-\P>U?YLQ3,3LR$T)SKGA)22LI(.:D@E:2*5),:4DOJ
M%.G\F2GV$?D;9N02SX^_<)+>5\9K<]=`\A<,R824DC)23BI():DBU:2&U)(Z
M13I_9M(<YL_<H[B\,O?*[&VKM]^F&.;?*K>69)(43`2OXLOEH9<[*(FY6Z)'
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MD<[V<570G%60I?!J24I(*2DCY:2"5)(J4DUJ2"VI4Z3S%U=!+[_:S%GL.`IF
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M.Q5+'X^X((J/Q[^VW__N>$A)>S@@+)3,2AFI\]4!L;W"`S+0RE<(J=TPH,R2
M+*9P3RDG%=RP)%7<L"8UW+`E=6I#G=?C"J4Y"R5',KD/AFJ\X,CUZC]GTY\<
MB2-_)J26Y'ZM^0S!:CI;S**;`!FWRAWYV(6C<*=FT^B-JM(]W*1_N,E9M-.5
MC^(.9^W(/U;CR#^/UM)J"#R;3*,%!9W:1A\04R3]_R\\0ZD5%F3S@<S]V>`X
M13NV=KWFAQ&<./)/.76TZA,WEP_T1*G-7`]_ON2.?.C"4;A/(X=IV'.9?YE1
M,7*8#L_,'R9+_K$:_UBN5VMI-0RWL<,41E:':3%6X$WEXT;VY<%=CM[^6M%'
MU(6>(Y_Y-2FQ),6\>V*IHZOA/%JLIA?Q>>0"^5&;._(/5SCRO4H7N__06W\F
M5^Q5._*Q&D<^5LM8G>JE4QY7>3_W$K!@]6<IG.J0$E)*RD@YJ2"5I(I4DQI2
M2^H4Z;P>5_TM6/U9DE=O-P+7I(24DC)23BI():DBU:2&U)(Z13I_QU5_"U9_
MEE3ULIQ$E]2U[^6RG)!24D;*206I)%6DFM206E*G2*?TN()PP8+0DCJE4>HE
M[)62,E).*D@EJ2+5I(;4DCI%.G]Q]1=?*M]4O2Q8%#KR$]PU*;'T2O7B>[GQ
MG#%63BK\AN%,)JY>?"\7OF*LFM3X#</P<?7B>[GPG8JEC\=KU:2;+KQ\XVW!
M<M)1>$!L+T^)[;7TK\8I*6.LG%1PPY)4<<.:U'##EM2I#75>35463I9?R9^M
MZ_RD]&9A229ZP:PX*@36KI?/7^+(SV922ZYZD5GQ110HXU:Y(Q^[<!3N%*?%
M[N'^KGKQ4=P(K1WYQVH<^>?16CI4+[/HE:A3V^@#<EPYN6`Y:>F5,L7U\O/[
MQ)$_N*DEN<MC"H?IQ'RR7K]+DG&KW)&/73AZN4YQ#_=W=8J/X@_(D`!9].&H
M8:_6TJ%.X0&Q8?KGK@^(J6#",^3G7@F&.B@L)Q>6Y$7U<.(L)_'R)M_+/;_$
MDMP-=I1:DF%ECI-\/8G\+SY.]N'\,,T9NW`DG0\[-7+B#+%D55T_+,ZF_0,>
M_B]Z#I4/ZG:X=A2>1]C!UO9ZX3P*MU&';?G+R\L^HBXO+06#;TU*+,D8=$\_
MM21_3`*O%HO%,GKW,7.!_-F8._('OG#D>Y66I-AW#U>Q5^W(QVH<^0U;2W+>
MN%B=ZJ53_FO*2[-X,%HV9$GE>>@54.)Z^?U/+06YR-@K=^1S43CRL4K&JMBK
M=N1C-8Y\K-:2RJM]0GTOG=?CRLLERTM+*RF<#F?U<A+=T%C[7NY@)Z24E)%R
M4D$J216I)C6DEM19DE=">4(ZI<=5G$M6G):"\;<F)8[\H4\MJ2$YA!_VL[\A
ME+L-_3`J'/E8)6-5[%4[\K$:1SY6:TD-R7"_=/Z.*R]EVHQ3VM:2?J?6MI>,
M4C_^;"_Y$PS<Z%*9N@W]BTGFR-]0R1WY\(6C,/QB%KWI6?I>;K\J1SY\[<B'
M;QRI\%=Q'>1[N?"=HSZ\3GQ<E[X\7U^R`+449'E-2AR%N[Z<1)E)?2^WZYDC
MGYG<D<],X4B'CZ:6I>_EPE>.?/C:D0_?./(#HB5UCD:R_%JU^:;J?\EBTY)*
M_M`KH,3U&K[+S+R=F9(R1SX5N2.?BL*1#(3@#(I+?=_+9]KNEP]?NUX^?./(
M[VI+ZAR-9#JN/^/9]=OJ^B7K4DOJ`CWT"BAQO?R%,+6D+M!V0]\K=QOZ7!2.
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MAM22.D4ZI<?5<3+)0DH'"J^2ME=`"2DE9:2<5)!*4D6J20VI)76*=/[D95R]
M^KQR2IONT55RH&!DK5>@A)22,E).*D@EJ2+5I(;4DCI%.G_'E6,KEF.6@L&V
M)B6DE)21<E)!*DD5J28UI);4*=+Y,T5&//N97_[,5].LAGHEO,/N*'P%7T[B
M!5N^E[LV)J24E)%R4D$J216I)C6DEM0ITNDV]4*8[E=.]Z&\4"D=2`U74&+6
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MZ#1OKQ[Y_3/R^R5Q:>-(31]Q`\CW\M=*&\N_R*?LE9%R4D$J216I)C6DEF1^
MR:7/1'"S?OAEEN%W+QXWSU\WZ\W#P^[D;ON[^=65RX6L8CCP\),P-Q?F-V'Z
M90-HF4E+?Y\2+7-IZ6^"HV7A?F$F;EDMKTU](;E'RTI:^B>!E@MIZ6^%H.52
M6OIU&FBYDI;^EF_<<C&1?>O7\L<M2]E&[E".[9ML(S?:QEHD;W(+::Q%\B9W
M0L9:)&]2XX^U2-ZD>AUIF4N+?/AQK$4R*@N^1EH6LF^R"GZL1?9-UG>/M<B^
MR3+EL1;9`UF`.](RDZ,P?!@CSNA,,BK?&3"RS5PR*LMEQUIDK^63VV,MLM?#
MVSSQX\QEKX?U57'+3+89WJA'BVPSO+6$%GFF\JTZ(WLPDUS+A^O&6F3TRK>;
MC+7(Z!W>18D?9RK;R/="CFPSE6WD&P_'6B37\NU\8RV2:_G>N9&6F>1:UGZ-
MM4BN9?7F2,M4MI&OF!YKD6V&S_OA^4BNA^(3+9)K^<+;L6B2:_ENUK$6R;5\
MZ^A(BQF(8RX;C/8W%Y:Q_I+DT1Q+BD<S+`D>RZ^\9WM=RENFW%-9=W!=C;;(
M\H-K\_XLMY%5"-?F/5FVR#(#>8)C+?*#7A]'SV9SJ$8BW9B38LS-:33B'Q?7
M'^5EAKMTLYS)SHZ&DIV]&=U963=RO1YM2:3%+`[AX\CZ!FD9.[CRYKNTC"5%
MUI1<FS?=&4V6EER;]][9(BM,Y%".[8$L@9"6T3U8R+[)2OB1:-)2CK;(DOOK
M=K1%5JY+M-%]DQ:S\)R/(ZO*)=I82S*7:,-,,SHEY1/1U^;SSB/1I,5\5)DM
MR?Q"HHV=,O()7XDVUB*?UY5H?<OY81?DQ]Z^WW[=M+?/7^^?=B</FR\R+9GT
M'S5_'GXN;OC'WG[$^=-V+[_R)I6Q_%Z7_*S?1E983,P'#[]LMWOW#]G=\\,/
M!7[XMP````#__P,`4$L#!!0`!@`(````(0"_'H?W@`X``)!3```9````>&PO
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M!I?MZ-R,`_4_NM?YA0=T;H:"^I^+MGC6GP+=&96NS^NO7XZ'GQ.Z3-$.G#[6
MZJ(W7ZK6S+G4#XKA[/I?)Q>=$*J5;ZJ9ARD-$SIO3G1%^.UKM(B^S'ZCLWBC
M8QXQ9LXC5B9"G6>JV=2'S(?<A\('X8/TH?2A\J'VH?&A=6!&J1WR2^/BS\BO
M:D;EUV3FT8"3<"^9)L)427W(?,A]*'P0/D@?2A\J'VH?&A]:!U@RZ4SY,Y*I
MFGF8TG^'P9K,O:'XJ&/<$;WP$CR$#!D&R4!RD`)$@$B0$J0"J4$:D-85EFRZ
M&/P9R5;-T,6%#JF3;?_2T`?%GV5["!FR#9*!Y"`%B`"1("5(!5*#-""M*RS;
M=!]FV0[/9<SE5D5W237)>.R%,FAD!9*"9"`Y2`$B0"1("5*!U"`-2.L*2QB-
ME1$)4]$\8;W$-$%QQF7LG>)#D,EJ"I*!Y"`%B`"1("5(!5*#-""M*RR'M/,C
M<JBB>0Y[<0<=2`J2@>0@!8@`D2`E2`52@S0@K2LL86H%Z<Z6/C]+531/F!;G
M+`5)03*0'*0`$2`2I`2I0&J0!J1UA26,9N,C$J:B><)Z<4<82`J2@>0@!8@`
MD2`E2`52@S0@K2LL86HQ,B)C73A/F2$ZZYTKFS]YL5'#I0TI0\J1"B2!))%*
MI`JI1FJ06D8\I6IN?OE9J]9TWBC4Y`Y#I!0I0\J1"B2!))%*I`JI1FJ06D8\
M?VHZ/B)__>R=9GQF9#VJV9]*J7/=0TJ1,J0<J4`22!*I1*J0:J0&J67$\Z>F
MV"/RU\_(J3V;/W>2WJV,5^JI`:74&9(I4H:4(Q5(`DDBE4@54HW4(+6,>/[4
MI'E$_OHY-LN?)GY)3+S)GGK\P4=IBI0AY4@%DD"22"52A50C-4@M(YY2-:T>
MD=)^%LY2ZD[,]9`$2M5363Y*,Z0<J4`22!*I1*J0:J0&J67$\Z>FU"/RU\_`
M6?XTN9=$H)2NF-Z0S)!RI`))($FD$JE"JI$:I)81SY^:88_(7S\A9_G3Y.8/
M*)T#94@Y4H$DD"12B50AU4@-4LN(YT]-N$?D3\_/W5N*IMOA+K.:N[-X_?QU
M(#N7C!+OZ4V&%7.D`DE8<IJ?>U-5::/,#;%DQ#.C9M8C,M-/Q-G(TN1F1I,=
M;.E\H.YA][6_U9D-,%N=(Q5(PI)NV7LH(6V`:;EDQ/(1C5M/=.%\/6&(IL7.
M>N+&NWG:*+-1J::%S5J&E&/%`DE@18E4LHH\#>/6`!&N`0S1),%)PZV?!EUQ
M,9Q6::AB-+_F%3,3E70?GL1)<G-S[<7D)L8V7B`)2W9#H3]IHOK^HMN;!/HK
M34S7'T_GN"5!A$L"31%-8YUTWO&LK&R4'55]6U314*:CXGF7NT6TN+O%W$&U
M`AL72-*2W=#(_[B@M%&T53Q5:J)^^05))41-0IU+M2$^\N[]5.F*=G"DMJ)-
ME8[J#_O\_C:0*6BHP(8$DC34M[V(;V+_*)0F)#"BU.1[1)KT7-U-4T^J"SNB
M(N\<6D5#E,E)BI1ITB,JBN[]/<FQ4H$DD"1O>K&``U"R2GPLJ>GTB"3ULV\V
MEC11%H8DS>_A8CY$V20!9>J[`VJHZDM(($=0IS!U["@52-*0'DET9?(.8VDB
M`@-)39E'Y$C/L-V!U),WD+P/"%?1$&5S!)39*)OO)/(F4'DH*HJ\HU+8*-.C
M0)*6W!Z].409BG)[Y,-.S:)'I%1/NMV4:G*'W2U<[(<@LW]I-)#=F0COG<$H
M[X#EMBW3?($D+'W2HPQ'>3V6-HIZY!E5\^H1&=73<#>C/3G/?U814(J4(>5(
M!9)`DD@E4H54(S5(+2.>/S7['I$_/5EW\S?,W\UH6$5`*5*&E",52`))(I5(
M%5*-U""UC%C^XG&K@BZ<3THTN>,/*47*D'*D`DD@2:02J4*JD1JDEA'/G[^<
M4%^;BI(KNN&-_.(433'\^9XANIL,]^@D\E;%*QME!G"*E"'E2`620))()5*%
M5",U2"TCGNUQJXT85QN:V&CMHQQ*,2I#RI$*)($DD4JD"JE&:I!:1CQ_:D9_
M^=4RU@L`YVIIR"[E5T@I4H:4(Q5(`DDBE4@54HW4(+6,>/[4FF%$_OHEACOM
MCGMR!ML**47*D'*D`DD@2:02J4*JD1JDEA'/GUH'N/E35\OX3GTY>_3E4B\I
MW+&IB5\N_0]WXB'*7BZ!,HS*D0HD@2212J0*J49JD%I&/-UJ&>*F^_-OJ="@
MA#M03VRX`J6ZHA.5(>5(!9)`DD@E4H54(S5(+2.>/[6<&)$_O?IPAZ0F]W()
ME*KOGO'/&S.D'*E`$D@2J42JD&JD!JEEQ/,W;G$3X^)&$QTB<[*ND%*D#"E'
M*I`$DD0JD2JD&JE!:AGQ_(U;W,2XN#%$YZPS@_2>)ZQLE,ERBI0AY4@%DD"2
M2"52A50C-4@M(Y;2Q;CU3A?.USN:W"&)E")E2#E2@220)%*)5"'52`U2RXCG
MSU_O?'Y+6>"BQI!S2B.E2!E2CE0@"22)5")52#52@]0RXOD;MX)9X`I&$QM_
MN(+!J`PI1RJ0!))$*I$JI!JI06H9\?R-6\$L<`5CJ'^)3[U<M$)*#?$+I_<A
M7V:CS(4S-V2;+Y"$(=Z\]QQ4VBC3?(E4(=5(#5)KJ-M4GN5QZYP%KG,,V32L
MD%)#-_V+8OC9N0TP&<@-V98+)&%H:-E[[BUM@&FY-&1;KI!J0T/+WC/\Q@:8
MEEM#@4RKI<?E4\R%7JDX4TQ#=JM72*DA>]7-D')#MJT"21BR;4FDTI!MJT*J
M#=FV&J364"!_:C4R(G\JW+N?:Z([E3-%\C]4I>\N=!7MWJ1(F27UC8W8>U*7
MVV+;573OG?6%C3+C1R!)2Z&N2EO\25>5C3)=U4B-I5!7K2T.=\6O+&JI,^)X
MZ961.]XUL>,5>Q\+KA9#E-FS%"FSI/;LYLJ;&.>V/+QKW7>C"AME^A)(TE*P
MK]*6?])79:-,7S528RG85VO+PWWQ0S9N%;?`59PA?LB\#\E6-LKL6HJ46;*;
MGL3>-3@/1WGW@,)&F1X%DK3D]NB=VV4XRNNQLE&FQQJIL>3VZ#W(:L-1MD=^
M$,<M)1>XE#3D'D3\PH"-,CN8(F66W!V$LT]OA-MC$ML=U&??$&5Z%+9Y0]*2
M[1&_O&.C3,4*J49J+'W2?&NCJ'EV>))QR](NG-_&#/%D>1/6E8TR.Y@B99;L
MWB2Q=Y_*PU'^X;%1ID>!)"VY/7HWX3(<Y?58V2C38XW46')Z7'BWD388Y0Q!
M?A`I]R/N;8D*]PZB)G80%_Z%TE1TYB)(F25U#_!V++>E=O=Q*F*C3"H%DK04
MZ*FTI9_T5-DHTU.-U%@*]-3:TG!/_&"-6X@GN!#7Y"[$D5*D#"E'*I`$DD0J
MD2JD&JE!:AGQ_(U;B">X$#=DI_XKI!0I0\J1"B2!))%*I`JI1FJ06D8\?^.6
MV`DNL36Q\=='.91B5(:4(Q5(`DDBE4@54HW4(+6,>/[\A?/__<4+^H$JN`YK
MHD6?71/Z/V.S,A7M`$Z1,J0<J4`22!*I1*J0:J0&2?U45Y>);H?Z;/<_O=7_
M4-!^>WS9KK9O;Z?)YO!#_:Q6<DL/;@;N?_/K,4G,CW[Y)8OKI7JT3%=X**$?
M"J.'IJ&2B$JZY9]?)Z$2NCX%ZB0QE71?"X<Z"RKIOBKJE\140A]<!UJ+:7_H
M,]90R0V5=,F"UFZII'MO!$KNJ.0NV-H]E=R'2N:T!?3EVL`6S&D+Z.6J4`EM
M`;TV%"B):`OH"W6A$MH"^JI8H"2F(T=?@@J44)5@C3G5H#>Q`S7F=*SI'>-0
M"1W1_LL2?M;F=$3IO=!0'3IN]'HCEM!OSWT+C@[5?2#^D3H/QE/7H9Z_+9;?
MZ(3!CA]IBT(;]*C.BU`\'</@(:0C&#R`=/Q"AX^>IBXS>M*(6T1/0Y?J@2>6
MT-/,I7I@B27TQ)!:"VTO/?^CUD(E]#2/6@N5T`M>2_7Z%O9#;SE126@(T;M=
M2_4^$]:A%XJ6Z@TB+*'7@Y;J?2`LH2?ZM#^A`TD/XVFK0R6/,8T5^C8:MO88
MTVBA[UF%2M1X";9&^_,8W!]ZX6ZY"I:D5*+>JL-^Z+TS*@EEAUZY6ZHWS+`.
MO7FW5"^:4<EL.,/H]Q`_UB_;9GU\V;V?)F_;9[JP7U_=TKW@V/^B8O^/\^&#
M%BOTJXB',_T28O>_K_3+EUOZ`(5^YVXZ>3X<SN8?JH/AMS2__A<``/__`P!0
M2P,$%``&``@````A`,_0!XGO"```A2H``!D```!X;"]W;W)K<VAE971S+W-H
M965T,30N>&ULK)I1C^(X$L??5[KO@'A?(`D!&G7WJDELWTJ[TNFT=_><AG03
M#1!$TM,SWW[+L9.X_,\RL+J78?KG<E%_E^UR3!Y_^78\C+[FEZHH3T_C8#(;
MC_+3MMP5I_>G\7_^D#^OQJ.JSDZ[[%">\J?Q][P:__+\CY\>/\O+EVJ?Y_6(
M/)RJI_&^KL_KZ;3:[O-C5DW*<WZBEK?R<LQJ^O/R/JW.ESS;-9V.AVDXFRVF
MQZPXC8V']>46'^7;6['-TW+[<<Q/M7%RR0]93?%7^^)<M=Z.VUO<';/+EX_S
MS]OR>"87K\6AJ+\W3L>CXW;]Z_NIO&2O!]+]+9AGV]9W\P>X/Q;;2UF5;_6$
MW$U-H*CY8?HP)4_/C[N"%.AA'UWRMZ?Q2[!6\W`\?7YL!NB_1?Y9.?\?5?OR
M4UV*W6_%*:?1ICSI#+R6Y1=M^NM.(^H\A=ZRR<"_+J-=_I9]'.I_EY__S(OW
M?4WICDF1%K;>?4_S:DLC2FXF8:P];<L#!4#_CHZ%GAHT(MFWYO.SV-7[IW&T
MF,3+6120^>@UKVI9:)?CT?:CJLOC_XQ18%T9)Z%U0I\#3JYTC&Q'^K0=PV`2
MKN(@7NBOO])S;GO2YWU?26X;P?1I.RXGRV#V$"VO?^'"]J//-M359![&RU4S
M4E="7=J>]'E3J%.3HB;C:59GSX^7\G-$RXB24)TSO2B#-3EK4VV^NDO^7^6>
MDJZ=O&@O3V.206FM:,)^?8[GT>/T*TVRK;79H$W`+9+60L\H[3;U@?"!](%R
MP)0D=CII&OT?=&HO6F<;X:8%O?#0$]5:M%U2'P@?2!\H!S!1-,5]41&M]N%U
MVN9*=Z(5R7(UYT%OK(V;4,\DZ4PZ84`$$`E$N82)HU7HB].;T)TS4WNAN4TC
MZ$S-V)-KC*)K<CN33BX0`40"42YA<DF:*_=Z#K5QHZJ-9F/(BK+OZ%QPG4EG
MU'9+@0@@$HAR"1-!(WB["&W,11BR,H5`[P`)D!2(`"*!*)>PB&G/NSUB;<PC
M-L0;]J4W[)U1-^Q`!!`)1+F$B=`'+V<3OSYWM#$788@[[$!2(`*(!*)<PB)^
MN"=B;<PC-H0B=F?[RAOVSJ@;=B`"B`2B7,)$!+3:;A_WQIK+L,@=>40I(H%(
M(E(,\<AUF71FC"[[T4J?YN[=7P-3<&F#;4=Y8Y&7G0<O.[U5VS%%)!!)1(HA
M+E273D?H]:6ARX0WTRQB*3)6#DK12B"2B!1#/')=&)W(=8IB&NP[ZU]@ZBM]
M3SO,&XMX?N*9GQ_3D:D$)'I?K7N)2#'$5>IZZ*C\07Y,]61B#'+"3`)`*2*!
M2")2#/'(=1&\/7)3,EGDMHJR32R&,W%GU0YPJD]!-$L=R0*11*08XF)T?;Q=
MC*FF3(Q;8)O#>Q(`2A$)1!*18HA'KHNB$_G?72:FMC))MMSR_/C'^Z"SZO,#
M2*"51*08XBIU(754_F"9F+++Q-A*W&\#20`H1200242*(1ZYKIZW1VYJ+8O<
MEE]VLHV]A\LDZ*SZ-``2:"41*8:8F/"N@M]8\X)OD;-T$T0I(H%((E(,\<AU
MF7;2H)=)&$]H)[FSGH3:D2?*(!+EG,9B_WG1=G2DIX@$(HE(,<1UWE7O0ZSW
M%CEA)HA21`*11*08XI%[]?[Z$@^QK%ODI<%[U$UZJVZA(!*()"+%$!=S5UD/
ML:Q;Q-*`91VM!"*)2#'$(]?%U5LH03S1%WGUOMA^V92T<FBF#Z0GHHLO<QVF
MS]'^(C%H29L2.3!W9&'H;V.V(UGUV3$=%ZL.B=ZJ]Q7'WL.^[*U:7\HBXXO+
M]@X`>G]P9?]1GO]*-CGM=./!(#1HT2M*>J0O"L-9X,W1U!HLFUOJ9D1%WZ>7
M'`;>F56V'8/F"C):1C//0O5^:%#X".BJ[21^(,&N4E/CW4(5&K1T2FR/K%(O
M1VEK$#G)!3>RM9H;6:L9RG([<5EWG1Q"/#E8Q!)HK`A96=Z%1VK[L`1V?=K9
M*%LKFZT5Z>+/((I]-Y>EB[N3+7^^WK9,S0F!)=$@EL0.6;7>/4,:6@,WB1:9
M7T?T399LK1;-H#TL46SW/?[4U'>Z()9^4;%;4KLV;]^?&H>\B%ODIKE'_9I;
M^N*MD9OJ%M&<[+<Z6*NMU:H9CR!<8OK[`&!$])'C2OK;(;F^B"-S<''S;Y%;
M=Q"EB`0BB4@QQ"9T=-?!I;'V$FAO)>A@T(UZ''LK,[$=5_U<31$)1!*18HB+
MN>LL$^%9QB*6!F/EH!2M!"*)2#'$([_KX!+AP<4B?B,<>ZLFZ:W:W3!%)!!)
M1(HA+D8?'9Q5\H/58`X:;#48Y(QY$@%*$0E$$I%BB$<^<!Q9-CO>G8\K^C<=
M[R1FD9<A_WJRM^HS9'Q1QQ8)M)*(%$-<IZ[;MV?(5'F6(8-8A@"E$2"!2")2
M#/'(O7/%W[QWB?#`81'/S\([&B2]59N,%)%`)!$IAKA*79-OSX^IX"P_!K'\
M`$HC0`*11*088I'/O3/#];7?6/-Z8I&7!O]ZLK?JTH!(()*(%$-<C%?N?R`&
MR_K<(#<-B%)$`I%$I!CBD=]5UNFE'G^WLH@B=\KZPK^%[*WZ--CS0/]CJD`K
MB4B_6:2#,&-EQ)@WA<Q[(\?\\IXG^>%0C;;EAWX+B/+V_-AA\XK2)EJN]>Y!
MX4#+BEJ:IUEH>:"6YD'1;YG/Z(VG9M^%%OTN5*,16L+V+2F_):(^=!(;BHWZ
MT+%FJ"6BEN;4!-[FU#(?[!-32_,(`'T6U-*\1N*W!#0&=`$Y$$%(8T`7?$,M
MI(>NQ(9:2`]=.0VUD!ZZOQEJ(3UT/S+0$E`?^BEGJ(7ZT$\E0RTT!O2[PU`+
MC0'=ZP^UT-RAN_"A%IH[=-<\T$)=!GM0AT%[&N;!40YHE.EWTX%O"&B4Z8?&
MH18:9;/I^]D,XW5"MP;8A^YPUOJ&!EOHY;Z7P8SIKQ^PW^@4#W$]80?XRWS]
M0DL<OWA#.1Q,(65P*-`-Y:])W[1332\!GK/W_/?L\EZ<JM$A?Z/M8=9<GEW,
M:X3FC]K>)KV6-;W^UUPL[>EUSYR>DV?ZL?:M+.OV#PITVKU`^OPG````__\#
M`%!+`P04``8`"````"$`:Z\WKK,M``!K!`$`&0```'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6RLG5V3VS;6K>]/U?D/+M^/+>JKI:XD;\6B^"52(JF/<^UQ
M.HEK8G?*=B8S__XLB-C:`!:BEN:=FW'FP<;>(-8&2(`0^[O_^=>GWU[]\^G+
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M^0\)>_4"$V3*T%`G9<::,E?Z,I$\,?\AP6Z\1DD9,T+NO49)F\3)F^O7*/F2
M.`FSO.T:)6$2)V-NO$;)G423Y]8T'4OZF/^0KKUZC6/)&O,?TJ.W7>-8DL;\
MAU2]/I[>#I/7>2Y,WW][_\-W7Y[_?(4[#()__?V]N5\EC\:=S()#&EWFQ;^:
M%C$?&B\_&C??OX:^F/"^8C+_YP_CQ>2[M__$_/O!VKQCF\2W6(F%F6R-VS0$
MZQ!D(<A#4(2@#$$5@DT(ZA`T(=B&8!>"-@1="/H0[$-P",$Q!"<'O(7$%YTA
M[7]#9^/&Z"P*O1/@"!^(*A92)0W!.@19"/(0%"$H0U"%8!.".@1-"+8AV(6@
M#4$7@CX$^Q`<0G`,P<D!GJBX`_PW1#5NOG^-_W4&[]17\9VU<4=X8+*ZF%R4
M)K(FDA')B11$2B(5D0V1FDA#9$MD1Z0ETA'IB>R)'(@<B9Q<XHF/>_A_0WSC
M!I,_4LQ1?Q:H/QA-KJE_,;FH3V1-)".2$RF(E$0J(ALB-9&&R);(CDA+I"/2
M$]D3.1`Y$CFYQ%,?CV&>^O%5B]R>C?599!'GW4"@J)`5D93(FDA&)"=2$"F)
M5$0V1&HB#9$MD1V1EDA'I">R)W(@<B1R<HDG(,;2'0(::U_`@4SP@.R,V[D_
M;E<7(U$Y);(FDA')B11$2B(5D0V1FDA#9$MD1Z0ETA'IB>R)'(@<B9Q<XFD*
M,>[0U%C[F@[$'91$4B)K(AF1G$A!I"12$=D0J8DT1+9$=D1:(AV1GLB>R('(
MD<C))9Z`6#/>(:"Q]@4<"`:EC+<5D93(FDA&)"=2$"F)5$0V1&HB#9$MD1V1
MEDA'I">R)W(@<B1R<HDG(%;N=PAHK'T!!^*.0"(ID361C$A.I"!2$JF(;(C4
M1!HB6R([(BV1CDA/9$_D0.1(Y.023T"S#^<I:#8DQK,WN(_>NR5A//GJGIT#
M80)W;IH/P4U3K604IXS6C#)&.:."4<FH8K1A5#-J&&T9[1BUC#I&/:,]HP.C
M(Z.3A_PL,-L8[K;4]<=;LP,;2CT@=R1;*P>EC-:,,D8YHX)1R:ABM&%4,VH8
M;1GM&+6,.D8]HSVC`Z,CHY.'?%W-3L8=N@X;'UB<RDA\9Q:J1FIGX<(H9;1F
ME#'*&16,2D85HPVCFE'#:,MHQZAEU#'J&>T9'1@=&>%UG-/WOJYFE^(.78=-
M#?A37=U]CO/F[\J\Z8#4WG@EM&:KC%'.J&!4,JH8;1C5C!I&6T8[1BVCCE'/
M:,_HP.C(Z.0A7U>S_W"'KL-VA:>K1?XM=Q'><B]6DA"I>4?E#_0UHXQ1SJA@
M5#*J&&T8U8P:1EM&.T8MHXY1SVC/Z,#HR.CD(5]JLU-QA]3#QH8GM;O788<P
MH=2\0/1']9I1QBAG5#`J&56,-HQJ1@VC+:,=HY91QZAGM&=T8'1D=/*0KZO9
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M&D9;1CM&+:..4<]HS^C`Z,CHY"%?U_MVI<S!+C-W.JM<BYPE[8I1RFC-*&.4
M,RH8E8PJ1AM&-:.&T9;1CE'+J&/4,]HS.C`Z,CIYR-?UOETI<TPNU-6BX6RO
M.;JV$BM%J2`\/NF->3GR;\QKM9(;<R9(?>6,"D&^^^",7:E6XKX2=';O]XS9
M;[G]#C4>MF>\C+=(F[X2*T6I(+_IX[!GK"]]O99)1?65,RHLFH[/)Q.GR6(<
M='JI%MHK;LO]7C%;$VZO#(<FWYACW]]^_?CA'^^>H2]&?V37>H(FG&_4/X[M
M!H<[/5BD5[,2*T6I19/1<,YRE`0'L=9J(!>3L9N<4:$5SR<XR7.I!N*Y\MSX
MW616^F$WC8W$IH\.S[__51_A%/JEDX;=`B^C+,(3C#.*@L.F*W.2W0S2Z66+
M,16TO*"U19@:S`5/1J/)?#X--J<RKI<+4N^%(/5>WN*]\NKY_6>6S]1_<_-K
MA%AF`5]ZS2Z\W=0:D!GJ3J\%F;,:6ZO)I8M205[%)!@_:VLU&498\B8)7JIE
MZD8R)Q>DP0I!5X.5?K!@EJC4!R+Y'8K<\SHT,C[=7C3FP?W;(HQ3IQ>#TW(K
MD^-A[EGD)2WWXF!EGD`<]\&AGDS<:Z;E@MQ\O"5B:2M>CUB)^W-$OTO-^M#-
MT1>ZU"XGW<0<4)"80?JL\$,@TZ68IB5]4D'J:VW1)0L#+YE6<?LW&.^Y6&FL
M0I#&*L-8@4J55HG'\KO1+,?NZ,9A]>;-BA9Y";8,%_UC:Z5YD@K2;%I;Y"4%
MYD;_;IQQQ5R0NB\$J?LR[CYX3JF\BEYGX<9W3V>=S?UA;)&7<Y-1,)&LQ$KS
M(!6D>;"V"#FG.D]&P>THTXIJ-5Z&F2=6&K$0I!'+>,1@*J^T8CRBWZ7WK6PF
MO+(1Y.;?9!3.C&*E"9(*T@196Q3D7S#`,JZ8"U+WA2!U7][DOO(J^IT%J>\8
MK"8S@MN(1>XRD%'*:,TH8Y0S*AB5C"I&&T8UHX;1EM&.4<NH8]0SVC,Z,#HR
M.GG(U]4\\-\^"4_L^D!'YCM!SK8-HY31FE'&*&=4,"H958PVC&I&#:,MHQVC
MEE''J&>T9W1@=&1T\I"O:[A<N_Z,,N%UF2!75VNE*&6K-:.,4<ZH8%0RJAAM
M&-6,&D9;1CM&+:..4<]HS^C`Z,CHY"%?5[/$<\>K689/%C>LCR9V<>@.W0%-
MS?K\GS_\+7@:6=D:*-:[Z62DSY=^PV(+M]L:Q@LWW"3,[4,:1@\IEV*W8?I@
MX3?,K`G^LQZSJPFWQP8D#0N>>%;FEPE#N]V&Z0.IW[#[EA$37D98Y-U2!RL'
MI6RU9I0QRAD5C$I&%:,-HYI1PVC+:,>H9=0QZAGM&1T8'1F=/.3K:M8;;L*]
M,/7:Y8F;918AS2]+XDFX<%Y-+E:7Y2&C-:.,4<ZH8%0RJAAM&-6,&D9;1CM&
M+:..4<]HS^C`Z,CHY"%/ZNE]J[*SN;\JL\@9KRM&*:,UHXQ1SJA@5#*J&&T8
MU8P:1EM&.T8MHXY1SVC/Z,#HR.CD(5_7^Y:&4UX:"O*'<'B'5:O+$&:T9I0Q
MRAD5C$I&%:,-HYI1PVC+:,>H9=0QZAGM&1T8'1F=/.1+?=_"%J]3PH6M1=X0
M'JP<E++5FE'&*&=4,"H958PVC&I&#:,MHQVCEE''J&>T9W1@=&1T\I"OZWT+
M6_.0&VQ8"/*'<+`CN%(K'<+6ERZ3UFR5,<H9%8Q*1A6C#:.:4<-HRVC'J&74
M,>H9[1D=&!T9G3SD2WW?6G?*:UV+G/&Z8I0R6C/*&.6,"D8EHXK1AE'-J&&T
M9;1CU#+J&/6,]HP.C(Z,3A[R=0W7NM<?I*>\P!6D+Y)7C%)!6+Q='K?'=$1!
MK62@9X+4?<ZH$'35?:E6XKX2I.XWC&I!OOO@2:-1*W&_%:3N=XQ:05?==VHE
M[GM!9_>^KF;Y?OL":6K,@Z=FB[3I*[%2E`IRFXY/S/FO=-9J)4W/!*FOG%$A
MZ*K[4JW$?25(W6\8U8)\]\&.0Z-6XGXK2-WO&+6"KKKOU$K<]X+.[GU=X<O3
M]3\Z(C(U7@*Y+=(K6HF5HM0BO`.R!SF"OEJK@5Q,QFYR1H56M)Z#'"K50#Q7
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MG`KR*H;;H&MKA1?G)@M&;_0UP'E09NI%YKE<D,8J!%V-58:Q@NFE4B\2:R-(
M8]6"KL9J_%C)FS`WU(O$V@G26*V@J[$Z/Q;U8:]>$,O/E/MVRF:\4V:1.8QZ
MN0>,E\'5KM1*KC85A+T6K<CI,43$&_"_2(^A'!.2.,[%L0ZQ0M#56*6U^JM8
ME7J16!M!&JL6=#56\T*LK7J16#M!&JL5=#56]T*L7KT@EI\><.S=.ZXOX6;&
M/)@]+/(2>!G<>5=243,_%:0WPK5%EZDBT3=S=JZ(!@MFE%P\:[!"D`8KPV#!
M,V.E59ST#4]';<1*8]6"-%83QIH$3=YJG2O!=F*EP5I!&JP+@X6]V&N=>#`_
M0^[;IYOQ/IU%WB/%F$X!BI4F?RI(A_[:(CN"DS?!72KC*KD@=5P(4L=EZ#@X
MV%5QE8T@=5P+4L>-[SA(LBU7V`E2MZT@==OY;JDC>J^*+^A]NW$SWHT3Y`YY
M/JDH5IJLJ2!-UK5%=LC/@W&1:8UXJIZGA5RL-%0A2$.5?JB'0(I*:UP)M1$K
M#54+TE"-'RJ\JJW6N!)J)U8:JA6DH3H_U$/PQ--KC7@H/S7NV]";\8:>1=Y8
MYQ.78J4IG@K2%%];9,[&79X?)J-@8&9<,1>D[@M!ZKZ\R7W%%3>"U'TM2-TW
M-[G?<L6=('7?"E+WW4WN>Z^B+_5]>WPSWN.SR-V39Y0R6C/*&.6,"D8EHXK1
MAE'-J&&T9;1CU#+J&/6,]HP.C(Z,3A[R=0WW^%YXH./-O-F`W.]%,DH9K1EE
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M`Z,CHY.'?%WO6P'/>04L2`^<K!BEC-:,,D8YHX)1R:ABM&%4,VH8;1GM&+6,
M.D8]HSVC`Z,CHY.'?%WO6PC/>2%LD3=>!RL'I6RU9I0QRAD5C$I&%:,-HYI1
MPVC+:,>H9=0QZAGM&1T8'1F=/.3K>M\J=LZK6$%8].B-,OSU^$JM9`<W9;1F
ME#'*&16,2D85HPVCFE'#:,MHQZAEU#'J&>T9'1@=&9T\Y$M]WRIVSJM8BYSQ
MNF*4,EHSRACEC`I&):.*T891S:AAM&6T8]0RZACUC/:,#HR.C$X>\G6];Q4[
MYU6L(/>6:ZT4I6RU9I0QRAD5C$I&%:,-HYI1PVC+:,>H9=0QZAGM&1T8'1F=
M/.3K>M\J=LZK6$$JXHI1RFC-*&.4,RH8E8PJ1AM&-:.&T9;1CE'+J&/4,]HS
M.C`Z,CIYR-<U7,6^L/3AI>O<(OV,TDJ02IT*PDAV;LS!2X.U6LF-.1.DOG)&
MA2#?O2[WSF\;2K42]Y4@=;]A5`ORW(^#-6>C5N)^*TC=[QBU@GSWP1NR3JW$
M?2](W>\9'03Y[G61?NZ<HUJ)^Y.@LWLO;1["/8;K:7,V]S<6!#EI(TBO)A6D
M5FM&F2"MF#,J!/G=$)P%*]5*NJ$2I.XWC&I!VM2&T5:0^MHQ:@7Y30U.;G1J
M)4WM!:G[/:.#(-?]>!3DVU&MQ/U)T-F]GQ#AWLX+"<$;.@\6:?^M!.G5I(+4
M:LTH$Z05<T:%(+<;)N/@?'>I5M(-E2!UOV%4"]*F-HRV@M37CE$K2'UUC'I!
MZFO/Z"!(?1T9G02=??E2W[=;]L"[98*T!2M!VO14D%JM&66"M&+.J!#D2QWL
M9I9JI5+;UJO[C5@IJ@5I4QM&6T%:<<>H%:2^.D:](/6U9W00I+Z.C$Z"SKY\
MJ<,--+-CF\SN_#3A`^^K"=)7I2M!SKESB_[ZW+D:B&`9N\D9%5K1>1P9ZX;Z
M\+R@5N*^8E\;1K56=-T'3SN-6HG[+?O:,6JUHNL^>-KIU$K<]^QKS^B@%<W+
MB#%]M_&H!N+YY+GQ<RC<K#OO^B\UAV[[=.,#;^)99'[FI,^4D^"&OI**>A@C
MM<C[(M28SC>*U?`UQR1YF(^3\#QUQMYS1H6XPE/3I:44L(Q932;!_:AB]QM&
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MXYF:P6[`@/P9;QKHN7H8K+P9SR(=46MK)3/>=#Q-YL$(SL235LL%Z7`M!*E5
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M5KR2`CNQTHBM((W8Q2)2"O1<<2](W1\$J?OC3>Y/7D4_P\*M^YOOIPO>Q;?(
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M]Z6@^?G7`<OE/`E_AER)B?K>"%+?M2#UW0@:?)N<'4V#\;45&W6^$Z3.6T'J
MO!-TM5]ZL5+W>T'J_B!(W1\%#6V?S6=)L@C&\TELSL[]S(J]F$CF;TQCW6_O
MW/XWN!;\CD*0^X[B(7@^7ZF19%1JD?E3.9>=5=JU7HO5\IP8>%,SPF9!,.ED
MXEV'9"Y(^[(05U<#EF(U!)SB+4`R#[*E$N<:;R-(X]7BZ6J\1JR&>`_+V709
MWJ2WXESC[01IO%8\78W7B176@)=NGX33>"_N\=!^L:(=Y[U8:2,.XOYJ(XYB
M956=S1;S9?BZY23>SU?MYS42F&[`[DO;VUZX+8R;X&X\(/?(K;5R4,IHS2AC
ME#,J&)6,*D8;1C6CAM&6T8Y1RZACU#/:,SHP.C(Z><C7.WP#<'T[8L';_H)0
M<LEG_BJZ6NDL97WI*80U6V6,<D8%HY)1Q6C#J&;4,-HRVC%J&76,>D9[1@=&
M1T8G#_E28^+PAO8+4AOS8`@/R!FOJP6AE-&:4<8H9U0P*AE5C#:,:D8-HRVC
M':.64<>H9[1G=&!T9'3RD*^KV7.\_0>("[M%J0],[P1Y0W@6[*:NU$J'L/7E
M#F%"&5?,&16,2D85HPVCFE'#:,MHQZAEU#'J&>T9'1@=&9T\Y$MM=OKND'K8
M&'3_-M]B0-X0)I2RU9I1QBAG5#`J&56,-HQJ1@VC+:,=HY91QZAGM&=T8'1D
M=/*0I^LRW*>]/C6?S?VI69".Q!6CE-&:4<8H9U0P*AE5C#:,:D8-HRVC':.6
M4<>H9[1G=&!T9'3RD*]KN#OZ@JZ\);H<D#M>&:6,UHPR1CFC@E')J&*T850S
M:AAM&>T8M8PZ1CVC/:,#HR.CDX=\7<-MRA=TY;W)I45Z8'7%*+4(WW:66^Z:
M4<85<T:%(#RPZ7-Z^*W<4JTD8B5(F[IA5`O2T\(-HZT@];5CU`I27QVC7M#9
MER]/N.WW@CR\O[>T2+>05H*TZ:D@;>>:429(*^:,"D&^/,%F3ZE6*H]MJKK?
MB)6B6I`VM6&T%:05=XQ:0>JK8]0+.OORY0GWSEZ0AS?&EA:Y\EBD34_%2MNY
M9I0)THHYHT*0)\\X>.53JI7*0^W:B)5&K`5I4QM&6T%:<<>H%:2^.D:]H+,O
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M-HQJK>BX'P=WW$:MQ/V6?>T8M5K1_A`FR*%.#<1S[[GQ10XW>4*1;]N77_+F
MCR!]T[!BE`K2]R1KB_!*7-J?L54N2-T7@M17R;XJMMH(4E^U(/75L*\M6^T$
MJ:]6D/KJV%?O6?D:A;LSMYVV6O(NC47^Z^5Y\&YN9:W<U\N"L+JX/.2/Z<=)
MUNIRR'DY3N;!;E^FGD3=7)#.!X6@J_%*/UXRGSXLPS95ZDGB;01IO%K0U7B-
M'P\_O<(O5X(39EOU)/%V@C1>*^AJO,Z/%_^Q5Z^N$-#+&YR2B<S@-_W^9ZCJ
M3]O"_',O]`L@,7//)5^8#H&U,'M<;[$8T?TJ$YM$Z^47IB.LN#"U*X5=/UI3
MB9D38G-A&J*^,`W1"),3APG^:@C]40\Q<@+L+DP#M!>F`3IA-D#TAU*]&`T!
M@@P(-XK,U''3#W&2$6\:"?/GC_#8QTK,W`GDPO2Q#QE@-Z&&0UW+V6(Q#QYT
MD0&#C7.X&!E@F0XH9`#9(0.L?W^4!2&0`505&4`AD`%DAPRP(>RYM/%\M`S_
M"M%6C)QK0`90`&0`!4`&>`'&X\@OEI`!;L4@`W#Q]!1WXQQ@JH9SP,#\.8!^
M$Y.,;%7-[_3"-+^1`8.=S>\I_@K2*%A)(0.L+ZV'#"#_R`"R0P9X_I-DDLR"
MQR7(3_4@/_F'_&0'^7W_"_QAGW!%`OFI(N2G`)"?[""_%V`<^]T0Y'<K!O*'
M6U9F`KA1?MZ^PE&><TKX$P#],D7,_`E@J.H,`L@_L,L#`_Z>$\M/]2"_9=X$
M0':0/_"_X-./8N.T"_*3?\A/_B&_Y_]A/%N&S_E0G^I!??(/]<D.ZGO^HS_>
M@?INQ4!]LTGD+LUO>W),1G9S22?K=\*"D1_^/$3,_+N_=:<C&-(/3.YLRX1^
M("(FSHT3REM7.K%@X)-[*.^Y7TSP8P#_IP`8]U0-PI-["$]V$-YS/QZ-'B9!
M3T!XJ@?AR3^$)SL([_F/_7X&NKOU`MW-[A/KKI\WN&GIGHSL)I:7!@/S9P#Z
MP894]6>`H:I[1O5B-YR63"8C^AWXQ41;@32PKKP)@-PC#2RS!TF3>7@4$VE@
M3=0]TH#<(PW(/=+`<[]`#H?+@8N)ND<6D'MD`;E'%GCN\5?CZ`<MR`)K<_8?
M9$&X,6=&___J+&DRXLV["T,Z7M:&=)K4L9)U$9X(!F\OG">]F`U'#V>CY6BY
M"+93\)1@6Z9S#++$,F^RN"4F$L>:V>..R62*Y1[-(!03J4,QD3JWQ$0V>3&3
M\>+A81Y93E!0)!0%14+=$A0YY@6-G]9%EKE!@RQ[:9OPMAVD9,0;A<+<M]01
MAD0:ZCIVN,$00Y(00Y(0PQV%&#*"&.8.8D@`8D@`8E";&&X9Q*`M,6A+#$(2
M@VS$]A%VB+!CA)U\%J1!N)%X_>U.,N(=PPO3U])82UH[99";&.0F!KF)06YB
MD)L8Y"8&N8E!;F*0FQCD)@:YB4%N8I";&.0F!KF)06YBD)L8Y"8&N5T6R!WN
M2;XD-V]&)J.!.:,6<A.#W,0@-S'(30QR$X/<Q"`W,<A-#'(3@]S$(#<QR$T,
M<A.#W,0@-S'(30QR$X/<Q"`W,<CM,E_N)-Q)?$'NLWVP=2`,MY++<\(DW!]>
M)6JF#PK,UA&[+,+R""LBK(RP*L(V$59'6!-AVPC;15@;85V$]1&VC[!#A!TC
M[.2S(`/,%I.[I'@I`X8M*?>,:)+8O2R=RR$WL33"(#?906YBD)L8Y"8&N8E!
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MF60H,H#<(0.((0,LTR8C`X@A`Z@N,H`8,H#J(@.((0/<NH%B9IOG'L6&;2%_
M@%KF*48,BEFFEP_%B$$QJ@O%B$$QRWS%@AT<C-F+F:,8N8-BQ*"89=ID*$8,
MBE%=*$8,BE%=*$8,BKEU`\7,ELD]BMDM%F^,6>8I1@R*6::7#\6(03&J"\6(
M03'+/,7H5*ICYBA&[J`8,2AV"2%UH1@Q*$9UH1@Q*&:9=@$4(P;%W+J!8F:W
MY![%C'VXR+%,FX%9D1@4LPS_.+-8L'L,$2]FTDL0D=Q!1&(0\5+7"1%^=!##
M[F(F(3!1DCN(2`PB7NJZ(8*K@*X7,PD!7<D=="4&72]UG1!T8-4QDQ"0VG47
M2&UV-NZ1VNZ$>(/3W1TY?YL;4A.#U);I46#H2@RZ4EWH2@RZ7NHZ/1+^47#H
M>C&3'H&NY`ZZ$H.N5!<B$H.(5!<B$H.(5!>#DQ@4<^L&BIG-B7L4&S8S_!N@
M9=YT2@R*68;\N0Q..IP$$2]FTL,0D=Q!1&(0\5)70_!I8\=,0D!$<@<1B4'$
M:(C@-2ATO9A)".A*[J`K,>AZJ:M701T%J2]F$@)2N^Y\J<V)+4_J\WNK>S_P
MGYS=!-.S,#<#F*525P\?!X>&UHZ%7%,F#,MJ87F$%<+@7;MM0@>0'3-Q5PES
M0FPBK!;FAP@/)S2.F838"G-"["*L%:9]%+P?ZQP+\=X+&[P'NIOM"'>(#Z<5
M]*WUC6^2<*:`[LN6^:<7Z.0K3E@,5?6-(7+!,B2L,QL$YU20$(.9R2;'+,@;
MY,C%F_0)<H2B(D<N=JZ[(&HI9K`VI\$7#^-Y^&H4.7-Q)2&1,Q02.7.QNQ(2
M.3.8X1\3,IDGRVGXNA=)=/$E,9%$%!-)=+&[$A.9Y,7$=\SX9#%2Z^(+,8/4
M,EL?86K==@P*!X,XFP;F'X+@D["VJG<(0I@^22!U!G?XIJ!T%O)D8/A'&/+$
M,O?4@S"U0U)8?\.AQ/%RF80G])`4Y!])0?Z1%&2'#/#\SQ9X+QC<5I``5`\)
M0/Z1`&0'M3W_L9/!$-NM%XAM-CY"L6\[]`JI6.R!^5,''WJ5JM[48=WIH02(
M/3#,$R(LQ"8[B&V9^L.D0'80^^+/'4'!O`.]J2KTIA#0F^R@MPUA/Y87.:<+
MO:D>]";_T)OLH/>+_J&W6R_0VVR;A'K?.+CMCHN.GG<)SB>9'/`'=SB`5F*&
M=HF.N%4,59&;PJ#WP%[X8*B8.561`M:=AD`*4`BD@`UA#R%CX?,0G$:#_E0/
M^I-_Z$]VT-_SCV-(X_#/#$)_J@?]R3_T)SOH[_F/G0*&_FZ]0'^S"?,?ZF_W
M;U0PZ#\P?[SS&5=KACT[T1KZ6W?>>!^8/][)#F);IOX@-ME!;.MO&(P/^.YB
M\/L=:$W5H#6YA]9D!ZT]]\E\O%@$_J$UU8/6Y!]:DQVT]OSC0#,=^876;KU`
M:[-]$VK]\N?.D['=]O&$'E@PT(.1@X$^F/D#W3)UAX$^L!<'.E6%]A0"VI,=
MM+<A[(T=`S'0!MI3-6A/[J$]V4%[WSU.S?HGWJ`\U8+RY!W*DQV4][WSB5\(
M[U8+A#>;.2R\+@YN.])JSAJ&>W:6^0.>C[1*51V@&/"#NXG.T,@#RS!A75T(
MV);H7($\L$Q#(`\H!/)@8-.'X1&<3\TB#\@]\H#<(P_(/?+`LJM7@&2@$$@&
M"H%DH!!(AH']]14@&5SW03*8?:(P&?YW)UO'=NM)1S3N!`-S1CYF`V+(@H%-
M\8^C>+!60V)8,W\A&3RIX6'01M"6(#$LTSQ#8EAW^.>OHR)7!K/9:,B5Z6B,
M8\3^N$:V6/\:$]EBF<9$M@SL^I4B@;R8$ZQ))^'O;I`^%!/I0S&1/K?$1$9Y
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M\GL:SV^3WM'K2=`"O"V(Q$E,:D=;,$8+AL?P\$K':`%VCR+>)E!NV)<)ZPQ3
M0*Q.8B:`J-J)&?Y1M1/T];"4H#C(1+QFCK0M01[@=6:D!%6B-4SJQNS1S=%>
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M__'\`IA]XOH>S/7%QBSZ96KBQ7(0]::F7JP,_3(U_1(K0[],3;_$RA!O9N+%
MYAO$FYEXL3+$FYEXL3+$FYEXL;)T"=GQT:)(KZ"DC);@XTN/YM-*7*=%21<M
MP?>'$"?6P_A^$.+$2O#I'\2)E>"K/8@3*\'7Y!`GUK/X-ASBQ$KP63?$B97@
M(VV($RO!9]$0)]:C^*(9XL1*\#$RQ(F5X#MBB!,KP;<E$2<VE^)+D8@3*\%'
M'A$G5H)/-B).K`0?242<V-R,3QXB3JP$7RM$G%@)OCV(.+&2TQPW._PQ>LZ=
M]`$MP)\8YQ+\)??',EJ"/\+^:/[$.M?!WT]_-'\=G4OPI\\?S5\WYY(>;>NC
M;=NC9!\M.:#D.(_-_(>'$>+$[J:'AP0EL?OFX6&,DECO;!%G&RW9H607+6E1
MTD7;UJ)M7;1M+=K61=O6HFU=-$X!;V746P%O9=1;`6]EU%N%5E?1D@U*-M&2
M&B5-M"2=8M[!M@BK7:"DC);4*&FB)2U*NFC).[3@7;0%*Y2LHB4I2M;1D@PE
M6;0D1TD>+2E04D;53J>8J[`M&^L#S%71DAIUFFA)BY(N6I).<2\9/H(;/'47
M*"FC)35*FFA)BY(N6I*.,2<.;W;"."@IHR7I&+/+L/-$=3"[1$O2,>XE>%$2
MZ3>4E$/)VXN[KS]\]_O[7YZ:]U]^^?CYZZO?GG[&AL?HO*/ZY>,OYO#%\'^^
M/?^.C9#7K_[^_.W;\Z?S?_[Z]/ZGIR_&`%OU/S\_?Y/_@]!O_WS^\H_SILH/
M_U\`````__\#`%!+`P04``8`"````"$`,`?N]I,+``!L/@``&````'AL+W=O
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MI]'WJ\%'H\YF^633W`Q)0AI6!YHQWVXG\^GUZ!N-\HV/66%,QB.*$&&'M$U;
MIJ!*@4B!3(%*@4Z!B<"(9#EI0R/_=VACTUAM0E6K`"*Q$B%"1.A2IJ!*@4B!
M3(%*@4Z!B0`3@F;O[Q#"IKD9TK_1()GQRE<^)AY)R3@J3B$G=8!40`00"40!
MT4!,3)A(M%+]#I%L&IJ,="@BE>:)2BXH?TVE4\A))2`5$`%$`E%`-!`3$Z82
M+6Q,I?YS6EA6;'0K1BABY0A5'D@!I`12`1%`)!`%1`,Q,6&%TK%AA7YP8;5I
MN`*.3&G1B@;(@@^0XA049"J!5$`$$`E$`=%`3$R8*'1N9:*\?O1M-*_=D?CH
M`RF!5$`$$`E$`=%`3$Q8H=:*QZ?5UPNUT;Q01^)"@91`*B`"B`2B@&@@)B:L
M4/(N9Q1JHWFACL2%`BF!5$`$$`E$`=%`3$Q8H=8<L4H_.*';/%P#CTB$>$I?
M)E.ZBSK-:405(H%((E*(-"+#$-?'NJCW#_G,F2XZSX5J5A[%8P%1B:A")!!)
M1`J11F08XC5;PW1&S<Y?L9H=8C4#*JT;H'D3156(!"*)2"'2B`Q#O&9K@,ZH
MV?DERM<=Y]A"M3Z_R`"5B"I$`I%$I!!I1(8A7K.U,V?4[-P/J]FA:7OA[VOV
M49V5*3./Z+32G=O'B?^MNJ@@J4`D$:D.1>EG.5]G=!<5TIN`VEWEREC_$ROC
M5L4+>P%[?-QNOJP:JH3F>L\),*?K1'_UZ%P4$\PA)IB/B@5S*!^[2\YQ!EJ=
M`D(QPMY)L2>AQ6E$2D3*HRXSR`2934C3(Y-U1*E,$WN8K49_-2^_THANM9Q$
M<JZ*B>103F?G;KS,K_@!+3+?<7HJN`R(SG9=QVS,.U8^:D)GOB@JN6@77:X@
ML0RHVZ(*Z-4MZK#%S!W/;#X>)SMEND2T.3X6K1O[I<CO&XC.T#&-'<K9CB^2
MO2IH--E!-<DCC3WJ1*A"%`V=UP3U';LE4X:.77H54)=>!S1OU9M?3GO4BW-S
M]:S%2]7+9MU,?N<H=4Z1*>C-(QNEBV08%9GOV-53!G1U$K7RZ*TAZ7-U'67(
MU:57`751.J1WX^^*],/Q%^?F"EKO^)J"[QN"-DOB#QU*AN"$S]8B<U%L"'K4
M%5V%J#>&H.\8#T%(KT*N+KT.B*5?)&NG"5%D:[IY,.EN<C!9[;%&6>E6-'6.
M5\_WGV[:C%QBC_A*NDC.)D7HV!5<>M2NY:=;G["2AB@V!;)D"HB0OAN0,J!N
MBRKDHIG<B9=N48>HJW8M6,PNKV;)YDS(W6Z.2YYZ^?2L_KZU8((>WZ/(R1:(
M2D05(H%((E*(-"+#$-?">N]X5O<XF>@L/7%6/5[_/&(U@Z$O,:I")!!)1`J1
M1F08XC6?Y_%IR4F7+(]8S>CQ,:I")!!)1`J11F08XC5;[QT?YP]>WT^\A^^6
MSI5'_);=(KGS7711P4>5B"I$`I%$I!!I1(8AK@^MMTR?-^:!#4_66(?8F`!4
MVH>+U#&*JA`)1!*10J01&89XS:EM?Z-F=.@3[]"[:Y8"48FH0B00240*D49D
M&.(U6X<8SX,W:G:&DJUW#D5'L+"G1WY02T05(H%((E*(-"+#$*_9>KJXYG;N
MCVDDGOD8=.+-83SY'2(UHM/UHO,Z[F:`[QAI5B*J$`E$$I%"I!$9AKA`UOS%
M`KTQ*)Q79(/"H:C`8@*H1%0A$H@D(H5((S(,L9KITO^<FMMPON!Y%->,J$14
M(1*()"*%2",R#/&:4^/W^G'.T>!YQ&IV41$J,:I")!!)1`J11F08XC6G!L].
M_CD=_#/G?H[.SR.J/)[[Z;.Z+NITXD=4(1*()"*%2",R#'%]SC.#.9I!CZ(!
M4"`J$56(!"*)2"'2B`Q#O.;4#+XQ#]#SY0ZQF@&5&%4A$H@D(H5((S(,\9JM
M\7K_&I\[GQ:O\1ZQFL'-E1A5(1*()"*%2",R#/&:K3V+:_Z@Z;<S/'&['B6F
M/WVHUT5U<]_EHHX!51@E$$E$"I%&9!CB^IQG!G,T@Q[1)D(U!:(2485(()*(
M%"*-R##$:T[-X!MS'RV?O8O$W6Z!J$14(1*()"*%2",R#/&:S_-W]DYD.MS!
MS!4^*CKT):(*D4`D$2E$&I%AB-5,CY9ZYOX'3'^;B#L_C^S$ZN[1+=(',UU4
MF!LEH@J10"01*40:D6&("W2>&;0K73(H/(I&0(&H1%0A$H@D(H5((S(,\9K[
MS.#T_`O!*9I!C_B8N$P?)'51W9APN2(5*XP2B"0BA4@C,@QQ?<XS@U,T@QY%
MU12(2D05(H%((E*(-"+#$*_Y/#,X13/H$:L9S2!&58@$(HE((=*(#$.\YO/,
MH)TAZ=P'YU?XJ$B&$E&%2""2B!0BC<@PQ&ON,X,?N!"<HAGTB"J/S@>7R0.9
MHHOJYK[+%4E6891`)!$I1!J188CK<YX9G*(9]"BJID!4(JH0"402D4*D$1F&
M>,WGF<$IFD&/6,W@#TN,JA`)1!*10J01&89XS>>9P2F:08]8S>`/2XRJ$`E$
M$I%"I!$9AEC-]#D7FD%[G^S,FT!M'NX%/2(QXKF?/KWOHDYS'U&%2""2B!0B
MC<A^U-9=N#A]W$=J[I.A7;U_J(OZZ>DPV#1?[0=HLRD]7CYA]W7<:GJUM$I3
M'6G+;!P^G$M;ICGU:=]N@98IM;2/OZ%E1BWM]V_0,J>6]HH36A;4TK[Y!2V7
MU'+9M]<Y]:'+Q9YZ<NI#%U5]+:0!77KTM$Q)`_+<?2WT62$YT[Z6";6TSQ32
MO<ZI#]W:[.F34Q^ZJ=?70EK3K:^^%M*:;A#UM9#6=!NEKX6T=A,]W;<)]:%G
M:SU])M2'GD#UM9#6])RFKX6TI@<4?2VD-=W&[VG)26N:Q#TM&:GC;EVE>YV1
M.O0F:$^?"6E-[PGTM5`V>IK>UT+9Z)ES7PMI34];>UI(G%YM2)I>94B87EU(
MEEY5,E*%WN/NV7)&%=+;SMBBLNG2OAC:US*CEKZC3&^-4K:^%OI^]E.O6G;S
M/=M867G[N!W(/?S3=/F)EC+<V95=2_HXC=2^'5U1":O>$@IJ*7I;Z"7>I7U%
M%[=>9C-JZ=L.O;^[M.^E8A]ZC7=I7T^EEM%II-*WOB_KA_J?Z_W#]ODP>*KO
M:2D>MV_J[=W7PNZ/HW^O]'-SI(]\Z:Q$GW?25]TU?5E)7[8.!_=-<PQ_V`V<
MOA.__3\```#__P,`4$L#!!0`!@`(````(0"?$(#.;S8``"ML`0`8````>&PO
M=V]R:W-H965T<R]S:&5E=#@N>&ULK-U;<]Q&FJ?Q^XW8[Z#0_4@LDL6#P_;$
MF(7S&3&[>ZV6Z;:B+=$AJ=W=WW[_*&0"^>8#4T3OQFR,/+_-`LAZ@$*]*)'Z
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M9L]?MO[T>PR^[&?V>.,>J#_=`X]O+N^.A^/-]/T^\\!;]T#]Z??XLN]1I]KY
M2]6?^[['>_=`_>GW^++O\:"CZ+S+Z3_V?9<'?SQ,_^'W^K+O\Z!#:-[K>BR]
ML.;!'T#3?_B]'M]<7QYO[\['X3-=#OX8FOYCYS?KCZ+IA/&[?>$WZX^CPWH@
MO?2;]4?2(3B47OK-^H/IL!Y-5\]^Q6_G\_W\\G%Z]_7=C]]_?OK'*[THJ^^7
MW]]-+_&'[Z:M^1>.^:E>7DK^[)5$+R'35OYKVLP/K_4DZ$7BBU[__OCQ<'/W
M_=L_])+UWJWY:6.-7?'@5TRO3]-F3S$D,:0Q9#'D,10QE#%4,=0Q-#&T,70Q
M]#$,,8P!O%6>I9%.I/\?C:;-3(W\L_N3AS7:913$K_`/.<60Q)#&D,60QU#$
M4,90Q5#'T,30QM#%T,<PQ#`&8(+HY0E!KO0BNWVU]>?(]"A=5\TY<F^?\)_<
MFO!$NK9+'I8E2Q1(`DDA&22'%)`24D%J2`-I(1VDAPR0,1332)<!-)I>X'>^
ML$V;T6NCCH3UE>WVPB;Y:5YT]5RU9<E2#9)`4D@&R2$%I(14D!K20%I(!^DA
M`V0,Q513(%/M^3-J6GV.XY_4GV91"2\/D!,D@:20#))#"D@)J2`UI(&TD`[2
M0P;(&(IYXG7L[GCBI]7VB9_E2N]E@O/D8,^3AV61KW."))`4DD%R2`$I(16D
MAC20%M)!>L@`&4,Q+?0D[F@QK;8M9@E/`L@)DD!22`;)(06DA%20&M)`6D@'
MZ2$#9`S%//%Z_[OCB9]6VR?>2?#J`SE!$D@*R2`YI("4D`I20QI("^D@/62`
MC*&8)UZS[8XG?EIMG_A9PB,><H(DD!2207)(`2DA%:2&-)`6TD%ZR``90S%/
M_'1K8,<S?UYNGWI'T2M_/$BLJY:7?E)"2DD9*2<5I))4D6I20VI)':DG#:31
MD,TSC83A>/[\^Z'I;DUT9C@*3PW2B9204E)&RDD%J215I)K4D%I21^I)`VDT
M9%M,T^".%O/PJ,G!'_$_35/$E">X/I!.I(24DC)23BI():DBU:2&U)(Z4D\:
M2*,AVV(:^W:TF*=$;6]M$0Z.YYM-#]-=1^4)3I43*2&EI(R4DPI22:I(-:DA
MM:2.U),&TFC(MIB&N1TMYMG/M'"D-\3!\'`5#0_3C5U[]IQ("2DE9:2<5)!*
M4D6J20VI)76DGC201D,VSS3R[<@S3X@F3S@TNE,%=)KNK=BS)R&EI(R4DPI2
M2:I(-:DAM:2.U),&TFC(MIA&OATMY@G1M`B'1M<"=)H^C9A:W"ZO=PDI)66D
MG%202E)%JDD-J25UI)XTD$9#ML4T!>YH,0^-ID4X1[H6H-/T\4Y\7H!2KLI(
M.:D@E:2*5),:4DOJ2#UI((V&;(MI,-S1PLV1X>5\IF@*B6^=3Q]PV?/B1$I(
M*2DCY:2"5)(J4DUJ2"VI(_6D@30:LGFF\7%'GGG:-*=*.("Z4P5T.H`24DK*
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ME)%R4D$J216I)C6DEM21>M)`&@W9/--`O2///'^;/!C)'RY!)U)"2DD9*2<5
MI))4D6I20VI)':DG#:31D&VQ;Y:_Y"SO*;R$N%4KG;@J(:6DC)23"E))JD@U
MJ2&UI([4DP;2:,BVF`;J'>?%/'^;\P(C^<,EZ$1*2"DI(^6D@E22*E)-:D@M
MJ2/UI($T&C(MIK\?NJ/%>;F]G'O2JW\PA=Q&EY!UU7()(26DE)21<E)!*DD5
MJ28UI);4D7K20!H-V3S[9ODKSO*.PG=;I!,I(:6DC)23"E))JD@UJ2&UI([4
MDP;2:,BVB&?YY__6PQ4'=D?!!R`/I!,I(:6DC)23"E))JD@UJ2&UI([4DP;2
M:,BVV#>=7W$Z=V3."T[G7)604E)&RDD%J215I)K4D%I21^I)`VDT9%OLF\ZO
M.)T[BCXFB7Y0YV%=M5Y"YFT%)U3"52DI(^6D@E22*E)-:D@MJ2/UI($T&K)Y
M]@WL5QS8'9E3A0,[5R6DE)21<E)!*DD5J28UI);4D7K20!H-V1;3B/SR=[YZ
MQN.;)Y[6D>.!="(EI)24D7)202I)%:DF-:26U)%ZTD`:#=D6^Z;SZ<4INI'E
M2+OP+T@/I!,I(:6DC)23"E))JD@UJ2&UI([4DP;2:,BVV#>=7W$Z]V2GD.CG
MV![65;[8B9204E)&RDD%J215I)K4D%I21^I)`VDT9//L&]BO.+`[,J<*!W:N
M2D@I*2/EI()4DBI236I(+:DC]:2!-!HR+:[W#>SGY79@=Z2ST9\$#Z03*2&E
MI(R4DPI22:I(-:DAM:2.U),&TFC(MM@WG5]S.G<4GA>D$RDAI:2,E),*4DFJ
M2#6I(;6DCM23!M)HR+;8-YU?<SIW-%VEUAM9=]$/U3ZLJ_S9<R(EI)24D7)2
M02I)%:DF-:26U)%ZTD`:#=D\^P;V:P[LCLRIPH&=JQ)22LI(.:D@E:2*5),:
M4DOJ2#UI((V&;(M]`_LU!W9/P3M?THF4D%)21LI)!:DD5:2:U)!:4D?J20-I
M-&1;[)O.KSF=.S+G!:=SKDI(*2DCY:2"5)(J4DUJ2"VI(_6D@30:LBWV3>?7
MG,X]F2GD+OYY\W75>@EQVUI/J(2K4E)&RDD%J215I)K4D%I21^I)`VDT9//L
M&]BO.;`[,J?*O"J@$U<EI)24D7)202I)%:DF-:26U)%ZTD`:#=D6^P;V:P[L
MGM8C_H%T(B6DE)21<E)!*DD5J28UI);4D7K20!H-V1;[IO-K3N>.@I/@@70B
M):24E)%R4D$J216I)C6DEM21>M)`&@V9%L=]T_EYN9W.'4532/R#Z^NJY1)"
M2D@I*2/EI()4DBI236I(+:DC]:2!-!JR>?8-[$<.[(["4X5T(B6DE)21<E)!
M*DD5J28UI);4D7K20!H-V1;[!O8C!W9/P26$="(EI)24D7)202I)%:DF-:26
MU)%ZTD`:#=D6^Z;S(Z=S1^:\X'3.50DI)66DG%202E)%JDD-J25UI)XTD$9#
MML6^Z?S(Z=R3G4+B'UQ?5ZV7$+>M]81*N"HE9:2<5)!*4D6J20VI)76DGC20
M1D,VS[Z!_<B!W9$Y53BP<U5"2DD9*2<5I))4D6I20VI)':DG#:31D&TQ3<TO
M_SC]Z(;LX`=T/:U'_`/I1$I(*2DCY:2"5)(J4DUJ2"VI(_6D@30:LBWV3>='
M3N>.S'G!Z9RK$E)*RD@YJ2"5I(I4DQI22^I(/6D@C89LBWW3^9'3N:-H"HE_
M<'U=M5Y"YFT%'RXF7)62,E).*D@EJ2+5I(;4DCI23QI(HR&;9]_`?N3`[LB<
M*O.J@$Y<E9!24D;*206I)%6DFM206E)'ZDD#:31D6MSL&]C/R^W`[BFXA)!.
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M]@WN-QS</=E+2/R#Z^NJ]1+BMK6>4`E7I:2,E),*4DFJ2#6I(;6DCM23!M)H
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M3QI(HR&;9]_`/OV;O-$/Z#HRIPH'=JY*2"DI(^6D@E22*E)-:D@MJ2/UI($T
M&K(MIJGYY9^TW[HA._BDW5-X"7&K5CIQ54)*21DI)Q6DDE21:E)#:DD=J2<-
MI-&0;;%O.K_E=.[(G!><SKDJ(:6DC)23"E))JD@UJ2&UI([4DP;2:,BVV#>=
MWW(Z=Q1]TA[_X/JZ:KV$S-L*/VGGJI24D7)202I)%:DF-:26U)%ZTD`:#=D\
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MMPWC>P#/?T)_ST'?T_J5/Y!.GL*O_'`?_<7[9%WEO_34T[KYC)1[LIN/_E)F
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M;]XX,J?*O"J@$U<EI)24D7)202I)%:DF-:26U)%ZTD`:#9D6AXM]=V_F]?9J
MMY@]6Z(7ZX=@V7*Z;%BR8>F&91N6;UBQ8>6&51M6;UBS8>V&=1O6;]BP8:.U
MJ-B^&SJ'"][1\1:<+<HSKPOLM&'*@W7*`U,>F/+`E`>F/##E@2D/3'E@R@-3
M'ICRP)0'ICRA17GVW:LY7/!FS6+KVU7E<>M64QZ8\L"4!Z8\,.6!*0],>6#*
M`U,>F/+`E`>F/##E@2D/3'E"B_+LN^5RN.`]%V_!F:(\\[K`E`>F/##E@2D/
M3'E@R@-3'ICRP)0'ICPPY8$I#TQY8,H#4Y[0HCS[[IP<+GCK9+%U9E0>MVXU
MY7&FM^++E':XC][DJ=BRS%^V5`R;4S&8BN&Q*@93,3Q6Q6`JAL>J&$S%\%@5
M@ZD8'JMB,!4+'QL5VW=/Y'#!FR*+K754S*U;3<6<V6+1&PT56Y8%Q;`Y%8.I
MV/+8\*"([B<HXK+,[T(1L3E%A"DB'JN(,$7$8Q41IHC+8]<O&9\W!*O\5ZRL
MX=:BK-,MC)?_1,?APMWR"'ZD8[$UH;*Z=:LIJS.;-;HIIJS+,O\=Z$3$YI05
MIJS+8]?GZ'`?W3Y3UF69WX6R8G/*"E/6Y;'A+J(C1Z6797X7*HW-J31,I9?'
MAKN([M+I#%Z6^5TH=;BY*/5T+V)/ZFE]/`(X6[,J-4RIG>F/X#4WNA&HU,LR
M_QTH-3:GU#"E7AX;[B*Z^:;4RS*_"Z7&YI0:IM3+8]==\!.)8)G?A5)C<TH-
M4^K-741WW)1Z6>9WH=3AYJ+4^^Z,'"YX:V0QD]JM6TVIG>FK65)?7O#RNBSS
MWX%28W-*#5/JY;'A+J+K@5(OR_PNE!J;4VJ84B^/?687.JN797X72HW-*35,
MJ9?'!KO`+>Q@F=^%4H>;BU+'=UFFOS=^.+Z9?HCOZZ\?WO_MIZ<)7K_:^"SY
M2C==W[_Z_,/K_SI<\.[+8MIY4#9ZO=;Y[QYJ#@IWFT9W'8*'1J_#.O^79?Y[
MU4&!S>F@@.F@6!X;[B)ZD=1!L2SSN]!!@<WIH(#IH%@>&^XB>A730;$L\[O0
M08'-Z:"`Z:!8'NL^THB.:IWZRPJ_=1T/X9;L\7"(;_3$Q\-_/_W^9\?#Y713
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MJLX70!U,,!U,,+W6P'1]@NDP@>DP@>F8@.D`@.D`@.D`@*DV3&UA:@M36YA"
MPI0MM"C;=$LIS/:M/.X6E,GC;+TGKCPPY8$I#TQY8,H#4QZ8\L"4!Z8\,.6!
M*0],>6#*`U,>F/+`E">T*(]>J7?EF=;';PMG"^Z)*P],>6#*`U,>F/+`E`>F
M/##E@2D/3'E@R@-3'ICRP)0'ICPPY0DMRC/=SMES]KC;/^;L<:8_@C=#T:"D
M8LLR_[JH8C`5@ZD83,5@*@93,9B*P50,IF(P%8.I&$S%8"H&4S&8BH46%9ON
MRNPI-JV/3ZC9[`D%4QZ8\L"4!Z8\,.6!*0],>6#*`U,>F/+`E`>F/##E@2D/
M3'E"B_),=U+VY'%W7LP)-5OP*U=T]L"4!Z8\,.6!*0],>6#*`U,>F/+`E`>F
M/##E@2D/3'E@R@-3GM"B/'J'ORO/M#X^>YR9=PLPY8$I#TQY8,H#4QZ8\L"4
M!Z8\,.6!*0],>6#*`U,>F/+`E"<TFV>Z0[(GSWE]E,?;>KOPX4`[+::7VN"R
M%=U\2X)E_K*5;EBV8?F&%1M6;EBU8?6&-1O6+G9^"J)G>)JU=[P^Z4X.3@!O
MX0E`TS/L'FN?X>AVGI[A95GP#,/T#,/T#"\61+R,[F'H25^6^5WH28?I28?I
M25\LW$5T&U4=EF5^%^H06M1A&D3W='"#:WB=F.YF32].I@-,'18+OX/X;X,'
MR_QWH"-]>:@W=8"IPV+A+J(/:=1A6>8WIPXP=8"IPV+A+J+O0AV697X7ZA!:
MU&&:+/=TF"=1,]U?.C,=8.JP6/`=7$2W9'4^+,O\=Z`.,'6`J<-BP2[BSX#4
M85GF=Z$.,'6`J<-BS^Q"'99E?A?J$%K481HA]W1P(Z<Y'YR95WZ8.CC[LQ_S
M4()EA?_BE0!;4@*8$BR/W?[$1<_^LL)O7<\^MJ1G'Z9G?WFLVWITCNF)7U;X
MK>N)#[<4/?'3<+CGB9^'27L".-->UDOI971@ZRJ\+/-?F5HL%CR4MT\WE\7W
M%-5H:VN7T7U<95N6^2]$V19[Y@M1NZUEE]&PJYR;RZ(O1(679?X+4>'%GOE"
ME'ES673E4_EEF?80E9^&S+#\]%G+S?5T;_T;]]`NW7AJ3K[9IE,\.`:BMU,Z
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MN;:6!:?`^717P669/PI5$*:"BX5[C2X<*KBU+-BKC7H5WY?X-__2RWD[T?T*
M9_8LO(ZN.0^'=9G__D^!!=\KWSRM#PV6Q1_TI]M;"YX2][J[;LU_(?GV0^,O
MI-A>%K]&E'^R+'I=JH)E_@NI`PN^U?@+:;:7Q>_BVC]9MGXAT4$R3?OAF?^-
MEV2]4.+6BC-S9YZF\O-C@W7)AJDIUF4;IH!8IUHPI8&I`TP=8'K287J&8=V&
M]1LV;-AH+<HSW038D\?=-`A?A*_"&PGN<WR:\F"=\L"4!Z8\,.6!*0],>6#*
M`U,>F/+`E`>F/##E@2D/3'E"B_),]P;VY''W$DR>V8*S0J^;,.6!*0],>6#*
M`U,>F/+`E`>F/##E@2D/3'E@R@-3'ICRP)0GM"B/WBCLRC.MCZ]TLYE_@^#R
M&N/$])Y$#PT^_E(QF(K!5`RF8C`5@ZD83,5@*@93,9B*P50,IF(P%8.I&$S%
M0HN*39/_GA/*W2DP)]1L]H2"*0],>6#*`U,>F/+`E`>F/##E@2D/3'E@R@-3
M'ICRP)0'ICRA17FF:7Y/GGGZ-P.<NN`#`)KR8)WRP)0'ICPPY8$I#TQY8,H#
M4QZ8\L"4!Z8\,.6!*0],>4*+\DSS^YX\;MXW9\]LVHM_@ZK+$4QY8,H#4QZ8
M\L"4!Z8\,.6!*0],>6#*`U,>F/+`E`>F/##E"2W*,PW@89YI(+NZ.]\)>?_W
M+U^?/N:/'_YZGM*^>6OD:A[F[9GE3`?(>JOA.OK03S679;ZP:L)4$Z::,-6$
MJ29,-6&J"5--F&K"5!.FFC#5A*DF3#5AJAE:5',:QL.:WYJ<W/!N3K;9[,D&
M4QZ8\L"4!Z8\,.6!*0],>6#*`U,>F/+`E`>F/##E@2D/3'E"LWFNX[L?W\AS
M7A^]]W.F4]J?*0\'VFG#D@U+-RS;L'S#B@TK-ZS:L'K#F@UK-ZS;L'[#A@T;
MK45YIAEZQ]ES/<_<YO7.F3E[:,J#>5UY8,H#4QZ8\L"4!Z8\,.6!*0],>6#*
M`U,>F/+`E`>F/*%%>::9-\QSOFE_G#YFVWNENG;C<_BZY\U>J:*/-W2NA9/W
M^<Z%8L(4$Z:8,,6$*29,,6&*"5-,F&+"%!.FF##%A"DF3#%ABAE:%'.:D,.8
MWWHIG"=J>ZZ%4[:[B70-4QZ8\L"4!Z8\,.6!*0],>6#*`U,>F/+`E`>F/##E
M@2D/3'E"B_),X_">///X;/,X"]^U7\.4!Z8\,.6!*0],>6#*`U,>F/+`E`>F
M/##E@2D/3'E@R@-3GM"B/-,XO"?//#[;/.%([<\>F/+`E`>F/##E@2D/3'E@
MR@-3'ICRP)0'ICPPY8$I#TQY8,H36I1G&H?WY''CL[D<S3:-;L'@%'WNK<O1
MLLR_'50QF(K!5`RF8C`5@ZD83,5@*@93,9B*P50,IF(P%8.I&$S%0HN*31/R
MGF+S1&U/J'#*]B<43'E@R@-3'ICRP)0'ICPPY8$I#TQY8,H#4QZ8\L"4!Z8\
M,.4)+<HSC;Q[\K@1V9Q0X=CL\\"4!Z8\,.6!*0],>6#*`U,>F/+`E`>F/##E
M@2D/3'E@R@-3GM"B/-/(NR?//"+;LR<<FWT>F/+`E`>F/##E@2D/3'E@R@-3
M'ICRP)0'ICPPY8$I#TQY8,H3FLUSW'G;X;P^NNW@32^AP>5H_03?%5N7K9<C
M6G*@I1N6;5B^8<6&E1M6;5B]8<V&M1O6;5B_8<.&C=:B8M,4O..$.LY3LSFA
MG)D[$;33@:8\X11^3JL\,.6!*0],>6#*`U,>F/+`E`>F/##E@2D/3'E@RA-:
ME&>::_?D<7-P>#DZAK.Q/WM@R@-3'ICRP)0'ICPPY8$I#TQY8,H#4QZ8\L"4
M!Z8\,.6!*4]H49YIKMV39YZ#[=D3SL8^#TQY8,H#4QZ8\L"4!Z8\,.6!*0],
M>6#*`U,>F/+`E`>F/##E"2W*,\VU>_*X.=B</;-%TQ'^$N=Q619<CF`J!E,Q
MF(K!5`RF8C`5@ZD83,5@*@93,9B*P50,IF(P%0LM*C:-NGN*S:.Q/:'"<=F?
M4#"=4##E@2D/3'E@R@-3'ICRP)0'ICPPY8$I#TQY8,H#4QZ8\H06Y9GFVCUY
MYCG8YG$6WJP[PI0'ICPPY8$I#TQY8,H#4QZ8\L"4!Z8\,.6!*0],>6#*`U.>
MT*(\TUR[)\\\!]L\X6SLSQZ8\L"4!Z8\,.6!*0],>6#*`U,>F/+`E`>F/##E
M@2D/3'E@RA-:E&>::\,\T\=*TYN_O1\J'=V`;*Y3R]`<CDW17]U_./B'KF>?
M4BX/]=<NI80I)4PI84H)4TJ84L*4$J:4,*6$*25,*6%*"5-*F%*&%J6<9N`P
MY3\/U^_>?_?SOTZ/7]X_?E+7B^DOMBR_.O,XS\SV3`OG:'^FP90'ICPPY8$I
M#TQY8,H#4QZ8\L"4!Z8\,.6!*0],>6#*`U.>T&R>FYWW(<[KH_L0WM8SY4&_
M;U'9M6ZUTX8E&Y9N6+9A^885&U9N6+5A]88U&]9N6+=A_88-&S9:B_),`^^.
ML^=F'I#-V>/,W'2@*4\X7)_/,N6!*0],>6#*`U,>F/+`E`>F/##E@2D/3'E@
MR@-3'ICRA!;EF0;>/7G<@!Q>CFYFB\:FZ&>Z=$(MR_RE1\5@*@93,9B*P50,
MIF(P%8.I&$S%8"H&4S&8BL%4#*9B,!4++2HVS<![BLTSLSVAPCG:78YN8,H#
M4QZ8\L"4!Z8\,.6!*0],>6#*`U,>F/+`E`>F/##E@2E/:%&>:>#=DV<>D&T>
M9^NE1V</3'E@R@-3'ICRP)0'ICPPY8$I#TQY8,H#4QZ8\L"4!Z8\,.4)+<HS
M#;Q[\LP#LLT3#LW^[($I#TQY8,H#4QZ8\L"4!Z8\,.6!*0],>6#*`U,>F/+`
ME`>F/*%%>::!-\SS[_]MO!LW.YLKU3)/!X/3$3_,ZQ^ZGG^*N3S47[T4$Z:8
M,,6$*29,,6&*"5-,F&+"%!.FF##%A"DF3#%ABAE:%',:C\.8WQB<;N9QVIYK
MX8CMSS68\L"4!Z8\,.6!*0],>6#*`U,>F/+`E`>F/##E@2D/3'E@RA-:E&<:
M>??D<2.R.:'"L=GG@2D/3'E@R@-3'ICRP)0'ICPPY8$I#TQY8,H#4QZ8\L"4
M!Z8\H45YII%W3YYY1+9G3S@V^SPPY8$I#TQY8,H#4QZ8\L"4!Z8\,.6!*0],
M>6#*`U,>F/+`E"<TF^=VYVV'\_KHMH,WO82N?_WA&/UFH8?#NLQ?>DX;EFQ8
MNF'9AN4;5FQ8N6'5AM4;UFQ8NV'=AO4;-FS8:"TJ-DW!.TZHVWEJ-B>4,W,G
M@J8\X<1]/O&4!Z8\,.6!*0],>6#*`U,>F/+`E`>F/##E@2D/3'E@RA-:E&<:
M>??DF4=DF\?9^L9-9P],>6#*`U,>F/+`E`>F/##E@2D/3'E@R@-3'ICRP)0'
MICPPY0DMRC.-O'ORS".RS1..S>YR=`M3'ICRP)0'ICPPY8$I#TQY8,H#4QZ8
M\L"4!Z8\,.6!*0],>4*+\DPC[YX\;D0.W\S=AF.SSP-3'F=Z:[E>M@[1_3X5
M6Y;YRY:*87,J!E.QY;'!+BZC'_!5Q&69WX4B8G.*"%/$Y;'/[$)=EV5^%^H:
M;B[J,,VV>SK,L[`]39R95S&8.C@S'2ZC7]BA#LLR_QVH`S:G#C!U6!X;/DG1
M+M1A6>9WH0[8G#K`U&%Y[#.[4(=EF=^%.H2;BSI,8^F>#FZ,->=#.-KZ\P&F
M#LY,AV/T)*G#LLQ_!^J`S:D#3!V6QP9/TI'GP[+,[T(=L#EU@*G#\MA@%_'O
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MT5>L-'BHTF`72H-U2F-V<7>\N-+_B_]U1?-`&^9NYPV`\_KH)<R;OI3UF3SB
MYQ_\LO",\1:>,<[<&7-]I1_V/!ZCO[Z:'OC(;+%U#_EBZQX*;VX/^B=+;X[Z
M\-\^:Z5?I7])Q!\TU6+K'NK%UG6--_M;B.-OHO7+YEU$8:89,SQC_KU+SMT\
MJIH3R5ET(N$O7OEEZU%^.GA;O_]DL?DWW5]=Z<F\C>[^*-?\=6B?_LE4+F?K
M#I3+V;H#Y7+F_H'/NYOC]<5]=$`H%_:@7-B#<F$/RF7V<'-[>W\37:+4*MQ^
MU&H:.-'J_^D?$+US,^SZ?/UT\*;W[<MY=LML[I'K,ZALL^D70?MG7]F<S?^`
MYO7]W?7MQ57TK*J;V]IZ<*L;]J!NV(.ZF3U<7E_=WUP<X]_LK7#8A<)A%PJ'
M72B<V85^@<GUS>U%="8K7;B'*-TTC")=\,[NA>\D[N:AUIYGX:#KWGF[=<&M
M-]7!.M6!J05,+6!J`5,+F)YXF)YXF)YXF)YXF)YF6+=A_88-&_9_.3O;Y;:M
M*XJ^BB8/4!,@P*])/6.+LDF;=$B_@=K23J9.E9'5Z>MW;8!B+K"WFK!_.,G:
MO`!TEH&#2Q#@YR$;:=/<M=3V!^<3B_-<=[`[]6SPM*#S^PJ&'GL?>HRAQQAZ
MC*''&'J,H<<8>HRAQQAZC*''&'J,H<<8>HRAIV0C/9K27J/G/`4>Z.E9L:?<
M5@MCZ#&&'F/H,88>8^@QAAYCZ#&&'F/H,88>8^@QAAYCZ#&&'F/H*=E(CV:Z
MU^@YSXP'>GHV_+I<.YK98.SRMN?.@S%C&#.&,6,8,X8Q8Q@SAC%C&#.&,6,8
M,X8Q8Q@SAC%C&#.&L9*-C&DN?(VQ\]QY8.P\QRX_:5@80X\Q]!A#CS'T&$./
M,?080X\Q]!A#CS'T&$./,?080X\Q]!A#3\E&>C3SO4;/>:8\T'-F`SW&T&,,
M/<;08PP]QM!C##W&T&,,/<;08PP]QM!C##W&T&,,/<;04[*1'DV2K]'33ZJ'
M)W/GB?9`CS'T&$./,?080X\Q]!A#CS'T&$./,?080X\Q]!A#CS'T&$./,?24
M;*AG.?X,XO__NERWJ-''$\^,H^MEVE2/I_NWU>]O^[U3.;L+[WL7V/O`-H%M
M`_L0V,?`=H'M`_L4V$^!'0([!O9YR$8R-4V^8E];]M/JP;YV9H-3/V?KRAEZ
M^N458]%C##W&T&,,/<;08PP]QM!C##W&T&,,/<;08PP]QM!3LI$>386OT7.>
M.I>=:GEFY:'0&7KL?>@QAAYCZ#&&'F/H,88>8^@QAAYCZ#&&'F/H,88>8^@Q
MAIZ2C?1H"GV-GG[*/=Q[;!K.P<T8>HRAQQAZC*''&'J,H<<8>HRAQQAZC*''
M&'J,H<<8>HRAQQAZ2C;2HRGO-7KZ*?)0SYD-V]'H`U.,7=Y6M"-C&#.&,6,8
M,X8Q8Q@SAC%C&#.&,6,8,X8Q8Q@SAC%C&#.&L9*-C&D6?(VQ?M8\-%;.I,^?
MXRV-L4,90X\Q]!A#CS'T&$./,?080X\Q]!A#CS'T&$./,?080X\Q])1LI$=3
MWFOT]%/DH9XS&[0C8^@QAAYCZ#&&'F/H,88>8^@QAAYCZ#&&'F/H,88>8^@Q
MAAYCZ"G92(^FO-?HZ:?(0SWEM/EY[S&&'F/H,88>8^@QAAYCZ#&&'F/H,88>
M8^@QAAYCZ#&&'F/H,8:>DHWT:,I[C9[S%'EP,M>SX>=XXZM?M*/+VXIV9`QC
MQC!F#&/&,&8,8\8P9@QCQC!F#&/&,&8,8\8P9@QCQC!6LI$QS8*O,=;/FH<[
M5#F3?MZAC+%#&4./,?080X\Q]!A#CS'T&$./,?080X\Q]!A#CS'T&$./,?24
M;*"GGHP_B?C?EY7Z]P\_;KBPHAT%M@[L+K!W@;T/;!/8-K`/@7T,;!?8/K!/
M@?T4V"&P8V"?AVRD1_/:/[_WU)-^'ESN/<^L^'S@-C#TE'/H;B]#CS'T&$./
M,?080X\Q]!A#CS'T&$./,?080X\Q]!A#CS'TE&RD1_/::_2<Y\%%.ZHGE[EQ
M^6'=Z!M-&+N\[=*.`L.8O0]CQC!F#&/&,&8,8\8P9@QCQC!F#&/&,&8,8\8P
M9@QC)>N-O?K^\^GTM+Y_NG_]XZ^GQZ^GV].W;]]O_O[P;ST(J.9Y:@6_>3Q]
M^>L/;]DQ5]W>2<4O8RY9I:S2UTL\JY5UDL<9,[<5!^3NJRJ>M<K:M$S.695U
MAU@?-U?6?=7%LX6R15[F4EGW11<;M]`XKC"$OX]/MI7E<4MJID]+T[@E-=-'
M=3&C9OJ<*&939=V7IFP[Y\JXP2*-6RCC.QHQDP<NZ,=,'KB:'#-YX+IES.2!
MBV8IFRGCKMZ8J=;<4AHSU9K[&5,V5ZVYRS!FJC6W;<5,M>:>H93--(X'S\1,
MXWC$2<Q4:YZO$3/5FH<[Q$RUYLD",5.MN5$]9:W&L=O&3.-X!E_,Y($'P,5,
M'GBB6,SD@<=9I6PF#SQW*F6-QO$X[I2U&L?#KV,F#SQX+F;RP"-O8R8//&\U
M9O+`DSU3UF@<OP$3,XWC!TAB)@_\^D7,Y('?68B9//"0_YC)`T^83]E4X_IO
M*]FQ8*IQ_"!>'"</_!I;RAIYX&?38B8/_`Y5S.2!GS5*V53C^!WNF&D<7\..
MF3SPB\$QDP=^FS9F\L`/H\9,'OKS/ZM9I656>9F5EEGE959:9O^0-5^F'%79
M;25'5794R5'_U>#Q,I=$+W0J=>F*>4SZRR>RD+MT-9&%%[KT1!8FV4*EK(K9
M@J+DWK"@)+DSJ-'F/JLVF[OLDJ7E?K]D:;G;+R@37R$/55I0)+[KFQ)*Q%=)
M4T(1<F==\`\J]]4%_YQR5YTSAIOSPGKFC.%VL910:VY@2@G5X5::E%`=[ME(
M";7FIH&0S!B3>_.,,;DSJS'GOCRGUKDKSZEU[LDZQ<EG.#/&Y'X\8TSNQC-J
MG7OQC%KG3CRCUKD/Z[0FG]6TC,D]N&5,[L`MM<[]MZ76N?NJ^>;>JU.9?":C
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MR8YD'Y,#R3$F:RYOW,6K&QN2;4QV)/N8'$B.,5ESJ>0N7BG9D&QCLB/9Q^1`
M<NR35Y<3R>^O?_SM_NMI?__X]9=_?;_Y=OK"A;#)7VB7-X^_?-4-"?W_/#W\
MQO7^'V[^]O#T]/!K]Y\_G^[_<7K4&WCSEX>'I^?_X>3DU7\>'O_976Q[_5\`
M``#__P,`4$L#!!0`!@`(````(0`UBF%_F@,``+$-```8````>&PO=V]R:W-H
M965T<R]S:&5E=#<N>&ULE%==;YLP%'V?M/^`>&^(R5<3):G:5=TF;=(T[>/9
M`1.L`D:VT[3_?O?:A`).%GA)X.9PSOWP,<[Z[C7/O!<F%1?%QB>CL>^Q(A(Q
M+_8;__>OIYM;WU.:%C'-1,$V_AM3_MWVXX?U4<AGE3*F/6`HU,9/M2Y70:"B
ME.54C43)"O@E$3*G&F[E/E"E9#0V#^59$(['\R"GO/`MPTKVX1!)PB/V**)#
MS@IM223+J(;\5<I+=6++HSYT.97/A_(F$GD)%#N><?UF2'TOCU9?]X60=)=!
MW:]D2J,3M[EQZ',>2:%$HD=`%]A$W9J7P3(`INTZYE`!MMV3+-GX]V3U$,[]
M8+LV#?K#V5$UKCV5BN-GR>-OO&#0;9@33F`GQ#-"O\88@H<#Y^DG,X$?THM9
M0@^9_BF.7QC?IQK&/8.*L+!5_/;(5`0=!9I1.$.F2&20`'QZ.<>E`1VAK^;[
MR&.=PM7MB$S'<T![.Z;T$T=&WXL.2HO\;X6IF"Q'6''`=\4QF8]FB_&$7"<)
M;#ZFO$>JZ78MQ=&#-0.2JJ2X`LD*B,_7`X4@]A[!&W_N>Y"K@B&\;,ELN0Y>
MH'%1A7FP&/A\Q]2(`$1K95#KKXQ@5,;.8BH/-M"4"<_+3(;(('CCP^=[\O-Q
MS6N5+6;:P$QK1*M`@/0O$,$P`RBK(4UJ8BMM03VD85'UET:PD:Z;:R-3XXCF
MR&#R_6D1W*:M(F"^1HT7QK88(H7@MI2-N!7@?MQ[N2.X35M%B-.9Y1!>!+=Y
M;<1-ET"OFOGBMA.2Q0@&=,6I^&!;PW!!J.D9,I_42ZRU=A'5%+ZBANB.F@V=
M*6F0[]$07>8JY`Z!#/*Z07>2/GD;7P7-A4\Z7C9SN"6XUU\;1&WLVEV&S!G$
MA4T$7S(#!F&="UU[5[.A,X,8Y&;BVOD4.C.(0>XEKGVKT)FD.P8V[V$RZV$(
MU\RD=G-S/YI=,,0@AQ/7XE7(+2GL>/S_5C/H]JH]A=PYA(-<;-`=ZDLN#CLN
M-G.8`OI*]JZ=#9/CAOGY*82#'&[0G8(N.3SL./Q*':ZK#8&IH[MYX";1W\(&
MW4GZDH7AQ-MB[OUZ,`]V1"J#PPP;;^=%9P[V@&Q/D#F3>_:)99GR(G'`PV\(
M9\(Z6A_,[\UNU(U/5_>0!?:J_@4.S"7=L^]4[GFAO(PEP#D>+:!\:8_<]D:+
M$G*'<[/0<%8VERG\-6)P+ASC3I`(H4\W*%#_V=K^`P``__\#`%!+`P04``8`
M"````"$`9VUT^:0(``!$*```&````'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;)R:VV[C.!*&[P?8=S!\GU@\Z!3$&;1$],X`,\!BL8=KQ582HVW+D)1.]]M/
M4<58K)(LR],722?^5*J?5>1/*7S\]<=AO_A>ULVN.JZ7XCY8+LKCIMKNCJ_K
MY7__\_4N62Z:MCANBWUU+-?+GV6S_/7I'[\\?E3UM^:M+-L%1#@VZ^5;VYX>
M5JMF\U8>BN:^.I5'^.2EJ@]%"S_6KZOF5)?%MKOHL%_)((A6AV)W7&*$AWI.
MC.KE9;<I3;5Y/Y3'%H/4Y;YH(?_F;7=J/J,=-G/"'8KZV_OI;E,=3A#B>;??
MM3^[H,O%8?/P^^NQJHOG/>C^(72Q^8S=_3`(?]AMZJJI7MI["+?"1(>:TU6Z
M@DA/C]L=*+##OJC+E_7RBW@P.EZNGAZ[`?K?KOQHO/\OFK?JXY_U;OO'[EC"
M:$.=;`6>J^J;17_?VE_!Q:O!U5^["ORK7FS+E^)]W_Z[^OBMW+V^M5#N$!19
M80_;GZ9L-C"B$.9>AC;2IMI#`O!U<=C9UH`1*7YTWS]VV_9MO531?1@'2@"^
M>"Z;]NO.AEPN-N]-6QW^CY!PH3"(=$'@NPLBPGLMPSBY)8IR4>#[9Q1Y<RK:
M!8'O?1"9A"*,K@M:X>!T8VV*MGAZK*N/!30PR&].A9T.X@$B?PXR#LEYV"^-
M.@RW#?+%1EDOH^4"!K2!5OG^)$3RN/H.Y=TX)D,&OO8,)?)AE"B@B/E$;..`
M@K,,J(\O8[Q'/K.UL,W6]HQ-/\-?^*E)>M]\2(B8(F:(1.*,D&2A#>8G:V%H
M77_81'J.B_DC`^4[#ZVF1'Z5,%,$R1YN,S]["Z^7,#3GS&*66H9(W'7-G11*
MA6G">B<GC$B36*0!8PQAHB0*`M5W#U$`T]]78'M>P?(TW33V(E8'V<?'.B`#
MB9S5,K'Y5<),$40%S#9?Q73V%J9U$++O3LP>F:0KA%3>X'4?Y_BQ[CY6L:(-
M9CX_[:7+?@Z1O.-;\K8PS[N/BWDC@WE#9_`A]S]6<12E?&4R/@']%R2ZGV`D
M=;NU\!;+Z2&W,$^=C5J&#*8NP)E2H=BRDON(2J32+(8A0`S3YUP9DGMZ2^X6
MYKFS<<V0P=R5C.,X.M\8&\8'P`XBU8]J!Q@$_.ERJ6<$3$]_Y.=-V>XJ*D.S
MX<T<@S+B))9,9DZ`*`TUDVD<,$N&M2^O@6;*0-,CBRA?>00R3@9DF<8,R0DB
M9`(%B_M>P8H01D5)HL*^W4@["6MWMTM!DR1N)ED261=ZO?0'=%`4C#.!F,DH
M5(JU/D_*]+06:)1^-81D/9$Y",MQEZ1IT@\C3@Y"B"B0G#"$N!.)C#W+HP)@
M'&X08&DZ*R3STDP@@_F'41C';.[FA+@+8Q&P9=D00DF9]B%H]M;QY@\_^J,_
M_+(/W(UM9I\20"%FKZ'3V<)$/E<"G@E8?QE*1&DJ^Q@T>>M[\Y-'E_23%UYD
MESU"KG>DB.!Q@^67"\I(%8=\%`QE1)BHU)OO5(5UP/DJT"_I)!YT$$(3,S07
M5Q$SB5`)U@;G2T#3I(48M)'OK'<JXGN>7!`@@;T';33C`'\0+CJ<-</Y^:-U
MDOSYABT3O@&/YD^`L?P1F)._9`X]O8AV--M-*S9ZF8/\N_-Y<!TQDPAI(?FW
MW+F[BBZG0K&U,'.0+\5K!'0$Q^"\5SK5L'*Q?J*(A!=2WEZ6:H'6\-MIWDY#
MVJNX%N9<F8,P3PG_4L4?)7+'3.DUTPQ5PQS:JM&PR%]ILA&G5JR#,HF04Q-T
M_^BHYPZ9%H-A+C!4#$!^::Z(L#0O"=\Q282<98A4IZQHN2,NY-<UH*%15)JF
M_1:2*F"./;,<0^<6BF^<[)LLD#N59^X85!L&L'GJ\W1*,`H2`C;#'D&5,/N>
M.4U&;)P_MV72MVBI99`F?#[GA($!M]M`VGR&(@K6!0^A6FXR<8GF2QV$W3QS
MD)L<,M#PVH6MTCEA1*S3R$O0E0/OY<H1AT%ZZ:E"WN3B'<WG!G=Q!^'-52BE
M#EF[Y`01<2P3OC@;@DAXF.UO0XM@'7.VC4OT5U($S;++'.2*$(:15N&@"+Z3
MCXHT)`P72338=V'S-70TLW+-\LL<Y$]KMA#GUQ$SB5`)S,JGUU@U?,`6FENX
M@WP)O$OR&8R99J@*9N)75(R8-W]9E"F$W%2$5TYTN<G=YU,JS31#%8P8MZWB
M%25HIO#U_!Y5:-8OF1HZ+D/RZXB91*@4&!-_5LPS/66O8DN4YO;M("P*>!7\
MXV7!,--EF62HEA$#GU&6$0/G;\,RY5MO%*3#.8+`M)1)ADH9<?#K6T,UXN"#
M5X,.PK+$<3+P#0=,2\$[^4S?IE0)\^^9#3;BXYK[N/(-.$H"#7\QY!V&B)\G
M+YUQ82XP5`PS\GD;*X4/U-0/>Z?M=A.9@[`L6BDEHL$JAG$N)(J;$A?F`D/%
MW&3J:L34>>MD#G+K<!+%_#50[H@+^3D->*L+#-&@F:G/ZZ[N*K9\\<U'YJ`+
M6729YHYQ>N-(!+QHAB!IHG74]RB5PLQ]II01DP^YR6N$IJ4@@U(2I89"?$!&
MRIMK5`>S]YDZ1FS>VT[C'-$(3>M`QLTC$25LTV9<$%<S^+-8/Q.ICA&3CZZ:
MO$;_AB1ZD^?O.3,'3>O`0)BFU$D4]GV#T\1%02).(]$#5`C<AUO\=5O4]BH^
M1_H[N((@-"WD.F/<S9S8-!7>5IMJL1;J/8C,6X"M<PZT\&=T!TUKF71P5Q9D
M7'_!BR3_/1(5\[=,7H^8?-B_QW>%&?HS][W<!9H2;!SCQ(0:_N#9;^*HF!&?
MG]%E(SX?<I^'XUA7WY[,8.RQ+AL'SV2`%N\Q`J7@H2T\2'0HZ]<R+_?[9K&I
MWNV!+`EG!,Z_/1\6^R+M@1OV^QP.D74GKE;G#^`,UZEX+?\LZM?=L5GLRQ<(
M&=S'T"TUG@+#']KJU!U?>JY:.+W5_?<-3NN5<*`GN`?XI:K:SQ_L<:'S^;^G
MOP```/__`P!02P,$%``&``@````A`#V==='R"@``^SL``!@```!X;"]W;W)K
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M?'J8!/KO9OAQ,/X].[R-/_K]YOGOF]T`:L-Y4F?@RSA^5>@?S^J_H/'2:MU-
M9^"?^]GS\++Z]G[\U_CC;\/F]>T(ISN%$:F!W3__V0R'-2@*8>[B5$5:C^^0
M`/R<;3>J-$"1U<_I\\?F^?CV.)?979I'4@`^^S(<CMU&A9S/UM\.QW'[/PT)
M#*6#Q!@$/C&($#<'D1@$/D^9Q#<'23`(?)Z"W)X)#'S2!#XQ2)S<B23*;I`D
MPQCP>4H$<KI2SQP;P^<I@3+4>*E/[%0GS>JX>GK8CS]F,/G@U!T^5FHJBWL(
MJ`I$0IFY"P0J0[7Y736:F@)]@*K^_I3G#\OO4(AK1"H'4E"DMI%$4J2QD;RD
M2&LC1421SH$(BO0.)#XC2]#J+!A4L2F87R@%/\[AYUFH@@VQTD@^J;B("UF6
M.4NNU@@4R#E*?$EN.B--&&G-CD0:<Y',PTD2E;%D1&\2BSQ.HSR^9$HT@DEJ
M:G1=4:E&3*OD?`JF458:,85@1&T3EE1AI-5(,9T3D8HR3UG5=780EDGO(XA8
M,!PN5O++)?HT`U4C)E;*Q-*('D21E7'.@%H#\//7915&VA.B5H$XS6@2G3YZ
M3B(23,C^U/R2Q$5((A-(<KM,JA&3B658:032.*MP26"JNMHFK)H*(ZU&M!)Q
MFN8IFUZ='8,ETOL(HA5L*Z96_C5*P4PCOIAK1.<N4QDG3,1:`Z:(ED1AI`TC
M72B3WAN#B`2[G2F26J3"\TXU8F*Q;:W2B!9+I(D0?#^J"5'P':W1AWUBMF&D
M(YVDLI319;&>ZKKW!B%2J<L!9A+"4JE&3"HV^2N-F"-E)5]K`L4$J43,Y&[L
M&+STVC#2V0C+I/<11"SP8ERLL*-2C:A8)5L?*HV88O&!UF&D"2/M"5$K.M0O
M6]'-HPOK<'\Z?%E.C2R)3@)LYNU"3:V84BS%"AE3*G8V:P=BY*D]U15,BXPN
M4%`CX:ZI<T1AR?1>A&JF?"J;B>'B$MK=@G\[[W$E,Y`5,C@0$;,MH,;CIJ:V
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M?9JI%5N_6!(5,J84;)BU`^%5TS@8%J9%1)^5K)#6'8APC-Z+T*I2]M90+%!5
MV@R;527XFE,)#>D!R%Q*MA?4"'BT;,)(&T:Z4":]-P;1*6;>WJ_31-.*X@:A
M0D;+M,B*+(JXU:Z1,96R2LK!\))R(#Q,=P73(_.+E*E>S-<']++]O.!7]U6L
M(>Q=YD)(?O.M)DR11DR)!H_[!&U)C#B)V(5%1XZKC;!(8[9U]X19"+AG$N7I
MY:J.2@73Z?HI&"N:EI;@*58(F<-D2M2(:#5!*0E_Z?+?.*+PLFE)&"66+%A/
MG2,,0WHO0L5R>/JPVXH=GIZ=L@H9+8A(BB3G5VLU0<`#<7N*QTW9;<%T*CZF
M(_V()"\SGDKO[XI*!GV9]77=?<%8M:)U5C)_4"%CCH6=V1H1K:J2#!XJ\C+3
M/9E1;-7"3!?.IO<B5#2'JP_?EU`/3)EHL$#0\58(:4G`?,)E#BND&A%3$B9L
MXT!LU70ZNB=U/44SZ5@FB<J%(KVCFTLF5#&'J;]",=O4"[YJ5W'8U8>1QH'8
MBNF>+HI9YZ9SA+DHHN]#>Q$JVDVF/K["U".C1R"R4C"_72/@K2VOXY[&V)[#
M3#=5V<K0L2R*[++WH41V%Q<5J42?\O2QOKMM.M62>WID/$K48:1Q('99Z6ST
M24DS65[&.LG1.8(PI/<B5+&;/'U\C:='2`]`%K'D7VRHD?"(V821-HQTP51Z
M;Q"BE%J?S*W1[U(GFFZ)EJM'1@NU$&61BS+B4Q`AGU9AI`TC71CI$?E5PE2N
MFTR]=)EZMOE7")VZS\NDM)ZYUP02,N,;1(.`*:@U!TF0I+2_`&%>7H@L4A:0
M[X8DQD+*LH@S(Q`5ZR9;+UVVGEM4A,QALE6B1D3K.4EE/V!TA+'5TOGH.*!6
MD>>LBCM'&)9-[T6H6I_R]=+V]7"A12U,A9`>2@Q_2FE\S6=:?VMD/,HV8:0E
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M(:0U*S/X:C%;86I"+%R6%0F/J"T)`G8T8JMZ1P!PM.;7E_5EMK<7*A?S]E?*
MY?#X@HE1)1KR#+5&!.?N+WQK.$Y+XDR2Q99O#8?IO0B5C;G\*V5SN'W!UJHJ
M,2TXO&:D_K#E#!&/L@V)`FLBVT?:P/&.'!?PM%Q:#SN\65"U/N7R$X?+YRZK
M0L@C11U&&D1T'2JU)-]F6AOA:VH7[JCW(E0S&!)W^>JBW6]<$]6*KV-L_:@0
MTJ,5199;7Y)#PJ-J$T;:,-(%4^F]0:AB-UE\]?2(*67=U4$&EZ=8P#/MLF#7
M`35"7JUT7QZD#4?IPD@?2)C*Q1Q_H+!LIR\$OU&1:`C?`8*'GP4\PN)KEV9,
M+?@VVI`XKL7+[`<>/EKW54D`^#9KED4IFP4]819I*F$F))=EDFIUD]F'%R%Y
M:0G^%=$*(5.'RZ69OCOA0&RI=%_>E<M$)K5BGDWGZ(IEHU[O5*-R)ZS5TJ]O
MZM?R/E:OPS]6^]?-[C!['U[@"[O170[S8*]?WM2_',>/Z?6[+^,17KJ<_OD&
M+]D.\&Y>=`?PRS@>3[^HUT//K^T^_1\``/__`P!02P,$%``&``@````A`#Q#
MI5,3`P``10H``!D```!X;"]W;W)K<VAE971S+W-H965T,CDN>&ULG)9;;YLP
M%,??)^T[(+\7,`GDHB15DZI;I4V:IEV>'3#!*F!D.TW[[7=L)X1+1]GZ$*#\
MSY_?.<>WU>U+D3O/5$C&RS7"KH\<6L8\8>5AC7[^>+B9(T<J4B8DYR5=HU<J
MT>WFXX?5B8LGF5&J''`HY1IE2E5+SY-Q1@LB75[1$MZD7!1$P:,X>+(2E"0F
MJ,B]P/<CKR"L1-9A*<9X\#1E,;WG\;&@I;(F@N9$`;_,6"4O;D4\QJX@XNE8
MW<2\J,!BSW*F7HTI<HIX^7@HN2#['/)^P5,27[S-0\^^8+'@DJ?*!3O/@O9S
M7G@+#YPVJX1!!KKLCJ#I&MWAY0YCY&U6ID"_&#W)QKTC,W[Z)%CRA944J@U]
MTAW8<_ZDI8^)_A<$>[WH!].!;\)):$J.N?K.3Y\I.V0*VAU"1CJQ9?)Z3V4,
M%04;-PBU4\QS`(!?IV!Z:$!%R(NYGEBBLC6:1&XX\R<8Y,Z>2O7`M"5RXJ-4
MO/AM12:CVB0XF\#U;(+A=F3PY!P,USK8#>8A#J/W$3R;CJG./5%DLQ+\Y,"0
M`V!9$3V`\1*<WRX'U$%K[[38A$"F$GKXO(DFTY7W#'6/SYIM7Q.T%;N^`L]J
MB0=<-1P4IPFG>S:!S@]#ZB#0(:<!&=;^)I&MU4P;FDX:NR%%BQ$^U&0<9M/B
M-0+OFBV8X0Z;U339@FX%K61F.K#P]5_MT6(#D_%L6MQEZWQX:S53\^'K-TU-
M=_;=W+R[P5/L3Q=O4\%\&4^EQ5VJ3J^V5@/?OU:U`[ZS$@LW"^>+\%KU5L6B
M-MNX$:>#.HS1-7<[XJRFR=C)8C>D:#'._H=1![TW*ZQFB'%(T6+4V^;H946+
M._7KS0JK:;+U9H65V!X'./KKK%BTV<;U6`=U&3LS8&LU3<9NCX<4K?IA6.::
M!1P'::+>Z_)9-(0Y*&ES_MO^89?^X?4/3@&ZU$V^7JO/&KL"1O-IO]?V(&"W
MNHH<Z%<B#JR43DY36"5\=P8K@K#'`/N@>&6VMCU7L'V;VPR.:Q3V/=\%<<JY
MNCSH@T9]`-S\`0``__\#`%!+`P04``8`"````"$`SR%E(;,"``"3!P``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6R455UOFS`4?9^T_V#YO3&0A*Q1
M2)6NZE9IDZ9I'\^.,6`58V0[3?OO=R].*3251E\,OAR?<S]\+YNK1UV3!VF=
M,DU&XUE$B6R$R5539O3WK]N+3Y0XSYN<UZ:1&7V2CEYM/W[8'(V]=Y64G@!#
MXS):>=^N&7.BDIJ[F6EE`U\*8S7WL+4E<ZV5/.\.Z9HE490RS55#`\/:3N$P
M1:&$O#'BH&7C`XF5-??@OZM4ZY[9M)A"I[F]/[07PN@6*/:J5OZI(Z5$B_5=
MV1C+]S7$_1@ON'CF[C9G]%H):YPI_`SH6'#T/.9+=LF`:;O)%42`:2=6%AG=
MQ>OK.*)LN^D2]$?)HQN\$U>9XQ>K\F^JD9!MJ!-68&_,/4+O<C3!879V^K:K
MP`]+<EGP0^U_FN-7J<K*0[F7$!$&MLZ?;J03D%&@F25+9!*F!@=@)5KAU8",
M\,?N>52YKS*:K&;+532/`4[VTOE;A924B(/S1O\-H/A$%4B2$PD\3R3S="H)
M"PYU\=UPS[<;:XX$+@U(NI;C%8S70/QV0!`)8G<(SFA*"?CJH`H/VR1--NP!
M,B=.F.N`@;7'Q#V"@6BO#&K3E1&,RIA:=.4Z&(8R+XZ,9.;OD4%P1F'MG5^F
M\][]H!PPBP%FT2-&R@"9'B""H080UD#ZA3A(!]`$:;A4TZ41W$GWR0V61=<2
MPY)!Y:?3(GA,>[)`]PUB7+Z=O-5[I!`\E@J6\PAP($^^[@@>TYXL75^.:GWY
M'EX$CWF#Y=Q=F&DC?[NYDT+7_[=3\>!8H^,"T[!GEFGZ*OUA!(81H:4MY6=9
MUXX(<\#QED#3]]9^].X2O"FO[8OU+HQDUG^!D=CR4G[GME2-([4L@#.:K2`<
M&X9JV'C3@J,P&(V'8=B]5O#SD]#X$<9>&..?-Z#,^M_I]A\```#__P,`4$L#
M!!0`!@`(````(0`LE&?1FQ(``/!<```9````>&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;*R<6W/;N):%WZ=J_H/+[R<6=;.M2G(J$L4[J4N=.?/LV$KB:MM*
M64JG^]_/!HG-#>R%5ELY4W-JG/ZPL`!B`R``D7S_SS^>GRY^W[T>'O<O'RZC
M=X/+B]W+_?[A\>7KA\O_^5?RCYO+B\/Q[N7A[FG_LOMP^>?N</G/C__]7^]_
M[E]_.WS;[8X7Y/!R^'#Y[7C\/KNZ.MQ_VSW?'=[MO^]>*.7+_O7Y[DC_^?KU
MZO#]=7?WT&9Z?KH:#@;3J^>[QY?+SF'V^A:/_9<OC_>[>'__XWGW<NQ,7G=/
M=T>J_^';X_<#NSW?O\7N^>[UMQ_?_W&_?_Y.%I\?GQZ/?[:FEQ?/][/\Z\O^
M]>[S$UWW']'X[IZ]V_\`^^?'^]?]8?_E^([LKKJ*XC7?7MU>D=/']P^/=`6F
MV2]>=U\^7'Z*9MOQY/+JX_NV@?[]N/MY</Y]<?BV_YF^/CY4CR\[:FV*DXG`
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MW!B73\;FPR5=%PVO`TT<OW^<7$?OKWZGP7YO-7/4*,6"%68X&MM8@Z4&B0:I
M!ID&N0:%!J4&E0:U!HT&*PW6&FPTV#K@BL+3QX@ZR?]'C(R-B1&W[IR!!&WH
MAVS!"LX2:[#4(-$@U2#3(->@T*#4H-*@UJ#18*7!6H.-!EL'>`&AR00",J)9
M+GR?XC%B<M$=R1DCT?36;_"YU;@#:>Q+%KVD#PJ0)9`$2`HD`Y(#*8"40"H@
M-9`&R`K(&L@&R-8E7HQHIH88F;7$F1.;L:&YD7J",[.I83+O1*-34>LE?=2`
M+($D0%(@&9`<2`&D!%(!J8$T0%9`UD`V0+8N\:)&`?*B=GI$&74;'&[4N24R
MR2V`Q$"60!(@*9`,2`ZD`%("J8#40!H@*R!K(!L@6Y=X#4]]]XR&-VJ_X2WI
MEM+FWKT`$EM"?_JQ%-VJL;3L11S3!(Q2()DEU_W-+0=20*X22`6Y:B`-Y%H!
M64.N#9"MF\N+!2WPSHB%4?NQL,2)!9#8$JJ#$XN1?ZM9]J(^%F"4`LGZ7*ZU
MNHOEO8BM"S`J@5262)AK(`WD6@%96^)>_?6-?_&;7L,UW+H^7L#,^8.[B#X]
M:QFU'S!+G(`!B2UQJQS=3OPZ+WL1USD!HQ1(UN=R`S;UK?->Q-8%&)5`JCZ7
M:ZWZ0MV+V+H!HQ60=9_+M;[V:[WI16R]=8V\(-)N]XP@&K4?1$N<(`*)+?&#
MJ#K>LA=QG1,P2H%D?2ZW.=3R,N]%;%V`40FDZG.)-1V,^2U=]R*V;L!H!63=
MYW*MU;9PTXO8>NL:>4$T9PUG1+&5^V%DY,014<S(C>1PH.]EHN*:)XS$/D64
M,?+MU?2<BXKM"T9B7R*J&)VTKT7%]@TCL5\A6C/R[=6HWXB*[;>,6GL_KF9O
M_/8I-NJVTK1L9^\Y(TKI[WC#@9I`%Z+BC#$C_VK4]+@4%6=,&$ECI8@R1KZ]
MFL=R4;%]P4CL2T05(]]>33FUJ-B^823V*T1K1M/VS&<XB"#*-A*R(M]RGD"4
MS8;[C"AW^W,ORA;1!L.)LIH&%V8[9V;O<=\]8D%.QDA-<LNP2LU7B:BX-5-$
MF:`3)>9AE2JQ$!676"*J!)THL6;5I`OI9'(SO1VIJ:=AD;3@"M%:T(D"-ZPZ
M5>"616V!_M1@C@#.Z#3=B0'Y<5/-S2FQZ0[21Q>(8D1+1`FB%%&&*$=4("H1
M58AJ1`VB%:(UH@VBK8?\6)B-_1FQZ,X!O%A8)-/.PARZF_`(BAG1BKP?YKB5
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MGHN*[0M&TO`EHHK12?M:5&S?,!+[%:(U(\\>]RK0.%O.&(BK.8-PX]K]<O[.
M/%9P_/9X_]M\3^.+=C^!P\`1+:WM[^;V),,-MT54F7Z`!C:J[A&(_;&\0^:'
M2">CFE*74:_B-DPL<A98*:),,KKV:L[+1<7V!7J5B"K)Z-JK>:D6%=LWZ+5"
MM):,YN$$VJBJKKL1`3MO/1MO4`_U,9,._K_VW_\J^/0H$D>_M?$G<484)2>(
M:OY<L$JV7S$C+R-L8*W*_!'[2$UPB7AQ6Z2,I,2,T<D2<ZLR?_ZZQ$*\N,22
MD918,3I98FU5PZC=P(X'-[?#&W7G;\2)RULQDO+6C$Z6MWE#>5MQHO+\KF0.
M2/0\,C03U9LG$;I2O1:P:$@''4ZKZ],N5HWZO7#,2%IAR<A,;/QTSQ#[3%<)
M*I%;-.6,8I\Q$ON<T4G[@E5B7S(2^XJ1V->,NA.J:$I'5/1__N%UPR)Q7S$2
M]S4C<=\P.N6^95'K[@??'$3IX$?TS*(-/T\C9_0%>[0E5S(WG<`L%OQ>K.X+
M"U;)Q<46M9U1`J_/Q%CEW:^P>_25D.YAD928L9=_GU8EYJPZ66)A57397&+)
M2$JLV.MDB36K;KLSL4$T&-%3G;H3P26NL,`U6YTL<,.J4P5NV;V]0K]?Z3.Q
M7[P_X5G9L$/TK`NWZ@)1C&B)*$&4(LH0Y8@*1"6B"E&-J$&T0K1&M$&T]9`?
M(WU6]HN/7@[[0S29GB?7:GDSMZJ3SRB)AF,;(UHB2A"EB#)$.:("48FH0E0C
M:A"M$*T1;1!M/>0'DF9K;Q(/K/C=19^1JT6?1;*)65`&O<-C1`<SSGU8K9"7
MHN(@)HA21!FB'%&!J$14(:H1-8QP<S4TAT_N??%OFM2>5;DW/8O<>0I0W)9#
ML:`4ITG5:GLI*FE2\$I1E0ER[(=J\9&+BNT+1"6B2I!KKT9^+2JV;SSD]V6Z
M+9W3\$:N^K)%;L,#BLV:PF3T&GZH;O1+47'5$T0IHDR0VS+J,"07%=L7B$I$
ME2#77M6^%A7;-Q[R&]Z</9S1XXU<-;Q%;L,#BH<]<JH^4-NCI:BXZ@FB%%$F
MR+'7!RVYJ-B^0%0BJ@2=L*]%Q?:-A_R&IV7Q.0UOY*KA+7)G;T#QT**_^J5\
M*0*N=<)(G%-$&:/>6<T`N0C8N6`DSB6BBE'OK$90+0)V;ACAI&X.ILYHZ5;N
MMS0C6O'(=#U4G7<A*JY4+,C)"(<C095>YB=AE=I.I:+B2F2"3E0B#ZJ&ZIBM
M"*M4)4I1<24J02<J48=5ZL;5B(KLO4$U"AUJ3,=F7WOZ3MYF5$&W!PNT\7""
MKI8]"YN1EMM\J3&BI2#72]WOD[!*-6XJ*BXQ0Y0+<DH<J5M%$50-58FEJ+C$
M"E$MR"T18A=L52G1#Z?9V;[]YC2R&V%G.<;(';F3:QBY<"(0<T;9Q2\M,D=J
MTB'T$RJ)9'14NDE35LF)0(8H%^1XC53MBZ!*EUB*2H((EUV+RBU1GS@$54Z)
M?A!#9P+#J7F3]N\&)1X#C#ID=K=.#*3[=#]3B8JO-4:TM(CZK3F:G]X,QE.<
M=/ORV"E%IXR1=+R<S:F)I:+Z=*K`C"4CF5`J1F)?O\F^\3+Z00D=`IA5XMM/
M_$;]_I^;9L[('6W#D;J'+$3%&6.+J+Z,EHP\+]V`"7O),$T9N4/+5E50+BHG
M/B,UNQ=!E=/1V^Y6BHIK7R&J!;DEJGM`$U0Y)?I1-)MU=W[\M>.VD=WS2_^:
M6^2/L[&Z?2Q$Q1<>"W*N$E<\78G*7MTKDJ"7TQ9MZZ>BXDID@DY4(@^J]`Q0
MA%5JQBE%Q96H!)VH1!U4Z657$U9))?Q>8<X(L%><_0JB.;/KMAQR`9-K=2^8
M6]7)`S[1<.O$B):($D0IH@Q1CJA`5"*J$-6(&D0K1&M$&T1;#_F!-(<5;B#_
M9@UKSS;<8=RA&]EN+4:`8D;NH<AXK/9<2U%Q$!-&8I\BRABY]L.AWBR*BNT+
M1F)?(JH8G;2O1<7V#:/`CM$<5IS1\/9LPVWX#GD-#R@>6>177<VR2U%QU1-&
MTC(IHHS12?M<5&Q?,!+[$E'%Z*1]+2JV;Q@%&MX<5IS1\/9LPVWX#GD-#R@>
M6>15'4ZC1,553QA)RZ2(,D:>/9Q&B8KM"T9B7R*J&)VTKT7%]@TC;/BQ/B/1
M*XDW/574NOB[:(O<>""*+;KN?W94>YRE"/AB$K1)$662,?S\32X"=B[0ID14
M24;KK";,6@3LW'@VWEP_#IU<1!-YK(M_DC]]#VAM5`2Z'?>4NKSL1":J@1<V
MXW7[H:3NN2Z+*"/7?\FJ;LLT&HVN1P.U@DTP6\K9Q#Q#56[1S<D5?X$92[2O
M4%6_R;[Q,OH1,KOEM\]-8[NY=N8FBZZ]/>%$+:@6K)*]4,Q(O)86W=!"6J(*
MVR/,F#(2^XR1V.>,QNW>.!I-!^-HJ-=^!:LD8\E(["M&HJH9=?8WD\&(_J<>
M:V!-F\V/A-F4GQ&);@_OONTQ[I`:$[*>[HX1K,H;$WU&&1,=NK:/?8VB\7@R
M47O>1`KD?"FZ9ZC*6=6YTR-ETPD]2^0W58'Y2LXG0ZY"56V1/^1TY1LOHQ\)
ML[%V(_%KMPV[/9<.,A]W2`T5M3U?L$HZ6\RH^TR;^2#$DE'W:\)H1"VHOQ&5
ML$:JD#(2\XR1F.>,.O/H9CH9#VY5]`L6B7O)2-PK1N)>,^K<I]?7MU-UEVE8
M$A@FP=.!_^0A+_H&G_X1RB(:(S(/Z1=-%B+BWA\SDA<XEHQNNN<G;V_&]`4]
MU92)%3DWI93S25?/&(E[SJAS'XY'M]/!9*1:LT#[DC.*?<5([&M&G7TTIL/$
M:_VN>N.Y=P.I^R9A]VFTY]WKU]UB]_1TN+C?_S#?&XP&`VJ,GMNO(0['LT]T
M(D!MJ5+H:9N9>6`$4SZ-IK-/5#RFT`9^9O:@F$(;I)E9L6`*?8_Q4]O?=/GT
MG<9V;:GYD*H5\)F/J.@`_T072&=#6/"<KB]T>?/);!N\N(A*H-<&`TY#2@F6
M0=O.F5D"8A[:?<[,2A!3:!,Z,UO,4,H-I=P$4VXII5U<J>:BI>7,K![1C7;<
M,[/PQ13:>,_,^A=3:/\]RX-UHPTBI83J1CL82@G5C1;4,[-FQG+HZ8Z9^;T;
M4^@WZ)GYF1E3Z#?DF?F9&%/H-^"9^9D74^9T/?-@#>AL8[8(IM`1Q\P<8*`;
M[<$I)5AK:H-EL`UHNS(S.Q)TH^<0Z'I";O1HS<P\;(!YZ`F;F7GF`%/H01MJ
M@]#0I"=!*"5T/?2H`J6$W.+AA%*"HX3*F0?S+"AE$4RA1Y@HIJ&ZT3,VE!*J
M&ST$0BFANB7D9I[TP#:@QYMFYH$/3*&GG*BM0S6@QW`H)5B#B&I`[]8$W"C%
MO$:$*?2.T,R\`80I]'K/;!-,B2/J.]T3P&ILT^LL5$ZH7].;*%1.*(5>(J%R
M0BEQ1%&@AYFP;O2B(Y432J%W%*F<4`J]7DCEA%+H[3TJ)]2B].(=E1-*H7?F
MJ)Q0"KWN1N6$4N@%:RHG-,-GE&)>AL8KI3>=J9Q0"KVW3.6$4N)H0N6$Q@*]
MY$OEA%+H_5PJ)Y1";]M2.:$4^EX+E1.<*2C%?$@E=#TT^P=3Z`,G5$XH#WTL
MA,H)W7KI.Q]43BB%/M%!Y812Z.L:5$XH):;A$QH)&0V>$*]HZ(3XF@9.B,<T
M;$+]/*-!$^(5#9D07].`"?&8ADNH?V<T6$*\HJ$2XFL:*"$>TS`)]>N,!DF(
M5S1$0GQ-`Z3E5_WT0=^;_G[W=5??O7Y]?#E</.V^T/IPT)X/O79?K.[^XVC?
M`/N\/]*7IFD)2=_6I2^+[V@G-##/P7S9[X_\']3YKOIOE7_\/P$```#__P,`
M4$L#!!0`!@`(````(0")`9PP3P0``*H1```9````>&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;)Q878^B2!1]GV3_`^%]@`)1,.JDE?3N)#/)9+([\XQ8*FF@
M"(5M][_?>[E(4]!3...#B!X.Y]R/NI2K3R]Y9CSS2J:B6)O,<DR#%XDXI,5I
M;?[W[^/'P#1D'1>'.!,%7YNO7)J?-G]]6%U%]23/G-<&,!1R;9[KNES:MDS.
M/(^E)4I>P"]'4>5Q#:?5R99EQ>-#<U&>V:[CS.T\3@N3&);5/1SB>$P3'HGD
MDO.B)I**9W$-^N4Y+>6-+4_NH<OCZNE2?DQ$7@+%/LW2^K4A-8T\67X^%:**
M]QGX?F&S.+EQ-R<C^CQ-*B'%L;:`SB:A8\^A'=K`M%D=4G"`83<J?ER;#VP9
ML<"T-ZLF0#]2?I6]SX8\B^O?57KXDA8<H@UYP@SLA7A"Z.<#?@47VZ.K'YL,
M?*N,`S_&EZS^+J[_\/1TKB'=/CA"8\O#:\1E`A$%&LOUD2D1&0B`=R-/L30@
M(O%+<[RFA_J\-KVYY2\<CP'<V'-9/Z9(:1K)1=8B_TD@UE(1B=N2P+$E8;XU
M<_U%\#LL7LL"QS^7,FM)X'B3XEINX#-_/FW(IN`TL8[B.MZL*G$UH(#!OBQC
M;`>V!.;W@PM11>P#@M?FW#0@;A(JXGGCA_[*?H8L)BUF2QAX[V'F*F8WQC`5
M$=T06""@M),+>;A?+H)1+M8&ZM_2%\&BD3YCBT6HWG9'@+YX5T5$8P1;=!!%
M*B3[?JD(A@)5HO;&2^H)`TGJ(COK[MP@=I.(2(=0U,-M[E>/X+4)H>F4^6&@
M:ML2)@B:V#M6.//#_FM01CN"PWM'.3`;Z1"*%>CVOA5<1SQ8C?2ECA<-+0VJ
M94L8<N0&;LB<A:>ZWA%$9T.'4&Q`V_5MZ.4C6)4_=QQ5VY8P748")W3ZKV%&
M"*ZSHD,H5A:J%<S(`N*@MX07#2T-EHTM830:=V/$W!GV^!CS5GN*#WS4Z"V>
MZ&,VZ0,O4GTP-BB;+6%T/@A!*QD\F.!+36^DXU!<A*H+?180K*KWWX)#ZQ1!
M=.()08WCD_B1?#U&,<"@F_MYT#MHT`,+PSIJ,3H/+:3M_E^8F`"I+G#F]:II
MP@5-R/Z:.W>&9<0(I+4Q"8FT+*H%G([W6Z!9JA]ZC$!:"Y.02,NB6L`)V;-P
M7T\SFJL@I!M7XZ9N05HKQ$-%Y7G>X!$@TE*H/N`V?^`#KU)[@[%A?S,":7T0
MY,V'YPR&9Z1E4:W@B.RE9*(Q:*#V4Q$,EL8M;B/`IM;!)"32LJ@.<#+>[X#F
MZ$1?Z(8M/0VR24BDA:@6<"CV+-S9%S1*^\EXIR]T\[:U0A`:=^_UA8Y"]8%C
M\?=]T#!5?8SZ0C=Q6Q\$Z?4%&]0F;JE_79MDA;;,M(W+>77B.YYETDC$!;?#
M#)ZPNV^[K?J#VVRVNQ]@IUS&)_XUKDYI(8V,'^%2Q\+'L(KVVG12B[+9).Y%
M#7ODYN,9_A/AL)UR+``?A:AO)[A9Z_YEV?P/``#__P,`4$L#!!0`!@`(````
M(0"5X(?QX@4``(TA```9````>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;)R:
M6V_B2!"%WU?:_V#Y?;#;@`-1R&AP=W9'VI56J[T\.\8$*Q@CV[G,O]]JMT.Z
MNMDJ$HTT@9FOBSY5A^9@Y^;K:[T/GLNVJYK#*A23.`S*0]%LJL/#*OS[K[LO
MBS#H^ORPR??-H5R%/\HN_'K[\T\W+TW[V.W*L@^@PJ%;A;N^/UY'45?LRCKO
M)LVQ/,#_;)NVSGMXVCY$W;$M\\VPJ-Y'21RG49U7A]!4N&XOJ=%LMU51RJ9X
MJLM#;XJTY3[O8?_=KCIV;]7JXI)R==X^/AV_%$U]A!+WU;[J?PQ%PZ`NKK\_
M')HVO]^#[E<QRXNWVL,3KWQ=%6W3-=M^`N4BLU%?\S):1E#I]F93@0+=]J`M
MMZOPF[A6TVD8W=X,#?JG*E\ZZW'0[9J77]IJ\UMU**';,"<]@?NF>=3H]XW^
M)U@<>:OOA@G\T0:;<IL_[?L_FY=?R^IAU\.XYZ!("[O>_)!E5T!'H<PDF>M*
M1;.'#<#?05UI:T!'\M?AYTNUZ7>K<)I.YE?Q5``>W)==?U?IDF%0/'5]4_]K
M(#&6,D62L0C\'(L(>'CAXNFX&%[NM'B2+.9BGO);B(R<H3LR[_/;F[9Y"<!R
ML.'NF&L#BVNHK-LRA>:>;POT0Z_YIA<-2X'N8);/MVD\NXF>H?_%R*Q])L%$
MYA/B"B/21U*!$74&B><G)@*9)ZW0:U=KRFK5BZ`G86!I34_UAWZL#3.S&*<;
M&4M(EE`4@73"9FV=]"PUO`JA]DG?U&GQVB!7PZ"3^7R1+J=3W($,(;&(I[/D
M?0A#DZ2-S.-EO%PL<!%E"+N-R;MGD$)@;(67N58OPDK3V#'<VC#V%MQ)LH1D
M"4412">\(UV=O&/U(LZQAJ%TLH1D"4412&>*==*.U3">H^=8@U#R#+$8/#V+
M%\MDX0Q:LC4412!Y5UC>97;5B[#,-';>,6O#4#I90K*$H@BD4X<EY\.$MZM>
MQ-G5,)1.EI`LH2@"Z5QBG;1=-8SGZ-G5(+8\Z^`;3L^,1Z2/.)96%($$"OA8
M_/@DAU58:AHO\2&_'B%;K+/-C$<DCR@2P6IUAOBP;X5)'O"A=?KD3&,W&8P0
MJ=;4(1#)5U$D@M7J'&&II=VK`RIGWY$A%&1G$-?B\@SC.$.1"%:IPX2E4I^Y
M_%DD3`2QTU`J8M?!?DYQ]IF-=8B.2!Y1)(+5PBM]0JU>Q1V]PD"$E(Q')(\H
M$L%J=:ZP9LLXV*00>Z;>`:R_"4(G2)$^XCO89QQG*/*5L$H=+RR5EZ4&84*)
MK385;J`?(5(N%6Y,H.>K*!+!:G7(<-1>\'XUT80Y@ZG\8CY=!8M('E$D@M7J
MJ&&I91QL@HD]4]_!?GAQ[9D)GI%G&,_"?IEW!,O4@<.2>>$A;&**+3<5[U\$
MAXFM!95EQJ&RB.2K*!)!:I-/A:9A%7<(CQ#UAN41R2.*1+!:)S31%DY,R+%G
MZEEX9$B1?E9R72[Y,HI$L$K8\<<=G.A53A`6SB63]0B1<DT=`I%\%44B6.VG
M0E-B\A!]"(\0(27C$<DCBD2P6MB,/5O&P9K&,_4=;!A2I(_X#O:9]P-V.-M4
M0B%8I<XDSAG,7^'55Y0=M:EP-K$>(5(NFX@D7T61"%9[)C3Q,2(Q88=Q,)N(
MLK$.T1#)(XI$L%HG-#$.-B&'/H,-8ZZ+_<^UW@0QYR_VC@S1"44B6*8.'(Z%
M9V`L1JZ)*;;<5#@7I=<)E65,C.`1R2.*1+#:3X6FQ(0=QL)L(LK&.L3@)(\H
M$D%J]5%DSY:>Z4`SA_#($`JR$3$N%VDL9O`'?\N7?!E%(EBE$Y9T$.8=//5#
M4RK<*TPC1,KU4Y-SE$N^BB(1K%;'%N?]RA_"4Q-V:`>/$*G6U"$0R5=1)(+5
MPHYMM8R#-<TYV#"$@@QNE>LRYI[<^?L7(T)4T3?<=97SB!%I;JB;6\;'_*'\
M/6\?JD,7[,LM>#B>7,$YW)K;Z>9)WQR'6\/W30^WP8>'._BUAQ+N&\<3@+=-
MT[\]T3?L3[](<?L?````__\#`%!+`P04``8`"````"$`I#(:V+`#``"C"P``
M&0```'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6R<EE%OHS@0Q]]/NN^`>&_`
M)AB(DE0-J+>5;J75Z7;OF8"3H`)&MM.TWW['F)#8Z=+NO81`?OXS_YFQ,\O[
MUZ9V7B@7%6M7+IKYKD/;@I55NU^YW_]]O(M=1\B\+?.:M73EOE'AWJ___&-Y
M8OQ9'"B5#BBT8N4>I.P6GB>*`VUR,6,=;>&7'>--+N&6[SW1<9J7_:*F]K#O
M$Z_)J];5"@O^&0VVVU4%S5AQ;&@KM0BG=2XA?G&H.G%6:XK/R#4Y?SYV=P5K
M.I#85G4EWWI1UVF*Q=.^93S?UN#[%<WSXJS=W]S(-U7!F6`[.0,Y3P=ZZSGQ
M$@^4ULNR`@<J[0ZGNY7[@!89\EUOO>P3]*.B)W'UW1$'=OJ+5^7?54LAVU`G
M58$M8\\*?2K5(UCLW:Q^["OPC3LEW>7'6O[#3E]HM3](*'<(CI2Q1?F645%`
M1D%FAD.E5+`:`H!/IZE4:T!&\M?^>JI*>5BY`9F%D1\@P)TM%?*Q4I*N4QR%
M9,U_&D*#E!;!@PA<!Q$4SN8XC.+?40D&%;B>5?!OAS(?1.!Z$<%QB$+RL2%/
M)Z?/=9;+?+WD[.1``X-]T>5J.Z`%**LD!U`JG9(Q[;_*.J1;B3PHE95+7`>6
M"VB5ES5!T=)[@?(6`[/1#'R.##*)]!T5WT2R,Z(:!QR,-J`^US;>[Y%SM`I6
MT:J>4>%O](/KT+#YWO26L/UEMPBY&#2"A3;X?+`*7KD@/J:-H-B,;J,9*-_(
MS$TB_9#(I@@C>GC-=?3GCIE.N5H$G745(4&)&>-&,U,N/B2R*<)P`4?`M8OI
MZ!5LU@!C*\,;S41]\]]A'_D!'!.FP]1@0C_QD]@J9::1ZR3@2R\:#F"W73M0
M=8A@];03M<AT0K"UQS::B;63*`GG260AJ8$@'$<1B2RSF<$$)(Z#,!CS83B)
M3"?3#A1L.[CL,[V?-3,XF`=!@,CEU3V2&D@0!22QVC$S"(02'U\((WPU<+QS
MA$[;4(ML&Y=":QN:T39([,_AG!\3J%UHXA?=TB/9)&+X2/Z/#[7(]F'E>J.9
MJ2A3C0P50Q%!OEVQS$1P'!"?C.DPC,!48E1DNA(];5K`<ZOA-P-TWMYA&),D
ML'RF%O3N&:!&)I6Q0<D^!+0//1/I_^F&\CU-:5T+IV!'->]@V)GCTW$6>\#J
M_\QZGJH933WWQA]@1.KR/?V:\WW5"J>F.Y#T9^KHX'K(TC>2=?UTL&42AJ/^
MZP&&80K_E_X,X!UC\GRC7C".U^N?````__\#`%!+`P04``8`"````"$``4+D
M&34$``#O#P``&0```'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6R4EV^/FS@0
MQM]7NN^`>-^`^9\H2;4![5VE5JJJN_8U(4Z"%G"$R6;WV]\,)L1V6I-*JVP@
M/S_,,S,P>/GIK:ZL5]KRDC4KF\Q<VZ)-P79E<UC9__W[_#&Q+=[ES2ZO6$-7
M]COE]J?U7Q^6%]:^\".EG04*#5_9QZX[+1R'%T=:YWS&3K2!7_:LK?,.#MN#
MPT\MS7?]HKIR/->-G#HO&ULH+-I'--A^7Q8T8\6YIDTG1%I:Y1W$SX_EB5_5
MZN(1N3IO7\ZGCP6K3R"Q+:NR>^]%;:LN%I\/#6OS;06^WTB0%U?M_N!.OBZ+
MEG&V[V8@YXA`[SW/G;D#2NOEK@0'F':KI?N5_406&8EL9[WL$_2CI!<N?;?X
MD5W^;LO=E[*AD&VH$U9@R]@+HI]W>`H6.W>KG_L*?&NM'=WGYZK[SB[_T/)P
M[*#<(3A"8XO=>T9Y`1D%F9D7HE+!*@@`/JVZQ-:`C.1O_?]+N>N.*]N/9F'L
M^@1P:TMY]URBI&T59]ZQ^J>`R"`E1+Q!!/X/(B2<!5X8)W^BX@\JP4W%FWE)
M2,)H.A9'^.K3E.5=OEZV[&)![T'D_)1C)Y,%*%_S(]R,&?M=PB!3*/*$*BL[
MLBW(!8<JOZXC+U@ZKU"98F`V@H'/D2$JD?Y"Q561[(I@S<'!:`-2*]OX=7FO
MT2*,T6*Y,?R-."&'YJG73>\)$JM(=H]$-X-*L%!).5C,>?#;GKP&C8N@^Z3T
M0=G5$#:"@3*.*=:*D$X2F8E07,!E9!?FE".\LB%%8V21%VG1"R;IVR>8)P'<
M95J.4QGQ`G\>N:&OE2J3&1*X012[MRY2'$#.'W>`L.H@GFL&!`+7'TWJZ9\D
M,A.A!`\WFQS\8TV$BZ::2#`F%Y-$9B(4%['JPMQ$"*LEN&\BP8@F\GT_]EVM
M2JD@9'^>WD)&1(D?WQ.DQZ<Y?H3U^+4.WPA&CD[OH4DB,Q%*]',U^L=Z"!=-
M]9!@3"XFB<Q$*"X(O!4\7H2>UJN@/XH&2#:@-TDZ,*+5B!^Y`?%B[8F<*5`2
MNC[\C4\-U06.MH=;B8A!J#Y0DU%9C+4!DEWHS32-9$9$M8`C4++P6#\1,3C-
MDVV`C%:$C@')C"JJ%1R#DA7SC4W$T%2K<==3`AKFFT^"(`RUNS\=A`23S+TH
M)-%M>/55S10F2*+0\V]=IYJ`7/R!":3U&T-[>&Z(@`Q)3J>1S(BH%G`>2G5X
ML*7$%)UH*=.H[5.=XDX!4F)PFQD1U0H.1<G*1$N)$3K14@*Z3COHEOCVRCE8
MD!$"W1*X<ZWK<`.&-H5,%,?SZ#80A06QOQ(;AYJV!YK2JN)6P<ZX=_+@E6T\
M.^[KGCQ\P=;.I[C?P_/.^`-LMT[Y@7[-VT/9<*NB>Y!T9S'DOA4;-G'0L5._
M7=FR#C9:_=<C;*PIO,"[,X#WC'77`[S`N%5?_P\``/__`P!02P,$%``&``@`
M```A`&M0).@F*@``008!`!D```!X;"]W;W)K<VAE971S+W-H965T,38N>&UL
MK-U;D]M&FN;Q^XW8[Z#0_4C%XJ$.87M"11!G@`!B=O=:+9=M15LJAZ1N]WS[
M>9)`,@__=$G4=LQ$V_[EBP2(!Z=,%LD?_O-?'WY_\<_'3Y_?/WW\\>7JU=7+
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MVU[G2H?0O%9W+'UCFBM[`)E_L6O=OMI<;V]N3\?A,[FL[#%D_N7"%VN/(G/"
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MLMK=A3O\8:GQ3Z1-6+(_EYQ#@1P@.:2`E)`*4D,:2`OI(#WD"!D@(V3R)<A(
MMP%D9"[P%U[83#>Z-NI(.%_95C?1:?(P%ZV?2^U<<DX-<H#DD`)20BI(#6D@
M+:2#])`C9(",D,F7(#4%%*3V_!EEJD_AV)WZ,(N2L+*'9)`#)(<4D!)206I(
M`VDA':2''"$#9(1,O@0[7L?N!3O>5(<[?I:UGF7^^CS9GXML.AGD`,DA!:2$
M5)`:TD!:2`?I(4?(`!DADR]!%MJ)%V1AJL,L9O%/`D@&.4!R2`$I(16DAC20
M%M)!>L@1,D!&R.1+L./U_'O!CC?5X8Y?Q+OZ0#+(`9)#"D@)J2`UI(&TD`[2
M0XZ0`3)")E^"':^Q[04[WE2'.WX6_XB'9)`#)(<4D!)206I(`VDA':2''"$#
M9(1,O@0[WDP-7+#G3^7AKK>DJYEWY5]'#ZVNZGSI)QU(.:D@E:2*5),:4DOJ
M2#WI2!I((VD**(S'#`G_'</S>6@9/<9&(XL',]FC$TNGD8LRJMF[&A?D>3%+
M!U;EI()4DBI236I(+:DC]:0C:2"-I"F@,$@SE/2#?/[!U@057>(6NM4)ZYUG
MB&=>4%4VB\PM:.E`RDD%J215I)K4D%I21^I)1])`&DE30&$\9AAY03SSJ%/]
MV5WZ8*8LE=CM/"-N)J_VI(QT(.6D@E22*E)-:D@MJ2/UI"-I((VD*:`P"S,X
M]+,P4Y+7VU<:NEPX=C=3P?%9-)-B\L^B;7RW.E?9?+.E+R_?`RDG%:225)%J
M4D-J21VI)QU)`VDDZ7TL[T@/DS.CRSBY[YAS,8O,N?DA[<*0'I:JY^]6_GAW
MF5(&'5Q/-NZ<5)!*4D6J20VI)76DGG0D#:21-`44!FF&IGZ07[E;S2/9X'(X
M4W"WVNYNPPCWYET3<]'T[U:@`ZMR4D$J216I)C6DEM21>M*1-)!&TA10&(\9
MP%X0SSS>#>*9R;N:[<W;4.$-+",=2#FI()6DBE23&E)+ZD@]Z4@:2"-I"BC,
MPHQI+\AB&0+[3PXS1;>DZ,VSO7EO+HX'=&!53BI():DBU:2&U)(Z4D\ZD@;2
M2)H""N,Q(U\_GN]]?W,>09LG2._I.[J>/:S.XVQ7A2?T<XV]V61N,4L'4DXJ
M2"6I(M6DAM22.E)/.I(&TDB:`@J"O+YLHN)4'DY4+!3<DE8W481[5V6SR$@'
M4DXJ2"6I(M6DAM22.E)/.I(&TDB:`@KC,7,`_GGV_!/#]3QEX-^2%O)O2:2,
M="#EI()4DBI236I(+:DC]:0C:2"-I"F@,(O+YAJN.=>P4'1+BMZKWKLJ=ZHL
MTP]N%'Q@54XJ2"6I(M6DAM22.E)/.I(&TDB:`@KCB><:OO.6='V>A'`WF]7M
M5?B(_;!4/3M*<C4NR+ES;T;]P*J<5)!*4D6J20VI)76DGG0D#:21-`44!FD&
MPA=<\^9Q<W#-6X;2P9Q>'.'^^ESEX@$=6)63"E))JD@UJ2&UI([4DXZD@322
MIH#">.+9B*_<DLZ3#G8O/Y@_!0V?N?>DC'0@Y:2"5)(J4DUJ2"VI(_6D(VD@
MC:0IH#`+,ZJ_X%29)P&"4V69%P@F[F[C/R"\/E?9$#/2@923"E))JD@UJ2&U
MI([4DXZD@322IH#">.()A>^])9UG&OQ;4OS74M=SU?.WI'.-"Q)T<#W9JIQ4
MD$I21:I)#:DE=:2>="0-I)$T!10&::8$+CC/YAF$X#Q;)A7"6U(4X?[Z7&5W
M?$8ZD')202I)%:DF-:26U)%ZTI$TD$;2%%`83SP;\95;TGG2P>[EA^N9@E$2
M*&/5@923"E))JD@UJ2&UI([4DXZD@322IH""+,S?ZUYPJIS*PPF%A<)1TFW\
MEP^NRH:8D0ZDG%202E)%JDD-J25UI)YT)`VDD30%%,9SV83"FA,*"_FG"BDC
M'4@YJ2"5I(I4DQI22^I(/>E(&D@C:0HHS"*>4/C.QX/U>:;!?SR(IA4>EJIG
M'P]<C3NIYL[]$2NK<E)!*DD5J28UI);4D7K2D3201M(44!AD//7P_/UG?9YA
ML'OY82%O+^])&>E`RDD%J215I)K4D%I21^I)1])`&DE30&$69@C_[8]JZWG$
M[S^J+13^S?5M=#KM794-,2,=2#FI()6DBE23&E)+ZD@]Z4@:2"-I"BB,Y[+9
M@S5G#Q8*3I6YRJ.,50=23BI():DBU:2&U)(Z4D\ZD@;22)H""K.X;/9`N]=,
MVP2GRD+>7V;;*D<9Z4#*206I)%6DFM206E)'ZDE'TD`:25-`819F%'[!96L>
MM`=98!R_-Y<P)::UNFL4Z,"JG%202E)%JDD-J25UI)YT)`VDD30%%&81C_;-
M<]EW_:7<FA,!EG3FN'>\[Z*W%_:NRB6W].7"/+`J)Q6DDE21:E)#:DD=J2<=
M20-I)$T!A<E=-A&PYD3`0MXILR=EI`,I)Q6DDE21:E)#:DD=J2<=20-I)$T!
M!5EL+IL(.)6'=Q=+[HC?DS+2@923"E))JD@UJ2&UI([4DXZD@322IH#"+"X;
M]>L;5>([_4+^>4'*2`=23BI():DBU:2&U)(Z4D\ZD@;22)H""K.(1_W/#Q8W
MY\&]O1,\6`IO(?%[-J[*+IB1#J2<5)!*4D6J20VI)76DGG0D#:21-`44QG/9
M6'[#L?Q"P:DR5WF4L>I`RDD%J215I)K4D%I21^I)1])`&DE30&$6EXWE-QS+
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M`7SE*8T#_<U";LOWI,R2O^6KN^B#<P=793<]M^2Z+TBEI;#[Z"-?E:NRW=>6
M7/<-J;44=A\=(IVKLMWWEESW1])@*>P^^@C'Z*IL]Y.E4_=AKI?-$&PX0V#)
M;?J>E%D*-SWZJ_B#J[*;GEMRW1>DTE+8??0>1>6J;/>U)==]0VHM^=WKJT?#
MOX'M7)7MOK?DNC^2!DMA]]$`9G15MOO)TJG[(-?M9;,-I_)PML&2V_0]*;,4
M;GI\2W15=M-S2Z[[@E1:"KN/+NF5J[+=UY9<]PVIM?1L]YVKLMWWEESW1])@
M*>P^NAR,KLIV/UDZ=1_F>MG,Q98S%Y;4<IYPO;Z*KK![5V4W*K,4OIKHVGEP
M57;!W)+;606IM!1V'UW<*E=ENZ\MN>X;4FLI[#ZZ`'6NRG;?6W+='TF#I=WI
M2RFOKU9(>4G"/>U/=IE$RI?-B6PY)V))@SLOY>B"N'=5]N5FCKP%5]&E[I"N
MBJY8N:NRW1>DTM$S:ZS25=$::U=EU]B06D?/K+&S5=LYTNWV=G>WCBX]O2W:
MG)_9CZ3!T3,K'&W5<RN<;-%IA>&EX;*9FBUG:A;RIF7VI(QT(.6D@E22*E)-
M:D@MJ2/UI"-I((VD*:`PB\MF:K:<J;$47*]6T8UU[ZKL\9Z1#J2<5)!*4D6J
M20VI)76DGG0D#:21-`44QG/9Y,V6DS<+!:?*7.51QJH#*2<5I))4D6I20VI)
M':DG'4D#:21-`859Z`B_8'9@:\JC)]6%PE,ENE+O[8+N!IR1#J2<5)!*4D6J
M20VI)76DGG0D#:21-`44QG/9Y,V6DS<+>>?%GI21#J2<5)!*4D6J20VI)76D
MGG0D#:21-`449G'9),R6DS"6W$FP)V6D`RDG%:225)%J4D-J21VI)QU)`VDD
M30&%65PV<;+EQ,E"P7DQ5WF4L>I`RDD%J215I)K4D%I21^I)1])`&DE30$$6
MN\LF.T[EX2W$DAOD[4F9)5WCSH.JU5WT3'9P5?:9++?DNB](I24W`UR1:DNN
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MWU79[GM+KOLC:;`4=A_-;8VNRG8_63IU'^9ZV03$CA,0EMRF[TF9I7#3<4M<
MNG?7MMPNZ+HO2*6EL/OHDEZY*KMG:DNN^X;46GJV^\Y5V>Y[2Z[[(VFP%'2/
MF6%79;N?+)VZ#W.-9R[FS\B],C]@]N6W]^_^_O"D1Q/=SQ+OSZXUD3G_C-*.
M$QJ6-&8X/]OP;0%;Y5YWMI#YB*6W8'1)/;@J^R)S]E602K>@WWUTS:M<E>V^
M9E\-J74+^MU'UZ7.5=GN>_9U)`UN0?-;57I;(#IT1U=@>YZ";L+PXZF2./S_
M>OKCK\+7EV:<T^<4RFXAC3^\$*/KY]Y6N<GNS%*P(-XN6*K,]WJY[E?1!2YW
M?=E]45AR:RPM/;O&ZIO66+N^[!H;2VZ-K:5GU]C9-:Y.;Q=LKF[OKF^C.W_O
M>K+K.UIRZQLL/;N^\1O6-[F>M+[P4-(U*9AU.WVFPURHOOTB8KJ(AE$SF2^E
M\G*.WUO<+57K\WLFF26W%PZ6S(7-_MC;-8^9\QKM'BWL@J[[TI+KOK+T;/>U
MK7)_*M98<MVWEESWG:7Y_<#53F\(ZO_"/QCH;9'K_6C)]3Y8<KV/EI[K?;)%
MI][#\.-YI--U1+_VN,1O+R,7'`N<:MHM%![%T7UA;ZO<B\L6,M\^X@4?OP-I
MJX+[%0^/\T:XPV,AM\;2]O7L&BM;]>P:ZZ5*WS!IU]A8<FML;5_/KK&S57?S
M.Y!7JZNU?J0R/HCP$H]<X6"[>G:%HZUZ;H63[?WT"L/C2EGCHK+:NH<3>V`E
M'D[\^Y/I)KJPS.1-C.UWH(QT(.6D@E22*E)-:D@MJ2/UI"-I((VD*:`@HYO+
MYLI.Y6$6EKPY9%)&.I!R4D$J216I)C6DEM21>M*1-)!&TA10F,5E$V,WG!A;
MR#\O2!GI0,I)!:DD5:2:U)!:4D?J24?20!I)4T!A%I=-<-UP@LM2^#9D-%+9
MNRI[?\A(!U).*D@EJ2+5I(;4DCI23SJ2!M)(F@(*X[ELGNJ&\U0+!:?*7.51
MQJH#*2<5I))4D6I20VI)':DG'4D#:21-`8597#:W=,.YI87TD7-[$NQ)&>E`
MRDD%J215I)K4D%I21^I)1])`&DE30&$69B;GVS];8::)HD<K2_[M?*ERE+'J
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M5?8UMJ3.D;_&^#V`9)6WQC#$>/A^>NMO]\K\K,)73DJ.Y&]G"@^?M3M\3G]O
ML'=5]K5FI,-"^H)@\V;Y[O9JL^-%][P^VU/!GDI+[G&TLIWK<'=7C_C]HIH+
M-I;<.W*M)==]]TW=]\&"82AFR.T_;U_^?NSM,FIW6_5@23O-O>AU=`_9NRJ[
M3[.%]+6RE@Z6@K[B'9C;OMQI6ECR3ZUE4QU5KLK?U.CJ7B>KO`/]=+@UKLIN
M?4OJ'/EKC.X!?;+*6V.88CP#<'IC]>(WP&XY,[!0>)YMHMO'WE79%YXY\EXE
MGWCF-4;=1_>*/-F7MR].>[]P578C2D?/;$25K(JO`'6Z*KKB-*[*;D3KZ)F-
MZ))5\6-7GZYR&Q$>%?$DQGQ47/P[T[?GV0WO!6RB>^?#4J5);5<5W:'VKL;N
MG8QT(.6D@E22*E)-:D@MJ2/UI"-I((VD*:`PR,LF16XY*;*0&1NY"W(<X=Y5
MN7CFOK2@I0.K<E)!*DD5J28UI);4D7K2D3201M(44!C/95,GMYPZ64CC&;N7
M]Z2,="#EI()4DBI236I(+:DC]:0C:2"-I"F@((N[>#;%7//6MZ>'S'?_^/SE
MZ4/Y^/[7TX7P:T^=IZ["F9:%S+CS?!IM=]&M>^^J;)H9Z4#*206I)%6DFM20
M6E)'ZDE'TD`:25-`87273<_<<7IF(>]BM2=EI`,I)Q6DDE21:E)#:DD=J2<=
M20-I)$T!A5FDYD^^ZZNW[SBALE!X%MW$SY2NRIU%<U_>9?+`JIQ4D$I21:I)
M#:DE=:2>="0-I)$T!10F%T^5?.=#W]UY#L5=ZJXWT03`PU+U[$.?JW%!SIU[
M?P!Q8%5.*D@EJ2+5I(;4DCI23SJ2!M)(F@(*@S0S#O[(_/DYDKMY@L+_]L*%
MHH>^*,*]JW+QS'UYU]$#JW)202I)%:DF-:26U)%ZTI$TD$;2%%`83SQQ\I5X
M.$ER-Y-W-=N3,M*!E),*4DFJ2#6I(;6DCM23CJ2!-)*F@,(LXNF/KV3!:8Z[
MF8);TO7&C:OGZ417Y4Z5\X*6#JS*206I)%6DFM206E)'ZDE'TD`:25-`83S_
MIGF(N^0\1#2K^+!4/7]+FGOR[C^96\P%B:J<506I)%6DFM206E)'ZDE'TD`:
M25-`89"7S4/<<1YBH>B6%$6X=U4VBXQT(.6D@E22*E)-:D@MJ2/UI"-I((VD
M*:`PGLOF(>XX#[%0<$N:JSS*6'4@Y:2"5)(J4DUJ2"VI(_6D(VD@C:0IH""+
MU=6_;R)B[BN<B;`6W;&B]RWV7MGY5$K8(6%YPHJ$E0FK$E8GK$E8F[`N87W"
MC@D;$C8F;`HM2C.>F_C.4=7JZCQKX0^KHAFD!UOV[$W,*_*RG?OW[FS*%J9L
M8<H6IFQARA:F;&'*%J9L8<H6IFQARA:F;&'*%J9L?8NRC><ZGG]Z7%UQ1L.:
MM]MUZLUUGF4)4SRH4SPPQ0-3/##%`U,\,,4#4SPPQ0-3/##%`U,\,,4#4SR^
M1?'$$QI?B^<\<6'/"IU.RWR#'NC.\[;7F^BL4V+G,KNH$H,I,9@2@RDQF!*#
M*3&8$H,I,9@2@RDQF!*#*3&8$H,I,9@2\RU*[+*9B]45IRZL>2>/XIGK/%,\
M,,4#4SPPQ0-3/##%`U,\,,4#4SPPQ0-3/##%`U,\,,4#4SR^1?%<-G.QNN+4
MQ=F\O_5-F.)9EG5UB@>F>&"*!Z9X8(H'IGA@B@>F>&"*!Z9X8(H'IGA@B@>F
M>'R+XKEL,F-UQ=D,:]Z9HK-GKO-,\<`4#TSQP!0/3/'`%`],\<`4#TSQP!0/
M3/'`%`],\<`4#TSQ^!;%8R8%_&E9\R3X7>^,K*[F^05_RO9LV@!WI]K&[XUX
M9=Z=:NDN.-=@"A.F,&$*$Z8P80H3IC!A"A.F,&$*$Z8P80H3IC!A"M.W*,S+
M)C165YS1L.:=5SK7YCK/=*[!=*[!%`],\<`4#TSQP!0/3/'`%`],\<`4#TSQ
MP!0/3/'`%(]O43R736BLKCBC<39W5BB>I<Z9XH$I'ICB@2D>F.*!*1Z8XH$I
M'ICB@2D>F.*!*1Z8XH$I'ICB\2V,9Q5/<7SER?Q4'TUC+.:=*?L5+4O8(6%Y
MPHJ$E0FK$E8GK$E8F[`N87W"C@D;$C8F;`HMBL<,>?T[U=?BF8?(P>UHM5AX
M.XK^/E.)G<O<[8BFQ%"GQ&!*#*;$8$H,IL1@2@RFQ&!*#*;$8$H,IL1@8\*4
MF%\7)69&P9<D-H^:P\3\D?3\MM5*!>;CJ=Y)IA,*IGA@B@>F>&"*!Z9X8(H'
MIGA@B@>F>&"*!Z9X8(H'IGA@BL>W*!XSY+TDGGF(K![M6?&P6BWF;CTZ>V"*
M!Z9X8(H'IGA@B@>F>&"*!Z9X8(H'IGA@B@>F>&"*!Z9X8(K'MR@>,^2]))YY
MB!S&XP^;[=D#4SPPQ0-3/##%`U,\,,4#4SPPQ0-3/##%`U,\,,4#4SPPQ0-3
M/+Y%\9@A[R7Q+$/DX.SQA\TV'ICB64Q/_FX4M8KF^Y38N<R>H$H,W2DQF!([
M+^NMXCK^Y*M79E>A$-&=0H0IQ&]9A7(]E]E5*%>_NR@',[:])(=Y+!R>)HL%
M5S&8<E@LR.$Z^N2`<CB7V5>@'-"=<H`IA_.R?@[1*G0RG<OL*I0#NE,.,.5P
M7O:952B'<YE=A7+PNXMR,,/22W)8AK'!^;!8D`-,.2RF?[CS81OM).5P+K.O
M0#F@.^4`4P[G9?U5\'PXE]E5*`=TIQQ@RN&\K+>*^+/]RN%<9E>A'/SNHAS,
M^-//87YKSWUYX#=]L_%J-0]CP]-DL2`>F.*935]EO'Q;;_2Y&25SKK"O2<F@
M)R4#4S+G9=/?!:R3XUQA>U<HZ$FAP!3*>=FE]^BH4A[G"MN[\O![BO(P`\[G
M\OBV+W-<Z9LPX^]D.9N:O/,@VMMZ(%L6=1\35$:+N0\8*I79KN</CJ[7ZYOU
M572344Q84#%A!8H)=0IF64'PL9WXLX_*"HLJ*ZQ"6:%.Z7S+*A28OV@8F/D<
M=!#85\:9I_IH&F"Q\`M\M_&?JJYLF?MX:'8V=UT\6%OK6=[E'.^WW)9IK?;(
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M%[2F!&'*"Z:\8,H+IKQ@"@>F<&`*!Z9P8(H"=DS8D+`Q85-H4;1F?.M'^[5;
MVS(>=I<HY36;-RNJ$PRF>&"*!Z9X8(H'IGA@B@>F>&"*!Z9X8(H'IGA@B@>F
M>&"*!Z9X?(OB,</>2^)9ALE!/+/INUK=Z82S3HF=R^S)H\1@2@RFQ&!*#*;$
M8$H,IL1@2@RFQ&!*#*;$8$H,IL1@2@RFQ'R+$C,#Y$L26P;406*SA2<43/'`
M%`],\<`4#TSQP!0/3/'`%`],\<`4#TSQP!0/3/'`%`],\?@6Q6/&RY?$LXRO
M@WC\,?<R>7H-4SPPQ0-3/##%`U,\,,4#4SPPQ0-3/##%`U,\,,4#4SPPQ0-3
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M'ICB@2D>F.*!*1[?HGC,</F2>);AM7^GTK?SF7B\,T`7-YCB@2D>F.*!*1Z8
MXH$I'ICB@2D>F.*!*1Z8XH$I'ICB@2D>F.+Q+8K'#*$OB6<><H=GSV+A[2B:
MM5-BYS+O=@138C`E!E-B,"4&4V(P)0938C`E!E-B,"4&4V(P)0938C`EYEN4
MF!D%^XG-<[D7?\G>2M/\G&6*IRH?;)E./O>P@5FFI2_O#-79Z`_73X__RA:F
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MMKXDGGDL'IY0_OA\F7Y:PQ0/3/'`%`],\<`4#TSQP!0/3/'`%`],\<`4#TSQ
MP!0/3/'`%(]O83R;>'[C*V?/J3Z:Q%@L.'MHF=Z&.]WCO+I#PO*$%0DK$U8E
MK$Y8D[`V85W"^H0=$S8D;$S8%%H4CQDM^V?/]]ZGS,TH?KY8S-PFO?M4]&<B
M>_T&=!R;HH0I2IBBA"E*F**$*4J8HH0I2IBBA"E*F**$*4J8HH0I2IBB]&V.
M\O7GWQX?OV1OO[S]Z8</CY]^?=P__O[[YQ?OGO[Q47O]6I\7]?S%I\=??GSY
MH%'#O4[;TWOUYV7FMC=ZZKQ_8U:D6U74IN6V9KEMNFUGVDZW."YW8]I.?P?`
MMEO3=ION\\ZTG?X*`,MMKM2F<SZUG9N5:4N_AFNS/LV8IY:[-NO3=&VJ;6W6
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M`^[-E]^G6K3=^M[U5(NV6]\"GFBYTV;K2Z93+3IN]97'J18=M>EMVVH]V^1Z
M=FK1SYTG>KO1%NC'MU,MV@+]%'2J15N@7R%.M>C`TF_B)EJV:MFF6Y3/-IG/
M5OEL4_D\;'7(;9.']E;Y;)/Y;)7/-IF/N6^D;QOFKI&^:6RT#S;)?;#1*]TD
M7^E&KW23?*4;O=)-\I6NM07)V\B;]?7]&_W$1F)?JV5*WU[,W25]<S'W__3E
MW-SATS?XM5)(W][72B%]<U\KA?2M?:UC-'EC?W.M"UGZMJ"6*7WA-_>@]"W(
MW('2-R!S_TFNY\VUK@?)%![4,B5O2P_FJ2+]4&&>*=*/%.:)(OE`\69EGL&2
M1Z]:)GV$*G$<K/1ZYO>E<-O75NMC)JEEM-7)];Q9W2F%Y!&OEFG^T^%X/==Z
M/?H[^,1ZKG5<ZX^34RTZ>M/KT:8E]X!6G[RVG9Z74FM_HZ<E/=&FUCX_1R5;
MM%U_\1"EH_`O'J%T%";7HP\I;.]/'RWA'GBCC4OO9W66VC*SPU)N3O:$OS&/
M;JG=\F"N3XD%'G2$)0\P'5_)"Y".KM3!I0]_;.]/G];AB]:'0+;WIT_ML$T?
M!MG>Z],?J6U0V\ZTI;9#;3>F+;4M:KLU;:D#2I^#V=Z?/K/$;='G8;;WI\\N
ML4V?B]G>ZX,PJ>U4V\ZTI;93;3>F+;6=:KLU;:GMU$\3WYL?:^66Z`=4[\UO
MI+)%/X!Z;W[CE"WZ`=-[\QNE;'DPKTO_D]H&?0!I>Z__2;7I@TC;>WWR*+4_
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ML4M=`4JU5,F65BU=LF50RYALR78KK2=U*RO54B5;6K5TR99!+6.R)=OJ]6R3
MKT<M5;*E54N7;!G4,B9;LJU>SS;Y>M12)5M:M73)ED$M8[(EV^C<WJ3.K%(M
M5;*E54N7;!G4,B9;LHVN%)OD6:^6*MG2JJ5+M@QJ&9,MV4:W@$WJFEBJI4JV
MM&KIDBV#6L9D2[;1U7*3O%:II4JVM&KIDBV#6L:YY?7Y>??S3S_\\?;7Q^[M
MIU_??_S\XO?'7S35>G7Z7/:G^2>\YO_X\O2'WLMX^>)O3U_T\UZG?_WM\>W/
MCY],M=[<_^7IZ8O]#UUT7__Y].GOI^G<G_Y'`````/__`P!02P,$%``&``@`
M```A`#=,PJ4H!```DPT``!D```!X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
MK%==CZ,V%'VOU/^`>-_P%4*"DJQ"".E*6ZFJMNTS`2=!`QAA9S+S[WN-C6/C
MZ2@K]648CN\]^-P/^V;]]:VIK5?4DPJW&]N;N;:%V@*757O9V'_]R+XL;8O0
MO"WS&K=H8[\C8G_=_OK+^H[[%W)%B%K`T)*-?:6TBQV'%%?4Y&2&.]3"RAGW
M34[AM;\XI.M17@Y.3>WXKKMPFKQJ;<X0]\]PX/.Y*E"*BUN#6LI)>E3G%/9/
MKE5'1K:F>(:NR?N76_>EP$T'%*>JKNC[0&I;31%_N[2XST\UZ'[SYGDQ<@\O
M!GU3%3TF^$QG0.?PC9J:5\[*`:;MNJQ``0N[U:/SQMYY\=%S;6>['@+T=X7N
M1/G?(E=\/_95^;UJ$40;\L0R<,+XA9E^*QD$SH[AG0T9^*.W2G3.;S7]$]]_
M0]7E2B'=(2ABPN+R/46D@(@"S<P/&5.!:]@`_+6:BI4&1"1_&Y[WJJ37C1TL
M9F'D!AZ86R=$:%8Q2MLJ;H3BYA]NY`DJ3A(($G@*DN=]P7+8`#R%KS=;AN%\
ML8R>)UD($G@*DJ=%.#P@0WS3G.;;=8_O%A0M2"9=SEK`BR/;&@/+PR!#_5^1
MAA`SDAUCV=BP+P@B@?)XW8:K8.V\0DH+89.8-IYNL1\M6/X8;3H%#E,@FP)'
M!7!`HM3I_R\Z&0O3.>XP&8&'<'\B:K087=(I<)@"V10X*H`F"BIQFKP`>NOC
MKAASQ9R@_M5<S>?ZIA-AHR9T8K*7)E*8@1P,)#.0HXIHXN:F.-;R/UF9C`5J
M&R*HE.9$2\*-@L_D2A,IUT`.!I(9R%%%-+D@;9I++YRQTX%>J^(EP?Q\^B"W
M`30<;T/&,8@=-YEP)%HI\GU_TIE[:32ZI1Q9+&6A'Z2-$L=PH9=-)HU&HJ-*
MI,F%6'\F]P?NAK/I`[EP8H]Z&8FNER.+E=SX7B+L5/)=+]3WG/+U:+A_AB@>
MI,=#JN^YNELFW+SAL`NBP)T8'"4+Q$)3#J>LJOQSA<Q85\B1R'\HE(A0.,E*
M*M8#Z7&0'F.>,H',N9RE:\A1730Y;,12+I#/Y3!C70Y'U(1)1,B)],BG?%U-
MF/20<H2-R,X2].@D1]5%DP.=HLKA]^%/MB'CT%5R1$V:1(3*I;[!5*PK21,(
M'V_8]9@)9#$D;149(N4WIB4(HYJI$F8)<=:,S??\P3,0ZI(%I&;V`3TZ*YH*
M%T9J?D<(:E`>XK[1D:/5<@B'YT=FUA\;D!'A(R<?B1K47]`>U36Q"GQCXR3C
MDB@?=9,PA@,3_"?X(8SA_#-Q&(UW0[-.[!,V,G]@G_@QW/<F3Q+$<%>:^&X>
M[T"7N9#,8[AM`'?DEV$D[O(+^CWO+U5+K!J=0:,[5'?/AVK^0L7I>\(4AF'(
M*PR&\.,'0=&YK$K.&-/QA7U`_IS:_@L``/__`P!02P,$%``&``@````A`&/H
M9O.B"@``^C```!D```!X;"]W;W)K<VAE971S+W-H965T,C$N>&ULK)M;;]LZ
M$L??%]CO8/C]V)8LWX0D![5UOV&Q.+O[[#I*8M2V`MMMVF]_AB)'0W+47+KM
M0]/\-/R+G*'(&8F]^?/[\3#X5I\O^^9T.W1&D^&@/NV:^_WI\7;XG[^B/Y;#
MP>6Z/=UO#\VIOAW^J"_#/^_^^8^;E^;\Y?)4U]<!*)PNM\.GZ_79'X\ONZ?Z
MN+V,FN?Z!%<>FO-Q>X5?SX_CR_.YWMZWC8Z'L3N9S,?'[?XTE`K^^3T:S</#
M?E<'S>[KL3Y=I<BY/FROT/_+T_[Y@FK'W7ODCMOSEZ_/?^R:XS-(?-X?]M<?
MK>AP<-SYZ>.I.6\_'V#<WQUONT/M]A<F?]SOSLVE>;B.0&XL.\K'O!JOQJ!T
M=W._AQ$(MP_.]</M\)/C5^YJ.+Z[:1WTWWW]<M'^/;@\-2_Q>7]?[$\U>!OB
M)"+PN6F^"-/T7B!H/&:MHS8"_SH/[NN'[=?#]=_-2U+O'Y^N$.X9C$@,S+__
M$=27'7@49$;N3"CMF@-T`/X>'/=B:H!'MM_;GR_[^^O3[7#JC=SES)G-P7[P
MN;Y<H[W0'`YV7R_7YO@_:>4H+:GB*A7XB2KNR/$F']&`N[4]@9]*8SE:SF;>
M?+EX?T=@6K<B\%.)S$>SQ63JB,&\,H"5:@<_53MGV@W@E7;.5#44_U`MW^SM
M6,:@#6FPO6[O;L[-RP">$W#RY7DKGCK'=[SA`(,I.]"%]V?1A;`*E4]"YG8X
M'PX@;A>8DM_N9LOES?@;3*.=LEES&\>TV*"%F#-"-K!!:(/(!K$-$AND-LAL
MD-N@L$%I@TH#8W!MYU^8GK_#OT)&^!<]LT9`#G<M9Z(%-@EL$-H@LD%L@\0&
MJ0TR&^0V*&Q0VJ#2@.%,F/"_PYE"!A8=;;)ZRYGIO;6RT6>T9YIL.I/.PXR$
MC$2,Q(PDC*2,9(SDC!2,E(Q4.C&<#8O![W"VD('%!4*J+0TKTY5K:31]S=N=
M2>=M1D)&(D9B1A)&4D8R1G)&"D9*1BJ=&-Z&%=SP=O]FBLNML&Z=BLY82S)?
M:&[V5O:,[8RP6<!(R$C$2,Q(PDC*2,9(SDC!2,E(I1/#AS!]/N!#86WZ4!+P
M(;IGPTC`2,A(Q$C,2,)(RDC&2,Y(P4C)2*43PV$P6PR'R<U_))*?Z]-^]V7=
MR#2L9S).89.76[\0,?THR:Q-05N;C;*1&5R[LTLRA>2S6Q:\E;4(AYT1!B1B
M0C$C2==*EYZ;*T[:&:%TQH1R1HJNE2Z],*7+S@BE*UW("(`HB7CV10'XJWD&
MU[Z5?`D5,P*2Z!%0-EH$))F[W6P/&8E8JYB1A+5*&<E8JYR1@K4J&:GT5H8C
M(8DV'-DS8R$=QRDKK$V'*0(_M.EH);`;9>1U'@NZ9ACJ4!+7:7/@N>-ZKI67
M1:Q-S'23SH:ZXSH3<YZEZE:3]E:3D=7;K-/`ON7L/@6S*2692U%WXE@[=:6W
M,"+@P*-LA."7%I-6Q0R-0JZ>07@KJU\;M)I2<!!1O$)$\]9GT^EB9CDU0@MZ
M+&)$))T@TOO$`Z2LINY/(D0J78@0T;T*1-2C4J&YG&4]43+:F&$2A0I;<J!B
M54L^KCCO7_\=6?I`AH>C6",BSV\X"A1REUW#$-%*/C[>W%G8CP\*T>X2(Z+;
M)8C(*D7M]N5&NRUEW"I'1%H%(M(JN59E6)DN%^4,<_GLHZN\2*&M54LA/6/A
M*.`HY"CB*.8HX2CE*.,HYZC@J.2H,I#I5U&ZZ'Y]?=$7KTML_TED9,VSB;4D
M;%1#S<L!1R%'$4<Q1PE'*4<91SE'!4<E1Y6!3)>*^N0#+I7E#(2('GV)-&=M
MQ&LE<+R&`HY"CB*.8HX2CE*.,HYRC@J.2HXJ`YG^$[6)[K]?VP1EA6.X52'*
MWS;BE:N8SX0"A=[(JLD*HQ9QK9BCA!I26N*M[,R:K%`^XUHY1P4UU.7M[)JL
M4+XRM,QXB-+GM7C@=O?&TB$K*",@"I'W-PY#@4(SVDU"CB+>,.8HX0U3CC+>
M,.>HX`U+CBJCH>E74='H?GW#?ZH`TM<)A2"??"7C=I05^2]`1+MQJ!`FW9#5
M+:QD..*M8D2DG2#2.^6RO!MO][/$FU1PAN:(Z%X%(AI'J5"7?+O63E09;<R`
MB,KH`P%1A90>$(G>2K.5%>6G@=,UQ.&&"DU%Q?7MSIF([REF\1+Q5C$BTDX0
MO9%GRQ[\/,]F/<Q1F.Y5("*?E`IU>38/B*YL!D042GI`?FTG4.46]6GM*`2;
M:O?@S";L2TIGA4$)5,,I#3E4R%NT<8+/J/#'CI,2HFD:4P]0.T$$QEVG>AX<
MJ>7*!\<9.>T-N[^L,60DBO?)$>G/$>M@J:Q>>8[T-D;8H&\]8?M_RJ-6T:QH
M%7(I$AN.`H4\K3Q2:"8=N/(\;S:UXH5"-&-B1'2[!!%9I0K!0X3>SKA5CHBT
M"D34L%0(GAO4J@PKT^6]%>F'RR-8_>WT7B'#S])*0P%:4?]#A31?1-PJ1D2^
M2!"15LJU,FZ5(R*M`A%IE0H9?E4#:JU,O]IEY^M[M%CXK?)(H3E42=U3/9M8
M!?F&K##8`4<A1Q%',4<)1RE'&4<Y1P5')4>50O`#!F2Z]&,5)\PRYE*)M/FW
M458:"A!1Z$.%C"FIM,@JQH8TC1)$9)5RK8Q;Y8A(JT!$6J5"QI34^V7Z3U2"
M^J;XQI24A:.>=KNJEJ1.;3@*$)E[I+54AF2%$S="1!_:8T1TQP21+N^YUL>V
ME*Q0/D-$\CDBDB\0&?(KNPXB*Y2O$+7RIN/MNO0-Q_,"5!QF$44\]7/#48!(
M[_IL8GDF)"OL>H2(/!,CHCLFB$QY*[5,R0KE,T0DGR,B^0(191<E1Q6B'B^_
M56V^ZWN:RXM-A0SG2RL-!6@ESUR)KVPA1Q$B<D6,B%R1((*H:TN_7>J3%7E:
M]8OD<[0B^0(1=;7DJ$+4XVF[_K2SZ_?5]2ZO2Q6"90V'M.$H0$0+8:B0L4!+
M>;F1M&^<8VQ(\@DBTDJY5L:M<D2D52`BK5(A8X'6^V6N$Z*>^<`"+<L?8X%6
MR'Q$K<5K`^_\VYV1GK0`$14:H4*0]8@RTG-7DQ7[7L.;Q8A(/$'T>GV"]\/Z
MQ%I8,E+!N9$CHGL5B&@@I4)4D%@K8F6T,2,B2I4/1$15-C0!UG`4M%VYM6,-
M'`4<A1Q%',4<)1RE'&4<Y1P5')4<B>.N-$;I/WE\59YU/-;GQWI3'PZ7P:[Y
M*HZF3L47I@[+<[/@*3PX:U_Q?#BY`T&W^<R'TR@]?.[#H8L>[KB^^*#1=V4*
M5]HGV;Z'`S>'-\Z\#2S2?@IK)+\"B8:?]5Z!?,,7"S)O`VF'+Q9A?@7R"O!+
MWQ4X:?RI?S30Y1ZE-0R_UQX&WS?V3Q[HM\^1[137A<[V2D%GU[V=A431W_1>
M@7S1%]D@'SHD-'"E+\2PV\*5/J=`$NF+79:K02[IB\V67X&4$D+9UP/(>>!*
M;P\<Z!N\^NY1@RMI[Q5XQ^Z7O5?@536H]?8-KH@WS?P^\!H9U/JN!`L?#N_P
M%LG"AY,WG!<+'X[-<!XL?3B5PGFR].&4">?%TH=3(\#'W82!D^?/V\>ZW)X?
M]Z?+X%`_P.,_:3^^GN79=?G+51VU^=Q<X<@YO+"!L]#P?PQJ2*,FXNOX0]-<
M\1=Q@^Y_+=S]#0``__\#`%!+`P04``8`"````"$`?K&.G=H%```\%@``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6RLF-MNHT@0AN]7VG=`W(\YV$",
MXHQB<]:NM%K-[EX3C&T48RP@AWG[K3X!W>5X'"DW(?Y<_4/]7727^_[[>WW4
M7LNVJYK32K=FIJZ5IZ+95J?]2O_G1_3M3M>Z/C]M\V-S*E?ZS[+3OS_\_MO]
M6],^=X>R[#50.'4K_=#W9]\PNN)0UGDW:\[E";[9-6V=]_"QW1O=N2WS+1U4
M'PW;-%VCSJN3SA3\]A:-9K>KBC)HBI>Z//5,I"V/>0_/WQVJ<R?4ZN(6N3IO
MGU_.WXJF/H/$4W6L^I]45-?JPD_WIZ;-GXZ0][NUR`NA33\@^;HJVJ9K=OT,
MY`SVH#CGI;$T0.GA?EM!!L1VK2UW*_W1\C-KH1L/]]2@?ZORK9O\KW6'YBUN
MJ^T?U:D$MV&>R`P\-<TS"4VW!,%@`XV.Z`S\U6K;<I>_'/N_F[>DK/:''J;;
M@8Q(8O[V9U!V!3@*,C/;(4I%<X0'@+]:79'2`$?R=WI]J[;]8:7/W9FU,%V(
MUI[*KH\JHJAKQ4O7-_5_+,;B2DS#YAIP'34<SYQ;GQ!9<!&X<A'X[\I-X?'H
M@\-5W'1X[BO#H.[I,+CR8?;,OG,LAR9\9>"2#X0K'[B<+6S'NZ-)7AEHP9PR
MB\GD<O]F-]ICL.FBLQ_D??YPWS9O&KQ2,"/=.2<OJ.63.XAY9P\R5,)'A0`5
M0%0>B<Q*=W4-)KF#ZGU]<#SWWGB%BBMXS!K'6'+$1D20\B*R@0I"%40JB%60
MJ"!5038!!M@R>`-U^!7>$!GBC<AJ+<!HEJT8(2+$D$`%H0HB%<0J2%20JB";
M`,F(^=<8061@79@4B>TZ<N9K'C.MI(4<LAE"!G<0"1&)$(D121!)$<FF1#()
MEIFOJ!8B`R\C3,7D5?)D"]8L:'[-I2%D<`F1$)$(D1B1!)$4D6Q*))=@F95<
MNKR_B&6%1%,S1!)K1B!S03:(!(B$B$2(Q(@DB*2(9%,B)0IS\XE$2;2<*",+
MNFO3Q7##8\;4`TZ\2:W8IO*ZA$.0<"Q")$8D&<A8AK8SE\LP'8*$=,8)?4;)
M#GA&R0ZVS\P\\*\_5,7SNF'MP85ZF,-^PG89(B*[Q,C4)1XS<8F1N4FW)=NT
M5(.&[T46$=?PAB*+$4F&462S`U75F^%[H9IQ#>P-Z:'5/=B&:&K,C^8,*?]J
M_R42LC.,S.$RK".VNY0G<,.'T;Z2[;B<0'<R#K-,>5C(@FQH%R9!RF8>#4K"
M@!C=+1EBID+*W5)^-XO-G^6:IA*1#3)P*ZGJ((V/G;VIY(B";"PC<\DA3WFB
M#0NRYT,%!9R,5H><D#=`-$VVI;K(@^Q!*$;2"9)..7&I9>[=`ELVU94L(TT@
M\LQRQC?UMH*D,K)Q',DEZ2D);\3`T:A`H.5@0LC1+TH0#XP%&N43@4;Y5,BS
MFEN"?:CFI%&R@Z2?5-_GJ8,W%9[%NE)H!,3[L^9(*3VU=^11T]H3:$PZ%.AZ
M]8FH\2%B@<;23@0:Y5.!)'E/62,S$35M=FQ[_-T@VTJZ4V2K.Q,[B*C+V[<3
MTF0I+S='2HTJ.\9&#!P3#CBBR_;X-BO+0BBB8,&Z\LX+^;$@8X'&.R9"BVP4
M']XQ%5%+NA1XSMW24=ZX3&C3V\F6DV876?[YM8#US'"?L92G;31K;RR$`HQ"
MC"*,8HP2C%*,,@G)7I"6=NK%A4X%CBE$JP)G-:BVIDTQSQFA@`^<=+@A1A%&
M,48)1BE&Y%B)/"J[(\N9'1.Q@X*Z;/?EICP>.ZUH7L@1D'4':0Z8G4^MK3D<
M4-%%`7VS$$=7RC>)ZT,+"36A<L]/:>^E\,SUH8G"\7`V]DAK2XE?DS.S"_%K
MVX>?NEAG#2E<RN!QX3^"21<&0&87N>/##X,+\:Z_OI3`QO4WEWC@^M"^8YW`
M\\-+\9'K0^^*XV/7APX6N#$X!&=WYWQ?_IFW^^K4:<=R!Q-KTEV^9:=_[$//
MV\^GIH=C.YA[."*"4]H23F=,LO3NFJ87'\@-AG/?A_\!``#__P,`4$L#!!0`
M!@`(````(0"SDMCN1B4``!G,```9````>&PO=V]R:W-H965T<R]S:&5E=#$Y
M+GAM;*R=67,;1[*V[T_$^0\*W8^$G0#"U@D3O2_H!<MW34NTI;`D*DAZ///O
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MK]Z+TH>?/GV13]`U^YO'^]]^?OO+>'T<C\9OWW_XZ=1"QR_W?ST-_G[S]/GA
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MAY&9O[L9CU;3%UI\+!W=5V#0X^/KVGR,?N[^^`\JC[X;:^?-KJO\#2HO?Z`"
M5S8\^GJLG3UY?<-/T'_='ZC!U?-D@MG6_6&\5X,1=WFZO>^G[FDE".Z>[S[\
M]/CPUQM97T7LZ<==MUJ/UQ,9$%@#^G%X7A7^;E&0U:!3^:63^?FM](G,]R=9
MRO[Y0>;A3^__*:O/1V-SRS9CVV(#BVZIZ60#%X0NB%P0NR!Q0>J"S`6Y"PH7
ME"[8NJ!R0>V"Q@6M"W8NV+O@X(+C`+R7+C[WLW3M?Z.?.YFNG]%#MP#:\1.G
M4V$!E\`%H0LB%\0N2%R0NB!S0>Z"P@6E"[8NJ%Q0NZ!Q0>N"G0OV+CBXX#@`
M5J?*,OS?Z-1.YG05/T_>R7)F]^*ML1G.<,=D<S8Y]S21D$A$)":2$$F)9$1R
M(@61DLB62$6D)M(0:8GLB.R)'(@<A\3J?+F._C<ZOY.1Q5^&V+GWYS<KI_=[
MH^FEWC^;G'N?2$@D(A(328BD1#(B.9&"2$ED2Z0B4A-IB+1$=D3V1`Y$CD-B
M];[<]5J][[]GQ^6YLSYU,CKGMB?2HR`;(@&1D$A$)":2$$F)9$1R(@61DLB6
M2$6D)M(0:8GLB.R)'(@<A\3J0)E+K^C`SMKN0$,&'4@D(!(2B8C$1!(B*9&,
M2$ZD(%(2V1*IB-1$&B(MD1V1/9$#D>.06!THVXA7=&!G;7=@3X8SD$A`)"02
M$8F))$12(AF1G$A!I"2R)5(1J8DT1%HB.R)[(@<BQR&Q.E`V<Z_HP,[:[D!#
M^G1&MUW9$`D,D3J<KZZ3U<B^NH9G(ZS%$0G%1)*SUU#:V5&E9R-(9T,AJSDD
M'_&*YNBL[>8P9-`<1`)#[.9P-@SAV0AUCD@H)I+T9#8Y;3YGX^7$:>7T;`#9
M;"AB-4678+':HM\5O^OR(\^?OWS\X_9!NE.V6IZK[E0J8/;$G8K=1B=A08-&
M8A08-!V=/LMD-';NM$,UP&>)6"9FE*ACMT5GY50-H)Q9,G8S=9M--WDPZ3JW
M:Z/]PX^_:R-)LYT;J=^PROTG`MY*ZYS:3;IG,&FF]J39P&IV=@R`5F<4&C09
MGYIR.AI-%XN9DYB(V"\&4O4$2-73:]0SR\]NOVY?1^VWZ)*MOI$U;+5^1VBU
M6H^Z',Z@U9R1L^GN\V5,3J;G)@J`+,>Q,WM"8S7MY]?XW?C&[H](9="1,9`&
M2X`N!DOM8,[ZD*F&1+(;M-LL#1O4,S^'K=COK40/5;[M4IS=G)7[[D$KSNW/
MNE$K.`9`UJ#E5NSENP3@0'YART>J!?D8:#@>354O1DR-X^6(&>1/8]MNTFX'
M\HHF[3<L5I/VR!F8SO#9="WN#LRS(YHA-%;G4>BH1%"QAM?*F>\QK(;CDF*E
M;BRGES*H_%TLNQF[?<`KFK'?-EC-:)#5W2MGH[[I'M_TXQ=M%@#INA4:9`T*
M61O=87B."*T86L-A2%:I7]ZY-<F@Y1ESW3WW*QK+W*(/IW&/K#$W'3D+R:9[
MAN".N;,C/G-HK&3,Z9R=CIS+402MH=6$1QY%3-01$5-_1&<IS]11ZS6,:(^_
M[B[X%4W:F3NW+@8-Q]]T1"NCL=(!$HS/COB`H4'.^',F6,2.,9#*)T`ZO-.K
MY#/+T6ZL[A[Y%8UE;JF'XZ]'P\U=]^Q(FG2``D8AHXA1S"AAE#+*&.6,"D8E
MHRVCBE'-J&'4,MHQVC,Z,#I:R.Y7&;NOZ=?.W)D$!@VR+F-"`:.04<0H9I0P
M2AEEC')&!:.2T991Q:AFU#!J&>T8[1D=&!TM9/5KMXZ\HE]/YG:_`@WZE5'`
M*&04,8H9)8Q21AFCG%'!J&2T950QJADUC%I&.T9[1@=&1PO9_>K;7TZ75^R/
M9+_G3EV#9MW^_)\?_N'<C6RT6*^FTY'>7]H5DZN\->"Z_,!U%>L\G;'7(U3,
MO4GI[F'$0XJ'%=-;6KMBW9Y@>.6ZOF)F-S&XB,DFT40^M9ASQ[/1XF'%](;4
MKEAW?SVLV.6=V:2_'1_>_QHTN'YN&`6,0D81HYA1PBAEE#'*&16,2D9;1A6C
MFE'#J&6T8[1G=&!TM)#=K]W=_ROZU6P6AJ/,H.'22RCH4B+=O%&KD%'$*&:4
M,$H998QR1@6CDM&64<6H9M0P:AGM&.T9'1@=+63W:[=1>46_]OL::[[VR)JO
MA(()H9!1Q"AFE#!*&66,<D8%HY+1EE'%J&;4,&H9[1CM&1T8'2UD]VNW&7M%
MOYJ]VW"^&B0==TYA3=U$UZ;+`MOS-6`4,HH8Q8P21BFCC%'.J&!4,MHRJAC5
MC!I&+:,=HSVC`Z.CA>RN?MTN=L*[6(.L*<R[6+8*&46,8D8)HY11QBAG5#`J
M&6T958QJ1@VCEM&.T9[1@='10G:_OFX7.^%=+-#@*12C`$AF\GFB\[-+M4)V
M)P)2^9A1`G11/E4KR&=`*I\S*H!L>>>NOU0KR&^!5+YB5`-=E&_4"O(MT$G>
MZE=YW/>:I?ED;N\D@+3J&T8!T+#J<F+?3OZ&:H6J1T`J'S-*@"[*IVH%^0Q(
MY7-&!9`M[^Q-2K6"_!9(Y2M&-=!%^4:M(-\"G>3M?O7M8L=RXEYN::]_F#SE
M'2V0?J(-H\`@J9]YY.NT5:@&^#`1R\2,$G4TRLX82M4`RAG+Y(P*=?37N50#
M*&]9IF)4JZ._SHT:0+FU9.RN]>4!NBOR*QZ`=\\5G(P`D*S<YY5WZAX"V,!*
M<^$!D.;"0X/,`_#)9#J=SE?.$(C8+P92]01(U5-;?;R:=M^BT:3)Z1Q$QGXY
MD*H70*I>VNJS\<U8OA/D/*7:LE\%I.HUD*HWMKJ_[JWE9_>]+]4RN>;A_913
M+0;9SZO&[L,56.ESRP!(;]!#@Z;=&0OY&L98OE0W<5LM8K\82-43(%5/;?7E
M?#2=CR9.13/VRX%4O0!2]=)6'T\7H]EX<N/(;]FQ`E+Y&DCE&UO>7_G6\K.[
MW$UB==FUZ[J<\UE3@X:3?+)R'O)M8*5#.0"R'-T-6&BL)+G:C8+1.TT8GB9E
MI"I8YV(@C94`78R5NK&<Y253%<3*@316`70Q5FG'&K^CL7%N5L2J(*RQ:J"+
ML1H[%K5AJRH2RQXI7;KJ^FVVS%6Z!O2H2[*>KP&3E?-I-\9Q>)P'2"XKZLC#
MHY>7Y>UOAH<)KY,GAK!.L03H8JS46/U=K$Q5T&4YD,8J@"[&*E^(M545Q*J`
M-%8-=#%6\T*L5E5H>'19KU<,CSY)-LRNR9[\-&*L`;QRKKP;6.G(#X#T0A@:
M=%XJQIK#-VN%-YBSHL10UF`)D`9+W6#./6.F+H/AZYZCR&&EL0H@C56ZL:9.
ME;?J<R%8!2L-5@-IL,8-YK9BJS[^8/8"(C>1KQDAG;FS&>R1=4LQH?-"4V.E
M@S\`TJD?&F1FL'SCU]XL1NP2`ZEP`J3"J2OL'`')V"4'4N$"2(5+6]@99%MV
MJ(!4M@92V<:6I89H+1>[0U^7C9MR-@YH..7Y3!.L=+`&0#I80X/,E%\X\R)2
M#_]0/2T+,:PT5`*DH5([U(W3%9EZ7`B5PTI#%4`:JK1#N9]JJQX70E6PTE`U
MD(9J[%`WSAU/JQ[^4/;0D!Y]S5SOS)VYWB-KKO/9K*FQTB$>`.D0#PWJ-C[G
M^X?IR)F8$3O&0"J?`*E\>I5\QHXYD,H70"I?7B6_9<<*2.5K()5OKI)O+4>K
MJV>OR_&=S.VN-D@N)KB!V3`*&(6,(D8QHX11RBACE#,J&)6,MHPJ1C6CAE'+
M:,=HS^C`Z&@ANU_='-_EXPTS3N89)!<0[=?>:H`"M@H918QB1@FCE%'&*&=4
M,"H9;1E5C&I&#:.6T8[1GM&!T=%"=K_**OB*I5F^?>0NS099\[6W&J"`K4)&
M$:.84<(H990QRAD5C$I&6T85HYI1PZAEM&.T9W1@=+20W:^^Y-U5![BZ<UC.
MU=<@'.!RGC%MM'AX0=6MFETQ7XKINHIQBFG6(U3,N?7::/&@8F.]TML5ZQ("
MPRWKU2?+9GTJ8;A[-0@5<^Z>-EH\J-A(=Z5VQ=R]=%>Q[KL%K_P%F]EYDZU!
MYTLGVWQKK+J]W/GNR-D-;=0&2WG`*&04,8H9)8Q21AFCG%'!J&2T950QJADU
MC%I&.T9[1@=&1PO9@^)UV^<9;Y\-&BS2&T8!HY!1Q"AFE#!*&66,<D8%HY+1
MEE'%J&;4,&H9[1CM&1T8'2UD]^OK=M$SWD4##>^?C96B@*U"1A&CF%'"*&64
M,<H9%8Q*1EM&%:.:4<.H9;1CM&=T8'2TD-VOK]L"SW@+;)`U7WNK`0K8*F04
M,8H9)8Q21AFCG%'!J&2T950QJADUC%I&.T9[1@=&1PM9_3I_W7[W9&[O=X$&
M^R*@P7P%DG7\?%F>CIVT5JA6N#!'0*H5,TJ`;'F](3GEPU*U@GP&I/(YHP+(
MDI\X=T6E6D%^"Z3R%:,:R)9W[EH:M8)\"Z3R.T9[(%M>;R-/C7-0*\@?@4[R
M]K!YW79ZSMMIH.&P,5;Z:0*V"AE%0.H8,TJ`[&9P[A]3M4(S9$`JGS,J@/0#
ME8RV0*I5,:J![*HZSQ8;M4)56R"5WS':`PWE)R-GO!W4"O)'H).\/2!>MP^?
M\SX<2-MO`Z2?)@!2JY!1!*2.,:,$:-@,TXFS.TS5"LV0`:E\SJ@`TJJ6C+9`
MJE4QJH%4JV'4`JG6CM$>2+4.C(Y`)RV[J]VM^>54VISWXT!:@PV05CT`4JN0
M402DCC&C!,CN:F>_G:J5=K6IO<KGL%)4`&E52T9;('6L&-5`JM4P:H%4:\=H
M#Z1:!T9'H).6W=6^9,>K3T;..?$!I,G\#9`>E@P,^ON3D6J`#HM8)F:4J./@
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M07+4J9_,\M1YZ:P4$;O%0+I`)T`JGD)<[N8&%75:+6/''$CE"R"5+_WRSL9E
MJXY:B<G$L:I@I1%K((W8^",ZUX56'2]$W,%*(^Z!-.+!%U'6&;NOCY:C/?#D
MEH;2_O/Q:7E]X<:L\W3V\CUR5E3GNK69&\?ABFJ0'L`(C=7Y7/MXM9P[DSJ"
MDKK%0"J>`*E5"G%[075:+6/''$CE"R"5+WWRTZDS;;;J>&$85+#2B#601FR\
M$6?.M:Q5QPL1=[#2B'L@C7CP1?0,O&''V@//S?1>?=9ZSDE?@^P5;^;TY\98
M62M>KR4':[!ZAL8**]YL,ALOG!D<04G=8B"=K@F06J40'ZYXU&H9.^9`*E\`
MJ7SIDY_.Z()\_M`7AD$%>8U8`VG$QA_1N;BWZG@AX@Y6&G$/I!$/OHC4A$?+
MT1YX;BKZ^H''6>EYC^P5;^:L4QMC)3\HAU$6`.F,"@TR*]YX,KX9+9V&C-@M
M!E+Q!$C%4XB_L.*93ZB..;14O@!2J](G/YTYMQQ;=;PP#"I8:<0:2",V_HC.
M9;M5QPL1=[#2B'L@C7CP1?0,O&$36@-O(6U/E]KN*-GEZ^S)S;[.&N0L=\XB
MM3%6P^4.2*=3:)!9[J;CZ63N7+`C]HJ!=*HF0*J=0OOR:L>..9#*%T`J7_KD
MI^Z/OV[5\<(0J&"E$6L@C=CX(SH7]E8=+T3<P4HC[H$TXL$7D0>=Y6@/.C?3
M?CK6\?*@XXS[HD?V4N=^[VQCK(9+'9!.I=`@+'73A7QGT;YEC=@K!M)IF@"I
M=@KMRRL=.^9`*E\`J7SIDY_.G5N-K3I>&`(5K#1B#:01&U]$&@(M.^Z`5'X/
MI/*'J^2/EJ,]PKI<O'MPZ*JMZZ+S=%:V'MDKV]RY@=D81VMEZQV'-W+&RCKH
M3.T604OG7`RD,S,!4JL4\OW.>#F;3&^<^^V,O7(@U2Z`5+NTM5>R]YFYC;!E
MMPI(Q6L@%6\@+BUVWG53N[3LN`-2^3V0RA\@W[>+?#MU-EI.G!X\6G[V<'(?
M#UQ]>[;@)P4&.6N6<U.U@:/.DP!(YTEHD)/U<R9^Q(XQD,HG0"J?0KY/%TYF
MJ]EB[MP_9>R6`ZEX`:3BI2U^,QN-^$NW[%8!J7@-I.(-Q"\NN"T[[H!4?@^D
M\@?(]PVS6JYF*S=)>[3<[.'4Y9K=U6DZ2!]?]4O_BSYC/3SB:)"S4KEW_L;*
M6JEZ+?G)-6P&0E@-$W8T(R-8Z5R+@71&)D`JGP(M3CF\U6HQ=K\HE\%$M7,@
MU2Z`5+L$ZK6[,3N:.?-K"QL5KX!4O`92\0;H8KNTL%+Y'9#*[X%4_@#4UWV^
MF(_'2V<^'V%S$K='5O=$P1U98WD_JBRKP]<C7/\3((M.T;D>&C1\1N&^=W$#
M/_UH@4&GGZK`"QLG](@"5BN3W!V/)%G@+#H1U'5*QD`:,(&4Y'L&%Q7G@IC"
MJ@\XDZ<`XX4S6C*(:[P<2.,54+H8KX15'^]F-9^MW(OT%N(:KP+2>#64+L9K
M8"4)EG,K3-UEO(6\W(6?K2CCO(.55F(/^8N5.,#*].I\OERLW,<M1ZB?/K4]
MKGV/(H8/;:][X+;@YQ(&#<[K;1@%C$)&$:.84<(H990QRAD5C$I&6T85HYI1
MPZAEM&.T9W1@=+20W=\RFJQU[(5T1&?N+%(&28^?QS/_8N#B;(7K7L`H9!0Q
MBADEC%)&&:.<4<&H9+1E5#&J&36,6D8[1GM&!T9'"]E=W25^AY>L%[JZSQ-;
M=ST]LJ8PH6!!*&04,8H9)8Q21AFCG%'!J&2T950QJADUC%I&.T9[1@=&1PO9
M_=KE'%_1KYVY,X4-TM,SFP6AP"#Y6@:F<,@H8L>840(DJX(N&NY/2Z5JA8@9
MD%8U9U0`Z=&EDM$62+4J1C60:C6,6J"3EM4]-V[B]_*T.YG;W0.D][,;(*UZ
M`*3U#!E%0.H8,TJ`[.YQ,L.I6IV[!TCE<T8%D%:U9+0%4JV*40VD6@VC%NBD
M97>/FR)]H7LX-7ICT+![#-*J![#2>H:,(B!UC!DE0%;WT!OQU$J[A^J5PTHC
M%D!:U9+1%D@=*T8UD&HUC%J@DY;=/5UF[_K%[:9/!`XO6D##[C%66O4`5E:3
MNFGI4*W0I!&0:L6,$B!+?N%ND-0*\AF0RN>,"B!;WMG-EFH%^2V0RE>,:B!+
MWFV<1JT@WP*=Y.U^=1-]+TP[SN[=&#3L5X/TTP2P&E9]XO[88JA6J'H$I%HQ
MHP1H*#]=./G.5*T@GP&I?,ZH`++EG3USJ5:0WP*I?,6H!AK*4^,T:@7Y%N@D
M;_>K+^,VW#]>E7&[X8P;T+"[C95^R,!8Z:%?IRM"-<"'B:"L,C&C1!T'=RP+
M)^.7JA7D,];*&17J.)"?.%?<4JT@OV6MBE&MCN94KC.&&C6`<FO)V)WL37X-
M?O/VNB1!]Q.YSITHD*8]-HP"($W:A`9)?A[UC]@J!E+Y!$BU4M;*V"H'4JT"
M2+5*UMJR506D6C60:C6LU5I6=A_Y$CDOGS>XX<2-07:N>^$D"C?&:ICK!K(?
M-3D7O=!8G4]<K2;CA7.0(U(E]&X,I.M!`G0Q7FK'&R]F-RLW-9JI$N+E0!JO
M`+H8K[3CR3GPR8@.`ZH2XE5`&J\&NABOL>/Y3YZW*B4![7$C%P/KANOJ)W`W
MG:>S<^F1_02.SB+#44=_`*2C/S3(G!I8+D=TI8K8*P92[01(M5-H7WR(E;%C
M#J3R!9#*EY#'EP'D9W7I5V_9K0)2\1I(Q1M;7`87G]%N+3>[N[MDS?#^NNON
MJTX`W_1I'NM6NT?V2N$^;=H81VNEZ!V'S^^-E5D65O/E<N'<ST80TD<_,9#.
MF@1(K5)HVQ/)D<_8,0=2^0)(Y4O(FV?@D\5HY?XF]Y;=*B`5KX%4O+'%)Q//
MR>C6<K.[V\T573^[.6UTTR-[=M.Y6V,U/!,$I*,X-,C,[IG\$#B]L):]8B"=
M(0F0:J>V]G@\'<^=VY^,O7(@U2Z`5+MTM)?RF];N[F++;A60BM=`*M[8XA/?
M8>36<K/Z>NDFGJ[NZY.GO9(;9$]M.NIJK(93&TB'<&C0^8HOOU_NW!1$[!4#
MZ?1(@%0[=;67?(Z"O7(@U2Z`5+NTM6\F\Y5[@[YEKPI(M6L@U6YL;>_QW]9R
ML[NZR^NXJ_C+-WM+DP[2>MP:Y,QI]W`I''7X!D`Z?$.#S)R>K,9TMI2=8B"5
M3H!4.K6EEU,Y0VB?(,S8*0=2Z0)(I4M;>C(:W4R=C[]EKPI(M6L@U6YL;=]Q
MV];RLCM9+E>>3M;O0EZUM5YV*L[<[I$]M^ELIW&TYG;O.#S,`JO^5,5X.J+O
MB\%"!UT,I%,D`=+V3(',89/QPCVND<%"I7,@E2Z`5+H$ZJ67,E"=`ZE;6*AT
M!:32-9!*-T!H$#[LVL+DI&UWN9LEZY;P_^B4R9(3:4`73YFH$78H@4$OG#*!
M57\>83Y:C59+)ZT105QG2@RD+9E`R<Y6.5>.%%;F_,-X.I,ME[LVF$;0>#G'
M*Z!T,5X)JS[>>+*\N5G0S3W4-6`%I!^PAM3%@`VLS`<<^8[MM%`_!;2'U$L)
MNNMR-TO.T!DT?#K,*&`4,HH8Q8P21BFCC%'.J&!4,MHRJAC5C!I&+:,=HSVC
M`Z.CA>S^=G-UEQ/M2\[)`>ESWPVC@%'(*&(4,TH8I8PR1CFC@E'):,NH8E0S
M:ABUC':,]HP.C(X6LOO5S>^]T*^<UUL:-.Q70@%;A8PB1C&CA%'**&.4,RH8
ME8RVC"I&-:.&4<MHQVC/Z,#H:"&[7[N4V?!6_H5^[<R=VSF#]'G&9DDH`-+>
M#QE%0*H5,TJ`),J%TQQJA5N(#$CE<T8%D%:U9+0%4JV*40VD6@VC%NBD97>/
MFR][H7LX2;8T2.NY810`:3U#1A&0:L6,$B"[>YR;L%2MM'NHJCFL-&(!I%4M
M&6V!U+%B5`.I5L.H!3IIV=WCYK=>Z!Y.:BT-TGIN&`5`6L^0402D6C&C!,CJ
M'CK-H5;:/535'%8:L0#2$Q@EHRV0.E:,:B#]V`VC%NBD977/RDU)7>Z>D[F]
MN`%I#3:,`B"K2=T#"Z%:H4DC()6/&25`EKS[,P&I6D$^`U+YG%$!9,L[.])2
MK2"_!5+YBE$-9,F[C=.H%>1;H).\W:]N_NF%?N6\T\H@K?J&40"D8SED%`&I
M5LPH`;*:P7VK3*I6:(8,2.5S1@605K5DM`52K8I1#:1:#:,6Z*1E=X^;.7JA
M>SA%M#)(EX<-HP!HV*3TE"Y4*S1I!*3R,:,$:"C/AVW4"O(9D,KGC`H@6][)
M*Y9J!?DMD,I7C&J@H3PU3J-6D&^!3O)VOWK30X-S&%=E!%><$@+23[1A%!BD
MAVV<)VBA&N##1"P3,TK4<7!#28=MU`KR&6OEC`IU',B[N?Q2K2"_9:V*4:V.
MYK"-DW]JU`#*K25C=[(O83/\#N-U"9L5)VP,LG/]=+`#CIJH"H#D_N-\OS]Q
M#U&$QNJ%K\RJ%MHB!M*("=#%B"DB]L_9ES>3A9MJS%0(X7(@#5<`70Q7VN'&
MB_%JYGX[;ZM*B%<!:;P:Z&*\QHXG7Q+FDS*M*DD\>QRYB:"K'P>N."=DD/W(
M@`YV&*OA(P,@S:.'!LDW]=%$$5O%0)IM3X#4,866^<&ZU6KL/H_.V"L'4NT"
M2+5+6WN^',N3(3NQO&6O"DBU:R#5;FQMW^&6UO*R>]9-!74]>]49CA5GA0RR
M%P4ZPP%''<,!D.:X0X.&A_+8*@92K01(M5+5&JXYSA4G8\<<2.4+()4O(6^^
M9^XY;K)EKPI(M6L@U6Y>UFXM+[MSY7[AG`\:RX;\^FG;>3J[IQ[9T]:=(9M5
M;V5-6X-TR(;&ZH4?V("6.L9`.B,2(+5*(6\.T<@YMAOG,6S&7CF0:A=`JEW:
MVO+L>.+^'/^6O2H@U:Z!5+NQM7T'65K+R^[L+N&"Y-_K.MND:K0FMZL>V3.9
MCFP8J^'Q'"`=PJ%!UDPV$=4JAJ-.AP1(K5)H]5/M1GZ0P#E+FK%3#J32!9!*
ME[;T>#%9+AWM+7M50*I=`ZEV8VO+81PZM=):7G;'RI6=.O;E`QJKSLV9PCUR
MIK`S-3;&T9K"O>/PC)VQ>FD*DV/,\@F0#L`4\N9B+-/,Z8R,G7(@G64%D$J7
MCK0<`'&OQ%3I"C*J7`.I<N,H\Z&5UG*R>EE^[L;;S:\\HM'+V-T.9L]F.J0!
ML^%T!IOJ!P_/3'8%@UMXYW(:P6RL\R`^,YTN"=@@1`HFKWOJMD&>HR`93`;R
M^9FI?`$VD"_/[.(GV,)L$*(Z,PU1@PU"-&!__PE:F/3RSF`8)L6PF/]'AS?&
M(TZ<@0VF^L;#`K#N+4V#'G>.3\C`Z$-T+_T9F/'`Z,T&JXD,#,-TG,G`,'(7
MH\I8Z<WDG3&GL3(;3>2<C#VE9;103!DM%%-&RS4Q90!9,:>R5YRZYT)E^%!,
M&3X44X;/-3%E1%DQO:=A9$P-8_9CZOW3Y_O[Y^#N^>[#3]_N'W^_W]Q__?KT
MYN/#G]^EE\;R$MD!?_-X_]O/;V^7LW5W+D`V56</E,RE9.XM64C)*8'H^LS&
MZ^Y-JAZUV41*3BNHX_/+;+'^I?LT/B<)U'^3W'&ZG=U(R2G3225+*5EZU592
M<EJC7)^%Q)%?O_#48"%QY,<2?"421[YN[RF92)/VI]W<.!-ITHFW22=2@XFW
M!A.I@9R>\L61&DR\-9B-Y).>ON3DUD`JX(W?-8`OA@3WQAY+;%FM/+4:2ROW
M"YT;>R*UZN\-G1+)$:Z[-""K28YOG7I+)#VW[I)O[".9M767/..27\;K7WQ#
M\%9&K7?\R9CUVD_71Z_^;/V+W')QX%L9$;XY)D]9I*J^T/(89=WEZEE+\N?2
M6+YJ2>I;&LM7(EEK:2Q?B22<I0:^$GGT(6J^&L@#JG7W?(/K)L^IUMUC#BZ1
MQU52`U^)/(]:=T\XV$<>2ZV[!QU<(D]6U]VC5"Z1YZ3KU%LBCSC7W3--]I$'
MENON"267W$H-;KTUD.>)Z^[9$_O(8T7I'U^)/#=<=X^=V$<>'ZZ[IT]<(D\1
MI1=\4UG.9D@;^":GG+20-O"5R"$):0-?B1QYD#;PE<@A`XGCF^IR9$#B^$KD
M:;_$\97(LWN)XRN1+V&ONZ]8>]I`2KIO1W.)?/5YW7VQF4OD6\OK[CO)7"+?
M_I4XOMDHW]Z5.+X2^>*MQ/&5R'=F)8ZO1'[+0>)X^U1*4F^)_*B"Q/'YR$\D
M2!Q?B?PH@<3QSF`I2;TE\E,`$L?G(]_BESB^$OEEEW7W4R[<HO([+>ON5UBX
M1'YB9=W]I@J7R`^FK+M?2.$2^8D2^3R^$2\_."*?QU<BOQ4BG\=7(K_\(9_'
M5R*O'I1KH7>$S&6$R-N&N&[R4J=UZBV1]S&MN[<ML8^\2FG=O2B)2^0M2.N#
MMT3>NKCNWK_%/O+RQ77W&BXND7<PBIKOD\K+^*3$-W;D16U2XNMM>:^7E/CB
MR`LGU]U[QK@&\M[)=?>Z,2Z1UT]*&_CJ)N\AE!)?W>2%=%+BJYN\OTQ*?''D
M!8S2/SXU>1.?E/C4Y,5M4N)3DS=WKC-OB;S`<]V]I(T_J;S'4\:!KR28RGHP
M]=9-2E)O22$EI;>DEI+&6W(K-;CUUF`C)=U;\+C6@91T;[[C$GDYZKI[`1Z7
MR#M2U]U[\+A$7I4J+>KK[6`B:\C$-^L3*4F])864E-Z26DH:;TDPE<_3OU/-
MN=5,I"3UEA124GI+:BEIO"5!=VGTM4!W8?3P0#Z^]]/+A_=QV8^O9;/M49(]
M\UHVQ%W)^_-'?/KPTX^[W^_+N\??OWQ_>O/U_C?9]HU.>:7'+[]WCP3Z_WE^
M^"';P;=O?GUX?G[X=OKS\_W=I_O'SD`>X_WV\/",_^D"_/7P^,=I:_GA_PL`
M``#__P,`4$L#!!0`!@`(````(0`A)>#_E`D``!TN```9````>&PO=V]R:W-H
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MQ<OZ8W?^9_F9%MO7MS--]Y!&I`86//\*B].&%"4W-_Y0>=J4.[H`^K>SWZJE
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M@ON6F&S!74(;1#:(;9#8(+5!9H/<!G,;+&RPM,%*`X:8M&]^AYC*#1W"^F+U
MK*7XU-CH*WI@"=R:M`H#B8#$0!(@*9`,2`YD#F0!9`EDI1-#;#H,?H?8R@T=
M+C2EVM%@JUT;]2^IW9JT:@.)@,1`$B`ID`Q(#F0.9`%D"62E$T-MNA$8:KN3
M"SYNE74E*HOQ5!-2D,D,2`@D`A(#28"D0#(@.9`YD`60)9"53@S!:*U<(9BR
M-@6KB2X8D!!(!"0&D@!)@61`<B!S(`L@2R`KG1B"C:\23%F;@M5$%PQ(""0"
M$@-)@*1`,B`YD#F0!9`ED)5.#,%4_::G1I>WI+(V!6O(6+9D0V23ABV1T]$?
M6G?RJ#7BO1T#28"D+=%<>]8]+&N-V'6N$T,.2J&OD$-9FW(T1).C(9H<+5$9
MI']K7V[4MO/EQD`2(&E+&J]]\T:>M>WL-=>)(8(J!:Y0H3(W96!$":/<$+V1
M>4DSL>)K"ALT$+DB1#%V3!"EV#%#E!L=31E4NOOUO>'5V3$E`3R:)T9T0]1D
M&-LR-!T';<?0U='WK%HC8JMA58OTA\/1Z-:RB=E&G">(4D%RH1`O8ZLZGC\>
M#2%>SC95/%-.E?!>(6>='QMRULBG;$Z3<V++V5KQ/(0J,:.-2AT910WJ>Y5V
M`W\P&:-VT"U!3RFB3)!<J&]GW[E8T5694JE\]0JIZO26_/'PGE09KHXF<^5-
M;:E:*^X82D=&$:-ZVKWIV*$4.$JXERR\%%'&J/8]Z(_Z]BSD;.)842K1O$*F
M.B\U9*J1N:)\:P_-E(KF\@D110UJ5I3O3^V1Q-@I090BRDS7@P%,0&YT,M>2
M2BZO$*G.10V1&D0JM-O.F\)AWEKQP@G5\\-Z$3**&#5'B$,CZ)-P'WTE@57&
M5LU*HI/)FL:<+1P+2>635VA4IY^&1C6R%I)5`<Z\UHH%"1%%@D3OH6_E2['+
MRO>M64G$BB.FB#)!>D0K@\A=5GI$<]FIC/,*2>L$U9"T0?JR&\-AWQKQ^$*O
M13(8'^^=3BMKPF+QQ>X31*F@"Q$SMY45,1<KBF@JJI)67=&_^A2S27[IYM9N
MY^'46EY/7FUU\6F%V+`Z(:((48PH090BRA#EB.:(%HB6B%8&,L57R;(N_N4Z
MR6MR:_V.W*#ZC8=Z\#MC*T$A(SHH9')\*V.,Q(J%CQF)KP11RLAT;VVJ3*S8
M?8YHCFB!:(EHQ:BZ5$-E_[K"HS(W"P]&(L,,4<AH5"5_CA),#%B!F)%X3A"E
MC%K/UB&:B0%[SAF)YSFB!:/6L[5CEV+`GE>,'$I?5]OX6-LPDJN>(0H9:?4<
MHIB1^$H0I8S$5X8H9R2^YH@6C,37$M&*D4,_51I\_3SPZTI"O[TQ(F6UG6YG
MZ&+%DQHBB@2IXK]O/?^(I5E"^5-KUR=BQ:%21)D@5ZA<FB^$FHL5AUH@6@IR
MA5I)LSN4>;*H`N6*^6KJ&>W\5JF=2F:-^>I;.>9,K'AD(:)(D!K9Z,;*VF)I
M=P^M>F^8B!7'2A%E@IRQ<FF_$&LN5AQK@6@IR!EK)>WN6.:4J:KKBBFKBS1C
MBS7(G#(KXYKYK14/+404"9)+'_:M,SAV6UGW@$2L.&***!.D1[3V=NZVLB+.
MQ8HC+A`M!>D1A^9#@Y7;2B*:DZ@*M2LFL:GK]'W7('T2L?I4GVC4NY,'&"**
M!.D#A-W7^M*M9(#-[FNM.&(J[AEE@L07/@D2*^XX1[1`M!1TP?U*K,B].3VJ
M(+UB>NKZU=AC#=*G9]BW$M:9WUKQ`$-$D2`9S;!OW:=BMQ5,#T1,I2-?1"9(
MCVC=A'.WE15Q+E;L?H%H*4B+.+!N(RNG55\BFI.H2MDK)K&I?/4]UB!C$@=P
M4+96/,#0!Q0)4O<`:V"QM,KP':D(N$VE(P?/!#DBY=)Z(=)<K-CM`M%2D"/2
M2EK=D<S)LJOXRX4D??)7G6OZ9+65.5_RK+'27EN&B")$,:($48HH0Y0CFB-:
M(%HB4E\ZJF'7`ZKUJ[]<K#_KVA?'UV)6[':GSJ;\4%\E5D]=6\R?3$Z"1_)$
M,EDM]'0C4,6^H\6G%F<?^@#SL9H%\$6NG)[(D8OW`_H<!2,_#H)'>OB##4^#
M@+ZH</!A0!\../@HH/?C#CX.Z#4P<JJ&@X@J16RA:C90!2NV4#4:J((36ZCB
M(V\N0:A^(V^N%JK&R)NK)9T$]/86HZ33@%YH(L\G`;W61$[O%0/U(A%;Z"UA
MH%X+8@L]BZ$^+F_T&"50#S:PS],D>'+QV228N7@X">C%-_H)*;3+/IX$]#(8
M[9-)0*^$B??:U4D?Y[ZO7XOE^OBZ/9PZN^*%MLGMC?HD]5A_WEO_<2[?J:JA
M;TW+,WV66_WWC3[#+N@!U>T-&;^4Y9G_4`':#[L?_@<``/__`P!02P,$%``&
M``@````A`*%0`K;U'```DYD``!D```!X;"]W;W)K<VAE971S+W-H965T,C`N
M>&ULK)U9<QPYCL??-V*_@T+O(]61=8;M"5?>9QTQN_NLELNVHBW+(:F[9[[]
M@IE$@L0_7:KJ[GD8NW\$01(`F02+F7[WSW\_?KOZ_?C\\O#T_?WU^&9T?77\
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M`F/VJ^?CY_?7'\?KPVIQ??OA76N@_WTX_O'B_/WJY>O3'^GSPZ?JX?N1K$U^
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M^#%_D5;'P>BM2!]S`)F_2,U^BN(DN>VF>+MB1'>O=Q_>/3_]<47+,/GTY<>=
M6=3':Z.-UXI.1;]Z_&SQH%7#:/EHU+R_)A/0NO!"*][O'V;+\;O;WVF5NK<R
M&Y11$B%+F"7)J(TTB#5(-$@UR#3(-2@T*#6H-*@U:#38:K#38*_!P0&WY)[>
M1S1Y_@X?&37&1VS=#0-QVL1W6<@27"72(-8@T2#5(-,@UZ#0H-2@TJ#6H-%@
MJ\%.@[T&!P=X#J$EZ>]PB%%#SU9GTDP7:DILK(P[LP+EI%ZD]Q*0&$@")`62
M`<F!%$!*(!60&D@#9`MD!V0/Y.`2SVGT4/@[G&;4T&))H>$L=6K>;#JAZ2FO
M]2*]UX#$0!(@*9`,2`ZD`%("J8#40!H@6R`[('L@!Y=X7J,'LN>UX3TL/X:,
M=.L<-NJF(^0))B&0"$@,)`&2`LF`Y$`*("60"D@-I`&R!;(#L@=R<(EG>(K=
M"PQOI'W#6^).@>ERJI:N7HB]$P&)@21`4B`9D!Q(`:0$4@&I@31`MD!V0/9`
M#B[Q?$'[PPM\8:1]7W3$G01`(B`QD`1("B0#D@,I@)1`*B`UD`;(%L@.R![(
MP26>X6E#?('AC;1O>$N<U0=(!"0&D@!)@61`<B`%D!)(!:0&T@#9`MD!V0,Y
MN,0S/"6X%QC>2/N&[X@;\4`B(#&0!$@*)`.2`RF`E$`J(#60!L@6R`[('LC!
M)9[AS?'`!99OQ7W3,Z(F^AW2=*DWK2P5]`_FB)%;<3(>^8^,V$I-QFV6&2Q7
M2U\@$37T4/''9A(L-]D]O9DPYQTJK"R:T";3&=O,[T$H4OUCC=&D'VYLT736
M#F0RGHU'@1ILXE7SQV)RDPO&TJ4RM&WE+FW,%M8,SS7W=#G78[%2KI_ZBJPK
MMKJL4\;C\6*Q\!4ETARXQ6S9W:&8,XC)W)Q-_N3(DK=[YFQ(>ZA#$^JCXR'5
MF=!6)#_R$")&8J'8(NNAY6(R7T*P]<W!J,R6%D9%3YK7KP_WOVZ>J'<47P,1
M.*5XL(<JW:[8<YI%OM-4KT)S`&;LXCJM0U,9<6RE@D4;@(O5?*P".6$]*V,F
M/_S,OE&/;CR[,2>F[0#_]?3C9P,DO_8C[+:?W@@[I!RX\J,I-`=U-$+/@7U%
M]FELI:P#IQ/Z'6*L;)6PIM;O_AC-?NS4&,]SHMW525QMS%$AS+R5FOLA2[E.
M["IZ3NR0=>)\M0J6*AE-6-&`%\W&!T9(9_W*B1>$;+>5\AS:(7_-7*ESCM"<
M@6J'=BB@34(_E2?X/.BD9J,VBJ>K\6HV4J9,6/F`C\T.!"QP>1S;C8SKY`ZY
M6Q!SODIC=%"$*$:4($H198AR1`6B$E&%J$;4(-HBVB':(SIXR)^'M-AY/AI8
M--TUQ8C3VN/ZPB)G'VX>>T9*4(0H1I0@2A%EB')$!:(2486H1M0@VB+:(=HC
M.GC(\\7DLNUA*^[[PB)G$H2((D0QH@11BBA#E",J$)6(*D0UH@;1%M$.T1[1
MP4.^+R[;SM+F3,\+1O0,Z5?8Z4H?TH@4/U@C1#&B!%&**$.4(RH0E8@J1#6B
M!M$6T0[1'M'!0[Y[S#;9?;2<7K;,AD<M6Q9Y4Z63<E"$4C&B!%&**$.4(RH0
ME8@J1#6B!M$6T0[1'M'!0[XO=(KQAB\PKS#;%_]Y$2**$,6($D0IH@Q1CJA`
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MGA18*7M2,`F6\YD*Y805H=>F>M_?W1.Z]+RG5>,/T2+E0GW>PU*."QDY+K2(
MSWN"51!,]'F/5\V;9%.]G]9C/.N\I]6BAFAWWKX7U>P/N:+C18M<+UIDO3A;
MSD<+?=[#B@:\J+>D[0C_RGG/%'>M%OFK)ISWB%0_)RUZX[S'2MGSGF"T'.%Y
M#RMO0\/WL=X(:A^?=VY)'M%3U2)G9QXBBA#%B!)$*:(,48ZH0%0BJA#5B!I$
M6T0[1'M$!P_Y/KIL@SC%#2(C-Z\-1OK(4:0D!*TNV5G&*)4@2A%EB')$!:(2
M486H1M0@VB+:(=HC.GC(=\]E>T9:C&&J=,B;*H`B6]&1BA$EB%)$&:(<48&H
M1%0AJA$UB+:(=HCVB`X>\GUQV1Z7;`F^L$@B/F0I01&B&%&"*$64(<H1%8A*
M1!6B&E&#:(MHAVB/Z.`AWQ=FH^SN`$^?,4SMOEJV+QM&8O@0480H1I0@2A%E
MB')$!:(2486H1M0@VB+:(=HC.GC(]X5.,M[P1;>M=_.EJ47T0.@SBV"DMEJA
M2,DC9*#B1"<2,5>TR<:"T@W_%\Z$)=KMH#\XL[>_(-"Z5,`;7(?\+=I290/A
MM)>2P0&*K11M.DV&/EXL%TOZ$5(/QJWG#2;0B<5I3[7B_NZ:D>LIS&Q%JA\,
MHIA1YY;I=+H83919$I9!QP1#"<19J6U;4PVK2QH\'P4CE6>'MJ*;VB**+;(^
M6M'1PU2G15XMWT,Z:7C#0Y@1!!;Y'M(IGDB)A_J*C&*6ZCPT,?^;3M3.+F&A
M`1?I_?\;@\%]?M`ASR]3^/%>I+CG$:+8(NN7Z6P\GR[`,7U[I,EWC-FLGK\.
M!$9<Q9A%GF,@5>.*3F(J2%9'7.18ROIJM@AF=$%!+0TL-.`KO='L<C5^!^SL
M=Y."?@<JG9WIJ\@;*V6>[[+@^WT-14:\"AO7&*421"FB#%&.J$!4(JH0U8@:
M1%M$.T1[1`</^8%ZV2XUP%VJ1>0<-GR(*$(4(TH0I8@R1#FB`E&)J$)4(VH0
M;1'M$.T1'3SD^^*R72J=,\&B89'K"T`15Z02F4X3=>85BQ3[-6$DZE-$&2-?
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M$ET[1J)KC[H.GI3OMLOR]!GFZ1:9R)`-Z%0]A$(KY9Z?,)))&UM$Y_#FC&N^
MH,L;ZGF08*V4D?QFG3&B:.H[!7ESSLU-VN9&-VI5+$0+1TO)2-JJ&,DX:E',
M%1N4VC(273M&HFN/N@Z>E.].<]#@[F+,+#SK9&QFCRBDY0TCVM?T1@RFZI@N
M9"D)RHB1!&5LD;W*,NQ9VP.IE;(BT9TQ<CLUX-E.%\US$T@#GH6V2E8L;56,
MI$>U15;QZD99H\$J6T:B>,?HY"#VTI;8?S)6N]R#Z*)8\X-!G^N</H.;]<<W
M'+0;B]Z:VUU%;VY;)-$46UUV;H_'RT40J*=78F7HC@IW(64DDR1C],;D[KI`
M5Q1^$@+0Q9(52UL5(^E1;1$IYDXV*+5E)+IVC*3B'G4=/"G?G_IXY_S)C2<]
M,XO<$`RF:K<2LI3$;L1()D5L$=]3HPM/@0[3!*NEC$1YQLCMU<#L[OK^\]G=
MCXT]5+)B::MB)`.I+;**ES?+D?<_E?HTJ&'+2-K9,3HYICTW;7_>F9K;-NJ@
MXB"::%Q^:-#V'M;]R[?11HO*ASKDG<('4V6(<-9+L<$C1F*(F-&\G9'C8+5:
MS-40$Y:1.9(RDIF4,:)5O'\R#82)[56WFZ`OJ?FGS`5KD;9*1M)6Q4@&4C/J
M%*]NZ+#=_9_:FC8L+NUL&4D[.T8GQ[1GJ<Z&TRX\_7$=6*9MSP\3?7C5KB`+
MO%UX_F7*&1YP,7(#/M`_A(4L)7:-+*([K1Q&,:-5&S/3Z7PVUI]N2EB33.24
MD2C/6!,%Q:F8Z89#UU;;7UEOQG03VOF?>O@6W(XT73*2IBMIFL=5,^K:6=ZH
M)V'#6D3QEI$HWK&6DV/:LU1GP]ED:I8U'3/6C6U[?LR0&W%I^2MW&6=&HUIF
M.J26&664T%;T-AI=13K78]/&5HK.'-HD8D8O(ZN9G[`BF9$I(YF1F47FS/!4
MQ-@>=-8=V&K:H4E;);9525L\CII1IUC9HF$=HG;+2(:P8QTGA["W4M9BB^4D
MP/AP1^'%QUR?N?VYQ+]5TP:%&'NFWV_86*F3/QZ*#)LR0A0C2A"EB#)$.:("
M48FH0E0C:A!M$>T0[1$=/.3[49_$G<X6YGCDQL@Y<D,4,7+7++H^[J]'L4BQ
M$Q-&HCY%E#'RU:M'<BY2K+Y`5"*J$-6(&D9XWCE_ZYCLK//.5HN_@C(2ZX2(
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M/=UP`]X>B+@G8D&@=KWAW$K)O(\8B:[8(O-J3^_#(%`'0XE4%*F)_D18RE+2
M8L9(6LREQ2[G4H%62)43;94L)6U5C*2MVF]K=*/&U4B5X;9\Q]%C]!+'&7'U
MU+;(#:T@T,<K<RLE,1DQDOPPMHA/Q?QG>B(5A@?6_CZ6LI2TE#&2EO*3+152
MX41+)4M)2Q4C::D^V5(C%89;\IUE,MP+9IE-B"5V-O,.^4EJH'XT"D6*UY2(
MD>B*+5*S3"5YB50<'J!U6M\O;C&3BHSRP19G:FTNI.*)%DN6<N>:[82,L986
MS;S6G\MJ6(F[T+A+B.\]FB&7>,^(JZEFD3?59NI`)YQ;*0G+B)&$96R1G6KF
M"WIZMO6-L?U35B.:,T:B.1?-8O]@IIZ1!58L&8GZBI&HKT6]<8GY_);?\<:K
MXWE@H?/\T]N*5MSW@$7NY5)$$:(848(H190ARA$5B$I$%:(:48-HBVB':(_H
MX"'?%SI7[\Y<+KZQO>B3>(FVF7X_96.E3AZZB`P'?(0H1I0@2A%EB')$!:(2
M486H1M0@VB+:(=HC.GC(=Z3)>\]_*"V,N)I4%DEB'K*4H(@1;21D4P<IITBQ
M$Q-&HBM%E#'RU:M5*Q<I5E\P:M7[EM&Y^AO+#2;B"XNDZR&BB)'?=?58B$6*
MNYXP$O4IHHR1KU[E!KE(L?J"T8!E=-[\AF4P/UY8)%T/$46,Y!0H1I0P$ETI
MHHR1;P:UT<]%2LS@=M4/D,O27//!5#UU+)*NARPE*&+DFL%6%)2PE%1,$66,
M?#.H9W`N4F(&MZN^&73RJ(_?SSI07&!.R4A&%"**+'(.[F)$"59,$652T5VD
M5(:6BY18Q_:^[:IO';*TM[YJZYQWQK0P:M2Z:Q'%IZRH<"N1*\JN+&(DN[+8
M(KX<-=&[T@3KI(Q$<\;(W>%.]!NQ.3?6_3RF%KI"=)!U?5.:#?X%CZHN'W"/
ME19]GN*:3"T"H4BQ?R-&DEO$%MG;1+-@L9S"70*LEC*2Q"5CY*4A:+6N[_UM
M(C5G"]$"=C.I@&LW'8+G35";4(@)-@N+O`C4]R5#D1)S=A7IPR",8BME/D8A
MT3Q7CZF$=5']7FHR41,T92DW,OL6G8IH8RL5M`?7>%K'BMN9X\7F4N<FVL;G
M3?-6C3_-+?)S?OT.>2A2;-&(D3@LMLC&K/DNU$3?DTVP6LI(W)4Q$N4Y*Q=4
M>%*^O8;S![D'<E9,+OOL@4>]8>3%D1YD*%)<,;+(C4F+Z%4LDZO2/]8WGNB7
M21/6)(MIRL@)/U%^*OQ8BL-OIE:F@C4/Q)_>QO_)^,/M_;)#*O[4ZA.*E!C4
M5I1XB*V4C;_E:F(NT_CY?\*:I%K*R(V_7OE)@W92LF:"07LUU&T_0"_;_2]Q
M]\_HC4BT%258(JXH(15;9)_/T]EH2?]PI%X<L5[*2+1GC+PE%%9";M`^HV]F
MZI"Q$#5@.1KP7W_<+(T6M1)V2$6B6OQ#6Y&D)!*[BNX5'2ME7N3J'R3!'&+1
MMDA1TDOAXP9;S%@]/;.E(AK9]NMG%W=8<3L5_.@TNW%XI/^5WY&7=G\OTV[#
MR+>1"H20I23$(HO<6W2,NJ$&TS'].#0#<]L^2."GJ#UC56X*,T';=KKZ:W3Z
M@+1@S0-KZ5L)S9G/<LQHEAURSQ\118AB1`FB%%&&*$=4("H158AJ1`VB+:(=
MHCVB@X?\"3"<5EU\_KCL\RJ9J/2I1?^9M+%2)\\?14;6G4ZYX^X8I1)$*:(,
M48ZH0%0BJA#5B!I$6T0[1'M$!P_YCC1IC;N2G3Y+6G99D)O46>18.404(8H1
M)8A21!FB'%&!J$14(:H1-8BVB':(]H@.'O)]8=*?"WQAQ-4CVB+GR&8)*&+D
MK^#JI\=8I'A")8Q$?8HH8^2JGRW5PR87*59?("H158AJ1`TC/!%:Z53Q=,2W
MXKZ5&8D90D01(]<,@?Z$;"Q2;(:$D:A/$66,Y`@R1U0@*A%5B&I$#:,!D_XM
MV>0*LTE&8HH04<3(M?1DI'*-6*3$TK9%49^RE*#,(N>$,T=4("H158AJ1(U%
M`Q<85R9A<I>(-L_\*QO/5J.*[RXKHW^4C2T5LI1S>\XB,HO)SNF6(1B\4^/8
M+4$U*:+,(KJ>:#6K3"L7`>Y@@6I*1)54M)K5+U2U"+#FQE/CK=<KG:/^N:2_
M5:,\T&>ELBW"^W=<T=GZ,Z)%_^>)3VRE?G+_3G2P#5)&TE+&2)*%7-1*X\%"
MA46!%4M&HKYB='(@M;1H_#FZ48'2B!8:BN\[D_NY$^F-IT"7*KK[GM5`<AKH
MZQ0A2\E<BAA)JA=;Y%\&6JAM<"(5Q;[N?9GN,A!+28L9(VDQ'VY1/:0+J7BB
MQ9*EI,6*D;18#[>HTME&*@ZWZ#M1I^%O.!%S[%6?\DIS>/V.I20^(T82_K%%
M/[E^)Q6DI0'GV?Y(2YE4Y.F8GVRID`HG6BI92EJJ&,F8ZI,M-5)AN"7?63JM
M?\-9F+ZO.N3]`P;T;T?XR6+(4A*-$2.)QM@B?\8MU66X1"H.#]#..-LO:3&3
MBN*T3DJUJ']^DXHG6BQ92EJL&,D8:XM4B^J1UTC%X19])](>2Y9-6@'?<*(1
M5X\VB]R%/="_=X8K*R71&3&2Z(PMHADG70_@)P*LF#(2]1DC49];1"]=FZ=+
M,%[HM^,+K%0R$M45(U%=6V37"G6:WW@5.OO?OGP]'E^CN]>[#^\>C\]?CN'Q
MV[>7J_NGW[[3@WX\,GWL^=7S\?/[ZX_+Q?HCJ:((5"5TH+(V9P)#)4LJ:=^E
M5'4^SD?KCW0A;:`.E9C7R@9*%E0R6.?C8KS^2,=+0W7&5*?=9ZH>;)9SZMM@
MG>ET;?Z9@P%MTX!*6E]H;=,9E<P&ZU`[W7$&U"&[T;>PL9V/P6S]D=ZBQ!+Z
MW.G:?+%SJ(3:H>]'#I2,5VOS3T,.E$S(HA0U0R5D-_J!8JAD0B7MNJ#',R&[
M=2?U4$)VHW_-:D`;#6=P-#28P;&0R88LMC&!-J2?ACXX\C%5H'^Z%'M$N?[:
MI$Q8$JTFZYCV[UA".<;:I!%80CG"VJ0!6/*10G:(;\CP0ZUOC-D']&Q,L`[P
MC\'Z(WVC%QO>D"^&.%V>6Q=T&V:@!IED,VB2D$I,#HUUZ%AH;0Y]!DI6(S+C
M4-!1ZDTE0]KHK&B=#);0D=':I-G8#IT<D>F'2N@6XMK<(<(Z=!EQ;:X280G=
M25R;&X=#)5,J&7(!75.CDB%;T\TM*AD*?+JU1"5#/=A0#S:#)71#<VTN4V'?
MZ*+F.A[L-5U4I)*A7M-%/2H9ZC7=7:.2H5[3O2TJ&>S!G-JAE_:P;_1BX3H?
M+*$7`]?FW3^L0R_9D;:AOM$K<Z1MJ(1>@"-M0R7T659:?88B9#,?KS?TXB?V
M(*02\R8LEM";R-2W(6WTFBR5#-6AEY#7YEU8U$;O(J_-*[%80J\DTWB&VJ'W
M9:EDJ`Z]0;PV+[*B-OKR[=I\T@]+Z`.X:_-E/RRA[^"NS5=NATJ65#*TK-+G
M.:ED:#V@;SZNS4<>![3-QE0RU`/Z'/#:?.<0Z]!7@=?F<X=80A\'7IM/_PZ5
M+*EDJ-?TS5(J&>HU?0AS;3YS.:"->FV^FX@E](WDM?GX(Y;0IY+7YAN06$)?
M3%Z;[R$/E2RI9*C7]"%7*AGJ-7T==&V^_3F@C7IM/B:))1OJP6:P)*02\Q5,
MK$.?D5Z;CT0/E2RI9*C7]"E;*AGJ-7T?=1T/]IH^N$DE;0]N^SW'RX=W/^Z^
M'.N[YR\/WU^NOAT_TYYVU%Y&>G[X8D[5NO]X??I!>]WKJU^>7E^?'MN_?CW>
M?3K2*]:C&\J</S\]O?)_T$!N_WAZ_K7=-W_X?P$```#__P,`4$L#!!0`!@`(
M````(0`U;<+<,@$``$`"```1``@!9&]C4')O<',O8V]R92YX;6P@H@0!**``
M`0``````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````"<D4%/PR`8AN\F_H>&
M>TOIEJFD98F:G5QBXLR,-X1O*[%0`FBW?R_KNCJC)X_D?7EXOH]ROM--\@G.
MJ]94B&0Y2L"(5BJSK=#S:I%>H\0';B1O6@,5VH-'<W9Y40I+1>O@T;467%#@
MDT@RG@I;H3H$2S'VH@;-?18;)H:;UFD>XM%ML>7BG6\!%WD^PQH"ESQP?`"F
M=B2B`2G%B+0?KND!4F!H0(,)'I.,X.]N`*?]GQ?ZY*RI5=C;.-.@>\Z6XAB.
M[9U78['KNJR;]!K1G^"7Y<-3/VJJS&%7`A`[[*?A/BSC*C<*Y.V>[=Y<DWA?
ME_AW5DK1VU'A@`>027R/'NU.R7IR=[]:(%;D9)KF-RF9K4A!IU,ZN7HM\:DU
MW&<C4`\"_R:>`*SW_OGG[`L``/__`P!02P,$%``&``@````A`,R%<'T0`P``
M`@P``!``"`%D;V-0<F]P<R]A<'`N>&UL(*($`2B@``$`````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````G%913]LP$'Z?M/]0Y1U2H$,#I4'0=@)I&]42
MV*/E.E=JX=C!=BJZ7[]SH[8)N-[H6V+?=_[NOO/YDJO74O26H`U7<AB='/>C
M'DBF"BZ?AM%#_NWH:]0SELJ""B5A&*W`1%?IYT_)5*L*M.5@>NA"FF&TL+:Z
MC&/#%E!2<XS;$G?F2I?4XJ]^BM5\SAF,%:M+D#8^[??/8WBU(`LHCJJMPZCQ
M>+FTASHM%'/\S&.^JI!PFEQ7E>",6HPR_<&95D;-;6_RRD`D<7LS0789L%IS
MNTK[2=S^33)&!8S0<3JGPD`2[Q:26Z`N:5/*M4F3I;U<`K-*]PS_@VD[C7HS
M:L#1&49+JCF5%FDYL^9G_2TJ8W7Z6^EGLP"P)HG1H%E<?[9MV]]\D`XNUA;X
MU;5T'AHFN-'EF',KP-S/IU1;#^7!19OSFD7#N"&T49%@;9")M)@O<B<;M;EJ
M,]_&,%+2*,$+:J$@-U10R8!D[R+]'WLRI?\^(K-XDJLT0]2<W%<HV-:W2WT3
M2(?5%N(0F57L`Y#U*2/:46U[RDUMN`3CW\SJLJ1ZM3Z3/TF.MP3K@UPSIFII
MO11^*@L&L["B,^&/:PR:+['BET"^<SKC@KO+ZG7F`GU>*%%@'R"3EQJU]-K]
M`K'6SE7,BN2:2D.9NU-^MW?82$H@.7W=<^Y(E26WC4*NC%`*BW<(&]!>IO7,
MP$N-FI+)TBGKY1G.Y\D!F%,OIB,"QHE2^`GYM0@A/)*$S/<KXU!>\FUU0JZ#
M(A&OZTVQDS%8RH4_)V&1SKR.PYC!`9@O!V#.O9AN,80B]UJ2'%_"FN)SM.T9
MNQZUIWY"AX0A_CL0QOCO@*]00[P"]L3/*H3X,">RI[#>=\!-\9(]915`Y/Z.
M'`HDAX\'GX,__$`S0&6\!1:&^*EU&DA(<I_A'JV]IJ&;$>Y.?N)AC#^GV=N'
M9U,>[71VAJTWX]5W+I_-0Y6K,3ZAF_FQNYAD"ZJA&"NVV=\M)+<X.FKAG(P6
M%-_(8F/S?L--NX_-2)^>#([[9WT<9%MK2;P;WM._````__\#`%!+`0(M`!0`
M!@`(````(0!NR'4D#`(``#@>```3``````````````````````!;0V]N=&5N
M=%]4>7!E<UTN>&UL4$L!`BT`%``&``@````A`+55,"/U````3`(```L`````
M````````````100``%]R96QS+RYR96QS4$L!`BT`%``&``@````A`$M'16(W
M`@``?1T``!H`````````````````:P<``'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L!`BT`%``&``@````A`%\AUX?B`P``]@X```\`````````````
M````X@H``'AL+W=O<FMB;V]K+GAM;%!+`0(M`!0`!@`(````(0"OM&;<HP0`
M`.`0```8`````````````````/$.``!X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"+0`4``8`"````"$`/0&UTV<$``"!$0``&0````````````````#*
M$P``>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+`0(M`!0`!@`(````(0`=
M<._WH0L``"1-```9`````````````````&@8``!X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L!`BT`%``&``@````A`!KOY]@I#```#%L``!D`````````
M````````0"0``'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"+0`4``8`
M"````"$`8L/JNGX:``"*SP``&0````````````````"@,```>&PO=V]R:W-H
M965T<R]S:&5E=#0Q+GAM;%!+`0(M`!0`!@`(````(0"CTVD*?P0``#L1```9
M`````````````````%5+``!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L!
M`BT`%``&``@````A`!0*-!-4!```%!$``!D`````````````````"U```'AL
M+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"+0`4``8`"````"$`<SG/-9,$
M``#"$0``&0````````````````"65```>&PO=V]R:W-H965T<R]S:&5E=#,U
M+GAM;%!+`0(M`!0`!@`(````(0!O[:P3.0H``&(R```9````````````````
M`&!9``!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L!`BT`%``&``@````A
M`&O`R`]&$@``/(```!D`````````````````T&,``'AL+W=O<FMS:&5E=',O
M<VAE970S,BYX;6Q02P$"+0`4``8`"````"$`S[$YCYD"``"L!@``&0``````
M``````````!-=@``>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+`0(M`!0`
M!@`(````(0"G$&7.)`0``+8-```9`````````````````!UY``!X;"]W;W)K
M<VAE971S+W-H965T,S0N>&UL4$L!`BT`%``&``@````A`(L+7AW3!```0A0`
M`!D`````````````````>'T``'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q0
M2P$"+0`4``8`"````"$`ZLSQ1Y<,```>60``&0````````````````""@@``
M>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+`0(M`!0`!@`(````(0"N;4"N
M[`(``-L(```9`````````````````%"/``!X;"]W;W)K<VAE971S+W-H965T
M-#0N>&UL4$L!`BT`%``&``@````A`(>_B/X2#0``F7X```T`````````````
M````<Y(``'AL+W-T>6QE<RYX;6Q02P$"+0`4``8`"````"$`8'$%8\IX``"R
MM`$`%`````````````````"PGP``>&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"
M+0`4``8`"````"$`[,_]2=<#``#N#@``&`````````````````"L&`$`>&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!`BT`%``&``@````A`&UP>05R!0``
MJQ8``!@`````````````````N1P!`'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;%!+`0(M`!0`!@`(````(0#[8J5ME`8``*<;```3`````````````````&$B
M`0!X;"]T:&5M92]T:&5M93$N>&UL4$L!`BT`%``&``@````A`#I/]D.:`@``
ME@8``!D`````````````````)BD!`'AL+W=O<FMS:&5E=',O<VAE970T.2YX
M;6Q02P$"+0`4``8`"````"$``=/^<R`'``"1)@``&0````````````````#W
M*P$`>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+`0(M`!0`!@`(````(0#2
M#:P?=P(``&8&```9`````````````````$XS`0!X;"]W;W)K<VAE971S+W-H
M965T-#<N>&UL4$L!`BT`%``&``@````A`*&0*>#-`@``\`<``!D`````````
M````````_#4!`'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"+0`4``8`
M"````"$`S-T&!5H#``"F"@``&0``````````````````.0$`>&PO=V]R:W-H
M965T<R]S:&5E=#0U+GAM;%!+`0(M`!0`!@`(````(0`O)>%7R0(``,H'```8
M`````````````````)$\`0!X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"
M+0`4``8`"````"$`L\BZ4`,)``!L.@``&0````````````````"0/P$`>&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+`0(M`!0`!@`(````(0!;L!DU8`(`
M`%L%```9`````````````````,I(`0!X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L!`BT`%``&``@````A`(:ZFDO=30``=_<!`!D`````````````````
M84L!`'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"+0`4``8`"````"$`
MNR?:PNX2``!M<```&0````````````````!UF0$`>&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+`0(M`!0`!@`(````(0"_'H?W@`X``)!3```9````````
M`````````)JL`0!X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L!`BT`%``&
M``@````A`,_0!XGO"```A2H``!D`````````````````4;L!`'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"+0`4``8`"````"$`:Z\WKK,M``!K!`$`
M&0````````````````!WQ`$`>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M`0(M`!0`!@`(````(0`P!^[VDPL``&P^```8`````````````````&'R`0!X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"+0`4``8`"````"$`GQ"`SF\V
M```K;`$`&``````````````````J_@$`>&PO=V]R:W-H965T<R]S:&5E=#@N
M>&UL4$L!`BT`%``&``@````A`#6*87^:`P``L0T``!@`````````````````
MSS0"`'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+`0(M`!0`!@`(````(0!G
M;73YI`@``$0H```8`````````````````)\X`@!X;"]W;W)K<VAE971S+W-H
M965T-BYX;6Q02P$"+0`4``8`"````"$`/9UUT?(*``#[.P``&```````````
M``````!Y00(`>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!`BT`%``&``@`
M```A`#Q#I5,3`P``10H``!D`````````````````H4P"`'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6Q02P$"+0`4``8`"````"$`SR%E(;,"``"3!P``&0``
M``````````````#K3P(`>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+`0(M
M`!0`!@`(````(0`LE&?1FQ(``/!<```9`````````````````-52`@!X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L!`BT`%``&``@````A`(D!G#!/!```
MJA$``!D`````````````````IV4"`'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"+0`4``8`"````"$`E>"'\>(%``"-(0``&0`````````````````M
M:@(`>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+`0(M`!0`!@`(````(0"D
M,AK8L`,``*,+```9`````````````````$9P`@!X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L!`BT`%``&``@````A``%"Y!DU!```[P\``!D`````````
M````````+70"`'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"+0`4``8`
M"````"$`:U`DZ"8J``!!!@$`&0````````````````"9>`(`>&PO=V]R:W-H
M965T<R]S:&5E=#$V+GAM;%!+`0(M`!0`!@`(````(0`W3,*E*`0``),-```9
M`````````````````/:B`@!X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L!
M`BT`%``&``@````A`&/H9O.B"@``^C```!D`````````````````5:<"`'AL
M+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"+0`4``8`"````"$`?K&.G=H%
M```\%@``&0`````````````````NL@(`>&PO=V]R:W-H965T<R]S:&5E=#$X
M+GAM;%!+`0(M`!0`!@`(````(0"SDMCN1B4``!G,```9````````````````
M`#^X`@!X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L!`BT`%``&``@````A
M`"$EX/^4"0``'2X``!D`````````````````O-T"`'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"+0`4``8`"````"$`H5`"MO4<``"3F0``&0``````
M``````````"'YP(`>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+`0(M`!0`
M!@`(````(0`U;<+<,@$``$`"```1`````````````````+,$`P!D;V-0<F]P
M<R]C;W)E+GAM;%!+`0(M`!0`!@`(````(0#,A7!]$`,```(,```0````````
M`````````!P'`P!D;V-0<F]P<R]A<'`N>&UL4$L%!@`````Z`#H`R`\``&(+
$`P``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2IAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Federal and state net operating loss carryforwards</a></td>
        <td class="nump">$ 8,762,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardExpirationDate', window );">Tax credit carryforwards, expiring date</a></td>
        <td class="text">Dec. 31,
				 2025<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Net operating loss carryforwards, limit description</a></td>
        <td class="text">The United States Tax Reform Act of 1986 contains provisions that may limit the Company's net operating loss carryforwards available to be used in any given year in the event of significant changes in the ownership interests of significant stockholders, as defined. The effect of an ownership change would be the imposition of an annual limitation on the use of NOL carryforwards attributable to periods before the change. The amount of the annual limitation depends upon the value of the Company immediately before the change, changes to the Company's capital during a specified period prior to the change, and the federal published interest rate.<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Federal research and development tax credit carryforwards [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
        <td class="nump">$ 197,700<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Federal and state net operating loss carryforwards, expiring date</a></td>
        <td class="text">Dec. 31,
				 2025<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLossCarryforwards</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsExpirationDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expiration date of each operating loss carryforward included in operating loss carryforward, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLossCarryforwardsExpirationDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLossCarryforwardsLimitationsOnUse</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Carryforwards<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506874<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TaxCreditCarryforwardAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardExpirationDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expiration date of the tax credit carryforward, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TaxCreditCarryforwardExpirationDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TaxCreditCarryforwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EXBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivative Liabilities (Details Textual)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Laibilities [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividend yields (4)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EBPAI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair value hierarchy, the Company's financial liabilities that were accounted for at fair value on a recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
        <td class="nump">$ 25,586,933<span></span></td>
        <td class="nump">$ 20,103,425<span></span></td>
        <td class="nump">$ 5,090,988<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Derivative liabilities warrant instruments [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair value hierarchy, the Company's financial liabilities that were accounted for at fair value on a recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,089,284<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Quoted Prices In Active Markets for Identical Assets (Level 1) [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair value hierarchy, the Company's financial liabilities that were accounted for at fair value on a recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Derivative liabilities Series A preferred stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair value hierarchy, the Company's financial liabilities that were accounted for at fair value on a recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Quoted Prices In Active Markets for Identical Assets (Level 1) [Member] | Derivative liabilities warrant instruments [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair value hierarchy, the Company's financial liabilities that were accounted for at fair value on a recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Significant Other Observable Inputs (Level 2) [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair value hierarchy, the Company's financial liabilities that were accounted for at fair value on a recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Significant Other Observable Inputs (Level 2) [Member] | Derivative liabilities Series A preferred stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair value hierarchy, the Company's financial liabilities that were accounted for at fair value on a recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Significant Other Observable Inputs (Level 2) [Member] | Derivative liabilities warrant instruments [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair value hierarchy, the Company's financial liabilities that were accounted for at fair value on a recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Significant Unobservable Inputs (Level 3) [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair value hierarchy, the Company's financial liabilities that were accounted for at fair value on a recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
        <td class="nump">25,586,933<span></span></td>
        <td class="nump">20,103,425<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Significant Unobservable Inputs (Level 3) [Member] | Derivative liabilities Series A preferred stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair value hierarchy, the Company's financial liabilities that were accounted for at fair value on a recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">16,014,141<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Significant Unobservable Inputs (Level 3) [Member] | Derivative liabilities warrant instruments [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair value hierarchy, the Company's financial liabilities that were accounted for at fair value on a recurring basis</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 4,089,284<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13495-108611<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34720828&amp;loc=SL20225862-175312<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiabilityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueNetAssetLiabilityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHKAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="4">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Placement Agent [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Placement Agent [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Placement Agent [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Placement Agent [Member]

</div>
          <div>Series A Perferred stock [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Placement Agent [Member]

</div>
          <div>Series A Perferred stock [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Placement Agent [Member]

</div>
          <div>Subordinated promissory note offering [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Placement Agent [Member]

</div>
          <div>Subordinated promissory note offering [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Placement Agent [Member]

</div>
          <div>Subordinated promissory note offering One [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Placement Agent [Member]

</div>
          <div>Acquisition of Medeor [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants</a></td>
        <td class="nump">5,881,575<span></span></td>
        <td class="nump">8,926,517<span></span></td>
        <td class="nump">4,865,234<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,251<span></span></td>
        <td class="nump">4,290,950<span></span></td>
        <td class="nump">944,453<span></span></td>
        <td class="nump">646,172<span></span></td>
        <td class="nump">637,578<span></span></td>
        <td class="nump">612,422<span></span></td>
        <td class="nump">106,875<span></span></td>
        <td class="nump">33,750<span></span></td>
        <td class="nump">106,875<span></span></td>
        <td class="nump">200,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.54<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 1.00<span></span></td>
        <td class="nump">$ 1.50<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 1.10<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ClassOfWarrantOrRightsExpiration', window );">Expiration</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2019<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2020<span></span></td>
        <td class="text">2019<span></span></td>
        <td class="text">2020<span></span></td>
        <td class="text">2019<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2020<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_ClassOfWarrantOrRightsExpiration">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Class of warrant or rights expiration.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_ClassOfWarrantOrRightsExpiration</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EAZAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Details 3) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Deficit [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares, Outstanding</a></td>
        <td class="nump">8,926,517<span></span></td>
        <td class="nump">4,865,234<span></span></td>
        <td class="nump">6,251<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ClassOfWarrantOrRightGranted', window );">Number of Shares, Granted</a></td>
        <td class="nump">35,086,253<span></span></td>
        <td class="nump">4,061,283<span></span></td>
        <td class="nump">5,478,360<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ClassOfWarrantOrRightExercised', window );">Number of Shares, Exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(619,377)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ClassOfWarrantOrRightForfeited', window );">Number of Shares, Forfeited</a></td>
        <td class="num">(868,213)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares, Outstanding</a></td>
        <td class="nump">5,881,575<span></span></td>
        <td class="nump">8,926,517<span></span></td>
        <td class="nump">4,865,234<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ClassOfWarrantOrRightVestedOutstanding', window );">Number of Shares, Outstanding and vested</a></td>
        <td class="nump">43,144,557<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price Per Share, Outstanding</a></td>
        <td class="nump">$ 0.54<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 1.00<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted', window );">Weighted Average Exercise Price Per Share, Granted</a></td>
        <td class="nump">1.58<span></span></td>
        <td class="nump">0.54<span></span></td>
        <td class="nump">0.05<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised', window );">Weighted Average Exercise Price Per Share, Exercised</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.08<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeited', window );">Weighted Average Exercise Price Per Share, Forfeited</a></td>
        <td class="nump">0.80<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted Average Exercise Price Per Share, Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.54<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedOutstanding', window );">Weighted Average Exercise Price Per Share, Outstanding and vested</a></td>
        <td class="nump">1.25<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_ClassOfWarrantOrRightExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Class Of Warrant Or Right Exercised.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_ClassOfWarrantOrRightExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeited">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Forfeited.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeited</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Granted.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGranted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Vested Outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_ClassOfWarrantOrRightForfeited">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Class of warrant or right forfeited.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_ClassOfWarrantOrRightForfeited</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_ClassOfWarrantOrRightGranted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Class Of Warrant Or Right Granted.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_ClassOfWarrantOrRightGranted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_ClassOfWarrantOrRightVestedOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Class Of Warrant Or Right Vested Outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_ClassOfWarrantOrRightVestedOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQCAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Schedule of future minimum lease payments</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2015</a></td>
        <td class="nump">$ 37,300<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2016</a></td>
        <td class="nump">38,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2017</a></td>
        <td class="nump">38,800<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2018</a></td>
        <td class="nump">9,700<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
        <td class="nump">$ 127,800<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Notes Payable<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Notes Payable [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">NOTES PAYABLE</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"><b>NOTE 3 &#8211; NOTES PAYABLE</b></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: left;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;">Subordinated 8% promissory notes payable consisted of the following at June 30, 2014 and December 31, 2013:</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: justify;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center;" colspan="2">June 30,<br />2014</td><td style="padding-bottom: 1.5pt; text-align: center;">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">December 31,&#160;<br />2013</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1179px; text-align: justify; text-indent: -9pt; padding-left: 9pt;">Subordinated 8% promissory notes due December 2013</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">-</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">216,000</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt;">Subordinated 8% promissory notes due September 2014</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">-</td><td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">684,000</td><td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; padding-left: 0pt;">Total notes payable</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">900,000</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt;">Less: debt discount</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">-</td><td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">(141,049</td><td style="padding-bottom: 1.5pt; text-align: left;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; padding-bottom: 4pt; padding-left: 0pt;">Total notes payable, less debt discount</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">$</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">-</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">$</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">758,951</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px;
 -webkit-text-stroke-width: 0px; margin: 0px;"><b>December 2012 Subordinated Promissory Notes Payable</b></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">In December 2012, the Company issued $216,000 of subordinated 8% promissory notes payable for cash proceeds of $180,000 which were due on December 6, 2013. In addition, the note holders received seven-year warrants to purchase 67,500 shares of common stock with an exercise price of $0.80 per share. The Company recorded the fair value of the warrants as a debt discount on the notes payable which resulted in a debt discount of $26,325. The difference between the face value and the cash proceeds of $36,000 was also treated as debt discount and was amortized to interest expense over the one year maturity of the notes. The Company also paid debt issuance costs of $25,100 to the placement agent that were recorded as deferred financing costs and amortized over the one year maturity of the notes. The effective interest rate was 36.9%. The Company also issued 33,750 warrants to purchase common stock at $0.80 per share to the placement agent which the Company recorded as a discount on the notes at the fair value of $13,089. All of the debt discount of $62,325 and deferred financing costs of $38,189 were fully amortized and recorded as interest expense during 2013 for these notes. These notes and accrued interest of approximately $960,900 were converted to 1,201,153 common stock upon the Share Exchange on May 20, 2014.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">The notes and accrued interest were automatically converted into common stock at $0.80 per share upon the Share Exchange on May 20, 2014. The warrants contained an anti-dilution provision if the Company raises equity in the future at a price lower than $0.80 per share, the warrants to purchase common stock and the notes payable conversion price will be adjusted for the anti-dilutive effects of such future issuance. As a result, the warrants issued with the debt are accounted for as derivative liabilities and recorded at fair value at each period end. The anti-dilution feature was eliminated upon the Share Exchange. The Company recorded the fair market value of the derivative financial instrument at the date of the Share Exchange on May 20, 2014.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"><b>September 2013 Subordinated Promissory Notes Payable</b></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">In September 2013, the Company issued $684,000 of subordinated 8% promissory notes payable for cash proceeds of $570,000 which are due in September 2014. In addition, the note holders received seven-year warrants to purchase 213,750 shares of common stock with an exercise price of $0.80 per share. The Company recorded the fair value of the warrants as a debt discount on the notes payable which resulted in a debt discount of $83,363. The difference between the face value and the cash proceeds of $114,000 was also treated as debt discount and is amortized to interest expense over the one year maturity of the notes. The Company also paid debt issuance costs of $68,400 to the placement agent that were recorded as deferred financing costs and are amortized over its one year maturity of the notes. The effective interest rate was 36.9%. The Company also issued 106,875 warrants to purchase common stock at $0.80 per share to the placement agent which the Company recorded as a discount on the notes at the fair value of $41,681. The Company has amortized debt discount for deferred financing costs of $219,773 and $31,357 to interest expense for these notes during the six months ended June 30, 2014 and for the year ended December 31, 2013, respectively.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size:
 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">The Company determined that there was a beneficial conversion feature on the September 2013 notes payable at the issuance date of approximately $186,800 which represented the difference between the effective conversion price of $0.60 per share and the fair value of the common stock as of the commitment date of $0.80 per share. The beneficial conversion feature was recorded as interest expense upon the Share Exchange.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">The notes and accrued interest of approximately $960,900 were automatically converted into 1,201,153 shares of common stock at $0.80 per share upon the Share Exchange on May 20, 2014. The warrants contained an anti-dilution feature if the Company raises equity in the future at a price lower than $0.80 per share, the warrants to purchase common stock and the notes payable conversion price will be adjusted for the anti-dilutive effects of such future issuance. As a result, the warrants issued with the debt are accounted for as derivative liabilities and recorded at fair value at balance sheet date. The anti-dilution feature was terminated upon the Share Exchange. The Company recorded the fair market value of the derivative financial instrument at the date of the Share Exchange on May 20, 2014.</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-indent: 0.5in;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;"><font style="background-color: white;">In May 6, 2014, the Company entered into a finance agreement for $77,850 for its director and officer liability insurance policy. The Company paid its initial down payment of approximately $6,800 and has eleven monthly installments of approximately $6,60. The interest rate is 3.436% per annum. At June 30, 2014, the Company owed $58,357 in co</font>nnection with this note payable.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesPayableAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>22
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%\V,S,T-64Y9E]B-C1B7S0W,V)?.&)B,%\U
M-S1F-C%A,#EB,F4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C,S
M-#5E.69?8C8T8E\T-S-B7SAB8C!?-3<T9C8Q83`Y8C)E+U=O<FMB;V]K+FAT
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7U-T871E;65N='-?;V9?3W!E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7U-T871E;65N=%]O9E]3=&]C/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A
M=&5D7U-T871E;65N='-?;V9?0V%S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^0G5S:6YE<W,\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#<N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y3=6UM87)Y7V]F7U-I9VYI9FEC86YT7T%C8V]U
M;G0\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y.;W1E
M<U]087EA8FQE/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#`Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^1&5R:79A=&EV95],:6%B:6QI=&EE<SPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,"YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K:&]L9&5R<U]%<75I='D\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,3$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y296QA=&5D7U!A<G1Y
M7U1R86YS86-T:6]N<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,BYH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/DEN8V]M95]487AE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,RYH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#$T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W5B<V5Q=65N
M=%]%=F5N=',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,34N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y3=6UM87)Y7V]F7U-I9VYI9FEC86YT7T%C8V]U;G0Q/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#$V+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W5M;6%R>5]O9E]3:6=N:69I
M8V%N=%]!8V-O=6YT,CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-RYH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/DYO=&5S7U!A>6%B;&5?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$X+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^1&5R:79A=&EV95],:6%B:6QI=&EE<U]4
M86)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,3DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3
M=&]C:VAO;&1E<G-?17%U:71Y7U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,"YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/E)E;&%T961?4&%R='E?5')A;G-A8W1I;VYS
M7U1A8CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970R,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN
M8V]M95]487AE<U]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C(N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y#;VUM:71M96YT<U]A;F1?0V]N=&EN9V5N8VEE<U\\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,C,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y"=7-I;F5S<U]$
M971A:6QS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#(T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M4W5M;6%R>5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT,SPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R
M-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U;6UA<GE?;V9?4VEG;FEF:6-A
M;G1?06-C;W5N=#0\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T,C8N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y3=6UM87)Y7V]F7U-I9VYI9FEC86YT7T%C8V]U;G0U/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#(W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W5M;6%R>5]O9E]3:6=N
M:69I8V%N=%]!8V-O=6YT-CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R."YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/DYO=&5S7U!A>6%B;&5?1&5T86EL<SPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R
M.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DYO=&5S7U!A>6%B;&5?1&5T86EL
M<U]497AT=6%L/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#,P+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^1&5R:79A=&EV95],:6%B:6QI=&EE<U]$971A:6QS/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#,Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1&5R:79A=&EV95],:6%B:6QI
M=&EE<U]$971A:6QS,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,BYH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/D1E<FEV871I=F5?3&EA8FEL:71I97-?1&5T86EL<S(\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,S,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:VAO;&1E<G-?
M17%U:71Y7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S0N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y3=&]C:VAO;&1E<G-?17%U:71Y7T1E=&%I;'-?,3PO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970S-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K:&]L9&5R<U]%
M<75I='E?1&5T86EL<U\R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,V+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^4W1O8VMH;VQD97)S7T5Q=6ET>5]$971A:6QS7S,\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,S<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=&]C:VAO;&1E<G-?
M17%U:71Y7T1E=&%I;'-?-#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S."YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/E-T;V-K:&]L9&5R<U]%<75I='E?1&5T86EL<U]493PO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970S.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K:&]L9&5R
M<U]%<75I='E?1&5T86EL<U]493$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-#`N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y3=&]C:VAO;&1E<G-?17%U:71Y7T1E=&%I;'-?5&4R
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#0Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4F5L871E
M9%]087)T>5]4<F%N<V%C=&EO;G-?1&5T/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#0R+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^4F5L871E9%]087)T>5]4<F%N<V%C=&EO;G-?
M1&5T,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970T,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN
M8V]M95]487AE<U]$971A:6QS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#0T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^26YC;VUE7U1A>&5S7T1E=&%I;'-?,3PO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970T-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN8V]M95]487AE<U]$971A
M:6QS7U1E>'1U86P\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@
M2%)E9CTS1")7;W)K<VAE971S+U-H965T-#8N:'1M;"(O/@T*("`@/"]X.D5X
M8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z
M3F%M93Y#;VUM:71M96YT<U]A;F1?0V]N=&EN9V5N8VEE<U\Q/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#0W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]M;6ET;65N='-?86YD
M7T-O;G1I;F=E;F-I97-?,CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T."YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/E-U8G-E<75E;G1?179E;G1S7T1E=&%I;',\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T-#DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`\+W@Z
M17AC96Q7;W)K<VAE971S/@T*("`\>#I3='EL97-H965T($A2968],T0B5V]R
M:W-H965T<R]R97!O<G0N8W-S(B\^#0H@(#QX.D%C=&EV95-H965T/C`\+W@Z
M06-T:79E4VAE970^#0H@(#QX.E!R;W1E8W13=')U8W1U<F4^1F%L<V4\+W@Z
M4')O=&5C=%-T<G5C='5R93X-"B`@/'@Z4')O=&5C=%=I;F1O=W,^1F%L<V4\
M+W@Z4')O=&5C=%=I;F1O=W,^#0H@/"]X.D5X8V5L5V]R:V)O;VL^#0H\+WAM
M;#X\(5ME;F1I9ETM+3X-"CPO:&5A9#X-"B`@/&)O9'D^#0H@("`\<#Y4:&ES
M('!A9V4@<VAO=6QD(&)E(&]P96YE9"!W:71H($UI8W)O<V]F="!%>&-E;"!8
M4"!O<B!N97=E<BX\+W`^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\V,S,T-64Y9E]B-C1B7S0W,V)?.&)B,%\U-S1F-C%A,#EB
M,F4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C,S-#5E.69?8C8T
M8E\T-S-B7SAB8C!?-3<T9C8Q83`Y8C)E+U=O<FMS:&5E=',O4VAE970P,2YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P15-$04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&]C
M=6UE;G0@86YD($5N=&ET>2!);F9O<FUA=&EO;CQB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1O8W5M96YT($%N9"!%
M;G1I='D@26YF;W)M871I;VX@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y(%)E9VES=')A;G0@
M3F%M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)U)%3$U!1$$@
M5$A%4D%0155424-3+"!)3D,N/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0V5N=')A;"!);F1E>"!+97D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<P,#`Q-34S-C0S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M;65N9&UE;G0@1FQA9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)V9A;'-E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$;V-U;65N="!4>7!E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG4RTQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y$;V-U;65N="!097)I;V0@16YD($1A=&4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/DIU;B`S,"P-"@D),C`Q-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT
M:71Y($9I;&5R($-A=&5G;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG4VUA;&QE<B!297!O<G1I;F<@0V]M<&%N>3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C,S-#5E.69?8C8T8E\T-S-B
M7SAB8C!?-3<T9C8Q83`Y8C)E#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S8S,S0U93EF7V(V-&)?-#<S8E\X8F(P7S4W-&8V,6$P.6(R92]7;W)K
M<VAE971S+U-H965T,#(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$513D%'/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N
M/3-$,3X\<W1R;VYG/D-O;G-O;&ED871E9"!"86QA;F-E(%-H965T<R`H55-$
M("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY#=7)R96YT(&%S<V5T<SH\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H
M(&5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#(U+#4V-"PS-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#,L-3(R+#0U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E<&%I9"!E>'!E;G-E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<X+#$U.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#,R-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F
M97)R960@9FEN86YC:6YG(&-O<W1S+"!N970@;V8@86-C=6UU;&%T960@86UO
M<G1I>F%T:6]N(&]F("0P(&%N9"`D-CDL-30V(')E<W!E8W1I=F5L>3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<X+#<R
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E1O=&%L(&-U<G)E;G0@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR-2PW-#(L-3`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPV,3$L-#DY/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&:7AE9"!A<W-E=',L
M(&YE="!O9B!A8V-U;75L871E9"!D97!R96-I871I;VX@;V8@)#(L,C,P(&%N
M9"`D,S<S+"!R97-P96-T:79E;'D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/CDL.#0Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^."PT.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(&%S<V5T<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3(L,3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L,3`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@87-S971S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2PW-C0L-#4P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPV
M,S(L,#DW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D-U<G)E;G0@;&EA8FEL:71I97,Z/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@
M<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S0V+#`Y
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$X,"PS,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%C8W)U960@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,X,BPP,C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT,S@L-C4X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;W1E('!A>6%B;&4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4X+#,U-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<FEV871I
M=F4@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(U+#4X-BPY,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR,"PQ,#,L-#(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6)O<F1I;F%T960@<')O;6ES<V]R
M>2!N;W1E<R!P87EA8FQE+"!N970@;V8@9&5B="!D:7-C;W5N="!O9B`D,"!A
M;F0@)#$T,2PP-#DL(')E<W!E8W1I=F5L>3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<U."PY-3$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C=7)R
M96YT(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-BPW-S,L-#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C$L-#@Q+#,U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]N9RUT97)M(&QI86)I;&ET>2`M
M(&%C8W)U960@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!L:6%B:6QI=&EE<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8L.#<S+#0Q,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q+#4X,2PS-3,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;6UI=&UE;G1S(&%N9"!C;VYT:6YG96YC:65S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY3=&]C:VAO;&1E<G,G(&1E9FEC:70Z/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"`D
M,"XP,#$@<&%R('9A;'5E+"`U,#`L,#`P+#`P,"!S:&%R97,@875T:&]R:7IE
M9"P@-#`L,CDT+#(Q-R!A;F0@-"PY-3@L-S<X('-H87)E<R!I<W-U960@86YD
M(&]U='-T86YD:6YG+"!R97-P96-T:79E;'D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0P+#(Y-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0L.34Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO;F%L('!A:60M:6X@
M8V%P:71A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-30L,38V
M+#`U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$V+#`Q-"PX-#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%C8W5M=6QA=&5D(&1E9FEC:70\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#4U+#,Q."PV-#<I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S,L.3@R+#8U.2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4;W1A;"!S=&]C:VAO;&1E<G,G(&1E9FEC:70\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#$L,3`X+#DV,2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-RPY-#DL,C4V*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L
M(&QI86)I;&ET:65S(&%N9"!S=&]C:VAO;&1E<G,G(&1E9FEC:70\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#<V-"PT-3`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#8S,BPP.3<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-E<FEE<R!!(%!R969E<G)E9"!3=&]C:R!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1O8VMH;VQD97)S
M)R!D969I8VET.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RQ686QU93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S+#8P-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VQA<W,@
M02!C;VYV97)T:6)L92!P<F5F97)R960@<W1O8VL@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K:&]L
M9&5R<R<@9&5F:6-I=#H\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL5F%L=64\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPS,S<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V,S,T-64Y
M9E]B-C1B7S0W,V)?.&)B,%\U-S1F-C%A,#EB,F4-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO-C,S-#5E.69?8C8T8E\T-S-B7SAB8C!?-3<T9C8Q
M83`Y8C)E+U=O<FMS:&5E=',O4VAE970P,RYH=&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\
M:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O
M;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y
M<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@
M4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P148Q044^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0V]N<V]L:61A=&5D($)A;&%N8V4@
M4VAE971S("A087)E;G1H971I8V%L*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F%T
M:6]N(&]F(&1E9F5R<F5D(&9I;F%N8VEN9R!C;W-T<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`V.2PU-#8\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W5M=6QA=&5D(&1E
M<')E8VEA=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPR
M,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS-S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1E8G0@9&ES8V]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,30Q+#`T.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!P87(@=F%L
M=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N
M,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y0<F5F97)R960@<W1O8VLL('-H87)E<R!A=71H;W)I>F5D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#`L,#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P,"PP,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y,:7%U:61A=&EO;B!686QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`P+C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#`N.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!P87(@=F%L=64\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU,#`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P,"PP,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM;VX@<W1O8VLL('-H87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0P+#(Y-"PR,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#DU."PW-S@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C
M:RP@<VAA<F5S(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT,"PR.30L,C$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-"PY-3@L-S<X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y397)I97,@02!0<F5F97)R
M960@4W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL('-H87)E<R!A=71H;W)I>F5D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4U+#`P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M969E<G)E9"!S=&]C:RP@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$S+#8P-"PQ,C@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:RP@
M<VAA<F5S(&]U='-T86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3,L-C`T+#$R.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0VQA<W,@02!C;VYV97)T:6)L92!P<F5F97)R
M960@<W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL('-H87)E<R!A=71H;W)I>F5D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#4P,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#4P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R969E<G)E9"!S=&]C:RP@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPS,S<L,S`Y/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T
M;V-K+"!S:&%R97,@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,L,S,W+#,P.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S8S,S0U93EF7V(V-&)?-#<S8E\X8F(P7S4W-&8V
M,6$P.6(R90T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V,S,T-64Y
M9E]B-C1B7S0W,V)?.&)B,%\U-S1F-C%A,#EB,F4O5V]R:W-H965T<R]3:&5E
M=#`T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%-E5!13X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY#;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!/<&5R871I;VYS("A54T0@
M)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^26YC;VUE(%-T871E;65N="!;06)S=')A
M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E)E=F5N=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY/<&5R871I;F<@97AP96YS97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P;65N
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH.#,Y+#DU.2D\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U+#(T
M."PV-CDI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH-C8W+#0W-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,BPQ,#8L.#4Y*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L-3(U
M+#(U-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@R+#0X.2PR,S4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5&]T86P@;W!E<F%T:6YG(&5X<&5N<V5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,BPY-#8L.#$X*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8L-S<S
M+#DR-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@S+#$U-BPW,#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y,;W-S(&9R;VT@;W!E<F%T:6]N<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3(L.30V+#@Q."D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V+#<W,RPY,C8I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,RPQ-38L-S`Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY/=&AE<B`H97AP96YS97,I(&EN8V]M93H\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3&]S<R!O;B!C:&%N9V4@:6X@9F%I<B!V86QU92!O9B!D97)I=F%T:79E(&QI
M86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W+#DU
M-"PY-S`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,3(L.#<W+#8W-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@S+#8X."PS-3,I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);G1E<F5S="!I;F-O;64\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-#$Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$R+#<U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^26YT97)E<W0@97AP96YS93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH-#,U+#8Q,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,C`L,S`W*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(W+#<R,2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A
M;"!O=&AE<B`H97AP96YS97,I(&EN8V]M93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH."PS.#DL,3<P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$S+#`Y-RPY.#(I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,RPW,#,L,S(Q*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#(Q
M+#,S-2PY.#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XD("@Q.2PX-S$L.3`X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-BPX-C`L,#,P*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,@
M<&5R(&-O;6UO;B!S:&%R92`M(&)A<VEC(&%N9"!D:6QU=&5D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#$N-S,I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@X+C$X*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,RXQ-RD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E=E:6=H=&5D(&%V97)A9V4@;G5M8F5R(&]F(&-O;6UO;B!S:&%R97,@;W5T
M<W1A;F1I;F<@+2!B87-I8R!A;F0@9&EL=71E9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3(L,S,R+#,S,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-#(Y+#(V-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,38V+#0Y.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C,S-#5E
M.69?8C8T8E\T-S-B7SAB8C!?-3<T9C8Q83`Y8C)E#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S8S,S0U93EF7V(V-&)?-#<S8E\X8F(P7S4W-&8V
M,6$P.6(R92]7;W)K<VAE971S+U-H965T,#4N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5)0D)+
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O;G-O;&ED871E9"!3=&%T96UE
M;G0@;V8@4W1O8VMH;VQD97)S)R!$969I8VET("A54T0@)"D\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^5&]T86P\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5R:65S($$@4')E9F5R<F5D
M(%-T;V-K(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D-L87-S($$@4')E9F5R<F5D(%-T;V-K(%M-96UB97)=/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D-O;6UO;B!3=&]C:R!;365M8F5R
M73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!9&1I=&EO;F%L
M(%!A:60M:6X@0V%P:71A;"!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y!8V-U;75L871E9"!$969I8VET(%M-96UB97)=/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"96=I;FYI;F<@
M0F%L86YC92!A="!$96,N(#,Q+"`R,#$Q/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B0@*#(L.#,Y+#DW,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,2PU,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#0L-#`Y+#(S,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-RPR-3`L-S(Q*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F5G:6YN:6YG
M($)A;&%N8V4L(%-H87)E<R!A="!$96,N(#,Q+"`R,#$Q/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#4Q.2PW-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K(&%N9"!W
M87)R86YT<R!T;R!A(')E;&%T960@<&%R='D@9F]R(&QI86)I;&ET:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-CDL,C<U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XX-CDL,#$Y/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M
M;6]N('-T;V-K(&%N9"!W87)R86YT<R!T;R!A(')E;&%T960@<&%R='D@9F]R
M(&QI86)I;&ET:65S+"!3:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U-2PW-3`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1F]R9VEV96YE<W,@;V8@;&EA8FEL:71I97,@8GD@9F]U;F1E<CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S4S+#(T-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,U,RPR-#8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y)<W-U86YC92!O9B!397)I97,@02!P<F5F97)R960@<W1O8VL@9F]R(&-O
M;G9E<G-I;VX@;V8@;&]A;G,@86YD(&%C8W)U960@:6YT97)E<W0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-30Q+#$X,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.#<Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4S.2PS,#$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)
M<W-U86YC92!O9B!397)I97,@02!P<F5F97)R960@<W1O8VL@9F]R(&-O;G9E
M<G-I;VX@;V8@;&]A;G,@86YD(&%C8W)U960@:6YT97)E<W0L(%-H87)E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.#<Y+#$R.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S
M<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S
M=&]C:R!F;W(@8V%S:&QE<W,@97AE<F-I<V4@;V8@=V%R<F%N=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[
M)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4T,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#4T,2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U
M86YC92!O9B!C;VUM;VX@<W1O8VL@9F]R(&-A<VAL97-S(&5X97)C:7-E(&]F
M('=A<G)A;G1S+"!3:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4T,2PT,S`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S
M=6%N8V4@;V8@8V]M;6]N('-T;V-K('1O(&%C<75I<F4@;&EC96YS92!A="!F
M86ER('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#$R
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU+#$Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E
M(&]F(&-O;6UO;B!S=&]C:R!T;R!A8W%U:7)E(&QI8V5N<V4@870@9F%I<B!V
M86QU92P@4VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ-RPP.#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@4V5R:65S($$@
M<')E9F5R<F5D('-T;V-K('1O(%=O;G!U;F<@9F]R('-E<G9I8V5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`P-BPP-S0\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<R-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PP,#0L,S0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@
M4V5R:65S($$@<')E9F5R<F5D('-T;V-K('1O(%=O;G!U;F<@9F]R('-E<G9I
M8V5S+"!3:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#<R-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!397)I97,@
M02!P<F5F97)R960@<W1O8VL@86YD('=A<G)A;G1S(&9O<B!C87-H+"!N970@
M;V8@;V9F97)I;F<@8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(L,34U+#DS.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0L.3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M+#$U,2PP,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!397)I97,@02!P
M<F5F97)R960@<W1O8VL@86YD('=A<G)A;G1S(&9O<B!C87-H+"!N970@;V8@
M;V9F97)I;F<@8V]S=',L(%-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0L.#DY+#,W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!F;W(@<V5R=FEC97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#4P-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR,"PT,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@
M<W1O8VL@9F]R('-E<G9I8V5S+"!3:&%R97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8X+#,U-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RUB
M87-E9"!C;VUP96YS871I;VX@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S<L,S,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S<L,S,U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8L.#8P+#`S,"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-BPX-C`L,#,P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YD
M:6YG($)A;&%N8V4@870@1&5C+B`S,2P@,C`Q,CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,RPW,3$L,S$Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L-3`T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L
M-#`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3`L,S@X+#4R-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$T+#$Q,"PW-3$I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;F1I;F<@0F%L86YC92P@4VAA
M<F5S(&%T($1E8RX@,S$L(#(P,3(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XX+#4P,RPU,#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPT,#(L,S@T/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES
M<W5A;F-E(&]F(%-E<FEE<R!!('!R969E<G)E9"!S=&]C:R!A;F0@=V%R<F%N
M=',@9F]R(&-A<V@L(&YE="!O9B!O9F9E<FEN9R!C;W-T<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PT.#0L-S$P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PQ,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L-#<Y+#8Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A
M;F-E(&]F(%-E<FEE<R!!('!R969E<G)E9"!S=&]C:R!A;F0@=V%R<F%N=',@
M9F]R(&-A<V@L(&YE="!O9B!O9F9E<FEN9R!C;W-T<RP@4VAA<F5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PQ,#`L-C(U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K
M('1O(&%C<75I<F4@365D96]R+"!);F,N(&%T(&9A:7(@=F%L=64\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-S4P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BPU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS+#<T-RPU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@
M=&\@86-Q=6ER92!-961E;W(L($EN8RX@870@9F%I<B!V86QU92P@4VAA<F5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K(&9O<B!S
M97)V:6-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38L.3$X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$V+#@V,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S
M=&]C:R!F;W(@<V5R=FEC97,L(%-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-38L,SDT/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A
M<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS.#(L,S0S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S@R+#,T,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q.2PX-S$L.3`X*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q.2PX
M-S$L.3`X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^16YD:6YG($)A;&%N8V4@870@1&5C+B`S,2P@,C`Q,SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3<L.30Y+#(U-BD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPV,#0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-"PY-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-BPP,30L.#0P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S,L.3@R+#8U.2D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN
M9R!"86QA;F-E+"!3:&%R97,@870@1&5C+B`S,2P@,C`Q,SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$S+#8P-"PQ,C@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-"PY-3@L-S<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:RP@4V5R:65S
M($$@=V%R<F%N=',@86YD(%-E<FEE<R!"('=A<G)A;G1S(&9O<B!C87-H+"!N
M970@;V8@;V9F97)I;F<@8V]S=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C(L,C(Y+#,R,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3<L,38T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C(L,C$R+#$U-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E
M(&]F(&-O;6UO;B!S=&]C:RP@4V5R:65S($$@=V%R<F%N=',@86YD(%-E<FEE
M<R!"(&9O<B!C87-H+"!N970@;V8@;V9F97)I;F<@8V]S="P@4VAA<F5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-RPQ-C,L-SDY/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!F;W(@<V5R=FEC97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L-S$T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L-C@U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S
M=6%N8V4@;V8@8V]M;6]N('-T;V-K(&9O<B!S97)V:6-E<RP@4VAA<F5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.2PP-3(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O
M8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$P+#,Q.2PQ,S<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PS,3DL,3,W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17-T
M86)L:7-H:6YG('=A<G)A;G0@9&5R:79A=&EV92!L:6%B:6QI=&EE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-"PS,S,L,38S*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0L,S,S
M+#$V,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y296-L87-S:69I8V%T:6]N(&]F(&1E<FEV871I=F4@;&EA8FEL
M:71I97,@=&\@05!)0R!U<&]N(%-H87)E($5X8VAA;F=E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV+#@P-"PV,C4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#@P-"PV,C4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VYV97)S:6]N(&]F(%-E<FEE<R!!('!R969E<G)E9"!S=&]C:RP@;F]T97,@
M<&%Y86)L92!A;F0@86-C<G5E9"!I;G1E<F5S="!T;R!C;VUM;VX@<W1O8VL\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDV,"PY,C(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,RPV,#0I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$T+#@P-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/CDU.2PW,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)S:6]N(&]F(%-E<FEE<R!!('!R969E
M<G)E9"!S=&]C:RP@;F]T97,@<&%Y86)L92!A;F0@86-C<G5E9"!I;G1E<F5S
M="!T;R!C;VUM;VX@<W1O8VLL(%-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#$S+#8P-"PQ,C@I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#@P-2PR-S@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N
M8V4@;V8@8V]M;6]N('-T;V-K(&%N9"!#;&%S<R!!('!R969E<G)E9"!S=&]C
M:R!I;B!C;VYN96-T:6]N('=I=&@@<VAA<F4@97AC:&%N9V4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,#`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#,S-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,S,W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PY
M.3,L,S(V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T;V-K(&%N9"!#;&%S<R!!
M('!R969E<G)E9"!S=&]C:R!I;B!C;VYN96-T:6]N('=I=&@@<VAA<F4@97AC
M:&%N9V4L(%-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS+#,S-RPS,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS+#,S-RPS,3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F%T:6]N(&]F(&)E;F5F
M:6-I86P@8V]N=F5R<VEO;B!F96%T=7)E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ.#8L-S(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3@V+#<R-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,2PS,S4L.3@X*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,2PS
M,S4L.3@X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^16YD:6YG($)A;&%N8V4@870@2G5N+B`S,"P@,C`Q-#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q+#$P."PY-C$I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,RPS,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#0P+#(Y-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-30L,38V+#`U-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-34L,S$X+#8T
M-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D5N9&EN9R!"86QA;F-E+"!3:&%R97,@870@2G5N+B`S,"P@,C`Q-#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M+#,S-RPS,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT,"PR.30L,C$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S8S,S0U93EF7V(V-&)?-#<S8E\X8F(P7S4W-&8V
M,6$P.6(R90T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V,S,T-64Y
M9E]B-C1B7S0W,V)?.&)B,%\U-S1F-C%A,#EB,F4O5V]R:W-H965T<R]3:&5E
M=#`V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%2C5"1SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY#;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!#87-H($9L;W=S("A54T0@
M)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0V%S:"!F;&]W<R!F<F]M(&]P97)A=&EN
M9R!A8W1I=FET:65S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B0@*#(Q+#,S-2PY.#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XD("@Q.2PX-S$L.3`X*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-BPX-C`L,#,P
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY!9&IU<W1M96YT<R!T;R!R96-O;F-I;&4@;F5T(&QO<W,@
M=&\@;F5T(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@86-T:79I=&EE<SH\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5P
M<F5C:6%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(L,S,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S<S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K(&ES<W5E
M9"!F;W(@<V5R=FEC97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C@L-S$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,RPW-C8L.3$X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PS,S`L.#0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:RUB87-E9"!C;VUP96YS
M871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#,Q.2PQ
M,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS.#(L,S0S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S<L,S,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ871I;VX@;V8@9&5B="!D:7-C;W5N
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S(W+#<W-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q."PV
M,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!;6]R=&EZ871I;VX@;V8@9&5F97)R960@9FEN
M86YC:6YG(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW
M."PW,C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV.2PU-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;W-S(&]N(&-H86YG92!I;B!F
M86ER('9A;'5E(&]F(&1E<FEV871I=F4@;&EA8FEL:71I97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C<L.34T+#DW,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#@W-RPV-S4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#8X
M."PS-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^0VAA;F=E<R!I;B!O<&5R871I;F<@87-S971S(&%N
M9"!L:6%B:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')E<&%I9"!E>'!E;G-E<R!A;F0@;W1H97(@87-S
M971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X.2PY.#,I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38P
M+#(X,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#$X,BPW,#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XU-C4L-S<Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-3<L,3`R*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,R+#(Y.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E
M9"!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PR
M.#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS,34L-S`T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S8Y+#DR-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('5S960@:6X@;W!E<F%T:6YG
M(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(L
M,38T+#(U-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@R+#(S-RPU,CDI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,2PU.#,L.3<U*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H(&9L
M;W=S(&9R;VT@:6YV97-T:6YG(&%C=&EV:71I97,\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4'5R8VAA<V4@;V8@9FEX
M960@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S+#8W
M,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@X+#@W,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@=7-E9"!I;B!I;G9E
M<W1I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,RPV-S,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH."PX-S$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H(&9L
M;W=S(&9R;VT@9FEN86YC:6YG(&%C=&EV:71I97,\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!S
M86QE(&]F(%-E<FEE<R!!('!R969E<G)E9"!S=&]C:R!A;F0@=V%R<F%N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS
M+#0Y-"PT,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS+#(R,"PP,3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@<V%L92!O9B!C;VUM
M;VX@<W1O8VL@86YD('=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR,BPR,CDL,S(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R;V-E961S(&9R;VT@<V%L97,@;V8@8V]M;6]N(&%N9"!#;&%S<R!!(%-E
M<FEE<R!!('!R969E<G)E9"!S=&]C:RP@<'5R<W5A;G0@=&\@4VAA<F4@17AC
M:&%N9V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,#`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y087EM96YT(&]F(&YO=&5S
M('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Y+#0Y
M,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,SDL.3DP*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!S=6)O<F1I
M;F%T960@<')O;6ES<V]R>2!N;W1E<R!P87EA8FQE+"!N970@;V8@9FEN86YC
M:6YG(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-3`Q+#8P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$U-"PY,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@8V%S:"!P<F]V:61E9"!B
M>2!F:6YA;F-I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C0L,C`Y+#@R.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,L.3DV+#`R.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,S,T+#DR.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!I
M;F-R96%S92!I;B!C87-H/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR,BPP-#$L.3`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PW-#DL-C(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2PW-3`L.34S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%T(&)E9VEN
M;FEN9R!O9B!T:&4@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS+#4R,BPT-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#<W,BPX,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,2PX-CD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@870@96YD(&]F
M('1H92!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U
M+#4V-"PS-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS+#4R,BPT-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#<W,BPX,C(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V%S:"!P86ED
M(&1U<FEN9R!T:&4@<&5R:6]D(&9O<CH\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC;VUE('1A>&5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#$P,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/DYO;BUC87-H(&EN=F5S=&EN9R!A;F0@9FEN86YC:6YG('1R
M86YS86-T:6]N<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V]N=F5R<VEO;B!O9B!397)I97,@02!0<F5F97)R960@
M4W1O8VL@86YD(%-U8F]R9&EN871E9"!.;W1E<R!T;R!C;VUM;VX@<W1O8VL\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDP,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[
M)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R<VEO;B!O9B!A8V-R=65D(&EN
M=&5R97-T('1O(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-C`L.3(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO
M=&4@<&%Y86)L92!I<W-U960@:6X@8V]N;F5C=&EO;B!W:71H(&1I<F5C=&]R
M(&%N9"!O9F9I8V5R(&EN<W5R86YC92!P;VQI8WD\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C<W+#@U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A
M;'5E(&]F(&1E<FEV871I=F4@<F5C;&%S<VEF:65D('1O(&%D9&ET:6]N86P@
M<&%I9"UI;BUC87!I=&%L(&EN(&-O;FYE8W1I;VX@=VET:"!3:&%R92!%>&-H
M86YG93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPX,#0L-C(U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@=V%R
M<F%N="!D97)I=F%T:79E<R!I<W-U960@=VET:"!U;FET<R!O9F9E<FEN9SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PS,S,L,38S/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)E;F5F:6-I86P@8V]N=F5R<VEO;B!F
M96%T=7)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#8L-S(W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@9&5R
M:79A=&EV97,@:7-S=65D(&EN(&-O;FYE8W1I;VX@=VET:"!I<W-U86YC92!O
M9B!P<F5F97)R960@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#<V,2PP-C,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY.#0L-#8U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E
M(&]F(&1E<FEV871I=F4@=V%R<F%N=',@:7-S=65D('1O(&QE;F1E<G,@:6X@
M8V]N;F5C=&EO;B!W:71H(&ES<W5A;F-E(&]F('-U8F]R9&EN871E9"!P<F]M
M:7-S;W)Y(&YO=&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.#,L,S8S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C8L,S(U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F('=A<G)A
M;G1S(&ES<W5E9"!I;B!C;VYN96-T:6]N('=I=&@@9&5F97)R960@9FEN86YC
M:6YG(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#$L-C@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3,L,#@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F(&1E<FEV871I
M=F4@=V%R<F%N=',@:7-S=65D(&9O<B!O9F9E<FEN9R!C;W-T<R!I;B!C;VYN
M96-T:6]N('=I=&@@=&AE(&ES<W5A;F-E(&]F(%-E<FEE<R!!('!R969E<G)E
M9"!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(T."PV-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW.2PV,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@9&5R:79A=&EV
M92!I<W-U960@=&\@5V]N<'5N9R!F;W(@<V5R=FEC97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,CDY+#$T,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^17AC:&%N9V4@;V8@;&]A;G,@86YD(&%C8W)U960@:6YT97)E
M<W0@9F]R(&-O;6UO;B!S=&]C:R!F<F]M(&9O=6YD97(\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PR,C(L,S(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y%>&-H86YG92!O9B!S=6)O<F1I;F%T960@;F]T97,@86YD
M(&%C8W)U960@:6YT97)E<W0@9F]R(%-E<FEE<R!!('!R969E<G)E9"!S=&]C
M:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+#4T,2PQ.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<VAL97-S(&5X97)C:7-E(&]F
M('=A<G)A;G1S(&9O<B!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U-"PQ
M-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8S
M,S0U93EF7V(V-&)?-#<S8E\X8F(P7S4W-&8V,6$P.6(R90T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B\V,S,T-64Y9E]B-C1B7S0W,V)?.&)B,%\U
M-S1F-C%A,#EB,F4O5V]R:W-H965T<R]3:&5E=#`W+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0G5S:6YE<W,\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY"=7-I;F5S
M<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y"55-)3D534SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@
M(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P
M<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[)SX\8CY.3U1%(#$@)B,X,C$Q.R!"55-)3D534SPO8CX\+W`^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P
M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L
M971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI
M=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@
M,'!X.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
M<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X
M="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US
M<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#LG/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ
M(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M
M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SY296QM861A(%1H97)A
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M92!I<R!L;V-A=&5D(&EN($YE=R!9;W)K($-I='DN/"]P/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R
M86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-6EN.R!L971T97(M<W!A
M8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z
M(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q
M-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R
M.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z
M(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P
M<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M
M=VED=&@Z(#!P>#LG/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@
M,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E
M>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M
M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E
M>'0M<W1R;VME+7=I9'1H.B`P<'@[)SY/;B!-87D@,C`L(#(P,30L(%)E;&UA
M9&$@5&AE<F%P975T:6-S+"!);F,N("@F(S@R,C`[4F5L;6%D828C.#(R,3LI
M(&-O;7!L971E9"!A(%-H87)E($5X8VAA;F=E('=I=&@@=&AE($-O;7!A;GDL
M('=H97)E8GD@=&AE($-O;7!A;GD@86-Q=6ER960@.30N-B4@;V8@=&AE(&ES
M<W5E9"!A;F0@;W5T<W1A;F1I;F<@8V%P:71A;"!S=&]C:R!O9B!296QM861A
M(&9R;VT@=&AE('-T;V-K:&]L9&5R<R!I;B!E>&-H86YG92`H)B,X,C(P.U-H
M87)E($5X8VAA;F=E)B,X,C(Q.RD@9F]R('1H92!I<W-U86YC92!O9B`R."PR
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M(&-O;6UO;B!S=&]C:R!A;F0@,RPS,S<L,S`Y('-H87)E<R!O9B!#;&%S<R!!
M(&-O;G9E<G1I8FQE('!R969E<G)E9"!S:&%R97,N/"]P/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R
M86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N
M;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P
M.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@
M(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P
M<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[)SY!<R!A(')E<W5L="!O9B!T:&4@4VAA<F4@17AC:&%N9V4L
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M8VL@=&\@-3`P+#`P,"PP,#`@<VAA<F5S(&%N9"!I=',@875T:&]R:7IE9"!P
M<F5F97)R960@<W1O8VL@=&\@,C`P+#`P,"PP,#`@<VAA<F5S+CPO9F]N=#X\
M+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P
M,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,"XU
M:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G
M:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE
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M;6%D82!F<F]M('1H92!D871E(&]F(&ET<R!I;F-E<'1I;VXL($UA>2`R-"P@
M,C`P-"X@07,@82!R97-U;'0@;V8@=&AE(%-H87)E($5X8VAA;F=E+"!T:&4@
M0V]M<&%N>2!B96-A;64@=&AE(&AO;&1I;F<@8V]M<&%N>2!A;F0@4F5L;6%D
M82!B96-A;64@=&AE('-U8G-I9&EA<GDN(%1H92!O<&5R871I;F<@96YT:71Y
M(&ES('1H870@;V8@4F5L;6%D82X\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M
M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N
M;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L
M.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E
M8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/"]P/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R
M86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N
M;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P
M.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@
M(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P
M<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[)SY);B!A9&1I=&EO;B!T;R!T:&4@;F]R;6%L(')I<VMS(&%S
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M9R!!9&UI;FES=')A=&EO;B`H)B,X,C(P.T9$028C.#(R,3LI(&%N9"!O=&AE
M<B!G;W9E<FYM96YT86P@<F5G=6QA=&EO;G,@86YD(&%P<')O=F%L(')E<75I
M<F5M96YT<RX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%\V,S,T-64Y9E]B-C1B7S0W,V)?.&)B,%\U-S1F-C%A,#EB,F4-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C,S-#5E.69?8C8T8E\T
M-S-B7SAB8C!?-3<T9C8Q83`Y8C)E+U=O<FMS:&5E=',O4VAE970P."YH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-U;6UA<GD@
M;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<SQB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@
M;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M54U-05)9($]&(%-)1TY)1DE#04Y4($%#0T]53E1)3D<@4$],24-)15,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M
M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@
M+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&(^3D]412`R("8C
M.#(Q,3L@4U5-34%262!/1B!324=.249)0T%.5"!!0T-/54Y424Y'(%!/3$E#
M2453/"]B/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L
M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N
M=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z
M(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K
M92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA
M<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO
M;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[
M('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=B
M86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQB/E!R:6YC:7!L97,@;V8@0V]N
M<V]L:61A=&EO;CPO8CX\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA
M<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO
M;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[
M('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=B
M86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/B8C,38P.SPO9F]N=#X\+W`^/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG
M/CQF;VYT('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^5&AE
M(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT<R!I;F-L=61E('1H
M92!#;VUP86YY)B,X,C$W.W,@86-C;W5N=',@86YD('1H;W-E(&]F('1H92!#
M;VUP86YY)B,X,C$W.W,@=VAO;&QY(&]W;F5D('-U8G-I9&EA<FEE<RX@06QL
M('-I9VYI9FEC86YT(&EN=&5R8V]M<&%N>2!A8V-O=6YT<R!A;F0@=')A;G-A
M8W1I;VYS(&AA=F4@8F5E;B!E;&EM:6YA=&5D(&EN(&-O;G-O;&ED871I;VXN
M/"]F;VYT/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L
M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N
M=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z
M(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K
M92UW:61T:#H@,'!X.R<^/&(^)B,Q-C`[/"]B/CPO<#X\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F
M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@
M;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA
M;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&(^57-E(&]F
M($5S=&EM871E<SPO8CX\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
M<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X
M="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US
M<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F
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M(&EN('1H92!5;FET960@4W1A=&5S("@F(S@R,C`[52Y3+B!'04%0)B,X,C(Q
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M<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P
M,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[
M(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W
M:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[)SXF(S$V,#L\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
M<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X
M="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US
M<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#LG/CQB/D-A<V@@86YD($-A<V@@17%U:79A
M;&5N=',\+V(^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C
M;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD
M96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[)SXF(S$V,#L\+W`^/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@
M;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA
M;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW
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M;G,@97AC965D(&9E9&5R86QL>2!I;G-U<F5D(&QI;6ET<RX\+W`^/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E
M.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQB
M/B8C,38P.SPO8CX\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[
M(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI
M;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C
M:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#LG/CQB/E!A=&5N=',\+V(^/"]P/CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT
M<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C
M:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@
M;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V
M,#L\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C
M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P
M>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[
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M;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[
M('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O
M<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\8CXF(S$V,#L\+V(^/"]P/CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@
M=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E
M<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M)SX\8CY&:7AE9"!!<W-E=',\+V(^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA
M<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO
M;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[
M('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V,#L\+W`^/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E
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M+"!W:&EC:"!I<R!T:')E92!Y96%R<RX\+W`^/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@
M;F]N93L-"B!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@
M+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]P/CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@
M=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E
M<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M)SX\8CY$97)I=F%T:79E<SPO8CX\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R
M9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N
M93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO<#X\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M
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M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E
M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A
M8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^
M)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO
M<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[)SX\8CY&86ER(%9A;'5E(&]F($9I;F%N8VEA;"!);G-T
M<G5M96YT<SPO8CX\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[
M(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI
M;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C
M:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M
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M.CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P
M,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T
M:#H@,'!X.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@
M,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E
M>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M
M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E
M>'0M<W1R;VME+7=I9'1H.B`P<'@[)SY,979E;"`Q("T@475O=&5D('!R:6-E
M<R!I;B!A8W1I=F4@;6%R:V5T<R!F;W(@:61E;G1I8V%L(&%S<V5T<R!O<B!L
M:6%B:6QI=&EE<RX\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[
M(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI
M;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C
M:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M
M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@
M+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^3&5V96P@,B`M(%9A
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M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M
M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A
M8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z
M(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q
M-C`[/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@
M(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P
M<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[)SY,979E;"`S("T@5F%L=6%T:6]N<R!F;W(@87-S971S(&%N
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M;&ET:65S+CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L
M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N
M=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z
M(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K
M92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA
M<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO
M;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[
M('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\8CY&86ER(%9A;'5E(&]N
M(&$@4F5C=7)R:6YG($)A<VES/"]B/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M
M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N
M;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L
M.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E
M8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]P/CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS
M<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C
M93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\
M+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P
M,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H
M:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z
M(#!P>#LG/D%S(')E<75I<F5D(&)Y($%C8V]U;G1I;F<@4W1A;F1A<F0@0V]D
M:69I8V%T:6]N("@F(S@R,C`[05-#)B,X,C(Q.RD@5&]P:6,@3F\N(#@R,"`F
M(S@R,3$[(#$P)B,Q-C`[/&D^1F%I<B!686QU92!-96%S=7)E;65N=#PO:3XL
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M(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ
M(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M
M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V,#L\+W`^/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X
M="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US
M<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#LG/E1H92!F;VQL;W=I;F<@=&%B;&4@<V5T
M<R!F;W)T:"P@8GD@;&5V96P@=VET:&EN('1H92!F86ER('9A;'5E(&AI97)A
M<F-H>2P@=&AE($-O;7!A;GDF(S@R,3<[<R!F:6YA;F-I86P@;&EA8FEL:71I
M97,@=&AA="!W97)E(&%C8V]U;G1E9"!F;W(@870@9F%I<B!V86QU92!O;B!A
M(')E8W5R<FEN9R!B87-I<R!A<R!O9B!*=6YE(#,P+"`R,#$T.CPO<#X\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT
M+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P
M86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT
M+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\+W`^/'1A8FQE
M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(&-A;&EB<FDL(&AE;'9E=&EC
M82P@<V%N<RUS97)I9CL@=VED=&@Z(#$U-C=P>#L@=&5X="UT<F%N<V9O<FTZ
M(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M
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M;VT[)SX\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<@8V]L<W!A;CTS
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M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^)B,Q-C`[
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<@8V]L<W!A;CTS
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M<CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<@8V]L<W!A;CTS1#(^3W1H97(\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R<^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG(&-O;'-P86X]
M,T0R/DED96YT:6-A;#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<@8V]L<W!A;CTS1#(^3V)S97)V86)L93PO=&0^/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<@8V]L<W!A
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M=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CLG(&-O;'-P86X],T0R/D%S<V5T<SPO=&0^/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G
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M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG(&-O;'-P86X],T0R/DIU;F4@
M,S`L/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I
M9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)SY$97-C
M<FEP=&EO;CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
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M9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP-"B!S97)I9CLG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&)O
M<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H
M.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N
M/3-$,CXH3&5V96P@,RD\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,2XU<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#$N-7!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B
M;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL
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M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`T<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^1&5R:79A
M=&EV92!L:6%B:6QI=&EE<R`F(S@R,3$[('=A<G)A;G0@:6YS=')U;65N=',\
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M.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y
M;&4Z(&1O=6)L93LG/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,30R<'@[
M('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA
M8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#1P=#L@8F]R9&5R+6)O='1O;2US
M='EL93H@9&]U8FQE.R<^+3PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X
M.R!T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@-'!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!P861D:6YG+6)O
M='1O;3H@-'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CLG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M-G!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@8F]R9&5R+6)O='1O;2UC;VQO<CH@
M8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#1P=#L@8F]R9&5R+6)O='1O
M;2US='EL93H@9&]U8FQE.R<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M-#)P>#L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!B;W)D97(M8F]T=&]M+6-O;&]R
M.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D97(M8F]T
M=&]M+7-T>6QE.B!D;W5B;&4[)SXM/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$V<'@[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`T<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U<'@[('!A9&1I
M;F<M8F]T=&]M.B`T<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$U<'@[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM
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M8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E
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M.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/B0\+W1D/CQT
M9"!S='EL93TS1"=W:61T:#H@,30Q<'@[('1E>'0M86QI9VXZ(')I9VAT.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED
M=&@Z(#1P=#L@8F]R9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R<^,C4L-3@V
M+#DS,SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N
M.B!L969T.R!P861D:6YG+6)O='1O;3H@-'!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^/"]T
M<CX\+W1A8FQE/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO
M<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[)SXF(S$V,#LF(S$V,#LF(S$V,#L\+W`^/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O
M;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E
M;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG
M.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O
M:V4M=VED=&@Z(#!P>#LG/E1H92!F;VQL;W=I;F<@=&%B;&4@<V5T<R!F;W)T
M:"P@8GD@;&5V96P@=VET:&EN('1H92!F86ER('9A;'5E(&AI97)A<F-H>2P@
M=&AE($-O;7!A;GDF(S@R,3<[<R!F:6YA;F-I86P@;&EA8FEL:71I97,@=&AA
M="!W97)E(&%C8V]U;G1E9"!F;W(@870@9F%I<B!V86QU92!O;B!A(')E8W5R
M<FEN9R!B87-I<R!A<R!O9B!$96-E;6)E<B`S,2P@,C`Q,SH\+W`^/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI
M;F1E;G0Z(#`N-6EN.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P
M86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT
M+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]P/CQT86)L92!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!W:61T:#H@,34V-W!X.R!T97AT+71R86YS9F]R;3H@;F]N93L@
M=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R
M9"US<&%C:6YG.B`P<'@[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O
M;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)R!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
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M8V%L+6%L:6=N.B!B;W1T;VT[)SX\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A
M;CTS1#(^26X@06-T:79E/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[
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M<CLG(&-O;'-P86X],T0R/D]T:&5R/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@
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M)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^56YO8G-E<G9A8FQE/"]T9#X\
M=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^5F%L=64@87,@;V8\+W1D
M/CQT9#XF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SX\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^
M07-S971S/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^26YP
M=71S/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^26YP=71S
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^1&5C96UB97(@
M,S$L/"]T9#X\=&0^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@
M8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)SY$97-C<FEP=&EO;CPO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O
M='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T
M.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/BA,
M979E;"`Q*3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P
M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M+C5P=#LG/B8C,38P.SPO=&0^/'1D#0H@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O
M='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED
M.R<@8V]L<W!A;CTS1#(^*$QE=F5L(#(I/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B
M;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T
M;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^*$QE=F5L(#,I/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M
M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU
M<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^
M,C`Q,SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG
M/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT9"!S='EL
M93TS1"=W:61T:#H@.#$U<'@[('1E>'0M86QI9VXZ(&QE9G0[)SY$97)I=F%T
M:79E(&QI86)I;&ET:65S("8C.#(Q,3L@=V%R<F%N="!I;G-T<G5M96YT<SPO
M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$V<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T
M9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$T,G!X.R!T97AT+6%L:6=N.B!R:6=H
M=#LG/BT\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[('1E>'0M
M86QI9VXZ(&QE9G0[)SXD/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$T,G!X
M.R!T97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D/CQT9"!S='EL93TS1"=W:61T
M:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q-7!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$U<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$T,7!X.R!T97AT+6%L:6=N.B!R:6=H=#LG/C0L,#@Y
M+#(X-#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U<'@[
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M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/D1E<FEV871I=F4@
M;&EA8FEL:71I97,@)B,X,C$Q.R!397)I97,@02!P<F5F97)R960@<W1O8VL\
M+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B;W)D97(M
M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU
M<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTM
M8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R
M9&5R+6)O='1O;2US='EL93H@<V]L:60[)SXM/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F]R
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M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P
M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I
M9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@8F]R9&5R
M+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N
M-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG/C$V+#`Q-"PQ-#$\
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M('-O;&ED.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T
M=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[
M)SXQ-BPP,30L,30Q/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('!A9&1I;F<M8F]T=&]M.B`T<'0[)SY4;W1A;"!D97)I=F%T:79E(&QI
M86)I;&ET:65S/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P
M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I
M9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/B0\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@8F]R9&5R+6)O='1O
M;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#1P=#L@8F]R
M9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R<^+3PO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`T<'0[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F]R9&5R
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M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B;W)D97(M8F]T=&]M
M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D
M97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[)SXD/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K
M.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y
M;&4Z(&1O=6)L93LG/C(P+#$P,RPT,C4\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P=#LG/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O<F1E<BUB;W1T
M;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O
M<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/B0\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA
M8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#1P=#L@8F]R9&5R+6)O='1O;2US
M='EL93H@9&]U8FQE.R<^,C`L,3`S+#0R-3PO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`T<'0[)SXF(S$V,#L\
M+W1D/CPO='(^/"]T86)L93X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P
M>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M
M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E<BUS
M<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C
M93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\
M+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N
M93L@=&5X="UI;F1E;G0Z(#`N-6EN.R!L971T97(M<W!A8VEN9SH@;F]R;6%L
M.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E
M8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]P/CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y
M.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M
M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A
M8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[)SY4:&4@9F]L;&]W:6YG('1A8FQE('-E=',@
M9F]R=&@@82!R96-O;F-I;&EA=&EO;B!O9B!C:&%N9V5S(&EN('1H92!F86ER
M('9A;'5E(&]F(&9I;F%N8VEA;"!L:6%B:6QI=&EE<R!C;&%S<VEF:65D(&%S
M(&QE=F5L(#,@:6X@=&AE(&9A:7(@=F%L=64@:&EE<F%R8VAY.CPO<#X\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT
M+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P
M86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT
M+7-T<F]K92UW:61T:#H@,'!X.R<^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA
M<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P
M,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[)SX\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R
M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO
M<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[
M("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQB/B8C,38P.SPO
M8CX\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@
M;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA
M;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW
M96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CPO<#X\=&%B;&4@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@8V%L:6)R:2P@:&5L=F5T:6-A+"!S
M86YS+7-E<FEF.R!W:61T:#H@,34V-W!X.R!T97AT+71R86YS9F]R;3H@;F]N
M93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M=V]R9"US<&%C:6YG.B`P<'@[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[
M(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)R!C96QL<W!A8VEN
M9STS1#`-"B!C96QL<&%D9&EN9STS1#`^/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z
M(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O
M='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,3`^4VEG;FEF:6-A;G0@
M56YO8G-E<G9A8FQE($EN<'5T<R`H3&5V96P@,RD\+W1D/CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\+W1R/CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG(&-O;'-P86X],T0R/E-I>"!-;VYT:"8C
M,38P.SQB<B`O/D5N9&5D/&)R("\^2G5N92`S,"P\+W1D/CQT9"!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG(&-O;'-P86X],T0R/EEE
M87(F(S$V,#L\8G(@+SY%;F1E9"8C,38P.SQB<B`O/D1E8V5M8F5R(#,Q+#PO
M=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
M=&0@8V]L<W!A;CTS1#(^/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/EEE87(\8G(@+SY%;F1E9#QB<B`O/D1E8V5M8F5R(#,Q+#PO<#X\+W1D
M/CQT9#XF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SX\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L
M86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O
M;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CXR,#$T/"]T9#X\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!B;W)D97(M8F]T
M=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[
M(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^,C`Q
M,SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM
M=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O
M;'-P86X],T0R/C(P,3(\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,2XU<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F
M.R<^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,#`S<'@[('1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
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M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXH,C`L,3`S+#0R-3PO
M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T
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M:6UE<RP@<V5R:68[)SXH-2PP.3`L.3@X/"]T9#X\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$U<'@[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^*3PO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q-7!X.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I
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M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^0VAA;F=E(&EN(&9A:7(@=F%L=64@
M;V8@9&5R:79A=&EV92!L:6%B:6QI=&EE<R!I;F-L=61E9"!I;B!N970@;&]S
M<R!F;W(@=&AE('-I>"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q-"!A;F0@
M9F]R('1H92!Y96%R<R!E;F1E9"8C,38P.R!$96-E;6)E<B`S,2P@,C`Q,R!A
M;F0@,C`Q,BP@<F5S<&5C=&EV96QY/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF
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M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^*#$R+#@W-RPV-S4\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/BD\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^*#,L-C@X+#,U,SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^*3PO=&0^/"]T<CX\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@(V-C965F9CLG/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/D%D9&ET:6]N<R`F(S@R,3$[('=A<G)A;G0@:6YS=')U;65N=',\+W1D
M/CQT9#X\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
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M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
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M="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
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M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
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M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^5')A;G-F97(@
M;V8@=V%R<F%N="!I;G-T<G5M96YT<R!T;R!A9&1I=&EO;F%L('!A:60@:6X@
M8V%P:71A;#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<-"B!R;VUA;B<L('1I;65S+"!S97)I9CLG/C8L.#`T+#8R-3PO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^+3PO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M)SXM/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^061D
M:71I;VYS("8C.#(Q,3L@8V]N=F5R<VEO;B!F96%T=7)E(&]F(%-E<FEE<R!!
M('!R969E<G)E9"!S=&]C:SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M
M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L
M:60[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM
M=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG/BT\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O
M='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,2XU<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B
M;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL
M93H@<V]L:60[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M
M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L
M:60[)SXH,2PW-C$L,#8S/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/BD\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&)O<F1E<BUB;W1T;VTM8V]L
M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R
M+6)O='1O;2US='EL93H@<V]L:60[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L
M86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O
M;2US='EL93H@<V]L:60[)SXH,2PR.#,L-C`V/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/BD\
M+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`T<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^16YD:6YG(&)A;&%N8V4\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!B;W)D97(M8F]T=&]M+6-O;&]R
M.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D97(M8F]T
M=&]M+7-T>6QE.B!D;W5B;&4[)SXD/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R
M9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D
M;W5B;&4[)SXH,C4L-3@V+#DS,SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`T<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^*3PO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&)O<F1E<BUB;W1T;VTM8V]L
M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB
M;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/B0\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B
M;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z
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M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`T<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^*3PO=&0^/"]T
M<CX\+W1A8FQE/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V,#L\+W`^
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P
M.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E
M+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
M>#LG/CQB/DEN8V]M92!487AE<SPO8CX\+W`^/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@
M;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA
M;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW
M96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO<#X\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E
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M(#,P+"`R,#$T(&%N9"!$96-E;6)E<B`S,2P@,C`Q,RP@=&AE($-O;7!A;GD@
M:&%D(')E8V]G;FEZ960@82!V86QU871I;VX@86QL;W=A;F-E('1O('1H92!F
M=6QL(&5X=&5N="!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&YE="!D969E<G)E
M9"!T87@@87-S971S('-I;F-E('1H92!L:6ME;&EH;V]D(&]F(')E86QI>F%T
M:6]N(&]F('1H92!B96YE9FET(&1O97,@;F]T(&UE970@=&AE(&UO<F4@;&EK
M96QY('1H86X@;F]T('1H<F5S:&]L9"X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@
M;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA
M;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW
M96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQB/B8C,38P.SPO8CX\
M+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P
M,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H
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M9F]R('5N8V5R=&%I;B!T87@@<&]S:71I;VYS(&%T($IU;F4@,S`L(#(P,30@
M86YD($1E8V5M8F5R(#,Q+`T*(#(P,3,N(%1H92!O<&5N('1A>"!Y96%R<RP@
M<W5B:F5C="!T;R!P;W1E;G1I86P@97AA;6EN871I;VX@8GD@=&AE(&%P<&QI
M8V%B;&4@=&%X:6YG(&%U=&AO<FET>2P@9F]R('1H92!#;VUP86YY('=E<F4@
M9G)O;2`R,#$P('1H<F]U9V@@,C`Q-"X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@
M;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA
M;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW
M96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO<#X\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E
M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A
M8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^
M/&(^4F5S96%R8V@@86YD($1E=F5L;W!M96YT/"]B/CPO<#X\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A
M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN
M9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO
M<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[
M/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P
M,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[
M(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W
M:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[)SY297-E87)C:"!A;F0@9&5V96QO<&UE;G0@8V]S=',@<')I;6%R
M:6QY(&-O;G-I<W0@;V8@<F5S96%R8V@@8V]N=')A8W1S(&9O<B!T:&4@861V
M86YC96UE;G0@;V8@<')O9'5C="!D979E;&]P;65N="P@<W1O8VLM8F%S960@
M8V]M<&5N<V%T:6]N+"!A;F0@8V]N<W5L=&%N=',N(%1H92!#;VUP86YY(&5X
M<&5N<V5S(&%L;"!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@8V]S=',@:6X@
M=&AE('!E<FEO9"!I;F-U<G)E9"X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R
M9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N
M93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO<#X\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M
M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A
M8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z
M(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&(^
M4W1O8VLM0F%S960@0V]M<&5N<V%T:6]N/"]B/CPO<#X\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F
M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@
M;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA
M;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]P
M/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P
M,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[)SY4:&4@0V]M<&%N>2!M96%S=7)E<R!T:&4@8V]S="!O9B!E;7!L;WEE
M92!S97)V:6-E<R!R96-E:79E9"!I;B!E>&-H86YG92!F;W(@86X@87=A<F0@
M;V8@97%U:71Y(&EN<W1R=6UE;G1S(&)A<V5D(&]N('1H92!G<F%N="UD871E
M(&9A:7(@=F%L=64@;V8@=&AE(&%W87)D+B!4:&%T(&-O<W0@:7,@<F5C;V=N
M:7IE9"!O=F5R('1H92!P97)I;V0@9'5R:6YG('=H:6-H(&%N(&5M<&QO>65E
M(&ES(')E<75I<F5D('1O('!R;W9I9&4@<V5R=FEC92!I;B!E>&-H86YG92!F
M;W(@=&AE(&%W87)D("T@=&AE(')E<75I<VET92!S97)V:6-E('!E<FEO9"X@
M5&AE(&=R86YT+61A=&4@9F%I<B!V86QU92!O9B!E;7!L;WEE92!S:&%R92!O
M<'1I;VYS(&ES(&5S=&EM871E9"!U<VEN9R!T:&4@0FQA8VLM4V-H;VQE<R!O
M<'1I;VX@<')I8VEN9R!M;V1E;"!A9&IU<W1E9"!F;W(@=&AE('5N:7%U92!C
M:&%R86-T97)I<W1I8W,@;V8@=&AO<V4@:6YS=')U;65N=',N($-O;7!E;G-A
M=&EO;B!E>'!E;G-E(&9O<B!O<'1I;VYS(&%N9"!W87)R86YT<R!G<F%N=&5D
M('1O(&YO;BUE;7!L;WEE97,@:7,@9&5T97)M:6YE9"!B>2!T:&4@9F%I<B!V
M86QU92!O9B!T:&4@8V]N<VED97)A=&EO;B!R96-E:79E9"!O<B!T:&4@9F%I
M<B!V86QU92!O9B!T:&4@97%U:71Y(&EN<W1R=6UE;G1S(&ES<W5E9"P@=VAI
M8VAE=F5R(&ES(&UO<F4@<F5L:6%B;'D@;65A<W5R960L(&%N9"!I<R!R96-O
M9VYI>F5D(&]V97(@=&AE('-E<G9I8V4@<&5R:6]D+B!4:&4@97AP96YS92!I
M<R!S=6)S97%U96YT;'D@861J=7-T960@=&\@9F%I<B!V86QU92!A="!T:&4@
M96YD(&]F(&5A8V@@<F5P;W)T:6YG('!E<FEO9"!U;G1I;"!S=6-H(&]P=&EO
M;G,@86YD('=A<G)A;G1S('9E<W0L(&%N9"!T:&4@9F%I<B!V86QU92!O9B!S
M=6-H(&EN<W1R=6UE;G1S+"!A<R!A9&IU<W1E9"P@:7,@97AP96YS960@;W9E
M<B!T:&4@<F5L871E9"!V97-T:6YG('!E<FEO9"X@061J=7-T;65N=',@=&\@
M9F%I<B!V86QU92!A="!E86-H(')E<&]R=&EN9R!D871E(&UA>2!R97-U;'0@
M:6X@:6YC;VUE(&]R(&5X<&5N<V4L(&1E<&5N9&EN9R!U<&]N('1H92!E<W1I
M;6%T92!O9B!F86ER('9A;'5E(&%N9"!T:&4@86UO=6YT(&]F(&5X<&5N<V4@
M<F5C;W)D960@<')I;W(@=&\@=&AE(&%D:G5S=&UE;G0N(%1H92!#;VUP86YY
M(')E=FEE=W,@:71S(&%G<F5E;65N=',@86YD('1H92!F=71U<F4@<&5R9F]R
M;6%N8V4@;V)L:6=A=&EO;B!W:71H(')E<W!E8W0@=&\@=&AE('5N=F5S=&5D
M(&]P=&EO;G,@;W(@=V%R<F%N=',@9F]R(&ET<R!V96YD;W)S(&]R(&-O;G-U
M;'1A;G1S+B!7:&5N(&%P<')O<')I871E+"!T:&4@0V]M<&%N>2!W:6QL(&5X
M<&5N<V4@=&AE('5N=F5S=&5D(&]P=&EO;G,@;W(@=V%R<F%N=',@870@=&AE
M('1I;64@=VAE;B!M86YA9V5M96YT(&1E96US('1H92!S97)V:6-E(&]B;&EG
M871I;VX@9F]R(&9U='5R92!S97)V:6-E<R!H87,@8V5A<V5D+CPO<#X\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E
M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A
M8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^
M)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO
M<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[)SX\8CY.970@3&]S<R!P97(@0V]M;6]N(%-H87)E/"]B
M/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P
M,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T
M:#H@,'!X.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@
M,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E
M>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M
M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E
M>'0M<W1R;VME+7=I9'1H.B`P<'@[)SY"87-I8R!N970@;&]S<R!P97(@8V]M
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M('!O<VET:6]N+CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@
M8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN
M9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I
M;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T
M<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ
M(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M
M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SY0;W1E;G1I86QL>2!D
M:6QU=&EV92!S96-U<FET:65S(&%R92!N;W0@:6YC;'5D960@:6X@=&AE(&-A
M;&-U;&%T:6]N(&]F(&1I;'5T960@;F5T(&QO<W,@<&5R('-H87)E(&%T=')I
M8G5T86)L92!T;R!C;VUM;VX@<W1O8VMH;VQD97)S(&)E8V%U<V4@=&\@9&\@
M<V\@=V]U;&0@8F4@86YT:2UD:6QU=&EV92!A<F4@87,@9F]L;&]W<R`H:6X@
M8V]M;6]N('-T;V-K(&5Q=6EV86QE;G0@<VAA<F5S*3H\+W`^/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R
M86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N
M;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P
M.SPO<#X\=&%B;&4@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=VED=&@Z(#$U-C=P>#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS
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M/E-I>"!-;VYT:"8C,38P.SQB<B`O/D5N9&5D)B,Q-C`[/&)R("\^2G5N92`S
M,"PF(S$V,#L\8G(@+SXR,#$T/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@
M8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y
M;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^/'`@<W1Y;&4],T0G;6%R9VEN+71O
M<#H@,'!X.R!M87)G:6XM8F]T=&]M.B`P<'@[)SY996%R/"]P/CQP('-T>6QE
M/3-$)VUA<F=I;BUT;W`Z(#!P>#L@;6%R9VEN+6)O='1O;3H@,'!X.R<^16YD
M960F(S$V,#L\8G(@+SY$96-E;6)E<B`S,2PF(S$V,#L\8G(@+SXR,#$S/"]P
M/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED
M=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P
M86X],T0R/EEE87(\8G(@+SY%;F1E9"8C,38P.SQB<B`O/D1E8V5M8F5R(#,Q
M+#QB<B`O/C(P,3(\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,2XU<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$P,#-P>#L@=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUL969T.B`P<'0[)SY#;&%S<R!!(&-O;G9E<G1I8FQE('!R969E
M<G)E9"!S=&]C:SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[('1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,30R<'@[
M('1E>'0M86QI9VXZ(')I9VAT.R<^,RPS,S<L,S`Y/"]T9#X\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$V<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#LG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$T,7!X.R!T97AT+6%L:6=N.B!R
M:6=H=#LG/BT\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M-7!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U<'@[('1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T
M:#H@,30Q<'@[('1E>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
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M.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R<^,3,V+#`T,2PR-S4\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^."PU,#,L-3`S
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M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^.#DL,C8U+#$V,#PO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT
M9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXT
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M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F]R9&5R+6)O='1O
M;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B
M;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M+6-O;&]R
M.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB
M;W1T;VTM<W1Y;&4Z('-O;&ED.R<^,RPS-C4L,3<Q/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED
M=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M
M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU
M<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^,3@L-C4T+#`Y-SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T
M=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D
M97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@
M<V]L:60[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T
M;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG
M/C8W-RPY-C(\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P
M861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L
M;W(Z("-C8V5E9F8[)SX\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P
M=#L@<&%D9&EN9RUL969T.B`U+C1P=#LG/E1O=&%L/"]T9#X\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#1P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L
M86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM
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M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[)SXF(S$V,#L\+W1D/CQT
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M97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P=#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O<F1E<BUB
M;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[
M(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M+6-O
M;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D97(M
M8F]T=&]M+7-T>6QE.B!D;W5B;&4[)SXQ-"PP-#8L-S`P/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#1P=#LG
M/B8C,38P.SPO=&0^/"]T<CX\+W1A8FQE/CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA
M<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO
M;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[
M('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\8CXF(S$V,#L\+V(^/"]P
M/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[
M('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O
M<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\8CY296-E;G0@06-C;W5N=&EN
M9R!0<F]N;W5N8V5M96YT<SPO8CX\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R
M9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P
M.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E
M+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
M>#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@
M=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A
M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN
M9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO
M<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/"]P/CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@
M=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E
M<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M)SY);B!*=6YE(#(P,30L('1H92!&05-"(&ES<W5E9"!!4U4@,C`Q-"TQ,"P@
M)B,X,C(P.T1E=F5L;W!M96YT(%-T86=E($5N=&ET:65S("A4;W!I8R`Y,34I
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M9G1E<B!$96-E;6)E<B`Q-2P@,C`Q-"P@86YD('1H92!I;G1E<FEM('!E<FEO
M9',@=&AE<F5I;BX@2&]W979E<BP@96%R;'D@861O<'1I;VX@:7,@<&5R;6ET
M=&5D+B!!8V-O<F1I;F=L>2P@=&AE($-O;7!A;GD@:&%S(&%D;W!T960@=&AI
M<R!S=&%N9&%R9"!D=7)I;F<@=&AE('-I>"!M;VYT:',@96YD:6YG($IU;F4@
M,S`L(#(P,30N/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T
M97AT+6%L:6=N.B!L969T.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\+W`^/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[(&-O
M;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E
M;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG
M.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O
M:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M
M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@;&5F=#L@8V]L;W(Z(",P,#`P,#`[
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M97AT+6%L:6=N.B!L969T.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V,#L\+W`^
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&QE
M9G0[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X
M="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US
M<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#LG/CQB/E-U8G-E<75E;G0@179E;G1S/"]B
M/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG
M;CH@;&5F=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W
M;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI
M="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]P/CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!L969T.R!C;VQO
M<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[)SY4:&4@0V]M<&%N>28C.#(Q-SMS(&UA;F%G96UE;G0@
M<F5V:65W960@86QL(&UA=&5R:6%L(&5V96YT<R!T:')O=6=H('1H92!D871E
M('1H92!F:6YA;F-I86P@<W1A=&5M96YT<R!W97)E(&ES<W5E9"!F;W(@<W5B
M<V5Q=65N="!E=F5N="!D:7-C;&]S=7)E(&-O;G-I9&5R871I;VXN/"]P/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C,S-#5E
M.69?8C8T8E\T-S-B7SAB8C!?-3<T9C8Q83`Y8C)E#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S8S,S0U93EF7V(V-&)?-#<S8E\X8F(P7S4W-&8V
M,6$P.6(R92]7;W)K<VAE971S+U-H965T,#DN:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.;W1E<R!087EA8FQE/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3F]T97,@
M4&%Y86)L92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.3U1%4R!005E!0DQ%/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
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M<F]K92UW:61T:#H@,'!X.R!M87)G:6XZ(#!P>#LG/CQB/DY/5$4@,R`F(S@R
M,3$[($Y/5$53(%!!64%"3$4\+V(^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C
M,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[
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M<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T
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M;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[)SY3=6)O<F1I;F%T960@."4@<')O;6ES<V]R>2!N
M;W1E<R!P87EA8FQE(&-O;G-I<W1E9"!O9B!T:&4@9F]L;&]W:6YG(&%T($IU
M;F4@,S`L(#(P,30@86YD($1E8V5M8F5R(#,Q+"`R,#$S.CPO<#X\<"!S='EL
M93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
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M9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[)SXF(S$V,#L\+W`^/'1A8FQE('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H
M.B`Q-38W<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@
M,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P
M>#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N="US:7IE+6%D:G5S
M=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B
M;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL
M93H@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/DIU
M;F4@,S`L/&)R("\^,C`Q-#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q+C5P=#L@=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!T97AT+6%L:6=N
M.B!C96YT97([)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M
M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L
M:60[)R!C;VQS<&%N/3-$,CY$96-E;6)E<B`S,2PF(S$V,#L\8G(@+SXR,#$S
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q
M-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q,3<Y<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`M.7!T.R!P861D:6YG+6QE9G0Z(#EP=#LG/E-U8F]R9&EN871E9"`X
M)2!P<F]M:7-S;W)Y(&YO=&5S(&1U92!$96-E;6)E<B`R,#$S/"]T9#X\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$V<'@[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/CQT9"!S
M='EL93TS1"=W:61T:#H@,30R<'@[('1E>'0M86QI9VXZ(')I9VAT.R<^+3PO
M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U<'@[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@=&5X="UA;&EG;CH@
M;&5F=#LG/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,30Q<'@[('1E>'0M
M86QI9VXZ(')I9VAT.R<^,C$V+#`P,#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B!W:&ET93LG/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T
M:69Y.R!P861D:6YG+6)O='1O;3H@,2XU<'0[('1E>'0M:6YD96YT.B`M.7!T
M.R!P861D:6YG+6QE9G0Z(#EP=#LG/E-U8F]R9&EN871E9"`X)2!P<F]M:7-S
M;W)Y(&YO=&5S(&1U92!397!T96UB97(@,C`Q-#PO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M
M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[('1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D
M97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@
M,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R!T97AT+6%L:6=N
M.B!R:6=H=#LG/BT\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,2XU<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O
M='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED
M.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED
M=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#L@=&5X="UA
M;&EG;CH@<FEG:'0[)SXV.#0L,#`P/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#$N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&IU<W1I9GD[('!A9&1I;F<M;&5F=#H@,'!T.R<^5&]T86P@;F]T
M97,@<&%Y86)L93PO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#LG/BT\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R<^.3`P+#`P,#PO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M('=H:71E.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[('!A
M9&1I;F<M8F]T=&]M.B`Q+C5P=#L@<&%D9&EN9RUL969T.B`P<'0[)SY,97-S
M.B!D96)T(&1I<V-O=6YT/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T
M.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#L@=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L
M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R
M+6)O='1O;2US='EL93H@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^+3PO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q
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M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[)SXF(S$V,#L\+W1D/CQT9"!S
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M.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#1P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I
M9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93L@=&5X="UA
M;&EG;CH@;&5F=#LG/B0\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D
M97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^
M-S4X+#DU,3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[
M('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CPO='(^/"]T86)L93X\
M<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN
M92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UA;&EG;CH@
M<W1A<G0[('1E>'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A
M8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA
M<F=I;CH@,'!X.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P
M,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T
M97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H
M86YS.B!A=71O.R!T97AT+6%L:6=N.B!S=&%R=#L@=&5X="UI;F1E;G0Z(#!P
M>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N;W)M86P[
M('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[#0H@+7=E8FMI="UT
M97AT+7-T<F]K92UW:61T:#H@,'!X.R!M87)G:6XZ(#!P>#LG/CQB/D1E8V5M
M8F5R(#(P,3(@4W5B;W)D:6YA=&5D(%!R;VUI<W-O<GD@3F]T97,@4&%Y86)L
M93PO8CX\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-I
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M;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO
M<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UA;&EG;CH@<W1A<G0[('1E>'0M
M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C
M93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R<^
M26X@1&5C96UB97(@,C`Q,BP@=&AE($-O;7!A;GD@:7-S=65D("0R,38L,#`P
M(&]F('-U8F]R9&EN871E9"`X)2!P<F]M:7-S;W)Y(&YO=&5S('!A>6%B;&4@
M9F]R(&-A<V@@<')O8V5E9',@;V8@)#$X,"PP,#`@=VAI8V@@=V5R92!D=64@
M;VX@1&5C96UB97(@-BP@,C`Q,RX@26X@861D:71I;VXL('1H92!N;W1E(&AO
M;&1E<G,@<F5C96EV960@<V5V96XM>65A<B!W87)R86YT<R!T;R!P=7)C:&%S
M92`V-RPU,#`@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!W:71H(&%N(&5X97)C
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M9',@;V8@)#,V+#`P,"!W87,@86QS;R!T<F5A=&5D(&%S(&1E8G0@9&ES8V]U
M;G0@86YD('=A<R!A;6]R=&EZ960@=&\@:6YT97)E<W0@97AP96YS92!O=F5R
M('1H92!O;F4@>65A<B!M871U<FET>2!O9B!T:&4@;F]T97,N(%1H92!#;VUP
M86YY(&%L<V\@<&%I9"!D96)T(&ES<W5A;F-E(&-O<W1S(&]F("0R-2PQ,#`@
M=&\@=&AE('!L86-E;65N="!A9V5N="!T:&%T('=E<F4@<F5C;W)D960@87,@
M9&5F97)R960@9FEN86YC:6YG(&-O<W1S(&%N9"!A;6]R=&EZ960@;W9E<B!T
M:&4@;VYE('EE87(@;6%T=7)I='D@;V8@=&AE(&YO=&5S+B!4:&4@969F96-T
M:79E(&EN=&5R97-T(')A=&4@=V%S(#,V+CDE+B!4:&4@0V]M<&%N>2!A;'-O
M(&ES<W5E9"`S,RPW-3`@=V%R<F%N=',@=&\@<'5R8VAA<V4@8V]M;6]N('-T
M;V-K(&%T("0P+C@P('!E<B!S:&%R92!T;R!T:&4@<&QA8V5M96YT(&%G96YT
M('=H:6-H('1H92!#;VUP86YY(')E8V]R9&5D(&%S(&$@9&ES8V]U;G0@;VX@
M=&AE(&YO=&5S(&%T('1H92!F86ER('9A;'5E(&]F("0Q,RPP.#DN($%L;"!O
M9B!T:&4@9&5B="!D:7-C;W5N="!O9B`D-C(L,S(U(&%N9"!D969E<G)E9"!F
M:6YA;F-I;F<@8V]S=',@;V8@)#,X+#$X.2!W97)E(&9U;&QY(&%M;W)T:7IE
M9"!A;F0@<F5C;W)D960@87,@:6YT97)E<W0@97AP96YS92!D=7)I;F<@,C`Q
M,R!F;W(@=&AE<V4@;F]T97,N(%1H97-E(&YO=&5S(&%N9"!A8V-R=65D(&EN
M=&5R97-T(&]F(&%P<')O>&EM871E;'D@)#DV,"PY,#`@=V5R92!C;VYV97)T
M960@=&\@,2PR,#$L,34S(&-O;6UO;B!S=&]C:R!U<&]N('1H92!3:&%R92!%
M>&-H86YG92!O;B!-87D@,C`L(#(P,30N/"]P/CQP('-T>6QE/3-$)V-O;&]R
M.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.R!O<G!H86YS.B!A=71O.R!T97AT+6%L:6=N.B!S=&%R=#L@=&5X="UT<F%N
M<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@875T
M;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED
M=&@Z(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M:6YD96YT.B`P+C5I;CLG/B8C
M,38P.SPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M<VEZ
M93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO
M<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO
M<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X
M="UA;&EG;CH@<W1A<G0[('1E>'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F
M;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[
M('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[(&UA<F=I;CH@,'!X.R<^5&AE(&YO=&5S(&%N9"!A8V-R=65D(&EN
M=&5R97-T('=E<F4@875T;VUA=&EC86QL>2!C;VYV97)T960@:6YT;R!C;VUM
M;VX@<W1O8VL@870@)#`N.#`@<&5R('-H87)E('5P;VX@=&AE(%-H87)E($5X
M8VAA;F=E(&]N($UA>2`R,"P@,C`Q-"X@5&AE('=A<G)A;G1S(&-O;G1A:6YE
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M>2`R,"P@,C`Q-"X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F
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M93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG
M:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UA;&EG;CH@<W1A<G0[
M('1E>'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET
M92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@
M,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@
M,'!X.R<^/&(^4V5P=&5M8F5R(#(P,3,@4W5B;W)D:6YA=&5D(%!R;VUI<W-O
M<GD@3F]T97,@4&%Y86)L93PO8CX\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P
M,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
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M<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P
M=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@
M9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UA;&EG
M;CH@<W1A<G0[('1E>'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N
M;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M
M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M(&UA<F=I;CH@,'!X.R<^26X@4V5P=&5M8F5R(#(P,3,L('1H92!#;VUP86YY
M(&ES<W5E9"`D-C@T+#`P,"!O9B!S=6)O<F1I;F%T960@."4@<')O;6ES<V]R
M>2!N;W1E<R!P87EA8FQE(&9O<B!C87-H('!R;V-E961S(&]F("0U-S`L,#`P
M('=H:6-H(&%R92!D=64@:6X@4V5P=&5M8F5R(#(P,30N($EN(&%D9&ET:6]N
M+"!T:&4@;F]T92!H;VQD97)S(')E8V5I=F5D('-E=F5N+7EE87(@=V%R<F%N
M=',@=&\@<'5R8VAA<V4@,C$S+#<U,"!S:&%R97,@;V8@8V]M;6]N('-T;V-K
M('=I=&@@86X@97AE<F-I<V4@<')I8V4@;V8@)#`N.#`@<&5R('-H87)E+B!4
M:&4@0V]M<&%N>2!R96-O<F1E9"!T:&4@9F%I<B!V86QU92!O9B!T:&4@=V%R
M<F%N=',@87,@82!D96)T(&1I<V-O=6YT(&]N('1H92!N;W1E<R!P87EA8FQE
M('=H:6-H(')E<W5L=&5D(&EN(&$@9&5B="!D:7-C;W5N="!O9B`D.#,L,S8S
M+B!4:&4@9&EF9F5R96YC92!B971W965N('1H92!F86-E('9A;'5E(&%N9"!T
M:&4@8V%S:"!P<F]C965D<R!O9B`D,3$T+#`P,"!W87,@86QS;R!T<F5A=&5D
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M+B!4:&4@0V]M<&%N>2!A;'-O(&ES<W5E9"`Q,#8L.#<U('=A<G)A;G1S('1O
M('!U<F-H87-E(&-O;6UO;B!S=&]C:R!A="`D,"XX,"!P97(@<VAA<F4@=&\@
M=&AE('!L86-E;65N="!A9V5N="!W:&EC:"!T:&4@0V]M<&%N>2!R96-O<F1E
M9"!A<R!A(&1I<V-O=6YT(&]N('1H92!N;W1E<R!A="!T:&4@9F%I<B!V86QU
M92!O9B`D-#$L-C@Q+B!4:&4@0V]M<&%N>2!H87,@86UO<G1I>F5D(&1E8G0@
M9&ES8V]U;G0@9F]R(&1E9F5R<F5D(&9I;F%N8VEN9R!C;W-T<R!O9B`D,C$Y
M+#<W,R!A;F0@)#,Q+#,U-R!T;R!I;G1E<F5S="!E>'!E;G-E(&9O<B!T:&5S
M92!N;W1E<R!D=7)I;F<@=&AE('-I>"!M;VYT:',@96YD960@2G5N92`S,"P@
M,C`Q-"!A;F0@9F]R('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$S
M+"!R97-P96-T:79E;'DN/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS
M.B!A=71O.R!T97AT+6%L:6=N.B!S=&%R=#L@=&5X="UI;F1E;G0Z(#!P>#L@
M=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N;W)M86P[('=I
M9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[)SX\+W`^/'`@<W1Y;&4]
M,T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z#0H@,3!P=#L@9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG
M:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UA;&EG;CH@<W1A<G0[
M('1E>'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET
M92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@
M,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@
M,'!X.R<^5&AE($-O;7!A;GD@9&5T97)M:6YE9"!T:&%T('1H97)E('=A<R!A
M(&)E;F5F:6-I86P@8V]N=F5R<VEO;B!F96%T=7)E(&]N('1H92!397!T96UB
M97(@,C`Q,R!N;W1E<R!P87EA8FQE(&%T('1H92!I<W-U86YC92!D871E(&]F
M(&%P<')O>&EM871E;'D@)#$X-BPX,#`@=VAI8V@@<F5P<F5S96YT960@=&AE
M(&1I9F9E<F5N8V4@8F5T=V5E;B!T:&4@969F96-T:79E(&-O;G9E<G-I;VX@
M<')I8V4@;V8@)#`N-C`@<&5R('-H87)E(&%N9"!T:&4@9F%I<B!V86QU92!O
M9B!T:&4@8V]M;6]N('-T;V-K(&%S(&]F('1H92!C;VUM:71M96YT(&1A=&4@
M;V8@)#`N.#`@<&5R('-H87)E+B!4:&4@8F5N969I8VEA;"!C;VYV97)S:6]N
M(&9E871U<F4@=V%S(')E8V]R9&5D(&%S(&EN=&5R97-T(&5X<&5N<V4@=7!O
M;B!T:&4@4VAA<F4@17AC:&%N9V4N/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C
M,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L
M971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O
M<G!H86YS.B!A=71O.R!T97AT+6%L:6=N.B!S=&%R=#L@=&5X="UI;F1E;G0Z
M(#!P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N;W)M
M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P<'@[)SXF(S$V,#L\
M+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G
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M="!O9B!A<'!R;WAI;6%T96QY("0Y-C`L.3`P('=E<F4@875T;VUA=&EC86QL
M>2!C;VYV97)T960@:6YT;R`Q+#(P,2PQ-3,@<VAA<F5S(&]F(&-O;6UO;B!S
M=&]C:R!A="`D,"XX,"!P97(@<VAA<F4@=7!O;B!T:&4@4VAA<F4@17AC:&%N
M9V4@;VX@36%Y(#(P+"`R,#$T+B!4:&4@=V%R<F%N=',@8V]N=&%I;F5D(&%N
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M;G0@870@=&AE(&1A=&4@;V8@=&AE(%-H87)E($5X8VAA;F=E(&]N($UA>2`R
M,"P@,C`Q-"X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT
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M(#!P>#L@=&5X="UI;F1E;G0Z(#`N-6EN.R<^)B,Q-C`[/"]P/CQP('-T>6QE
M/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T
M>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H
M=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+6%L:6=N.B!S=&%R=#L@
M=&5X="UI;F1E;G0Z(#!P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E
M+7-P86-E.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P
M<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@;6%R9VEN.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG
M/DEN($UA>2`V+"`R,#$T+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!F
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M<F%T92!I<R`S+C0S-B4@<&5R(&%N;G5M+B!!="!*=6YE(#,P+"`R,#$T+"!T
M:&4@0V]M<&%N>2!O=V5D("0U."PS-3<@:6X@8V\\+V9O;G0^;FYE8W1I;VX@
M=VET:"!T:&ES(&YO=&4@<&%Y86)L92X\+W`^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V,S,T-64Y9E]B-C1B7S0W,V)?.&)B
M,%\U-S1F-C%A,#EB,F4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO
M-C,S-#5E.69?8C8T8E\T-S-B7SAB8C!?-3<T9C8Q83`Y8C)E+U=O<FMS:&5E
M=',O4VAE970Q,"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q
M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA
M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/D1E<FEV871I=F4@3&EA8FEL:71I97,\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$97)I=F%T:79E($QA
M:6)I;&ET:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1%4DE6051)5D4@3$E!0DE,251)15,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M
M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@
M+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&(^3D]412`T("8C
M.#(Q,3L@1$52259!5$E612!,24%"24Q)5$E%4SPO8CX\+W`^/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R
M86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N
M;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQB/B8C
M,38P.SPO8CX\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E
M>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R
M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO
M<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[
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M92!A;F0@97%U:71Y(&]F9F5R:6YG<R!I;B`R,#$R(&%N9"`R,#$S+"!D;R!N
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M87,@9&5R:79A=&EV92!L:6%B:6QI=&EE<RX\+W`^/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C,#`P
M,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H
M:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z
M(#!P>#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P
M>#L@=&5X="UA;&EG;CH@;&5F=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A
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M;"!W87,@=7-E9"!F;W(@=&AE('9A;'5A=&EO;B!A="!*=6YE(#,P+"`R,#$T
M+CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P
M,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T
M:#H@,'!X.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M86QI
M9VXZ(&QE9G0[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N
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M:7-S=65D(&1U<FEN9R!T:&4@<VEX(&UO;G1H<R!E;F1E9"!*=6YE(#,P+"`R
M,#$T.CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M
M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@
M+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]P/CQT
M86)L92!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!W:61T:#H@,34V-W!X.R!T97AT+71R86YS
M9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z
M(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[(&)O<F1E<BUC;VQL87!S93H@
M8V]L;&%P<V4[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C
M:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)R!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<B!S='EL93TS1"=V
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M)R!C;VQS<&%N/3-$,CY*=6YE(#,P/"]T9#X\=&0^)B,Q-C`[/"]T9#X\+W1R
M/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^
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M.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N
M/3-$,CXR,#$T/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N
M-7!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q,3(Y<'@[('1E>'0M86QI9VXZ(&QE9G0[)SY#
M;VUM;VX@<W1O8VL@:7-S=6%B;&4@=7!O;B!E>&5R8VES92!O9B!W87)R86YT
M<R`F(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$W,W!X.R!T
M97AT+6%L:6=N.B!R:6=H=#LG/C,P+#`S-BPV-#@\+W1D/CQT9"!S='EL93TS
M1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$U<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3<R<'@[('1E>'0M86QI9VXZ(')I
M9VAT.R<^,S`L,#,V+#8T.#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X
M.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL
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M<FEG:'0[)SXR+C`P/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT9#Y%
M>&5R8VES92!P<FEC93PO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,2XU,"!A;F0@
M,BXR-3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXQ+C4P(&%N9"`R+C(U
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SY2:7-K(&9R964@:6YT97)E<W0@<F%T92`H
M,BD\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
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M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY%>'!E8W1E9"!L:69E(&EN('EE87)S
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0-"B!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[,"XS(&%N9"`U
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,"XS(&%N9"`T+CD\
M+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/D5X<&5C=&5D('9O;&%T:6QI='D@*#,I/"]T
M9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.S<Q(&%N9"`W,SPO9F]N
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M<R`H-"D\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[)SY.;VYE/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#LG/DYO;F4\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CPO=&%B;&4^/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI
M;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C
M:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P
M,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T
M:#H@,'!X.R<^/"]P/CQT86)L92!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!W:61T:#H@,34V
M-W!X.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[(&)O
M<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO
M;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^/'1D('-T>6QE
M/3-$)W=I9'1H.B`U-2XX,7!X.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D
M9&EN9RUL969T.B`P<'0[)SXH,2D\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M,30Y-BXX,7!X.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T
M.B`P<'0[)SY4:&4@;6%R:V5T('9A;'5E(&ES('1H92!C86QC=6QA=&5D(&9A
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M<F%T92!W87,@9&5T97)M:6YE9"!B>2!M86YA9V5M96YT('5S:6YG('1H92`Q
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.V%N9"`U("T@>65A<B!4<F5A
M<W5R>2!":6QL(&%S(&]F('1H92!M96%S=7)E;65N="!D871E+CPO9F]N=#X\
M+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX\
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M<F]U<"X\+W1D/CPO='(^/"]T86)L93X\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G
M:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W
M;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI
M="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[)B,Q-C`[/"]P/CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@
M=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E
M<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
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M+"`R,#$S(&%N9"!$96-E;6)E<B`S,2P@,C`Q,BP@<F5S<&5C=&EV96QY+"!A
M;F0@87,@;V8@1&5C96UB97(@,S$L(#(P,3,L(&%N9"!$96-E;6)E<B`S,2P@
M,C`Q,BP@<F5S<&5C=&EV96QY.CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G
M:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W
M;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI
M="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[)B,Q-C`[/"]P/CQT
M86)L92!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!W:61T:#H@,34V-W!X.R!T97AT+71R86YS
M9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z
M(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[(&)O<F1E<BUC;VQL87!S93H@
M8V]L;&%P<V4[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C
M:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)R!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D/B8C,38P.SPO=&0^/'1D/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O
M;'-P86X],T0R/DEN:71I86P\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9#XF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS
M<&%N/3-$,CY);FET:6%L/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[
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M/3-$,CYV86QU871I;VYS/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A
M;CTS1#(^=F%L=6%T:6]N<SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P
M86X],T0R/D1E8V5M8F5R)B,Q-C`[,S$L/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
M=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R<@8V]L<W!A;CTS1#(^1&5C96UB97(F(S$V,#LS,2P\+W1D/CQT9#XF(S$V
M,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R
M+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O
M;&ED.R<@8V]L<W!A;CTS1#(^,C`Q,SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
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M8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R
M9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CXR,#$S/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D
M97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@
M,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS
M1#(^,C`Q,CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P
M=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT9"!S
M='EL93TS1"=W:61T:#H@.#$U<'@[('1E>'0M86QI9VXZ(&QE9G0[)SY#;VUM
M;VX@<W1O8VL@:7-S=6%B;&4@=7!O;B!E>&5R8VES92!O9B!W87)R86YT<SPO
M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$V<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,30R<'@[('1E>'0M86QI9VXZ
M(')I9VAT.R<^,C(L,S,S+#4Y,SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M-G!X.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$V<'@[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T
M:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q-#)P>#L@=&5X="UA;&EG;CH@<FEG:'0[)SXQ.2PS
M.#4L,34W/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[('1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P
M>#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$T,7!X.R!T97AT+6%L:6=N.@T*(')I9VAT.R<^-#$L-S$X+#<U,#PO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U<'@[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#%P>#L@=&5X
M="UA;&EG;CH@<FEG:'0[)SXQ.2PS.#4L,34W/"]T9#X\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$U<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CPO
M='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z('=H:71E.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`M-2XU<'0[('!A9&1I;F<M;&5F=#H@-2XU
M<'0[)SY#;VUM;VX@<W1O8VL@:7-S=6%B;&4@=7!O;B!C;VYV97)S:6]N(&]F
M(%-E<FEE<R!!('!R969E<G)E9"!S=&]C:SPO=&0^/'1D/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C4Q+#`P-BPR-3`\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\
M=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^
M.#4L,#,U+#`R-3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[)SXQ,S8L,#0Q+#(W-3PO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@
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M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C`N
M,3D\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)3PO=&0^
M/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG
M/C`N,C`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)3PO
M=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#LG/C`N,S@\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)3PO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#LG/C`N,3D\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)3PO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/D5X<&5C=&5D(&QI9F4@:6X@>65A<G,\+W1D
M/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M)SXQ+C0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
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M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[)SXQ+C0\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C
M8V-E969F.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY%>'!E
M8W1E9"!V;VQA=&EL:71Y("@S*3PO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C8X/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/B4\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXW,CPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXE/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@
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M9"!D:79I9&5N9"!Y:65L9',@*#0I/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^3F]N93PO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SY.;VYE/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/DYO
M;F4\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R<^3F]N93PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/CPO='(^/"]T86)L93X\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M
M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N
M;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L
M.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E
M8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&(^)B,Q-C`[/"]B/CPO
M<#X\=&%B;&4@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=VED=&@Z(#$U-C=P>#L@=&5X="UT
M<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C
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M,R`M('EE87(@5')E87-U<GD@0FEL;"!A<R!O9B!T:&4@;65A<W5R96UE;G0@
M9&%T92X\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T
M;W`[)SX\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I
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M(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P
M<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[)SXF(S$V,#L\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N
M;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN
M.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z#0H@,'!X
M.R<^0VAA;F=E(&EN(&9A:7(@=F%L=64@;V8@9&5R:79A=&EV92!L:6%B:6QI
M=&EE<R!D=7)I;F<@=&AE('-I>"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q
M-"!W87,@87,@9F]L;&]W<SHF(S$V,#L\+W`^/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P
M,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H
M:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z
M(#!P>#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P
M>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M
M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A
M8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z
M(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/"]P
M/CQP('-T>6QE/3-$)V9O;G0Z(#$S<'@O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P
M,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[)SX\+W`^/'1A8FQE('-T>6QE/3-$)V9O;G0Z(#AP="]N;W)M86P@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=VED=&@Z(#$U-C=P>#L@
M=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E
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M1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&-E;G1E<CL@=&5X="UI;F1E
M;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[
M(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y
M;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6%L:6=N.B!C96YT97([('1E>'0M
M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
M(&YO<FUA;#LG(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SY"
M86QA;F-E(&%T($1E8V5M8F5R)B,Q-C`[,S$L/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P
M861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO
M<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@
M,'!X.R!T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P<'@[(&9O
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M/CQB<B`O/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SYI<W-U
M86YC92!O9B!N97<@=V%R<F%N=',@9'5R:6YG)B,Q-C`[/"]F;VYT/CPO9F]N
M=#X\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
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M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<Z(#!P>#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG
M.B`P<'@[('1E>'0M86QI9VXZ(&-E;G1E<CL@=&5X="UI;F1E;G0Z(#!P>#L@
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M93TS1"=P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y
M;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9SH@,'!X.R!T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P
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M/CPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M
M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
M(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6EN9&5N=#H@
M,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@8V5N=&5R.R!T
M97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[)R!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^0F%L86YC92!A="8C,38P.SPO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^/&)R("\^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/DIU
M;F4@,S`L/"]F;VYT/CPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG
M.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
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M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<Z(#!P>#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[
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M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<Z(#!P>#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[
M('1E>'0M86QI9VXZ(&-E;G1E<CL@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!B;W)D97(M8F]T
M=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[
M(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/G!E<FEO9#PO9F]N=#X\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y
M;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9SH@,'!X.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P
M>#L@=&5X="UA;&EG;CH@8V5N=&5R.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&)O<F1E<BUB
M;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P
M=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L#0H@<V5R:68[)SYL:6%B:6QI=&EE<SPO9F]N=#X\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[
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M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@8V5N=&5R.R!T97AT+6EN9&5N=#H@
M,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[
M(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I
M9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS
M<&%N/3-$,CX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^8V%P:71A;#PO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P
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M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@8V5N=&5R.R!T97AT+6EN9&5N
M=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M
M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C
M;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,C`Q-#PO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P
M<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R
M/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P
M>"`P<'@@,'!X(#$P<'@[('1E>'0M:6YD96YT.B`M,3!P>#L@9F]N="US='EL
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M861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@
M,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)#PO9F]N=#X\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN
M9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N
M;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,3$L-S8R+#$Q-3PO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M:6YD96YT
M.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6EN9&5N=#H@,'!X.R!F
M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@<FEG:'0[('1E>'0M:6YD
M96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXD/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@<FEG:'0[('1E
M>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXM)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UI;F1E
M;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[
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M.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^*28C,38P.SPO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M:6YD96YT
M.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
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M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^*28C,38P
M.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M
M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
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M9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX\=&0@<W1Y;&4],T0G
M<&%D9&EN9SH@,'!X(#!P>"`P<'@@,3!P>#L@=VED=&@Z(#8Q-W!X.R!T97AT
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M>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG
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M861D:6YG.B`P<'@[('=I9'1H.B`Q-#)P>#L@=&5X="UA;&EG;CH@<FEG:'0[
M('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW
M96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXR+#`S,"PU
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M93TS1"=P861D:6YG.B`P<'@[('=I9'1H.B`Q-G!X.R!T97AT+6EN9&5N=#H@
M,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=VED=&@Z(#$V<'@[('1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA
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M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W#0H@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXM)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=VED=&@Z(#$V<'@[('1E
M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z
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M861D:6YG.B`P<'@[('=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R!T
M97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F
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M,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('=I
M9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!X
M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=VED=&@Z(#$T,7!X.R!T97AT+6%L:6=N
M.B!R:6=H=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/B@V-C`L,S(W/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P
M>#L@=VED=&@Z(#$U<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXI/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=VED=&@Z(#$U<'@[('1E>'0M:6YD96YT
M.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
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M9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P
M<'@[('=I9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@<FEG:'0[('1E>'0M:6YD
M96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXM/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=VED=&@Z(#$U<'@[('1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA
M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^
M/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>"`P<'@@,'!X(#$P<'@[('1E>'0M
M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M,3!P>#L@9F]N="US='EL93H@
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M/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[
M('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW
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M.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O
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M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<Z(#!P>#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#L@
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN
M9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N
M;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^+3PO9F]N=#X\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6EN9&5N
M=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@;&5F=#L@
M=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI
M9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^*#$L,C8R+#@U.#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG
M.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O
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M9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P
M<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M
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M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X
M="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ
M(')I9VAT.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M+3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M
M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO
M<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG
M/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@@,'!X(#!P>"`Q,'!X.R!T97AT
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M9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[(&9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z#0H@;F]R;6%L.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD
M96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6%L:6=N.B!R:6=H
M=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N
M;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/C(L-#(T
M+#$V-SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E
M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z
M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN
M9SH@,'!X.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@
M=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG.B`P<'@[('1E>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!X
M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^+3PO9F]N=#X\+W1D/CQT9"!S='EL93TS
M1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6EN9&5N=#H@,'!X.R!F
M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E
M;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(')I9VAT
M.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^*#$L.30U
M+#8V.3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E
M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z
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M.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M
M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO
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M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z
M(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(')I9VAT.R!T
M97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^+3PO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T
M>6QE/3-$)W!A9&1I;F<Z(#!P>"`P<'@@,'!X(#$P<'@[('1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`M,3!P>#L@9F]N="US='EL93H@;F]R;6%L
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M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA
M;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P
M<'@[('1E>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
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M/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[
M(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y
M;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN
M9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N
M;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@<FEG
M:'0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
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M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[
M('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW
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M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P
M>#L@=&5X="UA;&EG;CH@<FEG:'0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M
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M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z
M(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(')I9VAT.R!T
M97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^*#$P-RPV-C(\
M+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6%L
M:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^*3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E
M>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG
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M="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@=VAI=&4[)SX\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X(#!P>"`P
M<'@@,3!P>#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z("TQ,'!X
M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
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M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[
M('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y
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M.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UI;F1E;G0Z
M(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG
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M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z
M(#!P>#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C
M,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E
M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z
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M="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E
M;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(')I9VAT
M.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^*#4S+#@S
M,3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M
M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO
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M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA
M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X
M.R!T97AT+6%L:6=N.B!R:6=H=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CLG/BT\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN
M9SH@,'!X.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!X.R!F
M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@(V-C965F9CLG/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@@,'!X
M(#!P>"`Q,'!X.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@+3$P
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M93TS1"=P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y
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M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@<FEG:'0[('1E>'0M
M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
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M,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E
M>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6%L:6=N
M.B!L969T.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@
M=&5X="UA;&EG;CH@<FEG:'0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y
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M1"=P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z
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M="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@<FEG:'0[('1E>'0M:6YD
M96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXH,3,V+#,U.3PO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXI/"]F
M;VYT/CPO=&0^/'1D#0H@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6EN
M9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N
M;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@;&5F
M=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N
M;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P
M.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M
M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^+3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[
M('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y
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M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P
M>#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P
M861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@
M,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^+3PO9F]N=#X\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD
M96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT9"!S='EL93TS1"=P861D:6YG
M.B`P<'@@,'!X(#!P>"`Q,'!X.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN
M9&5N=#H@+3$P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
M(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SY397)I97,@02!W87)R
M86YT<R!I<W-U960@:6X@36%Y(&%N9"!*=6YE(#(P,30@;V9F97)I;F<\+V9O
M;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6EN9&5N
M=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@;&5F=#L@
M=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI
M9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^+3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E
M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z
M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN
M9SH@,'!X.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@
M=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG.B`P<'@[('1E>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!X
M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^.#0R+#,W,#PO9F]N=#X\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M
M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
M(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6EN9&5N=#H@
M,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X
M="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ
M(')I9VAT.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
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M861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO
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M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@<FEG:'0[('1E>'0M:6YD96YT
M.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
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M+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P
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M.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@
M<FEG:'0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXQ
M,"PP-#`L.#(R/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P
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M("-C8V5E9F8[)SX\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X(#!P>"`P<'@@
M,3!P>#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z("TQ,'!X.R!F
M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^4V5R:65S($(@=V%R<F%N=',@:7-S=65D(&EN
M(&-O;FYE8W1I;VX@=VET:"!-87D@86YD($IU;F4@,C`Q-"!O9F9E<FEN9SPO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M:6YD
M96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6%L:6=N.B!L969T
M.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA
M;&EG;CH@<FEG:'0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO
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M:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA
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M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@<FEG:'0[('1E>'0M:6YD96YT.B`P
M<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[)SXR+#0Y-"PV-34\+V9O;G0^/"]T9#X\
M=&0-"B!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[
M('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW
M96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6EN
M9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N
M;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@;&5F
M=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N
M;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P
M.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M
M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^-RPT,#`L,C<U/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<Z(#!P>#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#L@
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y
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M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@<FEG:'0[('1E>'0M
M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
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M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M:6YD
M96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6%L:6=N.B!L969T
M.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA
M;&EG;CH@<FEG:'0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO
M<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[)SXY+#@Y-"PY,S`\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN
M9SH@,'!X.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!X.R!F
M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@=VAI=&4[)SX\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X(#!P>"`P
M<'@@,3!P>#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z("TQ,'!X
M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^4&QA8V5M96YT($%G96YT('=A<G)A;G1S
M(&ES<W5E9"!I;B!C;VYN96-T:6]N('=I=&@@36%Y(&%N9"!*=6YE(#(P,30@
M;V9F97)I;F<\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X
M.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
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M,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E
M>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&)O<F1E<BUB;W1T;VTM
M8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R
M9&5R+6)O='1O;2US='EL93H@<V]L:60[)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^+3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E
M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z
M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN
M9SH@,'!X.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@
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M9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P
M<'@[('1E>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&)O<F1E<BUB
M;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P
M=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^.3DV+#$S.#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[
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M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A
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M1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N
M=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M
M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
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M=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M:6YD96YT
M.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
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M97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@
M<V]L:60[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@<FEG
M:'0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
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M.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M
M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
M(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6%L:6=N.B!L
M969T.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=V5I9VAT.B!N;W)M86P[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K
M.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US
M='EL93H@<V]L:60[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG
M;CH@<FEG:'0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA
M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@
M8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T
M=&]M+7-T>6QE.B!S;VQI9#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXU+#8U
M,2PQ.#$\+V9O;G0^/"]T9#X\=&0-"B!S='EL93TS1"=P861D:6YG.B`P<'@[
M('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y
M;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C
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M93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD
M96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
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M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^,C`L,3`S+#0R-3PO9F]N=#X\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6EN9&5N
M=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@;&5F=#L@
M=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R
M9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D
M;W5B;&4[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)#PO9F]N=#X\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(')I9VAT.R!T
M97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D
M97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O
M=6)L93LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXT+#,S,RPQ-C,\+V9O;G0^
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6%L:6=N.B!L
M969T.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X
M="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
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M>6QE.B!D;W5B;&4[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^-RPY-30L.3<P
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA
M;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P
M<'@[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
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M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB
M;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXD
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA
M;&EG;CH@<FEG:'0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO
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M(#!P>"`T<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[
M(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[)SXI/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<Z(#!P>#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG
M.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O
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M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^,C4L-3@V+#DS,SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P
M861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P
M<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R
M/CPO=&%B;&4^/'`@<W1Y;&4],T0G9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@8V]L;W(Z(",P,#`P,#`[('1E
M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!M87)G:6XM=&]P.B`P<'@[(&UA<F=I;BUB;W1T
M;VTZ(#!P>#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M
M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CPO<#X\<"!S
M='EL93TS1"=F;VYT.B`Q,W!X+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ
M(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M
M86P[(&UA<F=I;BUT;W`Z(#!P>#L@;6%R9VEN+6)O='1O;3H@,'!X.R!W;W)D
M+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT
M97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[)B,Q-C`[/"]P/CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y
M.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M
M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A
M8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[)SY#:&%N9V4@:6X@9F%I<B!V86QU92!O9B!D
M97)I=F%T:79E(&QI86)I;&ET>2!D=7)I;F<@=&AE('EE87(@96YD960@1&5C
M96UB97(@,S$L(#(P,3,@=V%S(&%S(&9O;&QO=W,Z/"]P/CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO
M<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[)SXF(S$V,#L\+W`^/'1A8FQE('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M('=I9'1H.B`Q-38W<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN
M9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I
M;F<Z(#!P>#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N="US:7IE
M+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
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M)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X\=&0^)B,Q
M-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
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M97([)R!C;VQS<&%N/3-$,CY"86QA;F-E(&%T/"]T9#X\=&0^)B,Q-C`[/"]T
M9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R<@8V]L<W!A;CTS1#(^:7-S=6%N8V4@;V8@;F5W(&1E<FEV871I=F5S
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
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M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A
M;CTS1#(^1&5C96UB97(@,S$L/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L
M<W!A;CTS1#(^9'5R:6YG/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[
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M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R
M+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CXR,#$R/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M
M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU
M<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^
M=&AE('!E<FEO9#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CL@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB
M;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI
M9#LG(&-O;'-P86X],T0R/FQI86)I;&ET:65S/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M+6-O;&]R
M.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB
M;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^,C`Q,SPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^
M/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT9#XF(S$V,#L\+W1D/CQT9#XF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!W:&ET93LG/CQT9"!S='EL93TS1"=W:61T:#H@.#`R+CDS<'@[('1E
M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M.2XP-7!T.R!P861D:6YG
M+6QE9G0Z(#DN,#5P=#LG/D-O;G9E<G1I8FQE('!R969E<G)E9"!D97)I=F%T
M:79E(&QI86)I;&ET>2!I<W-U960@:6X@8V]N;F5C=&EO;B!W:71H(%-E<FEE
M<R!!('!R969E<G)E9"!S=&]C:R!O9F9E<FEN9SPO=&0^/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q-G!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$V<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$T,G!X.R!T97AT+6%L:6=N.B!R:6=H=#LG/C(L-#DR+#$V-CPO
M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[)SXF(S$V
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M)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@<FEG:'0[)SXW+#8R
M,BPP,SD\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U<'@[('1E>'0M
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M969T.B`Y+C`U<'0[)SY#;VYV97)T:6)L92!P<F5F97)R960@9&5R:79A=&EV
M92!L:6%B:6QI='D@:7-S=65D('1O(%=O;G!U;F<@9F]R('-E<G9I8V5S/"]T
M9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R<^.#@P+#(Q-#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
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M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXR+#`S,"PU.#D\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\
M+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!T97AT+6EN9&5N=#H@+3DN,#5P=#L@<&%D9&EN9RUL969T.B`Y
M+C`U<'0[)SY#;VYV97)T:6)L92!P<F5F97)R960@9&5R:79A=&EV92!L:6%B
M:6QI='D@:7-S=65D('1O(&QE;F1E<G,@:6X@8V]N;F5C=&EO;B!W:71H(&5X
M8VAA;F=E(&]F(&1E8G0@9F]R(%-E<FEE<R!!('!R969E<G)E9"!S=&]C:SPO
M=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#LG/CDU."PX-C$\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R<^+3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[)SXQ+#(V,"PY.3,\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T
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M.B`Y+C`U<'0[)SY787)R86YT<R!I<W-U960@:6X@8V]N;F5C=&EO;B!W:71H
M(%-E<FEE<R!!('!R969E<G)E9"!S=&]C:R!O9F9E<FEN9SPO=&0^/'1D/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C0W-2PP
M,#`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R<^,3$S+#$U,SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[)SXQ+#@S-BPP,30\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
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M+6%L:6=N.B!R:6=H=#LG/C(T,BPU,#`\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0-
M"B!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXR-#@L-C4U/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C<R-2PY
M,C@\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
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M,#5P=#L@<&%D9&EN9RUL969T.B`Y+C`U<'0[)SY787)R86YT<R!I<W-U960@
M=&\@;&5N9&5R<R!I;B!C;VYN96-T:6]N('=I=&@@<W5B;W)D:6YA=&5D('!R
M;VUI<W-O<GD@;F]T97,@;V9F97)I;F<\+W1D/CQT9#XF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXR.2PQ-3@\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
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M.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
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M.B`M.2XP-7!T.R!P861D:6YG+6)O='1O;3H@,2XU<'0[('!A9&1I;F<M;&5F
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M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I
M9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)SXQ,RPP
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M;&4Z('-O;&ED.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M
M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L
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M;W1T;VTM<W1Y;&4Z('-O;&ED.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K
M.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US
M='EL93H@<V]L:60[)SXX,2PU.#D\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B;W)D97(M8F]T
M=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[
M(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTM8V]L
M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R
M+6)O='1O;2US='EL93H@<V]L:60[)SXQ,S8L,S4Y/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^
M)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[)SY4;W1A;#PO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B
M;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D97(M8F]T=&]M
M+7-T>6QE.B!D;W5B;&4[)SXD/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M
M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L
M93LG/C4L,#DP+#DX.#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('!A9&1I;F<M8F]T=&]M.B`T<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
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M969T.R!P861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P=#LG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z
M(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T
M;VTM<W1Y;&4Z(&1O=6)L93LG/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E
M<BUB;W1T;VTM=VED=&@Z(#1P=#L@8F]R9&5R+6)O='1O;2US='EL93H@9&]U
M8FQE.R<^,3(L.#<W+#8W-3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`T<'0[)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X\=&0@
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M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X(#!P>"`P
M<'@@,"XR:6X[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N
M93L@=&5X="UI;F1E;G0Z("TP+C)I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA
M;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW
M96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CPO<#X\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!M87)G:6XZ(#!P>"`P<'@@,'!X(#`N,FEN.R!C;VQO<CH@(S`P
M,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`M,"XR
M:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[)SXF(S$V,#L\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N
M;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN
M.B`P<'@@,'!X(#!P>"`P+C)I;CL@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A
M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@+3`N,FEN.R!L971T97(M<W!A
M8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z
M(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/"]P
M/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[
M('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O
M<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SY#:&%N9V4@:6X@9F%I<B!V86QU
M92!O9B!D97)I=F%T:79E(&QI86)I;&ET>2!D=7)I;F<@=&AE('EE87(@96YD
M960@1&5C96UB97(@,S$L(#(P,3(@=V%S(&%S(&9O;&QO=W,Z/"]P/CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS
M<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C
M93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SXF
M(S$V,#L\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R
M.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z
M(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P
M<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M
M=VED=&@Z(#!P>#LG/CPO<#X\=&%B;&4@<W1Y;&4],T0G9F]N=#H@,3!P="]N
M;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=VED=&@Z
M(#$U-C=P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P
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M<&%N/3-$,CYO9B!D97)I=F%T:79E/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X\=&0^)B,Q
M-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(^)B,Q-C`[
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH-"B!B;W1T;VT[)SX\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[
M/"]T9#X\=&0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T
M9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
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M,CY"86QA;F-E(&%T/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS
M1#(^;&EA8FEL:71I97,@=7!O;B!I<W-U86YC92!O9B!N97<F(S$V,#L\8G(@
M+SYD97)I=F%T:79E<SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X]
M,T0R/DEN8W)E87-E)B,Q-C`[:6X@9F%I<B!V86QU92!O9CPO=&0^/'1D/B8C
M,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/D)A;&%N8V4@870\+W1D/CQT9#XF
M(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[)SX\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^1&5C96UB
M97(@,S$L/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^9'5R
M:6YG/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y
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M<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^,C`Q,3PO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\
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M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+7-T>6QE
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&)O<F1E<BUB;W1T;VTM
M8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R
M9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CYL:6%B:6QI
M=&EE<SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F
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M:61T:#H@.#`R+CDS<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`M.2XP-7!T.R!P861D:6YG+6QE9G0Z(#DN,#5P=#L@9F]N="US='EL93H@
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M/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T>6QE
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SXD/"]T9#X\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$T,G!X.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^+3PO=&0^/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@9F]N="US='EL93H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
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M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!F;VYT+7-T
M>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)#PO
M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG
M/C$L-C$Y+#0W.#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT
M+6%L:6=N.B!L969T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT
M.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P
M>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U<'@[('1E>'0M86QI
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M;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B!W:&ET93LG/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT
M+6EN9&5N=#H@+3DN,#5P=#L@<&%D9&EN9RUL969T.B`Y+C`U<'0[(&9O;G0M
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M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N
M="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\
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M93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^-3@Q+#`W,SPO=&0^
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M+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SXX.#`L,C$T
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\
M+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M.2XP-7!T.R!P861D:6YG+6QE9G0Z
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M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#LG/BT\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9`T*('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
M(&YO<FUA;#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[)SXY-3@L.#8Q/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
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M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M.2XP-7!T
M.R!P861D:6YG+6QE9G0Z(#DN,#5P=#L@9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+7=E:6=H=#H@;F]R;6%L.R<^5V%R<F%N=',@:7-S=65D(&EN(&-O;FYE
M8W1I;VX@=VET:"!397)I97,@02!P<F5F97)R960@<W1O8VL@;V9F97)I;F<\
M+W1D/CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N
M;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R<^+3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[
M)SXQ,3$L-S<W/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
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M=#H@;F]R;6%L.R<^-#<U+#`P,#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@+3DN
M,#5P=#L@<&%D9&EN9RUL969T.B`Y+C`U<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA
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M='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O
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M="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#LG/C(T,BPU,#`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SXF
M(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M.2XP-7!T.R!P861D
M:6YG+6QE9G0Z(#DN,#5P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R<^5V%R<F%N=',@:7-S=65D('1O(&QE;F1E<G,@:6X@
M8V]N;F5C=&EO;B!W:71H('-U8F]R9&EN871E9"!P<F]M:7-S;W)Y(&YO=&5S
M(&]F9F5R:6YG/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
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M;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW
M96EG:'0Z(&YO<FUA;#LG/C(L.#,S/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
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M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)O
M<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H
M.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)SXM/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ
M(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
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M9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
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M9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L
M86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O
M;2US='EL93H@<V]L:60[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O
M<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE
M.B!S;VQI9#LG/C$S+#`X.3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/"]T
M<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@=VAI=&4[)SX\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#1P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`T<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL-"B!B;W)D97(M
M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L
M93LG/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@8F]R
M9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z
M(#1P=#L@8F]R9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R<^+3PO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`T
M<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M-'!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
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M-'!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#1P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M
M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/B0\
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M.B`T<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O
M;2UW:61T:#H@-'!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[)SXD
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB
M;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[
M(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/C4L,#DP+#DX.#PO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`T<'0[)SXF(S$V,#L\+W1D/CPO='(^/"]T86)L93X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
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M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^4W1O8VMH;VQD97)S)R!%<75I='D\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C:VAO;&1E
M<G,G($1E9FEC:70@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4U1/0TM(3TQ$15)3)R!$149)0TE4/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R
M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO
M<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[
M("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQB/DY/5$4@-2`F
M(S@R,3$[(%-43T-+2$],1$524R8C.#(Q-SL@15%52519/"]B/CPO<#X-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@
M=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E
M<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@
M8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN
M9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I
M;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T
M<F]K92UW:61T:#H@,'!X.R<^/&(^0VQA<W,@02!#;VYV97)T:6)L92!0<F5F
M97)R960@4W1O8VL@*"8C.#(R,#M#;&%S<R!!(%-T;V-K)B,X,C(Q.RD\+V(^
M/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C
M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P
M>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[
M('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED
M=&@Z(#!P>#LG/CQB/B8C,38P.SPO8CX\+W`^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M
M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@
M+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^3VX@36%Y(#(P+"`R
M,#$T+"!296QM861A(%1H97)A<&5U=&EC<RP@26YC+B`H)B,X,C(P.U)E;&UA
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M8V4@;V8@,C@L,CDQ+#`W,R!S:&%R97,@;V8@8V]M;6]N('-T;V-K('1O('1H
M92!#;VUP86YY)B,X,C$W.W,@<W1O8VMH;VQD97)S+"!W:&EC:"!R97!R97-E
M;G1E9"`X,"XY)2!O9B!296QM861A)B,X,C$W.W,@:7-S=65D(&%N9"!O=71S
M=&%N9&EN9R!C;VUM;VX@<W1O8VL@869T97(@=&AE(&-O;G-U;6UA=&EO;B!O
M9B!T:&4@4VAA<F4@17AC:&%N9V4N($EN(&%D9&ET:6]N+"!T:&4@;W5T<W1A
M;F1I;F<@;W!T:6]N<R!A;F0@=V%R<F%N=',@=V5R92!E>&-H86YG960@9F]R
M(&]P=&EO;G,@86YD('=A<G)A;G1S('1O('!U<F-H87-E('-H87)E<R!O9B!C
M;VUM;VX@<W1O8VL@;V8@=&AE($-O;7!A;GD@870@82!R871I;R!O9B`Q,"!T
M;R`Q+B!0<FEO<B!T;R!T:&4@4VAA<F4@17AC:&%N9V4L('1H92!#;VUP86YY
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M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P
M,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[)SX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L
M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N
M=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z
M(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K
M92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@
M;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA
M;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW
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M;VXL(&QI<75I9&%T:6]N(&]R('=I;F1I;F<@=7`@;V8@=&AE($-O;7!A;GDL
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M.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M
M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A
M8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F
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M;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[
M('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O
M<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V,#L\+W`^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M
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M<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N
M<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R
M;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V,#L\
M+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P
M,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T
M:#H@,'!X.R<^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[
M(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI
M;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C
M:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#LG/D5A8V@@<VAA<F4@;V8@4V5R:65S($$@<')E
M9F5R<F5D('-T;V-K(&%U=&]M871I8V%L;'D@8V]N=F5R=&5D(&EN=&\@8V]M
M;6]N('-T;V-K(&]N(&$@;VYE(&9O<B!O;F4@8F%S:7,@=7!O;B!T:&4@4VAA
M<F4@17AC:&%N9V4N(%1H97)E('=E<F4@,2PS-C`L-#$S('-H87)E<R!T:&%T
M('=E<F4@8V]N=F5R=&5D('1O(&-O;6UO;B!S=&]C:RX@26X@861D:71I;VXL
M('1H92!C;VYV97)S:6]N('!R:6-E('=A<R!S=6)J96-T('1O(&%D:G5S=&UE
M;G0@=7!O;B!A(&9U='5R92!D;W=N(')O=6YD(&EF(&%N>2!F=71U<F4@<W1O
M8VL@;V9F97)I;F=S(&%R92!I<W-U960@8F5L;W<@)#`N.#`@<&5R('-H87)E
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M<&5R8V5N="`H-R4I('!E<B!A;FYU;2!O;B!T:&4@86UO=6YT('!A:60@9F]R
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M<F5D('-T;V-K(&%T($1E8V5M8F5R(#,Q+"`R,#$S('=A<R!A<'!R;WAI;6%T
M96QY("0Q,"PX.#,L,S`P+CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I
M;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[
M('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O
M<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.PT*("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO<#X-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS
M<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C
M93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SY)
M;B!!<')I;"`R,#$R+"!T:&4@0V]M<&%N>2!E>&-H86YG960@86X@86=G<F5G
M871E(&]F(#$L.#<Y+#$R."!S:&%R97,@;V8@4V5R:65S($$@<')E9F5R<F5D
M('-T;V-K('1O(&-O;G9E<G0@=&AE(&]U='-T86YD:6YG(&YO=&5S(&9R;VT@
M=&AE('EE87)S(#(P,#0@86YD(#(P,#4@=&]T86QI;F<@)#DW-2PP,#`@9G)O
M;2!L96YD97)S(&%N9"!A8V-R=65D(&EN=&5R97-T(&]F(&%P<')O>&EM871E
M;'D@)#4V-BPQ.#`N($EN(&%D9&ET:6]N+"!T:&4@0V]M<&%N>2!P<F]V:61E
M9"!T:&4@;&5N9&5R<R!W:71H(#8Q.2PS-S<@=V%R<F%N=',@=&\@<'5R8VAA
M<V4@8V]M;6]N('-T;V-K(&%T("0P+C@P('!E<B!S:&%R92P@86YD(&%L<V\@
M86QL;W=E9"!T:&4@;&5N9&5R<R!T;R!E>&5R8VES92!T:&4@=V%R<F%N=',@
M;VX@82!C87-H;&5S<R!B87-I<R!F;W(@-30Q+#0S,"!S:&%R97,@;V8@8V]M
M;6]N('-T;V-K+B!$=7)I;F<@,C`Q,BP@=&AE(&QE;F1E<G,@97AE<F-I<V5D
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M(&YO(&=A:6X@;W(@;&]S<R!O;B!T:&4@97AC:&%N9V4N/"]P/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E
M.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/B8C
M,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO
M<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[)SX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ
M(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
M97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D
M+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT
M97AT+7-T<F]K92UW:61T:#H@,'!X.R<^26X@07!R:6P@,C`Q,BP@=&AE($-O
M;7!A;GD@:7-S=65D(#$L-S(U+#`P,"!397)I97,@02!P<F5F97)R960@<W1O
M8VL@=&\@5V]N<'5N9R!I;B!E>&-H86YG92!F;W(@<V5R=FEC97,N(%1H92!#
M;VUP86YY(')E8V]R9&5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E(&]F(&%P<')O
M>&EM871E;'D@)#$L,S`U+#(P,"!B87-E9"!O;B!T:&4@9F%I<B!V86QU92!O
M9B!T:&4@4V5R:65S($$@<')E9F5R<F5D('-T;V-K(&%T('1H92!I<W-U86YC
M92!D871E+"!A;F0@<F5C;W)D960@87,@861D:71I;VYA;"!P86ED+6EN(&-A
M<&ET86P@9F]R(&%P<')O>&EM871E;'D@)#$L,#`V+#$P,"!A;F0@82!D97)I
M=F%T:79E(&QI86)I;&ET>2!F;W(@87!P<F]X:6UA=&5L>2`D,CDY+#$P,"X@
M5&AE($-O;7!A;GD@<F5C;W)D960@=&AE(&9A:7(@=F%L=64@;V8@=&AE('-H
M87)E<R!I<W-U960@87,@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N
M<V4@;V8@)#$L,S`U+#(P,"P@=VAI8V@@=V%S(')E8V]R9&5D(&%S(&5Q=6ET
M>2!F;W(@87!P<F]X:6UA=&5L>2`D,2PP,#8L,3`P(&%N9"!D97)I=F%T:79E
M(&QI86)I;&ET>2!F;W(@87!P<F]X:6UA=&5L>2`D,CDY+#$P,"X@5&AE(&9A
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M97)I=F%T:79E(&QI86)I;&ET>2X\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M
M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N
M;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L
M.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E
M8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]P/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG
M/D1U<FEN9R`R,#$R+"!I;B!A('-E<FEE<R!O9B!C;&]S:6YG<RP@=&AE($-O
M;7!A;GD@:7-S=65D(&EN=F5S=&]R<R`T+#@Y.2PS-S4@<VAA<F5S(&]F(%-E
M<FEE<R!!('!R969E<G)E9"!S=&]C:R!A;F0@,2PR,C0L.#0T('=A<G)A;G1S
M('1O('!U<F-H87-E('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@=VET:"!A;B!E
M>&5R8VES92!P<FEC92!O9B`D,"XX,"!P97(@<VAA<F4@9F]R(&=R;W-S('!R
M;V-E961S(&]F(&%P<')O>&EM871E;'D@)#,L.3$Y+#4P,"`H)#,L,C(P+#`Q
M."!N970@;V8@;V9F97)I;F<@8V]S=',I+B!);B!A9&1I=&EO;BP@=&AE($-O
M;7!A;GD@:7-S=65D('1H92!P;&%C96UE;G0@86=E;G0@-C$R+#0R,B!W87)R
M86YT<R!T;R!P=7)C:&%S92!C;VUM;VX@<W1O8VL@=VET:"!A;B!E>&5R8VES
M92!P<FEC92!O9B`D,"XX,"!P97(@<VAA<F4N($)O=&@@=&AE('=A<G)A;G1S
M(&%N9"!T:&4@4V5R:65S($$@<')E9F5R<F5D('-T;V-K(&-O;G1A:6X@86YT
M:2UD:6QU=&EO;B!F96%T=7)E<R!D965M960@=&\@8F4@9&5R:79A=&EV97,N
M(%1H92!A;G1I+61I;'5T:6]N('!R;W9I<VEO;B!W87,@96QI;6EN871E9"!U
M<&]N('1H92!3:&%R92!%>&-H86YG92X\+W`^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M
M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@
M+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]P/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P
M.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E
M+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
M>#LG/E1H92!T86)L92!B96QO=R!R969L96-T<R!T:&4@9W)O<W,@<')O8V5E
M9',@<F5C96EV960@:6X@8V]N;F5C=&EO;B!W:71H('1H92`R,#$R(&]F9F5R
M:6YG<R!A;&QO8V%T960@=&\@8V]M<&]N96YT<R!O9B!S=&]C:VAO;&1E<G,F
M(S@R,3<[(&5Q=6ET>2!A;F0@=&\@9&5R:79A=&EV92!L:6%B:6QI=&EE<R!B
M87-E9"!U<&]N(&9A:7(@=F%L=64Z/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@
M;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA
M;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW
M96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO<#X-"CQT
M86)L92!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!W:61T:#H@,34V-W!X.R!T97AT+71R86YS
M9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z
M(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[(&)O<F1E<BUC;VQL87!S93H@
M8V]L;&%P<V4[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C
M:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)R!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$
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M.3@\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[
M)SX-"CQT9"!S='EL93TS1"=P861D:6YG+6QE9G0Z(#!P=#LG/D%D9&ET:6]N
M86P@<&%I9"UI;BUC87!I=&%L/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,BPQ-3$L,#0P/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-
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M="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T.B`P<'0[)SY$97)I=F%T:79E
M('!R969E<G)E9"!S=&]C:R!C;VYV97)S:6]N(&9E871U<F4\+W1D/@T*/'1D
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M)SXX-S(L-C@X/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`Q+C5P=#L@<&%D9&EN9RUL969T.B`P<'0[)SY$97)I=F%T:79E)B,Q-C`[
M)B,Q-C`[5V%R<F%N=',@:7-S=65D('1O('!L86-E;65N="!A9V5N="!A<R!O
M9F9E<FEN9R!C;W-T<SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R
M+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O
M;&ED.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T
M;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG
M/C<Y+#8Q-3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@=VAI=&4[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!P861D:6YG+6QE9G0Z(#!P=#LG/DYE="!P<F]C965D<SPO=&0^#0H\
M=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.@T*(&QE
M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R<^,RPR,C`L,#$X/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F
M9CLG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`Q+C5P=#L@<&%D9&EN9RUL969T.B`P<'0[)SY/9F9E<FEN9R!C
M;W-T<R!P86ED(&EN(&-A<V@\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O
M<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE
M.B!S;VQI9#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M
M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L
M:60[)SXV.3DL-#@R/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/@T*/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B!W:&ET93LG/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`T<'0[('!A9&1I;F<M;&5F=#H@,'!T.R<^1W)O<W,@<')O8V5E
M9',\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O
M<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H
M.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/B0\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M
M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D
M97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[)SXS+#DQ.2PU,#`\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`T
M<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A
M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN
M9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO
M<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[
M/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C
M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P
M>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[
M('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED
M=&@Z(#!P>#LG/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X
M.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M
M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A
M8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[)SY$=7)I;F<@,C`Q,RP@:6X@82!S97)I97,@
M;V8@8VQO<VEN9W,L('1H92!#;VUP86YY(&ES<W5E9"!I;G9E<W1O<G,@-2PQ
M,#`L-C(U('-H87)E<R!O9B!397)I97,@02!P<F5F97)R960@<W1O8VL@86YD
M(#$L,C<U+#$U-B!W87)R86YT<R!T;R!P=7)C:&%S92!S:&%R97,@;V8@8V]M
M;6]N('-T;V-K(&9O<B!P<F]C965D<R!O9B!A<'!R;WAI;6%T96QY("0T+#`X
M,"PU,#`@*"0S+#0Y-"PT,C@@;F5T(&]F(&]F9F5R:6YG(&-O<W1S*2X@5&AE
M($-O;7!A;GD@86QS;R!I<W-U960@=&AE(&EN=F5S=&]R<R`Q+#(W-2PQ-38@
M=V%R<F%N=',@=&\@<'5R8VAA<V4@8V]M;6]N('-T;V-K('=I=&@@86X@97AE
M<F-I<V4@<')I8V4@;V8@)#`N.#`@<&5R('-H87)E+B!);B!A9&1I=&EO;BP@
M=&AE($-O;7!A;GD@:7-S=65D('1H92!P;&%C96UE;G0@86=E;G0@-C,W+#4W
M."!W87)R86YT<R!T;R!P=7)C:&%S92!C;VUM;VX@<W1O8VL@=VET:"!A;B!E
M>&5R8VES92!P<FEC92!O9B`D,"XX,"!P97(@<VAA<F4N($)O=&@@=&AE('=A
M<G)A;G1S(&%N9"!T:&4@4V5R:65S($$@<')E9F5R<F5D('-T;V-K(&-O;G1A
M:6X@86X@86YT:2UD:6QU=&EO;B!F96%T=7)E<R!D965M960@=&\@8F4@9&5R
M:79A=&EV97,L('-E92!.;W1E(#0N/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@
M;F]N93L@=&5X="UI;F1E;G0Z(#`N-6EN.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@
M+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]P/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P
M.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E
M+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
M>#LG/E1H92!T86)L92!B96QO=R!R969L96-T<R!T:&4@9W)O<W,@<')O8V5E
M9',@<F5C96EV960@:6X@8V]N;F5C=&EO;B!W:71H('1H92`R,#$S(&]F9F5R
M:6YG<R!A;&QO8V%T960@=&\@8V]M<&]N96YT<R!O9B!S=&]C:VAO;&1E<G,F
M(S@R,3<[(&5Q=6ET>2!A;F0@=&\@9&5R:79A=&EV92!L:6%B:6QI=&EE<R!B
M87-E9"!U<&]N(&9A:7(@=F%L=64Z/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@
M;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA
M;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW
M96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO<#X-"CQT
M86)L92!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!W:61T:#H@,34V-W!X.R!T97AT+71R86YS
M9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z
M(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[(&)O<F1E<BUC;VQL87!S93H@
M8V]L;&%P<V4[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C
M:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)R!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$
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M<"!S='EL93TS1"=M87)G:6XZ(#!P>#LG/C4L,3`P/"]P/@T*/"]T9#X-"CQT
M9"!S='EL93TS1"=W:61T:#H@,35P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.B`P<'0[)SY!9&1I=&EO;F%L('!A:60M:6XM
M8V%P:71A;#PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#LG/@T*/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'@[
M)SXQ+#0W.2PV,3`\+W`^#0H\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E
M969F.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN
M9RUL969T.B`P<'0[)SY$97)I=F%T:79E('=A<G)A;G0@;&EA8FEL:71I97,\
M+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[)SXQ,3,L,34S/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI
M=&4[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG
M+6QE9G0Z(#!P=#LG/D1E<FEV871I=F4@<')E9F5R<F5D('-T;V-K(&-O;G9E
M<G-I;VX@9F5A='5R93PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
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M(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O
M='1O;2US='EL93H@<V]L:60[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C
M:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM
M<W1Y;&4Z('-O;&ED.R<^,C0X+#8U-3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6QE9G0Z(#!P=#LG/DYE="!P
M<F]C965D<SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
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M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R
M+6)O='1O;2US='EL93H@<V]L:60[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B
M;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T
M;VTM<W1Y;&4Z('-O;&ED.R<^-3@V+#`W,CPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q
M-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX-"CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R!P861D:6YG+6QE9G0Z(#!P=#LG
M/D=R;W-S('!R;V-E961S/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R
M+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D;W5B
M;&4[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED
M=&@Z(#1P=#L@8F]R9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R<^-"PP.#`L
M-3`P/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D
M:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\+W1A8FQE
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+`T*('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P
M,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T
M:#H@,'!X.R<^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[
M(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI
M;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C
M:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\8CY#;VUM;VX@
M4W1O8VL\+V(^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[
M(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI
M;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C
M:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\=3Y#;VUM;VX@
M<W1O8VL@:7-S=65D(&EN(&-O;FYE8W1I;VX@=VET:"!S971T;&5M96YT(&%G
M<F5E;65N=',\+W4^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
M<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X
M="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US
M<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N
M<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R
M;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\+W`^#0H\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[
M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T
M97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M
M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X
M.R<^26X@07!R:6P@,C`Q,BP@=&AE($-O;7!A;GD@:7-S=65D(#(U-2PW-3`@
M<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!A;F0@=V%R<F%N=',@=&\@<'5R8VAA
M<V4@.#8X+#(Q,R!S:&%R97,@;V8@8V]M;6]N('-T;V-K('=I=&@@86X@97AE
M<F-I<V4@<')I8V4@;V8@)#`N.#`@<&5R('-H87)E('1H870@97AP:7)E(&EN
M($%P<FEL(#(P,3D@=&\@97AC:&%N9V4@=&AE(&]U='-T86YD:6YG(&QI86)I
M;&ET:65S(&]W960@=&\@=&AE(&9O=6YD97(@;V8@87!P<F]X:6UA=&5L>2`D
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M($YO=&4@."X\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@
M8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN
M9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I
M;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T
M<F]K92UW:61T:#H@,'!X.R<^/&D^)B,Q-C`[/"]I/CPO<#X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT
M<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C
M:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@
M;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\=3Y#
M;VUM;VX@<W1O8VL@:7-S=65D(&9O<B!S97)V:6-E<SPO=3X\+W`^#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E
M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A
M8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^
M)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O
M;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E
M;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG
M.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O
M:V4M=VED=&@Z(#!P>#LG/D1U<FEN9R`R,#$R+"!A;B!E>&5C=71I=F4@=V%S
M(&=R86YT960@,34S+#@P,B!S:&%R97,@;V8@8V]M;6]N('-T;V-K+B!4:&4@
M9W)A;G0@9&%T92!F86ER('9A;'5E(&]F('1H92!C;VUM;VX@<W1O8VL@=V%S
M("0P+C,P('!E<B!S:&%R92`H8F%S960@;VX@82!T:&ER9"!P87)T>2!V86QU
M871I;VXI+"!O<B!A<'!R;WAI;6%T96QY("0T-BPQ,#`@:6X@=&]T86PN(%1H
M92!V97-T:6YG('-C:&5D=6QE('!R;W9I9&5D('1H870@87!P<F]X:6UA=&5L
M>2`V."PS-3`@<VAA<F5S('9E<W1E9"!O;B!*=6QY(#$P+"`R,#$R+"`U-BPS
M.3`@<VAA<F5S('9E<W1E9"!O;B!*=6QY(#$P+"`R,#$S(&%N9"`R.2PP-3(@
M<VAA<F5S('9E<W1E9"!O;B!*86YU87)Y(#$P+"`R,#$T+B!!<R!A(')E<W5L
M="P@=&AE($-O;7!A;GD@<F5C;W)D960@<W1O8VLM8F%S960@8V]M<&5N<V%T
M:6]N(&5X<&5N<V4@;V8@87!P<F]X:6UA=&5L>2`D."PW,#`L("0Q-BPY,#`@
M86YD("0R,"PU,#`@9F]R('1H92!S:7@@;6]N=&AS(&5N9&5D($IU;F4@,S`L
M(#(P,30@86YD(&9O<B!T:&4@>65A<G,@96YD960@1&5C96UB97(@,S$L(#(P
M,3,@86YD(#(P,3(L(')E<W!E8W1I=F5L>2P@:6X@8V]N;F5C=&EO;B!W:71H
M('1H:7,@86=R965M96YT+B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ
M(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M
M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V,#LF(S$V,#L\
M+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P
M,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T
M:#H@,'!X.R<^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[
M(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI
M;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C
M:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#LG/CQU/D-O;6UO;B!S=&]C:R!I<W-U960@9F]R
M(&-A<V@\+W4^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[
M(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI
M;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C
M:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\+W`^#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E
M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A
M8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^
M3VX@36%Y(#$R+"!-87D@,34@86YD($IU;F4@,3`L(#(P,30L('1H92!#;VUP
M86YY(&-O;7!L971E9"!O;B!A('!R:79A=&4@<&QA8V5M96YT(&9O<B!T:&4@
M<V%L92!O9B!U;FET<R!F;W(@9W)O<W,@<')O8V5E9',@;V8@)#(U+#<T-2PV
M.3DN(%1H92!U;FET<R!C;VYS:7-T(&]F(#$W+#$V,RPW.3D@<VAA<F5S(&]F
M('1H92!#;VUP86YY)B,X,C$W.W,@8V]M;6]N('-T;V-K+"!397)I97,@02!W
M87)R86YT<R!T;R!P=7)C:&%S92`Q-RPQ-C,L-SDY('-H87)E<R!O9B!C;VUM
M;VX@<W1O8VL@870@86X@97AE<F-I<V4@<')I8V4@;V8@)#$N-3`@<&5R('-H
M87)E(&%N9"!397)I97,@0B!W87)R86YT<R!T;R!P=7)C:&%S92`X+#4X,2PX
M.30@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:RP@870@82!E>&5R8VES92!P<FEC
M92!O9B`D,BXR-2!P97(@<VAA<F4N(%1H92!397)I97,@02!787)R86YT<R!A
M<F4@97AE<F-I<V%B;&4@:6UM961I871E;'D@=&AR;W5G:"!/8W1O8F5R(#$P
M+"`R,#$T(&%N9"!T:&4@4V5R:65S($(@5V%R<F%N=',@87)E(&5X97)C:7-A
M8FQE(&EM;65D:6%T96QY('5P('1O(&$@<&5R:6]D(&]F(&9I=F4@>65A<G,@
M9G)O;2!T:&4@9&%T92!O9B!I<W-U86YC92X@5&AE($-O;7!A;GD@;6%Y(&-A
M;&P@=&AE(%-E<FEE<R!"('=A<G)A;G0@9F]R(')E9&5M<'1I;VX@=7!O;B!W
M<FET=&5N(&YO=&EC92!T;R!A;&P@:6YV97-T;W)S(&]F('1H92!-87D@86YD
M($IU;F4@,C`Q-"!U;FET<R`F(S$V,#LH)B,X,C(P.VEN=F5S=&]R<R8C.#(R
M,3LI(&%T(&%N>2!T:6UE(&EF('1H92!C;&]S:6YG('!R:6-E(&]F('1H92!C
M;VUM;VX@<W1O8VL@97AC965D<R`D,RXW-2!P97(@<VAA<F4@9F]R('1W96YT
M>2`H,C`I(&-O;G-E8W5T:79E('1R861I;F<@9&%Y<R!P<F]V:61E9"!T:&%T
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M961E96UE9"!B>2!T:&4@0V]M<&%N>2!A="`D,"XP,#$@<&5R('-H87)E+B8C
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M8V%L;"!F;W(@<F5D96UP=&EO;B!B>2!T:&4@0V]M<&%N>2X@)B,Q-C`[5&AE
M($-O;7!A;GD@<VAA;&P@9&ER96-T('1H92!397)I97,@0B!H;VQD97(@=&\@
M;6%K92!S=6-H('-O;&EC:71A=&EO;B!F964@<&%Y;65N="!D:7)E8W1L>2!T
M;R!T:&4@4&QA8V5M96YT($%G96YT(&%N9"!T:&4@4V5R:65S($(@=V%R<F%N
M="!H;VQD97(@<VAA;&P@8V]M<&QY('=I=&@@<W5C:"!D:7)E8W1I;VXN)B,Q
M-C`[/&9O;G0@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SY4
M:&4@0V]M<&%N>2!I<W-U960@=V%R<F%N=',@=&\@<'5R8VAA<V4@-"PR.3`L
M.34P('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@870@)#$N-3`@=&\@:71S(%!L
M86-E;65N="!!9V5N="`H)B,X,C(P.T%G96YT(%=A<G)A;G1S)B,X,C(Q.RDN
M(%1H92!!9V5N="!787)R86YT<R!A<F4@:6UM961I871E;'D@97AE<F-I<V%B
M;&4@86YD(&5X<&ER92!F:79E('EE87)S(&9R;VT@=&AE(&1A=&4@;V8@:7-S
M=6%N8V4N(%1H92!#;VUP86YY('!A:60@87!P<F]X:6UA=&5L>2`D,RPU,38L
M,#`P(&EN8VQU9&EN9R!E>'!E;G-E<R!T;R!T:&4@4&QA8V5M96YT($%G96YT
M(&%N9"!T:&4@;F5T('!R;V-E961S('=E<F4@87!P<F]X:6UA=&5L>2`D,C(L
M,C(Y+#,P,"XF(S$V,#L\+V9O;G0^06QL('1H92!W87)R86YT<R!I;B!T:&ES
M('1R86YS86-T:6]N(&AA=F4@86X@86YT:2UD:6QU=&EO;B!P<F]V:7-I;VX@
M86YD('-H86QL('1E<FUI;F%T92!U<&]N(&%N('5P+6QI<W1I;F<@;V8@=&AE
M($-O;7!A;GD@=&\@82!N871I;VYA;"!S96-U<FET:65S(&5X8VAA;F=E('-U
M8V@@87,@3EE312!O<B!.05-$05$N)B,Q-C`[/&9O;G0@<W1Y;&4],T0G8F%C
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M=7`@=&\@=&AE('!U<F-H87-E('!R:6-E('=I=&@@82!M87AI;75M('!E;F%L
M='D@;V8@<VEX('!E<F-E;G0@*#8E*2X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R
M86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N
M;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CPO<#X-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P
M,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG
M/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ
M(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
M97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D
M+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT
M97AT+7-T<F]K92UW:61T:#H@,'!X.R<^5&AE('1A8FQE(&)E;&]W(')E9FQE
M8W1S('1H92!G<F]S<R!P<F]C965D<R!R96-E:79E9"!I;B!C;VYN96-T:6]N
M('=I=&@@=&AE($UA>2!A;F0@2G5N92`R,#$T(&]F9F5R:6YG<R!A;&QO8V%T
M960@=&\@8V]M<&]N96YT<R!O9B!S=&]C:VAO;&1E<G,F(S@R,3<[(&5Q=6ET
M>2!A;F0@=&\@9&5R:79A=&EV92!L:6%B:6QI=&EE<R!B87-E9"!U<&]N(&9A
M:7(@=F%L=64Z/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[
M(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI
M;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C
M:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\+W`^#0H\=&%B
M;&4@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@8V%L:6)R:2P@:&5L=F5T
M:6-A+"!S86YS+7-E<FEF.R!W:61T:#H@,34V-W!X.R!T97AT+71R86YS9F]R
M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO
M<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[(&)O<F1E<BUC;VQL87!S93H@8V]L
M;&%P<V4[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE/3-$)W9E
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M.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B0\+W1D/@T*/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,3<L,38T
M/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG
M/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^061D:71I;VYA;"!P86ED+6EN+6-A<&ET86P\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,3<L.#<X+#DY-#PO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D/@T*/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[)SY$97)I=F%T:79E('=A<G)A;G0@;&EA8FEL:71I97,\
M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,RPS,S<L,#(U/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^#0H\+W1R
M/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z('=H:71E.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/D1E<FEV871I=F4@
M=V%R<F%N=',@:7-S=65D('1O('!L86-E;65N="!A9V5N="!A<R!O9F9E<FEN
M9R!C;W-T<SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N
M-7!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T
M=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[
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M9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B`C8V-E969F.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
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M9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D/@T*/"]T
M<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B!W:&ET93LG/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q+C5P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[)SY/9F9E<FEN9R!C;W-T<R!P86ED(&EN(&-A<V@\
M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!B
M;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T
M:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^)B,Q-C`[
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M.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y
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M<CX-"CPO=&%B;&4^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@
M8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN
M9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I
M;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T
M<F]K92UW:61T:#H@,'!X.R<^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R
M9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N
M93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO<#X-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS
M<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C
M93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\
M=3Y#;VUM;VX@<W1O8VL@:7-S=65D(&EN(&-O;FYE8W1I;VX@=VET:"!E>&5R
M8VES92!O9B!W87)R86YT<SPO=3X\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M
M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N
M;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L
M.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E
M8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]P/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG
M/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@
M(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P
M<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[)SY);B!!<')I;"`R,#$R+"!T=V\@;&5N9&5R<R!E>&5R8VES
M960@=&AE:7(@-C$X+#<V-B!W87)R86YT<R!O;B!A(&-A<VAL97-S(&)A<VES
M(&%N9"!R96-E:79E9"`U-#$L,CDS('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@
M;V8@=&AE($-O;7!A;GDN/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N
M;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN
M.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@
M=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R
M9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO<#X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT
M<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C
M:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@
M;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\=3Y#
M;VUM;VX@<W1O8VL@:7-S=65D(&9O<B!A8W%U:7-I=&EO;B!O9B!-961E;W(\
M+W4^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R
M.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z
M(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P
M<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M
M=VED=&@Z(#!P>#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA
M<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO
M;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[
M('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\+W`^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A
M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN
M9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO
M<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^26X@07!R
M:6P@,C`Q,BP@=&AE($-O;7!A;GD@:7-S=65D(#$W+#`X.2!S:&%R97,@;V8@
M8V]M;6]N('-T;V-K('1O($UE9&5O<B!);F,N("@F(S@R,C`[365D96]R)B,X
M,C(Q.RD@:6X@8V]N;F5C=&EO;B!W:71H('1H92!A8W%U:7-I=&EO;B!O9B!A
M(&QI8V5N<V4@86=R965M96YT+B!-86YA9V5M96YT(&1E=&5R;6EN960@=&AE
M(&9A:7(@=F%L=64@;V8@=&AE(&-O;6UO;B!S=&]C:R!T;R!B92`D,"XS,"!P
M97(@<VAA<F4@8F%S960@;VX@82!T:&ER9"!P87)T>2!V86QU871I;VXL(&%N
M9"!R96-O<F1E9"!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS92!T
M;R!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@;V8@87!P<F]X:6UA=&5L>2`D
M-2PQ,#`N($%T($1E8V5M8F5R(#,Q+"`R,#$S+"!T:&4@0V]M<&%N>2!I<W-U
M960@,C4L,#`P+#`P,"!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&EN(&5X8VAA
M;F=E(&9O<B!A;&P@=&AE(&]U='-T86YD:6YG('-T;V-K(&]F($UE9&5O<B!W
M:&]S92!O;FQY(&%S<V5T('=A<R!A('!E;F1I;F<@<F5S96%R8V@@86YD(&1E
M=F5L;W!M96YT('!R;VIE8W0N(%1H92!T<F%N<V%C=&EO;B!W87,@=F%L=65D
M(&%T(&ET<R!F86ER('9A;'5E(&]F("0S+#<U,"PP,#`@86YD('=A<R!E>'!E
M;G-E9"!T;R!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0@97AP96YS92X@5&AE
M(&9A:7(@=F%L=64@;V8@=&AE('-H87)E<R!W87,@9&5T97)M:6YE9"!V:6$@
M82!T:&ER9"!P87)T>2!V86QU871I;VXN/"]P/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R
M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO
M<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[
M("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CPO<#X-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS
M<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C
M93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\
M8CXF(S$V,#L\+V(^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
M<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X
M="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US
M<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#LG/CQB/D]P=&EO;G,@86YD('=A<G)A;G1S
M/"]B/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO
M<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M
M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N
M;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L
M.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E
M8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^5&AE($-O;7!A;GD@:&%S
M(&5S=&%B;&ES:&5D('1H92`R,#$R(%-T;V-K($]P=&EO;B!0;&%N("AT:&4@
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M861V:7-O<G,N(%1H92!0;&%N(&%L;&]W960@9F]R(#(L-#`Y+#0S-B!O<'1I
M;VYS('1O(&)E(&=R86YT960@:6X@2G5L>2`R,#$R+B!/;B!-87)C:"`Q,"P@
M,C`Q-"P@=&AE($)O87)D(&]F($1I<F5C=&]R<R!I;F-R96%S960@=&AE('-H
M87)E<R!U;F1E<B!T:&4@4&QA;B!T;R`T+#`P,"PP,#`N(%1H92!S:&%R96AO
M;&1E<G,@87!P<F]V960@=&\@:6YC<F5A<V4@=&AE('-H87)E<R!A=F%I;&%B
M;&4@=6YD97(@=&AE('!L86X@=&\@."PP-3@L.#0T+B!!="!*=6YE(#,P+"`R
M,#$T+"!N;R!S=&]C:R!A<'!R96-I871I;VX@<FEG:'1S(&AA=F4@8F5E;B!I
M<W-U960N(%-T;V-K(&]P=&EO;G,@87)E(&5X97)C:7-A8FQE(&=E;F5R86QL
M>2!F;W(@82!P97)I;V0@;V8@,3`@>65A<G,@9G)O;2!T:&4@9&%T92!O9B!G
M<F%N="!A;F0@9V5N97)A;&QY('9E<W0@;W9E<B!F;W5R('EE87)S+B!!<R!O
M9B!*=6YE(#,P+"`R,#$T+"`T+#8Y,RPV-S,@<VAA<F5S('=E<F4@879A:6QA
M8FQE(&9O<B!F=71U<F4@9W)A;G1S('5N9&5R('1H92!0;&%N+CPO<#X-"CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@
M=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E
M<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@
M8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN
M9&5N=#H@,'!X.PT*(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A
M8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[)SY4:&4@0V]M<&%N>2!U=&EL:7IE<R!T:&4@
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M<V5D('5P;VX@:71S('!E97(@9W)O=7`N(%1H92!#;VUP86YY(')O=71I;F5L
M>2!R979I97=S(&ET<R!C86QC=6QA=&EO;B!O9B!V;VQA=&EL:71Y(&-H86YG
M97,@:6X@9G5T=7)E('9O;&%T:6QI='DL('1H92!#;VUP86YY)B,X,C$W.W,@
M;&EF92!C>6-L92P@:71S('!E97(@9W)O=7`L(&%N9"!O=&AE<B!F86-T;W)S
M+CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@
M(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P
M<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G
M:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W
M;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI
M="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^5&AE($-O;7!A;GD@=7-E<R!T
M:&4@<VEM<&QI9FEE9"!M971H;V0@9F]R('-H87)E+6)A<V5D(&-O;7!E;G-A
M=&EO;B!T;R!E<W1I;6%T92!T:&4@97AP96-T960@=&5R;2!F;W(@96UP;&]Y
M964@;W!T:6]N(&%W87)D<R!F;W(@<VAA<F4M8F%S960@8V]M<&5N<V%T:6]N
M(&EN(&ET<R!O<'1I;VXM<')I8VEN9R!M;V1E;"X@5&AE($-O;7!A;GD@=7-E
M<R!T:&4@8V]N=')A8W1U86P@=&5R;2!F;W(@;F]N+65M<&QO>65E(&]P=&EO
M;G,@=&\@97-T:6UA=&4@=&AE(&5X<&5C=&5D('1E<FTL(&9O<B!S:&%R92UB
M87-E9"!C;VUP96YS871I;VX@:6X@:71S(&]P=&EO;BUP<FEC:6YG(&UO9&5L
M+CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@
M(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P
M<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G
M:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W
M;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI
M="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&(^4W1O8VLM8F%S960@8V]M
M<&5N<V%T:6]N("8C.#(Q,3L@;W!T:6]N<SPO8CX\+W`^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@8V5N=&5R.R!C;VQO
M<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T
M97AT+6%L:6=N.B!L969T.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[(&UA<F=I;BUT;W`Z(#!P>#L@;6%R9VEN+7)I9VAT.B`P<'@[(&UA
M<F=I;BUB;W1T;VTZ(#!P>#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG
M/E1H92!#;VUP86YY(&=R86YT960@86X@;V9F:6-E<B!O<'1I;VYS('1O('!U
M<F-H87-E(#8W-RPY-C(@86YD(#8V-2PW-3`@<VAA<F5S(&]F(&ET<R!C;VUM
M;VX@<W1O8VL@:6X@2G5L>2`R,#$R(&%N9"!397!T96UB97(@,C`Q,RP@<F5S
M<&5C=&EV96QY+B!%86-H(&]F('1H92!O<'1I;VYS(&=R86YT960@:&%V92!A
M('1E;BUY96%R('1E<FT@86YD(&%T(&%N("0P+C@P(&5X97)C:7-E('!R:6-E
M+B`R-24@;V8@96%C:"!O9B!T:&4@;W!T:6]N<R!V97-T(&EM;65D:6%T96QY
M(&%N9"!T:&4@<F5M86EN:6YG(#<U)2!O9B!T:&4@;W!T:6]N<R!V97-T(&EN
M(&5Q=6%L('%U87)T97)L>2!I;F-R96UE;G1S(&]V97(@82!F;W5R+7EE87(@
M<&5R:6]D+B!4:&4@9F%I<B!V86QU92!O9B!T:&4@;W!T:6]N<R!A<R!O9B!T
M:&4@9W)A;G0@9&%T97,@=V%S("0Q,#,L-S`P(&%N9"`D,S4Y+#$P,"P@<F5S
M<&5C=&EV96QY+CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X
M.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M
M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A
M8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F
M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@
M;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA
M;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/"]P/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG
M/D1U<FEN9R!.;W9E;6)E<B`R,#$S+"!T:&4@0V]M<&%N>2!G<F%N=&5D(&$@
M8V]N<W5L=&%N="!O<'1I;VYS('1O('!U<F-H87-E(#$X-RPU,#`@<VAA<F5S
M(&]F(&-O;6UO;B!S=&]C:RX@5&AE(&]P=&EO;G,@:&%V92!A(#$P('EE87(@
M=&5R;2!A;F0@86X@)#`N.#`@97AE<F-I<V4@<')I8V4N(#(U)2!O9B!T:&4@
M;W!T:6]N<R!V97-T(&]N('1H92!O;F4@>65A<B!A;FYI=F5R<V%R>2!O9B!T
M:&4@9W)A;G0@9&%T92!A;F0@=&AE(')E;6%I;FEN9R!O<'1I;VYS('9E<W0@
M:6X@97%U86P@<75A<G1E<FQY(&EN8W)E;65N=',@;W9E<B!T:&4@9F]L;&]W
M:6YG(#,@>65A<G,N(%1H92!F86ER('9A;'5E(&]F('1H92!O<'1I;VYS(&]N
M('1H92!G<F%N="!D871E('=A<R`D,3$T+#@P,"X\+W`^#0H\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A
M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN
M9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO
M<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/"]P/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P
M.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E
M+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
M>#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X
M.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M
M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A
M8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[)SY$=7)I;F<@1&5C96UB97(@,C`Q,R!A;F0@
M2F%N=6%R>2`R,#$T+"!T:&4@0V]M<&%N>2!G<F%N=&5D(&%N(&]F9FEC97(@
M;W!T:6]N<R!T;R!P=7)C:&%S92`S,S0L,3DY(&%N9"`Q+#`P,RPW-S0@<VAA
M<F5S(&]F(&-O;6UO;B!S=&]C:RP@<F5S<&5C=&EV96QY+B!4:&4@;W!T:6]N
M<R!H879E(&$@,3`@>65A<B!T97)M(&%N9"!A;B!E>&5R8VES92!P<FEC92!O
M9B`D,"XX,"!A;F0@)#$N-3`@<&5R('-H87)E+"!R97-P96-T:79E;'DN(#(U
M)2!O9B!T:&4@;W!T:6]N<R!V97-T(&]N('1H92!O;F4@86YN:79E<G-A<GD@
M;V8@=&AE(&=R86YT(&1A=&4@86YD('1H92!R96UA:6YI;F<@;W!T:6]N<R!V
M97-T('%U87)T97)L>2!O=F5R('1H92!F;VQL;W=I;F<@,R!Y96%R<RX@5&AE
M(&9A:7(@=F%L=64@;V8@=&AE(&]P=&EO;G,@;VX@=&AE(&=R86YT(&1A=&4@
M9'5R:6YG($1E8V5M8F5R(#(P,3,@86YD($IA;G5A<GD@,C`Q-"!W87,@)#$X
M,2PT,#`@86YD("0Y,S<L-C`P+"!R97-P96-T:79E;'DN/"]P/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E
M.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/B8C
M,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO
M<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[)SX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ
M(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
M97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D
M+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT
M97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/"]P/@T*/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R
M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO
M<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[
M("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/D1U<FEN9R!&96)R
M=6%R>2`R,#$T+"!T:&4@0V]M<&%N>2!G<F%N=&5D('1O('1H<F5E(&]F(&ET
M<R!B;V%R9"!O9B!D:7)E8W1O<G,L(&%N(&%G9W)E9V%T92!O9B!O<'1I;VYS
M('1O('!U<F-H87-E(#$T-2PY.#8@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:RP@
M<F5S<&5C=&EV96QY+B!%86-H(&]P=&EO;B!H87,@82`Q,"!Y96%R('1E<FT@
M86YD(&%N(&5X97)C:7-E('!R:6-E(&]F("0Q+C4P('!E<B!S:&%R92P@<F5S
M<&5C=&EV96QY+B`R-24@;V8@=&AE(&]P=&EO;G,@=F5S="!O;B!T:&4@;VYE
M('EE87(@86YN:79E<G-A<GD@;V8@=&AE(&=R86YT(&1A=&4@86YD('1H92!R
M96UA:6YI;F<@;W!T:6]N<R!V97-T('%U87)T97)L>2!O=F5R('1H92!F;VQL
M;W=I;F<@,R!Y96%R<RX@5&AE(&9A:7(@=F%L=64@;V8@=&AE(&]P=&EO;G,@
M;VX@=&AE(&=R86YT(&1A=&4@=V%S(&%P<')O>&EM871E;'D@)#$S-BPR,#`N
M/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C
M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z#0H@
M,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P
M>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW
M:61T:#H@,'!X.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R
M9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N
M93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/D1U<FEN9R!-87D@,C`Q-"P@
M=&AE($-O;7!A;GD@9W)A;G1E9"!T;R!I=',@=F%R:6]U<R!E;7!L;WEE97,L
M(&]P=&EO;G,@=&\@<'5R8VAA<V4@,S4P+#`P,"!S:&%R97,@;V8@8V]M;6]N
M('-T;V-K+"!R97-P96-T:79E;'DN($5A8V@@;W!T:6]N(&AA<R!A(#$P('EE
M87(@=&5R;2!A;F0@86X@97AE<F-I<V4@<')I8V4@;V8@)#$N-3`@<&5R('-H
M87)E+"!R97-P96-T:79E;'DN(#(U)2!O9B!T:&4@;W!T:6]N<R!V97-T(&]N
M('1H92!O;F4@>65A<B!A;FYI=F5R<V%R>2!O9B!T:&4@9W)A;G0@9&%T92!A
M;F0@=&AE(')E;6%I;FEN9R!O<'1I;VYS('9E<W0@<75A<G1E<FQY(&]V97(@
M=&AE(&9O;&QO=VEN9R`S('EE87)S+B!4:&4@9F%I<B!V86QU92!O9B!T:&4@
M;W!T:6]N<R!O;B!T:&4@9W)A;G0@9&%T92!W87,@)#(U,"PR,#`N/"]P/@T*
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P
M.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E
M+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
M>#LG/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X
M.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M
M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A
M8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[)SY);B!-87D@,C`Q-"P@=&AE($)O87)D(&]F
M($1I<F5C=&]R<R!G<F%N=&5D(&]P=&EO;G,@=&\@=&AR964@;V9F:6-E<G,@
M;W!T:6]N<R!B87-E9"!U<&]N(&$@<&5R8V5N=&%G92!O9B!T:&4@9G5L;'D@
M9&EL=71E9"!S:&%R97,@=&AA="!E>&ES="!A9G1E<B!T:&4@97AE<F-I<V4@
M;W(@9F]R9F5I='5R92!O9B!T:&4@4V5R:65S($$@=V%R<F%N=',@:6X@3V-T
M;V)E<B`R,#$T+B!4:&4@0V]M<&%N>2!W:6QL(')E8V]R9"!S=&]C:RUB87-E
M9"!C;VUP96YS871I;VX@97AP96YS92!A="!F86ER('9A;'5E('=H96X@=&AE
M(&]P=&EO;G,@87)E(&ES<W5E9"X@5&AE(&]P=&EO;B!P<FEC92!H87,@8F5E
M;B!E<W1A8FQI<VAE9"!A="!F86ER(&UA<FME="!V86QU92X\+W`^#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E
M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A
M8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^
M)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O
M;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E
M;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG
M.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O
M:V4M=VED=&@Z(#!P>#LG/D$@<W5M;6%R>2!O9B!T:&4@8VAA;F=E<R!I;B!O
M<'1I;VYS(&]U='-T86YD:6YG(&1U<FEN9R!T:&4@<VEX(&UO;G1H<R!E;F1E
M9"!*=6YE(#,P+"`R,#$T(&%N9"!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@
M,C`Q,R!A;F0@,C`Q,B!I<R!A<R!F;VQL;W=S.CPO<#X-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N
M<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R
M;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V,#L\
M+W`^#0H\=&%B;&4@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=VED=&@Z(#$U-C=P>#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS
M<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!B;W)D97(M8V]L
M;&%P<V4Z(&-O;&QA<'-E.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@
M,'!X.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,#X-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED
M=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P
M86X],T0R/DYU;6)E<B!O9CQB<B`O/E-H87)E<SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O
M;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B
M;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/E=E:6=H
M=&5D/&)R("\^079E<F%G93QB<B`O/D5X97)C:7-E/&)R("\^4')I8V4\8G(@
M+SY097(@4VAA<F4\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B
M;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL
M93H@<V]L:60[)R!C;VQS<&%N/3-$,CY796EG:'1E9#QB<B`O/D%V97)A9V4\
M8G(@+SY296UA:6YI;F<\8G(@+SY#;VYT<F%C='5A;#QB<B`O/E1E<FT@*%EE
M87)S*3PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,2XU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CL@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB
M;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI
M9#LG(&-O;'-P86X],T0R/D%G9W)E9V%T93QB<B`O/DEN=')I;G-I8SQB<B`O
M/E9A;'5E/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU
M<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^
M#0H\=&0^3W5T<W1A;F1I;F<@870@1&5C96UB97(@,S$L(#(P,3$\+W1D/@T*
M/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[)SXM/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT
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M969T.B`Q-RXS<'0[)SY'<F%N=&5D/"]T9#X-"CQT9"!S='EL93TS1"=W:61T
M:#H@,39P>#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$V
M<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q-#)P>#L@=&5X="UA;&EG;CH@<FEG:'0[)SXV-S<L.38R
M/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT
M+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$T
M,G!X.R!T97AT+6%L:6=N.B!R:6=H=#LG/C`N.#`\+W1D/@T*/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,35P>#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$U<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#%P>#L@=&5X="UA
M;&EG;CH@<FEG:'0[)SXM/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,35P
M>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$U<'@[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$T,7!X.R!T97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D
M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/@T*
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY/=71S=&%N9&EN9R!A
M;F0@97AP96-T960@=&\@=F5S="!A="!$96-E;6)E<B`S,2P@,C`Q,CPO=&0^
M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#LG/C8W-RPY-C(\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R<^,"XX,#PO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/CDN-3PO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M)SXM/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX-"CQT9"!S='EL
M93TS1"=T97AT+6EN9&5N=#H@+3@N-C5P=#L@<&%D9&EN9RUL969T.B`Q-RXS
M<'0[)SY'<F%N=&5D/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,2PQ.#<L-#0Y/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXD
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C`N.#`\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[)SXM/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.@T*
M("-C8V5E9F8[)SX-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M3W5T<W1A;F1I;F<@86YD(&5X<&5C=&5D('1O('9E<W0@870@1&5C96UB97(@
M,S$L(#(P,3,\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[)SXQ+#@V-2PT,3$\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,"XX,#PO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#LG/C@N.#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[)SXQ+#,P-2PP,#`\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!W:&ET93LG/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M+C5P=#LG/B8C,38P.R8C,38P.R8C,38P.T=R86YT960\+W1D/@T*/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^#0H\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F]R9&5R+6)O='1O;2UC
M;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D
M97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z
M(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O
M='1O;2US='EL93H@<V]L:60[)SXQ+#0Y.2PW-C`\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG
M/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N
M-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O
M;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^
M)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E
M<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q
M+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)SXQ+C4P/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O
M;3H@,2XU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O
M<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE
M.B!S;VQI9#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M
M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L
M:60[)SXY+C<\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B;W)D97(M8F]T=&]M+6-O
M;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E
M<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K
M.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US
M='EL93H@<V]L:60[)SXS+#`P,"PP,#`\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P
M.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@-'!T.R<^
M3W5T<W1A;F1I;F<@86YD(&5X<&5C=&5D('1O('9E<W0@870@2G5N92`S,"P@
M,C`Q-"8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#1P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T
M;VTM=VED=&@Z(#1P=#L@8F]R9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED
M=&@Z(#1P=#L@8F]R9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R<^,RPS-C4L
M,3<Q/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D
M:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
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M;2US='EL93H@9&]U8FQE.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[
M(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#1P=#L@8F]R9&5R+6)O='1O;2US='EL
M93H@9&]U8FQE.R<^."XY/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!P861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X-
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M='EL93H@9&]U8FQE.R<^-2PR,S@L,#`P/"]T9#X-"CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[
M/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@-'!T.R<^3W!T:6]N<R!E>&5R8VES86)L92!A
M="!*=6YE(#,P+"`R,#$T/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
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M-3(L,#`U/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P
M861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
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M='1O;2US='EL93H@9&]U8FQE.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA
M8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#1P=#L@8F]R9&5R+6)O='1O;2US
M='EL93H@9&]U8FQE.R<^.2XP/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T
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M<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO
M;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[
M('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V,#L\+W`^#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E
M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A
M8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^
M1F]R('1H92!S:7@@;6]N=&AS(&5N9&5D($IU;F4@,S`L(#(P,30@86YD(&9O
M<B!Y96%R<R!E;F1I;F<@1&5C96UB97(@,S$L(#(P,3,@86YD(#(P,3(L('1H
M92!#;VUP86YY(')E8V]R9&5D(&%P<')O>&EM871E;'D@)#$Q-2PU,#`L("0T
M+#@P,"!A;F0@)#`L(')E<W!E8W1I=F5L>2P@;V8@<W1O8VLM8F%S960@8V]M
M<&5N<V%T:6]N(&5X<&5N<V4@=&\@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT
M(&5X<&5N<V4N($9O<B!T:&4@<VEX(&UO;G1H<R!E;F1E9"!A;F0@9F]R('EE
M87)S(&5N9&EN9R!$96-E;6)E<B`S,2P@,C`Q,R!A;F0@,C`Q,BP@=&AE($-O
M;7!A;GD@<F5C;W)D960@87!P<F]X:6UA=&5L>2`D-S<L-S`P+"`D,3(Y+#8P
M,"!A;F0@)#,U+#$P,"P@<F5S<&5C=&EV96QY+"!O9B!S=&]C:R!B87-E9"!C
M;VUP96YS871I;VX@97AP96YS92!T;R!G96YE<F%L(&%N9"!A9&UI;FES=')A
M=&EV92!E>'!E;G-E+B!!="!*=6YE(#,P+"`R,#$T+"!A;F0@1&5C96UB97(@
M,S$L(#(P,3,@86YD(#(P,3(L('1H92!#;VUP86YY(&AA<R!U;G)E8V]G;FEZ
M960@<W1O8VL@8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4@;V8@87!P<F]X
M:6UA=&5L>2`D,2PW-C`L.3`P+"`D-3@Y+#4P,"!A;F0@)#`@<F5L871E9"!T
M;R!S=&]C:R!O<'1I;VYS+"!R97-P96-T:79E;'DN/"]P/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R
M86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N
M;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P
M.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@
M(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P
M<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X
M.R!W:&ET92US<&%C93H-"B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M
M=VED=&@Z(#!P>#LG/E1H92!W96EG:'1E9"!A=F5R86=E(&9A:7(@=F%L=64@
M;V8@;W!T:6]N<R!G<F%N=&5D(&1U<FEN9R!T:&4@<VEX(&UO;G1H<R!E;F1E
M9"!*=6YE(#,P+"`R,#$T(&%N9"!F;W(@=&AE('EE87)S(&5N9&5D($1E8V5M
M8F5R(#,Q+"`R,#$S(&%N9"`R,#$R('=A<R!A<'!R;WAI;6%T96QY("0P+C<R
M+"`D,"XU."!P97(@<VAA<F4@86YD("0P+C$U('!E<B!S:&%R92!R97-P96-T
M:79E;'DL(&]N('1H92!D871E(&]F(&=R86YT('5S:6YG('1H92!";&%C:RU3
M8VAO;&5S(&]P=&EO;B!P<FEC:6YG(&UO9&5L('=I=&@@=&AE(&9O;&QO=VEN
M9R!A<W-U;7!T:6]N<SH\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ
M(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
M97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D
M+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT
M97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R
M86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N
M;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CPO<#X-
M"CQT86)L92!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!W:61T:#H@,34V-W!X.R!T97AT+71R
M86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[(&)O<F1E<BUC;VQL87!S
M93H@8V]L;&%P<V4[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/@T*/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!P861D:6YG+6)O='1O;3H@
M,2XU<'0[)R!C;VQS<&%N/3-$,CY3:7@@36]N=&@\8G(@+SY%;F1E9"8C,38P
M.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU
M<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T
M;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG
M(&-O;'-P86X],T0V/D9O<B!T:&4@665A<G,@16YD960\8G(@+SY$96-E;6)E
M<B`S,2P\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P
M=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[)SX-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,2XU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@
M8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y
M;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^2G5N92`S,"P@,C`Q-#PO=&0^#0H\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T
M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R
M9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z
M(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X]
M,T0R/C(P,3,\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D
M97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@
M<V]L:60[)R!C;VQS<&%N/3-$,CXR,#$R/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/@T*/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^#0H\=&0^)B,Q
M-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\=&0^
M)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/B8C,38P.SPO=&0^#0H\
M=&0^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/B8C,38P.SPO=&0^
M#0H\=&0^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG
M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q,#`S<'@[)SY#=7)R96YT('!R:6-E
M(&]F(&-O;6UO;B!S=&]C:SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$V
M<'@[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!T
M97AT+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$T,G!X.R!T97AT+6%L:6=N.B!R:6=H=#LG/C(N,#`\+W1D/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
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M/3-$)W=I9'1H.B`Q-7!X.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W
M:61T:#H@,35P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/@T*/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@<FEG:'0[)SXP+C,P
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M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,2XU)2!T;R`Q+C8\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXE/"]T9#X-"CQT9#XF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,2XT
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)3PO=&0^
M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#LG/C`N-CPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/B4\+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^#0H\=&0@
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M:6=N.B!L969T.R<^)3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C`\+W1D/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXE/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M=VAI=&4[)SX-"CQT9#Y6;VQA=&EL:71Y/"]T9#X-"CQT9#XF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[-S8E
M('1O(#<W/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!R:6=H=#LG/C<S)2!T;R`X,#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
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M;&]R.B`C8V-E969F.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/D5X<&5C=&5D('1E<FT@*&EN('EE87)S*3PO=&0^#0H\=&0^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C8N,C4\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[)SXU+C<U('1O(#$P/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*
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M.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M
M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A
M8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[)SX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M
M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N
M;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L
M.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E
M8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[)B,Q-C`[/"]P
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P
M,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H
M:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z
M(#!P>#LG/CQB/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B`F(S@R,3$[('=A
M<G)A;G1S/"]B/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X
M.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M
M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A
M8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F
M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@
M;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA
M;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^26X@8V]N;F5C
M=&EO;B!W:71H('1H92!397)I97,@02!P<F5F97)R960@<W1O8VL@;V9F97)I
M;F=S+"!D=7)I;F<@,C`Q,R!A;F0@,C`Q,BP@=&AE($-O;7!A;GD@:7-S=65D
M('1H92!I;G9E<W1O<G,-"B`Q+#(W-2PQ-38@86YD(#$L,C(T+#@T-2!W87)R
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M:R!E>&5R8VES86)L92!A="`D,"XX,"!P97(@<VAA<F4N(%1H92!W87)R86YT
M<R!H879E(&$@<V5V96XM>65A<B!T97)M+B!4:&5S92!W87)R86YT<R!C;VYT
M86EN(&%N=&DM9&EL=71I;VX@9F5A='5R97,@=VET:"!D;W=N+7)O=6YD('!R
M;W1E8W1I;VXL('1H=7,@=&AE($-O;7!A;GD@86-C;W5N=',@9F]R('1H97-E
M('=A<G)A;G1S(&%S(&1E<FEV871I=F4@;&EA8FEL:71I97,N/"]P/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG
M/CQB/B8C,38P.SPO8CX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ
M(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E
M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A
M8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^
M26X@8V]N;F5C=&EO;B!W:71H('1H92!D96)T(&]F9F5R:6YG<R!I;B`R,#$S
M(&%N9"`R,#$R+"!T:&4@0V]M<&%N>2!I<W-U960@9&5B="!H;VQD97)S(#(Q
M,RPW-3`@86YD(#8W+#4P,"!W87)R86YT<RP@<F5S<&5C=&EV96QY+"!T;R!P
M=7)C:&%S92!C;VUM;VX@<W1O8VL@;V8@=&AE($-O;7!A;GDL(&5X97)C:7-A
M8FQE(&%T("0P+C@P('!E<B!S:&%R92X@1'5R:6YG(#(P,3,@86YD(#(P,3(L
M('1H92!#;VUP86YY(&%L<V\@:7-S=65D('1H92!P;&%C96UE;G0@86=E;G0@
M,3`V+#@W-2!A;F0@,S,L-S4P('=A<G)A;G1S+"!R97-P96-T:79E;'D@=&\@
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M+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@
M=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E
M<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@
M8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN
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M;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD
M96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M
M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@
M+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^1'5R:6YG(#(P,3(L
M('1H92!#;VUP86YY(&ES<W5E9"!I=',@9F]U;F1E<B`X-C@L,C$S('=A<G)A
M;G1S('1O('!U<F-H87-E(&-O;6UO;B!S=&]C:R!I;B!C;VYN96-T:6]N('=I
M=&@@82!T<F%N<V%C=&EO;B!T:&%T(&5X8VAA;F=E9"!D96)T(&9O<B!S=&]C
M:RX@5&AE<V4@=V%R<F%N=',@=V5R92!C86YC96QL960@8GD@=&AE($-O;7!A
M;GD@:6X@2F%N=6%R>2`R,#$T+"!S964@3F]T92`X+CPO<#X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT
M<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C
M:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@
M;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V
M,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z
M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@
M,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P
M>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW
M:61T:#H@,'!X.R<^26X@,C`Q,RP@=&AE($-O;7!A;GD@<'5R8VAA<V5D($UE
M9&5O<B!);F,N(&%N9"!I;B!C;VYN96-T:6]N('=I=&@@=&AE('!U<F-H87-E
M('1H92!#;VUP86YY(&ES<W5E9"!T:&4@4&QA8V5M96YT($%G96YT(#(P,"PP
M,#`@=V%R<F%N=',@=&\@<'5R8VAA<V4@8V]M;6]N('-T;V-K(&]F('1H92!#
M;VUP86YY+B!4:&4@=V%R<F%N=',@:&%V92!A('-E=F5N+7EE87(@=&5R;2!A
M;F0@=V5R92!F=6QL>2!V97-T960@=7!O;B!I<W-U86YC92!A;F0@:&%V92!A
M;B!E>&5R8VES92!P<FEC92!O9B`D,2XQ,"!P97(@<VAA<F4N(%1H92!#;VUP
M86YY(')E8V]R9&5D('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!O9B`D,C,W
M+#0P,"!I;B!C;VYN96-T:6]N('=I=&@@=&AE(&ES<W5A;F-E(&]F('1H97-E
M('=A<G)A;G1S+CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X
M.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M
M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A
M8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V,#L\+W`^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F
M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@
M;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA
M;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/"]P/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG
M/DEN(&-O;FIU;F-T:6]N('=I=&@@82!S=')A=&5G:6,@861V:7-O<B!A9W)E
M96UE;G0L(&1U<FEN9R`R,#$S(&%N9"`R,#$R+"!T:&4@0V]M<&%N>2!I<W-U
M960@=V%R<F%N=',@=&\@<'5R8VAA<V4@<VAA<F5S(&]F(&-O;6UO;B!S=&]C
M:RP@870@86X@97AE<F-I<V4@<')I8V4@;V8@)#`N,#`Q('!E<B!S:&%R92!T
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M>"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q-"P@=&AE('!E<F9O<FUA;F-E
M(&%C:&EE=F5M96YT('=A<R!M970N(%1H92!#;VUP86YY(')E8V]R9&5D('1H
M92!F86ER('9A;'5E(&]F('-T;V-K(&)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E
M;G-E(&]F(&%P<')O>&EM871E;'D@)#$P+#$Q.2PP,#`@8F%S960@=7!O;B!T
M:&4@0FQA8VLM4V-H;VQE<R!O<'1I;VX@<')I8VEN9R!M;V1E;"!F;W(@=&AE
M(#@L-C4U+#<X,R!V97-T960@;W!T:6]N<RX\+W`^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F
M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@
M;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA
M;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/"]P/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG
M/B8C,38P.SPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C
M;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD
M96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[)SX\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G
M:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W
M;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI
M="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^1'5R:6YG('1H92!S:7@@;6]N
M=&AS(&5N9&5D($IU;F4@,S`L(#(P,30@86YD(&9O<B!T:&4@>65A<G,@96YD
M960@1&5C96UB97(@,S$L(#(P,3,@86YD(#(P,3(L('1H92!#;VUP86YY(&ES
M<W5E9"!T;R!C;VYS=6QT86YT<R`Q,BPU,#`L(#(Q+#4P,"!A;F0@-#`L,#`P
M('=A<G)A;G1S+"!R97-P96-T:79E;'DL('1O('!U<F-H87-E('-H87)E<R!O
M9B!C;VUM;VX@<W1O8VL@;V8@=&AE($-O;7!A;GDN(%1H92!E>&5R8VES92!P
M<FEC92!O9B!T:&4@=V%R<F%N=',@:7-S=65D(&1U<FEN9R!T:&4@>65A<G,@
M96YD960@1&5C96UB97(@,S$L(#(P,3,@86YD(#(P,3(@=V5R92!A;&P@870@
M)#`N.#`@<&5R('-H87)E+B!4:&4@9W)A;G0@9&%T92!F86ER('9A;'5E(&]F
M('1H92!W87)R86YT<R!I<W-U960@9F]R('1H92!S:7@@;6]N=&AS(&5N9&5D
M($IU;F4@,S`L(#(P,30@86YD(&9O<B!T:&4@>65A<G,@96YD960@1&5C96UB
M97(L(#,Q+"`R,#$S(&%N9"`R,#$R('=A<R!A<'!R;WAI;6%T96QY("0Q-"PS
M,#`L("0Q,"PX,#`@86YD("0U+#8P,"P@<F5S<&5C=&EV96QY+"!A;F0@=&AE
M(&9A:7(@=F%L=64@=V%S(&%M;W)T:7IE9"!O=F5R('1H92!T97)M(&]F('1H
M92!A9W)E96UE;G1S+CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@
M,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E
M>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M
M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.PT*("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CPO<#X-"CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V,#LF(S$V
M,#L\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z
M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@
M,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P
M>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW
M:61T:#H@,'!X.R<^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
M<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X
M="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US
M<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#LG/D$@<W5M;6%R>2!O9B!T:&4@8VAA;F=E
M<R!I;B!O=71S=&%N9&EN9R!W87)R86YT<R!D=7)I;F<@=&AE('-I>"!M;VYT
M:',@96YD960@2G5N92`S,"P@,C`Q-"!A;F0@9F]R('1H92!Y96%R<R!E;F1E
M9"!$96-E;6)E<B`S,2P@,C`Q,R!A;F0@,C`Q,B!I<R!A<R!F;VQL;W=S.CPO
M<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P
M,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[
M(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W
M:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[)SXF(S$V,#L\+W`^#0H\=&%B;&4@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=VED
M=&@Z(#$U-C=P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@
M,'!X.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT+7-I>F4M861J
M=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@+7=E8FMI="UT97AT
M+7-T<F]K92UW:61T:#H@,'!X.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,#X-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R<^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O
M<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE
M.B!S;VQI9#LG(&-O;'-P86X],T0R/DYU;6)E<B!O9CQB<B`O/E-H87)E<SPO
M=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[
M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM
M=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O
M;'-P86X],T0R/E=E:6=H=&5D/&)R("\^079E<F%G93QB<B`O/D5X97)C:7-E
M/&)R("\^4')I8V4\8G(@+SY097(@4VAA<F4\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-C8V5E9F8[)SX-"CQT9"!S='EL93TS1"=W:61T:#H@,3$Y
M,7!X.R<^3W5T<W1A;F1I;F<@870@1&5C96UB97(@,S$L(#(P,3$\+W1D/@T*
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
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M9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$T,7!X.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$N,#`\
M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX-
M"CQT9#Y'<F%N=&5D/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^-2PT-S@L,S8P/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF
M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXD
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C`N-3`\
M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/@T*/"]T<CX-"CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^17AE<F-I<V5D/"]T9#X-"CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D
M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O<F1E<BUB;W1T
M;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@
M8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M+6-O
M;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E
M<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^*#8Q.2PS-S<\+W1D/@T*/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P
M=#LG/BD\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P
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M(#$N-7!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[
M)SX-"CQT9#Y/=71S=&%N9&EN9R!A="!$96-E;6)E<B`S,2P@,C`Q,CPO=&0^
M#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#LG/C0L.#8U+#(S-#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
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M86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O
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M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C
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M.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX-"CQT
M9#Y/=71S=&%N9&EN9R!A="!$96-E;6)E<B`S,2P@,C`Q,SPO=&0^#0H\=&0^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG
M/C@L.3(V+#4Q-SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^#0H\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[)SXP+C4T/"]T9#X-"CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M(V-C965F9CLG/@T*/'1D/D=R86YT960\+W1D/@T*/'1D/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXS-2PP.#8L,C4S
M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
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M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[)SY&;W)F96ET960@
M*#$I/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R<^
M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B
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M.B`T<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T
M=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG
M/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B;W)D
M97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@
M-'!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[)SXP+C@P/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O
M;3H@-'!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F
M9CLG/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`T<'0[)SY/=71S=&%N9&EN9R!A;F0@=F5S=&5D(&%T($IU;F4@
M,S`L(#(P,30\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T
M<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M
M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/B8C
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M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L
M93LG/C$N,C4\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`T<'0[)SX\+W1D/@T*/"]T<CX-"CPO=&%B;&4^
M#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P
M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L
M971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI
M=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@
M,'!X.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
M<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X
M="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US
M<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#LG/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ
M(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M
M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SY&;W(@=&AE('-I>"!M
M;VYT:',@96YD960@2G5N92`S,"P@,C`Q-"!A;F0@9F]R('1H92!Y96%R<R!E
M;F1I;F<@1&5C96UB97(@,S$L(#(P,3,@86YD(#(P,3(L('1H92!#;VUP86YY
M(')E8V]R9&5D(&%P<')O>&EM871E;'D@)#`L("0Q+#@P,"!A;F0@)#(L,C`P
M+"!R97-P96-T:79E;'DL(&]F('-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E
M>'!E;G-E(')E;&%T960@=&\@=V%R<F%N=',@=&\@<F5S96%R8V@@86YD(&1E
M=F5L;W!M96YT(&5X<&5N<V4N($9O<B!T:&4@<VEX(&UO;G1H<R!E;F1E9"!*
M=6YE(#,P+"`R,#$T(&%N9"!F;W(@=&AE('EE87)S(&5N9&EN9R!$96-E;6)E
M<B`S,2P@,C`Q,R!A;F0@,C`Q,BP@=&AE($-O;7!A;GD@<F5C;W)D960@=&\@
M9V5N97)A;"!A;F0@861M:6YI<W1R871I=F4@97AP96YS92!A<'!R;WAI;6%T
M96QY("0Q,BPQ,C0L-3`P+"`D,C0V+#$P,"!A;F0@)#`@;V8@<W1O8VLM8F%S
M960@8V]M<&5N<V%T:6]N(&5X<&5N<V4@<F5L871E9"!T;R!W87)R86YT<R!F
M;W(@=&AE('-I>"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q-"!A;F0@9F]R
M('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,R!A;F0@,C`Q,BP@
M<F5S<&5C=&EV96QY+B!!="!*=6YE(#,P+"`R,#$T(&%N9"!$96-E;6)E<B`S
M,2P@,C`Q,R!A;F0@,C`Q,BP@=&AE($-O;7!A;GD@:&%S('5N<F5C;V=N:7IE
M9"!S=&]C:R!B87-E9"!C;VUP96YS871I;VX@97AP96YS92!O9B!A<'!R;WAI
M;6%T96QY("0V+#4P,"P@)#,L-C`P(&%N9"`D,RPT,#`L(')E<W!E8W1I=F5L
M>2!R96QA=&5D('1O(&]U='-T86YD:6YG('=A<G)A;G1S+CPO<#X-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS
M<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C
M93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\
M+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P
M,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T
M:#H@,'!X.R<^)B,Q-C`[/"]P/@T*/'1A8FQE('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('=I
M9'1H.B`Q-38W<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N
M=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z
M(#!P>#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N="US:7IE+6%D
M:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`^#0H\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ('1O<#LG
M/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`V,W!X.R<^*#$I/"]T9#X-"CQT9"!S
M='EL93TS1"=W:61T:#H@,34P-'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^
M#0H\<"!S='EL93TS1"=M87)G:6XZ(#!P>#LG/E1H92!W87)R86YT<R!I<W-U
M960@=&\@37(N($)A8G5L('=E<F4@8V%N8V5L;&5D(&]N($IA;G5A<GD@,CDL
M(#(P,30L('-E92!.;W1E(#@N/"]P/@T*/"]T9#X-"CPO='(^#0H\+W1A8FQE
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N
M93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO<#X-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!L969T.R!C
M;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD
M96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[)SY4:&4@=V5I9VAT960@879E<F%G92!F86ER('9A
M;'5E(&]F('=A<G)A;G1S(&=R86YT960@9'5R:6YG('1H92!S:7@@;6]N=&AS
M(&5N9&5D($IU;F4@,S`L(#(P,30@86YD(&9O<B!T:&4@>65A<G,@96YD960@
M1&5C96UB97(@,S$L(#(P,3,@86YD(#(P,3(@=V%S("0Q+C0P+"`D,"XX,"!A
M;F0@)#`N,30@<&5R('-H87)E+"!R97-P96-T:79E;'DL(&]N('1H92!D871E
M(&]F(&=R86YT+"!U<VEN9R!T:&4@0FQA8VLM4V-H;VQE<R!O<'1I;VX@<')I
M8VEN9R!M;V1E;"!U<VEN9R!T:&4@9F]L;&]W:6YG(&%S<W5M<'1I;VYS.CPO
M<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO
M;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[
M('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V,#L\+W`^#0H\=&%B
M;&4@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@=VED=&@Z(#$U-C=P>#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N
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M9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T
M.R<@8V]L<W!A;CTS1#(^#0H\<"!S='EL93TS1"=M87)G:6XM=&]P.B`P<'@[
M(&UA<F=I;BUB;W1T;VTZ(#!P>#LG/E-I>"!-;VYT:"8C,38P.SQB<B`O/D5N
M9&5D+#PO<#X-"CQP('-T>6QE/3-$)VUA<F=I;BUT;W`Z(#!P>#L@;6%R9VEN
M+6)O='1O;3H@,'!X.R<^2G5N92`S,"P\+W`^#0H\+W1D/@T*/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^#0H\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X-
M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T
M;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@
M8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$-CY996%R
M($5N9&5D($1E8V5M8F5R(#,Q+#PO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/@T*/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CLG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTM8V]L
M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R
M+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CXR,#$T/"]T9#X-
M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\
M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C
M,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B
M;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T
M:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A
M;CTS1#(^,C`Q,SPO=&0^#0H\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#$N-7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O
M<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE
M.B!S;VQI9#LG(&-O;'-P86X],T0R/C(P,3(\+W1D/@T*/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^#0H\+W1R/@T*
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U
M;F0M8V]L;W(Z("-C8V5E9F8[)SX-"CQT9"!S='EL93TS1"=W:61T:#H@,3`P
M,W!X.R<^0W5R<F5N="!P<FEC92!O9B!C;VUM;VX@<W1O8VL\+W1D/@T*/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/@T*
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#)P>#L@=&5X="UA;&EG;CH@<FEG:'0[
M)SXR+C`P/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$V<'@[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X
M.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=W:61T:#H@,30Q<'@[('1E>'0M86QI9VXZ(')I9VAT.R<^)#`N.#`@+2`D
M,2XU,#PO=&0^#0H\=&0@<W1Y;&4],T0G=VED=&@Z(#$U<'@[('1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M-7!X.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@
M=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q-#%P>#L@=&5X="UA;&EG;CH@<FEG:'0[)SXP+C,P/"]T9#X-"CQT9"!S
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M9VXZ(')I9VAT.R<^,"XW)2!T;R`R+C`\+W1D/@T*/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXE/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,"XY)2!T;R`Q+C@\+W1D
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M.B!L969T.R<^)3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#LG/C`\+W1D/@T*/'1D('-T>6QE/3-$)W1E
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M=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#LG/C<S)2!T;R8C,38P.S@S/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C@R)2!T;R`X,SPO=&0^#0H\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B4\+W1D/@T*/"]T<CX-"CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B`C8V-E969F.R<^#0H\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/D5X<&5C=&5D('1E<FT@*&EN('EE87)S*3PO=&0^#0H\=&0^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C0@
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M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^
M#0H\+W1A8FQE/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS
M9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z
M(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M
M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQB/B8C,38P
M.SPO8CX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%\V,S,T-64Y9E]B-C1B7S0W,V)?.&)B,%\U-S1F-C%A,#EB,F4-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C,S-#5E.69?8C8T8E\T-S-B
M7SAB8C!?-3<T9C8Q83`Y8C)E+U=O<FMS:&5E=',O4VAE970Q,BYH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E)E;&%T960@4&%R
M='D@5')A;G-A8W1I;VYS/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^4F5L871E9"!087)T>2!4<F%N<V%C=&EO;G,@
M6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4D5,051%1"!005)462!44D%.4T%#5$E/3E,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G
M:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[
M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T
M97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M
M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X
M.R<^/&(^3D]412`V("8C.#(Q,3L@4D5,051%1"!005)462!44D%.4T%#5$E/
M3E,\+V(^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO
M<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[)SX\8CXF(S$V,#L\+V(^/"]P/CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\8CY0;&%C96UE
M;G0@06=E;G0\+V(^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X
M.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M
M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A
M8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V,#L\+W`^/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R
M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO
M<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[
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M86EN(&]N($9E8G)U87)Y(#(U+"`R,#$S+B!0=7)S=6%N="!T;R!T:&4@86=R
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M92`B3F]T97,@0V]N=F5R<VEO;B(I+B!);B!C;VYS:61E<F%T:6]N(&9O<B!I
M=',@<V5R=FEC97,L('1H92!P;&%C96UE;G0@86=E;G0@<F5C96EV960Z("AA
M*2!R92UA8W1I=F%T:6]N(&9E92!O9B`D,34L,#`P+"`H8BD@82!C87-H(&9E
M92!E<75A;"!T;R`W)2!O9B!T:&4@3F]T97,@0V]N=F5R<VEO;B!A;F0@,3`E
M(&]F('1H92!G<F]S<R!P<F]C965D<R!R86ES960@:6X@=&AE($9I;F%N8VEN
M9W,L(&%N9"`H8RD@;F]N+6%C8V]U;G1A8FQE(&5X<&5N<V4@<F5I;6)U<G-E
M;65N="!E<75A;"!T;R`R)2!O9B!T:&4@9W)O<W,@<')O8V5E9',@<F%I<V5D
M+B!4:&4@<&QA8V5M96YT(&%G96YT(&]R(&ET<R!D97-I9VYE97,@86QS;R!R
M96-E:79E9"!W87)R86YT<R!T;R!P=7)C:&%S92!S:&%R97,@;V8@=&AE($-O
M;7!A;GDF(S@R,3<[<R!C;VUM;VX@<W1O8VL@:6X@86X@86UO=6YT(&5Q=6%L
M('1O(#$P)2!O9B!T:&4@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!A;F0@=V%R
M<F%N=',@:7-S=65D(&]R(&ES<W5A8FQE(&%S('!A<G0@;V8@=&AE('5N:71S
M('-O;&0@:6X@=&AE(%-E<FEE<R!!(%!R969E<G)E9"!3=&]C:R!/9F9E<FEN
M9R!A;F0@3F]T97,@3V9F97)I;F=S+B!4:&4@86=R965M96YT(&%L<V\@<')O
M=FED97,@=&AA=#H@*&DI(&EF('1H92!#;VUP86YY(&-O;G-U;6UA=&5S(&%N
M>2!M97)G97(L(&%C<75I<VET:6]N+"!B=7-I;F5S<R!C;VUB:6YA=&EO;B!O
M<B!O=&AE<B!T<F%N<V%C=&EO;B`H;W1H97(@=&AA;B!A(%-H87)E($5X8VAA
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M('!E<FEO9"!O9B`Q,B!M;VYT:',@869T97(@=&5R;6EN871I;VX@;V8@=&AE
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M('1H92!&96)R=6%R>2`R-2P@,C`Q,R!E;F=A9V5M96YT(&%G<F5E;65N="X@
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M<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N
M<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R
M;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V,#L\
M+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P
M,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H
M:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z
M(#!P>#LG/D1U92!T;R!T:&4@4VAA<F4@17AC:&%N9V4L('1H92!A;G1I+61I
M;'5T:6]N(&9E871U<F4@9F]R('1H92!W87)R86YT<R!T:&%T('=E<F4@:7-S
M=65D(&9O<B!T:&4@4V5R:65S($$@4')E9F5R<F5D(%-T;V-K(&%N9"!.;W1E
M<R!/9F9E<FEN9R!W97)E('1E<FUI;F%T960L('-E92!.;W1E(#0N(%1H97)E
M('=E<F4@4V5R:65S($$@=V%R<F%N=',L(%-E<FEE<R!"('=A<G)A;G1S(&%N
M9"!0;&%C96UE;G0@06=E;G0@=V%R<F%N=',L('-E92!.;W1E(#4L(&-O;6UO
M;B!S=&]C:RX@5&AE<V4@=V%R<F%N=',@8V]N=&%I;B!A;B!A;G1I+61I;'5T
M:6]N(&9E871U<F4@86YD('-H86QL('1E<FUI;F%T92!U<&]N(&%N('5P+6QI
M<W1I;F<@=&\@82!N871I;VYA;"!S=&]C:R!E>&-H86YG92P@<V5E($YO=&4@
M-"X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C
M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P
M>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[
M('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED
M=&@Z(#!P>#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ
M(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
M97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D
M+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT
M97AT+7-T<F]K92UW:61T:#H@,'!X.R<^3VX@3V-T;V)E<B`R-"P@,C`Q,RP@
M=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&%N(&5N9V%G96UE;G0@86=R965M
M96YT('=H:6-H('=A<R!A;65N9&5D($1E8V5M8F5R(#$Y+"`R,#$S('=I=&@@
M:71S(%!L86-E;65N="!!9V5N="!T;R!A9'9I<V4@;VX@=&AE(&%C<75I<VET
M:6]N(&]F($UE9&5O<B!);F,N($EN(&-O;G-I9&5R871I;VX@9F]R(&ET<R!S
M97)V:6-E<RP@=&AE(%!L86-E;65N="!!9V5N="!W87,@96QI9VEB;&4@=&\@
M<F5C96EV93H@*&$I(&$@8V%S:"!S=6-C97-S(&9E92!E<75A;"!T;R`X)2!O
M9B!T:&4@=F%L=64@;V8@=&AE('1R86YS86-T:6]N('!L=7,@82`R)2!N;VXM
M<F5I;6)U<G-A8FQE(&5X<&5N<V4@9F5E('=H:6-H('=A<R!S=6)S97%U96YT
M;'D@;6]D:69I960@=&\@82!M87AI;75M(&]F("0Q-3`L,#`P('!L=7,L("AB
M*2`D-3`L,#`P(&9O<B!A($9A:7)N97-S($]P:6YI;VX@9F5E(&1E9'5C=&EB
M;&4@86=A:6YS="!T:&4@<W5C8V5S<R!F964L(&%N9"`H8RD@82`D-3`L,#`P
M(&%C=&EV871I;VX@9F5E+B!4:&4@86=R965M96YT(&%L<V\@<')O=FED97,@
M=&AA=#H@*&DI(&EF('1H92!#;VUP86YY(&-O;G-U;6UA=&5S(&%N>2!M97)G
M97(L(&%C<75I<VET:6]N+"!B=7-I;F5S<R!C;VUB:6YA=&EO;B!O<B!O=&AE
M<B!T<F%N<V%C=&EO;B`H;W1H97(@=&AA;B!T:&4@4VAA<F4@17AC:&%N9V4I
M('=I=&@@86YY('!A<G1Y(&EN=')O9'5C960@=&\@:70@8GD@=&AE(%!L86-E
M;65N="!!9V5N="P@=&AE('!L86-E;65N="!A9V5N="!W;W5L9"!R96-E:79E
M(&$@9F5E(&5Q=6%L('1O(#@E(&]F('1H92!A9V=R96=A=&4@8V]N<VED97)A
M=&EO;B!I;B!S=6-H('1R86YS86-T:6]N<RP@86YD("AI:2D@:68L('=I=&AI
M;B!A('!E<FEO9"!O9B`Q,B!M;VYT:',@869T97(@=&5R;6EN871I;VX@;V8@
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M+CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P
M,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T
M:#H@,'!X.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@
M,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E
M>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M
M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E
M>'0M<W1R;VME+7=I9'1H.B`P<'@[)SY/;B!&96)R=6%R>2`Q."P@,C`Q-"!A
M;F0@36%Y(#$Y+"`R,#$T+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@='=O
M(&5N9V%G96UE;G0@86=R965M96YT<R!W:71H('1H92!0;&%C96UE;G0@06=E
M;G0@9F]R('1H92!-87D@,C`Q-"!O9F9E<FEN9R!4:&4@0V]M<&%N>2!A9W)E
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M<&5R8V5N=#L@86YD("AB*2`H,B4I(&]F('1H92!G<F]S<R!P<F]C965D<R!O
M9B!T:&4@3V9F97)I;F<@<F5C96EV960@9G)O;2!I;G9E<W1O<G,@870@82!#
M;&]S:6YG(&%N9"!A;B!A8W1I=F%T:6]N(&9E92!O9B`D,C4L,#`P+B!4:&4@
M4&QA8V5M96YT($%G96YT(&]R(&ET<R!D97-I9VYE97,@86QS;R!R96-E:79E
M9"!F:79E+7EE87(@=V%R<F%N=',@=&\@<'5R8VAA<V4@-"PR.3`L.34P('-H
M87)E<R!O9B!296QM861A)B,X,C$W.W,@8V]M;6]N('-T;V-K(&%T(&$@<')I
M8V4@;V8@)#$N-3`@<&5R('-H87)E+B!4:&4@4&QA8V5M96YT($%G96YT('-H
M86QL(&%L<V\@8F4@96YT:71L960@=&\@=&AE(&-O;7!E;G-A=&EO;B!S970@
M9F]R=&@@86)O=F4@87,@=V5L;"!F;W(@86YY(&-A<V@@97AE<F-I<V4@;V8@
M5V%R<F%N=',@=VET:&EN('-I>"`H-BD@;6]N=&AS(&]F('1H92!F:6YA;"!C
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M=&4@;V8@)#(U+#`P,"!P97(@;6]N=&@@9F]R(&$@<&5R:6]D(&]F('-I>"!M
M;VYT:',@8V]M;65N8VEN9R!A9G1E<B!T:&4@36%Y(&]F9F5R:6YG<RX\+W`^
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P
M.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E
M+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
M>#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@
M8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN
M9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I
M;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T
M<F]K92UW:61T:#H@,'!X.R<^5&AE(%!L86-E;65N="!!9V5N="!A;'-O(')E
M8V5I=F5D(&-A<V@@<')O8V5E9',@9G)O;2!T:&4@0V]M<&%N>2!O9B!A<'!R
M;WAI;6%T96QY("0S+#`X.2PU,#`L("0U-30L-S`P(&%N9"`D-#<P+#,P,"P@
M9F]R('1H92!S:7@@;6]N=&AS(&5N9&5D($IU;F4@,S`L(#(P,30@86YD(&9O
M<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,R!A;F0@,C`Q,BP@
M<F5S<&5C=&EV96QY+"!F<F]M('1H92!E<75I='D@;V9F97)I;F=S(&EN($UA
M>2!A;F0@2G5N92`R,#$T(&%N9"!F<F]M('1H92!397)I97,@02!P<F5F97)R
M960@<W1O8VL@;V9F97)I;F=S+B!4:&4@4&QA8V5M96YT($%G96YT(')E8V5I
M=F5D(&-A<V@@<')O8V5E9',@9G)O;2!T:&4@0V]M<&%N>2!O9B`D-C@L-#`P
M(&%N9"`D,C4L,3`P+"!R97-P96-T:79E;'DL(&9O<B!T:&4@<W5B;W)D:6YA
M=&5D('!R;VUI<W-O<GD@;F]T97,@:7-S=65D(&1U<FEN9R`R,#$S(&%N9"`R
M,#$R+B!4:&4@4&QA8V5M96YT($%G96YT(&%L<V\@<F5C96EV960@82!S=')A
M=&5G:6,@861V:7-O<GD@9F5E(&]F(&%P<')O>&EM871E;'D@)#(W,BPP,#`@
M9F]R(')E<W1R=6-T=7)I;F<@=&AE($-O;7!A;GD@:6X@,C`Q,BX\+W`^/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG
M/B8C,38P.SPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L
M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N
M=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z
M(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K
M92UW:61T:#H@,'!X.R<^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L(&-A;&EB<FDL(&AE;'9E=&EC82P@<V%N<RUS97)I9CL@;6%R9VEN.B`P
M<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X
M="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US
M<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SY4
M:&4@4&QA8V5M96YT($%G96YT(')E8V5I=F5D('1H92!F;VQL;W=I;F<@=V%R
M<F%N=',@9'5R:6YG('1H92!Y96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$R
M.CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@8V%L
M:6)R:2P@:&5L=F5T:6-A+"!S86YS+7-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L
M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N
M=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z
M(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K
M92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M9F]N=#X\+W`^/'1A8FQE('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H.B`Q,#,Y+C,S
M<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L
M971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@8F]R
M9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N="US:7IE+6%D:G5S=#H@;F]N
M93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M
M=VED=&@Z(#!P>#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N
M-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O
M;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@
M8V]L<W!A;CTS1#(^3G5M8F5R(&]F('=A<G)A;G1S/"]T9#X\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M+6-O
M;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E
M<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^17AE<F-I<V4@
M<')I8V4@<&5R('-H87)E/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R
M9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z
M('-O;&ED.R<@8V]L<W!A;CTS1#(^17AP:7)A=&EO;CPO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/"]T<CX\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[
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M-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F
M.R<^/'1D('-T>6QE/3-$)W=I9'1H.B`V-C4N,S-P>#L@=&5X="UA;&EG;CH@
M;&5F=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R<^4V5R:65S($$@<')E9F5R<F5D(&]F9F5R:6YG/"]T9#X\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$P+C8V<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW
M96EG:'0Z(&YO<FUA;#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q,"XV-G!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=W:61T:#H@.31P>#L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<W1Y
M;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/C8Q,BPT,C(\+W1D
M/CQT9"!S='EL93TS1"=W:61T:#H@,3`N-C9P>#L@=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$P+C8V<'@[(&9O;G0M
M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,"XV-G!X.R!T97AT+6%L:6=N.B!L
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M:'0Z(&YO<FUA;#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3!P>#L@=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#DS+C,S
M<'@[('1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+7=E:6=H=#H@;F]R;6%L.R<^,C`Q.3PO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q,'!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SXF(S$V,#L\+W1D/CPO='(^/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z('=H:71E.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+7=E:6=H=#H@;F]R;6%L.R<^4W5B;W)D:6YA=&5D('!R;VUI<W-O<GD@
M;F]T92!O9F9E<FEN9SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q+C5P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!B
M;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T
M:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<W1Y
M;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@8F]R9&5R+6)O='1O
M;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B
M;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG/C,S+#<U,#PO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P
M=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T
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M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/C`N.#`\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,2XU
M<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P
M=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D
M9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^,C`Q.3PO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`Q+C5P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B
M;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,BXU<'0[(&)O<F1E<BUB;W1T
M;VTM<W1Y;&4Z(&1O=6)L93LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D
M97(M8F]T=&]M+7=I9'1H.B`R+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@
M9&]U8FQE.R<^-C0V+#$W,CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="US='EL93H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
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M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\
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M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N
M="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[
M/"]T9#X\+W1R/CPO=&%B;&4^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@8V%L:6)R:2P@:&5L=F5T:6-A+"!S86YS+7-E<FEF.R!M87)G:6XZ(#!P
M>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT
M+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P
M86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT
M+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C
M,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[
M(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI
M;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C
M:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#LG/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"!C86QI8G)I+"!H96QV971I8V$L('-A;G,M<V5R:68[(&UA<F=I
M;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[
M('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O
M<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^5&AE(%!L86-E;65N="!!9V5N="!R96-E:79E9"!T:&4@9F]L;&]W:6YG
M('=A<G)A;G1S(&1U<FEN9R!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@
M,C`Q,SH\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M(&-A;&EB<FDL(&AE;'9E=&EC82P@<V%N<RUS97)I9CL@;6%R9VEN.B`P<'@[
M(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI
M;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C
M:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V
M,#L\+V9O;G0^/"]P/CQT86)L92!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!W:61T:#H@,3`S
M.2XS,W!X.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P
M>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[
M(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O;G0M<VEZ92UA9&IU<W0Z
M(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@
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M86YT<SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F
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M;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN
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M:6=H=#H@;F]R;6%L.R<@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=V5I9VAT.B!N;W)M86P[)R!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N
M;W)M86P[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L
M+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\
M=&0@<W1Y;&4],T0G=VED=&@Z(#8V-2XS,W!X.R!T97AT+6%L:6=N.B!L969T
M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SY3
M97)I97,@02!P<F5F97)R960@;V9F97)I;F<\+W1D/CQT9"!S='EL93TS1"=W
M:61T:#H@,3`N-C9P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$P
M+C8V<'@[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UW96EG:'0Z(&YO<FUA;#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W=I9'1H.B`Y-'!X.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^-C,W+#4W.#PO=&0^/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q,"XV-G!X.R!T97AT+6%L:6=N.B!L969T.R!F
M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3`N-C9P>#L@9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$P+C8V<'@[('1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/B0\
M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@.3,N,S-P>#L@=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#LG/C`N.#`\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3!P>#L@=&5X="UA
M;&EG;CH@;&5F=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$P<'@[
M(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,'!X.R!T97AT+6%L:6=N
M.B!L969T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@.3,N,S-P>#L@
M=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[)SXR,#(P/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$P<'@[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UW96EG:'0Z(&YO<FUA;#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ#0H@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!W:&ET93LG/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F
M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SY3=6)O
M<F1I;F%T960@<')O;6ES<V]R>2!N;W1E(&]F9F5R:6YG/"]T9#X\=&0@<W1Y
M;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
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M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/C`N.#`\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/C(P,C`\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T>6QE
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SXF(S$V,#L\+W1D/CPO
M='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#$N-7!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT
M.B!N;W)M86P[)SY!8W%U:7-I=&EO;B!O9B!-961E;W(\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA
M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[
M(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T
M>6QE.B!S;VQI9#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N
M;W)M86P[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T
M=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[
M)SXR,#`L,#`P/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=V5I9VAT.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)#PO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!P861D:6YG+6)O='1O;3H@
M,2XU<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#LG/C$N,3`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P
M861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT+7-T
M>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([('!A9&1I;F<M8F]T
M=&]M.B`Q+C5P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R<^,C`R,#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!W:&ET93LG/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU
M<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
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M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`R+C5P=#L@8F]R9&5R
M+6)O='1O;2US='EL93H@9&]U8FQE.R<^.30T+#0U,SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R!F
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M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N
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M;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M<W1Y
M;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<W1Y;&4Z(&YO
M<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T>6QE
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M<W1Y;&4Z(&YO
M<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UW96EG:'0Z(&YO<FUA;#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@=VAI=&4[)SX\=&0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+7=E:6=H=#H@;F]R;6%L.R<@8V]L<W!A;CTS1#$R/CQP('-T>6QE/3-$
M)VUA<F=I;BUT;W`Z(#!P>#L@;6%R9VEN+6)O='1O;3H@,'!X.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CLG/E1H92!0;&%C96UE;G0@06=E;G0@<F5C96EV960@
M=&AE(&9O;&QO=VEN9R!W87)R86YT<R!D=7)I;F<@=&AE('-I>"!M;VYT:',@
M96YD960@2G5N92`S,"P@,C`Q-#H\+V9O;G0^/"]P/CPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M=VAI=&4[)SX\=&0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N
M="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\
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M.B`Q+C5P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
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M86X],T0R/D5X97)C:7-E/&)R("\^<')I8V4@<&5R)B,Q-C`[/&)R("\^<VAA
M<F4\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG
M+6)O='1O;3H@,2XU<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q+C5P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N
M;W)M86P[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T
M=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[
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M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
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M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
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M=&@Z(#)P=#L@8F]R9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<W1Y
M;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@8F]R9&5R+6)O='1O
M;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#)P=#L@8F]R
M9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R<^-"PR.3`L.34P/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N
M-7!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU
M<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/B0\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^,2XU,#PO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P
M=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
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M=#H@;F]R;6%L.R<^,C`Q.3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#L@9F]N="US='EL93H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\+W1R/CPO
M=&%B;&4^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@8V%L:6)R:2P@
M:&5L=F5T:6-A+"!S86YS+7-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P
M,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T
M:#H@,'!X.R<^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C
M;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD
M96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[)SX\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N
M;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN
M.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@
M=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R
M9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.R8C,38P.SPO<#X\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E
M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A
M8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^
M/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P
M,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[
M(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W
M:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[)SX\8CY!9'9I<V]R>2!&:7)M/"]B/CPO<#X\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F
M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@
M;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA
M;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&(^)B,Q-C`[
M/"]B/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z
M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@
M,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P
M>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW
M:61T:#H@,'!X.R<^3VX@1&5C96UB97(@-BP@,C`Q,2P@=&AE($-O;7!A;GD@
M96YT97)E9"!I;G1O(&%N(&%D=FES;W)Y(&%G<F5E;65N="!W:71H($IA;65S
M<R!#87!I=&%L($=R;W5P+"!,3$,@*&9O<FUE<FQY(&MN;W=N(&%S($%M97)A
M<VEA($-A<&ET86P@1W)O=7`L($Q,0RDL(&$@8V]N<W5L=&EN9R!F:7)M(&%F
M9FEL:6%T960@=VET:"!-<BX@4V5T:"P@82!$:7)E8W1O<B!O9B!T:&4@0V]M
M<&%N>2`H)B,X,C(P.T%D=FES;W)Y($9I<FTF(S@R,C$[*2!T;R!P<F]V:61E
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M:6-E(&]F("0P+C`P,2!P97(@<VAA<F4I+"!S964@3F]T92`U+B!4:&4@061V
M:7-O<GD@1FER;2!I<R!A;'-O(&5L:6=I8FQE('1O(&)E(')E:6UB=7)S960@
M=7!O;B!T:&4@<W5B;6ES<VEO;B!O9B!P<F]P97(@9&]C=6UE;G1A=&EO;B!F
M;W(@;W)D:6YA<GD@86YD(&YE8V5S<V%R>2!O=70M;V8M<&]C:V5T(&5X<&5N
M<V5S(&YO="!T;R!E>&-E960@)#4L,#`P('!E<B!M;VYT:"X\+W`^/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E
M.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CPO
M<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P
M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L
M971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI
M=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@
M,'!X.R<^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO
M<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[)SXF(S$V,#L\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R
M9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N
M93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CPO<#X\<`T*('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N
M<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R
M;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\8CY!8W%U
M:7-I=&EO;B!O9B!-961E;W(\+V(^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA
M<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO
M;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[
M('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\8CXF(S$V,#L\+V(^/"]P
M/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P
M,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[)SX\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R
M.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z
M(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P
M<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M
M=VED=&@Z(#!P>#LG/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P
M>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT
M+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P
M86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT
M+7-T<F]K92UW:61T:#H@,'!X.R<^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA
M<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO
M;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[
M('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SY);B!!<')I;"`R,#$R+"!T
M:&4@0V]M<&%N>2`H<W5B;&EC96YS964I(&5N=&5R960@:6YT;R!A(&QI8V5N
M<V4@86=R965M96YT('=I=&@@365D96]R("AL:6-E;G-E92D@86YD(&ES<W5E
M9"`Q-RPP.#D@<VAA<F5S(&]F('-T;V-K(&9O<B!T:&4@;&EC96YS92!A9W)E
M96UE;G0N(%1H92!#:&EE9B!%>&5C=71I=F4@3V9F:6-E<B!W87,@82!S:&%R
M96AO;&1E<B!O9B!-961E;W(N($%T($1E8V5M8F5R(#,Q+"`R,#$S+"!T:&4@
M0V]M<&%N>2!I<W-U960@,BPU,#`L,#`P('-H87)E<R!O9B!C;VUM;VX@<W1O
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M(&]F("0S+#<U,"PP,#`@86YD('=A<R!E>'!E;G-E9"!T;R!R97-E87)C:"!A
M;F0@9&5V96QO<&UE;G0@97AP96YS92X@5&AE(&9A:7(@=F%L=64@;V8@=&AE
M('-H87)E<R!W87,@9&5T97)M:6YE9"!V:6$@82!T:&ER9"!P87)T>2!V86QU
M871I;VXN)B,Q-C`[/&9O;G0@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@
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M86QT:65S(')E8V5I=F5D(&)Y(&QI8V5N<V5E.R!O<B`H:6DI('5P('1O(#(E
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M;'DN/"]F;VYT/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
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M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^26YC;VUE
M(%1A>&5S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@
M,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^26YC;VUE(%1A>&5S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DE.0T]-12!405A%4SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\8CY.3U1%(#<@
M)B,X,C$Q.R!)3D-/344@5$%815,\+V(^/"]P/CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ
M(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M
M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V,#L\+W`^/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P
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M=V%N8V4@86=A:6YS="!I=',@9&5F97)R960@=&%X(&%S<V5T<RX\+W`^/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG
M/B8C,38P.SPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L
M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N
M=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z
M(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K
M92UW:61T:#H@,'!X.R<^5&AE(&-O;7!O;F5N=',@;V8@=&AE($-O;7!A;GDF
M(S@R,3<[<R!D969E<G)E9"!T87@@87-S971S(&%R92!A<R!F;VQL;W=S(&%T
M.CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P
M,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T
M:#H@,'!X.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@
M,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E
M>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M
M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E
M>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\+W`^/'1A8FQE('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L(&-A;&EB<FDL(&AE;'9E=&EC82P@<V%N<RUS97)I
M9CL@=VED=&@Z(#$U-C=P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M
M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A
M8VEN9SH@,'!X.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT+7-I
M>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@+7=E8FMI
M="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,#X\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3LG/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED
M=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P
M86X],T0R/DIU;F4@,S`L)B,Q-C`[/&)R("\^,C`Q-#PO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@8F]R9&5R+6)O='1O
M;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B
M;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/D1E8V5M
M8F5R(#,Q+#QB<B`O/C(P,3,\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,2XU<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^1&5F97)R
M960@=&%X(&%S<V5T<SH\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#LG(&-O;'-P86X],T0R/B8C,38P.SPO=&0^
M/'1D/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R<@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q,3<W+C8W<'@[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I
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M+#4U-BPV,#`\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA
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M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXR+#<V-2PV,#`\+W1D/CQT
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^-"PR-#@L
M-S`P/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^+3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E
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M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,3DW+#<P,#PO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
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M9CLG/C0S-BPS,#`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUL969T.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
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M(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
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M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\
M+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D#0H@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.B`Q,'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
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M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/C(L.3`P
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^-#8L,#`P/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H
M:71E.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`Q+C5P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[)SY686QU871I;VX@86QL;W=A;F-E/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!B;W)D97(M8F]T=&]M
M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O
M<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!B;W)D97(M8F]T=&]M+6-O;&]R
M.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB
M;W1T;VTM<W1Y;&4Z('-O;&ED.R<^*#@L,#(X+#@P,#PO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M)SXI/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!B
M;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T
M:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!B;W)D97(M
M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU
M<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^*#,L,CDR+#8P,#PO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T
M=&]M.B`Q+C5P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[)SXI/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^5&]T86P\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!B;W)D97(M8F]T
M=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B
M;W)D97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[)SXD/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B
M;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D97(M8F]T=&]M
M+7-T>6QE.B!D;W5B;&4[)SXM/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#1P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!B;W)D97(M8F]T=&]M
M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D
M97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[)SXD/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M/"]T86)L93X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z
M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@
M,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P
M>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW
M:61T:#H@,'!X.R<^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X
M.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M
M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A
M8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V,#L\+W`^/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R
M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO
M<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[
M("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/E1H92!#;VUP86YY
M(&AA<R!M86EN=&%I;F5D(&$@9G5L;"!V86QU871I;VX@86QL;W=A;F-E(&%G
M86EN<W0@:71S(&1E9F5R<F5D('1A>"!A="!*=6YE(#,P+"`R,#$T(&%N9"!$
M96-E;6)E<B`S,2P@,C`Q,RX@02!V86QU871I;VX@86QL;W=A;F-E(&ES(')E
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M(&%L;&]W86YC92!H87,@8F5E;B!P<F]V:61E9"X\+W`^/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS
M9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z
M(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M
M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO
M<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P
M,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L
M971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI
M=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@
M,'!X.R<^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO
M<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[)SY!="!*=6YE(#,P+"`R,#$T+"!T:&4@0V]M<&%N>2!H
M860@9F5D97)A;"!A;F0@<W1A=&4@;F5T(&]P97)A=&EN9R!L;W-S(&-A<G)Y
M9F]R=V%R9',@;V8@87!P<F]X:6UA=&5L>2`D."PW-C(L,#`P+"!W:&EC:"!B
M96=I;B!E>'!I<FEN9R!I;B`R,#(U+B!4:&4@0V]M<&%N>2!A;'-O(&AA9"!F
M961E<F%L(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!T87@@8W)E9&ET(&-A
M<G)Y9F]R=V%R9',@;V8@87!P<F]X:6UA=&5L>2`D,3DW+#<P,"!W:&EC:"!W
M:6QL(&)E9VEN('1O(&5X<&ER92!I;B`R,#(U+B!4:&4@56YI=&5D(%-T871E
M<R!487@@4F5F;W)M($%C="!O9B`Q.3@V(&-O;G1A:6YS('!R;W9I<VEO;G,@
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M:6YT97)E<W0@<F%T92X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
M<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X
M="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US
M<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F
M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@
M;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA
M;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^02!R96-O;F-I
M;&EA=&EO;B!O9B!T:&4@<W1A='5T;W)Y('1A>"!R871E('1O('1H92!E9F9E
M8W1I=F4@=&%X(')A=&4@:7,@87,@9F]L;&]W<SH\+W`^/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS
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M<W!A8VEN9SH@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO<#X\=&%B;&4@<W1Y
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M;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)R!C96QL
M<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<B!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA
M;#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQT9"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
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M-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ
M(&-E;G1E<CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG
M.B!N;W)M86P[)R!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L
M971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG
M/E-I>"!-;VYT:"!%;F1E9"!*=6YE)B,Q-C`[,S`L/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('!A9&1I
M;F<M8F]T=&]M.B`Q+C5P=#L@=V]R9"US<&%C:6YG.B!N;W)M86P[)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D
M+7-P86-I;F<Z(&YO<FUA;#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
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M<F0M<W!A8VEN9SH@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\
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M<W!A8VEN9SH@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('!A9&1I;F<M8F]T
M=&]M.B`Q+C5P=#L@=V]R9"US<&%C:6YG.B!N;W)M86P[)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I
M;F<Z(&YO<FUA;#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
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M(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('!A9&1I;F<M8F]T=&]M.B`Q+C5P
M=#L@=V]R9"US<&%C:6YG.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA
M;#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T
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M<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^,C`Q
M,SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
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M;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&-E;G1E<CL@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B!N;W)M86P[(&)O
M<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H
M.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N
M/3-$,CX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
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M<F0M<W!A8VEN9SH@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\
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M9"US<&%C:6YG.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T
M97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG/B8C
M,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M<W!A
M8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A
M8VEN9SH@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
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M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P
M86-I;F<Z(&YO<FUA;#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z
M(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT
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M:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^)B,Q-C`[/"]F
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M)R!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M<W!A
M8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG/B8C,38P.SPO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M<W!A8VEN9SH@
M;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@
M;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@<W1Y;&4],T0G
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M=V]R9"US<&%C:6YG.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L
M971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG
M/E-T871U=&]R>2!F961E<F%L(&EN8V]M92!T87@@<F%T93PO9F]N=#X\+W1D
M/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!W:61T:#H@,39P>#L@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B!N;W)M86P[)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I
M;F<Z(&YO<FUA;#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#L@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B!N;W)M86P[)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P
M86-I;F<Z(&YO<FUA;#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
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M<V5R:68[('=I9'1H.B`Q-7!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W
M;W)D+7-P86-I;F<Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H.B`Q
M-7!X.R!T97AT+6%L:6=N.B!L969T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L
M.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H
M.B`Q-#%P>#L@=&5X="UA;&EG;CH@<FEG:'0[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B!N
M;W)M86P[)SXS-#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!W:61T
M:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#L@;&5T=&5R+7-P86-I;F<Z(&YO
M<FUA;#L@=V]R9"US<&%C:6YG.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
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M<&%C:6YG.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG/C,T/"]F
M;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H.B`Q-G!X.R!T97AT
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M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
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M<&%C:6YG.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG/B8C,38P
M.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!R
M:6=H=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B!N
M;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M<W!A8VEN9SH@
M;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG/C8N-CPO9F]N=#X\+W1D
M/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
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M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO
M<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO
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M9"US<&%C:6YG.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T
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M9SH@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O
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M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M<W!A8VEN9SH@;F]R;6%L
M.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG/B4\+V9O;G0^/"]T9#X\+W1R/CQT
M<B!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D
M+7-P86-I;F<Z(&YO<FUA;#L@=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT9"!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T
M97AT+6EN9&5N=#H@+3@N-C5P=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M<&%D9&EN9RUL969T.B`X+C8U<'0[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M=V]R9"US<&%C:6YG.B!N;W)M86P[)SY.;VXM9&5D=6-T:6)L92!E>'!E;G-E
M<SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M<W!A8VEN
M9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
M9SH@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O
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M8VEN9SH@;F]R;6%L.R<^/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'@[)SXH,3,N
M,3PO<#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA
M;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&QE='1E<BUS<&%C:6YG.B!N;W)M
M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^*24\+V9O;G0^/"]T9#X\=&0@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US
M<&%C:6YG.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG/B8C,38P
M.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L
M969T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO
M<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO
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M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
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M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I
M;F<Z(&YO<FUA;#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!T97AT+6%L:6=N.B!R:6=H=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA
M;#L@=V]R9"US<&%C:6YG.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
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M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!T97AT+6EN9&5N=#H@+3@N-C5P=#L@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@<&%D9&EN9RUL969T.B`X+C8U<'0[('=O<F0M<W!A8VEN
M9SH@;F]R;6%L.R<^3W1H97(\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T
M97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[
M(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@
M<FEG:'0[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@
M;F]R;6%L.R<^/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'@[)SXH,BXS/"]P/CPO
M=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[(&QE='1E
M<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^*24\
M+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M<W!A8VEN9SH@;F]R;6%L
M.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@
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M:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M=V]R9"US<&%C:6YG.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
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M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
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M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D#0H@<W1Y;&4],T0G9F]N=#H@,3!P="]N
M;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA
M;&EG;CH@;&5F=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C
M:6YG.B!N;W)M86P[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D
M97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@
M<V]L:60[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M<W!A8VEN9SH@
M;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG/B8C,38P.SPO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!R:6=H=#L@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B!N;W)M86P[(&)O
M<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H
M.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)SX\<"!S='EL
M93TS1"=M87)G:6XZ(#!P>#LG/B@R-2XR/"]P/CPO=&0^/'1D('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[(&QE='1E<BUS<&%C:6YG.B!N;W)M
M86P[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@=V]R9"US<&%C:6YG.B!N;W)M
M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG/BDE/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('!A9&1I
M;F<M8F]T=&]M.B`Q+C5P=#L@=V]R9"US<&%C:6YG.B!N;W)M86P[)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D
M+7-P86-I;F<Z(&YO<FUA;#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
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M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O
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M:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^)B,Q-C`[/"]F
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M86P[)SXH,C$N.#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT
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M+6-O;&]R.B!W:&ET93LG/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N
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M/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!P
M861D:6YG+6)O='1O;3H@-'!T.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O
M<F0M<W!A8VEN9SH@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R!B;W)D97(M8F]T=&]M
M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D
M97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA
M;#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT
M+6%L:6=N.B!R:6=H=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US
M<&%C:6YG.B!N;W)M86P[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B
M;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z
M(&1O=6)L93LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^,#PO9F]N=#X\+W1D
M/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
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M=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!P861D:6YG+6)O='1O;3H@-'!T.R!W;W)D+7-P86-I;F<Z(&YO<FUA
M;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&QE='1E<BUS<&%C:6YG.B!N;W)M
M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
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M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z
M(&YO<FUA;#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!T97AT+6%L:6=N.B!R:6=H=#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M=V]R9"US<&%C:6YG.B!N;W)M86P[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L
M86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM
M<W1Y;&4Z(&1O=6)L93LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&QE='1E<BUS
M<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^,#PO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
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M)3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M<W!A8VEN
M9SH@;F]R;6%L.R!P861D:6YG+6)O='1O;3H@-'!T.R!W;W)D+7-P86-I;F<Z
M(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT
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M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P
M86-I;F<Z(&YO<FUA;#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!T97AT+6%L:6=N.B!R:6=H=#L@;&5T=&5R+7-P86-I;F<Z(&YO
M<FUA;#L@=V]R9"US<&%C:6YG.B!N;W)M86P[(&)O<F1E<BUB;W1T;VTM8V]L
M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB
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M.B`T<'0[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B!N
M;W)M86P[)SXE/"]F;VYT/CPO=&0^/"]T<CX\+W1A8FQE/CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N
M<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R!W:&ET92US<&%C93H@
M;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D
M+7-P86-I;F<Z(&YO<FUA;#LG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R
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M=&%I;B!T87@@<&]S:71I;VYS(&%T($IU;F4@,S`L(#(P,30@86YD($1E8V5M
M8F5R(#,Q+"`R,#$S('1H870@=V]U;&0@869F96-T(&ET<R!E9F9E8W1I=F4@
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M<V4N/"]F;VYT/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
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M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]M;6ET
M;65N=',@86YD($-O;G1I;F=E;F-I97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M96YT(&%N9"!#;VYT
M:6YG96YC:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-/34U)5$U%3E13($%.1"!#3TY424Y'14Y#
M2453/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[(&UA<F=I;CH@,'!X.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQB/DY/5$4@."`F(S@R,3$[($-/34U)
M5$U%3E13($%.1"!#3TY424Y'14Y#2453/"]B/CPO<#X\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CL@;6%R9VEN.B`P<'@[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V9O;G0Z
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M;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[)SXF(S$V,#L\+W`^/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/E=O;G!U;F<\+W`^/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[(&UA<F=I;CH@,'!X.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CL@;6%R9VEN.B`P<'@[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R<^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ
M(#!P>#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N
M;W)M86P[)SX\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!F;VYT
M+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/D]N
M($%U9W5S="`R,"P@,C`P-RP@=&AE($-O;7!A;GD@96YT97)E9"!I;G1O(&$@
M3&EC96YS92!$979E;&]P;65N="!A;F0@0V]M;65R8VEA;&EZ871I;VX@06=R
M965M96YT('=I=&@@5V]N<'5N9RP@82!S:&%R96AO;&1E<B!O9B!T:&4@0V]M
M<&%N>2X@5V]N<'5N9R!H87,@97AC;'5S:79E('1E<G)I=&]R:6%L(')I9VAT
M<R!I;B!C;W5N=')I97,@:70@<V5L96-T<R!I;B!!<VEA('1O(&UA<FME="!U
M<"!T;R!T=V\@9')U9W,@=&AE($-O;7!A;GD@:7,@8W5R<F5N=&QY(&1E=F5L
M;W!I;F<@86YD(&$@<FEG:'0@;V8@9FER<W0@<F5F=7-A;"`H)B,X,C(P.U)/
M1E(F(S@R,C$[*2!F;W(@=7`@=&\@86X@861D:71I;VYA;"!F:79E(&1R=6=S
M('1H870@=&AE($-O;7!A;GD@;6%Y(&1E=F5L;W`@:6X@=&AE(&9U='5R92!A
M<R!D969I;F5D(&EN(&UO<F4@9&5T86EL(&EN('1H92!L:6-E;G-E(&%G<F5E
M;65N="X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@=&EM97,@
M;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6EN
M9&5N=#H@,"XU:6X[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G
M:6XZ(#!P>#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H
M.B!N;W)M86P[)SY4:&4@0V]M<&%N>2!R96-E:79E9"!A;B!U<&9R;VYT(&QI
M8V5N<V4@9F5E(&]F("0Q+#4P,"PP,#`@86YD('=I;&P@96%R;B!R;WEA;'1I
M97,@;V8@=7`@=&\@,3(E(&]F(&YE="!S86QE<R!F;W(@=7`@=&\@='=O(&QI
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M;VT@,34@>65A<G,@=&\@,C`@>65A<G,@869T97(@;&EC96YS:6YG(&]R(&]N
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M:V5T<R!I=',@<')O9'5C=',@:6X@07-I82X\+W`^/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M(&UA<F=I;CH@,'!X.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T
M<F5T8V@Z(&YO<FUA;#LG/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
M<'@[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R
M;6%L.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@
M9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[
M)SY4:&ER9"!087)T>2!,:6-E;G-O<CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R
M9VEN.B`P<'@[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C
M:#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ
M(#!P>#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N
M;W)M86P[)SX\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!F;VYT
M+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CPO
M<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!T:6UE<R!N97<@<F]M
M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&9O;G0M<VEZ92UA9&IU
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M8V5N<V5E.R!O<B`H:6DI('5P('1O(#(E(&]F(&YE="!S86QE<R!O9B!S=6)L
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M/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&9O;G0M<VEZ92UA
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M:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[)SXF(S$V,#L\+W`^
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@=&EM97,@;F5W(')O;6%N
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M96%S92!E>'!I<FEN9R!I;B`R,#$W(&9O<B!I=',@4&5N;G-Y;'9A;FEA(&]F
M9FEC92!L;V-A=&EO;BX@1G5T=7)E(&UI;FEM=6T@;&5A<V4@<&%Y;65N=',@
M87)E(&%S(&9O;&QO=W,Z/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P
M>#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M
M86P[)SXF(S$V,#L\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!F
M;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG
M/D9O<B!T:&4@>65A<B!E;F1E9"!*=6YE(#,P+#H\+W`^/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="]N;W)M86P@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[(&UA<F=I;CH@,'!X.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#LG/B8C,38P.SPO<#X\=&%B;&4@86QI9VX],T1C
M96YT97(@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[('=I9'1H.B`X,"4[(&)O<F1E<BUC;VQL87!S
M93H@8V]L;&%P<V4[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$
M,#X\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTM8V]L
M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R
M+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CY996%R/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T
M=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[
M(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^06UO
M=6YT/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^
M)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^,C`Q-3PO=&0^/'1D/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXS-RPS,#`\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!W:&ET93LG/CQT9"!S='EL93TS1"=W:61T:#H@,24[('1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@-3`E
M.R!T97AT+6%L:6=N.B!L969T.R<^,C`Q-CPO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q)3LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@
M=&5X="UA;&EG;CH@;&5F=#LG/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Y
M)3L@=&5X="UA;&EG;CH-"B!R:6=H=#LG/C,X+#`P,#PO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/C(P,3<\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[)SXS."PX,#`\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W
M:&ET93LG/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG
M+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,2XU<'0[)SXR,#$X/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[
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M<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^.2PW,#`\+W1D/CQT9"!S='EL93TS
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M;F<M8F]T=&]M.B`T<'0[)SY4;W1A;#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`T<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R
M9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D
M;W5B;&4[)SXD/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I
M9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/C$R-RPX
M,#`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG
M+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CPO=&%B;&4^/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@=&EM97,@;F5W(')O;6%N+"!T:6UE
M<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/B8C,38P.SPO<#X\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S
M97)I9CL@;6%R9VEN.B`P<'@[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R<^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G
M:6XZ(#!P>#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE+6%D:G5S=#H@
M;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[)SY4:&4@0V]M<&%N>2!I;F-U
M<G)E9"!R96YT(&5X<&5N<V4@;V8@87!P<F]X:6UA=&5L>2`D-C<L.#`P(&%N
M9"`D-C0L-C`P(&9O<B!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2PF(S$V,#LR
M,#$S(&%N9"`R,#$R+"!R97-P96-T:79E;'DL(&%N9"!A<'!R;WAI;6%T96QY
M("0Q,RPS,#`@9F]R('1H92!S:7@@;6]N=&AS(&5N9&5D($IU;F4@,S`L(#(P
M,30N/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L('1I;65S(&YE
M=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@9F]N="US:7IE
M+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\+W`^/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@=&EM97,@;F5W(')O;6%N+"!T
M:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!F;VYT+7-I>F4M861J=7-T.B!N
M;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/B8C,38P.SPO<#X\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'@[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[
M(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^/&(^3&5G86P\+V(^/"]P/CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L('1I;65S(&YE=R!R;VUA;BP@=&EM
M97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@9F]N="US:7IE+6%D:G5S=#H@;F]N
M93L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\8CX\+V(^)B,Q-C`[/"]P/CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L('1I;65S(&YE=R!R;VUA;BP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@9F]N="US:7IE+6%D:G5S=#H@
M;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\+W`^/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="]N;W)M86P@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[(&UA<F=I;CH@,'!X.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#LG/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN
M.B`P<'@[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@
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M;VYS(&EN(%-E<'1E;6)E<B`R,#$R(&%N9"!W87,@;&%T97(@<F5M;W9E9"!F
M<F]M(%)E;&UA9&$F(S@R,3<[<R!B;V%R9"!O9B!D:7)E8W1O<G,N)B,Q-C`[
M)B,Q-C`[5&AE($-O;7!L86EN="!A;&QE9V5S('1H870L(&1U<FEN9R!T:&4@
M8V]U<G-E(&]F(&%N(&%U9&ET+"!296QM861A(&1I<V-O=F5R960@87!P<F]X
M:6UA=&5L>2`D,2XU(&UI;&QI;VX@:6X@<75E<W1I;VYA8FQE(&5X<&5N<V5S
M(&EN8W5R<F5D(&)Y($UR+B!"86)U;"!D=7)I;F<@:&ES(&UA;F%G96UE;G0@
M;V8@=&AE(&-O;7!A;GD@9G)O;2`R,#`T('5N=&EL(&AI<R!R97-I9VYA=&EO
M;B!I;B`R,#$R("AT:&4@)B,X,C(P.U%U97-T:6]N86)L92!%>'!E;G-E<R8C
M.#(R,3LI+B!/=71S:61E('1H92!L87=S=6ET+"!296QM861A(&AA<R!A;'-O
M(&-A;F-E;&QE9"!W87)R86YT<R!T;R!P=7)C:&%S92`X-C@L,C$S(&-O;6UO
M;B!S=&]C:R`H=&AE("8C.#(R,#M#86YC96QL960@5V%R<F%N=',F(S@R,C$[
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M=&AA="!C;&]S960@;VX@36%Y(#(P+"`R,#$T+B8C,38P.R8C,38P.TUR+B!"
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M;W)M86P[)SX\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@=&EM
M97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT
M+6EN9&5N=#H@,"XU:6X[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V9O;G0Z
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M8V@@97AP96YS97,N)B,Q-C`[)B,Q-C`[1&5P96YD:6YG('5P;VX@=&AE(&]U
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M.R!M87)G:6XZ(#!P>#L@=&5X="UI;F1E;G0Z(#`N-6EN.R!F;VYT+7-I>F4M
M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/B8C,38P.SPO
M<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!T:6UE<R!N97<@<F]M
M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&9O;G0M<VEZ92UA9&IU
M<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^/&(^3W1H97(@4&]T
M96YT:6%L($QI=&EG871I;VXZ)B,Q-C`[)B,Q-C`[/"]B/DEN(&%D9&ET:6]N
M('1O('1H92!A9F]R96UE;G1I;VYE9"!D:7-P=71E<RP@4F5L;6%D82!H87,@
M8F5E;B!I;F9O<FUE9"!T:&%T($UR+B!"86)U;"!I<R!C;VYT96UP;&%T:6YG
M(&UA:VEN9R!A9&1I=&EO;F%L(&-L86EM<R!I;B!T:&4@4&5N;G-Y;'9A;FEA
M(&QI=&EG871I;VX@;W(@96QS97=H97)E+"!A<R!I<R!296QM861A+CPO<#X\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M:6YD96YT.B`P+C5I
M;CL@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M
M86P[)SXF(S$V,#L\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
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M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
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M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^4W5B<V5Q=65N="!%=F5N=',\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6)S
M97%U96YT($5V96YT<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y354)315%514Y4($5614Y44SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^/&(^3D]412`Y
M("8C.#(Q,3L@4U5"4T51545.5"!%5D5.5%,\+V(^/"]P/CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R<^)B,Q
M-C`[/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L
M:6=N.B!L969T.R<^3VX@2G5L>2`Q."P@,C`Q-"P@=&AE($-O;7!A;GD@96YT
M97)E9"!I;G1O(&%N(&%G<F5E;65N="!W:71H(&$@8V]N<W5L=&%N="!F;W(@
M:6YV97-T;W(@8V]M;75N:6-A=&EO;B!A;F0@<'5B;&EC(')E;&%T:6]N<R!F
M;W(@;VYE('EE87(N(%1H92!C;VYS=6QT86YT('-H86QL(')E8V5I=F4@86X@
M=7!F<F]N="!C87-H(&9E92!O9B`D,C4P+#`P,"!A;F0@)#(U,"PP,#`@<75A
M<G1E<FQY(&-A<V@@:6YS=&%L;&UE;G1S(&-O;6UE;F-I;F<@:6X@4V5P=&5M
M8F5R(#(P,30N($EN(&%D9&ET:6]N+"!T:&4@0V]M<&%N>2!S:&%L;"!I<W-U
M92`R-3`L,#`P('-H87)E<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS('=I=&AI
M;B!F:69T965N("@Q-2D@9&%Y<R!O9B!T:&4@86=R965M96YT(&%N9"!T:&4@
M<F5M86EN:6YG(#(U,"PP,#`@<VAA<F5S('-H86QL(&)E(&ES<W5E9"!I;B!S
M:7@@;6]N=&AL>2!I;G-T86QL;65N=',@8V]M;65N8VEN9R!I;B!397!T96UB
M97(@,C`Q-"X\+W`^/'`^/"]P/CQP/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
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M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%0D]!0SX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L
M:6-I97,@*%!O;&EC:65S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C
M;W5N=&EN9R!0;VQI8VEE<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<FEN8VEP;&5S(&]F($-O;G-O
M;&ED871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E
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M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E
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M;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD
M96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=B86-K9W)O=6YD+6-O
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M;B!C;VYS;VQI9&%T:6]N+CPO9F]N=#X\+W`^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y5<V4@;V8@17-T:6UA=&5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R
M9VEN.B`P.R<^/&(^57-E(&]F($5S=&EM871E<SPO8CX\+W`^/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@
M=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,#LG/E1H
M92!P<F5P87)A=&EO;B!O9B!F:6YA;F-I86P@<W1A=&5M96YT<R!I;B!C;VYF
M;W)M:71Y('=I=&@@86-C;W5N=&EN9R!P<FEN8VEP;&5S(&=E;F5R86QL>2!A
M8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E<R`H)B,X,C(P.U4N4RX@1T%!
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M;W=A;F-E+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-A<V@@86YD($-A<V@@17%U:79A;&5N=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#`[
M)SX\8CY#87-H(&%N9"!#87-H($5Q=6EV86QE;G1S(#PO8CX\+W`^/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I
M9CL@;6%R9VEN.B`P.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P
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M;6ET<RX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0871E;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CL@;6%R9VEN.B`P.R<^/&(^4&%T96YT<SPO8CX\+W`^
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V9O
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M<R!I<R!U;F-E<G1A:6XN/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1FEX960@07-S971S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T
M:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P.R<^/&(^
M1FEX960@07-S971S/"]B/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I
M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#`[)SXF(S$V
M,#L\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CL@;6%R9VEN.B`P.R<^1FEX960@87-S971S(&%R92!S
M=&%T960@870@8V]S="!L97-S(&%C8W5M=6QA=&5D(&1E<')E8VEA=&EO;BX@
M1FEX960@87-S971S(&%R92!C;VUP<FES960@;V8@8V]M<'5T97)S(&%N9"!S
M;V9T=V%R92X@1&5P<F5C:6%T:6]N(&ES(&-A;&-U;&%T960@=7-I;F<@=&AE
M('-T<F%I9VAT+6QI;F4@;65T:&]D(&]V97(@=&AE(&5S=&EM871E9"!U<V5F
M=6P@;&EF92!O9B!T:&4@<F5L871E9"!A<W-E=',L('=H:6-H(&ES('1H<F5E
M('EE87)S+CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1E<FEV871I=F5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@
M<F]M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P.R<^/&(^1&5R:79A=&EV
M97,\+V(^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O
M;6%N+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,#LG/B8C,38P.SPO<#X\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E
M<FEF.R!M87)G:6XZ(#`[)SY!;&P@9&5R:79A=&EV97,@87)E(')E8V]R9&5D
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M<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D9A:7(@5F%L=64@;VX@82!296-U<G)I;F<@0F%S:7,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G
M:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W
M;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI
M="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&(^1F%I<B!686QU92!O;B!A
M(%)E8W5R<FEN9R!"87-I<SPO8CX\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R
M9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N
M93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO<#X\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M
M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A
M8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z
M(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/"]P
M/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P
M,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[)SY!<R!R97%U:7)E9"!B>2!!8V-O=6YT:6YG(%-T86YD87)D($-O9&EF
M:6-A=&EO;B`H)B,X,C(P.T%30R8C.#(R,3LI(%1O<&EC($YO+B`X,C`@)B,X
M,C$Q.R`Q,"8C,38P.SQI/D9A:7(@5F%L=64@365A<W5R96UE;G0\+VD^+"!F
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M;VX@9FER;2P@<V5E($YO=&4@-"X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R
M9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N
M93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO<#X\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN
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M=7)R:6YG(&)A<VES(&%S(&]F($IU;F4@,S`L(#(P,30Z/"]P/CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C
M;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD
M96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[)SXF(S$V,#L\+W`^/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@
M;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA
M;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW
M96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CPO<#X\=&%B;&4@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@8V%L:6)R:2P@:&5L=F5T:6-A+"!S
M86YS+7-E<FEF.R!W:61T:#H@,34V-W!X.R!T97AT+71R86YS9F]R;3H@;F]N
M93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M=V]R9"US<&%C:6YG.B`P<'@[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[
M(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)R!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R<^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F
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M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
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M;W1A;#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG(&-O;'-P86X],T0R/DUA<FME=',@9F]R/"]T
M9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)R!C
M;VQS<&%N/3-$,CY/=&AE<CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<@8V]L<W!A;CTS1#(^4VEG;FEF:6-A;G0\+W1D
M/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG(&-O
M;'-P86X],T0R/D-A<G)Y:6YG/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\
M+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M)SX\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G
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M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CLG(&-O;'-P86X],T0R/E9A;'5E(&%S(&]F/"]T9#X\
M=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<@8V]L<W!A;CTS1#(^07-S971S/"]T9#X\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M)SXF(S$V,#L\+W1D/CQT9`T*('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG(&-O;'-P86X],T0R/DEN
M<'5T<SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
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M+#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!B
M;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T
M:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^1&5S8W)I
M<'1I;VX\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM
M=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O
M;'-P86X],T0R/BA,979E;"`Q*3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q+C5P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA
M8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M
M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/BA,979E;"`R*3PO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@8F]R9&5R
M+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N
M-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R
M/BA,979E;"`S*3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M+C5P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,2XU<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E
M<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S
M;VQI9#LG(&-O;'-P86X],T0R/C(P,30\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W=I9'1H.B`X,35P>#L@=&5X="UA
M;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#1P=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SY$97)I=F%T:79E
M(&QI86)I;&ET:65S("8C.#(Q,3L@=V%R<F%N="!I;G-T<G5M96YT<SPO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!P861D:6YG+6)O='1O;3H@-'!T
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT
M+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O
M<F1E<BUB;W1T;VTM=VED=&@Z(#1P=#L@8F]R9&5R+6)O='1O;2US='EL93H@
M9&]U8FQE.R<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#)P>#L@=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@
M8F]R9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D97(M8F]T=&]M+7-T>6QE
M.B!D;W5B;&4[)SXM/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[('1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`T<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[('!A9&1I;F<M8F]T=&]M
M.B`T<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[
M('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM
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M(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T
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M/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O
M='1O;3H@-'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CLG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M-7!X.R!P861D:6YG+6)O='1O;3H@-'!T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@8F]R9&5R
M+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#1P
M=#L@8F]R9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R<^)#PO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!B;W)D
M97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@
M-'!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[)SXR-2PU.#8L.3,S
M/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U<'@[('1E>'0M86QI9VXZ(&QE
M9G0[('!A9&1I;F<M8F]T=&]M.B`T<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\+W1R/CPO
M=&%B;&4^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C
M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P
M>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[
M('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED
M=&@Z(#!P>#LG/B8C,38P.R8C,38P.R8C,38P.SPO<#X\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z
M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@
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M(&)A<VES(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$S.CPO<#X\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L
M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N
M=#H@,"XU:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[)SXF(S$V,#L\+W`^/'1A8FQE('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[('=I9'1H.B`Q-38W<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT
M+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P
M86-I;F<Z(#!P>#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N="US
M:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[)SX\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^475O=&5D
M(%!R:6-E<SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/B8C
M,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/B8C,38P
M.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/B8C,38P.SPO
M=&0^/'1D/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3LG/CQT9#XF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$
M,CY);B!!8W1I=F4\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$
M,CY3:6=N:69I8V%N=#PO=&0^/'1D/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X]
M,T0R/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^
M/'1D#0H@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS
M1#(^5&]T86P\+W1D/CQT9#XF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\=&0^)B,Q-C`[/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@
M8V]L<W!A;CTS1#(^36%R:V5T<R!F;W(\+W1D/CQT9#XF(S$V,#L\+W1D/CQT
M9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M)R!C;VQS<&%N/3-$,CY/=&AE<CPO=&0^/'1D/B8C,38P.SPO=&0^/'1D/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O
M;'-P86X],T0R/E-I9VYI9FEC86YT/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@
M8V]L<W!A;CTS1#(^0V%R<GEI;F<\+W1D/CQT9#XF(S$V,#L\+W1D/CPO='(^
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\=&0^)B,Q
M-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^261E;G1I8V%L/"]T9#X\=&0^)B,Q
M-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
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M=&0^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
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M;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@
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M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C
M;VQS<&%N/3-$,CXH3&5V96P@,BD\+W1D/CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K
M.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US
M='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CXH3&5V96P@,RD\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T
M;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@
M8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CXR,#$S
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q
M-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$
M)W=I9'1H.B`X,35P>#L@=&5X="UA;&EG;CH@;&5F=#LG/D1E<FEV871I=F4@
M;&EA8FEL:71I97,@)B,X,C$Q.R!W87)R86YT(&EN<W1R=6UE;G1S/"]T9#X\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/CQT
M9"!S='EL93TS1"=W:61T:#H@,30R<'@[('1E>'0M86QI9VXZ(')I9VAT.R<^
M+3PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG
M;CH@;&5F=#LG/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,30R<'@[('1E
M>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M-G!X.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
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M,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N
M.B!L969T.R<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#%P>#L@=&5X
M="UA;&EG;CH@<FEG:'0[)SXT+#`X.2PR.#0\+W1D/CQT9"!S='EL93TS1"=W
M:61T:#H@,35P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T
M<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@=VAI=&4[)SX\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^1&5R:79A=&EV92!L:6%B
M:6QI=&EE<R`F(S@R,3$[(%-E<FEE<R!!('!R969E<G)E9"!S=&]C:SPO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O<F1E<BUB;W1T
M;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@
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M<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTM
M8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R
M9&5R+6)O='1O;2US='EL93H@<V]L:60[)SXM/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F]R
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M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M
M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L
M:60[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM
M=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG/C$V
M+#`Q-"PQ-#$\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P
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M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F]R
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M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B;W)D97(M8F]T
M=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B
M;W)D97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[)SXD/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L
M86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM
M<W1Y;&4Z(&1O=6)L93LG/BT\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!P861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P=#LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O<F1E<BUB;W1T;VTM8V]L
M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB
M;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/B0\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O
M<F1E<BUB;W1T;VTM=VED=&@Z(#1P=#L@8F]R9&5R+6)O='1O;2US='EL93H@
M9&]U8FQE.R<^,C`L,3`S+#0R-3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`T<'0[)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X\
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M97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N
M<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N
M;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CPO<#X\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
M97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O
M<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.@T*(#!P>#LG/B8C,38P.SPO<#X\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN
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M979E;"`S(&EN('1H92!F86ER('9A;'5E(&AI97)A<F-H>3H\+W`^/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI
M;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C
M:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#LG/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G
M:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[
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M:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ
M(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M
M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\8CXF(S$V,#L\+V(^
M/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO
M;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[
M('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\+W`^/'1A8FQE('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L(&-A;&EB<FDL(&AE;'9E=&EC82P@<V%N
M<RUS97)I9CL@=VED=&@Z(#$U-C=P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[
M('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O
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M:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA
M8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M
M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0Q,#Y3:6=N:69I8V%N="!5;F]B
M<V5R=F%B;&4@26YP=71S("A,979E;"`S*3PO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T
M>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\=&0^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<@8V]L<W!A;CTS1#(^4VEX($UO;G1H)B,Q-C`[
M/&)R("\^16YD960\8G(@+SY*=6YE(#,P+#PO=&0^/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<@8V]L<W!A;CTS1#(^665A<B8C
M,38P.SQB<B`O/D5N9&5D)B,Q-C`[/&)R("\^1&5C96UB97(@,S$L/"]T9#X\
M=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!C
M;VQS<&%N/3-$,CX\<"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M665A<CQB<B`O/D5N9&5D/&)R("\^1&5C96UB97(@,S$L/"]P/CPO=&0^/'1D
M/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3LG/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,2XU<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[
M(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T
M>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/C(P,30\+W1D/CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&)O<F1E<BUB;W1T;VTM
M8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R
M9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CXR,#$S/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!B
M;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T
M:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A
M;CTS1#(^,C`Q,CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
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M)SY"96=I;FYI;F<@8F%L86YC93PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M-G!X.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!T
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M*3PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,30Q<'@[('1E>'0M86QI9VXZ
M(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CLG/B@U+#`Y,"PY.#@\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M,35P>#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXI/"]T9#X\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$U<'@[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$U<'@[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)#PO=&0^/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^+3PO=&0^/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT
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M<B!T:&4@<VEX(&UO;G1H<R!E;F1E9"!*=6YE(#,P+"`R,#$T(&%N9"!F;W(@
M=&AE('EE87)S(&5N9&5D)B,Q-C`[($1E8V5M8F5R(#,Q+"`R,#$S(&%N9"`R
M,#$R+"!R97-P96-T:79E;'D\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/'`@<W1Y;&4]
M,T0G;6%R9VEN.B`P<'@[)SXH-RPY-30L.3<P/"]P/CPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^*3PO=&0^/'1D('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXH
M,3(L.#<W+#8W-3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^*3PO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
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M.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
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M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
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M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CLG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXH,S<\+V9O
M;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^,RPV.3D\+V9O
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M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^-BPX,#0L-C(U/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D/CQT9#XF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXM/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/BT\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SY!9&1I=&EO
M;G,@)B,X,C$Q.R!C;VYV97)S:6]N(&9E871U<F4@;V8@4V5R:65S($$@<')E
M9F5R<F5D('-T;V-K/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T
M;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B
M;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T
M:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^+3PO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q+C5P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
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M.R!P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^*3PO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^*3PO=&0^
M/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#1P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[)SY%;F1I;F<@8F%L86YC93PO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`T<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L
M86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM
M<W1Y;&4Z(&1O=6)L93LG/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M
M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L
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M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!B;W)D97(M8F]T=&]M+6-O;&]R
M.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D97(M8F]T
M=&]M+7-T>6QE.B!D;W5B;&4[)SXD/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R
M9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D
M;W5B;&4[)SXH-2PP.3`L.3@X/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#1P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXI/"]T9#X\+W1R/CPO
M=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y);F-O;64@5&%X97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<"!S='EL93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA
M;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#`[)SX\8CY);F-O;64@5&%X97,\
M+V(^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N
M+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,#LG/B8C,38P.SPO<#X\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF
M.R!M87)G:6XZ(#`[)SY4:&4@0V]M<&%N>2!A8V-O=6YT<R!F;W(@:6YC;VUE
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M<G1A:6XN($%T($IU;F4@,S`L(#(P,30@86YD($1E8V5M8F5R(#,Q+"`R,#$S
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M:68[(&UA<F=I;CH@,#LG/CQB/B8C,38P.SPO8CX\+W`^/'`@<W1Y;&4],T0G
M9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL('1I;65S+"!S97)I9CL@;6%R
M9VEN.B`P.R<^5&AE($-O;7!A;GD@9FEL97,@82!5+E,N($9E9&5R86P@:6YC
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M9"!F;W(@=6YC97)T86EN('1A>"!P;W-I=&EO;G,@870@2G5N92`S,"P@,C`Q
M-"!A;F0@1&5C96UB97(@,S$L(#(P,3,N(%1H92!O<&5N('1A>"!Y96%R<RP@
M<W5B:F5C="!T;R!P;W1E;G1I86P@97AA;6EN871I;VX@8GD@=&AE(&%P<&QI
M8V%B;&4@=&%X:6YG(&%U=&AO<FET>2P@9F]R('1H92!#;VUP86YY('=E<F4@
M9G)O;2`R,#$P('1H<F]U9V@@,C`Q-#PO<#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!$979E
M;&]P;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R
M:68[(&UA<F=I;CH@,#LG/CQB/E)E<V5A<F-H(&%N9"!$979E;&]P;65N=#PO
M8CX\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M86XL
M('1I;65S+"!S97)I9CL@;6%R9VEN.B`P.R<^)B,Q-C`[/"]P/CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@<V5R:68[
M(&UA<F=I;CH@,#LG/E)E<V5A<F-H(&%N9"!D979E;&]P;65N="!C;W-T<R!P
M<FEM87)I;'D@8V]N<VES="!O9B!R97-E87)C:"!C;VYT<F%C=',@9F]R('1H
M92!A9'9A;F-E;65N="!O9B!P<F]D=6-T(&1E=F5L;W!M96YT+"!S=&]C:RUB
M87-E9"!C;VUP96YS871I;VXL(&%N9"!C;VYS=6QT86YT<RX@5&AE($-O;7!A
M;GD@97AP96YS97,@86QL(')E<V5A<F-H(&%N9"!D979E;&]P;65N="!C;W-T
M<R!I;B!T:&4@<&5R:6]D(&EN8W5R<F5D+CPO<#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+4)A<V5D($-O
M;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE<RP@
M<V5R:68[(&UA<F=I;CH@,#LG/CQB/E-T;V-K+4)A<V5D($-O;7!E;G-A=&EO
M;CPO8CX\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="!T:6UE<R!N97<@<F]M
M86XL('1I;65S+"!S97)I9CL@;6%R9VEN.B`P.R<^)B,Q-C`[/"]P/CQP('-T
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M960N/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F5T($QO<W,@<&5R($-O;6UO;B!3:&%R93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I
M;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[
M('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O
M<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\8CY.970@3&]S<R!P97(@0V]M
M;6]N(%-H87)E/"]B/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P
M>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT
M+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P
M86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT
M+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SY"87-I8R!N970@
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M-SMS(&YE="!L;W-S('!O<VET:6]N+CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M
M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N
M;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L
M.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E
M8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]P/CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS
M<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C
M93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SY0
M;W1E;G1I86QL>2!D:6QU=&EV92!S96-U<FET:65S(&%R92!N;W0@:6YC;'5D
M960@:6X@=&AE(&-A;&-U;&%T:6]N(&]F(&1I;'5T960@;F5T(&QO<W,@<&5R
M('-H87)E(&%T=')I8G5T86)L92!T;R!C;VUM;VX@<W1O8VMH;VQD97)S(&)E
M8V%U<V4@=&\@9&\@<V\@=V]U;&0@8F4@86YT:2UD:6QU=&EV92!A<F4@87,@
M9F]L;&]W<R`H:6X@8V]M;6]N('-T;V-K(&5Q=6EV86QE;G0@<VAA<F5S*3H\
M+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P
M,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H
M:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z
M(#!P>#LG/B8C,38P.SPO<#X\=&%B;&4@<W1Y;&4],T0G9F]N=#H@,3!P="]N
M;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=VED=&@Z
M(#$U-C=P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P
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M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C
M;VQS<&%N/3-$,CY3:7@@36]N=&@F(S$V,#L\8G(@+SY%;F1E9"8C,38P.SQB
M<B`O/DIU;F4@,S`L)B,Q-C`[/&)R("\^,C`Q-#PO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;2UC;VQO
M<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M
M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/CQP('-T>6QE/3-$
M)VUA<F=I;BUT;W`Z(#!P>#L@;6%R9VEN+6)O='1O;3H@,'!X.R<^665A<CPO
M<#X\<"!S='EL93TS1"=M87)G:6XM=&]P.B`P<'@[(&UA<F=I;BUB;W1T;VTZ
M(#!P>#LG/D5N9&5D)B,Q-C`[/&)R("\^1&5C96UB97(@,S$L)B,Q-C`[/&)R
M("\^,C`Q,SPO<#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M
M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L
M:60[)R!C;VQS<&%N/3-$,CY996%R/&)R("\^16YD960F(S$V,#L\8G(@+SY$
M96-E;6)E<B`S,2P\8G(@+SXR,#$R/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C
M8V-E969F.R<^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,#`S<'@[('1E>'0M86QI
M9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@,'!T.R<^0VQA<W,@02!C;VYV97)T
M:6)L92!P<F5F97)R960@<W1O8VL\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M,39P>#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$T,G!X.R!T97AT+6%L:6=N.B!R:6=H=#LG/C,L,S,W+#,P.3PO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#%P>#L@=&5X
M="UA;&EG;CH@<FEG:'0[)SXM/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U
M<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=W:61T:#H@,35P>#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$T,7!X.R!T97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D
M/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T.B`P<'0[)SY397)I
M97,@02!P<F5F97)R960@<W1O8VL\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
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M/C@L-3`S+#4P,SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T.B`P<'0[)SY#
M;VUM;VX@<W1O8VL@=V%R<F%N=',\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXT,RPQ-#0L-34W/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C@Y+#(V
M-2PQ-C`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
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M.B`Q+C5P=#L@<&%D9&EN9RUL969T.B`P<'0[)SY#;VUM;VX@<W1O8VL@;W!T
M:6]N<SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O
M<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H
M.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@8F]R9&5R+6)O
M='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T
M.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG/C,L,S8U+#$W,3PO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M
M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L
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M;VTM<W1Y;&4Z('-O;&ED.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B
M;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL
M93H@<V]L:60[)SXV-S<L.38R/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ#0H@,2XU<'0[)SXF(S$V,#L\+W1D
M/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#LG/E1O=&%L/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P=#LG/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O<F1E<BUB;W1T
M;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O
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M,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[)SXF
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M-'!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#1P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M
M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B;W)D
M97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@
M-'!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[)SXQ-"PP-#8L-S`P
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB
M;W1T;VTZ(#1P=#LG/B8C,38P.SPO=&0^/"]T<CX\+W1A8FQE/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C96YT
M($%C8V]U;G1I;F<@4')O;F]U;F-E;65N=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@
M=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A
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M;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD
M96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[)SXF(S$V,#L\+W`^/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P
M,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H
M:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z
M(#!P>#LG/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L
M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N
M=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z
M(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K
M92UW:61T:#H@,'!X.R<^26X@2G5N92`R,#$T+"!T:&4@1D%30B!I<W-U960@
M05-5(#(P,30M,3`L("8C.#(R,#M$979E;&]P;65N="!3=&%G92!%;G1I=&EE
M<R`H5&]P:6,@.3$U*3H@16QI;6EN871I;VX@;V8@0V5R=&%I;B!&:6YA;F-I
M86P@4F5P;W)T:6YG(%)E<75I<F5M96YT<RP@26YC;'5D:6YG(&%N($%M96YD
M;65N="!T;R!687)I86)L92!);G1E<F5S="!%;G1I=&EE<R!'=6ED86YC92!I
M;B!4;W!I8R`X,3`L($-O;G-O;&ED871I;VXF(S@R,C$[+B!4:&4@9W5I9&%N
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M8F5G:6YN:6YG(&%F=&5R($1E8V5M8F5R(#$U+"`R,#$T+"!A;F0@=&AE(&EN
M=&5R:6T@<&5R:6]D<R!T:&5R96EN+B!(;W=E=F5R+"!E87)L>2!A9&]P=&EO
M;B!I<R!P97)M:71T960N($%C8V]R9&EN9VQY+"!T:&4@0V]M<&%N>2!H87,@
M861O<'1E9"!T:&ES('-T86YD87)D(&1U<FEN9R!T:&4@<VEX(&UO;G1H<R!E
M;F1I;F<@2G5N92`S,"P@,C`Q-"X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R
M9VEN.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[(&-O;&]R.B`C,#`P,#`P.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG
M/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG
M;CH@;&5F=#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W
M;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI
M="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]P/CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!L969T.R!C;VQO
M<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[)SY4:&4@0V]M<&%N>2!D;V5S(&YO="!E>'!E8W0@=&AE
M(&%D;W!T:6]N(&]F(&%N>2!O=&AE<B!R96-E;G0@86-C;W5N=&EN9R!P<F]N
M;W5N8V5M96YT<R!T;R!H879E(&$@;6%T97)I86P@:6UP86-T(&]N(&ET<R!F
M:6YA;F-I86P@<W1A=&5M96YT<RX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6)S97%U96YT($5V96YT<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQP('-T>6QE/3-$)V-O
M;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N
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M(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
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M=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z
M(#!P>#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P
M<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[
M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E>'0M:6YD
M96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@
M;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R!T97AT
M+6%L:6=N.B!L969T.R<^5&AE($-O;7!A;GDF(S@R,3<[<R!M86YA9V5M96YT
M(')E=FEE=V5D(&%L;"!M871E<FEA;"!E=F5N=',@=&AR;W5G:"!T:&4@9&%T
M92!T:&4@9FEN86YC:6%L('-T871E;65N=',@=V5R92!I<W-U960@9F]R('-U
M8G-E<75E;G0@979E;G0@9&ES8VQO<W5R92!C;VYS:61E<F%T:6]N+CPO<#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8S,S0U
M93EF7V(V-&)?-#<S8E\X8F(P7S4W-&8V,6$P.6(R90T*0V]N=&5N="U,;V-A
M=&EO;CH@9FEL93HO+R]#.B\V,S,T-64Y9E]B-C1B7S0W,V)?.&)B,%\U-S1F
M-C%A,#EB,F4O5V]R:W-H965T<R]3:&5E=#$W+FAT;6P-"D-O;G1E;G0M5')A
M;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP
M93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@
M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%2T@^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X]
M,T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W5M;6%R>2!O9B!3:6=N:69I8V%N
M="!!8V-O=6YT:6YG(%!O;&EC:65S("A486)L97,I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5M;6%R>2!O9B!3
M:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T<F%C=%T\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@
M=F%L=64L(&9I;F%N8VEA;"!L:6%B:6QI=&EE<R!M96%S=7)E9"!O;B!R96-U
M<G)I;F<@8F%S:7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
M97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D
M+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT
M97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/"]P/CQT86)L92!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"!C86QI8G)I+"!H96QV971I8V$L('-A;G,M<V5R
M:68[('=I9'1H.B`Q-38W<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT
M+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P
M86-I;F<Z(#!P>#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N="US
M:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[)SX\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<@8V]L<W!A
M;CTS1#(^475O=&5D(%!R:6-E<SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R<@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T
M9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R<@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
M=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R<@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\+W1R
M/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CLG(&-O;'-P86X],T0R/DEN($%C=&EV
M93PO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<@8V]L<W!A;CTS1#(^4VEG;FEF:6-A;G0\+W1D/CQT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/B8C,38P.SPO=&0^/'1D/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CLG(&-O;'-P86X],T0R/E1O=&%L/"]T
M9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$
M)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\=&0^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<@8V]L<W!A;CTS1#(^36%R:V5T<R!F;W(\+W1D/CQT9"!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CLG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T
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M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<@8V]L<W!A;CTS
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M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG(&-O;'-P86X],T0R/D]B<V5R=F%B;&4\+W1D/CQT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG(&-O;'-P86X],T0R/E5N;V)S
M97)V86)L93PO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
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M.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG(&-O;'-P86X],T0R/DEN<'5T<SPO=&0^
M/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<@8V]L
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M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!B;W)D97(M8F]T
M=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[
M(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^1&5S8W)I<'1I;VX\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@8F]R9&5R
M+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N
M-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R
M/BA,979E;"`Q*3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M+C5P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,2XU<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E
M<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S
M;VQI9#LG(&-O;'-P86X],T0R/BA,979E;"`R*3PO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@8F]R9&5R+6)O='1O;2UC
M;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D
M97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/BA,979E;"`S
M*3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM
M=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O
M;'-P86X],T0R/C(P,30\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,2XU<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F
M.R<^/'1D('-T>6QE/3-$)W=I9'1H.B`X,35P>#L@=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[)SY$97)I=F%T:79E(&QI86)I;&ET:65S("8C.#(Q,3L@=V%R<F%N="!I
M;G-T<G5M96YT<SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+`T*('-E<FEF.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[('1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#)P>#L@
M=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^+3PO=&0^/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q-G!X.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@
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M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U<'@[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$U<'@[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)#PO
M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^,C4L-3@V+#DS,SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X
M.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^/"]T<CX\+W1A8FQE
M/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P
M,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[)SX\+W`^/'1A8FQE('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H.B`Q-38W<'@[
M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T
M97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@8F]R9&5R
M+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@
M9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED
M=&@Z(#!P>#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\=&0^)B,Q-C`[
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
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M-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R<^/'1D/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/DUA<FME=',@
M9F]R/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y
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M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^/'1D/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X]
M,T0R/DED96YT:6-A;#PO=&0^/'1D/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X]
M,T0R/D]B<V5R=F%B;&4\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9#XF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N
M/3-$,CY5;F]B<V5R=F%B;&4\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9#XF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS
M<&%N/3-$,CY686QU92!A<R!O9CPO=&0^/'1D/B8C,38P.SPO=&0^/"]T<CX\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQT9#XF(S$V
M,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!C96YT97([)R!C;VQS<&%N/3-$,CY!<W-E=',\+W1D/CQT9#XF(S$V,#L\
M+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([)R!C;VQS<&%N/3-$,CY);G!U=',\+W1D/CQT9#XF(S$V,#L\+W1D
M/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT
M97([)R!C;VQS<&%N/3-$,CY);G!U=',\+W1D/CQT9#XF(S$V,#L\+W1D/CQT
M9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M)R!C;VQS<&%N/3-$,CY$96-E;6)E<B`S,2P\+W1D/CQT9#XF(S$V,#L\+W1D
M/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E
M<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S
M;VQI9#LG/D1E<V-R:7!T:6]N/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R
M9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z
M('-O;&ED.R<@8V]L<W!A;CTS1#(^*$QE=F5L(#$I/"]T9#X\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M+6-O
M;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E
M<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^*$QE=F5L(#(I
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B
M;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T
M:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A
M;CTS1#(^*$QE=F5L(#,I/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R
M9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z
M('-O;&ED.R<@8V]L<W!A;CTS1#(^,C`Q,SPO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@(V-C965F9CLG/CQT9"!S='EL93TS1"=W:61T:#H@.#$U<'@[('1E>'0M
M86QI9VXZ(&QE9G0[)SY$97)I=F%T:79E(&QI86)I;&ET:65S("8C.#(Q,3L@
M=V%R<F%N="!I;G-T<G5M96YT<SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M-G!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[('1E
M>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$T
M,G!X.R!T97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D/CQT9"!S='EL93TS1"=W
M:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$V<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$T,G!X.R!T97AT+6%L:6=N.B!R:6=H=#LG/BT\
M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U<'@[('1E>'0M86QI9VXZ
M(&QE9G0[)SXD/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$T,7!X.R!T97AT
M+6%L:6=N.B!R:6=H=#LG/C0L,#@Y+#(X-#PO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@
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M.B`Q+C5P=#LG/D1E<FEV871I=F4@;&EA8FEL:71I97,@)B,X,C$Q.R!397)I
M97,@02!P<F5F97)R960@<W1O8VL\+W1D/CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R
M9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z
M('-O;&ED.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T
M=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[
M)SXM/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN
M9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
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M9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D#0H@<W1Y
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M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O<F1E<BUB
M;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P
M=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@8F]R9&5R+6)O='1O;2UC
M;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D
M97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG/C$V+#`Q-"PQ-#$\+W1D/CQT9"!S
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M93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
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M9&1I;F<M8F]T=&]M.B`T<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@
M8F]R9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D97(M8F]T=&]M+7-T>6QE
M.B!D;W5B;&4[)SXD/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M
M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/BT\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O
M='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#1P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M
M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L
M93LG/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@8F]R
M9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z
M(#1P=#L@8F]R9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R<^,C`L,3`S+#0R
M-3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`T<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
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M9RUB;W1T;VTZ(#1P=#LG/CPO=&0^/"]T<CX\+W1A8FQE/CQD:78^)B,Q-C`[
M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y&86ER('9A;'5E(&]F('1H92!#;VUP86YY($QE=F5L(%1H<F5E
M(&9I;F%N8VEA;"!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQT86)L92!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!C
M86QI8G)I+"!H96QV971I8V$L('-A;G,M<V5R:68[('=I9'1H.B`Q-38X<'@[
M(&AE:6=H=#H@,C$S<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN
M9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I
M;F<Z(#!P>#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N="US:7IE
M+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[)SX\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#$N-7!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CLG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D
M97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@
M<V]L:60[)R!C;VQS<&%N/3-$,3`^4VEG;FEF:6-A;G0@56YO8G-E<G9A8FQE
M($EN<'5T<R`H3&5V96P@,RD\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,2XU<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CLG(&-O;'-P86X],T0R/E-I>"!-;VYT:"8C,38P.SQB<B`O/D5N
M9&5D/&)R("\^2G5N92`S,"P\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG(&-O;'-P86X],T0R/EEE87(F(S$V,#L\8G(@
M+SY%;F1E9"8C,38P.SQB<B`O/D1E8V5M8F5R(#,Q+#PO=&0^/'1D('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS
M1#(^/'`@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/EEE87(\8G(@
M+SY%;F1E9#QB<B`O/D1E8V5M8F5R(#,Q+#PO<#X\+W1D/CQT9#XF(S$V,#L\
M+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M)SX\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#$N-7!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CLG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CL@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M
M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L
M:60[)R!C;VQS<&%N/3-$,CXR,#$T/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#$N-7!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B
M;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T
M;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^,C`Q,SPO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q,#`S<'@[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^0F5G:6YN
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M86XG+"!T:6UE<RP@<V5R:68[)SXH,C`L,3`S+#0R-3PO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL
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M)SXH-2PP.3`L.3@X/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U<'@[('1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^*3PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M-7!X.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!T
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M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^0VAA;F=E(&EN(&9A:7(@=F%L=64@;V8@9&5R:79A=&EV
M92!L:6%B:6QI=&EE<R!I;F-L=61E9"!I;B!N970@;&]S<R!F;W(@=&AE('-I
M>"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q-"!A;F0@9F]R('1H92!Y96%R
M<R!E;F1E9"8C,38P.R!$96-E;6)E<B`S,2P@,C`Q,R!A;F0@,C`Q,BP@<F5S
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M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^*#$R+#@W-RPV
M-S4\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/BD\+W1D
M/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^*#,L-C@X+#,U,SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^*3PO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F
M9CLG/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/D%D9&ET:6]N
M<R8C.#(Q,3L@=V%R<F%N="!I;G-T<G5M96YT<SPO=&0^/'1D/CQF;VYT/B8C
M,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[)SXH-"PS,S,L,38S/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^*3PO9F]N
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M:68[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[)SXH,S<\+V9O;G0^/&9O;G0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R<^,RPV.3D\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N
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M969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
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M;65S+"!S97)I9CLG/D%D9&ET:6]N<R`F(S@R,3$[(&-O;G9E<G-I;VX@9F5A
M='5R92!O9B!397)I97,@02!P<F5F97)R960@<W1O8VL\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B;W)D97(M8F]T=&]M+6-O;&]R
M.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB
M;W1T;VTM<W1Y;&4Z('-O;&ED.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K
M.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US
M='EL93H@<V]L:60[)SXM/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!B;W)D97(M8F]T=&]M
M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O
M<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!B;W)D97(M8F]T=&]M+6-O;&]R
M.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB
M;W1T;VTM<W1Y;&4Z('-O;&ED.R<^*#$L-S8Q+#`V,SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M)SXI/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!B
M;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T
M:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!B;W)D97(M
M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU
M<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^*#$L,C@S+#8P-CPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T
M=&]M.B`Q+C5P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!B
M;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T
M:#H@-'!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[)SXD/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!B;W)D97(M8F]T=&]M
M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D
M97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[)SXH,C`L,3`S+#0R-3PO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`T
M<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^*3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I
M9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/B0\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&)O<F1E<BUB;W1T
M;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O
M<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/B@U+#`Y,"PY.#@\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@
M-'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/BD\+W1D/CPO='(^/"]T86)L93X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA<GD@;V8@86YT:2UD
M:6QU=&EV92!S96-U<FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'1A8FQE('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!W:61T:#H@,3`P)3L@8F]R9&5R
M+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@
M9F]N="US=')E=&-H.B!N;W)M86P[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R<^/'1D/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P
M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM
M=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O
M;'-P86X],T0R/E-I>"!-;VYT:"`\8G(@+SX@16YD960@/&)R("\^2G5N92`S
M,"P@/&)R("\^(#(P,30\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D
M97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@
M<V]L:60[)R!C;VQS<&%N/3-$,CX\<"!S='EL93TS1"=M87)G:6XM=&]P.B`P
M<'@[(&UA<F=I;BUB;W1T;VTZ(#!P>#LG/EEE87(\+W`^/'`@<W1Y;&4],T0G
M;6%R9VEN+71O<#H@,'!X.R!M87)G:6XM8F]T=&]M.B`P<'@[)SY%;F1E9"`\
M8G(@+SY$96-E;6)E<B`S,2P@/&)R("\^(#(P,3,\+W`^/"]T9#X\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M
M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O
M<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^665A<CQB
M<B`O/B!%;F1E9"`\8G(@+SY$96-E;6)E<B`S,2P\8G(@+SX@,C`Q,CPO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO
M=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT9"!S='EL93TS1"=W:61T
M:#H@-C0E.R!T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6QE9G0Z(#!P=#LG
M/D-L87-S($$@8V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K/"]T9#X\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=VED=&@Z(#DE.R!T97AT+6%L:6=N.B!R:6=H=#LG/C,L,S,W
M+#,P.3PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3L@=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Y)3L@=&5X
M="UA;&EG;CH@<FEG:'0[)SXM/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$E.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E
M.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
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M<F5D('-T;V-K/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R<^+3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[)SXQ,S8L,#0Q+#(W-3PO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXX+#4P,RPU,#,\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@,'!T.R<^0V]M;6]N('-T;V-K
M('=A<G)A;G1S/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R<^-#,L,30T+#4U-SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@
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M)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,2XU<'0[('!A
M9&1I;F<M;&5F=#H@,'!T.R<^0V]M;6]N('-T;V-K(&]P=&EO;G,\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B;W)D97(M8F]T=&]M
M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O
M<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z
M(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O
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M:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB
M;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P
M=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)SXQ."PV-30L,#DW/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T
M;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E
M<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S
M;VQI9#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I
M9VAT.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O
M;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^
M-C<W+#DV,CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@(V-C965F9CLG/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!T
M.R!P861D:6YG+6QE9G0Z(#4N-'!T.R<^5&]T86P\+W1D/CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA
M8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#1P=#L@8F]R9&5R+6)O='1O;2US
M='EL93H@9&]U8FQE.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D
M97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O
M=6)L93LG/C0Y+#@T-RPP,S<\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!P861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P=#LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O<F1E<BUB;W1T;VTM8V]L
M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB
M;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C
M:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D97(M8F]T=&]M+7-T
M>6QE.B!D;W5B;&4[)SXR-#,L.38P+#4S,CPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`T<'0[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F]R9&5R+6)O
M='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#1P=#L@
M8F]R9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTM8V]L
M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB
M;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/C$T+#`T-BPW,#`\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@-'!T.R<^
M)B,Q-C`[/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%\V,S,T-64Y9E]B-C1B7S0W,V)?.&)B,%\U
M-S1F-C%A,#EB,F4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C,S
M-#5E.69?8C8T8E\T-S-B7SAB8C!?-3<T9C8Q83`Y8C)E+U=O<FMS:&5E=',O
M4VAE970Q."YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/DYO=&5S(%!A>6%B;&4@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.;W1E<R!087EA8FQE(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-C:&5D=6QE(&]F('!R;VUI<W-O<GD@;F]T97,@9'5E(&QO86X\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/B8C,38P.SPO
M9&EV/CQT86)L92!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!W:61T:#H@,34V-W!X.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[(&)O<F1E<BUC;VQL
M87!S93H@8V]L;&%P<V4[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<B!S='EL
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M+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,CY*=6YE(#,P+#QB<B`O/C(P
M,30\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[('1E
M>'0M86QI9VXZ(&-E;G1E<CLG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q+C5P=#L@=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D
M97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@
M,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS
M1#(^1&5C96UB97(@,S$L)B,Q-C`[/&)R("\^,C`Q,SPO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/"]T<CX\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@(V-C965F9CLG/CQT9"!S='EL93TS1"=W:61T:#H@,3$W.7!X
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@+3EP=#L@<&%D
M9&EN9RUL969T.B`Y<'0[)SY3=6)O<F1I;F%T960@."4@<')O;6ES<V]R>2!N
M;W1E<R!D=64@1&5C96UB97(@,C`Q,SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q-G!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[
M('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$T,G!X.R!T97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D/CQT9"!S='EL93TS
M1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$U<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$T,7!X.R!T97AT+6%L:6=N.B!R:6=H=#LG
M/C(Q-BPP,#`\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[
M)SX\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@<&%D9&EN9RUB
M;W1T;VTZ(#$N-7!T.R!T97AT+6EN9&5N=#H@+3EP=#L@<&%D9&EN9RUL969T
M.B`Y<'0[)SY3=6)O<F1I;F%T960@."4@<')O;6ES<V]R>2!N;W1E<R!D=64@
M4V5P=&5M8F5R(#(P,30\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[
M(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R!T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO
M<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M
M8F]T=&]M+7-T>6QE.B!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXM/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N
M-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#L@=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM
M8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R
M9&5R+6)O='1O;2US='EL93H@<V]L:60[('1E>'0M86QI9VXZ(')I9VAT.R<^
M-C@T+#`P,#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P
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M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M)SXM/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#LG/CDP,"PP,#`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!P861D:6YG+6)O='1O;3H@
M,2XU<'0[('!A9&1I;F<M;&5F=#H@,'!T.R<^3&5S<SH@9&5B="!D:7-C;W5N
M=#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L
M86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O
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M;W1T;VTM<W1Y;&4Z('-O;&ED.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[
M(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T
M>6QE.B!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[)SXH,30Q+#`T.3PO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@=&5X="UA;&EG
M;CH@;&5F=#LG/BD\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@<&%D9&EN9RUB;W1T;VTZ
M(#1P=#L@<&%D9&EN9RUL969T.B`P<'0[)SY4;W1A;"!N;W1E<R!P87EA8FQE
M+"!L97-S(&1E8G0@9&ES8V]U;G0\+W1D/CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#1P
M=#L@8F]R9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R!T97AT+6%L:6=N.B!L
M969T.R<^)#PO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z
M(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T
M;VTM<W1Y;&4Z(&1O=6)L93L@=&5X="UA;&EG;CH@<FEG:'0[)SXM/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P=#L@=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`T<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
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M969T.R<^)B,Q-C`[/"]T9#X\+W1R/CPO=&%B;&4^/'`@<W1Y;&4],T0G8V]L
M;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M,38P.SPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
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M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%,D8^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^1&5R:79A=&EV92!,
M:6%B:6QI=&EE<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E<FEV871I=F4@3&%I8FEL:71I97,@
M6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4V-H961U;&4@;V8@1&5R:79A=&EV92!,:6%B:6QI=&EE<R!6
M86QU871I;VYS($UO9&5L<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[(&-O;&]R
M.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z
M(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN+71O<#H@,'!X
M.R!M87)G:6XM<FEG:'0Z(#!P>#L@;6%R9VEN+6)O='1O;3H@,'!X.R!W;W)D
M+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT
M97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]P/CQT86)L92!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!W:61T:#H@,34V-W!X.R!T97AT+71R86YS9F]R;3H@;F]N
M93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M=V]R9"US<&%C:6YG.B`P<'@[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[
M(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)R!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<B!S='EL93TS1"=V97)T:6-A;"UA
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M/3-$,CY*=6YE(#,P/"]T9#X\=&0^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D('-T>6QE/3-$)W!A
M9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE
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M;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@
M8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CXR,#$T
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q
M-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q,3(Y<'@[('1E>'0M86QI9VXZ(&QE9G0[)SY#;VUM;VX@<W1O
M8VL@:7-S=6%B;&4@=7!O;B!E>&5R8VES92!O9B!W87)R86YT<R`F(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$W,W!X.R!T97AT+6%L:6=N
M.B!R:6=H=#LG/C,P+#`S-BPV-#@\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M,39P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q-7!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$U<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=W:61T:#H@,3<R<'@[('1E>'0M86QI9VXZ(')I9VAT.R<^,S`L
M,#,V+#8T.#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T
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M+C`P/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT9#Y%>&5R8VES92!P
M<FEC93PO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SXD/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,2XU,"!A;F0@,BXR-3PO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[)SXQ+C4P(&%N9"`R+C(U/"]F;VYT/CPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SY2:7-K(&9R964@:6YT97)E<W0@<F%T92`H,BD\+W1D/CQT
M9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXQ
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M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SY%>'!E8W1E9"!L:69E(&EN('EE87)S/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/B8C,38P.S`N,R!A;F0@-3PO9F]N=#X\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\
M=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/C`N,R!A;F0@-"XY/"]F;VYT/CPO=&0^
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M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[)B,Q-C`[-S$@86YD(#<S)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXE/"]T9#X\
M+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SY%>'!E8W1E9"!D:79I9&5N9"!Y:65L9',@*#0I/"]T9#X\
M=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^
M3F]N93PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[)SY.;VYE/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^/"]T<CX\+W1A8FQE/CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P
M,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[
M(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W
M:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[)SXF(S$V,#L\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
M<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E
M.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CPO
M<#X\=&%B;&4@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=VED=&@Z(#$U-C=P>#L@=&5X="UT
M<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C
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M:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`P<'0[)SXH,BD\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL
M969T.B`P<'0[)SY4:&4@<FES:RUF<F5E(&EN=&5R97-T(')A=&4@=V%S(&1E
M=&5R;6EN960@8GD@;6%N86=E;65N="!U<VEN9R!T:&4@,3QF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[)SXF(S$V,#MA;F0@-2`M('EE87(@5')E87-U<GD@0FEL;"!A
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M;&ET>2!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS('!E97(@9W)O=7`N/"]T9#X\
M+W1R/CPO=&%B;&4^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O
M;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E
M;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG
M.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[#0H@+7=E8FMI="UT97AT+7-T
M<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ
M(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M
M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V,#LF(S$V,#L\
M+W`^/'1A8FQE('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H.B`Q-38W<'@[('1E>'0M
M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A
M8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@8F]R9&5R+6-O;&QA
M<'-E.B!C;VQL87!S93L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US
M=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
M>#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\=&0^)B,Q-C`[/"]T9#X\
M=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
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M,T0R/D%T/"]T9#X\=&0^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D/B8C,38P.SPO=&0^/'1D/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CLG(&-O
M;'-P86X],T0R/G9A;'5A=&EO;G,\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9#XF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C
M;VQS<&%N/3-$,CYV86QU871I;VYS/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@
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M;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL
M93H@<V]L:60[)R!C;VQS<&%N/3-$,CXR,#$S/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M+6-O;&]R
M.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB
M;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^,C`Q,CPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O
M='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T
M.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/C(P
M,3,\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([
M(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I
M9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS
M<&%N/3-$,CXR,#$R/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#$N-7!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^
M/'1D('-T>6QE/3-$)W=I9'1H.B`X,35P>#L@=&5X="UA;&EG;CH@;&5F=#LG
M/D-O;6UO;B!S=&]C:R!I<W-U86)L92!U<&]N(&5X97)C:7-E(&]F('=A<G)A
M;G1S/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#)P>#L@=&5X="UA
M;&EG;CH@<FEG:'0[)SXR,BPS,S,L-3DS/"]T9#X\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$V<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=W:61T:#H@,39P>#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$T,G!X.R!T97AT+6%L:6=N.B!R:6=H=#LG
M/C$Y+#,X-2PQ-3<\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q-7!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U<'@[
M('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W
M:61T:#H@,30Q<'@[('1E>'0M86QI9VXZ(')I9VAT.R<^-#$L-S$X+#<U,#PO
M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U<'@[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#%P>#L@
M=&5X="UA;&EG;CH@<FEG:'0[)SXQ.2PS.#4L,34W/"]T9#X\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$U<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A
M8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`M-2XU<'0[('!A9&1I;F<M;&5F=#H@
M-2XU<'0[)SY#;VUM;VX@<W1O8VL@:7-S=6%B;&4@=7!O;B!C;VYV97)S:6]N
M(&]F(%-E<FEE<R!!('!R969E<G)E9"!S=&]C:SPO=&0^/'1D/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C4Q+#`P-BPR-3`\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R<^.#4L,#,U+#`R-3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[)SXQ,S8L,#0Q+#(W-3PO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\
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M/C`N,3D\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)3PO
M=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#LG/C`N,C`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)3PO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#LG/C`N,S@\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)3PO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#LG/C`N,3D\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)3PO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/D5X<&5C=&5D(&QI9F4@:6X@>65A<G,\
M+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[)SXQ+C0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
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M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXQ+C0\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY%
M>'!E8W1E9"!V;VQA=&EL:71Y("@S*3PO=&0^/'1D/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9`T*
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M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXV.#PO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXE/"]T9#X\=&0^)B,Q-C`[/"]T
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M<&5C=&5D(&1I=FED96YD('EI96QD<R`H-"D\+W1D/CQT9#XF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SY.;VYE/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/DYO;F4\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R<^3F]N93PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[)SY.;VYE/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\+W1A8FQE/CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\8CXF(S$V,#L\
M+V(^/"]P/CQT86)L92!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!W:61T:#H@,34V-W!X.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[(&)O<F1E<BUC
M;VQL87!S93H@8V]L;&%P<V4[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R<^/'1D('-T>6QE/3-$)W=I
M9'1H.B`U-2XX,7!X.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL
M969T.B`P<'0[)SXH,2D\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,30X.2XV
M,G!X.R!P861D:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P
M=#LG/E1H92!M87)K970@=F%L=64@:7,@=&AE(&-A;&-U;&%T960@9F%I<B!V
M86QU92!O9B!T:&4@8V]M;6]N('-T;V-K('!U<G-U86YT('1O('1H92!V86QU
M871I;VX@=&5C:&YI<75E(&%S(&1E<V-R:6)E9"!A8F]V92X\+W1D/CPO='(^
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[)SX\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A9&1I;F<M;&5F=#H@,'!T.R<^
M*#(I/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUR:6=H=#H@-2XT<'0[('!A
M9&1I;F<M;&5F=#H@-2XT<'0[)SY4:&4@<FES:RUF<F5E(&EN=&5R97-T(')A
M=&4@=V%S(&1E=&5R;6EN960@8GD@;6%N86=E;65N="!U<VEN9R!T:&4@,2P@
M,B!O<B`S("T@>65A<B!4<F5A<W5R>2!":6QL(&%S(&]F('1H92!M96%S=7)E
M;65N="!D871E+CPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ('1O<#LG/CQT9"!S='EL93TS1"=P861D:6YG+7)I9VAT.B`U+C1P=#L@
M<&%D9&EN9RUL969T.B`P<'0[)SXH,RD\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG+7)I9VAT.B`U+C1P=#L@<&%D9&EN9RUL969T.B`U+C1P=#LG/E1H92!H
M:7-T;W)I8V%L('1R861I;F<@=F]L871I;&ET>2!W87,@9&5T97)M:6YE9"!B
M>2!C86QC=6QA=&EN9R!T:&4@=F]L871I;&ET>2!O9B!T:&4@0V]M<&%N>28C
M.#(Q-SMS('!E97(@9W)O=7`N/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L
M92!O9B!$97)I=F%T:79E($QI86)I;&ET:65S(&%T($9A:7(@5F%L=64\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P
M,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T
M:#H@,'!X.R<^)B,Q-C`[/"]P/CQT86)L92!S='EL93TS1"=F;VYT.B`X<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H
M.B`Q-38W<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@
M,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P
M>#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N="US:7IE+6%D:G5S
M=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\
M=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6%L:6=N.B!C96YT97([
M('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW
M96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6EN
M9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N
M;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@8V5N
M=&5R.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=V5I9VAT.B!N;W)M86P[)R!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^0F%L86YC92!A="!$96-E;6)E<B8C,38P.S,Q+#PO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P
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M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@8V5N=&5R.R!T97AT+6EN9&5N
M=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[)R!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^26YI=&EA
M;"!V86QU871I;VX@;V8@9&5R:79A=&EV93PO9F]N=#X\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
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M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CQB<B`O/CQF;VYT
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M9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[(&9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4]
M,T0G<&%D9&EN9SH@,'!X.R!T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD
M96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#LG(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SY);F-R
M96%S92`H9&5C<F5A<V4I(&EN(&9A:7(@=F%L=64@;V8@9&5R:79A=&EV93PO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M:6YD
M96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6EN9&5N=#H@,'!X
M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@8V5N=&5R.R!T97AT
M+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT
M.B!N;W)M86P[)R!C;VQS<&%N/3-$,CX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M1F%I<B!V86QU92!O9CPO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[9&5R:79A=&EV97,\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R<^)B,Q-C`[/&)R("\^=7!O;B!R96-L87-S('1O(&%D9&ET:6]N86P@<&%I
M9"UI;CPO9F]N=#X\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@
M,'!X.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X
M="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ
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M;65S+"!S97)I9CLG/CQB<B`O/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z
M(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N
M;W)M86P[)SY*=6YE(#,P+#PO9F]N=#X\+V9O;G0^/"]T9#X\=&0@<W1Y;&4]
M,T0G<&%D9&EN9SH@,'!X.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQT9"!S='EL93TS1"=P861D:6YG
M.B`P<'@[('1E>'0M86QI9VXZ(&-E;G1E<CL@=&5X="UI;F1E;G0Z(#!P>#L@
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y
M;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9SH@,'!X.R!T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P
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M93TS1"=P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y
M;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9SH@,'!X.R!T97AT+6%L:6=N.B!C96YT97([('1E>'0M:6YD96YT.B`P
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M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P
M861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&-E;G1E<CL@=&5X="UI;F1E;G0Z
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M/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[
M(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y
M;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6%L:6=N.B!C96YT97([('1E>'0M
M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
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M.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UI;F1E;G0Z
M(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&-E;G1E<CL@
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M.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT9"!S='EL93TS1"=P
M861D:6YG.B`P<'@@,'!X(#!P>"`Q,'!X.R!T97AT+6EN9&5N=#H@+3$P<'@[
M(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[)SY#;VYV97)T:6)L92!P<F5F97)R960@9&5R
M:79A=&EV92!L:6%B:6QI='D@:7-S=65D(&EN)B,Q-C`[8V]N;F5C=&EO;B!W
M:71H(%-E<FEE<R!!('!R969E<G)E9"!S=&]C:R!O9F9E<FEN9SPO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P
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M9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UI;F1E
M;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(')I9VAT
M.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)#PO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ
M(')I9VAT.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M+28C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[
M('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW
M96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6EN
M9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N
M;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@<FEG
M:'0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXD/"]F
M;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG
M;CH@<FEG:'0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA
M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M)SXH-RPR,30L.#`T/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z
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M9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG
M;CH@<FEG:'0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA
M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M)SXD/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X
M="UA;&EG;CH@<FEG:'0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z
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M;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X
M="UA;&EG;CH@<FEG:'0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z
M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[)SXD/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P
M>#L@=&5X="UA;&EG;CH@<FEG:'0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M
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M('-T>6QE/3-$)W!A9&1I;F<Z(#!P>"`P<'@@,'!X(#$P<'@[('=I9'1H.B`V
M,3=P>#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z("TQ,'!X.R!F
M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^0V]N=F5R=&EB;&4@<')E9F5R<F5D(&1E<FEV
M871I=F4@;&EA8FEL:71Y(&ES<W5E9"!T;R!7;VYP=6YG(&9O<B!S97)V:6-E
M<SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('=I9'1H
M.B`Q-G!X.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@
M=VED=&@Z(#$V<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P
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M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^,BPP,S`L-3@Y/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z
M(#!P>#L@=VED=&@Z(#$V<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD
M96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
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M=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('=I9'1H.B`Q-G!X
M.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T
M>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A
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M1"=P861D:6YG.B`P<'@[('=I9'1H.B`Q-G!X.R!T97AT+6EN9&5N=#H@,'!X
M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=VED=&@Z(#$V<'@[('1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP-"B!S97)I9CLG
M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[
M('=I9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@<FEG:'0[('1E>'0M:6YD96YT
M.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXH,2PS-S`L,C8R/"]F;VYT/CPO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=VED=&@Z(#$U<'@[('1E
M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z
M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[)SXI/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P
M>#L@=VED=&@Z(#$U<'@[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z
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M+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('=I9'1H.B`Q-#%P>#L@
M=&5X="UA;&EG;CH@<FEG:'0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y
M;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[)SXH-C8P+#,R-SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P
M861D:6YG.B`P<'@[('=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R!T
M97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^*3PO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('=I9'1H.B`Q-7!X.R!T
M97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=VED=&@Z(#$U
M<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M
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M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^+3PO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('=I9'1H.B`Q-7!X
M.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T
M>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M(V-C965F9CLG/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@@,'!X(#!P>"`Q
M,'!X.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@+3$P<'@[(&9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[)SY#;VYV97)T:6)L92!P<F5F97)R960@9&5R:79A
M=&EV92!L:6%B:6QI='D@:7-S=65D('1O(&QE;F1E<G,@:6X@8V]N;F5C=&EO
M;B!W:71H(&5X8VAA;F=E(&]F(&1E8G0@9F]R(%-E<FEE<R!!('!R969E<G)E
M9"!S=&]C:SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[
M('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW
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M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P
M>#L@=&5X="UA;&EG;CH@<FEG:'0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M
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M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UI;F1E;G0Z(#!P>#L@
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD
M96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
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M(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@
M=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA
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M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^*3PO9F]N=#X\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M
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M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@<FEG:'0[('1E
M>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXH.34V+#DY-CPO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA
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M=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
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M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@=VAI=&4[)SX\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X(#!P>"`P<'@@
M,3!P>#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z("TQ,'!X.R!F
M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^5V%R<F%N=',@:7-S=65D(&EN(&-O;FYE8W1I
M;VX@=VET:"!397)I97,@02!P<F5F97)R960@<W1O8VL@;V9F97)I;F<\+V9O
M;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6EN9&5N
M=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@;&5F=#L@
M=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI
M9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^,BPT,C0L,38W/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z
M(#!P>#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N
M="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P-"B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[
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M9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UI;F1E
M;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[
M('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW
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M="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^*3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P
M861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO
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M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@<FEG:'0[('1E>'0M:6YD96YT
M.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXH-#<X+#0Y.#PO9F]N=#X\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[
M('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW
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M9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG
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M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F
M9CLG/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@@,'!X(#!P>"`Q,'!X.R!T
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M9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P
M<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M
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M=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/C$L,C$W+#`X,SPO9F]N=#X\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[
M('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW
M96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6EN
M9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N
M;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@;&5F
M=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N
M;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P
M.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M
M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^+3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[
M('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y
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M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P
M>#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P
M861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@
M,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[
M)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^*#$L,3`Y+#0R,3PO9F]N=#X\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[
M('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW
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M9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E
M>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG
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M(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@
M=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG.B`P<'@[('1E>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!X
M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^+3PO9F]N=#X\+W1D/CQT9"!S='EL93TS
M1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\
M+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT9"!S='EL93TS1"=P861D:6YG.B`P
M<'@@,'!X(#!P>"`Q,'!X.PT*('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD
M96YT.B`M,3!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/E=A<G)A;G1S(&ES<W5E
M9"!T;R!L96YD97)S(&EN(&-O;FYE8W1I;VX@=VET:"!S=6)O<F1I;F%T960@
M<')O;6ES<V]R>2!N;W1E<R!O9F9E<FEN9SPO9F]N=#X\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y
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M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@<FEG:'0[('1E>'0M
M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
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M,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E
M>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6%L:6=N
M.B!L969T.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@
M=&5X="UA;&EG;CH@<FEG:'0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y
M;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[)SXM/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z
M(#!P>#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N
M="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS
M1"=P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z
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M="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@<FEG:'0[('1E>'0M:6YD
M96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXH,C4Y+#0R-SPO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
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M/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[
M('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW
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M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^*3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA
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M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@<FEG:'0[('1E>'0M:6YD96YT.B`P
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M9SH@,'!X(#!P>"`P<'@@,3!P>#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI
M;F1E;G0Z("TQ,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT
M.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
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M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI
M;F1E;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(')I
M9VAT.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,3,V
M+#,U.3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E
M>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z
M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN
M9SH@,'!X.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@
M=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG.B`P<'@[('1E>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!X
M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^+3PO9F]N=#X\+W1D/CQT9"!S='EL93TS
M1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6EN9&5N=#H@,'!X.R!F
M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N
M="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E
M;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D
M/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(')I9VAT
M.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^*#$S-BPS
M-3D\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT
M+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^*3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[
M('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW
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M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P
M>#L@=&5X="UA;&EG;CH@<FEG:'0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M
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M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P
M861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P
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M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX\=&0@<W1Y;&4]
M,T0G<&%D9&EN9SH@,'!X(#!P>"`P<'@@,3!P>#L@=&5X="UA;&EG;CH@;&5F
M=#L@=&5X="UI;F1E;G0Z("TQ,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^4V5R
M:65S($$@=V%R<F%N=',@:7-S=65D(&EN($UA>2!A;F0@2G5N92`R,#$T(&]F
M9F5R:6YG/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@
M=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA
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M="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[
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M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/C@T,BPS-S`\+V9O;G0^
M/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6%L:6=N.B!L
M969T.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X
M="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
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M861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P
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M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z
M(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(')I9VAT.R!T
M97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^+3PO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE
M9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT
M+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT
M.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@
M;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C
M,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E
M>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^,3`L,#0P+#@R,CPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P
M861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P
M<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R
M/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P
M>"`P<'@@,'!X(#$P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT
M.B`M,3!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
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M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA
M;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P
M<'@[('1E>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^+3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[
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M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P
M>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(')I9VAT.R!T97AT
M+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT
M.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
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M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[
M('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW
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M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P
M>#L@=&5X="UA;&EG;CH@<FEG:'0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M
M<W1Y;&4Z#0H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CLG/C<L-#`P+#(W-3PO9F]N=#X\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD
M96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6EN9&5N=#H@,'!X
M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\
M9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI
M;F1E;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(')I
M9VAT.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^+3PO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA
M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X
M.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA
M;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P
M<'@[('1E>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
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M(#!P>"`P<'@@,'!X(#$P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD
M96YT.B`M,3!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/E!L86-E;65N="!!9V5N
M="!W87)R86YT<R!I<W-U960@:6X@8V]N;F5C=&EO;B!W:71H($UA>2!A;F0@
M2G5N92`R,#$T(&]F9F5R:6YG/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<Z(#!P>#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P
M<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M
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M="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[
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M;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UI;F1E;G0Z(#!P
M>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S
M='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M
M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
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M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/C0L-C4U+#`T,SPO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI9VXZ
M(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T
M97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F
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M.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M
M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&)O<F1E<BUB;W1T;VTM8V]L
M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R
M+6)O='1O;2US='EL93H@<V]L:60[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M+3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M
M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO
M<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@
M,'!X.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X
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M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[
M('1E>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T
M>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&)O<F1E<BUB;W1T
M;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@
M8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)SX\9F]N="!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
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M9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^5&]T86P\+V9O
M;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6EN9&5N
M=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L-"B!T97AT+6%L:6=N.B!L969T
M.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B
M;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z
M(&1O=6)L93LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXD/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@<FEG:'0[
M('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW
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M(&9O;G0M=V5I9VAT.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@
M=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M86QI
M9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA
M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@
M8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#1P=#L@8F]R9&5R+6)O='1O
M;2US='EL93H@9&]U8FQE.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N
M;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B0\+V9O
M;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9SH@,'!X.R!T97AT+6%L:6=N
M.B!R:6=H=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B
M;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D97(M8F]T=&]M
M+7-T>6QE.B!D;W5B;&4[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^-"PS,S,L
M,38S/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X
M="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG
M.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
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M8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E
M<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/CQF;VYT('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M)SXD/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z(#!P>#L@=&5X
M="UA;&EG;CH@<FEG:'0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M<W1Y;&4Z
M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@8F]R9&5R+6)O='1O;2UC
M;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#1P=#L@8F]R9&5R
M+6)O='1O;2US='EL93H@9&]U8FQE.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/C<L.34T+#DW,#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P
M<'@[('1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD96YT.B`P<'@[(&9O;G0M
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M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<Z
M(#!P>#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#L@9F]N
M="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!B;W)D97(M
M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!T
M.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[)SX\9F]N="!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG.B`P
M<'@[('1E>'0M86QI9VXZ(')I9VAT.R!T97AT+6EN9&5N=#H@,'!X.R!F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&)O<F1E<BUB
M;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[
M(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[)SXH-BPX,#0L-C(U/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A
M9&1I;F<Z(#!P>"`P<'@@-'!X.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN
M9&5N=#H@,'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N
M;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^*3PO9F]N=#X\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG.B`P<'@[('1E>'0M:6YD96YT.B`P<'@[(&9O
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M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[)SXD/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<Z(#!P>#L@=&5X="UA;&EG;CH@<FEG:'0[('1E>'0M:6YD96YT
M.B`P<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
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M.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/"]T<CX\+W1A8FQE/CQP('-T>6QE/3-$)V9O;G0Z(#$S<'@O;F]R
M;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&-O;&]R.B`C
M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P
M>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;6%R9VEN+71O<#H@,'!X.R!M
M87)G:6XM8F]T=&]M.B`P<'@[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M)SX\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3-P>"]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@8V]L;W(Z(",P,#`P,#`[('1E>'0M
M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A
M8VEN9SH@;F]R;6%L.R!M87)G:6XM=&]P.B`P<'@[(&UA<F=I;BUB;W1T;VTZ
M(#!P>#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[
M("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.R8C,38P
M.SPO<#X\=&%B;&4@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=VED=&@Z(#$U-C=P>#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS
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M(&-O;'-P86X],T0R/DEN:71I86P@=F%L=6%T:6]N/"]T9#X\=&0^)B,Q-C`[
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R<@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T
M9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N
M=&5R.R<@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
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M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A
M;CTS1#(^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T
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M;F-E(&%T/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^:7-S
M=6%N8V4@;V8@;F5W(&1E<FEV871I=F5S/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
M=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R<@8V]L<W!A;CTS1#(^26YC<F5A<V4@:6X@9F%I<B!V86QU92!O9CPO=&0^
M/'1D/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CLG(&-O;'-P86X],T0R/D)A;&%N8V4@870\+W1D
M/CQT9#XF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SX\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^1&5C96UB97(-"B`S,2P\
M+W1D/CQT9#XF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,CYD=7)I;F<\+W1D
M/CQT9#XF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N/3-$,CYD97)I=F%T:79E/"]T
M9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^1&5C96UB97(@,S$L
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CLG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
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M.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US
M='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CYT:&4@<&5R:6]D/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T
M=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[
M(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^;&EA
M8FEL:71I97,\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU
M<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C
M96YT97([(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T
M=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[
M)R!C;VQS<&%N/3-$,CXR,#$S/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E
M969F.R<^/'1D/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
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M>6QE/3-$)W=I9'1H.B`X,#(N.3-P>#L@=&5X="UA;&EG;CH@;&5F=#L@=&5X
M="UI;F1E;G0Z("TY+C`U<'0[('!A9&1I;F<M;&5F=#H@.2XP-7!T.R<^0V]N
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M)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q-#)P>#L@=&5X="UA;&EG;CH@<FEG:'0[)SXQ+#8T
M-RPY,3`\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U<'@[('1E>'0M
M86QI9VXZ(&QE9G0[)SXD/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$T,7!X
M.R!T97AT+6%L:6=N.B!R:6=H=#LG/C<L-C(R+#`S.3PO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U<'@[)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=W:61T:#H@,35P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D
M/CQT9"!S='EL93TS1"=W:61T:#H@,30Q<'@[('1E>'0M86QI9VXZ(')I9VAT
M.R<^,3$L-S8R+#$Q-3PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C
M8V-E969F.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M
M:6YD96YT.B`M.2XP-7!T.R!P861D:6YG+6QE9G0Z(#DN,#5P=#LG/D-O;G9E
M<G1I8FQE('!R969E<G)E9"!D97)I=F%T:79E(&QI86)I;&ET>2!I<W-U960@
M=&\@5V]N<'5N9R!F;W(@<V5R=FEC97,\+W1D/CQT9#XF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXX.#`L,C$T/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\
M=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^
M,2PQ-3`L,S<U/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
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M.B`M.2XP-7!T.R!P861D:6YG+6QE9G0Z(#DN,#5P=#LG/D-O;G9E<G1I8FQE
M('!R969E<G)E9"!D97)I=F%T:79E(&QI86)I;&ET>2!I<W-U960@=&\@;&5N
M9&5R<R!I;B!C;VYN96-T:6]N('=I=&@@97AC:&%N9V4@;V8@9&5B="!F;W(@
M4V5R:65S($$@<')E9F5R<F5D('-T;V-K/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^.34X+#@V,3PO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9#XF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXM/"]T
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M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@<FEG:'0[)SXR+#(Q.2PX-30\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E
M969F.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M:6YD
M96YT.B`M.2XP-7!T.R!P861D:6YG+6QE9G0Z(#DN,#5P=#LG/E=A<G)A;G1S
M(&ES<W5E9"!I;B!C;VYN96-T:6]N('=I=&@@4V5R:65S($$@<')E9F5R<F5D
M('-T;V-K(&]F9F5R:6YG/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(')I9VAT.R<^-#<U+#`P,#PO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXQ,3,L,34S/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C$L
M.#,V+#`Q-#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[)SXR+#0R-"PQ-C<\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@
M+3EP=#L@<&%D9&EN9RUL969T.B`Y+C`U<'0[)SY787)R86YT<R!I<W-U960@
M87,@;V9F97)I;F<@8V]S=',@=&\@<&QA8V5M96YT(&%G96YT/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,C0R
M+#4P,#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[)SXR-#@L-C4U/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!R:6=H=#LG/C<R-2PY,C@\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
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M.B!L969T.R!T97AT+6EN9&5N=#H@+3DN,#5P=#L@<&%D9&EN9RUL969T.B`Y
M+C`U<'0[)SY787)R86YT<R!I<W-U960@=&\@;&5N9&5R<R!I;B!C;VYN96-T
M:6]N('=I=&@@<W5B;W)D:6YA=&5D('!R;VUI<W-O<GD@;F]T97,@;V9F97)I
M;F<\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[)SXR.2PQ-3@\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
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M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,S$S+#(U
M.#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[
M(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^/'1D#0H@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z("TY+C`U<'0[('!A9&1I;F<M
M8F]T=&]M.B`Q+C5P=#L@<&%D9&EN9RUL969T.B`Y+C`U<'0[)SY787)R86YT
M<R!I<W-U960@=&\@<&QA8V5M96YT(&%G96YT(&EN(&-O;FYE8W1I;VX@=VET
M:"!S=6)O<F1I;F%T960@<')O;6ES<V]R>2!N;W1E<R!O9F9E<FEN9SPO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O<F1E<BUB;W1T
M;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@
M8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@8F]R9&5R+6)O='1O;2UC;VQO
M<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M
M8F]T=&]M+7-T>6QE.B!S;VQI9#LG/C$S+#`X.3PO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O
M<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H
M.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@8F]R9&5R+6)O
M='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T
M.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG/C0Q+#8X,3PO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q
M+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T
M=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@
M8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED
M=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG/C@Q+#4X
M.3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B
M;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL
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M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/B0\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@8F]R9&5R+6)O
M='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#1P=#L@
M8F]R9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R<^-2PP.3`L.3@X/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ
M(#1P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`T<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O
M;2UW:61T:#H@-'!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[)SXD
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB
M;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[
M(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/C(L,3,T+#<V,CPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`T<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@-'!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
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M=&]M.B`T<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!L969T.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O
M='1O;2UW:61T:#H@-'!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[
M)SXD/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E
M<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T
M<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/C(P+#$P,RPT,C4\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O
M='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X\+W1R/CPO=&%B;&4^/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'@@,'!X(#!P>"`P+C)I;CL@8V]L;W(Z(",P
M,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@+3`N
M,FEN.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P
M>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW
M:61T:#H@,'!X.R<^)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I
M;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[
M('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O
M<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\+W`^/'1A8FQE('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[('=I9'1H.B`Q-38W<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
M97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D
M+7-P86-I;F<Z(#!P>#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@9F]N
M="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW
M96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[)SX\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@
M8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L
M<W!A;CTS1#(^26YI=&EA;"!V86QU871I;VX\+W1D/CQT9#XF(S$V,#L\+W1D
M/CQT9#XF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,CXF(S$V,#L\+W1D/CQT
M9#XF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!C;VQS<&%N/3-$,CXF
M(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q
M-C`[/"]T9#X\=&0@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
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M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T
M9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@8V]L<W!A;CTS
M1#(^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS
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M=R8C,38P.SQB<B`O/F1E<FEV871I=F5S/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
M=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R<@8V]L<W!A;CTS1#(^26YC<F5A<V4F(S$V,#MI;B!F86ER('9A;'5E(&]F
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^0F%L86YC92!A
M=#PO=&0^/'1D/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/CQT9#XF(S$V,#L\+W1D/CQT9#XF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N
M/3-$,CY$96-E;6)E<B`S,2P\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9#XF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS
M<&%N/3-$,CYD=7)I;F<\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9#XF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!C;VQS<&%N
M/3-$,CYD97)I=F%T:79E/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A
M;CTS1#(^1&5C96UB97(@,S$L/"]T9#X\=&0^)B,Q-C`[/"]T9#X\+W1R/CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D('-T>6QE
M/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P
M=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F
M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&)O<F1E
M<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q
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M=&AE('!E<FEO9#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M+C5P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N
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M=&]M.B`Q+C5P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M8V5N=&5R.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M
M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C
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M.R!T97AT+6EN9&5N=#H@+3DN,#5P=#L@<&%D9&EN9RUL969T.B`Y+C`U<'0[
M(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/D-O
M;G9E<G1I8FQE('!R969E<G)E9"!D97)I=F%T:79E(&QI86)I;&ET>2!I<W-U
M960@:6X@8V]N;F5C=&EO;B!W:71H(%-E<FEE<R!!('!R969E<G)E9"!S=&]C
M:R!O9F9E<FEN9SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^
M)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#)P>#L@=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#LG/BT\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[(&9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L
M969T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[
M)SXD/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$T,G!X.R!T97AT+6%L:6=N
M.B!R:6=H=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R<^.#<R+#8X.#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!T
M97AT+6%L:6=N.B!L969T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M,35P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U<'@[('1E>'0M
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M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$U<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M-7!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=V5I9VAT.B!N;W)M86P[)SXD/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$T,7!X.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^,BPT.3(L,38V/"]T9#X\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$U<'@[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<W1Y
M;&4Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#LG/B8C,38P.SPO=&0^
M/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@=&5X="UI;F1E;G0Z("TY+C`U<'0[('!A9&1I;F<M;&5F=#H@
M.2XP-7!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[)SY#;VYV97)T:6)L92!P<F5F97)R960@9&5R:79A=&EV92!L:6%B:6QI
M='D@:7-S=65D('1O(%=O;G!U;F<@9F]R('-E<G9I8V5S/"]T9#X\=&0@<W1Y
M;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
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M='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
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M<&%D9&EN9RUL969T.B`Y+C`U<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#LG/D-O;G9E<G1I8FQE('!R969E<G)E9"!D97)I
M=F%T:79E(&QI86)I;&ET>2!I<W-U960@=&\@;&5N9&5R<R!I;B!C;VYN96-T
M:6]N('=I=&@@97AC:&%N9V4@;V8@9&5B="!F;W(@4V5R:65S($$@<')E9F5R
M<F5D('-T;V-K/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
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M;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
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M;G0Z("TY+C`U<'0[('!A9&1I;F<M;&5F=#H@.2XP-7!T.R!F;VYT+7-T>6QE
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M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
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M(&9O;G0M=V5I9VAT.B!N;W)M86P[)SXT-S4L,#`P/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C
M8V-E969F.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('1E>'0M
M:6YD96YT.B`M.2XP-7!T.R!P861D:6YG+6QE9G0Z(#DN,#5P=#L@9F]N="US
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M;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
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M=V5I9VAT.B!N;W)M86P[)SXR-#(L-3`P/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@
M+3DN,#5P=#L@<&%D9&EN9RUL969T.B`Y+C`U<'0[(&9O;G0M<W1Y;&4Z(&YO
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M:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@
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M=#L@=&5X="UI;F1E;G0Z("TY+C`U<'0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P
M=#L@<&%D9&EN9RUL969T.B`Y+C`U<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UW96EG:'0Z(&YO<FUA;#LG/E=A<G)A;G1S(&ES<W5E9"!T;R!P;&%C
M96UE;G0@86=E;G0@:6X@8V]N;F5C=&EO;B!W:71H('-U8F]R9&EN871E9"!P
M<F]M:7-S;W)Y(&YO=&5S(&]F9F5R:6YG/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
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M9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L
M86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O
M;2US='EL93H@<V]L:60[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O
M<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE
M.B!S;VQI9#LG/C$S+#`X.3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O<F1E<BUB;W1T;VTM
M8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R
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M(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTM8V]L
M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R
M+6)O='1O;2US='EL93H@<V]L:60[)SXQ,RPP.#D\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF
M(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`T<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
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M;F<M8F]T=&]M.B`T<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R
M9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D
M;W5B;&4[)SXD/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I
M9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/C$L-#`R
M+#8S-3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I
M;F<M8F]T=&]M.B`T<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
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M:6YG+6)O='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#1P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B
M;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z
M(&1O=6)L93LG/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM
M=VED=&@Z(#1P=#L@8F]R9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R<^-2PP
M.3`L.3@X/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D
M9&EN9RUB;W1T;VTZ(#1P=#LG/B8C,38P.SPO=&0^/"]T<CX\+W1A8FQE/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C,S-#5E
M.69?8C8T8E\T-S-B7SAB8C!?-3<T9C8Q83`Y8C)E#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+S8S,S0U93EF7V(V-&)?-#<S8E\X8F(P7S4W-&8V
M,6$P.6(R92]7;W)K<VAE971S+U-H965T,C`N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5*0T%#
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K:&]L9&5R<R<@17%U:71Y
M("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU
M;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4W1O8VMH;VQD97)S)R!$969I8VET(%M!8G-T<F%C=%T\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R
M;W-S('!R;V-E961S(')E8V5I=F5D(&EN(&-O;FYE8W1I;VX@=VET:"!O9F9E
M<FEN9W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M
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M;VX@9F%I<B!V86QU93H\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
M<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X
M="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US
M<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO<#X\=&%B;&4@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@=VED=&@Z(#$U-C=P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[
M('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O
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M.B`P<'0[)SY!9&1I=&EO;F%L('!A:60M:6XM8V%P:71A;#PO=&0^/'1D/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C(L,34Q
M+#`T,#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T.B`P<'0[)SY$97)I=F%T
M:79E('=A<G)A;G0@;&EA8FEL:71I97,\+W1D/CQT9#XF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXQ,3$L-S<W/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\
M='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N
M9"UC;VQO<CH@=VAI=&4[)SX\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#L@<&%D9&EN9RUL969T.B`P<'0[)SY$97)I=F%T:79E('!R969E<G)E9"!S
M=&]C:R!C;VYV97)S:6]N(&9E871U<F4\+W1D/CQT9#XF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@
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M;W1T;VTM<W1Y;&4Z('-O;&ED.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K
M.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US
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M9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT
M.R<^,RPR,C`L,#$X/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
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M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
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M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P=#L@<&%D9&EN9RUL969T
M.B`P<'0[)SY'<F]S<R!P<F]C965D<SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`T<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R
M9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D
M;W5B;&4[)SXD/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I
M9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/C,L.3$Y
M+#4P,#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I
M;F<M8F]T=&]M.B`T<'0[)SXF(S$V,#L\+W1D/CPO='(^/"]T86)L93X\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E
M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A
M8V4Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^
M)B,Q-C`[/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO
M<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[)SY4:&4@=&%B;&4@8F5L;W<@<F5F;&5C=',@=&AE(&=R
M;W-S('!R;V-E961S(')E8V5I=F5D(&EN(&-O;FYE8W1I;VX@=VET:"!T:&4@
M,C`Q,R!O9F9E<FEN9W,@86QL;V-A=&5D('1O(&-O;7!O;F5N=',@;V8@<W1O
M8VMH;VQD97)S)B,X,C$W.R!E<75I='D@86YD('1O(&1E<FEV871I=F4@;&EA
M8FEL:71I97,@8F%S960@=7!O;B!F86ER('9A;'5E.CPO<#X\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A
M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN
M9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO
M<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^)B,Q-C`[
M/"]P/CQT86)L92!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!W:61T:#H@,34V-W!X.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[(&)O<F1E<BUC;VQL
M87!S93H@8V]L;&%P<V4[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,S<Y<'@[('1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@,'!T.R<^4&%R('9A;'5E(&]F
M(%-E<FEE<R!!('!R969E<G)E9"!S=&]C:R!I<W-U960\+W1D/CQT9"!S='EL
M93TS1"=W:61T:#H@,39P>#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@<FEG:'0[)SX\<"!S='EL
M93TS1"=M87)G:6XZ(#!P>#LG/C4L,3`P/"]P/CPO=&0^/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\
M+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT9"!S='EL93TS1"=P861D:6YG+6QE
M9G0Z(#!P=#LG/D%D9&ET:6]N86P@<&%I9"UI;BUC87!I=&%L/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^/'`@
M<W1Y;&4],T0G;6%R9VEN.B`P<'@[)SXQ+#0W.2PV,3`\+W`^/"]T9#X\=&0@
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M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V
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M<FEN9R!C;W-T<SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M
M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.@T*(')I9VAT.R!B
M;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T
M:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^,C0X+#8U
M-3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI
M=&4[)SX\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL
M969T.B`P<'0[)SY.970@<')O8V5E9',\+W1D/CQT9#XF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXS+#0Y-"PT,C@\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R
M/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@<&%D9&EN9RUL969T.B`P
M<'0[)SY/9F9E<FEN9R!C;W-T<R!P86ED(&EN(&-A<V@\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B;W)D97(M8F]T=&]M+6-O;&]R
M.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB
M;W1T;VTM<W1Y;&4Z('-O;&ED.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K
M.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US
M='EL93H@<V]L:60[)SXU.#8L,#<R/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T
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M<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T
M<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/B0\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@8F]R9&5R+6)O='1O;2UC;VQO
M<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#1P=#L@8F]R9&5R+6)O
M='1O;2US='EL93H@9&]U8FQE.R<^-"PP.#`L-3`P/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#1P=#LG/B8C
M,38P.SPO=&0^/"]T<CX\+W1A8FQE/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I
M;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[
M('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O
M<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\+W`^/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R
M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO
M<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[
M("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CPO<#X\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M
M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A
M8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z
M(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^5&AE
M('1A8FQE(&)E;&]W(')E9FQE8W1S('1H92!G<F]S<R!P<F]C965D<R!R96-E
M:79E9"!I;B!C;VYN96-T:6]N('=I=&@@=&AE($UA>2!A;F0@2G5N92`R,#$T
M(&]F9F5R:6YG<R!A;&QO8V%T960@=&\@8V]M<&]N96YT<R!O9B!S=&]C:VAO
M;&1E<G,F(S@R,3<[(&5Q=6ET>2!A;F0@=&\@9&5R:79A=&EV92!L:6%B:6QI
M=&EE<R!B87-E9"!U<&]N(&9A:7(@=F%L=64Z/"]P/CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SXF(S$V,#L\+W`^
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P
M.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E
M+7-P86-E.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
M>#LG/CPO<#X\=&%B;&4@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@8V%L
M:6)R:2P@:&5L=F5T:6-A+"!S86YS+7-E<FEF.R!W:61T:#H@,34V-W!X.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[(&)O<F1E<BUC
M;VQL87!S93H@8V]L;&%P<V4[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,S<Y<'@[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
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M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^061D:71I;VYA;"!P86ED+6EN+6-A<&ET86P\+W1D/CQT
M9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CLG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^,3<L.#<X+#DY-#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E
M969F.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^1&5R:79A
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M,S,W+#`R-3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M1&5R:79A=&EV92!W87)R86YT<R!I<W-U960@=&\@<&QA8V5M96YT(&%G96YT
M(&%S(&]F9F5R:6YG(&-O<W1S/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#$N-7!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R
M9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z
M('-O;&ED.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O
M='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED
M.R<^.3DV+#$S.#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
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M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="UF86UI
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M+6)O='1O;3H@,2XU<'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W
M:&ET93LG/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M3V9F97)I;F<@8V]S=',@<&%I9"!I;B!C87-H/"]T9#X\=&0@<W1Y;&4],T0G
M<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B
M;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T
M;VTM<W1Y;&4Z('-O;&ED.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@<FEG:'0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
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M(&QE9G0[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O
M='1O;2UW:61T:#H@-'!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[
M)SXD/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!B;W)D
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M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA
M<GD@;V8@8VAA;F=E<R!I;B!O<'1I;VYS(&]U='-T86YD:6YG/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`^/"]P/CQT86)L92!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!W:61T:#H@,34V-W!X.R!T97AT+71R86YS9F]R;3H@;F]N93L@
M=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R
M9"US<&%C:6YG.B`P<'@[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[(&9O
M;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)R!C96QL<W!A8VEN9STS
M1#`@8V5L;'!A9&1I;F<],T0P/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R<^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[
M(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T
M>6QE.B!S;VQI9#LG(&-O;'-P86X],T0R/DYU;6)E<B!O9CQB<B`O/E-H87)E
M<SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@
M8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED
M=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P
M86X],T0R/E=E:6=H=&5D/&)R("\^079E<F%G93QB<B`O/D5X97)C:7-E/&)R
M("\^4')I8V4\8G(@+SY097(@4VAA<F4\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L
M86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O
M;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CY796EG:'1E9#QB<B`O/D%V
M97)A9V4\8G(@+SY296UA:6YI;F<\8G(@+SY#;VYT<F%C='5A;#QB<B`O/E1E
M<FT@*%EE87)S*3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&-E;G1E<CL@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB
M;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI
M9#LG(&-O;'-P86X],T0R/D%G9W)E9V%T93QB<B`O/DEN=')I;G-I8SQB<B`O
M/E9A;'5E/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T
M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D/D]U
M='-T86YD:6YG(&%T($1E8V5M8F5R(#,Q+"`R,#$Q/"]T9#X\=&0^)B,Q-C`[
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M969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG
M:'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X
M="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[
M)SX\=&0@<W1Y;&4],T0G=VED=&@Z(#<Y,2XY,W!X.R!T97AT+6EN9&5N=#H@
M+3@N-C5P=#L@<&%D9&EN9RUL969T.B`Q-RXS<'0[)SY'<F%N=&5D/"]T9#X\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-#)P>#L@=&5X="UA;&EG;CH@<FEG
M:'0[)SXV-S<L.38R/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[('1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T
M:#H@,39P>#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X
M.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q-#)P>#L@=&5X="UA;&EG;CH@<FEG:'0[)SXP+C@P/"]T9#X\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$V<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$T,7!X.R!T97AT+6%L:6=N
M.B!R:6=H=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X
M.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$U<'@[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M,35P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@<FEG:'0[)SXF(S$V,#L\
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M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXV-S<L
M.38R/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXD/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M)SXP+C@P/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N
M.B!R:6=H=#LG/CDN-3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!L969T.R<^)#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(')I9VAT.R<^+3PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^/'1D('-T
M>6QE/3-$)W1E>'0M:6YD96YT.B`M."XV-7!T.R!P861D:6YG+6QE9G0Z(#$W
M+C-P=#LG/D=R86YT960\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@<FEG:'0[)SXQ+#$X-RPT-#D\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C`N.#`\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T
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M9"!T;R!V97-T(&%T($1E8V5M8F5R(#,Q+"`R,#$S/"]T9#X\=&0^)B,Q-C`[
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M(')I9VAT.R<^,2PS,#4L,#`P/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[)B,Q
M-C`[)B,Q-C`[1W)A;G1E9#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M
M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L
M:60[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM
M=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG/C$L
M-#DY+#<V,#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L
M86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O
M;2US='EL93H@<V]L:60[)SXD/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M
M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L
M:60[)SXQ+C4P/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
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M;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\
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M>6QE.B!S;VQI9#LG/C,L,#`P+#`P,#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO
M=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@-'!T.R<^3W5T<W1A;F1I
M;F<@86YD(&5X<&5C=&5D('1O('9E<W0@870@2G5N92`S,"P@,C`Q-"8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!B;W)D97(M
M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H-"B`T
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M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P
M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I
M9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/B0\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@8F]R9&5R+6)O='1O
M;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#1P=#L@8F]R
M9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R<^,2XQ,3PO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`T<'0[)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F]R
M9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z
M(#1P=#L@8F]R9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB;W1T
M;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O
M<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/C@N.3PO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`T<'0[)SXF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@8F]R
M9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z
M(#1P=#L@8F]R9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R<^)#PO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M+6-O
M;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D97(M
M8F]T=&]M+7-T>6QE.B!D;W5B;&4[)SXU+#(S."PP,#`\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@-'!T.R<^
M)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@-'!T.R<^3W!T:6]N<R!E>&5R8VES86)L92!A
M="!*=6YE(#,P+"`R,#$T/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#1P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T
M=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B
M;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T
M:#H@-'!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[)SXV-3(L,#`U
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB
M;W1T;VTZ(#1P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`T<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R
M+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D;W5B
M;&4[)SXD/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)O
M<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H
M.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/C`N.#`\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O
M;3H@-'!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#1P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T
M=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!B
M;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T
M:#H@-'!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D;W5B;&4[)SXY+C`\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O
M;3H@-'!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#1P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T
M=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93LG
M/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#L@8F]R9&5R
M+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#1P
M=#L@8F]R9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R<^-S@R+#0P,#PO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`T<'0[)SXF(S$V,#L\+W1D/CPO='(^/"]T86)L93X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D(&%V
M97)A9V4@9F%I<B!V86QU92!O9B!O<'1I;VYS(&=R86YT960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\=&%B;&4@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M=VED=&@Z(#$U-C=P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD
M96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
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M9&1I;F<M8F]T=&]M.B`Q+C5P=#LG(&-O;'-P86X],T0R/E-I>"!-;VYT:#QB
M<B`O/D5N9&5D)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T
M;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB
M;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA
M;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R
M9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z
M('-O;&ED.R<@8V]L<W!A;CTS1#8^1F]R('1H92!996%R<R!%;F1E9#QB<B`O
M/D1E8V5M8F5R(#,Q+#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3LG/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D
M97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@
M<V]L:60[)R!C;VQS<&%N/3-$,CY*=6YE(#,P+"`R,#$T/"]T9#X\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M
M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O
M<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^,C`Q,SPO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C
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M:6=N.B!B;W1T;VT[)SX\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^
M)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^)B,Q
M-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^)B,Q-C`[
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q,#`S<'@[)SY#=7)R96YT('!R:6-E(&]F
M(&-O;6UO;B!S=&]C:SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$V<'@[('1E>'0M86QI
M9VXZ(&QE9G0[)SXD/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$T,G!X.R!T
M97AT+6%L:6=N.B!R:6=H=#LG/C(N,#`\+W1D/CQT9"!S='EL93TS1"=W:61T
M:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q-G!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M=VED=&@Z(#$V<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$T,7!X.R!T97AT+6%L:6=N.B!R:6=H=#LG/C`N.#`\
M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U<'@[('1E>'0M86QI9VXZ
M(&QE9G0[)SXD/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$T,7!X.R!T97AT
M+6%L:6=N.B!R:6=H=#LG/C`N,S`\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M,35P>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@=VAI=&4[)SX\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG
M/E)I<VL@9G)E92!I;G1E<F5S="!R871E/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,2XU)2!T;R`Q+C8\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)3PO=&0^/'1D/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C$N-#PO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXE/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,"XV
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B4\+W1D/CPO
M='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG
M<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/D1I=FED96YD('EI96QD/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,#PO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXE/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,#PO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXE/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,#PO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXE/"]T9#X\+W1R/CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W
M:&ET93LG/CQT9#Y6;VQA=&EL:71Y/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[-S8E('1O(#<W/"]T
M9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B4\+W1D/CQT9#XF
M(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXW,R4@
M=&\@.#`\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)3PO
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M-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(')I9VAT.R<^-2XW-2!T;R`Q,#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI
M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@<FEG:'0[)SXU+C<U/"]T9#X\=&0@<W1Y;&4],T0G
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\+W1A8FQE/CQD
M:78^)B,Q-C`[/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3=6UM87)Y(&]F(&-H86YG97,@:6X@=V%R<F%N
M=',@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\=&%B;&4@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=VED=&@Z(#$U-C=P>#L@=&5X="UT
M<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C
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M;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@
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M;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL
M93H@<V]L:60[)R!C;VQS<&%N/3-$,CY796EG:'1E9#QB<B`O/D%V97)A9V4\
M8G(@+SY%>&5R8VES93QB<B`O/E!R:6-E/&)R("\^4&5R(%-H87)E/"]T9#X\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T
M9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B
M86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q,3DQ<'@[)SY/=71S=&%N9&EN9R!A="!$96-E;6)E<B`S,2P@,C`Q,3PO
M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$V<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,30R<'@[('1E>'0M86QI9VXZ
M(')I9VAT.R<^-BPR-3$\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q-7!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$U
M<'@[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$T,7!X.R!T97AT+6%L:6=N.B!R:6=H=#LG/C$N,#`\+W1D/CQT9"!S
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M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[
M(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T
M>6QE.B!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M
M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L
M:60[('1E>'0M86QI9VXZ(')I9VAT.R<^*#8Q.2PS-S<\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[('1E>'0M86QI9VXZ(&QE9G0[
M)SXI/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CH@
M8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T
M=&]M+7-T>6QE.B!S;VQI9#L@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/CQT
M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R
M+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O
M;&ED.R!T97AT+6%L:6=N.B!R:6=H=#LG/C`N.#`\+W1D/CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@,2XU<'0[('1E>'0M86QI9VXZ(&QE9G0[)SXF
M(S$V,#L\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^/'1D/D]U='-T86YD
M:6YG(&%T($1E8V5M8F5R(#,Q+"`R,#$R/"]T9#X\=&0^)B,Q-C`[/"]T9#X\
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M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T
M=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[
M('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=B
M;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T
M:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R!T97AT+6%L
M:6=N.B!R:6=H=#LG/C0L,#8Q+#(X,SPO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q+C5P=#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K
M.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US
M='EL93H@<V]L:60[('1E>'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X\=&0@<W1Y
M;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T
M;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#L@
M=&5X="UA;&EG;CH@<FEG:'0[)SXP+C4T/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#$N-7!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT9#Y/=71S=&%N9&EN9R!A
M="!$96-E;6)E<B`S,2P@,C`Q,SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T
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M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C,U+#`X-BPR
M-3,\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@
M;&5F=#LG/B0\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG
M/C$N-3@\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@-'!T.R<^1F]R9F5I=&5D("@Q*3PO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[)SXF(S$V,#L\+W1D/CQT9"!S
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M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[)SXF(S$V,#L\+W1D/CQT9"!S
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M:6=H=#LG/C`N.#`\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M-'!T.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[
M('!A9&1I;F<M8F]T=&]M.B`T<'0[)SY/=71S=&%N9&EN9R!A;F0@=F5S=&5D
M(&%T($IU;F4@,S`L(#(P,30\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O
M='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#1P=#L@
M8F]R9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R!T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO
M<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#1P=#L@8F]R9&5R+6)O
M='1O;2US='EL93H@9&]U8FQE.R!T97AT+6%L:6=N.B!R:6=H=#LG/C0S+#$T
M-"PU-3<\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@-'!T.R!T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#1P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H
M.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93L@=&5X="UA;&EG
M;CH@;&5F=#LG/B0\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O
M;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D97(M
M8F]T=&]M+7-T>6QE.B!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^,2XR
M-3PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[('1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CPO='(^/"]T86)L93X\9&EV/B8C
M,38P.SPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5V5I9VAT960@879E<F%G92!F86ER('9A;'5E(&]F('=A
M<G)A;G1S(&=R86YT960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\9&EV/B8C,38P.SPO9&EV/CQT86)L92!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!W:61T
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M9STS1#`^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\
M=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!P861D:6YG
M+6)O='1O;3H@,2XU<'0[)R!C;VQS<&%N/3-$,CX\<"!S='EL93TS1"=M87)G
M:6XM=&]P.B`P<'@[(&UA<F=I;BUB;W1T;VTZ(#!P>#LG/E-I>"!-;VYT:"8C
M,38P.SQB<B`O/D5N9&5D+#PO<#X\<"!S='EL93TS1"=M87)G:6XM=&]P.B`P
M<'@[(&UA<F=I;BUB;W1T;VTZ(#!P>#LG/DIU;F4@,S`L/"]P/CPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R9&5R+6)O
M='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T
M.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X],T0V/EEE
M87)S($5N9&5D($1E8V5M8F5R(#,Q+#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!C96YT97([)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K
M.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US
M='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CXR,#$T/"]T9#X\=&0@<W1Y;&4]
M,T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M+6-O
M;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E
M<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A;CTS1#(^,C`Q,SPO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P
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M<W1O8VL\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@-G!X.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#9P>#L@=&5X="UA;&EG;CH@;&5F=#LG
M/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@-39P>#L@=&5X="UA;&EG;CH@
M<FEG:'0[)SXR+C`P/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$Q<'@[('1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T
M:#H@-G!X.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#9P>#L@
M=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`U-G!X.R!T97AT+6%L:6=N.B!R:6=H=#LG/B0P+C@P("T@)#$N-3`\
M+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3%P>#L@=&5X="UA;&EG;CH@;&5F
M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`V<'@[)SXF(S$V
M,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@-G!X.R!T97AT+6%L:6=N.B!L
M969T.R<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`U-G!X.R!T97AT+6%L
M:6=N.B!R:6=H=#LG/C`N,S`\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3%P
M>#L@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO
M<CH@=VAI=&4[)SX\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/E)I
M<VLM9G)E92!I;G1E<F5S="!R871E/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,"XW)2!T;R`R+C`\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)3PO=&0^/'1D/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\
M+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C`N.24@=&\@
M,2XX/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B4\+W1D
M/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[
M)SXP+C8E('1O("XW/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F
M=#LG/B4\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/D1I=FED96YD('EI96QD/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,#PO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXE/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,#PO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXE/"]T9#X\=&0^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C
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M9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/C<U)2!T;R`W-CPO=&0^
M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXE/"]T9#X\=&0^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^-S,E('1O
M)B,Q-C`[.#,\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^
M)3PO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R
M:6=H=#LG/C@R)2!T;R`X,SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[)SXE/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY%>'!E8W1E9"!T97)M("AI;B!Y
M96%R<RD\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@<FEG:'0[)SXT(&%N9"`W/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS
M1"=T97AT+6%L:6=N.B!R:6=H=#LG/C0M-SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[)SXU/"]T9#X\=&0@<W1Y;&4]
M,T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\+W1A8FQE
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C,S
M-#5E.69?8C8T8E\T-S-B7SAB8C!?-3<T9C8Q83`Y8C)E#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+S8S,S0U93EF7V(V-&)?-#<S8E\X8F(P7S4W
M-&8V,6$P.6(R92]7;W)K<VAE971S+U-H965T,C$N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY296QA=&5D(%!A<G1Y(%1R86YS
M86-T:6]N<R`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E)E;&%T960@4&%R='D@5')A;G-A8W1I;VYS
M(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-C:&5D=6QE(&]F(')E8V5I=F5D('=A<G)A;G1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'`@<W1Y;&4],T0G8V]L;W(Z
M(",P,#`P,#`[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@
M;W)P:&%N<SH@875T;SL@=&5X="UA;&EG;CH@<W1A<G0[('1E>'0M:6YD96YT
M.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R
M;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M9F%M:6QY.B!C86QI8G)I
M+"!H96QV971I8V$L('-A;G,M<V5R:68[(&UA<F=I;CH@,'!X.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO
M<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
M:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/E1H92!0;&%C96UE;G0@06=E;G0@<F5C
M96EV960@=&AE(&9O;&QO=VEN9R!W87)R86YT<R!D=7)I;F<@=&AE('EE87(@
M96YD960@1&5C96UB97(@,S$L(#(P,3(Z/"]F;VYT/CPO<#X\<"!S='EL93TS
M1"=C;VQO<CH@(S`P,#`P,#L@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE
M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@
M;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+6%L:6=N.B!S=&%R=#L@=&5X
M="UI;F1E;G0Z(#!P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P
M86-E.B!N;W)M86P[('=I9&]W<SH@875T;SL@=V]R9"US<&%C:6YG.B`P<'@[
M("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@9F]N="UF86UI;'DZ
M(&-A;&EB<FDL(&AE;'9E=&EC82P@<V%N<RUS97)I9CL@;6%R9VEN.B`P<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M<#X\=&%B;&4@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=VED=&@Z(#$U-C=P>#L@=&5X="UT
M<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C
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M<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q
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M.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US
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M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C
M;VQS<&%N/3-$,CY%>'!I<F%T:6]N/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9#XF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG(&-O;'-P86X],T0R/B8C,38P
M.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T
M9#X\=&0^)B,Q-C`[/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
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M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!F;VYT+7=E
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M/3-$)W=I9'1H.B`Q-G!X.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T
M>6QE.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M,39P>#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US='EL93H@;F]R;6%L
M.R!T97AT+6%L:6=N.B!L969T.R<^)#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q-#%P>#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US='EL93H@;F]R
M;6%L.R!T97AT+6%L:6=N.B!R:6=H=#LG/C`N.#`\+W1D/CQT9"!S='EL93TS
M1"=W:61T:#H@,35P>#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US='EL
M93H@;F]R;6%L.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$U<'@[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O
M;G0M<W1Y;&4Z(&YO<FUA;#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q-7!X.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T>6QE.B!N
M;W)M86P[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=W:61T:#H@,30Q<'@[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M
M<W1Y;&4Z(&YO<FUA;#L@=&5X="UA;&EG;CH@8V5N=&5R.R<^,C`Q.3PO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!F;VYT+7=E:6=H=#H@;F]R;6%L
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M9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US='EL93H@;F]R;6%L.R!T97AT
M+6%L:6=N.B!L969T.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R
M9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z
M('-O;&ED.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z
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M;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UW
M96EG:'0Z(&YO<FUA;#L@9F]N="US='EL93H@;F]R;6%L.R!P861D:6YG+6)O
M='1O;3H@,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!F;VYT+7-T>6QE.B!N;W)M86P[('1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B0\+W1D/CQT9"!S='EL
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M=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M=V5I
M9VAT.B!N;W)M86P[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@=&5X="UA;&EG;CH@
M;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US='EL93H@;F]R
M;6%L.R!T97AT+6%L:6=N.B!C96YT97([('!A9&1I;F<M8F]T=&]M.B`Q+C5P
M=#LG/C(P,3D\+W1D/CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@;F]R;6%L
M.R!F;VYT+7-T>6QE.B!N;W)M86P[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I
M;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M(V-C965F9CLG/CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@;F]R;6%L.R!F
M;VYT+7-T>6QE.B!N;W)M86P[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!N;W)M86P[(&9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N
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M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M
M<W1Y;&4Z(&YO<FUA;#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US
M='EL93H@;F]R;6%L.R!T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O
M;3H@,BXU<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+7=E:6=H
M=#H@;F]R;6%L.R!F;VYT+7-T>6QE.B!N;W)M86P[('1E>'0M86QI9VXZ(')I
M9VAT.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T>6QE.B!N;W)M
M86P[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!N;W)M86P[
M(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA;#L@
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M.B!N;W)M86P[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`R
M+C5P=#LG/B8C,38P.SPO=&0^/"]T<CX\+W1A8FQE/CQP('-T>6QE/3-$)V-O
M;&]R.B`C,#`P,#`P.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z#0H@
M;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO
M<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UA;&EG;CH@<W1A<G0[('1E>'0M
M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C
M93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M9F%M:6QY.B!C
M86QI8G)I+"!H96QV971I8V$L('-A;G,M<V5R:68[(&UA<F=I;CH@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA
M;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
M,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W`^
M/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M<VEZ93H@,3!P=#L@
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN
M92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UA;&EG;CH@
M<W1A<G0[('1E>'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U=&\[('=O<F0M<W!A
M8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O
M;G0M9F%M:6QY.B!C86QI8G)I+"!H96QV971I8V$L('-A;G,M<V5R:68[(&UA
M<F=I;CH@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@
M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/E1H92!0
M;&%C96UE;G0@06=E;G0@<F5C96EV960@=&AE(&9O;&QO=VEN9R!W87)R86YT
M<R!D=7)I;F<@=&AE('EE87(@96YD960@1&5C96UB97(@,S$L(#(P,3,Z/"]F
M;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT
M+6%L:6=N.B!S=&%R=#L@=&5X="UI;F1E;G0Z(#!P>#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@875T;SL@
M=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z
M(#!P>#L@9F]N="UF86UI;'DZ(&-A;&EB<FDL(&AE;'9E=&EC82P@<V%N<RUS
M97)I9CL@;6%R9VEN.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE
M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]F;VYT/CPO<#X\=&%B;&4@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=VED
M=&@Z(#$U-C=P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@
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M.B!N;W)M86P[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1Y;&4Z
M(&YO<FUA;#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US='EL93H@
M;F]R;6%L.R!T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTM8V]L
M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R
M+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CY.=6UB97(@;V8@
M=V%R<F%N=',\+W1D/CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@;F]R;6%L
M.R!F;VYT+7-T>6QE.B!N;W)M86P[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!N;W)M86P[
M(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA;#L@
M9F]N="US='EL93H@;F]R;6%L.R!T97AT+6%L:6=N.B!C96YT97([(&)O<F1E
M<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q
M+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$
M,CY%>&5R8VES92!P<FEC92!P97(@<VAA<F4\+W1D/CQT9"!S='EL93TS1"=F
M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T>6QE.B!N;W)M86P[('!A9&1I
M;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O
M;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@<&%D9&EN
M9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N
M="UW96EG:'0Z(&YO<FUA;#L@9F]N="US='EL93H@;F]R;6%L.R!T97AT+6%L
M:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D
M97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@
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M-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N
M="US='EL93H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N
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M;#L@=&5X="UA;&EG;CH@8V5N=&5R.R<@8V]L<W!A;CTS1#(^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US='EL
M93H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T
M:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F
M.R<^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,#`S<'@[(&9O;G0M=V5I9VAT.B!N
M;W)M86P[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@=&5X="UA;&EG;CH@;&5F=#LG
M/E-E<FEE<R!!('!R969E<G)E9"!O9F9E<FEN9SPO=&0^/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q-G!X.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T>6QE
M.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,39P
M>#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US='EL93H@;F]R;6%L.R!T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$T,G!X.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T>6QE.B!N
M;W)M86P[('1E>'0M86QI9VXZ(')I9VAT.R<^-C,W+#4W.#PO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q-G!X.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT
M+7-T>6QE.B!N;W)M86P[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#L@9F]N="US='EL93H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
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M.SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R!F;VYT+7-T>6QE.B!N;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=W:61T:#H@,35P>#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N
M="US='EL93H@;F]R;6%L.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$T,7!X.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R!F;VYT+7-T>6QE.B!N;W)M86P[('1E>'0M86QI9VXZ(&-E;G1E<CLG
M/C(P,C`\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,35P>#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#L@9F]N="US='EL93H@;F]R;6%L.R!T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT9"!S
M='EL93TS1"=F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T>6QE.B!N;W)M
M86P[('1E>'0M86QI9VXZ(&QE9G0[)SY3=6)O<F1I;F%T960@<')O;6ES<V]R
M>2!N;W1E(&]F9F5R:6YG/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z
M(&YO<FUA;#L@9F]N="US='EL93H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US='EL93H@;F]R
M;6%L.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
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M97AT+6%L:6=N.B!R:6=H=#LG/C`N.#`\+W1D/CQT9"!S='EL93TS1"=F;VYT
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M('1E>'0M86QI9VXZ(&-E;G1E<CLG/C(P,C`\+W1D/CQT9"!S='EL93TS1"=F
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M;F]R;6%L.R!F;VYT+7-T>6QE.B!N;W)M86P[('!A9&1I;F<M8F]T=&]M.B`Q
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M;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@
M8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)SXR,#`L,#`P/"]T9#X\=&0@
M<W1Y;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US='EL93H@;F]R
M;6%L.PT*('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P
M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!N;W)M
M86P[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA
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M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA
M;#L@9F]N="US='EL93H@;F]R;6%L.R!P861D:6YG+6)O='1O;3H@,2XU<'0[
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@;F]R;6%L
M.R!F;VYT+7-T>6QE.B!N;W)M86P[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I
M;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O
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M<FUA;#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@
M<W1Y;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US='EL93H@;F]R
M;6%L.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/CQT9"!S
M='EL93TS1"=F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T>6QE.B!N;W)M
M86P[('1E>'0M86QI9VXZ(&QE9G0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L
M86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`R+C5P=#L@8F]R9&5R+6)O='1O
M;2US='EL93H@9&]U8FQE.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N
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M('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)V9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N
M="US='EL93H@;F]R;6%L.R!T97AT+6%L:6=N.B!R:6=H=#L@<&%D9&EN9RUB
M;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UW
M96EG:'0Z(&YO<FUA;#L@9F]N="US='EL93H@;F]R;6%L.R!T97AT+6%L:6=N
M.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/CQT
M9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T>6QE.B!N
M;W)M86P[('!A9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1Y;&4Z(&YO
M<FUA;#L@=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA
M;#L@9F]N="US='EL93H@;F]R;6%L.R!T97AT+6%L:6=N.B!C96YT97([('!A
M9&1I;F<M8F]T=&]M.B`R+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)V9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@=&5X
M="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#(N-7!T.R<^)B,Q-C`[
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M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA
M;#L@9F]N="US='EL93H@;F]R;6%L.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N
M="US='EL93H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N
M="UW96EG:'0Z(&YO<FUA;#L@9F]N="US='EL93H@;F]R;6%L.R!T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UW96EG
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M;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UW96EG
M:'0Z(&YO<FUA;#L@9F]N="US='EL93H@;F]R;6%L.R!T97AT+6%L:6=N.B!L
M969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT9"!S
M='EL93TS1"=F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T>6QE.B!N;W)M
M86P[)R!C;VQS<&%N/3-$,3(^/'`@<W1Y;&4],T0G;6%R9VEN+71O<#H@,'!X
M.R!M87)G:6XM8F]T=&]M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T
M>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M
M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^5&AE(%!L86-E;65N="!!9V5N="!R96-E:79E9"!T:&4@9F]L;&]W
M:6YG('=A<G)A;G1S(&1U<FEN9R!T:&4@<VEX(&UO;G1H<R!E;F1E9"!*=6YE
M(#,P+"`R,#$T.CPO9F]N=#X\+W`^/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UW
M96EG:'0Z(&YO<FUA;#L@9F]N="US='EL93H@;F]R;6%L.R!T97AT+6%L:6=N
M.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A
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M>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N
M="UW96EG:'0Z(&YO<FUA;#L@9F]N="US='EL93H@;F]R;6%L.R!T97AT+6%L
M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UW96EG
M:'0Z(&YO<FUA;#L@9F]N="US='EL93H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\
M=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US='EL93H@
M;F]R;6%L.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
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M<FUA;#L@=&5X="UA;&EG;CH@8V5N=&5R.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US='EL93H@;F]R;6%L
M.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R
M.B!W:&ET93LG/CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@;F]R;6%L.R!F
M;VYT+7-T>6QE.B!N;W)M86P[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!N;W)M86P[(&9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q
M-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N
M="US='EL93H@;F]R;6%L.R!T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB
M;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P
M=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$,CY.
M=6UB97(@;V8F(S$V,#L\8G(@+SYW87)R86YT<SPO=&0^/'1D('-T>6QE/3-$
M)V9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@=&5X
M="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^)B,Q-C`[
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M:7-E/&)R("\^<')I8V4@<&5R)B,Q-C`[/&)R("\^<VAA<F4\+W1D/CQT9"!S
M='EL93TS1"=F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T>6QE.B!N;W)M
M86P[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!N;W)M86P[
M(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA;#L@
M9F]N="US='EL93H@;F]R;6%L.R!T97AT+6%L:6=N.B!C96YT97([(&)O<F1E
M<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q
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M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^36%Y(&%N9"!*=6YE(#(P,30@;V9F97)I
M;F<\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&YO<FUA
M;#L@9F]N="US='EL93H@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4]
M,T0G9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US='EL93H@;F]R;6%L.R!T
M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N
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M="UA;&EG;CH@8V5N=&5R.R<^,C`R-#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M
M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@=&5X="UA;&EG
M;CH@;&5F=#LG/B8C,38P.SPO=&0^/"]T<CX\+W1A8FQE/CQP('-T>6QE/3-$
M)V-O;&]R.B`C,#`P,#`P.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z
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M/B8C,38P.SPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
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M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%,D8^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^26YC;VUE(%1A
M>&5S("A486)L97,I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^26YC;VUE(%1A>&5S(%M!8G-T<F%C=%T\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE
M(&]F(&1E9F5R<F5D('1A>"!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M
M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z
M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z
M(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@
M=&5X="UA;&EG;CH@<W1A<G0[('1E>'0M:6YD96YT.B`P<'@[('1E>'0M=')A
M;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(&%U
M=&\[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[(&UA<F=I;CH@,'!X.R<^)B,Q-C`[/"]P/CQT86)L92!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"!C86QI8G)I+"!H96QV971I8V$L('-A
M;G,M<V5R:68[('=I9'1H.B`Q-38W<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W
M;W)D+7-P86-I;F<Z(#!P>#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@
M9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[
M("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SX\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('!A9&1I;F<M8F]T=&]M.B`Q
M+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!C
M96YT97([(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T
M=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[
M)R!C;VQS<&%N/3-$,CY*=6YE(#,P+"8C,38P.SQB<B`O/C(P,30\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P
M.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!C96YT97([(&)O<F1E
M<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q
M+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS<&%N/3-$
M,CY$96-E;6)E<B`S,2P\8G(@+SXR,#$S/"]T9#X\=&0@<W1Y;&4],T0G<&%D
M9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y
M;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3LG/CQT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/D1E9F5R<F5D('1A>"!A<W-E=',Z/"]T9#X\=&0^)B,Q-C`[/"]T9#X\=&0@
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M<SPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG
M/B0\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,30R<'@[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N
M.B!R:6=H=#LG/C,L-34V+#8P,#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M-G!X.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q-7!X.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q-7!X.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D/CQT9"!S='EL
M93TS1"=W:61T:#H@,30Q<'@[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!R:6=H=#LG/C(L-S8U
M+#8P,#PO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!F;VYT+69A;6EL
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M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE
M9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@<FEG
M:'0[)SXT+#(T."PW,#`\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@
M;&5F=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T9#X\
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M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@<FEG:'0[)SXQ.3<L-S`P/"]T
M9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D
M/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M
M86QI9VXZ(')I9VAT.R<^-#,V+#,P,#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT
M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET
M93LG/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@<&%D9&EN9RUL969T.B`Q,'!T.R<^06-C<G5A
M;',\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M('1E>'0M86QI9VXZ(')I9VAT.R<^,C(L.3`P/"]T9#X\=&0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(')I9VAT.R<^
M-#0L-S`P/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
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M=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!R:6=H
M=#LG/C(L.3`P/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[
M)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO=&0^/'1D('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[('1E>'0M86QI9VXZ(')I9VAT.R<^-#8L,#`P/"]T9#X\=&0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CPO='(^/'1R
M('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M
M8V]L;W(Z('=H:71E.R<^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T
M.R!P861D:6YG+6)O='1O;3H@,2XU<'0[)SY686QU871I;VX@86QL;W=A;F-E
M/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L
M86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O
M;2US='EL93H@<V]L:60[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T
M9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O
M<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE
M.B!S;VQI9#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[('1E>'0M86QI9VXZ(')I9VAT.R<^*#@L,#(X+#@P,#PO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M86QI
M9VXZ(&QE9G0[)SXI/"]T9#X\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('!A9&1I;F<M8F]T=&]M
M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D#0H@<W1Y;&4],T0G8F]R9&5R+6)O
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M,RPR.3(L-C`P/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N
M-7!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/BD\+W1D/CPO='(^/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z
M("-C8V5E9F8[)SX\=&0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('!A9&1I;F<M8F]T=&]M.B`T<'0[
M)SY4;W1A;#PO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!P861D:6YG+6)O='1O;3H@-'!T
M.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO
M<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#1P=#L@8F]R9&5R+6)O
M='1O;2US='EL93H@9&]U8FQE.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/B0\+W1D
M/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R
M9&5R+6)O='1O;2UW:61T:#H@-'!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!D
M;W5B;&4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!T97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D/CQT9"!S='EL93TS
M1"=P861D:6YG+6)O='1O;3H@-'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/B8C
M,38P.SPO=&0^/'1D('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!P861D:6YG+6)O='1O;3H@-'!T.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CH@
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M;&4[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!T97AT+6%L:6=N.B!R:6=H=#LG/BT\+W1D/CQT9"!S='EL93TS1"=P
M861D:6YG+6)O='1O;3H@-'!T.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^/"]T<CX\+W1A8FQE/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4F5C;VYC:6QI871I;VX@;V8@=&AE('-T
M871U=&]R>2!T87@@<F%T92!T;R!T:&4@969F96-T:79E('1A>"!R871E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'1A8FQE('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[('=I9'1H.B`Q-38W<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
M97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D
M+7-P86-I;F<Z(&YO<FUA;#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@
M9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[
M("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG(&-E;&QS<&%C:6YG
M/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
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M;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
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M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
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M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R
M9"US<&%C:6YG.B!N;W)M86P[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F
M;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M
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M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M<W!A
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M<F0M<W!A8VEN9SH@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US='EL93H@;F]R
M;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B!N;W)M86P[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P
M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG/B8C,38P.SPO9F]N=#X\+W1D
M/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T
M;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@
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M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B!N;W)M86P[)SY996%R($5N
M9&5D($1E8V5M8F5R+#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,2XU<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I
M86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<VEZ93H@
M,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
M=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C
M:6YG.B!N;W)M86P[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT<B!S='EL
M93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T
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M;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
M,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;&5T=&5R+7-P86-I;F<Z(&YO
M<FUA;#L@=V]R9"US<&%C:6YG.B!N;W)M86P[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT+7-T
M>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M
M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
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M:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R
M9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z
M(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#L@9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L
M971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG
M/C(P,30\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ
M(#$N-7!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI
M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M;6%L.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q+C5P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA
M;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
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M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I
M;F<Z(&YO<FUA;#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T
M97AT+6%L:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K
M.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US
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M<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L
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M;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B!N
M;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT
M+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M<W!A
M8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG/B8C,38P.SPO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([(&)O
M<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H
M.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[(&9O;G0M<W1Y
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M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B!N;W)M86P[
M)SXR,#$R/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`Q+C5P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO
M<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
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M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
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M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B!N;W)M86P[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B!N;W)M86P[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M<W!A8VEN9SH@
M;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG/B8C,38P.SPO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
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M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
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M96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@
M;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG
M.B!N;W)M86P[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G9F]N
M="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW
M96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG/B8C,38P
M.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F
M;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M
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M:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^)B,Q-C`[/"]F
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M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R
M9"US<&%C:6YG.B!N;W)M86P[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y
M;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA
M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
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M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA
M;#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-T>6QE
M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
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M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO
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M;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
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M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I
M;F<Z(&YO<FUA;#L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT9"!S
M='EL93TS1"=W:61T:#H@,3`P,W!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N
M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z
M(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.@T*(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@
M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
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M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R
M9"US<&%C:6YG.B!N;W)M86P[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$V<'@[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<W1Y
M;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT
M.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA
M;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R
M;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US
M:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B!N;W)M86P[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$T,G!X.R!T97AT+6%L:6=N
M.B!R:6=H=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO
M<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
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M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO
M<FUA;#LG/C,T/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-G!X
M.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I
M>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M<W!A8VEN
M9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH
M96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M
M<W!A8VEN9SH@;F]R;6%L.R<^)3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W
M:61T:#H@,35P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z
M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
M.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA
M;#L@=V]R9"US<&%C:6YG.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N
M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z
M(&YO<FUA;#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W:61T
M:#H@,35P>#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@
M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B!N;W)M86P[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[
M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
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M:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B!N
M;W)M86P[)SXE/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X
M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F
M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I
M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P
M86-I;F<Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO
M<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-7!X.R!T
M97AT+6%L:6=N.B!L969T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
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M8VEN9SH@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q-#%P>#L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<W1Y;&4Z
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M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;&5T=&5R+7-P86-I;F<Z
M(&YO<FUA;#L@=V]R9"US<&%C:6YG.B!N;W)M86P[)SXS-#PO9F]N=#X\+W1D
M/CQT9"!S='EL93TS1"=W:61T:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T
M97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG/B4\
M+V9O;G0^/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI
M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W
M;W)D+7-P86-I;F<Z(&YO<FUA;#L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[
M)SX\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B!N;W)M86P[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
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M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
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M<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^)B,Q-C`[
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T
M97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG/B8C
M,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@
M9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L
M971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG
M/C8N-CPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F
M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I
M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M
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M('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
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M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
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M;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
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M;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B!N;W)M86P[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P
M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG/B4\+V9O;G0^/"]T9#X\=&0@
M<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO
M<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
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M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO
M<FUA;#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L
M:6=N.B!L969T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[
M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M
M86QI9VXZ(')I9VAT.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P
M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@
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M:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T
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M;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B!N;W)M86P[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P
M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L
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M;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-T>6QE
M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA
M;#LG/CQP('-T>6QE/3-$)VUA<F=I;CH@,'!X.R<^*#$S+C$\+W`^/"]T9#X\
M=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@9F]N="US='EL93H@;F]R
M;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B!N;W)M86P[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P
M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.PT*('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^*24\+V9O;G0^/"]T9#X\
M=&0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z
M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
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M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z
M(&YO<FUA;#LG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!L969T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P
M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M9SH@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
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M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;&5T=&5R+7-P86-I;F<Z
M(&YO<FUA;#L@=V]R9"US<&%C:6YG.B!N;W)M86P[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F
M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I
M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B!N;W)M86P[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#L@
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T
M97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG/B8C
M,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@
M9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L
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M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
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M9&EN9RUL969T.B`X+C8U<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
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M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^)B,Q-C`[/"]T
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M.R<^/'`@<W1Y;&4],T0G;6%R9VEN.B`P<'@[)SXH,BXS/"]P/CPO=&0^/'1D
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M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
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M-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M
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M8VEN9SH@;F]R;6%L.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B!N
M;W)M86P[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M
M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D
M+7-P86-I;F<Z(&YO<FUA;#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E
M>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
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M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M<W!A
M8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG/B8C,38P.SPO
M=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
M=#H-"B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
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M:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@
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M;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
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M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
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M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!R:6=H=#L@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B!N;W)M86P[)SX\
M<"!S='EL93TS1"=M87)G:6XZ(#!P>#LG/B@R-2XR/"]P/CPO=&0^/'1D('-T
M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@=&5X="UA;&EG;CH@;&5F
M=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@
M9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L
M971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG
M/BDE/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M+C5P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA
M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
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M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT
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M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM
M8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R
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M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M<W!A
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!L971T97(M
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M('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M
M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L
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M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
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M="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
M=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@=&5X="UA;&EG;CH@<FEG:'0[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@
M9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE
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M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
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M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[(&9O;G0M<W1Y;&4Z
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M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
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M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R!L971T
M97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(&YO<FUA;#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P
M=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&QE='1E<BUS<&%C:6YG.B!N;W)M
M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D
M97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O
M=6)L93L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA
M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@<FEG:'0[(&QE='1E<BUS
M<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO
M<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
M:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M=V]R9"US<&%C:6YG.B!N;W)M86P[)SXP/"]F;VYT/CPO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[('1E>'0M86QI9VXZ(&QE9G0[(&9O
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M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B!N;W)M86P[)SXE/"]F
M;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[(&9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z
M(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
M9SH@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@
M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
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M>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G
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M:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@;F]R;6%L.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L
M86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM
M<W1Y;&4Z(&1O=6)L93L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA
M;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
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M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;&5T=&5R+7-P86-I;F<Z
M(&YO<FUA;#L@=V]R9"US<&%C:6YG.B!N;W)M86P[)SXP/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[('1E>'0M86QI9VXZ
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M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B!N;W)M
M86P[)SXE/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M
M.B`T<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M
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M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT
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M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM
M8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E
M<BUB;W1T;VTM<W1Y;&4Z(&1O=6)L93L@9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N
M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG
M;CH@<FEG:'0[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
M9SH@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@
M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B!N;W)M86P[)SXP/"]F
M;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[('1E
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M="UW96EG:'0Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
M=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C
M:6YG.B!N;W)M86P[)SXE/"]F;VYT/CPO=&0^/"]T<CX\+W1A8FQE/CQD:78^
M)B,Q-C`[/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%\V,S,T-64Y9E]B-C1B7S0W,V)?.&)B,%\U-S1F-C%A,#EB,F4-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C,S-#5E.69?8C8T8E\T
M-S-B7SAB8C!?-3<T9C8Q83`Y8C)E+U=O<FMS:&5E=',O4VAE970R,RYH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;6UI=&UE
M;G1S(&%N9"!#;VYT:6YG96YC:65S("A486)L97,I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N="!A
M;F0@0V]N=&EN9V5N8VEE<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y38VAE9'5L92!O9B!F=71U<F4@
M;6EN:6UU;2!L96%S92!P87EM96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L('1I;65S
M(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@9F]N="US
M:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\+W`^
M/'1A8FQE(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E<FEF.R!W:61T:#H@.#`E
M.R!B;W)D97(M8V]L;&%P<V4Z(&-O;&QA<'-E.R!F;VYT+7-I>F4M861J=7-T
M.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[)SX\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@8V5N=&5R.R!B
M;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T
M:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<@8V]L<W!A
M;CTS1#(^665A<CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M+C5P=#LG/B8C,38P.SPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E
M;G1E<CL@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T
M;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG
M(&-O;'-P86X],T0R/D%M;W5N=#PO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M
M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C
M965F9CLG/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[
M/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/C(P,34\+W1D
M/CQT9#XF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T
M.R<^)#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,S<L
M,S`P/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@;&5F=#LG/B8C,38P
M.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y
M;&4],T0G=VED=&@Z(#4P)3L@=&5X="UA;&EG;CH@;&5F=#LG/C(P,38\+W1D
M/CQT9"!S='EL93TS1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=W:61T:#H@,24[('1E>'0M86QI9VXZ(&QE9G0[)SX\+W1D/CQT9"!S
M='EL93TS1"=W:61T:#H@.24[('1E>'0M86QI9VXZ(')I9VAT.R<^,S@L,#`P
M/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$E.R!T97AT+6%L:6=N.B!L969T
M.R<^)B,Q-C`[/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG
M;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T
M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/CQT9"!S='EL
M93TS1"=T97AT+6%L:6=N.B!L969T.R<^,C`Q-SPO=&0^/'1D/B8C,38P.SPO
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M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q
M+C5P=#LG/C(P,3@\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,2XU<'0[)SXF(S$V,#L\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L
M969T.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O
M;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R<^
M)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&)O
M<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H
M.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)SXY+#<P,#PO
M=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T
M=&]M.B`Q+C5P=#LG/B8C,38P.SPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R
M=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F
M9CLG/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O
M='1O;3H@-'!T.R<^)B,Q-C`[/"]T9#X\=&0@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#1P=#LG/E1O=&%L/"]T9#X\=&0@
M<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#1P=#LG/B8C,38P.SPO=&0^/'1D
M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&)O<F1E<BUB;W1T;VTM8V]L
M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB
M;W1T;VTM<W1Y;&4Z(&1O=6)L93LG/B0\+W1D/CQT9"!S='EL93TS1"=T97AT
M+6%L:6=N.B!R:6=H=#L@8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O
M<F1E<BUB;W1T;VTM=VED=&@Z(#1P=#L@8F]R9&5R+6)O='1O;2US='EL93H@
M9&]U8FQE.R<^,3(W+#@P,#PO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`T<'0[)SX\+W1D/CPO='(^/"]T86)L
M93X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S8S
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M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M,D%!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY"=7-I;F5S<R`H1&5T86EL
M<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DUA>2`R,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0G5S:6YE<W,@*%1E>'1U86QS*3PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/
M=VYE<G-H:7`@<&5R8V5N=&%G92!O9B!296QM861A/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XY-"XV,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@<VAA<F5S
M(&EN(&5X8VAA;F=E(&9O<B!O=VYE<G-H:7`@:6YT97)E<W0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(X+#(Y,2PP-S,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G
M92!O9B!A8W%U:7)E9"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C@P+CDP)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3=&]C:R!S<&QI="!R871I;R!D97-C<FEP=&EO
M;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=4:&4@;W5T<W1A
M;F1I;F<@;W!T:6]N<R!A;F0@=V%R<F%N=',@=V5R92!E>&-H86YG960@9F]R
M(&]P=&EO;G,@86YD('=A<G)A;G1S('1O('!U<F-H87-E('-H87)E<R!O9B!C
M;VUM;VX@<W1O8VL@;V8@=&AE($-O;7!A;GD@870@82!R871I;R!O9B`Q,"!T
M;R`Q+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!A;F0@0VQA<W,@02!P
M<F5F97)R960@<W1O8VL@:6X@8V]N;F5C=&EO;B!W:71H('-H87)E(&5X8VAA
M;F=E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`P+#`P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,#`L,#`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')E9F5R<F5D('-T;V-K+"!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P,"PP,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`P+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R969E<G)E9"!#;&%S<R!!(%M-96UB97)=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0G5S:6YE<W,@*%1E>'1U
M86QS*3PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@86YD($-L87-S($$@<')E
M9F5R<F5D('-T;V-K(&EN(&-O;FYE8W1I;VX@=VET:"!S:&%R92!E>&-H86YG
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,S,W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S
M=6%N8V4@;V8@8V]M;6]N('-T;V-K(&%N9"!#;&%S<R!!('!R969E<G)E9"!S
M=&]C:R!I;B!C;VYN96-T:6]N('=I=&@@<VAA<F4@97AC:&%N9V4L(%-H87)E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,S,W+#,P.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;6UO;B!3=&]C:R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D)U<VEN97-S("A497AT=6%L<RD\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S
M=6%N8V4@;V8@8V]M;6]N('-T;V-K(&%N9"!#;&%S<R!!('!R969E<G)E9"!S
M=&]C:R!I;B!C;VYN96-T:6]N('=I=&@@<VAA<F4@97AC:&%N9V4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,L,S,W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@
M;V8@8V]M;6]N('-T;V-K(&%N9"!#;&%S<R!!('!R969E<G)E9"!S=&]C:R!I
M;B!C;VYN96-T:6]N('=I=&@@<VAA<F4@97AC:&%N9V4L(%-H87)E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,S,W+#,Q,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
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M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%0E!!23X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#$^/'-T<F]N9SY3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C
M8V]U;G1I;F<@4&]L:6-I97,@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q
M-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY&86ER('9A;'5E(&AI97)A<F-H>2P@=&AE($-O;7!A;GDG<R!F
M:6YA;F-I86P@;&EA8FEL:71I97,@=&AA="!W97)E(&%C8V]U;G1E9"!F;W(@
M870@9F%I<B!V86QU92!O;B!A(')E8W5R<FEN9R!B87-I<SPO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5R:79A=&EV
M92!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`R-2PU.#8L.3,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`R,"PQ,#,L-#(U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+#`Y,"PY.#@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$97)I=F%T:79E(&QI86)I;&ET:65S('=A<G)A;G0@:6YS=')U;65N
M=',@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^1F%I<B!V86QU92!H:65R87)C:'DL('1H92!#;VUP86YY
M)W,@9FEN86YC:6%L(&QI86)I;&ET:65S('1H870@=V5R92!A8V-O=6YT960@
M9F]R(&%T(&9A:7(@=F%L=64@;VX@82!R96-U<G)I;F<@8F%S:7,\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<FEV
M871I=F4@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT+#`X.2PR.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^475O=&5D(%!R:6-E<R!);B!!8W1I=F4@36%R
M:V5T<R!F;W(@261E;G1I8V%L($%S<V5T<R`H3&5V96P@,2D@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M1F%I<B!V86QU92!H:65R87)C:'DL('1H92!#;VUP86YY)W,@9FEN86YC:6%L
M(&QI86)I;&ET:65S('1H870@=V5R92!A8V-O=6YT960@9F]R(&%T(&9A:7(@
M=F%L=64@;VX@82!R96-U<G)I;F<@8F%S:7,\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<FEV871I=F4@;&EA8FEL
M:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E%U;W1E9"!0<FEC97,@26X@06-T:79E
M($UA<FME=',@9F]R($ED96YT:6-A;"!!<W-E=',@*$QE=F5L(#$I(%M-96UB
M97)=('P@1&5R:79A=&EV92!L:6%B:6QI=&EE<R!397)I97,@02!P<F5F97)R
M960@<W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!V86QU92!H:65R87)C:'DL('1H92!#
M;VUP86YY)W,@9FEN86YC:6%L(&QI86)I;&ET:65S('1H870@=V5R92!A8V-O
M=6YT960@9F]R(&%T(&9A:7(@=F%L=64@;VX@82!R96-U<G)I;F<@8F%S:7,\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D1E<FEV871I=F4@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E%U;W1E9"!0<FEC97,@26X@
M06-T:79E($UA<FME=',@9F]R($ED96YT:6-A;"!!<W-E=',@*$QE=F5L(#$I
M(%M-96UB97)=('P@1&5R:79A=&EV92!L:6%B:6QI=&EE<R!W87)R86YT(&EN
M<W1R=6UE;G1S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@=F%L=64@:&EE<F%R8VAY+"!T:&4@
M0V]M<&%N>2=S(&9I;F%N8VEA;"!L:6%B:6QI=&EE<R!T:&%T('=E<F4@86-C
M;W5N=&5D(&9O<B!A="!F86ER('9A;'5E(&]N(&$@<F5C=7)R:6YG(&)A<VES
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y$97)I=F%T:79E(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:6=N:69I8V%N="!/=&AE
M<B!/8G-E<G9A8FQE($EN<'5T<R`H3&5V96P@,BD@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!V
M86QU92!H:65R87)C:'DL('1H92!#;VUP86YY)W,@9FEN86YC:6%L(&QI86)I
M;&ET:65S('1H870@=V5R92!A8V-O=6YT960@9F]R(&%T(&9A:7(@=F%L=64@
M;VX@82!R96-U<G)I;F<@8F%S:7,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<FEV871I=F4@;&EA8FEL:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-I9VYI9FEC86YT($]T:&5R($]B<V5R=F%B;&4@
M26YP=71S("A,979E;"`R*2!;365M8F5R72!\($1E<FEV871I=F4@;&EA8FEL
M:71I97,@4V5R:65S($$@<')E9F5R<F5D('-T;V-K(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@
M=F%L=64@:&EE<F%R8VAY+"!T:&4@0V]M<&%N>2=S(&9I;F%N8VEA;"!L:6%B
M:6QI=&EE<R!T:&%T('=E<F4@86-C;W5N=&5D(&9O<B!A="!F86ER('9A;'5E
M(&]N(&$@<F5C=7)R:6YG(&)A<VES/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97)I=F%T:79E(&QI86)I;&ET:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3:6=N:69I8V%N="!/=&AE<B!/8G-E<G9A8FQE($EN<'5T<R`H3&5V
M96P@,BD@6TUE;6)E<ET@?"!$97)I=F%T:79E(&QI86)I;&ET:65S('=A<G)A
M;G0@:6YS=')U;65N=',@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!V86QU92!H:65R87)C:'DL
M('1H92!#;VUP86YY)W,@9FEN86YC:6%L(&QI86)I;&ET:65S('1H870@=V5R
M92!A8V-O=6YT960@9F]R(&%T(&9A:7(@=F%L=64@;VX@82!R96-U<G)I;F<@
M8F%S:7,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1E<FEV871I=F4@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-I9VYI9FEC86YT
M(%5N;V)S97)V86)L92!);G!U=',@*$QE=F5L(#,I(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@
M=F%L=64@:&EE<F%R8VAY+"!T:&4@0V]M<&%N>2=S(&9I;F%N8VEA;"!L:6%B
M:6QI=&EE<R!T:&%T('=E<F4@86-C;W5N=&5D(&9O<B!A="!F86ER('9A;'5E
M(&]N(&$@<F5C=7)R:6YG(&)A<VES/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97)I=F%T:79E(&QI86)I;&ET:65S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2PU.#8L.3,S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C`L
M,3`S+#0R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3:6=N:69I8V%N="!5;F]B<V5R=F%B;&4@26YP=71S("A,
M979E;"`S*2!;365M8F5R72!\($1E<FEV871I=F4@;&EA8FEL:71I97,@4V5R
M:65S($$@<')E9F5R<F5D('-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@=F%L=64@:&EE
M<F%R8VAY+"!T:&4@0V]M<&%N>2=S(&9I;F%N8VEA;"!L:6%B:6QI=&EE<R!T
M:&%T('=E<F4@86-C;W5N=&5D(&9O<B!A="!F86ER('9A;'5E(&]N(&$@<F5C
M=7)R:6YG(&)A<VES/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y$97)I=F%T:79E(&QI86)I;&ET:65S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38L,#$T+#$T,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:6=N:69I
M8V%N="!5;F]B<V5R=F%B;&4@26YP=71S("A,979E;"`S*2!;365M8F5R72!\
M($1E<FEV871I=F4@;&EA8FEL:71I97,@=V%R<F%N="!I;G-T<G5M96YT<R!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY&86ER('9A;'5E(&AI97)A<F-H>2P@=&AE($-O;7!A;GDG<R!F
M:6YA;F-I86P@;&EA8FEL:71I97,@=&AA="!W97)E(&%C8V]U;G1E9"!F;W(@
M870@9F%I<B!V86QU92!O;B!A(')E8W5R<FEN9R!B87-I<SPO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5R:79A=&EV
M92!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-"PP.#DL,C@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
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M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%649!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=6UM
M87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@*$1E=&%I
M;',@,2D@*$9A:7(@5F%L=64L($EN<'5T<RP@3&5V96P@,R!;365M8F5R72P@
M55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y&86ER(%9A;'5E+"!);G!U=',L($QE=F5L(#,@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY&86ER(%9A;'5E($EN<'5T<RP@3&EA8FEL:71I97,L(%%U86YT
M:71A=&EV92!);F9O<FUA=&EO;B!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F5G:6YN:6YG(&)A
M;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,C`L,3`S
M+#0R-2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#4L,#DP+#DX."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#:&%N9V4@:6X@9F%I
M<B!V86QU92!O9B!D97)I=F%T:79E(&QI86)I;&ET:65S(&EN8VQU9&5D(&EN
M(&YE="!L;W-S(&9O<B!T:&4@<VEX(&UO;G1H<R!E;F1E9"!*=6YE(#,P+"`R
M,#$T(&%N9"!F;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$S
M(&%N9"`R,#$R+"!R97-P96-T:79E;'D\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#<L.34T+#DW,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@Q,BPX-S<L-C<U*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#,L-C@X+#,U,RD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D
M9&ET:6]N<R`M('=A<G)A;G0@:6YS=')U;65N=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#0L,S,S+#$V,RD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-S,L-CDY*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Q.2PP,CDI/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M<F%N<V9E<B!O9B`M('=A<G)A;G0@:6YS=')U;65N=',@=&\@861D:71I;VYA
M;"!P86ED(&EN(&-A<&ET86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C8L.#`T+#8R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I
M=&EO;G,@+2!C;VYV97)S:6]N(&9E871U<F4@;V8@4V5R:65S($$@<')E9F5R
M<F5D('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,2PW-C$L,#8S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#$L,C@S+#8P-BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N9&EN9R!B86QA;F-E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#(U+#4X-BPY,S,I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD
M("@R,"PQ,#,L-#(U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^)"`H-2PP.3`L.3@X*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^
M#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C,S-#5E.69?8C8T8E\T-S-B7SAB8C!?
M-3<T9C8Q83`Y8C)E#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8S
M,S0U93EF7V(V-&)?-#<S8E\X8F(P7S4W-&8V,6$P.6(R92]7;W)K<VAE971S
M+U-H965T,C<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O
M=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S
M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@
M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M
M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R
M:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE
M;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C
M;&%S<STS1')E<&]R="!I9#TS1$E$,$51,T%%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/E-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI
M8VEE<R`H1&5T86EL<R`R*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY%87)N:6YG<R!0
M97(@4VAA<F4L($)A<VEC+"!B>2!#;VUM;VX@0VQA<W,L($EN8VQU9&EN9R!4
M=V\@0VQA<W,@365T:&]D(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;G1I+61I;'5T:79E('-E
M8W5R:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0Y+#@T
M-RPP,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR-#,L.38P+#4S,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$T+#`T-BPW,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-L87-S($$@4')E9F5R<F5D
M(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^16%R;FEN9W,@4&5R(%-H87)E+"!"87-I8RP@8GD@
M0V]M;6]N($-L87-S+"!);F-L=61I;F<@5'=O($-L87-S($UE=&AO9"!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06YT:2UD:6QU=&EV92!S96-U<FET:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS+#,S-RPS,#D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N
M8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4V5R:65S($$@4&5R9F5R<F5D('-T;V-K(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M16%R;FEN9W,@4&5R(%-H87)E+"!"87-I8RP@8GD@0V]M;6]N($-L87-S+"!)
M;F-L=61I;F<@5'=O($-L87-S($UE=&AO9"!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06YT:2UD
M:6QU=&EV92!S96-U<FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3,V+#`T,2PR-S4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#4P,RPU,#,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO
M;B!S=&]C:R!W87)R86YT<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D5A<FYI;F=S(%!E<B!3:&%R92P@
M0F%S:6,L(&)Y($-O;6UO;B!#;&%S<RP@26YC;'5D:6YG(%1W;R!#;&%S<R!-
M971H;V0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%N=&DM9&EL=71I=F4@<V5C=7)I=&EE<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#,L,30T+#4U-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@Y+#(V
M-2PQ-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT+#@V-2PR,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!3=&]C:R!/<'1I;VYS(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M16%R;FEN9W,@4&5R(%-H87)E+"!"87-I8RP@8GD@0V]M;6]N($-L87-S+"!)
M;F-L=61I;F<@5'=O($-L87-S($UE=&AO9"!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06YT:2UD
M:6QU=&EV92!S96-U<FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS+#,V-2PQ-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ."PV-30L,#DW/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C<W+#DV,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C,S-#5E.69?8C8T8E\T-S-B
M7SAB8C!?-3<T9C8Q83`Y8C)E#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S8S,S0U93EF7V(V-&)?-#<S8E\X8F(P7S4W-&8V,6$P.6(R92]7;W)K
M<VAE971S+U-H965T,C@N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5.13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@
M4&]L:6-I97,@*$1E=&%I;',@5&5X='5A;"D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3:6=N:69I8V%N="!!8V-O
M=6YT:6YG(%!O;&EC:65S("A497AT=6%L*3PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^57-E9G5L(&QI9F4L(&%S<V5T<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S,@>65A<G,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
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M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%5$9!13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#$^/'-T<F]N9SY.;W1E<R!087EA8FQE("A$971A:6QS*2`H
M55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY3=6)O<F1I;F%T960@4')O;6ES<V]R>2!.
M;W1E<R!087EA8FQE(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&YO=&5S('!A>6%B;&4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#DP,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DQE<W,Z(&1E8G0@9&ES8V]U;G0\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q-#$L,#0Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&YO=&5S('!A>6%B
M;&4L(&QE<W,@9&5B="!D:7-C;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C<U."PY-3$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U8F]R9&EN871E9"`X
M)2!P<F]M:7-S;W)Y(&YO=&5S(&1U92!$96-E;6)E<B`R,#$S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6)O<F1I;F%T
M960@4')O;6ES<V]R>2!.;W1E<R!087EA8FQE(%M,:6YE($ET96US73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L
M(&YO=&5S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,38L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6)O<F1I;F%T960@."4@<')O;6ES
M<V]R>2!N;W1E<R!D=64@4V5P=&5M8F5R(#(P,30\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U8F]R9&EN871E9"!0<F]M
M:7-S;W)Y($YO=&5S(%!A>6%B;&4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;F]T97,@
M<&%Y86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-C@T+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?-C,S-#5E.69?8C8T8E\T-S-B7SAB8C!?-3<T9C8Q83`Y
M8C)E#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8S,S0U93EF7V(V
M-&)?-#<S8E\X8F(P7S4W-&8V,6$P.6(R92]7;W)K<VAE971S+U-H965T,S`N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$503T-)/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DYO
M=&5S(%!A>6%B;&4@*$1E=&%I;',@5&5X='5A;"D@*%531"`D*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,CXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y-87D@,#8L(#(P,30\8G(^1FEN86YC:6%L($%G
M<F5E;65N="!;365M8F5R73QB<CY$<G5G<SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/E-U8F]R9&EN871E9"`X
M)2!P<F]M:7-S;W)Y(&YO=&5S(&1U92!397!T96UB97(@,C`Q-#QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/D1E
M8V5M8F5R(#(P,3(@4W5B;W)D:6YA=&5D(%!R;VUI<W-O<GD@3F]T97,@4&%Y
M86)L93QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$R/&)R/D1E8V5M8F5R(#(P,3(@4W5B;W)D:6YA=&5D(%!R;VUI<W-O
M<GD@3F]T97,@4&%Y86)L93QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$S/&)R/E-E<'1E;6)E<B`R,#$S(%-U8F]R9&EN
M871E9"!0<F]M:7-S;W)Y($YO=&5S(%!A>6%B;&4\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CY397!T96UB97(@
M,C`Q,R!3=6)O<F1I;F%T960@4')O;6ES<V]R>2!.;W1E<R!087EA8FQE/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\
M8G(^4V5P=&5M8F5R(#(P,3,@4W5B;W)D:6YA=&5D(%!R;VUI<W-O<GD@3F]T
M97,@4&%Y86)L93QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-
M87D@,C`L(#(P,30\8G(^4V5P=&5M8F5R(#(P,3,@4W5B;W)D:6YA=&5D(%!R
M;VUI<W-O<GD@3F]T97,@4&%Y86)L93QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6)O<F1I;F%T960@4')O;6ES<V]R
M>2!.;W1E<R!087EA8FQE("A497AT=6%L*3PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^169F96-T:79E(&EN
M=&5R97-T(')A=&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,N-#0E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS-BXY,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS-BXY,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C@E(%!R;VUI<W-O<GD@;F]T97,@
M<&%Y86)L92!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`R,38L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`V.#0L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;W1E<R!P87EA8FQE(&1U
M92!D871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/D1E
M8R`V+`T*"0DR,#$S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^4V5P(#,P+`T*"0DR,#$T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$96)T(&1I<V-O=6YT
M(&%M;W)T:7IA=&EO;B!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)S<@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG-R!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O
M;2!.;W1E<R!087EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$X,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU-S`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@97AE<F-I
M<V4@<')I8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,"XX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,"XX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`P+C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,"XX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F('=A<G)A;G1S
M(&1E8G0@9&ES8V]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C8L,S(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.#,L,S8S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H('!R;V-E960@9F]R(&1E8G0@
M9&ES8V]U;G0@:6YT97)E<W0@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS-BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,30L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$96)T(&1I<V-O=6YT
M(&EN=&5R97-T(')A=&4@;V8@;6%T=7)I='D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)S$@>65A<CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<Q('EE87(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!U<F-H87-E
M(&]F('=A<G)A;G0@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8W+#4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(Q,RPW-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@<&%I9"!F;W(@9&5B
M="!I<W-U86YC92!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR-2PQ,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XV."PT,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%M;W)T:7IE9"!D969E<G)E9"!F
M:6YA;F-I;F<@8V]S=',@;6%T=7)I='D@9&%T93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG,2!Y96%R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S$@>65A<CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]T97,@
M<&%Y86)L92!I;G1E<F5S="!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XX+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I>F%T:6]N(&]F(&1E8G0@
M:7-S=6%N8V4@8V]S=',Q/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-C(L,S(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR,3DL-S<S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C$Y+#<W,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S(%9A;'5E
M(&9O<B!P;&%C96UE;G0@86=E;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,S,L-S4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3`V+#@W-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@=F%L=64@
M9F]R('!L86-E;65N="!A9V5N="P@4&5R('-H87)E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XX/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L
M=64@;V8@9&5B="!D:7-O=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$S+#`X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0Q+#8X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@9FEN86YC:6YG
M(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S@L
M,3@Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS,2PS-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS,2PS-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!D871E(&EF(&YO=&5S('!A
M>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XW-3@L.34Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$X-BPX,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO=&4@<&%Y86)L92P@8V]N
M=F5R<VEO;B!P<FEC92!P97(@<VAA<F4@*&EN($1O;&QA<G,@<&5R('-H87)E
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%C8W)U960@:6YT97)E<W0@8V]N=F5R=&5D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/CDV,"PY,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-C`L.3`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV
M97)S:6]N(&EN=&\@8V]M;6]N('-T;V-K('-H87)E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C`Q+#$U,SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C`Q+#$U,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3F]T92!P87EA8FQE(&ES<W5E9"!I;B!C;VYN96-T:6]N('=I=&@@9&ER96-T
M;W(@86YD(&]F9FEC97(@:6YS=7)A;F-E('!O;&EC>3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-S<L.#4P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<W+#@U,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1E8G0@:6X@8V]N;F5C=&EO;B!W:71H(&1O=VX@<&%Y;65N="!O
M9B!I;G-U<F%N8V4@<&]L:6-Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C8L.#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1&5B="!I;B!C;VYN96-T:6]N('=I=&@@
M<&%Y;65N="!O9B!M;VYT:&QY(&EN<W1A;&QM96YT+"!);G-U<F%N8V4@<&]L
M:6-Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8V,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYU;6)E<B!O9B!I;G-T86QL;65N=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!.;W1E<R!0
M87EA8FQE+"!#=7)R96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#4X+#,U-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?-C,S-#5E.69?8C8T8E\T-S-B7SAB8C!?-3<T9C8Q
M83`Y8C)E#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8S,S0U93EF
M7V(V-&)?-#<S8E\X8F(P7S4W-&8V,6$P.6(R92]7;W)K<VAE971S+U-H965T
M,S$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$4Q34%)/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/D1E<FEV871I=F4@3&EA8FEL:71I97,@*$1E=&%I;',I("A54T0@)"D\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#(^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$-#XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#(^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CY$96,N(#,Q+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/D1E8RX@,S$L
M(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^1F%I<B!686QU92P@07-S971S(&%N9"!,:6%B:6QI=&EE<R!-96%S
M=7)E9"!O;B!296-U<G)I;F<@86YD($YO;G)E8W5R<FEN9R!"87-I<R!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]M;6]N('-T;V-K(&ES<W5A8FQE('5P;VX@97AE<F-I<V4@
M;V8@=V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P
M+#`S-BPV-#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,2PW,3@L
M-S4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL,S@U+#$U-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K(&ES
M<W5A8FQE('5P;VX@8V]N=F5R<VEO;B!O9B!397)I97,@02!P<F5F97)R960@
M<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,S8L,#0Q+#(W-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C@U+#`S-2PP,C4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DUA<FME="!V86QU92!O9B!C;VUM;VX@<W1O8VL@
M;VX@;65A<W5R96UE;G0@9&%T92`H,2D\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1F;CX\<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Q+C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,"XX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E('!R:6-E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`P+C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#`N.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4FES:R!F<F5E
M(&EN=&5R97-T(')A=&4@*#(I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+C8P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1F;CX\<W5P/ELR73PO<W5P/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,"XS."4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/'-U<#Y;,ET\+W-U<#X\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`N,3DE/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CQS=7`^6S)=/"]S=7`^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D(&QI9F4@:6X@>65A<G,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG,B!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<Q('EE87(@-"!M;VYT:',@,C0@9&%Y<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^17AP96-T960@=F]L871I;&ET>2`H,RD\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XV."XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,UT\+W-U<#X\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C<S+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELS73PO<W5P/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!D:79I9&5N9"!Y
M:65L9',@*#0I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA>&EM=6T@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY&86ER(%9A;'5E+"!!<W-E=',@86YD($QI86)I;&ET:65S($UE
M87-U<F5D(&]N(%)E8W5R<FEN9R!A;F0@3F]N<F5C=7)R:6YG($)A<VES(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y%>&5R8VES92!P<FEC93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`R+C(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D(&QI9F4@:6X@>65A<G,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<T('EE87)S(#$P(&UO
M;G1H<R`R-"!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D('9O;&%T:6QI='D@*#,I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,RXP,"4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EN:6UU;2!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D9A:7(@5F%L=64L($%S<V5T<R!A;F0@3&EA8FEL:71I97,@365A
M<W5R960@;VX@4F5C=7)R:6YG(&%N9"!.;VYR96-U<G)I;F<@0F%S:7,@6TQI
M;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5X97)C:7-E('!R:6-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$N-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!L:69E(&EN('EE87)S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,R!M;VYT:',@,3@@9&%Y
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%>'!E8W1E9"!V;VQA=&EL:71Y("@S*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-S$N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN:71I86P@5F%L=6%T:6]N(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^1F%I<B!686QU92P@07-S971S(&%N9"!,:6%B:6QI=&EE<R!-96%S
M=7)E9"!O;B!296-U<G)I;F<@86YD($YO;G)E8W5R<FEN9R!"87-I<R!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]M;6]N('-T;V-K(&ES<W5A8FQE('5P;VX@97AE<F-I<V4@
M;V8@=V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,P
M+#`S-BPV-#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,BPS,S,L
M-3DS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL,S@U+#$U-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K(&ES
M<W5A8FQE('5P;VX@8V]N=F5R<VEO;B!O9B!397)I97,@02!P<F5F97)R960@
M<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,2PP,#8L,C4P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.#4L,#,U+#`R-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^36%R:V5T('9A;'5E(&]F(&-O;6UO;B!S=&]C:R!O
M;B!M96%S=7)E;65N="!D871E("@Q*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q+C$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#`N.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`P+C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,5T\+W-U<#X\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@<')I8V4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#`N.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,"XX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2:7-K(&9R
M964@:6YT97)E<W0@<F%T92`H,BD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$N-S`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CQS=7`^6S)=/"]S=7`^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XP+C$Y)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\<W5P/ELR73PO<W5P/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,"XR,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;,ET\+W-U<#X\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@;&EF92!I;B!Y96%R<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<Q('EE87(@-"!M;VYT:',@,C0@9&%Y<SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<Q('EE87(@-R!M;VYT:',@-B!D
M87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!V
M;VQA=&EL:71Y("@S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8X+C`P)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\<W5P/ELS73PO
M<W5P/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S(N,#`E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^
M6S-=/"]S=7`^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X
M<&5C=&5D(&1I=FED96YD('EI96QD<R`H-"D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^26YI=&EA;"!686QU871I;VX@6TUE;6)E<ET@?"!-87AI;75M
M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^1F%I<B!686QU92P@07-S971S(&%N9"!,:6%B:6QI=&EE<R!-
M96%S=7)E9"!O;B!296-U<G)I;F<@86YD($YO;G)E8W5R<FEN9R!"87-I<R!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^17AE<F-I<V4@<')I8V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,BXR-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!L:69E(&EN('EE87)S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-2!Y96%R<SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M>'!E8W1E9"!V;VQA=&EL:71Y("@S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-S,N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DEN:71I86P@5F%L=6%T:6]N(%M-96UB97)=
M('P@36EN:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64L($%S<V5T<R!A;F0@3&EA
M8FEL:71I97,@365A<W5R960@;VX@4F5C=7)R:6YG(&%N9"!.;VYR96-U<G)I
M;F<@0F%S:7,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E('!R:6-E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!L:69E
M(&EN('EE87)S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,R!M
M;VYT:',@,3@@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!V;VQA=&EL:71Y("@S*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S$N,#`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M9"!C;VQS<&%N/3-$-SX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1&EN;F5R1F]O=&YO=&4^#0H@("`@("`@(#QT9"!V86QI9VX],T1T
M;W`^6S%=/"]T9#X-"B`@("`@("`@/'1D(&-O;'-P86X],T0V('9A;&EG;CTS
M1'1O<#Y4:&4@;6%R:V5T('9A;'5E(&ES('1H92!C86QC=6QA=&5D(&9A:7(@
M=F%L=64@;V8@=&AE(&-O;6UO;B!S=&]C:R!P=7)S=6%N="!T;R!T:&4@=F%L
M=6%T:6]N('1E8VAN:7%U92!A<R!D97-C<FEB960@86)O=F4N/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1I;FYE<D9O;W1N;W1E/@T*
M("`@("`@("`\=&0@=F%L:6=N/3-$=&]P/ELR73PO=&0^#0H@("`@("`@(#QT
M9"!C;VQS<&%N/3-$-B!V86QI9VX],T1T;W`^5&AE(')I<VLM9G)E92!I;G1E
M<F5S="!R871E('=A<R!D971E<FUI;F5D(&)Y(&UA;F%G96UE;G0@=7-I;F<@
M=&AE(#$@86YD(#4@+2!Y96%R(%1R96%S=7)Y($)I;&P@87,@;V8@;65A<W5R
M96UE;G0@9&%T92X\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1&EN;F5R1F]O=&YO=&4^#0H@("`@("`@(#QT9"!V86QI9VX],T1T;W`^
M6S-=/"]T9#X-"B`@("`@("`@/'1D(&-O;'-P86X],T0V('9A;&EG;CTS1'1O
M<#Y4:&4@:&ES=&]R:6-A;"!T<F%D:6YG('9O;&%T:6QI='D@=V%S(&1E=&5R
M;6EN960@8GD@8V%L8W5L871I;F<@=&AE('9O;&%T:6QI='D@;V8@=&AE($-O
M;7!A;GDG<R!P965R(&=R;W5P+CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%\V,S,T-64Y9E]B-C1B7S0W,V)?.&)B,%\U-S1F-C%A,#EB,F4-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C,S-#5E.69?8C8T8E\T-S-B7SAB
M8C!?-3<T9C8Q83`Y8C)E+U=O<FMS:&5E=',O4VAE970S,BYH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P155)0DT^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^1&5R:79A=&EV92!,
M:6%B:6QI=&EE<R`H1&5T86EL<R`Q*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^1F%I<B!686QU92P@0F%L86YC92!3:&5E="!'<F]U<&EN9RP@1FEN86YC
M:6%L(%-T871E;65N="!#87!T:6]N<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I
M8FQE('!R969E<G)E9"!D97)I=F%T:79E(&QI86)I;&ET>3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#DU."PX-C$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!I
M<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<FEV871I=F4@;&EA8FEL:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#4X-BPY,S,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PQ
M,#,L-#(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-2PP.3`L.3@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=65D($EN($UA>2!!
M;F0@2G5N92`R,#$T($]F9F5R:6YG(%M-96UB97)=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64L($)A
M;&%N8V4@4VAE970@1W)O=7!I;F<L($9I;F%N8VEA;"!3=&%T96UE;G0@0V%P
M=&EO;G,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!I<W-U960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-U8F]R9&EN871E9"!P<F]M:7-S;W)Y(&YO=&5S(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D9A:7(@5F%L=64L($)A;&%N8V4@4VAE970@1W)O=7!I;F<L($9I;F%N8VEA
M;"!3=&%T96UE;G0@0V%P=&EO;G,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!I
M<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS,3,L,C4X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,CDL,34X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4&QA8V5M96YT($%G96YT(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D9A:7(@5F%L=64L($)A;&%N8V4@4VAE970@1W)O=7!I;F<L($9I;F%N8VEA
M;"!3=&%T96UE;G0@0V%P=&EO;G,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!I
M<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#(Q-RPP.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR-#(L-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&QA8V5M96YT($%G96YT(%M-96UB
M97)=('P@27-S=65D($EN($UA>2!!;F0@2G5N92`R,#$T($]F9F5R:6YG(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D9A:7(@5F%L=64L($)A;&%N8V4@4VAE970@1W)O=7!I;F<L($9I
M;F%N8VEA;"!3=&%T96UE;G0@0V%P=&EO;G,@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R
M86YT<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L
M-C4Q+#$X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4&QA8V5M96YT($%G96YT(%M-96UB97)=('P@4W5B;W)D
M:6YA=&5D('!R;VUI<W-O<GD@;F]T97,@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92P@
M0F%L86YC92!3:&5E="!'<F]U<&EN9RP@1FEN86YC:6%L(%-T871E;65N="!#
M87!T:6]N<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S(&ES<W5E9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S-BPS-3D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,RPP.#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y7;VYP=6YG('-E<G9I8V5S(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64L
M($)A;&%N8V4@4VAE970@1W)O=7!I;F<L($9I;F%N8VEA;"!3=&%T96UE;G0@
M0V%P=&EO;G,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!P<F5F97)R960@
M9&5R:79A=&EV92!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR+#`S,"PU.#D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX.#`L,C$T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AC:&%N
M9V4@;V8@9&5B="!F;W(@4V5R:65S($$@<')E9F5R<F5D('-T;V-K(%M-96UB
M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D9A:7(@5F%L=64L($)A;&%N8V4@4VAE970@1W)O=7!I;F<L($9I;F%N
M8VEA;"!3=&%T96UE;G0@0V%P=&EO;G,@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T
M:6)L92!P<F5F97)R960@9&5R:79A=&EV92!L:6%B:6QI='D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#(Q.2PX-30\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY
M-3@L.#8Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4V5R:65S($$@4&5R9F5R<F5D('-T;V-K(%M-96UB97)=/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A
M:7(@5F%L=64L($)A;&%N8V4@4VAE970@1W)O=7!I;F<L($9I;F%N8VEA;"!3
M=&%T96UE;G0@0V%P=&EO;G,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!P
M<F5F97)R960@9&5R:79A=&EV92!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PW-C(L,3$U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPT.3(L
M,38V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@:7-S=65D/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPT,C0L,38W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#<U
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-E<FEE<R!!(%!E<F9E<G)E9"!S=&]C:R!;
M365M8F5R72!\($ES<W5E9"!);B!-87D@06YD($IU;F4@,C`Q-"!/9F9E<FEN
M9R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY&86ER(%9A;'5E+"!"86QA;F-E(%-H965T($=R;W5P:6YG
M+"!&:6YA;F-I86P@4W1A=&5M96YT($-A<'1I;VYS(%M,:6YE($ET96US73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5V%R<F%N=',@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,"PP-#`L.#(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y397)I97,@0B!0<F5F97)R960@4W1O8VL@6TUE
M;6)E<ET@?"!)<W-U960@26X@36%Y($%N9"!*=6YE(#(P,30@3V9F97)I;F<@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^1F%I<B!686QU92P@0F%L86YC92!3:&5E="!'<F]U<&EN9RP@
M1FEN86YC:6%L(%-T871E;65N="!#87!T:6]N<R!;3&EN92!)=&5M<UT\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A
M<G)A;G1S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.2PX.30L,#,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F(&1E<FEV871I=F5S('5P;VX@
M<F5C;&%S<R!T;R!P86ED+6EN(&-A<&ET86P@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!686QU
M92P@0F%L86YC92!3:&5E="!'<F]U<&EN9RP@1FEN86YC:6%L(%-T871E;65N
M="!#87!T:6]N<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S(&ES<W5E9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&5R:79A=&EV92!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH-BPX,#0L-C(U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!V86QU92!O9B!D97)I=F%T
M:79E<R!U<&]N(')E8VQA<W,@=&\@<&%I9"UI;B!C87!I=&%L(%M-96UB97)=
M('P@27-S=65D($EN($UA>2!!;F0@2G5N92`R,#$T($]F9F5R:6YG(%M-96UB
M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D9A:7(@5F%L=64L($)A;&%N8V4@4VAE970@1W)O=7!I;F<L($9I;F%N
M8VEA;"!3=&%T96UE;G0@0V%P=&EO;G,@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT
M<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S
M<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@9&5R:79A=&EV97,@=7!O;B!R
M96-L87-S('1O('!A:60M:6X@8V%P:71A;"!;365M8F5R72!\(%-U8F]R9&EN
M871E9"!P<F]M:7-S;W)Y(&YO=&5S(%M-96UB97)=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64L($)A
M;&%N8V4@4VAE970@1W)O=7!I;F<L($9I;F%N8VEA;"!3=&%T96UE;G0@0V%P
M=&EO;G,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!I<W-U960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#4S+#@S,2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@
M;V8@9&5R:79A=&EV97,@=7!O;B!R96-L87-S('1O('!A:60M:6X@8V%P:71A
M;"!;365M8F5R72!\(%!L86-E;65N="!!9V5N="!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A
M;'5E+"!"86QA;F-E(%-H965T($=R;W5P:6YG+"!&:6YA;F-I86P@4W1A=&5M
M96YT($-A<'1I;VYS(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@:7-S=65D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,#<L-C8R*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I
M<B!V86QU92!O9B!D97)I=F%T:79E<R!U<&]N(')E8VQA<W,@=&\@<&%I9"UI
M;B!C87!I=&%L(%M-96UB97)=('P@4&QA8V5M96YT($%G96YT(%M-96UB97)=
M('P@27-S=65D($EN($UA>2!!;F0@2G5N92`R,#$T($]F9F5R:6YG(%M-96UB
M97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/D9A:7(@5F%L=64L($)A;&%N8V4@4VAE970@1W)O=7!I;F<L($9I;F%N
M8VEA;"!3=&%T96UE;G0@0V%P=&EO;G,@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT
M<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDY-BPQ
M,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D9A:7(@=F%L=64@;V8@9&5R:79A=&EV97,@=7!O;B!R96-L87-S
M('1O('!A:60M:6X@8V%P:71A;"!;365M8F5R72!\(%!L86-E;65N="!!9V5N
M="!;365M8F5R72!\(%-U8F]R9&EN871E9"!P<F]M:7-S;W)Y(&YO=&5S(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D9A:7(@5F%L=64L($)A;&%N8V4@4VAE970@1W)O=7!I;F<L($9I
M;F%N8VEA;"!3=&%T96UE;G0@0V%P=&EO;G,@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R
M86YT<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@9&5R:79A=&EV97,@=7!O
M;B!R96-L87-S('1O('!A:60M:6X@8V%P:71A;"!;365M8F5R72!\(%=O;G!U
M;F<@<V5R=FEC97,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92P@0F%L86YC92!3:&5E
M="!'<F]U<&EN9RP@1FEN86YC:6%L(%-T871E;65N="!#87!T:6]N<R!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;G9E<G1I8FQE('!R969E<G)E9"!D97)I=F%T:79E(&QI
M86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C8P+#,R
M-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D9A:7(@=F%L=64@;V8@9&5R:79A=&EV97,@=7!O;B!R96-L87-S
M('1O('!A:60M:6X@8V%P:71A;"!;365M8F5R72!\($5X8VAA;F=E(&]F(&1E
M8G0@9F]R(%-E<FEE<R!!('!R969E<G)E9"!S=&]C:R!;365M8F5R73PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER
M(%9A;'5E+"!"86QA;F-E(%-H965T($=R;W5P:6YG+"!&:6YA;F-I86P@4W1A
M=&5M96YT($-A<'1I;VYS(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E
M9F5R<F5D(&1E<FEV871I=F4@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@Y-38L.3DV*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5R:79A
M=&EV92!L:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!V86QU92!O9B!D97)I=F%T:79E
M<R!U<&]N(')E8VQA<W,@=&\@<&%I9"UI;B!C87!I=&%L(%M-96UB97)=('P@
M4V5R:65S($$@4&5R9F5R<F5D('-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64L
M($)A;&%N8V4@4VAE970@1W)O=7!I;F<L($9I;F%N8VEA;"!3=&%T96UE;G0@
M0V%P=&EO;G,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!P<F5F97)R960@
M9&5R:79A=&EV92!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#0L-30W+#,Q,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S(&ES<W5E9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-#<X+#0Y."D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L
M=64@;V8@9&5R:79A=&EV97,@=7!O;B!R96-L87-S('1O('!A:60M:6X@8V%P
M:71A;"!;365M8F5R72!\(%-E<FEE<R!!(%!E<F9E<G)E9"!S=&]C:R!;365M
M8F5R72!\($ES<W5E9"!);B!-87D@06YD($IU;F4@,C`Q-"!/9F9E<FEN9R!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY&86ER(%9A;'5E+"!"86QA;F-E(%-H965T($=R;W5P:6YG+"!&
M:6YA;F-I86P@4W1A=&5M96YT($-A<'1I;VYS(%M,:6YE($ET96US73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R
M<F%N=',@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E(&]F(&1E<FEV871I=F5S('5P
M;VX@<F5C;&%S<R!T;R!P86ED+6EN(&-A<&ET86P@6TUE;6)E<ET@?"!397)I
M97,@0B!0<F5F97)R960@4W1O8VL@6TUE;6)E<ET@?"!)<W-U960@26X@36%Y
M($%N9"!*=6YE(#(P,30@3V9F97)I;F<@6TUE;6)E<ET\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92P@
M0F%L86YC92!3:&5E="!'<F]U<&EN9RP@1FEN86YC:6%L(%-T871E;65N="!#
M87!T:6]N<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S(&ES<W5E9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC
M<F5A<V4@*&1E8W)E87-E*2!I;B!F86ER('9A;'5E(&]F(&1E<FEV871I=F4@
M;&EA8FEL:71I97,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92P@0F%L86YC92!3:&5E
M="!'<F]U<&EN9RP@1FEN86YC:6%L(%-T871E;65N="!#87!T:6]N<R!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E=A<G)A;G1S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5R:79A=&EV92!L:6%B
M:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPY-30L
M.3<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3(L.#<W+#8W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,L-C@X+#,U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8W)E87-E("AD96-R96%S92D@
M:6X@9F%I<B!V86QU92!O9B!D97)I=F%T:79E(&QI86)I;&ET:65S(%M-96UB
M97)=('P@27-S=65D($EN($UA>2!!;F0@2G5N92`R,#$T($]F9F5R:6YG(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D9A:7(@5F%L=64L($)A;&%N8V4@4VAE970@1W)O=7!I;F<L($9I
M;F%N8VEA;"!3=&%T96UE;G0@0V%P=&EO;G,@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R
M86YT<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DEN8W)E87-E("AD96-R96%S92D@:6X@9F%I<B!V
M86QU92!O9B!D97)I=F%T:79E(&QI86)I;&ET:65S(%M-96UB97)=('P@4W5B
M;W)D:6YA=&5D('!R;VUI<W-O<GD@;F]T97,@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!686QU
M92P@0F%L86YC92!3:&5E="!'<F]U<&EN9RP@1FEN86YC:6%L(%-T871E;65N
M="!#87!T:6]N<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S(&ES<W5E9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C4Y+#0R-RD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#`L-S,W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPX
M,S,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y);F-R96%S92`H9&5C<F5A<V4I(&EN(&9A:7(@=F%L=64@;V8@9&5R
M:79A=&EV92!L:6%B:6QI=&EE<R!;365M8F5R72!\(%!L86-E;65N="!!9V5N
M="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY&86ER(%9A;'5E+"!"86QA;F-E(%-H965T($=R;W5P:6YG
M+"!&:6YA;F-I86P@4W1A=&5M96YT($-A<'1I;VYS(%M,:6YE($ET96US73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5V%R<F%N=',@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q+#$P.2PT,C$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-S(U+#DR.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$V,BPX.#4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-R96%S92`H9&5C<F5A
M<V4I(&EN(&9A:7(@=F%L=64@;V8@9&5R:79A=&EV92!L:6%B:6QI=&EE<R!;
M365M8F5R72!\(%!L86-E;65N="!!9V5N="!;365M8F5R72!\($ES<W5E9"!)
M;B!-87D@06YD($IU;F4@,C`Q-"!/9F9E<FEN9R!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A
M;'5E+"!"86QA;F-E(%-H965T($=R;W5P:6YG+"!&:6YA;F-I86P@4W1A=&5M
M96YT($-A<'1I;VYS(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N=',@:7-S=65D/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#8U-2PP-#,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN
M8W)E87-E("AD96-R96%S92D@:6X@9F%I<B!V86QU92!O9B!D97)I=F%T:79E
M(&QI86)I;&ET:65S(%M-96UB97)=('P@4&QA8V5M96YT($%G96YT(%M-96UB
M97)=('P@4W5B;W)D:6YA=&5D('!R;VUI<W-O<GD@;F]T97,@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M1F%I<B!686QU92P@0F%L86YC92!3:&5E="!'<F]U<&EN9RP@1FEN86YC:6%L
M(%-T871E;65N="!#87!T:6]N<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S(&ES
M<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3,V+#,U.2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX
M,2PU.#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^26YC<F5A<V4@*&1E8W)E87-E*2!I;B!F
M86ER('9A;'5E(&]F(&1E<FEV871I=F4@;&EA8FEL:71I97,@6TUE;6)E<ET@
M?"!7;VYP=6YG('-E<G9I8V5S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64L($)A;&%N
M8V4@4VAE970@1W)O=7!I;F<L($9I;F%N8VEA;"!3=&%T96UE;G0@0V%P=&EO
M;G,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!P<F5F97)R960@9&5R:79A
M=&EV92!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#$L,S<P+#(V,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#$U,"PS-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU.#$L,#<S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC<F5A<V4@*&1E8W)E
M87-E*2!I;B!F86ER('9A;'5E(&]F(&1E<FEV871I=F4@;&EA8FEL:71I97,@
M6TUE;6)E<ET@?"!%>&-H86YG92!O9B!D96)T(&9O<B!397)I97,@02!P<F5F
M97)R960@<W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92P@0F%L86YC92!3:&5E
M="!'<F]U<&EN9RP@1FEN86YC:6%L(%-T871E;65N="!#87!T:6]N<R!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;G9E<G1I8FQE('!R969E<G)E9"!D97)I=F%T:79E(&QI
M86)I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PR-C(L
M.#4X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$L,C8P+#DY,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDU."PX-C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-R96%S92`H9&5C<F5A<V4I(&EN
M(&9A:7(@=F%L=64@;V8@9&5R:79A=&EV92!L:6%B:6QI=&EE<R!;365M8F5R
M72!\(%-E<FEE<R!!(%!E<F9E<G)E9"!S=&]C:R!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A
M;'5E+"!"86QA;F-E(%-H965T($=R;W5P:6YG+"!&:6YA;F-I86P@4W1A=&5M
M96YT($-A<'1I;VYS(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R
M<F5D(&1E<FEV871I=F4@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@W+#(Q-"PX,#0I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-RPV,C(L,#,Y/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV,3DL-#<X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R
M<F%N=',@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q
M+#DT-2PV-CDI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PX,S8L,#$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,S8S+#(R,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8W)E87-E("AD96-R96%S
M92D@:6X@9F%I<B!V86QU92!O9B!D97)I=F%T:79E(&QI86)I;&ET:65S(%M-
M96UB97)=('P@4V5R:65S($$@4&5R9F5R<F5D('-T;V-K(%M-96UB97)=('P@
M27-S=65D($EN($UA>2!!;F0@2G5N92`R,#$T($]F9F5R:6YG(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D9A:7(@5F%L=64L($)A;&%N8V4@4VAE970@1W)O=7!I;F<L($9I;F%N8VEA
M;"!3=&%T96UE;G0@0V%P=&EO;G,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!I
M<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL,3DX+#0U
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^26YC<F5A<V4@*&1E8W)E87-E*2!I;B!F86ER('9A;'5E(&]F(&1E
M<FEV871I=F4@;&EA8FEL:71I97,@6TUE;6)E<ET@?"!397)I97,@0B!0<F5F
M97)R960@4W1O8VL@6TUE;6)E<ET@?"!)<W-U960@26X@36%Y($%N9"!*=6YE
M(#(P,30@3V9F97)I;F<@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1F%I<B!686QU92P@0F%L86YC92!3
M:&5E="!'<F]U<&EN9RP@1FEN86YC:6%L(%-T871E;65N="!#87!T:6]N<R!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E=A<G)A;G1S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-RPT,#`L,C<U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);FET:6%L('9A;'5A=&EO
M;B!O9B!D97)I=F%T:79E(&QI86)I;&ET:65S('5P;VX@:7-S=6%N8V4@;V8@
M;F5W('=A<G)A;G1S('!E<FEO9"!;365M8F5R73PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY&86ER(%9A;'5E+"!"86QA
M;F-E(%-H965T($=R;W5P:6YG+"!&:6YA;F-I86P@4W1A=&5M96YT($-A<'1I
M;VYS(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1&5R:79A=&EV92!L:6%B:6QI=&EE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PS,S,L,38S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPQ,S0L-S8R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PT,#(L-C,U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^26YI=&EA;"!V86QU871I;VX@;V8@9&5R:79A=&EV92!L
M:6%B:6QI=&EE<R!U<&]N(&ES<W5A;F-E(&]F(&YE=R!W87)R86YT<R!P97)I
M;V0@6TUE;6)E<ET@?"!3=6)O<F1I;F%T960@<')O;6ES<V]R>2!N;W1E<R!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY&86ER(%9A;'5E+"!"86QA;F-E(%-H965T($=R;W5P:6YG+"!&
M:6YA;F-I86P@4W1A=&5M96YT($-A<'1I;VYS(%M,:6YE($ET96US73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R
M<F%N=',@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.#,L,S8S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C8L,S(U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YI=&EA;"!V86QU871I;VX@
M;V8@9&5R:79A=&EV92!L:6%B:6QI=&EE<R!U<&]N(&ES<W5A;F-E(&]F(&YE
M=R!W87)R86YT<R!P97)I;V0@6TUE;6)E<ET@?"!0;&%C96UE;G0@06=E;G0@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^1F%I<B!686QU92P@0F%L86YC92!3:&5E="!'<F]U<&EN9RP@
M1FEN86YC:6%L(%-T871E;65N="!#87!T:6]N<R!;3&EN92!)=&5M<UT\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A
M<G)A;G1S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(T."PV-34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW.2PV,34\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);FET:6%L('9A;'5A=&EO
M;B!O9B!D97)I=F%T:79E(&QI86)I;&ET:65S('5P;VX@:7-S=6%N8V4@;V8@
M;F5W('=A<G)A;G1S('!E<FEO9"!;365M8F5R72!\(%!L86-E;65N="!!9V5N
M="!;365M8F5R72!\(%-U8F]R9&EN871E9"!P<F]M:7-S;W)Y(&YO=&5S(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D9A:7(@5F%L=64L($)A;&%N8V4@4VAE970@1W)O=7!I;F<L($9I
M;F%N8VEA;"!3=&%T96UE;G0@0V%P=&EO;G,@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R
M86YT<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT,2PV.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,RPP.#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);FET:6%L('9A;'5A=&EO;B!O
M9B!D97)I=F%T:79E(&QI86)I;&ET:65S('5P;VX@:7-S=6%N8V4@;V8@;F5W
M('=A<G)A;G1S('!E<FEO9"!;365M8F5R72!\(%=O;G!U;F<@<V5R=FEC97,@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^1F%I<B!686QU92P@0F%L86YC92!3:&5E="!'<F]U<&EN9RP@
M1FEN86YC:6%L(%-T871E;65N="!#87!T:6]N<R!;3&EN92!)=&5M<UT\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;G9E<G1I8FQE('!R969E<G)E9"!D97)I=F%T:79E(&QI86)I;&ET>3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.3DL,30Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YI=&EA
M;"!V86QU871I;VX@;V8@9&5R:79A=&EV92!L:6%B:6QI=&EE<R!U<&]N(&ES
M<W5A;F-E(&]F(&YE=R!W87)R86YT<R!P97)I;V0@6TUE;6)E<ET@?"!%>&-H
M86YG92!O9B!D96)T(&9O<B!397)I97,@02!P<F5F97)R960@<W1O8VL@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^1F%I<B!686QU92P@0F%L86YC92!3:&5E="!'<F]U<&EN9RP@1FEN
M86YC:6%L(%-T871E;65N="!#87!T:6]N<R!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E
M<G1I8FQE('!R969E<G)E9"!D97)I=F%T:79E(&QI86)I;&ET>3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[
M)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^26YI=&EA;"!V86QU871I;VX@;V8@9&5R:79A=&EV92!L:6%B
M:6QI=&EE<R!U<&]N(&ES<W5A;F-E(&]F(&YE=R!W87)R86YT<R!P97)I;V0@
M6TUE;6)E<ET@?"!397)I97,@02!097)F97)R960@<W1O8VL@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M1F%I<B!686QU92P@0F%L86YC92!3:&5E="!'<F]U<&EN9RP@1FEN86YC:6%L
M(%-T871E;65N="!#87!T:6]N<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE
M('!R969E<G)E9"!D97)I=F%T:79E(&QI86)I;&ET>3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L-C0W+#DQ,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@W,BPV.#@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R86YT
M<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S
M<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,3,L,34S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3$Q+#<W-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN:71I86P@=F%L=6%T:6]N(&]F
M(&1E<FEV871I=F4@;&EA8FEL:71I97,@=7!O;B!I<W-U86YC92!O9B!N97<@
M=V%R<F%N=',@<&5R:6]D(%M-96UB97)=('P@4V5R:65S($$@4&5R9F5R<F5D
M('-T;V-K(%M-96UB97)=('P@27-S=65D($EN($UA>2!!;F0@2G5N92`R,#$T
M($]F9F5R:6YG(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64L($)A;&%N8V4@4VAE970@
M1W)O=7!I;F<L($9I;F%N8VEA;"!3=&%T96UE;G0@0V%P=&EO;G,@6TQI;F4@
M271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y787)R86YT<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C@T,BPS-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN:71I86P@=F%L=6%T:6]N(&]F(&1E
M<FEV871I=F4@;&EA8FEL:71I97,@=7!O;B!I<W-U86YC92!O9B!N97<@=V%R
M<F%N=',@<&5R:6]D(%M-96UB97)=('P@4V5R:65S($(@4')E9F5R<F5D(%-T
M;V-K(%M-96UB97)=('P@27-S=65D($EN($UA>2!!;F0@2G5N92`R,#$T($]F
M9F5R:6YG(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D9A:7(@5F%L=64L($)A;&%N8V4@4VAE970@1W)O
M=7!I;F<L($9I;F%N8VEA;"!3=&%T96UE;G0@0V%P=&EO;G,@6TQI;F4@271E
M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y787)R86YT<R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,BPT.30L-C4U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%\V,S,T-64Y9E]B-C1B7S0W,V)?.&)B,%\U-S1F
M-C%A,#EB,F4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C,S-#5E
M.69?8C8T8E\T-S-B7SAB8C!?-3<T9C8Q83`Y8C)E+U=O<FMS:&5E=',O4VAE
M970S,RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P15A"04,^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^1&5R:79A=&EV92!,:6%B:6QI=&EE<R`H1&5T86EL<R!497AT=6%L*3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*
M=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY$97)I=F%T:79E($QA:6)I;&ET:65S(%M!8G-T
M<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^17AP96-T960@9&EV:61E;F0@>6EE;&1S("@T*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\V,S,T-64Y9E]B-C1B7S0W,V)?.&)B,%\U-S1F-C%A,#EB
M,F4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C,S-#5E.69?8C8T
M8E\T-S-B7SAB8C!?-3<T9C8Q83`Y8C)E+U=O<FMS:&5E=',O4VAE970S-"YH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P141(044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O
M8VMH;VQD97)S)R!%<75I='D@*$1E=&%I;',I("A54T0@)"D\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P
M+"`R,#$T/&)R/D-O;6UO;B!3=&]C:R!;365M8F5R73QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/E-E<FEE<R!!
M(%!R969E<G)E9"!3=&]C:R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;&%S<R!O9B!3=&]C:R!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4&%R('9A;'5E(&]F(%-E<FEE<R!!('!R969E<G)E9"!S=&]C
M:R!I<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"PX
M.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`U+#$P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4&%R('9A;'5E(&]F(&-O;6UO;B!S=&]C:R!I<W-U960\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-RPQ-C0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I
M=&EO;F%L('!A:60M:6XM8V%P:71A;#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,BPQ-3$L,#0P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3<L.#<X+#DY-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-#<Y+#8Q,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5R:79A
M=&EV92!W87)R86YT(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,3$L-S<W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,RPS,S<L,#(U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$S+#$U,SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5R:79A=&EV
M92!P<F5F97)R960@<W1O8VL@8V]N=F5R<VEO;B!F96%T=7)E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-S(L-C@X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C0W+#DQ,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5R
M:79A=&EV92!787)R86YT<R!I<W-U960@=&\@<&QA8V5M96YT(&%G96YT(&%S
M(&]F9F5R:6YG(&-O<W1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XW.2PV,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XY.38L,3,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C0X+#8U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!P<F]C965D<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPR,C`L,#$X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C(L,C(R+#,Q.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M-#DT+#0R-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3V9F97)I;F<@8V]S=',@<&%I9"!I;B!C87-H/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XV.3DL-#@R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPU,38L,S<X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3@V+#`W
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D=R;W-S('!R;V-E961S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#,L.3$Y+#4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,C4L-S0U+#8Y.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"PP.#`L-3`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V,S,T-64Y9E]B
M-C1B7S0W,V)?.&)B,%\U-S1F-C%A,#EB,F4-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO-C,S-#5E.69?8C8T8E\T-S-B7SAB8C!?-3<T9C8Q83`Y
M8C)E+U=O<FMS:&5E=',O4VAE970S-2YH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P1558044^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VMH;VQD97)S)R!%<75I='D@*$1E
M=&%I;',@,2D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C:VAO;&1E
M<G,G($1E9FEC:70@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@4VAA<F5S+"!/=71S
M=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX-C4L
M-#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-C<W+#DV,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!3:&%R97,L($=R
M86YT960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-#DY+#<V
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L,3@W+#0T.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8W-RPY-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!3:&%R97,L($]U='-T86YD
M:6YG(&%N9"!E>'!E8W1E9"!T;R!V97-T/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS+#,V-2PQ-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#@V-2PT,3$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-S<L.38R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@
M;V8@4VAA<F5S+"!E>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-C4R+#`P-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E($5X97)C:7-E
M(%!R:6-E(%!E<B!3:&%R92P@3W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,"XP.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A
M9V4@17AE<F-I<V4@4')I8V4@4&5R(%-H87)E+"!'<F%N=&5D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$N-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I
M9VAT960@079E<F%G92!%>&5R8VES92!0<FEC92!097(@4VAA<F4L($]U='-T
M86YD:6YG(&%N9"!E>'!E8W1E9"!T;R!V97-T/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$N,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V
M97)A9V4@17AE<F-I<V4@4')I8V4@4&5R(%-H87)E+"!E>&5R8VES86)L93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT
M960@079E<F%G92!296UA:6YI;F<@0V]N=')A8W1U86P@5&5R;2P@3W5T<W1A
M;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<X('EE87)S
M(#$P(&UO;G1H<R`R-"!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)S@@>65A<G,@.2!M;VYT:',@,3@@9&%Y<SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<Y
M('EE87)S(#8@;6]N=&AS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y796EG:'1E9"!!=F5R86=E(%)E;6%I;FEN9R!#
M;VYT<F%C='5A;"!497)M+"!'<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG.2!Y96%R<R`X(&UO;G1H<R`Q,B!D87ES/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H
M=&5D($%V97)A9V4@4F5M86EN:6YG($-O;G1R86-T=6%L(%1E<FTL(&5X97)C
M:7-A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG.2!Y96%R
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!9V=R96=A=&4@26YT<FEN<VEC(%9A;'5E+"!/=71S=&%N9&EN9SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#,P-2PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06=G<F5G871E($EN=')I;G-I8R!686QU92P@1W)A;G1E
M9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPP,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%G9W)E9V%T92!);G1R:6YS:6,@5F%L=64L($]U='-T86YD:6YG/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#(S."PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,P-2PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@26YT<FEN<VEC(%9A;'5E+"!E>&5R
M8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W.#(L
M-#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
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M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%5T%!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:VAO;&1E<G,G
M($5Q=6ET>2`H1&5T86EL<R`R*2`H4W1O8VL@3W!T:6]N(%M-96UB97)=+"!5
M4T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T
M:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-U<G)E;G0@<')I8V4@;V8@8V]M;6]N('-T;V-K/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N.#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4FES:R!F<F5E(&EN=&5R97-T(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+C0P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`N-C`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$:79I9&5N9"!Y:65L9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y6;VQA
M=&EL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@R+C`P
M)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5F]L871I;&ET>2P@;6EN:6UU;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-S8N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-S,N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5F]L871I;&ET>2P@;6%X:6UU;3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S<N,#`E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#`N,#`E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M17AP96-T960@=&5R;2`H:6X@>65A<G,I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG-B!Y96%R<R`S(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-2!Y96%R<R`Y(&UO;G1H
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^36%X:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!
M<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE
M($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y2:7-K(&9R964@:6YT97)E<W0@<F%T93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2XV,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@=&5R;2`H:6X@
M>65A<G,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S$P('EE
M87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^36EN:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E;G-A=&EO
M;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y2:7-K(&9R964@:6YT97)E<W0@<F%T93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,2XU,"4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@=&5R;2`H
M:6X@>65A<G,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S4@
M>65A<G,@.2!M;VYT:',\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
M/5].97AT4&%R=%\V,S,T-64Y9E]B-C1B7S0W,V)?.&)B,%\U-S1F-C%A,#EB
M,F4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C,S-#5E.69?8C8T
M8E\T-S-B7SAB8C!?-3<T9C8Q83`Y8C)E+U=O<FMS:&5E=',O4VAE970S-RYH
M=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A
M8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C
M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14%:044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O
M8VMH;VQD97)S)R!%<75I='D@*$1E=&%I;',@,RD@*%531"`D*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R
M,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!<'(N
M(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E-T;V-K:&]L9&5R<R<@1&5F:6-I="!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M=6UB97(@;V8@4VAA<F5S+"!/=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^."PY,C8L-3$W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PX-C4L,C,T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPR-3$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB
M97(@;V8@4VAA<F5S+"!'<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS-2PP.#8L,C4S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-"PP-C$L,C@S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PT-S@L,S8P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R
M(&]F(%-H87)E<RP@17AE<F-I<V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#8Q.2PS-S<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(%-H87)E<RP@1F]R9F5I
M=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X-C@L,C$S*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3G5M8F5R(&]F(%-H87)E<RP@3W5T<W1A;F1I;F<\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4L.#@Q+#4W-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L.3(V+#4Q-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L.#8U+#(S
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYU;6)E<B!O9B!3:&%R97,L($]U='-T86YD:6YG(&%N9"!V97-T960\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0S+#$T-"PU-3<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E=E:6=H=&5D($%V97)A9V4@17AE<F-I<V4@4')I8V4@4&5R(%-H87)E+"!/
M=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P
M+C4T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`P+C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#`N.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!%>&5R8VES92!0
M<FEC92!097(@4VAA<F4L($=R86YT960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$N-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XP+C4T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,"XP-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@17AE
M<F-I<V4@4')I8V4@4&5R(%-H87)E+"!%>&5R8VES960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,"XP.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@
M17AE<F-I<V4@4')I8V4@4&5R(%-H87)E+"!&;W)F96ET960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C`N.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G
M92!%>&5R8VES92!0<FEC92!097(@4VAA<F4L($]U='-T86YD:6YG/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C4T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5V5I9VAT960@079E<F%G92!%>&5R8VES92!0<FEC92!097(@4VAA<F4L($]U
M='-T86YD:6YG(&%N9"!V97-T960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$N,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
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M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%331!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C
M:VAO;&1E<G,G($5Q=6ET>2`H1&5T86EL<R`T*2`H5V%R<F%N="!;365M8F5R
M72P@55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D($-O;7!E
M;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM96YT($%W
M87)D(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#=7)R96YT('!R:6-E(&]F(&-O;6UO;B!S=&]C
M:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XS/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M:7-K+69R964@:6YT97)E<W0@<F%T92P@;6EN:6UU;3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,"XW,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+CDP)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N-C`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2:7-K+69R964@
M:6YT97)E<W0@<F%T92P@;6%X:6UU;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,BXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ+C@P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`N-S`E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$:79I9&5N9"!Y:65L9#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y6
M;VQA=&EL:71Y+"!M:6YI;75M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XW-2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XW,RXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XX,BXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E9O;&%T:6QI='DL(&UA>&EM=6T\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<V+C`P)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@S+C`P)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@S
M+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^17AP96-T960@=&5R;2`H:6X@>65A<G,I/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<U('EE87)S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-87AI;75M(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E
M+6)A<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-U<G)E;G0@<')I
M8V4@;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^(#$N-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5X<&5C=&5D('1E<FT@*&EN('EE87)S*3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S<@>65A<G,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-R!Y96%R<SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUI
M;FEM=6T@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY3:&%R92UB87-E9"!#;VUP96YS871I;VX@07)R86YG
M96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R9"!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0W5R<F5N="!P<FEC92!O9B!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#X@,"XX/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@=&5R;2`H:6X@
M>65A<G,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-"!Y96%R
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<T('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?-C,S-#5E.69?8C8T8E\T-S-B7SAB8C!?-3<T9C8Q83`Y8C)E#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8S,S0U93EF7V(V-&)?-#<S
M8E\X8F(P7S4W-&8V,6$P.6(R92]7;W)K<VAE971S+U-H965T,SDN:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5"3T)+/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-T;V-K:&]L
M9&5R<R<@17%U:71Y("A$971A:6QS(%1E>'1U86PI("A54T0@)"D\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA>2`R,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y!<'(N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:R!C;VYV
M97)S:6]N(&)A<VES/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M3VYE(&9O<B!O;F4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K(&-O;G9E<G-I;VX@8F5N
M969I8VEA;&QY+"!$97-C<FEP=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)TUO<F4@=&AA;B`Y+CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5N9&5R<R!A;6]U;G0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#DW-2PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!8V-U<F5D(&EN=&5R97-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-38V+#$X,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G1S(&ES<W5E9"P@;G5M8F5R(&]F
M('-H87)E<R!O9B!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU-#$L-#,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU-#$L-#,P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@<')I8V4@
M<&5R('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P
M+C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`P+C4T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`P+C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@=&\@<'5R8VAA<V4@;V8@8V]M
M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C$Y
M+#,W-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-C$Y+#,W-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-H87)E(&)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,S`U+#(P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%D
M9&ET:6]N86P@<&%I9"`M:6X@8V%P:71A;#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L,#`V+#$P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<FEV871I=F4@;&EA8FEL
M:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CDY+#$P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D=R;W-S('!R;V-E961S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,RPY,3DL-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!S86QE(&]F(%-E
M<FEE<R!!('!R969E<G)E9"!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPT.30L-#(X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPR,C`L,#$X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4&QA8V5M96YT(&%G96YT(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,L-3$V+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W=N97)S:&EP('!E<F-E;G1A
M9V4@;V8@4F5L;6%D83PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.30N-C`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F('-H87)E<R!I;B!E>&-H86YG92!F
M;W(@;W=N97)S:&EP(&EN=&5R97-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR."PR.3$L,#<S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!E<F-E;G1A9V4@;V8@86-Q=6ER
M960@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,"XY
M,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4W1O8VL@<W!L:70@<F%T:6\@9&5S8W)I<'1I;VX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)U1H92!O=71S=&%N9&EN9R!O
M<'1I;VYS(&%N9"!W87)R86YT<R!W97)E(&5X8VAA;F=E9"!F;W(@;W!T:6]N
M<R!A;F0@=V%R<F%N=',@=&\@<'5R8VAA<V4@<VAA<F5S(&]F(&-O;6UO;B!S
M=&]C:R!O9B!T:&4@0V]M<&%N>2!A="!A(')A=&EO(&]F(#$P('1O(#$N/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@86YD($-L87-S($$@<')E9F5R
M<F5D('-T;V-K(&EN(&-O;FYE8W1I;VX@=VET:"!S:&%R92!E>&-H86YG93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R969E<G)E9"!#;&%S<R!!(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C
M:R!F;W(@<V5R=FEC97,L(%-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM
M;VX@<W1O8VL@86YD($-L87-S($$@<')E9F5R<F5D('-T;V-K(&EN(&-O;FYE
M8W1I;VX@=VET:"!S:&%R92!E>&-H86YG93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS+#,S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T
M;V-K(&%N9"!#;&%S<R!!('!R969E<G)E9"!S=&]C:R!I;B!C;VYN96-T:6]N
M('=I=&@@<VAA<F4@97AC:&%N9V4L(%-H87)E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS+#,S-RPS,#D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!3=&]C:R!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%>&5R8VES92!P<FEC92!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#`N.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@=&\@<'5R8VAA<V4@
M;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^.#8X+#(Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!F;W(@
M<V5R=FEC97,L(%-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR.2PP-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU-BPS.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XV."PS-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F]S<R!P<F]C965D<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2PW-#4L-CDY/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)
M<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@86YD($-L87-S($$@<')E9F5R<F5D
M('-T;V-K(&EN(&-O;FYE8W1I;VX@=VET:"!S:&%R92!E>&-H86YG93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#,S-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N
M8V4@;V8@8V]M;6]N('-T;V-K(&%N9"!#;&%S<R!!('!R969E<G)E9"!S=&]C
M:R!I;B!C;VYN96-T:6]N('=I=&@@<VAA<F4@97AC:&%N9V4L(%-H87)E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#,S-RPS,3`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!L86-E;65N="!!9V5N="!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!P<FEC92!P97(@<VAA<F4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y7
M87)R86YT('1O('!U<F-H87-E(&]F(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8Q,BPT,C(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92!B87-E
M9"!C;VUP96YS871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C8S-RPU-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^1W)O<W,@<')O8V5E9',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C(L,C(Y+#,P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV97-T;W)S(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R;V-E961S(&9R;VT@<V%L92!O9B!397)I97,@02!P<F5F97)R960@<W1O
M8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4L-S0U+#<P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4V5R:65S($$@4')E9F5R<F5D(%-T;V-K(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!S
M:&%R97,@8V]N=F5R=&5D('1O(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,V,"PT,3,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E<G)E9"!S
M=&]C:RP@;&EQ=6ED871I;VX@<')E9F5R96YC92P@5F%L=64\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#@X,RPS,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5R:65S
M($$@<')E9F5R<F5D('-T;V-K(&]U<W1A;F1I;F<\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#@W.2PQ,C@\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!P<FEC
M92!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`P+C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#`N.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,"XP.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@=&\@<'5R8VAA<V4@;V8@8V]M
M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#(W-2PQ-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#(R-"PX-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@
M9F]R('-E<G9I8V5S+"!3:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ+#<R-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PR-S4L,34V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E(&)A<V5D(&-O
M;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M,S`U+#(P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@<&%I9"`M:6X@8V%P:71A;#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#`V+#$P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E
M<FEV871I=F4@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,CDY+#$P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D=R;W-S('!R;V-E961S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-"PP.#`L-3`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)<W-U86YC
M92!O9B!397)I97,@02!P<F5F97)R960@<W1O8VL@<VAA<F5S('1O('!U<F-H
M87-E(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-2PQ,#`L-C(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-"PX.3DL,S<U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5R:65S($$@=V%R<F%N=',@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5V%R<F%N=',@:7-S=65D+"!N=6UB97(@;V8@<VAA<F5S(&]F(&-O;6UO
M;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-RPQ
M-C,L-SDY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y%>&5R8VES92!P<FEC92!P97(@<VAA<F4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E<FEE<R!"('=A
M<G)A;G1S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E=A<G)A;G1S(&ES<W5E9"P@;G5M8F5R(&]F('-H87)E<R!O
M9B!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^."PU.#$L.#DT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!P<FEC92!P97(@<VAA<F4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+C(U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y787)R
M86YT<R!R961E;7!T:6]N('1E<FUS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\9&EV/E1H92!#;VUP86YY(&UA>2!C86QL('1H92!397)I
M97,@0B!W87)R86YT(&9O<B!R961E;7!T:6]N('5P;VX@=W)I='1E;B!N;W1I
M8V4@=&\@86QL(&EN=F5S=&]R<R!O9B!T:&4@36%Y(&%N9"!*=6YE(#(P,30@
M=6YI=',@)B,Q-C`[*"8C.#(R,#MI;G9E<W1O<G,F(S@R,C$[*2!A="!A;GD@
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M:6YG('1H92!E>&5R8VES92!P<FEC92!O9B`D,BXR-2!P97(@<VAA<F4N(#QF
M;VYT('-T>6QE/3-$)V-O;&]R.B`C,68T.3=D.R<^)B,Q-C`[/"]F;VYT/D%N
M>2!W87)R86YT<R!N;W0@97AE<F-I<V5D(&]N('1H92!L87-T(&1A>2!O9B!T
M:&4@17AE<F-I<V4@4&5R:6]D+"!W:6QL(&)E(')E9&5E;65D(&)Y('1H92!#
M;VUP86YY(&%T("0P+C`P,2!P97(@<VAA<F4N/"]D:78^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097)C96YT
M86=E(&]F('-O;&EC:71A=&EO;B!F964@;VX@=V%R<F%N=',@97AE<F-I<V5D
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4N,#`E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M9V5N="!W87)R86YT<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y787)R86YT<R!I<W-U960L(&YU;6)E<B!O9B!S
M:&%R97,@;V8@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0L,CDP+#DU,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AE<F-I<V4@<')I8V4@<&5R('-H
M87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XU/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V,S,T
M-64Y9E]B-C1B7S0W,V)?.&)B,%\U-S1F-C%A,#EB,F4-"D-O;G1E;G0M3&]C
M871I;VXZ(&9I;&4Z+R\O0SHO-C,S-#5E.69?8C8T8E\T-S-B7SAB8C!?-3<T
M9C8Q83`Y8C)E+U=O<FMS:&5E=',O4VAE970T,"YH=&UL#0I#;VYT96YT+51R
M86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y
M<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*
M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15-0
M0TL^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W1O8VMH;VQD97)S)R!%<75I
M='D@*$1E=&%I;',@5&5X='5A;"`Q*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#(^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R
M/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#,^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87D@,C`L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^2G5N+B`Q,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y!<'(N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3$\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CY#
M;VYS=6QT86YT<R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/D-O;G-U;'1A;G1S(%M-96UB97)=
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3(\8G(^0V]N<W5L=&%N=',@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^3F]V+B`S,"P@,C`Q,SQB<CY#;VYS=6QT86YT<R!;
M365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!<'(N
M(#,P+"`R,#$R/&)R/D-O;6UO;B!3=&]C:R!;365M8F5R73QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/D-O;6UO
M;B!3=&]C:R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$S/&)R/D-O;6UO;B!3=&]C:R!;365M8F5R73QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R
M/&)R/D-O;6UO;B!3=&]C:R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y!<'(N(#,P+"`R,#$R/&)R/D-O;6UO;B!3=&]C:R!;
M365M8F5R73QB<CY-961E;W(@26YC(%M-96UB97)=/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D%P<BX@,S`L(#(P,3(\8G(^5V%R<F%N="!;
M365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*86XN
M(#$P+"`R,#$T/&)R/D-O;6UO;B!S=&]C:R!I<W-U960@9F]R('-E<G9I8V5S
M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU
M;"X@,3`L(#(P,3,\8G(^0V]M;6]N('-T;V-K(&ES<W5E9"!F;W(@<V5R=FEC
M97,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M2G5L+B`Q,"P@,C`Q,CQB<CY#;VUM;VX@<W1O8VL@:7-S=65D(&9O<B!S97)V
M:6-E<R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y*=6XN(#,P+"`R,#$T/&)R/D-O;6UO;B!S=&]C:R!I<W-U960@9F]R('-E
M<G9I8V5S(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3,\8G(^0V]M;6]N('-T;V-K(&ES<W5E9"!F;W(@
M<V5R=FEC97,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CY#;VUM;VX@<W1O8VL@:7-S=65D(&9O
M<B!S97)V:6-E<R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^26YT97)E<W0@97AP96YS92!D=64@9G)O;2!R96QA=&5D
M('!A<G1Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,S4S+#(T-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@<')O8V5E9',@
M9G)O;2!P<FEV871E('!L86-E;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(U+#<T-2PV.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C(L,C(Y+#,P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S=&]C:R!A;F0@=V%R<F%N=',@
M=&\@<'5R8VAA<V4@8V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(U-2PW-3`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R
M<F%N="!T;R!P=7)C:&%S92!O9B!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-C$Y+#,W-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C$Y+#,W-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPU,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M,2PU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.#8X+#(Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!P<FEC
M92!P97(@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`P+C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`P+C4T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`P+C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XX/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,"XS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3W5T<W1A;F1I;F<@;&EA8FEL:71I97,@;W=E
M9"!T;R!T:&4@9F]U;F1E<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XX-CDL,S`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F
M(&-O;6UO;B!S=&]C:R!F;W(@<V5R=FEC97,L(%-H87)E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CDL,#4R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-38L,SDT
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-C@L,S4V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@8V]M;6]N('-T;V-K(&9O
M<B!T:&4@<V5R=FEC97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,2PS,#4L,C`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D
M(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#4P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,3`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L-S`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38L
M.3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C`L-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@:6X@8V]N;F5C
M=&EO;B!W:71H(&%C<75I<W1I;VX@;V8@;&EC:65N<V4@86=R965M96YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-RPP.#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@<&5R('-H87)E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`P+C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYU;6)E<B!O9B!3:&%R97,L($=R86YT960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-#DY+#<V,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,3@W+#0T.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8W-RPY
M-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$L-3,X+#`Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3,L.#`R/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER('9A;'5E
M(&]F('1H92!C;VUM;VX@9W)A;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-BPQ,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#8L,3`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'
M<F%N="!D871E(&9A:7(@=F%L=64@;V8@=&AE(&-O;6UO;B!S=&]C:SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N
M,#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4VAA<F4@8F%S960@8V]M<&5N<V%T:6]N('-H87)E<R!V
M97-T960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L-C4U
M+#<X,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR.2PP-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-BPS.3`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV."PS-3`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A
M;F-E(&]F(&-O;6UO;B!S=&]C:R!T;R!F;W5N9&5R(&9O<B!C87-H/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@9F]R(&-A
M<VAL97-S(&5X97)C:7-E(&]F('=A<G)A;G1S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4T,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@9F]R(&-A<VAL97-S
M(&5X97)C:7-E(&]F('=A<G)A;G1S+"!3:&%R97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-C$X+#<V-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-30Q+#0S,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M-#$L,CDS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('!A<B!V86QU93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`P,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P;65N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@X,SDL.34Y*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-2PR
M-#@L-C8Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)"`H-C8W+#0W-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,L-S4P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&]U='-T86YD:6YG/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,"PR.30L,C$W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PY-3@L-S<X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%\V,S,T-64Y9E]B-C1B7S0W,V)?.&)B,%\U
M-S1F-C%A,#EB,F4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C,S
M-#5E.69?8C8T8E\T-S-B7SAB8C!?-3<T9C8Q83`Y8C)E+U=O<FMS:&5E=',O
M4VAE970T,2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P15!01TT^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^4W1O8VMH;VQD97)S)R!%<75I='D@*$1E=&%I;',@5&5X='5A;"`R
M*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD
M960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$-#XQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$-#XQ($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,CXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%P<BX@,S`L(#(P,3(\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q
M-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,3`L
M(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D9E
M8BX@,C@L(#(P,30\8G(^0F]A<F0@;V8@1&ER96-T;W)S(%M-96UB97)=/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\
M8G(^4&QA8V5M96YT($%G96YT(%M-96UB97)=/&)R/DUE9&5O<B!);F,@6TUE
M;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3F]V+B`S
M,"P@,C`Q,SQB<CY#;VYS=6QT86YT<R!;365M8F5R73QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/D-O;G-U;'1A
M;G1S(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3,\8G(^0V]N<W5L=&%N=',@6TUE;6)E<ET\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CY#
M;VYS=6QT86YT<R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/E-E<FEE<R!!(%!R969E<G)E9"!3
M=&]C:R!/9F9E<FEN9W,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CY397)I97,@02!0<F5F97)R
M960@4W1O8VL@3V9F97)I;F=S(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^4V5R:65S($$@4')E
M9F5R<F5D(%-T;V-K($]F9F5R:6YG<R!;365M8F5R73QB<CY);G9E<W1O<G,@
M6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,CQB<CY397)I97,@02!0<F5F97)R960@4W1O8VL@3V9F97)I
M;F=S(%M-96UB97)=/&)R/DEN=F5S=&]R<R!;365M8F5R73QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/E-E<FEE
M<R!!(%!R969E<G)E9"!3=&]C:R!/9F9E<FEN9W,@6TUE;6)E<ET\8G(^4&QA
M8V5M96YT($%G96YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^4V5R:65S($$@4')E9F5R<F5D
M(%-T;V-K($]F9F5R:6YG<R!;365M8F5R73QB<CY0;&%C96UE;G0@06=E;G0@
M6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,SQB<CY$96)T($]F9F5R:6YG<R!;365M8F5R73QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/D1E
M8G0@3V9F97)I;F=S(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^1&5B="!/9F9E<FEN9W,@6TUE
M;6)E<ET\8G(^1&5B="!(;VQD97)S(%M-96UB97)=/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^1&5B="!/9F9E
M<FEN9W,@6TUE;6)E<ET\8G(^1&5B="!(;VQD97)S(%M-96UB97)=/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^
M1&5B="!/9F9E<FEN9W,@6TUE;6)E<ET\8G(^4&QA8V5M96YT($%G96YT(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,3(\8G(^1&5B="!/9F9E<FEN9W,@6TUE;6)E<ET\8G(^4&QA8V5M
M96YT($%G96YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^4W1R871E9VEC($%D=FES;W(@06=R
M965M96YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIU;BX@,S`L(#(P,30\8G(^4W1O8VL@3W!T:6]N(%M-96UB97)=/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\
M8G(^4W1O8VL@3W!T:6]N(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^4W1O8VL@3W!T:6]N(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@
M,S`L(#(P,30\8G(^5V%R<F%N=',@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY787)R86YT<R!;
M365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$R/&)R/E=A<G)A;G1S(%M-96UB97)=/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^1F]U;F1E<B!7
M87)R86YT<R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87D@,S$L(#(P,30\8G(^3V9F:6-E<B!/<'1I;VYS(%M-96UB97)=
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIA;BX@,S$L(#(P
M,30\8G(^3V9F:6-E<B!/<'1I;VYS(%M-96UB97)=/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^3V9F:6-E<B!/
M<'1I;VYS(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIU;"X@,S$L(#(P,3(\8G(^3V9F:6-E<B!/<'1I;VYS(%M-96UB97)=
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3,\8G(^3V9F:6-E<B!/<'1I;VYS(%M-96UB97)=/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^4F5S96%R8V@@
M86YD($1E=F5L;W!M96YT($5X<&5N<V4@6TUE;6)E<ET\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY297-E87)C
M:"!A;F0@1&5V96QO<&UE;G0@17AP96YS92!;365M8F5R73QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/E)E<V5A
M<F-H(&%N9"!$979E;&]P;65N="!%>'!E;G-E(%M-96UB97)=/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^4F5S
M96%R8V@@86YD($1E=F5L;W!M96YT($5X<&5N<V4@6TUE;6)E<ET\8G(^5V%R
M<F%N=',@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,SQB<CY297-E87)C:"!A;F0@1&5V96QO<&UE;G0@
M17AP96YS92!;365M8F5R73QB<CY787)R86YT<R!;365M8F5R73QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/E)E
M<V5A<F-H(&%N9"!$979E;&]P;65N="!%>'!E;G-E(%M-96UB97)=/&)R/E=A
M<G)A;G1S(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIU;BX@,S`L(#(P,30\8G(^4V5L;&EN9RP@1V5N97)A;"!A;F0@061M
M:6YI<W1R871I=F4@17AP96YS97,@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY396QL:6YG+"!'
M96YE<F%L(&%N9"!!9&UI;FES=')A=&EV92!%>'!E;G-E<R!;365M8F5R73QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R
M/&)R/E-E;&QI;F<L($=E;F5R86P@86YD($%D;6EN:7-T<F%T:79E($5X<&5N
M<V5S(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/DIU;BX@,S`L(#(P,30\8G(^4V5L;&EN9RP@1V5N97)A;"!A;F0@061M:6YI
M<W1R871I=F4@17AP96YS97,@6TUE;6)E<ET\8G(^5V%R<F%N=',@6TUE;6)E
M<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,SQB<CY396QL:6YG+"!'96YE<F%L(&%N9"!!9&UI;FES=')A=&EV92!%
M>'!E;G-E<R!;365M8F5R73QB<CY787)R86YT<R!;365M8F5R73QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/E-E
M;&QI;F<L($=E;F5R86P@86YD($%D;6EN:7-T<F%T:79E($5X<&5N<V5S(%M-
M96UB97)=/&)R/E=A<G)A;G1S(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D5M<&QO>65E(%-E<G9I8V4@
M4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N+"!!;&QO8V%T:6]N(&]F(%)E8V]G
M;FEZ960@4&5R:6]D($-O<W1S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F('-H
M87)E<R!A=F%I;&%B;&4@9F]R(&=R86YT(&%U=&AO<FEZ960@=6YD97(@,C`Q
M,B!3=&]C:R!/<'1I;VX@4&QA;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L-#`Y+#0S-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@<VAA<F5S(&%V86EL86)L
M92!F;W(@9G5T=7)E(&=R86YT<R!U;F1E<B!S=&]C:R!O<'1I;VX@<&QA;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-CDS+#8W,SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M=&]C:R!O<'1I;VYS('!L86X@<W1O8VL@;W!T:6]N<R!E>&5R8VES86)L92!P
M97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,3`@>65A
M<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4W1O8VL@;W!T:6]N<R!E>&5R8VES86)L92!P97)I;V0@9&5S8W)I
M<'1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CY6
M97-T(&]V97(@9F]U<B!Y96%R<SPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<'1I;VYS('1O('!U<F-H
M87-E(&]F(&-O;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,30U+#DX-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ.#<L-3`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,2PP,#,L-S<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-C8U+#<U,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8W-RPY-C(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,S0L,3DY/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3=&]C:R!O<'1I;VYS('1E<FT\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<Q,"!Y96%R<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,3`@>65A<G,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M-R!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<W('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<W('EE87)S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S<@>65A<G,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG,3`@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG,3`@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG,3`@>65A<G,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,3`@>65A<G,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,3`@>65A
M<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@=F5S="!P97)C96YT9V%E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2XP,"4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C4N,#`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2XP,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2XP,"4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2XP,"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2XP
M,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E;6%I;FEN9R!O<'1I;VYS('9E<W0@
M<&5R8V5N=&%G93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<U+C`P)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<U+C`P)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E)E;6%I;FEN9R!O<'1I;VYS('9E<W0@<&5R:6]D(&1E
M<V-R:7!T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG3W!T:6]N<R!V97-T(&]N('1H92!O;F4@>65A<B!A;FYI=F5R<V%R>2!O
M9B!T:&4@9W)A;G0@9&%T92!A;F0@=&AE(')E;6%I;FEN9R!O<'1I;VYS('9E
M<W0@<75A<G1E<FQY(&]V97(@=&AE(&9O;&QO=VEN9R`S('EE87)S+CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I
M=CY/<'1I;VYS('9E<W0@;VX@=&AE(&]N92!Y96%R(&%N;FEV97)S87)Y(&]F
M('1H92!G<F%N="!D871E(&%N9"!T:&4@<F5M86EN:6YG(&]P=&EO;G,@=F5S
M="!I;B!E<75A;"!Q=6%R=&5R;'D@:6YC<F5M96YT(&]V97(@=&AE(&9O;&QO
M=VEN9R`S('EE87)S/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG3W!T
M:6]N<R!V97-T(&]N('1H92!O;F4@>65A<B!A;FYI=F5R<V%R>2!O9B!T:&4@
M9W)A;G0@9&%T92!A;F0@=&AE(')E;6%I;FEN9R!O<'1I;VYS('9E<W0@<75A
M<G1E<FQY(&]V97(@=&AE(&9O;&QO=VEN9R`S('EE87)S+CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/D]P=&EO
M;G,@=F5S="!O;B!T:&4@;VYE(&%N;FEV97)S87)Y(&]F('1H92!G<F%N="!D
M871E(&%N9"!T:&4@<F5M86EN:6YG(&]P=&EO;G,@=F5S="!Q=6%R=&5R;'D@
M;W9E<B!T:&4@9F]L;&]W:6YG(#,@>65A<G,\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG3W!T:6]N<R!V97-T
M(&EN(&5Q=6%L('%U87)T97)L>2!I;F-R96UE;G1S(&]V97(@82!F;W5R+7EE
M87(@<&5R:6]D+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\9&EV/D]P=&EO;G,@=F5S="!I;B!E<75A;"!Q=6%R=&5R
M;'D@:6YC<F5M96YT<R!O=F5R(&$@9F]U<BUY96%R('!E<FEO9#PO9&EV/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M9&EV/D]P=&EO;G,@=F5S="!O;B!T:&4@;VYE(&%N;FEV97)S87)Y(&]F('1H
M92!G<F%N="!D871E(&%N9"!T:&4@<F5M86EN:6YG(&]P=&EO;G,@=F5S="!Q
M=6%R=&5R;'D@;W9E<B!T:&4@9F]L;&]W:6YG(#,@>65A<G,\+V1I=CX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@;W!T:6]N<R!O;B!G<F%N="!D871E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$S-BPR
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q,30L.#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(U,"PR,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#DS-RPV,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#,U.2PQ,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$P,RPW,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$X,2PT,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,3$Y+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C,W+#0P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$U+#4P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L.#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#@P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(L,C`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-S<L-S`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3(Y+#8P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,U+#$P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#$R-"PU,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-#8L,3`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4VAA<F4@8F%S960@8V]M<&5N<V%T:6]N('-H87)E<R!V97-T960\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#8U-2PW.#,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^56YR
M96-O9VYI>F5D('-T;V-K(&)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PW-C`L.3`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU.#DL
M-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#4P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-C`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPT,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D(&%V97)A9V4@9F%I<B!V86QU92!O
M9B!O<'1I;VYS(&%N9"!W87)R86YT<R!G<F%N=&5D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P
M+C<R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`P+C4X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`P+C$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q+C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XQ-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5V%R<F%N=',@:7-S=65D+"!N=6UB97(@;V8@<VAA<F5S(&]F(&-O
M;6UO;B!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-30Q
M+#0S,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU-#$L-#,P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(W-2PQ-38\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(R-"PX-#4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,S<L
M-3<X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-C$R+#0R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C$S+#<U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8W+#4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P-BPX-S4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,RPW-3`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES92!P<FEC92!P97(@<VAA<F4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XX/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XX/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,"XU-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,2XU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`P+C$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`P+C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XX/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,"XX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`P+C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#`N.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`P+C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XX/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Q+C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$N-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,"XP.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XX/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E=A<G)A;G1S(&-O;G1R86-T=6%L('1E<FT\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-R!Y96%R<SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S<@>65A
M<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V%R<F%N="!T;R!P
M=7)C:&%S92!O9B!C;VUM;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8Q.2PS-S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-C$Y+#,W-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#4P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q
M+#4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-C@L,C$S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@=V%R<F%N=',@:7-S=65D/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q-"PS,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4L-C`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,3`L.#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3G5M8F5R(&]F('-H87)E<R!I;F-R96%S960@8GD@=&AE($)O
M87)D(&]F($1I<F5C=&]R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@<VAA<F5S(&EN8W)E87-E9"!B
M>2!S:&%R96AO;&1E<G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C@L,#4X+#@T-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?-C,S-#5E.69?8C8T8E\T-S-B7SAB8C!?-3<T9C8Q83`Y8C)E
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8S,S0U93EF7V(V-&)?
M-#<S8E\X8F(P7S4W-&8V,6$P.6(R92]7;W)K<VAE971S+U-H965T-#(N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5(2T%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/E)E;&%T
M960@4&%R='D@5')A;G-A8W1I;VYS("A$971A:6QS*2`H55-$("0I/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L
M(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%P
M<BX@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y*=6XN(#,P+"`R,#$T/&)R/E!L86-E;65N="!!9V5N="!;365M8F5R73QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S
M/&)R/E!L86-E;65N="!!9V5N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/E!L86-E;65N="!!
M9V5N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$S/&)R/E!L86-E;65N="!!9V5N="!;365M8F5R73QB
M<CY397)I97,@02!097)F97)R960@<W1O8VL@6TUE;6)E<ET\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CY0;&%C
M96UE;G0@06=E;G0@6TUE;6)E<ET\8G(^4V5R:65S($$@4&5R9F5R<F5D('-T
M;V-K(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D1E8RX@,S$L(#(P,3,\8G(^4&QA8V5M96YT($%G96YT(%M-96UB97)=/&)R
M/E-U8F]R9&EN871E9"!P<F]M:7-S;W)Y(&YO=&4@;V9F97)I;F<@6TUE;6)E
M<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,CQB<CY0;&%C96UE;G0@06=E;G0@6TUE;6)E<ET\8G(^4W5B;W)D:6YA
M=&5D('!R;VUI<W-O<GD@;F]T92!O9F9E<FEN9R!;365M8F5R73QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/E!L
M86-E;65N="!!9V5N="!;365M8F5R73QB<CY3=6)O<F1I;F%T960@<')O;6ES
M<V]R>2!N;W1E(&]F9F5R:6YG($]N92!;365M8F5R73QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/E!L86-E;65N
M="!!9V5N="!;365M8F5R73QB<CY!8W%U:7-I=&EO;B!O9B!-961E;W(@6TUE
M;6)E<ET\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^0VQA<W,@;V8@5V%R<F%N="!O<B!2:6=H="!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.=6UB97(@;V8@=V%R<F%N=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4L.#@Q+#4W-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L.3(V+#4Q-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L.#8U+#(S-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M+#(U,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0L,CDP+#DU,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/CDT-"PT-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV-#8L,3<R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C,W+#4W.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8Q,BPT,C(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#8L
M.#<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,S,L-S4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3`V+#@W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E('!R:6-E('!E<B!S
M:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XU-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,"XX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`P+C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#$N-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`P+C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XX/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,2XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%>'!I<F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<R,#$Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG,C`R,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<R,#$Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S(P,C`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,C`Q.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,C`R,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C,S-#5E.69?
M8C8T8E\T-S-B7SAB8C!?-3<T9C8Q83`Y8C)E#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S8S,S0U93EF7V(V-&)?-#<S8E\X8F(P7S4W-&8V,6$P
M.6(R92]7;W)K<VAE971S+U-H965T-#,N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$500D)+/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E)E;&%T960@4&%R='D@5')A;G-A8W1I
M;VYS("A$971A:6QS(%1E>'1U86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,"!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,"!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DUA>2`R,"P@,C`Q-#QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y!<'(N(#,P+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;"X@,3@L(#(P,30\8G(^
M4W5B<V5Q=65N="!%=F5N="!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y!<'(N(#,P+"`R,#$R/&)R/E-E<FEE<R!!(%!R969E
M<G)E9"!3=&]C:R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/E-E<FEE<R!!(%!R969E<G)E9"!3
M=&]C:R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y*=6XN(#,P+"`R,#$T/&)R/D-O;6UO;B!3=&]C:R!;365M8F5R73QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R
M/D-O;6UO;B!3=&]C:R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/D-O;6UO;B!3=&]C:R!;365M
M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P
M+"`R,#$T/&)R/DUE9&5O<B!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87D@,3DL(#(P,30\8G(^4&QA8V5M96YT($%G96YT
M(%M-96UB97)=/&)R/D1R=6=S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,#8L(#(P,3$\8G(^4&QA8V5M96YT($%G96YT(%M-96UB
M97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D]C="X@,C0L
M(#(P,3,\8G(^4&QA8V5M96YT($%G96YT(%M-96UB97)=/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^4&QA8V5M
M96YT($%G96YT(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^4&QA8V5M96YT($%G96YT(%M-96UB
M97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3(\8G(^4&QA8V5M96YT($%G96YT(%M-96UB97)=/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,#8L(#(P,3$\8G(^061V:7-O
M<GD@1FER;2!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$S/&)R/D%D=FES;W)Y($9I<FT@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M0VQA<W,@;V8@5V%R<F%N="!O<B!2:6=H="!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!9'9I<V]R>2!S97)V:6-E<R!F965S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3(L-3`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R
M-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`R-S(L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q,BPU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097)C96YT(&]F(&9U;&QY('9E
M<W1E9"!W87)R86YT<R!T;R!P=7)C:&%S92!C;VUM;VX@<W1O8VL\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4N,#`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ,BXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y%>&5R8VES92!P<FEC92!P97(@<VAA<F4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2XU/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#`N,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y)<W-U86YC92!O9B!W87)R86YT<R!T;R!P=7)C:&%S92!C;VUM
M;VX@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C0L,CDP+#DU,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F('=A<G)A;G1S
M('1O('!U<F-H87-E(&-O;6UO;B!S=&]C:R!D97-C<FEP=&EO;CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)U1H92!0
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M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1E<FT@;V8@=V%R<F%N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<U('EE87)S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%X:6UU;2!R96EM
M8G5R<V5M96YT(&5X<&5N<V5S+"!M;VYT:&QY/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E
M961S(&9R;VT@<V%L92!O9B!397)I97,@02!P<F5F97)R960@<W1O8VL\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M-#DT+#0R.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,L,C(P+#`Q.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#`X.2PU,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-30L-S`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#<P
M+#,P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@=&\@9F]U;F1E<B!F
M;W(@8V%S:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPP,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-T
M;V-K(&9O<B!S97)V:6-E<RP@4VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<R-2PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(W-2PQ-38\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.2PP
M-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU-BPS.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XV."PS-38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S
M=&]C:R!T;R!A8W%U:7)E($UE9&5O<BP@26YC+B!A="!F86ER('9A;'5E+"!3
M:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-RPP.#D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BPU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S96%R8V@@86YD(&1E=F5L
M;W!M96YT(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,L-S4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@
M:7-S=6%N8V4@;V8@<W5B;W)D:6YA=&5D('!R;VUI<W-O<GD@;F]T97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV
M."PT,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR-2PQ,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4F5L871E9"!P87)T>2!T<F%N<V%C=&EO;BP@1&5S
M8W)I<'1I;VX@;V8@5')A;G-A8W1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG26X@8V]N<VED97)A=&EO;B!F;W(@
M:71S('-E<G9I8V5S+"!T:&4@<&QA8V5M96YT(&%G96YT(')E8V5I=F5D.B`H
M82!R92UA8W1I=F%T:6]N(&9E92!O9B`D,34L,#`P+"`H8BD@82!C87-H(&9E
M92!E<75A;"!T;R`W)2!O9B!T:&4@3F]T97,@0V]N=F5R<VEO;B!A;F0@,3`E
M(&]F('1H92!G<F]S<R!P<F]C965D<R!R86ES960@:6X@=&AE($9I;F%N8VEN
M9W,L(&%N9"`H8RD@;F]N+6%C8V]U;G1A8FQE(&5X<&5N<V4@<F5I;6)U<G-E
M;65N="!E<75A;"!T;R`R)2!O9B!T:&4@9W)O<W,@<')O8V5E9',@<F%I<V5D
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M3F]T97,@3V9F97)I;F=S+CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
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M(&UO9&EF:65D('1O(&$@;6%X:6UU;2!O9B`D,34P+#`P,"!P;'5S+"`H8BD@
M)#4P+#`P,"!F;W(@82!&86ER;F5S<R!/<&EN:6]N(&9E92!D961U8W1I8FQE
M(&%G86EN<W0@=&AE('-U8V-E<W,@9F5E+"!A;F0@*&,I(&$@)#4P+#`P,"!A
M8W1I=F%T:6]N(&9E92X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3V9F97)I;F<@<')I8V4@9&5S8W)I<'1I
M;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<H82D@82!C87-H(&-O;6UI<W-I;VX@:6X@=&AE(&%M;W5N="!O9B!T96X@
M<&5R8V5N="`H,3`E*2!O9B!T:&4@9W)O<W,@<')O8V5E9',@;V8@=&AE($]F
M9F5R:6YG(')E8V5I=F5D(&9R;VT@:6YV97-T;W)S(&%T(&$@0VQO<VEN9R!A
M<R!W96QL(&%S(&$@;F]N+6%C8V]U;G1A8FQE(&5X<&5N<V4@<F5I;6)U<G-E
M;65N="!E<75A;"!T;R!T=V\@<&5R8V5N="`H8BD@*#(E*2!O9B!T:&4@9W)O
M<W,@<')O8V5E9',@;V8@=&AE($]F9F5R:6YG(')E8V5I=F5D(&9R;VT@:6YV
M97-T;W)S(&%T(&$@0VQO<VEN9R!A;F0@86X@86-T:79A=&EO;B!F964@;V8@
M)#(U+#`P,"X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y.=6UB97(@;V8@86=R965M96YT<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D%C=&EV871I;VX@9F5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#(U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)U<VEN97-S(&%C<75I
M<VET:6]N+"!$97-C<FEP=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<X)2!O9B!T:&4@86=G<F5G871E(&-O;G-I
M9&5R871I;VX@:6X@<W5C:"!T<F%N<V%C=&EO;G,L(&%N9"`H:6DI(&EF+"!W
M:71H:6X@82!P97)I;V0@;V8@,3(@;6]N=&AS(&%F=&5R('1E<FUI;F%T:6]N
M(&]F('1H92!S97)V:6-E<RX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG."4@;V8@=&AE(&%G9W)E9V%T92!C;VYS:61E
M<F%T:6]N(&EN('-U8V@@=')A;G-A8W1I;VYS+"!A;F0@*&EI*2!I9BP@=VET
M:&EN(&$@<&5R:6]D(&]F(#$R(&UO;G1H<R!A9G1E<B!T97)M:6YA=&EO;B!O
M9B!T:&4@<V5R=FEC97,N/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)O>6%L='D@<&%Y;65N=',@9&5S8W)I
M<'1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQD:78^*$$I(')O>6%L='D@<&%Y;65N=',@=7`@=&\@,B4@;VX@;F5T
M('-A;&5S(&]F(&QI8V5N<V5D('!R;V1U8W1S('1H870@87)E(&YO="!S;VQD
M(&)Y('-U8FQI8V5N<V5E(&%N9"`H0BD@;VX@96%C:"!A;F0@979E<GD@<W5B
M;&EC96YS92!E87)N960@<F]Y86QT>2!P87EM96YT(')E8V5I=F5D(&)Y(&QI
M8V5N<V5E(&9R;VT@:71S('-U8FQI8V5N<V5E(&]N('-A;&5S(&]F(&QI8V5N
M<V4@<')O9'5C="X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F]Y86QT>2!R96-E:79E9"!B
M>2!L:6-E;G-E92!D97-C<FEP=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CXF(S$V,#LH:2D@,C`E(&]F('1H
M92!R;WEA;'1I97,@<F5C96EV960@8GD@;&EC96YS964[(&]R("AI:2D@=7`@
M=&\@,B4@;V8@;F5T('-A;&5S(&]F('-U8FQI8V5N<V5E+B!4:&4@0V]M<&%N
M>2!W:6QL(&%L<V\@;6%K92!M:6QE<W1O;F4@<&%Y;65N=',@;V8@=7`@=&\@
M)#0@;6EL;&EO;B!A;F0@=7`@=&\@)#(@;6EL;&EO;BP@9F]R('1H92!F:7)S
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M8W1I=F5L>2X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?-C,S-#5E.69?8C8T8E\T-S-B7SAB8C!?-3<T
M9C8Q83`Y8C)E#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8S,S0U
M93EF7V(V-&)?-#<S8E\X8F(P7S4W-&8V,6$P.6(R92]7;W)K<VAE971S+U-H
M965T-#0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5!3$%#/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R
M;VYG/DEN8V]M92!487AE<R`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^1&5F97)R960@=&%X(&%S<V5T<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;W!E<F%T:6YG(&QO<W,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPU-38L-C`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#<V
M-2PV,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-T;V-K(&)A<V5D(&-O;7!E;G-A=&EO;CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-"PR-#@L-S`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5S
M96%R8V@@86YD(&1E=F5L;W!M96YT('1A>"!C<F5D:71S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ.3<L-S`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#,V+#,P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5A;',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(R+#DP,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0T+#<P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3W1H97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L.3`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#8L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y686QU871I;VX@86QL;W=A;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@X+#`R."PX,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,RPR.3(L-C`P*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?-C,S-#5E.69?8C8T8E\T-S-B7SAB8C!?-3<T9C8Q83`Y8C)E#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S8S,S0U93EF7V(V-&)?-#<S8E\X
M8F(P7S4W-&8V,6$P.6(R92]7;W)K<VAE971S+U-H965T-#4N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$5.3T%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DEN8V]M92!487AE
M<R`H1&5T86EL<R`Q*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XV($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY296-O;F-I;&EA=&EO
M;B!O9B!T:&4@<W1A='5T;W)Y('1A>"!R871E('1O('1H92!E9F9E8W1I=F4@
M=&%X(')A=&4\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4W1A='5T;W)Y(&9E9&5R86P@:6YC;VUE('1A>"!R871E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-"XP,"4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-"XP,"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-"XP
M,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-T871E("AN970@;V8@9F5D97)A;"!B96YE9FET*3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-BXV,"4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+C8P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8N-C`E/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.;VXM9&5D
M=6-T:6)L92!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,3,N,3`E*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#(Y+C<P)2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q."XX,"4I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,BXS,"4I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-H86YG92!I;B!V86QU871I;VX@86QL;W=A;F-E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-2XR,"4I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3`N.3`E*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Q+C@P)2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5F9F5C=&EV92!I;F-O;64@=&%X(')A=&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C,S-#5E.69?8C8T8E\T-S-B7SAB
M8C!?-3<T9C8Q83`Y8C)E#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+S8S,S0U93EF7V(V-&)?-#<S8E\X8F(P7S4W-&8V,6$P.6(R92]7;W)K<VAE
M971S+U-H965T-#8N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4R24%#/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/DEN8V]M92!487AE<R`H1&5T86EL<R!497AT=6%L*2`H55-$
M("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L
M(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^5&%X($-R961I="!#87)R>69O<G=A<F0@6TQI;F4@271E;7-=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&961E
M<F%L(&%N9"!S=&%T92!N970@;W!E<F%T:6YG(&QO<W,@8V%R<GEF;W)W87)D
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X+#<V,BPP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E1A>"!C<F5D:70@8V%R<GEF;W)W87)D<RP@97AP:7)I;F<@9&%T93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^1&5C(#,Q+`T*"0DR,#(U/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M970@;W!E<F%T:6YG(&QO<W,@8V%R<GEF;W)W87)D<RP@;&EM:70@9&5S8W)I
M<'1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=4:&4@56YI
M=&5D(%-T871E<R!487@@4F5F;W)M($%C="!O9B`Q.3@V(&-O;G1A:6YS('!R
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M97)E<W0@<F%T92X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D9E9&5R86P@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT
M('1A>"!C<F5D:70@8V%R<GEF;W)W87)D<R!;365M8F5R73PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY487@@0W)E9&ET($-A
M<G)Y9F]R=V%R9"!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1A>"!C<F5D:70@8V%R<GEF;W)W87)D
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q.3<L-S`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&
M961E<F%L(&%N9"!S=&%T92!N970@;W!E<F%T:6YG(&QO<W,@8V%R<GEF;W)W
M87)D<RP@97AP:7)I;F<@9&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^1&5C(#,Q+`T*"0DR,#(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%\V,S,T-64Y9E]B-C1B7S0W,V)?.&)B,%\U-S1F
M-C%A,#EB,F4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C,S-#5E
M.69?8C8T8E\T-S-B7SAB8C!?-3<T9C8Q83`Y8C)E+U=O<FMS:&5E=',O4VAE
M970T-RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P15%#04,^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O
M;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I97,@*$1E=&%I;',I("A5
M4T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY38VAE9'5L92!O9B!F=71U<F4@;6EN:6UU;2!L
M96%S92!P87EM96YT<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^,C`Q-3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`S-RPS,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/C(P,38\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^,C`Q-SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,S@L.#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#XR,#$X/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XY+#<P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1O=&%L/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$R-RPX,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
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M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%,U!"1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VUM:71M
M96YT<R!A;F0@0V]N=&EN9V5N8VEE<R`H1&5T86EL<R!497AT=6%L*2`H55-$
M("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XP($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^-B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXP($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C8@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P
M,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P
M+"`R,#$T/&)R/DUE9&5O<B!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#`W/&)R/DQI8V5N<VEN9R!!9W)E
M96UE;G1S(%M-96UB97)=/&)R/D1R=6=S/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA>2`S,2P@,C`Q-#QB<CY,:6-E;G-I;F<@06=R965M
M96YT<R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y*=6XN(#,P+"`R,#$T/&)R/DQI8V5N<VEN9R!!9W)E96UE;G1S(%M-96UB
M97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,#<\8G(^3&EC96YS:6YG($%G<F5E;65N=',@6TUE;6)E<ET\8G(^36EN
M:6UU;2!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#`W/&)R/DQI8V5N<VEN9R!!9W)E96UE;G1S(%M-96UB
M97)=/&)R/DUA>&EM=6T@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CY,96%S92!!9W)E96UE;G1S
M(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3,\8G(^3&5A<V4@06=R965M96YT<R!;365M8F5R73QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R
M/DQE87-E($%G<F5E;65N=',@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CY,96=A;"!;365M8F5R
M73QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY/<&5R871I;F<@3&5A<V5D($%S<V5T<R!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^475E<W1I;VYA8FQE(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,2PU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!L
M:6-E;G-E9"!P<F]D=6-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@<VAA<F5S(&5X8VAA;F=E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,34@>65A
M<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG,C`@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y2;WEA;'1I97,@9&5S8W)I<'1I;VX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C<L.#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C0L-C`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3,L,S`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^475E<W1I;VYA8FQE(&5X<&5N<V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@
M<W1O8VL@<VAA<F5S(&5X8VAA;F=E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C@V."PR,3,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)O>6%L=&EE<R!D97-C<FEP
M=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)TQI8V5N<V4@
M9F5E(&]F("0Q+#4P,"PP,#`@86YD('=I;&P@96%R;B!R;WEA;'1I97,@;V8@
M=7`@=&\@,3(E(&]F(&YE="!S86QE<R!F;W(@=7`@=&\@='=O(&QI8V5N<V5D
M('!R;V1U8W1S(&ET(&ES(&-U<G)E;G1L>2!D979E;&]P:6YG+CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y)<W-U86YC92!O9B!C;VUM;VX@<W1O8VL@=&\@86-Q=6ER92!-961E
M;W(L($QI8V5N<V4@86=R965M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`S+#<U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y2;WEA;'1Y('!A>6UE;G1S(&1E<V-R:7!T:6]N/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/BA!*2!R;WEA;'1Y
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M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y2;WEA;'1Y(')E8V5I=F5D(&)Y(&QI8V5N<V5E(&1E<V-R:7!T
M:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/B8C
M,38P.RAI*2`R,"4@;V8@=&AE(')O>6%L=&EE<R!R96-E:79E9"!B>2!L:6-E
M;G-E93L@;W(@*&EI*2!U<"!T;R`R)2!O9B!N970@<V%L97,@;V8@<W5B;&EC
M96YS964N(%1H92!#;VUP86YY('=I;&P@86QS;R!M86ME(&UI;&5S=&]N92!P
M87EM96YT<R!O9B!U<"!T;R`D-"!M:6QL:6]N(&%N9"!U<"!T;R`D,B!M:6QL
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M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-C,S-#5E.69?
M8C8T8E\T-S-B7SAB8C!?-3<T9C8Q83`Y8C)E#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+S8S,S0U93EF7V(V-&)?-#<S8E\X8F(P7S4W-&8V,6$P
M.6(R92]7;W)K<VAE971S+U-H965T-#DN:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$531T%#/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-U8G-E<75E;G0@179E;G1S("A$971A
M:6QS*2`H4W5B<V5Q=65N="!%=F5N="!;365M8F5R72P@55-$("0I/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;"X@,3@L(#(P,30\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U8G-E<75E;G0@
M179E;G0@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4W5B<V5Q=65N="!%=F5N="!;3&EN92!)=&5M<UT\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E5P9G)O
M;G0@8V%S:"!F964@<F5C96EV960@8GD@=&AE(&-O;G-U;'1A;G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C4P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S(&ES
M<W5E9"!T;R!T:&4@8V]N<W5L=&%N="!F;W(@:6YV97-T;W(@8V]M;75N:6-A
M=&EO;B!A;F0@<'5B;&EC(')E;&%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C4P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1&5S8W)I<'1I;VX@;V8@=&AE(&-O;7!A
M;GDG<R!A9W)E96UE;G0@=VET:"!A(&-O;G-U;'1A;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B=4:&4@8V]N<W5L=&%N="!S:&%L;"!R96-E
M:79E(&%N('5P9G)O;G0@8V%S:"!F964@;V8@)#(U,"PP,#`@86YD("0R-3`L
M,#`P('%U87)T97)L>2!C87-H(&EN<W1A;&QM96YT<R!C;VUM96YC:6YG(&EN
M(%-E<'1E;6)E<B`R,#$T+B!);B!A9&1I=&EO;BP@=&AE($-O;7!A;GD@<VAA
M;&P@:7-S=64@,C4P+#`P,"!S:&%R97,@;V8@=&AE($-O;7!A;GDG<R!W:71H
M:6X@9FEF=&5E;B`H,34I(&1A>7,@;V8@=&AE(&%G<F5E;65N="!A;F0@=&AE
M(')E;6%I;FEN9R`R-3`L,#`P('-H87)E<R!S:&%L;"!B92!I<W-U960@:6X@
M<VEX(&UO;G1H;'D@:6YS=&%L;&UE;G1S(&-O;6UE;F-I;F<@:6X@4V5P=&5M
M8F5R(#(P,30N/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%\V,S,T-64Y9E]B-C1B7S0W,V)?.&)B,%\U-S1F-C%A,#EB,F4-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-C,S-#5E.69?8C8T8E\T-S-B
M7SAB8C!?-3<T9C8Q83`Y8C)E+U=O<FMS:&5E=',O9FEL96QI<W0N>&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQX;6P@>&UL;G,Z;STS1")U<FXZ<V-H96UA<RUM:6-R;W-O9G0M8V]M.F]F
M9FEC93IO9F9I8V4B/@T*(#QO.DUA:6Y&:6QE($A2968],T0B+BXO5V]R:V)O
M;VLN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`Q+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970P,BYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,#,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#`T+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-2YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#8N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#`W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970P."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#DN:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$P+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970Q,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,3(N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$S+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-"YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,34N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#$V+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-RYH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3@N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#$Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970R,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C$N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(R+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970R,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,C0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(U+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-BYH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,C<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#(X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R.2YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S`N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#,Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970S,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S,N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,T+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970S-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,S8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,W
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S."YH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,SDN:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#0P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T
M,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#(N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0S+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970T-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M-#4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0V+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970T-RYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T-#@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#0Y+FAT;6PB+SX-"CPO>&UL/@T*+2TM+2TM/5].97AT4&%R=%\V,S,T-64Y
A9E]B-C1B7S0W,V)?.&)B,%\U-S1F-C%A,#EB,F4M+0T*
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPBBK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>May 20, 2014</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Jul. 18, 2014

</div>
          <div>Subsequent Event [Member]</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2012

</div>
          <div>Series A Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Series A Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Medeor [Member]</div>
        </th>
        <th class="th">
          <div>May 19, 2014

</div>
          <div>Placement Agent [Member]

</div>
          <div>Drugs</div>
        </th>
        <th class="th">
          <div>Dec. 06, 2011

</div>
          <div>Placement Agent [Member]</div>
        </th>
        <th class="th">
          <div>Oct. 24, 2013

</div>
          <div>Placement Agent [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Placement Agent [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Placement Agent [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Placement Agent [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 06, 2011

</div>
          <div>Advisory Firm [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Advisory Firm [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Advisory services fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 12,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 25,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 272,000<span></span></td>
        <td class="nump">$ 12,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_PercentageOfVestedWarrantsToPurchaseCommonStock', window );">Percent of fully vested warrants to purchase common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentWarrantsExercisePrice', window );">Exercise price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.50<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfWarrantsToPurchaseCommonStock', window );">Issuance of warrants to purchase common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,290,950<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfWarrantsToPurchaseCommonStockDescription', window );">Issuance of warrants to purchase common stock description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The Placement Agent shall also be entitled to the compensation set forth above as well for any cash exercise of Warrants within six (6) months of the final closing of the Offering as well as a five percent (5%) solicitation fee for any Warrants exercised as a result of any redemption of any Warrants. If the Company elects to call the warrants, the Placement Agent shall receive a warrant solicitation fee equal to 5% of the funds solicited by the Placement Agent upon exercise of the warrants.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_TermOfWarrants', window );">Term of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ReimbursementExpenses', window );">Maximum reimbursement expenses, monthly</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from sale of Series A preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">3,494,428<span></span></td>
        <td class="nump">3,220,018<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,089,500<span></span></td>
        <td class="nump">554,700<span></span></td>
        <td class="nump">470,300<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock to founder for cash</a></td>
        <td class="nump">2,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">250,000<span></span></td>
        <td class="nump">1,725,000<span></span></td>
        <td class="nump">1,275,156<span></span></td>
        <td class="nump">29,052<span></span></td>
        <td class="nump">56,394<span></span></td>
        <td class="nump">68,356<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock to acquire Medeor, Inc. at fair value, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">17,089<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,750,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSubordinatedLongTermDebt', window );">Proceeds from issuance of subordinated promissory notes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">68,400<span></span></td>
        <td class="nump">25,100<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction', window );">Related party transaction, Description of Transaction</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">In consideration for its services, the placement agent received: (a re-activation fee of $15,000, (b) a cash fee equal to 7% of the Notes Conversion and 10% of the gross proceeds raised in the Financings, and (c) non-accountable expense reimbursement equal to 2% of the gross proceeds raised. The placement agent or its designees also received warrants to purchase shares of the Company's common stock in an amount equal to 10% of the shares of common stock and warrants issued or issuable as part of the units sold in the Series A Preferred Stock Offering and Notes Offerings.<span></span></td>
        <td class="text">In consideration for its services, the Placement Agent was eligible to receive: (a) a cash success fee equal to 8% of the value of the transaction plus a 2% non-reimbursable expense fee which was subsequently modified to a maximum of $150,000 plus, (b) $50,000 for a Fairness Opinion fee deductible against the success fee, and (c) a $50,000 activation fee.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_InvestorOfferingPriceDescription', window );">Offering price description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">(a) a cash commission in the amount of ten percent (10%) of the gross proceeds of the Offering received from investors at a Closing as well as a non-accountable expense reimbursement equal to two percent (b) (2%) of the gross proceeds of the Offering received from investors at a Closing and an activation fee of $25,000.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_NumberOfEngagementAgreement', window );">Number of agreements</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ActivationFees', window );">Activation fee</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 25,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription', window );">Business acquisition, Description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">8% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the services.<span></span></td>
        <td class="text">8% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the services.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_RoyaltyPaymentsDescription', window );">Royalty payments description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text"><div>(A) royalty payments up to 2% on net sales of licensed products that are not sold by sublicensee and (B) on each and every sublicense earned royalty payment received by licensee from its sublicensee on sales of license product.</div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_RoyaltyReceivedByLicenseeDescription', window );">Royalty received by licensee description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text"><div>&#160;(i) 20% of the royalties received by licensee; or (ii) up to 2% of net sales of sublicensee. The Company will also make milestone payments of up to $4 million and up to $2 million, for the first commercial sale of product in the field that has a single active pharmaceutical ingredient, and for the first commercial sale of product in the field of product that has more than one active pharmaceutical ingredient, respectively.</div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentWarrantsExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price of the warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 12<br><br> -Section 13<br><br> -Sentence Column A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>invest_InvestmentWarrantsExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>invest_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_ActivationFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Activation fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_ActivationFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_InvestorOfferingPriceDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Offering price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_InvestorOfferingPriceDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_IssuanceOfWarrantsToPurchaseCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of Warrants to Purchase Common Stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_IssuanceOfWarrantsToPurchaseCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_IssuanceOfWarrantsToPurchaseCommonStockDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of Warrants to Purchase Common Stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_IssuanceOfWarrantsToPurchaseCommonStockDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_NumberOfEngagementAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_NumberOfEngagementAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_PercentageOfVestedWarrantsToPurchaseCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of vested warrants to purchase common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_PercentageOfVestedWarrantsToPurchaseCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_ReimbursementExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Reimbursement expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_ReimbursementExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_RoyaltyPaymentsDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of Royalty Payments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_RoyaltyPaymentsDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_RoyaltyReceivedByLicenseeDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Royalty Received by Licensee Description.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_RoyaltyReceivedByLicenseeDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_TermOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Term of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_TermOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of equity interests issued or issuable to acquire the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of other research and development expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSubordinatedLongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a borrowing where a lender is placed in a lien position behind debt having a higher priority of repayment (senior) in liquidation of the entity's assets or underlying collateral.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfSubordinatedLongTermDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 946<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 946<br><br> -SubTopic 225<br><br> -Section 45<br><br> -Paragraph 3<br><br> -Subparagraph (k)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6488370&amp;loc=d3e13550-115849<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProfessionalFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDescriptionOfTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph b<br><br> -Article 3A<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6452652&amp;loc=d3e36975-112693<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.10,11,23)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 10, 11, 23<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionDescriptionOfTransaction</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period pursuant to acquisitions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesAcquisitions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ETFAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Notes Payable (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_NotesPayableLineItems', window );"><strong>Subordinated Promissory Notes Payable [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Total notes payable</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">$ 900,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: debt discount</a></td>
        <td class="nump">0<span></span></td>
        <td class="num">(141,049)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Total notes payable, less debt discount</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">758,951<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Subordinated 8% promissory notes due December 2013</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_NotesPayableLineItems', window );"><strong>Subordinated Promissory Notes Payable [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Total notes payable</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">216,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Subordinated 8% promissory notes due September 2014</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_NotesPayableLineItems', window );"><strong>Subordinated Promissory Notes Payable [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Total notes payable</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">$ 684,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_NotesPayableLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_NotesPayableLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentUnamortizedDiscount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LoansPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Textual)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_SignificantAccountingPoliciesTextualsAbstract', window );"><strong>Significant Accounting Policies (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life, assets</a></td>
        <td class="text">3 years<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_SignificantAccountingPoliciesTextualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_SignificantAccountingPoliciesTextualsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentUsefulLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EALAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Income Taxes (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
        <td class="nump">$ 3,556,600<span></span></td>
        <td class="nump">$ 2,765,600<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Stock based compensation</a></td>
        <td class="nump">4,248,700<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
        <td class="nump">197,700<span></span></td>
        <td class="nump">436,300<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals</a></td>
        <td class="nump">22,900<span></span></td>
        <td class="nump">44,700<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
        <td class="nump">2,900<span></span></td>
        <td class="nump">46,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
        <td class="num">(8,028,800)<span></span></td>
        <td class="num">(3,292,600)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComponentsOfDeferredTaxAssetsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredTaxAssetsValuationAllowance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPOCI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Notes Payable (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>May 06, 2014

</div>
          <div>Financial Agreement [Member]

</div>
          <div>Drugs</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Subordinated 8% promissory notes due September 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>December 2012 Subordinated Promissory Notes Payable</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>December 2012 Subordinated Promissory Notes Payable</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>September 2013 Subordinated Promissory Notes Payable</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>September 2013 Subordinated Promissory Notes Payable</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>September 2013 Subordinated Promissory Notes Payable</div>
        </th>
        <th class="th">
          <div>May 20, 2014

</div>
          <div>September 2013 Subordinated Promissory Notes Payable</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_NotesPayableDetailsTextualAbstract', window );"><strong>Subordinated Promissory Notes Payable (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rates</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3.436%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">36.90%<span></span></td>
        <td class="nump">36.90%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">8% Promissory notes payable issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 216,000<span></span></td>
        <td class="nump">$ 684,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Notes payable due date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Dec.
				06,
				 2013<span></span></td>
        <td class="text">Sep. 30,
				 2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_DebtDiscountAmortizationPeriod', window );">Debt discount amortization period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from Notes Payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">180,000<span></span></td>
        <td class="nump">570,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock exercise price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.8<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Fair value of warrants debt discount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">26,325<span></span></td>
        <td class="nump">83,363<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_CashProceedForDebtDiscountInterestRate', window );">Cash proceed for debt discount interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">36,000<span></span></td>
        <td class="nump">114,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_DebtDiscountInterestRateOfMaturity', window );">Debt discount interest rate of maturity</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">1 year<span></span></td>
        <td class="text">1 year<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_PurchaseOfWarrantShares', window );">Purchase of warrant shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">67,500<span></span></td>
        <td class="nump">213,750<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Cash paid for debt issuance costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,100<span></span></td>
        <td class="nump">68,400<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_AmortizedDeferredFinancingCostsMaturityDate', window );">Amortized deferred financing costs maturity date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">1 year<span></span></td>
        <td class="text">1 year<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum', window );">Notes payable interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_AmortizationOfDebtIssuanceCosts1', window );">Amortization of debt issuance costs1</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">62,325<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">219,773<span></span></td>
        <td class="nump">219,773<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_WarrantsValueForPlacementAgent', window );">Warrants Value for placement agent</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">33,750<span></span></td>
        <td class="nump">106,875<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_WarrantsValueForPlacementAgentPerShare', window );">Warrants value for placement agent, Per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_FairValueOfDebtDisoumt', window );">Fair value of debt disount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">13,089<span></span></td>
        <td class="nump">41,681<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred financing costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">38,189<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">31,357<span></span></td>
        <td class="nump">31,357<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Issuance date if notes payable</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">758,951<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">186,800<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Note payable, conversion price per share (in Dollars per share)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.60<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InducedConversionOfConvertibleDebtExpense', window );">Accrued interest converted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">960,900<span></span></td>
        <td class="nump">960,900<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion into common stock share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,201,153<span></span></td>
        <td class="nump">1,201,153<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfDebtInConnectionWithCompensationPolicy', window );">Note payable issued in connection with director and officer insurance policy</a></td>
        <td class="nump">77,850<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">77,850<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_DebtInConnectionWithDownPaymentOfInsurancePolicy', window );">Debt in connection with down payment of insurance policy</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,800<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_DebtInConnectionWithPaymentOfMonthlyInstallemt', window );">Debt in connection with payment of monthly installment, Insurance policy</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">660<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_NumberOfInstallments', window );">Number of installments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">11<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Convertible Notes Payable, Current</a></td>
        <td class="nump">$ 58,357<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_AmortizationOfDebtIssuanceCosts1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amortization of debt issuance costs1.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_AmortizationOfDebtIssuanceCosts1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_AmortizedDeferredFinancingCostsMaturityDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amortized deferred financing costs maturity date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_AmortizedDeferredFinancingCostsMaturityDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_CashProceedForDebtDiscountInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash proceed for debt discount interest rate.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_CashProceedForDebtDiscountInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_DebtDiscountAmortizationPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair Value Of Warrant Price Per Share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_DebtDiscountAmortizationPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_DebtDiscountInterestRateOfMaturity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Debt discount interest rate of maturity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_DebtDiscountInterestRateOfMaturity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_DebtInConnectionWithDownPaymentOfInsurancePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Debt in connection with down payment of insurance policy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_DebtInConnectionWithDownPaymentOfInsurancePolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_DebtInConnectionWithPaymentOfMonthlyInstallemt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Debt in connection with payment of monthly installemt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_DebtInConnectionWithPaymentOfMonthlyInstallemt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_FairValueOfDebtDisoumt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of debt disount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_FairValueOfDebtDisoumt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_IssuanceOfDebtInConnectionWithCompensationPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Note payable issued in connection with director and officer policy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_IssuanceOfDebtInConnectionWithCompensationPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_NotesPayableDetailsTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_NotesPayableDetailsTextualAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_NumberOfInstallments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of monthly installments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_NumberOfInstallments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_PurchaseOfWarrantShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Purchase of warrant shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_PurchaseOfWarrantShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_WarrantsValueForPlacementAgent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants Value for placement agent .</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_WarrantsValueForPlacementAgent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_WarrantsValueForPlacementAgentPerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants Value for placement agent,per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_WarrantsValueForPlacementAgentPerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleNotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtConversionConvertedInstrumentSharesIssued1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The price per share of the conversion feature embedded in the debt instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentConvertibleConversionPrice1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentInterestRateEffectivePercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Minimum contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentInterestRateStatedPercentageRateRangeMinimum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentMaturityDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of debt discount (net of debt premium) that was originally recognized at the issuance of the instrument that has yet to be amortized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28567-108399<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For an unclassified balance sheet, the carrying amount (net of accumulated amortization) as of the balance sheet date of capitalized costs associated with the issuance of debt instruments (for example, legal, accounting, underwriting, printing, and registration costs) that will be charged against earnings over the life of the debt instruments to which such costs pertain.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 17<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredFinanceCostsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InducedConversionOfConvertibleDebtExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7656879&amp;loc=d3e7290-112610<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 40<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928171&amp;loc=d3e6835-112609<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InducedConversionOfConvertibleDebtExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 13, 16<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsOfDebtIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Price of a single share of a number of saleable stocks of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E1MAI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivative Liabilities (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">6 Months Ended</th>
        <th class="th" colspan="4">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th" colspan="2">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th" colspan="2">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_CommonStockIssuableUponExerciseOfWarrants', window );">Common stock issuable upon exercise of warrants</a></td>
        <td class="nump">30,036,648<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">41,718,750<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">19,385,157<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfSeriesAPreferredStockAndWarrantsShares', window );">Common stock issuable upon conversion of Series A preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">136,041,275<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">85,035,025<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_MarketValueOfCommonStockOnMeasurementPerStock', window );">Market value of common stock on measurement date (1)</a></td>
        <td class="nump">$ 2.00<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump">$ 1.50<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate (2)</a></td>
        <td class="nump">1.60%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
        <td class="nump">0.38%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
        <td class="nump">0.19%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life in years</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">2 years<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">1 year 4 months 24 days<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (3)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">68.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
        <td class="nump">73.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividend yields (4)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
        <td class="nump">$ 2.25<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life in years</a></td>
        <td class="text">4 years 10 months 24 days<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (3)</a></td>
        <td class="nump">73.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
        <td class="nump">$ 1.50<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life in years</a></td>
        <td class="text">3 months 18 days<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (3)</a></td>
        <td class="nump">71.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Initial Valuation [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_CommonStockIssuableUponExerciseOfWarrants', window );">Common stock issuable upon exercise of warrants</a></td>
        <td class="nump">30,036,648<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">22,333,593<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">19,385,157<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfSeriesAPreferredStockAndWarrantsShares', window );">Common stock issuable upon conversion of Series A preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">51,006,250<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">85,035,025<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_MarketValueOfCommonStockOnMeasurementPerStock', window );">Market value of common stock on measurement date (1)</a></td>
        <td class="nump">$ 1.17<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump">$ 0.30<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate (2)</a></td>
        <td class="nump">1.70%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
        <td class="nump">0.19%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
        <td class="nump">0.20%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life in years</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">1 year 4 months 24 days<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">1 year 7 months 6 days<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (3)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">68.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
        <td class="nump">72.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Expected dividend yields (4)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Initial Valuation [Member] | Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
        <td class="nump">$ 2.25<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life in years</a></td>
        <td class="text">5 years<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (3)</a></td>
        <td class="nump">73.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Initial Valuation [Member] | Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
        <td class="nump">$ 1.50<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected life in years</a></td>
        <td class="text">3 months 18 days<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (3)</a></td>
        <td class="nump">71.00%<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr>
        <td colspan="7"></td>
      </tr>
      <tr>
        <td colspan="7">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">The market value is the calculated fair value of the common stock pursuant to the valuation technique as described above.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[2]</td>
              <td style="vertical-align: top;" valign="top">The risk-free interest rate was determined by management using the 1 and 5 - year Treasury Bill as of measurement date.</td>
            </tr>
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[3]</td>
              <td style="vertical-align: top;" valign="top">The historical trading volatility was determined by calculating the volatility of the Company's peer group.</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_CommonStockIssuableUponExerciseOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock issuable upon exercise of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_CommonStockIssuableUponExerciseOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_IssuanceOfSeriesAPreferredStockAndWarrantsShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of series A preferred stock and warrants shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_IssuanceOfSeriesAPreferredStockAndWarrantsShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_MarketValueOfCommonStockOnMeasurementPerStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Market Value Of Common Stock On Measurement Per Stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_MarketValueOfCommonStockOnMeasurementPerStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Agreed upon price for the exchange of the underlying asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Risk-free interest rate assumption used in valuing an instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>NOTE 2 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="background-color: white;"><b>Principles of Consolidation</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="background-color: white;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="background-color: white;">The consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>Use of Estimates</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. The significant estimates are the valuation of derivative liabilities, stock-based compensation expenses and income taxes and its associated valuation allowance.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>Cash and Cash Equivalents</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The Company considers cash deposits and all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company's cash deposits are held at two high-credit-quality financial institutions. The Company's cash deposits at these institutions exceed federally insured limits.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>Patents</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>Fixed Assets</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">Fixed assets are stated at cost less accumulated depreciation. Fixed assets are comprised of computers and software. Depreciation is calculated using the straight-line method over the estimated useful life of the related assets, which is three years.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none;
 text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>Derivatives</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">All derivatives are recorded at fair value on the balance sheet. The Company has determined fair values using market based pricing models incorporating readily observable market data and requiring judgment and estimates.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>Fair Value of Financial Instruments</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The Company&#8217;s financial instruments primarily include cash, derivative liabilities, accounts payable and subordinated promissory notes. Due to the short-term nature of cash, derivative liability, accounts payable and promissory notes the carrying amounts of these assets and liabilities approximate their fair value. Derivatives are recorded at fair value at each period end. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">Level 1 - Quoted prices in active markets for identical assets or liabilities.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">Level 2 - Valuations for assets and liabilities that can be obtained from readily available pricing sources via independent providers for market transactions involving similar assets or liabilities. The Company's principal markets for these securities are the secondary institutional markets, and valuations are based on observable market data in those markets.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">Level 3 - Valuations for assets and liabilities that are derived from other valuation methodologies, including option pricing models, discounted cash flow models and similar techniques, and are not based on market exchange or dealer- or broker-traded transactions. Level 3 valuations incorporate certain assumptions and projections in determining the fair value assigned to such assets or liabilities.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>Fair Value on a Recurring Basis</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">As required by Accounting Standard Codification (&#8220;ASC&#8221;) Topic No. 820 &#8211; 10&#160;<i>Fair Value Measurement</i>, financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels. The estimated fair value of the derivative instruments which include Series A preferred stock with down-round protection provisions and warrants with down-round protection provisions was calculated with the assistance of a third party valuation firm, see Note
 4.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The following table sets forth, by level within the fair value hierarchy, the Company&#8217;s financial liabilities that were accounted for at fair value on a recurring basis as of June 30, 2014:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Quoted Prices</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">In Active</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Significant</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Total</td><td style="font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Markets for</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Other</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Significant</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Carrying</td><td style="font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Identical</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Observable</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Unobservable</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Value as of</td><td style="font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Assets</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Inputs</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Inputs</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">June 30,</td><td style="font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Description</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">(Level 1)</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">(Level 2)</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times,
 serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">(Level 3)</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">Derivative liabilities &#8211; warrant instruments</td><td style="width: 16px; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="width: 142px; text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">-</td><td style="width: 16px; text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 16px; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="width: 142px; text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">-</td><td style="width: 16px; text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 15px; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">25,586,933</td><td style="width: 15px; text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 15px; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">25,586,933</td><td style="width: 15px; text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;&#160;&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The following table sets forth, by level within the fair value hierarchy, the Company&#8217;s financial liabilities that were accounted for at fair value on a recurring basis as of December 31, 2013:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Quoted Prices</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">In Active</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Significant</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Total</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Markets for</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Other</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Significant</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Carrying</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Identical</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Observable</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Unobservable</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Value as of</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Assets</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Inputs</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Inputs</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">December 31,</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Description</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">(Level 1)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td
 style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">(Level 2)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">(Level 3)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left;">Derivative liabilities &#8211; warrant instruments</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">-</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">-</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">4,089,284</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">4,089,284</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">Derivative liabilities &#8211; Series A preferred stock</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">16,014,141</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">16,014,141</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt;">Total derivative liabilities</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">-</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">-</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">20,103,425</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">20,103,425</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as level 3 in the fair value hierarchy:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0"
 cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="10">Significant Unobservable Inputs (Level 3)</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Six Month&#160;<br />Ended<br />June 30,</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Year&#160;<br />Ended&#160;<br />December 31,</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td>&#160;</td><td colspan="2"><p style="text-align: center; font-family: 'times new roman', times, serif;">Year<br />Ended<br />December 31,</p></td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2012</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: left; font-family: 'times new roman', times, serif;">Beginning balance</td><td style="width: 16px; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;">$</td><td style="width: 142px; text-align: right; font-family: 'times new roman', times, serif;">(20,103,425</td><td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;">)</td><td style="width: 16px; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;">$</td><td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif;">(5,090,988</td><td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;">)</td><td style="width: 15px; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;">$</td><td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif;">-</td><td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-family: 'times new roman', times, serif;">Change in fair value of derivative liabilities included in net loss for the six months ended June 30, 2014 and for the years ended&#160; December 31, 2013 and 2012, respectively</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif;"><p style="margin: 0px;">(7,954,970</p></td><td style="text-align: left; font-family: 'times new roman', times, serif;">)</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif;">(12,877,675</td><td style="text-align: left; font-family: 'times new roman', times, serif;">)</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif;">(3,688,353</td><td style="text-align: left; font-family: 'times new roman', times, serif;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-family: 'times new roman', times, serif;">Additions &#8211; warrant instruments</td><td><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font: 10pt/normal 'times new roman', times, serif;">(4,333,163</font></td><td style="text-align: left;"><font style="font: 10pt/normal 'times new roman', times, serif;">)</font></td><td style="font-family: 'times new roman', times, serif;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-family: 'times new roman', times, serif;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-family: 'times new roman', times, serif;"><font style="font: 10pt/normal 'times new roman', times, serif;">(37</font><font style="font-size: 10pt;">3,699</font></td><td style="text-align: left; font-family: 'times new roman', times, serif;">)</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif;">(119,029</td><td style="text-align: left; font-family: 'times new roman', times, serif;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-family: 'times new roman', times, serif;">Transfer of warrant instruments to additional paid in capital</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: right; font-family: 'times new
 roman', times, serif;">6,804,625</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">Additions &#8211; conversion feature of Series A preferred stock</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(1,761,063</td><td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">)</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(1,283,606</td><td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;">Ending balance</td><td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(25,586,933</td><td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">)</td><td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(20,103,425</td><td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">)</td><td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(5,090,988</td><td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">)</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>Income Taxes</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future deductibility is uncertain. At June 30, 2014 and December 31, 2013, the Company had recognized a valuation allowance to the full extent of the Company&#8217;s net deferred tax assets since the likelihood of realization of the benefit does not meet the more likely than not threshold.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The Company files a U.S. Federal income tax return and various state returns. Uncertain tax positions taken on our tax returns will be accounted for as liabilities for unrecognized tax benefits. The Company will recognize interest and penalties, if any, related to unrecognized tax benefits in general and administrative expenses in the statements of operations. There were no liabilities recorded for uncertain tax positions at June 30, 2014 and December 31,
 2013. The open tax years, subject to potential examination by the applicable taxing authority, for the Company were from 2010 through 2014.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>Research and Development</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">Research and development costs primarily consist of research contracts for the advancement of product development, stock-based compensation, and consultants. The Company expenses all research and development costs in the period incurred.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>Stock-Based Compensation</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which an employee is required to provide service in exchange for the award - the requisite service period. The grant-date fair value of employee share options is estimated using the Black-Scholes option pricing model adjusted for the unique characteristics of those instruments. Compensation expense for options and warrants granted to non-employees is determined by the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured, and is recognized over the service period. The expense is subsequently adjusted to fair value at the end of each reporting period until such options and warrants vest, and the fair value of such instruments, as adjusted, is expensed over the related vesting period. Adjustments to fair value at each reporting date may result in income or expense, depending upon the estimate of fair value and the amount of expense recorded prior to the adjustment. The Company reviews its agreements and the future performance obligation with respect to the unvested options or warrants for its vendors or consultants. When appropriate, the Company will expense the unvested options or warrants at the time when management deems the service obligation for future services has ceased.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>Net Loss per Common Share</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">Basic net loss per common share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per common share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of Class A convertible preferred stock, Series A Preferred Stock, warrants for the purchase of common stock and options. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">Potentially dilutive securities are not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align:
 center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Six Month&#160;<br />Ended&#160;<br />June 30,&#160;<br />2014</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="margin-top: 0px; margin-bottom: 0px;">Year</p><p style="margin-top: 0px; margin-bottom: 0px;">Ended&#160;<br />December 31,&#160;<br />2013</p></td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Year<br />Ended&#160;<br />December 31,<br />2012</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: left; padding-left: 0pt;">Class A convertible preferred stock</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">3,337,309</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">-</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">-</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 0pt;">Series A preferred stock</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">136,041,275</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">8,503,503</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-left: 0pt;">Common stock warrants</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">43,144,557</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">89,265,160</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">4,.865,235</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">Common stock options</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">3,365,171</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">18,654,097</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">677,962</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt; padding-left: 5.4pt;">Total</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">49,847,037</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">243,960,532</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">14,046,700</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>Recent Accounting Pronouncements</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">In June 2014, the FASB issued ASU 2014-10, &#8220;Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation&#8221;. The guidance eliminates the definition of a development stage entity thereby removing the incremental financial reporting requirements from U.S. GAAP for development stage entities, primarily presentation of inception to date
 financial information. The provisions of the amendments are effective for annual reporting periods beginning after December 15, 2014, and the interim periods therein. However, early adoption is permitted. Accordingly, the Company has adopted this standard during the six months ending June 30, 2014.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The Company does not expect the adoption of any other recent accounting pronouncements to have a material impact on its financial statements.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>Subsequent Events</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The Company&#8217;s management reviewed all material events through the date the financial statements were issued for subsequent event disclosure consideration.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EUIBM">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Derivative Liabilities (Details 1) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible preferred derivative liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 958,861<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
        <td class="nump">25,586,933<span></span></td>
        <td class="nump">20,103,425<span></span></td>
        <td class="nump">5,090,988<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Issued In May And June 2014 Offering [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Subordinated promissory notes [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">313,258<span></span></td>
        <td class="nump">29,158<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Placement Agent [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">1,217,083<span></span></td>
        <td class="nump">242,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Placement Agent [Member] | Issued In May And June 2014 Offering [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="nump">5,651,181<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Placement Agent [Member] | Subordinated promissory notes [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">136,359<span></span></td>
        <td class="nump">13,089<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Wonpung services [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible preferred derivative liability</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">2,030,589<span></span></td>
        <td class="nump">880,214<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Exchange of debt for Series A preferred stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible preferred derivative liability</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">2,219,854<span></span></td>
        <td class="nump">958,861<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series A Perferred stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible preferred derivative liability</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">11,762,115<span></span></td>
        <td class="nump">2,492,166<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">2,424,167<span></span></td>
        <td class="nump">475,000<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series A Perferred stock [Member] | Issued In May And June 2014 Offering [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="nump">10,040,822<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series B Preferred Stock [Member] | Issued In May And June 2014 Offering [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="nump">9,894,030<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair value of derivatives upon reclass to paid-in capital [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
        <td class="num">(6,804,625)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair value of derivatives upon reclass to paid-in capital [Member] | Issued In May And June 2014 Offering [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair value of derivatives upon reclass to paid-in capital [Member] | Subordinated promissory notes [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="num">(53,831)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair value of derivatives upon reclass to paid-in capital [Member] | Placement Agent [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="num">(107,662)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair value of derivatives upon reclass to paid-in capital [Member] | Placement Agent [Member] | Issued In May And June 2014 Offering [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="nump">996,138<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair value of derivatives upon reclass to paid-in capital [Member] | Placement Agent [Member] | Subordinated promissory notes [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair value of derivatives upon reclass to paid-in capital [Member] | Wonpung services [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible preferred derivative liability</a></td>
        <td class="num">(660,327)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair value of derivatives upon reclass to paid-in capital [Member] | Exchange of debt for Series A preferred stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible preferred derivative liability</a></td>
        <td class="num">(956,996)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair value of derivatives upon reclass to paid-in capital [Member] | Series A Perferred stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible preferred derivative liability</a></td>
        <td class="num">(4,547,311)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="num">(478,498)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair value of derivatives upon reclass to paid-in capital [Member] | Series A Perferred stock [Member] | Issued In May And June 2014 Offering [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair value of derivatives upon reclass to paid-in capital [Member] | Series B Preferred Stock [Member] | Issued In May And June 2014 Offering [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Increase (decrease) in fair value of derivative liabilities [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
        <td class="nump">7,954,970<span></span></td>
        <td class="nump">12,877,675<span></span></td>
        <td class="nump">3,688,353<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Increase (decrease) in fair value of derivative liabilities [Member] | Issued In May And June 2014 Offering [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Increase (decrease) in fair value of derivative liabilities [Member] | Subordinated promissory notes [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="num">(259,427)<span></span></td>
        <td class="nump">200,737<span></span></td>
        <td class="nump">2,833<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Increase (decrease) in fair value of derivative liabilities [Member] | Placement Agent [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="num">(1,109,421)<span></span></td>
        <td class="nump">725,928<span></span></td>
        <td class="nump">162,885<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Increase (decrease) in fair value of derivative liabilities [Member] | Placement Agent [Member] | Issued In May And June 2014 Offering [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="nump">4,655,043<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Increase (decrease) in fair value of derivative liabilities [Member] | Placement Agent [Member] | Subordinated promissory notes [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="num">(136,359)<span></span></td>
        <td class="nump">81,589<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Increase (decrease) in fair value of derivative liabilities [Member] | Wonpung services [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible preferred derivative liability</a></td>
        <td class="num">(1,370,262)<span></span></td>
        <td class="nump">1,150,375<span></span></td>
        <td class="nump">581,073<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Increase (decrease) in fair value of derivative liabilities [Member] | Exchange of debt for Series A preferred stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible preferred derivative liability</a></td>
        <td class="num">(1,262,858)<span></span></td>
        <td class="nump">1,260,993<span></span></td>
        <td class="nump">958,861<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Increase (decrease) in fair value of derivative liabilities [Member] | Series A Perferred stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible preferred derivative liability</a></td>
        <td class="num">(7,214,804)<span></span></td>
        <td class="nump">7,622,039<span></span></td>
        <td class="nump">1,619,478<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="num">(1,945,669)<span></span></td>
        <td class="nump">1,836,014<span></span></td>
        <td class="nump">363,223<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Increase (decrease) in fair value of derivative liabilities [Member] | Series A Perferred stock [Member] | Issued In May And June 2014 Offering [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="nump">9,198,452<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Increase (decrease) in fair value of derivative liabilities [Member] | Series B Preferred Stock [Member] | Issued In May And June 2014 Offering [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="nump">7,400,275<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Initial valuation of derivative liabilities upon issuance of new warrants period [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
        <td class="nump">4,333,163<span></span></td>
        <td class="nump">2,134,762<span></span></td>
        <td class="nump">1,402,635<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Initial valuation of derivative liabilities upon issuance of new warrants period [Member] | Subordinated promissory notes [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">83,363<span></span></td>
        <td class="nump">26,325<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Initial valuation of derivative liabilities upon issuance of new warrants period [Member] | Placement Agent [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">248,655<span></span></td>
        <td class="nump">79,615<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Initial valuation of derivative liabilities upon issuance of new warrants period [Member] | Placement Agent [Member] | Subordinated promissory notes [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">41,681<span></span></td>
        <td class="nump">13,089<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Initial valuation of derivative liabilities upon issuance of new warrants period [Member] | Wonpung services [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible preferred derivative liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">299,141<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Initial valuation of derivative liabilities upon issuance of new warrants period [Member] | Exchange of debt for Series A preferred stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible preferred derivative liability</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Initial valuation of derivative liabilities upon issuance of new warrants period [Member] | Series A Perferred stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible preferred derivative liability</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,647,910<span></span></td>
        <td class="nump">872,688<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">113,153<span></span></td>
        <td class="nump">111,777<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Initial valuation of derivative liabilities upon issuance of new warrants period [Member] | Series A Perferred stock [Member] | Issued In May And June 2014 Offering [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="nump">842,370<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Initial valuation of derivative liabilities upon issuance of new warrants period [Member] | Series B Preferred Stock [Member] | Issued In May And June 2014 Offering [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Warrants issued</a></td>
        <td class="nump">$ 2,494,655<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Convertible Security<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509036<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleDebtFairValueDisclosures</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Liabilities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13495-108611<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34720828&amp;loc=SL20225862-175312<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of other liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESPCK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Details Textual 1) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="3">0 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>May 20, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 10, 2014</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Consultants [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Consultants [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Consultants [Member]</div>
        </th>
        <th class="th">
          <div>Nov. 30, 2013

</div>
          <div>Consultants [Member]</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2012

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2012

</div>
          <div>Common Stock [Member]

</div>
          <div>Medeor Inc [Member]</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2012

</div>
          <div>Warrant [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 10, 2014

</div>
          <div>Common stock issued for services [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 10, 2013

</div>
          <div>Common stock issued for services [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 10, 2012

</div>
          <div>Common stock issued for services [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Common stock issued for services [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Common stock issued for services [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Common stock issued for services [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Interest expense due from related party</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 353,246<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Aggregate proceeds from private placement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,745,699<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">22,229,300<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfCommonStockToPurchaseCommonStock', window );">Issuance of common stock and warrants to purchase common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">255,750<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_WarrantToPurchaseOfCommonStock', window );">Warrant to purchase of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">619,377<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">619,377<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,500<span></span></td>
        <td class="nump">21,500<span></span></td>
        <td class="nump">40,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">868,213<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.54<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 1.00<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 0.08<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.30<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesNoncurrent', window );">Outstanding liabilities owed to the founder</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">869,300<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">29,052<span></span></td>
        <td class="nump">56,394<span></span></td>
        <td class="nump">68,356<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsShareBasedCompensation', window );">Fair value of common stock for the services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,305,200<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">20,500<span></span></td>
        <td class="nump">5,100<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,700<span></span></td>
        <td class="nump">16,900<span></span></td>
        <td class="nump">20,500<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfCommonStockInConnectionWithAcquistionOfLicienseAgreement', window );">Issuance of common stock in connection with acquistion of liciense agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">17,089<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.30<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,499,760<span></span></td>
        <td class="nump">1,187,449<span></span></td>
        <td class="nump">677,962<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,538,010<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">153,802<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross', window );">Fair value of the common granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">46,100<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">46,100<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Grant date fair value of the common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.03<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Share based compensation shares vested</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,655,783<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">29,052<span></span></td>
        <td class="nump">56,390<span></span></td>
        <td class="nump">68,350<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock to founder for cash</a></td>
        <td class="nump">2,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants', window );">Issuance of common stock for cashless exercise of warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">541<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants', window );">Issuance of common stock for cashless exercise of warrants, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">618,766<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">541,430<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">541,293<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">$ (839,959)<span></span></td>
        <td class="num">$ (5,248,669)<span></span></td>
        <td class="num">$ (667,474)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 3,750,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">40,294,217<span></span></td>
        <td class="nump">4,958,778<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_IssuanceOfCommonStockInConnectionWithAcquistionOfLicienseAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of common stock in connection with acquistion of liciense agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_IssuanceOfCommonStockInConnectionWithAcquistionOfLicienseAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_IssuanceOfCommonStockToPurchaseCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of common stock to purchase common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_IssuanceOfCommonStockToPurchaseCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued for cashless exercise of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of shares issued for cashless exercise of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_WarrantToPurchaseOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrant to purchase of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_WarrantToPurchaseOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared and applicable to holders of share-based compensation, for example, but not limited to, non-vested shares, stock options, or restricted stock units.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DividendsShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseRelatedParty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of interest expense incurred on a debt or other obligation to related party.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpenseRelatedParty</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion (due beyond one year or one operating cycle) of other accrued expenses (expenses incurred at the end of the reporting period but not yet paid) not otherwise defined in the taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.24)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 24<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAccruedLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfPrivatePlacement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SaleOfStockPricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average grant-date fair value of non-vested options forfeited.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options vested.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value, before forfeitures, of stock or other type of equity granted of any equity-based compensation plan other than an employee stock ownership plan (ESOP).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockGrantedDuringPeriodValueSharebasedCompensationGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQNAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 25,564,351<span></span></td>
        <td class="nump">$ 3,522,450<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
        <td class="nump">178,158<span></span></td>
        <td class="nump">10,325<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Deferred financing costs, net of accumulated amortization of $0 and $69,546 respectively</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">78,724<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">25,742,509<span></span></td>
        <td class="nump">3,611,499<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net of accumulated depreciation of $2,230 and $373, respectively</a></td>
        <td class="nump">9,841<span></span></td>
        <td class="nump">8,498<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
        <td class="nump">12,100<span></span></td>
        <td class="nump">12,100<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">25,764,450<span></span></td>
        <td class="nump">3,632,097<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">746,098<span></span></td>
        <td class="nump">180,319<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
        <td class="nump">382,023<span></span></td>
        <td class="nump">438,658<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Note payable</a></td>
        <td class="nump">58,357<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
        <td class="nump">25,586,933<span></span></td>
        <td class="nump">20,103,425<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Subordinated promissory notes payable, net of debt discount of $0 and $141,049, respectively</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">758,951<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">26,773,411<span></span></td>
        <td class="nump">21,481,353<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Long-term liability - accrued expense</a></td>
        <td class="nump">100,000<span></span></td>
        <td class="nump">100,000<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">26,873,411<span></span></td>
        <td class="nump">21,581,353<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 500,000,000 shares authorized, 40,294,217 and 4,958,778 shares issued and outstanding, respectively</a></td>
        <td class="nump">40,294<span></span></td>
        <td class="nump">4,959<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">54,166,055<span></span></td>
        <td class="nump">16,014,840<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage', window );">Accumulated deficit</a></td>
        <td class="num">(55,318,647)<span></span></td>
        <td class="num">(33,982,659)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' deficit</a></td>
        <td class="num">(1,108,961)<span></span></td>
        <td class="num">(17,949,256)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' deficit</a></td>
        <td class="nump">25,764,450<span></span></td>
        <td class="nump">3,632,097<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series A Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock,Value</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">13,604<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Class A convertible preferred stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' deficit:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock,Value</a></td>
        <td class="nump">$ 3,337<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.15(1),(5))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.15)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 15<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph 1, 5<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertibleNotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net amount of current deferred finance costs capitalized at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredFinanceCostsCurrentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13495-108611<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34720828&amp;loc=SL20225862-175312<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cumulative net losses reported during the development stage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 915<br><br><br><br> -SubTopic 210<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472335&amp;loc=d3e37729-110921<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19, 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate carrying amounts, as of the balance sheet date, of assets not separately disclosed in the balance sheet.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 10<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Assets<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (g)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 340<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=47804770&amp;loc=d3e5879-108316<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENOAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Details 1)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation of the statutory tax rate to the effective tax rate</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory federal income tax rate</a></td>
        <td class="nump">34.00%<span></span></td>
        <td class="nump">34.00%<span></span></td>
        <td class="nump">34.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State (net of federal benefit)</a></td>
        <td class="nump">6.60%<span></span></td>
        <td class="nump">6.60%<span></span></td>
        <td class="nump">6.60%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
        <td class="num">(13.10%)<span></span></td>
        <td class="num">(29.70%)<span></span></td>
        <td class="num">(18.80%)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
        <td class="num">(2.30%)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
        <td class="num">(25.20%)<span></span></td>
        <td class="num">(10.90%)<span></span></td>
        <td class="num">(21.80%)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectiveIncomeTaxRateContinuingOperations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EJ5BG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (21,335,988)<span></span></td>
        <td class="num">$ (19,871,908)<span></span></td>
        <td class="num">$ (6,860,030)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
        <td class="nump">2,330<span></span></td>
        <td class="nump">373<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_CommonStockIssuedForServices', window );">Common stock issued for services</a></td>
        <td class="nump">8,714<span></span></td>
        <td class="nump">3,766,918<span></span></td>
        <td class="nump">1,330,849<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
        <td class="nump">10,319,137<span></span></td>
        <td class="nump">382,343<span></span></td>
        <td class="nump">37,335<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
        <td class="nump">327,776<span></span></td>
        <td class="nump">118,639<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
        <td class="nump">78,724<span></span></td>
        <td class="nump">69,546<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Loss on change in fair value of derivative liabilities</a></td>
        <td class="nump">7,954,970<span></span></td>
        <td class="nump">12,877,675<span></span></td>
        <td class="nump">3,688,353<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaid expenses and other assets</a></td>
        <td class="num">(89,983)<span></span></td>
        <td class="nump">160,283<span></span></td>
        <td class="num">(182,708)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="nump">565,779<span></span></td>
        <td class="num">(57,102)<span></span></td>
        <td class="nump">32,299<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
        <td class="nump">4,287<span></span></td>
        <td class="nump">315,704<span></span></td>
        <td class="nump">369,927<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(2,164,254)<span></span></td>
        <td class="num">(2,237,529)<span></span></td>
        <td class="num">(1,583,975)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Purchase of fixed assets</a></td>
        <td class="num">(3,673)<span></span></td>
        <td class="num">(8,871)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
        <td class="num">(3,673)<span></span></td>
        <td class="num">(8,871)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds from sale of Series A preferred stock and warrants</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">3,494,428<span></span></td>
        <td class="nump">3,220,018<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Proceeds from sale of common stock and warrants</a></td>
        <td class="nump">22,229,321<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sales of common and Class A Series A preferred stock, pursuant to Share Exchange</a></td>
        <td class="nump">2,000,000<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment of notes payable</a></td>
        <td class="num">(19,493)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(39,990)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ProceedsFromSubordinatedPromissoryNotesNetOfDeferredFinancingCosts', window );">Proceeds from subordinated promissory notes payable, net of financing costs</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">501,600<span></span></td>
        <td class="nump">154,900<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">24,209,828<span></span></td>
        <td class="nump">3,996,028<span></span></td>
        <td class="nump">3,334,928<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashPeriodIncreaseDecrease', window );">Net increase in cash</a></td>
        <td class="nump">22,041,901<span></span></td>
        <td class="nump">1,749,628<span></span></td>
        <td class="nump">1,750,953<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at beginning of the period</a></td>
        <td class="nump">3,522,450<span></span></td>
        <td class="nump">1,772,822<span></span></td>
        <td class="nump">21,869<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash at end of the period</a></td>
        <td class="nump">25,564,351<span></span></td>
        <td class="nump">3,522,450<span></span></td>
        <td class="nump">1,772,822<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_CashPaidDuringPeriodAbstract', window );"><strong>Cash paid during the period for:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest</a></td>
        <td class="nump">1,103<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing transactions:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ShareExchangeOfSubordinatedDebt', window );">Conversion of Series A Preferred Stock and Subordinated Notes to common stock</a></td>
        <td class="nump">900,000<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ShareExchangeOfAccruedInterest', window );">Conversion of accrued interest to common stock</a></td>
        <td class="nump">60,922<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfDebtInConnectionWithCompensationPolicy', window );">Note payable issued in connection with director and officer insurance policy</a></td>
        <td class="nump">77,850<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_FairValueOfDerivativesTerminatedInConnectionWithShareExchange', window );">Fair value of derivative reclassified to additional paid-in-capital in connection with Share Exchange</a></td>
        <td class="nump">6,804,625<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_FairValueOfDerivativesIssuedInConnectionWithIssuanceOfCommonStock', window );">Fair value of warrant derivatives issued with units offering</a></td>
        <td class="nump">4,333,163<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_BeneficialConversionFeature', window );">Beneficial conversion feature</a></td>
        <td class="nump">186,727<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_FairValueOfDerivativesIssuedInConnectionWithIssuanceOfPreferredStock', window );">Fair value of derivatives issued in connection with issuance of preferred stock</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">1,761,063<span></span></td>
        <td class="nump">984,465<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_FairValueOfDerivativeWarrantsIssuedToLendersInConnectionWithIssuanceOfSubordinatedPromissoryNotes', window );">Fair value of derivative warrants issued to lenders in connection with issuance of subordinated promissory notes</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">83,363<span></span></td>
        <td class="nump">26,325<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants issued in connection with deferred financing costs</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">41,681<span></span></td>
        <td class="nump">13,089<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_FairValueOfDerivativeWarrantsIssuedForOfferingCostsInConnectionWithTheIssuanceOfSeriesAPreferredStock', window );">Fair value of derivative warrants issued for offering costs in connection with the issuance of Series A preferred stock</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">248,655<span></span></td>
        <td class="nump">79,615<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_FairValueOfDerivativeIssuedToWonpungForServices', window );">Fair value of derivative issued to Wonpung for services</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">299,141<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ExchangeOfLoansAndAccruedInterestForCommonStockFromFounder', window );">Exchange of loans and accrued interest for common stock from founder</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">1,222,321<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ExchangeOfSubordinatedNotesAndAccruedInterestForSeriesAPreferredStock', window );">Exchange of subordinated notes and accrued interest for Series A preferred stock</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">1,541,180<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_CashlessExerciseOfWarrantsForCommonStock', window );">Cashless exercise of warrants for common stock</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">$ 54,143<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_BeneficialConversionFeature">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Beneficial conversion feature.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_BeneficialConversionFeature</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_CashlessExerciseOfWarrantsForCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cashless exercise of warrants for common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_CashlessExerciseOfWarrantsForCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_CashPaidDuringPeriodAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_CashPaidDuringPeriodAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_CommonStockIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued for services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_CommonStockIssuedForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_ExchangeOfLoansAndAccruedInterestForCommonStockFromFounder">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exchange of loans and accrued interest for common stock from founder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_ExchangeOfLoansAndAccruedInterestForCommonStockFromFounder</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_ExchangeOfSubordinatedNotesAndAccruedInterestForSeriesAPreferredStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exchange of subordinated notes and accrued interest for Series A preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_ExchangeOfSubordinatedNotesAndAccruedInterestForSeriesAPreferredStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_FairValueOfDerivativeIssuedToWonpungForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of derivative issued to Wonpung for services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_FairValueOfDerivativeIssuedToWonpungForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_FairValueOfDerivativesIssuedInConnectionWithIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of derivatives issued in connection with issuance of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_FairValueOfDerivativesIssuedInConnectionWithIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_FairValueOfDerivativesIssuedInConnectionWithIssuanceOfPreferredStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of derivatives issued in connection with issuance of preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_FairValueOfDerivativesIssuedInConnectionWithIssuanceOfPreferredStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_FairValueOfDerivativesTerminatedInConnectionWithShareExchange">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of derivative terminated in connection with share exchange and transferred to additional paid-in-capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_FairValueOfDerivativesTerminatedInConnectionWithShareExchange</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_FairValueOfDerivativeWarrantsIssuedForOfferingCostsInConnectionWithTheIssuanceOfSeriesAPreferredStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of derivative warrants issued for offering costs in connection with the issuance of Series A preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_FairValueOfDerivativeWarrantsIssuedForOfferingCostsInConnectionWithTheIssuanceOfSeriesAPreferredStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_FairValueOfDerivativeWarrantsIssuedToLendersInConnectionWithIssuanceOfSubordinatedPromissoryNotes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of derivative warrants issued to lenders in connection with issuance of subordinated promissory notes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_FairValueOfDerivativeWarrantsIssuedToLendersInConnectionWithIssuanceOfSubordinatedPromissoryNotes</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_IssuanceOfDebtInConnectionWithCompensationPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Note payable issued in connection with director and officer policy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_IssuanceOfDebtInConnectionWithCompensationPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_ProceedsFromSubordinatedPromissoryNotesNetOfDeferredFinancingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from subordinated promissory notes, net of deferred financing costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_ProceedsFromSubordinatedPromissoryNotesNetOfDeferredFinancingCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_ShareExchangeOfAccruedInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share exchange of accrued interest to common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_ShareExchangeOfAccruedInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_ShareExchangeOfSubordinatedDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share exchange of subordinated notes to common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_ShareExchangeOfSubordinatedDebt</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfDebtDiscountPremium</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 8<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AmortizationOfFinancingCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Depreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 480<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAdjustmentOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxesPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDerivativeLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidExpensesOther</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestPaid</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NoncashInvestingAndFinancingItemsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireProductiveAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOrSaleOfEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RepaymentsOfNotesPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EUXAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Details 1) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Deficit [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Shares, Outstanding</a></td>
        <td class="nump">1,865,411<span></span></td>
        <td class="nump">677,962<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Granted</a></td>
        <td class="nump">1,499,760<span></span></td>
        <td class="nump">1,187,449<span></span></td>
        <td class="nump">677,962<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Shares, Outstanding and expected to vest</a></td>
        <td class="nump">3,365,171<span></span></td>
        <td class="nump">1,865,411<span></span></td>
        <td class="nump">677,962<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, exercisable</a></td>
        <td class="nump">652,005<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Outstanding</a></td>
        <td class="nump">$ 0.08<span></span></td>
        <td class="nump">$ 0.08<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Granted</a></td>
        <td class="nump">$ 1.50<span></span></td>
        <td class="nump">$ 0.08<span></span></td>
        <td class="nump">$ 0.08<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, Outstanding and expected to vest</a></td>
        <td class="nump">$ 1.11<span></span></td>
        <td class="nump">$ 0.08<span></span></td>
        <td class="nump">$ 0.08<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share, exercisable</a></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Outstanding</a></td>
        <td class="text">8 years 10 months 24 days<span></span></td>
        <td class="text">8 years 9 months 18 days<span></span></td>
        <td class="text">9 years 6 months<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Granted</a></td>
        <td class="text">9 years 8 months 12 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, exercisable</a></td>
        <td class="text">9 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
        <td class="nump">$ 1,305,000<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue', window );">Aggregate Intrinsic Value, Granted</a></td>
        <td class="nump">3,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
        <td class="nump">5,238,000<span></span></td>
        <td class="nump">1,305,000<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, exercisable</a></td>
        <td class="nump">$ 782,400<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share Based compensation arrangement by share based payment award options granted intrinsic value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">&#160;</p><table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center;">&#160;</td><td style="font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td><td style="font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">June 30,&#160;<br />2014</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td><td style="font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">December 31,<br />2013</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-family: 'times new roman', times, serif;">Deferred tax assets:</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1177.671875px; font-family: 'times new roman', times, serif; text-align: left; padding-left: 10pt;">Net operating loss</td><td style="width: 16px; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 16px; font-family: 'times new roman', times, serif; text-align: left;">$</td><td style="width: 142px; font-family: 'times new roman', times, serif; text-align: right;">3,556,600</td><td style="width: 16px; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td><td style="width: 15px; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 15px; font-family: 'times new roman', times, serif; text-align: left;">$</td><td style="width: 141px; font-family: 'times new roman', times, serif; text-align: right;">2,765,600</td><td style="width: 15px; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-family: 'times new roman', times, serif; text-align: left; padding-left: 10pt;">Stock based compensation</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif; text-align: left;">&#160;</td><td style="font-family: 'times new roman', times, serif; text-align: right;">4,248,700</td><td style="font-family: 'times new roman', times, serif; text-align: left;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif; text-align: left;">&#160;</td><td style="font-family: 'times new roman', times, serif; text-align: right;">-</td><td style="font-family: 'times new roman', times, serif; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-family: 'times new roman', times, serif; text-align: left; padding-left: 10pt;">Research and development tax credits</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif; text-align: left;">&#160;</td><td style="font-family: 'times new roman', times, serif; text-align: right;">197,700</td><td style="font-family: 'times new roman', times, serif; text-align: left;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif; text-align: left;">&#160;</td><td style="font-family: 'times new roman', times, serif; text-align: right;">436,300</td><td style="font-family: 'times new roman', times, serif; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-family: 'times new roman', times, serif; padding-left: 10pt;">Accruals</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif; text-align: left;">&#160;</td><td style="font-family: 'times new roman', times, serif; text-align: right;">22,900</td><td style="font-family: 'times new roman', times, serif; text-align: left;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif; text-align: left;">&#160;</td><td style="font-family: 'times new roman', times, serif; text-align: right;">44,700</td><td style="font-family: 'times new roman', times, serif; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-family: 'times new roman', times, serif; padding-left: 10pt;">Other</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif; text-align: left;">&#160;</td><td style="font-family: 'times new roman', times, serif; text-align: right;">2,900</td><td style="font-family: 'times new roman', times, serif; text-align: left;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif; text-align: left;">&#160;</td><td style="font-family: 'times new roman', times, serif; text-align: right;">46,000</td><td style="font-family: 'times new roman', times, serif; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt;">Valuation allowance</td><td style="font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-family: 'times new roman', times, serif; text-align: right;">(8,028,800</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif; text-align: left;">)</td><td style="font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;">&#160;</td><td
 style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-family: 'times new roman', times, serif; text-align: right;">(3,292,600</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif; text-align: left;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-family: 'times new roman', times, serif; padding-bottom: 4pt;">Total</td><td style="font-family: 'times new roman', times, serif; padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-family: 'times new roman', times, serif; text-align: left;">$</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-family: 'times new roman', times, serif; text-align: right;">-</td><td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td><td style="font-family: 'times new roman', times, serif; padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-family: 'times new roman', times, serif; text-align: left;">$</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-family: 'times new roman', times, serif; text-align: right;">-</td><td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif; text-align: left;">&#160;</td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of the statutory tax rate to the effective tax rate</a></td>
        <td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: normal; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><td style="text-align: center; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="text-align: center; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;" colspan="2"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">Six Month Ended June&#160;30,</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;" colspan="6"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">Year Ended December,</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td></tr><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><td style="text-align: center; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;" colspan="2"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">2014</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;" colspan="2"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">2013</font></td><td style="padding-bottom:
 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;" colspan="2"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">2012</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td></tr><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;" colspan="2"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;" colspan="2"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;" colspan="2"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td></tr><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; background-color: #cceeff;"><td style="width: 1003px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant:
 normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">Statutory federal income tax rate</font></td><td style="width: 16px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="width: 142px; text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">34</font></td><td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">%</font></td><td style="width: 15px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="width: 15px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="width: 141px; text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">34</font></td><td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">%</font></td><td style="width: 15px; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="width: 15px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="width: 141px; text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">34</font></td><td style="width: 16px; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">%</font></td></tr><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; background-color: white;"><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">State (net of federal benefit)</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;
 letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">6.6</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">%</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">6.6</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">%</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">6.6</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">%</font></td></tr><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; background-color: #cceeff;"><td style="text-indent: -8.65pt; padding-left: 8.65pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">Non-deductible expenses</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><p style="margin: 0px;">(13.1</p></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal;
 word-spacing: normal;">)%</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">(29.7</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">)%</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">(18.8</font></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">)%</font></td></tr><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; background-color: white;"><td style="text-indent: -8.65pt; padding-left: 8.65pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">Other</td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><p style="margin: 0px;">(2.3</p></td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">)%</td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">-</td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">-</td><td style="text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</td></tr><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height:
 normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">Change in valuation allowance</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;"><p style="margin: 0px;">(25.2</p></td><td style="padding-bottom: 1.5pt; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">)%</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">(10.9</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">)%</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">(21.8</font></td><td style="padding-bottom: 1.5pt; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">)%</font></td></tr><tr style="vertical-align: bottom; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; background-color: white;"><td style="text-align: left; padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height:
 normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">Effective income tax rate</font></td><td style="padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">0</font></td><td style="padding-bottom: 4pt; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">%</font></td><td style="padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">0</font></td><td style="padding-bottom: 4pt; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">%</font></td><td style="padding-bottom: 4pt; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">0</font></td><td style="padding-bottom: 4pt; text-align: left; font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">%</font></td></tr></table><div>&#160;</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EWAAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Details 2) (Stock Option [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_CurrentPriceOfCommonStock', window );">Current price of common stock</a></td>
        <td class="nump">$ 2.00<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 0.03<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.40%<span></span></td>
        <td class="nump">0.60%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">82.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
        <td class="nump">76.00%<span></span></td>
        <td class="nump">73.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
        <td class="nump">77.00%<span></span></td>
        <td class="nump">80.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
        <td class="text">6 years 3 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years 9 months<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
        <td class="nump">1.60%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
        <td class="nump">1.50%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years 9 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_CurrentPriceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Current Price of Common Stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_CurrentPriceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2AAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Business (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>May 20, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_BusinessTextualsAbstract', window );"><strong>Business (Textuals)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage of Relmada</a></td>
        <td class="nump">94.60%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Issuance of shares in exchange for ownership interest</a></td>
        <td class="nump">28,291,073<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Percentage of acquired shares</a></td>
        <td class="nump">80.90%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplit', window );">Stock split ratio description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The outstanding options and warrants were exchanged for options and warrants to purchase shares of common stock of the Company at a ratio of 10 to 1.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange', window );">Issuance of common stock and Class A preferred stock in connection with share exchange</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 2,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500,000,000<span></span></td>
        <td class="nump">500,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">200,000,000<span></span></td>
        <td class="nump">200,000,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Preferred Class A [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_BusinessTextualsAbstract', window );"><strong>Business (Textuals)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange', window );">Issuance of common stock and Class A preferred stock in connection with share exchange</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,337<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares', window );">Issuance of common stock and Class A preferred stock in connection with share exchange, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,337,309<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Common Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_BusinessTextualsAbstract', window );"><strong>Business (Textuals)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange', window );">Issuance of common stock and Class A preferred stock in connection with share exchange</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 3,337<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares', window );">Issuance of common stock and Class A preferred stock in connection with share exchange, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,337,310<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_BusinessTextualsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_BusinessTextualsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance Of Common Stock And Preferred Stock In Connection With Share Exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance Of Common Stock And Preferred Stock In Connection With Share Exchange Shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of equity interests issued or issuable to acquire entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityMethodInvestmentOwnershipPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Stock Split<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6525746<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteStockSplit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Business<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Business [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">BUSINESS</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>NOTE 1 &#8211; BUSINESS</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">Relmada Therapeutics, Inc., formerly Camp Nine, Inc. (the &#8220;Company&#8221;), was formed as a Nevada corporation on May 31, 2012 and began as a manufacturer and retailer of surfboards and related accessories. The Company is a clinical stage biopharmaceutical company focused on drugs to treat pain. The Company has a portfolio of four products at different stages of development and an early stage pipeline of an additional three products. The Company&#8217;s&#8217;s approach is expected to reduce overall clinical development risks and potentially deliver valuable products in areas of high unmet medical needs. The Company&#8217;s office is located in New York City.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">On May 20, 2014, Relmada Therapeutics, Inc. (&#8220;Relmada&#8221;) completed a Share Exchange with the Company, whereby the Company acquired 94.6% of the issued and outstanding capital stock of Relmada from the stockholders in exchange (&#8220;Share Exchange&#8221;) for the issuance of 28,291,073 shares of common stock to the Company&#8217;s stockholders, which represented 80.9% of Relmada&#8217;s issued and outstanding common stock after the consummation of the Share Exchange. In addition, the outstanding options and warrants were exchanged for options and warrants to purchase shares of common stock of the Company at a ratio of 10 to 1. Prior to the Share Exchange, the Company had no other assets or liabilities. The principal shareholders of the Company contributed $2 million for 3,337,310 shares of the Company&#8217;s common stock and 3,337,309 shares of Class A convertible preferred shares.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">As a result of the Share Exchange, the stockholders of the Relmada became the principal stockholders of Relmada. In addition, i<font style="background-color: white;">n connection with the Share Exchange, the Company changed its name to Relmada Therapeutics, Inc. and increased its authorized common stock to 500,000,000 shares and its authorized preferred stock to 200,000,000 shares.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The Share Exchange was accounted for as a reverse merger rather than a business combination, wherein Relmada is considered the acquirer for accounting and financial reporting purposes. The statement of operations reflects the activities of Relmada from the date of its inception, May 24, 2004. As a result of the Share Exchange, the Company became the holding company and Relmada became the subsidiary. The operating entity is that of Relmada.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">In addition to the normal risks associated with a new business venture, there can be no assurance that the Company&#8217;s research and development will be successfully completed or that any product will be approved or commercially viable. The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with Food and Drug Administration (&#8220;FDA&#8221;) and other governmental regulations and approval requirements.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EF1AE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedAmortizationDeferredFinanceCosts', window );">Amortization of deferred financing costs</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 69,546<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
        <td class="nump">2,230<span></span></td>
        <td class="nump">373<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 141,049<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">200,000,000<span></span></td>
        <td class="nump">200,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Liquidation Value</a></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">$ 0.001<span></span></td>
        <td class="nump">$ 0.001<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">500,000,000<span></span></td>
        <td class="nump">500,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">40,294,217<span></span></td>
        <td class="nump">4,958,778<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">40,294,217<span></span></td>
        <td class="nump">4,958,778<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series A Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">255,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">13,604,128<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">13,604,128<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Class A convertible preferred stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">3,500,000<span></span></td>
        <td class="nump">3,500,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="nump">3,337,309<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="nump">3,337,309<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedAmortizationDeferredFinanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For an unclassified balance sheet, the accumulated amortization, as of the reporting date, representing the periodic charge to earnings of deferred costs which are associated with debt obligations existing as of the end of the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 17<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedAmortizationDeferredFinanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentUnamortizedDiscount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockLiquidationPreference</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair value, financial liabilities measured on recurring basis</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Quoted Prices</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">In Active</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Significant</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Total</td><td style="font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Markets for</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Other</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Significant</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Carrying</td><td style="font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Identical</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Observable</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Unobservable</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Value as of</td><td style="font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Assets</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Inputs</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Inputs</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">June 30,</td><td style="font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Description</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">(Level 1)</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">(Level 2)</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">(Level 3)</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left; font-family: 'times new roman', times, serif;">Derivative liabilities &#8211; warrant instruments</td><td style="width: 16px; font-family: 'times new roman', times,
 serif;">&#160;</td><td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;">$</td><td style="width: 142px; text-align: right; font-family: 'times new roman', times, serif;">-</td><td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 16px; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;">$</td><td style="width: 142px; text-align: right; font-family: 'times new roman', times, serif;">-</td><td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 15px; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;">$</td><td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif;">25,586,933</td><td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 15px; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;">$</td><td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif;">25,586,933</td><td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Quoted Prices</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">In Active</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Significant</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Total</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Markets for</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Other</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Significant</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Carrying</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Identical</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Observable</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Unobservable</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Value as of</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Assets</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Inputs</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Inputs</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">December 31,</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Description</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">(Level 1)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">(Level 2)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">(Level 3)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left;">Derivative liabilities &#8211; warrant instruments</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">-</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">-</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">4,089,284</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">4,089,284</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">Derivative liabilities &#8211; Series A preferred stock</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td
 style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">16,014,141</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">16,014,141</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt;">Total derivative liabilities</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">-</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">-</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">20,103,425</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">20,103,425</td><td style="text-align: left; padding-bottom: 4pt;"></td></tr></table><div>&#160;</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair value of the Company Level Three financial liabilities</a></td>
        <td class="text"><table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1568px; height: 213px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="10">Significant Unobservable Inputs (Level 3)</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Six Month&#160;<br />Ended<br />June 30,</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Year&#160;<br />Ended&#160;<br />December 31,</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td>&#160;</td><td colspan="2"><p style="text-align: center; font-family: 'times new roman', times, serif;">Year<br />Ended<br />December 31,</p></td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2012</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: left; font-family: 'times new roman', times, serif;">Beginning balance</td><td style="width: 16px; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;">$</td><td style="width: 142px; text-align: right; font-family: 'times new roman', times, serif;">(20,103,425</td><td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;">)</td><td style="width: 16px; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;">$</td><td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif;">(5,090,988</td><td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;">)</td><td style="width: 15px; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;">$</td><td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif;">-</td><td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-family: 'times new roman', times, serif;">Change in fair value of derivative liabilities included in net loss for the six months ended June 30, 2014 and for the years ended&#160; December 31, 2013 and 2012, respectively</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif;"><p style="margin: 0px;">(7,954,970</p></td><td style="text-align: left; font-family: 'times new roman', times, serif;">)</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif;">(12,877,675</td><td style="text-align: left; font-family: 'times new roman', times, serif;">)</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif;">(3,688,353</td><td style="text-align: left; font-family: 'times new roman', times, serif;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-family: 'times new roman', times, serif;">Additions&#8211; warrant instruments</td><td><font>&#160;</font></td><td style="text-align: left;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font: 10pt/normal 'times new roman', times, serif;">(4,333,163</font></td><td style="text-align: left;"><font style="font: 10pt/normal 'times new roman', times, serif;">)</font></td><td style="font-family: 'times new roman', times, serif;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-family: 'times new roman', times, serif;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-family: 'times new roman', times, serif;"><font style="font: 10pt/normal 'times new roman', times, serif;">(37</font><font style="font-size: 10pt;">3,699</font></td><td style="text-align: left; font-family: 'times new roman', times, serif;">)</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif;">(119,029</td><td style="text-align: left; font-family: 'times new roman', times, serif;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-family: 'times new roman', times, serif;">Transfer of warrant instruments to
 additional paid in capital</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif;">6,804,625</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">Additions &#8211; conversion feature of Series A preferred stock</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(1,761,063</td><td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">)</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(1,283,606</td><td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;">Ending balance</td><td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(25,586,933</td><td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">)</td><td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(20,103,425</td><td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">)</td><td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(5,090,988</td><td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">)</td></tr></table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of anti-dilutive securities</a></td>
        <td class="text"><table style="font: 10pt/normal times new roman, times, serif; width: 100%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td></td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Six Month <br /> Ended <br />June 30, <br /> 2014</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="margin-top: 0px; margin-bottom: 0px;">Year</p><p style="margin-top: 0px; margin-bottom: 0px;">Ended <br />December 31, <br /> 2013</p></td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Year<br /> Ended <br />December 31,<br /> 2012</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 64%; text-align: left; padding-left: 0pt;">Class A convertible preferred stock</td><td style="width: 1%;">&#160;</td><td style="width: 1%; text-align: left;">&#160;</td><td style="width: 9%; text-align: right;">3,337,309</td><td style="width: 1%; text-align: left;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%; text-align: left;">&#160;</td><td style="width: 9%; text-align: right;">-</td><td style="width: 1%; text-align: left;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%; text-align: left;">&#160;</td><td style="width: 9%; text-align: right;">-</td><td style="width: 1%; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 0pt;">Series A preferred stock</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">136,041,275</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">8,503,503</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-left: 0pt;">Common stock warrants</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">43,144,557</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">89,265,160</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">4,.865,235</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">Common stock options</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">3,365,171</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">18,654,097</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">677,962</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt; padding-left: 5.4pt;">Total</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">49,847,037</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">243,960,532</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">14,046,700</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19279-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESDAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">RELMADA THERAPEUTICS, INC.<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001553643<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">S-1<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Jun. 30,
				 2014<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Notes Payable (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Notes Payable [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ScheduleOfPromissoryNotesDueLoanTableTextBlock', window );">Schedule of promissory notes due loan</a></td>
        <td class="text"><div>&#160;</div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center;" colspan="2">June 30,<br />2014</td><td style="padding-bottom: 1.5pt; text-align: center;">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">December 31,&#160;<br />2013</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1179px; text-align: justify; text-indent: -9pt; padding-left: 9pt;">Subordinated 8% promissory notes due December 2013</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">-</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">216,000</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt;">Subordinated 8% promissory notes due September 2014</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">-</td><td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">684,000</td><td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; padding-left: 0pt;">Total notes payable</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">900,000</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt;">Less: debt discount</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">-</td><td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">(141,049</td><td style="padding-bottom: 1.5pt; text-align: left;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; padding-bottom: 4pt; padding-left: 0pt;">Total notes payable, less debt discount</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">$</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">-</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">$</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">758,951</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px;">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_ScheduleOfPromissoryNotesDueLoanTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Schedule of promissory notes due loan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_ScheduleOfPromissoryNotesDueLoanTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NotesPayableAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6UAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Operations (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Revenue</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="num">(839,959)<span></span></td>
        <td class="num">(5,248,669)<span></span></td>
        <td class="num">(667,474)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="num">(12,106,859)<span></span></td>
        <td class="num">(1,525,257)<span></span></td>
        <td class="num">(2,489,235)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="num">(12,946,818)<span></span></td>
        <td class="num">(6,773,926)<span></span></td>
        <td class="num">(3,156,709)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num">(12,946,818)<span></span></td>
        <td class="num">(6,773,926)<span></span></td>
        <td class="num">(3,156,709)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingGainsLossesAbstract', window );"><strong>Other (expenses) income:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Loss on change in fair value of derivative liabilities</a></td>
        <td class="num">(7,954,970)<span></span></td>
        <td class="num">(12,877,675)<span></span></td>
        <td class="num">(3,688,353)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
        <td class="nump">1,411<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">12,753<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
        <td class="num">(435,611)<span></span></td>
        <td class="num">(220,307)<span></span></td>
        <td class="num">(27,721)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other (expenses) income</a></td>
        <td class="num">(8,389,170)<span></span></td>
        <td class="num">(13,097,982)<span></span></td>
        <td class="num">(3,703,321)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (21,335,988)<span></span></td>
        <td class="num">$ (19,871,908)<span></span></td>
        <td class="num">$ (6,860,030)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share - basic and diluted</a></td>
        <td class="num">$ (1.73)<span></span></td>
        <td class="num">$ (8.18)<span></span></td>
        <td class="num">$ (3.17)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding - basic and diluted</a></td>
        <td class="nump">12,332,331<span></span></td>
        <td class="nump">2,429,267<span></span></td>
        <td class="nump">2,166,498<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5618551-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4C<br><br> -Subparagraph (a),(c),(d),(e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624171-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeGainLossOnDerivativeNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeStatementAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InterestExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentIncomeInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndServicesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LicenseAndServicesRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingGainsLossesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingGainsLossesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 9<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>NOTE 6 &#8211; RELATED PARTY TRANSACTIONS</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>Placement Agent</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">On December 6, 2011, the Company entered into an engagement agreement with its placement agent (&#8220;Placement Agent&#8221;) for the Series A Preferred Stock and Notes Offering (collectively the &#8220;Financings&#8221;), of which Mr. Seth, a director of the Company, is also the Head of Healthcare Investment Banking. The agreement was amended on April 12, 2012 and again on February 25, 2013. Pursuant to the agreement, the placement agent was engaged on an exclusive basis for the Series A Preferred Stock and Notes Offering and as a financial advisor for assisting the Company with the restructuring of its capitalization and negotiating the conversion of its outstanding debt obligations to enable a successful financing (the "Notes Conversion"). In consideration for its services, the placement agent received: (a) re-activation fee of $15,000, (b) a cash fee equal to 7% of the Notes Conversion and 10% of the gross proceeds raised in the Financings, and (c) non-accountable expense reimbursement equal to 2% of the gross proceeds raised. The placement agent or its designees also received warrants to purchase shares of the Company&#8217;s common stock in an amount equal to 10% of the shares of common stock and warrants issued or issuable as part of the units sold in the Series A Preferred Stock Offering and Notes Offerings. The agreement also provides that: (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than a Share Exchange in a going public transaction) with any party introduced to it by the placement agent, the placement agent would receive a success fee equal to 8% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the services described above, the Company requires a financing or advisory transaction the placement agent will have the right to act as the Company&#8217;s financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the February 25, 2013 engagement agreement. For a period ending one year after the expiration of all lock-up agreements entered into in connection with the Share Exchange, any change in the size of the Company board of directors must be approved by the placement agent. See Note 3 and 4 on the warrants issued with respect to the Series A Preferred Stock and subordinated promissory notes.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">Due to the Share Exchange, the anti-dilution feature for the warrants that were issued for the Series A Preferred Stock and Notes Offering were terminated, see Note 4. There were Series A warrants, Series B warrants and Placement Agent warrants, see Note 5, common stock. These warrants contain an anti-dilution feature and shall terminate upon an up-listing to a national stock exchange, see Note 4.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">On October 24, 2013, the Company entered into an engagement agreement which was amended December 19, 2013 with its Placement Agent to advise on the acquisition of Medeor Inc. In consideration for its services, the Placement Agent was eligible to receive: (a) a cash success fee equal to 8% of the value of the transaction plus a 2% non-reimbursable expense fee which was subsequently modified to a maximum of $150,000 plus, (b) $50,000 for a Fairness Opinion fee deductible against the success fee, and (c) a $50,000 activation fee. The agreement also provides that: (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than the Share Exchange) with any party introduced to it by the Placement Agent, the placement agent would receive a fee equal to 8% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the advisory services described above, the Company requires a financing or similar advisory transaction the Placement Agent will have the right to act as the Company&#8217;s financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the engagement agreement.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">On February 18, 2014 and May 19, 2014, the Company entered into two engagement agreements with the Placement Agent for the May 2014 offering The Company agreed to pay Placement Agent: (a) a cash commission in the amount of ten percent (10%) of the gross proceeds of the
 Offering received from investors at a Closing as well as a non-accountable expense reimbursement equal to two percent; and (b) (2%) of the gross proceeds of the Offering received from investors at a Closing and an activation fee of $25,000. The Placement Agent or its designees also received five-year warrants to purchase 4,290,950 shares of Relmada&#8217;s common stock at a price of $1.50 per share. The Placement Agent shall also be entitled to the compensation set forth above as well for any cash exercise of Warrants within six (6) months of the final closing of the Offering as well as a five percent (5%) solicitation fee for any Warrants exercised as a result of any redemption of any Warrants. If the Company elects to call the warrants, the Placement Agent shall receive a warrant solicitation fee equal to 5% of the funds solicited by the Placement Agent upon exercise of the warrants. The Company shall pay the Placement Agent a non-refundable financial advisory fee to be paid monthly, at the rate of $25,000 per month for a period of six months commencing after the May offerings.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The Placement Agent also received cash proceeds from the Company of approximately $3,089,500, $554,700 and $470,300, for the six months ended June 30, 2014 and for the year ended December 31, 2013 and 2012, respectively, from the equity offerings in May and June 2014 and from the Series A preferred stock offerings. The Placement Agent received cash proceeds from the Company of $68,400 and $25,100, respectively, for the subordinated promissory notes issued during 2013 and 2012. The Placement Agent also received a strategic advisory fee of approximately $272,000 for restructuring the Company in 2012.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal calibri, helvetica, sans-serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif;">The Placement Agent received the following warrants during the year ended December 31, 2012:</font></p><p style="font: 10pt/normal calibri, helvetica, sans-serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Number of warrants</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Exercise price per share</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Expiration</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 665.33px; text-align: left; font-style: normal; font-weight: normal;">Series A preferred offering</td><td style="width: 10.66px; font-style: normal; font-weight: normal;">&#160;</td><td style="width: 10.66px; text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="width: 94px; text-align: right; font-style: normal; font-weight: normal;">612,422</td><td style="width: 10.66px; text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="width: 10.66px; font-style: normal; font-weight: normal;">&#160;</td><td style="width: 10.66px; text-align: left; font-style: normal; font-weight: normal;">$</td><td style="width: 93.33px; text-align: right; font-style: normal; font-weight: normal;">0.80</td><td style="width: 10px; text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="width: 10px; font-style: normal; font-weight: normal;">&#160;</td><td style="width: 10px; text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="width: 93.33px; text-align: center; font-style: normal; font-weight: normal;">2019</td><td style="width: 10px; text-align: left; font-style: normal; font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">Subordinated promissory note offering</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">33,750</td><td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-weight:
 normal;">$</td><td style="text-align: right; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">0.80</td><td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">2019</td><td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 2.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="padding-bottom: 2.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">646,172</td><td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="padding-bottom: 2.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="padding-bottom: 2.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;">&#160;</td></tr></table><p style="font: 10pt/normal calibri, helvetica, sans-serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal calibri, helvetica, sans-serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif;">The Placement Agent received the following warrants during the year ended December 31, 2013:</font></p><p style="font: 10pt/normal calibri, helvetica, sans-serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1039.33px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: center; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Number of warrants</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: center; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Exercise price per share</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: center; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Expiration</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: center; font-style: normal; font-weight: normal;" colspan="2">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: center; font-style: normal; font-weight: normal;" colspan="2">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: center; font-style: normal; font-weight: normal;" colspan="2">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 665.33px; text-align: left; font-style: normal; font-weight: normal;">Series A preferred offering</td><td style="width: 10.66px; font-style: normal; font-weight: normal;">&#160;</td><td style="width: 10.66px; text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="width: 94px; text-align: right; font-style: normal; font-weight: normal;">637,578</td><td style="width: 10.66px; text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="width: 10.66px; font-style: normal; font-weight: normal;">&#160;</td><td style="width: 10.66px; text-align: left; font-style: normal; font-weight: normal;">$</td><td style="width: 93.33px; text-align: right; font-style: normal; font-weight: normal;">0.80</td><td style="width: 10px; text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="width: 10px; font-style: normal; font-weight: normal;">&#160;</td><td style="width: 10px; text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="width: 93.33px; text-align: center; font-style: normal; font-weight: normal;">2020</td><td style="width: 10px; text-align: left; font-style: normal; font-weight: normal;">&#160;</td></tr><tr style="vertical-align:
 bottom; background-color: white;"><td style="text-align: left; font-style: normal; font-weight: normal;">Subordinated promissory note offering</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">106,875</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">$</td><td style="text-align: right; font-style: normal; font-weight: normal;">0.80</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: center; font-style: normal; font-weight: normal;">2020</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">Acquisition of Medeor</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">200,000</td><td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">$</td><td style="text-align: right; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">1.10</td><td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">2020</td><td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 2.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="padding-bottom: 2.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">944,453</td><td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="padding-bottom: 2.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="padding-bottom: 2.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: center; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: center; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-style: normal; font-weight: normal;" colspan="12"><p style="margin-top: 0px; margin-bottom: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif;">The Placement Agent received the following warrants during the six months ended June 30, 2014:</font></p></td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: center; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: center; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt;
 border-bottom-style: solid;" colspan="2">Number of&#160;<br />warrants</td><td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: center; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Exercise<br />price per&#160;<br />share</td><td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: center; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Expiration</td><td style="text-align: left; padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: center; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 2.5pt; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">May and June 2014 offering</font></td><td style="padding-bottom: 2.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 2pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 2pt; border-bottom-style: double;">4,290,950</td><td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="padding-bottom: 2.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">$</td><td style="text-align: right; font-style: normal; font-weight: normal;">1.50</td><td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="padding-bottom: 2.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: center; font-style: normal; font-weight: normal;">2019</td><td style="text-align: left; padding-bottom: 2.5pt; font-style: normal; font-weight: normal;">&#160;</td></tr></table><p style="font: 10pt/normal calibri, helvetica, sans-serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>Advisory Firm</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">On December 6, 2011, the Company entered into an advisory agreement with Jamess Capital Group, LLC (formerly known as Amerasia Capital Group, LLC), a consulting firm affiliated with Mr. Seth, a Director of the Company (&#8220;Advisory Firm&#8221;) to provide non-investment banking related advisory services. The Advisory Firm is due a monthly fee of $12,500 and the agreement is terminable by either party with three months written notice and is to be issued fully vested warrants to purchase common stock equal to 12% of the fully diluted shares of the Company as of the Share Exchange (exercisable at an exercise price of $0.001 per share), see Note 5. The Advisory Firm is also eligible to be reimbursed upon the submission of proper documentation for ordinary and necessary out-of-pocket expenses not to exceed $5,000 per month.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p
 style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>Acquisition of Medeor</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">In April 2012, the Company (sublicensee) entered into a license agreement with Medeor (licensee) and issued 17,089 shares of stock for the license agreement. The Chief Executive Officer was a shareholder of Medeor. At December 31, 2013, the Company issued 2,500,000 shares of common stock in exchange for all the outstanding stock of Medeor whose only asset was a research and development project. The parties also amended the license agreement on December 31, 2013. The transaction was valued at its fair value of $3,750,000 and was expensed to research and development expense. The fair value of the shares was determined via a third party valuation.&#160;<font style="background-color: white;">The Company will make royalty and a milestone payments as defined in the amended license agreement. The Company (A) will make royalty payments up to 2% on net sales of licensed products that are not sold by sublicensee and (B) on each and every sublicense earned royalty payment received by licensee from its sublicensee on sales of license product by sublicensee, the higher of (i) 20% of the royalties received by licensee; or (ii) up to 2% of net sales of sublicensee. The Company will also make milestone payments of up to $4 million and up to $2 million, for the first commercial sale of product in the field that has a single active pharmaceutical ingredient, and for the first commercial sale of product in the field of product that has more than one active pharmaceutical ingredient, respectively.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph b<br><br> -Article 3A<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Deficit [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' DEFICIT</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>NOTE 5 &#8211; STOCKHOLDERS&#8217; EQUITY</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>Class A Convertible Preferred Stock (&#8220;Class A Stock&#8221;)</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">On May 20, 2014, Relmada Therapeutics, Inc. (&#8220;Relmada&#8221;) completed a Share Exchange with the Company, whereby the Company acquired 94.6% of the issued and outstanding capital stock of Relmada from the stockholders in exchange (&#8220;Share Exchange&#8221;) for the issuance of 28,291,073 shares of common stock to the Company&#8217;s stockholders, which represented 80.9% of Relmada&#8217;s issued and outstanding common stock after the consummation of the Share Exchange. In addition, the outstanding options and warrants were exchanged for options and warrants to purchase shares of common stock of the Company at a ratio of 10 to 1. Prior to the Share Exchange, the Company had no other assets or liabilities. The principal shareholders of the Company contributed $2 million for 3,337,310 shares of the Company&#8217;s common stock and 3,337,309 shares of Class A preferred convertible shares.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The Class A Stock shall has dividend rights to two times the amount of any dividend granted by the Board of Directors of the Company to the holders of common stock. In the event of any dissolution, liquidation or winding up of the Company, whether voluntary or involuntary, the holders of Class A Stock shall be entitled to participate in any distribution out of the assets of the Corporation on an equal basis per share with the holders of the Company&#8217;s common stock. The holders of Class A Stock shall have no right to vote on any matter submitted to a vote of the holders of the Company&#8217;s common stock, including the election of directors.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The Class A Stock is automatically converted on a monthly basis into common stock on a one for one basis by action of the Corporation, in the event the total of all shares of common stock and Class A Stock held by the shareholder do not exceed 9.9% of the issued and outstanding shares of common stock of the company. In no event, can Class A Stock be converted into common stock of the Corporation if such conversion would cause the holder to own, beneficially or otherwise, more than 9.9% of the Company&#8217;s stock.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>Series A Preferred Stock</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">Each share of Series A preferred stock automatically converted into common stock on a one for one basis upon the Share Exchange. There were 1,360,413 shares that were converted to common stock. In addition, the conversion price was subject to adjustment upon a future down round if any future stock offerings are issued below $0.80 per share. This anti-dilution feature for the Series A preferred stock and for the warrants, made these instruments a derivative liability. The anti-dilution feature was terminated upon the Share Exchange. The dividend rate was seven percent (7%) per annum on the amount paid for each Unit of the Series A preferred stock on an &#8220;as declared&#8221; basis. The Board of Directors has not declared any dividends on these shares. Each Series A preferred share had a liquidation value equal to the subscription price of each Series A preferred share plus any accrued and unpaid dividends. The liquidation preference of the Series A preferred stock at December 31, 2013 was approximately $10,883,300.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal;
 -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">In April 2012, the Company exchanged an aggregate of 1,879,128 shares of Series A preferred stock to convert the outstanding notes from the years 2004 and 2005 totaling $975,000 from lenders and accrued interest of approximately $566,180. In addition, the Company provided the lenders with 619,377 warrants to purchase common stock at $0.80 per share, and also allowed the lenders to exercise the warrants on a cashless basis for 541,430 shares of common stock. During 2012, the lenders exercised the warrants on a cashless basis resulting in the issuance of 541,430 shares of common stock. The Company determined that the fair value of the debt and accrued interest was more reliably determined than the fair value of the Series A preferred stock and warrants provided to the lenders and, accordingly, recorded no gain or loss on the exchange.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">In April 2012, the Company issued 1,725,000 Series A preferred stock to Wonpung in exchange for services. The Company recorded compensation expense of approximately $1,305,200 based on the fair value of the Series A preferred stock at the issuance date, and recorded as additional paid-in capital for approximately $1,006,100 and a derivative liability for approximately $299,100. The Company recorded the fair value of the shares issued as stock-based compensation expense of $1,305,200, which was recorded as equity for approximately $1,006,100 and derivative liability for approximately $299,100. The fair value of the shares was determined via a third party valuation, see Note 4. In addition, because the shares contained certain anti-dilution protection, the conversion feature of the preferred stock was accounted for as a derivative liability.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">During 2012, in a series of closings, the Company issued investors 4,899,375 shares of Series A preferred stock and 1,224,844 warrants to purchase shares of common stock with an exercise price of $0.80 per share for gross proceeds of approximately $3,919,500 ($3,220,018 net of offering costs). In addition, the Company issued the placement agent 612,422 warrants to purchase common stock with an exercise price of $0.80 per share. Both the warrants and the Series A preferred stock contain anti-dilution features deemed to be derivatives. The anti-dilution provision was eliminated upon the Share Exchange.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The table below reflects the gross proceeds received in connection with the 2012 offerings allocated to components of stockholders&#8217; equity and to derivative liabilities based upon fair value:</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 1379px; text-align: left; padding-left: 0pt;">Par value of Series A preferred stock issued</td>
<td style="width: 16px;">&#160;</td>
<td style="width: 16px; text-align: left;">$</td>
<td style="width: 141px; text-align: right;">4,898</td>
<td style="width: 15px; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-left: 0pt;">Additional paid-in-capital</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">2,151,040</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; padding-left: 0pt;">Derivative warrant liabilities</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">111,777</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-left: 0pt;">Derivative preferred stock conversion feature</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">872,688</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">Derivative&#160;&#160;Warrants issued to placement agent as offering costs</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">79,615</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-left: 0pt;">Net proceeds</td>
<td>&#160;</td>
<td style="text-align:
 left;">&#160;</td>
<td style="text-align: right;">3,220,018</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">Offering costs paid in cash</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">699,482</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-bottom: 4pt; padding-left: 0pt;">Gross proceeds</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">3,919,500</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">During 2013, in a series of closings, the Company issued investors 5,100,625 shares of Series A preferred stock and 1,275,156 warrants to purchase shares of common stock for proceeds of approximately $4,080,500 ($3,494,428 net of offering costs). The Company also issued the investors 1,275,156 warrants to purchase common stock with an exercise price of $0.80 per share. In addition, the Company issued the placement agent 637,578 warrants to purchase common stock with an exercise price of $0.80 per share. Both the warrants and the Series A preferred stock contain an anti-dilution features deemed to be derivatives, see Note 4.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The table below reflects the gross proceeds received in connection with the 2013 offerings allocated to components of stockholders&#8217; equity and to derivative liabilities based upon fair value:</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 1379px; text-align: left; padding-left: 0pt;">Par value of Series A preferred stock issued</td>
<td style="width: 16px;">&#160;</td>
<td style="width: 16px; text-align: left;">$</td>
<td style="width: 141px; text-align: right;">
<p style="margin: 0px;">5,100</p>
</td>
<td style="width: 15px; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-left: 0pt;">Additional paid-in-capital</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">
<p style="margin: 0px;">1,479,610</p>
</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; padding-left: 0pt;">Derivative warrant liabilities</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">113,153</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-left: 0pt;">Derivative preferred stock conversion feature</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,647,910</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">Derivative Warrants issued to placement agent as offering costs</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">248,655</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-left: 0pt;">Net proceeds</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">3,494,428</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">Offering costs paid in cash</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">586,072</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-bottom: 4pt; padding-left: 0pt;">Gross proceeds</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">4,080,500</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times,
 serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>Common Stock</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><u>Common stock issued in connection with settlement agreements</u></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">In April 2012, the Company issued 255,750 shares of common stock and warrants to purchase 868,213 shares of common stock with an exercise price of $0.80 per share that expire in April 2019 to exchange the outstanding liabilities owed to the founder of approximately $869,300. In addition, the founder forgave excess liabilities of approximately $353,246 and the Company recorded this as a contribution of additional paid-in-capital. On January 29, 2014, the Company cancelled the aforementioned warrants to the founder for failure to perform his fiduciary duties to the Company, see Note 8.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><i>&#160;</i></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><u>Common stock issued for services</u></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">During 2012, an executive was granted 153,802 shares of common stock. The grant date fair value of the common stock was $0.30 per share (based on a third party valuation), or approximately $46,100 in total. The vesting schedule provided that approximately 68,350 shares vested on July 10, 2012, 56,390 shares vested on July 10, 2013 and 29,052 shares vested on January 10, 2014. As a result, the Company recorded stock-based compensation expense of approximately $8,700, $16,900 and $20,500 for the six months ended June 30, 2014 and for the years ended December 31, 2013 and 2012, respectively, in connection with this agreement.&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><u>Common stock issued for cash</u></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">On May 12, May 15 and June 10, 2014, the Company completed on a private placement for the sale of units for gross proceeds of $25,745,699. The units consist of 17,163,799 shares of the Company&#8217;s common stock, Series A warrants to purchase 17,163,799 shares of common stock at an exercise price of $1.50 per share and Series B warrants to purchase 8,581,894 shares of common stock, at a exercise price of $2.25 per share. The Series A Warrants are exercisable immediately through October 10, 2014 and the Series B Warrants are exercisable immediately up to a period of five years from the date of issuance. The Company may call the Series B warrant for redemption upon written notice to all investors of the May and June 2014 units &#160;(&#8220;investors&#8221;) at any time if the closing price of the common stock exceeds $3.75 per share for twenty (20) consecutive trading days provided that there an effective registration statement.&#160;In sixty days (60) business days following the date the redemption notice &#8220;Exercise Period&#8221; that is sent to the investors, each may choose to exercise their Series B warrant or a portion of their Series B warrant, by paying the exercise price of $2.25 per share.&#160;<font style="color: #1f497d;">&#160;</font>Any warrants not exercised on the last day of the Exercise Period, will be redeemed by the Company at $0.001 per share.&#160;&#160;<font style="color:
 #1f497d;">T</font>he Placement Agent shall receive a warrant solicitation fee equal to five (5) % of the aggregate exercise price paid by the Series B holders upon such exercise, following a call for redemption by the Company. &#160;The Company shall direct the Series B holder to make such solicitation fee payment directly to the Placement Agent and the Series B warrant holder shall comply with such direction.&#160;<font style="background-color: white;">The Company issued warrants to purchase 4,290,950 shares of common stock at $1.50 to its Placement Agent (&#8220;Agent Warrants&#8221;). The Agent Warrants are immediately exercisable and expire five years from the date of issuance. The Company paid approximately $3,516,000 including expenses to the Placement Agent and the net proceeds were approximately $22,229,300.&#160;</font>All the warrants in this transaction have an anti-dilution provision and shall terminate upon an up-listing of the Company to a national securities exchange such as NYSE or NASDAQ.&#160;<font style="background-color: white;">A registration rights agreement was entered into in connection with the private placement that required the Company to file a registration statement for the resale of shares of common stock and common stock issuable upon the exercise of the Series A and Series B warrants. The Company was required to use commercially reasonable efforts to have the registration statement declared effective within 45 days from the filing date. If the SEC reviews the registration statement, the Company has 180 days to have the registration statement declared effective. If the registration statement is not filed on time or declared effective within the pre-requisite time frame, the penalty is one percent (1%) up to the purchase price with a maximum penalty of six percent (6%).</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="background-color: white;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The table below reflects the gross proceeds received in connection with the May and June 2014 offerings allocated to components of stockholders&#8217; equity and to derivative liabilities based upon fair value:</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p>
<table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 1379px; font-family: 'times new roman', times, serif;">Par value of common stock issued</td>
<td style="width: 16px; font-family: 'times new roman', times, serif;">&#160;</td>
<td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;">$</td>
<td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif;">17,164</td>
<td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="font-family: 'times new roman', times, serif;">Additional paid-in-capital</td>
<td style="font-family: 'times new roman', times, serif;">&#160;</td>
<td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman', times, serif;">17,878,994</td>
<td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman', times, serif;">Derivative warrant liabilities</td>
<td style="font-family: 'times new roman', times, serif;">&#160;</td>
<td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman', times, serif;">3,337,025</td>
<td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">Derivative warrants issued to placement agent as offering costs</td>
<td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td>
<td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">996,138</td>
<td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">Net proceeds</td>
<td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td>
<td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td>
<td style="text-align: right; font-family: 'times new roman', times, serif;">22,222,321</td>
<td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">Offering costs paid in cash</td>
<td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td>
<td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; font-family:
 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">3,516,378</td>
<td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;">Gross proceeds</td>
<td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td>
<td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">25,745,699</td>
<td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><u>Common stock issued in connection with exercise of warrants</u></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">In April 2012, two lenders exercised their 618,766 warrants on a cashless basis and received 541,293 shares of common stock of the Company.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><u>Common stock issued for acquisition of Medeor</u></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">In April 2012, the Company issued 17,089 shares of common stock to Medeor Inc. (&#8220;Medeor&#8221;) in connection with the acquisition of a license agreement. Management determined the fair value of the common stock to be $0.30 per share based on a third party valuation, and recorded stock-based compensation expense to research and development of approximately $5,100. At December 31, 2013, the Company issued 25,000,000 shares of common stock in exchange for all the outstanding stock of Medeor whose only asset was a pending research and development project. The transaction was valued at its fair value of $3,750,000 and was expensed to research and development expense. The fair value of the shares was determined via a third party valuation.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>Options and warrants</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The Company has established the 2012 Stock Option Plan (the &#8220;Plan&#8221;), which allows for the granting of common stock awards, stock appreciation rights, and incentive and nonqualified stock options to purchase shares of the Company&#8217;s common stock to designated employees, nonemployee directors, and consultants and advisors. The Plan allowed for 2,409,436 options to be granted in July 2012. On March 10, 2014, the Board of Directors increased the shares under the Plan to 4,000,000. The shareholders approved to increase the shares available under the plan to 8,058,844. At June 30, 2014, no stock appreciation rights have been issued. Stock options are exercisable generally for a period of 10 years from the date of grant and generally vest over four years. As of June 30, 2014, 4,693,673 shares were available for future grants under the Plan.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px;
 letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The Company utilizes the Black-Scholes option pricing model to estimate the fair value of stock options and warrants. The current price of common stock was determined from a third party valuation, see Note 4. The risk-free interest rate assumptions were based upon the observed interest rates appropriate for the expected term of the equity instruments. The expected dividend yield was assumed to be zero as the Company has not paid any dividends since its inception and does not anticipate paying dividends in the foreseeable future. The expected volatility was based upon its peer group. The Company routinely reviews its calculation of volatility changes in future volatility, the Company&#8217;s life cycle, its peer group, and other factors.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The Company uses the simplified method for share-based compensation to estimate the expected term for employee option awards for share-based compensation in its option-pricing model. The Company uses the contractual term for non-employee options to estimate the expected term, for share-based compensation in its option-pricing model.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>Stock-based compensation &#8211; options</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The Company granted an officer options to purchase 677,962 and 665,750 shares of its common stock in July 2012 and September 2013, respectively. Each of the options granted have a ten-year term and at an $0.80 exercise price. 25% of each of the options vest immediately and the remaining 75% of the options vest in equal quarterly increments over a four-year period. The fair value of the options as of the grant dates was $103,700 and $359,100, respectively.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">During November 2013, the Company granted a consultant options to purchase 187,500 shares of common stock. The options have a 10 year term and an $0.80 exercise price. 25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal quarterly increments over the following 3 years. The fair value of the options on the grant date was $114,800.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">During December 2013 and January 2014, the Company granted an officer options to purchase 334,199 and 1,003,774 shares of common stock, respectively. The options have a 10 year term and an exercise price of $0.80 and $1.50 per share, respectively. 25% of the options vest on the one anniversary of the grant date and the remaining options vest quarterly over the following 3 years. The fair value of the options on the grant date during December 2013 and January 2014 was $181,400 and $937,600, respectively.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">During February 2014, the Company granted to three of its board of directors, an aggregate of options to purchase 145,986 shares of common stock, respectively. Each option has a 10 year term and an exercise price of $1.50 per share, respectively. 25% of the options vest on the one year anniversary of the grant date and the remaining options vest quarterly over the following 3 years. The fair value of the options on the grant date was approximately $136,200.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent:
 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">During May 2014, the Company granted to its various employees, options to purchase 350,000 shares of common stock, respectively. Each option has a 10 year term and an exercise price of $1.50 per share, respectively. 25% of the options vest on the one year anniversary of the grant date and the remaining options vest quarterly over the following 3 years. The fair value of the options on the grant date was $250,200.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">In May 2014, the Board of Directors granted options to three officers options based upon a percentage of the fully diluted shares that exist after the exercise or forfeiture of the Series A warrants in October 2014. The Company will record stock-based compensation expense at fair value when the options are issued. The option price has been established at fair market value.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">A summary of the changes in options outstanding during the six months ended June 30, 2014 and years ended December 31, 2013 and 2012 is as follows:</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Number of<br />Shares</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Weighted<br />Average<br />Exercise<br />Price<br />Per Share</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Weighted<br />Average<br />Remaining<br />Contractual<br />Term (Years)</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Aggregate<br />Intrinsic<br />Value</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td>Outstanding at December 31, 2011</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="width: 791.93px; text-indent: -8.65pt; padding-left: 17.3pt;">Granted</td>
<td style="width: 16px;">&#160;</td>
<td style="width: 16px; text-align: left;">&#160;</td>
<td style="width: 142px; text-align: right;">677,962</td>
<td style="width: 16px; text-align: left;">&#160;</td>
<td style="width: 16px;">&#160;</td>
<td style="width: 16px; text-align: left;">$</td>
<td style="width: 142px; text-align: right;">0.80</td>
<td style="width: 16px; text-align: left;">&#160;</td>
<td style="width: 15px;">&#160;</td>
<td style="width: 15px; text-align: left;">&#160;</td>
<td style="width: 141px; text-align: right;">-</td>
<td style="width: 15px; text-align: left;">&#160;</td>
<td style="width: 15px;">&#160;</td>
<td style="width: 15px; text-align: left;">$</td>
<td style="width: 141px; text-align: right;">-</td>
<td style="width: 15px; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left;">Outstanding and expected to vest at December 31, 2012</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">677,962</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">0.80</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">9.5</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-indent: -8.65pt; padding-left: 17.3pt;">Granted</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,187,449</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">0.80</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">-</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color:
 #cceeff;">
<td style="text-align: left;">Outstanding and expected to vest at December 31, 2013</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1,865,411</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">0.80</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">8.8</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">1,305,000</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-bottom: 1.5pt;">&#160;&#160;&#160;Granted</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">1,499,760</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">1.50</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">9.7</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">3,000,000</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; padding-bottom: 4pt;">Outstanding and expected to vest at June 30, 2014&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">3,365,171</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1.11</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">8.9</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">5,238,000</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-bottom: 4pt;">Options exercisable at June 30, 2014</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">652,005</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">0.80</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">9.0</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">782,400</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">For the six months ended June 30, 2014 and for years ending December 31, 2013 and 2012, the Company recorded approximately $115,500, $4,800 and $0, respectively, of stock-based compensation expense to research and development expense. For the six months ended and for years ending December 31, 2013 and 2012, the Company recorded approximately $77,700, $129,600 and $35,100, respectively, of stock based compensation expense to general and administrative expense. At June 30, 2014, and December 31, 2013 and 2012, the Company has unrecognized stock based compensation expense of approximately $1,760,900, $589,500 and $0 related to stock options, respectively.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space:
 normal; -webkit-text-stroke-width: 0px;">The weighted average fair value of options granted during the six months ended June 30, 2014 and for the years ended December 31, 2013 and 2012 was approximately $0.72, $0.58 per share and $0.15 per share respectively, on the date of grant using the Black-Scholes option pricing model with the following assumptions:</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; padding-bottom: 1.5pt;" colspan="2">Six Month<br />Ended&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">For the Years Ended<br />December 31,</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">June 30, 2014</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2012</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
<td>&#160;</td>
<td style="text-align: center;" colspan="2">&#160;</td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 1003px;">Current price of common stock</td>
<td style="width: 16px;">&#160;</td>
<td style="width: 16px; text-align: left;">$</td>
<td style="width: 142px; text-align: right;">2.00</td>
<td style="width: 16px; text-align: left;">&#160;</td>
<td style="width: 16px;">&#160;</td>
<td style="width: 16px; text-align: left;">$</td>
<td style="width: 141px; text-align: right;">0.80</td>
<td style="width: 15px; text-align: left;">&#160;</td>
<td style="width: 15px;">&#160;</td>
<td style="width: 15px; text-align: left;">$</td>
<td style="width: 141px; text-align: right;">0.30</td>
<td style="width: 15px; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">Risk free interest rate</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.5% to 1.6</td>
<td style="text-align: left;">%</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">1.4</td>
<td style="text-align: left;">%</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.6</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left;">Dividend yield</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0</td>
<td style="text-align: left;">%</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0</td>
<td style="text-align: left;">%</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>Volatility</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;76% to 77</td>
<td style="text-align: left;">%</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">73% to 80</td>
<td style="text-align: left;">%</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">82</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left;">Expected term (in years)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">6.25</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">5.75 to 10</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">5.75</td>
<td style="text-align: left;">&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>Stock-based compensation &#8211; warrants</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">In connection with the Series A preferred stock offerings, during 2013 and 2012, the Company issued the investors
 1,275,156 and 1,224,845 warrants, respectively, to purchase common stock of the Company, exercisable at $0.80 per share. During 2013 and 2012, the Company also issued the Placement Agent 637,578 and 612,422 warrants, respectively to purchase common stock exercisable at $0.80 per share. The warrants have a seven-year term. These warrants contain anti-dilution features with down-round protection, thus the Company accounts for these warrants as derivative liabilities.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">In connection with the debt offerings in 2013 and 2012, the Company issued debt holders 213,750 and 67,500 warrants, respectively, to purchase common stock of the Company, exercisable at $0.80 per share. During 2013 and 2012, the Company also issued the placement agent 106,875 and 33,750 warrants, respectively to purchase common stock exercisable at $0.80 per share. The warrants have a seven-year term. These warrants contain anti-dilution features with down-round protection, thus the Company accounts for these warrants as derivative liabilities. The anti-dilution feature was been eliminated upon the Share Exchange.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">During 2012, warrant holders exercised 619,377 warrants to purchase common stock in a cashless exercise which resulted in the issuance of 541,430 shares of common stock.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">During 2012, the Company issued its founder 868,213 warrants to purchase common stock in connection with a transaction that exchanged debt for stock. These warrants were cancelled by the Company in January 2014, see Note 8.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">In 2013, the Company purchased Medeor Inc. and in connection with the purchase the Company issued the Placement Agent 200,000 warrants to purchase common stock of the Company. The warrants have a seven-year term and were fully vested upon issuance and have an exercise price of $1.10 per share. The Company recorded stock-based compensation of $237,400 in connection with the issuance of these warrants.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">In conjunction with a strategic advisor agreement, during 2013 and 2012, the Company issued warrants to purchase shares of common stock, at an exercise price of $0.001 per share that expires in seven years. The warrants have performance based requirements for vesting and will become fully vested upon completion of a public transaction. The Company has not recorded any stock based compensation expense prior to the Share Exchange since the performance requirements were not met. During the six months ended June 30, 2014, the performance achievement was met. The Company recorded the fair value of stock based compensation expense of approximately $10,119,000 based upon the Black-Scholes option pricing model for the 8,655,783 vested options.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">During the six months ended June 30, 2014 and for the years ended December 31, 2013 and 2012, the Company issued to consultants 12,500, 21,500 and 40,000 warrants, respectively, to purchase shares of common stock of the Company. The exercise price of the warrants issued during the years ended December 31, 2013 and 2012 were all at $0.80 per share. The grant date fair value of the warrants issued for the six months ended June 30, 2014 and for the years ended December, 31, 2013 and 2012 was approximately $14,300, $10,800 and $5,600, respectively, and the fair value was amortized over the term of the agreements.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal;
 -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">A summary of the changes in outstanding warrants during the six months ended June 30, 2014 and for the years ended December 31, 2013 and 2012 is as follows:</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td>&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Number of<br />Shares</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Weighted<br />Average<br />Exercise<br />Price<br />Per Share</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 1191px;">Outstanding at December 31, 2011</td>
<td style="width: 16px;">&#160;</td>
<td style="width: 16px; text-align: left;">&#160;</td>
<td style="width: 142px; text-align: right;">6,251</td>
<td style="width: 16px; text-align: left;">&#160;</td>
<td style="width: 15px;">&#160;</td>
<td style="width: 15px; text-align: left;">$</td>
<td style="width: 141px; text-align: right;">1.00</td>
<td style="width: 15px; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>Granted</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">5,478,360</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">0.50</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="padding-bottom: 1.5pt;">Exercised</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(619,377</td>
<td style="text-align: left; padding-bottom: 1.5pt;">)</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">0.80</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>Outstanding at December 31, 2012</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">4,865,234</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">&#160;</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="padding-bottom: 1.5pt;">Granted</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">4,061,283</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">0.54</td>
<td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td>Outstanding at December 31, 2013</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">8,926,517</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">0.54</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td>Granted</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">35,086,253</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">1.58</td>
<td style="text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="padding-bottom: 4pt;">Forfeited (1)</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(868,213</td>
<td style="text-align: left; padding-bottom: 4pt;">)</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">0.80</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; padding-bottom: 4pt;">Outstanding and vested at June 30, 2014</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td>
<td style="text-align: right;
 border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">43,144,557</td>
<td style="text-align: left; padding-bottom: 4pt;">&#160;</td>
<td style="padding-bottom: 4pt;">&#160;</td>
<td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td>
<td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1.25</td>
<td style="text-align: left; padding-bottom: 4pt;"></td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">For the six months ended June 30, 2014 and for the years ending December 31, 2013 and 2012, the Company recorded approximately $0, $1,800 and $2,200, respectively, of stock-based compensation expense related to warrants to research and development expense. For the six months ended June 30, 2014 and for the years ending December 31, 2013 and 2012, the Company recorded to general and administrative expense approximately $12,124,500, $246,100 and $0 of stock-based compensation expense related to warrants for the six months ended June 30, 2014 and for the years ended December 31, 2013 and 2012, respectively. At June 30, 2014 and December 31, 2013 and 2012, the Company has unrecognized stock based compensation expense of approximately $6,500, $3,600 and $3,400, respectively related to outstanding warrants.</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: top;">
<td style="width: 63px;">(1)</td>
<td style="width: 1504px; text-align: justify;">
<p style="margin: 0px;">The warrants issued to Mr. Babul were cancelled on January 29, 2014, see Note 8.</p>
</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The weighted average fair value of warrants granted during the six months ended June 30, 2014 and for the years ended December 31, 2013 and 2012 was $1.40, $0.80 and $0.14 per share, respectively, on the date of grant, using the Black-Scholes option pricing model using the following assumptions:</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0">
<tr style="vertical-align: bottom;">
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; padding-bottom: 1.5pt;" colspan="2">
<p style="margin-top: 0px; margin-bottom: 0px;">Six Month&#160;<br />Ended,</p>
<p style="margin-top: 0px; margin-bottom: 0px;">June 30,</p>
</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">Year Ended December 31,</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
<td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2012</td>
<td style="padding-bottom: 1.5pt;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="width: 1003px;">Current price of common stock</td>
<td style="width: 16px;">&#160;</td>
<td style="width: 16px; text-align: left;">$</td>
<td style="width: 142px; text-align: right;">2.00</td>
<td style="width: 16px; text-align: left;">&#160;</td>
<td style="width: 16px;">&#160;</td>
<td style="width: 16px; text-align: left;">&#160;</td>
<td style="width: 141px; text-align: right;">$0.80 - $1.50</td>
<td style="width: 15px; text-align: left;">&#160;</td>
<td style="width: 15px;">&#160;</td>
<td style="width: 15px; text-align: left;">$</td>
<td style="width: 141px; text-align: right;">0.30</td>
<td style="width: 15px; text-align: left;">&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">Risk-free interest rate</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.7% to 2.0</td>
<td style="text-align: left;">%</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.9% to 1.8</td>
<td style="text-align:
 left;">%</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0.6% to .7</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left;">Dividend yield</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0</td>
<td style="text-align: left;">%</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0</td>
<td style="text-align: left;">%</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">0</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left;">Expected volatility</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">75% to 76</td>
<td style="text-align: left;">%</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">73% to&#160;83</td>
<td style="text-align: left;">%</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">82% to 83</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left;">Expected term (in years)</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">4 and 7</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">4-7</td>
<td style="text-align: left;">&#160;</td>
<td>&#160;</td>
<td style="text-align: left;">&#160;</td>
<td style="text-align: right;">5</td>
<td style="text-align: left;">&#160;</td>
</tr>
</table>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitment and Contingencies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum lease payments</a></td>
        <td class="text"><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"></p><table align="center" style="font: 10pt/normal times new roman, times, serif; width: 80%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Year</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Amount</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">&#160;</td><td style="text-align: left;">2015</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">37,300</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 1%; text-align: left;">&#160;</td><td style="width: 50%; text-align: left;">2016</td><td style="width: 1%;">&#160;</td><td style="width: 1%; text-align: left;"></td><td style="width: 9%; text-align: right;">38,000</td><td style="width: 1%; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">&#160;</td><td style="text-align: left;">2017</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">38,800</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt;">2018</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">9,700</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="text-align: left; padding-bottom: 4pt;">Total</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">127,800</td><td style="text-align: left; padding-bottom: 4pt;"></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivative Liabilities (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Laibilities [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ScheduleOfDerivativeLiabilitiesValuationsModelsTableTextBlock', window );">Schedule of Derivative Liabilities Valuations Models</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Initial</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">At</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">valuation</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">June 30</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1129px; text-align: left;">Common stock issuable upon exercise of warrants &#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 173px; text-align: right;">30,036,648</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 172px; text-align: right;">30,036,648</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Market value of common stock on measurement date (1)</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">1.17</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">2.00</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Exercise price</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;"><font style="font: 10pt/normal 'times new roman', times, serif;">1.50 and 2.25</font></td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;"><font style="font: 10pt/normal 'times new roman', times, serif;">1.50 and 2.25</font></td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Risk free interest rate (2)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.7</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.6</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Expected life in years</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;0.3 and 5</font></td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;"><font style="font: 10pt/normal 'times new roman', times, serif;">0.3 and 4.9</font></td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Expected volatility (3)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;71 and 73</font></td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;&#160;71 and 73&#160;</font></td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Expected dividend yields (4)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">None</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">None</td><td style="text-align: left;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 55.81px; padding-right: 5.4pt; padding-left: 0pt;">(1)</td><td style="width: 1496.81px; padding-right: 5.4pt; padding-left: 0pt;">The market value is the calculated fair value of the common stock pursuant to the valuation technique as described above.</td></tr><tr style="vertical-align: top;"><td style="padding-right: 5.4pt; padding-left: 0pt;">(2)</td><td style="padding-right: 5.4pt; padding-left: 0pt;">The risk-free interest rate was determined by management using the 1<font style="font: 10pt/normal 'times new roman', times, serif;">&#160;and 5 - year Treasury Bill as of the measurement date.</font></td></tr><tr style="vertical-align: top;"><td style="padding-right: 5.4pt; padding-left: 0pt;">(3)</td><td style="padding-right: 5.4pt; padding-left: 0pt;">The historical trading volatility was determined by calculating the volatility of the Company&#8217;s peer group.</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal;
 -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Initial</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Initial</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">At</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">At</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">valuations</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">valuations</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">December&#160;31,</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">December&#160;31,</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2012</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2012</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left;">Common stock issuable upon exercise of warrants</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">22,333,593</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">19,385,157</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">41,718,750</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">19,385,157</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -5.5pt; padding-left: 5.5pt;">Common stock issuable upon conversion of Series A preferred stock</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">51,006,250</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">85,035,025</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">136,041,275</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">85,035,025</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -5.5pt; padding-left: 5.5pt;">Market value of common stock on measurement date (1)</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">0.80</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">0.30</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">1.50</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">0.80</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>Exercise price</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">0.80</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">0.80</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">0.80</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">0.80</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Risk free interest rate (2)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0.19</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0.20</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0.38</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0.19</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Expected life in years</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.4</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.6</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2.0</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.4</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Expected volatility (3)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td
 style="text-align: right;">68</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">72</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">68</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">73</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Expected dividend yields (4)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">None</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">None</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">None</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">None</td><td style="text-align: left;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 55.81px; padding-right: 5.4pt; padding-left: 0pt;">(1)</td><td style="width: 1489.62px; padding-right: 5.4pt; padding-left: 5.4pt;">The market value is the calculated fair value of the common stock pursuant to the valuation technique as described above.</td></tr><tr style="vertical-align: top;"><td style="padding-right: 5.4pt; padding-left: 0pt;">(2)</td><td style="padding-right: 5.4pt; padding-left: 5.4pt;">The risk-free interest rate was determined by management using the 1, 2 or 3 - year Treasury Bill as of the measurement date.</td></tr><tr style="vertical-align: top;"><td style="padding-right: 5.4pt; padding-left: 0pt;">(3)</td><td style="padding-right: 5.4pt; padding-left: 5.4pt;">The historical trading volatility was determined by calculating the volatility of the Company&#8217;s peer group.</td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Derivative Liabilities at Fair Value</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 8pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif;">Balance at December&#160;31,</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif;">Initial valuation of derivative</font><font style="font: 10pt/normal 'times new roman', times, serif;"><br /><font style="font-style: normal; font-variant: normal; font-weight: normal;">liabilities upon</font></font><font style="font: 10pt/normal 'times new roman', times, serif;"><br /><font style="font-style: normal; font-variant: normal; font-weight: normal;">issuance of new warrants during&#160;</font></font><font style="font: 10pt/normal 'times new roman', times, serif;"><br /><font style="font-style: normal; font-variant: normal; font-weight: normal;">the</font></font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif;">Increase (decrease) in fair value of derivative</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif;">Fair value of</font><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;derivatives<font style="font-style: normal; font-variant: normal; font-weight: normal;">&#160;<br />upon reclass to additional paid-in</font></font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif;">Balance at&#160;</font><font style="font: 10pt/normal 'times new roman', times, serif;"><br /><font style="font-style: normal; font-variant: normal; font-weight: normal;">June 30,</font></font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif;">2013</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif;">period</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif;">liabilities</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font: 10pt/normal 'times
 new roman', times, serif;">capital</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif;">2014</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px 0px 0px 10px; text-indent: -10px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">Convertible preferred derivative liability issued in&#160;connection with Series A preferred stock offering</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">$</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">11,762,115</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">$</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">$</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">(7,214,804</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">)&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">$</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">(4,547,311</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">)&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">$</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding: 0px 0px 0px 10px; width: 617px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">Convertible preferred derivative liability issued to Wonpung for services</font></td><td style="padding: 0px; width: 16px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; width: 16px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; width: 142px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">2,030,589</font></td><td style="padding: 0px; width: 16px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; width: 16px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; width: 16px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; width: 142px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-&#160;</font></td><td style="padding: 0px; width: 16px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; width: 16px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; width: 16px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times,
 serif;">&#160;</font></td><td style="padding: 0px; width: 141px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">(1,370,262</font></td><td style="padding: 0px; width: 15px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">)</font></td><td style="padding: 0px; width: 15px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; width: 15px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; width: 141px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">(660,327</font></td><td style="padding: 0px; width: 15px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">)</font></td><td style="padding: 0px; width: 15px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; width: 15px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; width: 141px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; width: 15px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">Convertible preferred derivative liability issued to lenders in connection with exchange of debt for Series A preferred stock</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">2,219,854</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">(1,262,858</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">)</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">(956,996</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">)</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">Warrants issued in connection with Series A preferred stock offering</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">2,424,167</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal
 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">(1,945,669</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">)</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">(478,498</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">)</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">Warrants issued as offering costs to placement agent</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">1,217,083</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">(1,109,421</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">)</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">(107,662</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">)</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding: 0px 0px 0px 10px;
 text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">Warrants issued to lenders in connection with subordinated promissory notes offering</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">313,258</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">(259,427</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">)</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">(53,831</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">)</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">Warrants issued to placement agent in connection with subordinated promissory notes offering</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">136,359</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">(136,359</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">)</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style:
 normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">Series A warrants issued in May and June 2014 offering</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">842,370</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">9,198,452</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">10,040,822</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">Series B warrants issued in connection with May and June 2014 offering</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">2,494,655</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style:
 normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">7,400,275</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">9,894,930</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">Placement Agent warrants issued in connection with May and June 2014 offering</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font: 10pt/normal 'times new roman', times, serif;">996,138</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font: 10pt/normal 'times new roman', times, serif;">4,655,043</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font: 10pt/normal 'times new roman', times, serif;">5,651,181</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">Total</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px;
 text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif;">$</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif;">20,103,425</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif;">$</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif;">4,333,163</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif;">$</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif;">7,954,970</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif;">$</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif;">(6,804,625</font></td><td style="padding: 0px 0px 4px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">)</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif;">$</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif;">25,586,933</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td></tr></table><p style="font: 13px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 13px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Initial valuation</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: center;">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">of derivative</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: center;">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">liabilities upon</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2"></td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: center;">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Balance at</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">issuance of new derivatives</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Increase in fair value of</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Balance at</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: center;">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">December
 31,</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">during</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">derivative</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">December 31,</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: center;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2012</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">the period</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">liabilities</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 802.93px; text-align: left; text-indent: -9.05pt; padding-left: 9.05pt;">Convertible preferred derivative liability issued in connection with Series A preferred stock offering</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">2,492,166</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">1,647,910</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">7,622,039</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">11,762,115</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt;">Convertible preferred derivative liability issued to Wonpung for services</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">880,214</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,150,375</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,030,589</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt;">Convertible preferred derivative liability issued to lenders in connection with exchange of debt for Series A preferred stock</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">958,861</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,260,993</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,219,854</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt;">Warrants issued in connection with Series A preferred stock offering</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">475,000</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">113,153</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,836,014</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,424,167</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -9pt; padding-left: 9.05pt;">Warrants issued as offering costs to placement agent</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">242,500</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">248,655</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">725,928</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,217,083</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt;">Warrants issued to lenders in connection with subordinated promissory notes offering</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">29,158</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">83,363</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">200,737</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">313,258</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td
 style="text-align: left; text-indent: -9.05pt; padding-bottom: 1.5pt; padding-left: 9.05pt;">Warrants issued to placement agent in connection with subordinated promissory notes offering</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">13,089</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">41,681</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">81,589</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">136,359</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt;">Total</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">5,090,988</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,134,762</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">12,877,675</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">20,103,425</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.2in; color: #000000; text-transform: none; text-indent: -0.2in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Initial valuation</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">of derivative</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">liabilities upon</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Balance at</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">liabilities upon issuance of new&#160;<br />derivatives</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Increase&#160;in fair value of</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Balance at</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">December 31,</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">during</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">derivative</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">December 31,</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: center; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2011</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: center; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">the period</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: center; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">liabilities</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight:
 normal;">&#160;</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: center; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2012</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 802.93px; text-align: left; text-indent: -9.05pt; padding-left: 9.05pt; font-style: normal; font-weight: normal;">Convertible preferred derivative liability issued in connection with Series A preferred stock offering</td><td style="width: 16px; font-style: normal; font-weight: normal;">&#160;</td><td style="width: 16px; text-align: left; font-style: normal; font-weight: normal;">$</td><td style="width: 142px; text-align: right; font-style: normal; font-weight: normal;">-</td><td style="width: 16px; text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="width: 16px; font-style: normal; font-weight: normal;">&#160;</td><td style="width: 16px; text-align: left; font-style: normal; font-weight: normal;">$</td><td style="width: 142px; text-align: right; font-style: normal; font-weight: normal;">872,688</td><td style="width: 16px; text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="width: 15px; font-style: normal; font-weight: normal;">&#160;</td><td style="width: 15px; text-align: left; font-style: normal; font-weight: normal;">$</td><td style="width: 141px; text-align: right; font-style: normal; font-weight: normal;">1,619,478</td><td style="width: 15px; text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="width: 15px; font-style: normal; font-weight: normal;">&#160;</td><td style="width: 15px; text-align: left; font-style: normal; font-weight: normal;">$</td><td style="width: 141px; text-align: right; font-style: normal; font-weight: normal;">2,492,166</td><td style="width: 15px; text-align: left; font-style: normal; font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt; font-style: normal; font-weight: normal;">Convertible preferred derivative liability issued to Wonpung for services</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">299,141</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">581,073</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">880,214</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt; font-style: normal; font-weight: normal;">Convertible preferred derivative liability issued to lenders in connection with exchange of debt for Series A preferred stock</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">-</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">958,861</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">958,861</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt; font-style: normal; font-weight: normal;">Warrants issued in connection with Series A preferred stock offering</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">-</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">111,777</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">363,223</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">475,000</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt; font-style: normal; font-weight: normal;">Warrants issued as offering costs to placement agent</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td
 style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">79,615</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">162,885</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">242,500</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt; font-style: normal; font-weight: normal;">Warrants issued to lenders in connection with subordinated promissory notes offering</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">-</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">26,325</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">2,833</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">29,158</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -9.05pt; padding-bottom: 1.5pt; padding-left: 9.05pt; font-style: normal; font-weight: normal;">Warrants issued to placement agent in connection with subordinated promissory notes offering</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">13,089</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">13,089</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">-</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,402,635</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">3,688,353</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">5,090,988</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_ScheduleOfDerivativeLiabilitiesValuationsModelsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Schedule Of Derivative Liabilities Valuations Models.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_ScheduleOfDerivativeLiabilitiesValuationsModelsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of derivative liabilities at fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify;"><b>NOTE 9 &#8211; SUBSEQUENT EVENTS</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left;">On July 18, 2014, the Company entered into an agreement with a consultant for investor communication and public relations for one year. The consultant shall receive an upfront cash fee of $250,000 and $250,000 quarterly cash installments commencing in September 2014. In addition, the Company shall issue 250,000 shares of the Company&#8217;s within fifteen (15) days of the agreement and the remaining 250,000 shares shall be issued in six monthly installments commencing in September 2014.</p><p></p><p></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>NOTE 7 &#8211; INCOME TAXES</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">No provision or benefit for federal or state income taxes has been recorded because the Company has incurred net losses for all periods presented and has provided a valuation allowance against its deferred tax assets.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The components of the Company&#8217;s deferred tax assets are as follows at:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center;">&#160;</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">June 30,&#160;<br />2014</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">December 31,<br />2013</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-family: 'times new roman', times, serif;">Deferred tax assets:</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1177.67px; text-align: left; padding-left: 10pt; font-family: 'times new roman', times, serif;">Net operating loss</td><td style="width: 16px; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;">$</td><td style="width: 142px; text-align: right; font-family: 'times new roman', times, serif;">3,556,600</td><td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 15px; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;">$</td><td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif;">2,765,600</td><td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 10pt; font-family: 'times new roman', times, serif;">Stock based compensation</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif;">4,248,700</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif;">-</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-left: 10pt; font-family: 'times new roman', times, serif;">Research and development tax credits</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif;">197,700</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif;">436,300</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-left: 10pt; font-family: 'times new roman', times, serif;">Accruals</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif;">22,900</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif;">44,700</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td
 style="padding-left: 10pt; font-family: 'times new roman', times, serif;">Other</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif;">2,900</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif;">46,000</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">Valuation allowance</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(8,028,800</td><td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">)</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(3,292,600</td><td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;">Total</td><td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">-</td><td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">-</td><td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The Company has maintained a full valuation allowance against its deferred tax at June 30, 2014 and December 31, 2013. A valuation allowance is required to be recorded when it is more likely than not that some portion or all of the net deferred tax assets will not be realized. Since the Company cannot be assured of realizing the net deferred tax asset, a full valuation allowance has been provided.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">At June 30, 2014, the Company had federal and state net operating loss carryforwards of approximately $8,762,000, which begin expiring in 2025. The Company also had federal research and development tax credit carryforwards of approximately $197,700 which will begin to expire in 2025. The United States Tax Reform Act of 1986 contains provisions that may limit the Company&#8217;s net operating loss carryforwards available to be used in any given year in the event of significant changes in the ownership interests of significant stockholders, as defined. The effect of an ownership change would be the imposition of an annual limitation on the use of NOL carryforwards attributable to periods before the change. The amount of the annual limitation depends upon the value of the Company immediately before the change, changes to the Company&#8217;s capital during a specified period prior to the change, and the federal published interest rate.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">A reconciliation of the statutory tax rate to the effective tax rate is as follows:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: normal; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform:
 none; text-indent: 0px; letter-spacing: normal; word-spacing: normal; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; vertical-align: bottom;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; letter-spacing: normal; word-spacing: normal;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">Six Month Ended June&#160;30,</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">Year Ended December,</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; vertical-align: bottom;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">2014</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">2013</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">2012</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; vertical-align: bottom;"><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal;
 word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 1003px; text-align: left; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">Statutory federal income tax rate</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 142px; text-align: right; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">34</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">%</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">34</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">%</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">34</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">%</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">State (net of federal benefit)</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">6.6</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">%</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">6.6</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">%</font></td><td style="font: 10pt/normal 'times new roman', times, serif;
 letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">6.6</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">%</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -8.65pt; letter-spacing: normal; padding-left: 8.65pt; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">Non-deductible expenses</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;"><p style="margin: 0px;">(13.1</p></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">)%</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">(29.7</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">)%</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">(18.8</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">)%</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-indent: -8.65pt; letter-spacing: normal; padding-left: 8.65pt; word-spacing: normal;">Other</td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;"><p style="margin: 0px;">(2.3</p></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;">)%</td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;">&#160;</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal;">-</td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal;">&#160;</td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">Change in valuation allowance</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td
 style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><p style="margin: 0px;">(25.2</p></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">)%</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">(10.9</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">)%</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">(21.8</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; padding-bottom: 1.5pt; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">)%</font></td></tr><tr style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal; vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; padding-bottom: 4pt; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">Effective income tax rate</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 4pt; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">0</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; padding-bottom: 4pt; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">%</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 4pt; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">0</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; padding-bottom: 4pt; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">%</font></td><td style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; padding-bottom: 4pt; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; letter-spacing: normal; word-spacing: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font:
 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">0</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; letter-spacing: normal; padding-bottom: 4pt; word-spacing: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">%</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: normal; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: normal; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; letter-spacing: normal; word-spacing: normal;">The Company has no uncertain tax positions at June 30, 2014 and December 31, 2013 that would affect its effective tax rate. The Company does not anticipate a significant change in the amount of unrecognized tax benefits over the next twelve months. Because the Company is in a loss carryforward position, the Company is generally subject to US federal and state income tax examinations by tax authorities for all years for which a loss carryforward is available. If and when applicable, the Company will recognize interest and penalties as part of income tax expense.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitment and Contingencies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
        <td class="text"><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"><b>NOTE 8 &#8211; COMMITMENTS AND CONTINGENCIES</b></p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;">&#160;</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"><b>License Agreements</b></p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;">&#160;</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;">Wonpung</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;">&#160;</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"></p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"></p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;">On August 20, 2007, the Company entered into a License Development and Commercialization Agreement with Wonpung, a shareholder of the Company. Wonpung has exclusive territorial rights in countries it selects in Asia to market up to two drugs the Company is currently developing and a right of first refusal (&#8220;ROFR&#8221;) for up to an additional five drugs that the Company may develop in the future as defined in more detail in the license agreement.</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; text-indent: 0.5in; font-size-adjust: none; font-stretch: normal;">&#160;</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;">The Company received an upfront license fee of $1,500,000 and will earn royalties of up to 12% of net sales for up to two licensed products it is currently developing. The licensing terms for the ROFR products are subject to future negotiations and binding arbitration. The terms of each licensing agreement will expire on the earlier of any time from 15 years to 20 years after licensing or on the date of commercial availability of a generic product to such licensed product in the licensed territory. The Company&#8217;s current focus is on developing and marketing its products in the United States and not Asia. It will be several years before the Company markets its products in Asia.</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"></p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;">&#160;</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;">Third Party Licensor</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;">&#160;</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"></p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"></p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"></p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"><font style="background-color: white;">Based upon the Medeor transaction, the Company assumed an obligation to pay a third party (A) royalty payments up to 2% on net sales of licensed products that are not sold by sublicensee and (B) on each and every sublicense earned royalty payment received by licensee from its sublicensee on sales of license product by sublicensee, the higher of (i) 20% of the royalties received by licensee; or (ii) up to 2% of net sales of sublicensee. The Company will also make milestone payments of up to $4 million and up to $2 million, for the first commercial sale of product in the field that has a single active pharmaceutical ingredient, and for the first commercial sale of product in the field of product that has more than one active pharmaceutical ingredient, respectively, see Note 6.</font></p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"></p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"><font style="background-color: white;"><i>&#160;</i></font></p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"><b>Leases</b></p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;">&#160;</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;">The Company currently leases its corporate office space for its New York City on a month-to month basis. The Company has a non-cancelable operating lease expiring in 2017 for its Pennsylvania office location. Future minimum lease payments are as follows:</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;">&#160;</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;">For the year ended June 30,:</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;">&#160;</p><table align="center" style="font: 10pt/normal times new roman, times, serif; width: 80%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Year</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Amount</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">&#160;</td><td style="text-align: left;">2015</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">37,300</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 1%; text-align: left;">&#160;</td><td style="width: 50%; text-align: left;">2016</td><td style="width: 1%;">&#160;</td><td style="width: 1%; text-align: left;"></td><td style="width: 9%; text-align:
 right;">38,000</td><td style="width: 1%; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">&#160;</td><td style="text-align: left;">2017</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">38,800</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; padding-bottom: 1.5pt;">2018</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">9,700</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="text-align: left; padding-bottom: 4pt;">Total</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">127,800</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;">&#160;</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"></p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; text-align: left; font-size-adjust: none; font-stretch: normal;">The Company incurred rent expense of approximately $67,800 and $64,600 for years ended December 31,&#160;2013 and 2012, respectively, and approximately $13,300 for the six months ended June 30, 2014.</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"></p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;">&#160;</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"><b>Legal</b></p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"><b></b>&#160;</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"></p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"></p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"><b>The Pennsylvania Litigation:&#160;&#160;</b>Relmada has sued its former President and Chief Scientific Officer, Najib Babul, in the United States District Court for the Eastern District of Pennsylvania.&#160;&#160;Mr. Babul resigned from his executive positions in September 2012 and was later removed from Relmada&#8217;s board of directors.&#160;&#160;The Complaint alleges that, during the course of an audit, Relmada discovered approximately $1.5 million in questionable expenses incurred by Mr. Babul during his management of the company from 2004 until his resignation in 2012 (the &#8220;Questionable Expenses&#8221;). Outside the lawsuit, Relmada has also cancelled warrants to purchase 868,213 common stock (the &#8220;Cancelled Warrants&#8221;) on the grounds, among others, that Babul could not and did not satisfy the conditions for holding or exercising the warrants after his voluntary resignation from the Company.&#160;&#160;The Company also has not exchanged Mr. Babul&#8217;s equity in Relmada for Company common stock pursuant to the Share Exchange that closed on May 20, 2014.&#160;&#160;Mr. Babul has answered the complaint, denying any liability, and has filed a counterclaim seeking specific performance and reinstatement of the Warrants, as well as compensatory damages and other relief.</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"></p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; text-indent: 0.5in; font-size-adjust: none; font-stretch: normal;">&#160;</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"><b>The Delaware Litigation:&#160;&#160;</b>After the Pennsylvania Litigation was brought against him, Mr. Babul brought an action in the Court of Chancery Delaware (the state in which Relmada is incorporated), demanding that Relmada advance his litigation expenses in the Delaware and Pennsylvania Litigation pursuant to, among other things, a Delaware Statute that requires a corporation to advance the reasonable litigation expenses of a former officer or director who is a party to litigation by reason of that relationship, and the Court ordered Relmada to advance such expenses.&#160;&#160;Depending upon the outcome of that litigation, Relmada may or may not be entitled to be reimbursed for the advanced expenses, but there can be no assurance that, even if Relmada prevails, Mr. Babul will be able to repay Relmada.</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; text-indent: 0.5in; font-size-adjust: none; font-stretch: normal;">&#160;</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;"><b>Other Potential Litigation:&#160;&#160;</b>In addition to the aforementioned disputes, Relmada has been informed that Mr. Babul is contemplating making additional claims in the Pennsylvania litigation or elsewhere, as is Relmada.</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; text-indent: 0.5in; font-size-adjust: none; font-stretch: normal;">&#160;</p><p style="font: 10pt/normal times new roman, times, serif; margin: 0px; font-size-adjust: none; font-stretch: normal;">Management believes that Relmada has meritorious claims against Mr. Babul and for its defenses against Mr. Babul&#8217;s claims, but the outcome of any litigation is impossible to predict with certainty at such time.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EBOAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="background-color: white;"><b>Principles of Consolidation</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="background-color: white;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><font style="background-color: white;">The consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</font></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
        <td class="text"><p style="font: 10pt times new roman, times, serif; margin: 0;"><b>Use of Estimates</b></p><p style="font: 10pt times new roman, times, serif; margin: 0;">&#160;</p><p style="font: 10pt times new roman, times, serif; margin: 0;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. The significant estimates are the valuation of derivative liabilities, stock-based compensation expenses and income taxes and its associated valuation allowance.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
        <td class="text"><p style="font: 10pt times new roman, times, serif; margin: 0;"><b>Cash and Cash Equivalents </b></p><p style="font: 10pt times new roman, times, serif; margin: 0;">&#160;</p><p style="font: 10pt times new roman, times, serif; margin: 0;">The Company considers cash deposits and all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company's cash deposits are held at two high-credit-quality financial institutions. The Company's cash deposits at these institutions exceed federally insured limits.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_PatentsPolicyTextBlock', window );">Patents</a></td>
        <td class="text"><p style="font: 10pt times new roman, times, serif; margin: 0;"><b>Patents</b></p><p style="font: 10pt times new roman, times, serif; margin: 0;">&#160;</p><p style="font: 10pt times new roman, times, serif; margin: 0;">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_FixedAssetsPolicyTextBlock', window );">Fixed Assets</a></td>
        <td class="text"><p style="font: 10pt times new roman, times, serif; margin: 0;"><b>Fixed Assets</b></p><p style="font: 10pt times new roman, times, serif; margin: 0;">&#160;</p><p style="font: 10pt times new roman, times, serif; margin: 0;">Fixed assets are stated at cost less accumulated depreciation. Fixed assets are comprised of computers and software. Depreciation is calculated using the straight-line method over the estimated useful life of the related assets, which is three years.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives</a></td>
        <td class="text"><p style="font: 10pt times new roman, times, serif; margin: 0;"><b>Derivatives</b></p><p style="font: 10pt times new roman, times, serif; margin: 0;">&#160;</p><p style="font: 10pt times new roman, times, serif; margin: 0;">All derivatives are recorded at fair value on the balance sheet. The Company has determined fair values using market based pricing models incorporating readily observable market data and requiring judgment and estimates.</p><p style="font: 10pt times new roman, times, serif; margin: 0;">&#160;</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value on a Recurring Basis</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>Fair Value on a Recurring Basis</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">As required by Accounting Standard Codification (&#8220;ASC&#8221;) Topic No. 820 &#8211; 10&#160;<i>Fair Value Measurement</i>, financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels. The estimated fair value of the derivative instruments which include Series A preferred stock with down-round protection provisions and warrants with down-round protection provisions was calculated with the assistance of a third party valuation firm, see Note 4.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The following table sets forth, by level within the fair value hierarchy, the Company&#8217;s financial liabilities that were accounted for at fair value on a recurring basis as of June 30, 2014:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Quoted Prices</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">In Active</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Significant</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Total</td><td style="font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Markets for</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Other</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Significant</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Carrying</td><td style="font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Identical</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Observable</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Unobservable</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Value as of</td><td style="font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Assets</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td
 style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Inputs</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Inputs</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">June 30,</td><td style="font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Description</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">(Level 1)</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">(Level 2)</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">(Level 3)</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">Derivative liabilities &#8211; warrant instruments</td><td style="width: 16px; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="width: 142px; text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">-</td><td style="width: 16px; text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 16px; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="width: 142px; text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">-</td><td style="width: 16px; text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 15px; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">25,586,933</td><td style="width: 15px; text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 15px; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">25,586,933</td><td style="width: 15px; text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;&#160;&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The following table sets forth, by level within the fair value hierarchy, the Company&#8217;s financial liabilities that were accounted for at fair value on a recurring basis as of December 31, 2013:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Quoted Prices</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">In Active</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Significant</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td
 style="text-align: center;" colspan="2">Total</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Markets for</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Other</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Significant</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Carrying</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Identical</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Observable</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Unobservable</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Value as of</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Assets</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Inputs</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Inputs</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">December 31,</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Description</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">(Level 1)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">(Level 2)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">(Level 3)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left;">Derivative liabilities &#8211; warrant instruments</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">-</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">-</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">4,089,284</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">4,089,284</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt;">Derivative liabilities &#8211; Series A preferred stock</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">16,014,141</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">16,014,141</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt;">Total derivative liabilities</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">-</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">-</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">20,103,425</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">20,103,425</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width:
 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as level 3 in the fair value hierarchy:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="10">Significant Unobservable Inputs (Level 3)</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Six Month&#160;<br />Ended<br />June 30,</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif;" colspan="2">Year&#160;<br />Ended&#160;<br />December 31,</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td>&#160;</td><td colspan="2"><p style="text-align: center; font-family: 'times new roman', times, serif;">Year<br />Ended<br />December 31,</p></td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: center; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2012</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: left; font-family: 'times new roman', times, serif;">Beginning balance</td><td style="width: 16px; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;">$</td><td style="width: 142px; text-align: right; font-family: 'times new roman', times, serif;">(20,103,425</td><td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;">)</td><td style="width: 16px; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;">$</td><td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif;">(5,090,988</td><td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;">)</td><td style="width: 15px; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;">$</td><td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif;">-</td><td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-family: 'times new roman', times, serif;">Change in fair value of derivative liabilities included in net loss for the six months ended June 30, 2014 and for the years ended&#160; December 31, 2013 and 2012, respectively</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif;"><p style="margin: 0px;">(7,954,970</p></td><td style="text-align: left; font-family: 'times new roman', times, serif;">)</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif;">(12,877,675</td><td style="text-align: left; font-family: 'times new roman', times, serif;">)</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif;">(3,688,353</td><td style="text-align: left; font-family: 'times new roman', times, serif;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-family: 'times new roman', times, serif;">Additions &#8211; warrant instruments</td><td><font style="font:
 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right;"><font style="font: 10pt/normal 'times new roman', times, serif;">(4,333,163</font></td><td style="text-align: left;"><font style="font: 10pt/normal 'times new roman', times, serif;">)</font></td><td style="font-family: 'times new roman', times, serif;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="text-align: left; font-family: 'times new roman', times, serif;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-family: 'times new roman', times, serif;"><font style="font: 10pt/normal 'times new roman', times, serif;">(37</font><font style="font-size: 10pt;">3,699</font></td><td style="text-align: left; font-family: 'times new roman', times, serif;">)</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif;">(119,029</td><td style="text-align: left; font-family: 'times new roman', times, serif;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; font-family: 'times new roman', times, serif;">Transfer of warrant instruments to additional paid in capital</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif;">6,804,625</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">Additions &#8211; conversion feature of Series A preferred stock</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(1,761,063</td><td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">)</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(1,283,606</td><td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;">Ending balance</td><td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(25,586,933</td><td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">)</td><td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(20,103,425</td><td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">)</td><td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(5,090,988</td><td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">)</td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
        <td class="text"><p style="font: 10pt times new roman, times, serif; margin: 0;"><b>Income Taxes</b></p><p style="font: 10pt times new roman, times, serif; margin: 0;">&#160;</p><p style="font: 10pt times new roman, times, serif; margin: 0;">The Company accounts for income taxes using the asset and liability method. Accordingly, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in the tax rate is recognized in income or expense in the period that the change is effective. Tax benefits are recognized when it is probable that the deduction will be sustained. A valuation allowance is established when it is more likely than not that all or a portion of a deferred tax asset will either expire before the Company is able to realize the benefit, or that future deductibility is uncertain. At June 30, 2014 and December 31, 2013 the Company had recognized a valuation allowance to the full extent of the Company&#8217;s net deferred tax assets since the likelihood of realization of the benefit does not meet the more likely than not threshold.</p><p style="font: 10pt times new roman, times, serif; margin: 0;"><b>&#160;</b></p><p style="font: 10pt times new roman, times, serif; margin: 0;">The Company files a U.S. Federal income tax return and various state returns. Uncertain tax positions taken on our tax returns will be accounted for as liabilities for unrecognized tax benefits. The Company will recognize interest and penalties, if any, related to unrecognized tax benefits in general and administrative expenses in the statements of operations. There were no liabilities recorded for uncertain tax positions at June 30, 2014 and December 31, 2013. The open tax years, subject to potential examination by the applicable taxing authority, for the Company were from 2010 through 2014</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
        <td class="text"><p style="font: 10pt times new roman, times, serif; margin: 0;"><b>Research and Development</b></p><p style="font: 10pt times new roman, times, serif; margin: 0;">&#160;</p><p style="font: 10pt times new roman, times, serif; margin: 0;">Research and development costs primarily consist of research contracts for the advancement of product development, stock-based compensation, and consultants. The Company expenses all research and development costs in the period incurred.</p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
        <td class="text"><p style="font: 10pt times new roman, times, serif; margin: 0;"><b>Stock-Based Compensation</b></p><p style="font: 10pt times new roman, times, serif; margin: 0;">&#160;</p><p style="font: 10pt times new roman, times, serif; margin: 0;">The Company measures the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. That cost is recognized over the period during which an employee is required to provide service in exchange for the award - the requisite service period. The grant-date fair value of employee share options is estimated using the Black-Scholes option pricing model adjusted for the unique characteristics of those instruments. Compensation expense for options and warrants granted to non-employees is determined by the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measured, and is recognized over the service period. The expense is subsequently adjusted to fair value at the end of each reporting period until such options and warrants vest, and the fair value of such instruments, as adjusted, is expensed over the related vesting period. Adjustments to fair value at each reporting date may result in income or expense, depending upon the estimate of fair value and the amount of expense recorded prior to the adjustment. The Company reviews its agreements and the future performance obligation with respect to the unvested options or warrants for its vendors or consultants. When appropriate, the Company will expense the unvested options or warrants at the time when management deems the service obligation for future services has ceased.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>Net Loss per Common Share</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">Basic net loss per common share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per common share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. Dilutive common stock equivalents are comprised of Class A convertible preferred stock, Series A Preferred Stock, warrants for the purchase of common stock and options. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">Potentially dilutive securities are not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares):</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Six Month&#160;<br />Ended&#160;<br />June 30,&#160;<br />2014</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="margin-top: 0px; margin-bottom: 0px;">Year</p><p style="margin-top: 0px; margin-bottom: 0px;">Ended&#160;<br />December 31,&#160;<br />2013</p></td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Year<br />Ended&#160;<br />December 31,<br />2012</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: left; padding-left: 0pt;">Class A convertible preferred stock</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">3,337,309</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">-</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">-</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 0pt;">Series A preferred stock</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">136,041,275</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">8,503,503</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-left: 0pt;">Common stock warrants</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">43,144,557</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">89,265,160</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">4,.865,235</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">Common stock options</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">3,365,171</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">18,654,097</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">677,962</td><td style="text-align: left; padding-bottom:
 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt; padding-left: 5.4pt;">Total</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">49,847,037</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">243,960,532</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">14,046,700</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>Recent Accounting Pronouncements</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">In June 2014, the FASB issued ASU 2014-10, &#8220;Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation&#8221;. The guidance eliminates the definition of a development stage entity thereby removing the incremental financial reporting requirements from U.S. GAAP for development stage entities, primarily presentation of inception to date financial information. The provisions of the amendments are effective for annual reporting periods beginning after December 15, 2014, and the interim periods therein. However, early adoption is permitted. Accordingly, the Company has adopted this standard during the six months ending June 30, 2014.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The Company does not expect the adoption of any other recent accounting pronouncements to have a material impact on its financial statements.</p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: left;"><b>Subsequent Events</b></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: left;">&#160;</p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; margin: 0px; text-align: left;">The Company&#8217;s management reviewed all material events through the date the financial statements were issued for subsequent event disclosure consideration.</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_FixedAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fixed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_FixedAssetsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_PatentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Patents.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_PatentsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.3A-02)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph k<br><br> -Article 1<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02, 03<br><br> -Article 3A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConsolidationPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41620-113959<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5579245-113959<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5579240-113959<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41638-113959<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(n))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph n<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41675-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativesPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for determining the fair value of financial instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13279-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 60<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueOfFinancialInstrumentsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpensePolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reporting subsequent events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UseOfEstimates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EDHAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="2">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Series A Preferred Stock [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_AllocationOfCashToPreferredStockIssuance', window );">Par value of Series A preferred stock issued</a></td>
        <td class="nump">$ 4,898<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5,100<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_AllocationOfCashToCommonStockIssuance', window );">Par value of common stock issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">17,164<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_AllocationOfCashToAdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
        <td class="nump">2,151,040<span></span></td>
        <td class="nump">17,878,994<span></span></td>
        <td class="nump">1,479,610<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_AllocationOfCashToDerivativeLiability', window );">Derivative warrant liabilities</a></td>
        <td class="nump">111,777<span></span></td>
        <td class="nump">3,337,025<span></span></td>
        <td class="nump">113,153<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_AllocationOfCashToDerivativePreferredStockConversion', window );">Derivative preferred stock conversion feature</a></td>
        <td class="nump">872,688<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,647,910<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_AllocationOfCashToDerivativeWarrantsIssuance', window );">Derivative Warrants issued to placement agent as offering costs</a></td>
        <td class="nump">79,615<span></span></td>
        <td class="nump">996,138<span></span></td>
        <td class="nump">248,655<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ProceedsFromIssuanceOfOfferingsNet', window );">Net proceeds</a></td>
        <td class="nump">3,220,018<span></span></td>
        <td class="nump">22,222,319<span></span></td>
        <td class="nump">3,494,425<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_OfferingCosts', window );">Offering costs paid in cash</a></td>
        <td class="nump">699,482<span></span></td>
        <td class="nump">3,516,378<span></span></td>
        <td class="nump">586,072<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ProceedsFromIssuanceOfOfferingsGross', window );">Gross proceeds</a></td>
        <td class="nump">$ 3,919,500<span></span></td>
        <td class="nump">$ 25,745,699<span></span></td>
        <td class="nump">$ 4,080,500<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_AllocationOfCashToAdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Allocation Of Cash to Additional Paid In Capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_AllocationOfCashToAdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_AllocationOfCashToCommonStockIssuance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Allocation of cash to common stock issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_AllocationOfCashToCommonStockIssuance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_AllocationOfCashToDerivativeLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Allocation Of Cash to Derivative Liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_AllocationOfCashToDerivativeLiability</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_AllocationOfCashToDerivativePreferredStockConversion">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Allocation Of Cash to Derivative Preferred Stock Conversion.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_AllocationOfCashToDerivativePreferredStockConversion</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_AllocationOfCashToDerivativeWarrantsIssuance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Allocation Of Cash to Derivative Warrants Issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_AllocationOfCashToDerivativeWarrantsIssuance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_AllocationOfCashToPreferredStockIssuance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Allocation Of Cash to Preferred Stock Issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_AllocationOfCashToPreferredStockIssuance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_OfferingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Offering Costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_OfferingCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_ProceedsFromIssuanceOfOfferingsGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds From Issuance Of Offerings Gross.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_ProceedsFromIssuanceOfOfferingsGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_ProceedsFromIssuanceOfOfferingsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from issuance of offerings net.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_ProceedsFromIssuanceOfOfferingsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfStockLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of received warrants</a></td>
        <td class="text"><p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-family: calibri, helvetica, sans-serif; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">The Placement Agent received the following warrants during the year ended December 31, 2012:</font></p><p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-family: calibri, helvetica, sans-serif; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Number of warrants</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Exercise price per share</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Expiration</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; font-weight: normal; font-style: normal; text-align: left;">Series A preferred offering</td><td style="width: 16px; font-weight: normal; font-style: normal;">&#160;</td><td style="width: 16px; font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="width: 142px; font-weight: normal; font-style: normal; text-align: right;">612,422</td><td style="width: 16px; font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="width: 16px; font-weight: normal; font-style: normal;">&#160;</td><td style="width: 16px; font-weight: normal; font-style: normal; text-align: left;">$</td><td style="width: 141px; font-weight: normal; font-style: normal; text-align: right;">0.80</td><td style="width: 15px; font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="width: 15px; font-weight: normal; font-style: normal;">&#160;</td><td style="width: 15px; font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="width: 141px; font-weight: normal; font-style: normal; text-align: center;">2019</td><td style="width: 15px; font-weight: normal; font-style: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt;">Subordinated promissory note offering</td><td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">33,750</td><td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt;">$</td><td style="font-weight: normal; font-style: normal; text-align: right; padding-bottom: 1.5pt;">0.80</td><td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: center; padding-bottom: 1.5pt;">2019</td><td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-weight: normal; font-style: normal; padding-bottom: 2.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; padding-bottom: 2.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">646,172</td><td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; padding-bottom: 2.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right; padding-bottom: 2.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; padding-bottom: 2.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right; padding-bottom: 2.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt;">&#160;</td></tr></table><p style="color: #000000; font-size: 10pt; font-style:
 normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-family: calibri, helvetica, sans-serif; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-family: calibri, helvetica, sans-serif; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">The Placement Agent received the following warrants during the year ended December 31, 2013:</font></p><p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-family: calibri, helvetica, sans-serif; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Number of warrants</td><td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Exercise price per share</td><td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Expiration</td><td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-weight: normal; font-style: normal;">&#160;</td><td style="font-weight: normal; font-style: normal;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: center;" colspan="2">&#160;</td><td style="font-weight: normal; font-style: normal;">&#160;</td><td style="font-weight: normal; font-style: normal;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: center;" colspan="2">&#160;</td><td style="font-weight: normal; font-style: normal;">&#160;</td><td style="font-weight: normal; font-style: normal;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: center;" colspan="2">&#160;</td><td style="font-weight: normal; font-style: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; font-weight: normal; font-style: normal; text-align: left;">Series A preferred offering</td><td style="width: 16px; font-weight: normal; font-style: normal;">&#160;</td><td style="width: 16px; font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="width: 142px; font-weight: normal; font-style: normal; text-align: right;">637,578</td><td style="width: 16px; font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="width: 16px; font-weight: normal; font-style: normal;">&#160;</td><td style="width: 16px; font-weight: normal; font-style: normal; text-align: left;">$</td><td style="width: 141px; font-weight: normal; font-style: normal; text-align: right;">0.80</td><td style="width: 15px; font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="width: 15px; font-weight: normal; font-style: normal;">&#160;</td><td style="width: 15px; font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="width: 141px; font-weight: normal; font-style: normal; text-align: center;">2020</td><td style="width: 15px; font-weight: normal; font-style: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; font-style: normal; text-align: left;">Subordinated promissory note offering</td><td style="font-weight: normal; font-style: normal;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right;">106,875</td><td style="font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="font-weight: normal; font-style: normal;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left;">$</td><td style="font-weight: normal; font-style: normal; text-align: right;">0.80</td><td style="font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="font-weight: normal; font-style: normal;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: center;">2020</td><td style="font-weight: normal; font-style: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;">Acquisition of Medeor</td><td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">200,000</td><td style="font-weight: normal; font-style: normal;
 text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt;">$</td><td style="font-weight: normal; font-style: normal; text-align: right; padding-bottom: 1.5pt;">1.10</td><td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: center; padding-bottom: 1.5pt;">2020</td><td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; font-style: normal; padding-bottom: 2.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; padding-bottom: 2.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">944,453</td><td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; padding-bottom: 2.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right; padding-bottom: 2.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; padding-bottom: 2.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: center; padding-bottom: 2.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 2.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; font-style: normal;">&#160;</td><td style="font-weight: normal; font-style: normal;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="font-weight: normal; font-style: normal;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="font-weight: normal; font-style: normal;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: center;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; font-style: normal;" colspan="12"><p style="margin-top: 0px; margin-bottom: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">The Placement Agent received the following warrants during the six months ended June 30, 2014:</font></p></td><td style="font-weight: normal; font-style: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; font-style: normal;">&#160;</td><td style="font-weight: normal; font-style: normal;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="font-weight: normal; font-style: normal;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="font-weight: normal; font-style: normal;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: center;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Number of&#160;<br />warrants</td><td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Exercise<br />price per&#160;<br />share</td><td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Expiration</td><td style="font-weight: normal; font-style: normal; text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: normal; font-style: normal;">&#160;</td><td style="font-weight: normal; font-style: normal;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="font-weight: normal; font-style: normal;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align:
 right;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="font-weight: normal; font-style: normal;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: center;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-weight: normal; font-style: normal;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">May and June 2014 offering</font></td><td style="font-weight: normal; font-style: normal;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: right;">4,290,950</td><td style="font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="font-weight: normal; font-style: normal;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left;">$</td><td style="font-weight: normal; font-style: normal; text-align: right;">1.50</td><td style="font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="font-weight: normal; font-style: normal;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: left;">&#160;</td><td style="font-weight: normal; font-style: normal; text-align: center;">2024</td><td style="font-weight: normal; font-style: normal; text-align: left;">&#160;</td></tr></table><p style="color: #000000; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-family: calibri, helvetica, sans-serif; margin: 0px;">&#160;</p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RelatedPartyTransactionsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section S99<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 28<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EYFAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 1) (Fair Value, Inputs, Level 3 [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Fair Value, Inputs, Level 3 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems', window );"><strong>Fair Value Inputs, Liabilities, Quantitative Information [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
        <td class="num">$ (20,103,425)<span></span></td>
        <td class="num">$ (5,090,988)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption', window );">Change in fair value of derivative liabilities included in net loss for the six months ended June 30, 2014 and for the years ended December 31, 2013 and 2012, respectively</a></td>
        <td class="num">(7,954,970)<span></span></td>
        <td class="num">(12,877,675)<span></span></td>
        <td class="num">(3,688,353)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_FairValueOfWarrantsInstruments', window );">Additions - warrant instruments</a></td>
        <td class="num">(4,333,163)<span></span></td>
        <td class="num">(373,699)<span></span></td>
        <td class="num">(119,029)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_TransferOfFairValueWarrantInstrumentsAdditionalPaidInCapital', window );">Transfer of - warrant instruments to additional paid in capital</a></td>
        <td class="nump">6,804,625<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ConversionOfSeriesAPreferredStock', window );">Additions - conversion feature of Series A preferred stock</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(1,761,063)<span></span></td>
        <td class="num">(1,283,606)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
        <td class="num">$ (25,586,933)<span></span></td>
        <td class="num">$ (20,103,425)<span></span></td>
        <td class="num">$ (5,090,988)<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_ConversionOfSeriesAPreferredStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Conversion Of Series A Preferred Stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_ConversionOfSeriesAPreferredStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_FairValueOfWarrantsInstruments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair Value Of Warrants Instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_FairValueOfWarrantsInstruments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_TransferOfFairValueWarrantInstrumentsAdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Transfer of fair value warrant instruments additional paid in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_TransferOfFairValueWarrantInstrumentsAdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueInputsLiabilitiesQuantitativeInformationLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in fair value adjustment on other assets (liabilities) carried at fair value under the fair value option on the statement of cash flows of Federal Home Loan Banks (FHLBanks).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInFairValueAdjustmentsOnAssetsAndLiabilitiesCarriedAtFairValueUnderFairValueOption</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>57
<FILENAME>0001213900-14-006670-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-14-006670-xbrl.zip
M4$L#!!0````(`%A%,$4W:^[4;"8!`)5`$P`1`!P`<F5L;2TR,#$T,#8S,"YX
M;6Q55`D``T<P&%1',!A4=7@+``$$)0X```0Y`0``[)UM<^)(DH"_;\3^!]:?
MEP:!L=N^[M[`@+OIM=L.VS,W&W<7A"P5N&;TPE1)M-F+N-]^54*`!!)(((DJ
M*2,V>L=Z09693V5EO65]^L>[:=1FB%!L6Y_/E`_-LQJR-%O'UN3SV2\OM_6/
M9__X\M>_?/I;O5[[BBQ$5`?I-9>R^[7!O^N_W3S=+5^O77Y@[W]HUOZK>=50
M+AJMIG)>:[:N6U?7K8M:]_Y_:O7Z\J=N5,I^AKWC_4#K@[*^YUWIVYIK(LNI
MW;.BC#%[]B=VWO@7!SIV;%+[U?^FXGU3X3_UXB*JJ_._UY[1U$'F*R(UY>+O
MM64QVNUKI<.*X7_I_948^)K_6V,JL.@U08;Y^>S-<:;7C<;/GS\_\`NJKG[0
M;-.3I7G19MI9/&Q@ZX_0P_R'/MADPIYLMAO\]BL3<?DXOZOCU0O!AR\:BYNK
M1[=^^F?;>U:YNKIJ>'=7CU(<]2#[4:7QV_W=L_:&3+6.+>JHEA8J"]Y1]LWG
M,;7/6\KEKC<63RQ?L&S+<LWHYW6'-)SY%#780W7V%")86[VW_Z7P"SJ:$J1Q
M(&,+=]50B49L`S7&JN;4T?O44"V5`32_97^?K4P_COV%BP:[NRHB<G9\ROL.
M>R1D=2?2ZIV%U5>/:K9K.60>?I8B[</$GC7\FQS"=KVIU-O*ZC67$%9=X][S
M[WKTAE_4$8Y^A]V(>!R]:V_1S_,[_(56^`5LS1!UHE]9W(N0QE*Q1J/?\6[Q
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M^[)\,5;B3XW(C_-2-;;*V8A6#0,&VWI`,D<E3I\Y=':)&ZK.W$JK$_C%P/V5
MMO6-%]I*\(/+N\LKZT\V0B@)S-;HB;V(O&?NV>^9K@G,;3&7N%0K9:Z_%](J
M<'T*KM5WX#I[KH-:K2+7S26_BA+BNGD1<;W[4R7Z"PM5/"*[^HQU:U@W`1-)
ML`R5_^P+#ZVNMZ7('P,60GN]@<08^"]<B(C!HZ%J7DWM3M@_+RQJ1?+2$"M,
MI:#HTM'#>-VT;3`1=;T86R?4ZV)XQ@DH*>A`UW>+5M+HV6'6X9`,_G29!#W;
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MFX-CK+;]D]7YT1V:J,;`DW8QT89T9).AI4E&1G8^8>^W=82O-]3FCY]O*$]>
M\-;S(G(VR1MS"YZ>TLPM;"DV^PDG:,8%:,;+R0DT_<`,A`L0+E0+UO]4"6&Q
M3ZE`#,E423ZN1M]=8YL/I1EQ/;$S&U+J(OW6)JSIF&$-2;)&>P\TGD_9+V4Q
M&%W6FU>I,+JL*SE@M!I:CJ0H\GIX?=?#>,Q41QZF?.Y6$DZBEG9%R5%$__0R
MEQ'C=>L!=BW&KI$U/%U#<9G+2M[;?PT\#E0KD@-_ZDB:<0HEI59S6A^=5JNP
M*C:W>B8K$3!L!9`<"4D9QJV$6A]:%7!@02G`<S@\L`+U%"M0RX,7+%D]\9+5
M\J`$:UQS7^-:0EA@`AB"Z..]"TRH`1PPFR;$;)JT#+FO%.M8)?-GU4#!%NF1
MX!DKTFIL51)FXN0)QBU1@@$FNS#IHU=G:%&'>"D]?3YL$U.>FN2'[2#:=]'+
M3UL.2+:E64XDQ,L$?!P6V`8<M-^TR];Z;(>UFRU/6#`@Y6A2I)KT3P'*"18!
MR,I)>+IZ8$X->XY00(MRP+$Q7;V\'"L/0+$+BM2)"Y%*4742O49)"T`E]S*W
MMLMT3^2*4Z(6Q$0*`B1D,"4T9/42JP:_K4H4HR2=#O+HB9$1^-G=-&FVB5:Q
MX)VM>;KSH'E"%'%-=UGAUK.U@_<I,Y,DD]0[Q%LW0`GD!(@.A>@9&0:V)HL3
M7`RFXJYNLBB!.H0],T.^EB7Q1XEP2B4Q@%4(6!L1DU0S4(5"=VP/$>;!BFIZ
M2X_T<<TR@%P8R$_(6][WR,H[?V%*HZH6\-(12R@>QNP/YJTD:?5WR.=W/9)(
M"0P=RA"?]RH=,A%"`2$'$$)OYL$[_I2,15W#D6<P++ELJ\F9#0F!G<-F[^1>
MZ1J_=!%6N::&Q%>F'_@]D"<\>7/VK7(MR_[46.&/70U[:!P..V1SWS.]BWCW
MU28ZMKRV)[2Z:!FSR(%U5E!E48\6/86$BJT4X)MYNB5+MK"1FJ2@9.:0.Z&P
MED%8`T,J!+`Y9#8`#B!10?$G7TG$`N0=./G)5R+1`FD$1#KY2B0R("M`L2=?
M"6E[V.0/\21LRRYP6[:X2,`NZPI:'39-5\K<L&.Q_#:&74*GV"4D+`ZPE*KH
MI53"H@"+7JJ]Z$58,&$-"ZQAD9=7J7;CG&H'C+"VO&5L6QJ+$C>ZP7>V-7E!
MQ.1]2CE,&R-)(/G&EDA@:2_XT5S".@J(/AI(GR"]2WNVP>-'(LLD^E[3)Y"Q
M4BSPJN#X56'ER+^[%K9)L,63I_)'";0V_R[)*F7WM*/<Y0,ECW%QH/1D8S9#
M:X:H8Y-E[H.*[L^-'_+94%`6%(N[1U@VHA-CF:9*A/O+4F.='5+Y5;`H=0/;
M\=O9TZ#,7_]F&SHB<KOG@_?"YX?MEFJ!V6R8+:?[%05;\+:[(@F>`0M-L-;5
M9YC:9)5HMBP4[A&P4B`$5@+<(Y6ZQ%/$C4JQOXKQ3;4F:+$1X-$KU.J-/J::
M8?-7?/=6RO6P>Q04V&.77%-9^#Q8IWL2QDLTT2$HV#`!<WJ:RS"9(RO>,,F4
M8X12LN7YHD(.VP:*)KMT,VRBH@V3;X),$6=9?42O#.6;;A;5#Y2O)E:HF@`K
M>;.B$C)G.GM"4YNPJMXU;==RH'^YD[5T.H,^9@FXK_A(>/'$PVCXZ5BO[)C*
M"3"'<943$%[AL97B$8?Q%2F\.%0*V?T^U$BA:R14%V`FL_&6,J].$7!XI4PK
M5'HN=6QSU+QBC;O!\6V'L%::$=<A,>*I$B-N'%C2KC<OZ\VKP"_N.;#$>T%I
M!C^8Z8$EC`TTW:8H\GHX/\3#>,Q41Q8)R23A)"H/290<N7L'9M:K>KN9O7<X
MP*R)DB4^6)*$02F2):YD`G-OY9&4)P-6FNR8!2:BRLWDR_9?`<]=D.?>;L.O
M4ATZMH5"5FWX(2B`MP=$H(4X40LA`28/FK.-2>L\XGI),FB>/'_E%A1*,R44
M[(76>8Y=Q!_V+-)U;%^'M+PG3<O+4%!R#CJ!!7%9V/8DZ4['W<(GG^.?VS'C
M\.OK0IV-N]UHI]9J$8=J[]?J1HOM;[:?WV)BRE'KHIKJ;2F*"=S*P0!$;4`$
MG,`,D!P)B<2+J,4\LKDJX,`9SP#/X?#`H=#[A`:\=N$%ITB?^!3I\J`$QT[G
M?NQT"6$ITVY$\7;\E1"82.\BU4E-";U*[B<W504.6-P+#*4=%88%8E7EH&Q[
MQX7:GUT>3)*M$%N>12\Z)&G6ARUE`CX.Z^`$&FH_Q).D?=G1O=F,0,*"`2E'
MDR)5()("%`A,#@Q0!^;4L.<(!;0H!QPQYQ3'R@-0[()B:.EHC"WLH#L\0_K0
M<E1K@E\-U*44.?1F?J_^;I/%N*2WZQJI%*T.%Y'$GZ04,K#I.4I:`"J#":$A
MLP96#7Y;E:AE2CH9Y!\P&2DC\+/;(6FVB581P)VMJ:M3G)X015S375:X]5SM
MX'W*S"3)%/4.\=9N)X&<`-&A$#TCP\#6Y"NR>&)0IN*N;K*V@?(#M%CKX&M9
M$G^4"*=4$@-8A8"U$8U+-?]4*'3']@M@%JRHIK?T2!_7+`/(A8%<T:/N@\>!
M)I`2&#J4H8@C?^5')MTYQD`(;,X]_>9<:=F)G[.1>YUK_,)%6..:&A)?F7[@
M]T">\.3-B0]B(J-P:7>GQ@I_[%K80^-PV!^;^X[I7<0'DG&'UY0L8Q8YL,X*
MJBSJT:*GD%"Q`/CQJ[GD\;XBY_N2E9&$ZR]&3_P</^^9>_4=FZZ<F46.69>1
MO)NR5-7Z>R&=`9`9`XDM`#(MD$&=`9`9[=&2U4MFO'<+/*7(8,KD+44"$SQF
M#F/0X5ZF#^L=FJC&P%/7`EFD(YL,+4T.:%,/4T<IX1B*=82O-W3H?VE#DX!Q
MON-#78VY+>HE"7H8+W0O!\+"#0C%:K)2"&\>?"99PM7-E,;%G`X'N3,+FQL0
MUL"0"A-L#IDM@0-(5%E(HDI968"\DZ?(.RDL+9!&\L1I)(4E`[)"YKYB3GS;
M0Y)'B"<A9V.I;0WI\TII5LB&5\7*#,GM*F5NR"Q5?AM#7I]3Y/41%@?8_'CJ
M4VJ%00'V,E;/YK`UL=I;$X4%$W8:"KNP[)0[#27A5:HAS5/E*1+6EK>,;4MC
M/8.-H8\[VYJ\(&+R<00Y3!LC22`Q[I9(8&DO^-%<PCJ'B#X:2)\@O4M[ML'[
M#$26A2Y[39]`QDJQP*N"XU>%E2/_[EK8)L$63Y[*'R70VOR[)*N4W=/.;)0/
ME#SF0H#2DXW3#:T9HHY-EAEJ*YI%,7Z8;T-!65`L;B9'V8A.C.6Q>R8EQ3H[
MI/*K8"EW9U:+[8C\G&E0YJ]_LPT=$;G=\\$92_/#=DNUP&PVS);3_8J";>6]
M;6#2_QZIU"6>-FY4BOW-BF\\-\5BC\:C5ZC5&WU,-</FK_A4EW*I\AX%!;8_
M)M=4%JC#$NJ3,%ZB\6U!P89Q]]/37(8Q?%GQAKF%'".4DJW$%Q5RV"%0--FE
MFU@1%6V8<Q%D9C#+ZB-Z92C?+*.H?J!\-;%"U018R9L5E9`YT]D3FMJ$5?6N
M:;N6`R.",92ETQ:,"LK->F7[EB?`'/J7)R"\PGW,XA&'?J847APJA>Q^'VJD
MT#42JDL%F$F4*^?!D@2)%+ER5C*!N>&DR#*;'`[IJ?`A/<)2"6?NB),:H=`S
M=X0E,E'3*`=A*5K%"AKZB&SORN;LBORI@;/(#*_D,(T"F8HSI[<%].Y0"]`K
M-KUMH/>P4SF`7@'HW8H<2KHN0Z@8`I9B[%TL>@B.&<0@HA.=&T*"13;E(SK+
M"`-\=/ZQ!OCH8Z=U'VWB[?%?SVC"ML-=T\$I])6)(X=MAT6/<$B$*K3MA?:_
MJD#&_IY4^<A8A1//&K)4]M%%3D%*7:0/K7MUWK7T[ZZ%V%OG<B52CY1LF1(P
M@7SR8M!SJ6.;H^;5Z+MJ<7N?ASA0FA'7=P\.LC]-V_+BR(7J;FW"HLP9UI`D
M:<GV#-'YY\'LDS(/)IC-B=-GI5M0<5YO*O7F5>`7`_=7&M8W7E":P0\N[V;D
M32(IBKP.IT%FYAT\L^;I'<"N1=DULH8K*6MX$(5L:WCKX^@6O6Z3$'T=.WP5
M^]#2\0SKKKH('&]LIMV'<1\3I/%,N[TW%EZ9JB0'"$;*M`X5=PM7A"-HU5L?
M\W0$8'ZAS+_M+UII_468F&S]!8L?[U42&5=N72_&]@=6JW8H;,JV$]:\8,J8
M;RLI\GK<X.+J>G="D$S[<.-&[KQF-TZJ(CQII]Z\R,^3=L#F`MA\VWTRJW=2
MN<\P)EFYSW6#&XF)<A5QO21G+Y[\Y,-(*-*UJ9VZ<I4]%'X,WHQF(NJZT&UJ
MI][*K4U-HR38L%5@FYJ'R7UGJ<2TJ<)7C"B'HZ1MA5IY#NM%ZC7R.@S_9%M?
M\AW62VY7UN5%8VQA!]WA&9\/8269X%<#=2E%#KV9WZN_VV1Q6K:7,9SIBRG6
MFJRB.$G,GU+00.+N.(F%C5'R&"<\A"WP&65&06G%]&&:/)&,;,UR*Y5B+W*9
M;;NX'\3/R<BGU=0S'!?UM@!:A291]"915K!@(`>(.'#)C1QD)-P$MR470'(X
M)!)OJTB(2\%[&:H"3E?7O;0EJO&H8M;X]]0I=F39L)`0G9TR`CQ'P*-IKND:
MBX218ZZ\15KZ/E]$;4^]-;>..I$DHDE*4RJA`:]=>!V_U5!TJ(K9-`@H[?%4
MJ[!AT8^5@YV$#BE2-H`E$2QEVI\LWH;@$@(C?\H<47+45`4.V#(%#"5@J&0G
M\`AURDV),(D-7`(5T'?=LGF7[;!ET[.$!0-2CB9%JF48*4"182>?()R$IR,'
MYM2PYP@%M"@''!O3D<O+L?(`%)DN?D`J1=59^!`E+0"5P4#OD%D#JP:_K4K4
M,B4=Y%VD'(F6$?C9[9`TVT2K".#.UCS=>=`\(8JXIKNL<.LYF,'[E)E)DJFG
M'>*MW4X".0&B0R%Z1H:!K<E79/&<<4S%7=UD;0-U"'MFAGPM2^*/$N&42F(`
MJQ"P-J)QJ<:5"X7NV'X!C&X7U?26'NGCFF4`N3"04QSCQ[Y!7<.19Q`U]1E]
M6Q(".X>-ILJ]LB1^J0"L*DD-"60:`$8R&FX?/:G69/',O?J.3=>4`YD,A^&3
MMWU+5:V_%](9`)DQD*S#!D"F!#*H,P`RHZ5VLGK)C)?@@:<4&4R9O*5(8(+'
M/*P)'UHS1'E^6CF0B]I'OB$"6#^_J759/57.4^[@N21C5Z;P3V1V(1Q,/)T@
MI^,$AY61T67R.%#3\]PM>E.N#1>10@$ANPBY<2FV$*5=C?6;*5ZMC[A'.K*)
M'%C$R.!#$90$6-C%PHOZWB-(QTZ/5:#YV":\@QM:+2,'#[%R;"]]J2`6?O+L
M2``DR-.YF8HZK*2,CR%-H23(CIA3KG%A#`S)#L'FD+L0.(!4A(6D(I25!<@L
M>(K,@L+2`HD"3YPH4%@R(.]?[BNTQ;<]I/&K9CP)2;,J:'7(6%-^&\->O:+W
MZ@F+`FR]JY[-)=XS?JI]VL+:,NY\^SO;FKP@8O)=AG*8-O9D^U5BL"V1P-)>
M9TQS"798E^710/H$Z5W:LPW>U!%9AG?WFCZ!C)5B@5<%QZ\**T?.'L,V8;T<
MF^A,H=XXIRR5/TJ@M?EW258INZ?MDI</E#PZ\4!I;M,)]TBE+O',<*-2["]#
M>.,+9A>S+X]>H59O]#'5#)N_X@-<RD'(/0H*+&Q(KJDL^(;!T9,P7J(87E"P
MH6]Q>IK+T$^1%6_H/^48H91LFDQ4R&'ZKFBR2]=Y%!5MZ%<*,OJ19?41O3*4
M;R1%5#]0OII8H6H"K.3-"M\`R73VA*8V856]:]JNY4#_<B=KZ70&?<P2<%_Q
MD?#BB8?1\-.Q7MDQE1-@#N,J)R"\PF,KQ2,.XRM2>'&H%++[?:B10M=(J"X5
M8";1.3D/EB1(I#@E9R43F!N.1:J\R4MG[0H:>E_S_\@:/YY(<MWRP;#YKK`A
MA;Y@R/RTO*?-0].2#M6#\]"T@(PT9"C5(4.I(!FK69IG#5DJ^^CB3`M*7:0/
MK7MUWK5T]A;B;SV,QXA/S\M!1*1DRW,K$LA7*0S@G![1SCK)^]B+"J`HTR$8
M(J.8]V$<PJ(HJ5L#=P*'XI3*AG#&3<4,#L>45,'*68[/5GMY9\$CL["T4Z@Y
MB!(G.A!MR@$2'63GL:NZ2+EH9PT+E`LFN[KK,`M&&Y9!RK+Q.P48HE>&\BW\
M%=4/E*\F5JB:`"O%'#8Z\OO@_FCA`WG"DS=_;5K`$807!"YGNJ59QYS5D:6)
M/QBKU>48;7+=5HK:O>-P91RJ[U9XJ#[>X%ZU+)>Y(T2JE+%S&;$OW<HS4;O+
ML"+NU%FXJXOZJ5)Q`^K[41]:.AIC"SOH#L^X9EA!)OC50%U*D4.9:=7?;;(X
M[\F;;T(36?:VI!3-)R0@8*5`./F$/'C*\LSE@Z^6O8K>0!65JXI&&@RJJ,Q5
M-.W4'=3.,JRO@(HI39<>PELY!@(@O(4J"N&MU%44PMO255$(;X6OG1#>2E(Q
M(22%T*_$^%8M7(.P2"Y\(92!D$$V:(4X9*?$-4'H!/80'D%5A7"K5%450L',
MJVK/I8YMCI0.JY/&=EU5/D9<YP$0^M-E`@QF[)_5)IZ-ZW)4C!AA`NA%296'
MP9E!B=-G(*Y,?EE7.H%?#-Q?:53??.%C\(/+NTD8^5N]7OO%PD[M&6E\@KE6
MJ]>7U__ZE^'_*?]]^^OC-_2.^IV+RX__>D)_XB_#MS_0;/`')N\_+R^T\_-S
MK=/I:"__^_9E,+B]&G[]CTOEHO/UF_+QZ\6U<GOY?:@,;\\'%Y>=SU^OOG_W
M/[`HB<L_S<G\Y;E_]L6_:"Y<U1=,[?.6<GG-[BU+OKRU_)N_'_UKHRGW[&\J
M0:O?U?&,\?,E\/`/UT1$=6QRX*>WWN<7^\BR3;Z):OMG?9/R4M%=OQOZB4:X
M]+LE7_SVEBJ3?CCB%Z=N0(7AW^.W4OY:G[B3[>)Y+M>[=:"A_>TK`IG:$\DO
M5D:FYG5R8'@M5JBZ?M(1OAYX?N8)33!U^#=_J":J^17]"8W7OO_B?C!J*J/O
M:L(@[>S+T^#NOMOOUEZ^#9ZZCX-?7H:]Y[_7AC]Z'SXUXC[-R[N^UV-%)CP!
MC8[>_XGF&94KV#S$?FM9D"Y3F\Y5=VNHDXP*,%8-BA;?#OW\\IM]6_/2[?#F
M):-//M>5Q0>#O[WYO<4,RF#1$&3TX74X$OY^Z%MAJ]]B`Y$>NSRQ258V?S95
M@_UJ;1&HLE"LUK/-J6K-@PB$/LS+M`YSZ1L+Y_C_#?YT\4PUF`2TZRS#7R_8
MC2RIW[E11GVD\3(IX;)&7#^K\7KK_0AOW&HZTC`K//U\QK6I?+RX^M1(5:Y\
M!&G%"-)*)HAR>=GZV&H)(4H[1I1V,E':G5;KO-,\I2@I^LZ[\>ITF%?L*$?(
MPCI=4Q7K@_<IBYU1SV7]+];L%&`&I=EN==8%CRS'407-2LG*Y4>E\S%%2?M^
M-W:1D`WU;.I0_[$?J!#=7GZ\;)VO2_S_[%UK;^,XLOU^@?L?A-F[LWN!)".)
M>G:P%W`_,@C0G03=:0SFTX5BT[9F;,DKR4EG?OT6*3\H6[(E\2$YR>S,HEO6
MXYQBL5A%%HN'`8F!SB'M'VGX+@IG__HI2Y;XIU]8//E.)X5:B1S#L'S&9!<0
MM((FKK.[EFGK=;#=)3%XR]GSW0S<-#`'Q!0LYNKTS[/\0H>I1B,"M2@!^YYE
M-$=]FTUQDK>$$K-I&CHS=C%?;P%*F(FL!4J=D)"#3-UW=WM*,S`"^ZUC%1R.
M$C3#(9F(3>^"Y^!AIG08]G1DL#:E%`D?5E&2="U'9PU++:PPIHP^A\%#.*.G
MK2D4K84\QR["+0?#C5B4@)%GZB9JB!BP/(*A)!N3Z7F-ZO7"]I#-=/;#@(KN
M#EW*#Q]Q2PUI'AX><':XT7#&>.!;0/?R6+^Q&I!BX"(S=X\,'1YH$SI1(30\
M$_S@P&#IIH/L#@3!:7;A3AU99C^1\YQFB&JT6K_);U9BB3.=/9,IO3BB$Q2$
M\VH6O09+2_=\T[/Z25*5I3),SW4=MZ=-K=)4F0:R7,?LO2!:'E_*TVUDNAMR
MR9NOF3SB)W^2!I.[AS0Z0:=?ZM(N_U3`N=G]$H/(7L.C#<6QUH%@U&"G!WO:
M@:2=TU/CO/J7HT@OKF<8R@@)7-KT'!\I#,05G4E?*XH[%?)2`QS7MRW?U4]4
M"`+C&PLA9#C]UX;^FEE%A'II9H4>W'%(3<\=3[><-G-/C=<-ON%%R:!9=IT<
M(K/CRA2//$@_+C%S_L*1Q3*@R!BD(\L+#6D)R_ZP/9_-"1*+4DZB1T=3Q8;E
M&879_L-ZVI$KY+@NL@RC+LJ=9=%!-*I<QX/?;N)HJ#+KB_Q3N81;&ZMLOL(R
M(R3P96Y5TTGLZD[2`I>X;N%5=XOB`O5\'F9S.FT6C0@:\,LP!+G2Y'?`T+4$
M(\?J%N=!1&;@RIB#08[.S&"68.^<VN:C>5'VQMY@0]#2"^ST'7HM>1>7]Q%R
M:^L0Z:MQ)%R!#L=ZOLUN&-A!T!:=*)MKZ:9OU8,W&(U"$E8$L[L@'%U''X)%
MF`4S)4X&F:WU+';8+0?#B5=8_I)E.(YNVXWP?B0!9TPS4J&#3/`G@)8LDC#%
M'_&8;%H%QV(Y7\[H29IT+F;W"269F,CW3(=5:7[<ZJ0@K(%M!*&CY<J2`NV!
MTW@VPDF:KQ2JV-QT;GK(]UW&`=O'H03ED652QDK5<3-L4^\[(S%#=E?H*XQ;
MG8E02_=-U/OF8?MNWIO+NW"=.377M'77['T?X_5\6^+FS'@]1ZYA%-+?I4BW
M1F:G2`MF@I?6=T9M@T#/9F/`?G)K;]\,'7F>;3J]9RC0P!F68>BN+=O"<7/N
MR,)Q^M_GANM;OFG+5BGNY-]F)JX8)?>3D:!YKGZ2X[!Q>\%Y3QD*M''[47`_
M.:NU<:*BZW,80#S?D32"M)JI%&'BBE-M_:3412`J#GU[([8_8]?/]A%IQ/8G
ML?K)F7=1X#`K9HUQ$(VZ<>KVMK<?`R6*@+PM\4T8,$H]F)/<I;\"THO+:I>H
M:`W'MRVGL,)?%YT$4J):2!=)Z"->)/#RU6.+&:;I9E'A=97E-I1T*!>5\N4"
MKEH8PCIG8895AC2*.7G?HR!_`7PA3&EZC))%0LO0K<*ZU!%0PAA(Z*.-P!>]
MM;L@N4WHB#JB:[AW.*'E5*6T`5.ME>&"@,N%KA>*[]2!*)94ZV9118K^G`Z6
MV31.2-N*;Z%55=G=+>6K?ZJ8[.)2SH`[N:6<MVV?+N]C3G`I8V1WP+==M^N3
MIJI,PRKE?9)\^Z"A>?7_7ELA.AMLF-YARCF1OM!MU;1'&E44P[YWUG[Q;-=)
M$<13;)W*]CQOEQDY"6-$"D"??B]EV/2*N(S^*IYKWWMN7QG+Z\.U&'\._[T,
M1ZO)`?(#CH8J@TN3Q&%>9=N5PA/(1G!4R<N&68/J9>!?`Y]`.M)#_O9T.@KV
M[?T0Z@`H`=@%AG\"L0OUE(_AMGS;<UWO`.I]9ZD%8H&2IFO3IN'R0:X]"@X6
M24D*5]GUA@OP__\93X+9)WJ8"+WC"Q[A.+F.AG6GB(XJ7,48V5882M5.,':U
M"E@!_G,X),<VD$5&G#S"7]*O^!%'%=NGKGYG#ZYIGFU\<,=[>R!"=Z0V`]+X
M*)_Z0+[B%),B&X"$R4]8G;-1"F9UOB'@Z8.)*%M7M(OFX2!%/EGPJFHQV<-Q
M7,NU.@#.F^]JFY;GL&<N243.VQ>*R,EF*KL-\%]Q1(JPD978T3R,Z.ELI.:*
M.FT!F?LF6ROZ""2QZ+E3I&T3_N<J0R]6;<C9&X['*DX#^+<+<M@A#)&KW\IS
M2\0J"S)LQV6G%O9`\"+D50A2;\5G=V$(0"BZT7W+\0RO*408MN(Y_ARGW3;T
M%@8_2GF-S8=268.7P]R6WOHU""/RZVVTO59UHI)@!:@^2Z$"E&@&W$/#@1KK
MTBB(U9P#511K,+B.'G%*R]7D:G8-$"&X4J`]ANFRJE,%1!!8H1%5(QQ"6]LH
MU$.J)[/\FC)GT70+VYEWOL\'C;?2E:DCW16&36C+6LAVC'IRH\>OW<117!PA
MU(4#R-418AOY,"*AV+DM/M)]U_=,1>!%AY">;["VOCYVL/M*G4/'<W2=330N
M`)"+C'>?U@'3KQRLF!U8RF$WVGK5*^`"=U3)ZP/<5M#W7,/7O4Z@J2P^()*G
M6%MN&@C9A>/X%$)3V`0->'X*D@B^DJZ7SDD)ZR&9'@UGRZQB\9-OU*I,PCA'
M%^SJTQ%D8DD(RXLY]R[8&07))/BZ1S4)XX+=O=6`Q&\XG$S)KK9'<(XF^&9)
ME/5V3!]C5@\E:UGYPK+A.(4SM-MA5<)6P`X3R_1-Q^TI6PZ]+<\5-2$X0L@0
M2;==#H'4RGK[W*]OKDAY/<-W"Y4P#JW6=\2K69+HH<H&W>"OF_(I'+G4V*M"
MHTBY,\2>;2=!HQ2%:14,/5M'\&^_&7:F<U)+3]7+G)+0'HK*3]7<S=!'@JH5
M3DTAH)KI;N(:1'4QH/XVBYB-$J4MD^#9_!U)B26E,M:;,Z+1Z@#7]#X>?,4T
MG+X+DNSY*DZ8>BC5Q=V%SLAZCF^2A4YNJ/WA*[:J*JFA^'J$PS>O?!(4VY?_
M@KZBDZK!KT<=VE8&Y"&76]*N+4%5U&';+BE@Q4_P=,3$/<"?!DT!CF6Q'@\`
M2'"08B`T"1]QA%6LL"(;F6Q=LJ.0U..7N`[;"P*BSI[O`97V8^7IZR'?:E??
M6Y9K9*<:G6_U8\][SL_%I9>!#0!_Q$D*VG,[_AP'4;H]]5!A.J%M&8:W'K!%
MX>ZG("38U9,CV;KZNN?Z;TK"5>#=1CXBF^#?A"A\Y#@Y"<@87=@-YOUA6B>&
M?!%$N9:RB'FE*PMB>9^F)#D"S0:&($BG,_`E/_W`R3!,(>Q>A]NJ=KSW!JO0
M^6#P)QL-<9743DE$`F:%3X!E>]_G_%5J19=N3J?$57@WS0BVJ(AQ?-!V8-1V
MG&9C=FO%5L[_2!NO/E?7P0$#8/KH)&35_2(*",M"1^9D7J:PQ"REG`)3$6DZ
M!T:"NV4RG`:$U"!-L22GMNCX&>;N:4$UL77*2>PAV2]0`@+/,NL1*XXSS@QC
M]Y#&%]#*TA9S#MKBOO7HJMD95_=V#ZFL2ZG7LA">N5#VOOOXMSA:+*,)C+GK
M4GJ*DO<,77=T4J^-"V<_B,I:O>HSJ=:K5:Y9DK+Y\AJ=YTAUW4)62:[>"Q22
ME&F8%HS[E;AWDL3X%EE<6IBXO<Y7)R:6O8')X%M%FS<XNQW?CN$>4#]Z,J2B
M<=`T;-M'7CWFM7'W4Q`=C9.](MEVW+3\NMWC92M)^W$5>IJAO_6TSL;=7DE`
MU.X`V42YCXSU+-=X"89#ZI[9TVEM2:,+6,8W)>&+VBS7=]YZVHL87:1O])9-
M]$6$L_TBRA7>6I[OH[*MRGR\3U.2O#F$*LDJJ=3Q(HAR%.\@SH=3=U:XY[VC
M%S5"#BQ@#H;PT93Z.`JJ<NZ=)E076F=T!!=@>$G<.394NI;[HD31UK\3PF6;
M,/@E>":PK5TZ^]>OHQ%XX@`/?PX?Z9:!()J$#S.<+VB_?_X2_`&VC[(A!/,3
MU@#88))@*H=4+<G&Y5][Q'!U;F?]=A23^*HWRX9HV,]JDNK`?=HSN75&G!.2
M@3A_F9%FOG1&G*&U[Y.?I@A7WJ^O5(?+0NM&F_"/3P]?$`"W3ZP%YR\:SGZV
MS`L7$<=BCVD:ID&.R.N%Q`[$#PJUJF+,,!SD^OOY)JTHUG4`-JG>ZP5\!2OM
MNJW73`+>0]<M+:&&Q/%>H@SDIT)W0HO#`.H6.NX*GF!+JTZ';LV4=^G6\8T^
M=E7%<RAV'TUVE^N,CN<8+U$D,N=4ZA$2&M5XKF'UHIDZC5K,?@Q!O0E+/,>S
MY4ED9Q?E09%P;3NF771=#9.W=/LZ];<=.<%BZ7Y'D^,AVWF9TA!7;ETT-?43
ME;:#_.,#1!?-W.,E3#6DA%HWT[6-WO3GKN>:3%^WS9[(8C4`&C;0GNV+P_!*
MKG];/J3XWTLBCT?XO_OG!<X5I'B]?D7N!FL5K5VD&_Q$?SDFAM+51%/?OWYD
MWJ'>`DP1VMY9&N^#%.P'J!N.TH#X6@K*3[L(V3NG8NS!4`14XE*\*I*\J2.>
MB:S=`Z2Z0BJO.62R%!K/&CHR?`/M'NC3%5:)NV_K\]Q9,+D*PH2:M4VYFH]@
MZA[A]D?,'`N0V\+KZ#N`2-=99GNF\4+!@;T60LAPT-[*CU@BIR$I>07V.I/R
MIUDX#R-X'YD<+WGS=R!(E?O3C^$TB"9X[ZWR==#Q=*LL]Y,?>W\%(DW5%`BS
M-!2ZB3-<4I"6EJW=1`B#)?B9\.7AATTIVRL<9,L$*U(UW]%]TUR7;I/%XT0D
M)38WQ?)T^TVPXJ;`2D81>L+EFXSE&E#?]MU-(MII2KG/F4;$3)BN)U&^.SL_
M3EO`'-..Y]L#<57)NC1Q#-Y>_";TQCB*\)#TS]_";%IP.Q3DFJYGIT1![AU]
MH0,[.2KV]<J*8Q+!]Q$R]T]??36BJY7,<2*JUN,1E1[E7%)T@)/K:4J/[S!L
M\1(L/S,O'T8SLC/I/8YH`F,PVQM;%4S^&9[CLF6AV\#L!4UY,W?B1;1(X`/R
MUK,.GMS8Z-O<&W\1*[;MIQM!$NOZ(:178Z+=G^GT'>Q/`)\=Z=ZF\.<A,*(0
M<[;R.7*=/$M9(F*Q5B]/RZP%=ZTJ@WD,O?POJBJW8V(#/H;I,%Y&&0P+\W`Y
M5]V510#B34X'T\AN+S@*B1^_4#U`INNZCA#\5V$$+L.Z4$2WNM`8"Z<:.+YM
M54JQ"(8+M-"V=SW7M)J#OH[RPXX_K@X]OHY*UU(4Y*DXGH=L9GRMB4P.&5Y#
M8GK0$5V[,S9B50OZ@^_J@LF`"5J`Z_KI!TD^P.EM-L6)@@+]GNGJWB$J9;BD
M,.%U4PQ'-[V#'48B%;&[2GQ?-)'!D(YSZ5WP'$`HH\!^F:;O'^*P@T@T?%YM
MLEU#-Y7B%ZI"MF.[KE#YD\4#Q2.@[[-Q>1U4$ECPQLB&[>I6!RR$JI,%`WA[
M#C<X(P77[I+X,1SAT?OG[RE9B+I=X(2FJPR&,%(JTJISP_:0S[HB]=%)X\1K
MK$P3N3:["Z\33F)C>--P+-.V>#F!>:-EG^YC6M$GP?#\:$ENQ1(/YCL0RXD`
MQ*DOGN<RFXN/`N)'+S:J=]AIQT;H*U3H.GK$J0)#=$`KA"+C-2=%_:@/32`A
ML;:DJ#+M",'M0XQ'Z542S[<K2,4UH_QO&'Y9KRE)/=-^U^'6=;:6!!]@I=1Y
M?2S+MRSS5*CSJO8!*[)%N(N$F?6^)?41P[ER$R<:7'.ED0I.4K6\5@"/:G#R
M+9B1E'&ZE*K<`Q*!2&CKMT0D)VFM/BB6PE>\6'E"MV.:\J=NIL?W?09V%1!!
M8(6V>R,<8C?:^9:/Z@F-+F.RRO!M^1`G([+5`X_@^CQ,TSAYIH_1FN8?5X.3
M@C6K(B>;.;Z,'[!:[IPNB*T;S@EQE^B#5'C7&U`J)WL0`M>0=0SK@Y-&B=?7
M]7VRSM$Q);$CGV7JOL?/B3Y"=[/M3E`JL'VNK?OL<FTU&&&0>1=E7<MW6*E+
M@2S8+=8MP]>-IICAMWB.[X,?9&`-1\HCG\:?%QO;U/B\S*`TRG><="/Y1M\6
M+/8CWQ;K4!IZ8<EX^^WM/BDV@QGB2,:=(+E0JMI&$!8A;=4:B]@]R^QVI2-H
MJE#O;._JLC&;0Y'6EG6@B*UTP.X^/XBE9/M%GGG^H;#M@*U&<A?/PJ&RR1%Q
MX-95*"NJ3^E.R?65KQ?,MJGX--%_<WUSHDN-''_7]>S]_3/U&(D5A=A$-!&T
MF`(EVZRU]!XG\]SH--]E)LO,R$8JKM>(1RJQ'`L7V".4UV5MBF\HW8#5`U42
MBU:V.O&B%9L@5"A_Q`UX0[WIMC)9"L.'0YPJ=+J;<+U3[A@23L4MKJ[*G[OQ
M/<MR#EO#9I!5\^>>"'(,G;/OJA:`A/F*:L#KE=8<]WW\&4<C4/AJ`@=FZA6<
M@.2@PV.[2#J]$AQO6AQ"AWO!"Q*<Q/F^#:'!Z`\(_$B(MJE]J&(5$A5.QSR(
M1B1L3N6S#,<SE,#NT'1>Q4GAP.U=?;Z?8D:ERZH9R=<?UW>,!N:3GU+O!,BI
MR:;E.?9KDZ#23K4>%7Z+H\4RFJ@]7]'W#<LXU+K5Z"2RDAQL-\0F2QNVD\F?
MXR`Z6M6-)(U<Q4OB.B@8=TW3W)[OVQZI&K+B]$4P3/FJP[J*U<4!.QI]#=LR
M#$_?TR(.T,I%($.W1".6I68D'V.&T_33#YP,PW1;]3PM=@/YF@2*9*VCN;JH
M9-`0IPU<H"0&?+?))(A6M37@<VD\"T?T+WE-M11"DF+=C6"V*>:5D@HLLSA=
M)O@>8+Z?"</_?S_/LLN%EF;/,_ROG\;PFG>:H2^R7Z(X`271_I&%<QB^(_RD
M@4D.HG^<:?3*F99"+QI?:O,@F831.TU?_+@$2+,X>:?]+4_2OM0(IO,,A)^.
MX77OM"B.\.IJ"+:=?(P^-\,9],[S=!&0O#5R'_GXI?8$O7E[E=[Z-`TS3*_A
M[7WG3_CASQ`^1=Z<9DG\)SY_"D?9-'_HIY\GV24A^D#^<'-[_TDSM)^#^>+R
M;YYI&)?:^^_?KF\^??M&[OGE87WW+PORI__^K]<C(BH2P]%?*?W72/HKV,Q@
M%&@0T27!`B^S<`@LKJ/AQ9E&T.%D]JQ]`,70;L((Y[]H_\RF>-.!3/V2+)P'
MT?/FBG'YOV?:4Y#F;QAI\*=`N\&/Y$/#.%G$25[H#O[]$CQKR#C3R)"E!=%(
M>\!@)_,G0+#+<3`DBR4)_2W!61#.X"_Q6`-C.'Z(@V24KGZBQV!KP1#"C30F
M(_P%(:6ML&DA>>-P%D;A$!HP)<=B:P]AO)@&(*PA)0[7AZN[Q_%PF<+K`.$H
M64Y2+8NU+,%!IBV","J^>4K!`JEL#$8])N#&\3+1%OD>6_@QTT;AF.Y^R_(O
MI^2FT?:4;DH!:..`B#L'MP@7&.!B<BN1R*9VHY9-$XPWKR^`V5@U]S)E_ZP%
M"[@_&$Z)'/"/!83RP`Y(@?^S',(W'J'Y9[.M@%AP29C^F4MY`4Y5E,'0!"A'
M@`Z>TAXA#*3;039\0T!+LDL)\FDXF<(@.<>9!II`7QV15/U*U/#0&$)&@A.&
M.=JF\+X;Z&F_Q\F?VH<P>[[H54^]L,/HS3Z_V6<YI&]S$VGJU$1:9UJUP=;^
MR9CDU6VL2:;&#3`3*ZG1_!1MDTWS%&93+=OV2##?\'[\\,Q>!.-*BP>,--^Z
M</Y.NC?Y-:33/M0^Q,L,C%<$(=A$&^;%9:&1B+<*]ZZ1CZ%)Z(/TEVD\(XLV
MI)/C-1J62!%H@0^TS@8`F8HD'S&],],WSG07:7F18W)Q2-W^%1)BR2M,#PN(
M2"`$>YF0ZJC$.P>*GG[A_YVA4GBX2@SLMX,Q*`S]/'COZ7(^7XV#N2"+5"^@
M43=6_XS>P+XW7I#KN5E^6J]D/$&;;<0XH@(JO0]DL%@F<%N*J\2TPK1I>ABC
M-#ILDU\,G;S"N-#NDI`T0ER"_ZSP_#08@=YK,:T-%N1%,.#)V;863CXB+)(0
M8I\%T1ORMK5V[*`AL4\2/BQ)H_R/J<W#V8S(D?!%9PBY9P@0;HE5M7>Q;4!`
MJX=UGWF8EM#6!N2;ZQK'@'(U=["ZKU\CTEN\H(3^@+A]T/C+65;>@\_VK=SJ
MOK4I?,##8([I)4;Q=QY8W;QC#T(B9R+>M:@?@N&?DX1,FIZOI$:9Y5AI4>G5
M`L[6V!_JL&L;$D)'C2C(^-#80WI/N-I<E#\4++,I^.%_X=&>_;5U_4S/_UMW
M-/I\\2FFDZT?-/<>S'L>D4/O7(0WQU!11[S?4V4:?`9Y[;[5.!CDO97DX&$(
M19()C$,PGDWI>$SB*^UAF4*XE=)AX8&>$4CZ&?6#P#E9ZWY(%[/2$'HGB:#@
MTRNO*,D_DW^4C-!$I<?KN3SB1Y#BNG`=1MY%G*X'O'0]R4>Z>IR7Z2+C-2C_
M#)-H*O_$9J-IF2,U@E>0'T(:?`WQ(H=.'4>+.(ZZ=:'5-%?K_L^8)F*+5JY,
M[@L`L1(+EBX?0"QAD#SGS.)US3&-Q(P9#<%!U!EKTUZEOKY.TJ_;1C%C]]I=
M7G%<S:ZD:4S.8`";0H?G@)+>F*1'0+M,\BY*DIC!8#V0-Y#GE@D-?FC7JO)T
M20@3@,-/^RX[M_,$KC-Y5;JD$V?C)9G:V0:*-,(BOC]T^]7\SN81.J7TF-]$
M1GBRWD)GAAY#,A^T-_T&]N$/L&ATUHER7KD%\/?<LA#S!I:6<'@(XPP/IQ&T
MZ`0>CD9+D"OYPW"V)+;H#$23`?],(^>YYG-99T!L05(`:2A(/)[9+'B@<XV/
M@):$/I-\.>6L((*=(!?8A#0I;+[`8+;BW`DCK;%!1*>QPBB*'W-CO?OE/S%(
M"P8:XG+-SHC@LI7K!6^"OX&OAS.PD]LW0L!-6H8*/J3-2;7@*H[SB/)CLIQH
M@]$\C$(01!XULE'RU<=!(32F42@=W"9D:B\B1.D@-%G.@FU`F#<A_8&.850Z
MC%'>IMJ)7KXJG(T>3J)P#$*-LL%F^*0;L$*RQ>9MP4O`@I=96/#Z]OW+E\'7
MW[7;*^W;]:\WUU?7'P8W]]K@PW_8>],FQ9%D4?1[F=5_D-7MOB_+3$EK`0'=
M,VV6M<VI>5W+J<J>>?VI3$"0J6DAT5HR*^?7/_>(T`82()"$A.+8S)PL0`K?
MPMW#PY?7GW[_>/O^XS^DSY]^>__Z_=O<*['^D##'9O4'^3+GRUC8/K-CK,UC
M)VE-L2%*VV<V0=I<TF:%4)#M,++=\B`K$S^2/HK%1RZ?.Q2DT&_BQSEF+8-[
M.+;MBB<^PDD)_!_WT<&@170<HK'-&_"9_,3.P<)`KOA`E5D%B6W.F9&^-\%U
MF1'B2(0/KF?W8?/TQBJ*@?1*,&8Y>Z6W=BNBQ^],7M_Z@`B(CM]OJO39FK.[
M%;(VO?C*J4`AHFY!>#%BPXZB24AKG5CW.^+0E`&JO<B:ZR74C+\[]$!&W7\_
M<TKY??!U(/WCYN9SYJS"SQX^YGN8[(2&9\*5^2>12"2Y[+@"A]T5O\]BQ]+E
MDIXH85467\,+N!73I9@VP>Z9\-'411,[`\='$G;S1?&CF1@%SP292!O^G4L_
M9B?RP<'HHQ-R``@?2Q/?8J8"A+15%]B,>1#2LQG&[/!$&MH+GDD2Q?[0(,4T
MX@'%E)5)D<]C1HYF:T02L(A3]].XRBS>?CVCH?QYJBE&`C0/][L8^L.664G\
M/HEC)$N!F+B/>*H=]'#G]5KMQ)8(TW*ID-`_L#,OB`?N&&&2^BH;Z?!@=*4"
M6@[E8P&ZT+>X.L6\-$PC`U-C6R`XJ'EP"`%3N#Q:NL*>"FBRJ'+&_+@5D.Z>
M)1E@!/7Q'ISH*.F!IK[-"%N,),*8B5G^/UO`@`Z])Z"#T1@\NA2HZ[E'%H#H
M7Z"I<?G$*%@.*-\@I-9JSWNI;0%-GGX$TS@('EO(@MM9^#;$.R<:\?1[J4J%
MGY]/C\]F('1IGW4I:V(=)4&#<EN",\?OH$'I^2'U*ZF48-#?!O>0WP)XZ'G.
M`126I\W=>J9X4_<-#R1R_M+>*WT$_,"0I6G@W3-]&V834W?RB:5JS^_9$Z`I
M0_3T+5\*X;=>@,G4/6274&0%]'AG?0=!8C.I^DV1/FLS)@712=SC23+4[YJ#
MHF,.G3F?AZN0*;P%)NGBL1.CH=+6XWB&]2Q:ST&S7-=A@*XF*C+?70:/\)N!
M]";U#IKE8]IS_GJ\A;_CR7R>"5Y?<$TK,U8$3N`+6CQ!OXV.V_@$688VN&K+
M.%P05ZA0N*+T8IH3@^[J$S&]\SIUSY\)63^CZDNU_A*:KZ_2@-=$251NTST+
MI*5IL8HKFF=",V5,F^:+^/>$!-N%:0L2T!ZE>)*,G_6Y1@.R_$D"B07Z0$/.
MZ8?N@MC4JXLJ]>!#CY@+"Z^V9D#1!UKNQ1]>F(')*_`PC(L__D^XN(NKVI+H
M9`_9V6M93IPZ%+Q_,:%=2G%^D)0TK18:K[=24E0&F@VD<3%!)0686?93?'./
MH32Y\"8COEE?\YEEU.=+M0G!=#S>!Q#3"?$2Y4U(HA1-_][U$'QO)3FL?2PZ
MD$4K/A6LM[D$*P`S/>^)'M&3"R(6!2RZ@<)<O>]4E^(/84LE"AV]UX.,!OR+
M8!4PNV*2X$0.[G+RM84&8TFMA>E'92E1;NDCO7^:T7<3ZX'%&7QBV[0\&8'&
M8.L:!WG0:FD4+RSV2N@C76&-\W<K8*]]22N%'0D!Q;KG5.8#+!,\8MH#MS)K
MTPLL+(]QXGAIZL(,;^68Z4O=5=Z%UH):1K!`P`H+#"1FP%-O^QHHBA&+>_A_
MF!;[%+GC:ZQG`WK_EW/)<N"L@.8RN=Y,KK68^T\30EGFZHJ8?DA-8$+RGWNX
MIWNMT'[#U&))E:ZE_PW=@#M63#YH&4?D.;&;7PNAH_G$^461/22@D!Y)`^GY
M5Z1G?%Z_E&L5J&;FY0#N#..IZ.EC<D#DLIL/IF7S!@W,P_?=T$.)?+!,3*WG
MJ>NHE.DD.8\MR#5O)AW-<AY<^X&^PUK!6W>6\B;774EM8UKTF;7SR1PO[JQ4
MC@)\Y#H+D^;[QQ=BR<,L5?XA(0\^Q\XPF-:0?T*ARANS)?A+Q,;J&?)L8^GE
M-A9*%G7THDW%:BH*7``YJ4_A9?<;AVJ9IAWQHD1Z![RTW<?HQ$U=4[ZM:&&(
M]5=(N+0C(%CM$HLYE^VX90(@LB"F#53$/V=(`@])CRY@>@L/I(@0J0V4G/7!
M+V6W,IE<*^[$_H?$:B".*T2!T;2/Z6,*$G</\>I'6#:Q`0O"`5AW^P4M`/6:
M7YF^)4(!O9:0GJ%\XT?IKPNL0TS*WS!]%GV@!;A1"YK.N57S=_/U=2:/]M9=
M6W/IHSN0)IJ2*?=2E:Q<61O;\`,]M](,5LH#^KV<"L$4A23P;@W;HP"`B$!D
MG-`@@&$C]*H.K0W6IN-)FEE5K`5-):GR6$O*@JP2>(K[A"%,OA]5S@>9S%?6
M"\CD88,0+2I??]=:229R%,%FQG=E/J4SC3,IM!MOVYUTS,(V:QO$A!??!O<\
MJI!Z1QR48,3CWG1RMYA=CF8E)[&H=+",WS#R0!EK>RO=;/75H!ET"_?1N::U
M-.ER57HB\'/Z#!WT"#9A2-VBQFU'4&"PCU'$)2`"R#GRZBE%W*7EK7!#$PE;
M^3Y_)@V%RU`#\G1QTX:M\[.$LS&LY5.[*8*;8>EB1CGU/>E)S^=GRN!>1C7*
ME,Z>W95I=U$0>MXZ$-`&6QN-139OY;#+1N31S-"CD5@KQ'^&#I%TWLBMKK!@
MY]@I/)X892[+16B#*K5FGB5C#O(#P:`A(`QH7'.L^<O5D3&.):%:/&<T4G]-
M&RNL?<`U^NL7"<&]]JW_DFN3CMB)UF.?!QX)YO>'TP9.H;;-U\8^Y?3?:VR@
MP?X=4\R+R$5;LP&%(MF?N4'@KA(J!XL<8>,?TJ_3=+]>FG`,?_IYKZ3E27#>
M2].[<HZ]!#U.F8,70E(#09R_O]#HHCRV_)G&EIM!YGA<MZ`_?A4!!-<:@2<V
MP7L':^3`[6T6D8Y0)]56I4<*HF-,NG4#TVX"":$PX/T?DNLGH3)RZ/,)KS<$
M9=J@3#M&G]<\G4FHLJ9\GRAQ1(ACGB*+LP`$>7+(\[OC"@+M(M"_^$VVY"Z%
M1FN(YJFJ/R&.FP==3$,5I!&D*4.:Z,*AQ1KL*$BB.#1[7=3[;V:;\S\WOXMB
MXH/1.MC\CB[]LT3[Z#&8WA!_[EGKN%EE'LUX%)J_)'YU.T6B%DIMBMD5SWA^
MV0J:"?X4\$>[`/X\?W;)'-(O@$,7R1^\L#\CN<K85FF[*>[_F<\)62[SS"XG
MR40=;>8.V&0)2&SB-CP.LZ0X+9-1D4Y1XZE%Z?RE0HI'C#00Z(I`/$!6,\MN
MTZIFL1T6"NW"#>$8S]#X82_T0VT3?`\;6K0$_NMCJ7\F,1#2)Z3O+-(W.H_T
M%=B)5G#O`.E3VRQ]VD@>30QYJNO'LD&(80O8*,2P;GE(^<,_T9S)Z%_]R!E-
MR)+WERW2BA'[SF:)OR%SLIH13])5FBFNMSY3_+QS3JEFVITXO9<N(G/ZE&O&
MXT,]);.:FX/C^%4$$'7>:%>(6''N<',P[$HJ:S^+*P4B/P^VVR*V*]NT.2CR
M<SK[)N2%^8G=%K'B+,`&!:PXE:PY('9FM#4'QJZ\L6Y+6D%V5I,&.S?1IT<`
MI(^&C4A7],OVY=N<<K_<YIR8T^[H]SV-Z1.MH$OI7)1ZZ=(2JI3._[ALJF#P
MJU*4SI9'47<21#5WR"=>X9YT@WH,!OW#>G0$UCLD\OB;*OKX4%8F4UF;%*=&
M'0"#P+X.594>'U^HR_,OZU**]`"-5=14J@%3Q,"ORS4M"0R_P*T+FF(%4XJA
MC;H*@C^"/VWACVK(BCJ40:,+1@E&U7L6."P?)KGT*)A=<K!@#9L5JU.3H*H0
MIE.S.4NPZ(B=+A@B&-(-AFB*K"JZ/-1&@C.]Y$S]F91=S#)#:HA\NVVY:3%-
MVI%6RI(Z76<./ES<(9P-Z/"E[213^#(_B3354]WT>9ZJGO.".$NU]3FB'1\A
M(.C083K,<E393!!)=*$NFTO]_%F#?:A%%7YR'ZPJFYF$4CK?2V*9.5(;VBB(
M3EZ44=^E#_"&^^SJ,T_Z";]^"QM_D?Z@R49%G2/F'\3T=M$Q]ZN=J6*U$&`?
M?3:3SM,6]W2BQ83:)69;1%DGN_:\>9I"Z;>T]8I@3:7Y68(UC;%&ZX@3=%2B
MG:HH>@4M`.@"KP@<W1Q6AFOC4+)"PF62N5K?Y.7$Q+8C%KLZ(&I=.8;%SOYE
MLJN2WA&,72-9F2KR=#+9NVH5_38.Y-:H=FY5ADRCW-J?8UH97BW(2BP/]&LV
M!]MR-B+L^=D5T53,!3[@D$"R73^>2B_Y<'Y=X?G5EP@>(K*C^^@HS.BG3W#H
MX+]*R+;=Q($^@U99ECSBKPFM/+:?SG<VK5PV=MZ2'K%.^GR8#J\RU366IZ.A
M/!TK.\YQ5:)=K+=ZSZDK$.K)>"P;XS)WU8(%5;)`EXW)1-9'Q>>Q.CC09`Y=
M>6AOX)03T#G$94MLHK]PS>,OA?(D`-]23E>]:`DPJ<J'BJ"Y&LJZKLNJH;>`
M-"\/@^$X.]8&.3K2!+="ZLX'^Y4^W@)Z\[7TOI&]FST$RG@Z;8Y-PB[N<$W4
MJ:QHTRY9Q5H/2;?T(A[.)7`PRK&$4N!*)C>;L$76ID7/1W-S;34TI;+%<O;\
MV8Z5#'FB#&6C5+IFH]=ONXWH,70JF])]Z1B<LZ+DZ!!^OI,\=QT`W,<$QB4Q
M@]"CD111Z]F+6L+Z]6PCS9IKY7T[8+]2Y;&ARHI1YMA?&=/;,:Q&R%4M<J5-
MX!2C&&V0J[K\Z8JZE+]U%H?<'3?7([_Q'5%#554K(+XZH!/^8458M6I7(4D=
MD*2JROF$)/5<DO;G;#0F2!TJ'CW#;`Z[EMJB5B-O\UJK]\[<71'IUOS.VUC4
M66W5:HKT61QND[DIT2P4EF%C,?$(4#RDT*>%M/?8--DG`<V3B?)TGJ05">[=
MQ4"Z@><]U&'VDRPMHN@3O($]Y6<>PR"5Z1%:BGOG6/\E2;;.,J3!+'QP[CH^
M^2LDX+3#SX/`LV8A*WT+7&EA+6$-]MV,!(^$.*E273\P`X(!<VG.NXI+YHKA
MYRXE\MT"386?%8`&_P98+"^5"40AFID^\0?2FP/16Q'3#_%WC(3$,><!?\H#
M^'P`!-^.'[F2N5[;3_@'?$V1Y$S@-<4LBPG^`=R>W\-'K@\PD=7:]4SO*4,.
M7#K]YADC-!S(X-]`9H`WL`GP#/E/X+EY@.-N#F$:$,_DY=(18!$VDN6G^0G?
M<@1@180&>!D]LH9]XB[8(![\=_1"GT,#Y!Z@;@+(';*T@BUA>;P';EL!/K'V
MW!F3B>AM"[((Y[2T^]&R;<3>!\-D6@ZB?$/3SECEMXE%XG@DI"O[*%J6?Y]]
M_<KU,"OM3X*\`3!A?P5L*7@:43,EX$!42&[F$)%!02SL\8^$L."%,[+$]Z;F
M%N%:D6A[!`SJ?]G7G`*R1+<'CBAB^X,CR3<A/!P"'AYB"3@&.=EP6_ENF;%)
MTKVY2!/8S"43"B?=HHC0]P"W%R!=-'T)<_;R9`KVPIPA1^EJW;L@"_`>AG9<
ME)_"'OPK5+A`^14AC,D%?(']>N_:BT$/E7ELVS=,6E\M>]JX+2T;]:+T^^#K
M0'I'P($'5!,C!Z('F\JA^^3!!-T4^LR"\"]`Y?\>;2_Z^[7K\SN9P/P3=`5*
M;.BE7N7'NF=CQIB?4:?X4>BD]EV04GI,/T<HT/?%OP3@@8"@LRC,H%Q-&U\H
M2Q8H(><)4UAMDZO_P@50'=_!WT@,?(VY6%D.6$:/Y>)RI1VWQ8AM*C4#+BAQ
MNE<9G+`;Z4@UQ\T@B"M["XY\6$!#<Y^^>OZ,:BQ&$%B8O8!:1)#+</8?M&"`
MZ=I%G83VGWR'8Y/#=,GLB3DO8%^M.=.QYG=J_4.PHA[H3SGV/F)J(RY+V`&X
ML(**Q0WO[BETO=0M??:28\7ZA?@$>[EP^7P@MKO&_=!K-=MKT<A(Q"*1"`#:
M#]`WM0`5"UP4/,J`9F5N#G\&/@,TYD%2U&`N'M#/6G''"EQ;=/+2+Y;9??XU
M'D2P8'N%*IJJ.9G"@.N$=F`ZF^8C5N8F-2,[P<YZZ6`F0W3AA-[K&_*1WOM*
M1>X5%;G7*9$3>J^OHI'6+#S(X;.3O,N4'%FM;?>)8.<U[P$GA:(G2,"KI($!
M\IV?^*E+#'[WH^G1(R#Y*Z3'V52^(]-T+E-)=Y@.>;U`SSQ;0D:U)[X%M9[)
M%-E&0`+C'VF]M@CI8%\63@$@8I#I8P"(Q]QGT,(/UB+&9`O^>&GIFOY-GP77
M-GF"+<CT<2$&"<7N,=CAKIEOS"(38$:".(R$B[S":XKKKW,X[&)4AOX8S0TR
M%\[&"P(>/6VOE(JLA8[U5TB#+6AU`"9X[]QGU'-I<":F^B"SS^/P#;XI`@Q-
M!\]/]1E6C%P@EM<1+A3\!8&U5AA]B3SQ;=91\[C@!XI$5**0X-;O<^3$\OV0
M+&3&3X*\CJ(W<!2"$XD=2^J"F<H"Z<AC6AR^\O&TP6*2`;PP)C'@G0*2QZ&(
MPV3:!/GR"(T2`7.X],&1T++A;?!=+D4?@.MR%(C<H`!]*H6[C,?*"!:9B@P#
M.(56=![$]R9@#*0;^EB<6IS%8@-T*K4K\PG]!W`R<D-\&/N%/VC"1;CFVS:2
M8-I.,;4"QXY%9EE@EA$Z/C:"2*,0N-P]BF#-^C8>>;#((X@`!@KO/,(/J3'Q
M6,0,,$;%20-9[LRV[DP>(PSNHS!OM%#H()F0?)PU`$/,&1H?IQQR%JY'O\MX
M7?_&X"$<-CT7@`>DLW$V%@SD:.Y=BTL26@D6E`3PS3OF("X`3S\CLBFL$$B.
M=ZR![T%*Y@35J7#E^H9\Y,I])('T&]91PVY`F5R!K'Q%@R-\N;[*!OCUUCPI
ML$?!F#/!8)[(YL5;]"4>"C#63CQJYN>F/0^9C9GA=13X3)&S$K_[D%=Q'^&1
M8$H'65R;8,%`Y4E.2*.!V*TW!1VHRS#P0?/2Q2)/AQDWF>IV^'[#O5BZ7F9E
MZDV`16*.SQO+#A&)TPD"&C]LF!QI5'90)NV3)3YEX%'_Z.F:426ZV*4$P7AP
M$<WHY1QB"QXEH2[/:VR.+-WP(H7`0OPV*A+DI%;A<_S-5_9-QM12J$,/O%:?
MI-&E4*")YW9S(+W#PP185X8C1E^(C^V?%M0">]1]<](7QU&@(Z$EEZG09SY=
M+--X"H%-0L,E7#YRQ&\1QE=D1?=A3*)XY%N8X9XA_SFZG["?F!SAMO+)'$ZB
M<<X`WF.F.Y_0XQ&70WXSNLA348?KIAF9FZ'/DBA<R7<!Q=!>T+LJ`.XZ!HR^
MS^>]U'WI"LL,\U4`WPPOZ^IQWF:>%@GTGA[->PEPP4V:S]ZB^8B<6-I8NKG!
MN@>UY\W]*F[4F_OM$;TZ3RM5.R;]N$E"9_044SK7@;OF6X1_$*$4;_JHCVV.
MKCOX'8>V!B[BHYX%0'`TW8SYL+VRV6TX1=VRO3G/57B\M]MF!"[^"Z6/@WJ`
MBUY(@9HF/)=XR\Y1S[JLZV-95XI[2K1ZT'49,NR:?GQL-\*R0%0\\[G=Z#<_
M]'ECWQY<X7]LV4];>C6<#0-5-V1EJ,I:F69Y+<5E(H\4'?];U8KGZ*"Q:;G2
M9]`H5-06@@]U61T.Y=%HW'W9F<J:,9+AT<ZC,I0'$T!%TRO;T<W;@8VB_4,V
M!X^,-N#?]ZGY"[B7N"W&8DYYN_FD3F1C-)25:0E5+!AU!D89X[$\-8H/W-5P
MJ3[/);=V.ZN?1X/L0/F#):B5TY<;$I_#@!E.Y<EP+"OZ*=O\X@9DMXI%&GC%
M4T.11_HIFUSPJ$X>J6`IAX8\5DIX^ZV<9M[JNT);C+HM4VZ%UP:TL0!FRSIW
MTF?/==R05\C4W[>B>Z2K.[FB>Q2IAPYM1OF]PZII\:J7Y1Z_N_GZBN?'2S=?
M?Z??7*N*'#>4U91?4N6,TM<`,\S>PIZC62E7M^[:FDM3=?3R9^FM;<6%M9CI
MQ0MZW\6=-[[$Z>)?6!$%3U%_3W-::-FM(]W`APNZ5N!*_S(]B\\(YC7-\=+_
M"*V%R3.U&!03A/NUZ]#S`ZM"BI!0?^$E%M%#A,/*:U,69&DY5KI50X*R3U'&
MY)S@B66+S3"O?.4^1-EQEC-GN`".29^1)#G>2V'+*H=IL?D_;FX^TSRV@M5H
MT792)\ASUF+Z8JL$5MR!V3J`RO-GJ=4MAV:TTUPRBCJM5?%9&CDOBHDHS=N"
M1/TU>.F-$V:0B%+G9O'`/7,)/$F*L=61S`4KRJZGA>C6*GZ4$@^[4/R/^XAE
M&+)$3(_62O`J%8OF*ZTLV`F;;6.R#2E\]@RFXMU;M"#?66"9#2_<V9X"A9]F
M"LGK2K#;]H3:K!`$$9HVC>TG1[I\)FZNPGH&\5(;OEM=VD]"<FGW&H]Y9&;B
MD:TS'ADJJ7L34P<E+/?QJ(Z"15A_(2R:R>G0Y(M=*@1T1_%Q7'`GO7UHW.WO
M`*&$W!0HMDSR?:IPCI4+8I,KVT[T%'E@&HQW>J$.(V;^TPK"'*W%6L1PKQJ=
MJ:0RE+U+6EC^W':QXC1;@)+2=W_[*?2O[TQS_?-7H*^UM.:F$R0'WL_@Y,[!
M0[P%A%_9[OS/7Y\_^UOTQ!LR"][$2\0_H6TEX!]?R/+O+UZSO[\9']Y^4]1O
M_S2=;^@7W2K*-_:?VT_?=.4;.$W9SU_\FA&A38:7Z[.Z.8$IRB*F,:B(M_0S
M[+UD.L'&IZSV)?FP2(QLRR'7]QL_=KWU/0CFS]CLQ\T*,_#2"_+D-%^><T42
MQ,]]C-^>(\A[9#:SU39*]3[=OI7TS-`/_.BK]/GFCYM7O[W=JP<OC&NM8-%A
M^6*"%XWS(HI&O>`^`SU4TFK$R8_HI:Y`4[O>$_JY0.JU^40C#KPM#ZM:HYJ>
M%KO0@^]!312+*EX$OYODMZC!.4L-3M[%T"Z^5)\R44-*0D;*>-W"5HU!7&1C
MGU1:D[O6280[Y8WG*M@H4>W2G7H,=3PMO##):(SKZ7:ZR#3.]MYGR+#D.*;?
M3C+55*U0/)_AH%J-_5GZU51*5%RD<`#6NVH3--60E1TW[6VO4(@E>9<2JD[`
MOY)U$$MX7>6+=9N24F);-S`'[<`#+$PII`1_CN&/,1GNU!75<*F9NHXMO;&1
MO4YS([-'M"V\C\WBZGU=TU11=@I2!^U,@1C]1GPX<R[(C,5@,9@JE)(P&CWB
MSQ7XG[(R+*Z`+L6FBL=]'FLL=N37[[(@,F#B^T>J@S*)P]5GYI8^?=0,PE$:
M8%CI_A<,*6#(>#21IZ/BHK0JV+(_>_O"XM[MOBGLV:53@\QX_NR$B]MT/$Z3
M,A&.STEXXR.U49]3IYP>W>6*?268<1@SWCN9^+:631+FZ3<_\(`J:XY^X-TO
M;0-K^O?X"W!(%S1E^@=U0D_)?"P`S?'!$*2;`L-@5[\#"6!#H\JFK]!&HK"`
M%+59C+O8^Y@.=(W3JI+.ICA7(&IJ:HSE$:P8-13=:'%*^Y/C>(+OQ)M;/J%=
M_FDGU!^4P41)>C]N]D3G'=3S&^@G'<9]F@F?\HVC60M9:C%ZL,;OK#'EUF,`
MD6;(NC9BD*3ZK$;S.1DL\$&V__LV%W3&SD>$SO9=VIH6ES4W_'C>,]_'%O)P
M_/@O:]L:ST:+^JS'7?!!<NG8,$S[PJ:;3Q$]*+)9"M*%UZ:U8$NBJ-&J`C8C
MAV([DE6`DK=\78-7QQ+,S#M:V8!S**@`Q;R@X/.N/3RGS+GC+Z0#V&(L2D&<
M)/7'F-.!G$@8W1A,?\Q!C.\<79?'(R5?+K.==H-->2O".YI/FB.+3-ARY8QW
MNL]*Z@^J+BN3Z4"ZP5F;2U[%L2ETAH9"QV<9%5"7"M5$5B=3/MHMQ!ZL";WQ
MX3286R+$BPYPXT=MB?TT$_P8$>3C?.Z%=)?PMV`6-4X$^$['(,#*/V`][!1%
MG+#T0#P^,^E595A$5D=ZE@'Q,`7:KEUZ&XT@@4\_F$\`V.Z2A\NW66?+2(F-
MY6!D.<*%:)T+<7N_<V_2'8BK82'5G/9F3O8C_,K=JP@/W9I4"\>J%O-TZ5!B
M.@$IZ;Q,!_GP,BX<YYG1I*:%,]SB\3?I^28XDI@[![;[2,T'O'@#5CEK_8O5
M/3?-6^ER0!<_FC5$DB&GF[.&LIVDF8'RX]DU'.+(I()^1\/`G(L-"+F=HEY0
MK/YI9^K-N:K@=%D/;'+IYBSO1+,'>1-N>%-\XO!Q/UEF+(E)H45K&E<4+HJ8
MOL\+`^G\DP199RP%>;JV+YKO$]G&!9^@(XQ`%[2.,`%M8D84F\FDDN@B.-,]
M3HIMU1YFO'>RN5EZ?G2&I[!4$)T9C=/1&9,'9ZP-,(:5A68TE9V/+R$V,\'&
MA?KIL1E5'98(SEAGBLT8$WE8;6S&(YOQ&2QHKCD^HRJ&/!F/6AN@&:JR,5&S
M\-]GXG%9D6"=,'8$:31U*H_'.B7Y#[HJZZ-QKMALQ&"*FT+`.MMU/-$QA7*.
M_6BKM$>.ID("X^PGX5*?W]S4S(+GSP03#HNFQ)TCDC%R5*.R,6O4,(!=<<C2
MHD?95-@@.DQ'9^>L.YXU:USCQ,H].O]N1%+5":C(V"?P2#SVC1V:\RU=HI*W
M8AK,>AMI19H_AI<-+DZK8#_]L16P,:T<ZER/8#>1D)`[@])%,0BAJ\Z^3<0Y
MI47,V!,!WG,[LS,VG-S6%)P1FH@71PI#1(OKC1;/3)M:(O^>$*;9]P6,F7T4
M`>/6*BEQ:]@J=K3'9B#A$>TXDW=7"<M[MIV,J#EB6@O32NK(7)A\PX+.N/,(
M.Y6C1OIA/)8G(X7^C6&%A06:(*`M&K$W!?B(H),C186ZW`\]^IHUM@AZRBH1
M&AC!M]!VEZ`:@#8.JF6ZW+:U8_XSKG1/[[@P*,9.T#9=*@##QWH>Y3UK*&SU
M;&S#\B5],-2-'ZDUP4:3*U#<&STULH1RL2?3#Z,)/?/38;-T&R`3D,:.@QX[
M*"ZNW>DT9UB)FYO<KDH%/9*R;90B7?H^5J#^C;/X'[(`@;B[P5,"M0T-]5JZ
MY-:T\34,[6TTS/0V>O/VR_M_W=R^_]=;Z;?W-Z_>__;^]OW;KWOO7GI!KC.U
M"V]_M[>;KZ]Y7^"/[D":J*.T2&6I9K'4[&BS,U>/;W)*2RM+:9J#L8#?Q>V$
M0?5$`0\,-3[2B,?3FOG\B?<%__0D#&HLT(_CSJ!/H_).VDGCONKLB3JS40=>
MWH)X#K^=)7WCJ/E8D.\\AHYK/$;.=^1$@VN^=GWJ\!'T%LT@"H@N+0_4\MRS
M:*N[R"/TY^X:G.WO48-A?C[(=/1$G%/=/EGT-B9AE/B6:7V,D)O4@V>N??;I
MY&X#J)\_>S1-R81&*4-!#P`LRK(9,O&I<;"BX%+^J$36NWC..U<#2TUPBND]
MRL8Q@MJ@3;-#LG=8A1=8N`8_>;D8@@(*4"&@10'X)8LQ+UQ\CG5-75K?Z9U4
M$-B,^JEVSO'0=G"LO#3F=)W,_1,V.WQ"Z:$'.\0C>RRDV/F9N?,!/P3RYS-'
MQ:R1AI7Y;/HHXI=A6#+!/I;6U-.9CHS)T9'?50#$F:NDO`.:Z!5[T$&A7^1(
M^[[NC`=)N`K$O0/[?VUZ3(_\"S8X-E__[%HX6V(!^\OU6'OZ`=507(U2I9Y6
M]_GQW\6&06%"/0=@B..S+NX\6$OOI$N],+OQ8/.SJ`".A8>/3<]VI:_6*K0Y
MEJ&/;_T'<5<D@&TLO?+`1L`Q3H)_W[M)L"4Z%,0$BL(W;-._PN+$ZZ_S>]=&
M(JR#*'Z#;U^Y"V+3P`8%)WIEZE5!,QW8VRR.=>S.^C=DT=QZCYWCTQ]%):2,
M3!5OY*0#(Z8.@+%=P:KQK;H)MFNUC@2>V>BL!#(13:YBML3=SXFB<<N?YWL<
M?+%<U`JR?S-71#?&<W1CK+[K3%'WP_=L2Y5=HD((;K8[.%36K.8L)(VUTQF)
MRK59(Y2MIKU+=?-6F^QW66,3.T&0FAO4Q.T]M:WVGDG_C,P0;GIMB8:/WO_%
M)W7P0>)P0\E.G!5V[RSQEK&^HZ$E^$"*;LC&<-(0-!7W\RQ#AUWM3$O0H:V]
M/1,P/FS</&>N_-'3)B;>AB193E?J9J>H$YO=%??5*:"_.E!+C`&NM5%?:=BU
M06N:\^4H0/SK;2;,>&9R;=[/EC]0<(D9L:M/;:"-,O>-796CSA"F66WVQ?+_
ME)8>V;RHOM(J5EK'=^A4!V65UX_M`=TX$?1FF@HFZ[^EP^[(0K*M)2TAPEH`
MORP]GS^KBZ(5;>,$`&7`JBI:J>7.3J>(.L/!]`*472S<#RY>#]"<H2N]-8JN
M<MD>JY1Y8_T4WK5&F59.GCQ"9:&KB&1G4^(+"Y,U`+,GB]@+7[H:MD;8/[K.
MMJ_<-2U;)1+[NXB**Q-!D0P=Q-51A5='@;O>$=H<C083.KLF"KSR"^#18%??
M[;S0SV;$:S@UCGDU7@IGBB`LGOUEVG-,?L`\A-UU>>O0P]*1(,I&2BZ+`S*_
M=ZR_L+H#,X[\N6?-,/UHYC[PA.*2MJV`MN5HF7,B/>I%2#D/CKW7.<?>1XIP
M7+XY>TI/R&6I)$@JM7)?A!Y!I&M6>GWKT1CBD_0*2X.22_O-T.)@EY/2'&-R
M/.BC&7-O@7!Z"*($F@A_E7;6M]D3B7O$F=2/W65ADMV:$$]")VN]0YQKLL*M
M-B\YOG%-IK?-9&A5PLUF2G!1_FY.9@Z-W10U<LB=W*IEVSNPG&"&1$XGB`/>
M4%?Z3YO%9_\N$HZ;R/FY&`C*9AV)E*>#4IY*!]TO#8C(LB2OPTFXG8:G'NGK
M?)I3M5.,+X`@FB"(D)`&):3VS,#)KL2NDHF!>R-JY\L&W#G46]-D7=?ET?2P
M:>2G0]-2.JA369^,9'54G-9Q*5F16^/.GS]+4V*HRF-U@JU4&X*G190X4B):
MG1^Z,>%]E#>.=Y2HXQUZ+U7)#)JO*.13A;=;Q37H2)45Q9"U'7+<E1M=$$-%
MA__RY+XNHZ+BN"A0,=JX^[A4SY8&<S)*JH4.)IAC?[R6R-@1L.<4=W4$=LQ&
M[BKL5<I,U18>_VI56G^W-YB`O>NP-YW!V(&R!&6@3DLNUII46F6@E16-%L&N
M%Y<1MA[VDV7F3!GS)Y6#U';"&1072'?E9%.^1*A].&B#MAC)5LC2V=+]VUG6
M8G1678^+;UE:#GF':5Y\.])J`RE*;002`HGV%3VU.E'4/KB3M<@8O812G\ET
M8&B'OII]2%\NBGU*OFB#=J>6^\B2ANW+]>,*=,Y!OQ-K<C;H=_E5.6F[U8U*
M4%$;2RGR_%E"D]=LBI/E;&C#@JE6AP]'I;,;?5X3Y/\L:"^DL5RE]B8=]/7W
MRW1G=WJL$^&P5E7BM&',<W9)E)"\3:/"`6<;H\SBY:KMNH)2LK>Q2@Y>EX!#
M=;S9S`FO",=7?):C&4C%]2Y]Y=XEX-!Z"7R_-8@CX\%M(5X%63$.XTD_%;WR
M^&F0]/5IGQ.S>[=YURU\XM'CP!@$).[8S!SJ74+:+43A9+`;A3XICDO`H0/*
M;XZA)2)=+0C[Z^6NXVROF7D).+1>(-^E):\6%1X3,37CJP9=GF569#1HL8U'
MYK;ITT'NR"'T.0!Z'!<,O!`&X))P:/U^2\Y?.[!MO^<4A4][M7NJ&?HC0CG=
MP*$RWC32,J`BNL6M&/K*]4O`H9>2NX8_W46O^7X)./1&=G&$1D*Y5`BQU^R_
M!!QZ(\)INLW-M17P-H5]9?PEX-!+X8TG<5XPU^LK6DK3)/ZONDV@:_5L)'J=
MZJ^<]-C)21M[BKHL6TY"UKGK.-COV'6D1RNX+^[0["[AGWA#=N&R=(@&804%
M+4'KAXO"1E7EL:')JGK@3+,+%;1+P*&-XG59F^5:2-K%X-!&^;JLW7(UEC5U
M*$^4#OO#+\5N::U\7=AN&<JCX5C65;6[@B9V2WOEZ[)VR_6ERU==G2EV!%AX
MZ,Q0QYNLS^M,VJ4`3.!*_W:==>C<`7`>ONO!FA]W.[+=;;PC`G4X0L5,[SB*
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MXR[JH<D7NZ?+6+5J]URI\G0XD@WCJ`38MC)+'#=;QI!+W3W#\40>3D68LQV@
MB[W3H;W30[]-I./L#-;0,8TL!B/-73^@#;_7MCEG\QK-._A?H9RZ*/B=4TZJ
MK*EC69D<WTOW,GEU"3A<)F?:N(MZ:.+%[NDR5JW:/5>JK"I3>:@=WYRDA<P2
MQ\N6,>1B=X\REHWCBAO;RBJQ=XH9\OQ9Q_%JU>[IH><F\FAVA&9VUT'Y(?;\
MMAPS@)^NX:WPE.L]`6`!\453Y4YOB\ZI+EW59>VR,L_%T?.".=/&/=1#\R]V
M3Y>Q:M7NN=)&&+:YJ+1.<?1L&4,N=>^,='FBBXAG.T`76Z=#6Z>'3IM(J-D7
MM=E(GQ'1FWYMD,XI,54W9'UT4<GHXOQYP9QIXQ[JH2,@=D^7L6K5[KFZ0!.T
MYPB*H\S%[NDJ5JW:/<+VB-W3*:S$[NET".>RTF[BWC2/VWUL/IA/DNDLI'^&
M#I%PX+T(S71:\(5RZCB/+@&'R^1,&W?/9*CAO!W!*;&'NH15J_;05%:G$WDX
MNJBB#K&++I@S;=Q%PH\3NZ=36+5J]ZB*K`P5>:+UT`B)=)N\:,VKO&C-9I*-
MB-Y<UE;HG-X25E_LGDYAU:K=H\G#Z5`V1J/=6.V\2+],;ET"#I?)F3;NH[$\
M5!19&^_91[WCU27@<)F<:>,N$KZ<V#V=PJI5NV<J3\"7F^H]O(L3R38IDGV.
M2Z-N:&F4B.*<>3](6(=&O&LF@)'0S8!-?VY^]V@M@GM`=C!:!YO?\95\U[86
M+:74R?JP[:02'HK8Y1T57;'+#_>DIH:LZJ+5EMCK'15@L=</)A6-?LO*4$Q$
M$+N]HR(L=KOPW\4N%[M<[').JA'8=%56)WO:K5WFK78SR6QMH<FM&YBV4'_G
M4'_#PAV]<,.932HEU`\=5'J-$DA39%71Y:$F4A#$'N^F"(L]OC=6H>NZK!HB
M5B&V>#<E6&SQO8F$T]%0GHJ":K'%.RK!8HOO:\1GR!-E*!O'>.KTO\,V[W71
M%5YL\=YO<6TDCR:&/-5[Z*FGXH\_!290-OK7>F-Y??W]T.6E*#BIT/_C!`D\
MT_&7\`;$UB%Y9+))$`##_;4YI_2-2+4RO3O+N0[<-?\A_X!)!O_L$:0E>91]
MA)FB]+,4W8'FLS\M@`>7]P//_9-$4H</Q2SX:2U(D16CK$`5DJ>$H'+H<W;2
M?T(_L)9/U1.P2MJ\OC>=.X(INDO3\J0'TPZ)Y"XET%K6@QE8#T2R+7-FV5;P
M)"U"S-"5@GLB/1'3DW"0Y4)Z0^9D-2.>I*LRYO+JTJ/I2_"?I6O;[J/_LZ!U
MKCJ+*4*5U@E4B:Z\1L8XIDNU*',S!L2US;4/:$=_17;!^B^Y-A?(A6@];B\\
M$LSO#R>3-">VS=?^^PN%_9L;*_SWP1=-J=ND'-*G3>*>KZ-UMKV)%T@%@-7Y
M^PLMC[\E%CD"ACDPDGC;0+QWK,`"J<&=;&+"_1EA:05!CEVES+5FSMUE'FCM
M1[I2(-SE\V<I0])!&6@%$$(03P4B\F"PR4RX/J]*%/+7J/R],FW3F1/)#,Y(
M>:R#HU"`8XUN7*(3_;-Z"G./F/ZV\W]&F(YE5Z=E-'V`.B/MV>GNG`"TP54X
MGAG-R^!&-"^.H+#DQT.?SEFXEGS+34IKBJK5A%(W"8)QE37L`7<AR)+OO0FZ
M9/>/7BE*U2?R5J^VZ?7$,9SA,9NZEA2H"%1J1*6N?B-<^TP4;3#5#^DR,ATH
M5%%%^@5_\[/$/V4W"JY#`<.8]MHC2^)Y9)%_GU#<'R2>WY.\P0_<^9_9-B%Y
MA(WTJ5$0==_WS#8%4C?0NQX>:OF7SDQ7R\.I)JN&<0H,)3%I#_:J;`S'\E15
M&L)^=`3VHY.P5W=@/Y8-39,5?7H*#)W%7E7EL0&BKXYJ0;^^XJ-S:,+`E?[M
M.NO0N9.6KH?W>P_6O'R0J"Z[-IDHLJ8..V^?KSN/@2JK(T76Q\6;JBN8H&94
MY-&D6#NVQ%4ZDSZP,<G"\_.<)/)]SK(W:+[&+*`ZH\AS:@N_IZ.)/#'4SLOM
M)>@0S5#DZ;0XB-`53#2P2E-Y,JK,,K79J_CW_NZ*Y4]/9V+<<#R2%:7X6-`5
M`515'0QR]S>2*D]T0U8NP,6#`[<VA`/WN"4JX7BWHIPV,/UXDX-:\.$+\"'6
M<8-6$QNTMH9'0TT>-;C[D_8;U6,RB6=:='G7C+61/-4FG<<#7!MU+"N3RC1R
MEQR"W8<&/\0[)LLQ`_CIVG-7\)3K/4F.&Q"_=0Z"-@6[VGUYG.BR;G3?/=`4
M11[KE9G4L^&A@[NF52=6;8DX9.]ZRVF,#1>A0LU1_24[HT5M+<&.$:O:H`%)
M5<K$Q@J$H?E,B#XQ::C*QJ1$2$LPZ0Q,FJCEHLR"26=1=X:LC^KF4NT="V-H
MAA$L2=O`0X1EV*RH'%:J7GP17(6`'`;#2%:FBCR=E/#=MB2D#'$%8PZ$09-5
M?8@W_8(Q[6*,JLF3\5@VREP5"\XTLF6R#33KXLS![3&.+,1/_CO0+.>H"OQK
M_F@C1?A(AZJ;$72-!EE9Z3LUZJ!!!]M3U-`*1&NH%4B;R5KS9FLY\AF41:.3
M-C<Z:6/E?NW=3!I#^KS%^.T`OE+1R%BFEG*K56+Q_%D_!*--W3XN06X:::G5
MZOX=FQ(E;33TR"XS\Z2?\*EV=?E(7M??=A_-(29:>HB6'NR(<WC/W&/O%$NV
MYCV*IN>=U);3^:#XMKTA(@E>G-BT1'"D=?U2!$O:T^JH(B+5E^I0;>N(<NBV
MJ,=$Y<*\NQ5"N>6.[]M0;IWB8L@JL2E+/,&9X)?)6).-'>DR9^+/J$[^Y/>1
MJ)P_!5TORJVCRH8ZE8?C_1RJ`BO!H?(<.KQU3ZT<:DN10:-6^]!^*'4=N.O?
M;J=*9RN0Z![$)RN%Z50&_2)HWB#-1Q-55L8EJN@$S4^F>>F.3^VP=G75VS9@
M[VKK]]-?(6X%$MV#N+Z@0'>HO:-E1.OH7;JS5FNI+FC>@]-@+7VL^BN)EZ!M
MNT-M%=O:CDMTPA`T/YGFNJ'+FB;.?TW2O'2#OG;8MW:<_RKIS=9?V6L%$MV#
M^%2RCZ>RL:-9NR!Y#=Z$H<F3B:!YDS0OW7RR'9:MC2>W6AH.]E<RQ4FN43U@
MR'JI#@R"Y*=G5$QT<8QKE.(EVZBVP]95>(H[I#7FR490]-!L9U.Y,@95-/UK
MGC^BQVD'F"0V4;OYT\@FJNOPVHE^<[1_0J<[SIVRAUO)DJXS1)6'BB8;NNC-
MV#+&Z%@T(^ME1CH)QC3!F&8:`.?VS/S;3Z%_?6>:ZY_?Q"F<[QT_\$(\\_DW
MSN)_R.(.%KJ!`]\#K;]]8_ESV_5#C]P"5*]L=_[GK\^?_2UZSU=,9KEW;0R=
MOOTKM(*GCW`.S'D(SY&(UQ>R_/N+U^SO;\:'M]\4]=L_3>>;IJC#6T7YQOYS
M^^F;KGS[9[CQ^8M?$9_>M)V;X1\?/]V^E4828_1$4]5?I*^WGU[_O__SZ;<W
M;[]\C3\?_R*]_=_?W]_^05D^BYE/6]<]?]8?PF5W1._0C^3FM6WZF'B63N'^
M'">AT7TK7472HRGQ[^DW\>?J+R_[+D\103<$J[\4^>1('\PG25-H@]2A+'TA
M]LI<F-+M/?',-0GA+`5HO7?F@XR$\9^E90OP7*T!9DPMD;[>FQZ1WD8E`C3:
MB+TY7L-O3.=)!HB)1V9/Z0\E<PY6!R5Z.AP8/V)=`7X;I:LX"\D-`S^`/VC*
MBKFV`N!%E((90[X$EM`'_90]P^AG7+"01B0+:`8?K&>(`(C::VD369O2PA_)
MQR<Q2HJ(KUR'0Q*X:9Q2*MW/`(04L.;WDD?6\!;L$K&0)LI@^F,*E<S#161(
MKVTN06#H\F"A_7"UHDTJ(T)F41T`4R5T1?`G,OU!^KWN&C_WZ7J/47#Y$7@6
MDW%!"93[.XP^AQ[\S"=%9.(PQ:P/0&@\!!>_415\A3H`)6<A$]P<^.7,\_?F
M`N1><N$S3P+E1P`*>#+5?&2`(BVM/<N96VN4&WQ;)!T;T*!_XUFS$)GR@R:M
M+-M&.B*^NJSK8UD'"!/$BOB=Y0T0B#^L3%,/1[HZ22J>I[0\^]V@E[JIGTCW
MV^7!/9KQ7G`'V#;L;U]:P#$&P%FP,QW5,L&CRS"E>]!<N:$3X*;"31S__`Z5
M$NPK;FU>N::WP!^]`5LS#]SM[<_U34HYI'<R59SX/7D@Z=5\W[5#IDQM"PS9
M@BM?#ZP?TZGA>F,E:@:IRGJ`9YW`])[P]Y83_U/>A"2/.#.`Q0FLP.87?R9&
M0$')!;1].H>.*30*41A$<$2:,H+*6[L>!QL?E,A?(8C7S/0M']MJ,7646/-\
M]5FH`YD*WH/,O?E`4)53)B,Z#W`(9>`\@1RC".*]Y<H*`H:NR7^Q/`8D&2@T
MM\-%U#V>V/Q^%(L:(_GHJ?H5FB@KG[`'S#!PT:F:@Z0^188:Q!#%4P*A"N[A
M8[9=+`=D,^ORX(\`(^8WP?]G/YRAXYOVTU+;$,4SI6OPKP!'=U&M8]M%SA7Z
M&EG8[XD=*\"4YR,M7+SL1Y^.H-_-_<\=;O=N=V[.MAM5D;"'*=0RN.K.!C@S
MDB)>#J6V]9&UA%T/_C)[S*<I#&X(2,W-$+S,9.NC2G`?@7(SXI`EZ$'**J0X
M*MI'RP?/<>5Z^`B`E<:XT&47^[^/Z$>Q@KCL;R/BTO/(@1"/_B']U@0-S'Q`
MT)F%];!%5O)@DTB[FN>%+#`J15@80I5U0Y&':AR(`7T>L*^2%3?6RXEYI.S)
MVK/FA(X(`O_R/^#Z4>^23E>A:704*E-:AD$(BRS`R$@TGP!M$SJG_(ML33#X
M#%YL3&?$=A^E'Y3!1$G<:<0*70OPX*\7%CM"2$MBTI=%,:AB6CN+^$=1_`4,
MG+F@-M''$T!\)P3`Y[7[8&YY_OI(#1"K%<\1W,68U/D,3QZ4CN@`(*;8!E6Z
M&O_XDJ)M.DZXDOB;^*%M;5H,$8(R]KMCQ6>4XK)K>D1)Q?+PC$CF-D"V2`7R
MF$PQ$'/.?GBR1!<H>C)S=O0YE'$<:R#1/9`'$Z4(QJ',S/F/];5G!RE^L`3Q
M\N>>12-G7.H`)++SQ6L[]"46))U[D6,6.I1L,;0,R?3J[#6$1R]W2U*P-3!+
M9P.SUFO/_6[!CB:PG7]0%7DRT65=42[.+WK^3)B^_>B##KT!J;7I2+5L&#:)
M#</.-._N/')GLK.Y*D_&4UG5)JD31*$H4K5-=?A67)JE)L<Q?ISVY@,@RI!N
M"/ACQ$Y(^-L?IJQ>F/T\*@K"WT6;R,+NS,1G49RLF(\,0U8G2H[)B)"%G^.^
M6]`/H[?3V`@VT=3'X_R`>/:D%FR:`YD!:/LNGO#<QXWWPYO(=U"H%C_TQ$M0
MVS0W_7N;P$&+V5'4IZ.A*@]UI>#@-I#>L-%Y"2^CE:)E%OO7@1>'=H"OX<?5
M])7)/@!N4R1=$&9LZ*(FXWYV_!]^0KM-Y;(1U14]W'D$S9N]^4:GX(T[S6N,
M>L)P-T,I^)&,L-!<^CO[28;E\1^$WDG<F1:-`MJN'YF3>)]<G`85^E,<'<H:
M#>X<J_)88^IZEUV(&K"F[W/3S5BS^B3>AQB8(H[/G"+R'?\F.4H?#A7*2`8K
M@HJ-Q?7**HP@JP#!#^,J/88%72IN4(#%Z,%=8VT.O\]&9+:@4A0P1@`557KY
M/?MRGJ-M0<%-RR=)/F)<2R<](BA:UXP<151,Z!9=:Z,B3B-,:#[9?N2.0JT0
MBT=Z(H@-P(-E`O6">PO.`'A)\I0,<L0-123,=Y.&&R9_1I(0(W\OW@^;])5S
M\%%,>LF2/CT!J`&[1]@Z9$8'*P[HIOA0?QLL24AOK"CBA<>V7NJ1GMN.C+>&
M<D<QX&X5>!@8<<C5KA9(H$\/O$-Y,D7W='2()XY[4I4U#1X:#DLE>%!'&*\0
M(V\U/NAN.+Q4RN\\](Y@W^`]A)^CF75Y"D[U"-3$U0_8>$F1%74"'*6N>[:/
MS<L=/GM4'HE;;Z,^T@"2#C7M`*?]8-0&TBN77Y7&;T6*[K0@7+GD!V10GP'0
MU`6=D91>\/.B.-1A97<EJ(-M:U\<IY=[JN<J!<6&C<)FX4D01[P$9RD5&_L2
M3#H!8<MMCX@_IT/64Z%/.,#.S200"U)'XY"P4]*Y<.F\9^XHT%WBYMD]W#3,
M&Z%"G-C^GWO)O6+A%>/-2XTWYT0[M3$`?TU<_Q%141]/\^=Q9(O_E:@8Y+.9
M<FD+;04S9ZERD:+EC0)YV?_4-LA;U3=%CQ=-/&&]_,`-F1SPDOPQ)OMPX24S
MQS,U51RZ"5D!QVZVSG37_$R7@^7!K"B-^:XR*-[O1!W!H6NH5+GJR?3>N8D.
MWC5)*53D<$GY\P=;P(?MIJWGY\(.J3^&!SFN[<8YN%TLV1Y/=GZ6'+DQ=K:8
MR>%5"H7XKP.:RFPU$=U!N[(E_ON1;;27PGX9J@V>K2:8Q\I!)Q3(1SC41R>.
MBO3#\V<5:8@X]-`?'?$IVR289AS0>+5_+S9[#?`8TZD\G&@=W^UY5>Y%$O:/
M3)"AA%#M+IVO0:3*=R:H0Y`.;1K!(Z8G2=(A),[(4=*A0$1A>H-^'Y%.KF+T
M8Z]B1GB'*1M:F:N8,3PT,DI=Q>`%RXZKE:&L3)3X:F4X'<I#K?AJ)7V73+.4
M4E<J"69[`#WV.N6H>QU]+(_&DQ;=ZY2]VLE<3K=JKPU&EB,T;/<N:71Q2=,.
M]T!<THA+FA9?TFSLT?2&X_W/5'Z^6*=/`.)"I\FH]3XFJ?*0!A`/951GXE>=
MOOS1P3O66\6%GE_^J+(Q',M3]2+N1<M>_TCBKJ<EX5]M.)&-D;CL.;L^B$,A
M_=$'XJJGV;T^FABR,A97/>*JYS0HX@AN]ZYZGC_K7C1'A+#ZA[X=M6)F%P:B
M`Y`0"4`T3(E$.MB7.VP-8+*C\Y1'Z%_,`H9"A'J*?A^1WE\)KHU&\GA4U#&B
MN-7TQ)C(FEK8F?OPBD3:>X)\7UL>[:`:@SME[3=XV?EF:Y+TY1?KV\':1"S1
MCX9W;]^\3XPI[:.S?:\=/0/LNL.&J-B@$1SGS!+;-9(C7=:&1GP5G5/RC8VF
ML*`X[G#-^TYN%Z1'L>Z!],F1_FDZ(3:GU:91G_A,NVRL=+=M?O]N`LQ4N<'K
M2)93&YCAO:"-Q=#(1.*A:$H(X=):A',+UUN$%-5L3_74=?BD7=?A3>H-*T=_
M6KU5*CN-<;H_A#"X?3:XF?)Y9@KF(;\Q\N-&X2KHT8FB[>Q81']+NWODM)_(
MFAUX,Q@8/6U@KN+V(@7]*%[*TG;3BR'KDX$]EERJF1$0S+A"G/SY/5F$-DFW
MI<*I"IE7&#A%+#:L^"B#XI\A?*FR(2!`F9$AZ],]/]-9PZVIK(RTG%]R@\%_
M/!Q(-VAV6*,H.=\Z'=)I9-.`RF/L.?*#:LA3WD'D!XWELD5-$7WK.^O,[$O8
MKFD!2#A$TCE<F?Z)K)D8^]5V*SS67PS)`UBLT;-_(-CK*3?+!NULY.0/>K[I
M\DJ+^DF(OB*]TS+'MPO"*HM]T1^D^>0MM"?T_X^H@:'&255R3UGQ>"WJ-JSI
MU7TZW3FV>*9-;67H6(%?T%WG!PV.V,.1;$RGS(U@/\:Q419KAZF.9=70Y?$T
M/:SHL)$:<29<[BD]]\6;33'SC^GJ8)3VHI!@?*U7!1$!>311Y<ET6+"4S`9/
MY2RE#;11MD=S*K4[3I8PZ3PL^C!-Y+16*[*PF',2W'MN>'<O?9H'+CH2:MKE
M2&6*OSKL=>&:#3L!F"R7]C!>HM_*?):X'^J"MUN-^L]E\_57)A[6;3N[?)0L
MA9+BD059L<;$-'/WT<,Y*SC,(4#*!+0I:2K/G\L$2G`LOA1))D^)8DO/7(L?
MSXQ;HUQ_HML9.VI3/YJ5421LV7*NV>`*<+#UP7BTT5,J>(1=\21=:<I+*MB1
MJP\*@,9K%N:3O^$M![2_.`K?<LD\/*#('0[/89ZH'P!]-WRZ]P[ZF+`0?=^5
M`:O-0@`;XS7THZ6+?5PM/F&&<@C_2)&:4S=%HK>11'ZF[$ZWLZ:`6MA<VPFB
MR$A,49FUD::,OG==GVPVC(6CRA;C\:0AK5TO-80DYV<RS@]9FT\1(OLW3=:L
MH3*/%'NDF-7E<#K.OYS'G^/'-R`3\=YFLTJBOK2\AY5M^G@2>XH$9(-V,OCD
M;$@24IQ66&S.':1->!5%S8=]#Q;/GV7QN,V`#\M\CC7T#<VC8G..>)8^4#YB
M`R8&S*W`Y$4AJ:;A=*=?C5Y*\:R2I+?R!AMHS@;'+^9@-!2);FDZ1B5Z2DY)
MI\ETPX8:R-)JD-K2:<W"<&(3D_+61BQ6YI^$K;Z%*8@5)1![@1V/X-HDW9;J
MC&C'5V%@4$OYQ&]=<#WV6EALATCN3'E(H\I=UUQ[,Y0UG`>](W8=<"L&3Z&"
MW$0PK2;9)Y%Q2.M*IM6SW[,Y`RF#D38D2#<>SRYO-:A(;;7C&\&96Z'1B&A^
M%C^F^_N8YZ12OMC`ALWFGIJL:2PR7J04N`V+F4#[3H-2I,X='Z=$)XEM55LE
M/?$0'B8P\80#/N,!C=^U;;'`RO9P.%-R3!XL1Z/BL7A\?"]`1<[TI8]_?'V+
MNO7CS=<W-_][K.C=9"T0GWT7!Q=89S_:_YH/V"BH^MGV%ZDA\0B?N;J!X])"
ML2FP?K&K"2+.G<T==S7SS8,?%<FX!6&LP#9;Z^:Z=UG19&UF(PQ<*>0E??A&
M.GS$(Z8/C,(%P:2#B:/2226#P9^+7CP+(G$#D(Y`V>&(V_1HZP"=F"\18'DB
MQ^#M:WCS@T4>_1VK;`XP]25UHK"W'P5BO'S!$Q8SG\A89CK1T0(^%B/+&]1>
M4PK[%OHM^,S2,U=\_"IL>-,.4"?2Z2WQI`_UQY?<8:6_BM0CG[!"[^'`',".
M#U?Q.U"(K._).XP?7PXRF[Z7Q\3>(GVP@BPP$;TD7)5EHMMG.E$S*F*"Y])[
M>PIEX>1BS3Q+QD&7#P1SF@%E0.1:U,G65R=+X5^:*\M^^GFOZ&T7S&[YA0<7
MR1ZQ<@4EM4>L>DH![A'+T=#J\(`U\VMPJR5KG24'Y0$M5<Q[_#)'5B<TL-`I
M0C493^3I=)=@M5V62I9-E0>^=/&QD+'42KJLZV-9T<J5/;9+Q(ZJAMRHRZM"
M[NHMX6U"C([@;NM*!ML!_71JR*I>JH*U.M%LD3ZO#*<]Y<J=W#L-ZWH:W==D
M75,O3RQ+5,D>#7^51=HME<A6:_/GS\X'/[MVT\=]T^BY)>;EX3^I^OQB]DHM
ME>VM@#E):CMI?U3/;=$AN9]!;!'#+U,AG<X$B`ZS(C.\[Q+4.Z0W"Z0?W7C2
M?)+[R'(T#74BCXU4DVV:&HY'`1O33V>F;_G1\&EVV3L:JK(V+:R1SB8[];2Z
M5NRYG04[YIRE`_%LX0]D05Q/Z.F^RTSOD-[?R$(=R\JDL,PE</G>D=X[\T$F
M]9?OJ71Y1$&6SL9F-"7;FM-BV:3\5/I@.N9=E#;(<EUYPN>>TF4VB6"S>'E?
M[;(<69P#RWIA%2`/,3U,FX4G%^2!V.Z:PKM=\DM;3@^DFV"[1+>@F0BF*=-4
MY0(^6$Z2NTOU&T\N3O?VB*TCY]CC/=96N`Y`9/H^86FX6)S#?EZ(#Z#R'V`A
MRV)-)ROC\Y01"\P1IX5;&=[\H&-+%(H&ZW_B1_1;["0@_Q%;<)O=G"3XNI1H
M/%AF$7-[ZA+T%>E9CG'K<<>SB"*?:&V,GVE%U'?:]-L#NMW(Y2<^1ODL_YY;
M6O016-=`B0D/EL<XTA5^ES+\^&':[,L($:IU+-+RX[H+VGV$%Z=DZRU`&A=(
M/O8O,)UD;J4K1YAQMAS,L:?E9_`OH!M6FEE+*V[6[G(!SY\N=4@9,,OR]:T[
MA^8)D]7:=I\(LA;9Q/_%*[-HX2(K%7&P04@\4,E</%@^?,O,%Z48I00_B6CR
M4)G*0]U(PSLC<2,7B[<L0>+3/E8?J(W,UE>_<H%DB-6;"!8D#Q:.<-9QO%G;
MJB""`U8:1IX%`X_^+BJUHU[+`S/.T>O2;S,?3,MFA3#Q>]?\O1-9&4WDR7!(
MW9Q,OQ*D7C%S6=7(C!"'>S\#+G(1>38+C.^(0SQ:*+-D1:!Q<;&J%!6)L<XW
MR)WD::P^E0!=;.L5>NQ)VO(%?K\!_U`VIKILC.,0!*L`B\E!^X*%.!Z`K;1)
M^)XZ(*W5KG2T;K/Z-0PLV_HO854-K_#6Z/KK'#8>*J<U+_*S<%%IY2X(K:#%
M)DFKJ/(ZZP9G%5[:HK-M/0\]C[GNO,QYJ[M3RG.FNZ7P7)0:XT9?[5G^G]=+
M.*=AY1YL`]A$'@()1XIPQ0&BVR-5%T%/)C-L9\8*_I+'N-(!.&E7*FXJ\``P
MIY4:`&.DO'DQAN4`M4/:B)0!%/]X86%5/-#BR2(V.VY0H.+Q=/\EGHOI9)LU
M;%ABQ@I&X8/H+;[DH\6AQQK\@S&)'E5<PIY!>S:WUK1"D=68)P_S4C3L*P@4
M9%J":H@-H!]<VT31"%AA8(IHN/":$-H)(UQG:PCA$S"EA!8+LIH]V@G#M.>A
M;4;GZM2KV4F10L7U5/*E7&@:P;J"*#W-;2)O0,,LGXNM!T`RJ0$2.JZ'Z&<T
MG,^UFV^!I\0<LQ4)[EW>S!`M9UY(95/393<_/AI[7EQ3,H=Q]ULMMH'8$]<9
MW9K=2C'8M+THR#+M7Q`M#<2]WEC>WPVQ?#Q<O12AGN^@^'C^M2CD&*MD]9=(
M`ALXMJ<S3N:T5K_E=*Q%C+;S;JJF`2/Z=>"N^0_Y!_1PE/TH2O5AA*I)BT?'
M4!-=B"5XCU[NN=H8C^6IH5$WP#`V6U^SMES9<'5\J.4]$M8!"X2S('BZ/>5`
M>HO]@+C;%ZT>`<8Z9`"%G6L\LC%53<_=M`,7:XN=;3`SD+01[4)#<MY+CX'I
M'B11RP^/K$S+0>T\'OV8_Y3#V]W`_W@`A_W$CLTK5E>,1TN3'BX9I.R@6A35
MCIWY.%J1M&MEP>X?5$7'WJ&L9:@^FM))W%G2]5.'"A/2.Z1Y5^2/L,M2:B3(
MTV2I"%VN+E,G8]I]=U?KY.@YKGUXI"FE?/9HGBW=$9V*'=;8"%[@6#AJ$AL0
M;^W_')U45A&QPVC4-DN/PEV[=1$',@4(TT/J4)Y@HZ,^"EX_D>ZWAN7*)KZ\
MCWMKQS,FMCJ?'NA'Z?I05J=3^C)55M#`CXL;?V:]I`/U4M'H$.I%9+N3;JYP
M@/(Z26\EZJI*';4XA%M<DTU4>1AY5%-]+!O"HQ+[72#=&Z2Y9G]'9MX>14[[
MPN&U!S_?SJ(KV,QU<*K)*7R5ZVT.1_)T8ARHX]E)>,U[0_J'J_B3%?OI7FD]
MVIU>ZV33ZU3=D+5V^://GPEEW>P6QM9O.W<O;MH'T[/<T$]G=N1Z9:-=R9=B
MCQYT2M2`B"W;E6)/-I=FGMV/.0E+T=9,;<#(P-+SDA]_D[H4-Z->J^9=+(?+
M$--Y:+-DLHCV+!^'B(,AS&5`HKR"J%B/SO);$HO>A6\V\4UW:(XF(;"!4)D^
MOA;KB`YDVY\O#L"D-M#C/7&R05_L@\VSGY)C'5<5J%-H?E0Z/R]Z(8C$GR1@
M[Q5;K8?HWTA^N%JEE'\JUR/6T*FJ`'XZ9A?U>\>,'39>3&(C.IGE\$7OTU)M
M0/>20/0!S6O'D>FY<7#CBORV(L<UOHBNQ>MHG((<`#HY?W^AL1Y.(=UY[I+F
M"WC23S1E@)JZ&K'M*K7^3?#VG+5FC8AU`W($3D/ZHVCH2OJSSVAR,Q\`V2FA
M!9V/I?.7Z.R1_O!UDFZ5_O@6CTQ7?Z#9>2DHOD7QFRB\E*;9>YR+[?C6//WA
MO]`CK)P"];1,HN5)*1_%W"Z4S&N\=A2W:!K/*8VUZ+/7U:XF,+DX3,KUHJH>
M@3K[`G+]-9ZJ@ZD>^Z21]WD]&1A4L44J!N$%!3,>Z)&&^0<[^^_`-]W6O*IF
MZ.7?,]0V7Y1B%\^!:Q"<RHEQ4*_W733`F^0&"3`ZB@#YG>./D(:"KO=[-V_5
M@%1.AE-Z_M>,?<-M=U]L^2)L#!U/\'=9V#S'0<G3`V<TAON54R=,XA[]TBT'
M93HHU2N^C?SHC(M2G4=R1H%19<Q-'0Y+M09MH]A<U#86YXPJ-S&.(F[&0NOM
M$B-5GA@C>9@;V>B4.%W4YIX,2O4I;R,_5%E7:`.Q-FWS\F,&-B'*^6M_&*'*
M."\K`&Q;F_^ZX%'EX70JCXU24E30MO\\<?EZ^56RUWQM;!J,!(>ZL:.F@['@
M5)OWDA[UQFJ`3>>>)C5<E_"D,WE!1\G>L&G).VSX1F,JXC!P=%F'(X$Z/FW*
M5#E:=X13=:N(PZ!0!^6.:_W@3<MVT61P^BB=B^-1._;/2-;TR<D6]A`2-WE>
M36PIS[=-MZO<,I^=%Z66;7=CI(%$E9O"*[9\8^PI&QWL!V]:MH>F`\&CENZ?
M\00[1C=L,/LY[J_?A43O>//=`ZJ"L,-E7!F4Z;6Q51J4+<>-!ZQL5G"K(VS!
M)$L_T,Y"K!_'1B<..6Y\?.Q@EGBN2"&JM2`W'F/7-L!-U:;88"3JW[;=OBU!
M4=J-(N]BSOO-KRS'`J::M#E^C.1V&W;\]:'(8-%AZ"!*=X[UW[C'_@ZPML?>
MJ'A]($\I[J/)E#;98IP%K&V3!YDRO:Q%\Y5+U$//GY7N1_G(2TLDD]63;-2?
M;W:%+%?5&/49/["Z,:?EA#(8PX:!_S>:I*9,,>$>J*/49QO[V\F92Q#Z$>P'
M-(:/IV@E=?JIUNNB]K*/Z&\@+0I.:R\XK>J.K8XZM()W;I:2?04]^0'U)+XQ
M+HE$7=@(Y-VKP#,R;C(M4908O5($3)N1RK$O%]3LC,`V43AY;`RV+_0IR(\4
M9,DM[#C;-MY+L%,HNH7]:2L)4)I.^XCD7%'TR#=\O6L2U`Y"M+?D4!OLC(9>
M1LWEKEJ[`VLN+[?8$&<[UT:`VHN2MH#Y8OE_2ML3U:I28Q55*PQ&/V*T3AT8
MI=?]L6VH['(`.X&"4@D7SE%:^R8SI*]E5.V\6`@$ZE'@^/>_XHF)[:)9\NS8
MH"IZ7"K-O(UB,-8I(D>4E;4,D4GY`OQVJ.FWF2&,5Y;#[DKR6G*=D;S&0&M7
M1?TIR(P&XQ'UL"ZGF!)1JG)!D:-"$>_=_59>$6@O"6&7&18:M;&FI)H)Z>DG
M^N\=G'_G8`H"R$></1`W.U][9$D\+\[P<9?P3U@74.5)%3NRA%C/<OJ1Y6"U
MF.OYSY])JJR-1[(Z,OA<*TT;RI/A*);(S:RG].R%S-Q0WM*:+R=O)M:S059Q
MKL5`>K,78M/VW338GVV@*,T.N[G#_S7TL3P:3]A@4WAXJ&D%8!=#O0]*FM\2
M]9CGD[M\\I">:$I_Y*=^AM.I3<NA,^>O::][9.>2F-C!WF=\7;B/SC7U_("K
M;L!8CNB'V9GWYGP./PK\*`\FO8[I2PO@_P-+)K,M<X9''A"5GN9B11IW0XO4
MJT[3CA'F0%C+IW:3J4#)+,@L2!0*=J3?KTOH,_>NO<`)$)JJT]'"=#>R*9TM
MU"'K6(>85(>HBB%/P)G'IW6&@%`AJ$(HV+G+TQP[-N3"ME:60Y-#Z<0/:JQH
M)MW;[VRT04\U4;_=F&17PF;DHA:KB6BN"YKLJ:R/QXDP%NXPW`C2W/3O;>(G
M;T``Y_>X24,;1=!B`HB;W738!>IHJ,I#O7!<<"^Y(X0S$<X<FV9110E*%13X
MQ)C(8-8.D]!-HVI*%&.3?<1G'#&MR"TGZN-D;G5:+3\2T*%SE&+;AE_/GK*0
M.AO#;'U"I(]@`:2)$.D>HO^>^6I9<8[D="%](`L"DO;>F0^HFY,CJ]0SB@2[
MX-"X>?K26/^5`S9'UJL[R"&B@-)=P":&X7DU\C)B!8^_88\7C.Q3M_RPK?J?
MPB(E?(,&!TP<.5Q`L;2ER?I58AOV$?T^(LU.D_\)G8SEHQ5NY,Z:2^;BP?)!
M^YAW'J':HT2H*E>S%,WY!/-:-$!=4=14D0^WQ&O+8X/7J.9)3\_,JB9X$*E,
M]SE3$Q[Y*X2'$1EVID+E%+5DHI,&9Z!=5GFJ"S4,<(7K%Q.PFME`I)2CD%53
M6-GGN$&J7!$^W%O=![CC2<_-.8])OH6(4'V?0BR#$E6[N.J*!/$1>W^UEKSU
M5G-^;P%QJ<W`,R-]7ZX6#K:&EAY3PJC(*APIT":EIE`>6*H5E9E-9&,TDL<3
M/>(;KU[KJ4;O)=+"C/4.Z8.UW!$UJ?G7,"[:38Q<4%,#OZ(U]9H:5UX/L^[U
MKAAJODW,];NW#620-GE18#<AQZ%UMV@T3+!]11'0U,CI[?'4F^LOR_4W*()3
M/JQ`&&R7SHK^E:2CP0C+_S>)'DWH3L\'QO>M7"^@E??Q9&YZB.'8Q;[/Y5F1
MY\^$3A&I$(+[)6<]I_JXQJJOUK8(8NCSCDTH:O#%T.=3BT_%T.?+&_K<3`&H
M.E4C%77$7-W:2R!+O6?W#$Y9&QV*PF460ZJ'E<.VIQ@2_V[EM+61/!Q/9+W<
MQ)/:\^^/&LA4;B;(>776#CT:Z6HQX:<.>*YXLDPIXNP@=UYQ4/>XU))9)">W
M36[('2E0\'N\CI8-RQW247R:7KXNO*V55_4L>S9#(`:]U0?/4%8,5=8FN]H_
M5:5NNLBOUAB$42GUU"V#T++9K!-YJAGR2"U?2=^^HT"E1JT>"]#:(Z$^DI4)
MQAA**<<V"@+L_DH'VYYEOLX[UUL2"S-HKM0RIXV6#IAHV1"0*YZ:?I*5&1YS
M&FPI?]HQ`*21`3JM'4?),^;$%"TN9<^?U0704)?5X5`>C4X+"(E10#5.GRS7
M[F8';W;N_WYV5A'Y-+U#NN3(HTQNC%7!9"":'YBD!VJR5CP1:-?0H]0TG71]
MPPF#D.HBP$&SB[9R*359U89\0)0V-'!P4C1(Z%CR5)0-FH=X9H+1UABFQJ<P
M&9QP>FKV%%:@;;0B2!$I+Y7LXK),A58426UG3FH+W/7.-!XC[N*^.]P1DU49
M%G6/>9$CPVF!I-_?YF3-@SKXX`VD5^8LM#=+R-U4S?@T*MC:43=^!H\SCQ8=
MW7RUT(2=$]I,D`.&P<4RV]@TN!_4P5"1>5%*-/5MF)2G;#EQ.6/?Y')SWY(?
M-SSX[8*VD+!?8C#:_L%HN6;R&HPUYQ'_('I++'?)0+4,@)G1:G+A-CUXF4B!
M[;2N[69$$W/:<#X;&\\FM7TF6PZ)+ID_\60M,8=-S&'KSAPV,8PK)ZV@Z\.X
MRE6B[*K#8&>!:SP:[,R^%^.Y6E>1LCL)!L=S7;=]/)<R&-.1*;`?2Z_;LIDI
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MXR2*>*[<YWBN'+5-U*%#F^1+G_A`*.D*+[>364CP=&JQ=Y9C.D@@/[T.S8=E
M,UHP+>DK">YER906E@?O<;VM84_8HPZG->&'_T/,!?X`_K\=W,^QA?5[.K2.
MHO3*=/Z$U?B,HH0PM!4G2PIQ'>EF[5DV=E9EN2`TA_4.ARK!=^_(S&/)4".6
M,S*0/H<>MO,/HL;9J8[E>8.C<#'&'KH8[3T^MT,?<V-GIF_Y1Y&9`@E82$M&
M4LR]Y1W4\76F#R\.HN222&KB@008\/3"><!2:H!\*"5S<VT%8'K_RY)/<06'
MW+F!9<8O`H<!#C(^;TN.#Z732MEDL!D8;_H&FJY,'#;N2O)#.-?X_C*T(Y!1
M6/"E+QAJK^-WOW@YD%B[>-\"WX>!@UCA@K"5'ZPY;NH\8H/$$"#LXF?IRGP)
M_[I&[^>!OX'P<0\C[)<K2U>SEWQ:$/V*_!4"$?&$_F,D<9N`L<F'2OP]'-Q\
M'V=JP8EMX4N>2<<5\?%"B:RS=K!7\Y>H4Z[YE"U*EB29V5K-0*P8*C$DVNZ5
MF%AODH#3:4%\<*((X7LE(LR^7ODI<8D]F?$O_O:8)0>;V89I:%.$*>@S3/O>
M;^0B(K@X'H-*":`(?FOTEM"A#`<'.*)IX0[)[(OL5O$W=S^E!Y`28Z`^[?(/
MTF*]E*P,]JSK\@H3KGW:37]%O#OL%&S.P17W+39#;8897#AK"O"<X80SNC5`
M9<&;O,Q<GRO^T3U2;K/9/IU;=><B`MN=_E_R80DXJP6]>E3ZGKL(YRR3TPJB
ML3\;DE"@CMS07D3BD.S+[!:8_)BT)`:ZW6&*6W8[XCR$$!1V"LY(SBU*2YE"
M31%;`Q]<JJ5!N_*\/7,9$#;!):8:%QV^OU&`YYXUPP3!F?M`-FL/Z!R"E`)$
M/>9%.O!I8Z12#AEP_`*=VT#U(9Z$$7%X`J6P:!=L*ULV)R<V.#,P.(!71)T,
M;&F0UBD;@C-M`DI_?WY/%B%FLQ$Z]`G--U<FFV8HU^*SVH^8X+R>`_P8&@^*
M:$Z;>Z\M+R8[=N/&\^!UN$ZUH,[Z&`63;;)R+%,A362:Y6K^EVPH%FGFFAZ5
MA\C$^](*SGK2C%>)/"2CK#;XAMX!3T5FV9O#*`US4Z]0$'G"9CSB8I>!]4/,
M7>!3"@&(%;P()<E!;3+HH1/::P_\34CR!Z,P/90_[S)RY!(;BR-D:(+]1K_Z
M,JX>?3[2E&21RL8?4M.&@S;Q?^)W)I,`^$>O4G,\X?V;`[J2W\=O!BV3&8!8
M/':T@!1T1]VC9HDA9V-6X(EP?6U'WBFJ/V8`0'RB,:D1I5.(]E`$>[W_X`3\
M"2P#'H"U(3-YQYR`Z:$R?=R+C]7JE!O2^)2\N2WPO6CE261B4IX?&J_TN+P#
MCRO;.\_'V;AW%GJ_0>REL],+/YOL<=`RXS$R+@:<,>$=<(;`4T=TPL@<._"5
M"8G``/JP`,`%!_>5N["6%O,P31";[]8J7/'C$YLW@N]GAZ@?^"?TX"F],RV/
MNL2?UI83G;N`]'#<I&C2HS48>^H<)+@EAR0S?F'V\-8^/W[;.ASLJV](PF&^
M>EM\]-C+/LU9]ZV599L[G/:M[=(MISW71>^A+N^[(8L/;^HD5:'VP7R*C-!P
MAVD+'MU<0?*30]CF-HF<3%R!+N=&KF1ZIAY]$]5*:_C=QCLR%@@]0?!?N4JA
M"H"%?E`=$`=UQYR&E57EQY<%$2OVZ?-GB5L;1Z26P&&^'?$DB/,9I=>VZ[-B
M./!M<5@4*H^2T3.D'`?M%Z;UP%9=:7M`+`L@QF$=*2?,J-$P(S-:FQS:$Z-;
MPO^R$;>YT;JAK$T5>3I*CRO_0NR5N3"+8W84ZO3,V]'6Y*U-*)G_3D&;H38+
MK,!F$L-BP:E.!8GNH_H_YAMU"=`(HQS%(\4`@'_'$ZR9!<*2SBOC961Z."]0
M%=O2G--ZDT$9X4":)9(X`BYCU<'<"A*N1,#$:R<CYNDKV(!X&A&A5FM!6!UF
M]$GT'+A[61>#X(4'Y=&<GGA21\!\OX]1-C'L_-?;(,?"/(JM_3)T%G[TRR10
MLKD$/6RE*9Z&*CM=DT&#6B#O12;W'W%=NNVV[.D3!36@4K(VK05C(AV#QMP\
MCY?(\CU!Y8[^AKN,B?.1JNQ%Z27,#B>!*U1I;AS8[:$YZ;4MS5-26<U)]4RL
MT:GB3F_4[48JNJQ,IKR9RF@TE,=1.Y7A6&'#_HYL*E.RIXR<`$MHJD\BYFAT
M4>[Q0;IFLE[T2!SZ6<?AI&BR8^829)-X)>CV@S&A(\Y94Z,1MNO9PB"BU*Y(
MZL;DR`Q)\H',<CAG9O139',W>*N-M?A<FKWQ3.,&U*5K]W`_]5J9'(PRV'1K
MYEFR=$_L!X)9O(`LH'#=18P1O>.Y6ZB%X^V9[661-[-PAW+46,,+A$MPZ`0.
M;>SK?'I6U3=#T:<#7>]#ZXR#,OJ37U;8QC_[OM.>/E>U=SSX,-8*-2'83?*\
MS<[;CH_F@D@9(D5Y"Y4BQ@L6*MO?^\AX!)5YK<8F08Y?1,!0EO/[:K6R0$?M
M_HQ1VCIFK`"W5%3@(SM%/V.MT>(/62.B[2->=+@K)%QLH@<&;9=0:L$#&+/Y
M_A-1/'S%Z59/1-ZDN]1Z!AS"AYK6/O2ZPK`?]O))SQ'^8UBU,2^A`*N&F50K
MAYK=3WE\B@Q[J37A%#<]+W(GJO14X?EQ7GQ)M;XC5K9?P5<!04D#7(Y5S0[<
MV^<VG!]L79?'HV)-5H^,'7T<:$"0CESX^;,##5&.$%2!ZTY[)+C8P,*[^W]6
M:+0:QK:^$\DFV%HS0EC3,HUJ=VV'=M\[_ZD#<!LX?V-<?!+:OP<N1Y@:Q>\`
M\W1I*%\Z?KUA:<I2)4U>\%_BIJ[:FSIQ'2]$Z!S7\;JXCA?7\9=W'7^YA_&R
M$=MNW/L+SK0[Y4#PIVW9#F<(1>7HV:KYU2;^ETE`$/00]&@.?I'1TJ($B<8S
M6O2Q/!I/VH=>5Q@F,EI$1LO6Y:!V9D8=HM*?/ZLFIZ6<!C\I>:7^\'>+[ASI
M$JIBR)/QZ(P8M(SFI?(VJE.OO:-SW=[N7CW9TF2_$MD2QYRL;_(:1K4I["&2
M^4X!6U-HFZH3[F,O)X!6'7Z-Y_*I`U7P\()R^4J9H=8$4,NX[9>>J5.?9K_T
M1+[I<"@/1_H)&^#29$ED?0F6UF>A+@/GNNR4.%6?&L9H!1+=@UB0_>QD/RJ&
M=$8LSJX#DQMC58O?$V=9LIS)Z\!=\U0\_D%D#UJ65;J[6=ZNO-)^,;T7JD!H
M8$'V_I!=&+Y&`Y@7G"Q*[_2/2+3.HC/SI)_PZ[W9UWT*=;<TWY?E8Z>Y%J=F
MYS-U=[ZVX.C9.;HW@_M"KB2$#R!<+T'V?I*]9QYOW2U6J@G@;$\,R"1D9H(O
MEW2[<\3=:C=OA`^".AX5U!P#6G]]6&J%^C)4<0*3X$H;+G5+K7%BKS#1@:7Q
MAB$][)%R02@GLI_=!3TC0S]1GN$?-]&4IW>6MZ*$F/6=)!M[H:_T^.0D/8L,
M>K6L[AX2'@\,2XT(QRFJ_S17./SYM;FV`J#0/^"\MY:EWWY[+5TAEL2SGZ0_
M'??1P4&1-_!OT[?,G)^_E'%F*@Z<MNEX^R5(K&0NEY9MT1HYNM@';R!])<$]
M_O:-Y9%YX'K1@,8(\"O&X8FF*1OR'WVN_O*2#@5E\Z^1#=<;(XTM.L/4I@MO
M36QFH]8RKY8LO,+'<91\?F,\RE35<$(>/4X&F1'<\`0?#XW-BV9`<(M.QV:S
MK_F`6OAQE`OPZ%D!3HQUW`##VG0.L\\G1_*Y<,O0AI41$:17WOC3S%C3>$"F
MJJ4F9.(K%I8=XCN2&:EI`IOQ)]D!WM(5GYE),<*AJ:DIFLGX5&6@*&K2,>4E
M[ATB?<2ZQU$!:>D8N_2P]UEJ<NV"S>ODT_.B:;NP$O`75UFX\Q`IG@R79X67
M'COD.P3'J.._W#"X=I?7:Z`-":()N3X2')<DWW'`G_3#QAC.7LZ^$RCW`67A
M-,8H/W_6%Z29VUA8?-E7=TFXCT(?"I1[@/)[1[H!7]7F<Z8S!PMP+VWP8L$K
M)"\WSD<2_V+S=,14IW25/,<<=^JOJV.<H)WRLIE?'LV"WGHE'SU_;Y$E.-UD
M'N+T:.D3G)'FX(X^@E]NLI?=N_:"]8UDZP^DFV"[16T6.PX3/:Y0%S<!*W-J
ML-"IYPX_'4%OV_0]X#W[`2"'1Z=H@':$_N.]"WBXCHV'!Q^<:P8KO)Z8<#*A
M-%F0!V*[:THZ\-S_`V<[AB\>B+#9%3T$P&&3YD3GT@=6V,:2O81*ESFG%@T7
M?S!MQ!8.*18<D9:FY;&/Z`F%#IJA-$#`\.?\,+#`@T`AU/Q';,'L*^GAA-$3
M7[<@[.@'+WR`P[`)WUO>@A_]\"%Z5AED;4WZ8G-G=LEMBJN/%K!G9?X)YR7W
MR;0#=N:!8ZIEPS$1]ADL^H30^Q*%:TF!LMAQ*B)VD2!&^^+F9<XZ\7O#-5(-
MCYAP>`7>^Z;-Q(J_EK:_681S/*K>XZG1(_3,Y8,0X[DXM>LH\%>O7N*KB,E9
M`!SPTK^";SQ$8@.0)`4?WAF_D(YK1Q%(KX*RO@%D!.,&0&P+W5MW]VR[75DO
M0>CBTS0#`84W;_%?)-0,%CR2D&B9)5%JJ2S-*;WICJ!$SV$G/,U>^\,0O[91
M\I%<_$,M^C"9/;^T/#^@FQW/[*#5$0Q^D*:X<[%86L1>,%[=,YT#>QY/_'2:
MO;0&.5^!W@UI3@`\!%*SL``FF:Y_W&JIS^.%5RY("OP+?%3GD-5A]ZT)_97]
M--B^R:=V[F\_A?[UG6FN?_["PC^?<4_>)MK#?V/Y<]OU0X_<@AEY98.F^_7Y
ML[]%C[UW`"5R:W[/^1V&M]#V?"'+O[]XS?[^9GQX^TU1O_W3=+YAJL&MHGQC
M_[G]]$U7OOTSW/C\Q:^]L<6QT_WQT^U;:2Q%`3Q5_45Z__'UIP]OI=N;_^_M
MUWY[XGT^IG_D45P6\O.D&7'`A`54R2S!]_``6Q?SE&`K@R[`K2D%YG=`'A7(
MC!`'-3-F@H!F)G,S]$G&*<)?P6,A[;")FAEV-,8$(\=G#?1R%SZVX?31(5Q0
M%8=/\>`RVMK8H.,C[J/I8/CVSK0<GWD?BZB%)T#&_"._EU'%/@LRVG:0SC6`
MP(UW2@QCO3?^)5=:J,MD^KRN$/X9_-Q#$O9:?K(H[QF(L2^/)4K:'QEC,0RC
MN$E[3CY4%44>2Q,\\Z>?CYJ/4BIMZ]"%&BGWB(J<\VMUT`-N!3$%XS89EPZX
M;+"LN)=2_62L8@!#*4C>;-OEG[?P/SH;NDQ3_-.^;@"&VOOLJ^IX/$@9K]RT
M4OP7LXO'"-Y'.`Q@>H%)DU7P6%!(R0BHI(E[U9HBLT)!UG:I-??V<E>'VJY.
M[J46T^71R)"-'=U`*\>O!$U'M7-MU"#7U,JXILEC8W00URK#K_'*S+J4QU=Z
M/S(S,?B-IS[B^+LK76OW+VK<2)5(VU#6AA-Y7*IC<"W8])X3U^?!HCZ?H:Y-
M_J7HGA`=Q#G>2NQH*-%[,5.G8['=6\"'H6[(^KGX4'=_G=,V^,U\[H6F+39Q
ML8^HR5.QA\_.AN'P?*JT>KN=Y.)6LXT_8=F%$)[B<Y[8PN?GPM`H.2ZE/5OX
MB-/UR6'A?VU?N;<NI'\$G]HX1>CLL%]-9$6;R)/*I@F58OI+(5>7*E>ZK$VU
MG1'.!N6JN<9+P^,`OG4#TSYX,QRY2!NWPO"@;D+EF^&<&^(R@;[FV"L$20A2
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M^D*0;=+-/,#7J].)00O%4`DGU2V\.')E8OW@R@H*ZP/V$M-\,"W;3!KIA#ZK
M^$0*W5D/H*^>@"A1^1T0Q:%P^>"E64LX;<(_6?FO'_W&?72(Y]];:RR&)D!4
M5L&0?H)6!+.R9!#JI-24T01.IH1AC\5\\=MXE?&C&V(E*%/9UFKM)ITIL"^5
MXV`;(TH4IH%Y,R"LY8&??/STVR8!@L"S9F$0T2`JXIDA']@J;&4&G+F"@W00
MF9KMY19D39R%GW0ARE3]QN75JQ6($Y.9K87DF*(`3A%CY[QE%A\594I8S0CT
MQ0):B@'V6,+B2C?SYJCS5"3S:RPI]>]9Y3IEE@2R0H1MZAGR-]3]<N:TOQK?
M3K1,'<0Z#+#[%BI!%(U(HM@NQ2+;^!O+3]4==;/H*/[T%".?KLT_`MU2D.:)
M[G8A,SUH[RX#V@O6[CJ@Y\\JHGR+BX'JYJ54KB*A)"AY!21'B%K;Y+OH@K@B
MH`I"^/TCT.GBLU4P<@Y*?;6^2Q^P5:/T-AZGF5`/2\Z$A(DMV$X"G;P%:RX!
M-,Y'_3_PD,IV=!2"%#OY%$'-O6$6#E"K>2:$NL_:]XQ.55R0+P13[-SV$4CL
MW%T[5Q>"*79N2PDD=NZNG:L)P10GG!-)U5[^"$J<@1*M4&VMHXJ@A*"$V"F9
MY9\_$Q(B]HK8*Y<K'ZWRC\L5L9V0W:(H>GZ#LH[P]FN<L!6E^"6-SFF65FW"
MGVG+UQ%J-:`3]G0K%(3:)%1A+\F.D$JO[RKD,F3IQ]KI,Q(JJ)`LG16;)E50
M46/4CI!*J""A@MJYLX0*$BI(J*"]*JCM9^_"+EXGWO%VBH.T:%.ZHB66R_BX
MS8>.O11!ID:S`SHE.0W3IEN6PQ@80F*:<U@[0@"A3EI#&Z%..B\QM:F3Y\^Z
M0@*A4%I#&Z%0.B\QG3[-5GN3G&F`<#T9&#1%=E]&+>M:'_VZ9=S]Z#K7"[((
MYX&%/23(=YQ117SADPH3TA+:G&1"XMXTZ48S]-LK51^H%.:UX"Q?]*4XBXI]
MWQ;:=,MUO-*F@[&0&:%1A$9I+6TZIE'4R6`B9*:<1FG[>;3RV]7:3J/[IZ4U
MK1[:)/FU0U;7J4<;Z.T]]/"]+02N2P)7//7CHFC5%CC:2Z&>25/;78T:0M\'
MD;(;C21>LY;SEI,WT:/Q,VLW:';H<2T9W-O\GJUOPF&;*7Y&K5TKP7<YLJ.!
M=FY/MAO;]@PQN&X0IOVA.:'-+DF;G2&$J`RF+9#M;J@#H2?;L6^%GA1ZLNG+
M6[455RW=4`?B!N9TS@Y;R->W\=BOIOK*=)E:EV@4#QOSW0=R-V,36TQOI052
MW04U</XS0QNI(I3C)9-;*,<62'47U(!0CBW8K4(Y"N681NWY,Z$>VZ$(#HVC
M_$3G.V_=B1X!HQBW?8*R$`//F^#`[3V17KNKM>D\2?<FO-N50F=.O,"T'!J1
M6KN^A>DZOF0&=,:OI"NRA'/J)--)9H1*NDH_U:7@'G[XZ(;V0C)IB$NR`C]G
MR/U`2J^]<!$Q-X"7!M;<6F-#*%/R0?582VL.'TKS.(4H@.?,E1LZM%U4Z'AD
M[L+O_DL6].6\;Y0ON0\`%_[8`:I+P2.Q8?D54/7>'TBOR-P,?4*_CX"P?'R]
M*=FN[TMST_.>0#`>36\14T'>_/T=+.:9MOTD^>'L/XAMX$J_?XV;6"&-?-K>
M*A7E(]_-E>68C*RS)_J9&0;WK@>+`!U@5<R.DIZ(Z;%_@5#-[W,A`QC,!].R
M46<-I/=+NN+C/0$\UFL;2`>?9Z%^M.#5,<T`+A`9X@?TP35Q3)O"`+*P-CU*
MX0SDM&!Y4+!=__93Z%_?F>;ZY_?TF5OS^QO+GP/4H4=N@0NO;'?^YZ_/G_TM
M^AT`M;*"%6PV_\99O(8W@H@29PX@Y#P)6]C!+?2%+/_^XC7[^YOQX>TW1?WV
M3]/YAF)YJRC?V']N/WW3E6\@L]G/7_RZ1ZML[+*=.@6?OO:!CM?FXC^A'T1:
MA'T>>"28WV_;OAG^\?'3[5MI(C$=.-%4]1?I]:</'][??GC[\?:K=//Q#?S[
MX^W[C_]X^_'U^[=?*9EGI?1CS9ADM7<+`(I(^YLU1S&5;NX\0JAP">+M`^C?
MKK,.G;N60-,Z\@@PTF!\<J2;\`Y^"C8?[;XRSMH8.F$0[#$8%Q?,5K0?WY`'
M8KMKW)'4W*#V)][<@C/&?UE2<+QCP4P%]Q(72AE]@7O3(_>N#785C5)JM4'T
M,^K!D.]S._2IIT$\,*A@5($<])Q(S?L<'0</39P%KA:QP6;3SV]\RT3C#93Y
MDP12N,9_!(^NM/#".W_3[L]#SP,HP>XO&$Y@MBA*)EN*-K*T/""01Y:A#Q!<
M18I>4W[Y\NG=E_B?ZB\OJ8UG*YI@N.$LA<2`AY:(1P0`^%5I*%9FO'CD%2W#
M`,PEVNX%N$`.90!X//#1@H!'9T>_LSD_S(C:@UKD*NM*#T:6<Q&J(.VW@A]%
M@$<+Y%NX7GKHOT?471*"8O"#*H\4188C!_/-T/T"Q\X!V)ZXLX5N+.6^JOV(
M_\!.J"`SW!5,1)&_&?PTS\4F,E2&"Z21^=?L"11.V`TK]CZ4`)3`Y"VPL]+^
M*Q<CA]RY@<7=5`1]!KRD<N[-+#@WX1=L%?9N`)R8X*8F:YJIW8Q8?U];\%Z7
M"2'0P+;89D9*(HLD(.!*4D?<\P50-(7_;2YAD=2K`0_^G@5ZU_"2>:Q,(H_8
MLJW@B;Z?^>G6/$(97^V',:P)13=VR")6(D^9\TKLM(U_B:D/M)V'/K(#`-O0
M"DRIX+_P8))PCRWVNP-'QH5$V^`R2N-)"!42>/2<=C/@$+P3SQ2,(#.RQ(V=
MU0BXBK^U!GU32S9/6\!HGU*QX#3W&8Y<3]Q<NEY+0&L=K008+04C';[:F0OV
MRD3=&JZY"O]`%@0-$\;BS/EVH,7T_7#%C*P[LZT[YBN"#E^##P1>&]T[:[IW
MKFY><L/ZA-_2PQ^WH&A;G91M!<.P;5"IFX7V$%6P#^XF!FC`-O)?$JJ>KUZ]
MQ%=1:X?_1L6<_A6U[_#6#4`2;P'>&;^0VCQ4V>E5X.V;0,8F*@L0H]0].)W,
MEEY9+\%J_ACYR(F3D;?X+VA'KRQX)"'1,DNBU%+9D!TU2Z;MH\O\)Y%6%CP0
M@)`D9(_=FA^&^+5-J_Z<1?2A%GTHQVX)<YE3EAS!P/=LF.>E18`SE%?H\V.D
MT+F#7YHLQKB&L\+*G).09BG"0^"'+"R`2:;K'[=:ZO-XX14SP2B7SB&K>\1?
MLSBH_80;CT@?7?!>C**`VMEW=$O`.%BQX(^M'*-EQ0BUD,@L9D7,J!.DB%,=
M>/I*SCTVI1Y5HW/76[L>.Q0L07-)]"Z&;GK\^B/`]8?K_2F]IH<#C/?3.X%K
M//OC']+,]"T_J^N8D@'0KN=8L4RC[9*[)G@(`J>>KLZ.-]3'=_`J9!PO^9DX
MCO]D/YB.949`V>Z<'Z#>L=/6RG*L5;CB[XIUJ,G.\TL7JZ7]GUO"A-9)Q3NN
MTO%L)!%G`68NNJQJ.\WH=;-$K]G__F).(V<OCH:17RI.E!_CA`50DK:Y]LG/
M4O176>@ED'B;7Q_^_87"_LVO_/'?,29Q!4)!@4!.'4`ZQX`A7T^UR^;DY#]`
M4`IS)?(K0PYMYG$NE&[HG6BE2.66EU32%&,KM^08ZB8/@KX=;3URTAM_..CW
M+/^(/J"/95U12JY2%^4+ZVXB\?HQ)[WG4!;P=XR4PI<`.XQ]CP,()1?<`?2>
M)Z?9)Y\_RS!N@L'9$Q:_A-TSKG;WE'PPRXU)^[?1=FI<=39C[_N`79,&;!>#
MH[;2TV,DI#9HIO*XC-`=Q>T&U4%N0F9ULAB_[=8-3/M@43P-B)JR=LO8^;I@
M4+5Q.:5W!'^/R7#MV2&R%C"V>7=:S,-R:-1C(=$[1YZ01R\YUVO/_6ZMS(#8
M3](/!A4I&N_\P1C*!OR-\0AV><A.R.GDS809-(L3'X,_M,V0)4UQR"ZDZNCW
MQD%5W_K.DRPWSN$T:51<0[9_"_!PY!W7[*V*1D;@I2!K(PD%&%L<0QV6"83^
M9@7\)N_G%`^SW*1/?B'VRER8-`CKAYC4%-!$EA5HKL^@GJQ%G$]V;Y&E]'6.
MERV8-RY]HL%63Y8^FO^Q9M(K<Q;:<G[:Q1L+X+?F`2C:T`MB=?;6]`/B.<G7
MH&G3:`SR8/_@#=A:J#U!\\,J]);OWL+\-#(/V3U1G%H/`'TEZX`I8U2[+%,(
M\+5-3'OQR,I]B%["R9%)09FYF`L.H"TL#Y2UZ_FY<$5VQ#8MI)AMDSO"KCQE
M:1'2V#7B/`<*<)OB2&:XL.#KB`D+RY]C8CW9M@.#47S+!PC]%1*?9K&E!UTE
MUFOV)"54XFLC>4`"S3N6,\1O,.?<\%'D-4492B%PUZ:_9N1EU\$LZJY)5_A0
M*MGN?].`O(TF;J6R[P;2IS!`*6*9/^:C'Z8QIK%_O.9DH7^;(&<\S\3H/%Y!
MA][\'D/V$V,B:V`Z\3X1KV\#3%C?!.9U_(Y_\W=D\@#Y?3AS_&$/FO"F.\G%
MYO"^S*X=&<7FM,""%4PL@"GL;Q\HX2^?.-F<!1<OE&7,G.1Y4R"!WMSR(V['
MR+`4*R3K@VL#C4WO*4-@RH!TWN4N$:/7]D@U5E6"G@JKX%@D?,^(,/DKQ`L9
MX&)$>`0[ONE)$Q5([H=8$X)I<;#>5TP-!=;R$A%*)BP=@+7@F0_F$\]21?=C
MYVZEK';\1RK>D>S1S0+[@SA/+)T+K\]Y<AESB/"QI85,-5EZ*=`7GEKA!>^?
M^`QZ4%0?K8F'B@N%@#[I$<NAY2%I@8\D0\:+GT>"M^P^A00DU\14-&EAKLP[
MGBI&A0->9(/JNVCOZD*S23,&\@T!]8/"?+!QO*&;-B@VKM2,S$"A8%:R>6>B
MP,$F7\DI_1M_[4@L_28RD<P6@EQB`^<Y)KG$$%+-%I4V\0*E:.?20JKX'G;Q
M$G</4&[!5`[LSNB'YN*![@54.G8"<LI<4##B15'@B_!,:86,XL3T(.<.=U/R
M'K3Y8<!5A8>JQ\/M%-\=\_2B"#R:2$-,GQN1/$AIEBEW2M@5KX>Z-K+'0""7
MUFKQ-*7`3;]E]L1?SU0`A<EFB;?WUIHIF10[,)H`RB8B8@I0FM,:P92K[-X0
M^)(R(LZ^<L.`%GA%:R>`)480D\T!"_Q_J,QG!%/\K0!U'BP_0_)8JQFZ#4EZ
M#0=J$0,D2[.0YK`#!\"8XF..2Y.[/$YF=$3(`P'Y6\9+KSV"Z;Q^6F"CE%C*
M#@#`(Y@)QI\0R>S'J!\Z@4;Z[`;(6%CV8`WT/JE8B`RRB:G):-+@,X+NB;^&
MW>9G?:H903X[=,_P7*Z$P9C4#C`3-+\TQ6)E4DN:JHV@)C96$1FMD-I:Z._8
M/GE$H:,&%=XLY*0\0!\2OWR&OL8#/SAD6`K*CQ;<N*$?L2>R.`EKHPP\/,4M
MR)*ISZV?93/LZ;MB]9'66,P=B]F-EF<%!RO?XIIAC;EW<UY.Q`N;0?\"X%17
M(HU2<I`4L)8K3$V7M'X-9SY8%'CR[0,^WG#U:KF:^'1T$@7!6CYMZ(6/6*8Z
MS92I?OW]U=>W__O[VX^WTMM_8;'J$7&BJL`LOT^.7SFY;_SD2/\,X="K3MBY
M8E?UFY,I@PGNJ9OA^*$=F`Z+,UC.`Z;.>O24$SK6G`_(P()LFGV;N`/T]YAK
MBG%<EJ.6>IE_;[+:;DST39<DS4W_/JY'TD9)-5+\C[]"\$N(!SC1W])CB6VS
M'#2:(>O,>6I;)E(Q'$@I_9\E`X/&`O-.I&@96L7G;Q3P9?8ZD@A665K@V(*!
MN%)'+^&\\Q0_DQ`S\HK`U,"F1N@V5F$`@)M`8:#%<'%TVGXJ@>.&;.4(>O:C
M1(T4*H-L$;Q#KR(IBS_#7_.G5BN->AMIT)]6UD5C[YT^55N?/3BO6&N>\I[A
MQX9N*YT^W%?27E!KEP;)%BET)GYXF+(<.!O1XH0H3D0/UW:X((4ZU)S3,)3/
M5:3KDYT:]][%!B;N(_KJ/B@L:V&96"$]D&Y`?Z:;L-!F(5%`-KM*4KOC@R\(
MYH?Z]^`JTE8G3/O.TQMK?Q.177HQK3]_]\FGY5OP"E8TDE^KQCS8S=[0,+\S
M'L10EG"9RBYYN$M4\LTHG&L\:O,(":UQSQ5/Y`'N/(SH,I^'R0J:UW6B:Y/N
M.?`]FMQ%_MU,NG;^]\'7@?2/FYO/F<!Y',-)W1\$O#*)Q))!;Z^QEFS-Y)05
M>[$N1<R36+L>KLO:"[&HCN\3+N-1V-?BKUK$!P%6?\S/"$'A,T&F8)F5%N70
M+W%LML'Q,#P2<@#BZ%,4<F%/4"H#!]T%[.!Y$)KT'@I\1)_?&RPLP-F+`OJH
M'F(:,9\RO>=3Y./UQLD,-[QQ@H4>3'JAE<)59J'ZZQDM](N#UYF0&6*0]!:*
M/D#\?=\%FB#F.>/B<H]K6160<:[`G<43'/R_MR`C\$*D<:->UK$Z`V%F]YKX
M1PIZJ:O:([G.<?#"S?/9:6-!Z%THWZ"V3<L9L:K'`IP7_'S$]@8_00&;0X]7
M]P?W<"*(<DY@(X!F\5D+K.AN+@I2TL5(0L=,D<__LP4,B/L]5O[AOGUT*5#7
M<XPG!-=P7*+-!9+]BZ<)*PBI8MGS7JH&?))Y!._'"-I[UCB,'4]"/$6B!050
M<PWD(;*-FP'.CZN?/YM!9T2?P]I%.7_M^H'/3NQ,\):@$WD?"'I'0=4SQ2_J
MT<9;;'B$]F7S,&O*C*TCVQ0+K`_S:=>-A_@^/6T$Z"/Q];IO84`=WX8](Y).
M&,D%`4AQB`;3\I..?QDAVR$SL4B]L[Z3Q0VU=IT0*PJOQ`#NHFPQ^"/WPN,7
M<%1#S4'LF.H#7RI<A4S\0.F`$%A1J>'FXVB8/8M>E-,&*ABF]Y@:]MUE@'=E
M`^E-ZATT,&_:<_[Z,,XB0-'$'-EKD'50Q@3<BD72@3'R(?`)L@QM4&K+V`>*
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M0$3`Y+F!-.'3?234=7H@-FMWO`YYBQ?P0=*1$)[=D#)BJP2>XOYP")/OIS/\
MDI?.V24VS0JRT*ORHO5WK96$NR);)?,V<T_I<%8F3K/QMMV1+?@Q_')M@YC$
M]Y91,YSD'?<6G"W@A/W$B,>/O8FOEUV.AKZ28)&5F*G(X^-1[:^$MN>\P5CC
MDK#C#,W[I&?_A?OH7-/P.;;C"0C+5X,_'RP_[E08Y[0>]@BFR*6\6OH0O6L$
M@0$/.^92NM%40MREY:U2S7Q*U+A<CGIH]!X^R@!H-45P*["N+?2(1'U.NM\`
MM.!>IEVXJ,K9L[?DPGN;1.NEMR_KOX\I=CSFSC/RMKQO$SUS[L_0EC<80``Q
MS]1K'=X\Y<+9*?R=C88UA6B#(K5FGB5C[/2!8'$S(`QH7&=;U*@C8QQ+0K5X
M5M7X9B]MZFB,DR-L1>-\KI?F"DZU/^^5M%,ZUY1;:+,GS?^&+BJ@SW`XYQ&-
MVI$Y'M<MZ(]?10"Q577>WTWPWL%K6'!ZFT6D(]3YFIRP>J0@.L:DW8T^*D1"
M*(P[3+9GC=R7;G&/NCZK#%JK(BC3!F7:,?J\QMEI%A]S)%19`[X/'N$082&.
M>8HLOH\4Y,DAS^^.*PBTBT#L5H3&[81&:XCFJ>RAVK%X_JQCQ'F/EU<-$4>0
MYE)($UTYM%B''05);>U*WQ!_[EGKN#[M\$:P)3G5E$@TTB#]ZC=ZX::^;`7-
M!'\*^*,)_K2:/[K@3SOY@Q?V9R17??VMHZDFZBB_HVY>-^0C,$MR;C,9%>D$
M-9Y8E,Y>*J1XQ$@#@:X(Q`-D-;-L0??A^L3VU*;;$?1#;1-\WH*[%?!?'TO]
M,XF!D#XA?6>1OM%YI*_`3K2">P=(G]IFZ=-&\FABR%-=/Y8-0@Q;P$8AAG7+
MPS$3-RXH9S2O::3($K^4+/'T[!#,%-=;GRG.6G&>,U=\3^+T7KJ(S.E3KAF/
M#_64S&IN#H[C5Q%`U'FC72%BQ;G#S<&P*ZFL_2S>^W5RR7X(&/F9L-T6LEWY
MILU!D9_5V3<Q+\Q0[+:(%><!-BA@Q<EDS0&Q,Z>M.3!V98YU6](*\K.:--FY
MB3X]`B`S6+()Z8I^V;Y\FU-NF-N<$W/:+7U'J%(Z$Z475"F=_W'95,'@5Z4H
MG2V/HNXDB&KND$^\PCWI!O48#/J']>@(K'=(Y/$W5?3QH:Q,IK(V*4Z-.@`&
M@7T=JFIC%$>^+L^_K$LIT@,T5E%+J09,$0._+L>T)##\`K<N:(H53"F&-NHJ
M"/X(_K2%/ZHAXS`QT.B"48)1]9X%#LN'2:X\"@9]'"Q8PV;%ZM0DJ"J$Z=1L
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M`'2!5P0.;@XKPZ4C4PL)ETGF:GV3EQ,3VXY8[.J`J'7E&!8[^Y?)KDIZ1S!V
MC61EJLC3R63OJE7TVSB06Z/:N549,HUR:W^.:65XM2`KL3S0KVF0'4/DV?AZ
M?G9%-!-S@0\X))!LUZ<A?#Y&]+NTPO.K+Q$\1&1']]%!F-%/Z1!U]JN$;-M-
M'.@S:)5ER2/^FM#*8_OI?&?3RF5CYRWI$>NDSX?IX"I376-Y.AK*T[&RXQQ7
M)=K%>JOWG+H"H9Z,Q[(Q+G-7+5A0)0MTV9A,9'U4?!ZK@P--YM"5A_8&3CD!
MG4)<ML0F^@O7S%R#/']6ZE(H3P;P/>6TU8M"<)H%)E7[4!$T5T-9UW59-?06
MD.;E83`<9\G.S+JC]=?Y03_)@:A"1O7Q%M";KZ7WC>S=["%0Q]-I<VP2EG&'
M<Z).946;=LDNUGI,NJ47\7`R@:-1CBV4`E<RN>&$+;(V+7I"FIMKJZ$YE=V4
M,T.>*$/9*)6NV>CUVVX3>@R5RJ9T7SH&YZPH.3J$G^\DSUT'`/<Q?7%)S"#T
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MX/)>#8<5%)5=[O#ZRY)OODW&6D2C*E@"A,40"Q`Q*?1IE>,]=K3U24#3&*(T
MBB=I18)[=S&0;N!Y#T7,?I*E110<@#>PI_S,8QA#,#U"ZR3O'.N_)$FF6(8T
MUH`/`L]]\E=(P*>"GP>!9\U"5I<4N-+"6L(:[+L9"1X)<5)UE'Y@!@1E3)KS
MEL^2N6+XN4N)?+?\@'Y6`!K\&V"QO%2B!H5H9OK$'TAO#D1O14P_Q-\Q$A+'
MG`?\*0_@\P$0?#M^Y$KF>FT_X1_P-462,X$7?+(D$_@'.+/S>_C(]0$FLEJ[
MGND]9<B!2Z??/&.$!G\9_@UD!G@#FP#/D/\$GIL'.(WD$*8!\4Q>RQH!%F$C
M67Z:G_`M1P!61&B`E]$C:Y!&=\'FI."_HQ?Z'!H@]P!W%4#ND*45;`G+XSUP
MVPKPB;7GSIA,1&];D$4XIW6WCY9M(_9^"/)@.8CR#<T*8F6Y)E;PHL=.5_91
MM"S_/OOZE>MATM"?!'D#8$J.&["EX&E$S92``U&5KYE#1`8%L;`!.Q+"@A?.
MR!+?FQHK@VM%HNT14-W_95]S"L@2W1XX08;M#XXDWX3P<`AX>(@EX!CD)"MM
MIR.E5[\W%VGZFKE40MFD.Q3Q^1[@[@*<BV;C8$95GDC!5I@SW"A9K7L71`'>
MP["."Z93R(/U0Z4&A%\1PGA<P!;8KO>NO1A4KH+M4PI(3]#*2\O&#2W]/O@Z
MD-X1<`Q`N27:&8@&TN!0!C^8L*E"GZD^_@7HJM\CN:"_7[L^C_4&YI\@Y$CK
MT$N]RH\WS<;L(C^C!_"CT$E)3)#:K4RQ1"C0]\6_!.`#T$,^,R.@%4P;7RA+
M%NP>YPE3XVR3ZZW"!5"/W,'?2`Q\C;E860ZH=(_E^'%M$Q?;Q\:`ZB\7M`^5
M,@8GR!$=U>2X&01Q96_!D0\+:&@>M-$8.6!9]CA5Y,#[</8?5+R`Y]K%O81F
MBWP'9\QA>V#VQ&PNF`5KSE2#^9T:K1"4OP?;7HZ-9DQKQ&0)0H8+*[@AW/#N
M7HH+:-99]ZS(VTI[9%^(3["[P(VS>(.EE>X:*?F6D9@]UT[G+`*<,R4&O8N.
M6@:718(+4-X/T`9:\`!X\=1E@HW`]"E_!KGC@>>1Y+::BP=4Z"NNP<&$HC%)
MOUAFUSK7Z/!@W=X*V4WE4J8PX#JA'9C.YFZ/]YY)=_U.L+/>`&BU$&W%($]2
M#Y#"M-!^O0>'X17"_CH%^B?:8QY>`7*/&^Z!?+9-QV^S$'^E7*"82&E4NBC$
M:3'AGK'/W#^722PXL[;[1+"7BO>`T[]0"Q-@$_4FR7?N)E)S!#;OT?2HXP!'
M!.H#I3(8F-BZ3+[N,,'A>H%6,9L63K<"O@5%V&12N>'%HM.<%M)%2(?U,1\<
M@(A!IH\!(!XS7;"E'JQ%C,D6_/'2TC7]FSX+9B5Y@BW(-E<A!@G%4.#!QC"[
MQ-Q9T`E!?/;`15YAZ.'ZZQQ<)'3EZ8]1=V!G`_"H%@2L*6V8D#J.A8X%)S#T
MT%&%`$SPWKG/J.=2CSZF^B`CH;'/CV^*`$,]P#-.?(85(Y?C.M<1+A3\!8&U
M5NBR1W9PFW54URVX,4]$)3I';OT^1TXLWP_)0F;\),CKR.4'-P2\`3N6U`73
M>P72D<>T^,SCHZUG!]D`7AB3&/!.`<D/+\1A,FV"?'F$'BV`.5SZP!VSX&P;
MPG>Y%'T`KLO1Z76#`O2I%.XRNG01+#(5&09P"JW(%\/W)F#``8,^%B<+9;'8
M`)U*[<I\0F,`%B/W7(@!`_B#7J*$:[YM(PFF#9)2*W#LV'&>G>89H6.7#40:
MA<#EMBZ"-6NH//)@D4<0`3Q=WGF$.X@Q\=@Q"S#&CB7T^./"\?#.Y`?+X#Z*
M#40+A0Z2"<G'60,PQ)RA017*(6?A>O2[C`G]-YXXP=7S7``>D):S;AT]07(T
M]Z[%)0EU,3O)`OCF';/V"\#3SXAL"BL$DN,=:^![D)(Y076::Y>/,+1I._W6
M]+#JTO],//JF1J-^%S@6.'(;/L(Q^3>L9@+Y12E:`7<I@4OX#1=(GKH;V;49
M>=BDUCPI<T/!F#/!8+[#9GPU^A(=4(RI$(\:YKEIST-F%688=00O)W(OXG<?
M\BINU1\)7JR0Q;4)-@>4E.2$].R,'?-2T(&""P,XQC,3$?DFS!S)5!O#]QL.
MP=+U,BM3^P\VA+DJ;RP[1"1.)PCHO;!A<J11V4&9M!>5>(&!1SV:IVM&E2A^
M3PF"T9,BFM$8+&(+/B"A3LIK;%`HW?!4P<!"_#;R`N4D8_!S_,U7]DW&.%*H
M0SCA@2U)HTNA0*/,+=U`>H?N/]A#AB,>?N%LZ%`G)J#A'`MCA:F`>'3.3&C)
M92KTF1<6RS0=PCUGIU4N'SGBMPCC4&A1W)-)%(\3[8]&7IZVZ;6J_1S%\^PG
M)D>XK7R<])Y<#6&\.EU_3`\T7`YY!'R1IZ(.UTTS,C=#G]V5N9+O`HJAO:"1
M70#N.@:,OL_G_4Q]Z0I3_?-5`-\,+^OJ,]IFGA8)M!@[W]Y&B:?T\VFB0\]!
M+?)ROXJ;Y>5^>T2_K-/2Q=M.Z(R68BKG.G#7?(/P#R*4XBT?]9++T70'O^/0
M]GQ%?-2S``B.IALB'K97-CO^I:A;MC_6N8I_]G:\BL#%?Z'T<5`/<-`+*5#3
ME,42;]DY;E&7=7TLZTIQ56>KATV6(<.N"83'=@0J"T3%<Q?;C7[S@Q<W]NW!
M57;'IMZVI5[R;!BHNB$K0U76RC2L:2DN$WFDZ/C?JE8\1Q7KIN5*GT"C0%%;
M"#[4974XE$>C<?=E9RIKQDB&1SN/RE`>3``53:]L1Y][`.]!FX/'11OP[_M4
M@`WN)6Z+L9@5VFX^J1/9&`UE95I"%0M&G8%1QG@L3XWB`_=>+F'?M;,>PG,K
MJ+(:>C3(CG4]6(9:.0.Q(0$Z#)CA5)X,Q[*BG[+1+VY,9:M8I(%?/#44>:2?
ML,T%CVKED0JV<FC(8Z6$OU_53-$D:VQ/VE<Z0^PC>;QAA2CPP&?/==R09Z[S
M=+(.I(RE*=J947"\A@*#^E+"`2G+`LK@.M/)ND<Z,2RUF2&4;4;YO</JPE"I
ML$S>=S=?7_%L<^GFZ^_TFVM5D>.6:YKR2ZJP1?H:8/;76]AS-&/DZM9=6W-I
MJHY>_BR]M:VX2`RSL'AI6EQ@+WV)DZ^_L)($GO#]GN:;T!(R1[J!#Q=TK<"5
M_F5Z%I^BQZOSXJ7_$5H+DV=1,2@F"#>H5NK=LVJ4"`GU%UZP$#U$.*R\TF-!
MEI9CI:ME$Y1]BC(FS@1/+)-KAEG:*_<ARERSG#G#!7!,2KV35',OA2VK@J-E
MD_^XN?E,<\P*5J/EATD)%<\GB^F+Y:JL5`(S:6@-1KRVY=#L<)KE11&G=1\^
M2\GF!281G7E==E3@S,M8G#"#0I34-HL'TIA+X$A25*B.9"Y64:8Z+:BT5O&C
ME'18!OP_[B.6-,@2,3U:=\`K/BR:2;2R8!]LUNUG2X)]]@PFR=U;M+#466#)
M"B^"V9Z2@)]F"B+K2GW;]E':K`X$$9HVC.TG1[H4)2YO9TT;>-D*WZTNK8N6
M7-H^P&/^F)GX8^N,/X8JZM[$I#X)2V<\JJ-@$=;@`0M0<EID^+F5'64=[TSY
M95SO]/:A44]]D^/E^O5L]O&.\N#H*2IB+OT,:^U-)]CXE&5O)Q\6R9%M.>3Z
M?N/'KK>^!\G\&<N[W3RIS)?>7`$$87,?XU?EB.T>"=VSL39*5&-F2XS;>P\%
M@DO-<6F?UA6\:(P7MP4%`ZGR/%:4B`U8;#O1X.2!Z7;>S8$ZTNB'TCK%''W.
MVD#PTP:ZF4G]*7N7M+#\N>UB76NV:":_QN\0;9Y1__-[L@AM;/H5]?^ZH;U?
M;IS%;TF/C0^\LO:3\P5SX]&GQ"(E_Q9/(B*@4Y\'NB=G?0Z8S3Q+ENZ)_4#P
MX@2H`&A<BY3U_HUQ_]_0Q0/@9P^K@9M!YGA<MQ._CUY%`%'^/O5B-\%[1[JA
M09MF$>D(=;["NZPER`/OK=0/!=$Q)NW.1Z@0":$PX/T?3.]/PBJ;A<K(H<\G
MC&8)RK1!F7:,/J]Y.U^ARIKR??`(AP@+<<Q39#/LE$0S7`1YMLGSN^,*`NTB
MT+]83S.\+18:K2&:LUBD$,?<@^XZ%*01I"E'FK@;17LUV%&0U%8,\8;X<\]:
MQXU\#R\SJ7\TSU$BT4C/AZO?,']+4MLQ=%#PIX`_FN!/J_FC"_ZTDS]'M&VJ
MDERUMZ^9%#3C.`*)-_#G`QOVD1[:$:=5J+_D#;8O)&ZF8<MAT#Q_5E(&=S>%
M.8(&Q8/K]C70.6*Q_8U6*L.K+"WK7T%PJQ):CFKG5F7ZY0!N%;0E.F*Q`T;,
M5HZ@8-MEL2VWX!+_U8MZ*XJV:,G:BORVXUWRDKEGS<%Q_"H"B#KO'2I$K#C#
MJSD8=EW]MY_%E0*1GZW4;1';E1/4'!3YF3=]$_+"+))NBUAQKD:#`E9\X=\<
M$#OS#IH#8]?M?K<EK>`.O4F#G7L=VR,`-ON:URY=T2_;=RMZRCU`FV\N3[M+
MZ0A52M\7]H(JI6_I+ILJ\2B,JE`ZVVU7W?=7U=QPG'AG<=(MQ#$8]`_KBB<R
M'!\ZIX\/905;B4^*+[!;/8^BU=B?NPWYH1KKX*D5U9NB/G52+C%\0W2Z%OS9
M>AHS5_K-(=60L8,>Z/26LTHPJB%&G6/BS58W97KI(2UR#>W!@M7*%MC%[E45
MPG08#*>HY8OK22X8(ABR!8.FR*JBRT.MQ``EP9D.<J;0]F53QQ;60PXS^*>I
M]G!5=GM+MY&+7W?`6](7?O1F!KYVG3D\1?O:U=%-KK(N:A.,"43-#355%TEG
M1U<@BZ*2)'"N*IL)%U)ZETCL`E-J0U60*$N_.W`:O)TS`[Y1O#M"3#H??`<=
M<[_:>:->"P'VT6?7'/O3B183:I>8;1$E?QC]&?>W4/HMJR04K*GT(ENPIC'6
M%`^N:Y<3=%1&@JHH>E6%2*_B^30ST\9)/X6$$[6:NQ>[.N!P7SF&Q<[^9;*K
MNJJ_JY&L3!5Y.IGL7;6RJK_]W!(UFL<60C=:FEES^D9YH%_?F\X='>VV-"U/
M>J#YZNZRX!(*1Z'9(9P/\`&'!)+M^K2>)6<4&/PH,PF,CBN+?OH$AP[^JX1L
M4OJD@<_H]!FTRK+D$7_-YJ;93^<[F]98;5V)N&?.A^GJ7::ZQO)T-)2G8V7'
M.:Y*M(OU5N\Y=05"/1F/96-<)J0O6%`E"W39F$QD?51\'JN#`TVF&I2']@9.
M.7AAXI=-18[^PB5SN!A_?#"I7Z3?6'S-<HQ(E0(FE>99$3170UG7=5DU]!:0
MYN5A,!QGB\[,NJ,UT/E!/\D%J$)&]?$6T)NO30]^HP^!0IU.FV.3L&T[W`MU
M*BO:M$N6K=:#SBV]2H>S!1QN<LR9%+C/GTDF-WZP2=:F14\Y<W-M-30XI9N2
M9L@392@;I3)3&KU"VVU$CZ%2V>RU2\?@G,FS1X?A8T<W4\(R=QT`'.>W2TMB
M!C@?$Q2&*&SI1>%$_5KV"/77,MZW`_8K51X;JJP898[NE3&]'?V3A5S5(E?:
M!$XQBM$&N:K+G\Y+##X"W+?.XI#[WXI6:^..J"&!O!407QW0VO2P?/-:M:N0
MI`Y(4E65"T*2>BY)^_,N&A.DW(J9I""FCKJ5=%U,4G!SXP36PK)#O!?_BN^E
M:[W]SF[IWP%&K]T5O)2^Z]/RK>EARI;_F7A?[TTOJ;IIKBIF@]Q%K9<5Y<?J
M"E;J*TBI__S?9(^EN`!!0GBB_&^)9H1G/HH3.S*_.R+I^+3S>MOIB5!L9&-<
M!^Z:EV/Q#R*4XBR-*"$_R<\H_XYMEF5R:S;9IF?7$PQ,%Y'LW@J;U1%ILI9-
M)CYS>K`Q_#$O$RZ"%?^%(L;A?&V;/H9$6<0TL%#K'QH>C3CRX\$2D#QQ<NNH
MZ8^%;9QT6=?'LJX47YM5"$?KL-^?*RFP;FO#KHW->?"%Q;&GF+9</9T-`U4W
M9&6HREJ9_+V6XC*11W!$A_]6M>(Y+@0WS9.[6KD.D_KHPK]TL^:Z"#[4974X
ME$>C<?=E9RIKQDB&1SN/RE`>3``53:]L1Y^[<>-!F\-=LWS/^EWW/MUE@RN)
MVV(L.LRUFT_J1#9&0UF9EE#%@E%G8)0Q'LM3H_A(70V7ZO-<<D/16?T\&F1;
M`1XL0:WLF]60^!P&S'`J3X9C6=%/V>87U]JL52S2P"N>&HH\TD_9Y()'=?)(
M!4LY-.2Q4L+;/X)%>^[7JK__PMLUC]BKU*L_P\.6[[O>TT<W(/Z;D/SFFDZV
M65V%UV8[>^U1"HNAIG7VE\L37X346CXUY-C5X#AEXI9%8Z32;<2BVXMC^@?E
MK742X4YYX[ENC#+70;D]QKHWR$95Q]/-)@G1ULAJC.OIME,[C6/2(1+2<DP<
MZ3OY45K'"A8V/FA8:1&2I`7`3C*)P2_'/%//Z!,->[3O\`?:/O@DEN1=2J@Z
M`?]*UD$LX76E2]1M2DJ);=W`'+0##[`PI9`2_#F&/\9DN%-75,.E9FZ?MO3&
M1HR=#7-@&W]M/ATSB%;<OA9A,%64G8+403M3($:_$=^',SB9!=+"\N>P[/;8
M;*&4A-&X7/Y<@?\I*\/BG*Q2;#I/-Y["S9]S"[#+@LB`B>\?J0[*A#>KCQ^6
M/GW4#,)1&F!8Z?X7#"E@R'@TD:>CXJOS*MA2./4DSK:.MKA"_^^7DF4PFPUR
MHE@GQ3^*=-+/'DS/,IU@X]-'/@\D^K`H$&M;#KF^W_BQZZWO30<<!S,,W"QI
M_,#T-H^U2G%$F/HV=-44V,!?]S%^>TXH>$\$5]IJ3;C!IC4+^!\1DL^)Y+^)
M>UFFZG&P/H?>"O@?W`6Q_=H"^[$X'1&SW[Y+V93)4\/X114%'I.GHB*#/)[G
M2LJ^4'X1[\6-Q[DGZAP?:-\*BK]W8,OEI#,T!\'-MI=4V8'P+"1]B-37&8G*
M+XX:H6PU1ZAN5B&)NKJZ"=+`%9JV=866^*B9=%QP<$)J^,(U?$:^$V]N^235
MMBYJ6'7P;5>%-V0EWC+>&C61+K129$4W9&.XOXE^*^_,RM!AUY5A"3JT]?XL
M`>.#Z?U)@J2'_#R39>Y(*U8"C_T6I849$.E*W>[0<%)`N4Q7`Y;/-%#;4H)1
M&G9MT)H`>(X"Q+_>1LIK[5DY#8*:)1?^J(*^N&!.%#:68,!;FAS;OKDM<M09
MPC2KS;Y8_I_2TB,X'`,\&^('DD>5EE:QTCJA!G%05GG]V![02W18RP6]P1K#
M%TR9X?P1LI!L:TD'IM`9)FVA9T6;.`%`&;#I*ZW4<6>G4T2=X>#8=N=M4G6Q
M:#^XMAE@@/1)NLJ9!]QMGB4`C%7*O/%)XQ=:HTHK)T\>H;+0542RLZGPA?5@
M+0A@]F01>^%+5\/6"/M'URENI=D5+5LE$OOOZ8ZX&DC?/^7G-5=]T=+$A4F/
M*9*A@[@XJO#B*'#7.P*;H]%@0K/#H[`KOSADI:Q%F2UY@9^MI/.I<<RK;^\)
MRG(2B+)\.G$0,)J'-DW-SDXZI%^F(U7KT/-#'`\2N/3+^*H%6#Z_=ZR_X#D3
M<W#\N6?-X'WFS'T@@V-L6P%MR]$RYSQZU(N0<AX<>J]S#KV/%&'X9&4Y@/'L
M"6CLF'<LEA?ZV`8:2:56[HO0(XAT30];TJU'(XA/TBO+MI$'G'V;@<7!+B>E
M.<;D>-!',^;>`N'T$$0)-!'MNYURUK?9$XE[Q)G4CSG1L##2=)X8J2>:.O[%
ME]:$>!(Z6>L=XER3%3Z3>7G^K!TFM]76->=H("RN2-6X4`C*)HN(3)6#,E5*
MQTHO#8BHMC5Y'>\9VUUXZI&^SF>G5%O@?0$$J;83\@401$A(K1)2>T+79%<^
M3LE\KKVAD/,E<>WL=Z!I=(SU:'I8HX;3H6DI'=2IK$]&LKJCF^NE)+/M[`0Q
M5.6Q.I''HWJ:072&#B7DH=5)?1NM+T9Y=<JC1!GOT'JIJ:IEIJD>8;6JN+T:
MJ;*B&+*V0XZ[<A$'8JCH\-\RT[=:BLI%-5ROG"U-=EPOIQ8ZF!6L#"9MV?I'
MP)Y3D=,1V#&%M*NP5RDS55MX_*M5N=C=WF`"]J[#WG3B60=RR96!6MQAI>49
MD,I`*RL:+8)=+S'0M&VPGRPS9TIT;F4.OSHHKFKMRLFF?%U'^W#0!FTQDJV0
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M>CMQ16B6X#;ONH4/37E$)0&,04#B=IV+T`-IVR6DW4(4W-W=*/1)<5P"#AU0
M?G,\H!+I:D'87R_Q]C8;(MBA#/O$S$O`H?4"^2XM>;6H\)B(B5C[->CR++,B
MHT&3]CTRMTW?QP`;<@A]#H!^;5H+X(4P`)>$0^OW6W+^VH%M^SVG]*CMWNR>
M:B8^B%!.-W"HC#>-%!Y71+>XH+NO7+\$''HIN6OXTUWTFN^7@$,O93<50.PU
M\R\!A\L4X.?/]E!N;JZM@#<[ZROK+P&'RQ3?_5[O\-*Y7E_Q0YHF\7_5;0)=
MJV<CT6O:MB.P,&,EZ=61!"2ER`(_T7X?\)WE)&2=NXY#YO2J\M$*[@O;?DCN
M$OZ)-V07+DN':!"6EMP2M'ZX*&Q451X;FJRJ!XZTN5!!NP0<VBA>E[59KH6D
M70P.;92OR]HM5V-94X?R1.FP/_Q2[);6RM>%[9:A/!J.95U5NRMH8K>T5[XN
M:[=<7[I\U57?OB/`PD-GACK>9'U>A\,N!6`"5_JWZZQ#YPZ`\_!=#];\N/N1
M[9[%'1&HPQ$J9GK'42SJ5]T2)#59T15Y-#EP>&YOV2BV7O=0;/G6.S&PTR-&
MBLU7-XK8::OR[5?0F;\EG+Q297VLR)JAG8)D_MB`EJ#XLAK,SHY'-?+8:E;U
M8\L9AB+KVOABN2@V7&=8U8L-=U3$ZH+8=[Z<H<L)8MD$`/=\K/+=S",BW^?W
MIG/':WYG`0UT[9PI=,'!TT/"V=W;09T+TFNRID[ER>CX^]_+Y-4EX'"9G&GC
M+CK^JNLR>70).%PF9]JX>ZY4#"N!$9I<$K...MRV`W2Q>[JT>Z8C0YY.C4MB
ME=@[+6/(A>Z='OIM9TA::F^$Y]]1I\.X"FPK:".*ORYR&W1.56GR4!O*JG'4
M;5#SO'K^3!PVV\J;7N^C'II\L7NZC%6K=L^5*D^'(]DPCDJ`;2NSQ'&S90RY
MU-TS'$_DX52$.=L!NM@['=H[/?3;1#K.SF`-'?;&8C#2W/4#VO![;9MS-O7-
MO(/_%<JIBX+?.>6DRIHZEI7)\;UT+Y-7EX##97*FC;NHAR9>[)XN8]6JW7.E
MRJHRE8?:\<U)6L@L<;QL&4,N=O<H8]DXKKBQK:P2>Z=E#+G0O=-#OZWY+)KG
MSSH4FME=!^6'V//;<LP`?KJ&M\)3KO<$@`7$%WDUG=X8G5->NJK+VF5EGHNC
MYP5SIHU[J(<.@-@]7<:J5;OG2AMAV*8CB9WBZ-E)AESJWAGI\D07$<]V@"ZV
M3H>V3@^=-I%0LR]JLY$^(Z(W_=H@G5-BJF[(^NBBDM'%^?.".=/&/=1#1T#L
MGBYCU:K=<W6!)D@<05O&D`O=.TU8'IQDWATNG9TE8O^(_=-F'HGV-2F2Q;UI
M'K?[V'PPGR3364C_#!TBX<![$9KIM.`+Y=1Q'ET"#I?)F3;NGLE0PWD[@E-B
M#W4)JU;MH:FL3B?R<'1111UB%UTP9]JXBX0?)W9/I[!JU>Y1%5D9*O)$ZZ$1
M$NDV>=&:5WG1FLTD&Q&]N:RMT#F]):R^V#V=PJI5NT>3A].A;(Q&@E=B%W4)
MJT-V48,WZF-YJ"BR-A;[2.RC3F'5*FLD?#FQ>SJ%5:MVSU2>@"\WU7MX%R>2
M;5(D^QR71MW0TB@1Q3GS?I"P#HUXUTP`(Z&;`9O^W/SNT5H$]X#L8+0.-K_C
M*_FN;2U:2JF3]6';224\%+'+.RJZ8I<?[DE-#5G51:LML=<[*L!BKQ],*AK]
MEI6AF(@@=GM'15CL=N&_BUTN=KG8Y9Q4([#IJJQ.+JK=6IM2V=I"DULW,.V>
M*K_]?=9KWM/#PAV]<,.932HEU0\=5'J-$DA39%71Y:$F4A`N:9>+/2[V>"I6
MH>NZK!HB5B&V>#<E6&SQO8F$T]%0GHJ":K'%.RK!8HOO:\1GR!-E*!O'>.KT
MO\,V[W71DD]L\=YO<6TDCR:&/-5[Z*FG(I`_!290-OK7>F-Y??W]T.6E*#RI
MT/_C!`D\T_&7\`;$UB%Y9+))$`##_;4YI_2-2+4RO3O+N0[<-?\A_X!)!O_L
M$:0E>91]A)FB]+,4W8'FLS\M@`>7]P//_9-$4H</Q2SX:2U(D16CK$#%Y*%B
M<[RP2M&EP\@8Q_OI!`KE(,\5"?#"-M<^$"#Z*]J9UG_)M;GX3^@'T7I\QWHD
MF-\?3C!I3FR;K_WW%PK[-U<7^.^#@_VIB'[.7DXKI3U?1^MLZ_,72`6`U?G[
M"RU/8918Y`@8YL!(XFT#\=ZQ`@NDYL&T0Q-3GL\(2RL(<NPJ9:Z6<NZ/\D!K
M/]*5`N$N)=`:U@.(X0/IH`2T`@@AAJ<"85OFS+)!*X(1#=?G58A"_AJ5OU>F
M;3IS(IG!&2F/=4@4"M"'Z,0E.M$_JY\P]XCI$ZR/6IJ61QT&A/&,,!W+KD[+
MZ!LR)ZL9\9X_DW15/B/U%V%<`7<F`-K@+$3L*,^,YJ5P(YX2GV%9^MFA3^<L
M7$O&VR:E-475:D*IFP0)[HFTACW@+@19\OTW09?L_M$K1:GZ9,KJU38-$!_#
M&1ZSJ6M)@8I`I494ZNKXP+7/1-$&4_V0/@_3@4(55:1?\#<_2_Q3NL!KUZ&`
M84Q[[9$E\3RR2!UZI$B?/^WHT!!/4$G>X`?N_,]LHX8\PD;ZU,B)OQ_RS#8%
M4G>`NQX>:OG7?DQ7R\.I)JN&<0H,)3%I#_:J;`S'\E15&L)^=`3VHY.P5W=@
M/Y8-39,5?7H*#)W%7E7EL0&BKXYJ0;^^`I!S:,+`E?[M.NO0N9.6KH?W>P_6
MO'R8J"Z[-IDHLJ8..V^?KSN/@2JK(T76Q\6;JBN8H&94Y-&D6#NVQ%4ZDSZP
M"2S@^7E.$OD^OS>=.QI87I!90'5&D>?4%GY/1Q-Y8JB=E]M+T"&:H<C3:7$0
MH2N8:&"5IO)D5)EE:K-7\>_]_>W*GY[.Q+CA>"0K2O&QH"L"J*HZ&.3N;R15
MGNB&K%R`BP<';FT(!^YQ2U3"\6Y%.6U@^O$F![7@PQ?@0ZSC%IDFMLAL#8^&
MFCRZ@-VO#2?Q3($NXS'61O)4FW0>#W!LU+&L3"K3QUUR!W8?&?P0;Y@LQPS@
MIVO/7<%3KO<D.6Y`_-:Y!]H4K&KWY7&BR[K1?>=`4Q1YK%=F4,^&AP[.FE:=
M6%7M&#Q_=JQRR-[UEM,9&RY"A;JC^DMV1HO:FC(=(UBU00.RJI2)C14(0_.9
M$'UBTE"5C4F)D)9@TAF8-%'+19D%D\ZB[@Q9']7-I=J[QL70#"-8DM9MAPC+
ML%E1.:Q8N/@BN`H!.0R&D:Q,%7DZ*>&];4E(&>(*QAP(@R:K^A!O^@5CVL48
M59,GX[%LE+DJ%IQI9,MD6QC6Q9F#&Q24*3EG1?/905'*0+.<HPKVK_FC)2K2
MJRC'1XH4]B@XDAK5-RRHKRV#Z#O0YKX#;2REK;VY0&-(G[<ZMAW`5RH:M1;[
M"[%H%95*B$6;BN^%U)Q(P5:4TV]*E+117Y]=9N9)/^%3[2JZ3U[7W^K[YA`[
MOJ2[4C!$??UIS#BQOKY<"\%C`_PE.Q4>1=/S#J[)*4,NOOIJB$B"%R=V$!`<
M:5WS@KUX/'\FF-)8YY&*B%3?S6.UE=SET&U1R7?EPKR[,KG<<L>749=;I[@V
MJ4ILRA)/<";X93+69&/'[?69^#.JDS_Y9=V5\Z>@"+W<.JILJ%-Y.-[/H2JP
M$APJSZ'#.VG4RJ%65AG7;;4/;4]0UY&[_NUVJG2V`HGN07RR4IA.9=`O@N8-
MTGPT465E7**L1=#\9)J7;L#2#FM75P%<`_:NMO8;_17B5B#1/8CK"PH(:E=/
M[=)M;@3-.TOS"S@+UM)4IK^2*'1MD]16L<?DN$1ANJ#YR337#5W6-''Z:Y+F
MI;MEM<.^M>/T5TFCI*IE;U>OA[9)7RNV4/<@/I7LXZEL[.B=+$A>@S]A:/)D
M(FC>),U+]X)KAVUKX]FME@Y@_95,<99K5`\8LEZJ(%J0_/2,BHDN#G*-4KQD
M7\-VV+H*SW&'=*H[V0B*EG;M[/%4QJ"*'ES-\T>T'.P`D\0F:C=_&ME$=1U>
M1?NG!MH_G;*#!4/JZ)0F#Q5--G31**UEC-&Q9$;6R\Q7$8QI@C'-=./,;6#W
MMY]"__K.--<_?YW?DT5HDT_+-W$JYV])U>U-\,ZTO']A>XU;?/@6('IEN_,_
M?WW^[&\>L5>I%[PV_?O/G@O'W(7_A<P)O&GQ#DZ%G_A!T,^^`8^3B.`7LOS[
MB]?L[V_&A[??%/7;/TWGFZ:HPUM%^<;^<_OIFZY\^V>X\?F+7Q&Q7G2?N[TG
M$NLY-R.V"^B0I0VG<5_"LG5P37P?S^"4^O`=(W_>J1U_CB6\\0'=ETP;&$)/
M\7#PG[NK-:")T0!WR9*4[ET;`^),QB::.OY%(G^%F.IK.O29G#1@S'::F3Z\
MD[:92=JT_$Q%L6>=`[.[4_00K+&'X%&%WZH^GN87O&6C:TJD;S^;2=>AXN0^
M%DXKU._GFS>]:^;P4)Y,CZW@/.^):X-'-_`IZCW826O36L`>N)Z;:RNOE?BQ
M_LGQ9V=^>:".5%D95C;%J\D@=0'5$S]">F1A96E7&X\S4;YTUF-;+L+W4WU3
M"<UIY8Z/#L"2F$'HE6Y@51<3]M7S=T#X=][%Y'`G!7S\UP&W+UOY=B+@6"DT
MI?/$VA1P/%A)?"1!?$9HBP[`1&A%5M0>:(%/V8Q9]$GH`0W.S6([5PJ-,9W*
MP\DITS3:=H%0)%/_R!S\15#N]&CI5)V6S*5LWU2);D9#>H%\Q6$\783QSB^X
M(HPGPGBM"^-E=F5ZB_'+)Y7;N'5BB42XK]ZSSFZ6J/*0'D,/84L'SD0=#0OJ
MLEKFJKSE)_Y.A@55V1B.P0_O=%2\;&!0$E'`O<`\?U9WX$`;3F1C)`*!9PD$
M#J=#>:B)0&"/=G3=^WDT,61E+`*!(A!8%H:AK$P4$0AL<*"J0/DR4:XRXOG!
M9,'*?X8.#7\.1?CS_.'/?B!?)N(+9M^:>98LW1/[@:`;``@#&M<BX%M/P)?"
MOC17EOWT\UZAVX[\@K98P?8N'>T]8MV38\-'K'GJ=(E2BZEC636*FVP?,E^B
M&H+6Y967![%$9/KX18[O[5#G,J>(T60\D:?3TOW:6R$]I:('Y<$N&4T74K6,
M@DRZ/I:5\CUR6B%41P3^-@)254A:G1'J^D7G")ZV+%;6#MBG4T-6]5-J%ZOG
M>`LBON6QV1F+[^!N:52?:YJLP7]UK4S?^M8+XL$!X:,AK^X&HI4R*#1V#NRZ
M/%(-6=\QG;&#6V6'SLZ]/2D/^0D7*WFKX=QI\MC>C5###4TK(-9&\G@XDHWI
M*6V%CA2ALLT93FNL@*T9MML[?+TW/?(*0]FOW=6:.+Z)$8FO&/'ZM,8__9LY
M>/E6\%1?FX;2<521.7M$(#6E"@]4,M7E%D0#ZYN80_\Q7,V(!^=-!&?F23_A
MAU3,Z\J+ZB:=_DT;?K*(=D2F&Y`=.+&G/WK[G7ASR\]\]MFSYMD/@."4Q(+"
MY2G\A:Q,R^$M4:,/4:5ZYCP(63`X^OB6>"OIZ@]B>OY+0>L4K6_N[CQR9P89
MRKX'&EJ.;\W3']*N195B7[VO2L]B8>`'IH/02&8@O0$+3Q6;KLIXQ;U]LCW6
M=:P@>[V:A<Z%0`U+"E3:ATI=T1>NM,93=3#58W<S;M,]&1@Y29_J>*`G.7JF
M$S1?2%3B+4-M1T61,1[+4Z,XF;):4)JOIMJ%NS*8%&<"5HOXZ`C$CRG/*EM/
MUC0T_:1#@W<8+[:\#V<AD>]K,N=)=`_$#_)<DFT5<";;L4\C-6L#RP3%]BN5
MKMCOZ:#$97J[Z%^BB?09[_4K<##.)!JJK$[&\G!8(N3:+@&YB`TJS@H=-[?;
MY<AGV\\38R0/<T(28C\WQX7)H+(2R:;IK\JZ4G(*<YL2+39AR?EKWQ%?E'$>
M`XTJ#Z=3>6R<4HQWF7-[ZBV5/)0]@Y'@3+MWT'10HM=Q3SC4BKVCHSDL9Q+/
M4:-^4FYL7`=]B/=+2SMUA7J^PR.DK=F*]N?/#LP_:D@='-KE4@='7AV?DC4K
M9@+5`(,Z*'.XNGR>M&K73`:GY@Y>%&_:L%]&LJ9/3K2>I;IT-#,IDF=D@GVD
M.5DT27++-'9:>%JUL8V1!C(D)A>V;'.7B]9=/D]:M6>F`\&;ENV7\423A^=H
M6)4W3O+8>H-]U0N?S2>L-[YY-+U%^FV8[4F7N/']<,4^JZV2090MU%JV4$T@
MJ?K\YH(W;J8H?[6^2Q^`F+24,DZO!T8N:H>Z:SG=!@7MG>O1[EXTW5UBE$J1
M+GT?6BGF9?SZ#HAG$^GWQQU!^D"9W(OZGA.D.#.OP>VZATS'4W$+X^-7$4#4
M?4L1R;&BZ%%>\>O0\[!IS1JKW#;;P!6BW\[\=&VPP_'O>F+^KG3L@Q+S6YF0
M?C+B>CV(-]:DBO[FB^7_*2T]0B0+50E>`GJ\NJ\-R59@EW[$VTEU8)1<\\?V
MH%"BA5Z[0%=.IGK3^9UOK`<+3NP+Z<DB=FL2L<OFV[5'`/H*>-5*&/_ZEVN;
M`;:(?&H+E9(GQP95LZ4GLK>&X6.=(E`ZO[@U")09E]L*5?LV3AZBO1(L1WK*
M;Y=P)H(:@S)M1D\\N]6%Q&@P'E'_I_MY\XA*58L5SNU86`\Y#_)/=]^3''^S
M@7<F&SVC\J]?HAECM;=Z$A<DHJ^3Z.M4+YW:W]>I_FB>.E6CH$SI-CHUQ[5*
MO&5WUPU9&QT&_*5%N-1#8IIMB'#A7RTKO1[)P_%$ULM43-7JMAU1JEFFINA<
M>FB'5HST;EVU@#68F.,52-W`I`3CRE"GLKXC4%#0LS@?M[J:ZS7'G>*=U2!3
M=M["E&)(HTI[C\_0FCXW0UIXK^EE`_GM.X1WJ8/##@U0;YEW7U7[4%8,5=8F
M9?-HCD>N*WQJB9(?E4WYZH"2;TUWE8D\U0QYI):]`FF3RUZ9@:JGU6[+#FGZ
M2%8F>+XO5G@M9SGL\LJ:T31>9??.]9;$PAND*_7P<T"9\I/J"ST:M./E8$F?
MT";&1-9*9,,.JSB?M9(O%=KMH]E1ZFRV@Q7=:BV![21@9S=2-=O/;3[4974X
ME$>CPT,QQTA7QUC4AAVO[LH\J'C'E[K^KN"2.E,?F/O\#3Y^1Z>2OGK*OU[G
M-^O4'?3?.Y^)9[F+Z#Z-WZ'1+]^8`7EG6AZ=)5';;?E.JE'N57.=;F@C<9O>
MG7JN`\L-\47KZ#TKT[NSG.O`77/.\`^B=RC1#5]2I)@!+E.NR*KMUL<O$IG>
M['O$#3ZO>TS5.TIM+7+,J_:Y4*;$96NBL%$4-K:UL/&H/!E],JFDZ.V(%)E3
M*K]&6P^7K7C;2B\Y)BVF6JP/?\E.]'_`8[UT+?VPL_EJB^EP&O</JGX[!NOF
MJ]^NVUO]I@S&M*I!*]/LAS[9FK(&93#E!7QE`]4M0H$5QY1IX9N+@2B&H^3L
MK!ST%?!F=7)<5_30NGJY,2M&'G>V%IE5R27/[TCU:#DF$XW5^YV*@*B:V[A5
MH+<W;<F!.`&/Z^[C4&^Y7*H:[IQQ_(*&@W@<OG?M!?'\MW^%8`,^N@&)KB8^
M>5]P#;^.RX`XRAKM<(7^7RJ0SH+_<02=ABJB^#G][,'T+-,)-CY]I'1)/BP*
M[]N60Z[O-W[L>NM[T_%_ELPP<+.'*C\PO2#O_B#_GH%:8[IJ"FPXL;F/\=MS
M+ACVW`LP#)?FRK*??I9`<UHSSY*E>V(_$-2DLN0#&-?\.H2%JU-Q:J0[OB%]
MQ7("9;<XE4O2#,C[KG`HF+?W1/IL`^%P`T@W=_B_'ID3ZP'U.7RY=&W;?<0K
M\$<NJ=(B]/#?^"TJ>HEL19MIIO//=&\B2/%&W8[["XD4$IF5R`V-GR\_HABX
MD>O+_<DR?0C.Q]7#L0JL"<%NDB>J2N/Q_S60RJ^\[K?[1%I;'O5!*T6LPIO8
MNDX-W/D_:T_)"X2AJ;:6NXQ_UG?(%Z:O8'#!%-^`=B!+XGG@*;I+^`,DO9!L
MF0KT0]<O>8U4[N55%>0?M5ZZ<E_5Y*%6?%5\)N1:SZA#VP:<RI_#6X<VQYQ2
MR]7Z\@IVT?%<2F<:P?&T>.Y6(ZC5=?]P/+R[7/NO(?HZEF-BE'<-1RK+]UWO
M"5X6D/WJ_&"83G/M3D"]#@^P3JCK'B"JR^,=&2#UR%B5M#J;(.U8N-@$G2("
M.Q;<:8L$#\^-7XGT[+TFJV%LZSM['"T=6C-"6-,R5>AV;8=N+SGRK95P&T-#
M5L?%1Y\*]\#E"%.C^!U@GBX-Y4O'K^LL+:PJ/.H"\ODS<04IKB!/D2`A/WV0
MG_J2*G215"$D4B15=#JIHFT1D#/&.UJ6O=$VDETX9THGCK2-<!?/G[TY*[62
MZL3DEJJO/,_UOMQ;S!)I).>&7]"C3_00>4DM2'=I/B])'\NC<7$YM,A+$GE)
M(B]II\9FE[S:F=G4OKRD!A.0ZK_$:.""ABZA*H8\V3&;L#T8-$3S6K)OZDRS
MZ2B=Z_9K]VK)EBK&.G)>4F?HF_E?H>5;>%;'2-<'LB"NU\D`ATC(S`%;4Q19
MV=&;[%"8GS\3^7QGS<E4!SNF'M>#XZ7S\*PYF;48HG/D9)[NN%]ZQI5(R-R`
M>SH<RL,=<V8JW`"7)DLB>T^PM#X+U6J<SVVGQ+FZ*)#1*22Z![$@^_G)7G+:
M0$MC2:?KP.1V6#UEX`<^A:]O>?+CB>FXOO5=6L&B]SY/RLU,_]J5D-LOH1*J
M1FAX0?9^DET8UD8#I!>>>!JG;&>1B0:)59?'W:=`^CDRN]-<BY.\\YE:4>:W
MX&C[<\$OX\)#>`#"\3H[V9\_$X07'N_Q6K""M*0N18(^F$]T%@B-X&#T)IL[
MFHGB]%BVTS-'9&VJR--:NL%U5*/4ETJZ<^YB[^C<4"II\63>!G1V!4UICM&O
MHH%#<H>1Y1*-W:?&"!T[O2=_!-`;7FIV:WZ_\7T2^#?.XC?+G.%$.(OXV2E"
MC0T`.M2$"C'<)88'2195,+O;;.R38-%EH^XA\^4V106!GX/7.E?T)[KQS`_=
M'3'>_@C?73#N",:E^T=ML*PX<;-^EE71V:$4))'AE0+SNV12T_OS%OX'<C['
M>1>#1<H4\*OC\<`8JY/Q:,M]*[61LK%C_!?W2]@E$@DD=TTP:.W<2;;K%]\7
M;5=T5ZV9CE_A^,)Q[;2U4N=271Z-#-G848!4.7Y'E7K7Q;4JY/10KJF5<4V3
MQ\;H(*Y5AM]Y+FMJ4![TM`>`^&`RYJD!LM6X`_7[&.6C**=*VU#6AA-YO*](
ML6787"(GKL^#1<TW$35L\B_$)Z8WOZ=7`@OR0&QW35-$T4F<@[=H[<LQZ;.8
MJ=.QV.XMX,-0-V3]7'QHAUTOVN`W\[D7FK;8Q,4^HB9/Q1X^.QN&P_.ITK;8
M[:)-_"FX)WM:F?19=,0&;@,7AL;^_BPMW<"UGZUSXNO_,NV0GJ<E$RNO3&>^
M)_6WH:!^#2'YIJ)A[0(]M36N)K*B3>3)CNU1Q85#`>5>GE6NGC]K)WLN1+)T
M69MJ.R.<#4I6V_RH".5A)*>W;F#:-6V'89U*=KBO'4W-L?E6`7Q0H"^//4VI
M"R%(W0"XI8*4FQR9EY!7*I<N/QWO[7))YH'U0-X[<W=%X$U?S(!\(7/7F<-K
MJ(=:6TY>JZ<M19]V+Q7LU)S$&DH/RM'\L%RVRT&SW64CQR"556U[BTIV^:B=
MIX5@\(5NWZUTLTOD]%?KN_0!UKB7WL:=?Q+N8T*LV.&7R'>AP@6#]ZKPVN)B
M729N8A:,RY6>/W!`\]O,@&9A"2Z3U8<IBE*QW\N@R^5[N#V7::&TNHN4\&[$
MH?=HZ8G+.85BN#36"LTO&"PTO]#\Q9I?/THQ/'\F5$/KD1*Z7S!8Z'ZA^PMU
MOR84PT6R5L0P#XEA7@Q*/95?P<D.(-4W3O;"=>@=5P4G+PIIP<D+0%IHVDOD
MJN#D12$M.'D!2`M->XE<[3DG>Q7].JYMKZ+H<:%AIM%'U\EQG.P_?]8%M+X&
M9A`&KO<D+<F">*8M6;36E?8X],R`'*;>MOO[]H[?G4"JI-7*L%5L[`XA=22C
M65/P[38`@M6M14H_,!E3[.6.(O5C.?Z.A`EN-5)':N:1V+8=0^I8$ZP*$]PQ
MI(0)OG`&"Q-\2=P4)E@P6IC@RV*U,,$7SN"=)KCOMS.%/=J%A'<'*;R*(=*5
M@W,IE_%US(PX9&D%+\4U<\>1.J'ZJJT[]_DSP=W3N2M\RY8C90R,R]FS@JFE
M0CH7@>M%,O`2#:K@K3"G%\]<84XOD*G"G'8=*6%.!6^%.>T>4L*<7B!3Q6U'
M_&FI6I3,/*OKR<"@K8>RHZ.C3[M.F<N5_H^N<[T@BW`>6#@#C7Q?$\<GOG`Q
M.XZ4<#$%;WO@8JXC)%>F=V<Y?((A?GNEZ@.5TF0M)+]+DO_\V0ZT7HK@1]>1
M$I9)\+8'ENGBF'NE30=CL6<OC:W"HG8>*6%1!6^%1>T>4E?J9#`1>_;2V+K;
MHO;]1F%W_42?[A,^!??$NW!_*VN^^J39RF%^:;9Z1UQ6&^C]#<MRVR`V_,5Q
MML<;_EKP6NSFWG%8[.8+0;B0UZTYJFWVMVU-^E=&&,0PNHXA]?K>=.Z(9#G2
M@VF'9F"YCF3:MOMH.O,#FQ$+GG<-J9(!Y9Y,(=W69D)>A+P<)B_<^:L^4#(:
M:`=$2@I4\*4Z:Y>XR0Z]@Q?6MFM(">TIK*V0E]98VXL3F"M5&4Q/,A["3^@.
M4L)/N%#&"KTO_`0A+\)/J#%Y7STTU5#X"9U'2F0@)I^>U,%Y<R\,A1O5VNM+
MBM;;Y9+,`^N!'#=;4_"[6TC5[08-"YV@A1O.;-)*X1!>LQ`7X317("_*"49#
MN,O=0>K(J)IP#MJ-E-#VPCD0XB*<`^$<"#,BG`/!5:'MA7,@Q$4X!\(Y$&:D
MX=[A/P4F;.+H7POK(4>I\$__]E/H7]^9YOKGK_-[L@AM\FD9WVJ\IY<:M^;W
M+V9`OI"YZ\PMVZ*5.[>XPBW(SBO;G?_YZ_-G?]M^S[LP"#WRP7*L5;CZ0IS`
MM#^;3ROXPW_G>I_6Q(-7.7>_$=,G?O:%$JR%DOF%+/_^XC7[^YOQX>TW1?WV
M3]/YIBGJ\%91OK'_W'[ZIBO?_AEN?/[BUTS*.]*-L>\G1E1I@T.;#$KGR"<2
M<&TN_A/ZE.M.HB@]$LSOMT4P2::G+)'H1OO[BSG0@'@OCH:,J_&)\F.LQD'K
MV^;:!P&-_BH+LS0GMLWE[N\O%/9OKC/PWP??XNZYZV3(;]J?2K)$7B#R@`*0
M6*-0_$',XIXG^:D'QQ3D-HG2S<H-00%4B52I*_K3RC:/+O2F#\+V'FT]<M(;
M?SCH]\S=H`_H8UE7E)*KU$7YPMR"2+Q^S#'PA[*`OV.D%+X$V&'L>QQ`*+G@
M#J#W/#G],<]+9&R;R,H.MAU/KR[MG7&U>^>HK@41-R;MWT2'UIP?W[QBQ_N`
M79,&+!>#HPZ[=;2$U`;-5!Z7$;JCN-V@.LA-%ZM.%N.WW;K@N)<Z5#8HB'LC
M&:6M?%TPJ-JXG-+;P=\#3GYY![L3#F3I$][;OT(K>/I`@GMW\=YY('Z`K_CT
MZ!#/O[?6GXF'_K!Y1W)/<3?^MT]+.*A]^V`^;9_C\CY_(86.Q5ZR!OA?2`LR
MM^#(XO_]A?[B5V4P'1H)M@<#E\;H5>C#>=[W;^;PM&_A`9>]YSWZ]?`._[WO
MAV3QR</_CX3Y&*YFQ/NT_'IOPO?LVUQT7\.YRUU]4T='X>O3UZ<QAE.M-M&F
MJC+6$Z2K@3^/(J_=U<QRZ)'_:T#6A0N\=^A7'B&-LW^B3+<I<0K<F6A&`,)_
M[]JPMWWVY$<W(/33KVO;"BH*5-S>$\D-`S\P'=SRDKM&4'T)_BD]FIYGPA:5
M'@%BB7R?TSXJ"SC%>_F_"UP)"`4_\XG$!$AREP#H:N4ZH&TPO`+_#F!)H!*<
M+)\D,Y!,S%NU7/Q&5?`5ZB"E0O90(4VQ=Z;E_<NT0_(!U`CP"[??OZW@_G?'
MG?G$>T#I>^^L`=EL1`G_&7H>8/_*]"W_-\N<P5?!$WW7#E'2U6]OR!P)JF8)
MG?=Y#-RKI_C/_[%`[P&YGGXC#\2^^6[YR<\8H/0+_0/!+9.2QM^_OGDA??>M
MGQW+!OWMA>3%3^V@A%9`":U.2F1TU/5(F2K3R221H5JHT0YRZP7DUILC-ZRF
MZ$-M=,GTSM&<11JU?GJ/1A-CJNL-TON],_?0,P/AHO__O1,O>4/#N]21^^3<
M^#X)_!MG$;W*(OYKL`T66=P$\2._.Z#,XW]]HG8DE_CO_D@;LQ9H%MV83/11
MBO+U$Z9U;&B!QE&UR7ALC$<]XT-9WZYV/HRGH^%TK#3-!H_8JT3G?5K^FWN?
M[QT?/"&Z1#?4B:I.%0U.$`<@5!W>+=B_^E@WIO7CW;K],M1U737T<HC?PC?^
M$@_,\0/\YZE?WRP6](2)415K\=YY;:ZMP+3;N@UR3BY-X'H6T6\,U[:)NS%1
MA@8>"TY&-Z89H/I`/!]^\6GYE8"Y\&\^>P3>ZI$%#0FT5>"W_!?=4`Q.F;U(
M58I^"]2_.C94)5:#=:/?@FVQ(U!SXP36PK)#S'GZBJ<QZ@N]_3ZWPP59O//<
M%0;*PH">USXMWYJ>`\<U_S/Q:/B49614(O4[0[_O/[Y[\:LZA`T]5E+^7B70
MMY,<W[["(O0D_=HV?1\D#B6,<CY7]K8X7T#$R4C1X3]]I^%K&A*F_XZ<GT,I
M.)P8(TT?"0K&%&1'HX,):(S'4T/K._WB[4N_N2DD7@N4]WZ;O9_IVE"?&LI(
MOP2^'^##U*2]5?#;AJHVO@3M<Q(53]#?DZEFC%3C$MR(JDA84H&K8`&'RG3<
M=PJV6H67OHG?[_A,)\.QHG>3[:6/855I\$XPOR9/65>'P]&H]P)SO*;5=3!5
M8[7O!#Q4T6Y13Q_KZ12IRJGWV7/7Q`N>/MNP+VZ<!68(K1&%WWVR#.W?K&7^
MM7[Y-*G/^A\)'@<LFX;R-]=T_,_F$][#OPZ!C@4<*Y_<L3/0-E7P_Q*H<\!H
M!DKX9)8*\W*1<E>6[[L>S>?RWX3DDT,.BBH/NX34`1AIX`O7AU&)S)428<OZ
M@#A15EH,<VF`LV^-TD:Q(#8NDSTHX[54<MY!J-P^NEO8Y";(ZD9*^Y?"IQ9"
M@(TCZYSMG??Y882X]\@V8SM`"L7(SX+._?R=Y9C.W#+M#7K$G]_<`1GPX[VD
M&"$I%'VH&Q40@W*![^BSR_]^Q9X&]Q@T&I+>_3:W")'LHA_,`!V\IS?`R&J"
MN25Y\RN2Y%K5KI5"84O#>`(FO-("D*F10XC.\%J97NO*H>C0:U/\R1O+GZ/O
M#!ZT%UC_I?XU["G+S:\<J9TSG\=_\.O?W="=@D0S3"F#2>KX,"=DX>.!9^_F
MKYL7NS:^.LF>((H`/QJY1GBT"\/1N#R&]"SZV;/FK3`ZW^`D^HV"E$9-8^5)
MJ3J:&.CRJ%1N>`K<]RZB4BAH]2-3II*M%F14BLP^7+(K_^Z83#>21:0L/WMD
M986KC^2PHWG#3IRAITM;2B!3`PW.Y@%.=-W0CZ8"R]XR_7NN7=^Y7MI8ICW^
MUIE`G?GP)5"H`N.SVT55'1Z-=]$//BTC__1,3J>:YZKE0W@J,@TYG\=@])D7
MZ,9IYZP0^\P[KS!7:12+80'@1R'6\`;++Z97=<!N/W*Q;\H;)GQ:4DBPG-Z9
MD]>N7U6]2Y5F<Z1FW.IBT$_!\.QJDD9&#D:3,OHFMI7\3HU'T9P[^KOS1TT2
MI5("U,K0:UIQEL1Q?\R2WJ(NDH`E;6");1-X\Y-FL<X[:6W&9.F91)D<$I#=
MA]RF&/"+W*W=H%:3&E2APC(T/:Y5V0=\*[$\4&-IZG0\UAM!M'0"0@L0C5)L
M:&4'.+N?;7-.;S9N[HKN"\_N(^DI-V(W_*>@>7:/B:4^*L9D/*H2V2BYY/PN
MU)Z(40E<JD"]>=^J!OQ3-;;\A.2&JS:&F51=F>141*>`/@&GLX6-AJHQ4?=B
ME;@=:0^,:>9#@X+-.@OZ1)UD;O-S`6\=;@=R35?U=,YH/=A5GEY3)W;IY5D5
M:F!A%E%<D$J#WOE>4)LN'HS"F^,=6&4[GRS".5F\3E7BII[$5[[]OB:.WP)K
MNID,:2C3]%']8$RJ0__LT8I*:(`?)T_PWY-%`F2ZK^,A)Z!F/6:TM?!R=;1Q
MG7$X2A43X^Q^=344B:/0[_'G#J9MN0XV(7OC/CH\+O9I"2\(/=2SGUW;FN>'
MSIM-4,OM6Z&DHNIE\-E)B/BA#X#HO?V$L)JV30I\MT@N"KJW-D`'8Q<9BK&)
MB1`U>N5?%3?J:1C5-UYXEW.RC!S5/+!3/2CB4I*HG^WO:]=Y^YUX<RL5O:\F
M(K]WWT[UR4A%=Z8<<&="Y]#6&N\!:>`@?FT>6J[3-FJ<6+--#T]C=9)$=MJ.
M3LW,U31=UT=3_4S4J+2:$T\ABJ(;QG#2$71J9N[)U(BBN06-@6Z<1?1(A9?=
M^[!BK5[B6X6R,)X7N9HYWF+:G*ZY4UTB.HA=S9S'Q`!#B\W:T;3Y8'I_DH!'
M%-,5ODZJ"S(&A"OK"W=8F$6R%G]_\<YU`P?.8=?J-S43ORX%]1EQK4X(2I"*
MQJCT=I&J;`WNH;CJH"8&HZ[A>A:Q&+9B!YW@`9;`=02>[D#I&JYG$0L#=Y`Z
M/I946\WS;\`2K5A[B,C3K++(XZCJ@+W`G0.31KA]?D)4I?F[@,EEL[2&Z1T%
MA/A&D^'H+WA&7"D",8^@+P0ROY<FD#;(G3/3*@)=O@BTBH=?+/_/=QXAE5<1
M[<B8'6XX(QH[Y2F*.MV-61ZP9T.P.J6_GSXLQUC1]LAV@_0I9=[W(Z@S!/6\
ML6-M1;!)`1BV8(.<<(3;;NFRB2#K;*(:'<*O/OYOD\=@Y!E73Q[,49D'9'%+
MO/SBBM**'\M#AA^TX9M]9BI9N'$@3^4=XCC^8)P/Q0/T[Z^?M3]:#%\5+&A:
MS!I6$87.\*^?]0_JI">89YSD7S^/FA3JTFAWF&/%)!_^H2KU[+1_N3:P':=F
M-G'PV(R"ZNS@,<X;!KH7V#.B6)_GL4TA>O08:ZVBT$F'CVT4Z>'#V'/T:!V*
M30K!L!44:HOUW5,+G&YXW3<Z%02T\NET;K5;F7&_.(%H)4??6`_6@CB+^CR%
M'=V$&P6L:M7>#%Y'6.6V`-85@I\<@FL+8`T2?*,F*UX-^SW9+N8VY"?^;5X#
MJP52E/K\U*$K^UJ:5X5*V72+S4*XT61BI&S:`6"=!XMJ&))-I!].-=4PNH!\
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MY9V+DA4Y)]>J/E8T0Q/DJ\8[N0;W1)N,SA:HJ)2>EQ@5JY)`9W(YL@(W'1G3
MZ=DNT\Y%SAH,R7`T'.OJV2)D;1/,LH;$,!1=&Q]-O4_!/?%^L\P9YC0!`W-^
MWY44@ZI0.<OE_!#'7:4.A`<@<R[<PYEO+2S3>_IJVB2-^V?/>@"ZQ)WY#\I)
MT$;=0!OW9<#WY>W3FJ48@HJP7`\HXGH+V,^8;G3HK8":=E;:BW99;E=,)SX=
MH?UT:O=I33=T3=-[1\<J-94*YXO)J&\DK%CK3?1."&']2J]*)K731>I`$%Y5
MQ^-Q%^2Q<EI6J1C'4T.]#+U8DHH5Z\;LN/'^D%%XF&4+4)K2\F?)&8(3X5`U
MSJ^6#T&^4O]24\?*Y/SNT0%X5[L!=144W_G/PC7PNW)-9>BC+JBJEA^&U8EN
M*.FRD)X0LE*G3QM-M4YLVA:?AA5EK%^DH6O7>3B;SZZ..N'N=>+\K&=&Q_6(
MEM5>@4R,T?E/?F<@8[7J=**#?]1',I[9+>6CGMM/]U@#?IT3QP03PLKTZ23+
M]\X'\^G&60`5"-[Y?UJ"+@0>-!UA+9&-T$J@VG[)7PJ5$[5\.[`X>;.W`XWF
ME5P[\&[W4?I:G0Y'AG$VA_ILE*S2`;Q6564ZU,YF0\]%Q&K=D&MM!$0\VW&Z
M7;JLL>/T]7F#DF<2W8Z:BG-$#"Z4-!?A&K;N/'^99.FKZWIAY^W6UU&,)\/I
MV:YDSD;(:CUQ96RDB_+Z0<.*'?&1/M$[<9AI@1]>@DT7KQ0O'L'>6<2C@E,]
MH4WMWH*@Z`D4?24H6K,C5B$QL]TQIX:J7X0;7'MHOS86J-/)<'01;G25/*A;
MIV03](:*HHW/EE;2E8N9NL@_-$8C97BV=)3:;^SKHINJ*$-EHG5"=[1JOT\G
MTZ&BGZV2OM9C=TTD&QDC53U?ZE+GKG;JXL-DJ.GC3DANTVQH5(-HP^GPF$14
MC]BKGV]LVYW3,3>?EJ]-__[6S8*.T)G.O/+A5SF6=X)!\%)`58-%Z3E"U=\!
MC%3LI5(5[J_=U<IUZD3\[5^A%3S!.FO7@7_R390L>XC#,%:-82'..2CL0/AF
ML;#PWZ;]V;1@*[TVUU9@VO7+K*8"YX;%K"L`K")4SLR_R7@RG1:SL*VX5U=&
M,<0*^BJ9_X90/\IZ()'V?JI?AJ-N"H?#5`$&9Q5=7<<>GJ/.H%QYX4_%>&?A
M>$W[V/GPR_IE-QIR<C2(U>/7!C9'3<KK)<N_P6DV80<VYR+RCB6E(:L.G;/J
MK2A"WDG\*^PSP<KNCJ?"9\^=$[+PWWGN*OKRTS(Z<?D?25"_*.N:IBAJQ,S]
M$)T*_%D%5\/_T]5I!["MKG,?G,J'L9-1`N7HP]>N'^0WP*U4$`WPX2<:!S.S
M=@F(SNO.C51#'T_.AD)U48")H8QWLV*/'/W#<_T&9$:?JM-1'+$X!*;3$3BO
M`AN-A]@VO",85]?<6)DH[6=TI47]\']3O33*4>CUZ[WID5>F3Q8H;\3QJ6]R
M@X[('8LY/R4_^6P^T>[ACZ:W^,2&G_^+^!A^=A;1%/1;%S_Z%`9^8#H+6/-C
MB#A4U-H[10H?P?)W)KBT"KE2*BQ"+FOYQG">2%U8-H5>:TE:JI==+DE5<,V'
MZ9$`?:7I<>T`<FFJZ\9('7><IO]@)S&'I8'4XJ8TLL=S\.@"F4YPAO+W^4B?
M*.DQ>(*N>^C*;GG?N1ZX8@_6G/@E"'WI\EN!W5$GX^%P>G%T*NL+[Z73<#H=
M&]W9MV^_$V]N^>;,)HW:7&.D*<JH.C)MX=&LO_)O8MW=XV\>B&?>$0X-@>-1
M09CW)&<;#E7?UICN@D"G":N]^%49*),F/9E=F'>,!V4[30L>5,:#HYM[%?)`
M'31[2JJ,!WXI@U":X*>%*:L2^>J0;"]MSZ5.+I.V)SAJN]7$J(RS=B;:'N[\
MM$<!*X-)A6[P@2AN476V?\E953K_"UF9ED-OE)S`,^=!:-HXKU*M1A'_^GGZ
MA_%A@Z2MP*^S5#]`1?_Z>?+'](,Z>2,(?Q+A2^MO)+RJ?-"&K:4\O;^JY'Q/
M-DU%[;2=_C'YH&IO^"5<PTA4*;;%AJ$!&E8GF4>@T>S)[N;NSB-W9D#>`Q26
MXUMS6O!22W#CS'>DIZ!:?EK5YLBM[+#CLV';>I*?T`\\FQ.DZ9/VD+Q*=7P`
M+4\[56W>HRKT_ZJU*7NDLAJ5FUTDWT!4+';CB3;<DKI:L(G%ZG7H>?`4/2A]
M6J:NSIJXJ>.YPGD)0CN.D'HD386P-X4=I77<V>SM:FV[3X30!1@'2F*FZ(U@
M=L#PAZHQFS3#LS)C+?9+Y+<ON,_HYQ_,[]8J7)7"FH61.HTU^)AEL:Z1UQ4G
MHQZC?;2!TAKLJMVCAV)VLD<4U\7?^'ZX8H;JB^7_^<XC:*6(!W[1%^#;N53T
M.LS21J>:63$J<`8/1;UM=*[%8.33.3UHL@=TKFO3'V"Z"NC?+SEO@OX%1K2`
M_E7DOYR=_M$I]XWU8"V(LZA.GQ]GTC=IS;SM*L[WAV+?05*?KM(%F:MUS06I
MS^VD])',#1V[!*D;.0/V@,S_<FUX#392:9TQG%1157`X[@V3FKNZK?/T&J8Z
M)T-KB=^L4S+6!?'/XJ;TGO#G=%S&=9WC+Y;X54E]70&L5A&>Q?3:9V@;5CF,
M#*TE?K.&5A#_3(:VDISV+A/^K(:V87W??>)796C'K2#\,>E1NU:MKCBCE)3_
M^GE41>;P7LRZ1+]#!15I-ZVB"*8[U*O.N!7>%/_Z657Z)9+U$#5S_2M$M:Z<
MO%\_CX6TUI#U]^OGX:73M38/ZM?/QA_ZI>_V.IW_/N_VINAZ]MW.^Z9R`#]Y
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M7>WB+WW^K;^S1<5Q@9+=Y>U[O8)]`->*,5B9M9>SD7(^/ZI[8:<Q/FU.DZ#0
M-H6^_4;N3/NM$\!O66"5^MCOG?D1[4W:2T%0\Z&=:YZV/\]Z>>"7P7(>;TUS
M46)51\?VB\&XB@%I![9![CB=3IJHU@L2?2$V/?"97O!T"TOXYIQJDU=/Z6^X
M@G;\T`X0C-Z2JZD@9%\TV5EBEGTA;HF]_=YY@,.3Z_G1;7;^H\62'H^2%-0^
MDF1EV)7=*(+D.21_0V;!"13&Q__'M1?$$Q)=`WF%`._7&8$'W]U9\YO%@P4V
M[>8.S.$QONJ^')PSQP^^DG5.'#SO\PI/O^WV2)5O']V'7*)L?]Z(`]^1'5?A
M+*#1OJROKF!<<[#@8B2CA[&U`X@BM$LK<Y3Z0D\1'FC'WA;A@;JH+<(#YR&Y
M"`^TF;Q"@,MJZ#R*57:!KK8ZA-"^K-\]$Y-;+I_Y66=YGU=V9,K.AVT=4;3)
MMW=DMDV4_,^M`.^:WSL+[-`9FC8ESBL7AP@MWU@>F:,C]?K>M+R566ZB1,O)
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MP\.P@.7GTNIUZ`?NZILZRH_\:\KVYR]^_>00:>EZ$A`I=08O7'@O>.^(&0`Q
M*X3P@^L1*;@W'6DZF.Z!,5H]"V;T+0]74#[Y[X$=9%%U<\HC(^+;;1;>?WP'
MCK-N*$,UW0ML)RYIK+,+_F;!;EA0D65?$&=.J%2V*+-UJW'-9*+KZ2X,A^)T
M`/?9QT&1`'!!!1DXHJ*^,AE`(DS&4U6;[)6`!)\T\K]9#HZXAR6MH)9F$INM
MZ\:C3#.M]/IIN&*]1^;$>C!G]DXQK`JZD6&HZ5CU-A1[PZP?0V0:4)[,0\\*
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M[1Z@S@!_'7?G#6-=7DF?U`UZ3Y"L!+(IR?5!`]@AYA??+!:TIMRT/YO6XKWS
MVEQ;@6DW<4>M*HJA9BX82@!X9L1JR0&IB!QO"!4KZX'\9IDSRZ8GUB88JDVG
M&01R`6D*TAHX5!J_SYX[)V3AO_/<%>8MF0[F_&?7O7$624I/+2?/;41T#11F
M.M?R.$!;@NIQU>N;#OY8V<B_:BU%RE:H;3)_.!T.M6XPOY9)I#G94B-@?UN9
M?UK!U@OINV_][%CVWU\$7DA>_-02*"OAFZY,IJ.+8=P&239NP'=;IM%X.*I(
MA.G!)WDDUUBR1,SD6-2!`"0=JSZ=ZN.H/.]X%)NATKG"/R-T1+4*J93=VV^_
MX^&DP,T[5==EM<-(-9+H13X4NXM-_2]D05@=PRWQ5M7`7/J:]-?_:P>_+*R'
M_WL7_')[3R0\WYG.D[0RGZ2Y:=M2`!^R1Z57TB-[F!8Z>#'X4KB&_WGTK"`@
MCN2X@34G4N!*^+@5*1K)7=)W?8`7F\Y"`M")A+!3*OO2_S57ZU_^#Q#UEROV
MYP3\R%_BQ^//U%]>2F8@(8R!M2*2Q5X[MUT?*W+76/H:K36G`B/Y=%.0[U1G
M23_H@_%(6A-/HA)*<0D>@6)/TI6FO$0V^&0>HN<M!9Y)ZWP7YI,/KW;Q.+S`
M&HH`WP\/FXY$EDLRI[_VR)WE8X-[BR[*&3%(,'L/'UO?82'ZOBL#5IN%`#;Q
M??;1TK5M]Q%71/`7\`;Z1XK4G+HI$D5%O])GX)*[2!&*`6KYD@]@($/P73%%
M98F8\WO&Z'O7]2G+2/0R^*GE;3,>:&5*:]>CL#`JY_Q,EF9/TMI\BA")WQIS
MYP?L)I,P82"A&"Y!Z(%N3S;Y^XNY:[O>S]+_49?#Z7CQRPN4SX20^.N?\.?X
M\0V(`E_81_K$RRTD`!+7AZT0(($CN=@@F2P]6B"J,T9H8-H"X0]2NP'(^`/6
M[JDID"D,?.?L*LK>W.>)Z@(@@#'F'>H_U[;F<-8.:.T-^>1$VW1WKX':U4-Q
M95>V]48Y7/)*&+C23(=86W`?G*?X=6UH;!<_Y,!_B.N7C='M+/;2\HN]U+*F
MB_IS1CJ1XS#@*D*G4C.LP?]-#SI;;^.RX8*DQ.!PKZH%V0G::$1S[4JBD^;F
M)S1F-_,YG.$6J6C31]>9A^"-%3"RZ7&R6S?%6<;O12*-\0W8V3ENU/S(-M_,
MYV)YN1ZW.2YV0I7#$*V(-!47UI>3!TT972#BK"+UG>N!?7X`Y^F@`WMK*'%R
MA?^)E%"-Z=DH47'%_8F4F(R/(T2Q57GO`*8.H7?C_[:">]9#FK60_@T<0'Q#
M/-ZK`YJT(.E5F4QWV=925,AT@TBN:VF[)O"@*3,J'Z=<B30=.(B\"*D,XO@M
M;\/V)L0<>78*HQ7G]->S37G\A^?Z^?&1LUJ<8?9*]5C$.DB<8S10'=3*_=EV
M+Y'99B\1WI+[HTN#(23Z=]PF[M\$3^YD<?-`/#C34C#?`&WB'B0M$,9=@P!3
MG2[.1Z,J.<5:U\6Y\E15[[0I4S"P]C8;Z&%Y\_,*Q3X_$7NBI\L`ZJ!%.VBM
M%]"Z'G<O_X+!T*<73NL\AQ)IO?5YW;36ILI(NT!:GQ"A*DC8GQBCT7A2H58^
MB%;'=-G*OO(F#.Y=S_IO0?CYI%&E^2(U5*9#O8J&G$6(Q(>:C1\\F):-K6M@
M%[P+L?<5-6C^[UC"P`J6*>4_VV9^YN9);5_S;Y2-J6Z,HUJ(X\&-,4Y][N,7
MZ7_SV#R^DOEAU>R,7S^KRA\<@U++YP*]]:LWQ)][UKHPG;8\O*GK4-QCD@O>
MC;1T0T]Z(J;GYUSZ'`I@C!'_;3KO>WYPF#G7J]'S/B\UBZ:@1<=X:D1E1KNA
MK@:YFJ9FYR-GI,+F32#7^/3KHCYH205"?6B?F&EW#$-U?:A.IPTRM*:18@7U
M_8H^'@\;Q*ZQV6#Y^`Y'TXG1(+HUS?CZ_]N[LN:VC23\5V:59%>J$B4"X"4G
M3I6LV%NJ4JR4C]K*DPLDA^3$($#CD,1_O]USX"((`L1!2O:+;((@IK^>GNZ>
M01_9DMJ/)3X5!!>W,DB]"SH!6(T1!6U:C&WV/$72WF37E9=9O'3/[W\-GPV@
MC,(B3=/?D'%N6HY:-[OM+HQZ#.K1T?R\%G/]58+:6\RU^B[M+>:&G9+V@-3J
M;I0E.W:&%,7M'6;?F1E5&,:'9Q):"49#.\RV8;2^EVP'8+.[QK8GJ:']8=LP
M6ML(M@VLH2U?%1@?Z-)D-C8//7(5'28ZY5-<#[`VE79-P`J<33>U0X^=8,MO
M"+[`)\PF]!LL2@)_7)^ZUAHN35S^$L43Y]PF/^GNX$DW)CI@-LGF>7<AQ+7R
MI]Z=9W6F7!R,$VUM9K?)D,RG<6S*7X<0T[89=M$PW3"W9L[SA'CJ$J9YB?0E
MB9PX17DO6(\_CE*BC*VO8-J:B$8VX05X78G-$7>/DJ=-[4E_L+6E/7-S"J((
MBP^GB^O=PC]'+H:1?O<S>?^]'88!'L99S:I\9`S#ERVY%->"JR%?-2L/4=0+
M:@E7ZR<.&3.I]4:-(V[V""(#U$CKM3B-#9U)9'0P,X:#%G&U=DB152)PH+>(
MM*%3BZPTX6X)7.4RB]Y3_W[VR7RJYY7IK3UQEC2,=KU#`M1;E@_4`P,W65S;
M8,(>J.6LEE&%C@)<*)TTI:`=,U,^4LL"(_]?:E,7%H`]O9XNP>R+VA4/5-4O
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MK$K8.Z5?O7D(?,\W;2S,G*I!HPK,\MI3S9BPD%L1N)+%>;1^#=4-RK'BQ7`_
M1\;S.-[[P?%]C6!U>>^/?G"_`1<DA^.C=`&D[X[C^UO1ZO(^3)=$^L'].GR8
MK1S7+GJ'D?=X$\_C3V[?0NCA@>S(@]U%=RPR1=TJRIFU<0[4SXQQ2M)1$Z45
M#P*T;F;L7)VDUK8+[!E'1&IS\8R%,";*I7Z@*UDDY"_7F;OF,HS7W5;M[)/S
MAD:_RN.)UOWRI^EN\B3K>J&&YAO%7BM3OZ5TVRTFC>#W4K4O'&M*W;Q==IU8
M1]W^:-13E7D*4;:C+]3;IQ5SB[8(+J!\,T?9U<BK<`N]WV$P575I%YZ6@1>$
MD,>@8.RXX`OP9>XZ2^9YCKM^[_A46:P#<Z'`CJ+QZ=>[QPF\W>E_N5P0)>UY
M8^C[F0CB:!UV8QU`RR[<6)NA&?4\ALVRW]$=17O#>=$2A'<'&=>3A%]/'QC*
MW#OF+@N]W4YW+$T061K`0;HEZT.]6RN*>N-W:F;Q07K;(H8=(-QT6S=1<EAY
MJ/NTR&ID$61F\6NJ:FE)`+4";V%FBS?E*PA>=(=\)=H#X^#J%[L/?YI7=GD=
M#[3?+HO17A%E.\LUY[`+:]861^HF&]<<I1!G;R'UJ^Y51EN[8LNWX/UUEX\N
M[G5@J]VH32+_'MN*6A8!!CC8BI1BX*R%W68=U<LV/,XD'N4]>/T%,<?.`R6F
M1QXI_!A[V6*_THGI+:*NJ\Z,*#:01^8O&&]#2TX'9P0XX2_"WKPS<'6ML)6N
MO*A<W7`0^->$6V'8E5`PY+3_RQGQ8FT_R8S2D)AP[*@O*W\$3'I@^3@,WA7K
M<2NOJ-]=D-M9HALKM>@$'@>,"3L4/\I[S_FG;,ZZ=$*1:C/L9KM!LJA'`0_N
M_Q+R)+"GGKHSZ@R;'H*W0(YS/$[513DQSLJUQC//Z&<M2^M??74:FR0CED_/
MEN/`]6@LX+"(1UEZ_U+2'^Y'=78S2=QH@ID;0ED+H/Q`HF$_>7"VFZC=75GC
MN]@[QY[C'.*A^Q%Y_,DLPG(P&F5`?1OL_(B<4:\>!FPYK(YIE/M9['I#CER.
M*KGE8WIL2N5N'ZT$]G_W9.L9H<%7H7HUN7J5NGOZBIRBX>@@^0^1WL:.XEK_
M');..3D=GX&*YQ8PH=*'H4K'`QP/K(F--37P$5A!0^O^$M76P(YJ*SD)Q#6Y
MS6*B*,<[F`![@N^JSOGO3B=GQ'9LH&CB!.!LCRWL=R[TA1O7.1$E>OY(%^13
M!@<DFZ;48W,;-Y/<45!\B1J@P_/5@;EH5!Y:=VD^_X.*&6T-\;C7QQ`_,9=(
M?41CC!W14Q*_0_#AJ$R\<D$B45Z1"6#C5R"&ZBDH_=R.AIR47>.O27@`280?
M&GD<,(28K/`%X46T2DK*>G/+Y'[B;^H*O9=QO>YEDO9"'H'IU&)SAA/@A^*!
MJR9<%%XP@=][R<4Q"F?[@;>WDQ_\&`]65H!>&P@OBKL2[82\XR,?%VRRX(1X
MP=B#`8`N:PV.YI3-F'!G3;(TG]@R6,IUV\6%RY\O5N_/\@IW(`F^'K.1X/L5
ML]6"G])I`&1Q.9N;S/9\(:H1MFAUFN$#DUJCFB@)AX[OP!Q7B2??=U4L(:1=
M[:SED",XL8G&U<KXJ8Y:<7*1X^12._+>8:V?;=%(Z3U`J&]F8)H(D_!!+D!-
MD1NY<4AL%$KJ1O_1B0@#63C5:Z8-A`+5W:;]T+G]"%WU'3.[\2[RK3TWYW)2
MBC6]K7_V(Q?C#S>8;[8ATU-O*3-H#G%=AQPJ<+S=))2MIY<99,9U_)L`)AR4
M0>SUA>B#=PO4@T'SQ4OV>_=66JSBZ[8!ORA2P.8<YF(N"\'$+`#NV@-0K3&=
MK%P0QLX(FYVKS;TIZU3B$S5=[?'-F8_EO\!I1!=2[K.YTI0F):8/J_"NI3EH
MP.B^K#D0NUYG;5K^6@:Z>;4?>&40&<OUSJC%>'I]1EQ!%+B'@BH2K)1;;!.;
M^L0S+>%P6L`3&YUO4/IH\,&]7:`Z=RG8%5]XD^,U>AKR3E$-[_3-&3Z*FC!5
M^!DVS6[\+O@&7(IIFI#(@L`SPP<*:^)[B5'0"TX1J6B\R*KZN'4:TC/U09+P
M9GTGQSK\G/W;7*Y^_4D;='\]!2'7HYV!X!\Z\5F<^Q6W`WQ=1/,[2\YOC*5B
MUZ..^!Z9.@I=FE\I63(+K;%-(YF!7XO'_MS#KRVUCY,7=77QG+N1XG33]7SN
M%>$I';@;2`8^1TZ<\I+`3;6F0M`6W(5!QP$=330U0`%LAY:@0P*?3>`A\!WL
M7!C0)!3!?J/%KH<#+QT0<_ADBV*E.T<'G;"B_"YKG2.$N1(65]Y_R%W9)_/I
MVO.H[]VON!ZTYW?@A]W`UF\-8'D^4!L1C/IPT$_DV96@KP%8=44[&OW^H!%8
M\!]U31X5)B*B[>D;:M,9VW*87'WRGCSVRF;6ZQ/?#>C)9?.TUC4C/;TW&N;.
M2&%R=X&^P<7K)^94'?:VL:1ZQL#8!32'Q(;0U19'?#7<.8T5T*4D`'_FPIX1
M"U=,)BYL9UO1BKU>65'-(+19J'7-IZY?-0R5OVUI9=8&W7R5CX14([4VKN<S
M?3>E&-HN]"(6G<97&6UPV-"O]'RSNDE7C3#JXOZHJX]&=<)X3[./I=JU]SNH
MJ,"]'"K>SF;"/18U=("8#[##QWQU>\(L)ICHOZ.XV[>PPD[@.^XZ<7,MKTQW
MQ6\9L73E&FANGP6E9.>EL*!"D.DQLH!7F`*[B06FK/"^FL*$<[`;/)IO,"@'
M?ANU+:*N)/3/"'6-<GY8U.\=.WJ+6#S"IZIT=[H7VFA4#G(6J2W!K2K6`%>_
M&AXQW'KE&6?7T-J'R]WPZ^D_@8@';DA-5W2N]B!R#_%K@\C:A::K&^6$)DUF
M69@W"RR(<&OON\^I72GJ6DFE6`+!89E3@PK5NE<OACFUKQV]KQ^0.0B+V0'O
MF25?$S?N)(N4E^XNU%FD-0:H^J;OX(#JWL)5!Y1Y0GTMHKCJ.3_YDCU$O)QP
MD;S3U%%[#MV)D/N#OGD;#0?)1--B+]HRL45)PEM;.)66+LRN[G<TO1-W*`N,
M7HS##5!<7)8RH16EM1B^.[:4F3W>O?VY+N>?)VY]MGDF$-^(>@1+>\-#'7=)
MKB<\N%*[&@WX<!B8BN_U'YC'E0Y_M;\T,40"B$L%96-@A*/@$`M#'2>))6$^
MF,PR963OF))`1J5CO,0<-(LMFD7*N`+Z0$6H)\:+LQF;8,+3A%L^3]WC/-K4
M]19L!1=$3)&7_@6/]99U2\XQHG-*9\Q60>J4:S61L!5[FAB&/#H!QN=0/A9;
MKAP1;")O-VT;8SZM<)Y4V\M`)%"]O[]+,\#W738.?,4#$6'EP0@S$2I!Y<B"
MN%BTZX)F##>EL-6:>B)U:R/T646BL.42)!IFVEIO#G0><E1FZ<5B[,T5#&21
M:2!"V0D&9X@0:!D9MH*_;IC>)Y^GFGG.Q&$>66&$C+?@,RVFB("$Q&.7BR^!
M[(6#!6J\=X$/%NQ/9F-8=ABF%-";`!RDVHS-CMPG(UL9%R%P#VBW]J='YV_L
M?MH*NM$64U.0QOT`8G1CBQ!'^T$,J=P+Y#LG<%O#>#7<"V)(XQX(6PF5T(?[
MS-VVU#L96(81V2K:+"^:5^_+S4)WF+V)B%^_M;D%`@M\A\^]!2MK\WP7L85[
ML_[3_,=Q>2D7[GD(6@!*&.)>J%M8/U7!;`>\C70`>0^6#1*!J\>,OUBV0!I2
MB%E^P;VT]=:BD0<%^^4#FE<1YBK$.,QMUL+DY@T<SQ6AR*X*$>K=7(1*Q/E:
MO[:G'[!FB%7G&Y'R*#DII1:LD?`>,K'4`;90K[FFP0YZ@X;`[M&/J'&P2=.T
M%2P7\#^<8.S/@ER,>QR2E$<Y-ZU=V#K]F)W)HCXJF1;5AA"%)=\^R2W64>';
M+.3"[<AH,-(U0]58VP8EE0C!:.W)*B>_2_47I8R?`_M%9B@F,V/.`6:&Q/(:
MPBP#+9V]@''^XBM,6=Q,5(']/0.K+[8GL'><BLH-H+DO$O'X2:`A%SZO9B[@
MO#&]!?@9>>9&ZP-4*R/];I1Q_6.8D_L6SP?"K*C4]:))>$IPD]0FZM8F'UPP
MOZM!3/P$9Q(6ZDW7AK%A4CF6J(*`2`Z-Y"3\\"TP7=B36[+>#F8AP[/46\,E
M_`?K!.!ART>Z\OGP!$F_(+<V,:=3?AIRGCAM$-3P;'JBAMF6Q2\SS69LYE-J
MDU.M?T:FYMJ+DMA4'JHZ5'!5P=WTL\6P8ZKR^&6%()ZU!O"*(XN5_-TZ\2`>
M("#_ZG3(.\?Q;<?'4@`BQ[S30=FQF/WUU4Q^=P<?R!._Y,/,OCX!,:'XPOQ$
M7G4="ZXN?'_UZO+R\?'QXFGL6A>..[\$3\NXQ*\O\<:3\-&6,TD\D;>S<USU
M0-B.@D3^I(CK:%\T]95ECJD%/S#'7Q)?7VZ0?>TFQS#=B7H(_'<'S?*.RYDY
M\3OJB2?$<:?4?7VB7735HWSG]4E$B+J*&6NY1)9F@)[/`/TY,$"OP@`CGP'&
M<V"`484!O7P&])X#`WI5&-#/9T#_.3"@7X4!@WP&#)X#`P;[,T#/MP+ZL5@!
M/8<!>A4KH.=;`?U8K$`^`RI8`3W?"NC'8@7R&5#!"NCY5D`_%BN0SX`*5D#/
MMP+ZL5B!?`94L`)ZOA70C\4*Y#.@@A4P\JV`<2Q6P,AA@%'%"ACY5L`X%BN0
MSX`*5L#(MP+&L5B!?`94L`)&OA4PCL4*Y#,@B\@$A2[UG,"=T#+'#!%M3TL+
MN&//7Y]0N_/Y8XIA,6^5'T<M3?<K]67\"?-$0(AI30)>E8[,3.8F@U,2A1A7
M@8LE0GT52O*@HEB)3R<+FWT+J`C<P1.8,59?QIK1%[]=)L`?`3=TP0V7>5\[
M,Y?29,@+KRDXI:)XDJ@TLS1M6;^,!+RZ&\+7^'%7GW1$.-0G[,`4N&ORAHF2
M=,#");\D?C@5T33'Q@M#\&+!L`@=+_7BNR9V)20/#D@%LYB_SN"(DAK%C-C-
M&^>'*TI=K*D7K++P)Z_<P0=^%;&Q5_@7/OX?4$L#!!0````(`%A%,$5-8(6P
M"`H``.**```5`!P`<F5L;2TR,#$T,#8S,%]C86PN>&UL550)``-',!A41S`8
M5'5X"P`!!"4.```$.0$``.5=W7/B-A!_[TS_!Y>^EA"2WK67:=HA(;EA)G?)
MA%P_GCK"%D%36Z*2'4+_^DH&)QCKRYC8,C=Y"!CM:G=_TDHKK>1??GN.0N\)
M4H8(/N_TCXX['L0^"1!^/.]\>;CN_MSY[==OO_GENV[WSXO[&V](_"2"./8^
M\3)3!`-O@>*9=_5?]RI`,:'>[RM>7O^(,SOJ>_SC0P)9`)8_>&,XCV$T@=3K
MO__!.SGN_^@=GYR=GI[UWWF#3UZW*VH*$?YG`ACTN&28G7=F<3P_Z_46B\71
M\X2&1X0^]DZ.CT][6<'.JN39,T.YTHO3K&R_]^>GF[$_@Q'H(LQB@/U7*L%&
M1M?_\.%#+_V5%V7HC*7T-\0'<6HKHUR>LH3XULV*=<6C;O^D>]H_>F9!1]B`
MDA#>PZF75G\6+^?PO,-0-`^%V.FS&873\PZ%8=05=CQ^?WHLJ+^_))B1$`4@
MAL$%"(6FXQF$,>MX@NF7^U%.<L$`!.#()U%/_-Y3T_>$8#X(_21,+7##Q<@)
M")]CB`,89"(*?KM6EC8$XN?XA\+TA.8ML&:?VG<*V"0U<L*ZCP#,>\(R/1C&
M+'N2VJI[W%_;^OOUX[\'C/%:+Q-*>=/.*@C!!(9IM7_+R_5JEO(2L-D`!^+?
MU;\)>@(AEX(-XDM`Z9)WV-]!F$"-]';TVS@/:%Y!0/VL#OZQ`'*^I:]+]%@2
M12FW+N(>(*.?4A+I#)S52W;1PR,T@)3[-.[2$L:%)',A``@[W@*BQUG,?ZH=
MPCL*YP`%5\]SB!DT-SAY>?<A4NBYAN3$)4B&<`JY>,$UPL(!71+VHMUGJ,/&
M0.@^2";-UVB=NH362C&CB^9R-6Q[E=&WD+%S4O6Z*#*'-%[>\?$XYFY6N-AY
M9.P-6C)GT=`K:^>NZ@3G-IY!:NP#FZ6<-7U.%3M74Z>E;Q"8H!#%"%K,"R6%
MZY5VX/LDX9.@.[`$D]!B8J$@:+"UJ`U><*$*9=WSI5Q2FL"@5%M2T[0%')7*
M[KE3'H`^<?>/>"OZ3&)HWWT,A*U`RJ2\>SYY""F/]F+T!$OU*"U9*Z#2*[X&
MZD=W@"K7F5K;@W3=YIT[:&PH9#>'<<3Z*K-K^H!;8__F+(4'%\JAD?_VF6"_
M[*3-GJ7;>.YN*?=F%..8^/_,2,CE8B*8C)<:/"6%ZX[UUTM`J22F]6-9Z09;
MEMK4DM7(HIKN>8Q+$D4$6T%1*-H*'(H*NM>!!T&`5C+<`12,\"68HU@(I/;*
M"HI60*)4U\79_Q,,2;HZ-X[!([S",:1SBA@<PBGR4<Q'C202YH;!,*$(/VY3
M:&.$RLQ;@?<^C&B.-[H-3G'Y%*'4(&PD=6/RI%5+,T.V'NC:IJ.LI.5PTMM*
M8_CUVV]>__:4?,'["E=;;$S?3F_GD*:5[9*%H6#TQND8BEIKWNU;UXP?UQO)
MVDV/0MFZ]R;O(8.\]8O<A`VGN19'([F>KM%]9"4`V[W1H+N+N1@?(>;*A2+<
M#"*$$8MINL1F!LQ$V0[(C/J[F*V1[AI^)IAD6HXP]U\6F!D(FUK(_@@0OB&,
MW>+79Z:T$Q-M@X.Y'3SJY6VE.=R+UD?X";)8>+F5CB,QD^9/--`I25J'F%IY
M]R+Z3#:SC]@NV4)8ME0U1_&UAVJ\.Z]T$?U<MRN4*U=SFDW>Z@9)9:4;;#I2
M`Q>R;V0:.AXI6BEF/Y:87)33:AH=L&GASG'MY'[,N.2DB.S?(*87V>?7(5E4
M#>E?^=08T;]66O/TG:,OZKZCY`EQ32Z67Q@,1OC%&PU\WDM-.]4EF-0=GNPZ
MN#48+Y:'I)`&D5?:Q5A_".<4^BBUAS:VVBC6<E3R*N\WEB^Z2?%D<W]OQ%@"
M@VM"QY`^(5_:G\TT+87`PAB6$_-Z>\EX!BB\`%Q-+KP8>4W]14'04MA,9K#+
MLZOY/$Q$:(S^2R6\G0[A)!XBEJ;3W%$8H232H&>F;3F0%L:QR]9K$M/5Z2RN
M;WH^RQK.+;*#0G+;)&L0W[L$(I\140C$MOKJ_V@C"K5+R+3ET')HK0VU1ODG
MMU'.GWQEZ3I>*9"E#`X.8[F9UA#_[-2LJ"C\5L)J*7BW:0\.V8)QUJ!^<+O?
M%E..R\*Z37Z(R!9,]!+LNX2N0OG5FFG%5289DYJ3ML$R7<9[(`/_WP11R$4,
M$B$--)X,-M,VNS1<$K9"HK?9-.;5J29VQ&1ZO\QRJS17&9/:[Q/P(0S8-<=;
M+(2(JR9NI_F4_-4W*.[_$5\'./@#4`JPOBU78^Q>0]<`+KFWH))1'4RG>-%B
M6]J-=;-;>AD"%&F'YE)\6MT(2IK,O<P,:2NF8Q!RE8QYVQ;$K4;7QCCN'=*X
MYV'=<KW+N'D\5IO^JB!I-7QJ0^SU^(1B)V:S\8R3":^22Q[#@#^/$&.$+E.9
MN)IB773S&BC-0N.^.+<2U[V9U;WSX:E%($4DV([Y-+U60]0@OF95))O7UH&R
MX_E1>U->&G$YGC6U-^6EOL!RH%4>+*J0@"0\RGKL&,(8H-`VXTA"^`8I1I):
MZE[MV<-E(_5*?$,`MI=85KK9M46UP0L'$66:NID@-(E'F,4TO=WZ"P:K#4<8
M9#O&VJPA$VU;X+*P@GD8R+9H),ZP@ALL'O<LYPW5]&_@%-6554VQDB_\W$[Y
M7),/64Q^=,B6LG("V"`,U_>CKW),'TA^22JK5R6C-7TC':HD`+G(P=XR^_6.
MUD!MI:N50TE&?``026U22R9E41;[>TE*,C@`G"I>8K)WK(H)++*%S!+$!X"1
MU";[S:C<`9^\$U[=B,GD.:^[\SHH]-06VV\JY0Y@9KL?Y<<O#8^#`J]HH?VF
M3NXV:?U(Y8=E[&D;6'<JK=B;3@=;KWZ%J5;K=:]Z!UO;]:\P-7BSL63,/T$V
M6#M,?59@!68'A9[&9OO<]-HGFK=XIUF"EM_7@6EJ.;O9PP&9PSC[-9Q.."!3
M*.>2FNS]RIT\DUF;HI`OU#JC;^EHESXOWWJLL-Z^.M']`)XA*[?0+B%\@Q5V
M22T-O3>.R[#*+;9[6URN>%/ONGL1XB7-01S=3]^?."5T`6B@2[$LPZ71G2\=
M1*J7X5F9QLT=S"T%^(?L6?8>QHWCS`,<7$`,ITB;8UV!:7N1+V$X%Z](E.ES
MR;^C.->*LQL[2Z*OX]1JR+4F<O%5F!;M5BA`G]*+E=/#6R"LV-EE#%N-NHW!
M7+SWH3A<&0X:*PC:"U[^R+!3%S@49!5ONUB9EP=4"\7>1!GJ]L(F,X5Y&>%M
M<HK$HC-*+]%C``<\FA?3/8A]5#;FL6#T)K>[&6MMZK[V&Y%XRZZ3.*'P$\(H
M2J+L;.90^V(;6PZUWSMM)Y<YF[,D(S>N$K>#4WG'J*7-7(RJ+'48X8<%^8M/
M%JWNB;7F]16@OVDY%Z,I>S5XK7!_3>"5V]?1"#:LYV*P9:W(-4GHWEK!*[.O
MHA%LV,XZYI+-"'M"C`FOBW_Y'U!+`P04````"`!813!%9L_YF00Z``!,*@0`
M%0`<`')E;&TM,C`Q-#`V,S!?9&5F+GAM;%54"0`#1S`85$<P&%1U>`L``00E
M#@``!#D!``#M?5MWX[:2[OM9:_Y#GY[7Z71T27:2-3FSY%NV9[DM']N=S#QQ
MT20D<39%*KRXK?WK!R!%BJ)P)0&AZ.@E<=L`6%4?+H6J0M6__\?;.OSPBI(T
MB*-?/XZ^^_[C!Q1YL1]$RU\_?GV^^?33Q__X?__R?_[]_W[Z]%\7CW<?KF(O
M7Z,H^_`%MUD$R/_P+<A6'Z[_^>G:#[(X^?![.=:'T7=XL.]&'_"/SSE*?7?[
M;Q^>T"9#ZQ>4?!C]^&\?QM^/IA^^'_\RF?PR^N'#[,N'3Y_(E\(@^L>+FZ(/
MF+(H_?7C*LLVOWS^_.W;M^_>7I+PNSA9?AY___WD<]7P8]GRE[<T.&C];5*U
M'7W^KR]W3]X*K=U/091F;N3M>Y%A:/U&/__\\^?BK[AI&OR2%OWO8L_-"ED)
MZ?K`;$'^]:EJ]HG\ZM-H_&DR^NXM]6NZ<!L_JS_3'."'S^4?/Q)QN8F7Q"%Z
M1(L/NQ^_/MX>=PNB[+,?K#_OVGQVPQ!_B=#P2[;=H%\_IL%Z$Z+J=ZL$+9@L
M5M\GE/]`:/Y7,MKG'M3@GU%$ILTG'RW</,PTTG8\MB9*X[4;1&8(+8?N16<Q
MQ*=UL=QT$GDP;A\*5YB8Q,M?T*>:<8UTTD;O0VT49S.M2V8W8$%319!H\`2%
MZT]DV_S^Q\GWQ2B7<93&8>"[&?(OW)!L;$\KA++TXX<V:X0D,H#KN]]Y\?IS
MP1:[ORG"'MP$'Q\KE`6>&_:E\G`PC20_9?B_Y)R;+YZRV/O'*@Y]?+!=H47@
M!5D'L@4#]B3](D^#"*5XN,P-0EGPV[UZ$O&4K]=NLHT73\$RPKJ!YT;9S//B
M/,JP-O&`)>$%2)%$M3'U,#"7^MA(C0/904_)PM@$"^.^+-S'&7IPM^Y+B-3F
M"J6C=E*>T5N62^];[/X]";M"2?"*]=!7=!>X+T$89,HKBSN$0?)DUPU_C+[+
MI+$%7_^9!]E6<5MB]C=%F/1:90]@BK1I7]*FQDA36Z["80R3*7VD",<Q3&CO
MR5B/TY/01Q02Y0JK@=GV.7&CU/7(Y5QQ*Q2-8I9(M3DJ.5A/DF\C_$'T[+ZA
M;E2R^_?6T=?K("-Z=#J+?*Q@$PT$10W]0XU0^?%Z*V8O*?HSQQ^Z?B5?4U6#
MZ;T+HGQ\AX@",@ON,`4'M&':4>0COZ*.#-;U0EC8YF+O8/R06,/BA'H%+JZ_
M"S=]*>[`>?IIZ;J;ST0HGU&8I=5O"C%]^GZT,W_]Z^[73GUAPDRA6_QC6GTE
M=%]06'S;83=VOB^%8X/B9Z+PR5!;-'1&;1AGR2'-;N)5H^W,$4KVO442KR7$
M57TR%A#[(4[P?O[K1]PC3S$E\8;03%9<:>+XQ<.K"$^\Z[#HAA<(6I(?]G\/
MXQ3YOW[,DAS9`^DR=--T=QF?O052LZO=QQF;@(YC&.-`6<,C@)'"`Q/14X/3
MI.WJP+Q*0>6XL3,Q`0?+XLO!@B9C.BQ4)MX/'LY5T^1N#)=#GX$Q8&INP`#T
MA"_)*)T]X"%1DA`K(R;WRX'-G[:?L7LY4R-0T9P1QS#1%P-C/^/R``:@FKZ"
MMYD0&FI[YX>!@,*BOH)C9!V/69IB77;VDF8)OCAQ@#ALZ/QH$0$5;>V(;&BB
MO\P3XK*11J#5WOF;12".A<L#X9AR,+O2I9NNR'47_X^895[=L+@`9Y=NDFSQ
M!?AW-\QY%QBI_LY/UJ&B0,`X[249`H,@WFDW;N!?OVVP#H1V?/+/E>/VSL_#
M08C%`)S][6IW]MT$$;&:7,9IS=X]XF'#[^B,OA\.2F)6*KS&UO$Z8$WV'')&
M1JPU9M`XHKP2_L2Z\!^2>(.2;/L0$E]RY)-==[,6+A5>-V=DQ!JC63<0<0!G
M/YMG*Y24;'$0:;1R1F;L+WH!:!$,;3\2;D3.R.8574T%)K3"V7,:<01XX1W[
M)B7N)+)#.".;5W:5"Z,*1W#62H-J^0LENY,SLGF_5X)`B"*%-3"WEEW06+J+
MB9+0O:@=G)%-*X!`UHS]D,D()'"2'/G'[/'QH?=Q1C9O_UTA8O,"1RV[C*-7
MK$`&>!:1\$+YM<3OZ(QL&@,Z`29F",Z!18UF%&/&Z^:,;1H&.B$F8@>.KJBV
MM&C3;VS34-`)'087%2A3ZZ`H+1W:#+-I(.@$"9V)"I$?K"/24FNP^LH\1?'?
M[N/(4U7YI(=TQC:M#QIT^#Z,PU%/&L3*+4YG;-.>H??N17B!HW-P8ENY:B*S
MES.V:=70`)6`-SCJ1R?C%$<DXX';-_BLP=%0#L.11&YT2FMG;-.T(1`STS-+
MXP*,78,L^CB2`J3=U!G;M&)T0H/&`ASM8.;[0?GI!S?P;Z-+=Q-D;LA3!^D]
MG+%-<T4G9#B<P-$9KM`K"N/"(?F4N4MT'64HV21!BG8OU;%.FJ_SX@W259[@
MX[/=@VO-Z#NX,[%I\^@$NQZF(:LF2BJ),[%I%^F$()T).$J'2+_JX<]T)D!,
M)AHN9TP&!>:4SX?OZT[WXNXPN<GY^9TLQ>?G=^?G=^?G=^?G=^?G=^?G=X9W
ML_/SN_/S.SB@#.#YW?ZN.UO'21;\LTBF2GLVP'<1RHXRG(=[2CR!1/0*;1+D
M!3NZ-R$JQ!T=\,,,?Y>#N]<GK+X=[#@7^C(,R;+XDMU&^,)>I(_^&KDE!YC%
M("T<WUS#H:"OU;>&*M#*<`+'UG=XO#^XR3PIF/4+U\(#2IY6;B+OX6(-8/4=
MH@IZTNS`,0X>DES0E\[R;!4G9-9)0]?N:/=58G?,:'S`":>BT7J;IKDR4&4G
MNX\5^X*TYZ$"Z$>0`,WSC%04(!43%%%J]+3[>+$O5"U&*KS^!@RONP!K1OY.
M9R)_0&4="#G,J+WMOGGLCAN3F0J[GZQCUXADZ*!Y2/2V^Y)2!3M)9BKL?H:$
MG8+*P>DUG`>5`B;V-W=X(`E5#48/N\\G>X&S9Z`&QKY-Y8A*.16#U\WND\E>
M$+6XJ'%BF#1.Z:X7%/4XN^S/+OMWY+(O(V;P^MS$41%"+^FVI_4;HNN>P0<8
M9U>+/J''F-H>C!.?)6TZ2"Q>WALXT#SZ6E`Z._;-JE_,Q<'8\,Z^?9"XP'?O
M-W1W(1Q';:VZZA6AH!$/Q]7*>&DBA(3;SZKW7!$>$2-P/*R/I)!+A/QK-XGP
M!3<58D3O8-7_K0@.DP,X3M.#`(SB+D]_F2->44H#6?6#JRXQ5<[@>%G[OF`:
MC.N;3CL<=4'%N$FQ!0[%N4TE78>V<%QEC/S&(39M$BQ8!5I'_A]NDKCX=O8<
MSYKUXV[BI/$^BO4XNO>8\'W;6EC4H53H1;2<>)HA+0>UX_?6@Y,^[/>R`',K
M/@PPO$)>@MP48;*7P2LBQ;ZEPRPI?8?C,9=B18?"R5BQQ30JG8NE7O2`DB`N
M7?;EKS$M90)#8G&;+^YB-TKW.9]NR2MQE-*"8K6.#]^OKIU='8JH&NI-5[,1
MV-4_8,=EKQ]+^;G2348:]O5>.X2;KD*\6UV_H<0+4GP^5>=2OXV!.2S\.`%=
M7.H(*NVW#>C"5GI<.TF9M0'6?:US)0)&=>/)Z"%/O)5+2!>6B5`9QF[69V5;
MA@)7<&*0N7.T/Z[T<>PFAU8&2PES-L?F3NO&!9'F'7V._XBC31XM\6Z#&[P&
MGKP]16D\NVFEN]A2E-G3$8&N#T5I&XK:@'9R4??'1@_6>QE86[$-$\].0[A'
MV7PQ7^`V>*<I'EKW6<'2X]O-6ZUK12NQJ^.=@CG4>ZUX^0_8R7NM'TLS<V4O
MHT&HYS/OSSQ("Q"[JN;-(>PFVM:EEK<Y`O3TA:M9]@/S>`R[V;>5$.J@A[<Y
M/<6)W@B_*K4*LLE4>PK)\UC\YJ+ZC>0YWF54V_FZE4_OKDQJ>1ZE&UC9H[K3
ML':2?^N"2^<DV,MC$(=Q;?>KKAL=3^2C<6PG'==S+%/9$KVJLP]MRZ;;'5O&
M0`!2BRL!UN&HIO(\B"5=%&WNN(R+OK;3CNM9NC4K]7*U'\',G7$=<6MTMIN!
M7`Z,#DNQYFT0R^\>?2O^TO4DK?L[$^C&+F5VZJ5H/VR=.^-Z8-@:P)G8C0*3
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MF%"#&N[C#%'>$!0O#6I5<I9G6&Y9X.U?']P@-\L3Q)T/QC[H3`?Q,M,H__N'
MN,.8*?P+G[DO.E-K+S[-XG^B";>7XHGM2ICD0T9N(TQ<A#SRU3^";'6PFRI9
M$M2&=J;07X_JY+3>5TX5,*%&8@>[49</.%,;MD.M.)J9(GOQ@+$/';Z9+C>P
M+'@)T06*BA0O;GBTJW$NL5V&<Z9#R23=E;MZ6[`?:'&/,`=>O$9W,3<MP$$[
M9SH4Z]\1V;7H&4YSTYFC+_(T(*D'KD@"K#"53P_-.`7FR=*-=C7`]EFI@Z(^
M&-Z)4BRFXI_XBEU4C\-3LI9?6@N0=03H&5TIJ;0)/EF9I36-?,)4U'I1H1UK
M6L1Q3G8-*=FU1EQ9YMMS=NS>A]\Y._8Y._:`LF/KR;P\H(S8+`;`(-(O\?*`
M<F#3B->1T)*A>E8J^S-66'(W3&<O^,;G>LS\3*SV5G);FU<8.>S"R3):SK`O
M*%O%_BV^D:=94;'G6X3OYJM@\X"5*"($JNE3>0PK6;*%6/#.&SFFP.QT%9N-
M9X<E'Y4]?N<HGB>%D0[KKO<YD=I\(5GC3,\'K"3D[C@/M'$,9\U7+.'CXJ5P
M)I,S`VV8'-Y&Q9\2A*2V`QW#6TGVW7.&].073H6$X\S8Q+M7_/9I$P:\6O2B
MKG;2@W<$5H:9D^0U!NFOM))A7!%)G<P:S(<[((^EE6SEEE#?LPRG/(.!VL'6
M(E?4=V0!'SJREIHHK:Z`%+^CG13C'<$2LR)(0VG:Y?B4K]=NLHT73\$R"A:!
MYT;9S//B/"+QE0]Q&'@!4G=(ZIE!=>!OF<`1[UR-,,\OR$US+-EY](B\/"$A
MGKC!?1PEU3\OW#3@NC&-?,="E5P=](L*[&K[AH7:O+KQ92QVG2(:MI.TEL3%
MMO[Q[P%*,%JK[1TI`"7PELH-`*!&L%;,!=-*)`LP)KB:S)T`"E/Q,>U")Y[2
M.+8]K_(P"6"69/:OCC805^Z)88?GZZUIO8TV>986+(^$/D9.+ZM^7^55*$"5
MRAYH[,:=L!L#\!0;Q&ZLU9=L#KQ))_`F`.HK&P1OSQXD_X*),$(COF5H^K!(
M!'!6J)Z@-3..8DT1A4>)1$6\@#G[-($#1`W5BQ(\+7/W\%]XO!VT`U@NFYGE
MHDTX&,G7,ZL(;:SJGTJ>4NT^AGS?8(\H&O]PE)`F=<+][[BQ*?>W^M%$%3/#
M?49E`\QJZP\)M`.I+S;PSB+JXW_AR<3I9;?^.6-%,'8V/A=@,*HW^7N4%?M\
MM<=O.1':\IWM1`S8\F=QQ0#GND7-!G2)>2[]8BRT>=WLUC.7!(".GH@M_E(]
M4=S!7"KN8&0M\&!G1=H+\/_GF-`@*^1Z&RWB9.WN)"(?9:`\J,V0`EEBI>,'
ME`:T&2S0!29)JZ0T\^<P@(&%`2@#?/;YGWW^9Y__V><_>)]_/]<C"#7;G.L1
MHL^_P2T)^_\:Q2\I2E[)P51R@.^/<>3A<ZPXL=+'UOUQ=Q5A)28U^CT8<08F
M-$3-4H)S.[^-O`3SAJY0^?_;:&_&\/\G+]\6I_.(9M.X=#&+R)]E=9>O^+J9
M[!-#%TQQ)J'YC\,(GM`X(T\B,AV^$,:#LN.LX>D^'1_SE1B_EY7'^R9`EN/5
MX,/.9_RY=$&>B-=4[&AHD##S_:#\X(,;^+?1I;O!7(8L[/J,:>4YOC%D>TK"
MX#//?<I+1NUW%KC"CE:=_=H1E&%7\"(3E`EW?&H3[K6;1)B,]`$E596?P),Q
MT_([6C#%/GDKY.<AJ7Q`(^UB6[X(+=QX(BNL\E@6#+!"`%BNR0Z\#=N^JC<T
MQ[X5M1."C,G`81/,5;QOL`>47),T&4M'>`"R:O;&`XA]4A,P\.R.P\\K25\`
M=$S`)Y74'PAETZRG`@V?!X/Y)AO9/ZH[.U/@_`Y6#58RLA:2;]!XU/AL::N2
ME_)!>ZL&HRY";E.OPP2D9[.9X6NE'X0YN4@_$:-W<;V^?O/"'%];;S#W)-8^
MKY*5MC7(V9I<3#G;DI;QK9J1NEZ<='$NV/9,VR-(8KH'=TON!;H*:!05O79C
M\FP'[,8ZRELT!^96JSAJ>.KB$RP1T#8=&K'#OHX?5OP1W,./&]LN`D$%A+YC
M4(D'HY8>4G?OKI'P,L?J8ON*31>T#"@'/+Q/:(#<MO5@I/.RS3A''C#I09K&
M29'#-;TBP08\I9;5WNH%FC?+*:<,AX=3"GH>*<NZ[F+U4MQ;W$TVX`2CW,5N
M5)UUXA<BE-;VZC5(ZEA\VN$@<3C!OD;N.DXRDASS*D@]P95-V-=>L05%E&0X
M@?-NN,F<>/506MLK?J"("YUV@5'D]!?=74+:\WWW?-\]NY^-WW[/ON6S;_GL
M6WYOOF7]SLRA^)GY/)B[)FMSLD'W&HNH/_N+!^,OAN$IL)?G48.G`%*&1IWV
M:,MY&NF25C1#`\K/J!4:(,J3'HR&Y"JP^2B#-\M57`5:DC&>QE5@I;2@-GD?
M\&%0*3K^\O.W6%7H=1<[50"U"?V`#X,A=90OX_;*<[W1R6[:O/Z"/^0$3J1=
M7>=;6D5E]#"4)<^(HLIA`<Z]H7K729Y;XUO[:^`%T;)1F+WQNO,9TY+2_R34
MHW1^QE0&/?D</1Q@Z5-!-_M@5.IA3A\@NKOU>70"M;_^_FR)SR;R>?[QS&KO
MC&R:Y+2O7\IQSN/<'#[-\^S0]<O):BO9TQE!#VE18`2JA>DVRE""TNS1S=#U
M8D&*+K^B!ZS-X+^YU%KEG<9Q1B`"7SCXR-@\))@$<[0VV9:,A7%&(*)@E$%J
M\P!UK7UQ,_*497N%IX_TPFIV<D8VK%>Z5U&;(X-7?/+A*F!M5D:P%6^&\)H-
M8EK%;XE>SMB&2:L[")(LP;GM/R2QAY"?DG=>DKL8JXLSMF$)Z[]@>/SHR(6D
M*4"!/+9[2`*/F^"E;N2,;5C'^H-QR($@QY&UPX42HON0H'60K^]1KY#E_2C.
MV$:-"=W'CY#%"N$?#00_N.EJM[9OXJ2Y*3=52V8DA%1O9VPCS*?G^23/6H7.
MW\QJ"\W/SA>5RB*C,=![.F,;!@B-6@.;K0J1GPRX:/+$6[GI/A]DL1<S`\`9
MS9TQ"$."FNPYO%0"_]GZ$80Y*Y.N+HH]-DUS-_+099Q2\YE*]'+&P[03"%C:
MWTCUKY%9?9KMHB5WEL!H67Q><.E4'<(9#\M&T(6_&BUH!H3F'ER$/?M[XQ/Y
MW:,;+=$7#,LZ7W>RW(D&=<;OP0"ARG$]'PQ8*)J7<<KF,1(L668_9S)`*X4,
M4S48!G)`5P&Z1>)<K(<^A*Y7N%)F2_J+0HE>SF18)@A)EFH8#*1DYG^]RO+3
M#8ZJMS,9EC%"D;4:GCYF"I9/=I^E?7=!B/,U<W706SN389D2!*S4XNYC,]"E
M,315G'+C%%F`J#V<R;#L"!+LU##U,1[HRO<0+;$6LB83::]]7""75$ZY"=Z0
M7VDIPCQQJD,YDV&9(OKP62-NP#CQ'&=N>*2DW$:D_`VA!?<8LW9%F;[.9(!F
M"UG&:F#L&S'Z)X^8#--HP6!E[X^U#LWAO:TL09$%A-RZ&D7AF*%=DY3'<";#
M,FUT8K`&%[)MXRHG6SK32:\V@#-Y;S:+-G<UIB:*5I5:5!U4N#-T7J'42P)6
MD3/)GLYT@#8*.;9J2.R'4]Q&?NXAOUF_I[%'D%EV_;9!4<ISXDN/X4R'9>WH
MQ&`-KOT0#$+9GN@=R43/JO:-TFM$E#'DBTY)^8&<Z;"L)]VYK+$V8$BI5.2=
MJ9/0$Y&8TC@BA39)BFL\X\HP+5*[BNE]5AW'F0[0^-*%R1H\`Z$<-"JNXF_1
M[CR8+_"DRA-",1\\U7&<Z;#,,IV9K,$S%.G1IJ>FY4L<9:MP2S8%-PP1V[2I
M-HHS'9;9I2.+-6P&+"[W.6&RF"WDBX7'G04.K:TS':!%A<5(+6C[%I2&JJ1F
M3.%W=*;#M*N(N=H'6]M)V'F%[XZO10701F%0Y1H5FLN_T^HV[XJ/^_.H+BN.
M&]S'4=*J,BXNHZGU.Q:J;NJ@7U2-4]LW+%3IU(TO8W'K%-&PLZW6DKC8UC_^
M/4`)1FNUO4.O*!0E:9`:`$`94*V8"Z:52!9@'AC69.X$4"@FQ[0+'^<KC6,[
M"ZP\3`*8)9G]JZ,-)=7":6$_06*%6R)'-R3?=R4RG3*:6\THJ[R6:%8E)E]@
M5EX1C2HX2>LV9C+/0CLLF^S">>Q=A@V+\C,W6AE*8"M]F!V(D2/IHWRU0Q0U
MD)-$5>;PTI)_<=](8+Q0^@?MK):=;4UBNM3;Y,*1=_D002SO9CNK95_EY-TB
M]S0IQPLO$CY;OF[BZ/H-'VI!XX4=TY8L/8#5[+*&#2#*DC"(Z-X92"T5@#FK
MZ.`_&%4=QVXZVU,`W$4B!A.X?'&3?Z!L%W3?+%@0-91^\O"!_)*%LM(@=I/G
MG@)B97'`20W3%$^^+HM65'N/*!&)L*_=[+T6S-=,*<!),4,C]S%(_W&3("1(
MF:$ZA*'<P/#A9PD#3J8;^J3=("]#_C-*>&^=15U-90,&CWI;"#JRWIA'^_<X
M=#,BGVV'54\?Q&YJ6``SX%@<.G+LF)\+5\%KX*/([S$3FD/823<+:!ZTA2'(
MZV,S1F5D+4CEP@W)]>AIA5#V6Q+GF^+MX2[U\KX4H5N*]DXE+J7CT#9#42ZV
M-**EHTPXW6T&D'0'0NS<YS'\;L)!&O?(8F.2CP.A]804`"(`4`@_@S\PQN::
M5)+V#<\F3"N9V^6#:G&A!9GN@$(X6&@(8.0S]]?"$HA;S3"H\+QP#R13$A9S
M5C-`X43H,U(8!4:HAV#IT3%6XQ(,Q)<KXD=K/O;M`K'"*%;+%O>#6(U+.#$C
MEVZ2;#'-CV@3DY>();N=<%8;R6KQY)Y8*W,*IUX:LU@]!UEV@7M[59?U*,8\
MS@"MT:-2W[QE>%P7W'(99JZ0&2N,Q@2<<[$O'D!T5DW`P---J9$#P@.,T\MJ
M6`U],3`V-"X/P`"ZZ`00M9?=N!AUA)A,P#EU--:\-6)*/:7]C,T8',UND*5,
MS02\]*^$RYP*NMD'LR4/<_H`T:2LSR-X.AA)EOJ\2Y8J/-F/&]L-AM*^RNF3
M@,XV&`B?B'._\'H_A,A?(G^67L9AB"\-B1M*:&O"WG9CGTX$LJ0<X"A^3_E+
M&OB!FVR?W!!)FHA8?0P%-YW21L1C#4YD<H.X>W>-?RRFMULD31*>RN+.IH*3
MY*U(7!@8T$FQ!6>_-0XA$'7)&);PU*"'(H8,U84RQ!Y1:@<[Y<L5UQ'#^<ED
M"`Q(S<3^Y*@7'':TYH9*EY_PG&-Q!><M1IM"X9Y([V"JB+GT4<:4M!PP>R[`
M+J#NR``YH71!!.]`^L\\"N($G\"8('R=(6'7,C=T7C<[!>DEE@<=+!$K8*"J
M_7-/'HK<)(AE_?3-]H8JT-MPTK?9@O,^K*+L:Y1ND!<L`CRGA`H[JX^I,O7J
M#OLC@3,`XG$"9S5IQ@C(2:43K%.D_2HRV]]&7]SM+/+Q5HQ(F_EB@4CDG"`'
MF$1?9VS3;LQ?"8>`*+$$9A6UBE)0@MYX)Y1$;V<,(LY7^Q,<2=;AF('GV0HE
MC9=O%(HY2$OT=L8@PGVU(RW).IS(`>I#1W'N=%XW9PPBO%<[MB*>!?X`TT]6
M"Q/=*@XQ#>GUGSDI*6\GIWHS(NI.X@TJM;V%AZ5/W@KY>6WMO-@6A(G>DW)Z
M67A&RI(E4R'D$3_L)Z%ZH]WM/P,58"6X/U,8@J-7]HRIMORFDRMCAD)(8^+]
MX`'M>MP/&'AV7/TQ[C;O7?3%P-C/N#S``:B:>:4B1@K$Q1&)&)(]?VC]`*37
M[G<&,9B"<^UM$2C<^ZCM;2?6%HJ;CA*+%S!K2A,XT,XF+2C!.Z(:J3W%KX?;
M;:TF[&8N!)9M[YAX<R;T65BT#HH:P6ZZ>HX/C\(J@R[+C"[;WVH*;\E+K"I#
M!E-"'U/1SE6MA`FE,YA7B.J`T+DQF+?YF(29[P?EZ`]NX-]&E^XFR-Q0'A'&
M`'">'JK#PF%)1V2S-#;'9E5FN6*ISG9S:/?#A,&.CC"\#GCL+EN[G.L-HW<7
M?)B#V<U\K0LO+GLZ@E5TXC>/%`XCN?'LOMDRCN*.0QUYBCL`>:C2E-[DYD5=
M!4366';?8^D"D,>=CL3"'<"K2E:HJX'L,>RFC=8%%HTK0=[?/B`])+&'D)_>
M8(;VE4:J>)OT'M$<WI(][>9O5@%$CI<*AC[EW1DP5)^ZC%-VT:.#1G8?P*@(
M]XCL_9WSY//YMR1.F?*5Z6OH6<OIYW3-38T&PP1@+41C?.H8C:)^TH6;(I\8
MNE"4NB6\"<ED6&0OW>Z;/+C;(JO!-S?Q[R0".OH/;C?Z0T1^RJ)?(5:DWS<L
M1)9H`97E(=(HEV$'K92LB)\A'K2#%9S2'T'Z)&FS#,;5T9WC/4N1_Q"Z$7E@
M*WZ78.!SMD-HCK!E[!-F6#_/))WB!.)@M3JEX/ECK]>;,-XB5!9;+*@0^F69
M?:R&"YG:!!@.=XX,P(!;U_7F@-FL_?T7T!8.2IV#"3#J4#K>[L&L6C$>V)I0
M$S60DTM5YO`.FX-R]ASIM\O>VSM4Y*K&M\B%(^]F.7N>O%ME[Z'+NT6NP0">
MW3.NH@CQ05UJE@&5V<%JH(X)(XV073C':V?V-51Z-OYMN[%&1LU_IQ`=G">W
M6ME5K$=K_-MVHZ\&,TM9H@.44]0$N](5M$_P=;MQ9X.;J<?"@Y,<\`0,[W11
MNU-V1X3=6+N!S]R&#`'E$#L!W^7EU?($+HFP&VLX]`F\EZ&.<%2-$_A%S/>+
M"M^D/,)(-&&-?-1N?*7Q"6I,9H(06VOQ5=-S?-4YONH<7W6.KS*3F.$O$7\E
M$@$8;XB>1`%0D@JQI,T(5V#P\M[``>*JU8L2/$?N[H6.T+%XT,YJ=!!S`="1
M:!,.1O+GD)YS2,\YI.<<T@-%]N>0GG-(SSFDYYT8`\\A/?O8D!,[]C@DG`-\
M=$CPG<;Y4+D^K4N/0\(YZD>'!-]Y\`^<$+5SX$\/T9W#?LYA/T.8M^>PGW/8
MSWN:P.>PGW/8SSGL1RGLYQF/E6,J;`49W,D$\QPUMA&<4Q$AC+`Y:&@C3(8F
M+E'$PCN+77DO!:V.X!'`>*YA93[<Y%S#"FB$R;F&E:#7N8:5P"%VF-PZY=?;
MIC8V$V>B4<1<T@WZ&LM/7JB(MM784%2($=$>DVZRF,<2;WYR@J4TM1J!("U6
M.N%PW`&-^N6*^[6@)Y@R0Z(]6\P''+-XMQRB1F(<C-P'VG0/*%AA`/D;#04A
M=$P%^G-GBVM'WN'HQ^]B+@&Y1=F=5#HO7PPMZ18?3REN+-"06LV`AVUT7<(4
M#8O".)R5GK^D@1^XR?;)K4OKBNQZK#Z&@AO,&/9X3`"*X]H31R;:?/&,9VCJ
M>H0<\;XJ[&S*K2]O^^/"P(!.BBTX2\PXA$`..F-8PC,@/A1EI!#>_[UBLQ'>
M1>D=+`<ER*TC.G!LAL"`9.:]M1DWO5GG%8L1.%8>/4]S#15"T_1P>J1867T$
MZ/F;+GR@'%6:@8)X0NTLA86E<29Q0%':VRU^QUX5K".)P0(84!H/G22LUZVV
M=DOBJ8)!)1^.M;1!WKY0*[[K<Q4#=B=G9/69GD)<$I\'X`#=(#?+$VH-<*E^
MSMCJ*[>^,#79@&.BV-.WNTP4=K.BL"[R>;&T_([.V*I]4`DK$1]P].Q#!V+S
M><T#OG]@?MTE+P13IKLSMOK$20$X66[@N%</*;X+\*'L%Y;K\@\H\E`1,"T-
M(7L(9VSUQ4]G&/D<P7E_P]@U=L[^3COGOJ\SMFI8ZK]Y'K("Y]$)X6B^N,23
M+:!5;*<U<\96'W8H8-&F6O"TXH1BKQ\M(P\%KX)W`L>-G;'-"#<5".BT5T#\
M9!V(7=S2+EYLGCP&RU5VGQ,!X/6+O#S!TL7+UPU#Y%]LJ[BR74.NXMYO9&=L
MTU2AM./U9[2:#S_#G`_7;UA]"E*T2^_2YH![LG49SQG;M(STQEZ&O?W%7'_\
MQNZ#S_%#GG@K-Y7+6,3OY8RA&T0DF:@%;]\D4M!4WBJO\"81+?$M)8C]YFWS
M)DZ>4/**YQ'?P:4RD#,9BM%$G:\:7?MFE.KZF=)#DSAP"GHZDZ$84B08J0&S
M;TII;!3I;>2%N8]GW,SW@Y*>!S?P;Z-+=Q-D;L@[\12&<29#,:VH<E7C:M_&
M<H6*T(;@%=T%[@O)@1!P=U-J>V<R%.L)D_P:DCZV$H;*\9#$'D)^>H-))QNS
M&Q'-9[Y8(+)MI[\E<4H3N71?9P+=_J'$2@V%?0,(G>1#$QR)C*U-;RPELM^`
MSF0H1I7N_-6H][&_L&*V:TJH+T)+E6FO%DO<![J/Z$R@6V<T,%B#V<>&P\HV
MBS\5I,2&FN*9=(_%YWEQ'F7$?$3RI40I]0"3[NM,H-M6E%BIH>AC/F$=;%4\
M9/&L4B1\>FMG`MV<(2!^[YNV?EPQWTZ2_$$IN>U7[@>ANT5F$&<"W>S1C:<:
M41.YLFDVL?01^:A,^500Q-R^9#H[4^@6##5>:C0,/'G?>[[Q.1>'@8=O:%D1
M>X+F466:K"R6/G-C4QK%F4*W4'1DJ@;*OK6BC-_[@K)5[)</T@C+\V\17N2K
M8",5_2$]AC,=BIU"B:4:3OM&BHL\Q<REZ<S##*2%A$M6*@?BSMXY3PJU%>_R
MM8>I80WE8*WG`\YT*&80??S6L\1^C$G%%-:,7X*HV*R>,K1A\G@;%7]*D%PT
MF([AG2ET2XUN;NOY8=^8<YR\\C[.2@/$TR;D1KB(NCK3H1AH9#BI,3-JBFF8
M#&J+4*66WT98(X]0\3COCR!;%;O.]9NW(@_6Q3:9SD,[TX$99WIQ6N-LP$JC
M@<3RJ#&(=OD!9SH(>X]6?FOD&48AVWF$1^=$PN=$PN\ID?![*X*MY4TVH*3"
MYTK6YTK6(%YCJZ($[RUVOV>_`ZIH32,>#`K=ZHG;O,7VJB=N-.=P`^BCN$I^
M%CAQ3ZO9B"5%+L\*G'>ZCRC$VZS_X";9MI'I)[W8-O\B*OLN/8B9[,=&=#(E
MIN`\D6\2)]0`CAL;RG\L7PM>2>IBY&JNP)PXO0$"HI^90NH$N4F;G^4?3,<M
MK9;>IL]LRBE$I=N<0"\Q[A@R<4+\HX9V2TQ+RY-*MT%5ZB;.(SRV7)4!:F.[
MF72E!<ND7;>*E"+ONV7\^ME'0;E7XQ_:6S3^E7.'EFYX'64!4^NAM!I"CEL&
MV;;D7%+!/`#;3:SEI&6)[5BX;7(U:QSF!&M9H>@LX1-H"E^0C^+D-O+X.W"K
MF9T,KM0Y2-ER*<2:$^`?<;3)HR5??`>-[)0\E17>$:D&E8#&VX+"(WG@TGR.
MGU"6A>@N=B/RBN1YA79GJ=@3K#2<J?RIYAYBJ'('Y_+>?!9$:)TGP7(75<1-
MD,#M9S=?9]=7450V#%;UNL$\!J^(Q'+-%U6TUN[]PCPBU+#5;U%/NTDZI9>0
M'",ZTM8Q,)B_A,&R@/LJ1\]Q\Q+!$CZG"_STFS(<P$DSUYH1`G0D>@TG\::`
M"3CYXUCO2@_3\DN>).P!AI.&4YX?'>GD5(+\.KZC%8T`/]%F!X9TY)P[:9XC
MZ`\<))D`GF+N]"G%AO(LH3-[<)+(S;,52F:>E^3(;R0AN8\C+T\2_BDF[#N<
M])M2K&A)!#?L?&2#2>:ISA>@;'/F\I$-)E.G!".`$LC-PF)PY-.IW5UH.+C)
M#3"<9)OR_&C)*J=R(V@_2BD?$9)_S1=W@1<0PF;+!+'N<)I&'DB63CV,`DHQ
MUZB\5VAH^%PHYBCOC&1T&5!V3@X'6G+-G:CV-:LP\+R@./VMT+1OH_*L9V6R
M,_BUX>3[-,0\H&QYQ6POR#Q4`8MZ%`5O+VWVA3.FXY##R1W:AT,M.?,T;B1'
ME![/[A?&[+Z/BWPDJ/HWOBHL4(#__0<BEWCDSUY1XBY1(:DK+-X;-TA$U5_L
M$36<C*AV9:0E42",&?Q[(87#/"D&YR;M<_`3P9KF7DNV0Z,&HV+JWZ-OQ5\Z
MV(D.^P\G,ZPT.X#R*7)-6CTP;`T`/R6L.C\F<RCRIE)M:+QTTU6(TCI%W=XO
MP+(P]!QV('EC-7!I,B.CG!59&[C2XPXD3:T.-@'E<6Q8P![<9)X4<BCGJH05
M2:+WD%+82C$#*&OC(TH1%LAJ%OE7Z!6%\6:]3YW,@8W;#WYV6VDV`*5.;$RN
M791QGJ69&Y$Z)G(+[*@;_#2WLER(4AC:3I8U/G6RK.OU)HRW".U\N0S#9NF/
M*CP4C\B+EU'P3WR5*XZCRSC-TCN)3%N:OV0C39>W0GY.?`%Z>!%F^S+Q/0M)
MP_0CS[K2&!+8L!.7W49X^T'[773'LR!?!J<7A*1EII"F3RR^,,"D;6"0*<S@
MP.UG.Q.:0/9*@,'+AV8(,B#Y-TQ@!R]+&O=V(,S:)=';:B8UX5+J<&6"EV/M
M"85XS.5O*$*)&V*B9_X:RSK-DJ+"8%4D2(BFTCA6<[1UQ%6503@/5PN?TS/^
MBD#S.6AG)J<;9%VGS3X<`(51-RDK[&;/4^0_A&YT[ZZ1\(@U\3DSN>7DE:DC
M<#DN7?VLP]GMW\-,`J+C69U2\)3!>H\FEKXRPD&H-##[&,IT*&EW-;0)T.<'
M3P9@P.V6B=>J6^JD(+;Y!IY]SJK[Z23`\+DWF*IDOEA@#379A7CQT:&UM9L:
M\(3@L)@WF,)DGRA2"AY&<T/Y!.$AQ.$?3N(31J;;;DFQR_1V1NR^D&^^`FF`
M3XBNE*GYJ)^IA(!]TVK7XE<";<\3&.71%&I`[H%FX#M!_DR\IP0HG1T67\/'
M,B(Q=X*S4::OG621\NN#<N3)LF4.E"OTDDEB0&EJ-Q]D)Y$SN#!X@WHB)GNT
M#+R9_QJD<5*_.19,>7XWNYD<N\UV,4?@SWYCQ5#,I(4<H!K($(Z.>QJ,HAV&
M4E&:**LR.DK4S^<+I`[8#2/8VIX&L$Z@\9&S]N]E$*Y8M3AH:#<=*&-R,[2)
M(\+-"?2V>#<<B\39:F8W0Z>\,"ED&U3+ZH2?LZ50%Z.UM9M<4UZJ+-H-&J5[
ME`"RFBU37JA4PN&H*,]!1M2XV\@G"<IR-Q3HJ=3VAC)<0E9)F7*`8X`^(I&D
MMBHF+E$+5L'F.194?>DXDJDTF=)Z*QL<23#%_('17VVB#$3S-0\WO*"6BYBD
MZUA<!0GRB")TN7*#9.V*(UOX'>TF1.VR#ND0B[D$@^3E*D"+ZS?DY21:=^=\
M%M?V9O>RFQ15'X8"%G5'P9HM]6<FTRE$#8G!O>YJ%Z8*VQE*8]JI8N#XR$Y#
M(W<@%0/'M@UEG24,MV*@E82MU#E(N?E2B`5SZ'9.%WJ8%&V69ZLX(?LBYZC6
M_BV[65E/]W;<A-P,F@E;GWUU@Y"<D#=Q<I-G>5+F:$R_DL#/1D@U"7AC+??N
M(]K-T&I\BFB0CD&C9N-K*?E<\]^[I%"$T))5ME-?81"["5%/`[>R0`S&ZW*_
M?852+PF*/\J`R^MO-^7HZ7$5R4*'<945'E]2T"QKY8DK>O%[V<T?>AKXQ!+0
M<?.36(>7<90EKD=R-CVC9"VS]%I=[&8*/?UJH[!OL)QA([<PIM?#RIJ[I.5:
M8C>VFP/TI,OIF'&#Q0P?$1%`$"V5(.+WLIO1\S18B26@HQ*B&FAR^H=49[O9
M.ZU">"P('14.6>\FJY3]\\6.BGE4Y_-G(<CM9#>-YVF0$PH`4'5#N>IA]RB;
M+Y[=-XXI26T@NTE"3V8G4A<*H-*([Z$NQO1=VYI,BPY0V4<I6=8E:0KF\,4O
M<\/FWXD\[^/LOU&VEW3SUL&9G2?YOC-]U[:RD\M22\%+&/7V&JFI6_65#HI@
MF_#UJ%'@3-^U7=""-`%5]*168:_/#>3E25'+^](-0^1?;-L%V7E!0_U&=J;O
MVIRI44J`:I!2N3F8_OOZ)!4+(]4Y)!K/F;YKRVIOV6@I,\HP+U0?E+2/,YH[
MT_=O>^6PKJ46*!^@I@?E4NQYXO=RIN_?_"J6@);ZEPS4ONXTYVK2[,F0`$^J
MLS-]__97:4%H*3TI-L!6=)3%O"2,KX<=G!_^4H;78^:'4EZ2+ANI>MD=AG1^
M^$L88ON(1TM%2_.E9;7.&]&(S@]_#<-J=^EHJ96I<=8\HLWN^'I(XF7BKFO_
M(BLF]3F^0/M>W#!B+1]P?OA+6#_U"4M+O4ZIB.';R$L0^>S.JK4K2B<7',SH
M[/SPK@V%:H(05>\T76J0E:%E5W#PU(4&J=:*.XFZ@?R.%LH`4@D2U?)C=[)0
MD$\H4A6+T_LHDM>M.(S]0GA\2!@A#"T>AO-.:@!E.2Q7RSO"MJ.OJQOKYYFD
M4YQ`$EY8G5(G>`U[F(CJ&;=E%^WC=[!:I\_4DJ;HP#P!@-D"J">CX'1G]C%3
MJ<_X2<_C!TY=-RJ5PCV7T\M,T3[Y0Y@K=@6D:FY@+ZI^4`$YY71C!B^)$S6I
MNT1!4V8O0\4,Y8X[P8)AZ"A<9DY=8B`2Z!G\7E9KPRE)7XX9DYGN\Q<\>!`5
M]C#,2Y"F<;*]CS-49=P7`"'9WVJEMPZ0R+-E,G^!D`KQ0I$?PF[1-Q,8';!F
M,`O!S/LS#]*@-)V7V7;XJ#`[V*WMIHX!EQ&#20*^N%M\(_O//$+D;W);%:^/
MW8IMZG(7\:([R9MFM;@1#ZZJ&S>Z&JK#U@>TKIZ"%E?`+Z`GCUHV5'_-`M`R
MK)I,\TZC*;U^VP1)81-C[9VB?G8+>:DB),V20&>P[*=^QB/FF!8(6\+=V5U]
M=E>?W=5G=_4[<C*>W=7GF71V5Y_=U6=WM6Y[65E,='L3)&N!H>RHI1EW,SQD
MJ)S#L0M<Y"G6,M.T80`4Z%N,'F8<TL8U+S8WL#$B/^)%+CP'A7T->3BEU2,.
M`/*(M3D"H_48A@Z(/F("PQ.H&4]!M`S1S"/5<![P;K_&9VB>!9X;WD;+!/F!
MN%"X]`A67=E22X;FF5-ASZ":P25`4.=2JK-5KW97=&0Y,QAU(.,C/?0FVG1-
M=Q5TFP,==GU=;R3=K-!7KS$;V98HLW%$P!?H<-Q^AGS7QE4Y(5-P<&M1*%0%
MJ.U-^;JE53>QP.E`,;D!H[;IP@>(?J8;*'B!GXWD)N)*C^VV=N,/V*N!X?*A
MD0\&B'JJ[7;P@D[9TZC=QU"\P.E.(AI#<$J5-ZF3#7!O-#85*Z!^_E#%S'68
MMM@`LWSZ0P+MR.F+#;RS1O\C@Y'-9(Z,%<'8V?A<6*J<VJV"\,B(Y=/8X<)@
M04=P[BFJU8[,&,`ZE0$>'=WS:>0.I`SPZ">`98"E)'P"$^\?<;3)10'E!XV<
MD0U;('7^44Q11Z3".17SEQ3]F9-+YBMQ08L#MQ@]G+$1&Z%YI9_-#IPH?@J1
MXE`:5A]G;.:1B_P%@"-R:9#VO$!>2[U0@G(GT`H7P(O!(;7B*P&MO3.V^8*)
MOSZD0-JS`0:8AR1>H#0M/GZ#N/6<VDV=\1#?)M&X,.@&W-=HG"]^[Y[$6W$8
M9SRDUT1=.=3MM*JN(4&1*)RLH<GN9P+LI+%ZRM\ZM\7_B"FGHE54NT>NHS,>
MTE,C>9X,OD\F.7W=J/G>3&E]279WQ@#,46KK2H$S@X^9):F0*">K/I(S!I>I
M1!-H+28-%C\GM4GVQ+"P.6SEC,'E*!')_9@!@T7*'U&P?LF3M'0_EY5#F:*E
M-G;&X%*.B"3,Y$-'S7%M*K&'D)_>8([W"_'0KD]"W(M?(/Q'ULG2;T!G`BY7
MB9QZW9%7'?7+S1=EN$??BK]T+<%0]W<FX-*@2,`KS9J.&N8GJ,W2`\[6`,X$
M7'J5[GA2>`-4XIQ+=/G[FSC9%0+HC.S10,YDB/8.=1XA52SG$=^(5>X,<G,,
M9S(DHTDG]@#5_YYG*Y0\HA1A.:VP1G"%7E$8;QIJ(0=3<6=G,B03BAI?@*I@
MT]6]9MJZNSA:DFO5%7K)E'5DUD#.9$AVF.X\`JH4C6=EEN1>5NPQEWAW67*/
M5EIS9S(D0XR($T!UEQE)E!KFH?FB\7LN;$HC.9,AF7AZ,*FE:++>=[.7\?J%
M[!J8BDM\O`>8ON(?!>7E;9N7I4YE&&<R)#M35PY-UETNG2-Q4J6Q+%PB,M9N
M03]G.B0CD31+)HLI5R7<KJ.EN]PE!DD0VF7WHJ+`Z>),AV3&D>'&9/7CXEUN
ML?@8L0:45LYT2(85!@.`:A53GOJ6[ZQNHPSA.V-67B;G2:&BOH2";4K'L,YT
MB):5OAQK*4/,\BW%6S?,MKOT/*G$2</NX4R'9!>18$9+)5^^X!^1AX)74ACT
M#I]N^-XN<]C+]'6F0[)K*+$EJGYK.A7M;81_1,_N&[*<?1:3<$E256276,[;
M19R0Q%JUE#E[,+^CA>RS5()$V6?9G2QDGQ6*E'$X<)D8=O99*FN"!PW,/@"R
MTO*A4H`76H9:*I%2*4(%/6WGC>5*7P$PF.E@#<(&Y+6#"?S@O7FH_#C"QPZ'
M#:WF9958)DPK^2$/8&"@3[9UG%/M/1*]K*9GU:J/U/S`2>@YWQ36V6AY%Z=I
MDU:>=L'N9*@6J%FLN.S`R=1%96]?7.3*S92U_,/>5BM,:EUH1WS!R73#GFS2
M4,H.8371I_[%>,2<[GP3)D"]"]9!5A"=SJ.O_"`;Z4&LY@C5#RR%/<'3"M.F
M*?+F(RC>5J6SR+^,(T(WBKS`MJEJ+T1$TL'/TA1EJ8RIBM_1@JGJR5LA/P_1
M?$$E362TDNENP7PE%#-C<4BR,VQ#UFVT0P+=$</T;92YT3+`G)5,7FR_N/\3
M)X7-6V#>4AP)@-%+%F#Z]%#G%\QU4$#ZGG`IBTN'T6P;SSI@UVD2,'@_3P1P
MYCB[,P*>X:[T3^(=L8Z+82?2%_:Q:L[KN$3IZ/)8A(,=.<14<*.UMVKATXL9
M@SV#&4^*?'?\K'*-)E8-=%I$3>$(CHWND53M$BBO=1LS]K83JJ5-3N"8M`NJ
MQ$Z@?2M#=C)I#?%`C!Q)ZZQO8TW40'0P59G#TYJ^8,&M<W:Q0VH[JY;#UB2F
M2[U-+AQYNV]R\FZVLUME2$[@;7KA[.3Z*D("J"/4[ZCE,`9'^S%;8M!VC2$>
M!/*@'?$$9H,SC1Z0D]\,C"=((*Y>X<[F*P^YN4^YVK59`+,^FL_)=R'UY+E1
M%6?/61V"GH9J"TD"U=5E)<&40:M']:AN]V4?4^/G'CM5'JN]J<I!9F0O9$6'
M+L"R,Y6?*Z(PMB1I`M/:U&YHMZA,)QE3>8`31%2:&2/_D63P#<7Y6ZCM#56=
M,;SM,%DQF$WU*LY?LD7.$32MF:DZ,P:G/84#@TE.+TE"EC!TRPP0G?((*PQA
MIYI*+S@4N3.8.[7QI3+3U?4;IB!:,M<"LX.AFBI&8>#QHB./*O=M:Q%S)OF6
M];"MJ:(H!D7-8F,8R4K[9<@[&L)N_8W.H6P*W.G(6GJ*%_E6*V_T6$@L9K0D
M%[7U(M]JK8T^8`C9$F4"-1WVW"J?4\4ZGSK(N47&G41X,ZN+C<#F5MTB42`S
MI;F%P&6.`%G[/)WP88<H:RP=:-_AQ`!(#LX]'V`,L'IKT5D."^;(6QH@>$&^
MFB$"XC+2B16\0!(]M0)M*F7<I2&%D,[`6H9>_'6#"8^R2S==W2"FW>2PE=7`
M6'F5@$XYG#@26P4,;+H].BATJLS!"3QI,2N709'=R>I#^-Z:^"$C`J<5Y4KY
MF7SD!=]N\3_^%U!+`P04````"`!813!%,AF9:`R$```Z)P@`%0`<`')E;&TM
M,C`Q-#`V,S!?;&%B+GAM;%54"0`#1S`85$<P&%1U>`L``00E#@``!#D!``#E
MO6N3Y#9R*/K]1MS_@+OGG+`442/-:.3=U8;M$]4O;>_V=+6G>R0[%(X-=A'5
M32^++)&LGNG]]1<`GU4$0``$F5GR!WM'74`2F<@7$HG,?_F_7[8Q>:%9'J7)
MO_[NW3=O?T=HLD[#*'GZU]]]>KAZ\\??_=]_^W__GW_Y_]Z\^8^SCS?D(EWO
MMS0IR`<V9A/1D'R.BF=R^8\WEV%4I!GYJ81%WGW#@'WSCK!_/NQI'@:O"W)/
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ME>C\<`"KG/3MOY$Y5GA'LR@-+Q.WI1[-GG7-]T60%2-6W9D_T[H?TB*(G5;<
MF3G36F^I&VV;>7/1E&E"ZD;3=J;'M1;]=5H3LJ4@U]3\WS?L^P<KHU\*FH0T
MK-?&9VJTI0`LM*Q0_NGZ`%C,U6V:'>*9T7C[AEN/M[]__U9@PO_RM]HT+1,F
M]D54O%XGFS3;"G6]?,R++%@7-2"Q=`'^;W_Y\9^O_O#'WW__Y[=__>O?S`%]
M^V\U!0X6G-$\W6=K:H5]N0F'*PL>_W9S_8<___#VC[__RW<?/EBLC!LV!H8;
M<)J\^73_NW]KC#:;1\J)I#.3_%+/_:]_*1?3X+;,#O<CR-;U0MD_!Y"K1GR[
M3IF]W15O#O#<9.EVU`;4ZTI'$>M;8ZZKT!0HYG3]S5/Z\FU(HV\Y(_)_"(Y\
M\_9=9<?_%_O3W\KO?J1/$?]<4MP&6RIAP:NK']_^Y<_?_?$/O__S]0]__L.[
M'__XU[_\33E_!L[[\Y^OO[OYR_=O?_CC7_[Z[B\_O+]^^^%&O:`^PU4\UHXC
M?"`$<]F1]HBG[,@P!RN=,W[.@OB:*=@O?Z6O0^I,/7%N]:5#0<$]U4`B1A(V
M%%PY#>Z#5!D-;<)4'+-DRB_D"O`J#IYLM,[A1$AU<XS",:<TOQ,^`)5^D5)_
M4+'(2#\5?]3V\8&!-5$D!^,A],?1@I5>#O\=A:Z045BI(B3DG7KGFS/R!3MU
MV&@(.0!(3:%"2<DDY4#F#8>$#T6E.[3[,ZA#=)LSK7=R%<4T.V=?>THS"]_D
M<!J<9W*\?(5?(H:1>AP*1:,A_X!+(J.]+9-L@OQ1X+#/WSP%P:[D%!H7>?V7
M8Y:I_ORW^X)]F?/J:G,5)4&RCH+X+LVC@2.[5'"L8$*I*DO$CSFPF4;2#6DF
MDGHF\$%^_+:8J#B'?09@Z(?@,1[TJA2SYM:`RL6KV>\7,00^7*2GNU3W:8D.
MP"GG<9#GJ\U]D:[_OOP2Y<[ZK@<(C9*3H'C,6F((UVIB$%-D;!AB):;:-#O-
MI=BQ^9BPNX"+=!M$B:G*DLR$4EM2)(;XJQR(1X&I=T*KQ)3;,*,B8\<,FB_O
M&$B:9304:_D@KOFM59D&%+@RTZ+9LY1B-%F29GS->.64'N.-1JKHW#9.B=D%
M&_T2%-$+)7$4/$8Q<[@8I@W"NP;A?%J$7VCVF,Z"<KN9-#/"#=Y.#<NDF:4:
M%,CY]$RS"*'SEDH-(U6O\LE0%DN%RC'CM<JC-%]+(/4Q"HEZZ;-IP@'%X`49
M)ISL,T7$3@[&&@_,M]!*CM:]T(D-P%'I)DKH-?NG^QFIA0#N3\B0TARX^3`B
MQB$T-\H-LCL/'>_.?"RVS'-:Y*990HI94.:DM_C>-:D8H(D.`I@/PT6C4:)R
M#M%J3RE[S,W3YWNFOY/"-9HN!P*M/%6HR7EH0:J18!+@!9D:B4",_Q,Z*Z#E
M-R-#H&.V&8-B0?Z\3$+^/Y>_[MEA-V:KR9?%>9!EKU'R]%,0[XU#^V;`P$)G
MAJCV6)%-($$2DC7_!VVG(C`L^'':]1X)S(%901[I4Y0D;""/@Q;/[.0B%C(1
M?NW#C7FPHVSKM'C!Q79M%(H^W&NA36:-S.R"*+S\LJ-)3BOU;>MHR(%`.QHJ
MU"21&CZ.5`,;CP.1FV&+"BT'@GC@#IQBXV?H>&T^L;FH8BME]@(]3_/&][FE
MQF?0`2A0GL4@<OU[A2J(5LT@8DHC2`O"IB'P+MSQVI1)*LSZKDO,$BK2>(+U
M>K_=Q_S=%PFV:59$_RA?Y;#?_O=;X9'\[]__L/CG[W]/&(H[NN9W+S%\WID=
M&VO-FA$/`QV<1QV8P>W7,2H#!V3_`M9Y5^IWY>+=*5D?G(G1F2HI)]D?A0$\
MNI3YT,7K'2.Y>#_'G,W=ULXP:6'`W;QI$>O[0N7P!1$3A#)NIDQCDMQNKZRP
MNHJ^<%M3B;[$#(5TE]%UU)JA[Q;?O:],T?L_O%_@-$0F3#MPVS7(L?.)X(H=
M9+-2"]B:H.Y4:`-TB,8Q)XI?B3S2/[4DC5XV4ILC81PCB]/GFKD]+KMK-^#K
M-N,;*Q"+H%QCZ3;)67=:;\_?.H'O`"WN_F87I)LV)8\9,)%H\YS&(3OF<F-6
MO+I>`QK#A;8W%@0X9KG.U,;1*UZGO#,<8Z$\(MJ=_$^$'<:C==1S;,'MFBUK
M&QD]2[X&$>3A&WRILM)`@+*<6J0T7#K+!;Z+F;5"J,:ADS8-<HEORRTFYFZ0
MV6;T)=?K=)\4^5WPRA]VN8;QY%"@S9L2N9XO6@TDU<CI0GQCC)@].KMR)#KK
MI.<ZLY"?CN5FE9]L3\.^1!L?SY0`P$YL&I0DG,;'$IGY06%S7)"!O,NUY!&C
MP]4`A\V8*]:^`[A-"SK2Z`Q`@S8^@\CV/)[.*PDQ8WIKY)X?88T='X76'IDQ
MII%=,N+*.=,FZ@>([B9*"P,N94*+F.8A9CW^%9>E<D>H<T1"8[),^&X@RV&0
MZ>:3(@_6"J.),M?<J&V1&1IEC#P1R.QJ9&*:YR2DCP4)HUP<*%"=^,PPN]\_
MIED8)>(V>L?D,LKS-'L]QK6ZNC[`MILV]>[[=XNWW_^@OZ\>38Z=*#KT,B4]
MKO-\+Y+B0D81$FT."8$H:V=2Q@5WJL9Z4AC<)W>G"9&K9.1/H#W!&ZW^,+]-
MXQ`!W-KZ10!1S-LQU@T=XUXFH3(DPGZ[9;3Q$@4W_PZT'SB"0$.1=.%:2**$
MJ-PLC_C?I,G3&^;*;AL9?B5O>+I@-[*(SE2/E1"7B+VM>(`8?0=KC\',Z^T[
M@H<A^K66QA"M%7=9,0:S;6NO`>X'MMNHV(I7FDEXGB9%E#S19"T7Q(&(KAH4
MM+G5H]F_%FA&"V-Z,!Z5&1V'UUJ'%[B%-&!-P^N!(;Z<LU*41<*CHI`P9&JC
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M1.%U<A[L(G9PM0YT*L!`&RHU>KTP93.2\*$D2D@U&)6A<D*(%VMYPQ!:RQ$"
MMU@#3&@62]1RX)SI54PKI>+9\WT1/-'+A/GRNRS*:?4P:-D^%+_89TR?'<\P
M3\(:_26X5"T/1.KG/S5#B!A#6K"+^ED6Z4`F)6C2FXC"_$Y$HY(*!]4*2BKP
MPF]AAQ*Y7TH<=FB'I\3RH%X#V).]J23;Q/GPID`@`U2VGHH$`K23(D5J1&`*
M43Z3$6KE54DNBTE!U`X=C]!94RCT+(AYWMG\)4+'(W$I#ELJ#,!]1K4F,*R9
MKU`#>&H-.-PTR^$@N'Y6(6A60P#79:\I+KT;8(&1D9K#<#>LY4G3"V,=0\Z:
M[E7[,<M.A4A9V42'#"]CT-!^AAT9=`YS=[HX6DE*C^(*FXQ#_:BL:*BH28K.
M2#HPOFGBEB77@PC[1:<.'_MW3$5OX^1@S<JB=:;FU]OW`%]W^R*83F=T87.=
M44$OTT$/],E1U<C%8=E(%,&9F6C6+22)QD?P+6!#3]5]2M><<>#'XCK)BVS/
M/_\IJ4I3,S2JUSFVGL8P0&C_P@3E?D#RL2#MI`7I3",74[W`<W]9Z(+C#<WS
M/R%^4^B\;_ZQ,8L20^P0N"]GK%",/#A3;0*5*G479*M,-#8,Q<7X'<WN>5*`
MJ5=F"`V\@^T0LH,Y56PN23-2SBZS2'B?92(`H/"5/.!:)9@TF25H?"$[IC7K
M%6O"L5!B*=:0+YL<GG')C#UHT![,(+*#XEC.(>TD5)9^!'Z5"/:RN-#923.&
M=<B$5'`KK"B6^8)N5O$``@Y+>(24J;@ARIITQ.=0O"(I/DBLG(SQ+"R;A.M@
M16C5II;Z,&==<!CMV2&ZIA+6F87>HIEB>"ASJ1I#E#9-PK;.1JW/LU`B>1/]
MNH_"*I;'?Z#)VO'0)P>%P\ZIT!P4Q\Y$TLY$?>(SQ;6+&MC+&F>^LC>$.OX$
M>6EC$7,9?!D[!!+:,IJAK7^R,V_H94QEUA&X8@B]C.8V&_MHSKT@0FH0@1EZ
MG@01=AEZ_600BS@4/O!`BS^,,(56K'G'Q.X-\QZ@*"DC**9:9^XPBJGV&H@]
MR,0)Y=ML:Y2PQ%*<&,C15(%&57KKT(=4S'3,S'$4,\6E#RW(16K*T(E]G1`W
ME%"%2NSYQ\E(009%KI-UNJ7"]=SJ>Y=IE8P*#+254J/7J]PL1I)FJ*;H#KA*
M']@T(Y6NW[$Y'Z>L>5U*GK]/LQ?V'_E'^D(3\TH<:@!PSU'4*/5C46)LV=ZQ
M&DVJX2@.&C;(*-8-^,AD@+<&7I?H&6O&%N,[F@6\6MMEU1[*54VK`4$K:AV*
MO:[>]5A2#\;:^]4-J[H)&$B=-$?^L3$]0UPXGV!]I#EE='EF,MYY<5XMR]0`
MZ8%`&:$AU/JZNQPO+%&W4,6EO'`TB#$:A52GY@0:"V7$@%HK9<)]\PG4CS1A
MLAWSQQ+A-DHB+M>\?)9:I+3Z9@@<M-4:1O>8(ZL9Y6.D@SF3"9K[?<XX](*#
M.>ALF2&K&EDT,SX%=!A-;5E_(I3]DJ$P[`BBL%(F2R_?[*<]GP]!!0(<RQ]1
MQLDG`F">@5*$M=Z`2GX!5$\98+I)<^M2!S(0T)9>CI9:(57AQ*_XP*]QGDFU
MF/`_$\ZBM8RDR<RZ"3T2'IX0^D,#W)W2R+U=4*`G]'/V6DT:B_!C$"4Y7X4V
MVB95W4-@H%RJ8?3Z_5?;&41,*34:S;\&#+EY0FY5/-.,?%5;_J]))#@/3W<"
M0W;4.@1FO`C1%)ROAB]FE;1_NZ4.U0J&`$*[#B8HJUML+X3<58X$21/2_8E-
M1N5;N*`JK!O#:_W,_DIY.>Q-$%4YH&4-)"S=QD?RH8TU-.7J.1,%7F@NN@>5
M!OJ:UW!E?S$UBLKY4-90@U`_-Z`>6OGU"U*/1F'[K%`I?ZJ,'1I;-\1>6B,W
MP%MS"DGY8<=P]_%T:,O51T?)3HKVHJ"GJ_'+![<J"H8RS/"1<=.,D2#N7W?]
MSU(X+6]7!Z"`A:>'D).?-@X.5'6,J)HT>YC(#V)5)%6@ARF*/0:/WJ$0C9TT
M$RI]C-A$HF8,NM#"/51\.!G:7AZCT@NGT.(P,#Q77?TQ9SH3I&+V$Z+HL.N2
MP<V]5!:,C+U,$.:3X<L@XUT(\OK=XEF01VN>D1+%^\+\Z>`0&"AC/XQ>KZ=!
M-:-]IKL@8E:97E7.0_!(PQZS6G8(LQYD73W:X%/)&_+88!C*,00SFX8,JK6;
M9MPYG]#]3*.G9UX8FVGWX(G>[K>/-%MMQ-HZ3TJ&95&KDAR_`FV*G8ESS.\U
M(%)!(B4H'IGL5ZP!%_*9:1)4-$D:FG0UPL'[+2SJ80IFMS'4H^1ISOY7U<,@
MMC0/O=I-@,&U;3=#M=\HJWXJQG6!K&L6[!.R$5MA8@YM-A6`;\MUG*?;79JP
M_\R77R+KTZ4>&+2)&T*UYY.63-F.8_S)1N)[WFBTAX;-MX8W<,93TN$B+M)M
M$"7&9R/I9+`3D0*5(9XCOY1#\2A$[:;HSP.:'0$IB?"!<E_"5LGU`4`K-AE*
MN@H(Y)=R&#Y-IMP<VZH;!SL#WK1=R6CR-BY:(&#-B`90&VC;_J9MVP[*?@X4
M-]%M)GLVYS/-@JE6&M81&#=%IX`"K>V4R/4?,Y8#21-<1*OW]!MFI/RTNP74
MY$VTT)0WJ+94B790431L,T%>WY:M[`A?=8'O/C$60)3<#!`6GP1Q?&;"B;?-
MNZB9,O:,T8&Q==CQ55XWJ:TU1X&PT?W.#?#HM3NO:Y]A:WMN@,MAUW,5(N"6
M?%P)^#'US3(:;X4<O_W]^[="BOE?_L8K#W**55''91+^'&19D!3Y0[K\2(7J
MN6-,^'J59IW^T**L[I!Y'O^!N2VU#Y+TDB(K<&15A;4)@TAJD.0A)4M2024"
M+&%P20?P0EY5?48[/BE9.K=<@CK\0NMS39TB)0')*NKL!'4VC#J:EPNCR1*F
M:]%;3SP,/&7*?`/N&7G3,%(GR9=ZF5][EGK<U%GR\"4HK\H+D290J!.Y.?:Y
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M<8T1"<.7G=;R`*X(2LUEH`D4+[=M@,(]IK=#W4;VZS1F>.&?!'5GJ8=,'O;`
MJB97Q"[,[R=-3@1HEW=U>%8LY"'].4UV^^2)^1]U;U!5@K%1UHO=1[`DQ]F2
M1IL75P?"&W!5JMQ#2BJ(X@!5PP3),9Z7*KKK@:*E"C\PY!5,1'$HCQ31!*!D
M1$`6=QJK2ZSRVEP4R;QZ4IE*K$W$MH0._0S#FAA^5>-$<1/K<-(D%'%0BX@B
M23Y)H@LAH5&,/L5Z,&0T5F-,IPH[R<95T.J6%JO-:L/&,'?V/,T+_RZD^4<Q
MNY0VI'/2HP>O,>HHO6BNPZ?5WR'B0U/YG<[7H',03Z=R#UX>U,'K!4FH*(N7
MUL1;\P^=CGLZAFR-N^J%9J?ES5JKN='>K:V.@U7Q_KQ?BZ]A](:MB#6#5H=X
M8#<OT<Z[(47N*8J>`_L=;[UVD#VG4EOHSQ-^>,J7XCZ=0\<HNG7*89^LN9M2
M^8X]LUCK>?!K+F%ME_S"(A<UY+S>=1_`Q7S/?40`ASON+@0$<6X/2)O<<'V@
M(4VS!;FI;[J>,BI*^*(X<LU,A.MD_<T)W_#+E,#HVWV)!@!7>:4"'M!Y]E>E
M<RL[^ZO7$5JNOLV?5,UYO\>?5+A/ZR)?)]TC">OQJ-XIHEQ&?;F+57M4S+DJ
M_W)6_V5,#-;I4T@BKXYDTIW,#TIT5Q=4Y0&A.9;S,WKUU[/VKV@CK+Z)=*0D
M%BV%FN-2T*60X2$*99C5$^V:X.KZ.)Q177SE4A+FQR1$&U8=HZ]L@JDCE!6$
M7G8*G+I]`SA<ZDJ8250QODP"[^2Q5<)ZW8LRZN>+9E6LKV[N9J"$\>A>_WK"
M(K(W1A&!'VX/'R[6>1,^@WI]X)@C>S)2.(3WKEMQN9\J?7.:*)\)`;3/_E3I
MJJB#64H)&!W14K$_N.0?/;73B+Y]]`!$YNW#$F.%O8YR@4O[-*@;B3F*A-3?
M",IAE*_C--]G],=]%/)US,?F!TFF14J*9\I3!_)]7#"O1>`?)2^44:/L#+Y/
MHK5P5X4;N-L_QM&ZK$LKB_7B#'(.:GT?M$:B[H4Q6K%=M6ZM-0P0LT-7H^S@
MQ(FI)^*VJ=#4W5GL@E=^OJT+SW8J:VT."]76!;8(_;+C][8GY=H=\/QH=Z[+
M\.`R775@40BUO3Z<39KM]:J+&#>=D>:78W\(3B+`IW47*95@5PHC$5VA3&[I
M9_&+UWA+"Q2S6>ZB[F":V?1RP*F$573X=D6\D6T1AWU.8R;7IU/^Q!3+8T56
M*[`Z_'Y2#D9/BD<[&<<B#*ZM2@6J4U?V6GU6/65O+5P55.UT0&DHOY@V=X7<
MVZ@KLVBOB!;D<5^0)"T(#Q;0$']<R)?2FJY?9<I3IU[H3W-BKNA%5&ZR_\@7
MW42)R`_S&OD:975/RTE66J$Q5)LL)>3R"U,ER1/[>[<U$R].W:]-?5F>6;SD
M[;E\%V42GQL!K=)(ZD_P'P\[V/'/2"O[DTMY@`A??I]G^LFN"VA-/_;C8<,V
M?DZ75K!7!=@0)OGA)N")9`".4(/NZ8#N.A"'(?"0+>C^553Y@V.(-Y<IP/?Z
M>@8:>M9F)Y!WZ).,BJ/'*9J$.522<ZKB6"TX8UB*?_8LR&G(,.`+D3+L8!!/
M#@4\3*Y"3IJC\>:1CR3=H9A"X*:X7!])9U6FHBB33[IRC^(L8;]7?.G57JVG
MW"NCG*%I<<*;%J!5&V9A>IW.`(_+]]O.C`S-2P`BB\Y+4>[WD7ZA<;KCK@WS
M8@/F+UPF1=U%OA.\E^5KGTONGS`%K8T(H/5$H6[81C+BB+BFDJW!)5C2\,13
M,H`,,KBK8T,$=Z&6Y&5/(M7>4P7,"#$HW)`W%[Y8U<-=NEH"O`2RKH(H*W,"
MZZY$%^RS+P&_JKN)@L<H%LQ9?O\Z^91$15Y7=NHIIV\LXUF>/PX<UO).2EUT
MBW^L:HS9]F<C[0=)YXNU"KE.B/AH6UI0TF>S%V&`BW%-3M#+O`@>XRA_YD2H
MWGZ2L*5AW'X$5=1J/DYCRKDM_M+I\::@4OWT(DK(7G!:\_(X+#EM5W+:BY33
MH&-9T^A"DY#6)(K0BWVXC*-ME+"%L`_)EO1IER;"1-5QN-YR'*^\/7P8R9VW
M%Q+J;$'G`RH+P+]1^E/M-8A$^2-P+N<@WD>ZCH,\CS;UZR^FV!0*K4C)\N[Z
MO*Q">TA`E/?;TS(;HQ/M,)N"9AU:-5<=6/3_3*K'X7[;F\(;TY>92NJ[WJ8%
MS?N7*?PPTM[$+/=%NF5+7I\WE9JO:%#L,ZHR`I*&K9-]'::3\X3$[$6UJ:+&
MN/B>_&Y;5!SO7I(WGR7M=TGU80C[`$O2<Z.2XPN>)<Q^V`6OHEJY]/)VZLL@
MAW;1OSW>1'*<F%R%:MI13ZP_D1D690J5VL9/N`S0P\:DY)U?GB&2K9`0=SJK
M`Y9_A82R<[$MLF/-])IW^)`SN=KUG=/+EG6XV.N$+2"A:\[B/T?%\\%!S#V+
MU_([>/)VK0EDG*G+Y?!80J\3TD(G'/S4H1@?>;G^:'1\1<K5_3F/8$E:V42B
M65)-J\^<5OE!*`;!Z>,46`K)<<*C>K+,K7723;"*V.%$X.^K2&X;QA-O6KE"
MYMS/0CBO^ANA'W]RW(?,1_>N^AS?U8W0>_/E(%[0Q^(ZR8M,,&MY+B@B=@H^
MHPG=1.LHB'N'!=.$8B?84+G%CH3H9R0^%J2%LR`=2`O2PI*<>!$4!?%$A`Z:
MG5:C&]]H_E"BF=`G_E()`M'E-F73_M%<>S_:(`Z67SU&YK6IUB,$?LZL:\8M
M?'U,60?Y\U6<?LZ7CVS1P;JPS[/6P(+/K-8BVG_*4PWGC,PG$#&#_%+/^2\T
M9MYF*PVSA0?W<3X&O:4%7\1=EKY$(0W/7C_E/*"WVM%,Y#,LF0/Q(I(8-&PK
M%7P'R%#FV(D(O5?#M"@YN09#'E_)5QP2.QA\31I@I(6F8??1!'!Y\>.%#H(&
M&R'-7+)(VB`>--/16"=W]M?:)F?>GT_PE^%_[_."JZ'\EA&.K?::::7\(?U(
M.2&CF#(DKA-V^*4W:<[^/EY-:-7KY.N!MI`S$+SG,;:?7)#JHT1\=<&O&)L/
M$ZZ[RD^3K_C'O^8_GXXR0TQW3LBLH3-OZA6SC_"_\G^+#=F75)4JRC^A<X/F
MTAM&KM1,2F/.",F.<4ND*B^A.&%UYL!%-`X6WH]4M#^C<'4LU@M97F!XP\V.
MRCT.&7';TXDZ-F\;;1NW#0,"O9,90+&?^=,);E<O]JZF;,;D7([0#;'J>J-]
MS:SJL09XD6&)6=/J5XF;Q]>49K%#L%V#O4$Q42?#ER(&NF3&LU4G4KO:\$#E
M192OTWU2W&5T&^VWIJ9]&!"4O3=!<2B`+:XOZFGDJVKBURC\`Q_XA1R_L)J&
MQGLP9DZM2V'*F5!"=Q4E`3L`)$_G:5Y8]S?1P@(/).@1'>+*9@(1,U#X)IY0
M"^N4@DV#XUJ&(_PAVH!7S0[`PXPZGP2R@W9&@YQ>T/)_KQ/I:TA3XV<*#LH$
MFJ/;+SY8SB!?U7._Y@$@^0-P%.;0'5<>=R%,/*LD'H;F854*LYH=8-;2DJ>U
M-M..H2'EM@F)G0>[J`ABUZ"^!61HJVI%!$.!;L/D%0BL,?)1R)\+R<Z/0MAY
M3HNR%V!'K/&%L^UYW\@N6S,^I+0SCWT71&%58MFNGZ<A-#PV6H&LH417L^OB
M\OZ;>XY(,W/&M4:JBG.74IORP948([;&.MZU-,8:QH64SN5:'*OSN_+!Z'@3
M?`P0G^7MHVPHGO5$4LU$;F2'\6P0VLD10F@_%?SJ:#;ES`HLC_S1JY<#K006
M'DLI1=1<$,5S["G/L?89YXXXULC4]A&Q.50SIZ4Q5'(FQM146YMH`1G:.%H1
MP4-*JG\I3=EAQ\E>CD9],+L*G36U9WDCLVK-[^!"?IWP[KU3Y)_K("/+/]<3
MP5+8&V`X4C:GH\-Q_GG4('XZ^><&[.^2?S[,^_,)/G/H1=[F0[I<_[J/,LH6
M&^[YNNA2!!ULC?HP0&A;;H)R+S93S1'5;,M9I)U&EM+XS+2NM7\<Z\;NO&1Y
M](4I+'G8:>JH&AABX'Z'L3`:N1NFDHC1R_#O79R`5^''FYCWZ#`-R@='AM^(
MY^#98\`BO$VRR_BW9PY?@/8EG(AB*>1MIAB*(\/T]#@^.K1I9*<7,S`0CS&Q
M@V'9F/$HD:5K2L/\BA&L+8YS6`ZG_"_*?JG+Y53=6HPM_LBO0'D!HXG3ORTN
M`98BTBV4=532:4%:N/5?^,UR#1M%R&%B\N1!3'75@`5!/BL(`N9;^!$HK;_A
M19IFO`9LEGB\E,X[DU5V'@?1UCIR80<<VO.P)86NM-Y](P,U#/%0J89">`UG
M`0>5KS&6`G(5T2LS"*D6//*KU?V_@R0`^QG9/=N_U>;RUWU4O([R)0XAH?(7
MCI$T]0F8*%?<74Y%D`/@`3\NL7E'9+LU0=5E_W?[C']-%/?7E\#&9?>E#&YO
MVV7</9_H?J2[*BBYVHCJ]8[9=$HXT%99@V"_A5X]E/-PV4)AJGPY]XL$"X2J
M>#/'YJ"W!JK[@PGP`7<$AJ3*R.8/B-2(0A5=/72_?TRSD#?IHR'[^S;*\S1[
M%=^[I05_P5IJZ\%WH_TZ[QX^`](=P@MYE):20R5=L*2%6RJ=A2@[M>+OP"M+
M"?PT=6X2E<Y$ET2[ED0'DK\0U:+$+:+V8>MH"MDWA(`F44,:U>-?)-T@_"DC
M=3,(;YH(X^7.=)<ZX,Z;%1$\7.+@3_(T1UW<V.XZJ/_&+FTFNJR97=#%ND3#
MX^-D<].@B08"5+!$BY3L=G%1]VR7O)M`D#]AA0^7OJA&@_<^89/!;:TYNVE#
M&(.\-F,)^?UN%XMZX4%<UPN_3C9IMA5.FG,U>4.PT+;1'/U>C?G.S+;&/.E,
MQIK,X`EG7GHJ3G/>WY('*^OD!B:K#2A\#_(MV=VLXKX5KX\IC<G51A"%%_N,
M6=M2@9B^6Q@&`!(E&$!)FD+#QY-R0FWOD+PT<$9)/)`/2Y2*9TIV)5J,AWHB
M!'`('XM1B0V2D[*)$*G/P`82-.OKX71+'X(O/*H9A=:)`4?3H6UQ'QW)<V!>
M1%X,$6H`T8V"\>H+/@2=853PDNF[>@DCS2D'98=HA1`H'C=WYL"]BC]8>)]A
MJF[C\[/ZF.6"ZWD=7PP\5.\QQ8RQRJK%0),3G[314]%WP#G_W!@PM`6P(4$O
M7E`W(&F?523=.Q\Q?TI'T=UTC$3[C<`[.L"[#5.RB4D>B$:="`ND63.]6:#2
MDN-'G,D.&I^N-MU[$5ZVV.A8-@0#Y&0VC%@O.G#84'>U.;R@Y;,`C9@C4IW>
MIMU$Z^/^PESF#K`M$U^*]"#Q$L%9SG5;ZR;3HJE!%]%$ABB2LYZA<*J/>V:2
MZ4]]5'5Q:C_$U-*;@`+M>#*(YK`NJ<LDJ;Q,D)"J&W*'.B6H$(MJ;Q]::7C?
MQJ[N&,(660-V,_D<;B!B))PC]$B;VEXV+C[LSGZ>;GEM,;'A=VD<K0=3R=V`
M@C@J#JCWG>B"ULE0=4L;?N780"*?&2@21AG[SS0K*YAN-M&:9FQ<OL]$/OI.
M@(=V<7[KY+".Q__6"6+O`P)3I*0#$A?157&J?49'K3E"^5\%428ZCO%/UB7_
M\P>:;4M7]7@-!\;(RL<<]R50%W0LD8XE@,,C99\WD63<@"0M3.:LDA8JX6`'
M'N?`>;&3T$?6AX-I!/Z:*=I$C$#,^PO",.)`@UA<&KZ)>$"K[&<@T2@3D\_=
M-YZ-?D7+7A+ZY(<>-]>[(@)812NT]$;F>WM1:\.NN0^=YEUYEUT&CS_=FI9.
M0T(C5W[\5T!\>Q_$,5?<56]5B=)NWIRR&=UVK/#>[604:E1/]5"\HX+RVN,3
M&F>?1.*M'],P4?*$P+V=GB024DA4<=0I10`>XIA")0RZPKZTS@CU>D83RHX=
M41"W4;<K&A3[S,[SU<$!]6OU"![S<3N:=**0U7@$5Z+C4%JW*&TF0LG=0?2(
M%3)'S4#&AMVP80&;W<DZK!<TH9]U]*$3<K5Z)/+M;1U=M)ZJPV5&IQ$.QE%!
MD)-UP^8FU$D[8W(%Y=L?DVHGW\JXKL14+N8AO:$)V]M<O2K-"^3Q(4VOJ\$7
M]O1,;%.=WY9AJW3_0TJJ3P^9`6VI!RQ^*QBM96'"NKY;K1:+E,05K0<TI+8@
M`B*'^G\"N9%Y^K.I;L>P[01Z>[X$\`:C9?C?^[S@0K':V-81U@.!>N@PA)K&
M@K0SN+"@JN[KA-5Q7%7GMZJ*SH#[K%8LJWUR8<*OT_J:5VFVJH+7HDC-L;)X
M>*8=?2$2@)>#D8%1*M3#BK#[G%Z([NQWLJ^3^O-E,3"9_\G6<.B#*I*_D=_A
MST5X$Z^(EU^N;XI*5293>_P%=-=#4E4]/2U?]+=$^=-S2_UI>2^NJ3<5[]LV
MUI[SSVFRVR=/G<+8[O%O#4P\H6XMXL:6I@UL5'"$K:DA(8U>VZ,NTSCMP;=&
MG>N<?"K4/06DY\`=<XQY6-XMP\F#PCY"8[4/*&[2(,F727CTD()]K9,]P`M5
M7J5['@*P<M%'?`;4[QY%GF->[[Z]$N`(@]=[A2746S<CJJS,6X'%XQE/0QJF
M!&)!&IYFV7O9Q%7`0=N-LNO71*1Q]UW1T0:9=SE>ZPR[C*-5CA>MVHV&BABH
M=!VF,9"^!?+S)1"?T1>1=&I6\H!<J7-G"T98/C^;G$[R]^=*)8,F=G"ZI$+B
MOGI54VJGUJ>.&EGK,:9Y?OF%9NLHIVU0_-`26#FVQD!!W5@+U&6E!_E44L_E
M:K6)_A[[JECR!GP@3&N$NS=+QUX6(J=S-IR1.9.V<CWL.EH*]7SWV:OL*4BB
M?PC>.$^3/(VCL*R(FX1,7>8UWZPV57&F(+YG?Q&5='7%SJ0WD7X^!G4_[HM4
MO2SR?1XE7%34=<_`[HZ]LH?VCMDG;YR(^%PTQ;D?Z)?B++;P%";[/G1UP0D(
M>BQOW4\LR,%'A-_=_0RW6LV'2/LETGZ*_,(_1L37<-60GX&69Y_NKV\O[^_1
MV.^I!=.HM.%$4CF?6F,GJ'2?\*J,HOP%/SM9FGH-!"C[K46JWT5ANPVR5W&_
M'CTET29:\_>U+0Q2`\%HMH?W3VN+!S=OQM8G+?'[JW(VFX90H8VA,?(][AUB
MV2E-EGN-77=\/WWXL/SXGV1U1>ZO?[R]OKH^7]X^D.7Y^>K3[</U[8_D;G5S
M?7Y]B<]0V3&X6:\3&^Z>LW9VV]G5UIQ(YT(9$@4BLO);35MEC%9"MR%:^Z#9
MC?G8B1?N\G""4H&!UOUJ]([YC(^<[3SBKMS-$;I=/5S>D[OE?R[/;B[1*>P!
MOC/2T'JFFU.&FHR@A(GQO@RF).&?:?ATT"NR7:RMYA[S"2@%/XXL??EL4M!N
M@N@QBL54C`;!`SMH[<9X7D`M&B-LT(AOP1NJ48322$L'G@C,51`[78Q/PNSY
M)<_EQ^N?E@_7/UV2F^OEV?7-]0/&4XT/Z3&TI*-%9\9@!K_B>TYC_MSU\M=]
M5(A'K+86=0`*E-$<1*YW:.],^"=R(0H+%1C-HMFV:2V?T9Y!,Z('2V8.&-IL
MV9!`S[GE;)$+>!+70J,P?UB=__7/JQMFANZ9S%Y>79]?/Z"S/M;L;196L^3M
M^<3Y(XU%;80@*UX?.JW$;"W+(!PHVV*`X#&G5E.(F$.ZDS":&-,=U!H9P^V#
MYTL/AL8&-+2IL2.#!2.?@K49B?SES?+A\H+<+3\^_"=Y^+B\O5^>/URO;O$=
M>1R8W<CLV',Z0'-K]_B@#@1<RU\=6MJ&UTB:W$^*"6"OX$%V&V@=/,1KH*+C
M;`RUL*"MWP"B:AX\"?-FB]WM^>K#)7E8_@?"H)T)2]KUFL=@HWAV?534<<'S
M5&1#T&0]ZE;+#BB4';-%O=\#LYXOXN\'`##:!Z>MUEH,EWU&QMK.5L42.K2=
ML2:&FMMS";N?@C$:3X+5AP_7#Q\N;Q_NR?+V@IRO1/;<Y2W*U#DW]C>R8$Z\
M/V/\?O^8TU_W;'F7+RX/L93SP2Z/U`CU,[/KH:0<B]$2#6V0_K)(OSMP;.9^
M+:0$!&TU="@:<![.G`,KI#Z=W5_^^R>F\LGE3USQHU/S@UQH=GLSP()S>FV=
M%T%E>UF=8"D\70T,N..&%K&^O]49OB@?)[R27ZK_!?2Q?"!WET7,6]C%E'?=
M.WQDB,9(F3#BP.EHD`OG$ZM/_%7]95Y$V\"BO8AB-K19ZB%SS%^?RHH*S9!9
MY<?=,EGCA<X:R=G,R`1)>6Q&NQ/DS_PPP_Z'IR^\!#&W@ZX&R`@8F"4R1%56
MM:0\^_-_=*;B$:]Y\,5CHVR85F^L+#AV1$VH.R;;1F*E+C^C``%:[TF)5L_Q
M*0?""XH_7!!59+)=.K+"2GKA&"ZCI)6,,576HR\T7.8YM;:'0]-A:J?KT.G5
MR^:#23D:7FH](H.@>J3#V@,Q&DDYQV&YT!0>'Q(*B+=<KG;9`!+TD5&+I/J5
M%2+7=A+TT!A`<V:T?/@$+EZ=%@--/:/.:ZQR>:8'2S-@X#WR!E#5]"(YJ"C6
MF8M'#B?#/"$!^4C7^TPT.#H+\@C/0=.*B<VZY1EP,$"^X4@+J(0#;?\T"*IS
M#/$(G7_<$-J^(2:TRRZ$MGL?:4X957A4Z8*^T#C=<0&__+*C24[MK)X)*+C'
M5R9H]I^ME+-$>+$SCU03T5_X^44;C9VS8-J!QV:F'#MCOLISD%'F5M#P/-WR
MA915-G=5Z4VF.-@2F<=\Q[9,[9;JDQ$</@%M&=W(TDL4X5#>/'(PI`MG04I(
M@N,;6$0`.PWKZHD^_'GPF[,>?=`9X1%28I9IXRPB\VF*RR!+V!DDOZ.96*[C
M+>@0&"B3/8Q>KQ]--8.P*43,P>,:>T+QEA;D)LUSLJ-MBQ$^%8UM-N1*K5TV
M8\D9JW[2SYTBI%F:L'^N:><D//(\:@T?VAH[$*3/R9\/ROH>`,'D6$]-B(^4
MVQ(U+=#97E=I,#*\CJ(`ET]NJ@",4NS!I-THA]^4HWLYYLC-L#<\T1AA*R:U
M>L<Q5@@5R0L_IJ)!/<,T,T@G5R=GZ."`YA[I$3SF+#&:5,/AI682M!!E)+E@
ML2Z'(TM.,I"CX0RE82$:(>F=0-M]$3Q1?KX.$EL#:@,*)'W)&,W^M7\;9A8S
M23457@W,@26"A"<O2.4"J76Z3?A<)*E0=K*G3HNR$KSY7'-Q&;_:=+M3+9-P
MFNX[H[X%?7P?2:A>`S4.CN>$''2=XZ'T$^WA,P=]T/@-/J7'Z(CO073FO!]G
MQYX]_4C7*5O?B->NPX#@[L:'4>P'K<0<TIF$*68W)9[@IMR:-0?NP,WX<I3+
MOZ;;1YIU^]S?,=RB/$^SUVXCIC%'?_>O@`8&QA"G[X"6L$@7&&FAD:-V7M`'
MBIFIPCCS.S/2((I-3$*)O$N$74N$1!!A5\)#%MH8K46&`Q]C5<@('7G/:.)-
M2?9/?B/`@X1/1I&C%Z>O@9V*7IR-'HP/WR/5B+/1`*\N]"K&@T&=T2IBQCO8
M]3,-]S%_G%"_4R@?Z;%SY$T4U.WI/M"`E[@+5TGS8$.</1\X#NYUP+Q^'#H4
MY)N4/3FKX(LG0\TSFD7]5I<'B3J?(?5W^#N;HU<VY!?Q,63>ZEQT%+1[*6FW
M:9Y>Q1W2;3NDRQK2/4(]4)I1AFR"3U-(+\`K18.E?DK2QYQF+WS%U\EN7_`C
M/F,;QC/<Y%H'L";Y-O@;2+^$5#\<7)BJN07I?H^(#Y+#+X)K0G"2OM2O4(OG
M]G[TAM]*D0<F;U2N(L%]N#G$V.Q9IW\9AO#^EDD1A5&\YYGX]WSQ`J'++^MX
M']+PBFT"YXU]><98;8[3BCVX@-Y6@,</]$A4G3/8_0QIOT/J#Q$N0Z3S*5%2
MKY?A#ZX+$5!UO]T&[,#*Z!.PK[QIJ)HWWT'L`/J684LOT+,`CXD`-FLZ.G1?
M,'6=!LG@J542+K`#"1/ILT5;J516FW[TB@$A',H<:L+F3M(SZDST>Y&KD*$>
M,R@8(G>S((HE1N<DQYJXG(L0>]%#;7F>CKO(W4>Q\_F'-*2Q8S#-PY=`;VW'
M$DFGQ%J(!V?&%B8I@2+0:0`$2LT)A.@6%P._(+O/]:)GAN]T?2@9B+.M=+7+
MHCG!V[F#H^&#O4%S)XB#"@F*SB4%`OV*C23@'I8O.=&_>1LG)%Y\+U[BF_E[
M:TK#G+\09DL0I]'59D-YB,Z/WV7[%20^ESUQ=/93U(VOP9$:'N$`20,19YS)
M.UU^S$1QB9H864V,*.$/WA(JVG:3SU'QS%1&!12EFS6>%&S`/@XR$K9-$YF6
M7'-F:>@C8I0-(<H+B8!1;9=FXJ$#+Q)3P+S^F4+\'9PN-PT#X7#)2_Z(BDAE
MW9]\R;C_A>WG6-?+^4OP3M@((NE\#W5=+@&ZJLZ5+T@-'5P=STBG-KR_?F8_
M,)^,:>.TA$+2?9$701(R44+HG(V5*4,W;:1`P6J;N^"5&[OEYR`+NTMN3J;+
M/-]OR[_YRESS\G4\5Y:>B&FJH:J/$/&5GHIJ/D4ZWP+75["4_)E&3\\\OS9@
M!U[^,'ISD,51*[.G+$C8*#3NTK1B:WE3Z5%FO9Q0Y4KWYR#CF^CH*_GX!/`M
MIB-9=`?4,M&A7Y63U%"1ND4344;J#WVN2:%QB$!O/D'Y`MW5Z!CE87)5.D)S
M>%&.JY8+ZX^>O9X'!7U*LV&=:')VM_D"DK"='5%TG-^!U#+[V2NI@8'KP1G(
MT:K!CLIK]>#C*UE7L%`&Z.9C!C3NY'@=81-YLU<0T$7NEWR53Z+8Y]FKW-VM
M/-T?!3K7R1W-HC2L3Q?+\G`A?KQ@B(Z]*P5=)%BL#WAK3$OVD\Z2N++3'-";
MHWFY-NXNEJM;D.9@6BVP'$+X$F>^"7:(-B+;J8%#?F.9`$_Y".7<*-*)0!.!
M!$EY<.,YC4,F&[S?=2$2'VMKMLH^<D3<:[BY?PA1Z-.:1+HH9W/?6PLKBH1"
M<*PQ!2#=1,(VUN@D#S!I<AN:931\"+[(WO&.SY*S`0]_/VM+#GU"6`F+]^%3
MO=<_@10Y?P0):X(4C""!M#\W@CM7)XDPSH>S%P<(K7"YV?!4I1?:]%G\R!R<
MHP>LGNY2';Z%QWUP(I1.1AJ`I&WB23A,@#?L?GP-+R0Z0KYZN9X70;$O>+R2
M:Y2,4ZE(Q2^T(6/]"V*?Q%W:+-T29U$#*4VT+_89_1`ET7:__<BCI7%U-,NO
MTFRU8X<OGB-X0]FA;;2?,N9C\%[+.%)I2PX)R*0"34K8=7PH)YLT(PUX4L)'
MH)G`R+4IR;6MR!5S"+P$&E@CJ@G9WL[S&2]@(^X55]E3D$3_$/KM/$WR-(["
MNFYVMXQVIUG[/?M+V39++,;JDM'#YT!O'+V0ZUA,ND#)`53"P!Z6OE\QQ=,4
MH&E!5YJEITY@+Z3\,=?P[90WSH(2IILHH=?LW[E1)I.G3X%D-'DCTR2"Q#]`
MQ!=`I&FRK1Y,<?'*4B.DZ&R?,V"YB`'N@SA?/N9%%JP+*T.C!`)J/C2H]3I[
M5$-)/9;\4H]&DW#B@LY7]>"O<=FJ(:X;MD`#+#=C]VX15O]`B^<TO$Y>:%YP
M$5U]3M@N/T>[.YKQMK#!D\QUDS=>-@8(UM';`N5>;V\QEY2323M[09KYI`6`
MX'9^#+(M2KMF&#^>?60<'(0!N,5SYF%]UV]+!IZQL5BE-)9KML1<-$DI%WN=
M,,9@"\VO\WQ/PU7&_Y>[J;=[7DF[RD.M?K4-,7OZ*G2PV1OQE-:J`WE!*D51
M`R?E=))FI`:_(.4'FF<]_F^Y1[0>FXI:8C@3<8YU+H;R/"CZI<RA%Y&PM%$[
M4?4Q--9_&DDT:U?F4PSGUUGGZ?:1U_(7#R+I3HG%=2)^RBBU=SV\?`O**_%$
M**5VZL#E;P7I3J^OF%#6\!=3>C0N(>B)2'5WX.0$Y92PTE)HG!V?`J7U@SQ*
MTXSW7M*,(?'7^UT<&<<%C.%!NS4&"/=N6CI3_JD6?#ZK?D,L)B)R1EQQ)#G_
ME5];1RD):;[.(I&(BLZ=,.5:LWMJ,Y8%Z!9AV.&"#;A-DZS?\,+4#_#W0?"^
M$!Y(IFX&4?=_$$'91:<#!$^OZ\*#O#&:>(=-+*%O?@(0O;/7YI]_CFC&:/_\
M*AI5++]$LDLDK;HRA`IM&HV1U[5+:2:07_AH/)>F;EML9$&L]A>`F;MJJ[_`
MBW0;1+WGH(.:Q`@HN#TP1%VC\SL,70Y'J-5M-MA,<UOL+@!#B[XVN9"L=Q]$
M\T-GE2P!A48/2]'4*=]RPJ)JJ?2._%+.PG"GZ8;<O^_3LKMIM*8Y0Z^LC,$<
ML2#[.ZT2`:]#7JYQ'<3U8X>O*O2_5N*/QPBI.=G.\BC9&%8ZOU-*IUZA24"`
MFQ(I6N;2^!V0-'I`ZCYZ2J(-$[&D(*OBF69D==3IKA&Z[V"%SIJKK(RBDBMA
MA>R]/Q/X'K$)?.\@=.^G$[HQKU3LT.N*7[_)9"-Z[T_,WKWW9._>`XEB]:S6
MSL(=3H*R:<=+[Y6$*'_'9+&&EMQI@]#MKEP]#2=1DA?9OLI"!5()8[9"O6HP
MLRKE?ZTAE3'_:875;S1YY&8*T,O'T9AG3Z34&72KCO.]0'S5@OX&-N]\1M9P
MLJ8>F1)`GF]I(1"H%_^J26K7'Q#4D,!/GSHD-;VVG^N0W:+;<_N?<GFG;=X&
MHR"?:49)L%ZG>U[O2<18V%^[5:$2PKMEU#+VR/D`C5DR9PNS0]\03\"=_=I]
M^_<][R!<!.4;:[9AV_9-]=ACH>%7T)@D6^)H0O_-6;(%MB!=<*0##]TK03]L
MXW0LL^(9Q`*D<_>,0DT67P"W,"Y$\2<\P!Z:[]UTB2M:,POL5?+/4?'<#4>5
M6!Q6]<@_'CF+E0T5L)PMD]=%H#%<GDFK.U-U/E4VA9.%%8\^U\UW$E]L1?M5
MWF5R-#UWHN[E?1%DQ;@PZ\2D/:-/49*4KG#,'VM,1(E+=D##3(?+LIBW@@AX
M'*$IE)B=GS2!!IO/&%PGZXS72[F@Y?]>)VT@(?SO??G^+U\ELJC"><#0H&&G
M%^NG)*19\U]EY5M3=VN&E4"Y9;,0N??8K/HH^:K^[-?\84O'J^M\FX<!RMO@
M)N^B7<+7I%K$46_F/5](]P\K:88YP`4#",'/RU=\C,:'1;=#^6U&E*SC?5CV
M=4UH06+>]97'9T15NN@+V:9)\9P3FO!!?]DSE_K]VP7A<BQ"H_705QID]2B&
MKXC'D_?OQ,CW8B3[QW<+PBB_*RNWQ2#M&*"$WL1[GTWWC*CVT0+<U/=(U^U%
MF*G_;0(*M/+'()J:8^IJTS8?Z4Q"D2[@AMPR#*.R+]\;V?4GHJXR$^P;LI[-
M9@(X7/[$2/I&*(H'!C+?\,?/S9>J[W0^4S,6+Z$7A=?)>;"+BJ#'S=(Z2Z,^
M`%)(:R1)>FW)*W"B-E;+QG6F10<F:8$2#I6GO59PH9L"3D43YO%(=14OJQNT
MU-AQ:O"6]A-1P[Y/X(0$Z3B$,LJHR8*D::`/E:*NI^9!GXQ0E^=IPNQY+NJU
MW3-7G>;+NZRJL2X>CEJY5L/00+TK$V1[YYIFCFAX*6:1)6GFE0^G$3Q+<,:P
MZV6M6VPW-!"E>-,.UKL&ZWP2K-T=L.FV%ID?9BRPPZZ8J;2"]$\(,AZ&SN]H
M5C>6BM9GK^?I=ILFYW&0V[T+MP<,7Y/<G`3:=@@5%%[)I2PVM1"7'NL%[UE7
M`B,"&L\XYT$9'OA^^)R6?ZSKW6%[!N[,*8;5MNW89)0!YA"%N-7G(;M'$`-0
M@`VN&KF^-A:L6);O&,P5AC.PUA@)4]DV'T3WLL&,#4W,B9X'_0A)U5#0[*V"
M?C+(85R#BE8BJL$X4OXGQ03FD#?$8NH#W`!_S5C05V:S>HD\ICDJ`]"@DTT&
MD>U=Z7MRA&X0)^";<8#1!;_1]L_'V\NDB,(HWO,;O'N>0B!NGRZ_E+>(5XP\
M/"%\7Y>>/U[]<LM3P$U/"WX^!G6"\$6J7IR@`Y>T@$D-F7`F)1W8JN-'^044
M;]:FI-6;AEAY`QG<UDTB3]HSE4]A&N%"=IX>+\L'(>PK=VD<K7G;R#$]).P@
M@Y[';(F@>[_=`B`U!,Q-**9&O6Y8@:Q?A1/;#Y_U7'A^/F?A+DMW-"M>[V*^
MOB3DM3!W/*[\*:>;?7P3;8P#AR:@H`R]&9J]6L?5K`41\T2.5#-S0<JYA$]&
MD,KFAF*%0\Q^72C:)(-X&Y-A`^9&6$B:UDDP%[,1+@`OAIO?!:^B-Z)U3\+^
M;%!3+D/FF'/$&%(-0O>J3[\GPS9(M2'SV9D+^MBYI%?44Y7*C60FE!61(M&O
M2?+8S>P!K(AJ2DX3K:/<!2@6N@VV5%G$5!OY4<*!CM-I$!Q@L@7AHT%KE;J1
MW";,-K!O(ZP=,ZG;*,_33!2!SR_X4QWC.Q/E9)`[$PTJ$N^V&DI*Z\<&8RC^
M9(O'_?XQS4+>?(.&Y(__A^Q:O!*!5\CP:AX\\,<."'((+?"3X8,DW6](<-0W
M00-2XU685XE:GM7NE@X.J#NK1]!(RMD$7#42'1`S$OM[QLZ-W'^/*`G/#E<I
M;FD"HP;<1,;XK#(L=Y[.M;KKWKZJD\\$L?$J)+02TM,#S5D7^);6E-2#)D6W
M0_.=4F[2(*E7<;[/,BJ]2]5ZRS(0T&<3.5K''"=&U9RU(-5`!/<:=F@\I$40
M5YIV5PY&HV@-^,SH-*5F,J^^U\/G=-19JIV/Y#C51<C(U^)I,7A/53ITNF>F
M[XB1-4%YLC+<LM:S*CZG:`]8/8&R.6,=2Y-?46?C_1RTNI"0';4.D313`'S*
M21RW],@=G*7>(]4'D^QE1S/P*>A/71))=#EW]<5PQMIS=:5:MTLCU72P>HM*
M='K5#IH2O7COD`8V1U__4+LS\S%8_9:8%VFYI]E+M(Z2I]5&LKS\@:TEE__D
M=@/E]=O0)T//A#21AQSO3=<4;&5TGIN`I\;4(*IA+Y^8#>&@+4Z!RLD@1T`-
M*FI>;<8B>H2$%1'[(YX3)D$]%LG1;DA$U.>Z`?GP%!Z_H$40Q76&JE.ZMP$X
M-(EA2G3UF6+5M#J=&V$VMQ.29E<'2!.YS;G8+G-.R\)0>5#7">,+FA<?V59=
M;C9EX<8[RGB+:=0GX^1M.Z`X$O"&41],FZI!$`YC01HHI`6#(+5[+-HM6E&-
M;\8FX\F-=F)IBWQ%,WZ>3X2[6L7V\'@P%_KP=X2(UE8B,(B&R_[C_R&]Z%]U
M#TC8'_<T1&/P=!QE=&Z4L!.4*?O`JVA%Q>L%DU(WNW4``8>1.D)JT"+5XPF?
M@,[V#&!S>R`J/&`>2K!`8F9D[&9A4R2\-N+DQ6%?1+EX'[C<IED1_4.<A^]$
M#PBK4]<`*-`3UR":4OFH9Y#N%%+.06!51F`6UI@%7<QVTV#F?G=FC9RT9C,S
MJM&:MN4-D-VCF8G@\)'12/YF?>&[IC3,>?F``;]3]6Y1/A_P+:\*(<D=KAA:
MUML`]$9/"1''Y[H3H`+Y5E<K,T,/='4",V.)4*YDA<ZU/6-V9D*?,`^0Z(4I
M^8^E64'@!Q@M^:#2(?U"LW644[*3H0!^J.PSD-&1LL<]4`?*3TGE5M&P-LAW
M&=U&^^TM-:YP90,2QY%S".W!,V@'0.M[?U7!^'I!&!@45F<<VE<'S9>:HJ-A
MUR]'8Y$<&-OB+&O"U6-JD@;Y<V45K]*LZQ]W`[-6AUQ#D+`E?4W1[MD(-I%4
M,PF;2@Y/P0>7%@CLG@=D=Q6RO%?9@0`>WE@@.A+/@B^R$[*='!N40;818D_!
MM2[DU:8.XAGE)1F``<E0,D)/'U@[4"D\9%//A$];<L=.+E/<V&^GPLX^EVE*
M])!D.IF+GSKGR5CVQCQI8;O]'.1MNS5QD+'KF*B"`?N,18E8+SA3C>Q&;<O!
M6/P,!UQ:[Y[DT^`RXE6*!W20>0D#8F3P$D4K0S-&SH/7LIWK1IR6\GS/.YR?
MI[FTBZH\D*@!`18_UZ+58[MJ-&>[,E!032!B!H8PNA4^I?O-F^<UOG=48[26
M8007A!YF/WT<>I#W1MC*91,OJ+I@54G)R9/XP$`JAUIYV,`%M:EV!.@5/6_C
M:W4'M69^*5B0B2#38QW66&\:K(7P-:ZK-'$$T$[/BS@RB^X@[,-6WE[2,:18
MWQ<\);Y-'>5_^\BVFGZ(DFB[W[K=*EA]`<<E@R51;#.Q2Y"=-.PR,B&@+D@%
M%^$EQ$BR'";0:6.?2*XB7(3#,7/;4#+&>S55?XV>V_3.Q951`\/@O^A055BQ
M,D=M)3T.O,-3WF(L@NR\(SD=^$=PM$_B&T.<SL>@3!I['$,".4)_U,T<1>;C
M59K=Q<%:/-!</LGKP/6#I0,@0"X8!M$Z9K.F)VF9`LJO,)LY1$R"OU<8BQ0/
M'^P:I())D+*_3I@`*X+D&L%,N-17"$:2-9GPUTVZK%P(0Y"@CH0QVO9*8M&D
MBN-Q*\:C^Z(2M(5(C<\GP=?=R_"UOS*$=S6^R'P..U$>]CRLY'A,V94@RL0W
M2O?F(F*,LC7S.Q1384JNJ-#0/S.I4QKX8'C_P@Z))@^QS@::I.^G0ZF5\5@@
M<1_TLJ&IMJ(3C#E#DMTH:7EBD6<Q#W1BD8.!3O-7H]>/',HCZ`BN2*9#!OPI
MP`#[&3;PT?'>G"7:DR>VN5LNSFTT\8P&&:/_5?2%AG74T:X7MC5<J$B^`P'Z
ME=Z3IS<<AK"ZBVZ@OH)#!*`FKH^JE[4'`AQ&ZN,T2/@;7DQ/!ES97!N==^3Q
M$3ZM*,;?"]9=)VM>M)Y]C1<GMSI4&P$$/5(;HBQO6R")RI-Z*ON'*.:.P%:.
M1U02NR91C6B4P'3Z@L/U.V1G:!NY'3Y!6P@M5)K`>9HP6U1$O*&&^&?.'_WS
M9Y"R>T.#JU4=0!Q)`'J4!^_\.]/K_\A%98_Y'_1Z1Y;[![5[L&`2VR`GGOJ2
M)O)%OF+B>Y'&<9#E[5]!*BJ.9$G[R_UA!L>0\G.QY[Z-72$>2ZCPIV]#Y.W2
M>$@Y>ZI*/2XQ_-$8JPK#=5"'RM;QP8EVYWD+YAY=3)PVU8ZKQ.8+FJ^S:"=S
MQ#0%E[5@``N,#Z`GKVM-._6YJVFD,P]!$'P,;DW%;BYCXG_#"7%S+4,^Q<9A
M"9D;"]Y0L7(#J9O/U%\GX7Y-P];E6&TZG@C7:I=?=C3)K<OFF`.&-O@V)#CF
MX&INUV%/-UU?O@Q!5``0A!I\(+U<K[.].&M71K[TZ`N$I6"MV=O(V-OR]KR>
M>[NL\WI?6L^D?#YX+0KW6AW%+:!"GL>MD)=Z\"V$YE`N@H6M7U^"(=?2ZL=`
M1_-1>'>T%Y/IE,ESIRZ7-`<']`ANS^"#YW!K[AY9@>.:?R?AM=?3Y.>H>+Y(
M/R>5-[#:L"_O,^XHW*5QM);5X]`7[K0"#EX"UY(4BE,W:8$0#H5P,(T[N=J0
M!A(I0:$X@7LE0I1P0UP3X3,G0LB)4!\8F&,2-43834.$<65U@:B`[++`53^8
M5>-U4`Z>=5WSM0]I4CS'KUS1!G%,#9/S+$&"52&R0ON8E3_64&2JK:/5*EBD
M!0;=5GLTZBHI[@CPML(Z*N'4T59@W8:"%@P.DH")F^CKJQY9R_V8_F][WD=.
MZ,2:R>S*'TD!P/9XDZ/4NZX3PRJGJ1F(QV&R0Z,T^-.AX>[R6.,AT7O8"A[I
MI,:@PYQ:9$9(\G42%5$0\\1EL4FY1?]5U5P0MT*-2#\N*4:29JBR92F,<1C8
M$K45T._'?($V\=9>T85=&Y%L)T+'O;LH]/Q/_AM@JW5#$MH$;8\)/S.OF.D<
MV12H<.KALA4<`MA[?)!P)L&_/J'GXXL/P1=>JD/)&5HA.)P,K4N.43GFENIW
M4"MD04X;O2+;B!EYJ"SW8J==#B=!Z9?CI?=XIOP=C^>BI;E6R\@(/J:'@+B?
MN>?7,R(%^#&FGW9I<EEU4&EJA=J=5\VAPG82L$!>T7!&3";U;,*GDWI^I]HO
MHB.O!Z3+V[RH1GK/D6YZ[G2:?B`Z(,^(-;)CM+6$&S08L!3O,0?NZEW":G-/
MLXCFR[NL>NXH/K],POI;RJKBDB.C+5"8([H]ZKVS>_VTA6FB$@A9D@9,I;P8
MH$9-@50EGP1UC="N#S*L&KKL&KJ(20B"_CXY@&&:*S`E`>.`IE$38/%S#Y(Z
M'/5QD_T1*NQ#D/V=%E6M@X[J7"4?:)#OLS)_DV;BCU9NEAUD4%?+E@C]4Q^?
MWQ8E.7"_5@GI0"D[X4XBPH[O,3TAWY0!.4BJ8O_8=I#G=8[)5^]Z+YT`?2^0
MO4?FA3DI@6%/S$4#S!=1:&J\+)G2W8JL]+QV$E4-5*7'Y&%`4)$'$Q0UY94Z
MLQ;MN1'+0TT7Y"[!>Z\Z<I!)\,64#V%%[&.4__TJH]2E"Z0U7.APL04!3.60
M3R=\/KJ6D!Z0%LAM.'*'_<V^^@[D<;0?)K0)LEMR-K2UW-%U0<,'FAGW0!B$
M@\M6'B!H;BK+:83/0U'[R`&Y!HDXVG!Q)*\TR/`T2C+E1P>+V6-&'%+V4QJS
MTTT<%:^^3*8",D:CJ22"M4RV$$[!;AKCW>#WTN+WU?O3L)IZ#G>VFUKVQB'3
M%]%+%-(D5$BTM>8[@(?1DAXA;"V]]7P`V?6-:X-36./T&M$XS,E7W^.I!&3+
MO,[F5L*Y`")Z]GH6Q#P`?_],:?%CENYW4?+TP&]GG`VN#B8:4ZM'7"VF"_+X
M2JJI1,PE]63RBYB.+P7*9K?MC,_P5H/P="?:>A;D4:Y(Y]4K``48<".C1*\7
MJ.\$XL4XP+1?)U);J5CM=@%P(>_C'J=\0=<%W99U8O,RJ=99L^I@HM&L>L0U
M#E"77R'3C\?OA9,N'=[<&9N"\QYB:;(LFM5)EFF7FFH#$JQIN!7:O:)YY6P2
M%$3%U8J$5P`_?ARJQWTPLNB%G3A?:%ZF]&1T'0=Y3HI4-"%_PQ^Z!KN(U_A%
ME_/KP.KZAN36?#Z?6)\_\T<1W;J%-F*MU8LVH*%-E1T9>JEL8G:.0+`G1/(Z
M66<,/TJ^"FGYKZ]Y2'RCD'L21\$CCSCQC#:T3T$<V-_(A-OS_HPB'V39*UO7
M1[I+>?&CTJ\8;<UMP4)9='OT^P4[RIFXS?EX/.N'Q2_-PV*UA`LCWQ3J9^,2
M^KE-6=T)$<!GZ1U%06OMW>1@/O$OLVK/#K-JW2R\#A2T1=>C><SJ58[Y62_W
M?C*!'E/$>V+<P*VR`8L:6>%A_IRW^=9#U4#(SK!*9D(VT.HAH6^1A<DD&BW_
MYS39[9,G_ACC)5H#.Z^F#&%BF)1\-*?M63.7F#L,=S$-GYAQS,]Y"Q"VE4'L
M:H.&0<+;(A.T^WJ[GD6J:23(23L1XQ'3#=/++VMQ7FHZJ/*>R:IG7YC-EC%W
M&YHO4]:>48+WCWD41D'V>A_$_(V6>)-E<9FF!@!EU'0H]62R&;L@?+1XGUAR
M):Z+M,%]TIJ*H4V:D=_:[]\&6_;/!W:BS`-1%=#MZLP`(KB],$&ZQYI==EP0
M/I'_9V<JWBLT\UTV4YRF6SSC]9F(FM"[.%B+2)'E39E\-MBEF`J9?M,H,9`T
M(S&=!LRQ:%:_?-+A`'=AI64N_=V4CK-@6E,_L(^Y5-N3PH!6Y0K$AMI*\Z%8
M2_+I]LI(/6LV"H[CE,[$8(_ISFP,C<T/D#'C,VR%_?1[8]RGN[<Q\W'77_9)
ME&;,C4ZS,$H"GMRKB_MIY4T+"UJ_#2!ZS'_E<-(=#QDE](G:`4Z[XVZ9:(,6
M)IQJI-4-V'3&8V/!%B#Z^:QI$F11:A6BD$X&"T\H4.GQ7_4SNDB$;BOT40C-
M/LS(2M7'/R7YCJZC3<08VRWPH`0$K<1U**K8;$$ZHQ%'%H9VSRR@,+!U(^OG
M\09D'X+791(R)4KYF-5F0WGND$WU>A-`8'7R#%"45483W?@(FRB*X/&IA,\E
M]60\9W'KS=170#/<28BW-)+G/66SVRB(&Y5]'I1OVVZB1"2O6Y_F1W\/6JEZ
M()CNS9G\P=F"-)!)`YK4L,DO'#H1X/&I:E\<9OE>;11[S9BU>=AT5I)/9NS?
MFH`"R\XT0E/>U+1MPKSH/K?H3$51B&0\BNV-N"0;L]<,#2Z[TIQE]1F5QOPZ
MGSBNBF>:W;0)L))%V5H\$Y#01LT,[6/>%;-(9YI"/A$%?]P0;:HT1])^T>`F
MUH)KC:RH.<O.>5Y_IN&^N0`^>SWG#\]4]0OD(0L-"+`PD!:M_BF]'-WFISR^
M$C$#LB2!-;&-HD2#FS6CD\8_72W$^>0C!P*M^56H]?P4P61M6A3F$X=VN\S>
M>6GV:D10:!F+T>S$L=J<!_GS0WJ8PU[72#<*#!D#`PD.6:!ZS&KM5%%TFDTF
M#VGOE4,-`+IEP@A$[X+.$TME7JS<YQB-IGU7!+];6JBW%$D/!%MI54?^+$75
MJX8Y[ADC5R_J`NIF$$%[')@B;:9H^@VF9M<R_E$]4#7KXQ8M`.IETMWD.%8Z
MIH<KF((9*V(F_HNUQ'I5-<LPC/A_!_%=$(77R7E9"<31FU%!0^+.J)$U4S/M
M?,(!\/NP"@0^C\8"UQ:KJA[,F_5$6/EP8$9M8J';1+0^S("0VC@Q>@GUJEHN
MFH!X'99Z'>G%R"`B\V+D2)NIEW9N$Z#MW2!,?4WB']<.5E41BFZU"M1.C/-F
M%O+-1._#:$36Q8=1R^M$BJ9J4U?%_CO1<$=_Q@0R$M_&C`C6BJ@)<53@NE='
MH%>X7LD@0QB#LIIEXSLGK\X==JZA`UI'R4(3V#A-YFI@;KVV2L9&A@P_@M;-
M&B"-5X5'&,S3<,@LJ8)5_\W-$O:JD*0)_M"4G2(9Y^D9:)&)E.1A?/Z\:5P]
MVO=3`D;G^FE(8*T(CV]Z6FCX@EU.%.C@>GQ_U^EZOJ%!,44^E%_7;]S&%X8;
M?P)^WY`2<'/[!C3`1`JM3F'S=`>H`8S6NY.0P%J1-9F`^"\&K1"7H5C>#(K2
M[DVEC$!4R@AX)E#U4F>=YL6I.'-N'%#H.>"$/#:5$ACGI2DTP`A%=I>E:TK#
M_(KA6T-=;>J74ODM+8S\,`,P(%Z7$7K]FCOE),)G-<S'F;292-A,__HH+8+8
MW)]RPHW]E3^M%Q,1.$?C]H<+Z4')[+39GX062-P><PE3.SG&XC5"$]30SKF5
ML?)9#F>".B7'2/3>4=2V]'P26^KH41BO6G@`XKJ?B/8O^3,B=\".]LALN93[
MAXVUC/6GL\8_9FEN=B=F!`BC1:Y1=+')8B[\[98CAN+OT]EFO\X%$!+>'8S1
M['8:3L:!XG!V,[I:8\;7:,]!1L^"G(;GZ79'DUQL_I(?A)[*OI2O[9"[X)7_
M:?DYR,)5^>#\)YKS'B))6#<)?DCYGU;[(B^")&2(W>Z=RJ;/M2[H=TLS;D#O
M$1Z'^^:1`R;=CY/.U_F[O.ZX:@5$+&%!5G7W[W(9A'VQ;01>I.+/;%2[F`4I
ME^-=>94M?.Z+("NL7$0$^U#^(-[.\"_D!P2;B%"72?B;(I/@/-KAO!<&%8T3
M#*5MS8I'S:MJ3\>V_5A&`Y.R09[1\6#*3X.][)Z$C%,:HQ^KN']"RF\N)CJ\
MV-?TGH>6?4TIYDWP.LJEOLP\-!`SFKOKM)P*?IR8037IBQ%,II=.1ZU??J'9
M.LIY`0:8LTE_`:=^")&1=$H%W_G>9`>*$4VF9J!F7\73=M9OSN]5BNPL#JY*
M7D]'Y0V[Z#_3Z.F9CV$6/7BB%<KT+HN&JW@@6>6I^L>C-P='7*=>)*E662MI
MGCL739!?9!#P.8WM&B`</\.46P4<%_HM4Q--^`BC8IWC8.%%]R,RR+G50<K2
M^H[SM3PN#?VYQ>LVN-C9W#UF-;=!'=7Q'70C+'2^(A"&_X3D7Z'X.3MYUR:(
ME+CYN1##\<ET.:=Z3C(G]VRA)V0J&AG9+=0R</`*5![G<*_M=,/,*OAQ&*]'
M7\>&CY2W11(YI4F1!>MB'\0/--N^<W*S<:P<A1>.@Q1H@V'-DDEGS80O&I\?
MCW4K+8BJ#97A</:Q4-GR+(!CV:/?`GBY"*?'YQD;Z])/,YY[32`O%.8GO-0B
MD#.]13BK+$(U[L`BU`:A#B;8:'OR#OX)!?P66&GRJ7*7[)\[P!.NY,G22UEW
M>3<X]&;RSKA=Q;N!X-TJ$XH\5;S[N=Z*H-J*K-F*=6<K>,]R)*\Q@%2W^F$'
MC-X^G4.:^O")YC3FLL13/W:Y;0M<;.U_R!'*S[9865CTJ6,PRF>60Y&[YCF=
MBY+A@]_RZ2FC3T%!KQFJ49)':]&F#T_FF6J!IWJ9,F9+<(38FO619H%EP\[?
MP#,/G[NCI-,<Z608T_-.A'3X,O&F)MS)WO2-MF_`J75ZXP8?91UT"M259Z99
M`6@5IJF(.GV<=&I#[5PU?"Z2:O0B5)03GBA=_O$3TXP:XHI6@<B*84VJ%(>+
M:DVI$4\R)GF(R>!5W0PK`#U43D74V0*'2(^#<]%58V/09ME-*LC#SO644CRC
M2EP_TW`?T]7&/6G[@2-B??GB[</@5RH>2=C3=Q7LYLWVJ)<CY!?QG?]"X]I,
MQH5F47C/+#B?U):?9E]9?HF,RPL=3H)R%XZ7+BW!0O@`\@L?`L*L!O0SL1,R
MBB.Z@%$R=;ON)+QCNW,;;.E%RB^6YGM7J%D#N,*?AK#'DG#YZSXJ7FO-70Y#
MJ+HGY+*)'YL-LMA\LGJYW<7I*Z6B*T[I)7Z@BC)#4N6D!@"EZ'4H]5B]&EOU
M22I'DU_*\3V>!SB,V2!CA`.8%1OD-*U%&V(S1-9-)?4W44*O"[HU;JC@\8OH
M+9<)T;S'9,@O'#P1\$_0P!DSVK1UIXZY;,0-W/D^RQA8\;IOM6'KV*:)D'BC
M%PGJV2!O!W3('+-R-;9Z:LI;8(GAI5F";M;H@LA.(,*;L9:(Y),@8I\4[[XI
MZ>&F($DO'Y08=2+XD+B<@$F]"J),Q"^7>;[?EC'.CU'^]ZN,\@`G93Q5?`P*
M_U5I1B_H9`VR!<DGN$/A7R_O!TCG^PO"5T#X$DB]!L(7\5LHLSF"X((J&TZ5
MJ*9*)J'*Z7HZMO(_K2-D*?PGJE_KO*R+Z"4*:1(J]*O?U#7CA9Q<AK,%B6?4
MITTV<[V$:=3IK!5B1E"ZH<)K1&.0<EQ`XC1IQJ>E4)^XOOPIC1F8."I>P3U2
MQ9)^4SZIDNP06K1=Q&_:+36F>3O@M^V+ZF5_?F]4*_B_*?WZ(4JB[7X+ZIC*
M5_2;\E!51$>@9!>D6@Z"6SQ0VK?C%F0K)\EORX/5:H+Y75F=&OAMZ=S@BT+G
M0EO<>F7_`SS<=A-PZ.!R.?^S/%[U'ASH8CEI_B=XP$>:`HLC?*@F3N!YD`XU
MHTI^,ZS@Y)X'F1`50K=.4CMHQN=!+G1MJVKP:H1?10EYI4&6?XW+@9U4=*=Y
M$&0JM_,IP?,XR//5YF?QCK9891]Y>:'.LW];MW(0'K0S:(!P+R.%3^&9*-4D
MDF9$3)NVQ,>8`F,.6+;=(C^7L_SW0C:H]S(=5D(B<^"J+*#H@?NXILK&R#,U
MU#1C\B)E7ZB>MINE1NH`P&1'ZE&2:[Y5J_E6E>:;K!2%;9*D'3[S-3UWR)'T
MO#584B4-A$B3+3DL0;X%O&YV(A-Q=<&.`5"@Q8`&T33GK686@M"2&VY]%3`=
M3NYU=:;8,F0E;LR$;[A6C9'D^5825VFVH=$H/Z`%@<<3Z*)ESF'-+)3>@`ZG
MOC*8#A=/'L'P%K4G.'Y0S<06;>I9F+V"GE!9^@7'$N5;Z,LBB0[!$1N0^#P%
M&=KFRJ$JUHLM4#(.7>VQ6Q0F?A%0L'L4OK?V%%P,I10[NAHJ$0:.X1[T;&Q^
MS*M?<^,[*C?@4-=/KJ2P"/D>-2AMQ^3-(/^14_L+(U^4:-`MWY;NF-K+N<Y#
M\2KAY)!TK7CN"U&+=KOXJI?_5HCP0TF$1%1@#.]^`[0`NP@>9?JT=[QC[-Y4
M(4G%9]57$H[1EX'OX#NB&!/(/FS6%H=HS'P])H>Y!9F+-A:J`5]A<HQL<@JG
M(SM5,S(Z:Z1G9E:FNNL?PSB6\1?P!'XMB.)9-H!NE*:GBX7ZA+N!.AWVP!RX
MME4IEG%M2WTRL\+4787Y-3ZSWICY-6EN%VM&$@)T^S8??2P4*=SMW>FQRV_`
M&U5>&$ZU&R`*UN3:T8^A`KF-]&,$Q]UD&4G.##>9,[BL)H1R"PI"WGN>,!.=
ML&,[>)4ZU;:<]#-N67$Z=>$,V!)^,Y;/@*T."%)$0U$_$ZB&!M8-X*/?].MI
M@I;5P"&5)EXOD*KX+>EF98&-Z8NKZ-;SFRAII"<X"ET,44L#&^'5.ABNG`:L
M])GD$,RL"L8T8:=91/-E[7DKFQ%I.A9+(<`V05<@U=,J8AQ9MN<UF%9$'C'Y
M/#DF(WJ&NR*#+&*IE1F#'ML:@1DMR6>#DMR/`,AG@D0`54@H6.0,6G(]8``O
ML1ZW`4E,2RL+ZAB53A!&2.;RB1%_A(65S0>UKW*$^KW&N?>-UK3:(`$OHW[Q
M0&90-0(R;$[5TC'C0YPT>:%9$3W&](Z!I5E&0]';R:ZYYQ`8L,<U@^CU+DO:
M&:294G7]1&"IW1%K?--U!\-=@V&NQ1`N6]Z,/_5Y\4;,.<),7B?\#C'-7$SD
M\5Q0\]A'Y)B+FA'HK*+-VJ.$2T%"UR(2]SDJGDDC'JU(I!OV#WY+#"D5YIQC
M;'?D+#>GS6DZ"):BF;-=.`OR2-;P5J$5E!#@+(T&J;Z1:?M#+D@[GH@)*,R+
M/3:E!5FWR#S*D`&T)$-<-V!$!E@.6'ZN:%#L&7/8WL?K@4%?H@^A:BQ8]1P$
MUFHD;GTQHPG=1.LHB./7!;F@^3J+1/P=C;FR8ERS2HH&7#OW(8HO8;41:RI+
M;%SG^9Z&YF4+]%!@CU`:Y.0G*,&:O-I(*8KE)%+.0F'@++%JZZ?D)2K5,8J7
MG$ZUS:N!STY#;&EP=!K@R?D$[?#XUFW]=T<9RR1%\&3=,,\()K0=-$3\F&F/
M`AB+PRZ="]).1E'A:"2VU4"DO8MM>-?(!EHP+I2$WD2_[J-01(;+'RBCG\@2
M,#6*QO"@S*,%PH/2V9E-VNF+,O<'1?4:+]CF);9Q!]O=$+9@1M26H;7FU)*;
MP3W8\]K'D3FQ`Z[^$$!HDVJ"LHUKVTQ$94I=L)2$0LM#9[K'6Z??E($-CY=F
MW#N?@-Y$"5UMSME>1(6I[3R8`V4?CQ9^S&LW:?+T1O3LX0.Y5)5#45B[H;4S
M=XMQ"0FVZ3[IK1C,8LE816N5)'PR'V,WN:%T3:.7X#&V/L!)($#;%BE2_>NH
M.FF[&87*=!@AL5RO]]Q`U#G6Z`R#FK^,+(&2N8!KI9;A*&:=**-_5#![?1[$
M,0W/7H^?(AJ''T=^!E7]5"OR6%12[511;B"3$C1_Q-&DC$U75M5;S=%1)&H0
MC40D<$&2X_`H^Q?.H*@?:;(OQ&@M2B,24BJ(#^D=8Z_G(.?FO;TQL<I/&0`%
MFJXRB*:";7G$?E=-&6)4$!-\.MBY9W].@1ZR[%`S,1Q.V#&2P?D<DCK4G,L?
MBYDZ'$-@H!R*8?04%P]AOB"JYYX(KCSM\1(/3U_$P],C0>/=64CQ3$E.LY=H
M/4%>A8N?8X^A&$C*[5IKM@O,73&4-:T[8B9H(/E+^76RCO<\HK@,PXBO)HCO
M@BB\3LZ#750$O:VW2#$9A@T=)K`DA"[9B:F>!@)I01`.@Z>[5E!0>#>>T.]@
MN>-8ON%9O7(TP:,0+BQOFPAERN\S.@HTBUZ8CGFA-U'P&,7BU&/L'D@G@SD%
M"E1ZKD`SCM0#7W'81GL$8A4"<-90QU!Z&ZCAICFS(](UI6%^Q=#D.51!PHN'
M'=X*+Y.PO0VV.J^/_`JT-70F3C_3H`1$.#>1&A1W88\?=/'R?RV\\H^H3.1$
M-,F#F)9!3/E-+SK[.4YP#-.I1DC-F,=CS;>J\@J'GRQOGMNCOSZ.UW]0/@(\
M2!V%4>3H7;'5LK_J\/JQ$JCR-QY24@,E7<\:NBS#-`31"'\=P>_&V4!CB"=`
M$R35(\;K$G6)B=&*9$P-:@8LRGD^3LY4\&V:+-=KGG/![V,OO_!(AOG#)W.`
ML"7[S5"6Q02J:83-([>\TEP[D]13$;R#\H4F=^(2AF;009-.A>:(HOK38HKL
MZL-&8@U*X)N+ZP@M<Q<':U'C3A3FT.B5ON)53`7QH)1H],X$]4!2UEB93#?8
MQ"M<40@$"F!R/P$.2'P*O52H_06M2"`H</-`LVW.+U+K5%_[JP9CR-"A%2LB
M6%3$61`!0*3M-B`0N!8>\8X*CG>N.A?PU&4TEM>=YRVRXBT8WG?7F?PC#6E9
M6U9\TL@TFT'"TS5&@J1Q0X^<M)-+T82.7KBBV"089BU"Q20(>>K38KQM3%=^
M;O-*LW+;CK%$8ONMI-"R@XI"!,?X[\VSU]7F/HVC=51NZA6EJZ1F*%VS5/5Q
MQA(T:.3`F@P]A[0!(.*F'1"$P2"KI,US!FJ%.@_R/)FYB_R&(<_+A=7(4[`>
MJ,CP1Q9[<-,#PU$()R4P,NI9A5#+@AM7:79?Y=M9%,DV``/C_9B@I\MYJJK)
M\/Z0I)Z(H4;G:.S*HT7YM$)D6N:38^?@!4V!(!:_QUCR-$Z/J=C-%POY2..@
MX&T[LN+U@6FK/!`%,/.SU^XORR_20HS:$Z<%9.A8B!41>DUERB%$C"&_\%%X
MJH*Z;[/1\=]ZCV$8^R+=!I'Q(P3)3*@40RD2`PQ8CL-3KEF]$=KL/.4NC/">
MNC`=ZC)+IH.>ZJ3H#'`'OI+_]E@@.UNHN6KX_*!DJ5%GA"3?QX5EWYS^+*`3
M0'_QDBA\/68ZAK:^H/2U<BCW5L$T.F]6SC$C6/<JW?/Z*2/:R\@A@*II%5*]
MIW7E.+Q-9KPC`JNWM<PVK+IUG&;KYN9T_<U3^O)M2*/2PV7_.'9LV9_^=D.?
M@O@R*2+ED>Q`LF53YM;J\F7WZR:Q$:0<`GB&&J2>3BFJJ3T5.Y0?4IYNI*S?
MFP>E&R4(''-%S0^`1QHS&IHH#07A1UC+#S2D:7:=K"W<O.,Y($Y>?^''.U^.
MX.]7D?E)"IJKO20YP<<4<DF3W3YY<O"-#F?"EFDY0J)WUU_^CM1SD&Z!0<T.
M"?W]O!(2B?8'%4`>TGM:%#&]28.$/U]Z>*:5PV*D)EQA0[\/LB2$]G%0^;QC
MM3EX^L/?!)4`"8=(.$C"8)(**/0=TP2T4!;PXD]?\I(6,:>%>$?(*X!L2J#?
M9E749L?#&PCNIS`1!\FUUD@E8O0VR$&#P+R_YLM99=%3E`B>RJU+7.N!05]S
M#:&J?R`LU%UW"H*PA"MF-_;J"OP*SXA1K9\UJ[AT5!`O>XI>:$)Y@E]=++5*
M]E\E_(-&+H@!&!!OPPB]?DBLF<0]BJ;.;S6/)]#QF=#>PVC<F!&LR_[6CU9X
M?IBP@(^O76E#X`[,B"T2:V\NFFK#;BR7(U3(ZC&.GL1&7NSI0]J]);,Z\>K@
M@)Y_]0@>\UP[FK#A_`AR<!^*P!"/0RID2#%W&?:X,!->R"ZO#21M.+`Q+&;S
M-P^H--*`ZI!FK.A`0&4"Z=%2]A&HAB\@%89/?&HKRR5+^._@/KLU!^D,K#D'
MPA<HX[73:/.B=\Q)60,5TY%9B[Q-P3$QF32S$9COT>@NGYXR^L31VAT@OJN0
MW:F0176L'F;O467#I+SMY0+@(+0VOBS8(#C@,+\!NKK(_G$\'WF-KS'8'@>E
M>;F8YK'6253S\HG]R93J,I5GD_"[H3#/YU"LBF>:+=?K;$_#3N756T:N?98Y
M^!+#`*'="!.4>^=(/H=4DTAGUH*T\Q#Y#DXX[HNZ?6136I@7U4@_ESW4-?%"
M<,?!F(V-?`93'IY/3)>Q`$Y#>8N`ZFAB>J8VA`9UO#9&MN?XUA.5;3[J,SB*
MDM_.>`I3\:;?%:,^D8-;4#>VU9["K7C6MQ]_G9RG24+%>[J?H^)YN?YU'^6%
MZ#][$ZTC_NDE.W19G;Y]?0XT=NZ%7,;G@^N$M)`)!TU:V'QT#9TTX!$8Y1D(
M=>Q<\U8;+:$^<T(%+:'8Z+@F5#`9H=QC_.AIA>S>P)_.&KY>\*:PYG.>[H.8
M5GW"[[)H3>]H)HR(J;NDG`_E(&D0ZKD*=2>!LAR@&$[8^-)#0G#W8('+07&*
M'<,AE^$`YNP,L9G6O1G@L1F%A2_A1QZ3HN'%/F.'0;:4*`U_XFWFQ)(>CWVO
M'[,TMZY(X?P=Z/#!"`))_7A2P5H0`4'=HG!!!!P$#LT$I#AL9<A##96-?BK!
MHS&XON3$*!`Q4DAFU!K2M2QY;/M)&/VSUW;(7?`JZ@Y_#K)P)0H,\M#*"\T9
MEM5_7Z79AD;LOW^FO!8A#9?L@!T\44&+"W8,Y/PBJ&!LQ.%6".8F0&Z*M).G
M+"+360_/T^N.J]9$Q*(6I%J&"+F6"ZO_1)JE+4B].%*MKM2OA*^/""TC5HC!
M\\&T/2610DZDC4H5XVH4#Z]R]`X=M+XY'>7_D\#S=L]?XM4O5*S=R2G6`.YJ
M3D/8*55S^4FFHL5'Q<E3?!:3USHC526MJ^LG:J5TX_-K)Q1F,Y]W.DF>426N
MGVFXYT?ZR^TN3E\IK4I+RF\OJLL-$2_[2-?I4Q+]@R$G?/WS-"_R!]Y)Q]C5
MG>3C8%[L1*3LR6OU':ZSZB_596LU9_+V>WQB^T52?I*(;Y)?Q%?ARR;,PI]Z
MOVA"YIPSL9VI='I?,+^+ZY^;:HTNI5EUH*`=$#V:_<1P/IHTPTD]'FLA5H-=
M-#)9PUL(SIEV55?U0.">7>A1L^!';'59C79MX)7"\);-6?`WIXP>S\LDO*`O
M-$YWV[;)F%VU'!N0T/K2#.U^/=5RED@([LQK'B2C*[SCL,V&):Q-]WA&5Y[&
M#.;3CS2A61"SE2W#;91$>9$Q`7MIVEN:E?UR`PKF>ENBWG.IR_D+4D$0#'X(
MHVEJB:>TV*B-U_N^#KL^YN'V9L/\ZJPZ%SO4*),"@'VJ+4>IE\I<#FNN!]`I
MT,'],7CGJ]X<+_6JA]A&5[9X=H[1%40>8I9VY""_S'A+9(O$<T0WY)ZG6A41
M8PQ2BP!7N7=LJ5'(/0HT2M:$V4RJ7;NR_Z0-6SQV:$$1!M"CJ6]RT!F/-0Q@
ML(MC&K"`=USIK,6]^4H?"(8^+#+4+/@16QC`:->,.[6HMFR$>W`O^BPO#]L+
M,U-#>6Z2BXMI!!#4Y31$N7_VJ3I2'[7D)LU4I%ZIS18/>ZD6^SN"+2_H8S',
MA7T'1#8/Q%N5(W#,4WP4$OXQH^6@(Z?>@#%*BI^GZ5.T7H8O49YFS<L#%_TT
M``M6-0TBVL\XKF:0:DK[4`JK.C+;3`--9+23(Y70G],X9$<\2Q5T.`M,`1TO
M7JI^JD$(E8^4]GK5(R/\F`;G=3F9Y9.;MI$"@&U6+D>I5V&I'D;$.'3=DJS1
M"`0:DJ>!C5^W:_RZM#)@2#6HCBL-FFJK67*^T^Q#5/",D>LDC%ZB<!_$)@V7
M]).A3J\J5(Y948SC*47M2"R]F(QV17M*U6T)(%?QIZOB`,U#BL_1[B%U:>KD
M"AXZRF=/#FFDI1K,*\9@;1DUD@&,@H%NNS\?\Y^E/&5V<Q%ES+JE67[^'$39
M-DCL[K$'H$`IV4'DCCE73.#:MIE"ZCD8+H-\XH7&<;?C1*T],6+#^61+7,9=
M?J'K/;_6KV[BW+*>=*"@#88>3?D-93.\N:!$YS1;[**1)1C>PODXTT_.]4V4
MT.N";HU=<-^?A;(K_LG7Z[+I_>4!_QH1G\.C\B=B0ZV-F(8'9WYEV5]P[UW4
MV?&[J,.G4,M]\9QF'"M;4^1_`=`&;`J23O"X\O@M)6D_.'<=0W!RMK2HGE$&
M+T$4\S=`9)-F9;40$C002-G\G(G4=_7UJT@8X@7?>PV>P#V.R43<_.'E!/(]
M(J!^!+G>ZJLTN]H7^ZQ\_)Y_XGM<7BR+S>5[:W3W,@(\R"7-*'(H)*EMKMK`
MX]4T2`FQ+)Z1$P%S6(*F5C_SD$2E7#8E29Y*DI2:I2Q&EI8DV4U!$OMZ[>AI
M`G-'.%Z9J"\31VN24>D.#<"<0^S^-SMV9NLHYVLIG5C+Y`<;R,"I$'9$D)=B
MJ_._.01R^*<.D.J`A>5NTP_J:84GE]<#"<X)[:"^FP9U]UJQ`-@CJ_[J)/\F
M^3+VPN])B_7`7]!\G44[&7-(5;TQ,!`WS@)5O9KJZR32F0[]>&4TFFH)).&$
M:-H[7$"8PKA1MH*J=IHLI73,2\CR(VW+G=5FK6W(I7FTIP<%^SIR",W>.\F*
M[[I]MXYJ[F/Q<IQQZ_:9.BK]CLB-F0(]9'Z*F1`:/'PUD4!/GLAYFA19L"[V
M0?Q`LZVU\W$\']S?Z".D=S$ZXPF?@,FI,,6EMJ[%%.L?YRV,W0XDS?(,1,;,
M#9#+RWC+SXL",K]BS3?J259(;U!M'4'`8.=[2*EL!!](VI'(3+HQ&KQB)G>+
M^<BGP#\:HZVW*R8X#;5<9HSMLU1@1DCR1\KS)*/DR52D^VIJ``2(<1Y$JY]D
M6TT@*,3;*T:I1#ZFP,C>:'M&"DKHK65BT'H;R91_L1\,"JK5FQE$4`-OBK2Y
M;I@Z-NB2-^()U6/Y@HX/(L(5UH^P$MUAO\)&;D<HG*:/PFI3?6B5-$T6C-P,
M/000+V,(*6D[)C&!QP-K9;)*.LU4H-T,)Y2:MB:U(-4=ID3K$P1^Q@18(7$T
MC.1*[6>8"!6V?MRWM%AM'H(OINZ)(W3H-%IK8KCW[5X0!H9S.@.$((SAC0(8
M.WK[9%$3(S^*^Y$]H6FZ-XD$V?PA+8*X^SM_2W";%O])B_:503<..N1GS+L8
MU,]M/)!ZQ".<MA5=^?G%H=IB'R:O3&.UGUX<YI4A>%0*1>5/2=:^62ISKG`I
M0$")T[E#$+)_`L^<:J]P7^1%D(3LG'C4*:]*,:&BO[*M2S;7LJ!]N?G(/V47
MNLXJ)`U!ZY64W=!1A,+@R=]0*:BHM)&>+'DY:?:],MT?;6_F>77(M*^KG!3(
MB/C7S]7NNJ2^J.:"Q+S4B/1XOV9H;-DN#BBL.R@@27CQ@`62&-:`;*BC5WK!
M&"&MGRKWKOY`FQ5W[IC@:@81]'K,%.G^B:,ZJS5\UDU\G33KU?E^;#2NC;7N
M9HHBS8*='EEDJ396XCM\168CNWZNR.HO7>?Y7EI20GL1<#0;^FJLAXS^6JS1
M(N5X:&?!&I'&N6^D)IH&D5'78.-P0>(X#$J,T<675%QF#,UP[5%^^V+/"]Z6
MM^_EFV?Y^>;'+,VM6^$X?P<\>.).('G:=PF+E,"J-)Y%5:]AH8E*"ZB([L<\
M$H9#"9CT<5G/FKR8KHE?5)4*T%AZ7_)C%F<8)SS@VD2H.CME(N_>Z`@>K->F
M,SEL5(<`ATQS3$P.$X4AP()["IXD0]^"=)18S*P=/M+Z#'>7I4]9L&U2`%4E
MIQ[2,]K.LB]QY^>K*/P0'\23JY9V#*E`+TB;HJJI5L=/Y8^T,Q]9_;JIR-:K
MH10EZXP*[?OX2HIG2OIUFG%Z+]XDTMR7\26.WLK07=>;5]W8/)=-9(QB'V:0
M$!274R,Y6$>NF4K.JMO::C*V:G'6."H$.)\2Q['EWZ9`$DE0Q4HL36NWZ65R
MQAKR<9#G3<AGE7WD=[X/O#Z*K5.C@03MJ&B1[!60YX,Y>U;#29H1,8'\(J8@
MK"`_N(=F!>2'-M!;R[('-I9:-*]3SP8Q83IDACJ6B=$8>GU88_(A>!5I.7_9
M)Y17.OZ^:4@&;W#'[`B:1B5F@J(V,$-2`FQ47+K5JP&A-"F*'FL:BX*S4_W@
M_KG;$Y`.;-*5V/6HUX&`BN7JT;+@0FS]Z0WV2QM]'-XL[[WI$[4_8]L#/9G1
MN;'MJ)ZH[:JZ$WT"Y?!,BUT^/78CZA7[W#YDV4QF$FA0>MA$_,9HBOUCFH51
MPA\9WC&\HCQ/L]?;M*!U+WJ+,Y`Q,)C:?^:H]ABO,Y6T<_F;-M&]3=_S>.X3
MDR]$=RVB"4=TL+DS0(1O:ER1Q/=LQ5138M!.1B=5+8X>B05<6/?$B@!N.@>E
MX^(/;Z4*PNK2S+/EV)P=>TDW\'RLQ7R$KEJN?]U'><3W>[7Y0$.:JIO4]K6S
M>C:(HZ-#IE=OI!W+[RW+T6@\&5=,TNDQL7=51B"S%:.1^"*#LJ)V/H8$980$
M?PA>ETG(`__\M\'#BUJ9:0&!^A,#*,HN0Y8'ER'`)Q6OF,FO>3#Z!-Z00V;U
M321NV,P;B!MP$/[&ML7W`!14H?@;30-N333^!F$G;;/-LP_*'^_<"",EA9]?
M?ME%F52O:.5O$!BHL3)`5<YO[6M"LJKXC;?WJN>A2)-UQ7!"--SMD_-.M4\,
MN6;(RIVBS3QDYLI4]H9-EJ'@C3F.AB\1/^U>1=G6YAS:GP9S`)4MOW?$J081
M/FHZO\TZ3\?CXH'.9TKFT1S,5)PSG^]UML^9H<WSSAG1)1U'!08Z&4>-WC%O
MU2-)-PB`-`MG8-.,<G#T.P;+@/R?&:5V>3C#@*".`"8HFK#C@M33\"7F&&^C
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MZY#C4,1`)\,"B[(V<&A-^&H^T;C+T@W-\RA-@OB*4NN(:&\^M%J6(-1[`-L9
M0O@8%-=^%@@T%P1YV9(D)QL)%N!F1,5;1M9#P5ACGN`WW7)7FY^<BGE+7BM;
MPH1YKF^->$]B&@C\!OTGI,6])\2<7T=O]G'\2M!6^YYXWQD!4-?^'B^;@U$H
M-V&WM>4Y77_SE+Y\&XD:X]R2OZ_^S77:^XX-+__ZMVOQ/YPUZN4X=6`RA`9E
MWXV1[=6E;&8T&FN!L361,X(-+CL^@'>K+HM(H?$'[/A4ZQU8,>D(7Z$N9MK6
M`G?W$4QA@?@&YH@JZ[UV*_3C=04\(-JM>H_8[/O!].<.IM(M16+E+255;=WM
MQ'1ZW7)!\W46[:PS=QW`@]Y8.9%CE#(B'5@H3/\$=##1522<D`[N*</>"8%3
ME7F58.-[1V?M,$+A\0YL[?>,?*:C*2"N46_9QSS&!W05#O2#5K,%=S0#`F?%
M>LU(W`XY3ZN]"RE#CY"ICS3:/NX9>W!R7Y:]NXV#]QH(H*Z`"JECGC@81^J!
M>$RY*1X?@B_1=K\EV0$^52?V?$&8-BZ>XU=$MMEMAVJ,D-E9K0P-FU*=`,UW
M@;<JGFGVD>:4D>-YF807](7&Z:ZS)M.+;@-(4+?>1D@>\Z"81.I9XMES9UZM
M-E#<ASOA=X!9V,&,RC$#NR,W9U'MA;DQ?\YZ>[ZF-,RO&`%:S[I;7.8F39ZX
M[;^@CX7#W;H-=`0W[W;$D-S+"P"$\Q/IGN`.:A=Q*&]XLVK"X:"P^A.1(.J0
M(-=4KD)Y]>\@&*:)`?92,9]*8`JJR/;K0C3].G\.LB>I7RY5E-*Y4#97@8C$
M"K7#2#4.A5%U0F`M1P#,=NK826LM-;PTIS#$HL):D!6O#^SDFP=K?N3H1)=6
MF\[?;0VD+7AH"VE/CCZSQF7]/@Z"=,8NND%M;B\ZOZ$RD?YHL!,T*-QH`&XA
M'47#R$2ZR<7\CZ'/T^TC-]EL#>=IDD<A+6M<B+65):G?F=I.*YC03Z0-$5>^
MEN[,7Y`#"*0#`H45]H7RNITO+K%XND<0DSR(\1QT7?C:Z*&X!5./N9@6635I
M5M=)$[DTSM?00\!@+YV'497GD:596^A03$)ZF6R/7X-6F4:&]&YX+%[(0M"F
M(F=PL6LF;QZZLUXF3\%3U6<KH^(?1G>ZNOF@G5CE"*G[K[;C23,!/L'-"1OF
M)`?U*`S7P>.10'(_;"`LPYU2U9(RMKZ&V!&;]UZRJ:`6O(>&M%1&Z2].\L;+
ML=2!S;HWU/_UE+OMM5PY,DLK9_MANRKE>="Z89?L7\7K=<(8D%E\'@*GX2H3
MH?#'>,!?-RUJ9?X-Z*.T(V',"I&5$$D-DI0P>4'2&NH"TO^?E3!!ES`:I,%/
MWV-$Q;9LFZV<C,GX2E^#N'B]"UZ%G^-Z+M>`@<W]TJ'7"P&7@TD]>E(A=#3T
M3@CM:H1P'K^M<#H*QA_O&3+_8%B\##+"AF1KO/A_I&L:O=#P[/6&G>^3G-H8
M?'-`(.=Q0Q15LE//(V>OI)X)IQB\HY?5Z#V^DKA&#U)-3+>!C_(-1'*TMY%$
M]1G?0@QG;%&2;G=IPG77:G-1-85]"+XL\YP6^?(Q+[)@;9W&9@84^F[>%/5>
MMX)F'C=R]4S"II)R+OFEGCU[[:5)$&Y0+!B*@1C])S2FW(F1C>[4;;AX/H'M
MK62U$U>#R=--FN?G09:];M+L<Y"%QDEH-B"A#O]V:"LYN!72!6D@$`Z"',``
M]!S\8'Q+"Y(V",9L!K@I'<'!VD.Z/?L"2BO[1_VW*H6=JQGVO\+G6B;A&4WH
M)I(^FM3JOQ%?@C;$HXAD).K\W\T/%4B>1M,"%4\J:K"HK+97ZI2OX1^#G-%A
MW9F%SIR/%QPC&S]::F!5R3FOAUX<J+CZN8RS\1\`B\8!&$3?6#.48`X=@$7S
MC`RC*V"-N_+E&'?IUP(48@?!C-/MG`0C-D?E*/"U92\T9TIHN5YG^R">PDF0
M?>4$'`0Y<48X!S5`(3$U2`0W#=YIHL+M%%P`C4CX,O]J>8`\\_.'L>['>S$;
MC2&OD3$[M//!*&[=C?&0+AF/<3W@)<N#=H>1`*7AIR#>E^YY'*>?^>O0T791
M`A*=$92B;21$S4S23/4G4C^4.";T2;S,G0_5%JM`A14^FZ;F73<#IF1<0/F\
MI8/IXMJY:"Q5B8B1B(GXZV9:2:M]R+0(XG&F2X[8`P>,UW!UV,K.;+4\-9]0
M7&XV5+2TNT[6Z9:RM7QDZO$\38HHV4?)4Q6S3I.\^NDCY42*XJB49L>;6%^?
MA39^_LC7JZ5=0R8E:"'%'`(Y!+$@=6.`"6]WW8^#TQ'H<"!7:LSK(WD1%/N"
MER/A$:2,TZM(Q2^T(6C]"SHK[%D8C2RU7TF$5EQ'BRNN*'^@&M_77'$PV-3X
M^_@4E*_@ATSNRBDH2`6<--"/)S4J#$%(>QIZM:AO*F)$)0D@5=%DO&[B_/B3
M*5PJAR^5+I/P)A6-@:MQ]MW,1GT+IU=D3"AW;2.`BLBX`-L9SXN8@FB9.0E5
MHO]54I[Q:E7S6-X,?WTB[HZ=/(WP<:R$"9>6N4V3D(9[-NPQII;%59WA8W9A
M%`1QUR0'`-O;MZE4B$N@WR-=V+`W'73K*LDGY97H9&*T*Z(1"%R:05Q]+,/_
MWI=-J2;Q.WK?.`5_0T(8=^U0%G3N0#M5Y\*`*F#7A/[YU+?/H!`$7!KA_)GM
M)AO@=CWIK(YM/HO9L[`CG[M**;]#HD3Z<D=R7W-ZSL@X4K8$>L%QH3J+:/AR
M8.S%$5J+R4+0TUTS(?5A%$08?5F$WDVQ1AQ!0-47*TYS?3.[6$LSF1]X-1)3
M/T,#`<IET"+52U20)_&37\2$WC4MF-$:WBFM_1G<)F">6WZ)K"V'&A"TH="A
M:,R`?#P(_SD2W48E#FT=,#?>!EMZD6Z#R+@JVA`85+KP`#U#?EP0/HO\4LY#
MKA?[^V>O''N;-VM7&/&2Z`/EE3UMU>+1;&A=V$-&^;Y,J0G+J9A2I@:1JA,J
MLN''<V3=?46FQ!9<\\NYTK#%A(0E@77\3930ZX)NC4M=#$!!I>&[R!D[''P2
M$;.0J_?>UMEK]^-]@W9_M^E>6AC=P1<K04&K?3V:QDY'.0.1YK?'2Z;ET2EW
M`ZX<X=AW67+&9K>CJQLA+&9D5<D'>9DB*UQJCXH[4KE(HDIZ=8K@A<R6C4P,
M&**:1%+QOORRB\H`YH4\8]M>\QR!1&G,>F@;&[5V)KF0Q,&Q63<C1&56;L&S
ME"+13B?$&.^WX&9WXR=E90Q&<%!L+779_#)KJ2T'^5AG+H&EUC>J]M84@3"/
M8\AQIA:M&-]$VZBLNIRODD_2'&.M$K2`#&V&K8A@)]P=`(0).`.!R"J/PKM?
MS?-8KF,.1%<<'-Q0VW._D;VV9GT(>:=!3O.K?;'/Z(<HB;;[;=,Q8$\U;[L'
ME*496'@C;HJ^1MP%B`4I@9`*2J<;R)ZR'Z.</T;Z3QIDY$/`^Z`7KX"UN"<B
MROWZF8;[F(JG1R4YMA4Y8@ZSZ2B"T+I;R8&AD;<1`G2R?[[/,GDW34-=:@0=
MC\TW),9(17!+OQ3DX3.-7]B(-"F><57T'4T.QG/_C-B^VW"\I8VW8'=TLGZ=
M/'Q.N7%R"%V;`D9NZP](X"SD"R[E/$&=`1/6?G;QGHP&C,-^?VIVN\_7/BQW
MCZDQRC/[*E5)M`]E>?")$['B1V3Q(.4<'(R<ST`/QH-_.%5;+I,`GP9=POX(
MM<`5X[IIS'H+&;U=[Q)AO,AS:*=HV7548&SVQ],S[3WF]F/;CSD;G5A/9-!/
MQ8B//8//6^1T(HS!ZI]ZX;0)[/'LPEK'.E>;PQ6&=;5^BT=N1K"@[*PAHKI8
M\)%\ADTS2F2/X&SV5&ML+#9T/HZ]3D*Z88)3T!O>Y/4Z*=A^\6(VY:+.7C\$
M_YUFYW&0YR[/Y6S!0YL;>W(<LW@+X4TL6@6W,-IVJRA?V3FR@I'"=N,#-&+0
MKL[^E9X+:"BU[D8&>Q%8$`&*"%A('_F-8`FM&7#GA_G$H>STS0S4\BFC5+A3
M;N\"U8"@-;T.Q6.&;L:2=O!T+P3'Q/CLL:)D0_%ER0XRH)'5&>*^&06*.WH&
MPB351/+)4#9"A4J/O41R!P*!&87%[9[_P,\K<2DN(=EE*:_XB"=?1<M<6END
MXRP3X<AHO!4L__;W[]\*AN=_86"?@MC.8/3F0=D'"0)]SF:_XM+_)JNNU+W(
MJ'XE!<VV:-2^BFNT6E[!,E"AV>H8?V/[Q'L`"HZ;%`ER`_'6-IYSHW[BC>!V
MQ`"SC[QV0E7[&(W2-V,^B]L/!>?-)TYW6;JF-,RO&.*5LKJB-/](UY0?E&R/
M'D/@H`\@P^@>\V$]@W#6(+4^YY-(/0N%,7+'\-_W-.<)\$&GVC@:(V7)IT8G
M%#,F'>&*E?[K:E,!#^\JYW7(.NDGSVV4AE!1>.VK32TE(;E3>.VSFB!'/$Q.
M'Z/Q"-/UGI\"Q`N4&1'Y!MRD&@F*U)*:2,F8<U0)43P#?'U@#KO=::HW&_9,
M)4%&=48I!Y$'R1D%\'AE@,!YNMVF"<F+=/UWDC\';(',CJU%D>79)=;/7G3.
MBR"B:L/@YL=&A6S,'1%,0GZX"&++7CWRR;`1P3XJPQDYXF1U*??S`,."PZA\
M3%^#N(B8=`,_8;5@#_.`H)RQ1ABRBW3_6&SV&C972_GQ7%`CUD>DUUV[&@'%
MUF/6;G+\`K1:%L2O%H_,8"G$8-A<R65@A$">\X8.<5QVJ]G\'&19D!3Y0WK'
M=O.9J8#2C[GG;HS12=$&'LCAT0[AGEO7F<U/E?5\\I"2&@*I?#\!`_Z4Z1%A
M=FK[7"-<I&17([SN.+L(CJ,S8XSDW.H@R>JCK+T8C]%!+;![<5*ZK`Y*5NZ!
M&@JHHZ!#3G%H%(-).9I<3G5H='8?'##"?@SVA1(R-V-0L(8=CB&I&B'VS='I
MHCTY&?D8THD@SH0"!?4A\4)]2)S?,[!>O>:("V#FQRP?B<W6B8#:.&OX?\87
M+OO'G/ZZ9SMV^<+^G^I%B_8"30H#^CI6@5CO!4LSC(AQD,]5[(EL<S6IV24P
M=KNQ3:Y1S@=[.*5&:)C5;A`V2QC:(?V3*/WVC/`R/NW8NI/B/,B?KZC=B>)H
M*N@QHH?&,9-4`P@?P5-!FDP0<O9*'IYY5"+)]W$1S-\/U@-6:X[5AF&5U5@]
MOI+BF1_$)\/*_3AAC1:R<X-<9H8/"U*!`;,1%L<*`PA([(3>USVV%`LT!PXG
M=#J_\DA<*>_;79"\_E-.@CI;G7R.BF<2:%0!%IMHZN6;LF.))C.6?_\W]F_V
M/X]!3MD/_S]02P,$%`````@`6$4P1<:I26*X4```>`$&`!4`'`!R96QM+3(P
M,30P-C,P7W!R92YX;6Q55`D``T<P&%1',!A4=7@+``$$)0X```0Y`0``[7U9
M=^,XEN;[G#/_(2;[M2,C+3FS*NMT=1]YRW*/P_+8CLKN)QY:A"1V4:22BR-4
MOWX`;J(HK"2H"S#T4A4904#X[G>Q7=SEW_[CVR;X\([BQ(_"O_YP\>-//WQ`
MX2+R_'#UUQ^^O-Y]_/,/__'O__M__=O_^?CQOZZ>'S[<1(ML@\+TPV?\S=)'
MWH>O?KK^</O/C[>>GT;QA[\7?7VX^!%W]N/%!_S'UPPEGKO[UP\O:)NBS1N*
M/US\\J\?)C]=7'[X:?*7Z?0O%[]\F'W^\/$C^:7`#__QYB;H`QY9F/SUAW6:
M;O_RZ=/7KU]__/86!S]&\>K3Y*>?II^J#W\HOOS+M\0_^/KKM/KVXM-_?7YX
M6:S1QOWHATGJAHM]*](-K=W%K[_^^BG_5_QIXO\ER=L_1`LWS64E'-<'YA?D
MOSY6GWTD?_7Q8O)Q>O'CM\3[@<@@C@+TC)8?\I__2[K;HK_^D/B;;4"&G?_=
M.D;+O_X0HV#SD<CQIU^F/Y'6_U+Q,PN]VS#UT]U]N(SB33[F'SZ0?K\\WQ\,
MGO3A>NZ/BVCSB?S[)VX7G_H-[SH*DRCP/3=%WI4;$")>U@BEB>38V.V'&MB3
M&V-9K%'J+]R@[R@/.],XY)<4_R\A+9DOYUL4YV1U$2JCHR&&.E^^I-'B'^LH
M\/":<8.6_L)/^PR9WN%`4KYVD_5=$'WM*^1]/ST'>I4E?H@2V?'4G_?\V9=L
MLW'C'9:]OPKQCK!P\<JQ6$097CK"U1.&O/"1[*`D.^LYY,<H17@J[MPW\JW4
MP`Z:]/SY&Q3[[WA>O:,'WWWS`S^5%Q"];5\*&[/F]H\,K_BR=!TW[#F49Q20
M"8+7R73W&KMAXBY45C)F\Y[#NL='H@UZ=;])$]5LT7L%VFS\-%\N\):,UQ$R
M%_`A35YK>#WTGOYO"?HCPUW?OI/^I2=ZJYF>52CB+QS=5B/93D\"X96L0'H!
ME%UJ6%3+!5)IC,?MAEA>E8;$ZT'[4JM&**OY0,NNTN`$G>A;@I5&==Q.WW+L
MMA93I8&)^]%T(+Q!J>L'JN?"JM5)5C6U(:KU>9+S;?EC%UK/N76GIX0P&0+"
MY*007M&W-).^K'?J6M]FJ:;ZE(;:AZ(F/G;[(?9Q-6EQNQAP>+++`+^/`0>H
M1K%,3]K/18I;`K/]4`.37NK9'0PU-.DEG-W!4$.;]AW:=+"A7?8=VN5@0U/<
MT$3=##S,WC.C[F?@@?:>)W4_`UV_U-9`42_##E)-1R4[TW=G5!,EI:'VH<A.
M$UI+[8-18X_=?KB[M1J!$AT-9Y7M)%/Y_C1;;%7OWO362H.B/8P'<5S\0HA6
M9&D@S^*_DF?QBU_R89=__>"^(89(FV_LOQ[T533Z].\?3C'")WQ:CKS;L-M0
M6ZU/.N:7%"_'/4;=:'^B<;]&J1MT&G&CY8G&^HBZR;9N=RJ9XE,.ZB;3?4N-
M8TV/QZDLR+T$\2JUC5&"EZ[<L^$!#^-@@'B-1:&'O&J(I(,>[C*Y0U.T./B)
M@+@01;%HG29_X_`ZG[TE:8S/355'`<&8=^](MW5^*E9NJ3&64L@EG*#%CZOH
M_9.'_$]DV.0/^?@__G11>C+]"_XKI_CE9[3RR0^&Z:.[090!LSYURK-.D[-9
M?#A6-UY4/>(_'A%VZ'I5?O%IFWOB?%RL_:#F>AE'&W7Y56.)A$@^1#&^0OSU
M!]PF2_`@HRWIJMK1!Z;@&B.)W>`>*_>W_XMV7`Y:WSH3>TDXAE*Q<'%B&F88
MAD>@W`7NBB'^@V^<J8UB;T.HQ#TYL;@K!*^X6X:TFY\XES8*NX6@DO442-;U
MX?4&'P<$0C_XUOG99NFWH50T7((L]'=^@.)K/))5%/.7^8,OG5]LI(`.I"+@
M9SH!G]HGP#9N#:="MJ-R)Q58NLE;+MHL^;ARW6VA!RA(D^IOV@I1_K73\(Z]
M\T,\#M\-GJ+$%YP@59IW/D1J0/5:.'&*QY]_"'2<5!1F2\^94)CGR0\8WQ+%
M<6GYX(P_'WQ07HZ`*+P.W"0I?;=GW_Q$ALUV&Z`C*IL:`864\=O-9A/03;1Q
M_9!#X_''0&==*5[H5%(QV,WA"S['H&3V5`TUQ_8Y#]CBS4EV*Z!#-9\BQLSD
MHK";UQI4+I"9D%'J]T!']"Y<LL;/OODKTOB.XK=H;^H$VC?Q*17=XS]*;9CU
MQT#G_,X[97/@V@B$F8>S),$7`(E#]^&'SI_,8.R`"3IK1P/7M7"FS:<%"-:N
MLY@(2YJ\UO?.GT$Y/.:%Q]_QV$=`(XFS)`_K^/^(#\^[&^1/[>FU&\<[/US]
MW0TRWD52JKWSJP$T4^AC'&$E(8V`?7PDV+J^=_MMB\($E1+B'X&.OW<N?K*)
M7B8&;=LH(*$WY3@+.PJZCI):,H^(QRR_H7,!:R%2I%@,AOW\8@_7!T*1W7F=
M"UB3D"*31V-GO^6H$M?T=#GUJAMM49SNG@*W,.[C76:[$4Y17C/G`M92)'N2
M$F$8QUUTGJY17(B$PV?C*^<"UB0D2U]KR-I645"VA$15@&%-/6J7%3+:,:R5
MC=`JO%P<AQQ(W#QENW`N#+$!25@45#"-8TUM()8W.K`;.1>PYB,E`H4Z0`&G
MZW8*NS07`<=5BB&)LRZU@7,!:V<2,,58QYE0QD)MG.&!'HF&SRZ]C7,!:V'J
M2C`;S3@6[>LHQ+^?^EA_FZG"Q$SS&SH36(M3)[K%D,9@E*`&Q8OYYC5S)K#&
MITYLBP!I.YN#SF^U24U5>UAS5"=N&3C8_JTV4:HT;6FZ#6N(ZD0H'0;;7=:>
MZW/K$(FO&LQ3!_ZWQRA<J!ZQI;MT)K`V+@TWKC[0QW&@.TC-*K,L.!-8JYG>
M>S9!H^^4!K<L<'.G<@[ES%;.!-9VIH%F`;IQ'-@Z&5`YXIQ8;T7C@]-VIH-U
M\F@X[XH<>BA?.Q-8\YF`(J:;!PW'*&QG9*F*0BDZVY\Z$UA+62<N:2#&<9Z:
M>9Y?#/O)];W[\-K=^BG!P#Y^TULX4UB36"=>.5C&\;1\@]Y1$.4.#B^INT*W
M(=X'MK&?H+(,![X_9)LL3_IUD\7XP-%NP;69]>W<F4('_G50&CVP^Q_GZ+F4
MH(]S2L<X9PH=']B!?SH,?0<U<WT=>O@X.%-CS'(:KN%,B(.9[$!CXP_+8YT#
MY<^!\N=`^7.@_#E0_APH;Q:'YT#Y<Z`\\_MSH+PA-HESH+RU@?)[P\9L$\6I
M_\]<^K1H-_[[O6PO-H78*Z$:Q2M`T\Z%\+CQ;:"`O`U0SE1X(`IFZ)6<KO3Z
M">`X_XZ*U!?R./:+&_26WH?X<IGG(OP2N@5Z+!X_R=UAN"9J05O@S``JBB&#
M91RO%H>'V"<WGL>YH+S\\>T)Q2]K+%WI-V16!]!Y`U3(ET<T#C^10[PYN&26
MI>LH)AHO37V[(70>@>Z4TY",P^&7AO,^23)EFHM&T`D&^E*\1Z'M,<$X>N=9
MFJ1NZ/DA+>.Z9$OHE`-]B6Y!J=C^941L/_CX-.J5YU3R#PC?@:09I[:&SE30
MG74FG(KY/UG-?,-'JL.)3:(U=/X#%>8EX53,_]EB[\X&5(5C&J>536D0!#`J
M?G\=R\R6/)TQ6D#G/.C%[!["WJPR+EKE3F6\9M!Y#GH1W,)1LZP]'=^I?7EJ
MJ23SY7R+XOPW3E[PHBA.6H]%PG6'T0+`6^?!7Y!<C<3M"\7O^#^29_2.0J[C
M.[,-L`\/6ZJ,B<(#,HIWC').A*LR):=,*FAF&V!''F5V>4#&\7[PC(G`0B0I
M=1N.V"5<#L7<=L#^/ES6Z$2+X(QB*O^&0BR8@+R1>1L_S.L\DAP88K8%+8$]
M@3KP+08TAGS#1X)16;.!78(ZD$J#,(9X\!I7L7\]1(D4D?NO@;V"NF^[!Q#&
M\7S[&(51!>\WUP\3@D[J5"5H">P.I$RR&,XX'FOWN:8(2@)R'N[_3I3W7=`6
MV'5'@D.6NX88V"C.7/?A.TKRO!7%!+DG\9#X;[@W>WH38&^<SEQS\(SC#E4!
M$I^C6U]"^]CTH/0(1__=V820W3R%>E,LA<J*F>4WA/:LZ4RT&-88TICC_4;J
M:'WP';0KC?J!JSWZ,41EW[IQB-4RJ1Z.K]S$7Q`KCA]D*?<93M`2VH%&F5X)
M//H"L.%L&K\C?[4F<01XRW=7Z#$CX3_S90ZY\4@EKP?=.H3VM%%6C^XPM?E>
M&?/45T::E0D*RL0D@*'['?.^2;0_!^^K!^]SI<F876.-WB_P7T>;;122-W+9
M"'Y:.]NB^!D8[&:V!4H8S$_]WI1X?A9#C`,2`XK=A(XMK)_)$F.VGB/[C8[L
M5Z1S\.!^,WR!A50>?0O\A*=((VWXVI[O@,+[Z=DPA4QRVP&_V2FR*H*BS10(
MP_`S2C%\Y%6&%"&U]`;`3W**G#(Q:#,.@F?C*._W]&RCXOFKU!'P&YWJA%;%
M-@8#8M\,.Z;$Q:NGV&F\TEF:8Z=O1EWS`MPO."8EVO!UW6BV^-X4$8MHG`)-
M0X6H&DH(BB&V)"DB::/7-A%[$$F,Y3D]/_TR_2DGA_R-0V*Y2#JF*E%BZ/WN
MQK$;ILEK-'M&^7;QA']N=Q?%C;2_K%H'O?N$?HF3(EL+2M@2DWK5H=!ZS?I0
M=`KU]J:'8WUZLY>&KET!M#1I,X'3#5K$R$T0!KSRWU&(N'X9PK8&1L>S]PLI
M--"^L8S%(M??(ABXN$H\Y=M3KOW%7V,<1:W=!`]WOGR(W##9E^KCN$=J[=_`
M,'K&GJ(3,6R]+#65:<:5#Z(SZC\`%:&O7P_D]:R;E$#WHUY+DYNL`[S$WGY#
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MQ<CB6*V%1:9%_#=7U=]('F"Z].I,;+'.]L<)GKA7MU[(GE$Z=>M,`&VS&LC6
MJ4)[B8S^%%);J*L+8L>CR%$_SG0DMEDJLN'21</K1>OIHKMB,#IRIN9:9^ED
M=SBB4%&/P*N))[P\MT[']2-OZTPML-`JH:G7"1@/R!.L$QU);S1VIM#NL#)$
M=E@#:G0CG_>/Z&O^+UW/#G5[9VJ!45494;T&V)WVDZOJ/52@U8$SA?9LE:6U
MPXIP@-(NJ\7MM\7:#5?X[YO^V\1E[MACCIU=4/=/.%,+K)Y#@*X7%:AJH,.K
M3S=S1^<?<J:`SK"ZM6-8!=P+;`PGFS*W(/)(F#&&EQ//V\>H#9RI!995,81Z
M7>GMTNKYR2*(DBQ&OY%"F*04J"%'EF.7S[Y&+]*',S6NN'Q/@U>%JM:)$;LB
M]E0'2B?.);0!5(7B/B:N"JV)01+[7>_.]>/B3E_Y7N_S\S=B$`M4]^&7T"<5
M]`K?A",!_B@^ENC]/><2VFBJ?M#5+X%Z)3+4N_$V\#=^F.<5IT+]LL7G+C)Y
MJD/7$4RQ7O7_#>?2`C/K(*AK_8$IP<P*UZ%Y2SU&*:($H^4A:_7Q?9:ET0:+
M8K$/8[M#;HK/7%QE&NP'G4MH4ZYT\->0(JC5K+?/DNEJQK^C#_>+SB5@QH1A
M=>=$RKJ7H]G'MB:8T#L4P7V(885H0<;[NY^N#S8`)<.16M?.);2-NI?541WL
M/H_+R)2D@XVQRP\XES!F:JTZ,(QZ[04T`EOB8::38LU-_;<`7:$PST?H!D<+
M,<?8T*4[YQ+:][=S9AAY@/5ZU-W]RH3B7-W*-%U:9&@^&GG-G-U%3_OF;;RT
MS59\-/R:R-Y>#47"O]L0:!+VR]OX,[21MU?>QI\;90Y[/R33>`2KB)3@(XF;
MK.^"Z&L"6`BI'H-:_:.C9@!EC_#238;Q%$?O/N;C:O<E(;?,NI3U#)_GWG/;
MFTRI9^7.S"F?1".#O=VIPQQ%C$&WHPRL';H;6S(''7U%E4!)G7G_DQ6%CI/'
M*%Q@6>5;S&OTC!;XO_T`'<!^C?0M&$/_-'#%)YVJ=P)1C:.L]0W"@\5W2H%_
M3_,SX-I1IZ"6=3,_$(*9OJH-HY-,N)*P#7!IJ=.S+2.1_G/?!%.++B\_6'=C
MN/6`*0YM*=YA3SJ;*$[]?^:@YDMBEKSQDT64A>E3C#9^MN$=541M@8MBP2F-
MC&2@\WX/H3]W?NABP98Y;:15Y[`9<-DM4[3F2"C:<GZ#*@R67)X%O\J&?Q]2
MW9HXNB/9`W`!+S@UDI</=!;GH32J%EM9UU#BVBW?"739,),4BR>C<:3Q/<:,
M=_"MZWME1)`P#%RN`^AZ9HK4RNH'"VKO6[4)-ZMCN+-%?L9+GMP=*>FGI!6M
MMM!UT092"`K*<9C8J%")>V+7,\UQ<^CJ:<.I!`4H;`&U4S\D:GE`A"JF-M"K
MD@)J?<H282TV2EGNPW>4Z'IUYG1F3%TU'<_.`ISCV''P%II?`EZC/"MHC+`4
MO(P`1L*B$L*VT%75.A)+UQ(IM*,XDLJ+3<OB`55&;1`M48.M;0TQ;\NI#8\Z
MMAQ.9\843-.QY0APCN.Q"(->(.0E=UB6^PB(PYB'XK\0_I=V[GO>?M2K8ZCJ
M:CU5@K%9]1;%*#RP&B45CDLH5(_T\_@Z</T-]V*MT@]T636MBJ2,?"3'8MK\
MB5_<@,32BP(6Q(VA*ZP-O]8<P1V#*>89;<M+P'R9QP^+3;2L)M#5U+1J``]D
M?P>%?E<BAN];4VE?LC<\2)(>`WGX[S=^DD3Q+@>2E]BY*8<I]$O0U#-4D36M
MNJ%1%N-P69"7JI;[$72%-:T+C!IL;0X)@+?J'&X>$=9^Z^!H![L15.&T?K=D
M/AYMKF_`-.,S-?D_<E1ZQX<F4E(%:WL<[[!BL_(0*;4WIK:9,OE2T+1M#T4$
M)AYMG(Y:&PS)<#"$-OQ)W^(/'5>=;;=!+B<WJ.1T'RZC>%,0)A$0*]>#,37-
ME/1!`1RT"QDK^H9L;JY_D!F4PZJP#50%LBZ,4*X*(FCCL$?F#I6O[C=R1?8]
MSN1M?0E5#DR.&J:33AO""'(458GBA/SM/X.JV-6/O,/QZWNI!/2D*AV=Z[?8
M<&]LR+V?91XH9?LPIAB7VKND"KQ*)XS*)GR0'6V^;%J=2`05:V<5-(,NLJ7&
M"V5[E<!G8B++UK!;R3HER6RU@BZ3I9M+"CSH1SAAQLDB<]UA7L-F9.Q3%/@+
MVAM;IWZ@BV+U9KP+8-@'-X8&-'+:[\/)DE<4;XJUJ%-*VEZ=0I?`ZJT;O=%#
MAQ`KJ4I5[>`0$S61JIJZ*'0,5>IJ8)51E`#TJQQ#;=12Q8J:0)>EZDVU`)N^
MI[+!-PF1>AXZM^F=_(=]0Y>J`IK_QT(PU+)*A5>YK14H7Z,'DB8S3MAP.?X*
M2LJE\X>ABV(-HWFZ)01KE]!CJZH%M0_4K\M`\1Q$N.V@JV#U41]I@!7[O6L4
MG7Q1NHOBJGY7[OO4G@"O:]28`[2B)CT6IOX_#ET7ZQ2+DQXI52K:N[[1"52T
M6I1_C\)M%JXD4@0J=@-=]&H8M>'CW=OGS-*`O5&1%#`6ED<B;IUW449V:Y8R
M=.\1JD:5-KWH![U6$<-LN/0W!'8U+:5]2DOGT.6E-"I.3RG4.F24#9@\1P8H
M26Z_H7CA)_ORILGAA.`YP<BTAZH:I4T/5(#65/?WAFU1?8H:%%=9XH<8Z:E+
M3<SCE1N6N1+W=3"(FN1%N&J(=1Y%-]B7R)#P%M#2/T#QBE[COJDKU[]B3;@*
MZ%-YJ)\"+GRABW'&[7<`:0WG6'>*E>,EVVS<>(>W2G\5^DM_@9?',CT8<7<B
MKZ$DHN;4^6R/1B!3LX'9"&`%X(I39E[+=0`\6[DB9TQ!:6!#^=.<8EH=1+>>
MW$UO_]M2'GG'GP-,F"H]M_S.QV@!/"48XF1,!C8&F[6?GDOZY`I5VY+J$I_D
M_O<WY*T.0A[W\I>8+3UZ!9E4RJ.5FWG=NP6>GOWX8\[B7O*P>:I3*I&"UT(E
M2[!4P4->0X@S(W5`:E-3N@_P`H<"X;-.CPKX[+Z9/:,@?Y]WXW3W&KMAXN:O
M9"??1UGCD)AAHJ8`<XPU)+59IM`+\#R3H(`QT]0PVCW7&J%VIYY>]4\K'4,Y
MK0`F%64T,K.(UPQXVO#ERY@Q`CQV3Q'R7N*GU<GV.LK--BB$L`YRAJ(TB93Z
M`9A64N.3F6AJ'0%//556&)-1&;/=T_,E>TO0'QGN\?:=8#[Y+:SU^U+Y->A-
M(&Y>K:%(W;18;:!O5FRQLNY4'"16VR:*MZV(_[9U?N/JOC\U'E"+P$FYW8C=
MS,+W+`&<4>1=^4*<9VZ3U-^X]/`-^H<.K$-S%S:/`(PA<0<]^9?"C)5I[\"Z
M(7>:NI*XC`P%?\(**L4BYVL'UD58A3,^"GVY+'7&8?K?D%?4MI%DB=W"@?7)
M56:*BT1;Z#/@FMH(_)1?2-F-'%A?VRZK)Q<,;&"TYAC"AC=@XX&7F6-%J;T#
MFPNA"_&RN+2%-X.FJRMMNO*3G-7$@4V%T(5I#I0Q!`D_8R*P$,D9\`:]HR#:
M$@4NZR0+I[=$:P<VT4$7RN5000<):S+[D50^5VZ"O&8*J/FV=`C'VH^AX_WM
M*7!#\7+?H3?P*O9=_'>[P=06LPNX7MRZ<8AEE3RA.)>"_)X@:`E=>+Z+'DA`
MTA>F"UH_^FM#/'$4XC\N4..D(Z\%JEU!EY_OHA9=,(+'Z@[SBJ2J'E+MH>O/
M=]HR9(&9&7#[6Y2GJ\!J'$L\<XB:0!>(5S;E"+`,%SG;A[/&V?4E=5>(G%7<
M4&(R*K2&KM:NS*0\K)I4FTUT^)#J)WG>M3T[H=<[,J]/M]`5W;NLWGWQUKID
MLRWP&4^=,$//:!%AW&H/WL*VT!7<N]D))$#5U!N6X?`&X2/I&[ZXL!/AE2%\
MTAM&QPZARZ]WV$-Z(*WUP:R2!VB;ZE6'[CU"5U%7UH=^4&N%Z&U(--?![)5@
M/[N7J5^G%VOD9:0*]CYG9?Z@C$\?C;CBS\@EKKS>/,1[41:3U(+YB247N]2U
M6^?O6.C`IAO_"(I4U8*0P/\EC-X2%+\3,=R'VRPE1Z)P@5OEY,MHX!`_9Z'O
MW4!B&(,'WWZ.SK!0/3_(R!/+"Q%)+J;;;XL@PWL728)(;O59E<:H;:576Q!U
M_9B%OH&#"&$P1\)3Y;0I3W(P1YI3)[9A71=JS6@=<V_PRA6YH?#@T:$7*Y+:
M=,-E=]P5-=4-S/2P.^&-<+)1)4V."SF5R>?(0X'XT-^_TS$EL-$BC5%$N`B$
M,$OKPVF'>Z5:E\`G]T$R)/60Q8"U&&$2),'L#B:D21*N\7FQY3A:(.0E^$*'
ML);D!^RJ9H3R^J[8(73HKF)2I-Y@1V"JV<.G.R;F,BV\$Y-R[=IU6,*[=@Z\
MF'=.LZ4#^+@,+WM!X(L0V11G7]W8:PJB/BG-DB3;%'_72]6Z_Q"PP46GVO42
M@I&1FZ+)554ID%ZN-/0*'`G:<^?KB-C(J-$]JGF6)JD;>GCKKJ!<[:[=%*VB
M6%DI%#H#CC7MJ0MJ0,<0BDK7_AG!OLH]KZ]V].6T7$E_*PJTA4_XE!AYOR-_
MM4Z1-\/W)7>%\G^\P>+K<`&&'!=P0&WG'1!89H/%[4*F3(6Y<8\K<6ICLZ6J
M=K76SN-GHG-R*;2Z]FEM4M4^B'5=U@.PW*HP\W`,&5:;]M.":CPRFI=.)^NT
M0H\VYF7M#G5D3QNWRR4IM4LL^Z48G_$ZUO*<45<@]6Z!K6(]M:@37LN?,1KI
M5-U6.E685?U[20+<\,[,4CR4SW[H;[+-,^$V*"\`I)[E?(N/^&3L#PA?#3IY
MOW;O?QPI@W6)PFZ/EJJ6Z`U*73\XEQ3M75*48>?K-9!<YUA&O_X]C[,(J#[A
M#'`5.ZDK0(FGN'<20U,4YJ+[YO.2NW+;`1WI-'+*V!0$H.U6A1:HFVCC^B%'
M!:C?@S\V"ABB$\N"8C>A3]48KP,W26:?\]`\#J'4[X$?`YG,T(ED0;";R$9]
M>B&)1]\"O^`I$D@;OK;KLBI[0YS6\*D<W>,_TS97C;T#/7D-M@7K%8UI&E7=
ML\C-,7,#WMV%^SU0`EG-Y%"8YP`>@=]BL49^1NDZ\N[#=Y3D]HOYUQ`/:>UO
MGU!,\BBZ*]HM3[D/H-2S0AIY)S,Y6"/0A$I`LP7&G>2I5`H)W(=X5!A]<I\D
M&?+F,?E_LE0^9F27+-V>RG_EJ(F>'P#*9=M1A[1A'H,3:R4,?-!Z(PDZ<@=>
MM&7*YC[,_RE&2&H9TM$]5";<GNK5%[(V_U38%T:J+T/^MR_;P%>/+MDWA<J,
MVU$O9.`8Z76:KX+A@D21[&]CQ2FN&%'^%_?DE!>BW-OE=S]=YVOE[;?%FGBG
ML0ZN&KJ&2H2KJ`4ZX<(ZI@ZG)<7V.J"N%#\`E2872&/VH,=0>*4AA@+8+,-W
M@=C_)_>8RVD%E7.WXRXB0**MK@KHH>%0NQ5XYC>$2LK;D6HQ&&V%5J`*$\OD
MR`-R-K`_29YJRC;\P6,4QL<9W#B`M?V&A<GQ=&*W^T&JEL35KO[CWWP48P[6
MNP>265S@/B#7`;!KJ%:^!2HEDL-(]*646N$]=P18Z'*@U`^P*X(\M0+5D,0Z
M$@W)$S@FN7PNA(_=G%;`?@O*[`F4@`IP!`\>-("33KQ/C'!W&)#WB7Z'",.(
MGW8BOFP%'.0[(/%[@&-Y(AC"YQ2V;,8)SHHB^&!.+2:YG\)6T!!2Q'-R.(9B
M]Y&NC%\6KND'WP%7R64R02>N/?01',AJ%<X]:,O8=-F%N=T&NJ;M*5=E&G9M
M^S60WW$#DG`]/OX8NI(MGQK&<PL5A=T+\0N*B7WS\'E!N"QS6D'7HF60Q)B@
M?!PC6+)UK'(/'+?T07X'NG;M*8V[NN2ES5L(V,;WB-)<))4X=A(O;>+&T,5T
M]=,M4"NN).S>LJB9P:^QH#`/'"7A-8.NT"M)&YUS$3"[TPR4?@%S*;^`B[-C
M0%];ZUZ%_E^&1>VG98K_911O]AEK%,RP<AW:_.2O"M3NY?<[>]]7)O?\F']^
MS#\_YI_P;<^0D_UP;WNV']B5UU(E@X-RIZ9X`>C>6;H(PO)W0=KD(S$/1U5?
MD\.LB\ESZV9=WK;ROA2WI=Z_9XIS0B?]D=_2=,A)USJXS;.>OZ1NG,*89>_#
M14R2`MZ@XO_OP[V%R/N?K(AD3^8AS5QT[6()(:]1"^T+OE+']7\5&=XY6CS\
MCYOB<*%1I4\B-%CG+48PWWZ8RRKM>*/B'T7/)%H!^V+H5!`YM-#>60QN\ZST
M2Y+.H$90CK]9U-'S_&*P3Z[OW8?7[A9+*&`QWZ=/8!</[7K14Q9&AH!?1R%6
MPB1/UT-]0&4IAK"A,2XANNB70CR&TD+C.(@#^Z38<Q)ON+WTCA\OSN*WH6?R
MP]+D_+"D[%FTKX/@QB$I*_N$XJHFE;^XVA71Z[F_CNA-2;DO"Y^3NF"TVRZH
MUYT4N(!N%_88BL"!:#?A?7U&#<D?3>.%3B45@]T<CB%Q-)T6.H5#9XV&=.?7
M[OL+^[*B0BL?Q8!%F/K=O.M\/Y65B4D7OP'PFX,,4T(`1M;L;@RXK+0JS=#!
M]\`6]"X$M<=ON4<R]1PG\S+-;P@=A:COG"K$:?GC\@Q?X#P_R(C1Y8580W)3
MS.VW19!YR+O#HB6Q@%F5N;PMCMF&7`%YMW4=_4/'1`IU@*X[NK!_1[[-9:ZX
M[\D0Q=ACN=*2+9.@U(E%YJ1.X$9PF7F*HRV*T]U30$"''HG6WI+;^I<$+;/@
MP5_R#(P2K2$+ERGSR;K+RJ`<2AE.L:*2+-I/[HX<7(!219(1).40)%9*VN<Z
MULAFO]PBD$<?`J]U#('05CG:T.TVKMV@MX9C@,`4?OPQY!)%)8.^#%$'/B;B
M'MT-$MJW64V`K=QT<F2(/(``12=C.<0[W\9/DBC.ZRPD-^0]G&>687T/;+CF
M"9RR0')0@)[XI$F:A\H\U4V`C=&]J6H",=0>W5SS>98Q]L>0I0@E=BSNP"TW
M;SU$;EC!$D?/4[Z&+"C(Y(2^4=%'/X);[^$J\R5T-U&<DHH`-WZR$-@?A6TA
MJP$J$BR#I?]\_;7@.T0K-T4>#.--P8BG+>5KR/I\BJS21Z_OW2]*W0#<0`%D
MUSW;*<YVBN_:<T_5:G%VRSN[Y9G+H7Y?+GM<]/@HAGLB-L)/R'R7.]'X#35N
MG)WMS'&V,^-UQ1![A_KKBO7Y_W4^K\#ZW]'947Q>@<O^/_3S"JPW&T_@*L\K
MP,G^3_.\`ARKW9NK`R2&GD&.1_WZ-5*EK&X"'=_<F[(#)$:Z_U/&C+]7GF6-
M1M#Y]/N3=HA%6U0`:)FJ.S]TPX7O!M+G248+T/KS"J=*SO`M+V12I6@A.9M>
M4/SN+_QP-5]2`">O>"P)_9^$YU&=/P.>S9ZC#'3UT8W>L/-O/=C9"B]V9*S\
M%9_U/70>>NTT478('G8S;74:W%PNK/5SN?@%+I!/@H_#1U11T(>XI7-AB)7G
MD`$!76PLH_-QN0_Q4%"2/KLINETNT8*$D#VA>$'(6O%B/)3Z<2X,<7[A4"MC
M-9*`.0(5:0I,THG!N3#$#T:9X#:*,51\/E3:SVY*(D)W-UAII2=TLY$S@3%.
MZ9Z];4Q&VCS(D"LWNUGA=Y?+^RE/[,;:BOFMG`F,J:H[@9*@8#-Z:@NU7"#D
M)21,6W+E935Q)H8X_RA/5!XB;1D]84NQDTC[I]A?<#/SU1\Y$T,L6<I4'F+0
MEMC2F.V4X@[]%*.-GVT>42\'\7TOS@3&(J5[PQ6"K+3C%[-,%-=NLBY7I+LH
M;FY#S0L`TW-%JK4S@3%.]=R3Y<%5W/[)U--5<\#S974XE#EAT5LZ$T/,4MU/
M66Q@%9M_-FNF/F7Q8NTF^T(!^>[#-"<R/G<FAIBIU)CCH*GH^M7B;1?+I*@"
MLLQWE23)W'"!KJ.$6B9#HI4SL=4*)0"UMUF8M-;.ZKV_'$'Y5A&N\H$+S!*J
M73@3VRQ071#63(_'/-7<<_+H`V]O4"5_]^R&*_39#_U-MNEDCQ9UZDS'8=Y2
MQ5SKDF%5=)JF'LJ"=R%8+)CMG*F55C`96#654'Y`#"HKQ_>\S@6^+SP%[B)_
MI)ZMZ)&V$JV<J6U&+DE0-8E0AJY.)%9))+N16;5VIK:9NQ3!U>3V-H3I);=1
M:JV\"$;9ACDSZ5\[4]O,50(P-5E0=BE=YZSFD;+8+D0V2FH+9VJ;K4H"4$UR
M;P,55,:9<(4/?!NBN_N#WA5R29FI._\;\JH#H3!WLFI7SM0V2U<?I+6B&&;[
M>B4)-X[.@_<AJ31&<.`6$]9"+M/6F5II%9.%5M-JLXVL?_Z:J:TV,0:8O5-'
M[U)Z4>(3_RX3C"1%Z<O4)UCK*ICY(ROM.JS<AS.US7C6"6*M&^.TGMUD9!=C
M.@JI=>!<CL\JUL97ZX-A%K#RM%J[])?F_QN4+&*?58]>LJ5S::453`Y83:C=
M\7#WH9<MD->L=]Q8V8A^WW[;HC#AN1))]^%<VF9/ZP2Q5@V;"T,33'NX)5AR
MJ*U6N^(%F)Q\D2<Z&<AWY%S:9IWKCK/6$QB/-<:.4-UER@<`@B0DT0=12,I/
MD^H^6,\+YUA2QX+IQ:+:CW-II6FO"\R:>,.<T6@(;J*O8;D#SI=8F;.8H.53
MK]J/<VF;T:\SS)KZWJ;`X:FO<7R.PG0=[,A2Y@8!8AOMU7IQ+FVS[74$69/>
MVZRG<Z%_S$CT;JZE9*RYUP^+6-JWSJ651CL6E)JDWD8ZT`-]XUBJ9K'C-W0N
M;37>B7'M0WLT/L^<(B?U#8K]=S<W'/KNFQ_DM1B!RF?MQ])(*#`+O;\A;^6'
MJQF)7RW&YR>+(,(;HTSVZAZ]*B6YUI1<IGKFG24)RL?9X.4S<LGPO'GX3.IF
M$O,0_N`Q"N/J/TD-SH252UO[;P"GX>['+&.NZQ2.W6F%:TE<[>H__LU',29I
MO7M`[R@0I3V2Z@`H!?@@?`M42B2'D>A+*;5\.AX#%F9+4NH'.`&Y/+4"U9#$
M:ECNH_L03Q,W((-U)1)9,SX'3C>NS`'-A,-$9O><SKVP!<M\_0UP/O(3K.1-
MJ):G52[\ZT5%`AI?`6<R/Q`]AYVCK.5VTO/9_48B'X0$'7P'E*6<(7\Z2>T!
M6TY3$:`BIJGY'7`:<CF:6@.V?+73L3<\<-+_#?([P!G13WDSTB0NL'2TK-0,
M^ZH:^2,?%L:7;13>?D/QPF^$0C.-YM(=0*=DU\XDY9"M)`PSTXGNGWJIA8NP
M5"H,_-0`JOU`IW\_A7ITD0EL_CR&DGQVXW^@M`SV:19/"ALW5!*N1?Z2I2%*
MG4`GFC^%>B@+9`QECYJ"S39%\:UJO12E]Q*VA<I??R*M49+#&'+[T8`^^\D_
M[F*$!*FD5+L`SV(/ISHL<6A+'&B8!A&OUD6*O%<4\S)BB)I"I\<'76P.Q:`M
M2R%L&14.TK]'`>87RW;78;VA=P*5AM\@_3D6B+:,AH:N.3?^N^^AT.NA1<TN
MH`H$&*1#;7$,EC<1VOGIXNS]!.C]=+6[<@-RF7]9(Y3^%D?9%H]6VK&)TWS4
M/DM\W'8_M31`-B[L^9HF[X=$:VF*`Y*`/"'U#&PC87T_'\CN5>2[$%=>DVEN
MC@L1BT$!]7QL=O/_1-+)83[2&BT%MO#Y5:$74YR1!*3254(-YPB*_UROR6-V
M,U*^BWHH]&**CU,G]5##.8;:0M=N'.\PVF>TC4@H;2&H3CJBUA.PMU1//5'&
M.H:WDCP+;9Z7)7"39+XL7@WY1TMF&V!7K'Z'2AXJRQV!FHB$I\?CCX%=M[C$
M,.8R#8/=9T+J\[YP`>>T`G:THE/$F)I<%,!.+SKIO>I$+[45M&^4.K],&-I6
M7]BG'WH-<=X]GE5UW!"WIFZV&S8H,$=&/03KK"7.T0J])<N!S8`<9:"KCV[T
M=A\*2*[<US)7KG"S./X8VI=).YETG:$#'X$AZ(4\<N8/)T\!\E;XSII<1T&`
MC\NQ&T@<'H2MH3V63J0@DI(8@VWH)7M+?,]WX]V+&R#)^SZKC3'N2=TN_#Q8
MVEP;@6Z+>T2/[@;_,9]);IYW27C"$#>&]BOB4\>@6PJ5W>>!I_R='=4U3L1O
M1-0&T"X_DE0QGH.8D$:PXS>+(Y`=3[!RTSYW+F#->?T6;18B;8[$<`?Y)BSA
M&DUOX%S`&O68[,B1N0=A]S+\GUGH1S'>I#`*?!XE'H0R%S1>,V<":\[C4$7G
M5@1F!(MQ_3#QLD"A&_N1[+M9\WMG8K,UCPE)F[L^T/FYA/,E3+9HX2]]K+["
M8S.KC3.!M;*Q26*0R@-B6C*F/"WX??C9W<U"#R\ZB'PS7^*18.T59&:2:.M,
M8$UD?"X.^5,"9?<.NU^U*&M6;0/:OQR[A4/_@THVBXY=.Q-#G.EZNM9V1Z\M
MP`;(6^*P0`7%`XBG/A*MG8DI9K,>'#,<+^30C^+)?IZN4=R(H:&`Y>B)1&MG
M8H@_G7X]D40_!HL[-=Y*G%:<U\R9F.)HIUTQ1+"U^0@<+QW0P7=E:O9S"!YL
M`O+!PVE''(HGQCZ4V><4DS=_D%A'`0:0W/Z1^>D.J&;`\4!(A0:)6<EO"##Q
M7A9KY&7U:\_5+G<;%(6\<EH!3R^A@)DF%QXBN^_J>D,,@$UI?)X$1E(*&+NI
M[1M8`&Q;X_'"N-_2,-C-H?[``EC[%YTBQLSDHK"<UTJ[BWV(5%2,PORT)[GT
MTMH!1X+V6WX9@"P/[FJA$B[#U.^!(S>%%-&994&Q>^(VTG2*`W3;WP*'8#(9
M89F+CX=O.7F-W4?FM8GZ/73`99=5E@7$M.SDLR#_VL]+D;O)^C4ZW/VKA,JL
M1V/9]@:%5Q[007DR5H`$ZK4CS6@[9[H2G93&)L52JI/)`&1D%O#CT<\\SR_&
M]>3ZWGUX[6[]E`Q2ED]&!]!1E/TXY8""S4HAS>OQ2PBS++I48^A0QGY\,@!I
MBT+16]"!-_[R2EU6'6B\<G5AE]D9=.2B+K:Y`+7YM!O`_CQ4V(+E^H,.3AQ<
M!TJ,T)FO.ZC!X?FQ<`I*\)==5(#5%W3PH2[Z>?A@4U5W(+XJ-J-^[&;W`1UL
MJ(MH&J[!,DGW(?@ICA8(><D=%L6^OE#E0IP\(MH3LV1+Z-!"%3+ET%04_KDW
MA1$^P6NBL!KD=92PZZP=?`0=%JA"S-'`*PY^M6@:_19'"9,:F;;0P7X:IU*-
M9V^4T#V;0!V$3IY7?T0>0J1LW96;((^\*J`P*=4\)EE=\Z31N_TG3^XNSR'T
MU8V]>>&']G>4D&2>H5<7E(G(7\VS-$G=T,/:]YB)WKI/-`1;?9=.)QY=YN=M
MG@?X)77C%"ATM*?,?BM.DF&1T)BUE0SX:]!^6$"Z2I?$&,(4OJ=U%MKMS/!U
M=JKO#:%8:&]#STZE+BM>DI?OP;7WZ+>`_>B@U)0FAS$4&AU^^OZ._-6:?/..
M8G>%9$O>P@X,VJ/0V,58(#1MCT/FGX43I4/94+-`WRC`G2T'4GFM$H)^]3HO
M^D.N7\#Y!>U<]/^D[SUP/.=R(/V7'`&T)R_\&5X@'6T/H/#+_)M87F^Z%H9G
M1!SK\R>P,.<R<P.2XOQ"I/)&#!+8-[K7K#!%@-J>G?5Z!6DQL*+VX5!%W2&&
M`>T@KJK14#+2]DYO]6K/WATAEO4.HX'VG8=:P#N*2I]3`[S:#WK[F:U6,5JY
M*;K'0O3#Q%_D665`K[&,,4&'&YA[A>4(K)X(O1]*>Q@MASVX"#5WN!^#CHF`
M/(0<2Z+6M0$RQ9T77:@UY/M\$NTEL'HB]'X\-<%HJ.?T=BBE$YVN6S\*';]B
MP"&:(I%:6WN_:QJ5(7!R=@#6D"*P\P.D0D+!?K]AJPNO1OQVYV\IH(@K:QU\
M!^T,JY,]NH*TX=I-<G<Q[>40>D^!&Y+R=.+",`/\'+`/ZY$^Z'89X2*W6_MN
M-]L@VB&4+];%H4B8YXO9!MI)="""Z>K$D\((ZHD]$Z$)]IWZ&VB_R>'WG"94
MRW,TYE"$D[SQ%;"+X('H.>S4@[5[1?[L?O,WV49(T,%WP#YL+?G326H/V'*:
M_%".IN9WP!Y8<C2U!FSY:M?9W/D@D3"S?^?0WD?#[YQ:9&1:XLZR"%#N.#A?
M-I(:LA[9F`W`O76TT$-Y3.,B'L$!N;/@:`5JGOWD'W<Q(D9HA/4@%=3W&?RW
MP9UJ!M#*DPKONX["UE#!:O#?!O>9L47#6<(;L/B=[3K^]RC`W9"\J1!:?OCK
MX(XXMNGYL?B^ZX!O>5&5%T=8=2\'`>Z<8[?6-Z2H+;1[Y,I?&+>`E;\8!+@S
MC^7*OY>BMKAO:.7OXB+%D]A@<2#"'X5.P#NX<@\FM<'R-X,ZLTW/SFP]RT.5
MJ:#G\3.)(FKX\7*PB)I:ZGHF`<N`K(\LFS1M\&5(`M,LS6D#[4C6)8)#@,?(
M,D/4,5>I"=28JUM9EE50#I&1Q82HH[Z+XB7R5>==W0K:CTH;>TU$8["B#+EC
MVAF`(0%+<W*X#B$_*E.W"&_B<ZK0VK+T:FK(QI$6C;OOE,_75;F4\E\3WMVW
M4W^6)B'KBE5S[K#!C]$"2%U.V7)=6I:S2P-<(ZL0=8'4[P@OZA3:<>Q4BM$$
MK*^Z$;!J=+L?R'8*[E)V*MTX0`Q;=FE,1Q%HWZ^3GD6TID0ZR0U%`*G?!4:U
M<W`WJE.M-53D^G((&?6F<GE^4SDG"#!O[@X2M&!U$!*^]Z8YSD)\1`A12&`+
M`C>Y[:#??4X0DB*`;[=2M$`),P)0OP=_0!(P1">6!<5N0LNCB##4\.`[X#<D
M)A-TXMI#MYNP<^S\.7;^'#M_CIT_Q\Z?8^=M7NW.L?/0%Y5S[/PY=OX<.Z\>
M@GWB6#3.$,!?4VP)QA'(\!Q0+R.OTT:A<88`_BYDM=KO90CK\VR@VIN71^(<
M7]]+>-K\PL>>1^(<7V^QUI_CZ\_Q]6?E/\?7G^/KH97['%^OY`OVBOO*,(:S
M1UA?'QVA6]?!A[;Z9K5!V/U25<,I749SL<@Z5[7;0#M6'5$CH)`R?KO9;`(2
MND4=?VR*3Q2-%SJ55`QV<_B"8A\ELZ=JJ#DVX4LRIQ6PHQ2=(L;,Y**`XI55
MP[88;.5'SZ2(_3&P9Y0,,]S!&YEMI!CLE0HMK8^!79H4:3D>O)%I1&8K#%V.
M%,JGP"Y,TI30ASZ*S"!1^([BU,<G*\6M2=`2V.U)97L2(QF#L;-;44;H:&VY
MHW][S&/W7[.@M"*PB].11G0T&W>$;MB9]AXO<`G^6+!#MSXSW@6H*SF4'9X"
MW?+[9O:6^)[OQKL7-_?UE+$`L=J`>\7(FH!X`,#\2341ND=$U'F^?,7S('$7
M!(-XB1<V!O<'X5+'H%L*E=WS^"GVW['RXU5LD<\`X;F<W@#<\4&.*CK/;$AC
M\"D>)!8:^JE?U6;/`J'MCFUS3#/TT[:0)#JY3#"VK\CE&',;PTQB0:9\[US`
MFK[8W+"68`8(N[ELA*A(&+Q:WSH7L#8N50ZI`&PWE51KTX-,Z-[1Q\Z%'08N
M^LBUF27!)U]A@DWPX/%=GGOL83=R)M#I`ZD<"><B!<8(CK54@'?(33/,CBJ_
M53MG`NU=U)?B)I(QA(;MD96WN]P@E]PG288\;HI';D-G8HC!28YH$90Q1$,=
M/HTUHV&>4+P@'*UX7H(RS9V)(9Y*,JS+`AI'G-`AV@<?'SV]G)[B'U"X0+FC
ML;0&L+MP)M!E1#IK`1^4MN,:;-D!^FI7/J)W6O3W;9V)(7:K'NO^(9IQU)H@
MXI@OK_%8?9X3>_,S9V*(U4J&RO;`M<5$@+)6QV:C!?+?!6[\QQ\[$^CB'@H,
MTH>OK2B#>95>'C-BPL$K#UIDL9_Z>.%Q@P!Y5[MV"FBQLWC7GIT)=)D/E>6Z
M/U9MA1S,4Z>39^N?&&)YZZPZ,@AABSLPO('*D;Y&3UF\6+N)7#8K?BMG:H'Q
M31*'OKH*L*D=")[""'&#U[9P]534G&H8)^ZB^`7%[UA_^69SE8Z<J44V.G5H
MPY5..*%J5-:*A.YBQ]$%04MG:I'=3@)+S79ORQWPG;U>X)+[<!%DI!#(S,.7
MG1S+D^M[]^&UN_53`DS&-B_LQIE:9,M3!5:KA=U&O1N4.U;Y[^C!=]](H@N?
MNQ%0OW>F%IGKF`AJ1J&,<XRSVE,<+1#RDCN,F^Q';DC.FO,E'A!6T>2W.$IH
MC$FW=:86&-R4T-1,VFUQH\,]-#<3[_;:S,PZO/?KT)E:9,7K#K%6&BB#'RMP
MHT9!C:$NSJG[JXS$-:Y[C\[4`G.@!HRU+IA5R14/TD_(8T."5?@12WZQB#+,
MPEN`2$J?,*%NW=)MG:D%ICPE-#6/1I5=K9W8\YAB$7/TKYVI!;8SP?AK=GJ;
MQ@QX#:7$#I/T6@DQ+55OA,)G49E.G$L+S&S=8.U]9$R:KE3+;_*,/%2D4\NA
M,-==F<;.I07V,C4X-95&91#9N^7@<T$4^`N_D/4=0O.PLMX+BY^K]>)<6F`/
MZXBK9MEFK[;"A_XS2M>15\0`$VG-OX9X2&M_*^7:)MV'<VF134P)5:T+-N="
MN<H2+)<DF2TP]"2W_15"J'P+RA>!>9Q?,/"V5K\>-]X+.(JBYP><2XL,;OH@
MURIF<Q*62ASX#O/FASES+RG:,J5S'^;_%",Y)UL=W3N7%E@$=0.NE<MNHR$]
M^VEA]-@&7-<]45/GTB)#H`R8FG+M>8_U&/P:5JG:9EE=H.Y#?'<*41X]_[N?
MKO.U\O;;8DTRHX@M?YV[=B[M,P'V`ELKB5&V0`W@BMUU0%4I?L"YM,6JJ!5R
MK3;:38\FY%2_."=5/R=5_YZ3JFO-U&*(@:A7HA;;$ZSK2=-BB'&'Q1#/S',,
MQ6Y"^^7U@+6O,!EAO;(<#]]N\DIKLY"X@^^`DZXKDM8>.E@6%HZW0:E41U[0
M_!RBXI;`>=@EF9(',X;@_F<4X-W#>W+C=-?(S)=<[9K_(CCGR'<"G/==]M"C
M!,CR1$I-1,+SS_''P.G>U9@2LUV#,BR1<W.,_'7X^$O@7.YT\5(67>K(#>/A
M&NM6%J3BHA=''T(G1I>F@3IR;8N<7C?9NR@+\;CDZI!0/X;.=2Y-"W/T1J2W
M3M#BQU7T_LE#?K'UX#^T=QS\5\X#6KG!;9CZS$,%Y2O3LY`SALPF9E@9%Z-@
M[N7M3Z`2@+.D=BS;]FB9>T+O]>0S\E`4WX<+_DK2^@PJQS95-I2E@S)<P[;5
MWZ-PFX4KOM0//H)*="TK\Z/!6GY-Z)UOU1`O@@[Y5O<W_9,G(Q='!^5/CP=O
MEZ_1"TK3`#U$;D@"HE[7J#P[B%]]E;J#3F7-X(K[QJL,<`0969O1<03D//97
MI<\4-[T+MQUT#FPI\J61&%GY\@YW[;\CXN8V7U:.;&4HS3PD.-@W'5%+8_)?
M"^>N'!8C:V3.WP)_E4OV)D.O4?.JQV*.T\3$--=TR@0@QE`^LZ6(`FHE6IF8
MX9JYG@IPC*%J)BND_+`@D>3NR>[`Q'S74MLH'Y*VY*>#>T]VC*$7]6!B1FO1
MV5@&D[;\J,;GM3,P&36=0#&.$2=#/7WV2O."9-AU?[HBU);N%'`#GZ=K%,\6
MBSC#8]WG?'J,PD46Q_R]6]C6Q!S73#600@.;L-3NQ)<&ILMF*H,ZM)%D11TN
M]:6!N;"9]$M@&46BTUF0=XX\.L[RXLHA7:X#$Y-9,[F7AP2>_53E!M<.S2IB
M@,E_S9</_L(GH&:K&+$N[)IZ-C$1ML*-3QFKOE2HD">&?77J_#R,-\-\<O#.
M!HPF)J:_9I\"."#T942%)):ZQ,W(76>52^EJM__DR=WEJ<J^NK$WS[$FO^67
MHONP.!VQLJT.^&LF)M1FJ],P^/5E=(6^E.0`#T_<>76P7"IO;<$)U:UCER:F
MYN9?5#J"U)?5%7H).\)X/*G>&)/J,<J3-Z'JO_&U;HE\_-^_(V+I0=X,'\[<
M%<IE?(.9N7/]6%3+#VY0)J8;YR^(8&("3F1KAOK_/9??85*I`16;]G,FYE@?
M3&59`@#.QCNH93&?<8_H:_XO'0R*A^U-3+FN:D<\1C22?+]<NVD/%6AU8&*N
M]6ZVY`-(^G+\ZC4H\;2X-H9?N\DZ0$F=!'7_:,:R)O7LUL24['13D@:@^G(&
MGT0U6@\EVG1#NE\3<\`K*8<24GVYADVIP_7DQO,X%V(Q321,CA*M3<P/S_9+
MD,,SBMS"SY@.+,KU+/1NT#L*HFV>JD?X_L1M9V+J>";;0B3Z$OR:,L?+*),L
M35(W)"7EY";W43,3L\C+S&HJ$'VI=DW,C3@YYT;LC&2Q1EY&'J1N-]L@VB%4
MNI\PGA6*9^S\9?(9+:)5Z/\3><79XCI*TD288G&(W[,U4^-`LK`[$=E]B.<]
MVJ]^)69!&B1.*^ADCT.Q3%<JOB!&J1K"S$G<=L`9)`5\*9$\DCR2W$.K,$&A
M1&O@7)-"]CJ<Y4>2A?(%!;C/U6\H1+$;8*0S;^.'/ME)2?W@JI:=4`F4^@'.
M8ME1'50A6IX#(W_N>L6_(C@(''P'G/7RQ%M_&[KEC`L=FQ*69]->$*'W%+CA
MH[M!PD/"$#\'G'+S2"$Z>I!U0V[W3E3/6'*Y*Y[9A;L.LPUPHLZA"*:K$T\*
M(\CHTBU1-O"[T4D5H(U\Q/DK@1]^3D(K'[^9R5^62WS*BDOO*#ZSM&^A$Y.>
MD%@6?-/2KNTSXTJQRO@</)OIZ8CE2&`,.6(8R<>[9<LO\I\".^B?]K(HD(01
MB8VU:X=2COVC=E"I9F4I4R)Z#\FP=+18ZWV4S`Y+`.)="A$O)L&J+],6*GFM
M/!^4Q5P6F&%<WJ"W5)(ZRJ?0>6L[,<7`85JMH1=B)D8K?S'SWOTDBNOP8L$$
MXS>#SDK;;6Z),8US-QRLT!!T>EHC3E(,P8#=J_2K4I>*1<"I;Q6Y$A.^AV7@
MUONWPB=)O/$>?`B=ZY8A7L9>>S1TPWBXSX-)(Q$+K<^@,]+*<T`9N&EGG3H[
MZFPE/.#0OH7.$RM/!FOT8.<7_96\@'.[RG-!';JVW1_4V_[53\GIZC[T2$:S
MS`T$1T?J]^!)7D][2F3*0)LQ%N9`>(2+)+#*9PDY5ZW][6MTRZ^)U;$GZ&RP
M;$(E%4`,SVX/BJN()"A8WO@Q6I`#PO7:]>.-*W:CX#>$3O_:A4>Z1HAQCL!=
MXGKMH^7M-[3(B%=B^=HH+@_/;@6=\54?_P*01KCO#5M;$CI[ZVF.``SD[#H-
M9I6H!$JSRI+:L6S;HS6N1"50=E*J;"@W%<IP[3YYZ)G-#Q+%%C7_$G@>T]/>
MB0:0GK8:*8;ZO+/<@PYS?\VR=!W%1$Y]'-Y5?PLZ;>H0ZD17W$%$IVO-U>LE
MVQKQN^L'9%+?1?%=EF9QD04Q^4*<0QL.W\1#C;4[=N\1.H?J\`JF04"&>ELW
M1IJ0H3;_NTP_1$`6<F*['RAT`IVT]$3:HBP3(SVVN:.^0<DB]O-_E-$,7GOH
MM*``2B$2!VQ)4)8'?S'V9F&UA;BL'+\5=([/$W$O%@*L_[?$"G`=A7GNE,P-
M7E&\D9GTK2;0N3P!YCE%`D:6`FWD+,90%X2<%2UE$/MCZ!R=IYW(Q]B-+`3Z
MC(B-R0]72OSR6T'GVSP1T6(A:*LB>@+&Y0YL4HVA,VO"\G\L"VVU035'TE8%
M$.;+$L$\K*LCL!2`VP@ZR>:)B!?*8`R50>5*WSVB=+Y\=;]Q#)9J'4'G[SR=
M-5)=+OK*BIZ+E/2JT7$Y=H/FT-(;1<%4*1KJLD2Y6/#U/G6#YK\3*AZC]+]1
MNB>I>3WL^XK9]_>=R[&;8T\N3GVE8J&7\1[U"QN9KEL%NJJJ!GF5S2$>0M5&
MX%R.W?0,(%!]E7!A\]<';I+4U3?F\3-!7>]V:)'%?NJCY-H-`N1=[:HT/.6'
MO+6]9\_.Y=AMYAH%I:]ZKWG*>##S]G5B*O@7JBHHZL^Y'+L!O[=X])7HU6L.
MJ@8K^8K#^-RY_"Z,_!STP)5T^>PVGQ>OQ2^S_%;.Y7=AYQ<+05_U6+U3^DMY
M6:FT=0]!@GNIQL[/WX6I7UH6^DJW#F;KKS`4Y>0D[/R'#9R?OS<;_S%^?05:
MS2O06QCIZ&+-J\7SKN0=NW1^_EZ,_GTDI*\BK'E:ET\UK4HGZM'Y^;LQXG<7
MD+Y*L]`J]XRVY8[]%$>KV-W4K_<LY_[7Z`KM6W%#,K3\@//S]V)IUR<O\%JW
M4N$7]^$B1F3(I0&U+#HG%VG!:.S\/':SM)HL]%6^/=:$4Q3+9*4X*TMFGKI4
M)FLX$L4R14T!RF52;76BFI?L1L"%*R4$K&*S'$?]R6Z%IF"O'7PZ&%Y#K?';
MS=H8BD7!7B..]*'CVVXWY(9E;3Q,I/>*OV47GN0W`*XU.11=E!,63P3`L<T#
M;OZ"78+9!KCH9)<=@X?%B&1%FJD5[@*<5L"5)[E4*;!;@['\=$`KGR!11);9
M"KBPHX`KQL[-A6-F]@EZW8M0L!GS6P$78U3B3@Z.ML57:SQO]H:'Y8?Y#1-+
MP4^2*-X]1BFJRF,(2)1L#UQ:L0.=\L#,3-4@'+]X@LIW`5UC<0A^#\`9F7YA
MMO@C\Q._,+@6^>'XC#(;0)=25.>/"\7(U`F?W1V^I/UG%B+R;W++*Z\-=)5$
M=<Y$:&`3(0QX1WF02%+(;PA=]U#;3?0`D>45FZ@`&V$1JFPWFD)7,93@3H'T
M%K#QVIE.[G\/7"91KYK(H#4T<1X53W+[;>O'.2>L#5[4#KJZHC+!TJBTK?U&
M/N"_XAXSC.7\CG]^QS^_XY_?\<_O^.=W_/,[_OD=_WMXQV=9*XO"S;L[/]X(
MS)1'7P*_PY^05RIVZ$N/GEWC*DOPQ2%)&J9;P:[/:&'BL[U@_V<CL=PG@P:,
M_!&O1\)]7=@6^`&?0YH\RVU`ANV]+WZX"M!L08J;/>$E;(.WE2SU%VYP'Z[P
M6'PD*L8KWP/PF[X4.[2G0A6`AM'+'[6@KJ]48^"7_:ZDRF(SK4RVS#/OX7,H
M[,M\5W[:&&"=+'1%)KII?ER\Q0)(=^0L&85$VP3'(&X[(Y_N!:<A(2#+'P9;
ML(0'(>KWT._[8I+HY#+!V&WS:F3^$!?&;7\+_7S/YH1A<:8!L)N_6IW+!2L'
M)[OPMML8^3PON^C2P&CS;P/UQ,@AR08$-#Z&?D;G4\-]%&JAL'R.:H\`,./Y
MO$T28X+R<9A`[;"%QB\,C-=0J!9^\2>.XZE9U<(O8"PQ+*D=R[8]VN&JA?\>
MA=M,Y(=[\)%S`5=K_4@NE*OST6!-6#EZ;`K96X+^R,A%Y)T\=8F=!1@MG(F!
M00JB0QL;BC9O:6-H%3L"L-HX$^"2[!R:I(G=0QG5A!6?WVC?.Q-@ZP>7'RE.
M]T#LYG.HD(;)Z$(:)GLC2>]LT#!</\71$B5)/N([Q"VUU/[4F1AH$SGDADXJ
M#8B9+C3[<I/SY=^[IWI6[,:9&!UD<$QL5Y`FN=E4-S\_3T5-)O"T_#/1BVEC
MZA9_Z]SG_T>,2!5.464=N8;.Q`@3BCS[\K`&#$'H,\M)[E8W;$;`*,UNR>;.
MQ$!KBW!6*X#39M(&85>B.*]Z3\[$P*P:NCAOX=06`ZZ7?E(V9`^$1>WA5\[$
MP.P90MJ.,1A9Z/X9^9NW#/>7/W4755B9O%`_=J8&VI6$]#"A:+O!@#H;XT/]
M`B$ON</BVB\@AV\KQ"<[_PN$_Y&UI_;KD"0ZMDHW^L.M]`>J.(XN=P%V%OU'
M]#7_EZYE"NKVSM3`2#89[9!&5RD#5'V<096AR%+>0QM:'3A3`RUB/=2!`J_2
MA]Z5=,S5A^+O[Z*XS)7?62^..G*FEEK8U&'N33%6^_MR8#<<HCMK2+,/9VJ9
ME:X30GV5Y$$7D'FZ1O$SY@G+>(V/43?H'071MG$4YZB$N+$SM<QFIP9-7T5U
M`Z\HS<2$#U&X(M?H&_3&2]VAUI$SM<SPUQWF2.J.XPF1QMDBS5?':[PNKKB'
M"MKGSM0RRY\(S$BJ>#.2PC1LF?-EX^^YK"OUY$PMLRGVP`E>@EMOJ/5UM'DC
MZQU&<(V/13[&EO]'CKH`PTLTI]*-<VF9:;,K2'U5O#6_%N6OF%%<)4O-WRYE
MWH8$[9Q+R^R2TJA,+<Y=E;:[#5?NJLS<$J/\#RP2.4V<2\LLAS*`3*VFG<>*
MYQ)FN$11OG(N+;/E,3",HO8U)0B]B(B\#_&H\))2F!_F<7ZM>`L$*ZR.;IU+
M2VUY?4'K*VNM=Y(_1SLW2'=E\J9$8H]EMW`N+;/%2>`!K@W-9^T9+9#_3@K%
M/N`309@@F3.23%OGTC)+FA(R??64VYR>(@7O?8C_B%[=;PBJ;&X]@AL_6011
MDL5((M,NIQ5$DMTZK\-\>5-2CL<V2Q*4RN0-EFH/G'J7+W'&1B<+;!39[(\`
MSK?Y33E</43X%HV7G]TRBDDR0Y[E4:$7Z!R^LN32=4,-J"X-`3Q!'P$FDZG\
MN_)EYB`U9NA=H1`M?:J+8_].@;/WZM8>%=PF!2GHU:=KDGPM/9@\U5.@HA)Q
M>@+.$#R`YO#!CB%OFL1\(8CC=Y3@N3);+.+,#7HN/)0.H8L!#[[HT#'#EKX;
MZGA#'`V43C*D`73B8=V'EA(3=*C$0!P3;]2"HB"(OA)O`17"CUM#EQ/6S#X5
M8/\0C5\+50C1*O?(,$,5'A'O"DO['+K^L&:R"T3:0CO2*'4#<'//Q=G>TR$W
MZ7*)\MS'];">\42]CD)\>\U(V=MM^42>E/_TC!91N/`#OY@#8KR:?L%&FY$^
MZ".P&="%T4*<WB'BDQ&0%(@9'LCNX&-E+5/J'=@&I5%95+11543?B2;F.3CQ
MS><ARC/!UWM-3Q5D=0MLP3)"]SBRT6;E,ESK'B-R",KP9V\!$KO^=^T2V.IE
MA+8QY`*=!.1TNI9?]V?>_V1%6I2^*UN[.V#SF!$Z1I')&,QG,M"OUZ08VGW8
MSPRC^9>`#79&Z*2:N,9A"Y07O)9[++!E$$C-&)(8+,L+C)$)J)+W&$Q-U,=)
M4?UN=B,;#4)<-':GA:5"$V3F9K8!-L7P:5*@=A3EO:G(I"IU"UH"&SVXC"F0
M;$0M;6VAQ;FGB#!)]^&'P/8$"5;H=!ZA&(%QDRJ,!XGTW/R&P-=Y;2MR$Y#E
MM9;IZ]<FRJ@AA!*M@*_'8KY4=MX*T0BF="?G:XX+,NSUM"O-7$!C>""@"N;V
MV]8O+M,W_`=0B=;`3BQ:Y_<1LC%XMK)57%H-9+L`KM.M?Q$X@C<&2SL;[H._
M\0O6DGGXA9\@3+H3Z.K@^K6"AE";31O"(DDRG/O%:Y(;>H7-=87"A0\6]=@8
MT:P](A5CI5(_`.;+O9(A-T')79;B\7SV0W^3;>H@Z4P&J6)/P(9.55Z$<U06
M]"@B*25A7V=Q3$_]TJTC8`-J![)[:<T>]?>D-/?AZ]?HOY$;R]T#)?L"MLJ>
M6G4.@(\CFE(>.?Y5I$^!ZMZ`[<$`*M2$/@X7,FGL=U$6:].ANC-@>_/I5:B)
M'+I6U4DUJ+_:`-NM3ZTK.MVR("*W>!<*4">;[^4F^[)8(R\+T'QYJ'%>%0G.
M=\F1:3Z..ZLD4KO?_._Q[%WB129%#R0[V#UF*UP1I_@"Y-7NL_L_49QG'A.X
M\RCV!'Q'E267KAKJ6$>M)7NT4HY!'7H#OI9VX+N3XC"@VZT\1;Y!/,'J_+Z)
MT,.(V0;X<MF1/[HR\$!:3CE92E7HIGT/?`G42S4#()@3$B.%Z@-:N0&3KO8G
MP%<O+0Q1,&DSX0"Y<9(0'\%AK?X&V!VHWS&LB<)R=[X<BMCQ=O\5L#O/@>@Y
M[-2#M7M#*^TP0H(.O@/VLFG)GTY2>\"6T^1^DZ.I^1VTWXL<3^T16[[>42H'
M"+8L1@OG`M;8U&\'XX"R_!1"0T;^B(_`0@.!L*US`6L]XM$F3_01)*C%EW$9
M^(P\%,7\VT#S&^<"UDHC)V/*\;\-8E11`XW%Z$$B$(C?T+F`M;_T6VW%V+2]
MO<(LNLVJJ&69#U*[J:K]P:%=T-*Y,.E%GLH<G7()7,!.8X(2<>6@/0R$Y"MB
M5AQC?>]<F/0^+L&<$`VTFQ;+=%8,-8]$V)'"PTP#6OM#YP+6"-.-(BJ,<7@_
M%=;:T'LF9`3B3&S4[YT+6`M-YR63B0;:,8DQ\6ZB["U=9AR>:)\Y%[#6F6Z3
MC@(".DD3@Y5KDD,J"(I,:%7-LN0U>LKBQ=K-BYIL2-;':/$/%F,*73@36!M.
M-S85`6I+IJ29Z?TH7]986LGMMT6>9HS)*ZN!,X&UY71DD0='6Y;U(0I<YCYW
MDJ41#[]U)B:%F,@RQ4)2D015)5J38Q_1P*+@ZDV65\1&L1]Y)+,?:IA$>)=_
MV2Y(K4FKZ.\"L-**W@6H!ZAQJJ<R[<2D2`VU2<S"4Y$&4Z$:JC#MQ#+KC!*R
M_7W?QI#ME^PM07]DN,?;]T)?0>*TV\.0<&1G-8'P63\<BM!'G?(YL$\Z1YBL
MK8H.PNX'^C8H_'N"9U]&"VCW<08Y<E3N,8R.3>';+K,-L(LWAR-I4D?BL-U"
M)O2FH7X/[*C-94>*4.VNV+"7PT-P#Q(OP:PFP'[9O9;>!Q,20#)N"5^V&&R8
M7KO)^@XQC6>'7P%[8/.D2SGQ'XU]'%.+;E,H;('%W]]%\0N*W_']IH/UA=$1
MM.>V-/6=X6F;H%X=]?E;YGMYU1'@]9=_\1<W`O;^[D`^#\J`K\;4*_XG,L0W
M-T'X/_X_4$L#!!0````(`%A%,$5MHQ6?MQ0``,?_```1`!P`<F5L;2TR,#$T
M,#8S,"YX<V155`D``T<P&%1',!A4=7@+``$$)0X```0Y`0``[5W=<^.V$7_O
M3/\'UB]-9R+K9-]=>YY<.O)7JHY]\MBZ)&\=B(0D3BA0(4C;RE]?`"0ED%B0
MH"3'X-$OB8_876!_6`"[^%C]\._G9>`\XHCZ(?E\-#A^=^1@XH:>3^:?C[Y.
MKGO_.OKWCW_]RP]_Z_5^/;^_<2Y#-UEB$CNWC&;F8\]Y\N.%<_5'[\KSXS!R
M?DYE.8-C)NQXX+`_)PFF'EI_[SS@58R74QPY@X_?.R?O!N^==R=GIZ=G@P_.
M\-;I]7A-U%W@)7)B%,UQ_`4M,5TA%W\^6L3QZJS??WIZ.HYPL$0>.G;#99]+
M>??QE+<[P+QEUV&TO,0SE`3QYZ/?$Q2(9AXY3%%"SSBK@2Q!7*![.CT.HSDC
M>3?H_WI[\R!:F4L-?/);@?IY&@4Y_6F?%T\1Q3DY+_7B#8-,_*&?%FY(@PJY
MO]XPP;)0OX+8)S1&Q-TV0FETIN+@TZ=/?5&:DQ(\1S'VM,(_]:,PP/V,+.=*
M:&^.T&K#-4-T*CBR`@%W[]V@=SHHL?10'.O96&'D3Y,8TYS-#1,21^LBH!2[
MQ_/PL9\5\MI.B[6Y210Q8]?Q9:5`,SWLPSRL`"#'S^X"IN<E`(-/'C&-89:T
M#-"&(-^E,(\HXBR#(@OU79B!%0#DK`/B]0I3L&M$":`+C5>1IA)6`M02X9G6
MT#[V6>FV%U81=FL,$T6NL,T9<N,>?EX%B"`V3:VOV;\WR(6$)$M8B!='?:Y:
MGQ'U&!6.?'?#5\^4,?!Y#1$2QBAF<^.//Z#5RB>SD'_FX^R,-W'"&!S^Q]?[
MD7:&$KKD<_"0>%<D]N/UB,F*ED+VD>,S."HI-K5Z>.837[2(S6I.;SNY2W\B
MXCFI#$<2\D._+"$7FE#LC<F/XF_6/Y3)$!Q\JLJX,A*(8RO0C-Y%@9L$^@KZ
M!7AWQ/LB)#0,?(^;VCD*^"3ZL,`XIBG8^F(8Z1,&[P,#!6=0R_Q.)L!));S!
MS%&X0VPBCA<X]ED[:C`OTL(=<&K>`<YW!8'_Z&R';/"BX]EXA2-1-3``-'1P
M1[ROZHBM)"><.5M9;UTPGCW$H?O;(@P\YFPS7]=W_;BB*V!ZN$L^&'4)[Q%9
MYM^=3.I;YS"[OT!T<1V$3S7#8TL&=\5'\]'!13E"5J<ZX#RA/L$TPWGS+QC.
M?W*OQJ=N$-(DPNP?.7VG('M(EDL4K=F4X,\)BXQ=Q+Q$5\1(+.2_8_;E^C@#
MU)`6AOM?9;@S:6+JV,ISM@*=7&*G.N1+R`+9.[1&TP"GL!>^P.!^*H,K>)R,
MJ5/X7;(`ZY'5\8AO?#3U`]:^W'[A(A#1P;LRHEMF1^+N%+3R"G_U>\)"P&Q>
M4+_#H`Z4.:#@,Z2\G8+T'@=\^69!1;R>1(A0Y$J.M+84AO>D#&_&[P@!CBRA
M4R"/"/L33]!S/A'('V`H3\M0IBR.X.D4>!?A<NG'PK,<$H_YG'QIQF3K%501
MP."^+X,KB1#[2P4AG4+[(9E2_'O"-+EZY'#DCE?I*XSK!]7%ROF<E+%C6`H'
M,ZQV5T$7UY0'[H>/N[NZSG?Y7]W:6C+#?<*]V48]E7'`_:1$@$WZ*97<K5[B
M44464\A=H7Z&\59"P$*4TDU(P9A$!K>*`(99"0;AT*6;>*NQ2F%2T96"2)\H
M02(4SW039UWH(J-=0P-CKL20^B"GF\A+P8T,MOH9QE<)(N7(IYN(2N$)*D4X
M,L+U9##B2JQ9&0YULPORO?E+'",_*&WPYQ]A>)5H,V=SOLL8NP6EF>-<`+H9
M"]P-0'!J[FQWN:-JCELR:`9-CF@V/'!7[16_9K*=P5MG:8$_V:&S3C2=M5<0
MFW?6R5MG:8&?X.<XR>\9[<0)=]P>!Z+;CLNJZ%;W2?L-A64*^`Y#7WU<VM'E
M1D6O8/GZ8A#C4R4VAC'NI@6#FSH%6ZZD@!%7(F/=OD\GS;L*T$$]YAI?Z50)
MEVM`[YI?5(5I87XQ(82[0(F?Z[J@DU..NK59#/&TQ3#H2E0-;WUV<JK18CFH
MP5HWR:BQ<Q7879MBM'">U,"M":E.U?BW$NZN!4\Z.$]KX#[5P*U&L)5PG[[!
M+8!X7P/W>PW<:MQ9"??[-[B!;8`Z*AAZ)>ZLAO[-3P&@K5M#-V1@%[PW/+(M
M=<';DEI$MVYEW9#!G6!T#UCMA(XMM+KC\8+?7D<$=T"#F\(=]>%K<"VL!H:T
M<%<HT:M!5W1S99!N,!2&`/`=AEJ)68M7&SIIYRIX`QVJNB55B4Y!6+NVA*KX
M%>8,?3$,LA*3PB!W<F*HN'A3F"@,Z&#PE0BUYH9.)V>2BG<@T``P)X?[1`EC
MS?JDFR.D_("D=+L'+H1Q5V/8\B.3;\;^^7]XFJY[/'-$_JLSGL3G\Q'UERO^
M.#?]MA`)BCCDO3Q?V/^82L?/RR`GX9(K,G&)+BJCD%6<B\CR%E7GYV)"PA6.
M^&E'/V_\4?\`^C#`F^I3[".KM`G0M*DVC`4'UBG"[+JI(J6A<%AU^GD>*_;7
M-KL5*V":A%'L$#![GRXM79KX[R9TA9@*%OZO7L[7XY]Z@Y/>Z>#XF7IIPQK4
MO]&H8?TY7[/ZX51_AC7G#+S*#P:552;<T]0IZ@,9^SB(:?ZEMQ5EJG5%`KNJ
MM@!LV=^]K8BF;8!R`IHT0N;+_[%/,Z`4@T;MD!DW_]JC4Y1$A":MV#")O_:H
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M-2?A+R%9)63.-&($C[Y;N=`U%-$&P]E!NZH%KJF,]IB*M&QGYO\%Q^/9>,9H
MV""Y"&G<U'0:B/P&3,E$VZ:FU42FE:;&#]!"(G1)1P?7,5>):9=^.<^_Z`UL
M-T'M,JN&.E88TXZ26F!"5\_N`I$Y^RY'%MSC4QV^J^<5)M3$GG:2VF;CVD%A
M8W/;0[:5!GB-_$C,)QL?$'Q7EKJ.(_*5^#SS>CI#*Q[Y,0C@H:MHEVE>!?[2
M)XC?K`#5_KIBQL6M(;<L1640U$.(;0.0H.<@7D:KXTU$RIO!.DSBD&_DN=OH
M^1JC.(EP&=47K*.K$"OSZ4M68N7$*FM`O*+>(\)T(5A<4O[%CQ>%@5JW"#65
MU@83/("B9BOX;C(M,C!)E\UV3AZ72\I7D[7!).ZBT,78H]=1N'Q(IF'D\>6.
M^5OLWSZE8;06LX<(&2^S'KUF),3-8T<)CD,(>SG0/#P]#&8\AKY#?F'K#SCT
MJB:SY["K,!;',[GC+O&TL(U>1]D&BR\I47%H4$/8!F6WLS/OH/(LS*8O'CJ)
M1H@<3FMP8C=E;0,@4I2T=>CI!$?+U(Y-?88]Y;1@EH,US,/'HG:@$U"+5B-9
M+4#L'!/,?UT.!8H/+6%12=7>(537F45_<&_;*(MK@7F`BN;;IZF^D_`&$_[8
M6*]XA5]5!^IAZ_HV$&<.>^$DI`S&9(%KSE>:H7Z(^MJ*?&YWZE%G'895G"U`
M8^M$:JZ5%+=B>/AT'29\<$K`[".D51C)LXY^ZZIN+!Y(7@N0TU\S*5I$*30U
M8VF!_G>L8UG+TRB$/Z,\#XK:Z@A2W0B;?Y/E69Q_?[4]IVO_&7M#2G&5+E5$
MENGS4R@6.=;9$=$K5$EEF4:7^!$'X8I_>8C1'/,@&)&U7CE3!NOT=/%RBJ,*
M_R_+EUNE^LXR+$/C`:_BO>'81XAM>+@+["6!",(*[;],,'=-Q.^`@!@T9+16
M;_`HF#NMHBYZ&WHXH`8P["3'6E3$?G=V`G#/1C]3R^->:![OF"#26(:U:(@-
MOW-$L2=OE6[N3[&`[S'_&:]J2'839"TNXR3F#Z+9##C/=3A?7[#9<,YF`P,X
M&O%;AL(XFB/B_R'D,9>'LHG>2]]`B?/239Z%\2P[%4,!<QMB(2*U?`F20PC[
MDP^AO/ALP3@C-YGBT8N`=.,3(9D>"BA)H#TG=ODO164Y8RAP^*@GL4<-]<8:
M'1'6`/%44+,G!!*V8==<),QCBYAT42_315)EZ'DB-0D*^,'QB%R@E1_GF8D$
M%/N):0-0\BNLNDT>`]IVJ+S9<<GM^U8$"_!5DS)-897SPB7RR6L-::F5XU7J
MQ%8H4B*Q2(_J'V_63[L-^>R9B^4`M.QI`&4V.@YJ4*G8GI[$(MM3&SDF)JI(
M5!9I(QL/Y)UIRNT9&2K0DZ?0H#LD*HNZ`VCG(L(FYE6@LTBCC=,^G+,&\@)%
M&3V)17K(`Z&8:1)89TR([1E"_`(9S\W(U\/A,HSB+!I+[T06-HVK"665\@:^
MWAWA[5[5=1C)3<^/%>]9%%F^$&K`T((S-UWCQ[-;?I/)C]>:7M416]6S=TGD
M+I!T+*K<>M=2%`;=Z]YASP80OYL+7;7.L;\L&FDC+JMZ39XPLDNKV4T:T?*!
MJF0%:0O&8.&=,IM0[@+DBO+AG/U'TK:.T"*;K6XJ6P;$.#/6;<N0+?1LE5]E
MWU[OG%^^X21FQC!9QO!V5X%@;YM,<Y'&+V>2DS!&@3*<1D1D?O1&Y.3=X$3>
MS#(B;\%03.=(O'$OF6?&_W>)J1OYJ[3NDC=:36SFN_U)EP'4V_^7X1/)FCV>
MC0AEU3&-E"<$S5GM-W%(IXT^MR&)%\&:;\6B@+'%-6!4,;;`[+\D/(H2W<B;
M7=ZVAXMEO7SF#<YQ]'KO2'DF<!1(1^[ET%%+85'D6'J%R(7Q=^F5&:P:\%CD
M'IBGNMDC2XZ%KOPMBG[#<>83R!OHY!8C_GL'R\S9*9V/-.2SR$G*WW_<HC7K
MFO\F!/.DI/DU$'68&I%;-&:'09"E9TTOO4S"TH/IS%SEH,68I05+AZI,>4:J
M4QZD;Z7F]:>^#7A:B8!Z$6Y=J3U(WW+-BQFVI`N!ADA4\'^KR(Q)]11A*J+E
M^!27@>V="$-L].PMQT5^>5>[G%2QM0`'.?7&UM7=7)O]@N/BX5XM<0MT+CRD
ME"_\%;^W0).:#F%"J"[/BIZ\!7K#=YN'?/S-!=WY>DN2;98,GU#D93>'?N(#
M%7N_8'^^8/\?LID+S?$]YIY]^JQ(Z)B@@&=FD$\`_O2:K3HJ.9#V(\*W)JGO
M*JG>7D9^"RSZ0OS&47P7^?IL&!4T%D7@%P&B=+,/-([NN:5G'2,K4TEFT1X*
MV-!\OZM6(XG0=IVNPVB&?8->D@AMU^EG3%D[I;<?=;H!#'OJN#E9>&%3S*:%
MW`O-2JGAR#.5DH*1_^(/5Y0GA+6KTVMT:3QVZ^5\`Z@8CWYS.=\`*HWGC^;R
M#H#2`:>84KYV9<-<4V[1#GDIO[Q&`Z7<(@W$%11M^\%2BUH_$C]>&D;0F6BI
MQ*)69X!.PNT-/=@)KR.TR".J.;I,SRNWBL#Z[B/$(BQXNWS*MR=Y&I\O+*A,
MG]EPJ=D/`92/N>O)6Q!7%N^U`9KJ"%J@&[@`TWOLX:78#N`[*+1NP5;I+;I#
M=<><"?[,6*2C$J_!TB?'UQB/-T_Y(7^V*6-A_X!SONI`U:7&KGH3J"6V:)&1
M?Y-$T04JM*CM_`5\$L2:-Z9*F44MS[+9:1TJ3;E%&MRR*2J,1L15VJZ46-3J
M+.FBTN;2=XM:+/DZPELIN':3\`''<2`R#O$#E,D"J\D6=Y9@D:O$YM"Y_XAY
M%@A^![/P8TECPAM?&#SUQ"UP)<;3P)^+.OB+Q5">B^4#PBJJ%F@)IL@V#P#J
MF2RR8K#9Y7O40_?WQ*?I<?X-?VO/K'9SO[X.@X;"+,)F/)LQ#RG295J`BRV:
MI[?^ACY9A(;"(BW`>'IS&*_;>:LAMT@__G!!KPY8:E'K'UA=,9[[[M![]&D8
MZ5^)UU):I!5'_3]AP-.W@SU2*K.HY<5]"C7O`%AL4?OS1RVI7SA\1+X0R/RG
MZX3_AH,X8:-?N3<HY;AA:LG>UCY"[#G&E'/X\+;)_\[V)$0^T_(K_X9\=MV<
MJ6HK_-[/G,6B':NLO?+VN`NZE76$%KE+<D>4+FAINDNALLH6LT;RL\CM/J':
M->5R>_8(-]?EZC2I([1>)>WD8$AOT<P@O4[/VCPF8KTJ)9*HH7NY,/MP>?GR
MK43]9*&EL&JB^"H.;/'FA6/=5H$AO453.Y0A5!PDU&01S6CV-D;=L_/#V6+1
M91P1)IE?GLTNTBY2?U_K8FKI[?$FBYZ_)BN9GL:B$`&.\($<?G6$-NFD_=D"
M[9M<<Y96Z0EV9!,NB[1-MSK]=*\S/8-2[RGI:2S2Q/"=>&O>A\-W'*Z>5WY>
M1\UU")G4(N\QVUM;7_O14C4UH-"B/GE@P`58_.("OF-KY9(M1HS=1<&(S/E"
M#^XJ-F"R2-?J!@.W&<WH+=)0,]U9.\/)5X%^;N3.-^:T)YS>'MB9*FO,85'T
M8MAF>`=A%V:+%@0>+H,9BLH%5D74]]A?3I.(BF_`;4Q->1ON%F27NW/?2#R`
MT%A>+:E%=I;'PU=DCN99#*E>$*BDDK5Y[<QE8KW-KX+2\D(L%;3`Y.[#-0KB
M=?8.F&HV2BN(+#*SK)GY;Y>=KV_8F&"#7S.$S,@MTN\&SU&@.$V%KQ;Y3/EP
MSE#EL;F7N&"20I7$IN&>M4X$=>O2'C109M5:>1DFTWB6!-DR*-]4*)>\V#[L
M`7]LF<EC0M+M$%.GM!&7/5NR4K/2;>3\1[7AJ_ME&GL42:=9'U>N+>5BBV;=
MKZM9%)*89RIBJ[I\4E,JL'*U[U-W@9?HQ[_^Y?]02P$"'@,4````"`!813!%
M-VONU&PF`0"50!,`$0`8```````!````I($`````<F5L;2TR,#$T,#8S,"YX
M;6Q55`4``T<P&%1U>`L``00E#@``!#D!``!02P$"'@,4````"`!813!%36"%
ML`@*``#BB@``%0`8```````!````I(&W)@$`<F5L;2TR,#$T,#8S,%]C86PN
M>&UL550%``-',!A4=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`6$4P16;/
M^9D$.@``3"H$`!4`&````````0```*2!#C$!`')E;&TM,C`Q-#`V,S!?9&5F
M+GAM;%54!0`#1S`85'5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`%A%,$4R
M&9EH#(0``#HG"``5`!@```````$```"D@6%K`0!R96QM+3(P,30P-C,P7VQA
M8BYX;6Q55`4``T<P&%1U>`L``00E#@``!#D!``!02P$"'@,4````"`!813!%
MQJE)8KA0``!X`08`%0`8```````!````I(&\[P$`<F5L;2TR,#$T,#8S,%]P
M<F4N>&UL550%``-',!A4=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`6$4P
M16VC%9^W%```Q_\``!$`&````````0```*2!PT`"`')E;&TM,C`Q-#`V,S`N
M>'-D550%``-',!A4=7@+``$$)0X```0Y`0``4$L%!@`````&``8`&@(``,55
$`@``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ESGAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events (Details) (Subsequent Event [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 18, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Subsequent Event [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_UpfrontCashFee', window );">Upfront cash fee received by the consultant</a></td>
        <td class="nump">$ 250,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued to the consultant for investor communication and public relations</a></td>
        <td class="nump">250,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventDescription', window );">Description of the company's agreement with a consultant</a></td>
        <td class="text">The consultant shall receive an upfront cash fee of $250,000 and $250,000 quarterly cash installments commencing in September 2014. In addition, the Company shall issue 250,000 shares of the Company's within fifteen (15) days of the agreement and the remaining 250,000 shares shall be issued in six monthly installments commencing in September 2014.<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_UpfrontCashFee">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Upfront cash fee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_UpfrontCashFee</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 855<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPPGM">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Details Textual 2) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="4">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="4">1 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 10, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Feb. 28, 2014

</div>
          <div>Board of Directors [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Placement Agent [Member]

</div>
          <div>Medeor Inc [Member]</div>
        </th>
        <th class="th">
          <div>Nov. 30, 2013

</div>
          <div>Consultants [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Consultants [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Consultants [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Consultants [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Series A Preferred Stock Offerings [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Series A Preferred Stock Offerings [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Series A Preferred Stock Offerings [Member]

</div>
          <div>Investors [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Series A Preferred Stock Offerings [Member]

</div>
          <div>Investors [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Series A Preferred Stock Offerings [Member]

</div>
          <div>Placement Agent [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Series A Preferred Stock Offerings [Member]

</div>
          <div>Placement Agent [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Debt Offerings [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Debt Offerings [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Debt Offerings [Member]

</div>
          <div>Debt Holders [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Debt Offerings [Member]

</div>
          <div>Debt Holders [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Debt Offerings [Member]

</div>
          <div>Placement Agent [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Debt Offerings [Member]

</div>
          <div>Placement Agent [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Strategic Advisor Agreement [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Stock Option [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Stock Option [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Stock Option [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Warrants [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Warrants [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Warrants [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Founder Warrants [Member]</div>
        </th>
        <th class="th">
          <div>May 31, 2014

</div>
          <div>Officer Options [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2014

</div>
          <div>Officer Options [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Officer Options [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2012

</div>
          <div>Officer Options [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Officer Options [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Research and Development Expense [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Research and Development Expense [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Research and Development Expense [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Research and Development Expense [Member]

</div>
          <div>Warrants [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Research and Development Expense [Member]

</div>
          <div>Warrants [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Research and Development Expense [Member]

</div>
          <div>Warrants [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Selling, General and Administrative Expenses [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Selling, General and Administrative Expenses [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Selling, General and Administrative Expenses [Member]</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014

</div>
          <div>Selling, General and Administrative Expenses [Member]

</div>
          <div>Warrants [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Selling, General and Administrative Expenses [Member]

</div>
          <div>Warrants [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Selling, General and Administrative Expenses [Member]

</div>
          <div>Warrants [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares available for grant authorized under 2012 Stock Option Plan</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,409,436<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_NumberOfSharesAvailableForFutureGrantsUnderStockOptionPlan', window );">Number of shares available for future grants under stock option plan</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,693,673<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_StockOptionsPlanStockOptionsExercisablePeriod', window );">Stock options plan stock options exercisable period</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_StockOptionsExercisablePeriodDescription', window );">Stock options exercisable period description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text"><div>Vest over four years</div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_OptionsToPurchaseOfcommonStock', window );">Options to purchase of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">145,986<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">187,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">350,000<span></span></td>
        <td class="nump">1,003,774<span></span></td>
        <td class="nump">665,750<span></span></td>
        <td class="nump">677,962<span></span></td>
        <td class="nump">334,199<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_StockOptionsContractualTerm', window );">Stock options term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_OptionsVestPercentage', window );">Options vest percentgae</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25.00%<span></span></td>
        <td class="nump">25.00%<span></span></td>
        <td class="nump">25.00%<span></span></td>
        <td class="nump">25.00%<span></span></td>
        <td class="nump">25.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_RemainingOptionsVestPercentage', window );">Remaining options vest percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">75.00%<span></span></td>
        <td class="nump">75.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_RemainingOptionsVestPeriodDescription', window );">Remaining options vest period description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Options vest on the one year anniversary of the grant date and the remaining options vest quarterly over the following 3 years.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text"><div>Options vest on the one year anniversary of the grant date and the remaining options vest in equal quarterly increment over the following 3 years</div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Options vest on the one year anniversary of the grant date and the remaining options vest quarterly over the following 3 years.<span></span></td>
        <td class="text"><div>Options vest on the one anniversary of the grant date and the remaining options vest quarterly over the following 3 years</div><span></span></td>
        <td class="text">Options vest in equal quarterly increments over a four-year period.<span></span></td>
        <td class="text"><div>Options vest in equal quarterly increments over a four-year period</div><span></span></td>
        <td class="text"><div>Options vest on the one anniversary of the grant date and the remaining options vest quarterly over the following 3 years</div><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_FairValueOfOptionsOnGrantDate', window );">Fair value of options on grant date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 136,200<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 114,800<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 250,200<span></span></td>
        <td class="nump">$ 937,600<span></span></td>
        <td class="nump">$ 359,100<span></span></td>
        <td class="nump">$ 103,700<span></span></td>
        <td class="nump">$ 181,400<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Stock-based compensation expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,119,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">237,400<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">115,500<span></span></td>
        <td class="nump">4,800<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">1,800<span></span></td>
        <td class="nump">2,200<span></span></td>
        <td class="nump">77,700<span></span></td>
        <td class="nump">129,600<span></span></td>
        <td class="nump">35,100<span></span></td>
        <td class="nump">12,124,500<span></span></td>
        <td class="nump">246,100<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Share based compensation shares vested</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,655,783<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock based compensation expense</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,760,900<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">589,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,500<span></span></td>
        <td class="nump">3,600<span></span></td>
        <td class="nump">3,400<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average fair value of options and warrants granted</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.72<span></span></td>
        <td class="nump">$ 0.58<span></span></td>
        <td class="nump">$ 0.15<span></span></td>
        <td class="nump">$ 1.40<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 0.14<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued, number of shares of common stock</a></td>
        <td class="nump">541,430<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">541,430<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,275,156<span></span></td>
        <td class="nump">1,224,845<span></span></td>
        <td class="nump">637,578<span></span></td>
        <td class="nump">612,422<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">213,750<span></span></td>
        <td class="nump">67,500<span></span></td>
        <td class="nump">106,875<span></span></td>
        <td class="nump">33,750<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share</a></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.54<span></span></td>
        <td class="nump">$ 1.00<span></span></td>
        <td class="nump">$ 1.50<span></span></td>
        <td class="nump">$ 0.11<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 0.08<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.50<span></span></td>
        <td class="nump">$ 1.50<span></span></td>
        <td class="nump">$ 0.08<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="nump">$ 0.80<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_WarrantsContractualTerm', window );">Warrants contractual term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_WarrantToPurchaseOfCommonStock', window );">Warrant to purchase of common stock</a></td>
        <td class="nump">619,377<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">619,377<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,500<span></span></td>
        <td class="nump">21,500<span></span></td>
        <td class="nump">40,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">868,213<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_FairValueOfWarrantsIssued', window );">Fair value of warrants issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 14,300<span></span></td>
        <td class="nump">$ 5,600<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 10,800<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased', window );">Number of shares increased by the Board of Directors</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_NumberOfSharesIncreasedByShareholders', window );">Number of shares increased by shareholders</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,058,844<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_FairValueOfOptionsOnGrantDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of options on grant date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_FairValueOfOptionsOnGrantDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_FairValueOfWarrantsIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of warrants issued.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_FairValueOfWarrantsIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_NumberOfSharesAvailableForFutureGrantsUnderStockOptionPlan">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares available for future grants under stock option plan</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_NumberOfSharesAvailableForFutureGrantsUnderStockOptionPlan</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_NumberOfSharesIncreasedByShareholders">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares increased by shareholders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_NumberOfSharesIncreasedByShareholders</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_OptionsToPurchaseOfcommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Options to purchase of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_OptionsToPurchaseOfcommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_OptionsVestPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Options vest percentgae.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_OptionsVestPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_RemainingOptionsVestPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Remaining options vest percentgae.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_RemainingOptionsVestPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_RemainingOptionsVestPeriodDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Remaining options vest period description</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_RemainingOptionsVestPeriodDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_StockOptionsContractualTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock Options Contractual Term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_StockOptionsContractualTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_StockOptionsExercisablePeriodDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock options exercisable period description</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_StockOptionsExercisablePeriodDescription</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_StockOptionsPlanStockOptionsExercisablePeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock options plan stock options exercisable period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_StockOptionsPlanStockOptionsExercisablePeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_WarrantsContractualTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrants contractual term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_WarrantsContractualTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_WarrantToPurchaseOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Warrant to purchase of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_WarrantToPurchaseOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense, net of income tax, recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested options awarded to employees as compensation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options vested.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The remaining number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EIBBK">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Statement of Stockholders' Deficit (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
        <th class="th">
          <div>Series A Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Class A Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Common Stock [Member]</div>
        </th>
        <th class="th">
          <div>Additional Paid-in Capital [Member]</div>
        </th>
        <th class="th">
          <div>Accumulated Deficit [Member]</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2011</a></td>
        <td class="num">$ (2,839,971)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">$ 1,520<span></span></td>
        <td class="nump">$ 4,409,230<span></span></td>
        <td class="num">$ (7,250,721)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2011</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">1,519,759<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesValue', window );">Issuance of common stock and warrants to a related party for liabilities</a></td>
        <td class="nump">869,275<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">256<span></span></td>
        <td class="nump">869,019<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesShares', window );">Issuance of common stock and warrants to a related party for liabilities, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">255,750<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Forgiveness of liabilities by founder</a></td>
        <td class="nump">353,246<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">353,246<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_StockIssuedDuringPeriodValueIssuedForConversionOfLoansAndAccruedInterest', window );">Issuance of Series A preferred stock for conversion of loans and accrued interest</a></td>
        <td class="nump">1,541,180<span></span></td>
        <td class="nump">1,879<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">1,539,301<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_StockIssuedDuringPeriodSharesIssuedForConversionOfLoansAndAccruedInterest', window );">Issuance of Series A preferred stock for conversion of loans and accrued interest, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,879,128<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants', window );">Issuance of common stock for cashless exercise of warrants</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">541<span></span></td>
        <td class="num">(541)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants', window );">Issuance of common stock for cashless exercise of warrants, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">541,430<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets', window );">Issuance of common stock to acquire license at fair value</a></td>
        <td class="nump">5,127<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">17<span></span></td>
        <td class="nump">5,110<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets', window );">Issuance of common stock to acquire license at fair value, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">17,089<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesValue', window );">Issuance of Series A preferred stock to Wonpung for services</a></td>
        <td class="nump">1,006,074<span></span></td>
        <td class="nump">1,725<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">1,004,349<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesShares', window );">Issuance of Series A preferred stock to Wonpung for services, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,725,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue', window );">Issuance of Series A preferred stock and warrants for cash, net of offering costs</a></td>
        <td class="nump">2,155,938<span></span></td>
        <td class="nump">4,900<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">2,151,038<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsShares', window );">Issuance of Series A preferred stock and warrants for cash, net of offering costs, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,899,375<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
        <td class="nump">20,507<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">68<span></span></td>
        <td class="nump">20,439<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">68,356<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
        <td class="nump">37,335<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">37,335<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(6,860,030)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num">(6,860,030)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2012</a></td>
        <td class="num">(3,711,319)<span></span></td>
        <td class="nump">8,504<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">2,402<span></span></td>
        <td class="nump">10,388,526<span></span></td>
        <td class="num">(14,110,751)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2012</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,503,503<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">2,402,384<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue', window );">Issuance of Series A preferred stock and warrants for cash, net of offering costs</a></td>
        <td class="nump">1,484,710<span></span></td>
        <td class="nump">5,100<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">1,479,610<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsShares', window );">Issuance of Series A preferred stock and warrants for cash, net of offering costs, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,100,625<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock to acquire Medeor, Inc. at fair value</a></td>
        <td class="nump">3,750,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">2,500<span></span></td>
        <td class="nump">3,747,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock to acquire Medeor, Inc. at fair value, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">2,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
        <td class="nump">16,918<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">57<span></span></td>
        <td class="nump">16,861<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">56,394<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
        <td class="nump">382,343<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">382,343<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(19,871,908)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(19,871,908)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2013</a></td>
        <td class="num">(17,949,256)<span></span></td>
        <td class="nump">13,604<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">4,959<span></span></td>
        <td class="nump">16,014,840<span></span></td>
        <td class="num">(33,982,659)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2013</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">13,604,128<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">4,958,778<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsValue', window );">Issuance of common stock, Series A warrants and Series B warrants for cash, net of offering cost</a></td>
        <td class="nump">22,229,321<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">17,164<span></span></td>
        <td class="nump">22,212,157<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsShares', window );">Issuance of common stock, Series A warrants and Series B for cash, net of offering cost, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">17,163,799<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
        <td class="nump">8,714<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">29<span></span></td>
        <td class="nump">8,685<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">29,052<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
        <td class="nump">10,319,137<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,319,137<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfFairValueOfWarrantDerivativeLiabilitiesIssuedInUnitsOfferingDuringPeriodValue.', window );">Establishing warrant derivative liabilities</a></td>
        <td class="num">(4,333,163)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(4,333,163)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfEliminatingDerivativeLiabilitiesUponShareExchangeDuringPeriodValue', window );">Reclassification of derivative liabilities to APIC upon Share Exchange</a></td>
        <td class="nump">6,804,625<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">6,804,625<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureValue', window );">Conversion of Series A preferred stock, notes payable and accrued interest to common stock</a></td>
        <td class="nump">960,922<span></span></td>
        <td class="num">(13,604)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14,805<span></span></td>
        <td class="nump">959,721<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureShares', window );">Conversion of Series A preferred stock, notes payable and accrued interest to common stock, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(13,604,128)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14,805,278<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange', window );">Issuance of common stock and Class A preferred stock in connection with share exchange</a></td>
        <td class="nump">2,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,337<span></span></td>
        <td class="nump">3,337<span></span></td>
        <td class="nump">1,993,326<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares', window );">Issuance of common stock and Class A preferred stock in connection with share exchange, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,337,309<span></span></td>
        <td class="nump">3,337,310<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Amortization of beneficial conversion feature</a></td>
        <td class="nump">186,727<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">186,727<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(21,335,988)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="num">(21,335,988)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Jun. 30, 2014</a></td>
        <td class="num">$ (1,108,961)<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">$ 3,337<span></span></td>
        <td class="nump">$ 40,294<span></span></td>
        <td class="nump">$ 54,166,055<span></span></td>
        <td class="num">$ (55,318,647)<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Jun. 30, 2014</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">3,337,309<span></span></td>
        <td class="nump">40,294,217<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance Of Common Stock And Preferred Stock In Connection With Share Exchange.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchange</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance Of Common Stock And Preferred Stock In Connection With Share Exchange Shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_IssuanceOfCommonStockAndPreferredStockInConnectionWithShareExchangeShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number shares of common stock issued for series A and series B warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of common stock issued for series A warrants and series B warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_IssuanceOfCommonStockForSeriesAWarrantsAndSeriesBWarrantsValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_IssuanceOfEliminatingDerivativeLiabilitiesUponShareExchangeDuringPeriodValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of eliminating derivative liabilities upon Share exchange during period value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_IssuanceOfEliminatingDerivativeLiabilitiesUponShareExchangeDuringPeriodValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_IssuanceOfFairValueOfWarrantDerivativeLiabilitiesIssuedInUnitsOfferingDuringPeriodValue.">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of fair value of warrant derivative liabilities issued in units offering during period value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_IssuanceOfFairValueOfWarrantDerivativeLiabilitiesIssuedInUnitsOfferingDuringPeriodValue.</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of Series A preferred stock and warrants for cash, net of offering costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of Series A preferred stock and warrants for cash, net of offering costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_IssuanceOfSeriesAPreferredStockAndWarrantsForCashNetOfOfferingCostsValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued for Wonpung for services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of shares issued for Wonpung for services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_IssuanceOfSeriesAPreferredStockToWonpungForServicesValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of common stock and warrants to a related party for liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of common stock and warrants to a related party for liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_IssuanceOfStockAndWarrantsToARelatedPartyForLiabilitiesValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Series A Preferred Stock Notes And Accrued Interest For Common Stock Automatic Conversion Feature Shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureShares</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Series A Preferred Stock Notes And Accrued Interest For Common Stock Automatic Conversion Feature Value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_SeriesAPreferredStockNotesAndAccruedInterestForCommonStockAutomaticConversionFeatureValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued for cashless exercise of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_StockIssuedDuringPeriodSharesIssuedForCashlessExerciseOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_StockIssuedDuringPeriodSharesIssuedForConversionOfLoansAndAccruedInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued for conversion of loans and accrued interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_StockIssuedDuringPeriodSharesIssuedForConversionOfLoansAndAccruedInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of shares issued for cashless exercise of warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_StockIssuedDuringPeriodValueIssuedForCashlessExerciseOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_StockIssuedDuringPeriodValueIssuedForConversionOfLoansAndAccruedInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of shares issued for conversion of loans and accrued interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_StockIssuedDuringPeriodValueIssuedForConversionOfLoansAndAccruedInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Beneficial Conversion Feature<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505963<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDecreaseForgiveness">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(f))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph f<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DebtInstrumentDecreaseForgiveness</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued which are neither cancelled nor held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period pursuant to acquisitions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesAcquisitions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued pursuant to acquisitions during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueAcquisitions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueIssuedForServices</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivative Liabilities<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Laibilities [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">DERIVATIVE LIABILITIES</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>NOTE 4 &#8211; DERIVATIVE LIABILITIES</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">ASC Topic No. 815 &#8211;&#160;<i>Derivatives and Hedging</i>&#160;provides guidance on determining what types of instruments or embedded features in an instrument issued by a reporting entity can be considered indexed to its own stock for the purpose of evaluating the first criteria of the scope exception in the pronouncement on accounting for derivatives. These requirements can affect the accounting for warrants and convertible preferred instruments issued by the Company. As the conversion features within the Series A preferred stock, and certain detachable warrants issued in connection with the subordinated promissory notes payable and equity offerings in 2012 and 2013, do not have fixed settlement provisions because their conversion and exercise prices may be lowered if the Company issues securities at lower prices in the future, the Company concluded that the instruments are not indexed to the Company&#8217;s stock and are to be treated as derivative liabilities.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The Company obtained valuations prepared by Vantage Point Advisors, Inc. for purposes of determining the fair value of the derivatives and stock compensation expense. In determining the fair value of the derivatives, the Company used the Monte Carlo Simulations using Geometric Brownian method for the initial valuation and then the Black-Scholes option pricing model was used for the valuation at June 30, 2014.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The following is a summary of the assumptions used in the valuation model as of the initial valuations of the derivative warrant instruments issued during the six months ended June 30, 2014:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Initial</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">At</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">valuation</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">June 30</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1129px; text-align: left;">Common stock issuable upon exercise of warrants &#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 173px; text-align: right;">30,036,648</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 172px; text-align: right;">30,036,648</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Market value of common stock on measurement date (1)</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">1.17</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">2.00</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Exercise price</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;"><font style="font: 10pt/normal 'times new roman', times, serif;">1.50 and 2.25</font></td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;"><font style="font: 10pt/normal 'times new roman', times, serif;">1.50 and 2.25</font></td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Risk free interest rate (2)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.7</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.6</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Expected life in years</td><td>&#160;</td><td
 style="text-align: left;">&#160;</td><td style="text-align: right;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;0.3 and 5</font></td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;"><font style="font: 10pt/normal 'times new roman', times, serif;">0.3 and 4.9</font></td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Expected volatility (3)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;71 and 73</font></td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;&#160;71 and 73&#160;</font></td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Expected dividend yields (4)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">None</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">None</td><td style="text-align: left;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 55.81px; padding-right: 5.4pt; padding-left: 0pt;">(1)</td><td style="width: 1496.81px; padding-right: 5.4pt; padding-left: 0pt;">The market value is the calculated fair value of the common stock pursuant to the valuation technique as described above.</td></tr><tr style="vertical-align: top;"><td style="padding-right: 5.4pt; padding-left: 0pt;">(2)</td><td style="padding-right: 5.4pt; padding-left: 0pt;">The risk-free interest rate was determined by management using the 1<font style="font: 10pt/normal 'times new roman', times, serif;">&#160;and 5 - year Treasury Bill as of the measurement date.</font></td></tr><tr style="vertical-align: top;"><td style="padding-right: 5.4pt; padding-left: 0pt;">(3)</td><td style="padding-right: 5.4pt; padding-left: 0pt;">The historical trading volatility was determined by calculating the volatility of the Company&#8217;s peer group.</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The following is a summary of the assumptions used in the valuation model as of the initial valuations of the derivative warrant instruments and convertible Series A preferred stock issued during the years ended December 31, 2013 and December 31, 2012, respectively, and as of December 31, 2013, and December 31, 2012, respectively:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Initial</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Initial</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">At</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">At</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">valuations</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">valuations</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">December&#160;31,</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">December&#160;31,</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2012</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2012</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left;">Common stock issuable upon exercise of warrants</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">22,333,593</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">19,385,157</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align:
 right;">41,718,750</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">19,385,157</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -5.5pt; padding-left: 5.5pt;">Common stock issuable upon conversion of Series A preferred stock</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">51,006,250</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">85,035,025</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">136,041,275</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">85,035,025</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -5.5pt; padding-left: 5.5pt;">Market value of common stock on measurement date (1)</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">0.80</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">0.30</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">1.50</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">0.80</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>Exercise price</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">0.80</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">0.80</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">0.80</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">0.80</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Risk free interest rate (2)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0.19</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0.20</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0.38</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0.19</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Expected life in years</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.4</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.6</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2.0</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.4</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Expected volatility (3)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">68</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">72</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">68</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">73</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Expected dividend yields (4)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">None</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">None</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">None</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">None</td><td style="text-align: left;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"><b>&#160;</b></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 55.81px; padding-right: 5.4pt; padding-left: 0pt;">(1)</td><td style="width: 1489.62px; padding-right: 5.4pt; padding-left: 5.4pt;">The market value is the calculated fair value of the common stock pursuant to the valuation technique as described above.</td></tr><tr style="vertical-align: top;"><td style="padding-right: 5.4pt; padding-left: 0pt;">(2)</td><td style="padding-right: 5.4pt; padding-left: 5.4pt;">The risk-free interest rate was determined by management using the 1, 2 or 3 - year Treasury Bill as of the measurement date.</td></tr><tr style="vertical-align: top;"><td style="padding-right: 5.4pt; padding-left: 0pt;">(3)</td><td style="padding-right: 5.4pt; padding-left: 5.4pt;">The historical trading volatility was determined by calculating the volatility of the Company&#8217;s peer group.</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width:
 0px;">Change in fair value of derivative liabilities during the six months ended June 30, 2014 was as follows:&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 13px/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><table style="font: 8pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif;">Balance at December&#160;31,</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif;">Initial valuation of derivative</font><font style="font: 10pt/normal 'times new roman', times, serif;"><br /><font style="font-style: normal; font-variant: normal; font-weight: normal;">liabilities upon</font></font><font style="font: 10pt/normal 'times new roman', times, serif;"><br /><font style="font-style: normal; font-variant: normal; font-weight: normal;">issuance of new warrants during&#160;</font></font><font style="font: 10pt/normal 'times new roman', times, serif;"><br /><font style="font-style: normal; font-variant: normal; font-weight: normal;">the</font></font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif;">Increase (decrease) in fair value of derivative</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif;">Fair value of</font><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;derivatives<font style="font-style: normal; font-variant: normal; font-weight: normal;">&#160;<br />upon reclass to additional paid-in</font></font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif;">Balance at&#160;</font><font style="font: 10pt/normal 'times new roman', times, serif;"><br /><font style="font-style: normal; font-variant: normal; font-weight: normal;">June 30,</font></font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif;">2013</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif;">period</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font: 10pt/normal 'times new roman', times,
 serif;">liabilities</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif;">capital</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: center; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font: 10pt/normal 'times new roman', times, serif;">2014</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px 0px 0px 10px; text-indent: -10px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">Convertible preferred derivative liability issued in&#160;connection with Series A preferred stock offering</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">$</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">11,762,115</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">$</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">$</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">(7,214,804</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">)&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">$</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">(4,547,311</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">)&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">$</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding: 0px 0px 0px 10px; width: 617px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">Convertible preferred derivative liability issued to Wonpung for services</font></td><td style="padding: 0px; width: 16px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; width: 16px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; width: 142px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">2,030,589</font></td><td style="padding: 0px; width: 16px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; width: 16px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; width: 16px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; width: 142px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new
 roman', times, serif;">-&#160;</font></td><td style="padding: 0px; width: 16px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; width: 16px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; width: 16px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; width: 141px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">(1,370,262</font></td><td style="padding: 0px; width: 15px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">)</font></td><td style="padding: 0px; width: 15px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; width: 15px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; width: 141px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">(660,327</font></td><td style="padding: 0px; width: 15px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">)</font></td><td style="padding: 0px; width: 15px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; width: 15px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; width: 141px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; width: 15px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">Convertible preferred derivative liability issued to lenders in connection with exchange of debt for Series A preferred stock</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">2,219,854</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">(1,262,858</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">)</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">(956,996</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">)</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">Warrants issued in connection with Series A preferred stock offering</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight:
 normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">2,424,167</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">(1,945,669</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">)</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">(478,498</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">)</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">Warrants issued as offering costs to placement agent</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">1,217,083</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">(1,109,421</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">)</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">(107,662</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">)</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px;
 font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">Warrants issued to lenders in connection with subordinated promissory notes offering</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">313,258</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">(259,427</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">)</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">(53,831</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">)</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">Warrants issued to placement agent in connection with subordinated promissory notes offering</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">136,359</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">(136,359</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">)</font></td><td
 style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">Series A warrants issued in May and June 2014 offering</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">842,370</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">9,198,452</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">10,040,822</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">Series B warrants issued in connection with May and June 2014 offering</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">2,494,655</font></td><td
 style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">7,400,275</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">9,894,930</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding: 0px 0px 0px 10px; text-align: left; text-indent: -10px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">Placement Agent warrants issued in connection with May and June 2014 offering</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font: 10pt/normal 'times new roman', times, serif;">996,138</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font: 10pt/normal 'times new roman', times, serif;">4,655,043</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font: 10pt/normal 'times new roman', times, serif;">-</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"><font style="font: 10pt/normal 'times new roman', times, serif;">5,651,181</font></td><td
 style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">Total</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif;">$</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif;">20,103,425</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif;">$</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif;">4,333,163</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif;">$</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif;">7,954,970</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif;">$</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif;">(6,804,625</font></td><td style="padding: 0px 0px 4px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">)</font></td><td style="padding: 0px; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif;">$</font></td><td style="padding: 0px; text-align: right; text-indent: 0px; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"><font style="font: 10pt/normal 'times new roman', times, serif;">25,586,933</font></td><td style="padding: 0px; text-align: left; text-indent: 0px; font-style: normal; font-weight: normal;"><font style="font: 10pt/normal 'times new roman', times, serif;">&#160;</font></td></tr></table><p style="font: 13px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 13px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; margin-top: 0px; margin-bottom: 0px; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">Change in fair value of derivative liability during the year ended December 31, 2013 was as follows:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: right;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Initial valuation</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: center;">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">of
 derivative</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: center;">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">liabilities upon</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2"></td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: center;">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Balance at</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">issuance of new derivatives</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Increase in fair value of</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Balance at</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: center;">&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">December 31,</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">during</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">derivative</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">December 31,</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: center;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2012</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">the period</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">liabilities</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 802.93px; text-align: left; text-indent: -9.05pt; padding-left: 9.05pt;">Convertible preferred derivative liability issued in connection with Series A preferred stock offering</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">2,492,166</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">1,647,910</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">7,622,039</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">11,762,115</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt;">Convertible preferred derivative liability issued to Wonpung for services</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">880,214</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,150,375</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,030,589</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt;">Convertible preferred derivative liability issued to lenders in connection with exchange of debt for Series A preferred stock</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">958,861</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,260,993</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,219,854</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt;">Warrants issued in connection with Series A preferred stock offering</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">475,000</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">113,153</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,836,014</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,424,167</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -9pt; padding-left: 9.05pt;">Warrants issued as offering costs to placement agent</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">242,500</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td
 style="text-align: left;">&#160;</td><td style="text-align: right;">248,655</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">725,928</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,217,083</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt;">Warrants issued to lenders in connection with subordinated promissory notes offering</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">29,158</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">83,363</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">200,737</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">313,258</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -9.05pt; padding-bottom: 1.5pt; padding-left: 9.05pt;">Warrants issued to placement agent in connection with subordinated promissory notes offering</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">13,089</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">41,681</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">81,589</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">136,359</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt;">Total</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">5,090,988</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,134,762</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">12,877,675</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">20,103,425</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.2in; color: #000000; text-transform: none; text-indent: -0.2in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.2in; color: #000000; text-transform: none; text-indent: -0.2in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px 0px 0px 0.2in; color: #000000; text-transform: none; text-indent: -0.2in; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">Change in fair value of derivative liability during the year ended December 31, 2012 was as follows:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Initial valuation</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">of derivative</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align:
 bottom;"><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">liabilities upon</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Balance at</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">liabilities upon issuance of new&#160;<br />derivatives</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Increase&#160;in fair value of</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">Balance at</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">December 31,</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">during</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">derivative</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">December 31,</td><td>&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: center; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2011</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: center; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">the period</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: center; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">liabilities</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: center; font-style: normal; font-weight: normal; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2012</td><td style="padding-bottom: 1.5pt; font-style: normal; font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 802.93px; text-align: left; text-indent: -9.05pt; padding-left: 9.05pt; font-style: normal; font-weight: normal;">Convertible preferred derivative liability issued in connection with Series A preferred stock offering</td><td style="width: 16px; font-style: normal; font-weight: normal;">&#160;</td><td style="width: 16px; text-align: left; font-style: normal; font-weight: normal;">$</td><td style="width: 142px; text-align: right; font-style: normal; font-weight: normal;">-</td><td style="width: 16px; text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="width: 16px; font-style: normal; font-weight: normal;">&#160;</td><td style="width: 16px; text-align: left; font-style: normal; font-weight: normal;">$</td><td style="width: 142px; text-align: right; font-style: normal; font-weight: normal;">872,688</td><td style="width: 16px; text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="width: 15px; font-style: normal; font-weight: normal;">&#160;</td><td style="width: 15px; text-align: left; font-style: normal; font-weight: normal;">$</td><td style="width: 141px; text-align: right; font-style: normal; font-weight: normal;">1,619,478</td><td style="width: 15px; text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="width: 15px; font-style: normal; font-weight: normal;">&#160;</td><td style="width: 15px; text-align: left; font-style: normal; font-weight: normal;">$</td><td style="width: 141px; text-align: right; font-style: normal; font-weight: normal;">2,492,166</td><td style="width: 15px; text-align: left; font-style: normal; font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt; font-style: normal; font-weight: normal;">Convertible preferred derivative liability issued to Wonpung for services</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">299,141</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">581,073</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">880,214</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt; font-style: normal; font-weight: normal;">Convertible preferred derivative liability issued to lenders in connection with exchange of debt for Series A preferred stock</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">-</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td
 style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">958,861</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">958,861</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt; font-style: normal; font-weight: normal;">Warrants issued in connection with Series A preferred stock offering</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">-</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">111,777</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">363,223</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">475,000</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt; font-style: normal; font-weight: normal;">Warrants issued as offering costs to placement agent</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">79,615</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">162,885</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">242,500</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: -9.05pt; padding-left: 9.05pt; font-style: normal; font-weight: normal;">Warrants issued to lenders in connection with subordinated promissory notes offering</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">-</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">26,325</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">2,833</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td><td style="text-align: right; font-style: normal; font-weight: normal;">29,158</td><td style="text-align: left; font-style: normal; font-weight: normal;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: -9.05pt; padding-bottom: 1.5pt; padding-left: 9.05pt; font-style: normal; font-weight: normal;">Warrants issued to placement agent in connection with subordinated promissory notes offering</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">13,089</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">-</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">13,089</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black;
 border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">-</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,402,635</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">3,688,353</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">5,090,988</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80748-113994<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5618551-113959<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4K<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5708775-113959<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 25<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4E<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624181-113959<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6441202&amp;loc=d3e80720-113993<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4H<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624258-113959<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624163-113959<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(n))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5708773-113959<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80784-113994<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4D<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624177-113959<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41620-113959<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5579245-113959<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5580258-113959<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5579240-113959<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41641-113959<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41638-113959<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4C<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624171-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQ3AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 2)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
        <td class="nump">49,847,037<span></span></td>
        <td class="nump">243,960,532<span></span></td>
        <td class="nump">14,046,700<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Class A Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
        <td class="nump">3,337,309<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series A Perferred stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump">136,041,275<span></span></td>
        <td class="nump">8,503,503<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Common stock warrants [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
        <td class="nump">43,144,557<span></span></td>
        <td class="nump">89,265,160<span></span></td>
        <td class="nump">4,865,235<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Common Stock Options [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities</a></td>
        <td class="nump">3,365,171<span></span></td>
        <td class="nump">18,654,097<span></span></td>
        <td class="nump">677,962<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>318</ContextCount>
  <ElementCount>331</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statement of Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/ConsolidatedStatementOfStockholdersDeficit</Role>
      <ShortName>Consolidated Statement of Stockholders' Deficit</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Disclosure - Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/Business</Role>
      <ShortName>Business</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>009 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.relmada.com/role/NotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>010 - Disclosure - Derivative Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/DerivativeLiabilities</Role>
      <ShortName>Derivative Liabilities</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>011 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>012 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>013 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>014 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>015 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>016 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>017 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>018 - Disclosure - Notes Payable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.relmada.com/role/NotePayableTables</Role>
      <ShortName>Notes Payable (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>019 - Disclosure - Derivative Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/DerivativeLiabilitiesTables</Role>
      <ShortName>Derivative Liabilities (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>020 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>021 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>022 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>023 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>024 - Disclosure - Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/BusinessDetails</Role>
      <ShortName>Business (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>025 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>026 - Disclosure - Summary of Significant Accounting Policies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/SummaryOfSignificantAccountingPoliciesDetails1</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>027 - Disclosure - Summary of Significant Accounting Policies (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/SummaryOfSignificantAccountingPoliciesDetails2</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>028 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>029 - Disclosure - Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.relmada.com/role/NotePayableDetails</Role>
      <ShortName>Notes Payable (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>030 - Disclosure - Notes Payable (Details Textual)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.relmada.com/role/NotePayableDetailsTextual</Role>
      <ShortName>Notes Payable (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>031 - Disclosure - Derivative Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/DerivativeLiabilitiesDetails</Role>
      <ShortName>Derivative Liabilities (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>032 - Disclosure - Derivative Liabilities (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/DerivativeLiabilitiesDetails1</Role>
      <ShortName>Derivative Liabilities (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>033 - Disclosure - Derivative Liabilities (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/DerivativeLiabilitiesDetailsTextual</Role>
      <ShortName>Derivative Liabilities (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>034 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>035 - Disclosure - Stockholders' Equity (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/StockholdersEquityDetails1</Role>
      <ShortName>Stockholders' Equity (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>036 - Disclosure - Stockholders' Equity (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/StockholdersEquityDetails2</Role>
      <ShortName>Stockholders' Equity (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>037 - Disclosure - Stockholders' Equity (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/StockholdersEquityDetails3</Role>
      <ShortName>Stockholders' Equity (Details 3)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>038 - Disclosure - Stockholders' Equity (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/StockholdersEquityDetails4</Role>
      <ShortName>Stockholders' Equity (Details 4)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>039 - Disclosure - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/StockholdersEquityDetailsTextual</Role>
      <ShortName>Stockholders' Equity (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>040 - Disclosure - Stockholders' Equity (Details Textual 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/StockholdersEquityDetailsTextual1</Role>
      <ShortName>Stockholders' Equity (Details Textual 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>041 - Disclosure - Stockholders' Equity (Details Textual 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/StockholdersEquityDetailsTextual2</Role>
      <ShortName>Stockholders' Equity (Details Textual 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>042 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>043 - Disclosure - Related Party Transactions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/RelatedPartyTransactionsDetailsTextual</Role>
      <ShortName>Related Party Transactions (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>044 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>045 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>046 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>047 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>048 - Disclosure - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/CommitmentsAndContingenciesDetailsTextual</Role>
      <ShortName>Commitments and Contingencies (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>049 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.relmada.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element us-gaap_DebtInstrumentInterestRateEffectivePercentage had a mix of decimals attribute values: 3 5.</Log>
    <Log type="Info">Process Flow-Through: 002 - Statement - Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2011'</Log>
    <Log type="Info">Process Flow-Through: 003 - Statement - Consolidated Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 004 - Statement - Consolidated Statements of Operations</Log>
    <Log type="Info">Process Flow-Through: 006 - Statement - Consolidated Statements of Cash Flows</Log>
  </Logs>
  <InputFiles>
    <File>relm-20140630.xml</File>
    <File>relm-20140630.xsd</File>
    <File>relm-20140630_cal.xml</File>
    <File>relm-20140630_def.xml</File>
    <File>relm-20140630_lab.xml</File>
    <File>relm-20140630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EM4AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Details 4) (Warrant [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_CurrentPriceOfCommonStock', window );">Current price of common stock</a></td>
        <td class="nump">$ 2.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.30<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
        <td class="nump">0.70%<span></span></td>
        <td class="nump">0.90%<span></span></td>
        <td class="nump">0.60%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
        <td class="nump">2.00%<span></span></td>
        <td class="nump">1.80%<span></span></td>
        <td class="nump">0.70%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
        <td class="nump">75.00%<span></span></td>
        <td class="nump">73.00%<span></span></td>
        <td class="nump">82.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
        <td class="nump">76.00%<span></span></td>
        <td class="nump">83.00%<span></span></td>
        <td class="nump">83.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">5 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_CurrentPriceOfCommonStock', window );">Current price of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"> 1.50<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
        <td class="text">7 years<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_CurrentPriceOfCommonStock', window );">Current price of common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"> 0.80<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
        <td class="text">4 years<span></span></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_CurrentPriceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Current Price of Common Stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_CurrentPriceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EJCAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">6 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Deficit [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ScheduleOfCashProceedsReceivedFromOfferingsTableTextBlock', window );">Gross proceeds received in connection with offerings</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The table below reflects the gross proceeds received in connection with the 2012 offerings allocated to components of stockholders&#8217; equity and to derivative liabilities based upon fair value:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px; text-align: left; padding-left: 0pt;">Par value of Series A preferred stock issued</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 141px; text-align: right;">4,898</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-left: 0pt;">Additional paid-in-capital</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">2,151,040</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-left: 0pt;">Derivative warrant liabilities</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">111,777</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 0pt;">Derivative preferred stock conversion feature</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">872,688</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">Derivative&#160;&#160;Warrants issued to placement agent as offering costs</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">79,615</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 0pt;">Net proceeds</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">3,220,018</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">Offering costs paid in cash</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">699,482</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 4pt; padding-left: 0pt;">Gross proceeds</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">3,919,500</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The table below reflects the gross proceeds received in connection with the 2013 offerings allocated to components of stockholders&#8217; equity and to derivative liabilities based upon fair value:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px; text-align: left; padding-left: 0pt;">Par value of Series A preferred stock issued</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 141px; text-align: right;"><p style="margin: 0px;">5,100</p></td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-left: 0pt;">Additional paid-in-capital</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;"><p style="margin: 0px;">1,479,610</p></td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-left: 0pt;">Derivative warrant liabilities</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">113,153</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 0pt;">Derivative preferred stock conversion feature</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,647,910</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">Derivative Warrants issued to placement agent as offering costs</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align:
 right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">248,655</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 0pt;">Net proceeds</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">3,494,428</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">Offering costs paid in cash</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">586,072</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 4pt; padding-left: 0pt;">Gross proceeds</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">4,080,500</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">The table below reflects the gross proceeds received in connection with the May and June 2014 offerings allocated to components of stockholders&#8217; equity and to derivative liabilities based upon fair value:</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; -webkit-text-stroke-width: 0px;"></p><table style="font: 10pt/normal calibri, helvetica, sans-serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1379px; font-family: 'times new roman', times, serif;">Par value of common stock issued</td><td style="width: 16px; font-family: 'times new roman', times, serif;">&#160;</td><td style="width: 16px; text-align: left; font-family: 'times new roman', times, serif;">$</td><td style="width: 141px; text-align: right; font-family: 'times new roman', times, serif;">17,164</td><td style="width: 15px; text-align: left; font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-family: 'times new roman', times, serif;">Additional paid-in-capital</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif;">17,878,994</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; font-family: 'times new roman', times, serif;">Derivative warrant liabilities</td><td style="font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif;">3,337,025</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">Derivative warrants issued to placement agent as offering costs</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">996,138</td><td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">Net proceeds</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif;">22,222,321</td><td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">Offering costs paid in cash</td><td style="padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">3,516,378</td><td style="text-align: left; padding-bottom: 1.5pt; font-family: 'times new roman', times, serif;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt; font-family: 'times new roman', times, serif;">Gross proceeds</td><td style="padding-bottom: 4pt; font-family: 'times
 new;">&#160;</td><td style="text-align: left; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; font-family: 'times new roman', times, serif; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">25,745,699</td><td style="text-align: left; padding-bottom: 4pt; font-family: 'times new roman', times, serif;">&#160;</td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of changes in options outstanding</a></td>
        <td class="text"><p></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Number of<br />Shares</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Weighted<br />Average<br />Exercise<br />Price<br />Per Share</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Weighted<br />Average<br />Remaining<br />Contractual<br />Term (Years)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Aggregate<br />Intrinsic<br />Value</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Outstanding at December 31, 2011</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;"></td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="width: 791.93px; text-indent: -8.65pt; padding-left: 17.3pt;">Granted</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">677,962</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">0.80</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Outstanding and expected to vest at December 31, 2012</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">677,962</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">0.80</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">9.5</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">-</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: -8.65pt; padding-left: 17.3pt;">Granted</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,187,449</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">0.80</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Outstanding and expected to vest at December 31, 2013</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1,865,411</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">0.80</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">8.8</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">1,305,000</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 1.5pt;">&#160;&#160;&#160;Granted</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">1,499,760</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">1.50</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">9.7</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">3,000,000</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt;">Outstanding and expected to vest at June 30, 2014&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width:
 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">3,365,171</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1.11</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">8.9</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">5,238,000</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 4pt;">Options exercisable at June 30, 2014</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">652,005</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">0.80</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">9.0</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">782,400</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted average fair value of options granted</a></td>
        <td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt;" colspan="2">Six Month<br />Ended&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">For the Years Ended<br />December 31,</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">June 30, 2014</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2012</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td><td style="text-align: center;" colspan="2">&#160;</td><td>&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px;">Current price of common stock</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 142px; text-align: right;">2.00</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">$</td><td style="width: 141px; text-align: right;">0.80</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">0.30</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Risk free interest rate</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.5% to 1.6</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">1.4</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0.6</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Dividend yield</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>Volatility</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;76% to 77</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">73% to 80</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">82</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Expected term (in years)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">6.25</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5.75 to 10</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5.75</td><td style="text-align: left;">&#160;</td></tr></table><div>&#160;</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_relm_ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock', window );">Summary of changes in warrants outstanding</a></td>
        <td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Number of<br />Shares</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Weighted<br />Average<br />Exercise<br />Price<br />Per Share</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px;">Outstanding at December 31, 2011</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">6,251</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">$</td><td style="width: 141px; text-align: right;">1.00</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>Granted</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5,478,360</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">0.50</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 1.5pt;">Exercised</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">(619,377</td><td style="padding-bottom: 1.5pt; text-align: left;">)</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">$</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">0.80</td><td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>Outstanding at December 31, 2012</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">4,865,234</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">&#160;</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 1.5pt;">Granted</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">4,061,283</td><td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">$</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">0.54</td><td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td>Outstanding at December 31, 2013</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">8,926,517</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">0.54</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td>Granted</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">35,086,253</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">$</td><td style="text-align: right;">1.58</td><td style="text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-bottom: 4pt;">Forfeited (1)</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">(868,213</td><td style="padding-bottom: 4pt; text-align: left;">)</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">$</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">0.80</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt;">Outstanding and vested at June 30, 2014</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">43,144,557</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">$</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">1.25</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td></tr></table><div>&#160;</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock', window );">Weighted average fair value of warrants granted</a></td>
        <td class="text"><div>&#160;</div><table style="font: 10pt/normal 'times new roman', times, serif; width: 625px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt;" colspan="2"><p style="margin-top: 0px; margin-bottom: 0px;">Six Month&#160;<br />Ended,</p><p style="margin-top: 0px; margin-bottom: 0px;">June 30,</p></td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">Years Ended December 31,</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-align: center;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2013</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2012</td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 388px;">Current price of common stock</td><td style="width: 6px;">&#160;</td><td style="width: 6px; text-align: left;">$</td><td style="width: 56px; text-align: right;">2.00</td><td style="width: 11px; text-align: left;">&#160;</td><td style="width: 6px;">&#160;</td><td style="width: 6px; text-align: left;">&#160;</td><td style="width: 56px; text-align: right;">$0.80 - $1.50</td><td style="width: 11px; text-align: left;">&#160;</td><td style="width: 6px;">&#160;</td><td style="width: 6px; text-align: left;">$</td><td style="width: 56px; text-align: right;">0.30</td><td style="width: 11px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Risk-free interest rate</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0.7% to 2.0</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0.9% to 1.8</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0.6% to .7</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Dividend yield</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">0</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left;">Expected volatility</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">75% to 76</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">73% to&#160;83</td><td style="text-align: left;">%</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">82% to 83</td><td style="text-align: left;">%</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left;">Expected term (in years)</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">4 and 7</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">4-7</td><td style="text-align: left;">&#160;</td><td>&#160;</td><td style="text-align: left;">&#160;</td><td style="text-align: right;">5</td><td style="text-align: left;">&#160;</td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_ScheduleOfCashProceedsReceivedFromOfferingsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of cash proceeds from offerings of tha reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_ScheduleOfCashProceedsReceivedFromOfferingsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_relm_ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Schedule Of Share Based Compensation Warrants Activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>relm_ScheduleOfShareBasedCompensationWarrantsActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>relm_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
